PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2593167-1	1989	To investigate the possibility of increased activity of cytotoxic anticancer drugs combined with cytokines, we treated human melanoma cells with combinations of etoposide (VP-16) and human recombinant interleukin-1 alpha (rIL-1 alpha).	Etoposide	161-170	host cell factor C1	Homo sapiens	172-177
2556011-2	1989	Following the development of bone metastases, further chemotherapy with etoposide (VP-16) and cis-platinum was not successful and the patient"s condition was rapidly fatal.	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
2589229-1	1989	Twenty-two patients with metastatic colorectal carcinoma were treated in a Phase I-II study of combination therapy with 5-fluorouracil (5-FU) and etoposide (VP-16).	Etoposide	146-155	host cell factor C1	Homo sapiens	157-162
2697195-4	1989	The outcome was invariably fatal before the use of etoposide (VP 16) in association with steroids and intrathecal methotrexate.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
2477515-7	1989	She was treated with etoposide (VP-16), high-dose cisplatin, vinblastine, and bleomycin and is currently without evidence of disease 46 months postmetastasis.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
2753092-0	1989	Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.	Etoposide	37-46	host cell factor C1	Homo sapiens	48-52
2568172-2	1989	The MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4"-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids melphalan and mitomycin C.	Etoposide	37-46	MX dynamin like GTPase 2	Homo sapiens	4-7
2545335-1	1989	Dipyridamole (DPM) enhanced the sensitivity of human ovarian carcinoma 2008 cells to etoposide (VP-16) producing a 5.5-fold reduction in 50% inhibitory concentration at a DPM concentration of 20 microM.	Etoposide	85-94	host cell factor C1	Homo sapiens	96-101
2549879-3	1989	Cisplatin plus etoposide (PVP), which was demonstrated to have a distinct activity in previously treated SCLC and to be not fully cross-resistant to CAV, has recently been incorporated into the first-line treatment.	Etoposide	15-24	SCLC1	Homo sapiens	105-109
2782919-1	1989	A 69 year-old woman with recurrent uterine cervical cancer was treated by etoposide because of ascites retention and elevated serum SCC level.	Etoposide	74-83	serpin family B member 3	Homo sapiens	132-135
2753092-1	1989	We have compared in various clonogenic assays the in vitro sensitivity to etoposide (VP16) of 1) human leukemic precursors (leukemia colony-forming units; L-CFU), 2) normal erythroid progenitors (erythroid burst-forming units; BFU-E, and 3) normal committed myeloid progenitors (granulocyte-macrophage colony-forming units; CFU-GM and more primitive hemopoietic precursors (PPC) that adhere to cultured marrow stromal cells.	Etoposide	74-83	host cell factor C1	Homo sapiens	85-89
2548282-13	1989	We added cisplatin to the combination of cyclophosphamide, doxorubicin, and etoposide (PACE).	Etoposide	76-85	furin, paired basic amino acid cleaving enzyme	Homo sapiens	87-91
2746758-3	1989	Moreover etoposide (VP-16) and hyperthermia at relatively low temperature enhanced the antitumor effect of rTNF-S.	Etoposide	9-18	host cell factor C1	Homo sapiens	20-25
2548593-0	1989	Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives.	Etoposide	63-72	host cell factor C1	Homo sapiens	74-79
2778659-8	1989	Etoposide binds to the extent of 94% to human serum albumin (HSA) and human plasma, but only 24% to bovine serum albumin (BSA) in vitro.	Etoposide	0-9	albumin	Homo sapiens	46-65
2778659-8	1989	Etoposide binds to the extent of 94% to human serum albumin (HSA) and human plasma, but only 24% to bovine serum albumin (BSA) in vitro.	Etoposide	0-9	albumin	Homo sapiens	46-59
2734645-2	1989	Etoposide (VP-16) administered intraperitoneally as part of a phase I trial produced dramatic relief of the obstruction.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2551366-0	1989	Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.	Etoposide	136-145	Topoisomerase 2	Drosophila melanogaster	86-102
2551366-6	1989	By employing a topoisomerase II mediated DNA religation assay [Osheroff, N. & Zechiedrich, E.L. (1987) Biochemistry 26, 4303-4309], etoposide was found to stabilize the enzyme-DNA cleavage complex (at least in part) by inhibiting the enzyme"s ability to religate cleaved DNA.	Etoposide	136-145	Topoisomerase 2	Drosophila melanogaster	15-31
2733097-4	1989	Recombinant human tumor necrosis factor (rTNF) and VP16 (etoposide), both well known cytotoxic and cytostatic anticancer agents, were tested singly and in combination against this metastatic model of human renal adenocarcinoma.	Etoposide	57-66	host cell factor C1	Homo sapiens	51-55
2624125-1	1989	Podophyllic acid piperidyl hydrazone nitroxide radical (GP-1) and etoposide (VP-16), derivatives of podophyllotoxin, inhibited DNA, RNA, protein and ATP synthesis of leukemia L7712 cells at a concentration of 5 micrograms/ml.	Etoposide	66-75	host cell factor C1	Homo sapiens	77-82
2540199-3	1989	The network production is abolished by omission of ATP, strongly inhibited by etoposide (VP-16), but only slightly inhibited by antibody to topoisomerase I, indicating that the major enzyme responsible for catenation is DNA topoisomerase II.	Etoposide	78-87	host cell factor C1	Homo sapiens	89-94
2539902-1	1989	Our human T-cell leukemia line, CEM/VM-1, selected for resistance to VM-26 (teniposide), is cross-resistant to several drugs that interact with topoisomerase II, including VP-16 (etoposide), 4"-(9-acridinylamino)methanesulphon-m-anisidide, daunorubicin, and mitoxantrone.	Etoposide	179-188	host cell factor C1	Homo sapiens	172-177
2543340-6	1989	A second trial was undertaken in which etoposide (VP-16) was added because of its synergism with cisplatin.	Etoposide	39-48	host cell factor C1	Homo sapiens	50-55
2538577-15	1989	Similarly, the substitution of etoposide for the doxorubicin in the CAV regimen was associated with prolonged survival and reduced cardiotoxicity.	Etoposide	31-40	caveolin 2	Homo sapiens	68-71
2550587-2	1989	A series of analogues of etoposide, the C-4 amino- and alkylamino-substituted 4"-demethyl-epipodophyllotoxins, have been synthesized and studied for their activity to inhibit type II human DNA topoisomerase as well as their activity in causing cellular protein-linked DNA breakage.	Etoposide	25-34	complement C4A (Rodgers blood group)	Homo sapiens	40-43
2539716-1	1989	Although the etoposide (VP-16) and cisplatin combination has shown therapeutic activity in lung cancer, human results to date have not matched the expectation of synergism raised by animal model studies.	Etoposide	13-22	host cell factor C1	Homo sapiens	24-29
2914288-2	1989	The compatibility of etoposide (VP-16-213) and cisplatin (CDDP) in an admixture solution was established by High Pressure Liquid Chromatography (HPLC) studies in vitro at room temperature.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
2536584-0	1989	Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
2564628-1	1989	In order to study the mechanism of etoposide (VP-16) resistance in human tumor cells and to assess the role of P-170 glycoprotein in VP-16 accumulation, we have examined the uptake and efflux of VP-16 in both sensitive and multidrug-resistant MCF-7 human breast and HL60 human promyelocytic leukemia cells.	Etoposide	35-44	host cell factor C1	Homo sapiens	46-51
2727988-0	1989	Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.	Etoposide	20-29	host cell factor C1	Homo sapiens	31-36
2727988-0	1989	Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.	Etoposide	20-29	GLI family zinc finger 2	Homo sapiens	59-64
2918334-1	1989	In this phase I study, we administered etoposide (VP-16) orally for 21 consecutive days to patients with advanced refractory cancers.	Etoposide	39-48	host cell factor C1	Homo sapiens	50-55
2702041-1	1989	Modified glutathione S-transferase (GST) activity was detected in MCF-7 cell lines selected in vitro for modest levels of resistance (2.6- to 13.7-fold) not only to Adriamycin but also to Novantrone, vincristine (VCR), and etoposide (VP-16).	Etoposide	223-232	glutathione S-transferase kappa 1	Homo sapiens	9-34
2563654-2	1989	C25X cells were cross-resistant to daunomycin and etoposide (VP-16) but not to vincristine or colchicine.	Etoposide	50-59	host cell factor C1	Homo sapiens	61-66
2702985-0	1989	Etoposide (VP-16) uptake by tumour spheroids and activity in the presence of Brij 30, formulation additives and sodium salicylate.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2620246-5	1989	Etoposide (VP-16), at 100 microM produced 3-3.5 log inhibition of ES cell lines and complete inhibition of CFU-GM growth.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2702041-1	1989	Modified glutathione S-transferase (GST) activity was detected in MCF-7 cell lines selected in vitro for modest levels of resistance (2.6- to 13.7-fold) not only to Adriamycin but also to Novantrone, vincristine (VCR), and etoposide (VP-16).	Etoposide	223-232	glutathione S-transferase kappa 1	Homo sapiens	36-39
2702041-1	1989	Modified glutathione S-transferase (GST) activity was detected in MCF-7 cell lines selected in vitro for modest levels of resistance (2.6- to 13.7-fold) not only to Adriamycin but also to Novantrone, vincristine (VCR), and etoposide (VP-16).	Etoposide	234-239	glutathione S-transferase kappa 1	Homo sapiens	9-34
2702041-1	1989	Modified glutathione S-transferase (GST) activity was detected in MCF-7 cell lines selected in vitro for modest levels of resistance (2.6- to 13.7-fold) not only to Adriamycin but also to Novantrone, vincristine (VCR), and etoposide (VP-16).	Etoposide	234-239	glutathione S-transferase kappa 1	Homo sapiens	36-39
2702041-3	1989	Overexpression of GST pi protein was also observed after in vitro exposure of MCF-7 cells to fractionated x-irradiation, which resulted in a subline that exhibited 5-fold resistance to VCR and 3-fold resistance to VP-16.	Etoposide	214-219	glutathione S-transferase kappa 1	Homo sapiens	18-21
2702041-4	1989	Northern blot analysis provided qualitative evidence that these changes in GST pi and mu appeared to be at the transcriptional level in these VCR- and VP-16-resistant MCF-7 sublines.	Etoposide	151-156	glutathione S-transferase kappa 1	Homo sapiens	75-78
2609973-1	1989	The interaction of the anticancer drug, etoposide (VP16-213), with DPPC bilayer vesicles was investigated by DSC and Laser Raman techniques.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-55
2513840-4	1989	The cytostatic agent etoposide (VP-16) was able to augment the hCG secretion on the choriocarcinoma cells but did not alter its production on term placenta.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
2513840-4	1989	The cytostatic agent etoposide (VP-16) was able to augment the hCG secretion on the choriocarcinoma cells but did not alter its production on term placenta.	Etoposide	21-30	chorionic gonadotropin subunit beta 5	Homo sapiens	63-66
3060442-3	1988	Treatment with high concentration of etoposide (VP-16) (10 to 80 micrograms/ml) resulted in a maximal depletion of 1.5 log, whereas more efficient tumor cell eradication (2.5 log) was achieved by 30-min incubation with 100 micrograms/ml4HC.	Etoposide	37-46	host cell factor C1	Homo sapiens	48-53
2851175-3	1988	The small cell lung cancer (SCLC) lines were generally more sensitive than the non-small cell lung cancer (NSCLC) lines to vincristine, thiotepa, and etoposide (VP-16).	Etoposide	150-159	host cell factor C1	Homo sapiens	161-166
2851179-1	1988	A multicenter Italian Cooperative Study Group (FONICAP) conducted a prospective, randomized trial comparing cisplatin and etoposide (VP-16) with single-agent etoposide.	Etoposide	122-131	host cell factor C1	Homo sapiens	133-138
2851179-4	1988	The overall response rates for the etoposide group and cisplatin/etoposide (VP-16) group were 7% and 26%, respectively (P less than 0.005).	Etoposide	65-74	host cell factor C1	Homo sapiens	76-81
2851180-6	1988	In summary, combination chemotherapy using cisplatin and etoposide (VP-16) appears to be the most active and safest regimen in NSCLC.	Etoposide	57-66	host cell factor C1	Homo sapiens	68-73
3069425-1	1988	Etoposide, a semisynthetic derivative of podophyllotoxin, has been commercially available for intravenous use for a number of years, and has been used as part of first-line combination chemotherapy programs for small cell lung cancer (SCLC).	Etoposide	0-9	SCLC1	Homo sapiens	235-239
3069425-3	1988	Etoposide for oral use has become commercially available and is approved for use in the treatment of SCLC.	Etoposide	0-9	SCLC1	Homo sapiens	101-105
3069425-4	1988	Although no clinical trials comparing intravenous and oral etoposide in SCLC have been reported, several pharmacokinetic studies have been described.	Etoposide	59-68	SCLC1	Homo sapiens	72-76
3069425-8	1988	Oral etoposide has been demonstrated to be effective in the treatment of SCLC.	Etoposide	5-14	SCLC1	Homo sapiens	73-77
2842045-0	1988	DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.	Etoposide	30-39	host cell factor C1	Homo sapiens	41-46
2842045-1	1988	Pleotropic resistant human breast cancer cells (MCF-7), selected for resistance to Adriamycin, were used to study the production of DNA strand breaks by etoposide (VP-16) and its relationship to drug cytotoxicity.	Etoposide	153-162	host cell factor C1	Homo sapiens	164-169
3056605-1	1988	Eighteen evaluable children with recurrent Langerhans" cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16-213), 200 mg/m2/day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug.	Etoposide	139-148	host cell factor C1	Homo sapiens	150-155
2844393-1	1988	The alkaloid derivative 4"-demethylepipodophyllotoxin 9-(4,6-O-ethylidene)-beta-D-glucopyranoside (etoposide, VP-16) is believed to exert cytotoxicity by causing double-stranded DNA breaks through interruption of the breaking-resealing reaction of topoisomerase II (topo II).	Etoposide	24-97	host cell factor C1	Homo sapiens	110-115
2844393-1	1988	The alkaloid derivative 4"-demethylepipodophyllotoxin 9-(4,6-O-ethylidene)-beta-D-glucopyranoside (etoposide, VP-16) is believed to exert cytotoxicity by causing double-stranded DNA breaks through interruption of the breaking-resealing reaction of topoisomerase II (topo II).	Etoposide	99-108	host cell factor C1	Homo sapiens	110-115
3181265-1	1988	With the aim of elucidating the structural requirements for O-demethylation of the antitumor agent VP-16-213 by cytochrome P-450, the binding of a series of podophyllotoxin derivatives to rat liver microsomal cytochrome P-450 was studied.	Etoposide	99-108	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	112-128
2841844-0	1988	Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2898143-5	1988	Infected cells became resistant to colchicine, vinblastine, doxorubicin, VP16 (etoposide), and puromycin, but not cisplatin, indicating that the presence of the human MDR1 gene is sufficient to cause multidrug resistance.	Etoposide	73-77	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
3292713-2	1988	Fifty-eight patients (85%) entered complete remission after treatment with etoposide (VP-16)/cytarabine (ara-C) (A), followed by daunorubicin (Dauno)/ara-C/thioguanine (6-TG) (B) and then VP-16/azacytidine (5-AZ) (C).	Etoposide	75-84	host cell factor C1	Homo sapiens	86-91
3133101-0	1988	Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin.	Etoposide	57-66	host cell factor C1	Homo sapiens	68-73
3133101-2	1988	Twenty-one patients with refractory germ cell tumors were treated with a chemotherapy regimen containing etoposide (VP-16) (V) 75 mg/m2/day (days 1 to 5), ifosfamide (I) 3 g/m2/day (days 1 and 2) with a 3.6 g/m2 continuous infusion of mesna (days 1 and 2), and high-dose cisplatin (hP) 40 mg/m2/day (days 1 to 5).	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
2839633-1	1988	In view of experimental and clinical data suggesting enhanced antiproliferative efficacy from a continuous infusion of etoposide (VP-16) concomitant with cisplatin (CDDP), we performed a dose-seeking study of a five-day infusion of VP-16, 30 mg/m2/24 h and CDDP, 18.5 to 25 mg/m2/24 h. Among eight patients with advanced solid tumors, dose-limiting toxicities were leukopenia and thrombocytopenia.	Etoposide	119-128	host cell factor C1	Homo sapiens	130-135
2839633-1	1988	In view of experimental and clinical data suggesting enhanced antiproliferative efficacy from a continuous infusion of etoposide (VP-16) concomitant with cisplatin (CDDP), we performed a dose-seeking study of a five-day infusion of VP-16, 30 mg/m2/24 h and CDDP, 18.5 to 25 mg/m2/24 h. Among eight patients with advanced solid tumors, dose-limiting toxicities were leukopenia and thrombocytopenia.	Etoposide	119-128	host cell factor C1	Homo sapiens	232-237
3044803-1	1988	We conducted a phase I trial with the combination carboplatin (CBDCA)-etoposide (VP-16) in thoracic cancer.	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
2898143-5	1988	Infected cells became resistant to colchicine, vinblastine, doxorubicin, VP16 (etoposide), and puromycin, but not cisplatin, indicating that the presence of the human MDR1 gene is sufficient to cause multidrug resistance.	Etoposide	79-88	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
3341784-7	1988	Recently, cisplatin, VP-16 (etoposide) and others are administered as trial use.	Etoposide	28-37	host cell factor C1	Homo sapiens	21-26
3410665-0	1988	Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors.	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
3410665-2	1988	Etoposide (VP-16), 150 mg/M2, given intravenously daily for 3 days every 3 weeks resulted in 3 complete responses and 6 partial responses in 154 patients with a spectrum of recurrent malignant solid tumors.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2449133-11	1988	Lately, VP-16 (etoposide) was found to be a useful salvage agent.	Etoposide	15-24	host cell factor C1	Homo sapiens	8-13
2896069-6	1988	Second, LoVo DOXR cells are cross-resistant to vincristine, actinomycin D, colchicine, etoposide, and gramicidin D, but not to 1-beta-D-arabinofuranosylcytosine.	Etoposide	87-96	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
2896069-7	1988	In contrast, HT1080 DOXR cells display cross-resistance to vincristine, actinomycin D, vinblastine, and etoposide; however, they are not cross-resistant to gramicidin D, and show an increased (approximately 18-fold) cross-resistance to 1-beta-D-arabinofuranosylcytosine.	Etoposide	104-113	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
3282425-0	1988	Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3282425-1	1988	Twenty-six patients with advanced adenocarcinoma of the pancreas were treated with etoposide (VP-16), 100-180 mg/m2 i.v., days 1, 2, and 3, monthly.	Etoposide	83-92	host cell factor C1	Homo sapiens	94-99
3276544-0	1988	Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
3276544-1	1988	In the present study we evaluated the effect of etoposide (VP-16-213) compared to mafosfamide-cyclohexylamine (Asta-Z 7654) on normal granulocyte-macrophage colony-forming unit (GM-CFU) growth, T-cell response to mitogens, and a clonogenic promyelocytic cell line (HL-60).	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
3356201-0	1988	Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213).	Etoposide	64-73	host cell factor C1	Homo sapiens	75-79
2855002-0	1988	Role of free radicals in etoposide (VP-16,213) action.	Etoposide	25-34	host cell factor C1	Homo sapiens	36-41
2832457-1	1987	Etoposide (VP-16) is a semisynthetic podophyllotoxin derivative that is active against a number of solid and hematologic malignancies.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3406503-0	1988	Phase-II-study with EAP (etoposide, adriamycin, cis-platinum) in patients with primary inoperable gastric cancer and advanced disease.	Etoposide	25-34	glutamyl aminopeptidase	Homo sapiens	20-23
3479271-1	1987	A 62-year-old woman receiving chemotherapy with etoposide showed discrepant uric acid values as measured by a direct phosphotungstic acid (PTA) method (150 mg/L) compared with a uricase technique (40 mg/L).	Etoposide	48-57	urate oxidase (pseudogene)	Homo sapiens	178-185
3305528-3	1987	The indications and side-effects of high dose methotrexate, ifosfamide and etoposide (VP-16) are summarized in tabular form.	Etoposide	75-84	host cell factor C1	Homo sapiens	86-91
3502785-2	1987	A cyclophosphamide derivative (ASTA-Z 7654) and etoposide (VP16-213) have been tested on lymphoma and leukemia cell lines in a model that may represent a bone marrow situation in complete remission.	Etoposide	48-57	host cell factor C1	Homo sapiens	59-63
3613140-4	1987	The clinical stage was considered to be T3N2M1 (American joint committee (AJC) stage III M1), and his performance status was 4, so he was given etoposide (VP-16) alone as the initial chemotherapy treatment.	Etoposide	144-153	host cell factor C1	Homo sapiens	155-160
2439659-1	1987	An intensive regimen of combined etoposide (VP-16) and 5-azacitidine (5-Az) was used to treat 96 children and adolescents with refractory or relapsed acute nonlymphocytic leukemia (ANLL).	Etoposide	33-42	host cell factor C1	Homo sapiens	44-49
3037127-3	1987	These drugs, such as adriamycin and etoposide (VP 16), are in widespread use in the treatment of human cancer.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
3037127-4	1987	The rTNF significantly enhanced the cytotoxic efficacy of the topoisomerase-targeted drugs actinomycin D, adriamycin, etoposide (VP 16) and teniposide (VM 26) against MBT-2 cells in vitro.	Etoposide	118-127	tumor necrosis factor	Rattus norvegicus	4-8
3037127-4	1987	The rTNF significantly enhanced the cytotoxic efficacy of the topoisomerase-targeted drugs actinomycin D, adriamycin, etoposide (VP 16) and teniposide (VM 26) against MBT-2 cells in vitro.	Etoposide	118-127	host cell factor C1	Homo sapiens	129-134
3815383-1	1987	Etoposide (VP-16) is a semisynthetic epipodophyllotoxin that exhibits cell cycle phase specific cytotoxicity and enhanced effectiveness with increasing duration of drug exposure.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3611870-0	1987	[Anticancer effect of VP16-213 (etoposide) on three choriocarcinoma cell lines].	Etoposide	32-41	host cell factor C1	Homo sapiens	22-26
3829015-1	1987	Cisplatin (CPDD) and etoposide (VP-16) have activity as single agents in children with recurrent soft tissue sarcoma, with response rates approximating 20%.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
3027268-0	1987	Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
3469013-4	1987	Further, even though this cell line is approximately equal to 40-fold cross-resistant to the cytotoxic effect of etoposide (VP-16), it is similar to drug-sensitive CEM cells in the cellular pharmacology of [3H]VP-16 as determined by zero time binding, initial influx rate, steady state drug concentration, and unidirectional efflux.	Etoposide	113-122	host cell factor C1	Homo sapiens	124-129
3100035-8	1987	With vincristine and etoposide at three different doses, TGDs increased 2.4- to 3-fold in combination with Fluosol-DA and carbogen breathing.	Etoposide	21-30	TDP-glucose 4,6-dehydratase	Homo sapiens	57-61
3040275-6	1987	Furthermore, VP-16 stimulated glutathione reductase in liver.	Etoposide	13-18	glutathione reductase	Mus musculus	30-51
2822274-11	1987	However, following mitogenesis with phytohemagglutinin and interleukin-2, proliferating lymphocytes become as sensitive to etoposide as cultured cell lines with regard to DNA cleavage.	Etoposide	123-132	interleukin 2	Homo sapiens	59-72
3469424-0	1987	[Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].	Etoposide	19-28	host cell factor C1	Homo sapiens	30-35
3469424-4	1987	Although CR was not achieved in any patients with acute leukemia, and PR was in three (33.3%), it was found that etoposide was most effective for the patients with the M4 or M5 subtype in the FAB classification.	Etoposide	113-122	FA complementation group B	Homo sapiens	192-195
3794452-1	1986	The study dealt with anti-tumor and adverse effects of etoposide and cisplatin on human choriocarcinoma cell line (GCH-1) transplantable in nude mice in relation to the rate of their uptake into tumor tissue.	Etoposide	55-64	GTP cyclohydrolase 1	Homo sapiens	115-120
3041238-1	1987	The two demethylepipodophyllotoxin glycosides, teniposide (VM-26) and etoposide (VP-16), have previously been reported to interact with DNA topoisomerase II by stabilizing a topoisomerase II-DNA covalent intermediate.	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
3756767-0	1986	Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
3015372-2	1986	A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin.	Etoposide	101-110	nescient helix-loop-helix 1	Homo sapiens	66-70
3581419-1	1987	Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory.	Etoposide	33-42	host cell factor C1	Homo sapiens	44-49
3621455-0	1987	Drug monitoring of etoposide (VP16-213).	Etoposide	19-28	host cell factor C1	Homo sapiens	30-34
3621455-18	1987	The t1/2 beta of etoposide was increased in older patients.	Etoposide	17-26	interleukin 1 receptor like 1	Homo sapiens	4-13
3643849-0	1986	Pharmacokinetics of high dose etoposide (VP 16-213).	Etoposide	30-39	host cell factor C1	Homo sapiens	41-46
3020702-5	1986	A three drug combination of doxorubicin (Adriamycin), cyclophosphamide, and etoposide (ACE) has been used at the University of Maryland Cancer Center (UMCC) for more than a decade in sequential studies.	Etoposide	76-85	angiotensin I converting enzyme	Homo sapiens	87-90
2430876-6	1986	Also after treatment with Etoposide (VP-16), an increase of G2/M compartment was observed, and on the morphological manifestation enlarged nuclear cells or double-or multiple-nuclear cells were observed.	Etoposide	26-35	host cell factor C1	Homo sapiens	37-42
3753024-0	1986	[Phase II study of etoposide (VP-16-213) in genitourinary tumors.	Etoposide	19-28	host cell factor C1	Homo sapiens	30-35
3753024-2	1986	A co-operative phase II study of the semisynthetic podophyllotoxin derivative Etoposide (VP-16) was undertaken in patients with genitourinary tumors.	Etoposide	78-87	host cell factor C1	Homo sapiens	89-94
3020707-0	1986	A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
3020753-2	1986	Here we describe a case with unresectable hepatocellular carcinoma who achieved a complete response and has survived for more than 2 years, following treatment with a combination of adriamycin and etoposide (VP 16-213).	Etoposide	197-206	host cell factor C1	Homo sapiens	208-213
3015377-1	1986	Evidence suggests that the anticancer agents etoposide (VP16-213) and teniposide (VM26) produce DNA breaks and cytotoxicity by interaction with type II topoisomerase.	Etoposide	45-54	host cell factor C1	Homo sapiens	56-60
3011257-1	1986	To evaluate postulated dose-response relationships of etoposide (VP-16) for patients with recurrent small cell carcinoma of the lung, a prospectively randomized study was undertaken.	Etoposide	54-63	host cell factor C1	Homo sapiens	65-70
3016271-3	1986	It has been reported that the action of etoposide (VP-16) (14) as an antitumor agent is mediated through its interaction with DNA topoisomerase II which results in DNA breakage inside the cell.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
3012008-0	1986	Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3012008-2	1986	Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50% response rates.	Etoposide	29-38	host cell factor C1	Homo sapiens	40-45
3963859-0	1986	[Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].	Etoposide	1-10	host cell factor C1	Homo sapiens	12-17
3724190-1	1986	Ten patients with Stage III-IV ovarian adenocarcinoma were treated with the drug combination etoposide (VP-16) plus cisplatin (DDP).	Etoposide	93-102	host cell factor C1	Homo sapiens	104-109
3724190-0	1986	Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3084428-0	1986	Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage.	Etoposide	23-32	host cell factor C1	Homo sapiens	34-39
3830728-1	1985	Antitumor effect and toxicity of etoposide (VP 16) in combination with cis-diamminedichloroplatinum (DDP) were studied on the in vitro C108 line and its in vivo counterpart, the M1087 line, both deriving from Lewis lung carcinoma.	Etoposide	33-42	host cell factor C1	Homo sapiens	44-49
3002282-0	1986	[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
3835288-0	1985	[A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
2992752-5	1985	The results of the use of this assay report for SCCL spheroid responses to various concentrations of doxorubicin hydrochloride, cytosine arabinoside, mechlorethamine hydrochloride, cisplatin, or etoposide.	Etoposide	195-204	SCLC1	Homo sapiens	48-52
4061373-0	1985	Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
3866799-5	1985	The combinations VP-16-213/IFN-beta and cis-platinum/IFN-beta produced the most pronounced synergistic effects.	Etoposide	17-22	interferon beta 1	Homo sapiens	27-35
3936181-1	1985	Cisplatin (Platinol)-containing regimens, especially in combination with etoposide (VP-16) (VePesid), vindesine, and/or mitomycin-C, have proven beneficial to patients with non-small-cell lung cancer.	Etoposide	73-82	host cell factor C1	Homo sapiens	84-89
3936181-1	1985	Cisplatin (Platinol)-containing regimens, especially in combination with etoposide (VP-16) (VePesid), vindesine, and/or mitomycin-C, have proven beneficial to patients with non-small-cell lung cancer.	Etoposide	92-99	host cell factor C1	Homo sapiens	84-89
4060251-0	1985	Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.	Etoposide	34-43	host cell factor C1	Homo sapiens	23-28
4061373-1	1985	Eighteen patients with advanced and heavily pretreated squamous cell carcinoma of the head and neck were treated with etoposide (VP-16).	Etoposide	118-127	host cell factor C1	Homo sapiens	129-134
3931320-1	1985	In June 1981 the authors activated a trial to evaluate the therapeutic effectiveness of the combination mitomycin C (MMC) + etoposide (VP 16) in previously untreated gastric carcinoma with measurable neoplastic lesions.	Etoposide	124-133	host cell factor C1	Homo sapiens	135-140
4015122-0	1985	[Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].	Etoposide	19-28	host cell factor C1	Homo sapiens	30-35
3975657-0	1985	Bioavailability and pharmacokinetics of etoposide (VP-16).	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
4004921-0	1985	Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action.	Etoposide	64-73	host cell factor C1	Homo sapiens	75-80
3859585-0	1985	Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3895100-2	1985	In a phase I/II study the tolerable doses and antileukemic efficacy of the combination AMSA and etoposide (VP 16-213) was assessed in 20 patients with refractory acute myeloid leukemia.	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
3884152-1	1985	Bioavailability of an oral preparation of the antineoplastic drug etoposide (VP-16) was studied in 13 patients with advanced malignancies.	Etoposide	66-75	host cell factor C1	Homo sapiens	77-82
2983434-0	1985	High-dose etoposide (VP-16) in small-cell lung cancer.	Etoposide	10-19	host cell factor C1	Homo sapiens	21-26
2990749-0	1985	Drug monitoring of etoposide (VP16-213).	Etoposide	19-28	host cell factor C1	Homo sapiens	30-34
2983434-1	1985	Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
3883504-0	1985	Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.	Etoposide	30-39	host cell factor C1	Homo sapiens	41-46
4039635-0	1985	Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen.	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
4039984-0	1985	Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.	Etoposide	67-76	host cell factor C1	Homo sapiens	78-83
3864390-11	1985	The combination of DDP and VP-16 (etoposide) was tested most often, followed by Bleo (bleomycin) as a single agent.	Etoposide	34-43	host cell factor C1	Homo sapiens	27-32
2990749-7	1985	Preliminary pharmacokinetic data for etoposide (VP16-213) together with calibration data are presented, and are discussed with reference to the sensitivity and detection limit of the new experimental method.	Etoposide	37-46	host cell factor C1	Homo sapiens	48-52
4039984-9	1985	CSF levels in two of these patients receiving high-dose etoposide were 1.28% and 2.09% of the serum concentrations.	Etoposide	56-65	colony stimulating factor 2	Homo sapiens	0-3
2981292-3	1985	Patients not in complete remission after the four cycles of AVC received two courses of VP-16 (etoposide) and cisplatin: the complete remission rate increased to 49% and 48% respectively.	Etoposide	95-104	host cell factor C1	Homo sapiens	88-93
3007254-0	1985	[Ifosfamide and adriamycin after induction with cisplatin and etoposide (VP-16) in pulmonary microcytoma.	Etoposide	62-71	host cell factor C1	Homo sapiens	73-78
2981293-0	1985	Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2981293-1	1985	Seventy-eight patients with evaluable small-cell lung cancer (SCLC) were treated with etoposide (VP-16) and cisplatin after their disease failed to respond to, or relapsed after, induction combination chemotherapy, consisting primarily of cyclophosphamide, doxorubicin (Adriamycin), and vincristine (CAV).	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
6690078-0	1984	Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.	Etoposide	29-38	host cell factor C1	Homo sapiens	18-23
4048874-4	1985	These observations suggest that SPG treatment induced an interphase block in the G2 phase of the cell cycle, analogous to the cell action of the newer podophyllotoxin derivatives teniposide and etoposide.	Etoposide	194-203	SPG16	Homo sapiens	32-35
6095666-1	1984	Thirty-seven patients with persistent or metastatic gestational trophoblastic disease were treated with oral etoposide (VP16-213).	Etoposide	109-118	host cell factor C1	Homo sapiens	120-124
6539169-0	1984	Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.	Etoposide	20-29	host cell factor C1	Homo sapiens	31-35
6732252-1	1984	The lethal and kinetic effects of Etoposide on a cell line of human small cell carcinoma of the lung (PC-6) were analyzed in vitro using flow cytometric measurement of DNA content.	Etoposide	34-43	proprotein convertase subtilisin/kexin type 5	Homo sapiens	102-106
6732252-3	1984	When PC-6 cells were exposed to Etoposide for 1 hour then washed, a increase of cells in G2 phase was observed followed by prompt recovery.	Etoposide	32-41	proprotein convertase subtilisin/kexin type 5	Homo sapiens	5-9
6539305-1	1984	A human tumour cell line resistant to etoposide ( VP16 -213) has been produced by fractionated X-irradiation exposure in vitro.	Etoposide	38-47	host cell factor C1	Homo sapiens	50-54
3839284-0	1985	Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.	Etoposide	24-33	host cell factor C1	Homo sapiens	17-22
6208991-9	1984	VP-16 (etoposide) has just become commercially available and is an important drug both in leukemia and lymphoma.	Etoposide	7-16	host cell factor C1	Homo sapiens	0-5
6380707-4	1984	These clones also showed cross-resistance to deoxyadenosine and thymidine, but normal sensitivity to arabinosylcytosine and adenosine, and increased sensitivity to the etoposide VP16-213.	Etoposide	168-177	host cell factor C1	Homo sapiens	178-182
6204257-3	1984	In addition, etoposide (VP-16) was used in seven patients, bleomycin in six, cisplatin in five, 5-fluorouracil in two, and cis-retinoic acid in four patients.	Etoposide	13-22	host cell factor C1	Homo sapiens	24-29
6318994-0	1983	Etoposide (VP-16) in the treatment of lung cancer.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
6481426-0	1984	Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.	Etoposide	22-31	host cell factor C1	Homo sapiens	15-20
6678864-1	1983	The epipodophyllotoxin derivatives, etoposide (VP-16) and teniposide (VM-26), are highly lipophilic anticancer drugs supplied with novel commercial solvent systems.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
6686849-0	1983	Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-70
6686849-1	1983	Sixty-eight patients with non-small cell lung cancer were treated in a prospectively randomized study with cyclophosphamide, doxorubicin (Adriamycin), and etoposide (VP16-213) with cisplatinum (CAE +/- P).	Etoposide	155-164	host cell factor C1	Homo sapiens	166-170
6366676-0	1983	[Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin.	Etoposide	85-94	host cell factor C1	Homo sapiens	74-79
6684989-0	1983	Combined chemotherapy with ifosfamide and cisplatin and with ifosfamide and etoposide (VP-16) in non-small cell carcinoma of the bronchus.	Etoposide	76-85	host cell factor C1	Homo sapiens	87-92
7083450-0	1982	Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-15
7127332-0	1982	Proceedings of the German Cancer Society (Clinical Oncology Section) and Bristol-Myers GmbH Symposium on Etoposide (VP-16).	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
7160031-0	1982	[Etoposide: VP-16].	Etoposide	1-10	host cell factor C1	Homo sapiens	12-17
7044594-0	1982	VP16-213 (etoposide).	Etoposide	10-19	host cell factor C1	Homo sapiens	0-4
6290053-0	1982	Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU.	Etoposide	68-77	host cell factor C1	Homo sapiens	79-84
6282482-0	1982	Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.	Etoposide	34-42	angiotensin I converting enzyme	Homo sapiens	44-47
7083455-0	1982	Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.	Etoposide	42-51	host cell factor C1	Homo sapiens	53-57
7083456-2	1982	Previous studies in vitro on the influence of extracellular protein binding of Teniposide (VM26) and Etoposide (VP16-213) on subsequent cellular uptake by experimental murine tumor cells [Cancer Res 38:2549 (1978); Drug Metab Rev 8:119 (1978)] suggested that a timed-sequential combination of VM26 and VP16-213 may increase the bioavailability of VP16-213.	Etoposide	101-110	host cell factor C1	Homo sapiens	112-116
7083457-0	1982	A phase I trial of continuous infusion VP16-213 (etoposide).	Etoposide	49-58	host cell factor C1	Homo sapiens	39-43
7083462-0	1982	The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.	Etoposide	22-31	host cell factor C1	Homo sapiens	12-16
7083462-1	1982	Since 1976 we have used VP16-213 (Etoposide; NSC-141540) in several groups of patients with gestational choriocarcinoma.	Etoposide	34-43	host cell factor C1	Homo sapiens	24-28
999818-6	1976	The conncentrations of drug necessary to inhibit thymidine and uridine uptake into HeLa cells by 50% are 10 and 5 muM, respectively, for podophyllotoxin, and 25 and 20 muM for VP-16-213.	Etoposide	176-181	latexin	Homo sapiens	168-171
7031350-0	1981	[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author"s transl)].	Etoposide	1-10	host cell factor C1	Homo sapiens	11-16
34031359-2	2021	Here we show that the long non-coding satellite III RNA (SatIII) generates resistance against the topoisomerase IIa (TOP2A) inhibitor etoposide in lung cancer.	Etoposide	134-143	DNA topoisomerase II alpha	Homo sapiens	117-122
33968195-9	2021	Accordingly, the targeting of Wip1 phosphatase by RNA interference increased the phosphorylation of DDR elements, but decreased the rate of apoptosis in response to etoposide or doxorubicin in Jurkat cells.	Etoposide	165-174	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	30-34
34031359-5	2021	In response to stress, SatIII recruits TOP2A to nuclear stress bodies, which protects TOP2A from a complex formation with etoposide and results in decreased DNA damage after treatment.	Etoposide	122-131	DNA topoisomerase II alpha	Homo sapiens	39-44
34031359-5	2021	In response to stress, SatIII recruits TOP2A to nuclear stress bodies, which protects TOP2A from a complex formation with etoposide and results in decreased DNA damage after treatment.	Etoposide	122-131	DNA topoisomerase II alpha	Homo sapiens	86-91
34031359-6	2021	We show that BRD4 inhibitors reduce the expression of SatIII, restoring etoposide sensitivity.	Etoposide	72-81	bromodomain containing 4	Homo sapiens	13-17
34004138-5	2021	Rather than altering the DNA damage response to exogenous stimuli, such as X-irradiation or etoposide treatment, mutant CARD14 increased DNA double-strand breaks under conditions of replication stress.	Etoposide	92-101	caspase recruitment domain family member 14	Homo sapiens	120-126
33756345-4	2021	Here, we show that repairable DSBs induced by a 1 h Etoposide treatment results in three specific posttranslational modifications (PTMs) of HIC1.	Etoposide	52-61	HIC ZBTB transcriptional repressor 1	Homo sapiens	140-144
33969609-6	2021	Additionally, the non-lethal doses of etoposide and cisplatin can induce SCLC cell stemness in a concentration-dependent manner and reduce the lysosome iron concentration dependent on Ferritin expression, which is positively regulated by HIF-1alpha/beta.	Etoposide	38-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	238-253
33975537-0	2021	Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome.	Etoposide	30-39	high mobility group box 1	Homo sapiens	72-77
33963183-4	2021	Conditional knock-out of Sox9 from the vasculature (Sox9fl/fl/Cdh5-CreER RosaYFP) depletes EVP while enhancing Rbpj expression and canonical Notch signalling.	Etoposide	91-94	SRY (sex determining region Y)-box 9	Mus musculus	25-29
34034210-2	2021	These compounds (e.g. etoposide) promote DNA damage and are associated with KMT2A rearrangements.	Etoposide	22-31	lysine methyltransferase 2A	Homo sapiens	76-81
33963183-4	2021	Conditional knock-out of Sox9 from the vasculature (Sox9fl/fl/Cdh5-CreER RosaYFP) depletes EVP while enhancing Rbpj expression and canonical Notch signalling.	Etoposide	91-94	SRY (sex determining region Y)-box 9	Mus musculus	52-56
33963183-4	2021	Conditional knock-out of Sox9 from the vasculature (Sox9fl/fl/Cdh5-CreER RosaYFP) depletes EVP while enhancing Rbpj expression and canonical Notch signalling.	Etoposide	91-94	cadherin 5	Mus musculus	62-66
33896825-1	2021	BACKGROUND: To investigate the prognostic role of lung immune prognostic index LIPI in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with platinum plus etoposide chemotherapy.	Etoposide	172-181	lipase I	Homo sapiens	79-83
33924765-0	2021	PKCalpha Inhibition as a Strategy to Sensitize Neuroblastoma Stem Cells to Etoposide by Stimulating Ferroptosis.	Etoposide	75-84	protein kinase C alpha	Homo sapiens	0-8
33924765-5	2021	Both combined approaches are able to sensitize CSCs to Etoposide by decreasing intracellular GSH levels, inducing a metabolic switch from OXPHOS to aerobic glycolysis, down-regulating glutathione-peroxidase-4 activity and stimulating lipid peroxidation, thus leading to ferroptosis.	Etoposide	55-64	glutathione peroxidase 4	Homo sapiens	184-208
33923614-7	2021	Exposure of ND cells to the DNA-damaging agent etoposide inflicted a senescent phenotype, increased expression of apical kinases of the DNA damage pathway and elevated expression levels of microRNA-145.	Etoposide	47-56	microRNA 145	Homo sapiens	189-201
33575800-6	2021	For etoposide, increased STARD5 predicted expression associated with decreased etoposide IC50 (p = 8.5 x 10-8).	Etoposide	4-13	StAR related lipid transfer domain containing 5	Homo sapiens	25-31
33575800-6	2021	For etoposide, increased STARD5 predicted expression associated with decreased etoposide IC50 (p = 8.5 x 10-8).	Etoposide	79-88	StAR related lipid transfer domain containing 5	Homo sapiens	25-31
33575800-7	2021	Functional studies in A549, a lung cancer cell line, revealed that knockdown of STARD5 expression resulted in decreased sensitivity to etoposide following exposure for 72 (p = 0.033) and 96 hours (p = 0.0001).	Etoposide	135-144	StAR related lipid transfer domain containing 5	Homo sapiens	80-86
33896825-10	2021	CONCLUSION: Prognosis of patients with pretreatment LIPI score of 2 is poorer than those with LIPI score of 0-1 among ES-SCLC who received first-line platinum plus etoposide chemotherapy; Further studies are still recommended to confirm our findings in prospective studies.	Etoposide	164-173	lipase I	Homo sapiens	52-56
33880064-2	2021	In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen.	Etoposide	192-201	colony stimulating factor 3	Homo sapiens	84-121
33661553-3	2021	The optimized cationic LPH Eto  with a particle size of 109.66 +- 5.17 nm and Eto entrapment efficiency (EE %) of 80.33 +- 2.55 is used to incorporate siRNA targeting CD47 (siCD47), a do not eat me marker on the surface of cancer cells.	Etoposide	27-30	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	167-171
33661553-3	2021	The optimized cationic LPH Eto  with a particle size of 109.66 +- 5.17 nm and Eto entrapment efficiency (EE %) of 80.33 +- 2.55 is used to incorporate siRNA targeting CD47 (siCD47), a do not eat me marker on the surface of cancer cells.	Etoposide	78-81	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	Mus musculus	167-171
33551437-4	2021	Thus, we originally developed the MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) regimen for r/r NHL and validated the safety and efficacy of this regimen in a clinical setting.	Etoposide	103-112	metaxin 1	Homo sapiens	34-37
33705657-8	2021	We further demonstrate for the first time that BRAT1 can be inhibited by curcusone D, resulting in impaired DNA damage response, reduced cancer cell migration, potentiated activity of the DNA damaging drug etoposide, and other phenotypes similar to BRAT1 knockdown.	Etoposide	206-215	BRCA1 associated ATM activator 1	Homo sapiens	47-52
33691100-6	2021	Dual deficiency in Poltheta and tyrosyl-DNA phosphodiesterase 2 (TDP2) causes severe cellular sensitivity to etoposide, which demonstrates MMEJ as an independent DPC repair pathway.	Etoposide	109-118	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	32-63
33712558-10	2021	Therefore, in CRC, PRDX1 plays a key role in maintaining intracellular homeostasis under conditions of high metabolic activity by reinforcing UBE2F-CUL5-mediated degradation of NOXA, which is also evidenced in the resistance of CRC cells to etoposide treatment.	Etoposide	241-250	peroxiredoxin 1	Homo sapiens	19-24
33712558-10	2021	Therefore, in CRC, PRDX1 plays a key role in maintaining intracellular homeostasis under conditions of high metabolic activity by reinforcing UBE2F-CUL5-mediated degradation of NOXA, which is also evidenced in the resistance of CRC cells to etoposide treatment.	Etoposide	241-250	ubiquitin conjugating enzyme E2 F (putative)	Homo sapiens	142-147
33712558-10	2021	Therefore, in CRC, PRDX1 plays a key role in maintaining intracellular homeostasis under conditions of high metabolic activity by reinforcing UBE2F-CUL5-mediated degradation of NOXA, which is also evidenced in the resistance of CRC cells to etoposide treatment.	Etoposide	241-250	cullin 5	Homo sapiens	148-152
33712558-10	2021	Therefore, in CRC, PRDX1 plays a key role in maintaining intracellular homeostasis under conditions of high metabolic activity by reinforcing UBE2F-CUL5-mediated degradation of NOXA, which is also evidenced in the resistance of CRC cells to etoposide treatment.	Etoposide	241-250	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	177-181
33691100-6	2021	Dual deficiency in Poltheta and tyrosyl-DNA phosphodiesterase 2 (TDP2) causes severe cellular sensitivity to etoposide, which demonstrates MMEJ as an independent DPC repair pathway.	Etoposide	109-118	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	65-69
33570788-10	2021	Furthermore, the overexpression of PLAC8 promoted cell viability and proliferation, acting as a protective mechanism of trophoblasts against the cytotoxicity of etoposide (VP-16).	Etoposide	161-170	placenta associated 8	Homo sapiens	35-40
33570788-10	2021	Furthermore, the overexpression of PLAC8 promoted cell viability and proliferation, acting as a protective mechanism of trophoblasts against the cytotoxicity of etoposide (VP-16).	Etoposide	161-170	host cell factor C1	Homo sapiens	172-177
33627632-8	2021	The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide.	Etoposide	140-149	RAB11 family interacting protein 1	Homo sapiens	24-27
33508757-8	2021	TAP1 significantly improved the anti-proliferation effect of the anti-androgens (Charcoal dextran-stripped serum (CDSS)+Bicalutamide, Enzalutamide) and chemotherapeutic agents (Abiraterone, Docetaxel, Etoposide) in vitro.	Etoposide	201-210	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	0-4
33446509-3	2021	We recently demonstrated that an etoposide-resistant K562 clonal subline, K/VP.5, with reduced levels of TOP2alpha/170, expresses high levels of a novel C-terminal truncated TOP2alpha isoform (90 kDa, TOP2alpha/90).	Etoposide	33-42	DNA topoisomerase II alpha	Homo sapiens	105-118
33446509-3	2021	We recently demonstrated that an etoposide-resistant K562 clonal subline, K/VP.5, with reduced levels of TOP2alpha/170, expresses high levels of a novel C-terminal truncated TOP2alpha isoform (90 kDa, TOP2alpha/90).	Etoposide	33-42	DNA topoisomerase II alpha	Homo sapiens	105-114
33446509-3	2021	We recently demonstrated that an etoposide-resistant K562 clonal subline, K/VP.5, with reduced levels of TOP2alpha/170, expresses high levels of a novel C-terminal truncated TOP2alpha isoform (90 kDa, TOP2alpha/90).	Etoposide	33-42	DNA topoisomerase II alpha	Homo sapiens	201-213
33627632-8	2021	The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide.	Etoposide	140-149	ATP binding cassette subfamily B member 1	Homo sapiens	32-36
33627632-8	2021	The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide.	Etoposide	140-149	RAB11 family interacting protein 1	Homo sapiens	75-78
33627632-8	2021	The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide.	Etoposide	140-149	tumor protein p53	Homo sapiens	89-92
33438746-4	2021	Here, we use label-free quantitative phosphoproteomics to examine the temporal effects of exposure of U2OS cells to either etoposide (ETO) or hydroxyurea (HU) by monitoring the phosphorylation status of RelA and its protein binding partners.	Etoposide	123-132	RELA proto-oncogene, NF-kB subunit	Homo sapiens	203-207
33592119-10	2021	Patients treated with cytarabine had the highest yield of CD34+ cells (median 7.5 x 106 /kg vs 5.8 and 2.4 for etoposide and cyclophosphamide, P = .001).	Etoposide	111-120	CD34 molecule	Homo sapiens	58-62
33659204-1	2020	Introduction: We performed this clinical trial to evaluate the efficacy and safety of apatinib and oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer (MBC).	Etoposide	104-113	erb-b2 receptor tyrosine kinase 2	Homo sapiens	131-135
33659204-15	2020	Conclusion: Apatinib combined with etoposide capsules is effective and tolerable in heavily pretreated, metastatic HER2-negative breast cancer patients.	Etoposide	35-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-119
33536335-4	2021	Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib.	Etoposide	146-155	ATR serine/threonine kinase	Homo sapiens	53-56
33536335-4	2021	Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib.	Etoposide	146-155	checkpoint kinase 1	Homo sapiens	79-83
33536335-4	2021	Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib.	Etoposide	146-155	schlafen family member 11	Homo sapiens	105-111
32786121-7	2021	We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells.	Etoposide	79-88	SUMO specific peptidase 1	Homo sapiens	21-26
32636079-1	2021	BACKGROUND: Second-line salvage therapy for patients with metastatic germ-cell cancer (GCC) after the first-line combination of VIP (etoposide, ifosfamide, cisplatin) therapy has not been established.	Etoposide	133-142	vasoactive intestinal peptide	Homo sapiens	128-131
32786121-7	2021	We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells.	Etoposide	79-88	tumor protein p53	Homo sapiens	99-102
32786121-7	2021	We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells.	Etoposide	79-88	H3 histone pseudogene 16	Homo sapiens	136-139
33305533-15	2021	For MyHC-IIa, gene expression was down-regulated by ~2.6-fold and ~4.5-fold in Daun and Etop treatment, respectively (P < 0.0001).	Etoposide	88-92	myosin, heavy polypeptide 2, skeletal muscle, adult	Mus musculus	4-12
33141998-0	2021	The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells.	Etoposide	63-72	maternally expressed 3	Homo sapiens	11-15
33141998-0	2021	The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells.	Etoposide	63-72	glycerophosphodiester phosphodiesterase 1	Homo sapiens	16-22
33141998-0	2021	The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells.	Etoposide	63-72	vestigial like family member 4	Homo sapiens	26-31
33141998-12	2021	LncRNA MEG3 participated in the senescent progress of tumor cells induced by etoposide via the miR-16-5p/VGLL4 axis.	Etoposide	77-86	maternally expressed 3	Homo sapiens	7-11
33141998-12	2021	LncRNA MEG3 participated in the senescent progress of tumor cells induced by etoposide via the miR-16-5p/VGLL4 axis.	Etoposide	77-86	glycerophosphodiester phosphodiesterase 1	Homo sapiens	95-101
33141998-12	2021	LncRNA MEG3 participated in the senescent progress of tumor cells induced by etoposide via the miR-16-5p/VGLL4 axis.	Etoposide	77-86	vestigial like family member 4	Homo sapiens	105-110
33141998-13	2021	CONCLUSIONS: Our study confirmed the regulatory role of the lncRNA MEG3/miR-16-5p/VGLL4 axis in the low-dose etoposide-induced tumor cell senescence model, which has potential clinical application value to treat malignant tumors.	Etoposide	109-118	maternally expressed 3	Homo sapiens	67-71
33141998-13	2021	CONCLUSIONS: Our study confirmed the regulatory role of the lncRNA MEG3/miR-16-5p/VGLL4 axis in the low-dose etoposide-induced tumor cell senescence model, which has potential clinical application value to treat malignant tumors.	Etoposide	109-118	glycerophosphodiester phosphodiesterase 1	Homo sapiens	72-78
33141998-13	2021	CONCLUSIONS: Our study confirmed the regulatory role of the lncRNA MEG3/miR-16-5p/VGLL4 axis in the low-dose etoposide-induced tumor cell senescence model, which has potential clinical application value to treat malignant tumors.	Etoposide	109-118	vestigial like family member 4	Homo sapiens	82-87
33323971-4	2021	Here, we investigate A3B expression upon treatment with chemotherapeutic drugs that activate p53, including 5-fluorouracil, etoposide and cisplatin.	Etoposide	124-133	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	21-24
33413292-7	2021	ADT and subsequent chemotherapy with etoposide and cisplatin (EP) were performed for prostate cancer, which resulted in decreased PSA and NSE and reduction of all metastases.	Etoposide	37-46	aminopeptidase puromycin sensitive	Homo sapiens	130-133
33148531-2	2021	The aim of this present study was to investigate the Nrf2 inhibitory effect of Trigonelline, its mechanism of action and its possible use in combinatorial treatment with anti- lung cancer drugs, Cisplatin and Etoposide.	Etoposide	209-218	NFE2 like bZIP transcription factor 2	Homo sapiens	53-57
33148531-7	2021	Nrf2 knockdown experiment in NSCLC cells obliterated the effect of Trigonelline- Cisplatin and Trigonelline-Etoposide combination, indicating the role of Nrf2 inhibition in augmenting drug sensitivity.	Etoposide	108-117	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
33413292-7	2021	ADT and subsequent chemotherapy with etoposide and cisplatin (EP) were performed for prostate cancer, which resulted in decreased PSA and NSE and reduction of all metastases.	Etoposide	37-46	enolase 2	Homo sapiens	138-141
33419031-8	2021	Furthermore, ALDH1B1-overexpressing HT29 cells exhibited enhanced resistance against doxorubicin, fluorouracil (5-FU) and etoposide.	Etoposide	122-131	aldehyde dehydrogenase 1 family member B1	Homo sapiens	13-20
33952826-2	2021	In this study, we investigated the short-term effect of etoposide, another bitter-tasting P-gp substrate, on P-gp transport function in the same cell line.	Etoposide	56-65	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
33952826-9	2021	These results suggest that etoposide induces release of CCK, causing activation of the CCK receptor followed by phosphorylation of ERM proteins, which recruit intracellular P-gp for trafficking to the gastrointestinal membrane, thereby increasing the functional activity of P-gp.	Etoposide	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	274-278
33952826-2	2021	In this study, we investigated the short-term effect of etoposide, another bitter-tasting P-gp substrate, on P-gp transport function in the same cell line.	Etoposide	56-65	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
33952826-3	2021	We found that etoposide exposure significantly increased both the P-gp protein level in the plasma membrane fraction and the efflux rate of rhodamine123 (Rho123) in Caco-2 cells within 10 min.	Etoposide	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
33952826-5	2021	These results indicated that etoposide rapidly enhances P-gp function in Caco-2 cells.	Etoposide	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
33952826-6	2021	In contrast, P-gp expression in whole cells at both the mRNA and protein level was unchanged by etoposide exposure, compared with the levels in non-treated cells.	Etoposide	96-105	ATP binding cassette subfamily B member 1	Homo sapiens	13-17
33952826-7	2021	Furthermore, etoposide increased the level of phosphorylated ezrin, radixin and moesin (P-ERM) proteins in the plasma membrane fraction of Caco-2 cells within 10 min.	Etoposide	13-22	moesin	Homo sapiens	80-86
33952826-9	2021	These results suggest that etoposide induces release of CCK, causing activation of the CCK receptor followed by phosphorylation of ERM proteins, which recruit intracellular P-gp for trafficking to the gastrointestinal membrane, thereby increasing the functional activity of P-gp.	Etoposide	27-36	cholecystokinin	Homo sapiens	56-59
33952826-9	2021	These results suggest that etoposide induces release of CCK, causing activation of the CCK receptor followed by phosphorylation of ERM proteins, which recruit intracellular P-gp for trafficking to the gastrointestinal membrane, thereby increasing the functional activity of P-gp.	Etoposide	27-36	ATP binding cassette subfamily B member 1	Homo sapiens	173-177
33389482-2	2021	BACKGROUND: A combination of etoposide (VP-16) and cisplatin (CDDP) is the standard treatment for certain colon cancers.	Etoposide	29-38	host cell factor C1	Homo sapiens	40-45
33368642-1	2021	Etoposide-induced 2.4 (EI24) exerts tumor suppressor activity through participating in cell apoptosis, autophagy, and inflammation.	Etoposide	0-9	etoposide induced 2.4 mRNA	Mus musculus	23-27
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily M member 7	Homo sapiens	0-5
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily V member 1	Homo sapiens	69-74
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily M member 2	Homo sapiens	76-81
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily A member 1	Homo sapiens	83-88
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily C member 5	Homo sapiens	90-95
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily V member 4	Homo sapiens	97-102
32948812-6	2021	TRPM7 gene expression levels were similar in both cell lines whereas TRPV1, TRPM2, TRPA1, TRPC5, TRPV4, and TRPM8 gene expression levels were downregulated in the etoposide-resistant WERI-Rb1 cells.	Etoposide	163-172	transient receptor potential cation channel subfamily M member 8	Homo sapiens	108-113
32948812-7	2021	In the presence of extracellular Ca2+, 1 mM Asc induced larger intracellular Ca2+ transients in the etoposide-resistant WERI-Rb1 than in their etoposide-sensitive counterpart.	Etoposide	100-109	RB transcriptional corepressor 1	Homo sapiens	125-128
33206996-3	2021	Using the human promyelocytic cell line HL-60 as a model, we found that overexpression of patient-derived JAGN1 mutants, but not silencing of JAGN1, augmented cell death in response to the pro-apoptotic stimuli, etoposide, staurosporine, and thapsigargin.	Etoposide	212-221	jagunal homolog 1	Homo sapiens	106-111
33278510-10	2021	In agreement with these findings, experiments conducted in cells and in mice treated with etoposide showed irreversible inhibition of endogenous CREBBP activity and decreased H3K18 and H3K27 acetylation.	Etoposide	90-99	CREB binding protein	Mus musculus	145-151
33935126-0	2021	Impact of RARalpha and miR-138 on retinoblastoma etoposide resistance.	Etoposide	49-58	retinoic acid receptor alpha	Homo sapiens	10-18
33935126-5	2021	METHODS: RARalpha and miR-138 expression in etoposide resistant RB cell lines and chemotherapy treated patient tumors compared to non-treated tumors was revealed by Real-Time PCR.	Etoposide	44-53	retinoic acid receptor alpha	Homo sapiens	9-17
33935126-9	2021	The study presented revealed that RARalpha is downregulated in etoposide resistant RB cells, while miR-138 is endogenously upregulated.	Etoposide	63-72	retinoic acid receptor alpha	Homo sapiens	34-42
33935126-11	2021	Overexpression of RARalpha increases apoptosis levels and reduces tumor cell growth of aggressive etoposide resistant RB cells in vitro and in vivo.	Etoposide	98-107	retinoic acid receptor alpha	Homo sapiens	18-26
33935126-13	2021	CONCLUSIONS: Our findings show that RARalpha acts as a tumor suppressor in retinoblastoma and is downregulated upon etoposide resistance in RB cells.	Etoposide	116-125	retinoic acid receptor alpha	Homo sapiens	36-44
33097595-6	2020	More importantly, mouse embryonic fibroblasts (MEFs) expressing the SMURF2 S384A mutant show a weakened ability to sustain the DSB response compared to those expressing wild type SMURF2 following etoposide treatment.	Etoposide	196-205	SMAD specific E3 ubiquitin protein ligase 2	Mus musculus	68-74
33510870-5	2021	Molecular docking simulations of known ABCB5 substrates such as taxanes, anthracyclines, camptothecin and etoposide were then used to identify at least three putative binding sites for chemotherapeutic drugs transported by ABCB5.	Etoposide	106-115	ATP-binding cassette, sub-family B (MDR/TAP), member 5	Mus musculus	39-44
33510870-5	2021	Molecular docking simulations of known ABCB5 substrates such as taxanes, anthracyclines, camptothecin and etoposide were then used to identify at least three putative binding sites for chemotherapeutic drugs transported by ABCB5.	Etoposide	106-115	ATP-binding cassette, sub-family B (MDR/TAP), member 5	Mus musculus	223-228
33257682-4	2020	Knocking down ASH2L in these cells and in the NT2D1 testicular cancer cell line rendered them resistant to bleomycin, etoposide, and cisplatin but did not affect their sensitivity toward ATM or ATR inhibitors.	Etoposide	118-127	ASH2 like, histone lysine methyltransferase complex subunit	Homo sapiens	14-19
33257565-2	2020	Here, we report that HCMV infection or treatment of ARPE-19 diploid epithelial cells with DNA-damaging agents, etoposide or zeocin, induces HSATII RNA expression, and a kinase-independent function of ATM is required for the induction.	Etoposide	111-120	ATM serine/threonine kinase	Homo sapiens	200-203
33284891-12	2020	As of September 12, 2020, the patient has undergone four cycles of VIP (etoposide, ifosfamide, cisplatin) chemotherapy after relapse, and the patient"s condition is currently in partial remission.	Etoposide	72-81	vasoactive intestinal peptide	Homo sapiens	67-70
32945942-3	2020	The ICE (ifosfamide, cyclophosphamide, and etoposide) regimen is often used as salvage therapy for r/r DLBCL.	Etoposide	43-52	carboxylesterase 2	Homo sapiens	4-7
33203838-7	2020	In contrast, overexpression of GARP promoted their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide, doxorubicin, and irradiation.	Etoposide	150-159	leucine rich repeat containing 32	Homo sapiens	31-35
33174633-8	2021	Low-intensity pulsed ultrasound only increased the expression level of IgM in the docetaxel group but decreased the level of interleukin 6 in the etoposide group (P < .05).	Etoposide	146-155	interleukin 6	Rattus norvegicus	125-138
32866497-5	2020	Further, we found that FAM122A deletion greatly increases TOP2alpha protein level, and significantly and specifically enhances TOP2 poisons (etoposide and doxorubicin)-induced DNA damage effects in cancer cells.	Etoposide	141-150	PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1	Homo sapiens	23-30
32939879-0	2020	A DNA repair player, ring-finger protein 43, relieves etoposide-induced topoisomerase II poisoning.	Etoposide	54-63	ring finger protein 43	Homo sapiens	21-43
32939879-6	2020	However, after exposure to various types of DNA damaging agents, RNF43-/- cells become more sensitive to topoisomerase II inhibitors, etoposide, and ICRF193, than wild type cells.	Etoposide	134-143	ring finger protein 43	Gallus gallus	65-70
32939879-7	2020	Our results also showed that depletion of RNF43 results in apoptosis upon etoposide-mediated DNA damage.	Etoposide	74-83	ring finger protein 43	Gallus gallus	42-47
32939879-8	2020	The delay in resolution of gammaH2AX and 53BP1 foci formation after etoposide treatment, as well as epistasis analysis with DNAPKcs suggested that RNF43 might participates in DNA repair of etoposide-induced DSB via non-homologous end joining.	Etoposide	68-77	ring finger protein 43	Gallus gallus	147-152
32939879-8	2020	The delay in resolution of gammaH2AX and 53BP1 foci formation after etoposide treatment, as well as epistasis analysis with DNAPKcs suggested that RNF43 might participates in DNA repair of etoposide-induced DSB via non-homologous end joining.	Etoposide	189-198	ring finger protein 43	Gallus gallus	147-152
32939879-9	2020	Disturbed gammaH2AX foci formation in MEFs following pulse etoposide treatment supported the notion that RNF43 also functions DNA repair in mammalian cells.	Etoposide	59-68	ring finger protein 43	Homo sapiens	105-110
32901871-5	2020	In the present study, we demonstrated that shRNA-mediated CHK1 silencing suppressed cell proliferation and enhanced the cytotoxic effects of etoposide (VP16) in the chronic myeloid leukemia (CML) cell line K562 through the results of CCK-8, and comet assay.	Etoposide	141-150	checkpoint kinase 1	Homo sapiens	58-62
32901871-5	2020	In the present study, we demonstrated that shRNA-mediated CHK1 silencing suppressed cell proliferation and enhanced the cytotoxic effects of etoposide (VP16) in the chronic myeloid leukemia (CML) cell line K562 through the results of CCK-8, and comet assay.	Etoposide	152-156	checkpoint kinase 1	Homo sapiens	58-62
32901871-8	2020	Second, we tested the therapeutic effect of VP16 combined with CCT245737, an orally bioavailable CHK1 inhibitor, and observed strong synergistic anticancer effects in K562 cells.	Etoposide	44-48	checkpoint kinase 1	Homo sapiens	97-101
33099543-13	2021	In this pilot study including few patients by subgroups, patients with KRAS (HR=3.60, 95%CI [1.06-12.04]) and BRAF (HR=4.25, 95%CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide, while the two patients with RB1 mutations had shorter PFS under FOLFIRI-based chemotherapy.	Etoposide	214-223	KRAS proto-oncogene, GTPase	Homo sapiens	71-75
33121007-1	2020	CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours.	Etoposide	66-75	carboxylesterase 2	Homo sapiens	80-98
33121007-1	2020	CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours.	Etoposide	66-75	carboxylesterase 2	Homo sapiens	100-104
33097055-0	2020	Lactate-induced MRP1 expression contributes to metabolism-based etoposide resistance in non-small cell lung cancer cells.	Etoposide	64-73	ATP binding cassette subfamily C member 1	Homo sapiens	16-20
33097055-8	2020	RESULTS: Here we showed that exposure to chemotherapeutic drug etoposide induces an exacerbation of ROS production which activates HIF-1alpha-mediated the metabolic reprogramming toward increased glycolysis and lactate production in non-small cell lung cancer (NSCLC).	Etoposide	63-72	hypoxia inducible factor 1 subunit alpha	Homo sapiens	131-141
33097055-14	2020	The increased lactic acid in extracellular environment plays important role in etoposide resistance through upregulation of MRP expression.	Etoposide	79-88	ATP binding cassette subfamily C member 1	Homo sapiens	124-127
33099543-13	2021	In this pilot study including few patients by subgroups, patients with KRAS (HR=3.60, 95%CI [1.06-12.04]) and BRAF (HR=4.25, 95%CI [1.11-16.40]) mutations had shorter progression-free survival (PFS) under platinum-etoposide, while the two patients with RB1 mutations had shorter PFS under FOLFIRI-based chemotherapy.	Etoposide	214-223	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	110-114
33085644-4	2020	Here, we assessed the expression of several HSP70- and HSP90-related factors under various stresses and found that BAG5 expression is distinctively elevated in etoposide- or H2O2-treated SH-SY5Y cells.	Etoposide	160-169	heat shock protein family A (Hsp70) member 4	Homo sapiens	44-49
33101710-10	2020	Moreover, SEMGs (especially SEMG1) strongly increased the number of Annexin V-positive apoptotic cells manifesting an increased sensitivity to genotoxic drugs including doxorubicin, etoposide, and cisplatin.	Etoposide	182-191	semenogelin 1	Homo sapiens	28-33
33101710-10	2020	Moreover, SEMGs (especially SEMG1) strongly increased the number of Annexin V-positive apoptotic cells manifesting an increased sensitivity to genotoxic drugs including doxorubicin, etoposide, and cisplatin.	Etoposide	182-191	annexin A5	Homo sapiens	68-77
33085644-4	2020	Here, we assessed the expression of several HSP70- and HSP90-related factors under various stresses and found that BAG5 expression is distinctively elevated in etoposide- or H2O2-treated SH-SY5Y cells.	Etoposide	160-169	BAG cochaperone 5	Homo sapiens	115-119
33017104-5	2020	TRIM29 triallelic knockout (TRIM29-/-/-/+) cells were sensitive to etoposide, but resistant to camptothecin.	Etoposide	67-76	tripartite motif containing 29	Gallus gallus	0-6
33194045-12	2020	Additionally, knockdown of caspase-8 reduced the doxorubicin, carboplatin, cisplatin, and etoposide sensitivity towards A549 cells.	Etoposide	90-99	caspase 8	Homo sapiens	27-36
32584450-0	2020	Prostate cancer cells modulate the differentiation of THP-1 cells in response to etoposide and TLR agonists treatments.	Etoposide	81-90	GLI family zinc finger 2	Homo sapiens	54-59
32584450-7	2020	In co-culture methods, Our results demonstrate that the apoptosis of etoposide-treated cancer cells increases in the presence of M0 macrophages and THP-1 cells incubated with the supernatant of TLR4 agonists-treated PC3 cells.	Etoposide	69-78	GLI family zinc finger 2	Homo sapiens	148-153
32584450-7	2020	In co-culture methods, Our results demonstrate that the apoptosis of etoposide-treated cancer cells increases in the presence of M0 macrophages and THP-1 cells incubated with the supernatant of TLR4 agonists-treated PC3 cells.	Etoposide	69-78	toll like receptor 4	Homo sapiens	194-198
32584450-8	2020	These results evidence for clear protective effects of M0 macrophages and THP-1 cells incubated with the supernatant of PC3 cells treated with TLR4 agonists (THP-1+SUP+TLR4a) on etoposide-induced cancer cell apoptosis.	Etoposide	178-187	GLI family zinc finger 2	Homo sapiens	74-79
32584450-8	2020	These results evidence for clear protective effects of M0 macrophages and THP-1 cells incubated with the supernatant of PC3 cells treated with TLR4 agonists (THP-1+SUP+TLR4a) on etoposide-induced cancer cell apoptosis.	Etoposide	178-187	toll like receptor 4	Homo sapiens	143-147
32584450-8	2020	These results evidence for clear protective effects of M0 macrophages and THP-1 cells incubated with the supernatant of PC3 cells treated with TLR4 agonists (THP-1+SUP+TLR4a) on etoposide-induced cancer cell apoptosis.	Etoposide	178-187	GLI family zinc finger 2	Homo sapiens	158-163
33076532-0	2020	Nonhistone Proteins HMGB1 and HMGB2 Differentially Modulate the Response of Human Embryonic Stem Cells and the Progenitor Cells to the Anticancer Drug Etoposide.	Etoposide	151-160	high mobility group box 1	Homo sapiens	20-25
33076532-0	2020	Nonhistone Proteins HMGB1 and HMGB2 Differentially Modulate the Response of Human Embryonic Stem Cells and the Progenitor Cells to the Anticancer Drug Etoposide.	Etoposide	151-160	high mobility group box 2	Homo sapiens	30-35
33076532-1	2020	HMGB1 and HMGB2 proteins are abundantly expressed in human embryonic stem cells (hESCs) and hESC-derived progenitor cells (neuroectodermal cells, hNECs), though their functional roles in pluripotency and the mechanisms underlying their differentiation in response to the anticancer drug etoposide remain to be elucidated.	Etoposide	287-296	high mobility group box 1	Homo sapiens	0-5
33076532-1	2020	HMGB1 and HMGB2 proteins are abundantly expressed in human embryonic stem cells (hESCs) and hESC-derived progenitor cells (neuroectodermal cells, hNECs), though their functional roles in pluripotency and the mechanisms underlying their differentiation in response to the anticancer drug etoposide remain to be elucidated.	Etoposide	287-296	high mobility group box 2	Homo sapiens	10-15
33076532-3	2020	The objective of this work was to determine whether HMGB1/2 proteins could modulate the sensitivity of hESCs and hESC-derived progenitor cells (hNECs) to etoposide.	Etoposide	154-163	high mobility group box 1	Homo sapiens	52-59
33076532-4	2020	We observed that HMGB1 KD knockdown (KD) and, to a lesser extent, HMGB2 KD enhanced the sensitivity of hESCs to etoposide.	Etoposide	112-121	high mobility group box 1	Homo sapiens	17-22
33076532-4	2020	We observed that HMGB1 KD knockdown (KD) and, to a lesser extent, HMGB2 KD enhanced the sensitivity of hESCs to etoposide.	Etoposide	112-121	high mobility group box 2	Homo sapiens	66-71
33076532-5	2020	Enhanced accumulation of 53BP1 on telomeres was detected by confocal microscopy in both untreated and etoposide-treated HMGB1 KD hESCs and hNECs, indicating that the loss of HMGB1 could destabilize telomeres.	Etoposide	102-111	high mobility group box 1	Homo sapiens	120-125
33076532-5	2020	Enhanced accumulation of 53BP1 on telomeres was detected by confocal microscopy in both untreated and etoposide-treated HMGB1 KD hESCs and hNECs, indicating that the loss of HMGB1 could destabilize telomeres.	Etoposide	102-111	high mobility group box 1	Homo sapiens	174-179
33076532-6	2020	On the other hand, decreased accumulation of 53BP1 on telomeres in etoposide-treated HMGB2 KD hESCs (but not in HMGB2 KD hNECs) suggested that the loss of HMGB2 promoted the stability of telomeres.	Etoposide	67-76	high mobility group box 2	Homo sapiens	85-90
33076532-7	2020	Etoposide treatment of hESCs resulted in a significant enhancement of telomerase activity, with the highest increase observed in the HMGB2 KD cells.	Etoposide	0-9	high mobility group box 2	Homo sapiens	133-138
33076532-9	2020	Changes in telomerase activity in the etoposide-treated HMGB2 KD hESCs or hNECs coincided with the appearance of DNA damage markers and could already be observed before the onset of apoptosis.	Etoposide	38-47	high mobility group box 2	Homo sapiens	56-61
33076532-10	2020	Collectively, we have demonstrated that HMGB1 or HMGB2 differentially modulate the impact of etoposide treatment on human embryonic stem cells and their progenitor cells, suggesting possible strategies for the enhancement of the efficacy of this anticancer drug.	Etoposide	93-102	high mobility group box 1	Homo sapiens	40-45
33076532-10	2020	Collectively, we have demonstrated that HMGB1 or HMGB2 differentially modulate the impact of etoposide treatment on human embryonic stem cells and their progenitor cells, suggesting possible strategies for the enhancement of the efficacy of this anticancer drug.	Etoposide	93-102	high mobility group box 2	Homo sapiens	49-54
33130749-3	2020	Bleomycin, etoposide, and cisplatin(BEP)chemotherapy resulted decreased his serum AFP.	Etoposide	11-20	alpha fetoprotein	Homo sapiens	82-85
33017104-5	2020	TRIM29 triallelic knockout (TRIM29-/-/-/+) cells were sensitive to etoposide, but resistant to camptothecin.	Etoposide	67-76	tripartite motif containing 29	Gallus gallus	28-34
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	86-95	H2A histone family, member X	Gallus gallus	119-146
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	86-95	tripartite motif containing 29	Gallus gallus	181-187
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	86-95	tumor protein p53 binding protein 1	Gallus gallus	241-279
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	86-95	tripartite motif containing 29	Gallus gallus	296-302
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	223-232	H2A histone family, member X	Gallus gallus	119-146
33017104-6	2020	Foci formation assays to assess DNA repair activities showed that the dissociation of etoposide-induced phosphorylated H2A histone family member X (gamma-H2AX) foci was retained in TRIM29-/-/-/+ cells, and the formation of etoposide-induced tumor suppressor p53-binding protein 1 (53BP1) foci in TRIM29-/-/-/+ cells was slower compared with wild-type (WT) cells.	Etoposide	223-232	tripartite motif containing 29	Gallus gallus	181-187
33074323-11	2020	Programmed cell death ligand 1 (PD-L1) inhibitor (durvalumab and atezolizumab) plus etoposide-based chemotherapy, compared with etoposide-based chemotherapy alone, showed the most favorable OS (hazard ratio, 1.40; 95% CI, 1.09-1.80) and the best DCR (odds ratio [OR], 0.42; 95% CI, 0.21-0.81).	Etoposide	84-93	CD274 molecule	Homo sapiens	0-30
33074323-11	2020	Programmed cell death ligand 1 (PD-L1) inhibitor (durvalumab and atezolizumab) plus etoposide-based chemotherapy, compared with etoposide-based chemotherapy alone, showed the most favorable OS (hazard ratio, 1.40; 95% CI, 1.09-1.80) and the best DCR (odds ratio [OR], 0.42; 95% CI, 0.21-0.81).	Etoposide	84-93	CD274 molecule	Homo sapiens	32-37
33074323-11	2020	Programmed cell death ligand 1 (PD-L1) inhibitor (durvalumab and atezolizumab) plus etoposide-based chemotherapy, compared with etoposide-based chemotherapy alone, showed the most favorable OS (hazard ratio, 1.40; 95% CI, 1.09-1.80) and the best DCR (odds ratio [OR], 0.42; 95% CI, 0.21-0.81).	Etoposide	128-137	CD274 molecule	Homo sapiens	0-30
33074323-11	2020	Programmed cell death ligand 1 (PD-L1) inhibitor (durvalumab and atezolizumab) plus etoposide-based chemotherapy, compared with etoposide-based chemotherapy alone, showed the most favorable OS (hazard ratio, 1.40; 95% CI, 1.09-1.80) and the best DCR (odds ratio [OR], 0.42; 95% CI, 0.21-0.81).	Etoposide	128-137	CD274 molecule	Homo sapiens	32-37
32671611-3	2020	Cell proliferation analysis and Flow cytometry analysis were utilized to detect TRAF4"s function on the growth-inhibitory effect of etoposide.	Etoposide	132-141	TNF receptor associated factor 4	Homo sapiens	80-85
32966352-9	2020	In extensive stage small cell lung cancer the platinum-etoposide treatment with PD-L1 inhibitor is a new standard, but we do not have any effective biomarkers yet.	Etoposide	55-64	CD274 molecule	Homo sapiens	80-85
31885313-0	2020	Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.	Etoposide	11-28	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	36-42
31885313-0	2020	Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.	Etoposide	11-28	3-phosphoinositide dependent protein kinase 1	Homo sapiens	43-48
31885313-0	2020	Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.	Etoposide	11-28	AKT serine/threonine kinase 1	Homo sapiens	94-97
31885313-0	2020	Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.	Etoposide	11-28	mechanistic target of rapamycin kinase	Homo sapiens	98-102
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	66-72
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	3-phosphoinositide dependent protein kinase 1	Homo sapiens	73-78
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	AKT serine/threonine kinase 1	Homo sapiens	90-93
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	mechanistic target of rapamycin kinase	Homo sapiens	94-98
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	beclin 1	Homo sapiens	232-237
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	mechanistic target of rapamycin kinase	Homo sapiens	506-510
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	3-phosphoinositide dependent protein kinase 1	Homo sapiens	552-557
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	605-611
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Etoposide	42-59	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	612-617
32671611-8	2020	TRAF4 reduced the growth-inhibitory effect of etoposide via reducing the number of S-phase cells and suppressing cell apoptosis.	Etoposide	46-55	TNF receptor associated factor 4	Homo sapiens	0-5
32820040-4	2020	MYCN overexpression also suppressed response to cisplatin-etoposide chemotherapy, with similar findings made upon MYCL overexpression.	Etoposide	58-67	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	0-4
32974192-3	2020	Previously, we demonstrated that etoposide-induced 2.4-kb mRNA (EI24) is the target of miR-483-3p, which promoted the growth, migration, and drug resistance in ESCC, suggesting that EI24 participates in repressing the tumorigenesis and progression of ESCC.	Etoposide	33-42	EI24 autophagy associated transmembrane protein	Homo sapiens	64-68
32599072-9	2020	Combining mTOR inhibition with cisplatin/etoposide decreased PDX tumor volume 96% compared to cisplatin/etoposide alone at 70 days (P<0.002).	Etoposide	104-113	mechanistic target of rapamycin kinase	Homo sapiens	10-14
32974192-3	2020	Previously, we demonstrated that etoposide-induced 2.4-kb mRNA (EI24) is the target of miR-483-3p, which promoted the growth, migration, and drug resistance in ESCC, suggesting that EI24 participates in repressing the tumorigenesis and progression of ESCC.	Etoposide	33-42	EI24 autophagy associated transmembrane protein	Homo sapiens	182-186
32248578-0	2020	Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.	Etoposide	105-114	thioredoxin	Homo sapiens	0-13
32762742-5	2020	A prompt rebiopsy revealed a rare mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitor, and subsequently treatment with carboplatin and etoposide was effective.	Etoposide	169-178	epidermal growth factor receptor	Homo sapiens	61-93
32750061-6	2020	Genotoxicity assay was performed to detect the sensitivity of APTX mutated cells to H2O2, MMC, MMS and etoposide.	Etoposide	103-112	aprataxin	Homo sapiens	62-66
32248578-6	2020	RESULTS: Trx1 knockdown sensitised DLBCL cells to doxorubicin (p < 0.0001) but decreased etoposide-induced cell death (p < 0.00001).	Etoposide	89-98	thioredoxin	Homo sapiens	9-13
32248578-7	2020	In DLBCL patients who received etoposide containing frontline treatment, low cytoplasmic Trx1 expression was associated with inferior five-year overall survival (46% vs 76%, p = 0.026) and disease-specific survival (68% vs 90%, p = 0.026).	Etoposide	31-40	thioredoxin	Homo sapiens	89-93
32248578-8	2020	CONCLUSIONS: Strong Trx1 expression appears to increase drug resistance to doxorubicin but sensitises cells to etoposide.	Etoposide	111-120	thioredoxin	Homo sapiens	20-24
32248578-9	2020	This implies that Trx1 expression might be the first predictive biological marker to select the patients who might benefit from adding etoposide to R-CHOP immunochemotherapy.	Etoposide	135-144	thioredoxin	Homo sapiens	18-22
32268442-1	2020	The use of dexamethasone plus thalidomide in combination with a continuous infusion of cisplatin, doxorubicin, cyclophosphamide, and etoposide (DTPACE) was first described in relapsed myeloma (MM) and showed effectiveness as induction therapy before autologous stem cell transplant (ASCT)1 .	Etoposide	133-142	solute carrier family 1 member 4	Homo sapiens	283-289
32615949-0	2020	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.	Etoposide	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	19-32
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	interleukin 6	Homo sapiens	286-290
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	interleukin 10	Homo sapiens	292-297
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	C-X-C motif chemokine ligand 8	Homo sapiens	299-303
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	C-C motif chemokine ligand 2	Homo sapiens	305-310
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	interferon gamma	Homo sapiens	312-321
32238729-4	2020	Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient"s general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-gamma, and TNF-alpha declined after etoposide administration.	Etoposide	164-173	tumor necrosis factor	Homo sapiens	327-336
32801749-9	2020	It follows that PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) regimen may be a promising choice for patients with R/R ENKTL and warrants further investigation.	Etoposide	42-51	programmed cell death 1	Homo sapiens	16-20
31560739-7	2020	Moreover, anchorage-independent growth of GC cells was decreased and the cells became more sensitive to 5-fluorouracil and etoposide treatment when CLIC4 was overexpressed.	Etoposide	123-132	chloride intracellular channel 4	Homo sapiens	148-153
32501506-5	2020	We also observed an enrichment of DNA secondary structure-prone sites overlapping transcription start sites (TSSs) and CCCTC-binding factor (CTCF) binding sites, and uncovered an increase in DSBs at highly stable DNA secondary structure regions, in response to etoposide, an inhibitor of topoisomerase II (TOP2) re-ligation activity.	Etoposide	261-270	CCCTC-binding factor	Homo sapiens	119-139
32501506-5	2020	We also observed an enrichment of DNA secondary structure-prone sites overlapping transcription start sites (TSSs) and CCCTC-binding factor (CTCF) binding sites, and uncovered an increase in DSBs at highly stable DNA secondary structure regions, in response to etoposide, an inhibitor of topoisomerase II (TOP2) re-ligation activity.	Etoposide	261-270	CCCTC-binding factor	Homo sapiens	141-145
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	65-70
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	C-X-C motif chemokine ligand 8	Homo sapiens	111-115
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	307-312
32615949-10	2020	CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	307-312
32662244-5	2020	Time-lapse fluorescence microscopy using an endogenous p16-mCherry reporter revealed that serum starvation, etoposide, and hydrogen peroxide stimulate autophagy and drive p16 recruitment to acidic cytoplasmic vesicles within 4 hr.	Etoposide	108-117	cyclin dependent kinase inhibitor 2A	Homo sapiens	55-58
32662244-5	2020	Time-lapse fluorescence microscopy using an endogenous p16-mCherry reporter revealed that serum starvation, etoposide, and hydrogen peroxide stimulate autophagy and drive p16 recruitment to acidic cytoplasmic vesicles within 4 hr.	Etoposide	108-117	cyclin dependent kinase inhibitor 2A	Homo sapiens	171-174
32615949-5	2020	RESULTS: Retrospective analysis of the clinical data revealed that the etoposide with G-CSF mobilization group showed the highest yield of CD34+ cells and the lowest change in white blood cell counts during mobilization.	Etoposide	71-80	colony stimulating factor 3	Homo sapiens	86-91
32615949-5	2020	RESULTS: Retrospective analysis of the clinical data revealed that the etoposide with G-CSF mobilization group showed the highest yield of CD34+ cells and the lowest change in white blood cell counts during mobilization.	Etoposide	71-80	CD34 molecule	Homo sapiens	139-143
32615949-6	2020	In in vitro experiments, etoposide triggered interleukin (IL)-8 secretion from the BMSCs and caused long-term BMSC toxicity.	Etoposide	25-34	C-X-C motif chemokine ligand 8	Homo sapiens	45-63
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	23-32	colony stimulating factor 3	Homo sapiens	38-43
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	23-32	C-X-C motif chemokine ligand 8	Homo sapiens	80-84
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	23-32	matrix metallopeptidase 9	Homo sapiens	106-110
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	23-32	C-X-C motif chemokine ligand 12	Homo sapiens	132-137
32615949-9	2020	In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide.	Etoposide	200-209	colony stimulating factor 3	Homo sapiens	38-43
32376439-3	2020	The present study investigated if the BCS IV drug substance etoposide could be solubilized to a concentration saturating P-gp after oral administration.	Etoposide	60-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	121-125
32528131-6	2020	Loss of RPS11 led to resistance to etoposide and doxorubicin and impaired the induction of proapoptotic gene APAF1 following treatment.	Etoposide	35-44	ribosomal protein S11	Homo sapiens	8-13
32145118-0	2020	Mec (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplantat in acute myeloid leukemia.	Etoposide	19-28	C-C motif chemokine ligand 28	Homo sapiens	0-3
32576812-5	2020	Cells with defective hSSB1 SUMOylation are sensitive to ionizing radiation, and global inhibition of SUMOylation by either knocking out UBC9 or adding SUMOylation inhibitors significantly enhances the sensitivity of cancer cells to etoposide.	Etoposide	232-241	nucleic acid binding protein 2	Homo sapiens	21-26
32404568-1	2020	Methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide (MTX-HOPE) chemotherapy was originally reported in 2007 as a salvage regimen for relapsed or refractory non-Hodgkin"s lymphoma.	Etoposide	59-68	metaxin 1	Homo sapiens	70-73
32560557-0	2020	Expression Changes and Impact of the Extracellular Matrix on Etoposide Resistant Human Retinoblastoma Cell Lines.	Etoposide	61-70	RB transcriptional corepressor 1	Homo sapiens	87-101
32560557-10	2020	Downregulation of Brevican, Collagen IV, Tenascin-R, MMP2, TIMP2, and ITGA5 was also verified in Etoposide resistant Y79 cells compared to sensitive ones.	Etoposide	97-106	tenascin R	Homo sapiens	41-51
32560557-10	2020	Downregulation of Brevican, Collagen IV, Tenascin-R, MMP2, TIMP2, and ITGA5 was also verified in Etoposide resistant Y79 cells compared to sensitive ones.	Etoposide	97-106	matrix metallopeptidase 2	Homo sapiens	53-57
32560557-10	2020	Downregulation of Brevican, Collagen IV, Tenascin-R, MMP2, TIMP2, and ITGA5 was also verified in Etoposide resistant Y79 cells compared to sensitive ones.	Etoposide	97-106	TIMP metallopeptidase inhibitor 2	Homo sapiens	59-64
32560557-10	2020	Downregulation of Brevican, Collagen IV, Tenascin-R, MMP2, TIMP2, and ITGA5 was also verified in Etoposide resistant Y79 cells compared to sensitive ones.	Etoposide	97-106	integrin subunit alpha 5	Homo sapiens	70-75
32549188-8	2020	Loss of POLA2 also slows DSB repair kinetics after treatment with etoposide and inhibits both of the major double strand break repair pathways: non-homologous end-joining and homologous recombination.	Etoposide	66-75	DNA polymerase alpha 2, accessory subunit	Homo sapiens	8-13
32414923-7	2020	Treatments with drugs used to poison/inhibit TOP2A function, such as etoposide and ICRF-193, do not phenocopy the effects on chromosome structure of TOP2A degradation by AID.	Etoposide	69-78	DNA topoisomerase II alpha	Homo sapiens	45-50
32547627-2	2020	Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
32466590-2	2020	Based on our finding that MYSM1 colocalizes with gammaH2AX foci in human peripheral blood mononuclear cells, leukemia cells, and melanoma cells upon induction of DNA double-strand breaks with topoisomerase inhibitor etoposide, we applied a mass spectrometry-based proteomics approach to identify novel 2A-DUB/MYSM1 interaction partners in DNA-damage responses.	Etoposide	216-225	Myb like, SWIRM and MPN domains 1	Homo sapiens	26-31
32466590-3	2020	Differential display of MYSM1 binding proteins significantly enriched after exposure of 293T cells to etoposide revealed an interacting network of proteins involved in DNA damage and replication, including factors associated with poor melanoma outcome.	Etoposide	102-111	Myb like, SWIRM and MPN domains 1	Homo sapiens	24-29
32073751-6	2020	In contrast, overexpression of GARP in ASCs increased their proliferative capacity and rendered them more resistant to etoposide-induced DNA damage and apoptosis, in a TGF-beta-dependent manner.	Etoposide	119-128	leucine rich repeat containing 32	Homo sapiens	31-35
32528464-7	2020	Incubation of healthy and SSc dendritic cells with etoposide, a carnitine transporter inhibitor, inhibited the production of pro-inflammatory cytokines such as IL-6 through inhibition of fatty acid oxidation.	Etoposide	51-60	interleukin 6	Homo sapiens	160-164
32429253-4	2020	Ex vivo response of primary AML blasts towards cytarabine (Ara C), daunorubicin (DNR), etoposide (VP16), and cladribine (2-CdA) was associated with the expression of 101, 345, 206, and 599 genes, respectively (p < 0.001, FDR 0.004-0.416).	Etoposide	87-96	cytidine deaminase	Homo sapiens	123-126
32429253-4	2020	Ex vivo response of primary AML blasts towards cytarabine (Ara C), daunorubicin (DNR), etoposide (VP16), and cladribine (2-CdA) was associated with the expression of 101, 345, 206, and 599 genes, respectively (p < 0.001, FDR 0.004-0.416).	Etoposide	98-102	cytidine deaminase	Homo sapiens	123-126
32109764-4	2020	We demonstrate that "RADAR-MS" can quantify induction of TOP1- or TOP2-DNA adducts in cells treated with topotecan or etoposide, respectively, and also identify intermediates in physiological adduct repair.	Etoposide	118-127	DNA topoisomerase I	Homo sapiens	57-61
32189037-6	2020	CsA shares with ETO activation of CK2 kinase.	Etoposide	16-19	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	0-3
32189037-6	2020	CsA shares with ETO activation of CK2 kinase.	Etoposide	16-19	casein kinase 2, alpha prime polypeptide	Mus musculus	34-37
32216001-6	2020	To test this hypothesis, we detected gene rearrangements in etoposide-treated or non-treated CD34+ cells cultured with cytokines using inverse PCR.	Etoposide	60-69	CD34 molecule	Homo sapiens	93-97
32216001-7	2020	In the etoposide-treated cells, variable-sized rearrangement bands were detected in the RUNX1 and MLL genes at 3 h of culture, which decreased after 7 days.	Etoposide	7-16	RUNX family transcription factor 1	Homo sapiens	88-93
32216001-7	2020	In the etoposide-treated cells, variable-sized rearrangement bands were detected in the RUNX1 and MLL genes at 3 h of culture, which decreased after 7 days.	Etoposide	7-16	lysine methyltransferase 2A	Homo sapiens	98-101
32006654-5	2020	Single cell gel electrophoresis assay and H2DCFDA analysis revealed that the expression of ALDH3A1 protected HCE-2 cells from H2O2-, tert-butyl peroxide- and etoposide-induced oxidative and genotoxic effects.	Etoposide	158-167	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	91-98
32332775-4	2020	This interaction was enhanced by treatment with the antineoplastic drug etoposide, which suggests a role for the IL-1alpha p53 interaction in genotoxic stress.	Etoposide	72-81	interleukin 1 alpha	Homo sapiens	113-122
32332775-4	2020	This interaction was enhanced by treatment with the antineoplastic drug etoposide, which suggests a role for the IL-1alpha p53 interaction in genotoxic stress.	Etoposide	72-81	tumor protein p53	Homo sapiens	123-126
32112707-5	2020	In a small sample size, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) achieved better outcomes than a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).	Etoposide	24-33	DNA damage inducible transcript 3	Homo sapiens	231-235
32006654-5	2020	Single cell gel electrophoresis assay and H2DCFDA analysis revealed that the expression of ALDH3A1 protected HCE-2 cells from H2O2-, tert-butyl peroxide- and etoposide-induced oxidative and genotoxic effects.	Etoposide	158-167	carboxylesterase 2	Homo sapiens	109-114
32145932-6	2020	Functional effects of mutations on MCM9 were explored based on etoposide-induced DNA damage response, and DNA repair capacity was evaluated by histone H2AX phosphorylation level.	Etoposide	63-72	minichromosome maintenance 9 homologous recombination repair factor	Homo sapiens	35-39
31030314-3	2020	They exhibited better cytostatic effects than etoposide (GI50 = 0.56-36.62 muM), parthenolide (GI50 = 3.58-25.97 muM) and VK3 (GI50 = 3.41-22.59 muM) against several of the cancer cell lines.	Etoposide	46-55	latexin	Homo sapiens	75-78
32032616-9	2020	Lower levels of inflammatory cytokines, ROS, MMP-2, RANKL, OPN and plasmin reflected less severe arthritic destruction after etoposide treatment in arthritic mice.	Etoposide	125-134	secreted phosphoprotein 1	Mus musculus	59-62
32032616-9	2020	Lower levels of inflammatory cytokines, ROS, MMP-2, RANKL, OPN and plasmin reflected less severe arthritic destruction after etoposide treatment in arthritic mice.	Etoposide	125-134	matrix metallopeptidase 2	Mus musculus	45-50
32032616-9	2020	Lower levels of inflammatory cytokines, ROS, MMP-2, RANKL, OPN and plasmin reflected less severe arthritic destruction after etoposide treatment in arthritic mice.	Etoposide	125-134	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	52-57
32252198-1	2020	Objective: To screen the interaction proteins of WW domain containing protein 1 (WWP1), and explore the effects of WWP1 and etoposide induced 24 (EI24) on cell proliferation in hepatocellular carcinoma (HCC).	Etoposide	124-133	EI24 autophagy associated transmembrane protein	Homo sapiens	146-150
31529315-9	2020	Moreover, it sensitized cells to the chemotherapeutic agents such as cisplatin, pemetrexed, and etoposide (VP-16), and this effect by dinaciclib may induce cell cycle arrest via abrogating CDK2 activity.	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
31529315-9	2020	Moreover, it sensitized cells to the chemotherapeutic agents such as cisplatin, pemetrexed, and etoposide (VP-16), and this effect by dinaciclib may induce cell cycle arrest via abrogating CDK2 activity.	Etoposide	96-105	cyclin dependent kinase 2	Homo sapiens	189-193
31917123-6	2020	We administered VIP (etoposide, ifosfamide, cisplatin) chemotherapy for a recurrent liver tumor, and obtained complete pathological remission.	Etoposide	21-30	vasoactive intestinal peptide	Homo sapiens	16-19
31980168-7	2020	A small portion of Dbx1+ cells resided in the VP fraction.	Etoposide	46-48	developing brain homeobox 1	Mus musculus	19-23
32183896-8	2020	CASE PRESENTATION: We presented a case report of a 29-year-old Asian man diagnosed as having stage IV disseminated extranodal natural killer/T cell lymphoma, nasal type, with skin and bone marrow involvement, whose disease was primary refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy, but obviously responded to treatment with two cycles of single-agent pralatrexate treatment.	Etoposide	321-330	asparaginase and isoaspartyl peptidase 1	Homo sapiens	301-315
31915278-15	2020	As RV vaccines cover a narrow range of viral strains, the identification of VP2 L124 residue lays the foundations for the design of drugs that specifically block NSP5-VP2 interaction as a broad-spectrum RV antiviral.	Etoposide	76-84	sperm antigen with calponin homology and coiled-coil domains 1	Homo sapiens	162-166
32193368-5	2020	Using Top2alpha inhibitor (ICRF193 or Etoposide)-treated primary T cells as a model, we demonstrated that disrupting the DNA topology promoted DNA damage and T cell apoptosis via Top2cc accumulation that is associated with protein-DNA breaks (PDB) at genomic DNA.	Etoposide	38-47	DNA topoisomerase II alpha	Homo sapiens	6-15
31980741-4	2020	MEK5 knockdown by RNA interference sensitizes prostate cancer cells to ionizing radiation (IR) and etoposide treatment, as assessed by clonogenic survival and short-term proliferation assays.	Etoposide	99-108	mitogen-activated protein kinase kinase 5	Homo sapiens	0-4
32143590-7	2020	RESULTS: Y79/EDR cells showed resistance to etoposide, carboplatin and vincristine at different concentrations.	Etoposide	44-53	paternally expressed 10	Homo sapiens	13-16
32143590-10	2020	Further studies involving downregulation of ARHGAP9 with a specific siRNA showed that ARHGAP9 altered the cellular sensitivity of Y79 cells to etoposide and carboplatin.	Etoposide	143-152	Rho GTPase activating protein 9	Homo sapiens	44-51
32143590-10	2020	Further studies involving downregulation of ARHGAP9 with a specific siRNA showed that ARHGAP9 altered the cellular sensitivity of Y79 cells to etoposide and carboplatin.	Etoposide	143-152	Rho GTPase activating protein 9	Homo sapiens	86-93
31836624-9	2020	Transfection of K562 cells with miR-9-3p or miR-9-5p mimics led to decreased TOP2alpha/170 protein levels without a change in TOP2alpha/170 mRNA, and resulted in attenuated etoposide-induced DNA damage (gain-of-miRNA-inhibitory function).	Etoposide	173-182	microRNA 9-3	Homo sapiens	32-40
31836624-9	2020	Transfection of K562 cells with miR-9-3p or miR-9-5p mimics led to decreased TOP2alpha/170 protein levels without a change in TOP2alpha/170 mRNA, and resulted in attenuated etoposide-induced DNA damage (gain-of-miRNA-inhibitory function).	Etoposide	173-182	microRNA 95	Homo sapiens	44-52
31836624-10	2020	Conversely, transfection of miR-9-3p or miR-9-5p inhibitors in K/VP.5 cells (overexpressed miR-9 and low TOP2alpha/170) led to increased TOP2alpha/170 protein expression without a change in TOP2alpha/170 mRNA, and resulted in enhancement of etoposide-induced DNA damage (loss-of-miRNA-inhibitory function).	Etoposide	241-250	microRNA 9-3	Homo sapiens	28-36
31836624-10	2020	Conversely, transfection of miR-9-3p or miR-9-5p inhibitors in K/VP.5 cells (overexpressed miR-9 and low TOP2alpha/170) led to increased TOP2alpha/170 protein expression without a change in TOP2alpha/170 mRNA, and resulted in enhancement of etoposide-induced DNA damage (loss-of-miRNA-inhibitory function).	Etoposide	241-250	microRNA 95	Homo sapiens	40-48
31836624-12	2020	SIGNIFICANCE STATEMENT: Results presented here indicate that miR-9-3p and miR-9-5p decrease TOP2alpha/170 expression levels in acquired resistance to etoposide.	Etoposide	150-159	microRNA 9-3	Homo sapiens	61-69
31836624-12	2020	SIGNIFICANCE STATEMENT: Results presented here indicate that miR-9-3p and miR-9-5p decrease TOP2alpha/170 expression levels in acquired resistance to etoposide.	Etoposide	150-159	microRNA 95	Homo sapiens	74-82
31836624-12	2020	SIGNIFICANCE STATEMENT: Results presented here indicate that miR-9-3p and miR-9-5p decrease TOP2alpha/170 expression levels in acquired resistance to etoposide.	Etoposide	150-159	DNA topoisomerase II alpha	Homo sapiens	92-101
31527828-8	2020	Moreover, downregulation of HADHA increased the susceptibility to doxorubicin (P = 0.002) and etoposide (P = 0.004).	Etoposide	94-103	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha	Homo sapiens	28-33
31980741-5	2020	Mechanistically, MEK5 downregulation impairs phosphorylation of the catalytic subunit of DNA-PK at serine 2056 in response to IR or etoposide treatment.	Etoposide	132-141	mitogen-activated protein kinase kinase 5	Homo sapiens	17-21
30620620-5	2020	Consistent with this observation, cells depleted of FKBP25 form fewer Rad51 repair foci in response to etoposide and ionizing radiation, and they are reliant on the SSA repair factor Rad52 for viability.	Etoposide	103-112	FKBP prolyl isomerase 3	Homo sapiens	52-58
30620620-5	2020	Consistent with this observation, cells depleted of FKBP25 form fewer Rad51 repair foci in response to etoposide and ionizing radiation, and they are reliant on the SSA repair factor Rad52 for viability.	Etoposide	103-112	RAD51 recombinase	Homo sapiens	70-75
31964620-4	2020	PS at 0.1 muM [3H]-DAC was markedly decreased in the presence of 100 muM irinotecan or etoposide, while CLmet was markedly decreased in the presence of 100 muM cytarabine or gemcitabine.	Etoposide	87-96	arylacetamide deacetylase	Homo sapiens	19-22
31285546-8	2020	p140Cap also increases sensitivity of neuroblastoma cells to doxorubicin and etoposide treatment, as well as to a combined treatment with chemotherapy drugs and Src inhibitors.	Etoposide	77-86	SRC kinase signaling inhibitor 1	Homo sapiens	0-7
31924205-7	2020	Two alpha-helices in the head domain of SCARB2 bind to the G-H loop of VP1 and the E-F loop of VP2 capsid proteins of EV-A71.	Etoposide	71-74	scavenger receptor class B member 2	Homo sapiens	40-46
31887632-6	2020	Ectopic RIP3 expression significantly sensitized lung cancer cells to the cytotoxicity of anticancer drugs such as cisplatin, etoposide, vincristine, and adriamycin.	Etoposide	126-135	receptor interacting serine/threonine kinase 3	Homo sapiens	8-12
31995761-5	2020	We validate the ARK assay with genetic mutants with established deficiencies in DPC repair and demonstrate its robustness by using common DPC-inducing reagents, including formaldehyde, camptothecin, and etoposide.	Etoposide	203-212	AXL receptor tyrosine kinase	Homo sapiens	16-19
33747282-0	2021	Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients.	Etoposide	91-100	DNA topoisomerase II alpha	Homo sapiens	10-15
33747282-0	2021	Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients.	Etoposide	91-100	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	20-25
33747282-4	2021	We undertook this retrospective study to determine the influence of SNPs in TOP2A (rs34300454; rs13695; rs11540720) and ERCC1 (rs11615; rs3212986) genes on the efficiency and toxicity of chemotherapy with platinum and etoposide in SCLC Caucasian patients.	Etoposide	218-227	DNA topoisomerase II alpha	Homo sapiens	76-81
31940492-3	2020	In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide.	Etoposide	233-242	F-box and WD repeat domain containing 7	Homo sapiens	30-35
31940492-3	2020	In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide.	Etoposide	233-242	KIT ligand	Homo sapiens	78-93
31940492-3	2020	In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide.	Etoposide	233-242	KIT ligand	Homo sapiens	95-98
31940492-3	2020	In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide.	Etoposide	233-242	tumor protein p53	Homo sapiens	138-141
31940492-6	2020	Biologically, FBXW7 inactivation sensitizes cancer cells to radiation or etoposide by stabilizing p53 to induce cell-cycle arrest and apoptosis.	Etoposide	73-82	F-box and WD repeat domain containing 7	Homo sapiens	14-19
31940492-6	2020	Biologically, FBXW7 inactivation sensitizes cancer cells to radiation or etoposide by stabilizing p53 to induce cell-cycle arrest and apoptosis.	Etoposide	73-82	tumor protein p53	Homo sapiens	98-101
33747282-12	2021	Conclusions: SNPs in ERCC1 and TOP2 genes may be associated with the toxicities and survival of SCLC patients treated with cisplatin and etoposide.	Etoposide	137-146	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	21-26
32968740-0	2020	RAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells.	Etoposide	25-34	RAD51 recombinase	Homo sapiens	0-5
31605433-4	2020	Spalax fibroblasts undergo replicative senescence (RS) and etoposide-induced senescence (EIS), evidenced by an increased activity of senescence-associated beta-galactosidase (SA-beta-Gal), growth arrest, and overexpression of p21, p16, and p53 mRNAs.	Etoposide	59-68	H3 histone pseudogene 16	Homo sapiens	226-229
31605433-4	2020	Spalax fibroblasts undergo replicative senescence (RS) and etoposide-induced senescence (EIS), evidenced by an increased activity of senescence-associated beta-galactosidase (SA-beta-Gal), growth arrest, and overexpression of p21, p16, and p53 mRNAs.	Etoposide	59-68	cyclin dependent kinase inhibitor 2A	Homo sapiens	231-234
31605433-4	2020	Spalax fibroblasts undergo replicative senescence (RS) and etoposide-induced senescence (EIS), evidenced by an increased activity of senescence-associated beta-galactosidase (SA-beta-Gal), growth arrest, and overexpression of p21, p16, and p53 mRNAs.	Etoposide	59-68	tumor protein p53	Homo sapiens	240-243
31655809-4	2020	For this particular group we evaluated the efficacy and safety of fludarabine, cytarabine, granulocyte colony-stimulating factor (FLAG) in combination with etoposide (FLAG-Eto) in 36 patients.	Etoposide	156-165	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	172-175
32053083-4	2020	Furthermore, BIT 1 shows moderate synergistic effect with the standard chemotherapy drugs etoposide, and doxorubicin, whereas BIT 2 and 3 showed moderate additive effect to antagonistic effect.	Etoposide	90-99	peptidyl-tRNA hydrolase 2	Homo sapiens	13-18
32968740-4	2020	The purpose of this study was to evaluate the impact of RAD51 inhibitor on genomic toxicity caused by etoposide, a chemotherapeutic agent.	Etoposide	102-111	RAD51 recombinase	Homo sapiens	56-61
32968740-9	2020	A small molecule inhibitor of RAD51 increased cytotoxicity while reducing genomic toxicity and instability caused by etoposide, in both EAC cell lines.	Etoposide	117-126	RAD51 recombinase	Homo sapiens	30-35
31669256-8	2020	Immunofluorescence analysis revealed high MRP1 and MRP4 expression at the plasma membrane of tumor cells as well as AGS cells in culture, in which MRP inhibition resulted in selective sensitization to cytotoxic MRP substrates, such as sorafenib, docetaxel, etoposide, and doxorubicin.	Etoposide	257-266	prolactin family 2, subfamily c, member 2	Mus musculus	42-46
31669256-8	2020	Immunofluorescence analysis revealed high MRP1 and MRP4 expression at the plasma membrane of tumor cells as well as AGS cells in culture, in which MRP inhibition resulted in selective sensitization to cytotoxic MRP substrates, such as sorafenib, docetaxel, etoposide, and doxorubicin.	Etoposide	257-266	MARCKS-like 1	Mus musculus	42-45
31429692-4	2020	METHODS: Molecular docking studies were performed on a 50 series of ganoderic acids reported in the NCBI-PubChem database and FDA approved anti-cancer drugs, to find out binding energy, an interacting residue at the active site of Human DNA-Topoisomerase II beta and compare with the molecular arrangements of the interacting residue of etoposide with the Human DNA topoisomerase II beta.	Etoposide	337-346	DNA topoisomerase II beta	Homo sapiens	237-262
31818176-7	2020	Using etoposide-induced primary cortical neurons injury model, we found that miR-23a was decreased in this cell model and miR-23a overexpression-suppressed etoposide induced the activity of caspase 3 and the releases of inflammatory mediators in primary cortical neurons.	Etoposide	6-15	microRNA 23a	Mus musculus	77-84
31818176-7	2020	Using etoposide-induced primary cortical neurons injury model, we found that miR-23a was decreased in this cell model and miR-23a overexpression-suppressed etoposide induced the activity of caspase 3 and the releases of inflammatory mediators in primary cortical neurons.	Etoposide	6-15	microRNA 23a	Mus musculus	122-129
31818176-7	2020	Using etoposide-induced primary cortical neurons injury model, we found that miR-23a was decreased in this cell model and miR-23a overexpression-suppressed etoposide induced the activity of caspase 3 and the releases of inflammatory mediators in primary cortical neurons.	Etoposide	6-15	caspase 3	Mus musculus	190-199
31818176-7	2020	Using etoposide-induced primary cortical neurons injury model, we found that miR-23a was decreased in this cell model and miR-23a overexpression-suppressed etoposide induced the activity of caspase 3 and the releases of inflammatory mediators in primary cortical neurons.	Etoposide	156-165	microRNA 23a	Mus musculus	122-129
31818176-7	2020	Using etoposide-induced primary cortical neurons injury model, we found that miR-23a was decreased in this cell model and miR-23a overexpression-suppressed etoposide induced the activity of caspase 3 and the releases of inflammatory mediators in primary cortical neurons.	Etoposide	156-165	caspase 3	Mus musculus	190-199
32063972-16	2020	Overall prognosis of GEP-PDNECA patients following platinum and etoposide therapy in our series was relatively favorable but remained poor in the presence of distant metastases.	Etoposide	64-73	granulin precursor	Homo sapiens	21-24
31702387-5	2020	Functionally, knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs, including vincristine (VCR), carboplatin (CBP), cisplatin (DDP), VP-16 (etoposide), and 5-fluorouracil (5-Fu).	Etoposide	207-216	urothelial cancer associated 1	Homo sapiens	27-31
32098913-0	2020	beta-Actin facilitates etoposide-induced p53 nuclear import.	Etoposide	23-32	POTE ankyrin domain family member F	Homo sapiens	0-10
32098913-0	2020	beta-Actin facilitates etoposide-induced p53 nuclear import.	Etoposide	23-32	tumor protein p53	Homo sapiens	41-44
31709727-8	2020	By sequencing the coding area of BECN 1 gene of CSQT-2 and HCC-LM3 cells, we found that the predicted translational products of BECN 1 gene contained RLPS295 VP (R, arginine; L, leucine; P, proline; S, serine; V, valine), a classic 14-3-3zeta binding motif.	Etoposide	158-160	beclin 1	Homo sapiens	33-39
31709727-8	2020	By sequencing the coding area of BECN 1 gene of CSQT-2 and HCC-LM3 cells, we found that the predicted translational products of BECN 1 gene contained RLPS295 VP (R, arginine; L, leucine; P, proline; S, serine; V, valine), a classic 14-3-3zeta binding motif.	Etoposide	158-160	beclin 1	Homo sapiens	128-134
31849293-4	2020	Our recent studies have demonstrated that neuroblastoma cells resistant to etoposide, a common chemotherapeutic drug, show a partial monoallelic deletion of the locus coding for miRNA 15a and 16-1. leading to a loss of these miRNAs and the activation of GSH-dependent responses.	Etoposide	75-84	microRNA 15a	Homo sapiens	178-187
31583565-0	2020	Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.	Etoposide	69-78	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	14-20
31583565-1	2020	Etoposide (VP-16) is the topoisomerase 2 (Top2) inhibitor used for treating of glioma patients however at high dose with serious side effects.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
31608820-6	2020	In this study, we analyze the repair of etoposide-induced TOP2ccs in wild-type and TDP2-deficient (TDP2-/-) TK6 cells in the absence and presence of MG132, a potent proteasome inhibitor.	Etoposide	40-49	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	83-87
31608820-6	2020	In this study, we analyze the repair of etoposide-induced TOP2ccs in wild-type and TDP2-deficient (TDP2-/-) TK6 cells in the absence and presence of MG132, a potent proteasome inhibitor.	Etoposide	40-49	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	99-103
31608820-9	2020	In cell survival assays, MG132 increased the etoposide sensitivity of TDP2-/- cells, supporting the TDP2-independent and proteasome-dependent pathway among these multiple repair pathways.	Etoposide	45-54	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	70-74
31608820-10	2020	We also demonstrated that TDP2 released TOP2 from DNA that contained etoposide-induced TOP2cc without proteolytic degradation in vitro.	Etoposide	69-78	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	26-30
31949489-0	2020	MiR-129-5p sensitization of lung cancer cells to etoposide-induced apoptosis by reducing YWHAB.	Etoposide	49-58	microRNA 1295a	Homo sapiens	0-9
31949489-0	2020	MiR-129-5p sensitization of lung cancer cells to etoposide-induced apoptosis by reducing YWHAB.	Etoposide	49-58	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta	Homo sapiens	89-94
31949489-10	2020	Overexpression of miR-129-5p promotes VP16-induced lung cancer cell apoptosis and YWHAB was shown to be a direct downstream target of miR-129-5p.	Etoposide	38-42	microRNA 1295a	Homo sapiens	18-28
31949489-11	2020	Conclusion: Overexpression of expression miR-129-5p contributes to etoposide-induced lung cancer apoptosis by modulating YWHAB.	Etoposide	67-76	microRNA 1295a	Homo sapiens	41-51
31949489-11	2020	Conclusion: Overexpression of expression miR-129-5p contributes to etoposide-induced lung cancer apoptosis by modulating YWHAB.	Etoposide	67-76	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta	Homo sapiens	121-126
31889167-5	2019	In the present study, we identified four short-lived lncRNAs, designated as OIP5-AS1, FLJ46906, LINC01137, and GABPB1-AS1, which showed significantly upregulated expression following exposure to hydrogen peroxide (oxidative stress), mercury II chloride (heavy metal stress), and etoposide (DNA damage stress) in human HepG2 cells.	Etoposide	279-288	OIP5 antisense RNA 1	Homo sapiens	76-84
31889167-5	2019	In the present study, we identified four short-lived lncRNAs, designated as OIP5-AS1, FLJ46906, LINC01137, and GABPB1-AS1, which showed significantly upregulated expression following exposure to hydrogen peroxide (oxidative stress), mercury II chloride (heavy metal stress), and etoposide (DNA damage stress) in human HepG2 cells.	Etoposide	279-288	NHSL1 antisense RNA 1	Homo sapiens	86-94
31889167-5	2019	In the present study, we identified four short-lived lncRNAs, designated as OIP5-AS1, FLJ46906, LINC01137, and GABPB1-AS1, which showed significantly upregulated expression following exposure to hydrogen peroxide (oxidative stress), mercury II chloride (heavy metal stress), and etoposide (DNA damage stress) in human HepG2 cells.	Etoposide	279-288	ZC3H12A divergent transcript	Homo sapiens	96-105
31889167-5	2019	In the present study, we identified four short-lived lncRNAs, designated as OIP5-AS1, FLJ46906, LINC01137, and GABPB1-AS1, which showed significantly upregulated expression following exposure to hydrogen peroxide (oxidative stress), mercury II chloride (heavy metal stress), and etoposide (DNA damage stress) in human HepG2 cells.	Etoposide	279-288	GA binding protein transcription factor subunit beta 1	Homo sapiens	111-117
31889167-5	2019	In the present study, we identified four short-lived lncRNAs, designated as OIP5-AS1, FLJ46906, LINC01137, and GABPB1-AS1, which showed significantly upregulated expression following exposure to hydrogen peroxide (oxidative stress), mercury II chloride (heavy metal stress), and etoposide (DNA damage stress) in human HepG2 cells.	Etoposide	279-288	prostaglandin D2 receptor	Homo sapiens	81-84
31604667-12	2019	An ARID1A-deficient case that was resistant to multiple cytotoxic drugs, including paclitaxel plus carboplatin in the adjuvant and etoposide plus irinotecan in the first-line treatment, exhibited a dramatic response to gemcitabine in the second-line treatment.	Etoposide	131-140	AT-rich interaction domain 1A	Homo sapiens	3-9
31855962-0	2019	Isobaric tags for relative and absolute quantitation-based quantitative proteomic analysis of X-linked inhibitor of apoptosis and H2AX in etoposide-induced renal cell carcinoma apoptosis.	Etoposide	138-147	X-linked inhibitor of apoptosis	Homo sapiens	94-125
31855962-0	2019	Isobaric tags for relative and absolute quantitation-based quantitative proteomic analysis of X-linked inhibitor of apoptosis and H2AX in etoposide-induced renal cell carcinoma apoptosis.	Etoposide	138-147	H2A.X variant histone	Homo sapiens	130-134
31855962-3	2019	This study investigated the regulatory mechanism of XIAP in etoposide-induced apoptosis in two Caki-1 cell lines with high or low XIAP expression.	Etoposide	60-69	X-linked inhibitor of apoptosis	Homo sapiens	52-56
31473257-4	2019	In this research, we found that knockdown of JMJD8 in cancer cells significantly increased cell proliferation, and attenuated ionizing irradiation or etoposide treatment-induced DNA double-strand breaks (DSBs) level through enhancing the expression of Ku70 and Ku80 which are key participants in the non-homologous end-joining repair of DSBs.	Etoposide	150-159	jumonji domain containing 8	Homo sapiens	45-50
31473257-4	2019	In this research, we found that knockdown of JMJD8 in cancer cells significantly increased cell proliferation, and attenuated ionizing irradiation or etoposide treatment-induced DNA double-strand breaks (DSBs) level through enhancing the expression of Ku70 and Ku80 which are key participants in the non-homologous end-joining repair of DSBs.	Etoposide	150-159	X-ray repair cross complementing 6	Homo sapiens	252-256
31473257-4	2019	In this research, we found that knockdown of JMJD8 in cancer cells significantly increased cell proliferation, and attenuated ionizing irradiation or etoposide treatment-induced DNA double-strand breaks (DSBs) level through enhancing the expression of Ku70 and Ku80 which are key participants in the non-homologous end-joining repair of DSBs.	Etoposide	150-159	X-ray repair cross complementing 5	Homo sapiens	261-265
31638261-5	2019	In the present, down regulation of RAD51 by shRNA and imatinib sensitized Jurkat cells to etoposide by decreasing the activity of homologous recombination (HR).	Etoposide	90-99	RAD51 recombinase	Homo sapiens	35-40
31677199-3	2019	We recently described a population of vasopressin-expressing RGCs (VP-RGC) which send axonal projections to the SCN.	Etoposide	67-69	arginine vasopressin	Rattus norvegicus	38-49
31677199-8	2019	Our data suggest that optogenetic stimulation of VP-RGC axons within the SCN influences the activity of SCN cells in a vasopressin dependent manner.	Etoposide	49-51	arginine vasopressin	Rattus norvegicus	119-130
32048620-16	2019	A combination of oral etoposide (VP-16) and pazopanib needs further evaluation in a large number of patients in a randomized trial.	Etoposide	22-31	host cell factor C1	Homo sapiens	33-38
31638261-6	2019	We found that the suppression of RAD51 by shRNA inhibited tumor cells proliferation and enhanced apoptosis of Jurkat cells after etoposide treatment.	Etoposide	129-138	RAD51 recombinase	Homo sapiens	33-38
31638261-7	2019	Importantly, downregulation of RAD51 by imatinib obviously increased the apoptosis of Jurkat cell after etoposide treatment.	Etoposide	104-113	RAD51 recombinase	Homo sapiens	31-36
31384951-5	2019	When the exogenous DNA DSBs were introduced by Etoposide, we found that Rad51-mediated homologous recombination (HR) was used to repair the broken DNA.	Etoposide	47-56	RAD51 recombinase	Homo sapiens	72-77
31411059-12	2019	mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide.	Etoposide	118-127	tumor necrosis factor	Homo sapiens	60-69
31411059-12	2019	mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide.	Etoposide	118-127	interleukin 1 alpha	Homo sapiens	71-75
31411059-12	2019	mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide.	Etoposide	118-127	C-X-C motif chemokine ligand 8	Homo sapiens	77-81
31411059-12	2019	mRNA expression of proinflammatory and profibrotic factors (TNF-alpha, IL-1, IL-8, MMP3) was elevated by hyperoxia or etoposide.	Etoposide	118-127	matrix metallopeptidase 3	Homo sapiens	83-87
31646843-7	2019	The results indicated that etoposide-treated astrocytes showed cellular senescence phenotypes including increased SA-beta-gal-positive cells number, increased nuclear size and increased senescence-associated secretory phenotypes (SASP) such as IL-6.	Etoposide	27-36	interleukin 6	Rattus norvegicus	244-248
31615546-11	2019	The evolution was favorable under a treatment including etoposide (VP-16).	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
31260151-7	2019	Exogenous DeltaN-HtrA3L/S promoted apoptotic death of lung cancer cells treated with etoposide and caused a significant decrease of cellular XIAP levels, in a way dependent on HtrA3 proteolytic activity.	Etoposide	85-94	HtrA serine peptidase 3	Homo sapiens	17-22
31348687-4	2019	Moreover, we find that DNA damages caused by methyl methanesulfonate (MMS) or etoposide promote the formation of Ku70-Pol-beta complexes at the repair foci.	Etoposide	78-87	X-ray repair cross complementing 6	Homo sapiens	113-117
31348687-4	2019	Moreover, we find that DNA damages caused by methyl methanesulfonate (MMS) or etoposide promote the formation of Ku70-Pol-beta complexes at the repair foci.	Etoposide	78-87	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	118-126
31401398-8	2019	Six drugs (afatinib, celecoxib, doramapimod, mifepristone, MK-2206 and rosiglitazone) were evaluated for their ability to reverse resistance of MRP1-overexpressing H69AR lung cancer cells against vincristine, doxorubicin and etoposide.	Etoposide	225-234	ATP binding cassette subfamily C member 1	Homo sapiens	144-148
31122751-9	2019	Despite second-line chemotherapy with R-ICE (rituximab-ifosfamide, carboplatin and etoposide), the patient died.	Etoposide	83-92	carboxylesterase 2	Homo sapiens	40-43
31374424-3	2019	These results exhibited more effectivity than anticancer agent etoposide (35muM) and merbarone (40-50muM).	Etoposide	63-72	latexin	Homo sapiens	76-79
31632920-11	2019	Disrupting CD47 in PC3 cells increased resistance to etoposide but, in contrast to Jurkat cells, not to ionizing radiation.	Etoposide	53-62	CD47 molecule	Homo sapiens	11-15
31632920-11	2019	Disrupting CD47 in PC3 cells increased resistance to etoposide but, in contrast to Jurkat cells, not to ionizing radiation.	Etoposide	53-62	proprotein convertase subtilisin/kexin type 1	Homo sapiens	19-22
31090963-0	2019	NEK5 interacts with topoisomerase IIbeta and is involved in the DNA damage response induced by etoposide.	Etoposide	95-104	NIMA related kinase 5	Homo sapiens	0-4
31090963-0	2019	NEK5 interacts with topoisomerase IIbeta and is involved in the DNA damage response induced by etoposide.	Etoposide	95-104	DNA topoisomerase II beta	Homo sapiens	20-40
31090963-4	2019	The effect of NEK5 in double-strand breaks caused by etoposide was accessed by alkaline comet assay and revealed that NEK5-silenced cells are more sensitive to etoposide treatment.	Etoposide	53-62	NIMA related kinase 5	Homo sapiens	14-18
31090963-4	2019	The effect of NEK5 in double-strand breaks caused by etoposide was accessed by alkaline comet assay and revealed that NEK5-silenced cells are more sensitive to etoposide treatment.	Etoposide	53-62	NIMA related kinase 5	Homo sapiens	118-122
31090963-4	2019	The effect of NEK5 in double-strand breaks caused by etoposide was accessed by alkaline comet assay and revealed that NEK5-silenced cells are more sensitive to etoposide treatment.	Etoposide	160-169	NIMA related kinase 5	Homo sapiens	14-18
31090963-4	2019	The effect of NEK5 in double-strand breaks caused by etoposide was accessed by alkaline comet assay and revealed that NEK5-silenced cells are more sensitive to etoposide treatment.	Etoposide	160-169	NIMA related kinase 5	Homo sapiens	118-122
31090963-5	2019	Topoisomerase IIbeta (TOPIIbeta) is a target of etoposide that leads to the production of DNA breaks.	Etoposide	48-57	DNA topoisomerase II beta	Homo sapiens	0-20
31090963-7	2019	The complex NEK5/TOPIIbeta is formed immediately after etoposide treatment.	Etoposide	55-64	NIMA related kinase 5	Homo sapiens	12-16
31271486-6	2019	Furthermore, we show that HMGA2 significantly reduced genotoxic DNA damage in each tested cancer cell model during treatment with the TOP2A poison etoposide or the catalytic TOP2A inhibitor merbarone.	Etoposide	147-156	high mobility group AT-hook 2	Homo sapiens	26-31
31271486-6	2019	Furthermore, we show that HMGA2 significantly reduced genotoxic DNA damage in each tested cancer cell model during treatment with the TOP2A poison etoposide or the catalytic TOP2A inhibitor merbarone.	Etoposide	147-156	DNA topoisomerase II alpha	Homo sapiens	134-139
31585638-10	2019	Notably, replication of SD18 stimulated IFN-beta response in CEF cells and overexpression of the VP4 or VP4Delta proteins significantly inhibited IFN-beta promoter activation, which could be the strategy of APV to escape from the host innate immunity.	Etoposide	97-100	interferon omega 1	Gallus gallus	146-154
31399497-7	2019	In these cells, etoposide robustly induced TOP2B covalent complexes, but we could not detect doxorubicin-induced TOP2-DNA complexes, and doxorubicin suppressed etoposide-induced TOP2-DNA complexes.	Etoposide	16-25	DNA topoisomerase II beta	Homo sapiens	43-48
31554835-5	2019	Here we report that GRK2 knockdown slowed cell growth, diminished proliferation, and enhanced cisplatin- and etoposide-induced apoptosis in medulloblastoma cell lines UW228-2 and Daoy.	Etoposide	109-118	G protein-coupled receptor kinase 2	Homo sapiens	20-24
31554835-7	2019	Cisplatin and etoposide increased phosphorylation of AKT (S473) and GRK2 knockdown mitigated this increase.	Etoposide	14-23	AKT serine/threonine kinase 1	Homo sapiens	53-56
31554835-7	2019	Cisplatin and etoposide increased phosphorylation of AKT (S473) and GRK2 knockdown mitigated this increase.	Etoposide	14-23	G protein-coupled receptor kinase 2	Homo sapiens	68-72
31554835-8	2019	Cisplatin and etoposide attenuated ERK phosphorylation, but GRK2 knockdown did not alter this effect.	Etoposide	14-23	mitogen-activated protein kinase 1	Homo sapiens	35-38
31554835-9	2019	Wildtype GRK2 reversed the increase in cisplatin- and etoposide-induced apoptosis caused by GRK2 knockdown.	Etoposide	54-63	G protein-coupled receptor kinase 2	Homo sapiens	9-13
31554835-9	2019	Wildtype GRK2 reversed the increase in cisplatin- and etoposide-induced apoptosis caused by GRK2 knockdown.	Etoposide	54-63	G protein-coupled receptor kinase 2	Homo sapiens	92-96
31554835-11	2019	These data demonstrate that GRK2 contributes to proliferation and survival of these medulloblastoma cell lines and to their protection from cisplatin- and etoposide-induced apoptosis.	Etoposide	155-164	G protein-coupled receptor kinase 2	Homo sapiens	28-32
31585638-10	2019	Notably, replication of SD18 stimulated IFN-beta response in CEF cells and overexpression of the VP4 or VP4Delta proteins significantly inhibited IFN-beta promoter activation, which could be the strategy of APV to escape from the host innate immunity.	Etoposide	104-107	interferon omega 1	Gallus gallus	146-154
31505885-5	2019	The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay found that miR-21 overexpression induced drug resistance to topoisomerase inhibitors (SN-38, doxorubicin, and etoposide/VP-16).	Etoposide	203-212	microRNA 21	Homo sapiens	104-110
31551763-4	2019	Our data suggested that DLD-1 colon cancer cells with BAX/BAK double-knockout were selectively resistant to a panel of FDA-approved drugs (27 out of 66), including etoposide.	Etoposide	164-173	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
31551763-4	2019	Our data suggested that DLD-1 colon cancer cells with BAX/BAK double-knockout were selectively resistant to a panel of FDA-approved drugs (27 out of 66), including etoposide.	Etoposide	164-173	BCL2 antagonist/killer 1	Homo sapiens	58-61
31551763-6	2019	Amongst these genes, XPC responsible for DNA repairment and cellular respiration demonstrated the highest tolerance towards etoposide treatment accompanying upregulated glycolysis as revealed by metabolic stress assay in DLD-1 colon cancer cells deficient with XPC.	Etoposide	124-133	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	21-24
31551763-6	2019	Amongst these genes, XPC responsible for DNA repairment and cellular respiration demonstrated the highest tolerance towards etoposide treatment accompanying upregulated glycolysis as revealed by metabolic stress assay in DLD-1 colon cancer cells deficient with XPC.	Etoposide	124-133	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	261-264
31449404-5	2019	We recently reported that enzyme-mediated DNA cleavage complexes (in which TopoII is covalently linked to the cleaved DNA during catalysis) formed in the presence of the anticancer drug etoposide persisted approximately 3-fold longer with TopoIIalpha than TopoIIbeta.	Etoposide	186-195	DNA topoisomerase II beta	Homo sapiens	256-266
31528096-12	2019	Apoptosis induced by GAS2 was dependent on p53, which was increased by etoposide addition.	Etoposide	71-80	growth arrest specific 2	Homo sapiens	21-25
31523390-6	2019	Drivers with pre-treatment expression predicting etoposide response (e.g., PARP9) generally synergized with etoposide.	Etoposide	49-58	poly(ADP-ribose) polymerase family member 9	Homo sapiens	75-80
31523390-6	2019	Drivers with pre-treatment expression predicting etoposide response (e.g., PARP9) generally synergized with etoposide.	Etoposide	108-117	poly(ADP-ribose) polymerase family member 9	Homo sapiens	75-80
31523390-7	2019	Drivers repressed by etoposide (e.g., PLK1) displayed standalone cytotoxicity.	Etoposide	21-30	polo like kinase 1	Homo sapiens	38-42
31523390-8	2019	Drivers, whose modulation evoked etoposide-like gene expression changes (e.g., mTOR), were cytotoxic both alone and in combination with etoposide.	Etoposide	33-42	mechanistic target of rapamycin kinase	Homo sapiens	79-83
31523390-8	2019	Drivers, whose modulation evoked etoposide-like gene expression changes (e.g., mTOR), were cytotoxic both alone and in combination with etoposide.	Etoposide	136-145	mechanistic target of rapamycin kinase	Homo sapiens	79-83
31528096-12	2019	Apoptosis induced by GAS2 was dependent on p53, which was increased by etoposide addition.	Etoposide	71-80	tumor protein p53	Homo sapiens	43-46
31516823-3	2019	Our results show that treatment using clinical doses of etoposide for 24 h induces the generation of DNA double strand breaks in the BCR3 of RUNX1 gene in KG-1 cells, but not in Colo320 cells, even though both cell lines express RUNX1 gene.	Etoposide	56-65	BCR pseudogene 3	Homo sapiens	133-137
31516823-0	2019	Etoposide-induced DNA damage in a chromosomal breakpoint of RUNX1 gene is independent of RUNX1 expression.	Etoposide	0-9	RUNX family transcription factor 1	Homo sapiens	89-94
31516823-3	2019	Our results show that treatment using clinical doses of etoposide for 24 h induces the generation of DNA double strand breaks in the BCR3 of RUNX1 gene in KG-1 cells, but not in Colo320 cells, even though both cell lines express RUNX1 gene.	Etoposide	56-65	RUNX family transcription factor 1	Homo sapiens	141-146
31516823-0	2019	Etoposide-induced DNA damage in a chromosomal breakpoint of RUNX1 gene is independent of RUNX1 expression.	Etoposide	0-9	RUNX family transcription factor 1	Homo sapiens	60-65
31516823-3	2019	Our results show that treatment using clinical doses of etoposide for 24 h induces the generation of DNA double strand breaks in the BCR3 of RUNX1 gene in KG-1 cells, but not in Colo320 cells, even though both cell lines express RUNX1 gene.	Etoposide	56-65	RUNX family transcription factor 1	Homo sapiens	229-234
31516823-4	2019	These findings suggest that chromatin accessibility and DNA damage generation at the BCR3 due to treatment with etoposide, is independent of RUNX1 gene expression.	Etoposide	112-121	BCR pseudogene 3	Homo sapiens	85-89
31308291-3	2019	The aim of this study was to determine if YM155, a small-molecule survivin inhibitor, potentiates the chemotherapeutic efficacy of etoposide against canine OSA in vitro and in vivo.	Etoposide	131-140	baculoviral IAP repeat containing 5	Canis lupus familiaris	66-74
31382912-0	2019	Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN).	Etoposide	10-19	C-type lectin domain family 3 member B	Homo sapiens	109-111
31438997-3	2019	METHODS: We used the transwell chamber assay to test effects of Topoisomerase inhibitors Etoposide (VP-16), Adriamycin (ADM) and Irinotecan (CPT-11) on the migration and invasion of cancer cells.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
31239178-2	2019	Compound 12 (IC50 = 4.14 microM) and compound 10c (IC50 = 5.98 microM) were found to be 2.5 fold, and 1.74 fold more potent when compared with standard Etoposide (IC50 = 10.44 microM), against A549 (lung cancer cells).	Etoposide	152-161	Rho GTPase activating protein 9	Homo sapiens	46-49
31406141-5	2019	We showed that ectopic expression of SAMD12-AS1 promotes cell growth and blocks apoptosis, while knockdown of SAMD12-AS1 inhibits cell proliferation and enhances etoposide-induced apoptosis.	Etoposide	162-171	SAMD12 antisense RNA 1	Homo sapiens	110-120
31382912-1	2019	BACKGROUND: Etoposide (E) at 100 mg/m2 combined with Cisplatin (P) at 20 mg/m2 represents an induction 2-day regimen embedded in our clinical practice for patients with advanced GCT or TN at high risk of early death.	Etoposide	12-21	C-type lectin domain family 3 member B	Homo sapiens	185-187
31329620-5	2019	In this study, we show that etoposide triggers the interaction of Apaf-1 with Cullin-4B, resulting in enhanced Apaf-1 ubiquitination.	Etoposide	28-37	apoptotic peptidase activating factor 1	Homo sapiens	66-72
31221825-0	2019	T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide.	Etoposide	65-74	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	0-35
31396480-5	2019	EI24 (etoposide-induced gene 2.4 kb; PIG8, p53-induced gene 8) acts as a tumor suppressor, inhibiting cell growth and inducing apoptosis in breast, cervical, and prostate cancer cells.	Etoposide	6-15	EI24 autophagy associated transmembrane protein	Homo sapiens	0-4
31396480-5	2019	EI24 (etoposide-induced gene 2.4 kb; PIG8, p53-induced gene 8) acts as a tumor suppressor, inhibiting cell growth and inducing apoptosis in breast, cervical, and prostate cancer cells.	Etoposide	6-15	EI24 autophagy associated transmembrane protein	Homo sapiens	37-41
31396480-5	2019	EI24 (etoposide-induced gene 2.4 kb; PIG8, p53-induced gene 8) acts as a tumor suppressor, inhibiting cell growth and inducing apoptosis in breast, cervical, and prostate cancer cells.	Etoposide	6-15	tumor protein p53	Homo sapiens	43-46
31336593-6	2019	We found a correlation between BCL6 overexpression and resistance to etoposide.	Etoposide	69-78	BCL6 transcription repressor	Homo sapiens	31-35
31329620-5	2019	In this study, we show that etoposide triggers the interaction of Apaf-1 with Cullin-4B, resulting in enhanced Apaf-1 ubiquitination.	Etoposide	28-37	cullin 4B	Homo sapiens	78-87
31329620-5	2019	In this study, we show that etoposide triggers the interaction of Apaf-1 with Cullin-4B, resulting in enhanced Apaf-1 ubiquitination.	Etoposide	28-37	apoptotic peptidase activating factor 1	Homo sapiens	111-117
30910588-4	2019	Pgp expression was increased in OST-EC50 cells, inducing resistance to doxorubicin, etoposide, vincristine and actinomycin D (p &lt; 0.05).	Etoposide	84-93	phosphoglycolate phosphatase	Homo sapiens	0-3
31311995-4	2019	Functional inhibition of ABCB1 using vardenafil or verapamil significantly (p &lt;= 0.05-0.001) potentiated the response to three chemotherapeutic drugs (vincristine, etoposide and methotrexate).	Etoposide	167-176	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
30992301-0	2019	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.	Etoposide	41-50	C-C motif chemokine ligand 28	Homo sapiens	22-25
31097220-1	2019	Etoposide-induced 2.4 kb transcript (EI24, also known as PIG8) is a p53 target gene involved in cell growth suppression and apoptosis and known to be frequently altered in human cancers.	Etoposide	0-9	EI24 autophagy associated transmembrane protein	Homo sapiens	37-41
31097220-1	2019	Etoposide-induced 2.4 kb transcript (EI24, also known as PIG8) is a p53 target gene involved in cell growth suppression and apoptosis and known to be frequently altered in human cancers.	Etoposide	0-9	EI24 autophagy associated transmembrane protein	Homo sapiens	57-61
31097220-1	2019	Etoposide-induced 2.4 kb transcript (EI24, also known as PIG8) is a p53 target gene involved in cell growth suppression and apoptosis and known to be frequently altered in human cancers.	Etoposide	0-9	tumor protein p53	Homo sapiens	68-71
30910588-5	2019	Increased expression of ABCG1 and Pgp protein in the HOS-EC50.SR cells induced resistance to etoposide and doxorubicin (p &lt; 0.01), which was directly correlated with ABCG1 expression (r &gt; 0.88, p &lt; 0.001).	Etoposide	93-102	ATP binding cassette subfamily G member 1	Homo sapiens	24-29
30910588-5	2019	Increased expression of ABCG1 and Pgp protein in the HOS-EC50.SR cells induced resistance to etoposide and doxorubicin (p &lt; 0.01), which was directly correlated with ABCG1 expression (r &gt; 0.88, p &lt; 0.001).	Etoposide	93-102	phosphoglycolate phosphatase	Homo sapiens	34-37
30910588-5	2019	Increased expression of ABCG1 and Pgp protein in the HOS-EC50.SR cells induced resistance to etoposide and doxorubicin (p &lt; 0.01), which was directly correlated with ABCG1 expression (r &gt; 0.88, p &lt; 0.001).	Etoposide	93-102	ATP binding cassette subfamily G member 1	Homo sapiens	169-174
30478995-0	2019	CtIP promotes G2/M arrest in etoposide-treated HCT116 cells in a p53-independent manner.	Etoposide	29-38	RB binding protein 8, endonuclease	Homo sapiens	0-4
30506132-0	2019	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).	Etoposide	95-104	vacuole membrane protein 1	Homo sapiens	184-189
30478995-4	2019	In addition, the phosphorylation levels of Ser317 and Ser345 in Chk1 and of Ser216 in CDC25C were lower in CtIP-deficient HCT116 cells than in control cells after Eto treatment.	Etoposide	163-166	checkpoint kinase 1	Homo sapiens	64-68
30478995-0	2019	CtIP promotes G2/M arrest in etoposide-treated HCT116 cells in a p53-independent manner.	Etoposide	29-38	tumor protein p53	Homo sapiens	65-68
30478995-4	2019	In addition, the phosphorylation levels of Ser317 and Ser345 in Chk1 and of Ser216 in CDC25C were lower in CtIP-deficient HCT116 cells than in control cells after Eto treatment.	Etoposide	163-166	cell division cycle 25C	Homo sapiens	86-92
30478995-2	2019	In this study, we show that knockdown of CtIP, a corepressor of CtBP, promotes cell proliferation and alleviates G2/M phase arrest in etoposide (Eto)-treated HCT116 cells.	Etoposide	134-143	RB binding protein 8, endonuclease	Homo sapiens	41-45
30478995-4	2019	In addition, the phosphorylation levels of Ser317 and Ser345 in Chk1 and of Ser216 in CDC25C were lower in CtIP-deficient HCT116 cells than in control cells after Eto treatment.	Etoposide	163-166	RB binding protein 8, endonuclease	Homo sapiens	107-111
30478995-2	2019	In this study, we show that knockdown of CtIP, a corepressor of CtBP, promotes cell proliferation and alleviates G2/M phase arrest in etoposide (Eto)-treated HCT116 cells.	Etoposide	145-148	RB binding protein 8, endonuclease	Homo sapiens	41-45
30478995-5	2019	Our results indicate that CtIP may enhance cell sensitivity to Eto by promoting G2/M phase arrest, mainly through the ATR-Chk1-CDC25C pathway rather than the p53-p21/GADD45a pathway.	Etoposide	63-66	RB binding protein 8, endonuclease	Homo sapiens	26-30
30478995-3	2019	Although the expression of p21 and growth arrest and DNA damage inducible alpha (GADD45a), which are important targets of p53, was downregulated in CtIP-deficient HCT116 cells, p53 deletion did not affect G2/M arrest after Eto treatment.	Etoposide	223-226	H3 histone pseudogene 16	Homo sapiens	27-30
30478995-5	2019	Our results indicate that CtIP may enhance cell sensitivity to Eto by promoting G2/M phase arrest, mainly through the ATR-Chk1-CDC25C pathway rather than the p53-p21/GADD45a pathway.	Etoposide	63-66	ATR serine/threonine kinase	Homo sapiens	118-121
30478995-3	2019	Although the expression of p21 and growth arrest and DNA damage inducible alpha (GADD45a), which are important targets of p53, was downregulated in CtIP-deficient HCT116 cells, p53 deletion did not affect G2/M arrest after Eto treatment.	Etoposide	223-226	growth arrest and DNA damage inducible alpha	Homo sapiens	81-88
31417239-7	2019	Results: ROC analysis of etoposide resistance revealed that the most significant single gene mutation indicating resistance to etoposide was CSMD3, and the accuracy of predicting resistance to etoposide proved to be the highest when there was any mutation in CSMD3/PCLO/RYR1/EPB41L3, area under the curve =0.804 (95% confidence interval: 0.679-0.930,P &lt;0.001).	Etoposide	25-34	CUB and Sushi multiple domains 3	Homo sapiens	141-146
30798416-0	2019	ANKRD49 inhibits etoposide-induced intrinsic apoptosis of GC-1 cells by modulating NF-kappaB signaling.	Etoposide	17-26	ankyrin repeat domain 49	Homo sapiens	0-7
30798416-5	2019	Nuclear staining with Hoechst 33258 and annexin V-FITC/PI, as well as analysis of caspase 3 activity, mitochondrial membrane potential, and apoptotic protein expression, showed that etoposide-induced apoptosis was attenuated by ANKRD49 overexpression but promoted by RNA interference-induced ANKRD49 knockdown.	Etoposide	182-191	caspase 3	Homo sapiens	82-91
30798416-5	2019	Nuclear staining with Hoechst 33258 and annexin V-FITC/PI, as well as analysis of caspase 3 activity, mitochondrial membrane potential, and apoptotic protein expression, showed that etoposide-induced apoptosis was attenuated by ANKRD49 overexpression but promoted by RNA interference-induced ANKRD49 knockdown.	Etoposide	182-191	ankyrin repeat domain 49	Homo sapiens	228-235
30798416-5	2019	Nuclear staining with Hoechst 33258 and annexin V-FITC/PI, as well as analysis of caspase 3 activity, mitochondrial membrane potential, and apoptotic protein expression, showed that etoposide-induced apoptosis was attenuated by ANKRD49 overexpression but promoted by RNA interference-induced ANKRD49 knockdown.	Etoposide	182-191	ankyrin repeat domain 49	Homo sapiens	292-299
30798416-7	2019	Examination of the subcellular distribution of the NF-kappaB p65 subunit after treatment with an NF-kappaB signaling inhibitor or p65 small interfering RNA demonstrated that ANKRD49 modulated etoposide-induced GC-1 cell apoptosis via the NF-kappaB pathway.	Etoposide	192-201	RELA proto-oncogene, NF-kB subunit	Homo sapiens	61-64
30798416-7	2019	Examination of the subcellular distribution of the NF-kappaB p65 subunit after treatment with an NF-kappaB signaling inhibitor or p65 small interfering RNA demonstrated that ANKRD49 modulated etoposide-induced GC-1 cell apoptosis via the NF-kappaB pathway.	Etoposide	192-201	ankyrin repeat domain 49	Homo sapiens	174-181
31085259-12	2019	These results suggest that etoposide transport in MDCKII MRP2 cells is a model system to investigate MRP2 interactions, and that surfactants may not have a large potential for increasing oral bioavailability of drugs through inhibition of MRP2 transport activity.	Etoposide	27-36	ATP binding cassette subfamily C member 2	Canis lupus familiaris	57-61
31417239-7	2019	Results: ROC analysis of etoposide resistance revealed that the most significant single gene mutation indicating resistance to etoposide was CSMD3, and the accuracy of predicting resistance to etoposide proved to be the highest when there was any mutation in CSMD3/PCLO/RYR1/EPB41L3, area under the curve =0.804 (95% confidence interval: 0.679-0.930,P &lt;0.001).	Etoposide	127-136	CUB and Sushi multiple domains 3	Homo sapiens	141-146
31417239-8	2019	Conclusion: This study found that a panel with four genes (CSMD3, EPB41L3, PCLO, and RYR1) can accurately predict sensitivity to etoposide.	Etoposide	129-138	CUB and Sushi multiple domains 3	Homo sapiens	59-64
31417239-8	2019	Conclusion: This study found that a panel with four genes (CSMD3, EPB41L3, PCLO, and RYR1) can accurately predict sensitivity to etoposide.	Etoposide	129-138	erythrocyte membrane protein band 4.1 like 3	Homo sapiens	66-73
31417239-8	2019	Conclusion: This study found that a panel with four genes (CSMD3, EPB41L3, PCLO, and RYR1) can accurately predict sensitivity to etoposide.	Etoposide	129-138	piccolo presynaptic cytomatrix protein	Homo sapiens	75-79
31085259-0	2019	MRP2-mediated transport of etoposide in MDCKII MRP2 cells is unaffected by commonly used non-ionic surfactants.	Etoposide	27-36	ATP binding cassette subfamily C member 2	Canis lupus familiaris	0-4
31085259-0	2019	MRP2-mediated transport of etoposide in MDCKII MRP2 cells is unaffected by commonly used non-ionic surfactants.	Etoposide	27-36	ATP binding cassette subfamily C member 2	Canis lupus familiaris	47-51
31085259-6	2019	In MDCKII MRP2 cells a polarized transport of etoposide and digoxin in the secretory (basolateral to apical) direction with efflux ratios of 5.5 +- 0.7 and 18.5 +- 4.2, respectively, was measured.	Etoposide	46-55	ATP binding cassette subfamily C member 2	Canis lupus familiaris	10-14
31085259-8	2019	Transport of etoposide was therefore mainly MRP2-mediated and used as a probe to investigate pharmaceutical excipients.	Etoposide	13-22	ATP binding cassette subfamily C member 2	Canis lupus familiaris	44-48
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Etoposide	15-24	ATP binding cassette subfamily C member 2	Canis lupus familiaris	49-53
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Etoposide	15-24	ATP binding cassette subfamily C member 2	Canis lupus familiaris	108-112
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Etoposide	15-24	PGP	Canis lupus familiaris	117-121
31085259-10	2019	In conclusion, etoposide transport across MDCKII MRP2 cells was modulated by cyclosporin A, an inhibitor of MRP2 and P-gp, but not by specific P-gp inhibitors (valspodar and zosuquidar), which suggests that etoposide transport is primarily influenced by MRP2.	Etoposide	15-24	ATP binding cassette subfamily C member 2	Canis lupus familiaris	108-112
31091068-0	2019	Deazaflavin Inhibitors of TDP2 with Cellular Activity Can Affect Etoposide Influx and/or Efflux.	Etoposide	65-74	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	26-30
30841958-0	2019	miR-374a Inhibitor Enhances Etoposide-Induced Cytotoxicity Against Glioma Cells Through Upregulation of FOXO1.	Etoposide	28-37	microRNA 374a	Homo sapiens	0-8
30841958-0	2019	miR-374a Inhibitor Enhances Etoposide-Induced Cytotoxicity Against Glioma Cells Through Upregulation of FOXO1.	Etoposide	28-37	forkhead box O1	Homo sapiens	104-109
30841958-6	2019	More importantly, we found that knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells.	Etoposide	78-87	microRNA 374a	Homo sapiens	45-53
30841958-9	2019	Since Bim and Noxa act as key proapoptotic proteins in mitochondrial apoptosis, miR-374a inhibitor was able to enhance the etoposide-induced apoptosis pathway in glioma.	Etoposide	123-132	BCL2 like 11	Homo sapiens	6-9
30841958-9	2019	Since Bim and Noxa act as key proapoptotic proteins in mitochondrial apoptosis, miR-374a inhibitor was able to enhance the etoposide-induced apoptosis pathway in glioma.	Etoposide	123-132	microRNA 374a	Homo sapiens	80-88
31417239-8	2019	Conclusion: This study found that a panel with four genes (CSMD3, EPB41L3, PCLO, and RYR1) can accurately predict sensitivity to etoposide.	Etoposide	129-138	ryanodine receptor 1	Homo sapiens	85-89
31417239-7	2019	Results: ROC analysis of etoposide resistance revealed that the most significant single gene mutation indicating resistance to etoposide was CSMD3, and the accuracy of predicting resistance to etoposide proved to be the highest when there was any mutation in CSMD3/PCLO/RYR1/EPB41L3, area under the curve =0.804 (95% confidence interval: 0.679-0.930,P &lt;0.001).	Etoposide	127-136	CUB and Sushi multiple domains 3	Homo sapiens	141-146
30614034-0	2019	Signaling Crosstalk of FHIT, p53, and p38 in etoposide-induced apoptosis in MCF-7 cells.	Etoposide	45-54	fragile histidine triad diadenosine triphosphatase	Homo sapiens	23-27
30982575-5	2019	Additionally, Ad5-EMC6 enhances the sensitivity of gastric cancer cells to the chemotherapeutic drug etoposide.	Etoposide	101-110	ER membrane protein complex subunit 6	Homo sapiens	14-22
31081052-5	2019	The results revealed that TGF-beta1 treatment protected tumor cells from various apoptotic stresses, including 5-fluorouracil, etoposide and gamma-irradiation.	Etoposide	127-136	transforming growth factor beta 1	Homo sapiens	26-35
31197190-0	2019	Human Sialic acid O-acetyl esterase (SIAE) - mediated changes in sensitivity to etoposide in a medulloblastoma cell line.	Etoposide	80-89	sialic acid acetylesterase	Homo sapiens	6-35
31197190-0	2019	Human Sialic acid O-acetyl esterase (SIAE) - mediated changes in sensitivity to etoposide in a medulloblastoma cell line.	Etoposide	80-89	sialic acid acetylesterase	Homo sapiens	37-41
31197190-11	2019	Here we show that the GD3 acetylation pathway is dysregulated in MB and as a proof-of-principle we show that increased GD3 expression sensitises an MB cell line to etoposide.	Etoposide	164-173	GRDX	Homo sapiens	22-25
31197190-11	2019	Here we show that the GD3 acetylation pathway is dysregulated in MB and as a proof-of-principle we show that increased GD3 expression sensitises an MB cell line to etoposide.	Etoposide	164-173	GRDX	Homo sapiens	119-122
31289584-2	2019	Data regarding the efficacy of etoposide and cisplatin (EP) as a standard treatment of the primary tumor site in GEP-NEC are limited.	Etoposide	31-40	granulin precursor	Homo sapiens	113-116
30900772-8	2019	Blood or bone marrow samples from typical CK/MK AML patients showed defective p53 signaling upon induction by etoposide.	Etoposide	110-119	tumor protein p53	Homo sapiens	78-81
30614034-0	2019	Signaling Crosstalk of FHIT, p53, and p38 in etoposide-induced apoptosis in MCF-7 cells.	Etoposide	45-54	tumor protein p53	Homo sapiens	29-32
30614034-0	2019	Signaling Crosstalk of FHIT, p53, and p38 in etoposide-induced apoptosis in MCF-7 cells.	Etoposide	45-54	mitogen-activated protein kinase 14	Homo sapiens	38-41
30614034-4	2019	The time course study showed that the expression of FHIT, p53, and p38MAPK started after 1 hour following etoposide treatment.	Etoposide	106-115	fragile histidine triad diadenosine triphosphatase	Homo sapiens	52-56
30614034-4	2019	The time course study showed that the expression of FHIT, p53, and p38MAPK started after 1 hour following etoposide treatment.	Etoposide	106-115	tumor protein p53	Homo sapiens	58-61
30614034-5	2019	FHIT overexpression led to increase p53 expression, p38 activation, and augmented apoptosis following etoposide-induced DNA damage compared to wild-type cells.	Etoposide	102-111	fragile histidine triad diadenosine triphosphatase	Homo sapiens	0-4
30614034-6	2019	However, FHIT knockdown blocked p53 expression, delayed p38 activation, and completely inhibited etoposide-induced apoptosis.	Etoposide	97-106	fragile histidine triad diadenosine triphosphatase	Homo sapiens	9-13
30614034-8	2019	Thus, activation of p38 upon etoposide treatment leads to increase in FHIT and p53 expression.	Etoposide	29-38	mitogen-activated protein kinase 14	Homo sapiens	20-23
30614034-8	2019	Thus, activation of p38 upon etoposide treatment leads to increase in FHIT and p53 expression.	Etoposide	29-38	fragile histidine triad diadenosine triphosphatase	Homo sapiens	70-74
30614034-8	2019	Thus, activation of p38 upon etoposide treatment leads to increase in FHIT and p53 expression.	Etoposide	29-38	tumor protein p53	Homo sapiens	79-82
30614034-9	2019	In p53 knockdown MCF-7, the FHIT induction was hampered but p38 activation was induced in lower doses of etoposide.	Etoposide	105-114	tumor protein p53	Homo sapiens	3-6
30614034-9	2019	In p53 knockdown MCF-7, the FHIT induction was hampered but p38 activation was induced in lower doses of etoposide.	Etoposide	105-114	mitogen-activated protein kinase 14	Homo sapiens	60-63
30614034-11	2019	Our data demonstrated that the exposure of MCF-7 cells to etoposide increases apoptosis through a mechanism involving the activation of the p38-FHIT-p53 pathway.	Etoposide	58-67	mitogen-activated protein kinase 14	Homo sapiens	140-143
30614034-11	2019	Our data demonstrated that the exposure of MCF-7 cells to etoposide increases apoptosis through a mechanism involving the activation of the p38-FHIT-p53 pathway.	Etoposide	58-67	fragile histidine triad diadenosine triphosphatase	Homo sapiens	144-148
30614034-11	2019	Our data demonstrated that the exposure of MCF-7 cells to etoposide increases apoptosis through a mechanism involving the activation of the p38-FHIT-p53 pathway.	Etoposide	58-67	tumor protein p53	Homo sapiens	149-152
30797456-8	2019	In addition, this strategy was successfully applied for quantitative detection of Cyt c in cell lysates of H2O2 or etoposide (anticancer drug)-induced apoptotic cells, providing great potential application for cell-based oxidation pressure determination and screening of anticancer drugs.	Etoposide	115-124	cytochrome c, somatic	Homo sapiens	82-87
30920135-5	2019	We also observed that stromal CYP3A4 expression is up-regulated by drugs commonly used in AML induction therapy, cytarabine, etoposide and daunorubicin, resulting in cross-resistance.	Etoposide	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
30545921-3	2019	The AALL1131 trial was designed to determine, in a randomized fashion, whether substitution with cyclophosphamide/etoposide (experimental arm 1) would improve the 4-year disease-free survival of children, adolescents, and young adults with very high-risk B-cell acute lymphoblastic leukemia compared to a modified Berlin-Frankfurt-Munster regimen (control arm).	Etoposide	114-123	kallikrein related peptidase 4	Homo sapiens	138-143
30998359-0	2019	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.	Etoposide	176-185	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	80-84
30725116-5	2019	In response to 20 microM etoposide, the DNA/RNA-binding protein, non-POU domain-containing octamer-binding protein (NONO) and its dimerization partner splicing factor, proline/glutamine-rich (SFPQ) formed complexes with IGFBP-3, demonstrated in basal-like TNBC cell lines HCC1806 and MDA-MB-468.	Etoposide	25-34	non-POU domain containing octamer binding	Homo sapiens	65-114
30725116-5	2019	In response to 20 microM etoposide, the DNA/RNA-binding protein, non-POU domain-containing octamer-binding protein (NONO) and its dimerization partner splicing factor, proline/glutamine-rich (SFPQ) formed complexes with IGFBP-3, demonstrated in basal-like TNBC cell lines HCC1806 and MDA-MB-468.	Etoposide	25-34	non-POU domain containing octamer binding	Homo sapiens	116-120
30725116-5	2019	In response to 20 microM etoposide, the DNA/RNA-binding protein, non-POU domain-containing octamer-binding protein (NONO) and its dimerization partner splicing factor, proline/glutamine-rich (SFPQ) formed complexes with IGFBP-3, demonstrated in basal-like TNBC cell lines HCC1806 and MDA-MB-468.	Etoposide	25-34	splicing factor proline and glutamine rich	Homo sapiens	192-196
30725116-5	2019	In response to 20 microM etoposide, the DNA/RNA-binding protein, non-POU domain-containing octamer-binding protein (NONO) and its dimerization partner splicing factor, proline/glutamine-rich (SFPQ) formed complexes with IGFBP-3, demonstrated in basal-like TNBC cell lines HCC1806 and MDA-MB-468.	Etoposide	25-34	insulin like growth factor binding protein 3	Homo sapiens	220-227
30977678-0	2019	ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide.	Etoposide	119-128	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
30977678-0	2019	ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide.	Etoposide	119-128	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
30977678-1	2019	P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide.	Etoposide	243-252	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
30977678-1	2019	P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide.	Etoposide	243-252	ATP binding cassette subfamily B member 1	Homo sapiens	16-20
30977678-1	2019	P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide.	Etoposide	243-252	ATP binding cassette subfamily B member 1	Homo sapiens	38-43
30977678-6	2019	Accumulation of methotrexate, doxorubicin, actinomycin D, and etoposide was significantly lower in cells overexpressing wild-type P-gp than in untransfected control cells, indicating that these drugs are substrates of P-gp.	Etoposide	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
30977678-6	2019	Accumulation of methotrexate, doxorubicin, actinomycin D, and etoposide was significantly lower in cells overexpressing wild-type P-gp than in untransfected control cells, indicating that these drugs are substrates of P-gp.	Etoposide	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	218-222
30977678-8	2019	Methotrexate and etoposide were transported to a greater extent by variant P-gp than wild-type protein.	Etoposide	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
31106192-3	2019	In particular, compound 12h showed high activity with IC50 values ranging from 1.2 to 22.8 muM, with much better cytotoxic activity than the control drug etoposide (IC50: 8.4 to 78.2 muM).	Etoposide	154-163	latexin	Homo sapiens	183-186
30659606-5	2019	The effects on the major subpopulations of thymocytes based on multicolour flow cytometry studies were, first, the CD4-  CD8- double-negative (DN) cells, mainly DN2-4, were reduced with infection, LPS and Eto treatment, but not with Dex.	Etoposide	205-208	CD4 antigen	Mus musculus	115-118
30659606-6	2019	Second, the CD8+  CD3lo immature single-positive cells (ISPs) were highly sensitive to infection, LPS and Eto, but not Dex.	Etoposide	106-109	CD3 antigen, epsilon polypeptide	Mus musculus	18-21
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Etoposide	27-30	CD4 antigen	Mus musculus	75-78
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Etoposide	27-30	transcription factor Dp 1	Mus musculus	124-127
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Etoposide	27-30	transcription factor Dp 2	Mus musculus	137-140
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Etoposide	27-30	transcription factor Dp 2	Mus musculus	150-153
30659606-8	2019	Fourth, both CD4+ and CD8+ single-positive (SP) thymocytes were lowered by Eto and Dex, but not during infection.	Etoposide	75-78	CD4 antigen	Mus musculus	13-16
30943920-12	2019	This was associated with a reduction of Ataxia Telangiectasia Mutated (ATM) activation by etoposide, indicating a profound dampening of the DNA damage signalling in hypoxic conditions.	Etoposide	90-99	ATM serine/threonine kinase	Homo sapiens	40-69
30943920-12	2019	This was associated with a reduction of Ataxia Telangiectasia Mutated (ATM) activation by etoposide, indicating a profound dampening of the DNA damage signalling in hypoxic conditions.	Etoposide	90-99	ATM serine/threonine kinase	Homo sapiens	71-74
30943920-13	2019	As a consequence, p53 activation by etoposide was reduced, and cell survival enhanced.	Etoposide	36-45	tumor protein p53	Homo sapiens	18-21
30784913-0	2019	Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.	Etoposide	62-71	tumor protein p53	Homo sapiens	47-51
30576620-1	2019	H460 non-small cell lung, HCT116 colon and 4T1 breast tumor cell lines induced into senescence by exposure to either etoposide or doxorubicin were able to recover proliferative capacity both in mass culture and when enriched for the senescence-like phenotype by flow cytometry (based on beta-galactosidase staining and cell size, and a senescence-associated reporter, BTG1-RFP).	Etoposide	117-126	galactosidase, beta 1	Mus musculus	287-305
30576620-1	2019	H460 non-small cell lung, HCT116 colon and 4T1 breast tumor cell lines induced into senescence by exposure to either etoposide or doxorubicin were able to recover proliferative capacity both in mass culture and when enriched for the senescence-like phenotype by flow cytometry (based on beta-galactosidase staining and cell size, and a senescence-associated reporter, BTG1-RFP).	Etoposide	117-126	BTG anti-proliferation factor 1	Mus musculus	368-372
30576620-1	2019	H460 non-small cell lung, HCT116 colon and 4T1 breast tumor cell lines induced into senescence by exposure to either etoposide or doxorubicin were able to recover proliferative capacity both in mass culture and when enriched for the senescence-like phenotype by flow cytometry (based on beta-galactosidase staining and cell size, and a senescence-associated reporter, BTG1-RFP).	Etoposide	117-126	tripartite motif-containing 27	Mus musculus	373-376
30784913-1	2019	BACKGROUND: Etoposide-induced gene 24 (EI24) is an induction target of TP53-mediated apoptosis in human cancer cells.	Etoposide	12-21	EI24 autophagy associated transmembrane protein	Homo sapiens	39-43
30784913-1	2019	BACKGROUND: Etoposide-induced gene 24 (EI24) is an induction target of TP53-mediated apoptosis in human cancer cells.	Etoposide	12-21	tumor protein p53	Homo sapiens	71-75
30858166-0	2019	Alteration of 28S rRNA 2"-O-methylation by etoposide correlates with decreased SMN phosphorylation and reduced Drosha levels.	Etoposide	43-52	drosha ribonuclease III	Homo sapiens	111-117
30970518-4	2019	In two AML cell lines and primary AML cells from two patients, etoposide induced necroptosis via cIAP1/2 degradation when caspase activity was inhibited by Z-VAD-fmk, but treatment with extracellular HMGB1 prevented this necroptosis.	Etoposide	63-72	baculoviral IAP repeat containing 2	Homo sapiens	97-104
30970518-4	2019	In two AML cell lines and primary AML cells from two patients, etoposide induced necroptosis via cIAP1/2 degradation when caspase activity was inhibited by Z-VAD-fmk, but treatment with extracellular HMGB1 prevented this necroptosis.	Etoposide	63-72	high mobility group box 1	Homo sapiens	200-205
30966857-4	2019	Activation of p53 by treatment with either etoposide or the small-molecule MDM2 inhibitor nutlin 3A yields strikingly similar genome-wide binding of p53 and concomitant changes to local chromatin modifications and structure.	Etoposide	43-52	tumor protein p53	Homo sapiens	14-17
30966857-4	2019	Activation of p53 by treatment with either etoposide or the small-molecule MDM2 inhibitor nutlin 3A yields strikingly similar genome-wide binding of p53 and concomitant changes to local chromatin modifications and structure.	Etoposide	43-52	tumor protein p53	Homo sapiens	149-152
30995853-8	2019	Second-line treatment with VIP (etoposide, ifosfamide, cisplatin) did not reverse the progression and the patient was consulted at our institute.	Etoposide	32-41	vasoactive intestinal peptide	Homo sapiens	27-30
30532073-9	2019	Moreover, the senescent phenotype induced by DNA damage reagents, such as Etoposide, is at least in part mediated by MDM2-dependent WRN degradation as it can be significantly attenuated by ectopic expression of WRN.	Etoposide	74-83	MDM2 proto-oncogene	Homo sapiens	117-121
30532073-9	2019	Moreover, the senescent phenotype induced by DNA damage reagents, such as Etoposide, is at least in part mediated by MDM2-dependent WRN degradation as it can be significantly attenuated by ectopic expression of WRN.	Etoposide	74-83	WRN RecQ like helicase	Homo sapiens	132-135
30532073-9	2019	Moreover, the senescent phenotype induced by DNA damage reagents, such as Etoposide, is at least in part mediated by MDM2-dependent WRN degradation as it can be significantly attenuated by ectopic expression of WRN.	Etoposide	74-83	WRN RecQ like helicase	Homo sapiens	211-214
30858166-7	2019	Our previous work has shown that SMN, Drosha and various stresses, including etoposide treatment, may alter regulatory RNP formation.	Etoposide	77-86	drosha ribonuclease III	Homo sapiens	38-44
30858166-8	2019	Here we demonstrate that etoposide treatment decreases the phosphorylation of SMN, reduces Drosha levels and increases the 2"-O-methylation of two sites within 28S rRNA.	Etoposide	25-34	drosha ribonuclease III	Homo sapiens	91-97
30890736-7	2019	Here we show that TLP-mediated global transcriptional repression after DSBs is crucial for apoptosis induction by DNA-damaging agents such as etoposide and doxorubicin.	Etoposide	142-151	TATA-box binding protein like 1	Homo sapiens	18-21
30890736-8	2019	Compared to control cells, TLP-knockdown cells were resistant to etoposide-induced apoptosis and exhibited an elevated level of global transcription after etoposide exposure.	Etoposide	65-74	TATA-box binding protein like 1	Homo sapiens	27-30
30890736-8	2019	Compared to control cells, TLP-knockdown cells were resistant to etoposide-induced apoptosis and exhibited an elevated level of global transcription after etoposide exposure.	Etoposide	155-164	TATA-box binding protein like 1	Homo sapiens	27-30
30716336-7	2019	Our study proved that exosomes arising from KG1A cells could propel BMSCs to generate IL-8, which could regulate the effect of etoposide treatment.	Etoposide	127-136	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
30807965-8	2019	Results showed that etoposide was present in influents of wastewater treatment plants in several months and different wastewater treatment plants and hospital effluents in the range 375.8-5141 ng L-1, while cyclophosphamide was present in some months in effluents from only one wastewater treatment plant and hospital effluents in the range 55.94-1212 ng L-1.	Etoposide	20-29	immunoglobulin kappa variable 1-16	Homo sapiens	196-199
30807965-8	2019	Results showed that etoposide was present in influents of wastewater treatment plants in several months and different wastewater treatment plants and hospital effluents in the range 375.8-5141 ng L-1, while cyclophosphamide was present in some months in effluents from only one wastewater treatment plant and hospital effluents in the range 55.94-1212 ng L-1.	Etoposide	20-29	immunoglobulin kappa variable 1-16	Homo sapiens	355-358
30716336-8	2019	Furthermore, IL-8 inhibition by its antibody increased the sensitivity of AML cells to cell death triggered via etoposide.	Etoposide	112-121	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
30387535-4	2019	Overlap of MLL bcr sequences associated with both infant acute leukemia and therapy-related leukemia following exposure to the topoisomerase II inhibitor etoposide led to the hypothesis that exposure during pregnancy to biochemically similar compounds may promote infant acute leukemia.	Etoposide	154-163	lysine methyltransferase 2A	Homo sapiens	11-14
30387535-6	2019	We show bioflavonoids genistein and quercetin most biochemically similar to etoposide have a strong association with MLL-AF9 bcr translocations, while kaempferol, fisetin, flavone, and myricetin have a weak but consistent association, and other compounds have a minimal association in both embryonic stem (ES) and hematopoietic stem cell (HSC) populations.	Etoposide	76-85	lysine methyltransferase 2A	Homo sapiens	117-120
30387535-6	2019	We show bioflavonoids genistein and quercetin most biochemically similar to etoposide have a strong association with MLL-AF9 bcr translocations, while kaempferol, fisetin, flavone, and myricetin have a weak but consistent association, and other compounds have a minimal association in both embryonic stem (ES) and hematopoietic stem cell (HSC) populations.	Etoposide	76-85	MLLT3 super elongation complex subunit	Homo sapiens	121-124
30650062-14	2019	P-gp inhibition increases sensitivity to doxorubicin and etoposide, suggesting that MDR1 is involved in sensitivity to these drugs and could be a potential target for cytotoxic treatment improvement in ACC.	Etoposide	57-66	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
30650062-14	2019	P-gp inhibition increases sensitivity to doxorubicin and etoposide, suggesting that MDR1 is involved in sensitivity to these drugs and could be a potential target for cytotoxic treatment improvement in ACC.	Etoposide	57-66	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
30650062-0	2019	MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.	Etoposide	57-66	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
30328531-0	2019	Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.	Etoposide	36-45	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	13-19
30328531-9	2019	CONCLUSIONS: UGT1A1*28 and UGT1A1*6 mutations might be regarded as predictors for etoposide-induced grade 4 neutropenia.	Etoposide	82-91	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	27-33
30328531-1	2019	BACKGROUND: The association between UGT1A1 polymorphism and etoposide-induced toxicities is still not clear.	Etoposide	60-69	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	36-42
30328531-2	2019	The aim of this study was to assess the association between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and severe hematologic toxicities in Japanese patients receiving etoposide plus platinum chemotherapy for small-cell lung cancer.	Etoposide	200-209	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	60-107
30328531-2	2019	The aim of this study was to assess the association between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and severe hematologic toxicities in Japanese patients receiving etoposide plus platinum chemotherapy for small-cell lung cancer.	Etoposide	200-209	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	109-115
30328531-6	2019	The incidence of grade 4 neutropenia during the first cycle of etoposide-based chemotherapy was higher in patients with homozygous (hmz) polymorphisms for UGT1A1*28 and *6 (*28/*28, *6/*6, and *6/*28) than in patients with wild-type (wt) (*1/*1) and heterozygous (htz) (*1/*28 and *1/*6) polymorphisms (88% vs 43% P = 0.03).	Etoposide	63-72	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	155-161
30328531-9	2019	CONCLUSIONS: UGT1A1*28 and UGT1A1*6 mutations might be regarded as predictors for etoposide-induced grade 4 neutropenia.	Etoposide	82-91	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	13-19
30144069-3	2019	STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	107-116	serine/threonine kinase 31	Homo sapiens	0-5
30144069-3	2019	STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	107-116	tumor protein p53	Homo sapiens	69-72
30144069-3	2019	STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	118-120	serine/threonine kinase 31	Homo sapiens	0-5
30144069-3	2019	STK31 overexpression significantly activated PDCD5 stabilization and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	118-120	tumor protein p53	Homo sapiens	69-72
30763736-7	2019	Interestingly, Notch2 signalling also regulated chemoresistance of human GBM cells to etoposide.	Etoposide	86-95	notch receptor 2	Homo sapiens	15-21
30847181-3	2019	Treatment of these lymphomas consists of aggressive chemotherapy with dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE regimen).	Etoposide	130-139	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	141-146
30606675-2	2019	So, we design and prepare acid-controlled release complexes of podophyllotoxin (POD) and etoposide (VP-16) with pH-labile acyclic cucurbit[n]urils, and their characteristics and inclusion complexation behaviors were investigated via fluorescence spectroscopy, nuclear magnetic resonance and X-ray power diffraction.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
30774957-0	2019	Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide.	Etoposide	68-77	synuclein alpha	Homo sapiens	19-41
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	Etoposide	37-46	solute carrier organic anion transporter family member 1B1	Homo sapiens	151-158
30593505-7	2019	Additionally, we noted that DeltaN-TDP2 retains phosphodiesterase activity and is protective against etoposide-induced cell death, but co-immunoprecipitates with fewer high-molecular-weight ubiquitinated peptide species, suggesting partial loss-of-function of TDP2"s ubiquitin-association domain.	Etoposide	101-110	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	35-39
30774957-9	2019	Conclusions: The results indicate that NAC has the ability to counteract etoposide-induced toxicity rather than preventing the etoposide cytotoxic effects over sperm DNA, suggesting that the administration of NAC to cells formerly exposed to etoposide is preferable to its prophylactic use.	Etoposide	73-82	synuclein alpha	Homo sapiens	39-42
30774957-10	2019	As the results evidenced that NAC seems to be more efficient in attenuating sperm etoposide cytotoxic effects instead of being used as a chemoprophylactic agent, this reinforces the idea that there might be a new NAC mechanism over DNA.	Etoposide	82-91	synuclein alpha	Homo sapiens	30-33
30774957-10	2019	As the results evidenced that NAC seems to be more efficient in attenuating sperm etoposide cytotoxic effects instead of being used as a chemoprophylactic agent, this reinforces the idea that there might be a new NAC mechanism over DNA.	Etoposide	82-91	synuclein alpha	Homo sapiens	213-216
30683842-5	2019	CRBN depletion enhances the interaction between p53 and Bcl-2/Bcl-XL, reduces mitochondrial membrane potential, increases the cleavage of caspase-3 and poly(ADP-ribose) polymerase 1, and thus promotes DNA damage-induced apoptosis in cell lines and primary cells upon etoposide treatment.	Etoposide	267-276	cereblon	Mus musculus	0-4
30500985-9	2019	CONCLUSIONS AND IMPLICATIONS: The model could accurately predict the effects of anti-tumour drugs that involve the Bcl-2 family pathway, as shown with ABT-199 or etoposide.	Etoposide	162-171	BCL2 apoptosis regulator	Homo sapiens	115-120
30529266-7	2019	In contrast to a caspase-resistant mutant (D366/405/406E) the arrestin-3-(1-366) fragment reduces the apoptosis of etoposide-treated cells.	Etoposide	115-124	arrestin 3	Homo sapiens	62-72
30177841-9	2019	In addition, we demonstrated that Gjb4-mediated Src activation enhanced chemoresistance of cancer cells toward gemcitabine and etoposide.	Etoposide	127-136	gap junction protein, beta 4	Mus musculus	34-38
30177841-9	2019	In addition, we demonstrated that Gjb4-mediated Src activation enhanced chemoresistance of cancer cells toward gemcitabine and etoposide.	Etoposide	127-136	Rous sarcoma oncogene	Mus musculus	48-51
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	Etoposide	37-46	solute carrier organic anion transporter family member 1B3	Homo sapiens	160-167
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	Etoposide	37-46	solute carrier organic anion transporter family member 2B1	Homo sapiens	172-179
30217652-6	2019	By using xCELLigence system, we demonstrated that mifepristone enhances toxicity of etoposide in a dose dependent manner with concomitant caspase-3 activity.	Etoposide	84-93	caspase 3	Homo sapiens	138-147
30683842-6	2019	Moreover, Crbn knockout mice exhibit increased mortality upon etoposide challenge.	Etoposide	62-71	cereblon	Mus musculus	10-14
30683842-5	2019	CRBN depletion enhances the interaction between p53 and Bcl-2/Bcl-XL, reduces mitochondrial membrane potential, increases the cleavage of caspase-3 and poly(ADP-ribose) polymerase 1, and thus promotes DNA damage-induced apoptosis in cell lines and primary cells upon etoposide treatment.	Etoposide	267-276	transformation related protein 53, pseudogene	Mus musculus	48-51
30357526-11	2019	CONCLUSION: Oral etoposide retains some efficacy in selected heavily pre-treated patients with HER2-negative MBC, with the advantages of oral administration.	Etoposide	17-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
30774430-9	2019	Finally, similar to HHT treatment, depletion of thioredoxin sensitizes AML to ETP treatment.	Etoposide	78-81	thioredoxin	Homo sapiens	48-59
30655741-8	2019	Overexpression of Ulk2 significantly inhibited the proliferation of A549 and H460 cells (P&lt;0.05) and sensitized the NSCLC cell lines to cisplatin- and etoposide-induced inhibition of proliferation, and to cisplatin-induced apoptosis, with a significant difference identified compared with the control group (P&lt;0.05).	Etoposide	154-163	unc-51 like autophagy activating kinase 2	Homo sapiens	18-22
30391675-5	2019	The elevated RRAD expression was then confirmed in senescent human fibroblasts that were induced by Ras, H2O2, ionizing radiation, hydroxyurea, etoposide and replicative passage, respectively.	Etoposide	144-153	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	13-17
31161851-3	2019	In this study, we report an unexpected favorable response to etoposide and cisplatin (EP) from an EGFR-mutant patient who developed SCLC transformation at disease progression after the administration of erlotinib with a progression-free survivalof 7.7 months.	Etoposide	61-70	epidermal growth factor receptor	Homo sapiens	98-102
31875206-6	2019	Tdp1"s unique catalytic cycle, which is centered on the formation of Tdp1-DNA covalent reaction intermediate, allows for two principally different targeting strategies: (1) catalytic inhibition of Tdp1 catalysis to prevent Tdp1-mediated repair of DNA-adducts that enhances the effectivity of chemotherapeutics; and (2) poisoning of Tdp1 by stabilization of the Tdp1- DNA covalent reaction intermediate, which would increase the half-life of a potentially toxic DNA-adduct by preventing its resolution, analogous to topoisomerase targeted poisons such as topotecan or etoposide.	Etoposide	567-576	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
30483138-0	2018	Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.	Etoposide	9-18	caspase 3	Homo sapiens	90-99
29143233-2	2019	The objective of this study was to test whether etoposide alters glucosyl-ceramide, ceramide, sphingosine, and sphingosine-1-phosphate (sphingosine-1-P) levels in parental retinoblastoma cells (WERI Rb1) or their etoposide-resistant subclones (WERI EtoR).	Etoposide	48-57	RB transcriptional corepressor 1	Homo sapiens	199-202
30531974-7	2018	We also report that the DNA damaging drug Etoposide increases the translocation of Tau to the nucleus whilst reducing its phosphorylation.	Etoposide	42-51	microtubule associated protein tau	Homo sapiens	83-86
30380886-10	2018	Results of the CCF were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and teniposide or hyperforin being substrates of OATP2B1, respectively.	Etoposide	124-133	solute carrier organic anion transporter family member 2B1	Homo sapiens	183-190
29113504-8	2018	Besides, combined treatment of etoposide with Mcl-1 and Survivin siRNAs co-transfection leads to synergistically enhance etoposide-induced cytotoxic and apoptotic effects (p &lt; .05).	Etoposide	121-130	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	46-51
29113504-9	2018	The results showed that Mcl-1 and Survivin play a major role in the U937 cells survival and their resistance relative to etoposide.	Etoposide	121-130	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	24-29
30527181-0	2018	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.	Etoposide	46-55	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	77-83
30527181-2	2018	Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, suggesting that polymorphisms of UGT1A1 might be predictive of etoposide toxicity.	Etoposide	127-136	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-53
30527181-2	2018	Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, suggesting that polymorphisms of UGT1A1 might be predictive of etoposide toxicity.	Etoposide	127-136	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	55-61
30527181-2	2018	Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, suggesting that polymorphisms of UGT1A1 might be predictive of etoposide toxicity.	Etoposide	127-136	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	201-207
30527181-2	2018	Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, suggesting that polymorphisms of UGT1A1 might be predictive of etoposide toxicity.	Etoposide	231-240	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-53
30527181-2	2018	Uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) is thought to be largely responsible for the glucuronidation of etoposide as well as that of irinotecan, suggesting that polymorphisms of UGT1A1 might be predictive of etoposide toxicity.	Etoposide	231-240	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	55-61
30527181-10	2018	CONCLUSION: Our results reveal an association between UGT1A1 polymorphisms and toxicity of platinum-etoposide doublet therapy in SCLC patients, suggesting that close monitoring for toxicity, especially nephrotoxicity, is warranted for patients with such variant alleles receiving this treatment.	Etoposide	100-109	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	54-60
30520728-3	2018	RNA-Seq analysis of TFEB/TFE3 double-knockout cells exposed to etoposide reveals a profound dysregulation of the DNA damage response, including upstream regulators and downstream p53 targets.	Etoposide	63-72	transcription factor EB	Homo sapiens	20-24
30520728-3	2018	RNA-Seq analysis of TFEB/TFE3 double-knockout cells exposed to etoposide reveals a profound dysregulation of the DNA damage response, including upstream regulators and downstream p53 targets.	Etoposide	63-72	transcription factor binding to IGHM enhancer 3	Homo sapiens	25-29
30520728-3	2018	RNA-Seq analysis of TFEB/TFE3 double-knockout cells exposed to etoposide reveals a profound dysregulation of the DNA damage response, including upstream regulators and downstream p53 targets.	Etoposide	63-72	tumor protein p53	Homo sapiens	179-182
30533000-2	2018	Pharmacokinetic drug-drug interaction between mitotane, a strong CYP3A4 inducer, and etoposide, which is a substrate of CYP3A4, may contribute to chemoresistance.	Etoposide	85-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
30281394-7	2018	Upon exposure to gamma irradiation or etoposide treatment, each conditional Smc5 mutant demonstrated an increase in enlarged round spermatids with multiple acrosomes and supernumerary chromosome content.	Etoposide	38-47	structural maintenance of chromosomes 5	Mus musculus	76-80
30483138-3	2018	We observed that on a set of myeloid leukemia cell lines, etoposide at high (50 uM) dose promoted a rapid caspase-3-mediated apoptosis, whereas at low (0.5 uM) dose, it induced morphological and functional granulocytic differentiation and caspase-2-dependent, but caspase-3-independent, cell death, displaying features consistent with apoptosis.	Etoposide	58-67	caspase 3	Homo sapiens	106-115
30483138-3	2018	We observed that on a set of myeloid leukemia cell lines, etoposide at high (50 uM) dose promoted a rapid caspase-3-mediated apoptosis, whereas at low (0.5 uM) dose, it induced morphological and functional granulocytic differentiation and caspase-2-dependent, but caspase-3-independent, cell death, displaying features consistent with apoptosis.	Etoposide	58-67	caspase 2	Homo sapiens	239-248
30483138-3	2018	We observed that on a set of myeloid leukemia cell lines, etoposide at high (50 uM) dose promoted a rapid caspase-3-mediated apoptosis, whereas at low (0.5 uM) dose, it induced morphological and functional granulocytic differentiation and caspase-2-dependent, but caspase-3-independent, cell death, displaying features consistent with apoptosis.	Etoposide	58-67	caspase 3	Homo sapiens	264-273
30533258-3	2018	In the present study, we report that BRG1 depletion increased the percentage of apoptotic cells in etoposide-treated cells.	Etoposide	99-108	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	37-41
30352856-8	2018	The loss of BRCA1 caused marked increases of pathological TOP2ccs in G1 phase following exposure to etoposide, which generates pathological TOP2ccs.	Etoposide	100-109	BRCA1 DNA repair associated	Homo sapiens	12-17
30352856-10	2018	BRCA1-deficient cells showed a decrease in etoposide-induced MRE11 foci in G1 phase, suggesting that BRCA1 repairs pathological TOP2ccs by promoting the recruitment of MRE11 to TOP2cc sites.	Etoposide	43-52	BRCA1 DNA repair associated	Homo sapiens	0-5
30352856-10	2018	BRCA1-deficient cells showed a decrease in etoposide-induced MRE11 foci in G1 phase, suggesting that BRCA1 repairs pathological TOP2ccs by promoting the recruitment of MRE11 to TOP2cc sites.	Etoposide	43-52	MRE11 homolog, double strand break repair nuclease	Homo sapiens	61-66
30352856-10	2018	BRCA1-deficient cells showed a decrease in etoposide-induced MRE11 foci in G1 phase, suggesting that BRCA1 repairs pathological TOP2ccs by promoting the recruitment of MRE11 to TOP2cc sites.	Etoposide	43-52	BRCA1 DNA repair associated	Homo sapiens	101-106
30352856-10	2018	BRCA1-deficient cells showed a decrease in etoposide-induced MRE11 foci in G1 phase, suggesting that BRCA1 repairs pathological TOP2ccs by promoting the recruitment of MRE11 to TOP2cc sites.	Etoposide	43-52	MRE11 homolog, double strand break repair nuclease	Homo sapiens	168-173
30352856-12	2018	BRCA1 thus plays a critical role in removing pathological TOP2ccs induced by estrogens as well as etoposide.	Etoposide	98-107	BRCA1 DNA repair associated	Homo sapiens	0-5
30630783-6	2018	Recombinant human endo-statin combined with carboplatin and etoposide was more effective in treating advanced small cell lung cancer as it managed to reduce the level of serum tumor markers of CY211, CEA and CA199 with less side effects and high tolerance in patients, thus worthy of popularization and application in clinical trials.	Etoposide	60-69	CEA cell adhesion molecule 3	Homo sapiens	200-203
30297860-2	2018	The mechanism of the Top2s poisons such as etoposide (VP-16) was reported as stabilizing the Top2-DNA complex and engendering permanent DNA breakage.	Etoposide	43-52	host cell factor C1	Homo sapiens	54-59
30297860-6	2018	Through the comparison of the structures of hTop2beta-DNA-etoposide ternary complex and hTop2beta-DNA binary complex, it could be observed that the distance between drug-binding sites Arg503 of the two monomers was 26.62 A in hTop2beta-DNA-etoposide ternary complex and 34.54 A in hTop2beta-DNA binary complex, respectively.	Etoposide	58-67	DNA topoisomerase II beta	Homo sapiens	44-53
30114644-9	2018	Similar findings were observed when EID3-expressing MCF-7 cells were treated with etoposide, a topoisomerase II inhibitor.	Etoposide	82-91	EP300 interacting inhibitor of differentiation 3	Homo sapiens	36-40
29774773-2	2018	We show that Ang-1 is rapidly downregulated in the injured brain after controlled cortical impact (CCI), a mouse experimental traumatic brain injury (TBI) model and in etoposide-induced neuronal apoptosis in vitro.	Etoposide	168-177	angiopoietin 1	Mus musculus	13-18
29774773-4	2018	Ang-1 treatment phosphorylates receptors Tunica interna endothelial cell kinase 2 (Tie2), and beta1-integrin and limits the etoposide-induced decrease in protein kinase B (Akt) activity.	Etoposide	124-133	angiopoietin 1	Mus musculus	0-5
29774773-6	2018	After both TBI and etoposide treatment microRNA (miR)-711 are upregulated, consistent with its putative role as a negative regulator of Ang-1.	Etoposide	19-28	angiopoietin 1	Mus musculus	136-141
29774773-8	2018	Increased levels of miR-711 and Ang-1 mRNA are found in the RNA-induced silencing complex complex site of miR-mediated degradation of target mRNAs after etoposide treatment and the miR-711mimic downregulates Ang-1.	Etoposide	153-162	angiopoietin 1	Mus musculus	32-37
29774773-8	2018	Increased levels of miR-711 and Ang-1 mRNA are found in the RNA-induced silencing complex complex site of miR-mediated degradation of target mRNAs after etoposide treatment and the miR-711mimic downregulates Ang-1.	Etoposide	153-162	angiopoietin 1	Mus musculus	208-213
30349193-3	2018	Previous studies have shown that 4beta-1,2,3-triazole derivatives of podophyllotoxin exhibit more potent anticancer activity and better binding to topoisomerase-II than etoposide.	Etoposide	169-178	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-42
29775808-1	2018	OBJECTIVE: The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive-stage SCLC after treatment with platinum and etoposide.	Etoposide	161-170	SCLC1	Homo sapiens	122-126
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	Etoposide	220-229	mitogen-activated protein kinase 8	Homo sapiens	60-63
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	Etoposide	220-229	AKT serine/threonine kinase 1	Homo sapiens	64-67
30121250-9	2018	In summary, for the first time, we report that the stepwise JNK-AKT-NF-kappaB pathway is related to P-gp induction and DON elicited P-gp induction induces cells to resist exogenous toxic compounds, such as DON, Digoxin, Etoposide, etc.	Etoposide	220-229	nuclear factor kappa B subunit 1	Homo sapiens	68-77
30177851-0	2018	A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.	Etoposide	112-121	MYB proto-oncogene, transcription factor	Homo sapiens	54-57
30177851-0	2018	A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.	Etoposide	112-121	MYB proto-oncogene, transcription factor	Homo sapiens	139-142
30177851-5	2018	Our work shows that teniposide and etoposide, chemotherapeutic agents causing DNA-damage by inhibiting topoisomerase II, potently inhibit MYB activity and induce degradation of MYB in AML cell lines.	Etoposide	35-44	MYB proto-oncogene, transcription factor	Homo sapiens	138-141
30177851-5	2018	Our work shows that teniposide and etoposide, chemotherapeutic agents causing DNA-damage by inhibiting topoisomerase II, potently inhibit MYB activity and induce degradation of MYB in AML cell lines.	Etoposide	35-44	MYB proto-oncogene, transcription factor	Homo sapiens	177-180
30177851-8	2018	Teniposide and etoposide therefore act like double-edged swords that might be particularly effective to inhibit tumor cells with deregulated MYB.	Etoposide	15-24	MYB proto-oncogene, transcription factor	Homo sapiens	141-144
29908837-0	2018	Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia.	Etoposide	163-172	1-acylglycerol-3-phosphate O-acyltransferase 2	Homo sapiens	14-20
29908837-0	2018	Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia.	Etoposide	163-172	hypoxia inducible factor 1 subunit alpha	Homo sapiens	131-136
29908837-7	2018	Knockdown of AGPAT2 by siRNA reduced lipid droplet accumulation and cell viability under hypoxia and increased cancer cell sensitivity to the chemotherapeutic etoposide.	Etoposide	159-168	1-acylglycerol-3-phosphate O-acyltransferase 2	Homo sapiens	13-19
30213983-3	2018	To this end, a MYCN-amplified neuroblastoma cell line (HTLA-230) was treated with increasing etoposide concentrations and an etoposide-resistant cell line (HTLA-ER) was obtained.	Etoposide	93-102	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	15-19
30213983-4	2018	HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio.	Etoposide	25-34	BCL2 associated X, apoptosis regulator	Homo sapiens	74-77
30213983-4	2018	HTLA-ER cells, following etoposide exposure, evaded apoptosis by altering Bax/Bcl2 ratio.	Etoposide	25-34	BCL2 apoptosis regulator	Homo sapiens	78-82
30143009-8	2018	WTAP promoted DLBCL cell proliferation and improved the ability to confront apoptosis, while knockdown of WTAP in DLBCL cell lines allowed a significant higher apoptosis rate after treatment with Etoposide, an anti-tumor drug.	Etoposide	196-205	WT1 associated protein	Homo sapiens	106-110
30149619-0	2018	Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3.	Etoposide	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	91-96
30149619-0	2018	Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3.	Etoposide	0-9	caspase 3	Homo sapiens	101-110
30149619-6	2018	When etoposide was administered, heat shock accompanied with an accumulation of Hsp70 led to an inhibition of etoposide-induced apoptosis.	Etoposide	5-14	heat shock protein family A (Hsp70) member 4	Homo sapiens	80-85
30149619-6	2018	When etoposide was administered, heat shock accompanied with an accumulation of Hsp70 led to an inhibition of etoposide-induced apoptosis.	Etoposide	110-119	heat shock protein family A (Hsp70) member 4	Homo sapiens	80-85
30149619-8	2018	Competitive protein-protein interaction and immunoprecipitation assays showed that BT44 caused dissociation of the Hsp70-Caspase-3 complex, thus augmenting the anti-tumor activity of etoposide and highlighting the potential role of molecular separators in cancer therapy.	Etoposide	183-192	heat shock protein family A (Hsp70) member 4	Homo sapiens	115-120
30149619-8	2018	Competitive protein-protein interaction and immunoprecipitation assays showed that BT44 caused dissociation of the Hsp70-Caspase-3 complex, thus augmenting the anti-tumor activity of etoposide and highlighting the potential role of molecular separators in cancer therapy.	Etoposide	183-192	caspase 3	Homo sapiens	121-130
29069929-0	2018	Recombinant human erythropoietin prevents etoposide- and methotrexate-induced toxicity in kidney and liver tissues via the regulation of oxidative damage and genotoxicity in Wistar rats.	Etoposide	42-51	erythropoietin	Homo sapiens	18-32
29678622-10	2018	TRIM8 stabilizes the turnover of XIAP during genotoxic stress and forms complex with XIAP and caspase-3 to inhibit its activation in presence of etoposide.	Etoposide	145-154	tripartite motif containing 8	Homo sapiens	0-5
29678622-10	2018	TRIM8 stabilizes the turnover of XIAP during genotoxic stress and forms complex with XIAP and caspase-3 to inhibit its activation in presence of etoposide.	Etoposide	145-154	X-linked inhibitor of apoptosis	Homo sapiens	85-89
29678622-10	2018	TRIM8 stabilizes the turnover of XIAP during genotoxic stress and forms complex with XIAP and caspase-3 to inhibit its activation in presence of etoposide.	Etoposide	145-154	caspase 3	Homo sapiens	94-103
29759988-8	2018	Also, imetelstat potentiation of etoposide, a DNA-damaging drug that acts preferentially during S-G2 phases of the cell cycle, depends on functional ATM signaling.	Etoposide	33-42	ATM serine/threonine kinase	Homo sapiens	149-152
29886322-3	2018	As a result, most of the compounds were more potent than the positive drugs Etoposide (VP-16) and Doxorubicin which were widely used in clinical for antitumor.	Etoposide	76-85	host cell factor C1	Homo sapiens	87-92
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	hemoglobin subunit zeta	Homo sapiens	0-3
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	X-ray repair cross complementing 6	Homo sapiens	77-81
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	X-ray repair cross complementing 5	Homo sapiens	86-90
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	hemoglobin subunit zeta	Homo sapiens	173-176
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	231-249
29769340-6	2018	HBZ was found to interact with two vital members of the NHEJ core machinery, Ku70 and Ku80, and to be recruited to DSBs in a bZIP-dependent manner in vitro We observed that HBZ expression also resulted in a bZIP-dependent delay in DNA protein kinase (DNA-PK) activation following treatment with etoposide.	Etoposide	295-304	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	251-257
29412022-7	2018	ETS was effectively loaded into the channels of PAA-MSN via electrostatic interactions.	Etoposide	0-3	moesin	Homo sapiens	52-55
29941883-0	2018	DNA damage response induced by Etoposide promotes steroidogenesis via GADD45A in cultured adrenal cells.	Etoposide	31-40	growth arrest and DNA damage inducible alpha	Homo sapiens	70-77
29941883-11	2018	Specifically, GADD45A plays a crucial role in the steroidogenic processes triggered by EP-stimulated genotoxic stress.	Etoposide	87-89	growth arrest and DNA damage inducible alpha	Homo sapiens	14-21
29946852-7	2018	In patients with negative PSA levels, chemotherapy with cisplatin and etoposide is the first line treatment, for which response rates in the range of 30-60% with a median survival time of usually less than 1 year can be achieved.	Etoposide	70-79	kallikrein related peptidase 3	Homo sapiens	26-29
29134688-11	2018	CONCLUSION: NF during etoposide priming is associated with lower likelihood of proceeding to transplant, lower CD34+ cell dose collection, more apheresis days required for collection and a higher 30-day readmission rate following transplant discharge.	Etoposide	22-31	CD34 molecule	Homo sapiens	111-115
29653431-0	2018	Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.	Etoposide	56-65	nicotinamide phosphoribosyltransferase	Homo sapiens	14-19
29653431-0	2018	Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.	Etoposide	56-65	sirtuin 2	Homo sapiens	88-93
29653431-0	2018	Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.	Etoposide	56-65	tumor protein p53	Homo sapiens	94-97
29653431-6	2018	Etoposide decreased protein abundance of NAD-dependent deacetylases SIRTUIN1.	Etoposide	0-9	sirtuin 1	Homo sapiens	68-76
29653431-7	2018	After combining etoposide and FK866 treatment SIRTUIN2 was further decreased and accumulation and acetylation of the downstream target p53 was further enhanced in MOLT4 cells.	Etoposide	16-25	sirtuin 2	Homo sapiens	46-54
29653431-7	2018	After combining etoposide and FK866 treatment SIRTUIN2 was further decreased and accumulation and acetylation of the downstream target p53 was further enhanced in MOLT4 cells.	Etoposide	16-25	tumor protein p53	Homo sapiens	135-138
29653431-9	2018	Targeting NAMPT could be a novel therapeutic strategy to enhance the efficacy of chemotherapeutic agents such as etoposide against leukemia.	Etoposide	113-122	nicotinamide phosphoribosyltransferase	Homo sapiens	10-15
29635055-1	2018	The aim of the present work was to investigate the ability of nonionic surfactants to increase the oral absorption of the P-glycoprotein substrate etoposide in vitro and in vivo.	Etoposide	147-156	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	122-136
29635055-4	2018	In cell cultures, polysorbate 20 (PS20) decreased P-glycoprotein mediated efflux of etoposide.	Etoposide	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-64
29635055-7	2018	Unexpectedly, co-administration of etoposide with 25% PS20 significantly reduced the absorption fraction of etoposide in mdr1a KO rats.	Etoposide	35-44	ATP binding cassette subfamily B member 1A	Rattus norvegicus	121-126
29635055-7	2018	Unexpectedly, co-administration of etoposide with 25% PS20 significantly reduced the absorption fraction of etoposide in mdr1a KO rats.	Etoposide	108-117	ATP binding cassette subfamily B member 1A	Rattus norvegicus	121-126
29635055-9	2018	In conclusion, PS20 increases oral bioavailability of etoposide through inhibition of P-glycoprotein.	Etoposide	54-63	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	86-100
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	catenin beta 1	Homo sapiens	124-136
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	CD274 molecule	Homo sapiens	142-147
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	DNA topoisomerase II beta	Homo sapiens	161-166
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	catenin beta 1	Homo sapiens	197-209
29786670-9	2018	We found that USP47 contributes to cell viability and chemoresistance in NCI-N87 gastric carcinoma cells treated with etoposide and camptothecin.	Etoposide	118-127	ubiquitin specific peptidase 47	Homo sapiens	14-19
29514855-0	2018	The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIalpha (TOP2alpha/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2alpha/170 Isoform.	Etoposide	106-115	DNA topoisomerase II alpha	Homo sapiens	72-81
30159287-0	2018	Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia.	Etoposide	34-43	electron transfer flavoprotein subunit alpha	Homo sapiens	26-32
30159287-2	2018	The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients" outcome.	Etoposide	84-93	electron transfer flavoprotein subunit alpha	Homo sapiens	76-82
29748582-4	2018	Furthermore, USP49 rendered HCT116 cells more sensitive to etoposide (Eto)-induced DNA damage and was upregulated in response to several types of cell stress, including DNA damage.	Etoposide	59-68	ubiquitin specific peptidase 49	Homo sapiens	13-18
29748582-4	2018	Furthermore, USP49 rendered HCT116 cells more sensitive to etoposide (Eto)-induced DNA damage and was upregulated in response to several types of cell stress, including DNA damage.	Etoposide	70-73	ubiquitin specific peptidase 49	Homo sapiens	13-18
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	CD274 molecule	Homo sapiens	232-237
29765039-5	2018	We further identify a non-canonical mesenchymal-epithelial transition (MET) activity of etoposide, which suppresses the EMT/beta-catenin/STT3/PD-L1 axis through TOP2B degradation-dependent nuclear beta-catenin reduction, leading to PD-L1 downregulation of CSCs and non-CSCs and sensitization of cancer cells to anti-Tim-3 therapy.	Etoposide	88-97	hepatitis A virus cellular receptor 2	Homo sapiens	316-321
29759113-5	2018	Here, we show that ARP8, a subunit of the INO80 chromatin remodeling complex, is phosphorylated after etoposide treatment.	Etoposide	102-111	actin related protein 8	Homo sapiens	19-23
29759113-5	2018	Here, we show that ARP8, a subunit of the INO80 chromatin remodeling complex, is phosphorylated after etoposide treatment.	Etoposide	102-111	INO80 complex ATPase subunit	Homo sapiens	42-47
29759113-6	2018	The etoposide-induced phosphorylation of ARP8 is regulated by ATM and ATR, and attenuates its interaction with INO80.	Etoposide	4-13	actin related protein 8	Homo sapiens	41-45
29759113-6	2018	The etoposide-induced phosphorylation of ARP8 is regulated by ATM and ATR, and attenuates its interaction with INO80.	Etoposide	4-13	ATM serine/threonine kinase	Homo sapiens	62-65
29759113-6	2018	The etoposide-induced phosphorylation of ARP8 is regulated by ATM and ATR, and attenuates its interaction with INO80.	Etoposide	4-13	ATR serine/threonine kinase	Homo sapiens	70-73
29759113-6	2018	The etoposide-induced phosphorylation of ARP8 is regulated by ATM and ATR, and attenuates its interaction with INO80.	Etoposide	4-13	INO80 complex ATPase subunit	Homo sapiens	111-116
29759113-8	2018	These findings suggest that the phosphorylation of ARP8, regulated by ATM, plays an important role in maintaining the fidelity of DNA repair to prevent the etoposide-induced 11q23 abnormalities.	Etoposide	156-165	actin related protein 8	Homo sapiens	51-55
29759113-8	2018	These findings suggest that the phosphorylation of ARP8, regulated by ATM, plays an important role in maintaining the fidelity of DNA repair to prevent the etoposide-induced 11q23 abnormalities.	Etoposide	156-165	ATM serine/threonine kinase	Homo sapiens	70-73
29514855-0	2018	The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIalpha (TOP2alpha/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2alpha/170 Isoform.	Etoposide	106-115	DNA topoisomerase II alpha	Homo sapiens	182-191
29514855-2	2018	We previously characterized a C-terminally truncated isoform (TOP2alpha/90), detectable in human leukemia K562 cells but more abundantly expressed in a clonal subline, K/VP.5, with acquired resistance to the anticancer agent etoposide.	Etoposide	225-234	DNA topoisomerase II alpha	Homo sapiens	62-71
29514855-7	2018	Forced expression of TOP2alpha/90 in K562 cells suppressed, whereas siRNA-mediated knockdown of TOP2alpha/90 in K/VP.5 cells enhanced, etoposide-mediated DNA strand breaks compared with similarly treated cells transfected with empty vector or control siRNAs, respectively.	Etoposide	135-144	DNA topoisomerase II alpha	Homo sapiens	96-105
29514855-8	2018	In addition, forced expression of TOP2alpha/90 in K562 cells inhibited etoposide cytotoxicity assessed by clonogenic assays.	Etoposide	71-80	DNA topoisomerase II alpha	Homo sapiens	34-43
29584430-6	2018	One bicyclic peptide was shown to inhibit the interaction between a pro-apoptotic protein (Bim) and either endogenous Bcl2A1 or Mcl-1, to induce apoptosis of SKMel28 human melanoma cells, and to sensitize them for enhanced cell death by the anticancer drug etoposide.	Etoposide	257-266	BCL2 like 11	Homo sapiens	91-94
29643533-8	2018	MICB mRNA expression also increased slightly in another breast cancer cell SK-BR-3 treated by topoisomerase II inhibitors etoposide and camptothecin (P&lt;0.05).	Etoposide	122-131	MHC class I polypeptide-related sequence B	Homo sapiens	0-4
29643533-9	2018	Furthermore, etoposide and camptothecin upregulated MICA/B surface protein expression in MCF-7 cells (P&lt;0.05), and the upregulation was found in both living and apoptotic cells.	Etoposide	13-22	MHC class I polypeptide-related sequence A	Homo sapiens	52-56
29643533-10	2018	Our study showed that etoposide induced-MICA/B expression in MCF-7 was inhibited by caffeine at different concentrations.	Etoposide	22-31	MHC class I polypeptide-related sequence A	Homo sapiens	40-44
29643533-12	2018	Similarly, NF-kappaB inhibitor PDTC also inhibited MICA/B mRNA and protein expressions induced by etoposide significantly when MCF-7 cells were incubated with PDTC at the concentrations of 10, 50 and 100 mumol/L (P&lt;0.05), indicating that NF-kappaB was also involved in this process.	Etoposide	98-107	nuclear factor kappa B subunit 1	Homo sapiens	11-20
29643533-12	2018	Similarly, NF-kappaB inhibitor PDTC also inhibited MICA/B mRNA and protein expressions induced by etoposide significantly when MCF-7 cells were incubated with PDTC at the concentrations of 10, 50 and 100 mumol/L (P&lt;0.05), indicating that NF-kappaB was also involved in this process.	Etoposide	98-107	MHC class I polypeptide-related sequence A	Homo sapiens	51-55
29643533-12	2018	Similarly, NF-kappaB inhibitor PDTC also inhibited MICA/B mRNA and protein expressions induced by etoposide significantly when MCF-7 cells were incubated with PDTC at the concentrations of 10, 50 and 100 mumol/L (P&lt;0.05), indicating that NF-kappaB was also involved in this process.	Etoposide	98-107	nuclear factor kappa B subunit 1	Homo sapiens	241-250
29643533-13	2018	EMSA showed that the binding of NF-kappaB to MICA/B promoter enhanced in MCF-7 cells after etoposide treatment.	Etoposide	91-100	nuclear factor kappa B subunit 1	Homo sapiens	32-41
29643533-13	2018	EMSA showed that the binding of NF-kappaB to MICA/B promoter enhanced in MCF-7 cells after etoposide treatment.	Etoposide	91-100	MHC class I polypeptide-related sequence A	Homo sapiens	45-49
29306194-3	2018	Downregulation of PARP1 made cancer cells vulnerable to death triggered by the anticancer drugs (WP631 and etoposide) and H2O2.	Etoposide	107-116	poly(ADP-ribose) polymerase 1	Homo sapiens	18-23
29643533-4	2018	Electrophoretic mobility shift assay (EMSA) was taken to investigate whether etoposide enhanced the binding of NF-kappaB to MICA/B gene promoter.	Etoposide	77-86	nuclear factor kappa B subunit 1	Homo sapiens	111-120
29643533-4	2018	Electrophoretic mobility shift assay (EMSA) was taken to investigate whether etoposide enhanced the binding of NF-kappaB to MICA/B gene promoter.	Etoposide	77-86	MHC class I polypeptide-related sequence A	Homo sapiens	124-128
29643533-5	2018	RESULTS: Three topoisomerase inhibitors etoposide, camptothecin and doxorubicine upregulated MICA and MICB mRNA expressions in breast cancer cell MCF-7.	Etoposide	40-49	MHC class I polypeptide-related sequence A	Homo sapiens	93-97
29643533-5	2018	RESULTS: Three topoisomerase inhibitors etoposide, camptothecin and doxorubicine upregulated MICA and MICB mRNA expressions in breast cancer cell MCF-7.	Etoposide	40-49	MHC class I polypeptide-related sequence B	Homo sapiens	102-106
29643533-6	2018	Comparing to no-drug-treated cells, MICA mRNA levels increased to (1.68+-0.17), (2.54+-0.25) and (3.42+-0.15) fold, and levels of MICB mRNA increased to (1.82+-0.24), (1.56+-0.05) and (5.84+-0.57) fold respectively in cancer cells treated by etoposide at the concentrations of 5, 20 and 100 mumol/L (P&lt;0.05).	Etoposide	242-251	MHC class I polypeptide-related sequence A	Homo sapiens	36-40
29397400-10	2018	We suggest that the damage to mitochondria is a major contributing factor involved in ETP-induced cardiotoxicity and the activation of the p53-mediated ferroptosis pathway by ETP is likely the critical pathway in ETP-induced cardiotoxicity.	Etoposide	175-178	tumor protein p53	Homo sapiens	139-142
29397400-10	2018	We suggest that the damage to mitochondria is a major contributing factor involved in ETP-induced cardiotoxicity and the activation of the p53-mediated ferroptosis pathway by ETP is likely the critical pathway in ETP-induced cardiotoxicity.	Etoposide	175-178	tumor protein p53	Homo sapiens	139-142
29471073-4	2018	We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect.	Etoposide	14-23	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	48-54
29571988-10	2018	MiR-192 and miR-662 inhibition sensitized SCC cells to etoposide but not to cisplatin.	Etoposide	55-64	microRNA 192	Homo sapiens	0-7
29571988-10	2018	MiR-192 and miR-662 inhibition sensitized SCC cells to etoposide but not to cisplatin.	Etoposide	55-64	microRNA 662	Homo sapiens	12-19
29571988-10	2018	MiR-192 and miR-662 inhibition sensitized SCC cells to etoposide but not to cisplatin.	Etoposide	55-64	serpin family B member 3	Homo sapiens	42-45
29571988-14	2018	Overexpression of miR-192 and miR-662 might be useful as a marker of resistance to etoposide.	Etoposide	83-92	microRNA 192	Homo sapiens	18-25
29571988-14	2018	Overexpression of miR-192 and miR-662 might be useful as a marker of resistance to etoposide.	Etoposide	83-92	microRNA 662	Homo sapiens	30-37
29467274-6	2018	We show that SAR is cytotoxic to NSCLC cells, which exhibit resistance to genotoxic therapies, such as ionizing radiation, cisplatin, and etoposide.	Etoposide	138-147	sarcosine dehydrogenase	Homo sapiens	13-16
29471073-4	2018	We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect.	Etoposide	14-23	tumor protein p53	Homo sapiens	58-62
29471073-7	2018	Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.	Etoposide	60-69	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	95-101
29471073-7	2018	Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone.	Etoposide	60-69	tumor protein p53	Homo sapiens	156-159
29471073-4	2018	We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect.	Etoposide	14-23	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	138-144
29471073-4	2018	We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect.	Etoposide	14-23	tumor protein p53	Homo sapiens	158-161
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	prohibitin 2	Homo sapiens	53-56
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	94-100
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	tumor protein p53	Homo sapiens	115-119
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	prohibitin 2	Homo sapiens	206-209
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	244-250
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	prohibitin 2	Homo sapiens	206-209
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	prohibitin 2	Homo sapiens	206-209
29471073-5	2018	Co-incubation experiments with the drugs and 2.5 muM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression.	Etoposide	74-83	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	244-250
29309885-6	2018	Upregulation of p53 and p21 upon etoposide treatment is attenuated in HBXIP knock-down cells.	Etoposide	33-42	tumor protein p53	Homo sapiens	16-19
29309885-6	2018	Upregulation of p53 and p21 upon etoposide treatment is attenuated in HBXIP knock-down cells.	Etoposide	33-42	H3 histone pseudogene 16	Homo sapiens	24-27
29309885-0	2018	HBXIP regulates etoposide-induced cell cycle checkpoints and apoptosis in MCF-7 human breast carcinoma cells.	Etoposide	16-25	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	0-5
29309885-3	2018	In this study, we investigate the effects of HBXIP gene silencing on etoposide chemosensitivity in MCF-7 human breast cancer cells.	Etoposide	69-78	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	45-50
29309885-6	2018	Upregulation of p53 and p21 upon etoposide treatment is attenuated in HBXIP knock-down cells.	Etoposide	33-42	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	70-75
29309885-4	2018	We find that etoposide increases HBXIP expression and promotes mobilization of HBXIP to the nucleus in MCF-7 cells.	Etoposide	13-22	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	33-38
29309885-4	2018	We find that etoposide increases HBXIP expression and promotes mobilization of HBXIP to the nucleus in MCF-7 cells.	Etoposide	13-22	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	79-84
29309885-7	2018	Moreover, HBXIP gene silencing sensitizes etoposide-induced cell apoptosis and cleavage of caspase-9 and PARP in MCF-7 cells.	Etoposide	42-51	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	10-15
29309885-5	2018	Knockdown of HBXIP alleviates etoposide-induced G2/M or S phase arrest.	Etoposide	30-39	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	13-18
29309885-7	2018	Moreover, HBXIP gene silencing sensitizes etoposide-induced cell apoptosis and cleavage of caspase-9 and PARP in MCF-7 cells.	Etoposide	42-51	poly(ADP-ribose) polymerase 1	Homo sapiens	105-109
29309885-8	2018	Knockdown of HBXIP expression by RNAi abrogates the etoposide-activated ERK and Akt.	Etoposide	52-61	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	13-18
29309885-8	2018	Knockdown of HBXIP expression by RNAi abrogates the etoposide-activated ERK and Akt.	Etoposide	52-61	mitogen-activated protein kinase 1	Homo sapiens	72-75
29309885-8	2018	Knockdown of HBXIP expression by RNAi abrogates the etoposide-activated ERK and Akt.	Etoposide	52-61	AKT serine/threonine kinase 1	Homo sapiens	80-83
29309885-9	2018	These results indicate that HBXIP can modulate the etoposide sensitivity of MCF-7 cell lines and further implicate HBXIP as a target for human breast cancer.	Etoposide	51-60	late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	Homo sapiens	28-33
29511910-9	2018	We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.	Etoposide	79-88	granulin precursor	Homo sapiens	138-141
29447373-3	2018	Therefore, as a first step toward constraining the distribution of etoposide-induced DNA cleavage sites and developing sequence-specific topoisomerase II-targeted anticancer agents, we covalently coupled the core of etoposide to oligonucleotides centered on a topoisomerase II cleavage site in the PML gene.	Etoposide	216-225	PML nuclear body scaffold	Homo sapiens	298-301
29447373-6	2018	Results indicate that OTIs can be used to direct the sites of etoposide-induced DNA cleavage mediated by topoisomerase IIalpha and topoisomerase IIbeta.	Etoposide	62-71	DNA topoisomerase II beta	Homo sapiens	105-151
29328447-2	2018	Western blot analysis revealed that vincristine (VCR), etoposide (ETO) and carboplatin (CBP) significantly increased the expression of HMGB1 in Weri-Rb-1 and Y79 cells compared with the untreated control (P&lt;0.01).	Etoposide	55-64	high mobility group box 1	Homo sapiens	135-140
29328447-2	2018	Western blot analysis revealed that vincristine (VCR), etoposide (ETO) and carboplatin (CBP) significantly increased the expression of HMGB1 in Weri-Rb-1 and Y79 cells compared with the untreated control (P&lt;0.01).	Etoposide	66-69	high mobility group box 1	Homo sapiens	135-140
28690315-4	2018	Abrogation of nucleolin sensitized DLBCL cells to TopIIA targeting agents (doxorubicin/etoposide).	Etoposide	87-96	nucleolin	Homo sapiens	14-23
28690315-8	2018	Nucleolin silencing decreased TopIIA decatenation activity, but enhanced formation of TopIIA-DNA cleavable complexes in the presence of etoposide.	Etoposide	136-145	nucleolin	Homo sapiens	0-9
29541168-0	2018	Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.	Etoposide	0-9	tumor protein p53	Homo sapiens	26-29
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	191-200	cofilin 1	Homo sapiens	33-40
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	191-200	cofilin 1	Homo sapiens	74-81
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	191-200	PTEN induced kinase 1	Homo sapiens	127-132
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	191-200	parkin RBR E3 ubiquitin protein ligase	Homo sapiens	133-138
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	202-205	cofilin 1	Homo sapiens	33-40
29321664-6	2018	Here we report that knockdown of cofilin attenuates and overexpression of cofilin potentiates mitochondrial fission as well as PINK1/PARK2-dependent mitophagy induced by staurosporine (STS), etoposide (ETO), and carbonyl cyanide 3-chlorophenylhydrazone (CCCP).	Etoposide	202-205	cofilin 1	Homo sapiens	74-81
29541168-5	2018	The present study evaluated the radiosensitization potential of etoposide in p53-defective CCA KKU-M055 and KKU-M214 cell lines.	Etoposide	64-73	tumor protein p53	Homo sapiens	77-80
29541168-6	2018	Treatment with etoposide enhanced the responsiveness of two p53-defective CCA cell lines to radiation independent of G2 checkpoint function.	Etoposide	15-24	tumor protein p53	Homo sapiens	60-63
29541168-8	2018	These findings indicate that etoposide could be used as a radiation sensitizer for p53-defective tumors, independent of the function of G2 checkpoint.	Etoposide	29-38	tumor protein p53	Homo sapiens	83-86
29681946-8	2018	We inhibited RAD51 in CSC-enriched cultures using RES or siRNA against RAD51 messenger RNA and observed a decrease in cell viability and induction of apoptosis when treated simultaneously with VP16.	Etoposide	193-197	RAD51 recombinase	Homo sapiens	13-18
29467390-6	2018	In this study, we show that FGF1 favors survival of COV434 cells upon treatment with etoposide and cisplatin, two common chemotherapeutic molecules used for ovarian cancer.	Etoposide	85-94	fibroblast growth factor 1	Homo sapiens	28-32
29467390-7	2018	Etoposide and cisplatin induced mitochondrial depolarization, cytochrome c release and caspase activation in COV434 cells.	Etoposide	0-9	cytochrome c, somatic	Homo sapiens	62-74
29467390-10	2018	Etoposide induced p21 expression as expected, but p21 protein levels were even increased in the presence of FGF1.	Etoposide	0-9	H3 histone pseudogene 16	Homo sapiens	18-21
29467390-10	2018	Etoposide induced p21 expression as expected, but p21 protein levels were even increased in the presence of FGF1.	Etoposide	0-9	fibroblast growth factor 1	Homo sapiens	108-112
29467390-14	2018	Indeed, p53 accumulates at mitochondria upon etoposide treatment and inhibition of p53 mitochondrial localization using pifithrin-micro inhibits apoptosis of COV434 cells.	Etoposide	45-54	tumor protein p53	Homo sapiens	8-11
29467390-15	2018	FGF1 also decreases mitochondrial accumulation of p53 induced by etoposide.	Etoposide	65-74	fibroblast growth factor 1	Homo sapiens	0-4
29467390-15	2018	FGF1 also decreases mitochondrial accumulation of p53 induced by etoposide.	Etoposide	65-74	tumor protein p53	Homo sapiens	50-53
29581848-9	2018	Finally, HLX inhibited transcription of B-cell differentiation factors MSX1, BCL11A and SPIB and of pro-apoptotic factor BCL2L11/BIM, thereby suppressing Etoposide-induced cell death.	Etoposide	154-163	H2.0 like homeobox	Homo sapiens	9-12
29458417-5	2018	We found that upon serum deprivation or etoposide-induced DNA damage, female, but not male GBM astrocytes, respond with increased p16 and p21 activity, and cell cycle arrest.	Etoposide	40-49	cyclin dependent kinase inhibitor 2A	Mus musculus	130-133
29458417-5	2018	We found that upon serum deprivation or etoposide-induced DNA damage, female, but not male GBM astrocytes, respond with increased p16 and p21 activity, and cell cycle arrest.	Etoposide	40-49	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	138-141
29844877-10	2018	During 0-2 hour etoposide treatment, RABL6 transcription was robustly increased at 0.5 and 1 hour in MCF7 cells and at 2 hours in T47D cells, while FAS-AS1 transcription was dramatically and steadily elevated in both cell lines.	Etoposide	16-25	RAB, member RAS oncogene family like 6	Homo sapiens	37-42
29368155-6	2018	SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) or other L-asparaginase-containing therapy is promising for advanced-stage ENKL, followed by either autologous or allogeneic hematopoietic stem cell transplantation.	Etoposide	62-71	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	0-5
29844877-10	2018	During 0-2 hour etoposide treatment, RABL6 transcription was robustly increased at 0.5 and 1 hour in MCF7 cells and at 2 hours in T47D cells, while FAS-AS1 transcription was dramatically and steadily elevated in both cell lines.	Etoposide	16-25	FAS antisense RNA 1	Homo sapiens	148-155
29387836-0	2018	Alkaline phosphatase-triggered assembly of etoposide enhances its anticancer effect.	Etoposide	43-52	alkaline phosphatase, placental	Homo sapiens	0-20
29415984-3	2018	Here, we show that stable knockdown of UHRF1 renders retinoblastoma cells sensitized to conventional chemotherapeutic drugs such as etoposide and camptothecin, resulting in enhanced DNA damage and apoptotic cell death.	Etoposide	132-141	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	39-44
29415984-5	2018	Conversely, overexpression of UHRF1 increased the XRCC4 expression and stable knockdown of XRCC4 sensitized retinoblastoma cells to etoposide treatment, suggesting that XRCC4 is a key mediator for the drug sensitivity upon UHRF1 depletion in retinoblastoma cells.	Etoposide	132-141	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	30-35
29415984-5	2018	Conversely, overexpression of UHRF1 increased the XRCC4 expression and stable knockdown of XRCC4 sensitized retinoblastoma cells to etoposide treatment, suggesting that XRCC4 is a key mediator for the drug sensitivity upon UHRF1 depletion in retinoblastoma cells.	Etoposide	132-141	X-ray repair cross complementing 4	Homo sapiens	91-96
29493383-12	2018	Following miR-130a knockdown, SKNO-1 demonstrated increased sensitivity to etoposide.	Etoposide	75-84	microRNA 130a	Homo sapiens	10-18
29415984-5	2018	Conversely, overexpression of UHRF1 increased the XRCC4 expression and stable knockdown of XRCC4 sensitized retinoblastoma cells to etoposide treatment, suggesting that XRCC4 is a key mediator for the drug sensitivity upon UHRF1 depletion in retinoblastoma cells.	Etoposide	132-141	X-ray repair cross complementing 4	Homo sapiens	91-96
29571245-0	2018	Rosemary extract modulates fertility potential, DNA fragmentation, injury, KI67 and P53 alterations induced by etoposide in rat testes.	Etoposide	111-120	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	84-87
29571245-4	2018	Sperms counts, motility and viability and KI67 immunoreactivity in testes were significantly decreased while; sperm abnormalities, testicular injury, P53 and DNA damage were a significantly increased in Etoposide group as compared to control group.	Etoposide	203-212	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	150-153
29571245-5	2018	Co-administration of rosemary with Etoposide improved the sexual toxicity, fertility potential, testicular injury, KI67, P53 and DNA damage induced by Etoposide.	Etoposide	35-44	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	121-124
29571245-7	2018	Etoposide treatment induced testicular DNA damage, injury and decreased in KI67 and P53 expressions.	Etoposide	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	84-87
29186352-4	2018	We observed that PRL increased viability of breast cancer cells treated with doxorubicin or etoposide.	Etoposide	92-101	prolactin	Homo sapiens	17-20
29133590-4	2018	Intriguingly, Ca2+-dependent activation of AMPK in two different LKB1-null cancer cell lines caused G1-phase cell-cycle arrest, and enhanced cell viability/survival after etoposide treatment, with both effects being abolished by knockout of AMPK-alpha1 and alpha2.	Etoposide	171-180	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	43-47
29133590-2	2018	In this study, etoposide activates the alpha1 but not the alpha2 isoform of AMPK, primarily within the nucleus.	Etoposide	15-24	adrenoceptor alpha 1D	Homo sapiens	39-45
29133590-4	2018	Intriguingly, Ca2+-dependent activation of AMPK in two different LKB1-null cancer cell lines caused G1-phase cell-cycle arrest, and enhanced cell viability/survival after etoposide treatment, with both effects being abolished by knockout of AMPK-alpha1 and alpha2.	Etoposide	171-180	serine/threonine kinase 11	Homo sapiens	65-69
29133590-4	2018	Intriguingly, Ca2+-dependent activation of AMPK in two different LKB1-null cancer cell lines caused G1-phase cell-cycle arrest, and enhanced cell viability/survival after etoposide treatment, with both effects being abolished by knockout of AMPK-alpha1 and alpha2.	Etoposide	171-180	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	241-252
29133590-5	2018	The CDK4/6 inhibitor palbociclib also caused G1 arrest in G361 but not HeLa cells and, consistent with this, enhanced cell survival after etoposide treatment only in G361 cells.	Etoposide	138-147	cyclin dependent kinase 4	Homo sapiens	4-10
29133590-2	2018	In this study, etoposide activates the alpha1 but not the alpha2 isoform of AMPK, primarily within the nucleus.	Etoposide	15-24	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	76-80
29133590-6	2018	These results suggest that AMPK activation protects cells against etoposide by limiting entry into S-phase, where cells would be more vulnerable to genotoxic stress.Implications: These results reveal that the alpha1 isoform of AMPK promotes tumorigenesis by protecting cells against genotoxic stress, which may explain findings that the gene encoding AMPK-alpha1 (but not -alpha2) is amplified in some human cancers.	Etoposide	66-75	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	27-31
29133590-6	2018	These results suggest that AMPK activation protects cells against etoposide by limiting entry into S-phase, where cells would be more vulnerable to genotoxic stress.Implications: These results reveal that the alpha1 isoform of AMPK promotes tumorigenesis by protecting cells against genotoxic stress, which may explain findings that the gene encoding AMPK-alpha1 (but not -alpha2) is amplified in some human cancers.	Etoposide	66-75	adrenoceptor alpha 1D	Homo sapiens	209-215
29133590-6	2018	These results suggest that AMPK activation protects cells against etoposide by limiting entry into S-phase, where cells would be more vulnerable to genotoxic stress.Implications: These results reveal that the alpha1 isoform of AMPK promotes tumorigenesis by protecting cells against genotoxic stress, which may explain findings that the gene encoding AMPK-alpha1 (but not -alpha2) is amplified in some human cancers.	Etoposide	66-75	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	227-231
29372665-2	2018	Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal).	Etoposide	67-76	tumor protein p53	Homo sapiens	151-154
29079319-4	2018	MATERIALS AND METHODS: PINCH-1 expression was studied in two estrogen positive(T47D and MCF-7) and one estrogen negative cell lines before and after treatment with six drugs (Cyclophosphamide, Celecoxib, Doxorubicin, Paclitaxel, Etoposide and Tamoxifen).	Etoposide	229-238	LIM zinc finger domain containing 1	Homo sapiens	23-30
29084722-3	2018	We report that SAMHD1 was activated by dephosphorylation following ETO treatment, along with loss of expression of MCM2 and CDK1, and reduction in dNTP levels.	Etoposide	67-70	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	15-21
29084722-5	2018	The ETO-induced block was completely rescued by depletion of SAMHD1 in MDM Concordantly, infection by HIV-2 and SIVsm encoding the SAMHD1 antagonist Vpx was insensitive to ETO treatment.	Etoposide	4-7	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	61-67
29084722-5	2018	The ETO-induced block was completely rescued by depletion of SAMHD1 in MDM Concordantly, infection by HIV-2 and SIVsm encoding the SAMHD1 antagonist Vpx was insensitive to ETO treatment.	Etoposide	4-7	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	131-137
29084722-5	2018	The ETO-induced block was completely rescued by depletion of SAMHD1 in MDM Concordantly, infection by HIV-2 and SIVsm encoding the SAMHD1 antagonist Vpx was insensitive to ETO treatment.	Etoposide	4-7	vpx protein	Simian immunodeficiency virus	149-152
29298978-5	2018	Finally, we identify SMARCA4 as a marker and driver of sensitivity to topoisomerase II inhibitors, mitoxantrone, and etoposide, in AML by showing that cell lines transduced to have high SMARCA4 expression reveal dramatically increased sensitivity to these agents.	Etoposide	117-126	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	21-28
29298978-5	2018	Finally, we identify SMARCA4 as a marker and driver of sensitivity to topoisomerase II inhibitors, mitoxantrone, and etoposide, in AML by showing that cell lines transduced to have high SMARCA4 expression reveal dramatically increased sensitivity to these agents.	Etoposide	117-126	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	186-193
29301327-5	2018	Moreover, non-replicative, TLS-capable DNA polymerases can negatively impact cancer treatment by synthesizing DNA past lesions generated from treatments such as cisplatin, oxaliplatin, etoposide, bleomycin, and radiotherapy.	Etoposide	185-194	FUS RNA binding protein	Homo sapiens	27-30
29030066-0	2018	Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.	Etoposide	0-9	tumor protein p53	Homo sapiens	68-71
29030066-3	2018	In this study, we found that etoposide induces proliferation suppression, cell apoptosis and increases caspase-3 activity in A549 cells.	Etoposide	29-38	caspase 3	Homo sapiens	103-112
29030066-4	2018	Furthermore, etoposide treatment up-regulates the expression of NMI and ARF, enhances the interaction of NMI and ARF and promotes the p53 transcriptional activities.	Etoposide	13-22	tumor protein p53	Homo sapiens	134-137
29030066-6	2018	These investigations demonstrated etoposide-induced NMI can suppress tumor proliferation and promote cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.	Etoposide	34-43	tumor protein p53	Homo sapiens	138-141
28947136-2	2018	Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple chemotherapeutic agents (i.e. vincristine (VCR), etoposide (ETO), doxorubicin, actinomycin D and cyclophosphamide) to induce apoptosis in rhabdomyosarcoma (RMS) cells.	Etoposide	194-203	BCL2 like 1	Homo sapiens	56-62
28947136-2	2018	Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple chemotherapeutic agents (i.e. vincristine (VCR), etoposide (ETO), doxorubicin, actinomycin D and cyclophosphamide) to induce apoptosis in rhabdomyosarcoma (RMS) cells.	Etoposide	194-203	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	73-78
28947136-2	2018	Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple chemotherapeutic agents (i.e. vincristine (VCR), etoposide (ETO), doxorubicin, actinomycin D and cyclophosphamide) to induce apoptosis in rhabdomyosarcoma (RMS) cells.	Etoposide	205-208	BCL2 like 1	Homo sapiens	56-62
28947136-2	2018	Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple chemotherapeutic agents (i.e. vincristine (VCR), etoposide (ETO), doxorubicin, actinomycin D and cyclophosphamide) to induce apoptosis in rhabdomyosarcoma (RMS) cells.	Etoposide	205-208	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	73-78
30516086-8	2018	Etoposide-induced DNA damage affected the phosphorylation of gamma-H2AX, CHK1 and CHK2 without affecting cell viability.	Etoposide	0-9	checkpoint kinase 1	Homo sapiens	73-77
30516086-8	2018	Etoposide-induced DNA damage affected the phosphorylation of gamma-H2AX, CHK1 and CHK2 without affecting cell viability.	Etoposide	0-9	checkpoint kinase 2	Homo sapiens	82-86
29372665-2	2018	Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal).	Etoposide	67-76	cyclin dependent kinase inhibitor 1A	Homo sapiens	207-214
29372665-2	2018	Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal).	Etoposide	78-81	tumor protein p53	Homo sapiens	151-154
29372665-2	2018	Chemoresistant ESC-like embryonal carcinoma PA1 cells treated with etoposide (ETO) were previously found to undergo prolonged G2 arrest with transient p53-dependent upregulation of opposing fate regulators, p21CIP1 (senescence) and OCT4A (self-renewal).	Etoposide	78-81	cyclin dependent kinase inhibitor 1A	Homo sapiens	207-214
29192327-5	2018	In line with these findings in in vivo chicken chorioallantoic (CAM) assays, etoposide-resistant cell lines generated significantly increased numbers of tumors with higher tumor weights compared to their parental counterparts.	Etoposide	77-86	calmodulin 2	Gallus gallus	64-67
28395566-2	2018	Here, we found in chemotherapeutic drug etoposide-induced apoptosis, WT1 protein was cleaved into smaller fragment by caspase-3 in leukemic cells.	Etoposide	40-49	WT1 transcription factor	Homo sapiens	69-72
28395566-2	2018	Here, we found in chemotherapeutic drug etoposide-induced apoptosis, WT1 protein was cleaved into smaller fragment by caspase-3 in leukemic cells.	Etoposide	40-49	caspase 3	Homo sapiens	118-127
30526461-7	2018	Among these inhibitors, etoposide (RMSD value -96.6481) showed high binding capacity with the receptor CD20 which was further subjected to virtual screening.	Etoposide	24-33	keratin 20	Homo sapiens	103-107
29953987-0	2018	17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells.	Etoposide	50-59	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	107-152
29403558-5	2018	A number of differentially expressed proteins were detected between the original Caki-1 cell line and the XIAP-knockdown Caki-1 cell line; 87 at 0 h (prior to etoposide treatment), 178 at 0.5 h and 169 at 3 h, while no differentially expressed proteins were detected (ratio &gt;1.5 or &lt;0.5; P&lt;0.05) at 12 h after etoposide treatment.	Etoposide	159-168	X-linked inhibitor of apoptosis	Homo sapiens	106-110
29403558-5	2018	A number of differentially expressed proteins were detected between the original Caki-1 cell line and the XIAP-knockdown Caki-1 cell line; 87 at 0 h (prior to etoposide treatment), 178 at 0.5 h and 169 at 3 h, while no differentially expressed proteins were detected (ratio &gt;1.5 or &lt;0.5; P&lt;0.05) at 12 h after etoposide treatment.	Etoposide	319-328	X-linked inhibitor of apoptosis	Homo sapiens	106-110
29953987-4	2018	In this study, we report whether Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) enhanced etoposide-induced cytotoxicity in NSCLC cells through modulating the XPC expression.	Etoposide	106-115	heat shock protein 90 alpha family class A member 1	Homo sapiens	33-38
29953987-5	2018	We found that etoposide increased XPC expression in an AKT activation manner in 2 squamous cell carcinoma H1703 and H520 cells.	Etoposide	14-23	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	34-37
29953987-5	2018	We found that etoposide increased XPC expression in an AKT activation manner in 2 squamous cell carcinoma H1703 and H520 cells.	Etoposide	14-23	AKT serine/threonine kinase 1	Homo sapiens	55-58
29953987-4	2018	In this study, we report whether Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) enhanced etoposide-induced cytotoxicity in NSCLC cells through modulating the XPC expression.	Etoposide	106-115	N-methylpurine DNA glycosylase	Homo sapiens	92-95
29953987-6	2018	Knockdown of XPC using siRNA or inactivation of AKT by pharmacological inhibitor PI3K inhibitor (LY294002) enhanced the cytotoxic effects of etoposide.	Etoposide	141-150	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	13-16
29953987-6	2018	Knockdown of XPC using siRNA or inactivation of AKT by pharmacological inhibitor PI3K inhibitor (LY294002) enhanced the cytotoxic effects of etoposide.	Etoposide	141-150	AKT serine/threonine kinase 1	Homo sapiens	48-51
29953987-4	2018	In this study, we report whether Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) enhanced etoposide-induced cytotoxicity in NSCLC cells through modulating the XPC expression.	Etoposide	106-115	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	175-178
29953987-7	2018	In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide.	Etoposide	148-157	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	36-39
29953987-7	2018	In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide.	Etoposide	148-157	AKT serine/threonine kinase 1	Homo sapiens	48-51
28846114-7	2017	Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced apoptosis in MCF-7 cells, and causes sensitization to DNA-damaging drug etoposide and DNA repair inhibitor olaparib.	Etoposide	160-169	tumor protein, translationally-controlled 1	Homo sapiens	26-30
29953987-7	2018	In contrast, enforced expression of XPC cDNA or AKT-CA (a constitutively active form of AKT) reduced the cytotoxicity and cell growth inhibition of etoposide.	Etoposide	148-157	AKT serine/threonine kinase 1	Homo sapiens	88-91
29953987-8	2018	Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of etoposide in NSCLC cells, which were associated with the downregulation of XPC expression and inactivation of AKT.	Etoposide	75-84	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
29953987-8	2018	Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of etoposide in NSCLC cells, which were associated with the downregulation of XPC expression and inactivation of AKT.	Etoposide	75-84	N-methylpurine DNA glycosylase	Homo sapiens	19-22
29953987-8	2018	Hsp90 inhibitor 17-AAG enhanced cytotoxicity and cell growth inhibition of etoposide in NSCLC cells, which were associated with the downregulation of XPC expression and inactivation of AKT.	Etoposide	75-84	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	150-153
29953987-9	2018	Our findings suggested that the Hsp90 inhibition induced XPC downregulation involved in enhancing the etoposide-induced cytotoxicity in H1703 and H520 cells.	Etoposide	102-111	heat shock protein 90 alpha family class A member 1	Homo sapiens	32-37
29953987-9	2018	Our findings suggested that the Hsp90 inhibition induced XPC downregulation involved in enhancing the etoposide-induced cytotoxicity in H1703 and H520 cells.	Etoposide	102-111	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	57-60
29018079-3	2017	SETD2 mutations led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non-DNA damaging agent, l-asparaginase.	Etoposide	102-111	SET domain containing 2	Mus musculus	0-5
29263678-6	2017	An increased level of phosphorylated focal adhesion kinase (FAK) subsequently facilitated the reproliferation of SKOV3 cells, and VP-16-induced repopulation effects were partially reversed by the FAK inhibitor PF562271.	Etoposide	130-135	protein tyrosine kinase 2	Homo sapiens	37-58
29371922-4	2017	We investigate the effect of CagA on etoposide-induced apoptosis in gastric cancer cells to elucidate whether CagA play a role in gastric carcinogenesis via impairing DNA damage-dependent apoptosis.	Etoposide	37-46	S100 calcium binding protein A8	Homo sapiens	29-33
29371922-6	2017	In the presence of etoposide, viability of parental AGS cells was decreased in a time-and dose-dependent manner, whereas CagA-expressing AGS cells were less susceptible to etoposide induced cell-killing effect.	Etoposide	19-28	S100 calcium binding protein A8	Homo sapiens	121-125
29371922-6	2017	In the presence of etoposide, viability of parental AGS cells was decreased in a time-and dose-dependent manner, whereas CagA-expressing AGS cells were less susceptible to etoposide induced cell-killing effect.	Etoposide	172-181	S100 calcium binding protein A8	Homo sapiens	121-125
29371922-7	2017	Suppression of etoposide-induced apoptosis was shown in CagA-expressing but not in parental AGS cells by DNA fragmentation, cell cycle, and annexin-V assays.	Etoposide	15-24	S100 calcium binding protein A8	Homo sapiens	56-60
29371922-8	2017	This inhibitory effect of etoposide-induced apoptosis conferred by CagA was also demonstrated in SCM1 and MKN45 gastric cancer cell lines, with two additional chemotherapeutics, 5-FU and cisplatin.	Etoposide	26-35	S100 calcium binding protein A8	Homo sapiens	67-71
29371922-8	2017	This inhibitory effect of etoposide-induced apoptosis conferred by CagA was also demonstrated in SCM1 and MKN45 gastric cancer cell lines, with two additional chemotherapeutics, 5-FU and cisplatin.	Etoposide	26-35	X-C motif chemokine ligand 1	Homo sapiens	97-101
29371922-9	2017	The effect of Akt activation on inhibition of etoposide-induced cytotoxicity by CagA was also evaluated.	Etoposide	46-55	S100 calcium binding protein A8	Homo sapiens	80-84
29371922-11	2017	Enhancement of etoposide cytotoxicity by a PI-3-kinase inhibitor, LY294002, was evident in parental but was attenuated in CagA-expressing AGS cells.	Etoposide	15-24	S100 calcium binding protein A8	Homo sapiens	122-126
29263678-6	2017	An increased level of phosphorylated focal adhesion kinase (FAK) subsequently facilitated the reproliferation of SKOV3 cells, and VP-16-induced repopulation effects were partially reversed by the FAK inhibitor PF562271.	Etoposide	130-135	protein tyrosine kinase 2	Homo sapiens	196-199
28716816-4	2017	Targeting S1PR1 by shRNA markedly enhances etoposide-induced apoptosis in NB cells and abrogates EMDR, while overexpression of S1PR1 significantly protects NB cells from multidrug-induced apoptosis via activating JAK-STAT3 signaling.	Etoposide	43-52	sphingosine-1-phosphate receptor 1	Homo sapiens	10-15
29371957-4	2017	The magnitude of the AMH level decline was significantly greater for combination chemotherapy than for single-agent dactinomycin D therapy (61.80% vs. 27.57%) (p = 0.0004) and was higher in patients whose regimens included etoposide (73.69% vs 40.51%) (p = 0.0359).	Etoposide	223-232	anti-Mullerian hormone	Homo sapiens	21-24
29371957-5	2017	After chemotherapy completion, AMH levels showed a further decline, and cumulative AMH concentration change was associated with doses of vincristine (p = 0.009) and etoposide (p = 0.032).	Etoposide	165-174	anti-Mullerian hormone	Homo sapiens	83-86
29174536-3	2017	Irinotecan and etoposide inhibited the uptake of [3H]-uridine and [3H]-DAC at 10 s and 5 min, while cytarabine and gemcitabine only inhibited that of [3H]-DAC at 5 min.	Etoposide	15-24	arylacetamide deacetylase	Homo sapiens	71-74
29174536-3	2017	Irinotecan and etoposide inhibited the uptake of [3H]-uridine and [3H]-DAC at 10 s and 5 min, while cytarabine and gemcitabine only inhibited that of [3H]-DAC at 5 min.	Etoposide	15-24	arylacetamide deacetylase	Homo sapiens	155-158
29174536-4	2017	Irinotecan and etoposide inhibited [3H]-DAC uptake in negative control small interfering RNA (siRNA)- or dCK siRNA-transfected cells at 10 s, whereas cytarabine and gemcitabine did not.	Etoposide	15-24	arylacetamide deacetylase	Homo sapiens	40-43
29174536-4	2017	Irinotecan and etoposide inhibited [3H]-DAC uptake in negative control small interfering RNA (siRNA)- or dCK siRNA-transfected cells at 10 s, whereas cytarabine and gemcitabine did not.	Etoposide	15-24	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	105-108
29065392-4	2017	Here we report that Ku80 can be cleaved by caspases-2 at D726 upon a transient etoposide treatment.	Etoposide	79-88	X-ray repair cross complementing 5	Homo sapiens	20-24
28958946-7	2017	In contrast, the presence of TPGS significantly increased etoposide in-vivo rat permeability, attributable to P-gp inhibition, similarly to the effect of the potent P-gp inhibitor GF120918 (10microg/mL).	Etoposide	58-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	110-114
28692049-3	2017	Tumor cells that overexpress Mdm2 have reduced DNA double-strand breaks in response to doxorubicin or etoposide.	Etoposide	102-111	MDM2 proto-oncogene	Homo sapiens	29-33
27667581-4	2017	The stability of the complexes of COX-1, COX-2, Topo I, Topo IIbeta and aromatase with the most potent inhibitor curcumin and those of the respective drugs, namely ibuprofen, aspirin, topotecan, etoposide, and exemestane were also analyzed through MD simulation analyses which revealed better stability of curcumin complexes than those of respective drugs.	Etoposide	195-204	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	34-39
28716816-5	2017	Elevated S1PR1 expression and STAT3 activation are also observed in human NB cells with acquired resistance to etoposide.	Etoposide	111-120	sphingosine-1-phosphate receptor 1	Homo sapiens	9-14
28716816-5	2017	Elevated S1PR1 expression and STAT3 activation are also observed in human NB cells with acquired resistance to etoposide.	Etoposide	111-120	signal transducer and activator of transcription 3	Homo sapiens	30-35
28716816-6	2017	We show in vitro and in human NB xenograft models that treatment with FTY720, an FDA-approved drug and antagonist of S1PR1, dramatically sensitizes drug-resistant cells to etoposide.	Etoposide	172-181	sphingosine-1-phosphate receptor 1	Homo sapiens	117-122
29063171-7	2017	In patients with negative PSA levels, chemotherapy with cisplatin and etoposide is the first line treatment, for which response rates in the range of 30-60% with a median survival time of usually less than 1 year can be achieved.	Etoposide	70-79	kallikrein related peptidase 3	Homo sapiens	26-29
29221178-3	2017	We found that, in chemo-resistant U87RETO glioblastoma cells, cytotoxic stress induced by etoposide promotes accumulation and large-scale fission of mitochondria, associated with the detection of HERV-WE1 (syncytin-1) and HERV-FRD1 (syncytin-2) in these organelles.	Etoposide	90-99	endogenous retrovirus group W member 1, envelope	Homo sapiens	206-216
28757527-6	2017	DNA damage induced by etoposide was accompanied by the formation of RAD51 foci that were colocalized with gammaH2AX.	Etoposide	22-31	RAD51 recombinase	Homo sapiens	68-73
29221178-3	2017	We found that, in chemo-resistant U87RETO glioblastoma cells, cytotoxic stress induced by etoposide promotes accumulation and large-scale fission of mitochondria, associated with the detection of HERV-WE1 (syncytin-1) and HERV-FRD1 (syncytin-2) in these organelles.	Etoposide	90-99	endogenous retrovirus group FRD member 1, envelope	Homo sapiens	233-243
28702823-5	2017	In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL.	Etoposide	32-34	TNF superfamily member 10	Homo sapiens	7-12
28702823-0	2017	Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.	Etoposide	0-9	TNF receptor superfamily member 10b	Homo sapiens	112-115
28702823-5	2017	In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL.	Etoposide	32-34	TNF superfamily member 10	Homo sapiens	110-115
28702823-0	2017	Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.	Etoposide	0-9	TNF superfamily member 10	Homo sapiens	106-111
28702823-11	2017	An induction of apoptosis and DR5 expression was noticed in xenograft mice and in TNBC patient-derived metastatic cells after TRAIL+ET treatment.	Etoposide	132-134	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	30-33
28702823-3	2017	In this work, the DR5 mediated anticancer potential of topoisomerase inhibitor etoposide (ET) and doxorubicin (DOX) against TNBC has been evaluated.	Etoposide	79-88	TNF receptor superfamily member 10b	Homo sapiens	18-21
32300400-5	2017	Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP).	Etoposide	113-122	lysine methyltransferase 2A	Homo sapiens	14-17
28702823-3	2017	In this work, the DR5 mediated anticancer potential of topoisomerase inhibitor etoposide (ET) and doxorubicin (DOX) against TNBC has been evaluated.	Etoposide	90-92	TNF receptor superfamily member 10b	Homo sapiens	18-21
28702823-4	2017	ET and DOX enhanced the DR5 expression in TNBC cells, whereas non-topoisomerase inhibitors pifithrin-alpha (PIF) and dexamethasone (DEX) failed to do so.	Etoposide	0-2	TNF receptor superfamily member 10b	Homo sapiens	24-27
28751496-5	2017	The requirement for Nup153 and Nup50 in promoting 53BP1 recruitment to damage foci induced by either etoposide or olaparib is abrogated in cells deficient for BRCA1 or its partner BARD1, but not in cells deficient for BRCA2.	Etoposide	101-110	nucleoporin 153	Homo sapiens	20-26
28751496-5	2017	The requirement for Nup153 and Nup50 in promoting 53BP1 recruitment to damage foci induced by either etoposide or olaparib is abrogated in cells deficient for BRCA1 or its partner BARD1, but not in cells deficient for BRCA2.	Etoposide	101-110	nucleoporin 50	Homo sapiens	31-36
28751496-5	2017	The requirement for Nup153 and Nup50 in promoting 53BP1 recruitment to damage foci induced by either etoposide or olaparib is abrogated in cells deficient for BRCA1 or its partner BARD1, but not in cells deficient for BRCA2.	Etoposide	101-110	tumor protein p53 binding protein 1	Homo sapiens	50-55
32300400-5	2017	Patients with MLL- and CDKN2A-positive DLBCL may benefit from therapy with a dose-adjusted regimen of rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) compared to traditional rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP).	Etoposide	113-122	cyclin dependent kinase inhibitor 2A	Homo sapiens	23-29
28959361-0	2017	Effect of etoposide-induced alteration of the Mdm2-Rb signaling pathway on cellular senescence in A549 lung adenocarcinoma cells.	Etoposide	10-19	MDM2 proto-oncogene	Homo sapiens	46-50
28611105-7	2017	Then, we show that despite being more cytotoxic, F14512 is less efficient than etoposide at producing TOP2alpha cleavage-complex (TOP2alphacc) in cells.	Etoposide	79-88	DNA topoisomerase II alpha	Homo sapiens	102-111
28611105-8	2017	Finally, we report that compared with TOP2alphacc mediated by etoposide, those generated by F14512 persist longer in the genome, are not dependent on TDP2 for cleaning break ends from TOP2alpha, are channeled to a larger extent to resection-based repair processes relying on CtIP and BRCA1 and promote RAD51 recruitment to damaged chromatin.	Etoposide	62-71	DNA topoisomerase II alpha	Homo sapiens	38-47
28959361-1	2017	The present study aimed to investigate the effect of various concentrations of etoposide (VP-16) on the E3 ubiquitin-protein ligase Mdm2 (Mdm2)-retinoblastoma (Rb) signaling pathway in the cellular senescence of A549 lung adenocarcinoma cells.	Etoposide	79-88	host cell factor C1	Homo sapiens	90-95
28959361-1	2017	The present study aimed to investigate the effect of various concentrations of etoposide (VP-16) on the E3 ubiquitin-protein ligase Mdm2 (Mdm2)-retinoblastoma (Rb) signaling pathway in the cellular senescence of A549 lung adenocarcinoma cells.	Etoposide	79-88	MDM2 proto-oncogene	Homo sapiens	132-136
28959361-1	2017	The present study aimed to investigate the effect of various concentrations of etoposide (VP-16) on the E3 ubiquitin-protein ligase Mdm2 (Mdm2)-retinoblastoma (Rb) signaling pathway in the cellular senescence of A549 lung adenocarcinoma cells.	Etoposide	79-88	MDM2 proto-oncogene	Homo sapiens	138-142
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	Etoposide	167-176	midkine	Mus musculus	95-98
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	Etoposide	167-176	Janus kinase 2	Mus musculus	80-84
28645808-5	2017	Under the clinical diagnosis of Ewing-like sarcoma of the abdominal wall with multiple lung metastases, several cycles of ICE (ifosfamide, carboplatin and etoposide) therapy were performed.	Etoposide	155-164	caspase 1	Homo sapiens	122-125
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	tumor protein p53	Homo sapiens	80-83
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	H3 histone pseudogene 16	Homo sapiens	98-101
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	ATM serine/threonine kinase	Homo sapiens	142-171
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	ATM serine/threonine kinase	Homo sapiens	173-176
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	checkpoint kinase 1	Homo sapiens	179-198
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	checkpoint kinase 1	Homo sapiens	200-204
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	tumor protein p53	Homo sapiens	240-243
28928376-5	2017	Subsequent administration of Oligo-Fucoidan to etoposide-treated cells promotes p53 accumulation, p21 expression and significant decreases in ataxia-telangiectasia-mutated (ATM), checkpoint kinase 1 (Chk1) and gamma-H2AX phosphorylation in p53+/+ cells compared with p53-/- cells.	Etoposide	47-56	tumor protein p53	Homo sapiens	240-243
28928376-6	2017	Similarly, co-administration of Oligo-Fucoidan with etoposide inhibits ATM, Chk1 and gamma-H2AX phosphorylation, particularly in the presence of p53.	Etoposide	52-61	ATM serine/threonine kinase	Homo sapiens	71-74
28928376-6	2017	Similarly, co-administration of Oligo-Fucoidan with etoposide inhibits ATM, Chk1 and gamma-H2AX phosphorylation, particularly in the presence of p53.	Etoposide	52-61	checkpoint kinase 1	Homo sapiens	76-80
28928376-6	2017	Similarly, co-administration of Oligo-Fucoidan with etoposide inhibits ATM, Chk1 and gamma-H2AX phosphorylation, particularly in the presence of p53.	Etoposide	52-61	tumor protein p53	Homo sapiens	145-148
28928376-7	2017	Furthermore, Oligo-Fucoidan supplementation increases cancer cell death and attenuates the adverse effects induced by etoposide that decreases production of the pro-inflammatory cytokine IL-6 and chemokine CCL2/MCP-1.	Etoposide	118-127	interleukin 6	Homo sapiens	187-191
28928376-7	2017	Furthermore, Oligo-Fucoidan supplementation increases cancer cell death and attenuates the adverse effects induced by etoposide that decreases production of the pro-inflammatory cytokine IL-6 and chemokine CCL2/MCP-1.	Etoposide	118-127	C-C motif chemokine ligand 2	Homo sapiens	206-210
28928376-7	2017	Furthermore, Oligo-Fucoidan supplementation increases cancer cell death and attenuates the adverse effects induced by etoposide that decreases production of the pro-inflammatory cytokine IL-6 and chemokine CCL2/MCP-1.	Etoposide	118-127	C-C motif chemokine ligand 2	Homo sapiens	211-216
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	Etoposide	167-176	mitogen-activated protein kinase 3	Mus musculus	99-106
28906490-9	2017	Cells with lower levels of POPX2 exhibit higher TAK1 activity in response to etoposide (VP-16) treatment.	Etoposide	77-86	protein phosphatase, Mg2+/Mn2+ dependent 1F	Homo sapiens	27-32
28906490-9	2017	Cells with lower levels of POPX2 exhibit higher TAK1 activity in response to etoposide (VP-16) treatment.	Etoposide	77-86	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	48-52
28906490-9	2017	Cells with lower levels of POPX2 exhibit higher TAK1 activity in response to etoposide (VP-16) treatment.	Etoposide	77-86	host cell factor C1	Homo sapiens	88-93
28906490-12	2017	On the other hand, cells with higher levels of POPX2 are more vulnerable to apoptosis induced by etoposide.	Etoposide	97-106	protein phosphatase, Mg2+/Mn2+ dependent 1F	Homo sapiens	47-52
28485010-0	2017	The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.	Etoposide	16-25	ALK receptor tyrosine kinase	Homo sapiens	73-76
28481869-4	2017	Mechanistic studies indicate that at both the protein and the mRNA level, depleting GATA3 leads to reduced expression of CtIP, an essential HR factor involved in end resection, thereby suppressing the repair of DSBs by HR and sensitizing cells to etoposide induced DNA DSBs.	Etoposide	247-256	GATA binding protein 3	Homo sapiens	84-89
28481869-4	2017	Mechanistic studies indicate that at both the protein and the mRNA level, depleting GATA3 leads to reduced expression of CtIP, an essential HR factor involved in end resection, thereby suppressing the repair of DSBs by HR and sensitizing cells to etoposide induced DNA DSBs.	Etoposide	247-256	RB binding protein 8, endonuclease	Homo sapiens	121-125
28481869-6	2017	Overexpression of CtIP in GATA3 depleted cells rescues the decline of HR, and cell survival in the presence of etoposide.	Etoposide	111-120	RB binding protein 8, endonuclease	Homo sapiens	18-22
28481869-6	2017	Overexpression of CtIP in GATA3 depleted cells rescues the decline of HR, and cell survival in the presence of etoposide.	Etoposide	111-120	GATA binding protein 3	Homo sapiens	26-31
29088858-9	2017	In addition, we demonstrated that metformin treatment also impaired the cross-resistance of A549/R and PC9/R to cisplatin, etoposide and 5-fluorouracil.	Etoposide	123-132	proprotein convertase subtilisin/kexin type 9	Homo sapiens	103-106
28485010-8	2017	Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.	Etoposide	41-50	ALK receptor tyrosine kinase	Homo sapiens	139-142
28820960-1	2017	This month: Lysosomal iron linked to cell death in cancer stem cells, non-enzymatic catalyst SynCAc for histone acylation, cytotoxins ivermectin and etoposide bring new anti-fungals out of the crypt, and 2"-deoxy-ADPR as second messenger activating TRPM2.	Etoposide	149-158	transient receptor potential cation channel subfamily M member 2	Homo sapiens	249-254
29048426-6	2017	In both cell lines, the genotoxic drug etoposide induced a classical mitochondrial p53-dependent apoptosis.	Etoposide	39-48	tumor protein p53	Homo sapiens	83-86
29048426-8	2017	Both rFGF1 addition and etoposide treatment increased fgf1 expression in SH-SY5Y cells.	Etoposide	24-33	fibroblast growth factor 1	Homo sapiens	54-58
29234490-4	2017	In some contexts, Geminin inhibition induces cancer-selective cell cycle arrest and apoptosis and/or sensitizes cancer cells to Topoisomerase IIalpha inhibitors such as etoposide, which is used in combination chemotherapies for medulloblastoma.	Etoposide	169-178	geminin	Mus musculus	18-25
29234490-9	2017	Geminin knockdown likewise impaired human medulloblastoma cell growth, activating G2 checkpoint and DNA damage response pathways, triggering spontaneous apoptosis, and enhancing G2 accumulation of cells in response to etoposide treatment.	Etoposide	218-227	geminin DNA replication inhibitor	Homo sapiens	0-7
28611047-7	2017	Smurf2 was a determinant of Topo IIalpha protein levels in normal and cancer cells and tissues, and its levels affected cell sensitivity to the Topo II-targeting drug etoposide.	Etoposide	167-176	SMAD specific E3 ubiquitin protein ligase 2	Homo sapiens	0-6
28814318-12	2017	Following knockdown of ANXA2 in NB cell line SK-N-BE(2) using shRNA, we demonstrate enhanced drug sensitivity for doxorubicin (2.77-fold) and etoposide (7.87-fold) compared with control.	Etoposide	142-151	annexin A2	Homo sapiens	23-28
28450160-0	2017	A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.	Etoposide	57-66	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	119-127
28473198-8	2017	The viability of gastric cancer cells upon treatment with chemotherapy drugs including etoposide, cisplatin and doxorubicin was reduced by PAQR3 overexpression, but enhanced by PAQR3 knockdown.	Etoposide	87-96	progestin and adipoQ receptor family member 3	Homo sapiens	139-144
28766886-9	2017	Chk-1 inhibitors such as rabusertib increased the cytotoxicity of etoposide/carboplatin to the SCLC lines in an additive to greater than additive manner.	Etoposide	66-75	checkpoint kinase 1	Homo sapiens	0-5
28766886-12	2017	Only 10-15% of the SCLC lines had an increased response to etoposide/carboplatin when simultaneously exposed to the PARP inhibitor talazoparib.	Etoposide	59-68	collagen type XI alpha 2 chain	Homo sapiens	116-120
28473198-8	2017	The viability of gastric cancer cells upon treatment with chemotherapy drugs including etoposide, cisplatin and doxorubicin was reduced by PAQR3 overexpression, but enhanced by PAQR3 knockdown.	Etoposide	87-96	progestin and adipoQ receptor family member 3	Homo sapiens	177-182
28749466-5	2017	In addition, loss of MARCH2 sensitized HCT116 cells to the chemotherapy drugs etoposide and cisplatin.	Etoposide	78-87	membrane associated ring-CH-type finger 2	Homo sapiens	21-27
28429052-15	2017	After 6 weeks, the CD68+, Gr1+, CD11b+, and CD45+ cell populations were still relatively increased in etoposide-treated bone marrow.	Etoposide	102-111	integrin subunit alpha M	Homo sapiens	32-37
28429052-17	2017	Gene expression in the marrow for the leptin receptor and CXCL12 were reduced with short-term etoposide, and an increased ratio of RANKL/OPG mRNA was observed.	Etoposide	94-103	leptin receptor	Homo sapiens	38-53
28429052-17	2017	Gene expression in the marrow for the leptin receptor and CXCL12 were reduced with short-term etoposide, and an increased ratio of RANKL/OPG mRNA was observed.	Etoposide	94-103	C-X-C motif chemokine ligand 12	Homo sapiens	58-64
28957780-8	2017	Etoposide single agent treatment and combination treatment with piroxicam down-regulated survivin expression, but was not followed by increased apoptotic activity.	Etoposide	0-9	baculoviral IAP repeat containing 5	Canis lupus familiaris	89-97
28736504-10	2017	Importantly, these cells were more tolerant to cisplatin and etoposide treatment, showed a lower level of nuclear Caspase-3 in treated cells and harbored drug resistant CSCs.	Etoposide	61-70	caspase 3	Homo sapiens	114-123
28159923-7	2017	Of note, the combination of Vandetanib, GDC-0941 and Etoposide results in MYC-amplified and SHH-TP53-mutated cell lines in complete loss of cell viability.	Etoposide	53-62	sonic hedgehog signaling molecule	Homo sapiens	92-95
28159923-7	2017	Of note, the combination of Vandetanib, GDC-0941 and Etoposide results in MYC-amplified and SHH-TP53-mutated cell lines in complete loss of cell viability.	Etoposide	53-62	tumor protein p53	Homo sapiens	96-100
28484083-6	2017	As expected, the combination of etoposide and cisplatin synergistically inhibited HM-1 cell proliferation.	Etoposide	32-41	cholinergic receptor muscarinic 1	Homo sapiens	82-86
28718810-6	2017	DNA2 can be a major protein involved in the repair of complex DNA damage containing a DSB and a 5" adduct resulting from a chemical group bound to DNA 5" ends, created by ionizing radiation and several anticancer drugs, including etoposide, mitoxantrone and some anthracyclines.	Etoposide	230-239	DNA replication helicase/nuclease 2	Homo sapiens	0-4
28484083-7	2017	Strikingly, when etoposide and cisplatin were combined with PI3K inhibitor BEZ235, the growth of HM-1 cells was significantly reduced.	Etoposide	17-26	cholinergic receptor muscarinic 1	Homo sapiens	97-101
28484083-8	2017	Taken together, the data implied the combination of etoposide and cisplatin with BEZ235 not only inhibited HM-1 cell proliferation but also increased cell apoptosis.	Etoposide	52-61	cholinergic receptor muscarinic 1	Homo sapiens	107-111
28484083-11	2017	Next, HM-1 was treated with PI3K inhibitors, BKM120 and/or BEZ235, in combination with two well-known genotoxic drugs, etoposide and/or cisplatin, to evaluate which combination could serve as a more effective treatment approach.	Etoposide	119-128	cholinergic receptor muscarinic 1	Homo sapiens	6-10
28343997-9	2017	Results of parallel experiments with etoposide, a topoisomerase IIalpha inhibitor that triggers DNA DSBs, suggested that both DNA DSBs and Aurora B mislocalization contribute to chromatin bridge formation.	Etoposide	37-46	aurora kinase B	Homo sapiens	139-147
28526406-3	2017	HER2-upregulated cisplatin- or etoposide-resistant SCLC cells were sensitive to trastuzumab-mediated ADCC.	Etoposide	31-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4
27925196-7	2017	Our results demonstrate that SIRT1-silenced cells are more resistant to H2 O2 and etoposide treatment showing decreased ROS accumulation, gamma-H2AX phosphorylation, caspase-3 activation and PARP cleavage.	Etoposide	82-91	sirtuin 1	Homo sapiens	29-34
27925196-7	2017	Our results demonstrate that SIRT1-silenced cells are more resistant to H2 O2 and etoposide treatment showing decreased ROS accumulation, gamma-H2AX phosphorylation, caspase-3 activation and PARP cleavage.	Etoposide	82-91	caspase 3	Homo sapiens	166-175
27925196-7	2017	Our results demonstrate that SIRT1-silenced cells are more resistant to H2 O2 and etoposide treatment showing decreased ROS accumulation, gamma-H2AX phosphorylation, caspase-3 activation and PARP cleavage.	Etoposide	82-91	collagen type XI alpha 2 chain	Homo sapiens	191-195
28693210-8	2017	The patient was positive for vimentin expression and refractory to etoposide and cisplatin chemotherapy, and succumbed to the disease 18 months after diagnosis.	Etoposide	67-76	vimentin	Homo sapiens	29-37
28060382-4	2017	Cells with decreased PACS1 expression were refractory to cell death mediated by a variety of stimuli that operate through the mitochondrial pathway, including human granzyme B, staurosporine, ultraviolet radiation and etoposide, but remained sensitive to TRAIL receptor ligation.	Etoposide	218-227	phosphofurin acidic cluster sorting protein 1	Homo sapiens	21-26
29137250-4	2017	This chaperone-mediated mutated p53-TAp73alpha complex induced chemoresistance to DNA damaging reagents, like Cisplatin, Doxorubicin, Etoposide or Camptothecin.	Etoposide	134-143	tumor protein p53	Homo sapiens	32-35
28533362-6	2017	cGAS deletion also abrogated SASP induced by spontaneous immortalization or DNA damaging agents, including radiation and etoposide.	Etoposide	121-130	cyclic GMP-AMP synthase	Mus musculus	0-4
28587258-3	2017	Here we report a combination of ICG-PDT with a chemotherapy drug etoposide (VP-16), aiming to enhance the anticancer efficacy, to circumvent limitations of PDT using ICG, and to reduce side effects of VP-16.	Etoposide	65-74	host cell factor C1	Homo sapiens	76-81
28587258-3	2017	Here we report a combination of ICG-PDT with a chemotherapy drug etoposide (VP-16), aiming to enhance the anticancer efficacy, to circumvent limitations of PDT using ICG, and to reduce side effects of VP-16.	Etoposide	65-74	host cell factor C1	Homo sapiens	201-206
28587395-8	2017	However, the IC50 for etoposide in sensitive K562 cells was markedly lower than that of K562/ADM cells (50.6+-16.5 and 194+-8.46 microM, respectively), suggesting that the higher expression levels of MDR1 and/or BCL-2 mRNA in resistant cells may be partially responsible for this effect.	Etoposide	22-31	ATP binding cassette subfamily B member 1	Homo sapiens	200-204
28587395-8	2017	However, the IC50 for etoposide in sensitive K562 cells was markedly lower than that of K562/ADM cells (50.6+-16.5 and 194+-8.46 microM, respectively), suggesting that the higher expression levels of MDR1 and/or BCL-2 mRNA in resistant cells may be partially responsible for this effect.	Etoposide	22-31	BCL2 apoptosis regulator	Homo sapiens	212-217
28542143-4	2017	Importantly, E2F1 stabilization in response to etoposide-induced DNA damage or during the S phase of cell cycle, as revealed by cyclin A silencing, is associated with K63-poly-ubiquitinylation of E2F1 on lysine 161/164 residues and involves cIAP1.	Etoposide	47-56	E2F transcription factor 1	Homo sapiens	13-17
28498400-0	2017	TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.	Etoposide	42-51	tripartite motif containing 28 L homeolog	Xenopus laevis	0-6
28498400-0	2017	TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.	Etoposide	42-51	E2F transcription factor 1 L homeolog	Xenopus laevis	68-72
28498400-3	2017	Here, we demonstrated that the stable silencing of TRIM28 expression by a specific siRNA lentivirus vector increased the sensitivity of NSCLC cells to chemotherapeutic agent etoposide.	Etoposide	174-183	tripartite motif containing 28 L homeolog	Xenopus laevis	51-57
28498400-5	2017	Using FCM and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay, we found that TRIM28 siRNA in combination with etoposide increased apoptosis in vitro and in vivo which was induced by E2F1 activity, since the expression of E2F1 and its target genes was significantly increased in the cotreatment group.	Etoposide	152-161	DNA nucleotidylexotransferase L homeolog	Xenopus laevis	53-56
28498400-5	2017	Using FCM and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay, we found that TRIM28 siRNA in combination with etoposide increased apoptosis in vitro and in vivo which was induced by E2F1 activity, since the expression of E2F1 and its target genes was significantly increased in the cotreatment group.	Etoposide	152-161	tripartite motif containing 28 L homeolog	Xenopus laevis	119-125
28498400-5	2017	Using FCM and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay, we found that TRIM28 siRNA in combination with etoposide increased apoptosis in vitro and in vivo which was induced by E2F1 activity, since the expression of E2F1 and its target genes was significantly increased in the cotreatment group.	Etoposide	152-161	E2F transcription factor 1 L homeolog	Xenopus laevis	224-228
28498400-5	2017	Using FCM and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay, we found that TRIM28 siRNA in combination with etoposide increased apoptosis in vitro and in vivo which was induced by E2F1 activity, since the expression of E2F1 and its target genes was significantly increased in the cotreatment group.	Etoposide	152-161	E2F transcription factor 1 L homeolog	Xenopus laevis	263-267
28498400-6	2017	Cell proliferation and apoptosis were almost completely abolished in the PAa cells cotreated with TRIM28 siRNA and etoposide following knockdown of E2F1.	Etoposide	115-124	E2F transcription factor 1 L homeolog	Xenopus laevis	148-152
28508578-1	2017	The murine mouse lymphoblastic lymphoma cell line (EL4) tumor model is an established in vivo apoptosis model for the investigation of novel cancer imaging agents and immunological treatments due to the rapid and significant response of the EL4 tumors to cyclophosphamide and etoposide combination chemotherapy.	Etoposide	276-285	epilepsy 4	Mus musculus	241-244
28545464-13	2017	Consistent with this concept, we demonstrate that inhibition of autophagy by LC3-knockdown significantly increased etoposide- and doxorubicin-induced apoptosis.	Etoposide	115-124	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	77-80
28508578-1	2017	The murine mouse lymphoblastic lymphoma cell line (EL4) tumor model is an established in vivo apoptosis model for the investigation of novel cancer imaging agents and immunological treatments due to the rapid and significant response of the EL4 tumors to cyclophosphamide and etoposide combination chemotherapy.	Etoposide	276-285	epilepsy 4	Mus musculus	51-54
28542143-4	2017	Importantly, E2F1 stabilization in response to etoposide-induced DNA damage or during the S phase of cell cycle, as revealed by cyclin A silencing, is associated with K63-poly-ubiquitinylation of E2F1 on lysine 161/164 residues and involves cIAP1.	Etoposide	47-56	cyclin A2	Homo sapiens	128-136
28542143-4	2017	Importantly, E2F1 stabilization in response to etoposide-induced DNA damage or during the S phase of cell cycle, as revealed by cyclin A silencing, is associated with K63-poly-ubiquitinylation of E2F1 on lysine 161/164 residues and involves cIAP1.	Etoposide	47-56	E2F transcription factor 1	Homo sapiens	196-200
28542143-4	2017	Importantly, E2F1 stabilization in response to etoposide-induced DNA damage or during the S phase of cell cycle, as revealed by cyclin A silencing, is associated with K63-poly-ubiquitinylation of E2F1 on lysine 161/164 residues and involves cIAP1.	Etoposide	47-56	baculoviral IAP repeat containing 2	Homo sapiens	241-246
28791810-3	2017	OBJECTIVES: The aim of the present study was to assess the effect of PJ-34 (PARP-1 inhibitor) on the cytotoxicity of different antileukemic drugs with different DNA damaging mechanisms and potency (doxorubicin, etoposide, cytarabine and chlorambucil) in human leukemic Jurkat and HL-60 cells.	Etoposide	211-220	poly(ADP-ribose) polymerase 1	Homo sapiens	76-82
29088754-0	2017	MiR-302a sensitizes leukemia cells to etoposide by targeting Rad52.	Etoposide	38-47	membrane associated ring-CH-type finger 8	Homo sapiens	0-3
29088754-0	2017	MiR-302a sensitizes leukemia cells to etoposide by targeting Rad52.	Etoposide	38-47	RAD52 homolog, DNA repair protein	Homo sapiens	61-66
29088754-1	2017	miR-302a have been reported to participate in various physiological and pathological processes, however, a role for miR-302a in etoposide (VP-16) resistance of acute myeloid leukemia (AML) has not been reported.	Etoposide	128-137	microRNA 302a	Homo sapiens	116-124
29088754-1	2017	miR-302a have been reported to participate in various physiological and pathological processes, however, a role for miR-302a in etoposide (VP-16) resistance of acute myeloid leukemia (AML) has not been reported.	Etoposide	128-137	host cell factor C1	Homo sapiens	139-144
28291743-3	2017	Herein, lactobionic acid-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS-LA conjugate) has been developed as a potential asialoglycoprotein receptor (ASGPR)-targeted nanocarrier and an efficient inhibitor of P-glycoprotein (P-gp) to enhance etoposide (ETO) efficacy against HCC.	Etoposide	264-273	asialoglycoprotein receptor 1	Homo sapiens	144-171
28291743-3	2017	Herein, lactobionic acid-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS-LA conjugate) has been developed as a potential asialoglycoprotein receptor (ASGPR)-targeted nanocarrier and an efficient inhibitor of P-glycoprotein (P-gp) to enhance etoposide (ETO) efficacy against HCC.	Etoposide	264-273	asialoglycoprotein receptor 1	Homo sapiens	173-178
28291743-3	2017	Herein, lactobionic acid-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS-LA conjugate) has been developed as a potential asialoglycoprotein receptor (ASGPR)-targeted nanocarrier and an efficient inhibitor of P-glycoprotein (P-gp) to enhance etoposide (ETO) efficacy against HCC.	Etoposide	275-278	asialoglycoprotein receptor 1	Homo sapiens	144-171
28291743-3	2017	Herein, lactobionic acid-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS-LA conjugate) has been developed as a potential asialoglycoprotein receptor (ASGPR)-targeted nanocarrier and an efficient inhibitor of P-glycoprotein (P-gp) to enhance etoposide (ETO) efficacy against HCC.	Etoposide	275-278	asialoglycoprotein receptor 1	Homo sapiens	173-178
28291743-9	2017	Interestingly, ETO-loaded TPGS-LA NPs also exhibited a great inhibitory effect on P-gp compared to the ETO-loaded TPGS NPs.	Etoposide	15-18	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
28052399-6	2017	In addition to this, CS2 could also act as a Topo II inhibitor at a much lower concentration than etoposide and induce apoptosis, making it a potent anticancer agent.	Etoposide	98-107	chorionic somatomammotropin hormone 2	Homo sapiens	21-24
28089818-9	2017	Enzyme-linked immunosorbent assay results revealed distinct differences in IL-6 and IL-8 secretions by NP cells in response to etoposide in the presence of NCCM.	Etoposide	127-136	C-X-C motif chemokine ligand 8	Homo sapiens	84-88
28400607-4	2017	We found that PID1 increased the apoptosis induced by cisplatin and etoposide in medulloblastoma and glioblastoma cell lines.	Etoposide	68-77	phosphotyrosine interaction domain containing 1	Homo sapiens	14-18
28400607-6	2017	Etoposide and cisplatin increased NFkappaB promoter reporter activity and etoposide induced nuclear translocation of NFkappaB.	Etoposide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	34-42
28400607-6	2017	Etoposide and cisplatin increased NFkappaB promoter reporter activity and etoposide induced nuclear translocation of NFkappaB.	Etoposide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	117-125
28400607-6	2017	Etoposide and cisplatin increased NFkappaB promoter reporter activity and etoposide induced nuclear translocation of NFkappaB.	Etoposide	74-83	nuclear factor kappa B subunit 1	Homo sapiens	117-125
28400607-7	2017	Etoposide also increased PID1 promoter reporter activity, PID1 mRNA, and PID1 protein, which were diminished by NFkappaB inhibitors JSH-23 and Bay117082.	Etoposide	0-9	phosphotyrosine interaction domain containing 1	Homo sapiens	25-29
28400607-7	2017	Etoposide also increased PID1 promoter reporter activity, PID1 mRNA, and PID1 protein, which were diminished by NFkappaB inhibitors JSH-23 and Bay117082.	Etoposide	0-9	phosphotyrosine interaction domain containing 1	Homo sapiens	58-62
28400607-7	2017	Etoposide also increased PID1 promoter reporter activity, PID1 mRNA, and PID1 protein, which were diminished by NFkappaB inhibitors JSH-23 and Bay117082.	Etoposide	0-9	phosphotyrosine interaction domain containing 1	Homo sapiens	58-62
28400607-7	2017	Etoposide also increased PID1 promoter reporter activity, PID1 mRNA, and PID1 protein, which were diminished by NFkappaB inhibitors JSH-23 and Bay117082.	Etoposide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	112-120
28400607-10	2017	These data demonstrate for the first time that etoposide- and cisplatin-induced apoptosis in medulloblastoma and glioblastoma cell lines is mediated in part by PID1, involves NFkappaB, and may be regulated by proteasomal degradation.	Etoposide	47-56	phosphotyrosine interaction domain containing 1	Homo sapiens	160-164
28400607-10	2017	These data demonstrate for the first time that etoposide- and cisplatin-induced apoptosis in medulloblastoma and glioblastoma cell lines is mediated in part by PID1, involves NFkappaB, and may be regulated by proteasomal degradation.	Etoposide	47-56	nuclear factor kappa B subunit 1	Homo sapiens	175-183
28387728-4	2017	MVs isolated from UV-treated DU145 and A431 epidermoid carcinoma cells as well as etoposide-treated DU145 cells induced phosphorylation of ataxia-telangiectasia mutated (ATM) at serine 1981 (indicative of ATM activation) and phosphorylation of histone H2AX at serine 139 (gammaH2AX) in naive DU145 cells.	Etoposide	82-91	ATM serine/threonine kinase	Homo sapiens	139-168
28387728-4	2017	MVs isolated from UV-treated DU145 and A431 epidermoid carcinoma cells as well as etoposide-treated DU145 cells induced phosphorylation of ataxia-telangiectasia mutated (ATM) at serine 1981 (indicative of ATM activation) and phosphorylation of histone H2AX at serine 139 (gammaH2AX) in naive DU145 cells.	Etoposide	82-91	ATM serine/threonine kinase	Homo sapiens	170-173
28387728-4	2017	MVs isolated from UV-treated DU145 and A431 epidermoid carcinoma cells as well as etoposide-treated DU145 cells induced phosphorylation of ataxia-telangiectasia mutated (ATM) at serine 1981 (indicative of ATM activation) and phosphorylation of histone H2AX at serine 139 (gammaH2AX) in naive DU145 cells.	Etoposide	82-91	ATM serine/threonine kinase	Homo sapiens	205-208
28387728-6	2017	Etoposide and UV are known to induce DDR primarily through the ATM and ATM- and Rad3-related (ATR) pathways, respectively.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	63-66
28387728-6	2017	Etoposide and UV are known to induce DDR primarily through the ATM and ATM- and Rad3-related (ATR) pathways, respectively.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	71-74
28242760-5	2017	Using RNA sequencing, we found that inhibition of TOP2 religation activity by etoposide in AIRE-expressing cells had a synergistic effect on genes with low expression levels.	Etoposide	78-87	autoimmune regulator	Homo sapiens	91-95
27982581-6	2017	Etoposide caused rapid accumulation of 53bp1-GFP in DNA damage foci, which was later followed by the concentration dependent nuclear accumulation of p53-GFP and subsequent induction of p21-GFP.	Etoposide	0-9	tumor protein p53	Homo sapiens	149-152
27982581-6	2017	Etoposide caused rapid accumulation of 53bp1-GFP in DNA damage foci, which was later followed by the concentration dependent nuclear accumulation of p53-GFP and subsequent induction of p21-GFP.	Etoposide	0-9	H3 histone pseudogene 16	Homo sapiens	185-188
27982581-7	2017	While etoposide caused activation of Srxn1-GFP, a modest activation of DNA damage reporters was observed for DEM at high concentrations.	Etoposide	6-15	sulfiredoxin 1	Homo sapiens	37-42
27982581-8	2017	Interestingly, Nrf2 knockdown caused an inhibition of the DNA damage response at high concentrations of etoposide, while Keap1 knockdown caused an enhancement of the DNA damage response already at low concentrations of etoposide.	Etoposide	104-113	NFE2 like bZIP transcription factor 2	Homo sapiens	15-19
27982581-8	2017	Interestingly, Nrf2 knockdown caused an inhibition of the DNA damage response at high concentrations of etoposide, while Keap1 knockdown caused an enhancement of the DNA damage response already at low concentrations of etoposide.	Etoposide	219-228	kelch like ECH associated protein 1	Homo sapiens	121-126
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Etoposide	66-75	recombination activating 1	Homo sapiens	99-103
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Etoposide	66-75	recombination activating 2	Homo sapiens	108-112
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Etoposide	66-75	recombination activating 1	Homo sapiens	209-213
28213501-4	2017	In this article, we show that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA levels in primary pre-B cells, pro-B cells, and pro-T cells, indicating that inhibition of Rag1 and Rag2 expression is a prevalent DSB response among immature lymphocytes.	Etoposide	66-75	recombination activating 2	Homo sapiens	218-222
28113103-7	2017	Analyses of caspase 3 activity, p53 acetylation and SIRT1 protein levels revealed the apoptotic nature of etoposide-evoked cell death and that fisetin and luteolin augmented the etoposide-induced acetylation of p53 and decreased SIRT1 levels.	Etoposide	178-187	tumor protein p53	Homo sapiens	211-214
28113103-7	2017	Analyses of caspase 3 activity, p53 acetylation and SIRT1 protein levels revealed the apoptotic nature of etoposide-evoked cell death and that fisetin and luteolin augmented the etoposide-induced acetylation of p53 and decreased SIRT1 levels.	Etoposide	178-187	sirtuin 1	Homo sapiens	229-234
28089818-9	2017	Enzyme-linked immunosorbent assay results revealed distinct differences in IL-6 and IL-8 secretions by NP cells in response to etoposide in the presence of NCCM.	Etoposide	127-136	interleukin 6	Homo sapiens	75-79
28030535-1	2017	BACKGROUND: Etoposide (VP-16), a podophyllotoxin derivative, is used in conditioning regimens before allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.	Etoposide	12-21	host cell factor C1	Homo sapiens	23-28
28038450-6	2017	miRNA targets prediction showed SMAD2, LTBR and etoposide induced 2.4 (EI24) were potential target genes of miR-455-3p, and then it was confirmed by qRT-PCR assay.	Etoposide	48-57	EI24 autophagy associated transmembrane protein	Homo sapiens	71-75
28185889-0	2017	MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1.	Etoposide	33-42	microRNA 29a	Homo sapiens	9-19
28185889-0	2017	MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1.	Etoposide	33-42	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	89-94
28185889-5	2017	We show that miR-29b significantly increases etoposide toxicity in HeLa cells.	Etoposide	45-54	microRNA 29b-1	Homo sapiens	13-20
28185889-6	2017	Because Mcl-1 protein has been recognized as a miR-29 family target, we evaluated downregulation of Mcl-1 protein splicing variant expression induced by miR-29 precursors and confirmed a key role of Mcl-1 protein in enhancing etoposide toxicity.	Etoposide	226-235	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	8-13
28185889-7	2017	Despite downregulation of Mcl-1 by all three miR-29 family members, only miR-29b significantly enhanced etoposide toxicity.	Etoposide	104-113	microRNA 29b-1	Homo sapiens	73-80
28185889-11	2017	In conclusion, we show that miR-29b has the synergistic effect with etoposide treatment in the HeLa cells and that this effect is linked to Mcl-1 protein expression and nuclear shuttling of miR-29b.	Etoposide	68-77	microRNA 29b-1	Homo sapiens	28-35
28185889-11	2017	In conclusion, we show that miR-29b has the synergistic effect with etoposide treatment in the HeLa cells and that this effect is linked to Mcl-1 protein expression and nuclear shuttling of miR-29b.	Etoposide	68-77	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	140-145
28185889-11	2017	In conclusion, we show that miR-29b has the synergistic effect with etoposide treatment in the HeLa cells and that this effect is linked to Mcl-1 protein expression and nuclear shuttling of miR-29b.	Etoposide	68-77	microRNA 29b-1	Homo sapiens	190-197
28153734-8	2017	Direct interaction between Survivin and Etoposide was confirmed by surface plasmon resonance assay, and molecular docking analysis suggested the structural information on how Etoposide inhibits the Survivin and Borealin interaction.	Etoposide	40-49	cell division cycle associated 8	Homo sapiens	211-219
28395449-0	2017	[O-GlcNAc glycosylation influences the biological behaviors and etoposide-induced apoptosis of Nalm-6 cells].	Etoposide	64-73	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	1-9
28395449-1	2017	Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells.	Etoposide	115-124	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	37-45
28395449-1	2017	Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells.	Etoposide	115-124	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	79-82
28395449-1	2017	Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells.	Etoposide	126-130	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	37-45
28395449-1	2017	Objective: To explore the effects of O-GlcNAc glycosylation and its key enzyme OGT on the biological behaviors and etoposide (Vp16) -induced apoptosis of Nalm-6 cells.	Etoposide	126-130	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	79-82
28153734-8	2017	Direct interaction between Survivin and Etoposide was confirmed by surface plasmon resonance assay, and molecular docking analysis suggested the structural information on how Etoposide inhibits the Survivin and Borealin interaction.	Etoposide	175-184	cell division cycle associated 8	Homo sapiens	211-219
28103122-2	2017	Here, we report that ATG3 is a relatively stable protein in unstressed cells, but it is degraded in response to DNA-damaging agents such as etoposide or cisplatin.	Etoposide	140-149	autophagy related 3	Homo sapiens	21-25
28195382-0	2017	Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage.	Etoposide	72-81	ATM serine/threonine kinase	Homo sapiens	16-19
28069693-3	2017	Here, we demonstrate that treatment with non-cytotoxic levels of environmental chemicals (benzene and diethylnitrosamine) or chemotherapeutic agents (etoposide and doxorubicin) generates significant DNA breakage within RET at levels similar to those generated by fragile site-inducing laboratory chemicals.	Etoposide	150-159	ret proto-oncogene	Homo sapiens	219-222
28195382-3	2017	This study evaluated chemical specificity of the p53 pathway response by manipulating p53 or its upstream kinases and assessing the effect on DNA damage and cellular responses to prototype chemicals: etoposide (ETP, topoisomerase II inhibitor) and methyl methane sulfonate (MMS, alkylating agent).	Etoposide	211-214	tumor protein p53	Homo sapiens	49-52
27993669-6	2017	Suppression of etoposide-induced cell death correlated with a downregulation of p53 expression, which, among other functions, regulates the expression of death receptor 5, one of the activators of caspase-8.	Etoposide	15-24	tumor protein p53	Homo sapiens	80-83
27993669-6	2017	Suppression of etoposide-induced cell death correlated with a downregulation of p53 expression, which, among other functions, regulates the expression of death receptor 5, one of the activators of caspase-8.	Etoposide	15-24	TNF receptor superfamily member 10b	Homo sapiens	154-170
27993669-6	2017	Suppression of etoposide-induced cell death correlated with a downregulation of p53 expression, which, among other functions, regulates the expression of death receptor 5, one of the activators of caspase-8.	Etoposide	15-24	caspase 8	Homo sapiens	197-206
28195382-0	2017	Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage.	Etoposide	72-81	ATR serine/threonine kinase	Homo sapiens	24-27
28195382-0	2017	Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage.	Etoposide	72-81	tumor protein p53	Homo sapiens	47-50
28228219-6	2017	The treatment of SCLC is still confined to chemotherapy regimens of etoposide plus cisplatin (EP) and other classic treatments because the surgical treatment of SCLC, particularly for IIIa treatment, has yet to reach a consensus.	Etoposide	68-77	SCLC1	Homo sapiens	17-21
28259205-0	2017	Erratum to "Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells" [Life Sci.	Etoposide	64-73	erythropoietin	Homo sapiens	12-26
27593939-6	2017	The association of Ku70 with UBE2S was enhanced, and the complex was recruited to double-stranded break (DSB) sites in response to etoposide treatment.	Etoposide	131-140	X-ray repair cross complementing 6	Homo sapiens	19-23
27593939-6	2017	The association of Ku70 with UBE2S was enhanced, and the complex was recruited to double-stranded break (DSB) sites in response to etoposide treatment.	Etoposide	131-140	ubiquitin conjugating enzyme E2 S	Homo sapiens	29-34
28196907-7	2017	However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis.	Etoposide	51-60	sirtuin 1	Homo sapiens	78-87
28196907-7	2017	However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis.	Etoposide	51-60	sirtuin 1	Homo sapiens	89-94
28196907-7	2017	However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis.	Etoposide	51-60	MDM2 proto-oncogene	Homo sapiens	109-113
28196907-7	2017	However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis.	Etoposide	51-60	tumor protein p53	Homo sapiens	228-231
28196907-7	2017	However, upon genotoxic stress through exposure to etoposide, the deacetylase sirtuin 1 (SIRT1) deacetylated MDM2 at Lys182 and Lys185, thereby promoting self-ubiquitination and less ubiquitination and subsequent degradation of p53, thus increasing p53-dependent apoptosis.	Etoposide	51-60	tumor protein p53	Homo sapiens	249-252
28110185-4	2017	In this study, we constructed human topoisomerase II alpha (hTop2alpha) homology model docked with Amsacrine based on crystal structure of human Top2beta in complex with etoposide.	Etoposide	170-179	DNA topoisomerase II alpha	Homo sapiens	60-70
28110185-4	2017	In this study, we constructed human topoisomerase II alpha (hTop2alpha) homology model docked with Amsacrine based on crystal structure of human Top2beta in complex with etoposide.	Etoposide	170-179	DNA topoisomerase II beta	Homo sapiens	145-153
27907860-1	2017	Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro.	Etoposide	160-169	host cell factor C1	Homo sapiens	171-176
31093350-3	2017	In this report, we present the clinical presentation, diagnosis, and management of a patient with HPV-related SCC of the oropharynx that responded favorably to chemotherapy with cisplatin plus etoposide and concomitant radiation therapy, a regimen typically used in SCLC.	Etoposide	193-202	serpin family B member 3	Homo sapiens	110-113
27749622-5	2017	Plerixafor in combination with granulocyte-colony stimulating factor showed its efficacy in mobilizing 6x10 CD34+/kg HSCs able to rescue two HDC cycles of carboplatin-etoposide, leading to stable hematopoietic engraftment.	Etoposide	167-176	colony stimulating factor 3	Homo sapiens	31-68
27907860-1	2017	Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro.	Etoposide	160-169	BCL2 apoptosis regulator	Homo sapiens	182-187
28081228-12	2017	In contrast to cisplatin, functional p53-knock-down increased the resistance of MSC to etoposide.	Etoposide	87-96	tumor protein p53	Homo sapiens	37-40
29791117-7	2017	The present findings suggest that MDR1 represents a molecular signature for prediction of treatment efficacy of topoisomerase inhibitors, especially that of etoposide, which may be a clinically useful anti-tumour agent for cOSA; however, further study is necessary to refine the treatment protocol.	Etoposide	157-166	ATP binding cassette subfamily B member 1	Canis lupus familiaris	34-38
27718545-5	2017	In contrast, NGF differentiated PC12 cells of later passage number are more sensitive to injury induced by etoposide than lower passage number but only after 72 h. Passage number also affects the adherence phenotype of the PC12 cells, complicating screening assays.	Etoposide	107-116	nerve growth factor	Rattus norvegicus	13-16
28112719-3	2017	CD271 expression was increased in drug-sensitive cells but not resistant cells in response to DNA-damaging chemotherapeutics etoposide, fotemustine and cisplatin.	Etoposide	125-134	nerve growth factor receptor	Homo sapiens	0-5
27619527-7	2017	In addition, the UCNP@PDA@AP has been successfully used to monitor etoposide induced intracellular releasing of Cyt c, providing the possibility for cell-based screening of apoptosis-inducing drugs.	Etoposide	67-76	cytochrome c, somatic	Homo sapiens	112-117
27909249-6	2017	Under normoxia, transcriptionally inactive forms of unmodified HIF-1alpha or its C-terminal domain alone are also targeted to mitochondria, stimulate production of VDAC1-DeltaC and increase resistance to etoposide- or doxorubicin-induced apoptosis.	Etoposide	204-213	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-73
28070169-8	2017	Furthermore, overexpression of TFF3 decreased the sensitivity of cervical cancer cells to etoposide by increasing P-glycoprotein (P-gp) functional activity.	Etoposide	90-99	trefoil factor 3	Homo sapiens	31-35
27926506-5	2017	When scar fibroblasts were pre-treated with PSC833 or probenecid, a P-glycoprotein or MRP1 inhibitor respectively, the resistance to verapamil or etoposide was strongly attenuated.	Etoposide	146-155	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
27926506-5	2017	When scar fibroblasts were pre-treated with PSC833 or probenecid, a P-glycoprotein or MRP1 inhibitor respectively, the resistance to verapamil or etoposide was strongly attenuated.	Etoposide	146-155	ATP binding cassette subfamily C member 1	Homo sapiens	86-90
28070169-8	2017	Furthermore, overexpression of TFF3 decreased the sensitivity of cervical cancer cells to etoposide by increasing P-glycoprotein (P-gp) functional activity.	Etoposide	90-99	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
28070169-8	2017	Furthermore, overexpression of TFF3 decreased the sensitivity of cervical cancer cells to etoposide by increasing P-glycoprotein (P-gp) functional activity.	Etoposide	90-99	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
27903968-7	2017	In addition, bosutinib enhanced doxorubicin (Dox)- and etoposide (VP-16)-induced cytotoxicity in NB cells.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
28051100-3	2017	Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	172-181	protein phosphatase with EF-hand domain 1	Homo sapiens	28-34
28051100-3	2017	Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	172-181	casein kinase 2 alpha 2	Homo sapiens	89-97
28051100-3	2017	Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	172-181	tumor protein p53	Homo sapiens	134-137
28051100-3	2017	Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	183-185	protein phosphatase with EF-hand domain 1	Homo sapiens	28-34
28051100-3	2017	Overexpression of wild-type PPEF-1, but not inactive PPEF-1D172N, efficiently suppressed CK2alpha-mediated stabilization of PDCD5 and p53-mediated apoptosis in response to etoposide (ET).	Etoposide	183-185	casein kinase 2 alpha 2	Homo sapiens	89-97
28121937-0	2017	VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.	Etoposide	5-14	vasoactive intestinal peptide	Homo sapiens	0-3
27702691-3	2017	We demonstrate that paclitaxel and etoposide, but not cisplatin, confer ASMase-mediated endothelial injury within minutes.	Etoposide	35-44	sphingomyelin phosphodiesterase 1	Homo sapiens	72-78
28977798-8	2017	RESULTS: Beclin-1 was upregulated in drug-resistant cells and patients with lower sensitivity to etoposide/cisplatin therapy.	Etoposide	97-106	beclin 1	Homo sapiens	9-17
29279550-7	2017	Patients with ALK-positive ALCL are usually treated with anthracycline-based regimens, such as combination cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOEP (CHOP plus etoposide), which provide a favorable prognosis, except in patients with multiple International Prognostic Index factors.	Etoposide	195-204	ALK receptor tyrosine kinase	Homo sapiens	14-17
27974648-2	2017	Using antibody specific for the N-terminal of TOP2alpha, immunoassays indicated the existence of two TOP2alpha isoforms, 170 and 90 kDa, present in K562 leukemia cells and in an acquired etoposide (VP-16)-resistant clone (K/VP.5).	Etoposide	187-196	DNA topoisomerase II alpha	Homo sapiens	46-55
27974648-2	2017	Using antibody specific for the N-terminal of TOP2alpha, immunoassays indicated the existence of two TOP2alpha isoforms, 170 and 90 kDa, present in K562 leukemia cells and in an acquired etoposide (VP-16)-resistant clone (K/VP.5).	Etoposide	187-196	DNA topoisomerase II alpha	Homo sapiens	101-110
27974648-2	2017	Using antibody specific for the N-terminal of TOP2alpha, immunoassays indicated the existence of two TOP2alpha isoforms, 170 and 90 kDa, present in K562 leukemia cells and in an acquired etoposide (VP-16)-resistant clone (K/VP.5).	Etoposide	198-203	DNA topoisomerase II alpha	Homo sapiens	46-55
27974648-2	2017	Using antibody specific for the N-terminal of TOP2alpha, immunoassays indicated the existence of two TOP2alpha isoforms, 170 and 90 kDa, present in K562 leukemia cells and in an acquired etoposide (VP-16)-resistant clone (K/VP.5).	Etoposide	198-203	DNA topoisomerase II alpha	Homo sapiens	101-110
27974648-3	2017	TOP2alpha/90 expression was dramatically increased in etoposide-resistant K/VP.5 compared with parental K562 cells.	Etoposide	54-63	DNA topoisomerase II alpha	Homo sapiens	0-9
27974648-9	2017	Immunodetection of complex of enzyme-to-DNA and single-cell gel electrophoresis (Comet) assays demonstrated that K562 cells transfected with a TOP2alpha/90 expression plasmid exhibited reduced etoposide-mediated TOP2alpha-DNA covalent complexes and decreased etoposide-induced DNA damage, respectively, compared with similarly treated K562 cells transfected with empty vector.	Etoposide	193-202	DNA topoisomerase II alpha	Homo sapiens	143-152
27974648-9	2017	Immunodetection of complex of enzyme-to-DNA and single-cell gel electrophoresis (Comet) assays demonstrated that K562 cells transfected with a TOP2alpha/90 expression plasmid exhibited reduced etoposide-mediated TOP2alpha-DNA covalent complexes and decreased etoposide-induced DNA damage, respectively, compared with similarly treated K562 cells transfected with empty vector.	Etoposide	193-202	DNA topoisomerase II alpha	Homo sapiens	212-221
27974648-9	2017	Immunodetection of complex of enzyme-to-DNA and single-cell gel electrophoresis (Comet) assays demonstrated that K562 cells transfected with a TOP2alpha/90 expression plasmid exhibited reduced etoposide-mediated TOP2alpha-DNA covalent complexes and decreased etoposide-induced DNA damage, respectively, compared with similarly treated K562 cells transfected with empty vector.	Etoposide	259-268	DNA topoisomerase II alpha	Homo sapiens	143-152
27974648-11	2017	Further studies are underway to characterize the mechanism(s) by which TOP2alpha/90 plays a role in acquired resistance to etoposide and other TOP2alpha targeting agents.	Etoposide	123-132	DNA topoisomerase II alpha	Homo sapiens	71-80
27181628-6	2017	Notch1 knockdown in combination with doxorubicin, etoposide, or gemcitabine compared to chemotherapy alone decreased cell viability by 12, 20, and 26%, respectively (p &lt; 0.05).	Etoposide	50-59	notch receptor 1	Homo sapiens	0-6
27677634-4	2017	Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34+ CD38- stem cells resistant to eradication by IM alone, but not in normal hematopoietic stem cells, CML and normal mature CD34- cells, and other leukemia and lymphoma cell lines.	Etoposide	15-18	CD34 molecule	Homo sapiens	80-84
27677634-4	2017	Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34+ CD38- stem cells resistant to eradication by IM alone, but not in normal hematopoietic stem cells, CML and normal mature CD34- cells, and other leukemia and lymphoma cell lines.	Etoposide	15-18	CD38 molecule	Homo sapiens	86-90
27677634-4	2017	Treatment with Eto combined with IM markedly induced apoptosis in primitive CML CD34+ CD38- stem cells resistant to eradication by IM alone, but not in normal hematopoietic stem cells, CML and normal mature CD34- cells, and other leukemia and lymphoma cell lines.	Etoposide	15-18	CD34 molecule	Homo sapiens	207-211
28341109-0	2017	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.	Etoposide	128-137	neural cell adhesion molecule 1	Homo sapiens	23-27
28121937-1	2017	We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS).We analyzed the medical records of patients with advanced or relapsed STS who had undergone VIP treatment as second-line or more chemotherapy between January 2000 and December 2015.	Etoposide	75-84	vasoactive intestinal peptide	Homo sapiens	55-58
27974636-0	2017	Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.	Etoposide	25-34	myeloperoxidase	Homo sapiens	0-15
27974636-1	2017	Myeloperoxidase is expressed exclusively in granulocytes and immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantrone to chemical forms that have altered DNA damaging properties.	Etoposide	135-144	myeloperoxidase	Homo sapiens	0-15
27974636-4	2017	We show here that myeloperoxidase activity leads to elevated accumulation of etoposide- and mitoxantrone-induced TOP2A and TOP2B-DNA covalent complexes in cells, which are converted to DNA double-strand breaks.	Etoposide	77-86	myeloperoxidase	Homo sapiens	18-33
27974636-4	2017	We show here that myeloperoxidase activity leads to elevated accumulation of etoposide- and mitoxantrone-induced TOP2A and TOP2B-DNA covalent complexes in cells, which are converted to DNA double-strand breaks.	Etoposide	77-86	DNA topoisomerase II alpha	Homo sapiens	113-118
27974636-4	2017	We show here that myeloperoxidase activity leads to elevated accumulation of etoposide- and mitoxantrone-induced TOP2A and TOP2B-DNA covalent complexes in cells, which are converted to DNA double-strand breaks.	Etoposide	77-86	DNA topoisomerase II beta	Homo sapiens	123-128
27974636-6	2017	This is a significant finding because TOP2B has been linked to genetic damage associated with leukemic transformation, including etoposide-induced chromosomal breaks at the MLL and RUNX1 loci.	Etoposide	129-138	DNA topoisomerase II beta	Homo sapiens	38-43
27974636-6	2017	This is a significant finding because TOP2B has been linked to genetic damage associated with leukemic transformation, including etoposide-induced chromosomal breaks at the MLL and RUNX1 loci.	Etoposide	129-138	lysine methyltransferase 2A	Homo sapiens	173-176
27974636-6	2017	This is a significant finding because TOP2B has been linked to genetic damage associated with leukemic transformation, including etoposide-induced chromosomal breaks at the MLL and RUNX1 loci.	Etoposide	129-138	RUNX family transcription factor 1	Homo sapiens	181-186
27913458-2	2016	Treatment with epipodophyllotoxins like etoposide has been associated with a short interval between treatment and development of t-AML, with fusion oncogenes like KMT2A/MLL-MLLT3 and a better prognosis.	Etoposide	40-49	lysine methyltransferase 2A	Homo sapiens	163-168
27840903-1	2016	This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells.	Etoposide	70-79	host cell factor C1	Homo sapiens	81-85
27840903-1	2016	This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells.	Etoposide	70-79	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
27604276-6	2016	This model was used to determine the capacity of a number of DNA-damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues.	Etoposide	111-120	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	131-134
28208865-4	2016	The patient was administered 3-cycles of neo-adjuvant chemotherapy with ifosphamide, carboplatin and etoposide (ICE-chemotherapy) and subsequently 3 more cycles of chemotherapy post surgery, followed by radiation.	Etoposide	101-110	carboxylesterase 2	Homo sapiens	112-115
27707625-5	2016	Compounds 9, 11, and 13 inhibited the function of topoisomerase II more strongly than etoposide with almost same magnitude (around 90% and 30% inhibition at 100 and 20muM, respectively) which were higher than those of etoposide (72% and 18% inhibition).	Etoposide	86-95	latexin	Homo sapiens	167-170
31051014-0	2016	PPIP5K1 Suppresses Etoposide-triggered Apoptosis.	Etoposide	19-28	diphosphoinositol pentakisphosphate kinase 1	Homo sapiens	0-7
31051014-4	2016	We observed that PPIP5K1 overexpression decreased sensitivity of cells toward several cytotoxic agents, including etoposide, cisplatin, and sulindac.	Etoposide	114-123	diphosphoinositol pentakisphosphate kinase 1	Homo sapiens	17-24
27852227-9	2016	The combinatorial, but not separate, treatment with low doses of 5-aza-2"-deoxycytidine (0.1 muM) and etoposide (0.5 muM) caused a long-lasting (almost 70 days) reduction in clonogenic/replating ability of DLD-1 cells.	Etoposide	102-111	latexin	Homo sapiens	117-120
27764813-10	2016	Subsequent investigation of therapeutic responsiveness upon treatment with the current systemic gold standard EDP-M (etoposide, doxorubicin, cisplatin and mitotane) demonstrated maintenance of the clinically observed drug resistance for MUC-1 exclusively.	Etoposide	117-126	mucin 1, cell surface associated	Homo sapiens	237-242
27664008-5	2016	We found that dietary flavonoids could inhibit Chk1 phosphorylation and decrease clonogenic cell growth once breast cancer cells receive ultraviolet irradiation, cisplatin, or etoposide treatment.	Etoposide	176-185	checkpoint kinase 1	Homo sapiens	47-51
27895586-0	2016	Weakening Impact of Excessive Human Serum Albumin (eHSA) on Cisplatin and Etoposide Anticancer Effect in C57BL/6 Mice with Tumor and in Human NSCLC A549 Cells.	Etoposide	74-83	albumin	Mus musculus	36-49
27931810-4	2016	As part of the Japanese Environmental Mutagen Society/Mammalian Mutagenicity Study Group collaborative study, we conducted Pig-a and PIGRET assays to detect Pig-a mutations in rats treated with etoposide.	Etoposide	194-203	phosphatidylinositol glycan anchor biosynthesis class A	Sus scrofa	157-162
27484510-3	2016	It has been reported that the stabilizing effect of etoposide on transient cleavable DNA-topoisomerase IIbeta complex attributes to its secondary malignancy.	Etoposide	52-61	DNA topoisomerase II beta	Homo sapiens	89-109
27639682-3	2016	Cellular uptake efficiencies of DC and DP in human alveolar type II epithelial cells were significantly enhanced compared to DMEP and etoposide (VP-16), which were demonstrated to be concentration-, time- and energy-dependent.	Etoposide	134-143	host cell factor C1	Homo sapiens	145-150
27514406-8	2016	IMPLICATIONS: This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy.	Etoposide	260-269	tumor protein p53	Homo sapiens	157-161
27514406-6	2016	Furthermore, tumors that relapsed after cisplatin treatment in our model develop a robust etoposide sensitivity that is independent of the Ercc1 status and depends solely on previous cisplatin exposure.	Etoposide	90-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	139-144
27814490-5	2016	The defects in Mre11 compromise the repair of etoposide-induced Top2-DNA covalent complexes, and MRE11-/- and MRE11-/H129N cells accumulate high levels of Top2 covalent conjugates even in the absence of exogenous damage.	Etoposide	46-55	MRE11A homolog A, double strand break repair nuclease	Mus musculus	15-20
27814490-5	2016	The defects in Mre11 compromise the repair of etoposide-induced Top2-DNA covalent complexes, and MRE11-/- and MRE11-/H129N cells accumulate high levels of Top2 covalent conjugates even in the absence of exogenous damage.	Etoposide	46-55	MRE11A homolog A, double strand break repair nuclease	Mus musculus	110-115
27661668-11	2016	Depending on Nrf2-induced proteasome activity, IMC-cocultured NCM460 or Colo320 cancer cells were less sensitive to apoptosis (TRAIL-/etoposide induced).	Etoposide	134-143	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
27514406-8	2016	IMPLICATIONS: This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy.	Etoposide	260-269	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	189-194
27980999-4	2016	The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle"s suppression on migration and invasion of non-small cell lung cancer (NSCLC).	Etoposide	51-60	host cell factor C1	Homo sapiens	39-43
27619661-11	2016	Notably, the ectopic expression of cFLIPL resists the sensitivity of cancer cells against apoptosis inducers Etoposide and HA14-1.	Etoposide	109-118	CASP8 and FADD like apoptosis regulator	Homo sapiens	35-41
27895801-4	2016	Cisplatin, etoposide and doxorubicin were shown to increase the cellular expression of AURKB, while ATRA, Am80 and TAC-101 downregulated its expression.	Etoposide	11-20	aurora kinase B	Homo sapiens	87-92
27817234-9	2016	At the onset of the lymphonodular metastasis systemic chemotherapy with ifosfamide (1000 mg/m2, D1-3) - etoposide (100 mg/m2, D1-3) was started allowing complete clinical remission of the lymphadenomegaly and stability of the asymptomatic neurological status.	Etoposide	104-113	leiomodin 1	Homo sapiens	96-100
27792189-5	2016	By using a human osteosarcoma cell line (U2OS), we show that after the CRISPR-Cas9-mediated removal of the SMC5/6 subunit NSMCE2, treatment with the topoisomerase II inhibitor etoposide triggered an increased sensitivity in cells lacking NSMCE2.	Etoposide	176-185	structural maintenance of chromosomes 5	Homo sapiens	107-113
27792189-5	2016	By using a human osteosarcoma cell line (U2OS), we show that after the CRISPR-Cas9-mediated removal of the SMC5/6 subunit NSMCE2, treatment with the topoisomerase II inhibitor etoposide triggered an increased sensitivity in cells lacking NSMCE2.	Etoposide	176-185	NSE2 (MMS21) homolog, SMC5-SMC6 complex SUMO ligase	Homo sapiens	122-128
27792189-5	2016	By using a human osteosarcoma cell line (U2OS), we show that after the CRISPR-Cas9-mediated removal of the SMC5/6 subunit NSMCE2, treatment with the topoisomerase II inhibitor etoposide triggered an increased sensitivity in cells lacking NSMCE2.	Etoposide	176-185	NSE2 (MMS21) homolog, SMC5-SMC6 complex SUMO ligase	Homo sapiens	238-244
27833761-7	2016	The results show that caspase-2 is a key mitochondrial-injuring caspase during etoposide and gemcitabine-induced apoptosis of E1A-positive cells, and that caspase-2 is required for induction of caspase-3 activity by both chemotherapeutic agents.	Etoposide	79-88	caspase 2	Homo sapiens	22-31
27980999-4	2016	The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle"s suppression on migration and invasion of non-small cell lung cancer (NSCLC).	Etoposide	51-60	host cell factor C1	Homo sapiens	45-49
27562137-0	2016	The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin"s lymphoma.	Etoposide	40-49	vascular endothelial growth factor A	Homo sapiens	100-104
27562137-10	2016	CONCLUSION: Metronomic chemotherapy with prednisone, etoposide, and cyclophosphamide resulted in higher ORR and DCR, fewer adverse effects, and longer PFS in patients with relapsed or refractory NHL, with significant reduction in serum CECs and VEGF levels.	Etoposide	53-62	vascular endothelial growth factor A	Homo sapiens	245-249
27473919-0	2016	Etoposide induces pancreatic beta-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
27473919-7	2016	Additionally, pretreatment with both SP600125 and PD98059 effectively suppressed etoposide-induced beta-cell cytotoxicity, apoptosis, and GSK-3 protein phosphorylation; however, LiCl did not reverse JNK and ERK1/2 phosphorylation.	Etoposide	81-90	mitogen-activated protein kinase 8	Rattus norvegicus	199-202
27473919-0	2016	Etoposide induces pancreatic beta-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway.	Etoposide	0-9	Eph receptor B1	Rattus norvegicus	65-68
27473919-7	2016	Additionally, pretreatment with both SP600125 and PD98059 effectively suppressed etoposide-induced beta-cell cytotoxicity, apoptosis, and GSK-3 protein phosphorylation; however, LiCl did not reverse JNK and ERK1/2 phosphorylation.	Etoposide	81-90	mitogen activated protein kinase 3	Rattus norvegicus	207-213
27473919-3	2016	Here, the results showed that in RIN-m5F cells (a beta-cell-derived cell line), the number of viable cells was significantly decreased after 24h of etoposide treatment and underwent mitochondria-dependent apoptotic signals accompanied by mitochondrial dysfunction, and increases in the population of sub-G1 hypodiploid cells and apoptotic cells, caspase-3 activity, and the activation of caspase cascades.	Etoposide	148-157	caspase 3	Rattus norvegicus	346-355
27473919-8	2016	Taken together, these results suggest that etoposide is capable of causing cytotoxicity on pancreatic beta-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway.	Etoposide	43-52	mitogen-activated protein kinase 8	Rattus norvegicus	147-150
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	Etoposide	38-47	mitogen activated protein kinase 3	Rattus norvegicus	79-157
27473919-8	2016	Taken together, these results suggest that etoposide is capable of causing cytotoxicity on pancreatic beta-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway.	Etoposide	43-52	Eph receptor B1	Rattus norvegicus	151-154
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	Etoposide	38-47	mitogen activated protein kinase 14	Rattus norvegicus	166-169
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	Etoposide	38-47	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	Etoposide	38-47	mitogen activated protein kinase 3	Rattus norvegicus	242-248
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	D-amino acid oxidase	Homo sapiens	38-41
28057998-2	2016	In the present case, we reported that a 58-year-old male patient presenting with testicular tumors who developed acute peripheral arterial disease during combination CTx with bleomycin, etoposide, and cisplatin.	Etoposide	186-195	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	166-169
27680712-2	2016	The therapeutic effects of etoposide(VP-16), a widely used anticancer agent, on HSCs apoptosis and liver fibrosis resolution are still unclear.	Etoposide	27-36	host cell factor C1	Homo sapiens	37-42
32263493-2	2016	Herein, etoposide (ETO) was loaded onto oxidized carbon nanohorns (oxCNHs), which were modified by polyethylene glycol (PEG) and further functionalized with the targeting ligand P-gp monoclonal antibody (PA) in an attempt to overcome MDR.	Etoposide	8-17	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
32263493-2	2016	Herein, etoposide (ETO) was loaded onto oxidized carbon nanohorns (oxCNHs), which were modified by polyethylene glycol (PEG) and further functionalized with the targeting ligand P-gp monoclonal antibody (PA) in an attempt to overcome MDR.	Etoposide	19-22	ATP binding cassette subfamily B member 1	Homo sapiens	178-182
27666530-7	2016	Studies using MAPK inhibitors reveal that inhibition of extracellular signal regulated kinase (ERK) protects ETO-induced cytotoxicity by inhibiting DNA damage and caspase 3/7 activity.	Etoposide	109-112	caspase 3	Homo sapiens	163-172
27666530-8	2016	Eventually, ERK inhibitor treated cells are protected from ETO-induced nuclear envelope (NE) rupture and DNA leakage through inhibition of caspase activity.	Etoposide	59-62	mitogen-activated protein kinase 1	Homo sapiens	12-15
27666530-9	2016	Taken together, these data suggest that ETO mediates cytotoxicity in HK-2 cells through ROS and ERK pathways, which highlight the preventive avenues in ETO-induced cytotoxicity in kidney.	Etoposide	40-43	mitogen-activated protein kinase 1	Homo sapiens	96-99
27666530-9	2016	Taken together, these data suggest that ETO mediates cytotoxicity in HK-2 cells through ROS and ERK pathways, which highlight the preventive avenues in ETO-induced cytotoxicity in kidney.	Etoposide	152-155	mitogen-activated protein kinase 1	Homo sapiens	96-99
27649656-11	2016	SENP5-depleted HepG2 cells exhibited hypersensitivity to IR and etoposide treatment with defective checkpoint activation including decreased activation of ATR and phosphorylation of ATR targets.	Etoposide	64-73	SUMO specific peptidase 5	Homo sapiens	0-5
27424190-7	2016	Furthermore, co-expression of PNMA5 and MOAP-1 in MCF-7 cells significantly enhanced chemo-sensitivity of MCF-7 to Etoposide treatment, indicating that PNMA5 and MOAP-1 interact synergistically to promote apoptotic signaling in MCF-7 cells.	Etoposide	115-124	PNMA family member 5	Homo sapiens	30-35
27424190-7	2016	Furthermore, co-expression of PNMA5 and MOAP-1 in MCF-7 cells significantly enhanced chemo-sensitivity of MCF-7 to Etoposide treatment, indicating that PNMA5 and MOAP-1 interact synergistically to promote apoptotic signaling in MCF-7 cells.	Etoposide	115-124	modulator of apoptosis 1	Homo sapiens	40-46
27424190-7	2016	Furthermore, co-expression of PNMA5 and MOAP-1 in MCF-7 cells significantly enhanced chemo-sensitivity of MCF-7 to Etoposide treatment, indicating that PNMA5 and MOAP-1 interact synergistically to promote apoptotic signaling in MCF-7 cells.	Etoposide	115-124	PNMA family member 5	Homo sapiens	152-157
27424190-7	2016	Furthermore, co-expression of PNMA5 and MOAP-1 in MCF-7 cells significantly enhanced chemo-sensitivity of MCF-7 to Etoposide treatment, indicating that PNMA5 and MOAP-1 interact synergistically to promote apoptotic signaling in MCF-7 cells.	Etoposide	115-124	modulator of apoptosis 1	Homo sapiens	162-168
27666530-0	2016	Etoposide induced cytotoxicity mediated by ROS and ERK in human kidney proximal tubule cells.	Etoposide	0-9	mitogen-activated protein kinase 1	Homo sapiens	51-54
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	83-86	synuclein alpha	Homo sapiens	5-8
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	83-86	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	166-169
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	83-86	mitochondrially encoded NADH dehydrogenase 4	Homo sapiens	174-177
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	83-86	PPARG coactivator 1 alpha	Homo sapiens	264-274
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	83-86	PPARG coactivator 1 beta	Homo sapiens	279-288
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	103-106	synuclein alpha	Homo sapiens	5-8
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	103-106	mitochondrially encoded NADH dehydrogenase 1	Homo sapiens	166-169
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	103-106	mitochondrially encoded NADH dehydrogenase 4	Homo sapiens	174-177
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	103-106	PPARG coactivator 1 alpha	Homo sapiens	264-274
27666530-5	2016	When NAC, a well-known reactive oxygen species (ROS) scavenger, is co-treated with ETO, it inhibits an ETO-induced increase in mitochondrial mass, mitochondrial DNA (ND1 and ND4) copy number, intracellular ATP level, and mitochondrial biogenesis activators (TFAM, PGC-1alpha and PGC-1beta).	Etoposide	103-106	PPARG coactivator 1 beta	Homo sapiens	279-288
27666530-6	2016	Moreover, co-treatment with ETO and NAC inhibits ETO-induced necrosis and cell swelling, but not apoptosis.	Etoposide	49-52	synuclein alpha	Homo sapiens	36-39
27666530-7	2016	Studies using MAPK inhibitors reveal that inhibition of extracellular signal regulated kinase (ERK) protects ETO-induced cytotoxicity by inhibiting DNA damage and caspase 3/7 activity.	Etoposide	109-112	mitogen-activated protein kinase 1	Homo sapiens	14-18
27666530-7	2016	Studies using MAPK inhibitors reveal that inhibition of extracellular signal regulated kinase (ERK) protects ETO-induced cytotoxicity by inhibiting DNA damage and caspase 3/7 activity.	Etoposide	109-112	mitogen-activated protein kinase 1	Homo sapiens	56-93
27666530-7	2016	Studies using MAPK inhibitors reveal that inhibition of extracellular signal regulated kinase (ERK) protects ETO-induced cytotoxicity by inhibiting DNA damage and caspase 3/7 activity.	Etoposide	109-112	mitogen-activated protein kinase 1	Homo sapiens	95-98
27558965-4	2016	Our data also indicate that RNF168 deficiency, including in human breast cancer cell lines, confers resistance to the anti-cancer drug and TOP2 inhibitor etoposide.	Etoposide	154-163	ring finger protein 168	Homo sapiens	28-34
27419628-5	2016	The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio.	Etoposide	120-129	collagen type XI alpha 2 chain	Homo sapiens	256-260
27419628-5	2016	The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio.	Etoposide	120-129	caspase 9	Homo sapiens	270-279
27419628-5	2016	The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio.	Etoposide	120-129	BCL2 apoptosis regulator	Homo sapiens	318-323
27419628-5	2016	The results showed that both glutamine deprivation and BPTES pretreatments increased the toxic effects of cisplatin and etoposide on HCC1937 cells, as demonstrated by their reduced proliferation, increased expression of apoptosis-related proteins (cleaved-PARP, cleaved-caspase 9, and cleaved-caspase 3) and decreased Bcl-2/BAX ratio.	Etoposide	120-129	BCL2 associated X, apoptosis regulator	Homo sapiens	324-327
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	proline dehydrogenase 1	Homo sapiens	28-33
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	tumor protein p53	Homo sapiens	82-85
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	proline dehydrogenase 1	Homo sapiens	122-127
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	D-amino acid oxidase	Homo sapiens	129-132
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	epsin 3	Homo sapiens	134-138
27545311-7	2016	Among these genes, 2 genes (PRODH and DAO) were found to be directly regulated by p53, and ectopic expression of 4 genes (PRODH, DAO, EPN3, and GPR172B) affected senescence phenotypes induced by etoposide treatment.	Etoposide	195-204	solute carrier family 52 member 1	Homo sapiens	144-151
26751770-7	2016	In response to DNA damage induced by etoposide, interaction between both proteins is disrupted, thus avoiding CHK2 degradation and promoting its stabilization.	Etoposide	37-46	checkpoint kinase 2	Homo sapiens	110-114
27540302-0	2016	High expression of S100A8 gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway.	Etoposide	69-78	S100 calcium binding protein A8	Homo sapiens	19-25
27504190-10	2016	Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P &lt; 0.05; R = 0.40, P &lt; 0.05 respectively).	Etoposide	121-124	albumin	Homo sapiens	190-193
27527606-11	2016	Consistent with p53 status, apoptosis was markedly increased in ACH2 and NCHA2 cells compared with uninfected and latently infected J1.1 cells upon treatment with other anticancer drugs such as doxorubicin and etoposide.	Etoposide	210-219	acyl-CoA thioesterase 1	Homo sapiens	64-68
27510889-7	2016	The sensitivity of female germ cells to etoposide coincided with topoisomerase IIalpha expression: in the developing ovary of both mouse and human, topoisomerase IIalpha was expressed in germ cells only prior to follicle formation.	Etoposide	40-49	ATPase, class II, type 9A	Mus musculus	79-86
27510889-7	2016	The sensitivity of female germ cells to etoposide coincided with topoisomerase IIalpha expression: in the developing ovary of both mouse and human, topoisomerase IIalpha was expressed in germ cells only prior to follicle formation.	Etoposide	40-49	ATPase, class II, type 9A	Mus musculus	162-169
27303923-5	2016	Hypoxic melanoma cells sorted for VEGF-R2/CD133 positivity also undergo apoptosis when exposed to Etoposide and Bevacizumab.	Etoposide	98-107	prominin 1	Homo sapiens	42-47
27540302-4	2016	In this study, we investigated the correlation of S100A8 at the transcription level with clinical parameters in 91 de novo AML patients and explored its mechanisms of chemoresistance to etoposide in vitro.	Etoposide	186-195	S100 calcium binding protein A8	Homo sapiens	50-56
27540302-7	2016	HL-60 cells transfected with S100A8 showed resistance to etoposide with a higher level IC50 value and lower apoptosis rate compared with HL-60 cells transfected with empty vector.	Etoposide	57-66	S100 calcium binding protein A8	Homo sapiens	29-35
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Etoposide	238-247	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	34-37
26873069-4	2016	Our aim was to evaluate the in vitro effects of some of the anticancer agents such as cetuximab, paclitaxel, etoposide, docetaxel, and ifosfamide on the activity of hPON1 in this study.	Etoposide	109-118	paraoxonase 1	Homo sapiens	165-170
27570640-3	2016	Using microRNA array and washout and rechallenge experiments, we found that short term treatment of leukemia cells with etoposide led a few days later to transient resistance that was associated with a corresponding transient increase in expression of ABCB1 mRNA, as well as microRNA (miR)-135b and miR-196b.	Etoposide	120-129	ATP binding cassette subfamily B member 1	Homo sapiens	252-257
27570640-3	2016	Using microRNA array and washout and rechallenge experiments, we found that short term treatment of leukemia cells with etoposide led a few days later to transient resistance that was associated with a corresponding transient increase in expression of ABCB1 mRNA, as well as microRNA (miR)-135b and miR-196b.	Etoposide	120-129	microRNA 135b	Homo sapiens	275-294
27570640-3	2016	Using microRNA array and washout and rechallenge experiments, we found that short term treatment of leukemia cells with etoposide led a few days later to transient resistance that was associated with a corresponding transient increase in expression of ABCB1 mRNA, as well as microRNA (miR)-135b and miR-196b.	Etoposide	120-129	microRNA 196b	Homo sapiens	299-307
26991014-3	2016	We observed that knockdown of AE2 sensitized immortalized H69 human cholangiocytes to not only bile salt-induced apoptosis (BSIA) but also etoposide-induced apoptosis.	Etoposide	139-148	solute carrier family 4 member 2	Homo sapiens	30-33
26991014-4	2016	Because the toxicity of etoposide is pH-independent, there could be a more general mechanism for sensitization of AE2-depleted cholangiocytes to apoptotic stimuli.	Etoposide	24-33	solute carrier family 4 member 2	Homo sapiens	114-117
26768307-0	2016	Enhanced delivery of etoposide across the blood-brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles.	Etoposide	21-30	melanotransferrin	Homo sapiens	99-116
26768307-1	2016	Melanotransferrin antibody (MA) and tamoxifen (TX) were conjugated on etoposide (ETP)-entrapped solid lipid nanoparticles (ETP-SLNs) to target the blood-brain barrier (BBB) and glioblastom multiforme (GBM).	Etoposide	70-79	melanotransferrin	Homo sapiens	0-17
26768307-1	2016	Melanotransferrin antibody (MA) and tamoxifen (TX) were conjugated on etoposide (ETP)-entrapped solid lipid nanoparticles (ETP-SLNs) to target the blood-brain barrier (BBB) and glioblastom multiforme (GBM).	Etoposide	81-84	melanotransferrin	Homo sapiens	0-17
27473573-4	2016	CASE PRESENTATION: We report a case of acquired EBV-triggered HLH with progression to t-AML following etoposide therapy with cytogenetic abnormality for t (11; 19) (q23; p13) resulting in MLL gene fusion.	Etoposide	102-111	H3 histone pseudogene 6	Homo sapiens	170-173
27473573-4	2016	CASE PRESENTATION: We report a case of acquired EBV-triggered HLH with progression to t-AML following etoposide therapy with cytogenetic abnormality for t (11; 19) (q23; p13) resulting in MLL gene fusion.	Etoposide	102-111	lysine methyltransferase 2A	Homo sapiens	188-191
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Etoposide	238-247	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	94-99
27374090-4	2016	Indeed, co-treatment with the pan-Pim kinase inhibitor AZD1208 or expression of a kinase-dead Pim-1 mutant sensitized FLT3-ITD cell lines to apoptosis triggered by chemotherapy drugs including the topoisomerase 2 inhibitors daunorubicin, etoposide and mitoxantrone, but not the nucleoside analog cytarabine.	Etoposide	238-247	fms related receptor tyrosine kinase 3	Homo sapiens	118-122
27378523-5	2016	Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16).	Etoposide	129-138	host cell factor C1	Homo sapiens	140-145
27235629-0	2016	Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.	Etoposide	63-72	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	13-44
27216197-8	2016	Unexpectedly, IL6-type cytokine signaling inducing STAT3 activation rendered cervical cancer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide.	Etoposide	179-188	interleukin 6	Homo sapiens	14-17
27216197-8	2016	Unexpectedly, IL6-type cytokine signaling inducing STAT3 activation rendered cervical cancer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide.	Etoposide	179-188	signal transducer and activator of transcription 3	Homo sapiens	51-56
27235629-5	2016	We found that NSC111041 inhibits TDP2"s binding to DNA without getting intercalated into DNA and enhanced etoposide"s cytotoxicity synergistically in TDP2-expressing cells but not in TDP2 depleted cells.	Etoposide	106-115	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	150-154
27235629-5	2016	We found that NSC111041 inhibits TDP2"s binding to DNA without getting intercalated into DNA and enhanced etoposide"s cytotoxicity synergistically in TDP2-expressing cells but not in TDP2 depleted cells.	Etoposide	106-115	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	150-154
27174643-8	2016	In line with this, these cells are also more sensitive to the ROS-producing chemotherapeutic drugs etoposide/Vp16 and Ara-C.	Etoposide	99-108	host cell factor C1	Homo sapiens	109-113
20301580-9	1993	MANAGEMENT: Treatment of manifestations: Treatment of XLP-related HLH is similar to that of other life-threatening genetic hemophagocytic disorders and includes immunosuppressive agents such as steroids and etoposide or anti-thymocyte globulin.	Etoposide	207-216	SH2 domain containing 1A	Homo sapiens	54-57
27563402-2	2016	Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by &gt;10-fold.	Etoposide	193-202	aldo-keto reductase family 1 member C3	Homo sapiens	40-46
27106081-7	2016	The bromodomain inhibitors effectively decreased etoposide-induced release of IL-6 and IL-8.	Etoposide	49-58	interleukin 6	Homo sapiens	78-82
27106081-7	2016	The bromodomain inhibitors effectively decreased etoposide-induced release of IL-6 and IL-8.	Etoposide	49-58	C-X-C motif chemokine ligand 8	Homo sapiens	87-91
27166195-2	2016	We show here that the DNA damaging agents cisplatin and etoposide upregulate Noxa expression, which is required for the phosphorylation of MCL-1 at Ser64/Thr70 sites, proteasome-dependent degradation, and apoptosis.	Etoposide	56-65	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	77-81
27166195-2	2016	We show here that the DNA damaging agents cisplatin and etoposide upregulate Noxa expression, which is required for the phosphorylation of MCL-1 at Ser64/Thr70 sites, proteasome-dependent degradation, and apoptosis.	Etoposide	56-65	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	139-144
27297620-0	2016	Activity of cyclin B1 in HL-60 cells treated with etoposide.	Etoposide	50-59	cyclin B1	Homo sapiens	12-21
27376029-12	2016	Several clinically available chemotherapeutic drugs (carboplatin, paclitaxel, and etoposide) and drugs at the developmental stage (Wee-1 and heat shock protein 90 inhibitors) show a sensitizing effect on tumor cells treated with carbon ions.	Etoposide	82-91	WEE1 G2 checkpoint kinase	Homo sapiens	131-136
27297620-5	2016	Etoposide caused decrease in cell viability, induced apoptosis and G2/M arrest accompanied by enhanced expression of cyclin B1.	Etoposide	0-9	cyclin B1	Homo sapiens	117-126
27297620-6	2016	Changes in expression and localization of cyclin B1 may constitute a part of the mechanism responsible for resistance of HL-60 cells to etoposide.	Etoposide	136-145	cyclin B1	Homo sapiens	42-51
26663398-4	2016	Functional studies in vitro determined that four AML-directed chemotherapeutics (cytarabine, daunorubicin, etoposide, and mitoxantrone) are substrates for OATP1B1 and the mouse ortholog Oatp1b2.	Etoposide	107-116	solute carrier organic anion transporter family member 1B1	Homo sapiens	155-162
27272789-5	2016	RESULTS: MPS1 inhibition sensitized murine tumour cells to etoposide but not to IR.	Etoposide	59-68	Ttk protein kinase	Mus musculus	9-13
27272789-6	2016	In addition, MPS1 inhibition altered cell-cycle progression and exacerbated centrosome abnormalities, resulting in enhanced MC induced by etoposide but not by IR.	Etoposide	138-147	Ttk protein kinase	Mus musculus	13-17
27272789-7	2016	CONCLUSION: MPS1 inhibition promotes the etoposide-induced aberrant mitosis and, consequently, the induction of tumour cell death.	Etoposide	41-50	Ttk protein kinase	Mus musculus	12-16
26663398-4	2016	Functional studies in vitro determined that four AML-directed chemotherapeutics (cytarabine, daunorubicin, etoposide, and mitoxantrone) are substrates for OATP1B1 and the mouse ortholog Oatp1b2.	Etoposide	107-116	solute carrier organic anion transporter family, member 1b2	Mus musculus	186-193
27247490-5	2016	Additionally, ABCG2 loss-of-function induced anti-proliferation and apoptosis-promoting functions in RCSCs, and multidrug resistance to cisplatin, carboplatin, vincristine, doxorubicin, and etoposide was greatly improved in these cells.	Etoposide	190-199	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-19
27035096-6	2016	Combination of PA with Eto/Cpt promoted disruption of the dynamics of actin filaments, leading to subsequent enhancement of apoptotic cell death via induction of caspase-3, -8, and -9, accompanied by increased phosphorylation of p38.	Etoposide	23-26	caspase 3	Homo sapiens	162-183
27035096-6	2016	Combination of PA with Eto/Cpt promoted disruption of the dynamics of actin filaments, leading to subsequent enhancement of apoptotic cell death via induction of caspase-3, -8, and -9, accompanied by increased phosphorylation of p38.	Etoposide	23-26	mitogen-activated protein kinase 14	Homo sapiens	229-232
26300006-3	2016	Comet assays demonstrated that DNA repair was delayed in cells silenced for the expression of ZNF281 and treated with etoposide.	Etoposide	118-127	zinc finger protein 281	Homo sapiens	94-100
27220325-7	2016	Consistent with this, isoeugenol exacerbated etoposide-induced cytotoxicity, which generates TOP2-mediated PDBs for which TDP2 is required for processing.	Etoposide	45-54	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	122-126
27284433-6	2016	The patient was treated with chemotherapy with the VIP protocol (cisplatin, etoposide and ifosfamide).	Etoposide	76-85	vasoactive intestinal peptide	Homo sapiens	51-54
27247353-10	2016	Associating drug response with micro-RNA expression indicated that lines most sensitive to etoposide and topotecan expressed high miR-200c-3p and low miR-140-5p and miR-9-5p.	Etoposide	91-100	microRNA 95	Homo sapiens	165-173
27119507-4	2016	It has been suggested that MLL fusions render cells susceptible to additional chromosomal damage upon exposure to etoposide.	Etoposide	114-123	lysine methyltransferase 2A	Homo sapiens	27-30
26300006-4	2016	Furthermore, the expression of 10 DNA damage response genes was downregulated in cells treated with etoposide and silenced for ZNF281.	Etoposide	100-109	zinc finger protein 281	Homo sapiens	127-133
27060144-5	2016	We further identify a Tdp2 active site SNP that ablates Tdp2 Mg(2+) binding and catalytic activity, impairs Tdp2 mediated NHEJ of tyrosine blocked termini, and renders cells sensitive to the anticancer agent etoposide.	Etoposide	208-217	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	22-26
27060144-5	2016	We further identify a Tdp2 active site SNP that ablates Tdp2 Mg(2+) binding and catalytic activity, impairs Tdp2 mediated NHEJ of tyrosine blocked termini, and renders cells sensitive to the anticancer agent etoposide.	Etoposide	208-217	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	56-60
27150447-10	2016	Three courses of induction systemic chemotherapy (cisplatin, etoposide, and bleomycin) normalized his serum alpha-fetoprotein and DUPAN-2 levels.	Etoposide	61-70	alpha fetoprotein	Homo sapiens	108-125
27060144-5	2016	We further identify a Tdp2 active site SNP that ablates Tdp2 Mg(2+) binding and catalytic activity, impairs Tdp2 mediated NHEJ of tyrosine blocked termini, and renders cells sensitive to the anticancer agent etoposide.	Etoposide	208-217	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	56-60
27183435-3	2016	We herein established that the etoposide (VP16)-resistant SKOV3 human ovarian cancer cell clones (SKOV3/VP16 cells) and mRNA expression of LRIG1 were significantly reduced by the treatment of VP16 in a concentration-dependent manner.	Etoposide	31-40	leucine rich repeats and immunoglobulin like domains 1	Homo sapiens	139-144
26902420-3	2016	In human colon cancer cells, both homeoproteins interact with the DNA repair factor KU70/80, but functional studies reveal opposite effects: HoxB7 stimulates DNA repair and cell survival upon etoposide treatment, whereas Cdx2 inhibits both processes.	Etoposide	192-201	homeobox B7	Homo sapiens	141-146
27183435-8	2016	Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy.	Etoposide	171-175	ATP binding cassette subfamily C member 1	Homo sapiens	31-36
27183435-8	2016	Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy.	Etoposide	171-175	BCL2 apoptosis regulator	Homo sapiens	41-46
27183435-8	2016	Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy.	Etoposide	171-175	leucine rich repeats and immunoglobulin like domains 1	Homo sapiens	87-92
27183435-8	2016	Furthermore, the expression of MRP-1 and Bcl-2 was also inhibited, suggesting that the LRIG1could negatively control MRP-1 and the apoptosis to improve the sensitivity of VP16-related chemotherapy.	Etoposide	171-175	ATP binding cassette subfamily C member 1	Homo sapiens	117-122
26986476-0	2016	PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway.	Etoposide	29-38	phosphatase and tensin homolog	Homo sapiens	0-4
26986476-0	2016	PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway.	Etoposide	29-38	ATM serine/threonine kinase	Homo sapiens	85-88
26986476-6	2016	In the present study, we assessed the contribution of PTEN to the etoposide-induced G2/M cell cycle arrest.	Etoposide	66-75	phosphatase and tensin homolog	Homo sapiens	54-58
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	phosphatase and tensin homolog	Homo sapiens	37-41
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	ATM serine/threonine kinase	Homo sapiens	63-66
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	ATM serine/threonine kinase	Homo sapiens	163-166
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	H2A.X variant histone	Homo sapiens	189-193
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	tumor protein p53	Homo sapiens	195-198
26986476-8	2016	The results showed that knockdown of PTEN strongly antagonized ATM activation in response to etoposide treatment, and thereby reduced the phosphorylation level of ATM substrates, including H2AX, P53 and Chk2.	Etoposide	93-102	checkpoint kinase 2	Homo sapiens	203-207
26986476-9	2016	Furthermore, depletion of PTEN reduced the etoposide-induced phosphorylation of CDC25C and strikingly compromised etoposide-induced G2/M arrest in the MCF-7 cells.	Etoposide	43-52	phosphatase and tensin homolog	Homo sapiens	26-30
26986476-9	2016	Furthermore, depletion of PTEN reduced the etoposide-induced phosphorylation of CDC25C and strikingly compromised etoposide-induced G2/M arrest in the MCF-7 cells.	Etoposide	43-52	cell division cycle 25C	Homo sapiens	80-86
26986476-9	2016	Furthermore, depletion of PTEN reduced the etoposide-induced phosphorylation of CDC25C and strikingly compromised etoposide-induced G2/M arrest in the MCF-7 cells.	Etoposide	114-123	phosphatase and tensin homolog	Homo sapiens	26-30
26986476-10	2016	Altogether, we demonstrated that PTEN plays a unique role in etoposide-induced G2/M arrest by facilitating the activation of the ATM pathway, and PTEN was required for the proper activation of checkpoints in response to DNA damage in MCF-7 cells.	Etoposide	61-70	phosphatase and tensin homolog	Homo sapiens	33-37
26986476-10	2016	Altogether, we demonstrated that PTEN plays a unique role in etoposide-induced G2/M arrest by facilitating the activation of the ATM pathway, and PTEN was required for the proper activation of checkpoints in response to DNA damage in MCF-7 cells.	Etoposide	61-70	ATM serine/threonine kinase	Homo sapiens	129-132
27009862-0	2016	Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells.	Etoposide	42-51	CD44 molecule (Indian blood group)	Homo sapiens	55-59
27009862-4	2016	Drugs that performed best in docking were examined in molecular dynamics simulations, identifying etoposide as a potential CD44 antagonist.	Etoposide	98-107	CD44 molecule (Indian blood group)	Homo sapiens	123-127
27009862-6	2016	Etoposide-treated MDA-MB-231 cells developed an epithelial morphology; increased their expression of E-cadherin; and reduced their levels of EMT-associated genes and cell migration.	Etoposide	0-9	cadherin 1	Homo sapiens	101-111
27009862-8	2016	Moreover, etoposide decreased the proportion of CD44+/CD24- cells, lowered chemoresistance, and blocked mammosphere formation.	Etoposide	10-19	CD44 molecule (Indian blood group)	Homo sapiens	48-52
27009862-8	2016	Moreover, etoposide decreased the proportion of CD44+/CD24- cells, lowered chemoresistance, and blocked mammosphere formation.	Etoposide	10-19	CD24 molecule	Homo sapiens	54-58
27009862-9	2016	Our data indicate that etoposide blocks CD44 activation, impairing key cellular functions that drive malignancy, thus rendering it a candidate for further translational studies and a potential lead compound in the development of new CD44 antagonists.	Etoposide	23-32	CD44 molecule (Indian blood group)	Homo sapiens	40-44
27009862-9	2016	Our data indicate that etoposide blocks CD44 activation, impairing key cellular functions that drive malignancy, thus rendering it a candidate for further translational studies and a potential lead compound in the development of new CD44 antagonists.	Etoposide	23-32	CD44 molecule (Indian blood group)	Homo sapiens	233-237
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Etoposide	224-233	ATPase, Cu++ transporting, alpha polypeptide	Gallus gallus	74-79
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Etoposide	224-233	ATPase copper transporting beta	Gallus gallus	159-164
26988911-1	2016	We previously reported that ATP7B is involved in cisplatin resistance and ATP7A confers multidrug resistance (MDR) in cancer cells.In this study, we show that ATP7B expressing cells also are resistant to doxorubicin, SN-38, etoposide, and paclitaxel as well as cisplatin.In ATP7B expressing cells, doxorubicin relocated from the nuclei to the late-endosome at 4 hours after doxorubicin exposure.	Etoposide	224-233	ATPase copper transporting beta	Gallus gallus	159-164
27069137-8	2016	Moreover, depletion of PANDA prevented accumulation of p53 protein, as a result of DNA damage, induced by the genotoxic agent etoposide.	Etoposide	126-135	promoter of CDKN1A antisense DNA damage activated RNA	Homo sapiens	23-28
27551516-3	2016	Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand.	Etoposide	109-118	CREB regulated transcription coactivator 1	Mus musculus	27-33
26988802-9	2016	Further evaluation of endogenous topo-mediated DNA relaxation in cells has been conducted to find that, 5d inhibited endogenous topo-mediated pBR322 plasmid relaxation is more efficient (78.0 +- 4.7% at 50 muM) than Etoposide (36.0 +- 1.7% at 50 muM).	Etoposide	216-225	latexin	Homo sapiens	206-209
26967250-7	2016	We further show that DNA damage, such as exposure to methyl methanesulfonate (MMS), etoposide or arsenic, increases Cdc25A acetylation.	Etoposide	84-93	cell division cycle 25A	Homo sapiens	116-122
27069137-8	2016	Moreover, depletion of PANDA prevented accumulation of p53 protein, as a result of DNA damage, induced by the genotoxic agent etoposide.	Etoposide	126-135	tumor protein p53	Homo sapiens	55-58
27044816-6	2016	In Doxorubicin and Etoposide resistant MCF-7 cell lines, APOBEC3B expression was approximately five-fold increased (23% and 24% respectively) with higher signal intensity (1.92 and 1.44 signal/cell, respectively) compared to drug sensitive MCF-7 cell line (5%, 1.00 signal/cell) with statistical significance.	Etoposide	19-28	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	57-65
26701338-1	2016	Solid lipid nanoparticles (SLNs) comprising complex internal lipids were conjugated with melanotransferrin antibody (MA) to carry anticancer etoposide across the blood-brain barrier (BBB) for managing glioblastoma multiforme (GBM).	Etoposide	141-150	melanotransferrin	Homo sapiens	89-106
26827764-4	2016	Carboplatin- and etoposide-resistant MCC cell lines exhibited increased expression of ABCB5, along with enhanced ABCB1 and ABCC3 transcript expression.	Etoposide	17-26	ATP binding cassette subfamily B member 5	Homo sapiens	86-91
26827764-4	2016	Carboplatin- and etoposide-resistant MCC cell lines exhibited increased expression of ABCB5, along with enhanced ABCB1 and ABCC3 transcript expression.	Etoposide	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	113-118
26827764-4	2016	Carboplatin- and etoposide-resistant MCC cell lines exhibited increased expression of ABCB5, along with enhanced ABCB1 and ABCC3 transcript expression.	Etoposide	17-26	ATP binding cassette subfamily C member 3	Homo sapiens	123-128
26827764-5	2016	ABCB5-expressing MCC cells in heterogeneous cancers preferentially survived treatment with carboplatin and etoposide in vitro and in human MCC xenograft-bearing mice in vivo.	Etoposide	107-116	ATP binding cassette subfamily B member 5	Homo sapiens	0-5
26827764-6	2016	Moreover, patients with MCC also exhibited enhanced ABCB5 positivity after carboplatin- and etoposide-based chemotherapy, pointing to clinical significance of this chemoresistance mechanism.	Etoposide	92-101	ATP binding cassette subfamily B member 5	Homo sapiens	52-57
26895377-4	2016	Overexpression of miR-30e in HCT116 cells not only inhibited gammaIR-, etoposide- or miR-34a-induced caspase-3-like DEVDase activities and cell death, but greatly accelerated and augmented their senescent phenotype.	Etoposide	71-80	microRNA 30e	Homo sapiens	18-25
26895377-4	2016	Overexpression of miR-30e in HCT116 cells not only inhibited gammaIR-, etoposide- or miR-34a-induced caspase-3-like DEVDase activities and cell death, but greatly accelerated and augmented their senescent phenotype.	Etoposide	71-80	caspase 3	Homo sapiens	101-110
26858249-0	2016	Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner.	Etoposide	58-67	inhibitor of DNA binding 1, HLH protein	Homo sapiens	44-47
26858249-0	2016	Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner.	Etoposide	58-67	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	91-96
26858249-0	2016	Inhibitor of Differentiation/DNA Binding 1 (ID1) Inhibits Etoposide-induced Apoptosis in a c-Jun/c-Fos-dependent Manner.	Etoposide	58-67	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
26858249-4	2016	Here, we determined for the first time that up-regulating ID1 upon etoposide activation was mediated through AP-1 binding sites within theID1promoter and confirmed that ID1 enhanced cell resistance to DNA damage-induced apoptosis in esophageal squamous cell carcinoma cells.	Etoposide	67-76	inhibitor of DNA binding 1, HLH protein	Homo sapiens	58-61
26858249-4	2016	Here, we determined for the first time that up-regulating ID1 upon etoposide activation was mediated through AP-1 binding sites within theID1promoter and confirmed that ID1 enhanced cell resistance to DNA damage-induced apoptosis in esophageal squamous cell carcinoma cells.	Etoposide	67-76	inhibitor of DNA binding 1, HLH protein	Homo sapiens	138-141
26858249-5	2016	Ablation of c-Jun/c-Fos or ID1 expression enhanced etoposide-mediated apoptosis through increasing activity of caspase 3 and PARP cleavage.	Etoposide	51-60	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
26858249-5	2016	Ablation of c-Jun/c-Fos or ID1 expression enhanced etoposide-mediated apoptosis through increasing activity of caspase 3 and PARP cleavage.	Etoposide	51-60	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
26858249-5	2016	Ablation of c-Jun/c-Fos or ID1 expression enhanced etoposide-mediated apoptosis through increasing activity of caspase 3 and PARP cleavage.	Etoposide	51-60	inhibitor of DNA binding 1, HLH protein	Homo sapiens	27-30
26858249-5	2016	Ablation of c-Jun/c-Fos or ID1 expression enhanced etoposide-mediated apoptosis through increasing activity of caspase 3 and PARP cleavage.	Etoposide	51-60	caspase 3	Homo sapiens	111-120
26858249-5	2016	Ablation of c-Jun/c-Fos or ID1 expression enhanced etoposide-mediated apoptosis through increasing activity of caspase 3 and PARP cleavage.	Etoposide	51-60	poly(ADP-ribose) polymerase 1	Homo sapiens	125-129
27103979-3	2016	We investigated the efficacy and safety of chemo mobilization with an intermediate dose etoposide (VP-16; 200 mg/m(2) on days 1-3) and granulocyte-colony stimulating factor (G-CSF)(5 microg/kg twice daily from day 4 through the final day of collection).	Etoposide	88-97	host cell factor C1	Homo sapiens	99-104
26801660-6	2016	Western blot assay showed that ectopic expression of miR-483-3p in ESCC cells could downregulate the protein level of etoposide induced 2.4 (EI24), which is a tumor suppressor and has not been reported in ESCC.	Etoposide	118-127	microRNA 483	Mus musculus	53-60
26801660-6	2016	Western blot assay showed that ectopic expression of miR-483-3p in ESCC cells could downregulate the protein level of etoposide induced 2.4 (EI24), which is a tumor suppressor and has not been reported in ESCC.	Etoposide	118-127	etoposide induced 2.4 mRNA	Mus musculus	141-145
26646449-11	2016	Downregulation of SIRT1 by RNAi promoted etoposide-induced DNA damage in myeloid leukemia cells accompanied by reduced NHEJ activity, and increased Ku70 acetylation.	Etoposide	41-50	sirtuin 1	Homo sapiens	18-23
26646449-12	2016	Furthermore, SIRT1 knockdown resulted in cell cycle arrest, induction of apoptosis and reduction of K562 cell proliferation accompanied by enhanced p53 and FOXO1 acetylation in K562 cells after etoposide treatment.	Etoposide	194-203	sirtuin 1	Homo sapiens	13-18
26646449-12	2016	Furthermore, SIRT1 knockdown resulted in cell cycle arrest, induction of apoptosis and reduction of K562 cell proliferation accompanied by enhanced p53 and FOXO1 acetylation in K562 cells after etoposide treatment.	Etoposide	194-203	tumor protein p53	Homo sapiens	148-151
26646449-12	2016	Furthermore, SIRT1 knockdown resulted in cell cycle arrest, induction of apoptosis and reduction of K562 cell proliferation accompanied by enhanced p53 and FOXO1 acetylation in K562 cells after etoposide treatment.	Etoposide	194-203	forkhead box O1	Homo sapiens	156-161
26910393-9	2016	Moreover, miR-495 inhibits etoposide-induced cell death.	Etoposide	27-36	microRNA 495	Homo sapiens	10-17
26880199-5	2016	Moreover, the interaction between CtIP and BRCA1, although dispensable for resection of endonuclease-generated DSB ends, is required for resection of Top2-adducted DSBs, as well as for cellular resistance to etoposide during genomic DNA replication.	Etoposide	208-217	retinoblastoma binding protein 8 S homeolog	Xenopus laevis	34-38
26881775-8	2016	CD10 augmented melanoma cell resistance to apoptosis mediated by etoposide and gemcitabine.	Etoposide	65-74	membrane metalloendopeptidase	Homo sapiens	0-4
26588458-14	2016	ICE (ifosfamide, carboplatin, etoposide) chemotherapy was administered prior to and after RT for a total of 6-8 cycles.	Etoposide	30-39	caspase 1	Homo sapiens	0-3
26927112-0	2016	Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide).	Etoposide	183-192	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	72-77
26880199-5	2016	Moreover, the interaction between CtIP and BRCA1, although dispensable for resection of endonuclease-generated DSB ends, is required for resection of Top2-adducted DSBs, as well as for cellular resistance to etoposide during genomic DNA replication.	Etoposide	208-217	breast cancer 1 L homeolog	Xenopus laevis	43-48
26973857-0	2016	EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.	Etoposide	70-79	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	0-4
26893544-8	2016	Curcumin modified the cytotoxic action of etoposide in HL-60 cells through intensification of free radical production because preincubation with N-acetyl-l-cysteine (NAC) significantly reduced the cytotoxic effect of curcumin itself and a combination of two compounds.	Etoposide	42-51	X-linked Kx blood group	Homo sapiens	166-169
26708503-2	2016	Consistent with previous findings that NRF2-ARE contributes to chemotherapeutic resistance of cancer cells, we found that stable knockdown of NRF2 by lentiviral shRNA in human acute monocytic leukemia (AML) THP-1 cells enhanced the cytotoxicity of several chemotherapeutic agents, including arsenic trioxide (As2O3), etoposide and doxorubicin.	Etoposide	317-326	NFE2 like bZIP transcription factor 2	Homo sapiens	142-146
26973857-2	2016	The tumor suppressor, p53 is central for apoptotic response to multiple DNA damaging agents used to treat aggressive B-cell lymphomas, including etoposide.	Etoposide	145-154	tumor protein p53	Homo sapiens	22-25
26973857-3	2016	It has been demonstrated that etoposide induced DNA damage and therapeutic efficacy is enhanced by combination with inhibitors of the histone methyltransferase, enhancer of zeste homolog 2 (EZH2).	Etoposide	30-39	PR/SET domain 9	Homo sapiens	134-159
26973857-3	2016	It has been demonstrated that etoposide induced DNA damage and therapeutic efficacy is enhanced by combination with inhibitors of the histone methyltransferase, enhancer of zeste homolog 2 (EZH2).	Etoposide	30-39	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	161-188
26973857-3	2016	It has been demonstrated that etoposide induced DNA damage and therapeutic efficacy is enhanced by combination with inhibitors of the histone methyltransferase, enhancer of zeste homolog 2 (EZH2).	Etoposide	30-39	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	190-194
26973857-5	2016	Using B-cell lymphoma cell lines resistant to etoposide induced cell death; we show that p53 is dramatically down regulated and MDMX, a negative regulator of p53, is significantly up regulated.	Etoposide	46-55	tumor protein p53	Homo sapiens	89-92
26973857-5	2016	Using B-cell lymphoma cell lines resistant to etoposide induced cell death; we show that p53 is dramatically down regulated and MDMX, a negative regulator of p53, is significantly up regulated.	Etoposide	46-55	MDM4 regulator of p53	Homo sapiens	128-132
26625199-4	2016	In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest.	Etoposide	60-69	tumor protein p53	Homo sapiens	10-13
26625199-4	2016	In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest.	Etoposide	60-69	hemoglobin subunit zeta	Homo sapiens	71-74
26625199-4	2016	In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest.	Etoposide	60-69	tumor protein p53	Homo sapiens	83-86
26625199-4	2016	In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest.	Etoposide	60-69	cyclin dependent kinase inhibitor 1A	Homo sapiens	110-113
26625199-4	2016	In HCT116 p53+/+ cells treated with the DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of p21/CDKN1A and GADD45A expression, which was associated with a delay in G2 phase-arrest.	Etoposide	60-69	cyclin dependent kinase inhibitor 1A	Homo sapiens	114-120
26727221-0	2016	Glycogen Synthase Kinase-3beta and Caspase-2 Mediate Ceramide- and Etoposide-Induced Apoptosis by Regulating the Lysosomal-Mitochondrial Axis.	Etoposide	67-76	glycogen synthase kinase 3 beta	Homo sapiens	0-30
26420828-5	2016	We found that etoposide-induced DSBs are efficiently resected into 3" single-stranded DNA in cells and the major nuclease for resection is the DNA2 protein.	Etoposide	14-23	DNA replication helicase/nuclease 2 S homeolog	Xenopus laevis	143-147
26727221-0	2016	Glycogen Synthase Kinase-3beta and Caspase-2 Mediate Ceramide- and Etoposide-Induced Apoptosis by Regulating the Lysosomal-Mitochondrial Axis.	Etoposide	67-76	caspase 2	Homo sapiens	35-44
26727221-8	2016	These results demonstrate the importance of GSK-3beta and caspase-2 in ceramide- and etoposide-induced apoptosis through mechanisms involving Mcl-1 destabilization and the lysosomal-mitochondrial axis.	Etoposide	85-94	glycogen synthase kinase 3 beta	Homo sapiens	44-53
26727221-8	2016	These results demonstrate the importance of GSK-3beta and caspase-2 in ceramide- and etoposide-induced apoptosis through mechanisms involving Mcl-1 destabilization and the lysosomal-mitochondrial axis.	Etoposide	85-94	caspase 2	Homo sapiens	58-67
26727221-8	2016	These results demonstrate the importance of GSK-3beta and caspase-2 in ceramide- and etoposide-induced apoptosis through mechanisms involving Mcl-1 destabilization and the lysosomal-mitochondrial axis.	Etoposide	85-94	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	142-147
27249756-2	2016	The standard first-line chemotherapy regimen in the United States and Europe remains cisplatin or carboplatin plus etoposide in the treatment of limited stage (LS-SCLC) and extensive stage (ES-SCLC) disease.	Etoposide	115-124	SCLC1	Homo sapiens	163-167
26548759-5	2016	We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine).	Etoposide	238-247	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
26581212-2	2016	Etoposide produces Top2-attached single-strand breaks (Top2-SSB complex) and double-strand breaks (Top2-DSB complex) that are thought to induce cell death in tumor cells.	Etoposide	0-9	small RNA binding exonuclease protection factor La	Homo sapiens	60-63
26581212-9	2016	Therefore, FEN1 may play an important role in the repair of Top2-SSB complexes in etoposide-treated cells.	Etoposide	82-91	flap structure-specific endonuclease 1	Homo sapiens	11-15
26581212-9	2016	Therefore, FEN1 may play an important role in the repair of Top2-SSB complexes in etoposide-treated cells.	Etoposide	82-91	small RNA binding exonuclease protection factor La	Homo sapiens	65-68
26467917-7	2016	HDC was carmustine, etoposide, cytarabine, and melphalan (BEAM).	Etoposide	20-29	histidine decarboxylase	Homo sapiens	0-3
26613402-7	2016	EVP suppressed expression of SOD1, and increased expression of HSP70, in both H2O2-treated C2C12 myoblasts and sciatic-denervated mice.	Etoposide	0-3	superoxide dismutase 1, soluble	Mus musculus	29-33
26613402-7	2016	EVP suppressed expression of SOD1, and increased expression of HSP70, in both H2O2-treated C2C12 myoblasts and sciatic-denervated mice.	Etoposide	0-3	heat shock protein 1B	Mus musculus	63-68
26548759-5	2016	We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine).	Etoposide	238-247	ATP binding cassette subfamily C member 1	Homo sapiens	75-80
24937381-0	2016	Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations.	Etoposide	81-90	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	94-108
24937381-1	2016	A receptor level interaction of etoposide with P-glycoprotein (P-gp) and subsequent intestinal efflux has an adverse effect on its oral absorption.	Etoposide	32-41	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	47-61
24937381-1	2016	A receptor level interaction of etoposide with P-glycoprotein (P-gp) and subsequent intestinal efflux has an adverse effect on its oral absorption.	Etoposide	32-41	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	63-67
24937381-2	2016	The present work is aimed to enhance the bioavailability of etoposide by co-administering it with quercetin (a P-gp inhibitor) in dual-loaded polymeric nanoparticle formulation.	Etoposide	60-69	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	111-115
28442670-4	2016	Although the AFP returned to normal level after four courses of BEP (bleomycin, etoposide and cisplatin), the retroperitoneal lymph nodes continued to grow.	Etoposide	80-89	alpha fetoprotein	Homo sapiens	13-16
27334858-6	2016	A substantial high yield of CD34(+) cells was achieved when patients were treated with a dose-modified IVE regimen, compared with that during the previous regimen (two with the ifosfamide, carboplatin, and etoposide [ICE] regimen, one with high-dose cyclophosphamide and one with the original IVE regimen).	Etoposide	206-215	CD34 molecule	Homo sapiens	28-32
26788519-7	2016	Overexpression of Cdk5r1 in beta-cells confers protection against apoptosis induced by etoposide and thapsigargin, but not camptothecin.	Etoposide	87-96	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	Mus musculus	18-24
28132989-6	2016	We administered two courses of systemic chemotherapy consisting of cisplatin (CDDP) plus an etoposide (VP-16), a first-line treatment usually administered to patients with small cell carcinoma of the lung.	Etoposide	92-101	host cell factor C1	Homo sapiens	103-108
26796799-1	2016	OBJECTIVE: To investigate the changes of ID1 expression in tumor cells treated with etoposide, cisplatin and ultraviolet (UV) irradiation, and explore the effect of ID1 on chemotherapeutic drug- and UV-induced apoptosis.	Etoposide	84-93	inhibitor of DNA binding 1, HLH protein	Homo sapiens	41-44
24021429-3	2016	Since the protein is involved in cancer pathology, we first investigated the effects of bleomycin, etoposide, and cisplatin (BEP) on MTA1 signaling in the testis.	Etoposide	99-108	metastasis associated 1	Rattus norvegicus	133-137
26796799-2	2016	METHODS: In the present study, upon onset of apoptosis induced by various kinds of inducers such as etoposide, cisplatin and UV irradiation, the expression level of ID1 was detected by Western blot and real-time PCR.	Etoposide	100-109	inhibitor of DNA binding 1, HLH protein	Homo sapiens	165-168
26796799-5	2016	RESULTS: ID1 expression presented a profound down-regulation in the HCT116 cells treated with etoposide, cisplatin and UV irradiation(P&lt;0.05 for all).	Etoposide	94-103	inhibitor of DNA binding 1, HLH protein	Homo sapiens	9-12
26796799-7	2016	Upon etoposide treatment, ID1 expression level was decreased via induction of mRNA instability, but not the protein degradation changes.	Etoposide	5-14	inhibitor of DNA binding 1, HLH protein	Homo sapiens	26-29
26796799-8	2016	Additionally, ectopic expression of ID1 in the HCT116 cells alleviated etoposide-, cisplatin- and UV-induced apoptosis.	Etoposide	71-80	inhibitor of DNA binding 1, HLH protein	Homo sapiens	36-39
26796799-10	2016	CONCLUSIONS: These observations indicate that the treatment with etoposide reduces the amount of ID1 by induction of mRNA instability, and exogenously introduced ID1 protects cells against etoposide-, cisplatin- and UV irradiation-induced apoptosis.	Etoposide	65-74	inhibitor of DNA binding 1, HLH protein	Homo sapiens	97-100
26796799-10	2016	CONCLUSIONS: These observations indicate that the treatment with etoposide reduces the amount of ID1 by induction of mRNA instability, and exogenously introduced ID1 protects cells against etoposide-, cisplatin- and UV irradiation-induced apoptosis.	Etoposide	189-198	inhibitor of DNA binding 1, HLH protein	Homo sapiens	162-165
26690546-0	2015	Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells.	Etoposide	23-32	cyclin dependent kinase 2	Homo sapiens	80-84
26690546-7	2015	Pharmacological inactivation of Chk2, CDK2 or ERK1/2 or depletion of CDK2 or Chk2 inhibited the centrosome amplification in ETO-treated ACT cells.	Etoposide	124-127	checkpoint kinase 2	Homo sapiens	32-36
26690546-7	2015	Pharmacological inactivation of Chk2, CDK2 or ERK1/2 or depletion of CDK2 or Chk2 inhibited the centrosome amplification in ETO-treated ACT cells.	Etoposide	124-127	cyclin dependent kinase 2	Homo sapiens	38-42
26690546-7	2015	Pharmacological inactivation of Chk2, CDK2 or ERK1/2 or depletion of CDK2 or Chk2 inhibited the centrosome amplification in ETO-treated ACT cells.	Etoposide	124-127	mitogen-activated protein kinase 3	Homo sapiens	46-52
26690546-7	2015	Pharmacological inactivation of Chk2, CDK2 or ERK1/2 or depletion of CDK2 or Chk2 inhibited the centrosome amplification in ETO-treated ACT cells.	Etoposide	124-127	cyclin dependent kinase 2	Homo sapiens	69-73
26690546-7	2015	Pharmacological inactivation of Chk2, CDK2 or ERK1/2 or depletion of CDK2 or Chk2 inhibited the centrosome amplification in ETO-treated ACT cells.	Etoposide	124-127	checkpoint kinase 2	Homo sapiens	77-81
26046675-8	2015	Furthermore, transfection with constitutive active MKK1 or AKT vectors could rescue the XRCC1 protein level and also the cell survival suppressed by co-treatment with etoposide and resveratrol.	Etoposide	167-176	AKT serine/threonine kinase 1	Homo sapiens	59-62
26824008-10	2015	Our patient received a systemic combination chemotherapy with steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) regimen, resulting in a complete clinical and radiological remission.	Etoposide	133-142	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	144-149
26657054-1	2015	Etoposide, a topoisomerase 2 (TOP2) inhibitor, is associated with the development of KMT2A (MLL)-rearranged infant leukemia.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	85-90
26657054-1	2015	Etoposide, a topoisomerase 2 (TOP2) inhibitor, is associated with the development of KMT2A (MLL)-rearranged infant leukemia.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	92-95
26657054-3	2015	The present study examined the mechanism underlying the development of KMT2A (MLL)-rearranged infant leukemia in response to in utero exposure to etoposide in a mouse model.	Etoposide	146-155	lysine methyltransferase 2A	Homo sapiens	71-76
26657054-3	2015	The present study examined the mechanism underlying the development of KMT2A (MLL)-rearranged infant leukemia in response to in utero exposure to etoposide in a mouse model.	Etoposide	146-155	lysine methyltransferase 2A	Homo sapiens	78-81
26657054-5	2015	Etoposide-induced Kmt2a breakage was detected in fetal liver hematopoietic stem cells using a newly developed chromatin immunoprecipitation (ChIP) assay.	Etoposide	0-9	lysine (K)-specific methyltransferase 2A	Mus musculus	18-23
26632252-3	2015	Previously we demonstrated that hsa-miR-195 targets BCL2, induces apoptosis and augmented the effect of etoposide in breast cancer cells.	Etoposide	104-113	microRNA 195	Homo sapiens	36-43
26046675-0	2015	Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.	Etoposide	21-30	mitogen-activated protein kinase 3	Homo sapiens	76-82
26046675-0	2015	Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.	Etoposide	21-30	AKT serine/threonine kinase 1	Homo sapiens	87-90
26046675-8	2015	Furthermore, transfection with constitutive active MKK1 or AKT vectors could rescue the XRCC1 protein level and also the cell survival suppressed by co-treatment with etoposide and resveratrol.	Etoposide	167-176	X-ray repair cross complementing 1	Homo sapiens	88-93
26046675-0	2015	Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.	Etoposide	21-30	X-ray repair cross complementing 1	Homo sapiens	100-137
26046675-0	2015	Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.	Etoposide	21-30	X-ray repair cross complementing 1	Homo sapiens	139-144
26046675-9	2015	These findings suggested that down-regulation of XRCC1 expression by resveratrol can enhance the chemosensitivity of etoposide in NSCLC cells.	Etoposide	117-126	X-ray repair cross complementing 1	Homo sapiens	49-54
26046675-1	2015	Etoposide (VP-16), a topoisomerase II inhibitor, is an effective anti-cancer drug used for the treatment of non-small-cell lung cancer (NSCLC).	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
26152239-0	2015	Progression of chromosomal damage induced by etoposide in G2 phase in a DNA-PKcs-deficient context.	Etoposide	45-54	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	72-80
26046675-4	2015	However, the role of ERK1/2 and AKT-mediated XRCC1 expression in etoposide treatment alone or combined with resveratrol-induced cytotoxicity in NSCLC cells has not been identified.	Etoposide	65-74	AKT serine/threonine kinase 1	Homo sapiens	32-35
26046675-4	2015	However, the role of ERK1/2 and AKT-mediated XRCC1 expression in etoposide treatment alone or combined with resveratrol-induced cytotoxicity in NSCLC cells has not been identified.	Etoposide	65-74	X-ray repair cross complementing 1	Homo sapiens	45-50
26046675-5	2015	In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975.	Etoposide	15-24	X-ray repair cross complementing 1	Homo sapiens	45-50
26046675-5	2015	In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975.	Etoposide	15-24	AKT serine/threonine kinase 1	Homo sapiens	87-90
26046675-5	2015	In this study, etoposide treatment increased XRCC1 mRNA and protein expression through AKT and ERK1/2 activation in two NSCLC cells, H1703 and H1975.	Etoposide	15-24	mitogen-activated protein kinase 3	Homo sapiens	95-101
26046675-6	2015	Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide.	Etoposide	172-181	X-ray repair cross complementing 1	Homo sapiens	13-18
26046675-6	2015	Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide.	Etoposide	172-181	X-ray repair cross complementing 1	Homo sapiens	53-58
26046675-6	2015	Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide.	Etoposide	172-181	mitogen-activated protein kinase 3	Homo sapiens	84-90
26046675-6	2015	Knockdown of XRCC1 in NSCLC cells by transfection of XRCC1 siRNA or inactivation of ERK1/2 and AKT resulted in enhancing cytotoxicity and cell growth inhibition induced by etoposide.	Etoposide	172-181	AKT serine/threonine kinase 1	Homo sapiens	95-98
26046675-8	2015	Furthermore, transfection with constitutive active MKK1 or AKT vectors could rescue the XRCC1 protein level and also the cell survival suppressed by co-treatment with etoposide and resveratrol.	Etoposide	167-176	mitogen-activated protein kinase kinase 1	Homo sapiens	51-55
26547055-4	2015	As a result, we identified 2 novel compounds 2ca" and 2jc" more potent than etoposide 1 (25-60 fold) having high selectivity against the human THP-1 leukemia cell line and a minimal toxicity (IC50 of 9.3 +- 0.8 and 19.6 +- 1.4 nM respectively) which represent the best candidates for further pharmacological optimization.	Etoposide	76-85	GLI family zinc finger 2	Homo sapiens	143-148
26319900-7	2015	Suppression of RGS10 leads to an increase in cell proliferation, even in the presence of etoposide.	Etoposide	89-98	regulator of G protein signaling 10	Homo sapiens	15-20
26398583-4	2015	in the present study, inhibition of SIRT1 deacetylase by shRNA sensitized Jurkat cells to etoposide by reducing the activity of non-homologous end joining (NHEJ) and homologous recombination (HR).	Etoposide	90-99	sirtuin 1	Homo sapiens	36-41
26438158-3	2015	Here, we report that PARP inhibitors synergize with temozolomide (TMZ) or SN-38 to induce apoptosis and also somewhat enhance the cytotoxicity of doxorubicin, etoposide, or ifosfamide, whereas actinomycin D and vincristine show little synergism.	Etoposide	159-168	poly(ADP-ribose) polymerase 1	Homo sapiens	21-25
26397184-5	2015	Anticancer agents including doxorubicin, cisplatin and etoposide each induced HMGB1 upregulation, promoted cytosolic HMGB1 translocation and the elevation of autophagic activity in human NB cells.	Etoposide	55-64	high mobility group box 1	Homo sapiens	78-83
26397184-5	2015	Anticancer agents including doxorubicin, cisplatin and etoposide each induced HMGB1 upregulation, promoted cytosolic HMGB1 translocation and the elevation of autophagic activity in human NB cells.	Etoposide	55-64	high mobility group box 1	Homo sapiens	117-122
26398583-5	2015	Silencing of SIRT1 deacetylase by shRNA resulted in enhanced apoptosis and cell cycle arrest, while reduced colony formation of Jurkat cells after etoposide treatment was accompanied by elevated acetylation of FOXO1.	Etoposide	147-156	sirtuin 1	Homo sapiens	13-18
26398583-5	2015	Silencing of SIRT1 deacetylase by shRNA resulted in enhanced apoptosis and cell cycle arrest, while reduced colony formation of Jurkat cells after etoposide treatment was accompanied by elevated acetylation of FOXO1.	Etoposide	147-156	forkhead box O1	Homo sapiens	210-215
26556501-0	2015	Effect of ATM and HDAC Inhibition on Etoposide-Induced DNA Damage in Porcine Early Preimplantation Embryos.	Etoposide	37-46	ATM serine/threonine kinase	Homo sapiens	10-13
26459854-7	2015	However, the SMILE regimen (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) was able to suppress tumor growth in this case.	Etoposide	83-92	CREB/ATF bZIP transcription factor	Homo sapiens	13-18
26435500-5	2015	Immunofluorescence analysis showed that p73 moves to the mitochondria and colocalizes with Hades during etoposide-induced apoptosis.	Etoposide	104-113	tumor protein p73	Homo sapiens	40-43
26515462-0	2015	Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
26515462-0	2015	Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
26227317-9	2015	Induction of DNA damage by mitoxantrone and etoposide repressed HO-1 transcription, whereas hydrogen peroxide and doxorubicin induced its expression.	Etoposide	44-53	heme oxygenase 1	Homo sapiens	64-68
26374553-2	2015	The aim of this study was to assess the efficacy and safety of ifosfamide in combination with carboplatin and etoposide (ICE) in previously untreated patients with SCLC.	Etoposide	110-119	carboxylesterase 2	Homo sapiens	121-124
26551008-0	2015	Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer.	Etoposide	6-15	signal transducer and activator of transcription 3	Homo sapiens	129-134
26551008-3	2015	We developed a novel Etoposide analogue, Quinazolino-4beta-amidopodophyllotoxin (C-10) that show better efficacy in regulating cell proliferation and angiogenesis.	Etoposide	21-30	homeobox C10	Homo sapiens	81-85
26551008-5	2015	Docking studies clearly demonstrated the binding of Etoposide and C-10 to STAT3.	Etoposide	52-61	signal transducer and activator of transcription 3	Homo sapiens	74-79
26421495-10	2015	Finally, micronucleus analyses following ETO treatment revealed a higher frequency of micronucleus containing gammaH2AX signals on TDP1kd cells.	Etoposide	41-44	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	131-135
26458825-0	2015	Akt is translocated to the mitochondria during etoposide-induced apoptosis of HeLa cells.	Etoposide	47-56	AKT serine/threonine kinase 1	Homo sapiens	0-3
26458825-3	2015	During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis.	Etoposide	7-16	AKT serine/threonine kinase 1	Homo sapiens	50-53
26458825-3	2015	During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis.	Etoposide	7-16	diablo IAP-binding mitochondrial protein	Homo sapiens	132-170
26458825-3	2015	During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis.	Etoposide	7-16	diablo IAP-binding mitochondrial protein	Homo sapiens	172-176
26458825-3	2015	During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis.	Etoposide	7-16	diablo IAP-binding mitochondrial protein	Homo sapiens	177-183
26458825-3	2015	During etoposide-induced apoptosis of HeLa cells, Akt enhances the interaction of second mitochondria-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and X-linked inhibitor of apoptosis protein by phosphorylating Smac at serine 67, and thus promotes apoptosis.	Etoposide	7-16	diablo IAP-binding mitochondrial protein	Homo sapiens	248-252
26458825-4	2015	However, the detailed mechanisms underlying Akt regulation in etoposide-mediated apoptosis remain to be determined.	Etoposide	62-71	AKT serine/threonine kinase 1	Homo sapiens	44-47
26458825-5	2015	The present study investigated whether etoposide triggers the translocation of Akt into the mitochondria.	Etoposide	39-48	AKT serine/threonine kinase 1	Homo sapiens	79-82
26458825-6	2015	It was found that Akt activity was increased and sustained during apoptosis triggered by etoposide in HeLa cells.	Etoposide	89-98	AKT serine/threonine kinase 1	Homo sapiens	18-21
26458825-8	2015	Concomitantly, the depletion of Akt in the nuclear fraction was observed after etoposide treatment from analysis of confocal microscopy.	Etoposide	79-88	AKT serine/threonine kinase 1	Homo sapiens	32-35
26458825-9	2015	The results suggest that etoposide-stimulated Akt is translocated into the mitochondria, thereby possibly enhancing its interaction with Smac and promoting apoptosis in HeLa cells.	Etoposide	25-34	AKT serine/threonine kinase 1	Homo sapiens	46-49
26458825-9	2015	The results suggest that etoposide-stimulated Akt is translocated into the mitochondria, thereby possibly enhancing its interaction with Smac and promoting apoptosis in HeLa cells.	Etoposide	25-34	diablo IAP-binding mitochondrial protein	Homo sapiens	137-141
26421495-4	2015	We found that TDP1kd cells are hypersensitive to etoposide (ETO).	Etoposide	49-58	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	14-18
26421495-4	2015	We found that TDP1kd cells are hypersensitive to etoposide (ETO).	Etoposide	60-63	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	14-18
26421495-5	2015	Moreover, we established in a chromatin context that following treatment with ETO, TDP1kd cells accumulate increased amounts of Top2alpha cleavage complexes, removing them with an altered kinetics.	Etoposide	78-81	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	83-87
26421495-5	2015	Moreover, we established in a chromatin context that following treatment with ETO, TDP1kd cells accumulate increased amounts of Top2alpha cleavage complexes, removing them with an altered kinetics.	Etoposide	78-81	DNA topoisomerase II alpha	Homo sapiens	128-137
26421495-6	2015	We also showed that TDP1 depleted cells accumulate increased gammaH2AX and pS296Chk1 signals following treatment with ETO.	Etoposide	118-121	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	20-24
26421495-6	2015	We also showed that TDP1 depleted cells accumulate increased gammaH2AX and pS296Chk1 signals following treatment with ETO.	Etoposide	118-121	checkpoint kinase 1	Homo sapiens	80-84
26259609-0	2015	Etoposide Induces Necrosis Through p53-Mediated Antiapoptosis in Human Kidney Proximal Tubule Cells.	Etoposide	0-9	tumor protein p53	Homo sapiens	35-38
26216446-6	2015	Taken together, these results suggest that the retention of CBX7 expression may play a role in the modulation of chemosensitivity of lung cancer patients to the treatment with irinotecan and etoposide.	Etoposide	191-200	chromobox 7	Homo sapiens	60-64
26259609-7	2015	Thus, our study demonstrated that p53 protects against apoptosis, and leads to etoposide-induced necrosis.	Etoposide	79-88	tumor protein p53	Homo sapiens	34-37
26361737-3	2015	Compounds 10a, 10g, 11a, 11f, 11g, 12a, 12f, and 12g especially showed stronger topoisomerase II inhibitory activity as compared to etoposide at both 100 muM and 20 muM.	Etoposide	132-141	latexin	Homo sapiens	165-168
26450900-8	2015	A similar effect on DHX9 splicing was also elicited by treatment with the chemotherapeutic drug etoposide, indicating a more general mechanism of regulation in response to DNA damage.	Etoposide	96-105	DExH-box helicase 9	Homo sapiens	20-24
26040247-1	2015	The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
26463638-3	2015	In this study was assessed the involvement of ABCB1 gene in the mechanisms of resistance to etoposide in AML cells.	Etoposide	92-101	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
26463638-11	2015	Knockdown of the ABCB1 gene correlated with increased sensitivity of the resistant HL-60 cells to etoposide and was observed to lower the cytotoxic index (IC50 etoposide value) after transfection.	Etoposide	98-107	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
26463638-11	2015	Knockdown of the ABCB1 gene correlated with increased sensitivity of the resistant HL-60 cells to etoposide and was observed to lower the cytotoxic index (IC50 etoposide value) after transfection.	Etoposide	160-169	ATP binding cassette subfamily B member 1	Homo sapiens	17-22
26463638-12	2015	CONCLUSIONS: Our results indicate that product of the ABCB1 gene have effective role in resistance to etoposide in acute myeloid leukemia cells.	Etoposide	102-111	ATP binding cassette subfamily B member 1	Homo sapiens	54-59
26279089-3	2015	In this study, claudin 1 promotes migration in luminal-like MCF7 human breast cancer cells and increases their sensitivity to tamoxifen, etoposide, and cisplatin.	Etoposide	137-146	claudin 1	Homo sapiens	15-24
26153782-12	2015	Inhibition and knock down of P-gp by CsA and siRNA, respectively, enhanced etoposide- and doxorubicin-induced cell death in the EBV-positive T-cell lines.	Etoposide	75-84	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
26232556-0	2015	Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells.	Etoposide	52-61	erythropoietin	Homo sapiens	0-14
26232556-0	2015	Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells.	Etoposide	52-61	AKT serine/threonine kinase 1	Homo sapiens	100-103
26232556-4	2015	The present study was designed to investigate the effect of erythropoietin on the proliferation, and protection against vincristine- and etoposide-induced cell death in neuroblastoma (MSN), and embryonic kidney (HEK 293) cells.	Etoposide	137-146	erythropoietin	Homo sapiens	60-74
26232556-4	2015	The present study was designed to investigate the effect of erythropoietin on the proliferation, and protection against vincristine- and etoposide-induced cell death in neuroblastoma (MSN), and embryonic kidney (HEK 293) cells.	Etoposide	137-146	moesin	Homo sapiens	184-187
26232556-10	2015	Erythropoietin induced proliferation and protection against vincristine and etoposide in MSN cells.	Etoposide	76-85	erythropoietin	Homo sapiens	0-14
26232556-10	2015	Erythropoietin induced proliferation and protection against vincristine and etoposide in MSN cells.	Etoposide	76-85	moesin	Homo sapiens	89-92
26232556-14	2015	SIGNIFICANCE: These results indicate that erythropoietin induces proliferation of MSN cells, and that it can ameliorate vincristine- and etoposide-induced apoptosis of these cells.	Etoposide	137-146	erythropoietin	Homo sapiens	42-56
26516353-3	2015	We measured trafficking of the UBXN2A protein in response to two different DNA damage stresses, UVB irradiation and the genotoxic agent Etoposide, in colon cancer cell lines.	Etoposide	136-145	UBX domain protein 2A	Homo sapiens	31-37
26516353-8	2015	In contrast, the shRNA-mediated depletion of UBXN2A leads to significant reduction in apoptosis in colon cancer cells exposed to UVB and Etoposide.	Etoposide	137-146	UBX domain protein 2A	Homo sapiens	45-51
26516353-9	2015	Leptomycin B (LMB), which was able to block UBXN2A nuclear export following Etoposide treatment, sustained p53-mot-2 interaction and had partially antagonistic effects with Etoposide on cell apoptosis.	Etoposide	76-85	UBX domain protein 2A	Homo sapiens	44-50
24969687-9	2015	These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR.	Etoposide	35-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	78-92
24969687-9	2015	These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR.	Etoposide	35-38	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	94-98
24969687-9	2015	These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR.	Etoposide	181-184	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	78-92
24969687-9	2015	These changes in the absorption of ETP may be closely related to variation in P-glycoprotein (P-gp) activity in the intestine and indicate that the pharmacokinetics and toxicity of ETP are altered by repeated oral coadministration of MOR.	Etoposide	181-184	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	94-98
26202083-0	2015	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCzeta and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	Etoposide	120-129	BCL10 immune signaling adaptor	Homo sapiens	0-5
26202083-0	2015	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCzeta and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	Etoposide	120-129	3-phosphoinositide dependent protein kinase 1	Homo sapiens	65-69
26202083-0	2015	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCzeta and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	Etoposide	120-129	protein kinase C zeta	Homo sapiens	71-78
26202083-0	2015	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCzeta and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	Etoposide	120-129	caspase 3	Homo sapiens	83-92
26202083-4	2015	In the present study, we aimed to further clarify the interactions between PKCzeta, Bcl10 and other proteins co-immunoprecipitated from NMs isolated from untreated and etoposide (also known as VP-16; 2.0 microg/ml)-treated C4-I cells using biochemical and proteomics analyses.	Etoposide	168-177	protein kinase C zeta	Homo sapiens	75-82
26202083-4	2015	In the present study, we aimed to further clarify the interactions between PKCzeta, Bcl10 and other proteins co-immunoprecipitated from NMs isolated from untreated and etoposide (also known as VP-16; 2.0 microg/ml)-treated C4-I cells using biochemical and proteomics analyses.	Etoposide	168-177	BCL10 immune signaling adaptor	Homo sapiens	84-89
26202083-4	2015	In the present study, we aimed to further clarify the interactions between PKCzeta, Bcl10 and other proteins co-immunoprecipitated from NMs isolated from untreated and etoposide (also known as VP-16; 2.0 microg/ml)-treated C4-I cells using biochemical and proteomics analyses.	Etoposide	168-177	host cell factor C1	Homo sapiens	193-198
26063742-10	2015	Similarly, colon tumor cells are rendered less viable when cosuppression of MCM complexes occurs during exposure to the crosslinking agent oxaliplatin or topoisomerase inhibitor etoposide.	Etoposide	178-187	methylmalonyl-CoA mutase	Homo sapiens	76-79
26295158-8	2015	MRP2 expression involved an ATP-dependent stimulation of the MEK/ERK signaling pathway that was associated with an increase in relative resistance of Caco-2 cells to etoposide.	Etoposide	166-175	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
26295158-8	2015	MRP2 expression involved an ATP-dependent stimulation of the MEK/ERK signaling pathway that was associated with an increase in relative resistance of Caco-2 cells to etoposide.	Etoposide	166-175	mitogen-activated protein kinase kinase 7	Homo sapiens	61-64
26295158-9	2015	Abolition of MRP2 expression using shRNA significantly reduced the protective effect of MRP2 toward etoposide as well as to cisplatin and doxorubicin.	Etoposide	100-109	ATP binding cassette subfamily C member 2	Homo sapiens	13-17
26295158-9	2015	Abolition of MRP2 expression using shRNA significantly reduced the protective effect of MRP2 toward etoposide as well as to cisplatin and doxorubicin.	Etoposide	100-109	ATP binding cassette subfamily C member 2	Homo sapiens	88-92
26146158-3	2015	In this paper we build an optimal control model to optimize the scheduling problem along one cycle of chemotherapy treatment using a single anticancer drug etoposide (VP-16).	Etoposide	156-165	host cell factor C1	Homo sapiens	167-172
26378048-3	2015	IGFBP-3 was upregulated 1.4- to 13-fold in response to doxorubicin and etoposide in MCF-10A, Hs578T, MCF-7 and T47D cells, which express low to moderate basal levels of IGFBP-3.	Etoposide	71-80	insulin like growth factor binding protein 3	Homo sapiens	0-7
26365969-0	2015	Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.	Etoposide	42-51	carboxylesterase 2	Homo sapiens	53-56
26365969-2	2015	This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma.	Etoposide	85-94	carboxylesterase 2	Homo sapiens	96-99
26253167-0	2015	M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.	Etoposide	103-112	myoregulin	Homo sapiens	0-9
26253167-10	2015	Etoposide-induced cancer cell apoptosis was markedly reduced in the presence of THP-1 M2 macrophages, while apoptosis was increased in cells co-cultured with M1 macrophages.	Etoposide	0-9	GLI family zinc finger 2	Homo sapiens	80-85
26253167-0	2015	M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.	Etoposide	103-112	GLI family zinc finger 2	Homo sapiens	35-40
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	265-274	arachidonate 5-lipoxygenase	Homo sapiens	70-84
26251638-0	2015	Etoposide induces cell death via mitochondrial-dependent actions of p53.	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	68-71
26251638-5	2015	RESULTS: Here we demonstrate that treatment of MEFs with higher concentrations of etoposide induce apoptosis and activate the transcription-dependent functions of p53.	Etoposide	82-91	transformation related protein 53, pseudogene	Mus musculus	163-166
26251638-8	2015	Treatment with PES, which inhibits the mitochondrial arm of the p53 pathway inhibited etoposide-induced cell death at all concentrations tested.	Etoposide	86-95	transformation related protein 53, pseudogene	Mus musculus	64-67
26251638-10	2015	The more recently characterized effects of p53 at the mitochondria, likely involving its interactions with BCL-2 family members, are thus more important for etoposide"s actions.	Etoposide	157-166	transformation related protein 53, pseudogene	Mus musculus	43-46
26251638-10	2015	The more recently characterized effects of p53 at the mitochondria, likely involving its interactions with BCL-2 family members, are thus more important for etoposide"s actions.	Etoposide	157-166	B cell leukemia/lymphoma 2	Mus musculus	107-112
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	265-274	arachidonate 5-lipoxygenase	Homo sapiens	86-91
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	265-274	tumor protein p53	Homo sapiens	182-185
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	276-279	arachidonate 5-lipoxygenase	Homo sapiens	70-84
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	276-279	arachidonate 5-lipoxygenase	Homo sapiens	86-91
26070487-3	2015	Through an unbiased genome-wide ChIP-seq analysis, we have found that 5-lipoxygenase (ALOX5, 5-LO) which is a key enzyme of leukotriene (LT) biosynthesis, is a direct target gene of p53 and its expression is induced by genotoxic stress via actinomycin D (Act.D) or etoposide (Eto) treatment.	Etoposide	276-279	tumor protein p53	Homo sapiens	182-185
25954860-5	2015	It has been demonstrated that most chemotherapy drugs exert their anti-cancer effects via p53-mediated apoptosis, and in accordance, with this, the present study showed that treatment with etoposide significantly increased p53 levels.	Etoposide	189-198	tumor protein p53	Homo sapiens	90-93
25840825-2	2015	Unravelling the status of this important glycolytic pathway enzyme under sub-lethal doses of etoposide, a commonly used anti-proliferative genotoxic drug to induce mild/moderate DNA damage in HeLa cells as a model system and discern its effect on: PKM2 expression, phosphorylation, dimer: tetramer ratio, activity and associated effects, was pertinent.	Etoposide	93-102	pyruvate kinase M1/2	Homo sapiens	248-252
25840825-9	2015	It was apparent that the sub-lethal doses of etoposide induced inadequate damage to DNA in cancer cells in culture promoted pro-survival conditions due to Y105-phosphorylation of PKM2, its stable dimerization and inactivation, a unique association not known earlier, indicating what might happen in tumour revivals or recurrences.	Etoposide	45-54	pyruvate kinase M1/2	Homo sapiens	179-183
25972552-5	2015	In response to DNA damage activation, LMP1 and LMP2A coexpression reduced gammaH2AX (S139) phosphorylation and caspase cleavage induced by a lower dose (5 muM) of the topoisomerase II inhibitor etoposide.	Etoposide	194-203	LMP2A	Human gammaherpesvirus 4	47-52
25954860-4	2015	Knockdown of PTEN in the CCRCC cell line ACHN blocked etoposide-induced apoptosis and etoposide-impaired cell proliferation was also inhibited.	Etoposide	54-63	phosphatase and tensin homolog	Homo sapiens	13-17
25954860-5	2015	It has been demonstrated that most chemotherapy drugs exert their anti-cancer effects via p53-mediated apoptosis, and in accordance, with this, the present study showed that treatment with etoposide significantly increased p53 levels.	Etoposide	189-198	tumor protein p53	Homo sapiens	223-226
25955691-7	2015	In addition, following treatment with etoposide or carboplatin, HSP70/gp96 expression increased, demonstrating a "transfer expression" pattern: The cytosol expression decreased while the surface expression increased.	Etoposide	38-47	heat shock protein family A (Hsp70) member 4	Homo sapiens	64-69
25954860-7	2015	This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC.	Etoposide	234-243	phosphatase and tensin homolog	Homo sapiens	122-126
25954860-7	2015	This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC.	Etoposide	234-243	AKT serine/threonine kinase 1	Homo sapiens	146-149
25954860-7	2015	This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC.	Etoposide	234-243	MDM2 proto-oncogene	Homo sapiens	150-154
25954860-7	2015	This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC.	Etoposide	234-243	tumor protein p53	Homo sapiens	192-195
25954860-4	2015	Knockdown of PTEN in the CCRCC cell line ACHN blocked etoposide-induced apoptosis and etoposide-impaired cell proliferation was also inhibited.	Etoposide	54-63	La ribonucleoprotein 6, translational regulator	Homo sapiens	41-45
25954860-4	2015	Knockdown of PTEN in the CCRCC cell line ACHN blocked etoposide-induced apoptosis and etoposide-impaired cell proliferation was also inhibited.	Etoposide	86-95	phosphatase and tensin homolog	Homo sapiens	13-17
25955691-7	2015	In addition, following treatment with etoposide or carboplatin, HSP70/gp96 expression increased, demonstrating a "transfer expression" pattern: The cytosol expression decreased while the surface expression increased.	Etoposide	38-47	heat shock protein 90 beta family member 1	Homo sapiens	70-74
25955691-8	2015	These alterations progressed steadily with notable alterations following treatment with etoposide for 24 h or carboplatin for 72 h. Additionally, at the end of treatment, release of HSP70/gp96 to the extracellular environment increased.	Etoposide	88-97	heat shock protein family A (Hsp70) member 4	Homo sapiens	182-187
25964101-7	2015	In ovarian cancer cells, where &gt;90% have inactivated p53, Nutlin combined with the genotoxic agents, cisplatin or etoposide, had a cooperative lethal effect resulting in increased DNA damage and apoptosis.	Etoposide	117-126	tumor protein p53	Homo sapiens	56-59
25955691-8	2015	These alterations progressed steadily with notable alterations following treatment with etoposide for 24 h or carboplatin for 72 h. Additionally, at the end of treatment, release of HSP70/gp96 to the extracellular environment increased.	Etoposide	88-97	heat shock protein 90 beta family member 1	Homo sapiens	188-192
26622554-5	2015	In addition, a higher decrease in the cell viability of etoposide-treated HBL-2 cells was observed in cells pretreated with neuraminidase compared with cells that were not pretreated.	Etoposide	56-65	neuraminidase 1	Homo sapiens	124-137
26059173-7	2015	Notably, betulin significantly enhanced cytotoxicity and PARP cleavage in etoposide-treated RCC4 cells, and downregulated the expression of multidrug resistance protein 1 (MDR1).	Etoposide	74-83	collagen type XI alpha 2 chain	Homo sapiens	57-61
26059173-7	2015	Notably, betulin significantly enhanced cytotoxicity and PARP cleavage in etoposide-treated RCC4 cells, and downregulated the expression of multidrug resistance protein 1 (MDR1).	Etoposide	74-83	solute carrier family 49 member 4	Homo sapiens	92-96
26622554-6	2015	Furthermore, the caspase-3, caspase-8 and caspase-9 activities in etoposide-induced apoptosis demonstrated a greater increase upon neuraminidase pretreatment compared with no neuraminidase pretreatment.	Etoposide	66-75	caspase 3	Homo sapiens	17-26
26622554-6	2015	Furthermore, the caspase-3, caspase-8 and caspase-9 activities in etoposide-induced apoptosis demonstrated a greater increase upon neuraminidase pretreatment compared with no neuraminidase pretreatment.	Etoposide	66-75	caspase 8	Homo sapiens	28-37
26622554-6	2015	Furthermore, the caspase-3, caspase-8 and caspase-9 activities in etoposide-induced apoptosis demonstrated a greater increase upon neuraminidase pretreatment compared with no neuraminidase pretreatment.	Etoposide	66-75	caspase 9	Homo sapiens	42-51
26622554-6	2015	Furthermore, the caspase-3, caspase-8 and caspase-9 activities in etoposide-induced apoptosis demonstrated a greater increase upon neuraminidase pretreatment compared with no neuraminidase pretreatment.	Etoposide	66-75	neuraminidase 1	Homo sapiens	131-144
26622554-6	2015	Furthermore, the caspase-3, caspase-8 and caspase-9 activities in etoposide-induced apoptosis demonstrated a greater increase upon neuraminidase pretreatment compared with no neuraminidase pretreatment.	Etoposide	66-75	neuraminidase 1	Homo sapiens	175-188
26225773-6	2015	Moreover, we demonstrate that SIRT1 is involved in the pro-survival effects elicited by E2 through GPER, like the prevention of cell cycle arrest and cell death induced by the DNA damaging agent etoposide.	Etoposide	195-204	sirtuin 1	Homo sapiens	30-35
26063074-11	2015	Furthermore, down-regulation of SAE2 expression inhibited migration and invasion, simultaneously increased the sensitivity of H446 to etoposide and cisplatin.	Etoposide	134-143	ubiquitin like modifier activating enzyme 2	Homo sapiens	32-36
26216189-7	2015	GATA-3 deficient cells generated by expressing a GATA-3 shRNA construct were sensitive to apoptosis induced by etoposide and TNF-alpha.	Etoposide	111-120	GATA binding protein 3	Homo sapiens	0-6
26216189-7	2015	GATA-3 deficient cells generated by expressing a GATA-3 shRNA construct were sensitive to apoptosis induced by etoposide and TNF-alpha.	Etoposide	111-120	GATA binding protein 3	Homo sapiens	49-55
25592050-5	2015	Etoposide levels of 10 muM were found to maximise toxicity to tumours (6.5% viability) while stem cells maintained a surviving fraction of 40%.	Etoposide	0-9	latexin	Homo sapiens	23-26
26124323-6	2015	CD114-positive sub-populations grew faster than CD114-negative ones and demonstrated resistance to temozolomide, etoposide, and nifurtimox.	Etoposide	113-122	colony stimulating factor 3 receptor	Homo sapiens	0-5
25916500-2	2015	The MGH was used as cationic lipid in developing etoposide loaded cationic self-microemulsifying drug delivery system (ECS) intended to be delivered by intratumoral route.	Etoposide	49-58	epistatic circling SWR/J	Mus musculus	119-122
25929614-1	2015	Review of the management of 6 young girls with vaginal yolk sac tumor over 25 years showed that the alpha-fetoprotein levels normalized in 5/6 within 4 cycles of primary cisplatin, bleomycin, etoposide (PEB)/carboplatin, etoposide, bleomycin (JEB)/cisplatin, vinblastine, bleomycin (PVB) chemotherapy.	Etoposide	221-230	alpha fetoprotein	Homo sapiens	100-117
25963833-0	2015	Quantitative Proteomics Reveals Dynamic Interactions of the Minichromosome Maintenance Complex (MCM) in the Cellular Response to Etoposide Induced DNA Damage.	Etoposide	129-138	minichromosome maintenance complex component 7	Homo sapiens	96-99
26158294-9	2015	Treatment with nutlin-3a or etoposide induced CST5 in a p53-dependent manner.	Etoposide	28-37	cystatin D	Homo sapiens	46-50
26158294-9	2015	Treatment with nutlin-3a or etoposide induced CST5 in a p53-dependent manner.	Etoposide	28-37	tumor protein p53	Homo sapiens	56-59
25915157-6	2015	CYP3A4, the liver"s major drug-metabolizing enzyme, was at least partially responsible for BM stroma"s ability to protect multiple myeloma (MM) and leukemia cells from bortezomib and etoposide, respectively, both in vitro and in vivo.	Etoposide	183-192	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	36-45	programmed cell death 5	Homo sapiens	20-25
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	36-45	tumor protein p53	Homo sapiens	59-62
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	36-45	programmed cell death 5	Homo sapiens	129-134
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	36-45	tumor protein p53	Homo sapiens	138-141
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	47-49	programmed cell death 5	Homo sapiens	20-25
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	47-49	tumor protein p53	Homo sapiens	59-62
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	47-49	programmed cell death 5	Homo sapiens	129-134
26077467-4	2015	Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleavage, indicating an essential role of PDCD5 in p53 activation.	Etoposide	47-49	tumor protein p53	Homo sapiens	138-141
25945730-3	2015	Herein, we describe the synthesis and biological evaluation of a focused library of etoposide analogues, with the identification of two novel small molecules exhibiting TOP2B-dependent toxicity.	Etoposide	84-93	DNA topoisomerase II beta	Homo sapiens	169-174
26218605-7	2015	Using peptides spanning the identified LANA cleavage sites, we show that caspase activity can be inhibited in vitro and that a cell-permeable peptide spanning the C-terminal cleavage site could inhibit cleavage of poly (ADP-ribose) polymerase and increase viability in cells undergoing etoposide-induced apoptosis.	Etoposide	286-295	LANA	Human gammaherpesvirus 8	39-43
26322249-5	2015	Among those, medium-dose etoposide (ETP) in addition to the standard CY + TBI conditioning regimen appears to be promising for allo HSCT in adult ALL when transplanted in ALL patients aged under 50 years in CR1 and also in CR2, showing an excellent outcome without increasing relapse or transplant-related mortality (TRM) rates.	Etoposide	25-34	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	207-210
26322249-5	2015	Among those, medium-dose etoposide (ETP) in addition to the standard CY + TBI conditioning regimen appears to be promising for allo HSCT in adult ALL when transplanted in ALL patients aged under 50 years in CR1 and also in CR2, showing an excellent outcome without increasing relapse or transplant-related mortality (TRM) rates.	Etoposide	36-39	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	207-210
26168167-4	2015	De novo expression of gal-7 in prostate cancer cells increases their sensitivity to apoptosis in response to etoposide and cisplatin.	Etoposide	109-118	galectin 7	Homo sapiens	22-27
26154885-3	2015	Most of the derivatives (IC50 = 1-20 muM) were found to have stronger cell growth inhibitory activity than positive control etoposide.	Etoposide	124-133	latexin	Homo sapiens	37-40
25529820-7	2015	These mechanical stimuli prevented cell death induced within 6 hours by etoposide (50 muM), related to PTHrP overexpression; and this effect was abolished by the calcium antagonist verapamil (1 muM), a phospholipase C (PLC) inhibitor (U73122; 10 muM), and a PKA activation inhibitor, Rp-cAMPS (25 muM), in these cells.	Etoposide	72-81	parathyroid hormone-like peptide	Mus musculus	103-108
25929614-1	2015	Review of the management of 6 young girls with vaginal yolk sac tumor over 25 years showed that the alpha-fetoprotein levels normalized in 5/6 within 4 cycles of primary cisplatin, bleomycin, etoposide (PEB)/carboplatin, etoposide, bleomycin (JEB)/cisplatin, vinblastine, bleomycin (PVB) chemotherapy.	Etoposide	192-201	alpha fetoprotein	Homo sapiens	100-117
25901027-7	2015	Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant.	Etoposide	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
25901027-7	2015	Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant.	Etoposide	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	165-169
25908039-0	2015	Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.	Etoposide	151-160	epidermal growth factor receptor	Homo sapiens	80-84
26136652-4	2015	In this study we show that small molecule inhibitors and gene silencing of MRP1 had a significant effect on GBM cell response to temozolomide (150 muM), vincristine (100 nM), and etoposide (2 muM).	Etoposide	179-188	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Etoposide	128-137	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Etoposide	128-137	ATP binding cassette subfamily C member 4	Homo sapiens	45-75
26136652-6	2015	The presence of MK571 (inhibitor of MRP1 and multidrug resistance protein 4 (MRP4) led to an enhanced effect of vincristine and etoposide in reducing cell viability over a 72 h period.	Etoposide	128-137	ATP binding cassette subfamily C member 4	Homo sapiens	77-81
26136652-7	2015	Specific MRP1 inhibition led to a significant increase in vincristine and etoposide-induced cell death in all three cell lines assessed.	Etoposide	74-83	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
26015568-5	2015	Whereas Bok(-/-) mouse embryonic fibroblasts exposed to thapsigargin, A23187, brefeldin A, DTT, geldanamycin, or bortezomib manifested reduced activation of the mitochondrial apoptotic pathway, the death response to other stimuli such as etoposide, staurosporine, or UV remained fully intact.	Etoposide	238-247	BCL2-related ovarian killer	Mus musculus	8-11
25914138-6	2015	Inhibition of Topo II by etoposide, teniposide, or Topo II siRNA increased CETP expression in human hepatic cell line, HepG2 cells, which was associated with increased CETP secretion and mRNA expression.	Etoposide	25-34	cholesteryl ester transfer protein	Homo sapiens	75-79
25914138-6	2015	Inhibition of Topo II by etoposide, teniposide, or Topo II siRNA increased CETP expression in human hepatic cell line, HepG2 cells, which was associated with increased CETP secretion and mRNA expression.	Etoposide	25-34	cholesteryl ester transfer protein	Homo sapiens	168-172
25914138-7	2015	Meanwhile, inhibition of LXR expression by LXR siRNA attenuated induction of CETP expression by etoposide and teniposide.	Etoposide	96-105	cholesteryl ester transfer protein	Homo sapiens	77-81
25914138-8	2015	Etoposide and teniposide induced LXRalpha expression and LXRalpha/beta nuclear translocation while inhibiting expression of receptor interacting protein 140 (RIP140), an LXR co-repressor.	Etoposide	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	33-41
25914138-8	2015	Etoposide and teniposide induced LXRalpha expression and LXRalpha/beta nuclear translocation while inhibiting expression of receptor interacting protein 140 (RIP140), an LXR co-repressor.	Etoposide	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	57-65
25914138-8	2015	Etoposide and teniposide induced LXRalpha expression and LXRalpha/beta nuclear translocation while inhibiting expression of receptor interacting protein 140 (RIP140), an LXR co-repressor.	Etoposide	0-9	nuclear receptor interacting protein 1	Homo sapiens	124-156
25914138-8	2015	Etoposide and teniposide induced LXRalpha expression and LXRalpha/beta nuclear translocation while inhibiting expression of receptor interacting protein 140 (RIP140), an LXR co-repressor.	Etoposide	0-9	nuclear receptor interacting protein 1	Homo sapiens	158-164
26022350-4	2015	Stable isotope labelling by amino acids in cell culture (SILAC) coupled to high-resolution mass spectrometry (MS) was implemented to globally characterise cellular protein levels induced by KSR1 in the presence of doxorubicin or etoposide.	Etoposide	229-238	kinase suppressor of ras 1	Homo sapiens	190-194
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	158-162	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	117-121
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	158-162	ATM serine/threonine kinase	Homo sapiens	190-193
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	158-162	ATM serine/threonine kinase	Homo sapiens	190-193
25088203-7	2015	Furthermore, the phosphorylation of ATM targets, including gammaH2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP.	Etoposide	222-226	ATM serine/threonine kinase	Homo sapiens	36-39
25088203-7	2015	Furthermore, the phosphorylation of ATM targets, including gammaH2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP.	Etoposide	222-226	checkpoint kinase 2	Homo sapiens	92-96
25088203-7	2015	Furthermore, the phosphorylation of ATM targets, including gammaH2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP.	Etoposide	222-226	checkpoint kinase 2	Homo sapiens	98-102
25088203-7	2015	Furthermore, the phosphorylation of ATM targets, including gammaH2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP.	Etoposide	222-226	tumor protein p53	Homo sapiens	132-135
25088203-11	2015	Stable expression of these BMI1 mutants decreased ETOP-induced ATM pS1981 and CHK2 pT68, but not ETOP-elicited gammaH2AX in MCF7 cells.	Etoposide	50-54	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	27-31
25088203-11	2015	Stable expression of these BMI1 mutants decreased ETOP-induced ATM pS1981 and CHK2 pT68, but not ETOP-elicited gammaH2AX in MCF7 cells.	Etoposide	50-54	ATM serine/threonine kinase	Homo sapiens	63-66
25088203-11	2015	Stable expression of these BMI1 mutants decreased ETOP-induced ATM pS1981 and CHK2 pT68, but not ETOP-elicited gammaH2AX in MCF7 cells.	Etoposide	50-54	checkpoint kinase 2	Homo sapiens	78-82
25088203-12	2015	Furthermore, ectopic expression of BMI1 in non-transformed breast epithelial MCF10A cells also compromised ETOP-initiated ATM pS1981 and gammaH2AX.	Etoposide	107-111	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	35-39
25088203-12	2015	Furthermore, ectopic expression of BMI1 in non-transformed breast epithelial MCF10A cells also compromised ETOP-initiated ATM pS1981 and gammaH2AX.	Etoposide	107-111	ATM serine/threonine kinase	Homo sapiens	122-125
25088203-13	2015	Taken together, we provide compelling evidence that BMI1 decreases ETOP-induced G2/M checkpoint activation via reducing NBS1-mediated ATM activation.	Etoposide	67-71	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	52-56
25088203-13	2015	Taken together, we provide compelling evidence that BMI1 decreases ETOP-induced G2/M checkpoint activation via reducing NBS1-mediated ATM activation.	Etoposide	67-71	nibrin	Homo sapiens	120-124
25088203-13	2015	Taken together, we provide compelling evidence that BMI1 decreases ETOP-induced G2/M checkpoint activation via reducing NBS1-mediated ATM activation.	Etoposide	67-71	ATM serine/threonine kinase	Homo sapiens	134-137
25088203-0	2015	BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation.	Etoposide	16-25	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	0-4
25088203-0	2015	BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation.	Etoposide	16-25	ATM serine/threonine kinase	Homo sapiens	64-67
25088203-3	2015	We report here that BMI1 has a role in G2/M checkpoint activation in response to etoposide (ETOP) treatment.	Etoposide	81-90	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	20-24
25088203-3	2015	We report here that BMI1 has a role in G2/M checkpoint activation in response to etoposide (ETOP) treatment.	Etoposide	92-96	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	20-24
25088203-4	2015	Ectopic expression of BMI1 in MCF7 breast cancer and DU145 prostate cancer cells significantly reduced ETOP-induced G2/M arrest.	Etoposide	103-107	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	22-26
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	16-20	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	117-121
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	16-20	ATM serine/threonine kinase	Homo sapiens	190-193
25088203-6	2015	Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981).	Etoposide	16-20	ATM serine/threonine kinase	Homo sapiens	190-193
25653093-5	2015	Importantly, CHK1 downregulation sensitizes prostate tumor cells to etoposide but not to docetaxel treatment.	Etoposide	68-77	checkpoint kinase 1	Homo sapiens	13-17
25909287-4	2015	We find that NRMT1 knockdown significantly enhances the sensitivity of breast cancer cell lines to both etoposide treatment and gamma-irradiation, as well as, increases proliferation rate, invasive potential, anchorage-independent growth, xenograft tumor size, and tamoxifen sensitivity.	Etoposide	104-113	N-terminal Xaa-Pro-Lys N-methyltransferase 1	Homo sapiens	13-18
25819384-6	2015	A multivariate analysis showed that among the patients with ED, FGFR1 amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR]=7.1; 95% confidence interval [CI]=2.0-25.4; P=0.003).	Etoposide	166-175	fibroblast growth factor receptor 1	Homo sapiens	64-69
26221234-6	2015	He was subsequently treated with five courses of the salvage chemotherapy regimen ICE (ifosfamide, carboplatin and etoposide) and achieved PR again.	Etoposide	115-124	carboxylesterase 2	Homo sapiens	82-85
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	96-105	ATP binding cassette subfamily C member 1	Rattus norvegicus	27-31
25772707-2	2015	Oral etoposide (VP-16) has previously been found to be clinically active in MBC patients in phase II trials.	Etoposide	5-14	host cell factor C1	Homo sapiens	16-21
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	96-105	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	96-105	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	107-111	ATP binding cassette subfamily C member 1	Rattus norvegicus	27-31
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	107-111	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	107-111	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	314-323	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25543328-2	2015	In this study, we screened MRP1 interfering RNA (MRP1-siRNA) molecules that are able to reverse etoposide (VP16) resistance in multidrug resistance rat glioma cell line C6/VP16, and identified one siRNA molecule that is able to effectively deplete the expression of MRP1 gene and reverse tumor cells resistance to etoposide.	Etoposide	314-323	ATP binding cassette subfamily C member 1	Rattus norvegicus	49-53
25633564-6	2015	Apomorphine, benzamil, etoposide, CGS-15943, kenpaullone, and rutaecarpine (all at 10 mumol/L) significantly inhibited hepcidin mRNA expression by Hep3B cells without affecting cell viability.	Etoposide	23-32	hepcidin antimicrobial peptide	Homo sapiens	119-127
25662950-0	2015	Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-kappaB activity in gastric cancer cells.	Etoposide	54-63	insulin like growth factor binding protein 3	Homo sapiens	0-44
26191229-8	2015	Stable Bcl-2 overexpression led to reduced apoptosis rates as well as Cyt-C and Caspase-3 expressions in Jurkat cells after VP-16 application, which was similar in leucocytes of remission patients.	Etoposide	124-129	BCL2 apoptosis regulator	Homo sapiens	7-12
26191229-8	2015	Stable Bcl-2 overexpression led to reduced apoptosis rates as well as Cyt-C and Caspase-3 expressions in Jurkat cells after VP-16 application, which was similar in leucocytes of remission patients.	Etoposide	124-129	caspase 3	Homo sapiens	80-89
25607114-0	2015	Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor.	Etoposide	42-51	vascular endothelial growth factor A	Homo sapiens	78-82
25607114-3	2015	Increased levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) were observed when SMMC-7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide-induced DNA damage, as indicated by the failure of upregulation of gammaHA2X.	Etoposide	219-228	hypoxia inducible factor 1 subunit alpha	Homo sapiens	53-63
25607114-3	2015	Increased levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) were observed when SMMC-7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide-induced DNA damage, as indicated by the failure of upregulation of gammaHA2X.	Etoposide	219-228	vascular endothelial growth factor A	Homo sapiens	69-103
25607114-3	2015	Increased levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) were observed when SMMC-7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide-induced DNA damage, as indicated by the failure of upregulation of gammaHA2X.	Etoposide	219-228	vascular endothelial growth factor A	Homo sapiens	105-109
25607114-5	2015	However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2.	Etoposide	60-69	vascular endothelial growth factor A	Homo sapiens	32-36
25521291-5	2015	Incubation of tongue cancer cells CAL 27 and SCC-25 in medium containing doxorubicin, 5-fluorouracil, trichostatin A, or etoposide significantly increased the expression of miR-375 and its primary transcript pri-miR-375.	Etoposide	121-130	microRNA 375	Homo sapiens	173-180
25521291-5	2015	Incubation of tongue cancer cells CAL 27 and SCC-25 in medium containing doxorubicin, 5-fluorouracil, trichostatin A, or etoposide significantly increased the expression of miR-375 and its primary transcript pri-miR-375.	Etoposide	121-130	microRNA 375	Homo sapiens	212-219
25607114-5	2015	However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2.	Etoposide	60-69	cyclin B1	Homo sapiens	192-201
25607114-5	2015	However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2.	Etoposide	60-69	cyclin dependent kinase 1	Homo sapiens	206-210
25607114-7	2015	In conclusion, the present study suggests a significant role of VEGF in the chemoresistance of etoposide in hypoxia.	Etoposide	95-104	vascular endothelial growth factor A	Homo sapiens	64-68
25662950-0	2015	Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-kappaB activity in gastric cancer cells.	Etoposide	54-63	nuclear factor kappa B subunit 1	Homo sapiens	114-123
25662950-7	2015	Finally, the growth inhibition induced by etoposide was significantly enhanced by IGFBP-3 overexpression along with concomitant suppression of NF-kappaB activity.	Etoposide	42-51	insulin like growth factor binding protein 3	Homo sapiens	82-89
25607114-5	2015	However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2.	Etoposide	60-69	BCL2 apoptosis regulator	Homo sapiens	151-168
25607114-5	2015	However, co-treatment with anti-VEGF significantly restored etoposide-induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B-cell lymphoma 2 (Bcl-2), procaspase 3, cyclin B1 and Cdc2.	Etoposide	60-69	BCL2 apoptosis regulator	Homo sapiens	170-175
25662950-7	2015	Finally, the growth inhibition induced by etoposide was significantly enhanced by IGFBP-3 overexpression along with concomitant suppression of NF-kappaB activity.	Etoposide	42-51	nuclear factor kappa B subunit 1	Homo sapiens	143-152
25662950-8	2015	These findings indicate that IGFBP-3 enhances etoposide-induced cell growth inhibition by blocking the NF-kappaB signaling pathway in gastric cancer cells.	Etoposide	46-55	insulin like growth factor binding protein 3	Homo sapiens	29-36
25662950-8	2015	These findings indicate that IGFBP-3 enhances etoposide-induced cell growth inhibition by blocking the NF-kappaB signaling pathway in gastric cancer cells.	Etoposide	46-55	nuclear factor kappa B subunit 1	Homo sapiens	103-112
25875766-4	2015	Treatment of HuH7 cells with etoposide (25 muM, 30 min) or gamma irradiation (4 Gy) increased the phosphorylation of H2AX by 1.94 +- 0.13 and 2.0 +- 0.02 fold, respectively.	Etoposide	29-38	H2A.X variant histone	Homo sapiens	117-121
26137037-10	2015	The lesion disappeared following five cycles of methotrexate+ etoposide+actinomycin D therapy, which was performed as postoperative chemotherapy, and the patient"s serum hCG level decreased to below the detection limit.	Etoposide	62-71	hypertrichosis 2 (generalised, congenital)	Homo sapiens	170-173
25928457-5	2015	The impact of VEGF inhibition on etoposide penetration into the CSF was analyzed.	Etoposide	33-42	vascular endothelial growth factor A	Homo sapiens	14-18
25736313-7	2015	Ectopic overexpression of INPP4B conferred leukemic resistance to cytosine arabinoside (ara-C), daunorubicin, and etoposide.	Etoposide	114-123	inositol polyphosphate-4-phosphatase type II B	Homo sapiens	26-32
25879815-12	2015	CONCLUSIONS: To our knowledge, this is the first case report in which intrathecal etoposide was successfully used to treat MC from NSCLC after failure of MTx.	Etoposide	82-91	metaxin 1	Homo sapiens	154-157
25875766-14	2015	Finally, depletion of Reptin was synergistic with etoposide or gamma irradiation to reduce cell growth and colony formation.	Etoposide	50-59	RuvB like AAA ATPase 2	Homo sapiens	22-28
25926730-9	2015	Immunohistochemical study was also performed to show the expression of tumor-suppressor PTEN, and it was found that the tumor tissues from the group of mice treated with a combination of free (Dox + ETP) showed greater loss of cytoplasmic PTEN than tumor tissues obtained from the groups of mice treated with CML-Lip-(Dox + ETP) or DPPC-Lip-(Dox + ETP).	Etoposide	199-202	phosphatase and tensin homolog	Mus musculus	88-92
25754205-6	2015	Finally, treatment of MCF-7 cells with etoposide, a cytotoxic anti-cancer drug, increased CSC formation and SOX2, OCT3/4, and NANOG expression via Delta133p53, thus potentially increasing the risk of cancer recurrence.	Etoposide	39-48	SRY-box transcription factor 2	Homo sapiens	108-112
25754205-6	2015	Finally, treatment of MCF-7 cells with etoposide, a cytotoxic anti-cancer drug, increased CSC formation and SOX2, OCT3/4, and NANOG expression via Delta133p53, thus potentially increasing the risk of cancer recurrence.	Etoposide	39-48	POU class 5 homeobox 1	Homo sapiens	114-120
25754205-6	2015	Finally, treatment of MCF-7 cells with etoposide, a cytotoxic anti-cancer drug, increased CSC formation and SOX2, OCT3/4, and NANOG expression via Delta133p53, thus potentially increasing the risk of cancer recurrence.	Etoposide	39-48	Nanog homeobox	Homo sapiens	126-131
25926730-9	2015	Immunohistochemical study was also performed to show the expression of tumor-suppressor PTEN, and it was found that the tumor tissues from the group of mice treated with a combination of free (Dox + ETP) showed greater loss of cytoplasmic PTEN than tumor tissues obtained from the groups of mice treated with CML-Lip-(Dox + ETP) or DPPC-Lip-(Dox + ETP).	Etoposide	199-202	phosphatase and tensin homolog	Mus musculus	239-243
25821946-0	2015	Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line.	Etoposide	43-52	TERF2 interacting protein	Homo sapiens	0-4
25889892-9	2015	RESULTS: Results showed that hypoxia down-regulated miR-196b expression that was induced by etoposide.	Etoposide	92-101	microRNA 196b	Homo sapiens	52-60
25889892-10	2015	miR-196b overexpression increased the etoposide-induced apoptosis and reversed the protection of cell death observed under hypoxia.	Etoposide	38-47	microRNA 196b	Homo sapiens	0-8
25724377-1	2015	New research shows that inhibiting the histone modifier EZH2 may make non-small cell lung cancers harboring BRG1 or EGFR mutations more sensitive to etoposide, a common chemotherapy.	Etoposide	149-158	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	56-60
25724377-1	2015	New research shows that inhibiting the histone modifier EZH2 may make non-small cell lung cancers harboring BRG1 or EGFR mutations more sensitive to etoposide, a common chemotherapy.	Etoposide	149-158	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	108-112
25724377-1	2015	New research shows that inhibiting the histone modifier EZH2 may make non-small cell lung cancers harboring BRG1 or EGFR mutations more sensitive to etoposide, a common chemotherapy.	Etoposide	149-158	epidermal growth factor receptor	Homo sapiens	116-120
25483709-4	2015	Notably, overexpression of ANP32B(WT) and ANP32B(D163A) moderately increased and significantly enhanced etoposide-induced apoptosis and caspase-3 activation, whereas expression of ANP32B(1-163) produced no effect.	Etoposide	104-113	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	27-33
25483709-4	2015	Notably, overexpression of ANP32B(WT) and ANP32B(D163A) moderately increased and significantly enhanced etoposide-induced apoptosis and caspase-3 activation, whereas expression of ANP32B(1-163) produced no effect.	Etoposide	104-113	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	42-48
25483709-4	2015	Notably, overexpression of ANP32B(WT) and ANP32B(D163A) moderately increased and significantly enhanced etoposide-induced apoptosis and caspase-3 activation, whereas expression of ANP32B(1-163) produced no effect.	Etoposide	104-113	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	42-48
25543088-2	2015	In this study we show decreased MYBBP1A protein levels in tumor cells after treatment with etoposide, a potent inducer of DNA damage.	Etoposide	91-100	MYB binding protein 1a	Homo sapiens	32-39
25821946-0	2015	Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line.	Etoposide	43-52	telomeric repeat binding factor 2	Homo sapiens	26-30
25543088-4	2015	We found an inverse regulation of MYBBP1A and AKT phosphorylation (pAKT(Ser473)), which was characteristic for the pre-senescent state after etoposide administration in vitro.	Etoposide	141-150	MYB binding protein 1a	Homo sapiens	34-41
25543088-4	2015	We found an inverse regulation of MYBBP1A and AKT phosphorylation (pAKT(Ser473)), which was characteristic for the pre-senescent state after etoposide administration in vitro.	Etoposide	141-150	AKT serine/threonine kinase 1	Homo sapiens	46-49
25821946-5	2015	Both Rap1 and TRF2 expression were upregulated in SGC7901 and its MDR variant SGC7901/VCR after etoposide treatment, which was more marked in SGC7901/VCR than in SGC7901.	Etoposide	96-105	TERF2 interacting protein	Homo sapiens	5-9
25821946-5	2015	Both Rap1 and TRF2 expression were upregulated in SGC7901 and its MDR variant SGC7901/VCR after etoposide treatment, which was more marked in SGC7901/VCR than in SGC7901.	Etoposide	96-105	telomeric repeat binding factor 2	Homo sapiens	14-18
25821946-6	2015	Rap1 silencing by siRNA in SGC7901/VCR partially reversed the etoposide resistance.	Etoposide	62-71	TERF2 interacting protein	Homo sapiens	0-4
25821946-7	2015	And Rap1 silencing partially reversed the TRF2-mediated resistance to etoposide in SGC7901.	Etoposide	70-79	TERF2 interacting protein	Homo sapiens	4-8
25821946-7	2015	And Rap1 silencing partially reversed the TRF2-mediated resistance to etoposide in SGC7901.	Etoposide	70-79	telomeric repeat binding factor 2	Homo sapiens	42-46
25821946-9	2015	Furthermore, phosphorylation of ATM targets, including gammaH2AX and serine 15 (S15) on p53, were increased in Rap1 silencing cells in response to etoposide.	Etoposide	147-156	ATM serine/threonine kinase	Homo sapiens	32-35
25821946-9	2015	Furthermore, phosphorylation of ATM targets, including gammaH2AX and serine 15 (S15) on p53, were increased in Rap1 silencing cells in response to etoposide.	Etoposide	147-156	tumor protein p53	Homo sapiens	88-91
25821946-9	2015	Furthermore, phosphorylation of ATM targets, including gammaH2AX and serine 15 (S15) on p53, were increased in Rap1 silencing cells in response to etoposide.	Etoposide	147-156	TERF2 interacting protein	Homo sapiens	111-115
25821946-10	2015	Thus, we confirm that Rap1, interacting with TRF2 in the shelterin complex, also has an important role in TRF2-mediated DNA damage response in gastric cancer cells treated by etoposide.	Etoposide	175-184	TERF2 interacting protein	Homo sapiens	22-26
25821946-10	2015	Thus, we confirm that Rap1, interacting with TRF2 in the shelterin complex, also has an important role in TRF2-mediated DNA damage response in gastric cancer cells treated by etoposide.	Etoposide	175-184	telomeric repeat binding factor 2	Homo sapiens	45-49
25821946-10	2015	Thus, we confirm that Rap1, interacting with TRF2 in the shelterin complex, also has an important role in TRF2-mediated DNA damage response in gastric cancer cells treated by etoposide.	Etoposide	175-184	telomeric repeat binding factor 2	Homo sapiens	106-110
25890358-0	2015	TNFalpha sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-kappaB-mediated expression of Fas.	Etoposide	65-74	tumor necrosis factor	Homo sapiens	0-8
25811801-6	2015	However, although mutant IDH reduced cell sensitivity to the apoptotic inducer etoposide, D-2HG exhibited no effect on apoptosis.	Etoposide	79-88	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	25-28
25890358-12	2015	Moreover, TNFalpha sensitized NBL cells to DNA-damaging agents (i.e. cisplatin and etoposide) that induce the expression of FasL.	Etoposide	83-92	tumor necrosis factor	Homo sapiens	10-18
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	solute carrier organic anion transporter family member 1B3	Homo sapiens	0-7
25890358-12	2015	Moreover, TNFalpha sensitized NBL cells to DNA-damaging agents (i.e. cisplatin and etoposide) that induce the expression of FasL.	Etoposide	83-92	Fas ligand	Homo sapiens	124-128
25890358-13	2015	Priming to FasL-, cisplatin-, and etoposide-induced cell death could only be achieved in NBLs that display TNFalpha-induced upregulation of Fas.	Etoposide	34-43	tumor necrosis factor	Homo sapiens	107-115
25890358-15	2015	CONCLUSIONS: In summary, our findings reveal that TNFalpha sensitizes NBL cells to FasL-induced cell death by NF-kappaB-mediated upregulation of Fas and unveil a new mechanism through which TNFalpha enhances the efficacy of currently used NBL treatments, cisplatin and etoposide.	Etoposide	269-278	tumor necrosis factor	Homo sapiens	50-58
25890358-15	2015	CONCLUSIONS: In summary, our findings reveal that TNFalpha sensitizes NBL cells to FasL-induced cell death by NF-kappaB-mediated upregulation of Fas and unveil a new mechanism through which TNFalpha enhances the efficacy of currently used NBL treatments, cisplatin and etoposide.	Etoposide	269-278	Fas ligand	Homo sapiens	83-87
25890358-15	2015	CONCLUSIONS: In summary, our findings reveal that TNFalpha sensitizes NBL cells to FasL-induced cell death by NF-kappaB-mediated upregulation of Fas and unveil a new mechanism through which TNFalpha enhances the efficacy of currently used NBL treatments, cisplatin and etoposide.	Etoposide	269-278	tumor necrosis factor	Homo sapiens	190-198
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	203-206
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	212-215
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	212-215
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	212-215
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	212-215
25618019-7	2015	OATP1B3 showed highly significant interactions with a variety of antineoplastic compounds including chlorambucil, mitoxantrone, vinblastine, vincristine, paclitaxel and etoposide, with Ki values of 40.6 muM, 3.2 muM, 15.9 muM, 30.6 muM, 1.8 muM and 13.5 muM, respectively.	Etoposide	169-178	latexin	Homo sapiens	212-215
25568206-9	2015	However, expression of these genes did not attain the levels observed when p53 was activated in response to etoposide treatment and remained lower than those measured in mock-infected cells.	Etoposide	108-117	tumor protein p53	Homo sapiens	75-78
25612622-9	2015	Monoallelic deletion and promoter hypermethylation caused underexpression of PTPRK messenger RNA in NKTCL, and methylation of the PTPRK promoter significantly correlated with inferior overall survival (P = .049) in NKTCL patients treated with the steroid-dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide regimen.	Etoposide	316-325	protein tyrosine phosphatase receptor type K	Homo sapiens	130-135
25750273-0	2015	The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.	Etoposide	66-75	tumor protein p53	Homo sapiens	79-82
25395162-0	2015	Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.	Etoposide	50-59	signal transducer and activator of transcription 1	Homo sapiens	16-21
25395162-0	2015	Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.	Etoposide	50-59	histone deacetylase 4	Homo sapiens	22-27
25395162-0	2015	Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.	Etoposide	50-59	ATP binding cassette subfamily B member 1	Homo sapiens	77-99
25395162-6	2015	The combined treatment was demonstrated to enhance etoposide-induced apoptosis and reduce expression levels of HDAC4, P-gp and phospho-Stat1.	Etoposide	51-60	phosphoglycolate phosphatase	Homo sapiens	118-122
25395162-6	2015	The combined treatment was demonstrated to enhance etoposide-induced apoptosis and reduce expression levels of HDAC4, P-gp and phospho-Stat1.	Etoposide	51-60	signal transducer and activator of transcription 1	Homo sapiens	135-140
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	58-67	signal transducer and activator of transcription 1	Homo sapiens	32-37
25639153-9	2015	This was further supported by in vitro experiments in HepG2 cells treated with carboplatin and etoposide showing a dose-dependent decrease in CPS1 protein expression.	Etoposide	95-104	carbamoyl-phosphate synthase 1	Homo sapiens	142-146
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	58-67	histone deacetylase 4	Homo sapiens	123-128
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	58-67	phosphoglycolate phosphatase	Homo sapiens	133-137
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	58-67	signal transducer and activator of transcription 1	Homo sapiens	155-160
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	58-67	phosphoglycolate phosphatase	Homo sapiens	247-251
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	209-218	signal transducer and activator of transcription 1	Homo sapiens	32-37
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	209-218	histone deacetylase 4	Homo sapiens	123-128
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	209-218	phosphoglycolate phosphatase	Homo sapiens	133-137
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	209-218	signal transducer and activator of transcription 1	Homo sapiens	155-160
25395162-7	2015	In addition, the suppression of Stat1 with siRNA enhanced etoposide-induced apoptosis and reduced the expression levels of HDAC4 and P-gp, suggesting that Stat1 is essential in the regulation of resistance to etoposide, and in the upregulation of P-gp.	Etoposide	209-218	phosphoglycolate phosphatase	Homo sapiens	247-251
25395162-9	2015	These results suggest that the upregulation of Stat1 and HDAC4 determines etoposide resistance through P-gp expression in human A549 lung cancer cells.	Etoposide	74-83	signal transducer and activator of transcription 1	Homo sapiens	47-52
25395162-9	2015	These results suggest that the upregulation of Stat1 and HDAC4 determines etoposide resistance through P-gp expression in human A549 lung cancer cells.	Etoposide	74-83	histone deacetylase 4	Homo sapiens	57-62
25395162-9	2015	These results suggest that the upregulation of Stat1 and HDAC4 determines etoposide resistance through P-gp expression in human A549 lung cancer cells.	Etoposide	74-83	phosphoglycolate phosphatase	Homo sapiens	103-107
25866761-4	2015	Covalently bound to a nanoparticle, tetrac as nanotetrac acts at the integrin to increase intracellular residence time of chemotherapeutic agents such as doxorubicin and etoposide that are substrates of P-gp.	Etoposide	170-179	ATP binding cassette subfamily B member 1	Homo sapiens	203-207
25605014-9	2015	Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition.	Etoposide	169-178	DNA topoisomerase II alpha	Homo sapiens	60-65
25605014-9	2015	Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition.	Etoposide	169-178	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	70-74
25690288-3	2015	Among the synthesized compounds, compound 21a shows the highest activity, with IC50 values ranging from 0.49 to 6.70 muM, which is more potent than the control drugs etoposide and cisplatin.	Etoposide	166-175	latexin	Homo sapiens	117-120
25499082-3	2015	Here, we found that OTU deubiquitinase 5 (OTUD5) was bound to PDCD5 in response to etoposide treatment and increased the stability of PDCD5 by mediating deubiquitination of PDCD5 at Lys-97/98.	Etoposide	83-92	OTU deubiquitinase 5	Homo sapiens	20-40
25499082-3	2015	Here, we found that OTU deubiquitinase 5 (OTUD5) was bound to PDCD5 in response to etoposide treatment and increased the stability of PDCD5 by mediating deubiquitination of PDCD5 at Lys-97/98.	Etoposide	83-92	OTU deubiquitinase 5	Homo sapiens	42-47
25499082-3	2015	Here, we found that OTU deubiquitinase 5 (OTUD5) was bound to PDCD5 in response to etoposide treatment and increased the stability of PDCD5 by mediating deubiquitination of PDCD5 at Lys-97/98.	Etoposide	83-92	programmed cell death 5	Homo sapiens	62-67
25499082-3	2015	Here, we found that OTU deubiquitinase 5 (OTUD5) was bound to PDCD5 in response to etoposide treatment and increased the stability of PDCD5 by mediating deubiquitination of PDCD5 at Lys-97/98.	Etoposide	83-92	programmed cell death 5	Homo sapiens	134-139
25499082-3	2015	Here, we found that OTU deubiquitinase 5 (OTUD5) was bound to PDCD5 in response to etoposide treatment and increased the stability of PDCD5 by mediating deubiquitination of PDCD5 at Lys-97/98.	Etoposide	83-92	programmed cell death 5	Homo sapiens	134-139
25414256-4	2015	Exposure of normal rat epithelial cells to etoposide caused cellular senescence, as manifested by enlarged cell size, a flattened cell body, reduced cell proliferation, enhanced beta-galactosidase activity, and elevated p53 and p21.	Etoposide	43-52	galactosidase, beta 1	Rattus norvegicus	178-196
25414256-4	2015	Exposure of normal rat epithelial cells to etoposide caused cellular senescence, as manifested by enlarged cell size, a flattened cell body, reduced cell proliferation, enhanced beta-galactosidase activity, and elevated p53 and p21.	Etoposide	43-52	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	220-223
25414256-4	2015	Exposure of normal rat epithelial cells to etoposide caused cellular senescence, as manifested by enlarged cell size, a flattened cell body, reduced cell proliferation, enhanced beta-galactosidase activity, and elevated p53 and p21.	Etoposide	43-52	KRAS proto-oncogene, GTPase	Rattus norvegicus	228-231
25524659-11	2015	Furthermore, AIOLOS overexpression synergistically increased the cytotoxic effects of etoposide and downregulated NF-kappaB expression.	Etoposide	86-95	IKAROS family zinc finger 3	Homo sapiens	13-19
25524659-12	2015	Our findings revealed that lentivirus-mediated AIOLOS overexpression in Jurkat cells induced cell apoptosis, arrested the cell cycle at the G0/G1 phase, and synergistically increased the sensitivity of Jurkat cells to etoposide by inhibiting NF-kappaB activity.	Etoposide	218-227	IKAROS family zinc finger 3	Homo sapiens	47-53
25767606-6	2015	RESULTS: Flow cytometry showed that Docetaxel, Paclitaxel, Gemzar and Cisplatin induced apoptosis more when they were added before somatostatin, whereas etoposide induced apoptosis more after somatostatin treatment.	Etoposide	153-162	somatostatin	Homo sapiens	192-204
25887473-3	2015	Proliferation inhibition and apoptosis in NGDN over-expressing myeloid multidrug-resistant leukemia cells (K562/A02-NGDN) was significantly higher than in control K562/A02 cells following treatment with vincristine, etoposide, and epirubicin, indicating that NGDN over-expression can increase the sensitivity of multidrug-resistant leukemia cells to chemotherapeutic drugs.	Etoposide	216-225	neuroguidin	Homo sapiens	42-46
26045996-4	2015	Overexpression of miR-1469 in lung cancer cells increased cell apoptosis induced by etoposide.	Etoposide	84-93	microRNA 1469	Homo sapiens	18-26
25666857-0	2015	IER3 is a crucial mediator of TAp73beta-induced apoptosis in cervical cancer and confers etoposide sensitivity.	Etoposide	89-98	immediate early response 3	Homo sapiens	0-4
25666857-9	2015	Moreover, etoposide, a DNA-damaging chemotherapeutics, upregulated TAp73beta and IER3 in a c-Abl tyrosine kinase-dependent manner, and the etoposide chemosensitivity of HeLa cells was largely determined by TAp73beta-induced IER3.	Etoposide	10-19	immediate early response 3	Homo sapiens	81-85
25666857-9	2015	Moreover, etoposide, a DNA-damaging chemotherapeutics, upregulated TAp73beta and IER3 in a c-Abl tyrosine kinase-dependent manner, and the etoposide chemosensitivity of HeLa cells was largely determined by TAp73beta-induced IER3.	Etoposide	10-19	immediate early response 3	Homo sapiens	224-228
25666857-11	2015	Thus, our findings suggest that IER3 is a putative tumor suppressor in the cervix, and the c-Ab1/p73beta/IER3 axis is a novel and crucial signaling pathway that confers etoposide chemosensitivity.	Etoposide	169-178	calcium voltage-gated channel auxiliary subunit beta 1	Homo sapiens	91-96
25666857-11	2015	Thus, our findings suggest that IER3 is a putative tumor suppressor in the cervix, and the c-Ab1/p73beta/IER3 axis is a novel and crucial signaling pathway that confers etoposide chemosensitivity.	Etoposide	169-178	immediate early response 3	Homo sapiens	105-109
25444898-8	2015	However, DNAJB1 knockdown in A549 cells increased the etoposide-induced activation of the p53-mediated apoptosis pathway and repressed cancer cell growth.	Etoposide	54-63	DnaJ heat shock protein family (Hsp40) member B1	Homo sapiens	9-15
25444898-8	2015	However, DNAJB1 knockdown in A549 cells increased the etoposide-induced activation of the p53-mediated apoptosis pathway and repressed cancer cell growth.	Etoposide	54-63	tumor protein p53	Homo sapiens	90-93
24038446-0	2015	Phosphorylation of Smac by Akt promotes the caspase-3 activation during etoposide-induced apoptosis in HeLa cells.	Etoposide	72-81	diablo IAP-binding mitochondrial protein	Homo sapiens	19-23
24038446-0	2015	Phosphorylation of Smac by Akt promotes the caspase-3 activation during etoposide-induced apoptosis in HeLa cells.	Etoposide	72-81	AKT serine/threonine kinase 1	Homo sapiens	27-30
24038446-0	2015	Phosphorylation of Smac by Akt promotes the caspase-3 activation during etoposide-induced apoptosis in HeLa cells.	Etoposide	72-81	caspase 3	Homo sapiens	44-53
24038446-3	2015	In this report, nevertheless, we focused our view on the novel role of Akt which involves in a pro-apoptotic action by phosphorylating second mitochondria derived activator of caspases (Smac) protein during etoposide-induced apoptotic processes.	Etoposide	207-216	AKT serine/threonine kinase 1	Homo sapiens	71-74
24038446-3	2015	In this report, nevertheless, we focused our view on the novel role of Akt which involves in a pro-apoptotic action by phosphorylating second mitochondria derived activator of caspases (Smac) protein during etoposide-induced apoptotic processes.	Etoposide	207-216	diablo IAP-binding mitochondrial protein	Homo sapiens	186-190
24038446-5	2015	The cellular interaction of wild-type Smac with XIAP was enhanced with similar activation kinetics of Akt activity, while this interaction was markedly attenuated in cells expressing the phosphorylation-defective mutant S67A-Smac during etoposide-induced apoptosis.	Etoposide	237-246	diablo IAP-binding mitochondrial protein	Homo sapiens	38-42
24038446-5	2015	The cellular interaction of wild-type Smac with XIAP was enhanced with similar activation kinetics of Akt activity, while this interaction was markedly attenuated in cells expressing the phosphorylation-defective mutant S67A-Smac during etoposide-induced apoptosis.	Etoposide	237-246	diablo IAP-binding mitochondrial protein	Homo sapiens	225-229
24038446-7	2015	Taken together, we propose that the phosphorylation of Smac by Akt might be a novel mechanism that involves in amplification of caspase cascade pathway during etoposide-induced apoptosis in HeLa cells.	Etoposide	159-168	diablo IAP-binding mitochondrial protein	Homo sapiens	55-59
24038446-7	2015	Taken together, we propose that the phosphorylation of Smac by Akt might be a novel mechanism that involves in amplification of caspase cascade pathway during etoposide-induced apoptosis in HeLa cells.	Etoposide	159-168	AKT serine/threonine kinase 1	Homo sapiens	63-66
25301452-4	2015	Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin.	Etoposide	26-35	solute carrier organic anion transporter family member 4A1	Homo sapiens	107-114
25301452-4	2015	Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin.	Etoposide	26-35	solute carrier organic anion transporter family member 5A1	Homo sapiens	116-123
25301452-4	2015	Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin.	Etoposide	26-35	solute carrier organic anion transporter family member 6A1	Homo sapiens	125-132
25301452-4	2015	Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin.	Etoposide	26-35	synaptophysin	Homo sapiens	151-164
25247290-9	2015	Disease control coincided with supplementary etoposide therapy initiated to boost apoptotic cell death, when systemic HMGB1 levels drastically declined and the molecule emerged mainly in its oxidized, noninflammatory isoform.	Etoposide	45-54	high mobility group box 1	Homo sapiens	118-123
25055799-0	2015	UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.	Etoposide	159-168	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
25055799-1	2015	The uridine diphosphate glucuronosyltransferase (UGT) gene 1A1*6 polymorphism, which affects irinotecan metabolism, has been associated with improved survival in lymphoma patients treated with of carboplatin, dexamethasone, etoposide and irinotecan (CDE-11).	Etoposide	224-233	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	4-47
25055799-1	2015	The uridine diphosphate glucuronosyltransferase (UGT) gene 1A1*6 polymorphism, which affects irinotecan metabolism, has been associated with improved survival in lymphoma patients treated with of carboplatin, dexamethasone, etoposide and irinotecan (CDE-11).	Etoposide	224-233	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	49-52
26163637-0	2015	Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.	Etoposide	87-96	chorionic gonadotropin subunit beta 5	Homo sapiens	30-33
26424010-0	2015	SPATA4 Counteracts Etoposide-Induced Apoptosis via Modulating Bcl-2 Family Proteins in HeLa Cells.	Etoposide	19-28	spermatogenesis associated 4	Homo sapiens	0-6
26424010-0	2015	SPATA4 Counteracts Etoposide-Induced Apoptosis via Modulating Bcl-2 Family Proteins in HeLa Cells.	Etoposide	19-28	BCL2 apoptosis regulator	Homo sapiens	62-67
26424010-4	2015	SPATA4 protected HeLa cells from etoposide-induced apoptosis through the mitochondrial apoptotic pathway, in the way that SPATA4 suppressed decrease of the mitochondrial membrane potential, the release of cytochrome c, and subsequent activation of caspase-9 and -3.	Etoposide	33-42	spermatogenesis associated 4	Homo sapiens	0-6
26424010-4	2015	SPATA4 protected HeLa cells from etoposide-induced apoptosis through the mitochondrial apoptotic pathway, in the way that SPATA4 suppressed decrease of the mitochondrial membrane potential, the release of cytochrome c, and subsequent activation of caspase-9 and -3.	Etoposide	33-42	spermatogenesis associated 4	Homo sapiens	122-128
26424010-4	2015	SPATA4 protected HeLa cells from etoposide-induced apoptosis through the mitochondrial apoptotic pathway, in the way that SPATA4 suppressed decrease of the mitochondrial membrane potential, the release of cytochrome c, and subsequent activation of caspase-9 and -3.	Etoposide	33-42	cytochrome c, somatic	Homo sapiens	205-217
26424010-4	2015	SPATA4 protected HeLa cells from etoposide-induced apoptosis through the mitochondrial apoptotic pathway, in the way that SPATA4 suppressed decrease of the mitochondrial membrane potential, the release of cytochrome c, and subsequent activation of caspase-9 and -3.	Etoposide	33-42	caspase 9	Homo sapiens	248-264
26424010-7	2015	In conclusion, SPATA4 protects HeLa cells against etoposide-induced apoptosis through the mitochondrial apoptotic pathway.	Etoposide	50-59	spermatogenesis associated 4	Homo sapiens	15-21
25737788-7	2015	Conventional induction therapy for HLH is dexamethasone and etoposide (VP-16), followed by or with cyclosporine.	Etoposide	60-69	host cell factor C1	Homo sapiens	71-76
25533622-6	2015	In addition, downregulation of SRC also abolished radiation-acquired resistance of breast cancer cells to anticancer agents such as cisplatin, etoposide, paclitaxel, and IR.	Etoposide	143-152	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	31-34
26288115-3	2015	In this study, claudin 1 promotes migration in luminal-like MCF7 human breast cancer cells and increases their sensitivity to tamoxifen, etoposide, and cisplatin.	Etoposide	137-146	claudin 1	Homo sapiens	15-24
25700942-0	2015	Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.	Etoposide	86-95	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	0-3
25700942-0	2015	Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.	Etoposide	86-95	brain derived neurotrophic factor	Mus musculus	29-33
25700942-0	2015	Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.	Etoposide	86-95	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	34-38
25700942-3	2015	In this study we evaluated the effect of AZD6918 on the sensitivity of TrkB-expressing NB cells or tumors to etoposide, a topoisomerase II inhibitor.	Etoposide	109-118	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	71-75
25700942-4	2015	TrkB-expressing NB cells were treated with AZD6918 and etoposide in the presence or absence of BDNF in vitro and cell survival was determined.	Etoposide	55-64	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	0-4
25700942-6	2015	Our study showed that AZD6918 induced cell death as a single agent and attenuated BDNF/TrkB-induced protection from etoposide in vitro.	Etoposide	116-125	brain derived neurotrophic factor	Mus musculus	82-86
25700942-6	2015	Our study showed that AZD6918 induced cell death as a single agent and attenuated BDNF/TrkB-induced protection from etoposide in vitro.	Etoposide	116-125	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	87-91
25700942-8	2015	Our data indicate that as a Trk inhibitor AZD6918 increased the sensitivity of NB to etoposide.	Etoposide	85-94	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	28-31
24401038-0	2015	Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery.	Etoposide	15-24	albumin	Homo sapiens	39-52
25659035-3	2015	Here we show that in human cells exposed to ionizing radiation or genotoxic drugs etoposide and neocarzinostatin, DAXX became rapidly phosphorylated in an ATM kinase-dependent manner.	Etoposide	82-91	death domain associated protein	Homo sapiens	114-118
26506264-5	2015	Transient siRNA suppression of p21(WAF1) in the BCP-ALL 697 cell line resulted in a moderate depletion of the cell fraction in G1 phase and marked increase in PS externalization following exposure to etoposide.	Etoposide	200-209	cyclin dependent kinase inhibitor 1A	Homo sapiens	31-34
26506264-5	2015	Transient siRNA suppression of p21(WAF1) in the BCP-ALL 697 cell line resulted in a moderate depletion of the cell fraction in G1 phase and marked increase in PS externalization following exposure to etoposide.	Etoposide	200-209	cyclin dependent kinase inhibitor 1A	Homo sapiens	35-39
26506264-6	2015	Furthermore, stable lentiviral p21(WAF1) silencing in the BCP-ALL Nalm-6 cell line accelerated PS externalization and cell death following exposure to etoposide and vorinostat, supporting previous findings.	Etoposide	151-160	cyclin dependent kinase inhibitor 1A	Homo sapiens	31-34
26506264-6	2015	Furthermore, stable lentiviral p21(WAF1) silencing in the BCP-ALL Nalm-6 cell line accelerated PS externalization and cell death following exposure to etoposide and vorinostat, supporting previous findings.	Etoposide	151-160	cyclin dependent kinase inhibitor 1A	Homo sapiens	35-39
26102294-3	2015	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).	Etoposide	37-46	tumor protein p53	Homo sapiens	104-107
26102294-3	2015	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).	Etoposide	37-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	144-151
26102294-3	2015	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).	Etoposide	48-51	tumor protein p53	Homo sapiens	104-107
26102294-3	2015	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).	Etoposide	48-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	144-151
26102294-5	2015	PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe.	Etoposide	24-27	cyclin dependent kinase inhibitor 1A	Homo sapiens	80-87
26102294-9	2015	p16ink4a, the inducer of terminal senescence, underwent autophagic sequestration in the cytoplasm of ETO-treated cells, allowing alternative cell fates.	Etoposide	101-104	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-8
24401038-3	2015	The purpose of this study was to develop a formulation of etoposide-loaded bovine serum albumin (BSA) nanosuspensions, to study in vitro characterization, and to estimate the in vivo safety and tissue distribution of etoposide-loaded BSA nanosuspensions for parenteral delivery.	Etoposide	58-67	albumin	Homo sapiens	82-95
26349604-2	2015	Ectopic expression of GLI1 in PW cells induced anchorage-independent growth and increased resistance to staurosporine-induced apoptosis, and overexpression of GLI1 in H441 cells caused resistance to apoptosis induced by staurosporine and etoposide.	Etoposide	238-247	GLI family zinc finger 1	Homo sapiens	22-26
25125202-8	2015	In the subsequent case study, a patient with relapsed SmCC with high SSTR2 expression on GaTate PET underwent PRCRT with radiosensitising etoposide with evidence of a complete metabolic response for 4 months.	Etoposide	138-147	somatostatin receptor 2	Homo sapiens	69-74
25866679-4	2015	As expected, etoposide-treated wild-type p53-containing cell lines, LFS 2852 and control Jurkat, showed a greater rate of caspase- and annexin V-induced apoptotic cell death compared to the p53-mutant LFS 2673 cell line although mitochondrial and nuclear assays could not detect apoptosis in these organelles.	Etoposide	13-22	tumor protein p53	Homo sapiens	41-44
25866679-4	2015	As expected, etoposide-treated wild-type p53-containing cell lines, LFS 2852 and control Jurkat, showed a greater rate of caspase- and annexin V-induced apoptotic cell death compared to the p53-mutant LFS 2673 cell line although mitochondrial and nuclear assays could not detect apoptosis in these organelles.	Etoposide	13-22	annexin A5	Homo sapiens	135-144
25866679-4	2015	As expected, etoposide-treated wild-type p53-containing cell lines, LFS 2852 and control Jurkat, showed a greater rate of caspase- and annexin V-induced apoptotic cell death compared to the p53-mutant LFS 2673 cell line although mitochondrial and nuclear assays could not detect apoptosis in these organelles.	Etoposide	13-22	tumor protein p53	Homo sapiens	190-193
26774631-0	2015	Inhibition of myeloperoxidase activity have impact on the formation of DNA double-strand breaks induced by etoposide in HL-60 cell line.	Etoposide	107-116	myeloperoxidase	Homo sapiens	14-29
26774631-1	2015	Many studies have shown the role of myeloperoxidase (MPO) in leukemogenic activity of etoposide.	Etoposide	86-95	myeloperoxidase	Homo sapiens	36-51
26774631-1	2015	Many studies have shown the role of myeloperoxidase (MPO) in leukemogenic activity of etoposide.	Etoposide	86-95	myeloperoxidase	Homo sapiens	53-56
26774631-8	2015	NAC exerted similar impact as ABAH on the level of gH2AX induced by etoposide.	Etoposide	68-77	X-linked Kx blood group	Homo sapiens	0-3
26774631-9	2015	The results of this study suggest that MPO contributes to increase of the DSBs level induced by low concentrations of etoposide in myeloid cells.	Etoposide	118-127	myeloperoxidase	Homo sapiens	39-42
25758091-0	2015	Erratum for Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DZXX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related Myelodysplastic syndrome.	Etoposide	163-172	RANBP2 like and GRIP domain containing 2	Homo sapiens	26-37
25758091-0	2015	Erratum for Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DZXX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related Myelodysplastic syndrome.	Etoposide	163-172	nucleoporin 98 and 96 precursor	Homo sapiens	44-49
26349604-2	2015	Ectopic expression of GLI1 in PW cells induced anchorage-independent growth and increased resistance to staurosporine-induced apoptosis, and overexpression of GLI1 in H441 cells caused resistance to apoptosis induced by staurosporine and etoposide.	Etoposide	238-247	GLI family zinc finger 1	Homo sapiens	159-163
26349604-5	2015	Downregulation of GLI1 expression in A549 cells by siRNA transfection increased sensitivity to etoposide-induced apoptosis, and downregulation of NDRG1 expression in H441 cells by siRNA transfection increased sensitivity to etoposide-induced apoptosis.	Etoposide	95-104	GLI family zinc finger 1	Homo sapiens	18-22
25490093-6	2014	Consistently, in p53siRNA transfected U2-OS cells we observed loss of miR-34a induction after etoposide exposure associated with a partial gain of gene methylation and cell cycle progress towards G2/M phase.	Etoposide	94-103	tumor protein p53	Homo sapiens	17-20
25922565-8	2015	Importantly, this ETOP-mediated suppression of melanoma tumor growth was blocked by exogenous administration of a PAF-R agonist, CPAF.	Etoposide	18-22	platelet-activating factor receptor	Mus musculus	114-119
25460505-6	2015	We show that inactivation of mTOR with siRNA or pharmacological inhibition of mTORC1/2 kinase prevents etoposide-induced S and G2/M cell cycle arrest.	Etoposide	103-112	mechanistic target of rapamycin kinase	Homo sapiens	29-33
25460505-6	2015	We show that inactivation of mTOR with siRNA or pharmacological inhibition of mTORC1/2 kinase prevents etoposide-induced S and G2/M cell cycle arrest.	Etoposide	103-112	CREB regulated transcription coactivator 1	Mus musculus	78-84
25490093-0	2014	p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.	Etoposide	56-65	tumor protein p53	Homo sapiens	0-3
31171989-3	2015	It has been found that both doxorubicin and etoposide (VP-16) act on topoisomerase II, induce DNA cleavage, and form double-strand breaks, causing tumor cell death.	Etoposide	44-53	host cell factor C1	Homo sapiens	55-60
25948303-4	2015	Then, we revealed that repeated oral treatment with etoposide (ETP) increases P-gp levels in the small intestinal membrane via RhoA/ROCK activation, leading to decrease in analgesia of morphine, a P-gp substrate drug, with alteration of its disposition after oral administration.	Etoposide	52-61	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
25948303-4	2015	Then, we revealed that repeated oral treatment with etoposide (ETP) increases P-gp levels in the small intestinal membrane via RhoA/ROCK activation, leading to decrease in analgesia of morphine, a P-gp substrate drug, with alteration of its disposition after oral administration.	Etoposide	52-61	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
25948303-4	2015	Then, we revealed that repeated oral treatment with etoposide (ETP) increases P-gp levels in the small intestinal membrane via RhoA/ROCK activation, leading to decrease in analgesia of morphine, a P-gp substrate drug, with alteration of its disposition after oral administration.	Etoposide	63-66	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
25948303-4	2015	Then, we revealed that repeated oral treatment with etoposide (ETP) increases P-gp levels in the small intestinal membrane via RhoA/ROCK activation, leading to decrease in analgesia of morphine, a P-gp substrate drug, with alteration of its disposition after oral administration.	Etoposide	63-66	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
25948303-6	2015	Of particular interest is that among ERM proteins, radixin may contribute, at least in part, to increased expression of P-gp in the small intestine under repeated oral treatment with ETP.	Etoposide	183-186	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
25490093-3	2014	In this study we evaluated the cascade of events determined by etoposide-induced DNA damage in OS cell lines with different p53 status focusing on methylation status and expression of miR-34a that modulate tumor cell growth and cell cycle progression.	Etoposide	63-72	tumor protein p53	Homo sapiens	124-127
25490093-6	2014	Consistently, in p53siRNA transfected U2-OS cells we observed loss of miR-34a induction after etoposide exposure associated with a partial gain of gene methylation and cell cycle progress towards G2/M phase.	Etoposide	94-103	microRNA 34a	Homo sapiens	70-77
25490093-3	2014	In this study we evaluated the cascade of events determined by etoposide-induced DNA damage in OS cell lines with different p53 status focusing on methylation status and expression of miR-34a that modulate tumor cell growth and cell cycle progression.	Etoposide	63-72	microRNA 34a	Homo sapiens	184-191
25490093-4	2014	Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase.	Etoposide	118-127	tumor protein p53	Homo sapiens	10-13
25490093-8	2014	In conclusion, cell response to etoposide-induced DNA damage was not compromised in cells with dominant-negative p53 expression.	Etoposide	32-41	tumor protein p53	Homo sapiens	113-116
25490093-4	2014	Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase.	Etoposide	118-127	tumor protein p53	Homo sapiens	79-82
25585637-7	2014	A transient reactivation of mTOR favored geroconversion in etoposide-treated confluent cells.	Etoposide	59-68	mechanistic target of rapamycin kinase	Mus musculus	28-32
25490093-4	2014	Wild-type p53 U2-OS cells and U2-OS cells expressing dominant-negative form of p53 (U2- OS175) were more sensitive to etoposide than p53-deficient MG63 and Saos-2 cells, showing increased levels of unmethylated miR-34a, reduced expression of CDK4 and cell cycle arrest in G1 phase.	Etoposide	118-127	tumor protein p53	Homo sapiens	79-82
25220407-6	2014	Etoposide-induced formation of these complexes and repression of ANT2 were relatively late events co-incident with production and secretion of, and dependent on, TGF-beta.	Etoposide	0-9	solute carrier family 25 member 6	Homo sapiens	65-69
25220407-6	2014	Etoposide-induced formation of these complexes and repression of ANT2 were relatively late events co-incident with production and secretion of, and dependent on, TGF-beta.	Etoposide	0-9	transforming growth factor beta 1	Homo sapiens	162-170
25220407-8	2014	Knock-down of ANT2, together with etoposide treatment, further intensified ROS production and DNA damage signaling, leading to enhanced apoptosis.	Etoposide	34-43	solute carrier family 25 member 6	Homo sapiens	14-18
25123151-10	2014	Exposure of etoposide on MCF-7 cells showed RhoC upregulation together with reduced membranous expression of E-cadherin and disorganization of actin fibers.	Etoposide	12-21	ras homolog family member C	Homo sapiens	44-48
24169729-8	2014	However, he manifested high-grade fever, pancytopenia, and elevated soluble interleukin-2 receptor with a prominent hemophagocytosis in bone marrow aspirates and was treated with etoposide for hemophagocytic lymphohistiocytosis (HLH) complication.	Etoposide	179-188	interleukin 2	Homo sapiens	76-89
25123151-10	2014	Exposure of etoposide on MCF-7 cells showed RhoC upregulation together with reduced membranous expression of E-cadherin and disorganization of actin fibers.	Etoposide	12-21	cadherin 1	Homo sapiens	109-119
24944079-1	2014	ICE/R-ICE (ifosfamide, carboplatin, and etoposide without or with rituximab) chemotherapy followed by autologous stem cell transplantation is an established regimen in refractory/relapsed lymphoma.	Etoposide	40-49	carboxylesterase 2	Homo sapiens	0-3
24944079-1	2014	ICE/R-ICE (ifosfamide, carboplatin, and etoposide without or with rituximab) chemotherapy followed by autologous stem cell transplantation is an established regimen in refractory/relapsed lymphoma.	Etoposide	40-49	carboxylesterase 2	Homo sapiens	6-9
25406032-4	2014	Whereas etoposide treatment reduced the interaction of DBC1 with SENP1, it promoted that with PIAS3, resulting in an increase in DBC1 sumoylation.	Etoposide	8-17	cell cycle and apoptosis regulator 2	Homo sapiens	55-59
25771877-3	2014	Ectopic expression of C-terminal phospho-mutants of PTEN, in PTEN deficient human glioblastoma cells, U87MG, resulted in reduced viability and DNA repair after etoposide induced DNA damage compared to cells expressing wild type PTEN.	Etoposide	160-169	phosphatase and tensin homolog	Homo sapiens	52-56
25771877-3	2014	Ectopic expression of C-terminal phospho-mutants of PTEN, in PTEN deficient human glioblastoma cells, U87MG, resulted in reduced viability and DNA repair after etoposide induced DNA damage compared to cells expressing wild type PTEN.	Etoposide	160-169	phosphatase and tensin homolog	Homo sapiens	61-65
25771877-3	2014	Ectopic expression of C-terminal phospho-mutants of PTEN, in PTEN deficient human glioblastoma cells, U87MG, resulted in reduced viability and DNA repair after etoposide induced DNA damage compared to cells expressing wild type PTEN.	Etoposide	160-169	phosphatase and tensin homolog	Homo sapiens	61-65
25771877-4	2014	Also, after etoposide treatment phosphorylation of PTEN increased at C-terminal serine 380 and threonine 382/383 residues in PTEN positive HEK293T cells and wild type PTEN transfected U87MG cells.	Etoposide	12-21	phosphatase and tensin homolog	Homo sapiens	51-55
25771877-4	2014	Also, after etoposide treatment phosphorylation of PTEN increased at C-terminal serine 380 and threonine 382/383 residues in PTEN positive HEK293T cells and wild type PTEN transfected U87MG cells.	Etoposide	12-21	phosphatase and tensin homolog	Homo sapiens	125-129
25771877-4	2014	Also, after etoposide treatment phosphorylation of PTEN increased at C-terminal serine 380 and threonine 382/383 residues in PTEN positive HEK293T cells and wild type PTEN transfected U87MG cells.	Etoposide	12-21	phosphatase and tensin homolog	Homo sapiens	125-129
25771877-6	2014	Additionally, phospho-PTEN translocated to nucleus after etoposide treatment as revealed by indirect immunolabeling.	Etoposide	57-66	phosphatase and tensin homolog	Homo sapiens	22-26
25771877-7	2014	Further, phosphorylation dependent nuclear foci formation of PTEN was observed after ionizing radiation or etoposide treatment which colocalized with gammaH2AX.	Etoposide	107-116	phosphatase and tensin homolog	Homo sapiens	61-65
25771877-8	2014	Additionally, etoposide induced gammaH2AX, Mre11 and Ku70 foci persisted for a longer period of times in U87MG cells after ectopic expression of PTEN C-terminal phospho-mutant constructs compared to wild type PTEN expressing cells.	Etoposide	14-23	MRE11 homolog, double strand break repair nuclease	Homo sapiens	43-48
25771877-8	2014	Additionally, etoposide induced gammaH2AX, Mre11 and Ku70 foci persisted for a longer period of times in U87MG cells after ectopic expression of PTEN C-terminal phospho-mutant constructs compared to wild type PTEN expressing cells.	Etoposide	14-23	X-ray repair cross complementing 6	Homo sapiens	53-57
25771877-8	2014	Additionally, etoposide induced gammaH2AX, Mre11 and Ku70 foci persisted for a longer period of times in U87MG cells after ectopic expression of PTEN C-terminal phospho-mutant constructs compared to wild type PTEN expressing cells.	Etoposide	14-23	phosphatase and tensin homolog	Homo sapiens	145-149
25771877-8	2014	Additionally, etoposide induced gammaH2AX, Mre11 and Ku70 foci persisted for a longer period of times in U87MG cells after ectopic expression of PTEN C-terminal phospho-mutant constructs compared to wild type PTEN expressing cells.	Etoposide	14-23	phosphatase and tensin homolog	Homo sapiens	209-213
24810107-3	2014	RESULTS: Using in vivo microdialysis, we found that EVP-6124 [(R)-7-chloro-N-quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide], a high-affinity alpha7 nAChR partial agonist, at 0.1 mg/kg, s.c., increased DA efflux in the medial prefrontal cortex (mPFC) and NAC.	Etoposide	52-55	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	151-156
24810107-8	2014	Pretreatment with the selective alpha7 nAChR antagonist, methyllycaconitine (MLA, 1.0 mg/kg), significantly blocked cortical DA and Glu efflux induced by EVP-6124 (0.1 mg/kg), suggesting that the effects of EVP-6124 on these neurotransmitters were due to alpha7 nAChR agonism.	Etoposide	154-157	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	39-44
24810107-8	2014	Pretreatment with the selective alpha7 nAChR antagonist, methyllycaconitine (MLA, 1.0 mg/kg), significantly blocked cortical DA and Glu efflux induced by EVP-6124 (0.1 mg/kg), suggesting that the effects of EVP-6124 on these neurotransmitters were due to alpha7 nAChR agonism.	Etoposide	154-157	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	262-267
25063076-6	2014	It also potentiated etoposide-induced accumulation and phosphorylation of the pro-apoptotic transcription factor p53.	Etoposide	20-29	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	113-116
25063076-9	2014	The specific HDAC1 inhibitor MS275 only moderately enhanced etoposide-induced neuronal death.	Etoposide	60-69	histone deacetylase 1	Rattus norvegicus	13-18
25409517-10	2014	Finally, CD137 stimulation suppressed etoposide-induced cell death not only in the EBV-positive T- or NK-cell lines, but also in the patients" cells.	Etoposide	38-47	TNF receptor superfamily member 9	Homo sapiens	9-14
25406032-4	2014	Whereas etoposide treatment reduced the interaction of DBC1 with SENP1, it promoted that with PIAS3, resulting in an increase in DBC1 sumoylation.	Etoposide	8-17	SUMO specific peptidase 1	Homo sapiens	65-70
25406032-4	2014	Whereas etoposide treatment reduced the interaction of DBC1 with SENP1, it promoted that with PIAS3, resulting in an increase in DBC1 sumoylation.	Etoposide	8-17	cell cycle and apoptosis regulator 2	Homo sapiens	129-133
25406032-7	2014	Consistently, SENP1 knockdown promoted etoposide-induced apoptosis, whereas knockdown of PIAS3 or SUMO2/3 and overexpression of sumoylation-deficient DBC1 mutant inhibited it.	Etoposide	39-48	SUMO specific peptidase 1	Homo sapiens	14-19
24923454-2	2014	Currently, for patients with relapsed/refractory ENKL, L-asparaginase-based regimens such as L-asparaginase, ifosfamide, methotrexate, etoposide, and dexamethasone (SMILE) or L-asparaginase, methotrexate, and dexamethasone (AspaMetDex) are recommended.	Etoposide	135-144	asparaginase and isoaspartyl peptidase 1	Homo sapiens	55-69
25397519-15	2014	CONCLUSIONS: CD4 count was higher in EVP-treated patients compared to controls.	Etoposide	37-40	CD4 molecule	Homo sapiens	13-16
25109285-0	2014	Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers.	Etoposide	38-47	sirtuin 1	Homo sapiens	0-5
25128152-4	2014	Several anticancer drugs have been identified as ABCG2 substrates including mitoxantrone, etoposide and topotecan.	Etoposide	90-99	ATP binding cassette subfamily G member 2	Canis lupus familiaris	49-54
25011391-3	2014	Here, we monitored the interactions between protein kinase-Czeta (PKCzeta) and Bcl10 protein in untreated and etoposide (VP-16)-treated C4-I cells by means of a new combined morphological approach and validated it by taking stock of our previous proteomic and biochemical work (Chiarini et al.	Etoposide	110-119	protein kinase C zeta	Homo sapiens	44-74
25011391-3	2014	Here, we monitored the interactions between protein kinase-Czeta (PKCzeta) and Bcl10 protein in untreated and etoposide (VP-16)-treated C4-I cells by means of a new combined morphological approach and validated it by taking stock of our previous proteomic and biochemical work (Chiarini et al.	Etoposide	110-119	BCL10 immune signaling adaptor	Homo sapiens	79-84
25011391-3	2014	Here, we monitored the interactions between protein kinase-Czeta (PKCzeta) and Bcl10 protein in untreated and etoposide (VP-16)-treated C4-I cells by means of a new combined morphological approach and validated it by taking stock of our previous proteomic and biochemical work (Chiarini et al.	Etoposide	110-119	host cell factor C1	Homo sapiens	121-126
25190507-3	2014	The transfection of leukemic HL-60 cells with an STYK1 expression vector resulted in the resistance to doxorubicin and etoposide and decreased drug-induced caspase-3/7 activity and sub-G1 population.	Etoposide	119-128	serine/threonine/tyrosine kinase 1	Homo sapiens	49-54
25109285-3	2014	Here, we investigated the induction of Sirt1 expression by etoposide-induced genotoxic stress to gain insights into thyroid carcinogenesis and identify novel therapeutic targets.	Etoposide	59-68	sirtuin 1	Homo sapiens	39-44
25109285-7	2014	The induction of Sirt1 and Sirt3 was cell type-specific and the expression levels of these genes correlated with apoptotic cell death and cell viability after etoposide-induced genotoxic stress.	Etoposide	159-168	sirtuin 1	Homo sapiens	17-22
25109285-7	2014	The induction of Sirt1 and Sirt3 was cell type-specific and the expression levels of these genes correlated with apoptotic cell death and cell viability after etoposide-induced genotoxic stress.	Etoposide	159-168	sirtuin 3	Homo sapiens	27-32
25109285-8	2014	Sirt1-Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress.	Etoposide	158-167	sirtuin 1	Homo sapiens	0-5
25109285-8	2014	Sirt1-Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress.	Etoposide	158-167	forkhead box P3	Homo sapiens	6-11
25109285-8	2014	Sirt1-Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress.	Etoposide	158-167	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
25109285-8	2014	Sirt1-Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress.	Etoposide	158-167	H3 histone pseudogene 16	Homo sapiens	53-56
25109285-8	2014	Sirt1-Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress.	Etoposide	158-167	two pore segment channel 1	Homo sapiens	108-112
25242524-2	2014	CS1, a novel 2-phenylnaphthalene, had potent cytotoxicity against nine tested tumor cell lines and showed 6-10-fold less toxicity against normal cell lines compared with etoposide.	Etoposide	170-179	myozenin 2	Homo sapiens	0-3
25274752-4	2014	Since mechanical loading plays a crucial role in maintaining osteocyte viability, CCL7 was tested for protective activity and found to be protective against cell death induced by dexamethasone and etoposide.	Etoposide	197-206	chemokine (C-C motif) ligand 7	Mus musculus	82-86
25417880-6	2014	miR-720 overexpression in kasumi-1 cells induced significantly increased cell apoptosis (P=0.017), elevated apoptosis sensitivity to etoposide (P=0.004), and reduced cell proliferation (P&lt;0.01).	Etoposide	133-142	MLX interacting protein	Homo sapiens	0-3
26000396-4	2014	The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 +- 1.2 and 41.13 +- 2.4% (at 5 muM) respectively when tested in PC3 cells.	Etoposide	34-37	latexin	Homo sapiens	102-105
26000396-4	2014	The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 +- 1.2 and 41.13 +- 2.4% (at 5 muM) respectively when tested in PC3 cells.	Etoposide	42-45	latexin	Homo sapiens	102-105
26000396-6	2014	Our data shows that CUR and ETP after encapsulation in nanoemulsion (F5) were effectively delivered intracellularly in PC3 cells and the cytotoxicity of F5 was enhanced by 1.5 fold as compared to ETP + CUR at 5 muM concentration.	Etoposide	28-31	latexin	Homo sapiens	211-214
25709376-3	2014	Significantly, compound 17h showed superior cytotoxic activity compared with etoposide (IC50 6.30 to&gt;10 muM), a clinically available anticancer drug.	Etoposide	77-86	latexin	Homo sapiens	107-110
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	NADH:ubiquinone oxidoreductase subunit B7	Homo sapiens	57-60
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	NADH:ubiquinone oxidoreductase subunit B9	Homo sapiens	62-65
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	nucleophosmin 1	Homo sapiens	67-70
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	CD79b molecule	Homo sapiens	75-78
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	NADH:ubiquinone oxidoreductase subunit B9	Homo sapiens	127-130
25353380-3	2014	The results showed that six compounds (b6, b8, b11, b16, b18, b22, b23 and b29) displayed promising activities, with compounds b22 and b29 in particular showing higher levels of activity than etoposide against all five cancer cell lines.	Etoposide	192-201	CD79b molecule	Homo sapiens	135-138
24926618-3	2014	In our study, NLK-deficient HCT116 cells were found to be resistant to etoposide-induced cell death.	Etoposide	71-80	nemo like kinase	Homo sapiens	14-17
25046000-4	2014	Seven of them (melphalan, cisplatin, vincristine, etoposide, paclitaxel, methotrexate, and cytarabine) caused the production of IL-1beta in cells pretreated with lipopolysaccharide.	Etoposide	50-59	interleukin 1 beta	Homo sapiens	128-136
25341047-10	2014	Moreover, Lxn enhanced the cytotoxicity of chemotherapeutic agent, VP-16, on FDC-P1 cells.	Etoposide	67-72	latexin	Mus musculus	10-13
25250818-5	2014	Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide.	Etoposide	15-24	microRNA 34a	Homo sapiens	36-43
25261981-9	2014	Conditional overexpression of DEPP elevates cellular ROS levels and sensitizes to H2O2 and etoposide-induced cell death.	Etoposide	91-100	DEPP1 autophagy regulator	Homo sapiens	30-34
25250818-5	2014	Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide.	Etoposide	15-24	tumor protein p53	Homo sapiens	56-59
25250818-5	2014	Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide.	Etoposide	15-24	microRNA 34a	Homo sapiens	95-102
25250818-5	2014	Treatment with etoposide, increased miR-34a levels in a p53-dependent fashion and the level of miR-34a transcription was correlated with the cell sensitivity to etoposide.	Etoposide	161-170	microRNA 34a	Homo sapiens	95-102
25092292-2	2014	Investigators have described changes in miR-15b expression following exposure to several stress-inducing anticancer agents, including ionizing radiation (IR), etoposide, and hydrogen peroxide.	Etoposide	159-168	microRNA 15b	Homo sapiens	40-47
24786831-5	2014	PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation.	Etoposide	109-118	proline, glutamate and leucine rich protein 1	Homo sapiens	0-5
24934296-8	2014	Digoxin was mainly transported via P-gp, estrone-3-sulphate via Bcrp and Mrp"s and etoposide via P-gp and Mrp"s.	Etoposide	83-92	phosphoglycolate phosphatase	Rattus norvegicus	97-101
25215539-8	2014	Upon stimulation by DNA-damaging drug etoposide in vitro, mutant B cells showed increased cleavage of caspase 3.	Etoposide	38-47	caspase 3	Mus musculus	102-111
24786831-5	2014	PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation.	Etoposide	109-118	tumor protein p53	Homo sapiens	15-18
24308435-0	2014	Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.	Etoposide	60-69	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	71-76
25216516-6	2014	Biologically, NEDD4-1 overexpression sensitizes cancer cells to etoposide-induced apoptosis by reducing SAG levels through targeted degradation.	Etoposide	64-73	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	14-21
24637229-6	2014	Convection-enhanced delivery (CED) of etoposide was tested on cell-based PDGF(+)PTEN(-/-)p53(-/-) and retroviral-based PDGF(+)PTEN(-/-) mouse proneural glioma models.	Etoposide	38-47	phosphatase and tensin homolog	Mus musculus	80-84
24637229-6	2014	Convection-enhanced delivery (CED) of etoposide was tested on cell-based PDGF(+)PTEN(-/-)p53(-/-) and retroviral-based PDGF(+)PTEN(-/-) mouse proneural glioma models.	Etoposide	38-47	phosphatase and tensin homolog	Mus musculus	126-130
24637229-8	2014	TOP2B transcript correlated with susceptibility to etoposide in mouse proneural cell lines and in 139 human cancer cell lines from the Cancer Cell Line Encyclopedia.	Etoposide	51-60	topoisomerase (DNA) II beta	Mus musculus	0-5
25471501-3	2014	SALL4 expression in H69AR was blocked by the siRNA, and then the drug-sensitivities of H69AR cell lines to chemotherapeutic drugs such as cisplatin, doxorubicin, and etoposide were evaluated by cell counting kit assay.	Etoposide	166-175	spalt like transcription factor 4	Homo sapiens	0-5
24910417-4	2014	Herein, we report the results of a cisplatin-based therapy: APE (actinomycin D, cisplatin, and etoposide).	Etoposide	95-104	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	60-63
25147782-7	2014	Moreover, combined use of NBDHEX and etoposide synergistically increased cytotoxicity, suggesting a role for GSTM4 as an inhibitor of apoptosis.	Etoposide	37-46	glutathione S-transferase mu 4	Homo sapiens	109-114
24973211-6	2014	Thus, in apoptosis of neuronal and non-neuronal cells induced by various stimuli including staurosporine, etoposide, or 6-hydroxydopamine, the cleavage of anamorsin was found to be blocked in the presence of caspase inhibitor.	Etoposide	106-115	cytokine induced apoptosis inhibitor 1	Mus musculus	155-164
24928685-8	2014	Moreover, RNF121 knockdown enhanced etoposide-induced apoptosis.	Etoposide	36-45	ring finger protein 121	Homo sapiens	10-16
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Etoposide	49-58	checkpoint kinase 1	Homo sapiens	109-113
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Etoposide	49-58	checkpoint kinase 2	Homo sapiens	115-119
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Etoposide	49-58	replication protein A2	Homo sapiens	124-129
24953561-5	2014	In this study, we investigated the effect of DNA-PKcs inhibitor, wortmannin, on the cytotoxic mechanism of etoposide and cisplatin in MO59K and MO59J human glioblastoma cell lines.	Etoposide	107-116	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	45-53
24755241-9	2014	Knockdown of TRAF6 sensitizes the cells to treatment of the conventional anti-cancer drugs 5-fluorouracil and etoposide.	Etoposide	110-119	LOC222344	Homo sapiens	13-18
24953561-9	2014	These data suggest that wortmannin sensitization to etoposide and cisplatin in human glioma cells is mediated by inhibition of not only DNA-PKcs activity but other enzymes from PI3-K family, e.g. ATM and ATR.	Etoposide	52-61	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	136-144
24953561-9	2014	These data suggest that wortmannin sensitization to etoposide and cisplatin in human glioma cells is mediated by inhibition of not only DNA-PKcs activity but other enzymes from PI3-K family, e.g. ATM and ATR.	Etoposide	52-61	ATM serine/threonine kinase	Homo sapiens	196-199
25057207-5	2014	In an etoposide-induced in vitro model of apoptosis in primary cortical neurons, miR-23a and miR-27a were markedly downregulated as early as 1 h after exposure, before the upregulation of proapoptotic Bcl-2 family molecules.	Etoposide	6-15	microRNA 615	Mus musculus	81-84
25057207-5	2014	In an etoposide-induced in vitro model of apoptosis in primary cortical neurons, miR-23a and miR-27a were markedly downregulated as early as 1 h after exposure, before the upregulation of proapoptotic Bcl-2 family molecules.	Etoposide	6-15	microRNA 615	Mus musculus	93-96
25057207-6	2014	Administration of miR-23a and miR-27a mimics attenuated etoposide-induced changes in Noxa, Puma, and Bax, reduced downstream markers of caspase-dependent (cytochrome c release and caspase activation) and caspase-independent (apoptosis-inducing factor release) pathways, and limited neuronal cell death.	Etoposide	56-65	microRNA 615	Mus musculus	18-21
25057207-6	2014	Administration of miR-23a and miR-27a mimics attenuated etoposide-induced changes in Noxa, Puma, and Bax, reduced downstream markers of caspase-dependent (cytochrome c release and caspase activation) and caspase-independent (apoptosis-inducing factor release) pathways, and limited neuronal cell death.	Etoposide	56-65	microRNA 615	Mus musculus	30-33
24743655-5	2014	Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific.	Etoposide	77-86	tumor protein p53	Homo sapiens	114-118
24878528-0	2014	High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6.	Etoposide	40-49	BCL6 transcription repressor	Homo sapiens	96-101
24878528-4	2014	BCL-6 expression was induced by glucose but down-regulated by etoposide.	Etoposide	62-71	BCL6 transcription repressor	Homo sapiens	0-5
24878528-6	2014	The molecular mechanism by which glucose prevented etoposide-induced tumor cell death was shown to involve the BCL-6 mediated caspase pathway.	Etoposide	51-60	BCL6 transcription repressor	Homo sapiens	111-116
24878528-7	2014	Our data suggest that glucose-induced BCL-6 overexpression could abrogate the etoposide chemotherapy effect on tumor cell death.	Etoposide	78-87	BCL6 transcription repressor	Homo sapiens	38-43
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	general transcription factor IIA subunit 1	Homo sapiens	15-20
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	TATA-box binding protein like 1	Homo sapiens	25-28
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	general transcription factor IIA subunit 1	Homo sapiens	119-124
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	TATA-box binding protein like 1	Homo sapiens	125-128
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	general transcription factor IIA subunit 1	Homo sapiens	119-124
24835508-8	2014	Recruitment of TFIIA and TLP to the upstream promoter was augmented in etoposide-treated cells, in which the amount of TFIIA-TLP complex is increased, and TFIIA-reactive TLP was required for the recruitment of both factors.	Etoposide	71-80	TATA-box binding protein like 1	Homo sapiens	125-128
24835508-9	2014	It was confirmed that etoposide-stimulated transcription depends on TLP.	Etoposide	22-31	TATA-box binding protein like 1	Homo sapiens	68-71
24869908-8	2014	PDZK1 overexpression was associated with resistance to paclitaxel/5-fluorouracil/etoposide only at low concentrations.	Etoposide	81-90	PDZ domain containing 1	Homo sapiens	0-5
25161875-10	2014	SG1 not only sensitizes the XIAP-overexpressing leukemia cell line Molt3/XIAP to etoposide treatment but also different neuroblastoma cell lines endogenously expressing high XIAP levels.	Etoposide	81-90	X-linked inhibitor of apoptosis	Homo sapiens	28-32
24743655-5	2014	Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific.	Etoposide	77-86	tumor protein p53	Homo sapiens	185-189
24965603-6	2014	RESULTS: Etoposide induced proliferation-independent DNA damage and activation of multiple DDR proteins in primary AML cells and ATM +/+but not ATM -/- cell lines.	Etoposide	9-18	ATM serine/threonine kinase	Homo sapiens	129-132
24967963-5	2014	Functionally, miR-424 overexpression decreases the sensitivity of cancer cells (HCT116 and A375) to doxorubicin (Dox) and etoposide.	Etoposide	122-131	microRNA 424	Homo sapiens	14-21
24651037-2	2014	In medulloblastoma cells PDE5 inhibitors interacted in a greater than additive fashion with vincristine/etoposide/cisplatin to cause cell death.	Etoposide	104-113	phosphodiesterase 5A	Homo sapiens	25-29
23851503-5	2014	External signal transmitted through IL-17RB activated nuclear factor-kappaB to upregulate antiapoptotic factor Bcl-2 and induced etoposide resistance.	Etoposide	129-138	interleukin 17 receptor B	Homo sapiens	36-43
24905922-7	2014	Furthermore, we demonstrated that the over-expression of CDCA2 in human primary fibroblasts was able to partially counteract etoposide-induced senescence by mitigating the activation of DNA Damage Response.	Etoposide	125-134	cell division cycle associated 2	Homo sapiens	57-62
24858818-8	2014	Notably, SYC-522 treatment significantly increased the sensitivity of MLL-rearranged leukemia cells to chemotherapeutics, such as mitoxantrone, etoposide and cytarabine.	Etoposide	144-153	lysine methyltransferase 2A	Homo sapiens	70-73
24887326-7	2014	Inhibition of ABCB1 using vardenafil or verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines.	Etoposide	103-112	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
24887326-7	2014	Inhibition of ABCB1 using vardenafil or verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines.	Etoposide	103-112	ATP binding cassette subfamily B member 1	Homo sapiens	116-121
24668193-10	2014	Experimental results showed that downregulation of HIP-55 decreased the viability and increased the apoptosis of A549 cells treated with the anticancer agent etoposide.	Etoposide	158-167	drebrin like	Homo sapiens	51-57
24766193-10	2014	These results are consistent with the hypothesis that etoposide quinone contributes to etoposide-related leukemogenesis through an interaction with topoisomerase IIbeta.	Etoposide	54-63	DNA topoisomerase II beta	Homo sapiens	148-168
24695317-0	2014	The SUMO-targeted ubiquitin ligase RNF4 localizes to etoposide-exposed mitotic chromosomes: implication for a novel DNA damage response during mitosis.	Etoposide	53-62	ring finger protein 4	Homo sapiens	35-39
24766193-2	2014	Despite its wide clinical use, 2-3% of patients treated with etoposide eventually develop treatment-related acute myeloid leukemias (t-AMLs) characterized by rearrangements of the MLL gene.	Etoposide	61-70	lysine methyltransferase 2A	Homo sapiens	180-183
25283008-2	2014	The patient underwent 4 cycles of neoadjuvant chemotherapy (cisplatin, bleomycin, and etoposide), which normalized the AFP level and reduced the tumor size, allowing complete resection without a support of extracorporeal circulation.	Etoposide	86-95	alpha fetoprotein	Homo sapiens	119-122
24821838-1	2014	The etoposide-induced protein Ei24 was initially identified as a p53-responsive, proapoptotic factor, but no clear function has been described.	Etoposide	4-13	etoposide induced 2.4 mRNA	Mus musculus	30-34
24821838-1	2014	The etoposide-induced protein Ei24 was initially identified as a p53-responsive, proapoptotic factor, but no clear function has been described.	Etoposide	4-13	transformation related protein 53, pseudogene	Mus musculus	65-68
24821838-5	2014	Induction of endogenous Ei24 expression through etoposide treatment similarly inhibited nuclear import in a mouse embryonic fibroblast model.	Etoposide	48-57	etoposide induced 2.4 mRNA	Mus musculus	24-28
24795145-4	2014	RanBPM was also recruited to aggresomes following treatment with the proteasome inhibitor MG132 and the DNA-damaging agent etoposide.	Etoposide	123-132	RAN binding protein 9	Homo sapiens	0-6
24732433-4	2014	Through this route, WFA acted as an effective DR5 activator capable of potentiating the biologic effects of celecoxib, etoposide, and TRAIL.	Etoposide	119-128	TNF receptor superfamily member 10b	Homo sapiens	46-49
24868599-0	2014	FTY720 enhances chemosensitivity of colon cancer cells to  doxorubicin and etoposide via the modulation of  P-glycoprotein and multidrug resistance protein 1.	Etoposide	75-84	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
24868599-0	2014	FTY720 enhances chemosensitivity of colon cancer cells to  doxorubicin and etoposide via the modulation of  P-glycoprotein and multidrug resistance protein 1.	Etoposide	75-84	ATP binding cassette subfamily B member 1	Homo sapiens	127-157
24569089-8	2014	In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (&gt;80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents.	Etoposide	132-141	AKT serine/threonine kinase 1	Homo sapiens	86-89
24695317-3	2014	Here we showed that administration of etoposide, an anticancer DNA topoisomerase II poison, to mitotic human cervical cancer HeLa cells induced SUMO-2/3-dependent localization of RNF4 to chromosomes.	Etoposide	38-47	small ubiquitin like modifier 2	Homo sapiens	144-150
24695317-3	2014	Here we showed that administration of etoposide, an anticancer DNA topoisomerase II poison, to mitotic human cervical cancer HeLa cells induced SUMO-2/3-dependent localization of RNF4 to chromosomes.	Etoposide	38-47	ring finger protein 4	Homo sapiens	179-183
24695317-5	2014	This suggests that RNF4 functions as a STUbL in the etoposide-induced damage response during mitosis.	Etoposide	52-61	ring finger protein 4	Homo sapiens	19-23
24695317-6	2014	Indeed, RNF4-depletion sensitized mitotic HeLa cells to etoposide and increased cells with micronuclei.	Etoposide	56-65	ring finger protein 4	Homo sapiens	8-12
24553146-4	2014	Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to &gt;20 muM), a clinically available anticancer drug.	Etoposide	116-125	latexin	Homo sapiens	54-57
24529846-10	2014	MRP1, which encodes an etoposide efflux pump, is significantly upregulated in etoposide-resistant sublines.	Etoposide	23-32	ATP binding cassette subfamily C member 1	Homo sapiens	0-4
24529846-11	2014	Two DNA damage response proteins TOPBP1 and EDD were found to be downregulated in etoposide-resistant sublines.	Etoposide	82-91	DNA topoisomerase II binding protein 1	Homo sapiens	33-39
24529846-11	2014	Two DNA damage response proteins TOPBP1 and EDD were found to be downregulated in etoposide-resistant sublines.	Etoposide	82-91	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	44-47
24569990-5	2014	Depletion of c-Abl or c-Src with shRNA decreased irradiation- and etoposide-induced apoptosis, suggesting that inhibitors of these kinases may be useful therapeutically.	Etoposide	66-75	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	13-18
24569990-5	2014	Depletion of c-Abl or c-Src with shRNA decreased irradiation- and etoposide-induced apoptosis, suggesting that inhibitors of these kinases may be useful therapeutically.	Etoposide	66-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-27
24618884-7	2014	Evidence for the physical association of HMGB1 comes from Western blot analysis of microparticles derived from RAW 264.7 macrophage cells stimulated by lipopolysaccharide (LPS) or induced to undergo apoptosis by treatment with etoposide or staurosporine in vitro.	Etoposide	227-236	high mobility group box 1	Mus musculus	41-46
24554706-4	2014	ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments.	Etoposide	109-118	activating transcription factor 3	Homo sapiens	0-4
24672010-5	2014	Knockdown of endogenous MEF2D with a short-hairpin RNA (shRNA) increases sensitivity to etoposide-induced DNA damage and neuronal cell death.	Etoposide	88-97	myocyte enhancer factor 2D	Mus musculus	24-29
24553146-4	2014	Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to &gt;20 muM), a clinically available anticancer drug.	Etoposide	116-125	latexin	Homo sapiens	84-87
24553146-4	2014	Among the new analogs, compounds 12e (IC50: 0.60-0.75 muM) and 12h (IC50: 1.12-2.03 muM) showed superior potency to etoposide (IC50: 2.03 to &gt;20 muM), a clinically available anticancer drug.	Etoposide	116-125	latexin	Homo sapiens	84-87
24559410-7	2014	The BCL2 levels reduced by the hairpin-binding compound led to chemosensitization to etoposide in both in vitro and in vivo models.	Etoposide	85-94	BCL2 apoptosis regulator	Homo sapiens	4-8
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Etoposide	209-218	tumor protein, translationally-controlled 1	Homo sapiens	12-52
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Etoposide	209-218	tumor protein, translationally-controlled 1	Homo sapiens	54-58
24606760-1	2014	BACKGROUND: Translationally controlled tumor protein (TCTP), alternatively called fortilin, is believed to be involved in the development of the chemoresistance of tumor cells against anticancer drugs such as etoposide, taxol, and oxaliplatin, the underlying mechanisms of which still remain elusive.	Etoposide	209-218	tumor protein, translationally-controlled 1	Homo sapiens	82-90
24606760-2	2014	METHODS: Cell death analysis of TCTP-overexpressing HeLa cells was performed following etoposide treatment to assess the mitochondria-dependent apoptosis.	Etoposide	87-96	tumor protein, translationally-controlled 1	Homo sapiens	32-36
24606760-6	2014	RESULTS: In the present study, we confirmed that adenoviral overexpression of TCTP protects HeLa cells from cell death induced by cytotoxic drugs such as taxol and etoposide.	Etoposide	164-173	tumor protein, translationally-controlled 1	Homo sapiens	78-82
24606760-7	2014	TCTP antagonized the mitochondria-dependent apoptotic pathway following etoposide treatment, including mitochondrial membrane damage and resultant cytochrome c release, activation of caspase-9, and -3, and eventually, the cleavage of EGFR and PLC-gamma.	Etoposide	72-81	tumor protein, translationally-controlled 1	Homo sapiens	0-4
24606760-7	2014	TCTP antagonized the mitochondria-dependent apoptotic pathway following etoposide treatment, including mitochondrial membrane damage and resultant cytochrome c release, activation of caspase-9, and -3, and eventually, the cleavage of EGFR and PLC-gamma.	Etoposide	72-81	cytochrome c, somatic	Homo sapiens	147-159
24606760-7	2014	TCTP antagonized the mitochondria-dependent apoptotic pathway following etoposide treatment, including mitochondrial membrane damage and resultant cytochrome c release, activation of caspase-9, and -3, and eventually, the cleavage of EGFR and PLC-gamma.	Etoposide	72-81	epidermal growth factor receptor	Homo sapiens	234-238
24606760-9	2014	CONCLUSIONS: TCTP protects the cancer cells from etoposide-induced cell death by inhibiting the mitochondria-mediated apoptotic pathway.	Etoposide	49-58	tumor protein, translationally-controlled 1	Homo sapiens	13-17
24461734-5	2014	Analyses of XLF-null cells (which were viable) showed that they were highly sensitive to ionizing radiation and a radiomimetic DNA damaging agent, etoposide.	Etoposide	147-156	non-homologous end joining factor 1	Homo sapiens	12-15
24486906-6	2014	Bimodal p53 dynamics was largely influenced by cellular MDM2 and elevated p53/MDM2 ratios with increasing etoposide favor mono-ubiquitination.	Etoposide	106-115	tumor protein p53	Homo sapiens	8-11
24486906-6	2014	Bimodal p53 dynamics was largely influenced by cellular MDM2 and elevated p53/MDM2 ratios with increasing etoposide favor mono-ubiquitination.	Etoposide	106-115	tumor protein p53	Homo sapiens	74-77
24486906-6	2014	Bimodal p53 dynamics was largely influenced by cellular MDM2 and elevated p53/MDM2 ratios with increasing etoposide favor mono-ubiquitination.	Etoposide	106-115	MDM2 proto-oncogene	Homo sapiens	78-82
24492005-3	2014	We demonstrate that G9a upregulates p21 via interaction with PCAF, and provide evidence that the activating complex is recruited to the p21 promoter upon DNA damage-inducing agent etoposide treatment.	Etoposide	180-189	euchromatic histone lysine methyltransferase 2	Homo sapiens	20-23
24492005-3	2014	We demonstrate that G9a upregulates p21 via interaction with PCAF, and provide evidence that the activating complex is recruited to the p21 promoter upon DNA damage-inducing agent etoposide treatment.	Etoposide	180-189	H3 histone pseudogene 16	Homo sapiens	136-139
23939952-3	2014	In the present study, we show that knockdown of LMP1 renders the EBV-positive NPC cell line CG-1 resistant to various genotoxic drugs (cisplatin, etoposide, and adriamycin).	Etoposide	146-155	PDZ and LIM domain 7	Homo sapiens	48-52
24338822-6	2014	Induction of transient G0/G1 cycle arrest through CDK4/6 inhibition protected hRPTC from DNA damage and caspase 3/7 activation following exposure to the nephrotoxins cisplatin, etoposide, and antimycin A.	Etoposide	177-186	cyclin dependent kinase 4	Homo sapiens	50-56
24413181-7	2014	Furthermore, triapine abrogates etoposide-induced CtIP phosphorylation and DSB resection as evidenced by marked attenuation of RPA32 phosphorylation.	Etoposide	32-41	RB binding protein 8, endonuclease	Homo sapiens	50-54
24413181-7	2014	Furthermore, triapine abrogates etoposide-induced CtIP phosphorylation and DSB resection as evidenced by marked attenuation of RPA32 phosphorylation.	Etoposide	32-41	replication protein A2	Homo sapiens	127-132
24413181-8	2014	Concurrently, triapine obliterates etoposide-induced BRCA1 foci and sensitizes BRCA1 wild-type EOC cells to etoposide.	Etoposide	35-44	BRCA1 DNA repair associated	Homo sapiens	53-58
24649349-0	2014	Treatment of etoposide combined with 15-deoxy-Delta12,14-prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator-activated receptor-gamma-independent pathways.	Etoposide	13-22	peroxisome proliferator activated receptor gamma	Homo sapiens	145-193
24649349-5	2014	Our results demonstrated that the topoisomerase-II inhibitor etoposide (VP-16) exhibited cytotoxic effects synergistically with 15d-PGJ2.	Etoposide	61-70	host cell factor C1	Homo sapiens	72-77
24587252-5	2014	Ambra1 expression was detected by Western blot in SW620 cells treated with staurosporine or etoposide.	Etoposide	92-101	autophagy and beclin 1 regulator 1	Homo sapiens	0-6
24587252-10	2014	Ambra1 expression decreased during staurosporine- or etoposide-induced apoptosis.	Etoposide	53-62	autophagy and beclin 1 regulator 1	Homo sapiens	0-6
24587252-12	2014	When Ambra1 expression was reduced by siRNA, SW620 cells were more sensitive to staurosporine- or etoposide-induced apoptosis.	Etoposide	98-107	autophagy and beclin 1 regulator 1	Homo sapiens	5-11
24507776-4	2014	We show here that knockdown of ERCC6L2 in human A549 cells significantly reduced their viability upon exposure to the DNA-damaging agents mitomycin C and Irofulven, but not etoposide and camptothecin, suggesting a role in nucleotide excision repair.	Etoposide	173-182	ERCC excision repair 6 like 2	Homo sapiens	31-38
24551118-12	2014	Consistently, inhibition of autophagy by knockdown of beclin1 or Atg5 sensitized NE differentiated LNCaP cells to etoposide, a chemotherapy drug.	Etoposide	114-123	beclin 1	Homo sapiens	54-61
24551118-12	2014	Consistently, inhibition of autophagy by knockdown of beclin1 or Atg5 sensitized NE differentiated LNCaP cells to etoposide, a chemotherapy drug.	Etoposide	114-123	autophagy related 5	Homo sapiens	65-69
23748345-6	2014	FLT3, PIM or CHK1 inhibitors synergized with DNA-damaging agents to induce apoptosis, allowing cells to bypass the etoposide-induced G2/M arrest.	Etoposide	115-124	fms related receptor tyrosine kinase 3	Homo sapiens	0-4
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Etoposide	73-82	nuclear factor kappa B subunit 1	Homo sapiens	184-193
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	61-70	phosphoglycolate phosphatase	Mus musculus	140-154
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	61-70	phosphoglycolate phosphatase	Mus musculus	156-160
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	61-70	ras homolog family member A	Mus musculus	200-204
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	61-70	phosphoglycolate phosphatase	Mus musculus	304-308
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	72-75	phosphoglycolate phosphatase	Mus musculus	140-154
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	72-75	phosphoglycolate phosphatase	Mus musculus	156-160
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	72-75	ras homolog family member A	Mus musculus	200-204
24311454-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) activates the ezrin/radixin/moesin (ERM) scaffold proteins for P-glycoprotein (P-gp) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling, leading to increased ileal P-gp expression.	Etoposide	72-75	phosphoglycolate phosphatase	Mus musculus	304-308
24311454-3	2014	Here, we examined whether PtdIns(4,5)P2 and PI4P5K are involved in the increased expression of ileal P-gp following the ERM activation by ETP treatment.	Etoposide	138-141	phosphoglycolate phosphatase	Mus musculus	101-105
24311454-7	2014	ETP treatment significantly increased PI4P5K, ERM, and P-gp expression in the ileal membrane.	Etoposide	0-3	phosphoglycolate phosphatase	Mus musculus	55-59
24311454-8	2014	This effect was suppressed following the coadministration of ETP with rosuvastatin (a RhoA inhibitor) or fasudil (a ROCK inhibitor).	Etoposide	61-64	ras homolog family member A	Mus musculus	86-90
24311454-10	2014	PtdIns(4,5)P2 and PI4P5K may contribute to the increase in ileal P-gp expression observed following the ETP treatment, possibly through ERM activation via the RhoA/ROCK pathway.	Etoposide	104-107	phosphoglycolate phosphatase	Mus musculus	65-69
24311454-10	2014	PtdIns(4,5)P2 and PI4P5K may contribute to the increase in ileal P-gp expression observed following the ETP treatment, possibly through ERM activation via the RhoA/ROCK pathway.	Etoposide	104-107	ras homolog family member A	Mus musculus	159-163
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	BRCA1 DNA repair associated	Homo sapiens	112-117
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	nuclear factor kappa B subunit 1	Homo sapiens	152-173
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	nuclear factor kappa B subunit 1	Homo sapiens	175-184
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	BRCA1 DNA repair associated	Homo sapiens	196-201
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	nuclear factor kappa B subunit 1	Homo sapiens	206-215
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	nuclear factor kappa B subunit 1	Homo sapiens	206-215
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	BCL2 apoptosis regulator	Homo sapiens	292-296
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Etoposide	85-94	X-linked inhibitor of apoptosis	Homo sapiens	301-305
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Etoposide	73-82	nuclear factor kappa B subunit 1	Homo sapiens	28-37
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Etoposide	73-82	BRCA1 DNA repair associated	Homo sapiens	52-57
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Etoposide	73-82	BRCA1 DNA repair associated	Homo sapiens	157-162
24184161-10	2014	The depletion of COX-2 or ET-1 also suppressed VEGF-C-induced increases in the bcl-2/bax ratio and chemoresistance against etoposide and cytosine arabinoside in AML cells.	Etoposide	123-132	prostaglandin-endoperoxide synthase 2	Homo sapiens	17-22
24184161-10	2014	The depletion of COX-2 or ET-1 also suppressed VEGF-C-induced increases in the bcl-2/bax ratio and chemoresistance against etoposide and cytosine arabinoside in AML cells.	Etoposide	123-132	endothelin 1	Homo sapiens	26-30
24184161-10	2014	The depletion of COX-2 or ET-1 also suppressed VEGF-C-induced increases in the bcl-2/bax ratio and chemoresistance against etoposide and cytosine arabinoside in AML cells.	Etoposide	123-132	vascular endothelial growth factor C	Homo sapiens	47-53
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	DNA topoisomerase II beta	Homo sapiens	47-56
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	DNA topoisomerase II beta	Homo sapiens	58-63
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	RUNX family transcription factor 1	Homo sapiens	94-99
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	DNA topoisomerase II alpha	Homo sapiens	164-174
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	DNA topoisomerase II beta	Homo sapiens	187-192
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	RUNX family transcription factor 1	Homo sapiens	222-227
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	232-239
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	DNA topoisomerase II beta	Homo sapiens	187-192
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	138-147	RUNX family transcription factor 1	Homo sapiens	222-227
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	308-317	DNA topoisomerase II beta	Homo sapiens	47-56
24327541-4	2014	Using a leukemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on RUNX1 where translocations occur.	Etoposide	308-317	DNA topoisomerase II beta	Homo sapiens	58-63
24327541-6	2014	Specifically, we identified a TOP2B-dependent increase in the number of nuclei displaying juxtaposed RUNX1 and RUNX1T1 loci following etoposide treatment.	Etoposide	134-143	DNA topoisomerase II beta	Homo sapiens	30-35
24327541-6	2014	Specifically, we identified a TOP2B-dependent increase in the number of nuclei displaying juxtaposed RUNX1 and RUNX1T1 loci following etoposide treatment.	Etoposide	134-143	RUNX family transcription factor 1	Homo sapiens	101-106
24327541-6	2014	Specifically, we identified a TOP2B-dependent increase in the number of nuclei displaying juxtaposed RUNX1 and RUNX1T1 loci following etoposide treatment.	Etoposide	134-143	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	111-118
24444537-2	2014	The purpose of our study was to investigate the safety and efficacy in terms of prostate-specific antigen (PSA) response of a low-dose oral combination of etoposide and prednisone in patients with CRPC.	Etoposide	155-164	kallikrein related peptidase 3	Homo sapiens	80-111
24019108-1	2014	Oxidative stress or excessive antioxidant levels-caused redox imbalance can alter apoptotic responses, and N-acetyl-L-cysteine (NAC) was able to inhibit H2 O2 -mediated cell death, but unable to prevent apoptosis induced by other chemicals such as etoposide.	Etoposide	248-257	X-linked Kx blood group	Homo sapiens	128-131
23748345-6	2014	FLT3, PIM or CHK1 inhibitors synergized with DNA-damaging agents to induce apoptosis, allowing cells to bypass the etoposide-induced G2/M arrest.	Etoposide	115-124	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	6-9
23748345-7	2014	Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition.	Etoposide	14-23	checkpoint kinase 1	Homo sapiens	32-36
23748345-7	2014	Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition.	Etoposide	14-23	cell division cycle 25C	Homo sapiens	67-73
23748345-7	2014	Consistently, etoposide-induced CHK1-dependent phosphorylations of CDC25C on Ser 216 and histone H3 on Thr11 were decreased upon FLT3 inhibition.	Etoposide	14-23	fms related receptor tyrosine kinase 3	Homo sapiens	129-133
23178489-6	2014	In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib.	Etoposide	200-209	insulin like growth factor binding protein 3	Homo sapiens	96-103
24272769-4	2014	We treated four consecutive patients affected by progressive OPG with lower cumulative doses of cisplatin/etoposide.	Etoposide	106-115	basic transcription factor 3 pseudogene 11	Homo sapiens	61-64
24272769-11	2014	Our results confirm the effectiveness and the low-toxicity profile of the cisplatin/etoposide regimen for treatment of children affected by OPG.	Etoposide	84-93	basic transcription factor 3 pseudogene 11	Homo sapiens	140-143
23318437-10	2014	The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response.	Etoposide	78-87	tumor protein p53	Homo sapiens	18-21
23318437-10	2014	The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response.	Etoposide	78-87	MDM2 proto-oncogene	Homo sapiens	26-30
23318437-10	2014	The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response.	Etoposide	78-87	ring finger protein 2	Homo sapiens	44-48
24367089-8	2014	We explored the relationship between two distinct functions of APIP/MtnB, cell death inhibition, and methionine salvage, by measuring the ability of enzymatic mutants to inhibit cell death, and determined that APIP/MtnB functions as a cell death inhibitor independently of its MtnB enzyme activity for apoptosis induced by either hypoxia or etoposide, but dependently for caspase-1-induced pyroptosis.	Etoposide	341-350	APAF1 interacting protein	Homo sapiens	63-67
24367089-8	2014	We explored the relationship between two distinct functions of APIP/MtnB, cell death inhibition, and methionine salvage, by measuring the ability of enzymatic mutants to inhibit cell death, and determined that APIP/MtnB functions as a cell death inhibitor independently of its MtnB enzyme activity for apoptosis induced by either hypoxia or etoposide, but dependently for caspase-1-induced pyroptosis.	Etoposide	341-350	APAF1 interacting protein	Homo sapiens	210-214
24321095-8	2014	Promoter assays showed that Top2a siRNA, etoposide and shikonin reduce Bmal1 promoter activity.	Etoposide	41-50	aryl hydrocarbon receptor nuclear translocator like	Homo sapiens	71-76
23178489-6	2014	In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib.	Etoposide	200-209	epidermal growth factor receptor	Homo sapiens	136-140
24336569-5	2014	A screen for resistance to the nucleotide analog 6-thioguanine identified all expected members of the DNA mismatch repair pathway, whereas another for the DNA topoisomerase II (TOP2A) poison etoposide identified TOP2A, as expected, and also cyclin-dependent kinase 6, CDK6.	Etoposide	191-200	DNA topoisomerase II alpha	Homo sapiens	177-182
23178489-6	2014	In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib.	Etoposide	200-209	insulin like growth factor binding protein 3	Homo sapiens	145-152
24429382-7	2014	While the wild type WRN relocalized to the nucleoli after 24 hours recovery from etoposide-induced DSBs, the mutant WRN remained mostly in the nucleoplasm.	Etoposide	81-90	WRN RecQ like helicase	Homo sapiens	20-23
24296429-0	2014	Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.	Etoposide	42-51	ferrochelatase	Homo sapiens	12-15
25493440-0	2014	The antioxidant quercetin protects HL-60 cells with high myeloperoxidase activity against pro-oxidative and apoptotic effects of etoposide.	Etoposide	129-138	myeloperoxidase	Homo sapiens	57-72
25493440-1	2014	The protective action of quercetin against the pro-oxidant and apoptotic effect of etoposide was investigated in HL-60 cells with a high level of myeloperoxidase (MPO) activity and in cells treated with MPO inhibitor, 4-aminobenzoic acid hydrazide (ABAH).	Etoposide	83-92	myeloperoxidase	Homo sapiens	146-161
25493440-1	2014	The protective action of quercetin against the pro-oxidant and apoptotic effect of etoposide was investigated in HL-60 cells with a high level of myeloperoxidase (MPO) activity and in cells treated with MPO inhibitor, 4-aminobenzoic acid hydrazide (ABAH).	Etoposide	83-92	myeloperoxidase	Homo sapiens	203-206
25493440-2	2014	Quercetin significantly protected MPO-rich cells against the pro-oxidative (p&lt;0.05) and apoptotic (p&lt;0.05) effects of etoposide.	Etoposide	124-133	myeloperoxidase	Homo sapiens	34-37
24989004-0	2014	Changes in PtdIns(4,5)P2 induced by etoposide treatment modulates small intestinal P-glycoprotein via radixin.	Etoposide	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	83-97
24989004-10	2014	In conclusion, ETP treatment appears to up-regulate PtdIns(4,5)P2 expression via RhoA/ROCK signaling, leading to the activation of ERM, presumably through the physical interaction of radixin with PtdIns(4,5)P2.	Etoposide	15-18	ras homolog family member A	Homo sapiens	81-85
24568469-0	2014	Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide.	Etoposide	108-117	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	19-24
24568469-12	2014	Furthermore, Mcl-1 down-regulation significantly increased apoptosis sensitivity to etoposide.	Etoposide	84-93	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-18
24141009-0	2014	High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.	Etoposide	10-19	DNA damage inducible transcript 3	Homo sapiens	208-212
24989004-10	2014	In conclusion, ETP treatment appears to up-regulate PtdIns(4,5)P2 expression via RhoA/ROCK signaling, leading to the activation of ERM, presumably through the physical interaction of radixin with PtdIns(4,5)P2.	Etoposide	15-18	radixin	Homo sapiens	183-190
25087953-0	2014	Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing human leukemic K-562 cells.	Etoposide	35-44	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
24989004-0	2014	Changes in PtdIns(4,5)P2 induced by etoposide treatment modulates small intestinal P-glycoprotein via radixin.	Etoposide	36-45	radixin	Homo sapiens	102-109
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	61-70	radixin	Homo sapiens	160-167
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	61-70	moesin	Homo sapiens	168-174
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	61-70	ras homolog family member A	Homo sapiens	219-223
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	72-75	radixin	Homo sapiens	160-167
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	72-75	moesin	Homo sapiens	168-174
24989004-1	2014	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) via Ras homolog gene family member A (RhoA)/Rho-associated coiled-coil containing protein kinase (ROCK) signaling in the small intestine.	Etoposide	72-75	ras homolog family member A	Homo sapiens	219-223
24351551-1	2014	Etoposide and morphine are well known P-glycoprotein (P-gp) substrates.	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	38-52
24351551-1	2014	Etoposide and morphine are well known P-glycoprotein (P-gp) substrates.	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-58
24989004-5	2014	Here, we examined the involvement of PtdIns(4,5)P2 in the mechanism by which ETP treatment increases small intestinal P-gp levels, and we determined which protein within ERM contributes to this phenomenon.	Etoposide	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
24626184-6	2014	In the absence of functional p53, p68 stimulates the expression of PLK1 both at basal levels and in response to the clinically relevant drug, etoposide.	Etoposide	142-151	DEAD-box helicase 5	Homo sapiens	34-37
24351551-9	2014	That is, morphine and quinidine significantly increased the bioavailability of etoposide believed to be due to competitive P-gp inhibition in the intestine.	Etoposide	79-88	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	123-127
24434574-4	2014	We thereby investigated a possible combination of Ad-mda-7 and anticancer agents and found that Ad-mda-7 with 5-fluorouracil (5-FU), cisplatin, mitomycin C or etoposide produced greater cytotoxic effects than those by Ad-mda-7 or the agent alone.	Etoposide	159-168	interleukin 24	Homo sapiens	99-104
24434574-4	2014	We thereby investigated a possible combination of Ad-mda-7 and anticancer agents and found that Ad-mda-7 with 5-fluorouracil (5-FU), cisplatin, mitomycin C or etoposide produced greater cytotoxic effects than those by Ad-mda-7 or the agent alone.	Etoposide	159-168	interleukin 24	Homo sapiens	99-104
24626184-6	2014	In the absence of functional p53, p68 stimulates the expression of PLK1 both at basal levels and in response to the clinically relevant drug, etoposide.	Etoposide	142-151	polo like kinase 1	Homo sapiens	67-71
24626184-8	2014	However, its recruitment is stimulated by etoposide in cells lacking p53, suggesting that p53 can oppose association of p68 with the PLK1 promoter.	Etoposide	42-51	tumor protein p53	Homo sapiens	90-93
24626184-8	2014	However, its recruitment is stimulated by etoposide in cells lacking p53, suggesting that p53 can oppose association of p68 with the PLK1 promoter.	Etoposide	42-51	DEAD-box helicase 5	Homo sapiens	120-123
24626184-8	2014	However, its recruitment is stimulated by etoposide in cells lacking p53, suggesting that p53 can oppose association of p68 with the PLK1 promoter.	Etoposide	42-51	polo like kinase 1	Homo sapiens	133-137
24188742-6	2014	PAX3 knock-down significantly augmented the cytotoxic effect of chemotherapeutic agents, etoposide, vincristine and cisplatin, commonly used to treat neuroblastoma.	Etoposide	89-98	paired box 3	Homo sapiens	0-4
24400988-4	2014	HD etoposide and G-CSF chemomobilization resulted in successful collection (&gt;2 x 10(6) CD34+ cells/kg) in 82.3% of patients within a median 2 (1-6) apheresis days.	Etoposide	3-12	CD34 molecule	Homo sapiens	90-94
24025432-6	2014	We found that the Ku70 (XRCC6)-binding-site mutations (A453H/V454H) of Ku80 and nuclear localization signal (NLS)-dysfunctional mutations (K565A/K566A/K568A) affected the ability to complement etoposide sensitivity.	Etoposide	193-202	X-ray repair cross complementing 6	Homo sapiens	18-22
24025432-6	2014	We found that the Ku70 (XRCC6)-binding-site mutations (A453H/V454H) of Ku80 and nuclear localization signal (NLS)-dysfunctional mutations (K565A/K566A/K568A) affected the ability to complement etoposide sensitivity.	Etoposide	193-202	X-ray repair cross complementing 6	Homo sapiens	24-29
24056736-3	2014	We exploited this system to examine select post-translational modifications (PTMs) present on a transcriptionally inert population of endogenous human p53, as well as on p53 activated in response to etoposide treatment of normal human fibroblasts.	Etoposide	199-208	tumor protein p53	Homo sapiens	170-173
24056736-7	2014	Despite the differences in activity, including greater in vitro sequence-specific DNA binding activity exhibited by p53 isolated from etoposide-treated cells, few differences were observed in the location, nature, or relative frequencies of PTMs on the two populations of human p53.	Etoposide	134-143	tumor protein p53	Homo sapiens	116-119
24732641-0	2014	MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.	Etoposide	64-73	MDM2 proto-oncogene	Homo sapiens	0-4
24220725-0	2014	Extract of Bryophyllum laetivirens reverses etoposide resistance in human lung A549 cancer cells by downregulation of NF-kappaB.	Etoposide	44-53	nuclear factor kappa B subunit 1	Homo sapiens	118-127
24220725-3	2014	We first found that lung cancer A549 cells resistant to etoposide (A549RT-eto) exhibit upregulation of NF-kappaB and SIRT1 in comparison to A549 parental cells.	Etoposide	56-65	nuclear factor kappa B subunit 1	Homo sapiens	103-112
24732641-0	2014	MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.	Etoposide	64-73	tumor protein p53	Homo sapiens	19-23
24220725-3	2014	We first found that lung cancer A549 cells resistant to etoposide (A549RT-eto) exhibit upregulation of NF-kappaB and SIRT1 in comparison to A549 parental cells.	Etoposide	56-65	sirtuin 1	Homo sapiens	117-122
24220725-10	2014	Taken together, we suggest that upregulation of NF-kappaB determines etoposide resistance through P-gp expression in human A549 lung cancer cells.	Etoposide	69-78	nuclear factor kappa B subunit 1	Homo sapiens	48-57
24492044-4	2014	After two courses of the SMILE (dexamethasone, methotrexate (MTX), ifosfamide, L-asparaginase, etoposide) regimen, the response was stable disease.	Etoposide	95-104	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	25-30
24220725-10	2014	Taken together, we suggest that upregulation of NF-kappaB determines etoposide resistance through P-gp expression in human A549 lung cancer cells.	Etoposide	69-78	ATP binding cassette subfamily B member 1	Homo sapiens	98-102
24220725-11	2014	We herein demonstrated that B. laetivirens extract reverses etoposide resistance in human A549 lung cancer cells through downregulation of NF-kappaB.	Etoposide	60-69	nuclear factor kappa B subunit 1	Homo sapiens	139-148
24468315-3	2014	However, in recent years, novel therapeutic approaches such as simultaneous chemoradiotherapy or l-asparaginase-based regimens including SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) improved the response to therapy and survival of ENKL patients.	Etoposide	199-208	asparaginase and isoaspartyl peptidase 1	Homo sapiens	97-111
24324754-0	2013	Etoposide induces nuclear re-localisation of AID.	Etoposide	0-9	activation induced cytidine deaminase	Homo sapiens	45-48
24882643-0	2014	[Effect of repeated oral treatment with etoposide on the expression of intestinal P-glycoprotein and oral morphine analgesia].	Etoposide	40-49	ATP binding cassette subfamily B member 1	Homo sapiens	82-96
24882643-5	2014	Previously, we have found that repeated oral treatment with etoposide (ETP), an anticancer drug, attenuates analgesia of oral morphine, a substrate drug for P-gp, by increasing the expression and activity of intestinal P-gp.	Etoposide	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
24882643-5	2014	Previously, we have found that repeated oral treatment with etoposide (ETP), an anticancer drug, attenuates analgesia of oral morphine, a substrate drug for P-gp, by increasing the expression and activity of intestinal P-gp.	Etoposide	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	219-223
24882643-5	2014	Previously, we have found that repeated oral treatment with etoposide (ETP), an anticancer drug, attenuates analgesia of oral morphine, a substrate drug for P-gp, by increasing the expression and activity of intestinal P-gp.	Etoposide	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
24882643-5	2014	Previously, we have found that repeated oral treatment with etoposide (ETP), an anticancer drug, attenuates analgesia of oral morphine, a substrate drug for P-gp, by increasing the expression and activity of intestinal P-gp.	Etoposide	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	219-223
24882643-10	2014	This review article introduces the result of our previous research as well as recent findings on the involvement of ERM via activation of RhoA/ROCK in the increased expression of intestinal P-gp and decreased oral morphine analgesia induced by repeated oral treatment with ETP.	Etoposide	273-276	ras homolog family member A	Homo sapiens	138-142
24882643-10	2014	This review article introduces the result of our previous research as well as recent findings on the involvement of ERM via activation of RhoA/ROCK in the increased expression of intestinal P-gp and decreased oral morphine analgesia induced by repeated oral treatment with ETP.	Etoposide	273-276	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
24262885-5	2013	Compound 3a showed comparable topoisomerase II inhibitory activity to etoposide (VP-16) at 100 muM concentration.	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
24136166-5	2013	The ectopic expression of DDR1 significantly increased the survival of collagen-treated DG75 Burkitt lymphoma cells, following etoposide treatment.	Etoposide	127-136	discoidin domain receptor tyrosine kinase 1	Homo sapiens	26-30
24324754-5	2013	Here we show that AID is completely re-localised to the nucleus during drug withdrawal following etoposide treatment, in the period in which double strand breaks (DSBs) are repaired.	Etoposide	97-106	activation induced cytidine deaminase	Homo sapiens	18-21
24324079-8	2013	The gene manipulation study revealed that the increase of activated AKT and BCL2 was responsible for the resistance to all tested drugs, while the up-regulation of CAV1 only attenuated cell death mediated by doxorubicin and etoposide.	Etoposide	224-233	caveolin 1	Homo sapiens	164-168
24189100-3	2013	Here, we show that loss of TSC2 or PTEN enhanced etoposide-induced DNA damage and apoptosis, which was blunted by suppression of MTOR with either rapamycin or RNA interference.	Etoposide	49-58	phosphatase and tensin homolog	Mus musculus	35-39
24189100-3	2013	Here, we show that loss of TSC2 or PTEN enhanced etoposide-induced DNA damage and apoptosis, which was blunted by suppression of MTOR with either rapamycin or RNA interference.	Etoposide	49-58	mechanistic target of rapamycin kinase	Mus musculus	129-133
24189100-6	2013	Furthermore, loss of TSC2 or PTEN impaired either etoposide or nutrient starvation-induced autophagy, which in turn, leads to CREB1 hyperactivation.	Etoposide	50-59	phosphatase and tensin homolog	Homo sapiens	29-33
24189100-6	2013	Furthermore, loss of TSC2 or PTEN impaired either etoposide or nutrient starvation-induced autophagy, which in turn, leads to CREB1 hyperactivation.	Etoposide	50-59	cAMP responsive element binding protein 1	Homo sapiens	126-131
24189100-8	2013	CREB1 induced DNA damage and subsequent apoptosis in response to etoposide in autophagy-defective cells.	Etoposide	65-74	cAMP responsive element binding protein 1	Homo sapiens	0-5
23838380-8	2013	Teniposide (2.7A) and etoposide (2.7A), despite small chemical differences, are bound in two distinctly different sites at or near IB.	Etoposide	22-31	trafficking protein particle complex subunit 9	Homo sapiens	131-133
23838380-10	2013	Etoposide is bound between the exterior of IB and IIA and exhibits an extensive hydrogen bonding network.	Etoposide	0-9	trafficking protein particle complex subunit 9	Homo sapiens	43-45
24324754-8	2013	Analysis of DSB dynamics shows that AID is re-localised in response to etoposide treatment, however re-localisation occurs substantially after DSB formation and the levels of re-localisation do not correlate with gammaH2AX levels.	Etoposide	71-80	activation induced cytidine deaminase	Homo sapiens	36-39
24289229-9	2013	DSS1 knockdown, however, increased the susceptibility to the DNA-damaging drugs camptothecin and etoposide and caused early apoptosis in p53 wild type MCF7 and p53-insufficient MDA-MB-231 cells.	Etoposide	97-106	SEM1 26S proteasome subunit	Homo sapiens	0-4
24049059-3	2013	Our previous studies indicated that ( NO/ NO-derived species react with etoposide (VP-16) in vitro and form products that show significantly reduced activity toward HL60 cells and lipopolysaccharide (LPS)-induced macrophages.	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
24260231-4	2013	In cells expressing BCR/ABL, FLT3-ITD, or Jak2-V617F, etoposide induced a sustained activation of Chk1, thus leading to the G2/M arrest of cells.	Etoposide	54-63	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	20-27
24092808-9	2013	These results indicate that prolonged exposure to TKIs targeting EGFR and HER2 induce resistance to doxorubicin, etoposide, and m-AMSA through downregulation of Topo IIalpha.	Etoposide	113-122	epidermal growth factor receptor	Homo sapiens	65-69
24092808-9	2013	These results indicate that prolonged exposure to TKIs targeting EGFR and HER2 induce resistance to doxorubicin, etoposide, and m-AMSA through downregulation of Topo IIalpha.	Etoposide	113-122	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-78
23997120-3	2013	Here we show that phosphorylated (pT371)TRF1 is recruited to sites of DNA damage, forming damage-induced foci in response to ionizing radiation (IR), etoposide and camptothecin.	Etoposide	150-159	telomeric repeat binding factor 1	Homo sapiens	40-44
24038465-3	2013	To understand the structural basis of this drug action, we previously determined the structure of human Top2 beta-isoform forming a cleavage complex with the drug etoposide and DNA, and described the insertion of drug into DNA cleavage site and drug-induced decoupling of catalytic groups.	Etoposide	163-172	DNA topoisomerase II beta	Homo sapiens	104-113
23981337-0	2013	Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.	Etoposide	34-43	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
23981337-0	2013	Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.	Etoposide	34-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-138
23981337-1	2013	Etoposide is recognized as a dual P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) substrate drug with poor water-solubility.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
23981337-1	2013	Etoposide is recognized as a dual P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) substrate drug with poor water-solubility.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	50-54
23981337-1	2013	Etoposide is recognized as a dual P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) substrate drug with poor water-solubility.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-78
23981337-1	2013	Etoposide is recognized as a dual P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) substrate drug with poor water-solubility.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-85
23981337-6	2013	In vitro Caco-2 cell models were applied to study the effects of P-gp and CYP3A inhibition by SMEDDS on the cellular accumulation of etoposide.	Etoposide	133-142	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
23981337-6	2013	In vitro Caco-2 cell models were applied to study the effects of P-gp and CYP3A inhibition by SMEDDS on the cellular accumulation of etoposide.	Etoposide	133-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-79
23981337-9	2013	Cellular uptake studies demonstrated that P-gp inhibition by SMEDDS played an important role in etoposide uptake.	Etoposide	96-105	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
24260231-4	2013	In cells expressing BCR/ABL, FLT3-ITD, or Jak2-V617F, etoposide induced a sustained activation of Chk1, thus leading to the G2/M arrest of cells.	Etoposide	54-63	fms related receptor tyrosine kinase 3	Homo sapiens	29-33
24260231-4	2013	In cells expressing BCR/ABL, FLT3-ITD, or Jak2-V617F, etoposide induced a sustained activation of Chk1, thus leading to the G2/M arrest of cells.	Etoposide	54-63	Janus kinase 2	Homo sapiens	42-46
24260231-4	2013	In cells expressing BCR/ABL, FLT3-ITD, or Jak2-V617F, etoposide induced a sustained activation of Chk1, thus leading to the G2/M arrest of cells.	Etoposide	54-63	checkpoint kinase 1	Homo sapiens	98-102
24260231-6	2013	The PI3K inhibitor GD-0941 or the Akt inhibitor MK-2206 showed similar effects with imatinib on etoposide-treated BCR/ABL-expressing cells, including those expressing the imatinib-resistant T315I mutant, while expression of the constitutively activated Akt1-myr mutant conferred resistance to the combined treatment of etoposide and imatinib.	Etoposide	96-105	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	114-121
24260231-7	2013	GSK3 inhibitors, including LiCl and SB216763, restored the sustained Chk1 activation and mitigated apoptosis in cells treated with etoposide and the inhibitors for aberrant kinases, PI3K, or Akt.	Etoposide	131-140	checkpoint kinase 1	Homo sapiens	69-73
24260231-7	2013	GSK3 inhibitors, including LiCl and SB216763, restored the sustained Chk1 activation and mitigated apoptosis in cells treated with etoposide and the inhibitors for aberrant kinases, PI3K, or Akt.	Etoposide	131-140	AKT serine/threonine kinase 1	Homo sapiens	191-194
24232736-4	2013	Among them, compound 35 showed the highest potency against all five cancer cell lines tested, with IC50 values ranging from 0.59 to 2.90 muM, which is significantly more active than the drug etoposide currently in clinical use.	Etoposide	191-200	latexin	Homo sapiens	137-140
24273274-3	2013	HOXA5 expression was then enhanced or suppressed by transfection of the cells with HOXA5 expression plasmids or small interference RNA (siRNA), and the chemosensitivity of transfected cells to cisplatin (DDP) and etoposide (VP-16) was evaluated using cell counting kit-8 (CCK8) assay.	Etoposide	213-222	homeobox A5	Homo sapiens	0-5
23879966-9	2013	Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM).	Etoposide	89-98	latexin	Homo sapiens	36-39
24168400-10	2013	Furthermore, ERIC levels were increased following DNA damage by the chemotherapeutic drug Etoposide, and inhibition of ERIC expression enhanced Etoposide -induced apoptosis.	Etoposide	90-99	E2F1-regulated inhibitor of cell death	Homo sapiens	13-17
24168400-10	2013	Furthermore, ERIC levels were increased following DNA damage by the chemotherapeutic drug Etoposide, and inhibition of ERIC expression enhanced Etoposide -induced apoptosis.	Etoposide	144-153	E2F1-regulated inhibitor of cell death	Homo sapiens	119-123
24014029-2	2013	Here, we identified that etoposide-induced 2.4 mRNA (Ei24)/p53-induced gene 8 (Pig8), a p53 target gene involved in apoptosis and autophagy, was up-regulated in Rb(-/-) mouse embryonic fibroblasts (MEFs).	Etoposide	25-34	etoposide induced 2.4 mRNA	Mus musculus	53-57
24014029-2	2013	Here, we identified that etoposide-induced 2.4 mRNA (Ei24)/p53-induced gene 8 (Pig8), a p53 target gene involved in apoptosis and autophagy, was up-regulated in Rb(-/-) mouse embryonic fibroblasts (MEFs).	Etoposide	25-34	transformation related protein 53, pseudogene	Mus musculus	59-62
24014029-2	2013	Here, we identified that etoposide-induced 2.4 mRNA (Ei24)/p53-induced gene 8 (Pig8), a p53 target gene involved in apoptosis and autophagy, was up-regulated in Rb(-/-) mouse embryonic fibroblasts (MEFs).	Etoposide	25-34	etoposide induced 2.4 mRNA	Mus musculus	79-83
24014029-2	2013	Here, we identified that etoposide-induced 2.4 mRNA (Ei24)/p53-induced gene 8 (Pig8), a p53 target gene involved in apoptosis and autophagy, was up-regulated in Rb(-/-) mouse embryonic fibroblasts (MEFs).	Etoposide	25-34	transformation related protein 53, pseudogene	Mus musculus	88-91
24003224-9	2013	RASSF6 depletion delays DNA repair in UV- and VP-16-treated cells and increases polyploid cells after VP-16 treatment.	Etoposide	46-51	Ras association domain family member 6	Homo sapiens	0-6
24003224-9	2013	RASSF6 depletion delays DNA repair in UV- and VP-16-treated cells and increases polyploid cells after VP-16 treatment.	Etoposide	102-107	Ras association domain family member 6	Homo sapiens	0-6
24136231-6	2013	P22077 also significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) in NB cells with an intact USP7-HDM2-p53 axis.	Etoposide	83-92	host cell factor C1	Homo sapiens	94-99
23700229-4	2013	Using a panel of neuroblastoma cell lines, we found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) on neuroblastoma cell lines.	Etoposide	159-168	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	57-61
23700229-4	2013	Using a panel of neuroblastoma cell lines, we found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) on neuroblastoma cell lines.	Etoposide	159-168	host cell factor C1	Homo sapiens	170-175
23680186-9	2013	SelW-knockdown cells were also more sensitive to DNA damage induced by etoposide, than control cells.	Etoposide	71-80	selenoprotein W	Homo sapiens	0-4
24148306-5	2013	Treatment with PRL (200 ng/ml) increased cell proliferation in HeLa cells determined by the MTT assay at day 3 and after 1 day a protective effect against etoposide induced apoptosis in HeLa, SiHa and C-33A cervical cancer cell lines analyzed by the TUNEL assay.	Etoposide	155-164	prolactin	Homo sapiens	15-18
24055188-6	2013	Interestingly in HepG2 cells, resveratrol exhibited the same levels of cytotoxicity as etoposide (10 muM) when the cells treated with &gt;= 25 muM for 48-72 h. In contrast to HepG2, resveratrol significantly enhanced anti-proliferative effects of etoposide in HCT-116 cells.	Etoposide	87-96	latexin	Homo sapiens	101-104
24055188-6	2013	Interestingly in HepG2 cells, resveratrol exhibited the same levels of cytotoxicity as etoposide (10 muM) when the cells treated with &gt;= 25 muM for 48-72 h. In contrast to HepG2, resveratrol significantly enhanced anti-proliferative effects of etoposide in HCT-116 cells.	Etoposide	87-96	latexin	Homo sapiens	143-146
24055188-7	2013	P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression.	Etoposide	51-60	tumor protein p53	Homo sapiens	0-3
24055188-7	2013	P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression.	Etoposide	131-140	tumor protein p53	Homo sapiens	0-3
24055188-7	2013	P53 expression was up-regulated by resveratrol and etoposide and pre-incubation of both cells with resveratrol increased levels of etoposide-induced p53 expression.	Etoposide	131-140	tumor protein p53	Homo sapiens	149-152
24055188-9	2013	It seems that resveratrol exerts differential synergistic effect with etoposide on proliferation of cancer cells from different origin which is mainly accompanied by p53 activation.	Etoposide	70-79	tumor protein p53	Homo sapiens	166-169
24103454-0	2013	MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.	Etoposide	87-96	microRNA 23a	Homo sapiens	0-7
24103454-2	2013	The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC).	Etoposide	144-153	microRNA 23a	Homo sapiens	66-73
24103454-2	2013	The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC).	Etoposide	144-153	DNA topoisomerase II alpha	Homo sapiens	112-128
24103454-2	2013	The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC).	Etoposide	144-153	DNA topoisomerase II alpha	Homo sapiens	130-135
24103454-6	2013	RESULTS: Overexpression of mir-23a could significantly potentiate the in vitro and in vivo anti-tumor effect of etoposide; however, ectopic expression of miR-23a fails to sensitize HCC cells to 5-fluorouracil treatment, indicating the miR-23a-induced cancer cell hypersensitivity in chemotherapy is TOP2A-specific though miR-23a overexpression could not directly up-regulate TOP2A expression.	Etoposide	112-121	microRNA 23a	Homo sapiens	27-34
23978459-0	2013	Simvastatin-induced up-regulation of gap junctions composed of connexin 43 sensitize Leydig tumor cells to etoposide: an involvement of PKC pathway.	Etoposide	107-116	gap junction protein alpha 1	Homo sapiens	63-74
23978459-2	2013	The authors investigated the involvement of Cx43-mediated gap junction intercellular communication (GJIC) in the effect of simvastatin on the cellular toxicity induced by etoposide in this study.	Etoposide	171-180	gap junction protein alpha 1	Homo sapiens	44-48
23978459-3	2013	The results showed that a major component of the cytotoxicity of therapeutic levels of etoposide is mediated by gap junctions composed of connexin 43(Cx43) and simvastatin at the dosage which does not induce cytotoxicity enhances etoposide toxicity by increasing gap junction coupling.	Etoposide	87-96	gap junction protein alpha 1	Homo sapiens	138-149
23978459-3	2013	The results showed that a major component of the cytotoxicity of therapeutic levels of etoposide is mediated by gap junctions composed of connexin 43(Cx43) and simvastatin at the dosage which does not induce cytotoxicity enhances etoposide toxicity by increasing gap junction coupling.	Etoposide	87-96	gap junction protein alpha 1	Homo sapiens	150-154
23879966-9	2013	Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM).	Etoposide	89-98	latexin	Homo sapiens	120-123
23879966-9	2013	Pre-incubation of VPA17 cells in 30 muM silibinin for 5 days also reversed resistance to etoposide (IC50 = 5.50 to 0.65 muM) and doxorubicin (IC50 = 0.625 to 0.035 muM).	Etoposide	89-98	latexin	Homo sapiens	120-123
24083030-7	2013	Overexpression of MK in wild type neuroblastoma cells leads to acquired drug resistance to doxorubicin and to the related drug etoposide.	Etoposide	127-136	midkine	Homo sapiens	18-20
24436715-11	2013	In the human NP cells, NCCM inhibits Etoposide- mediated apoptosis via suppression of activated caspase-8, caspase-9, and mainly caspase-3/7.	Etoposide	37-46	caspase 8	Homo sapiens	96-105
24436715-11	2013	In the human NP cells, NCCM inhibits Etoposide- mediated apoptosis via suppression of activated caspase-8, caspase-9, and mainly caspase-3/7.	Etoposide	37-46	caspase 9	Homo sapiens	107-116
24436715-15	2013	Here, we demonstrate that soluble factors secreted by the NCD IVD NP strongly protect murine NP cells not only from IL-1beta + FasL but also from Etoposide-induced apoptosis via suppression of activated caspase-9 and caspase-3/7.	Etoposide	146-155	caspase 9	Mus musculus	203-212
23948281-6	2013	siRNA-mediated inhibition of HDAC4 sensitized a T-ALL cell line to etoposide-induced cell death.	Etoposide	67-76	histone deacetylase 4	Homo sapiens	29-34
24002654-6	2013	TOP2beta, a target of several chemotherapeutic drugs including VP-16, was abundantly expressed in the GCs of growing follicles.	Etoposide	63-68	topoisomerase (DNA) II beta	Mus musculus	0-8
24086652-0	2013	The broken MLL gene is frequently located outside the inherent chromosome territory in human lymphoid cells treated with DNA topoisomerase II poison etoposide.	Etoposide	149-158	lysine methyltransferase 2A	Homo sapiens	11-14
24086652-5	2013	It was demonstrated that exposure of human Jurkat cells to etoposide resulted in frequent cleavage of MLL genes.	Etoposide	59-68	lysine methyltransferase 2A	Homo sapiens	102-105
24086652-7	2013	Using confocal microscopy and 3D modelling, we demonstrated that in cells treated with etoposide and cultivated for 1 h under normal conditions, ~9% of the broken MLL alleles were present outside the chromosome 11 territory, whereas in both control cells and cells inspected immediately after etoposide treatment, virtually all MLL alleles were present within the chromosomal territory.	Etoposide	87-96	lysine methyltransferase 2A	Homo sapiens	163-166
24086652-7	2013	Using confocal microscopy and 3D modelling, we demonstrated that in cells treated with etoposide and cultivated for 1 h under normal conditions, ~9% of the broken MLL alleles were present outside the chromosome 11 territory, whereas in both control cells and cells inspected immediately after etoposide treatment, virtually all MLL alleles were present within the chromosomal territory.	Etoposide	87-96	lysine methyltransferase 2A	Homo sapiens	328-331
23843628-5	2013	Interestingly, SMC6 and DNA Topoisomerase IIalpha colocalize at stretched strands that join kinetochores during the metaphase II to anaphase II transition, and both are observed on stretched lagging chromosomes at anaphase II following treatment with Etoposide.	Etoposide	251-260	structural maintenance of chromosomes 6	Homo sapiens	15-19
23954287-4	2013	Moreover, we showed that etoposide, a DNA damaging agent, activates p53 transcription through the E2F1 pathway.	Etoposide	25-34	tumor protein p53	Homo sapiens	68-71
23954287-4	2013	Moreover, we showed that etoposide, a DNA damaging agent, activates p53 transcription through the E2F1 pathway.	Etoposide	25-34	E2F transcription factor 1	Homo sapiens	98-102
23792163-6	2013	Moreover, silencing the expression of WSB-1 by RNA interference rescues HIPK2 expression in hypoxic HCC cells and promotes etoposide-induced cell death in hypoxic HCC cells.	Etoposide	123-132	WD repeat and SOCS box containing 1	Homo sapiens	38-43
23835407-0	2013	miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells.	Etoposide	85-94	microRNA 375	Homo sapiens	0-7
23835407-0	2013	miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells.	Etoposide	85-94	tumor protein p53	Homo sapiens	20-23
23835407-8	2013	In addition, the expression of miR-375 desensitizes cells to ionizing radiation and etoposide.	Etoposide	84-93	microRNA 375	Homo sapiens	31-38
23835407-10	2013	These results demonstrate that miR-375 targets p53 to regulate the response to ionizing radiation and etoposide treatment.	Etoposide	102-111	microRNA 375	Homo sapiens	31-38
23835407-10	2013	These results demonstrate that miR-375 targets p53 to regulate the response to ionizing radiation and etoposide treatment.	Etoposide	102-111	tumor protein p53	Homo sapiens	47-50
23872129-0	2013	Wogonin attenuates etoposide-induced oxidative DNA damage and apoptosis via suppression of oxidative DNA stress and modulation of OGG1 expression.	Etoposide	19-28	8-oxoguanine DNA-glycosylase 1	Mus musculus	130-134
23872129-4	2013	Etoposide induced a significant down-regulation of mRNA expression of the OGG1 repair gene and marked biochemical alterations characteristic of oxidative DNA stress, including increased 8-OHdG, enhanced lipid peroxidation and reduction in reduced glutathione.	Etoposide	0-9	8-oxoguanine DNA-glycosylase 1	Mus musculus	74-78
23872129-7	2013	Conclusively, our study indicates that wogonin has a protective role in the abatement of etoposide-induced oxidative DNA damage and apoptosis in the bone marrow cells of mice via suppression of oxidative DNA stress and enhancing DNA repair through modulation of OGG1 repair gene expression.	Etoposide	89-98	8-oxoguanine DNA-glycosylase 1	Mus musculus	262-266
23834154-10	2013	Additionally, miR-21 downregulation increased K562 and KYO-1 cellular sensitivity to etoposide or doxorubicin.	Etoposide	85-94	microRNA 21	Homo sapiens	14-20
23859074-2	2013	In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide.	Etoposide	132-141	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	55-59
23796964-6	2013	We also establish that increased etoposide-induced multinucleation in HepG2 cells is dependent on the catalytic activity of Akt, as phosphatidylinositol-3-kinase inhibitors as well as the overexpression of kinase-defective Akt reversed this phenotype.	Etoposide	33-42	AKT serine/threonine kinase 1	Homo sapiens	124-127
23796964-7	2013	Moreover, ectopic expression of wild type PTEN reduced the frequency of etoposide-induced multinucleated HepG2 cells, and restored HepG2 etoposide sensitivity.	Etoposide	137-146	phosphatase and tensin homolog	Homo sapiens	42-46
23949216-2	2013	This results from a high resistance of GBM tumor cells to current therapeutic options, including etoposide (VP-16).	Etoposide	97-106	host cell factor C1	Homo sapiens	108-113
23796964-8	2013	Taken together, these results implicate the Akt/PTEN cellular axis as a major determinant of the etoposide resistance of HCC cells.	Etoposide	97-106	AKT serine/threonine kinase 1	Homo sapiens	44-47
23796964-6	2013	We also establish that increased etoposide-induced multinucleation in HepG2 cells is dependent on the catalytic activity of Akt, as phosphatidylinositol-3-kinase inhibitors as well as the overexpression of kinase-defective Akt reversed this phenotype.	Etoposide	33-42	AKT serine/threonine kinase 1	Homo sapiens	223-226
23796964-8	2013	Taken together, these results implicate the Akt/PTEN cellular axis as a major determinant of the etoposide resistance of HCC cells.	Etoposide	97-106	phosphatase and tensin homolog	Homo sapiens	48-52
23796964-7	2013	Moreover, ectopic expression of wild type PTEN reduced the frequency of etoposide-induced multinucleated HepG2 cells, and restored HepG2 etoposide sensitivity.	Etoposide	72-81	phosphatase and tensin homolog	Homo sapiens	42-46
23889332-7	2013	The virus, Ad5PTD(ASH1-SCG3-E1A), shows selective and efficient killing of neuroblastoma cell lines in vitro, including cisplatin-, etoposide-, and doxorubicin-insensitive neuroblastoma cells.	Etoposide	132-141	achaete-scute family bHLH transcription factor 1	Homo sapiens	18-22
23898097-3	2013	RESULTS: Patient cohorts treated with etoposide had significant improvement in mOS (15.66 months vs. 13.27 months, p=0.026, 49 vs. 795 cohorts) and significant survival gain advantage (p=0.022) over cohorts treated without etoposide.	Etoposide	38-47	Moloney sarcoma oncogene	Mus musculus	79-82
23889332-7	2013	The virus, Ad5PTD(ASH1-SCG3-E1A), shows selective and efficient killing of neuroblastoma cell lines in vitro, including cisplatin-, etoposide-, and doxorubicin-insensitive neuroblastoma cells.	Etoposide	132-141	secretogranin III	Homo sapiens	23-27
23690541-7	2013	Unexpectedly, induction of p53 by etoposide was not inhibited by cordycepin, whereas (1) expression of Sp1 (required for the induction of p21(WAF1/CIP1) and activation of p16(INK4a) by genotoxic stress) was attenuated by cordycepin, (2) DNA binding activity of Sp1 was also inhibited, and (3) selective inhibition of Sp1 reproduced the suppressive effect of cordycepin on senescence.	Etoposide	34-43	tumor protein p53	Homo sapiens	27-30
22488521-4	2013	On the other hand, these cells become sensitive to etoposide when Akt was inhibited.	Etoposide	51-60	AKT serine/threonine kinase 1	Homo sapiens	66-69
23708668-4	2013	In the present study, we showed that the levels of BLH were significantly reduced during apoptosis induced by the antitumor agents bleomycin, etoposide and hydroxycamptothecin, and inhibited by the caspase inhibitors Q-VD-oph and Z-DEVD-FMK.	Etoposide	142-151	bleomycin hydrolase	Homo sapiens	51-54
23690541-2	2013	Etoposide- or doxorubicin-treated cells exhibited senescent morphology, growth arrest, and positive staining for senescence-associated beta-galactosidase.	Etoposide	0-9	galactosidase beta 1	Homo sapiens	135-153
23466610-5	2013	Herein, we report the effects of etoposide and teniposide on macrophage ABCA1 expression and cholesterol efflux.	Etoposide	33-42	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	72-77
23474493-5	2013	CBX8 cooperated with SIRT1 for suppressing p53 acetylation induced by Sirtinol and etoposide/TSA.	Etoposide	83-92	chromobox 8	Homo sapiens	0-4
23474493-5	2013	CBX8 cooperated with SIRT1 for suppressing p53 acetylation induced by Sirtinol and etoposide/TSA.	Etoposide	83-92	sirtuin 1	Homo sapiens	21-26
23474493-5	2013	CBX8 cooperated with SIRT1 for suppressing p53 acetylation induced by Sirtinol and etoposide/TSA.	Etoposide	83-92	tumor protein p53	Homo sapiens	43-46
23769828-4	2013	In the present studies, we developed a CLN3 siRNA-inhibited primary rat neuron model to further study etoposide-induced calcium changes and apoptosis in CLN3 disease followed by recovery experiments with amlodipine.	Etoposide	102-111	CLN3 lysosomal/endosomal transmembrane protein, battenin	Rattus norvegicus	39-43
23769828-4	2013	In the present studies, we developed a CLN3 siRNA-inhibited primary rat neuron model to further study etoposide-induced calcium changes and apoptosis in CLN3 disease followed by recovery experiments with amlodipine.	Etoposide	102-111	CLN3 lysosomal/endosomal transmembrane protein, battenin	Rattus norvegicus	153-157
23909136-0	2013	Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation.	Etoposide	85-94	ATP binding cassette subfamily B member 1	Homo sapiens	98-112
23909136-1	2013	The purpose of this work is intended to investigate the potential of self-nanoemulsifying (SNE) drug delivery system for enhanced oral bioavailability of etoposide by P-glycoprotein (P-gp) modulation.	Etoposide	154-163	ATP binding cassette subfamily B member 1	Homo sapiens	167-181
23909136-1	2013	The purpose of this work is intended to investigate the potential of self-nanoemulsifying (SNE) drug delivery system for enhanced oral bioavailability of etoposide by P-glycoprotein (P-gp) modulation.	Etoposide	154-163	ATP binding cassette subfamily B member 1	Homo sapiens	183-187
23666235-2	2013	The aim of this multicenter phase I study is to establish the recommended dose (RD) of the combination therapy with temozolomide (TMZ) and oral etoposide (VP-16) in children with relapsed or refractory malignant glioma and brainstem glioma at diagnosis.	Etoposide	144-153	host cell factor C1	Homo sapiens	155-160
23782464-6	2013	BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV irradiation or etoposide when compared to cells reconstituted to express wild-type BAK.	Etoposide	192-201	BCL2 antagonist/killer 1	Homo sapiens	0-3
23782464-6	2013	BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV irradiation or etoposide when compared to cells reconstituted to express wild-type BAK.	Etoposide	192-201	BCL2 associated X, apoptosis regulator	Homo sapiens	4-7
23782464-6	2013	BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV irradiation or etoposide when compared to cells reconstituted to express wild-type BAK.	Etoposide	192-201	BCL2 antagonist/killer 1	Homo sapiens	67-70
23430060-7	2013	GP7 or etoposide induced sub-G(1) peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells.	Etoposide	7-16	caspase 3	Mus musculus	84-101
23430060-7	2013	GP7 or etoposide induced sub-G(1) peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells.	Etoposide	7-16	B cell leukemia/lymphoma 2	Mus musculus	151-156
23430060-7	2013	GP7 or etoposide induced sub-G(1) peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells.	Etoposide	7-16	BCL2-like 1	Mus musculus	161-167
23430060-7	2013	GP7 or etoposide induced sub-G(1) peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells.	Etoposide	7-16	BCL2-associated X protein	Mus musculus	185-188
23430060-7	2013	GP7 or etoposide induced sub-G(1) peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells.	Etoposide	7-16	BCL2-antagonist/killer 1	Mus musculus	193-196
23430060-9	2013	GP7- or etoposide-induced apoptotic DNA fragmentation of human OS cells was inhibited by the pan caspase inhibitor and caspase-9 inhibitor, not by caspase-8 inhibitor whereas it was not inhibited by the pan caspase inhibitor in mouse OS cells.	Etoposide	8-17	caspase 9	Homo sapiens	119-128
23430060-9	2013	GP7- or etoposide-induced apoptotic DNA fragmentation of human OS cells was inhibited by the pan caspase inhibitor and caspase-9 inhibitor, not by caspase-8 inhibitor whereas it was not inhibited by the pan caspase inhibitor in mouse OS cells.	Etoposide	8-17	caspase 8	Homo sapiens	147-156
23782464-6	2013	BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV irradiation or etoposide when compared to cells reconstituted to express wild-type BAK.	Etoposide	192-201	BCL2 antagonist/killer 1	Homo sapiens	67-70
23782464-6	2013	BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV irradiation or etoposide when compared to cells reconstituted to express wild-type BAK.	Etoposide	192-201	BCL2 antagonist/killer 1	Homo sapiens	67-70
23774063-3	2013	We report that PC cells that express high levels of MUC1 exhibit increased resistance to chemotherapeutic drugs (gemcitabine and etoposide) in comparison with cells that express low levels of MUC1.	Etoposide	129-138	mucin 1, cell surface associated	Homo sapiens	52-56
23609451-3	2013	Knockdown of TR4 levels in the established PCa stem/progenitor cells and the CD133(+) population of the C4-2 PCa cell line with lentiviral TR4 siRNA led to increased drug sensitivity to the two commonly used chemotherapeutic drugs, docetaxel and etoposide, judging from significantly reduced IC50 values and increased apoptosis in the TR4 knockdown cells.	Etoposide	246-255	nuclear receptor subfamily 2 group C member 2	Homo sapiens	13-16
23466610-9	2013	Expression of ABCG1 and fatty acid synthase (FAS), another two LXR-targeted genes, was also induced by etoposide and teniposide.	Etoposide	103-112	ATP binding cassette subfamily G member 1	Mus musculus	14-19
23466610-9	2013	Expression of ABCG1 and fatty acid synthase (FAS), another two LXR-targeted genes, was also induced by etoposide and teniposide.	Etoposide	103-112	fatty acid synthase	Mus musculus	24-43
23466610-9	2013	Expression of ABCG1 and fatty acid synthase (FAS), another two LXR-targeted genes, was also induced by etoposide and teniposide.	Etoposide	103-112	fatty acid synthase	Mus musculus	45-48
23466610-9	2013	Expression of ABCG1 and fatty acid synthase (FAS), another two LXR-targeted genes, was also induced by etoposide and teniposide.	Etoposide	103-112	nuclear receptor subfamily 1, group H, member 3	Mus musculus	63-66
23466610-10	2013	In vivo, administration of mice with either etoposide or teniposide induced macrophage ABCA1 expression and enhanced reverse cholesterol transport from macrophages to feces.	Etoposide	44-53	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	87-92
23466610-11	2013	Taken together, our study indicates that etoposide and teniposide increase macrophage ABCA1 expression and cholesterol efflux that may be attributed to the anti-atherogenic properties of etoposide.	Etoposide	41-50	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	86-91
23466610-8	2013	Etoposide and teniposide also increased ABCA1 promoter activity in an LXR-dependent manner and formation of the LXRE-LXR/RXR complex indicating that transcriptional induction had occurred.	Etoposide	0-9	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	40-45
23466610-11	2013	Taken together, our study indicates that etoposide and teniposide increase macrophage ABCA1 expression and cholesterol efflux that may be attributed to the anti-atherogenic properties of etoposide.	Etoposide	187-196	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	86-91
23466610-8	2013	Etoposide and teniposide also increased ABCA1 promoter activity in an LXR-dependent manner and formation of the LXRE-LXR/RXR complex indicating that transcriptional induction had occurred.	Etoposide	0-9	nuclear receptor subfamily 1, group H, member 3	Mus musculus	70-73
23698047-6	2013	The best antiproliferative effect against HL-60 cells was found for compounds 3 and 17, with IC50 values of 22.3 and 23.2 muM, lower than that found for the reference compound etoposide (2.23 muM).	Etoposide	176-185	latexin	Homo sapiens	192-195
23568456-5	2013	Based on phase II evidence and subset analyses available, we believe that the addition of etoposide to standard regimens and consolidation of first remissions with autologous stem cell transplantation (autoSCT) provides the best outcome in patients with PTCL and currently use CHOEP followed by ASCT for eligible patients with the common PTCL subtype: PTCL-NOS, AITL, and ALK negative ALCL.	Etoposide	90-99	ALK receptor tyrosine kinase	Homo sapiens	372-375
23605997-3	2013	We found that both TNFalpha, which induces the extrinsic apoptotic pathway, and etoposide (VP-16), which induces the intrinsic apoptotic pathway, stimulated U937V cell death without cell disintegration.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-96
23691072-4	2013	In particular, potency and efficacy of DNA synthesis-targeting agents such as gemcitabine and etoposide could be profoundly underestimated by ATP and MTS-reduction assays.	Etoposide	94-103	MLRL	Homo sapiens	150-153
23508810-0	2013	Time-dependent changes in the activation of RhoA/ROCK and ERM/p-ERM in the increased expression of intestinal P-glycoprotein by repeated oral treatment with etoposide.	Etoposide	157-166	ras homolog family member A	Homo sapiens	44-48
23422328-6	2013	At Indiana University, we recommend etoposide (VP-16), ifosfamide and cisplatin (VIPx4) instead of bleomycin, etoposide and platinum (BEPx4) to prevent pulmonary complications, as these patients require extensive thoracic surgical resection.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
23065812-1	2013	Etoposide (VP-16) is a hydrophobic anticancer agent inhibiting Topoisomerase II, commonly used in pediatric brain chemotherapeutic schemes as mildly toxic.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
23149547-1	2013	The DNA repair protein Ku70 is a key player in chemoresistance to anticancer agents (e.g., etoposide) or radioresistance.	Etoposide	91-100	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	23-27
23508810-0	2013	Time-dependent changes in the activation of RhoA/ROCK and ERM/p-ERM in the increased expression of intestinal P-glycoprotein by repeated oral treatment with etoposide.	Etoposide	157-166	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	58-67	ras homolog family member A	Homo sapiens	276-280
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	69-72	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	69-72	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
23508810-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) increased ileal membrane localization of P-glycoprotein (P-gp) and that this was possibly mediated by increased expression of the ezrin/radixin/moesin (ERM)/phosphorylated ERM (p-ERM) via activation of RhoA/ROCK.	Etoposide	69-72	ras homolog family member A	Homo sapiens	276-280
23508810-4	2013	We examined the relationships between time-dependent changes in protein expressions of ileal P-gp and those of RhoA, ROCK, ERM, and p-ERM, and in oral morphine analgesia after initiation or cessation of repeated oral treatment with ETP.	Etoposide	232-235	ATP binding cassette subfamily B member 1	Homo sapiens	93-97
23508810-5	2013	Ileal membrane localization of RhoA was increased 3 days after initiating ETP treatment; on 5 or 7 days, that of ROCK, ERM, and p-ERM was increased along with increments in P-gp expression, leading to decreases in oral morphine analgesia.	Etoposide	74-77	ras homolog family member A	Homo sapiens	31-35
23500643-0	2013	Mouse embryonic stem cells undergo charontosis, a novel programmed cell death pathway dependent upon cathepsins, p53, and EndoG, in response to etoposide treatment.	Etoposide	144-153	transformation related protein 53, pseudogene	Mus musculus	113-116
23500643-0	2013	Mouse embryonic stem cells undergo charontosis, a novel programmed cell death pathway dependent upon cathepsins, p53, and EndoG, in response to etoposide treatment.	Etoposide	144-153	endonuclease G	Mus musculus	122-127
23500643-6	2013	Finally, EndoG was newly identified as a protease participating in the DNA fragmentation observed during ETO-induced PCD.	Etoposide	105-108	endonuclease G	Mus musculus	9-14
23613938-9	2013	Furthermore, using this reporter gene system, we found that etoposide (VP-16) and 5-fluorouracil (5-FU) activated miRNA-16 expression in vitro and in vivo, and the upregulation of miRNA-16 is p38MAPK dependent but NF-kappaB independent.	Etoposide	60-69	host cell factor C1	Homo sapiens	71-76
23750173-0	2013	Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma.	Etoposide	84-93	DNA damage inducible transcript 3	Homo sapiens	74-78
23646141-4	2013	Here we show that while HIGD1A resides in mitochondria during physiological hypoxia, severe metabolic stress, such as glucose starvation coupled with hypoxia, in addition to DNA damage induced by etoposide, triggers its nuclear accumulation.	Etoposide	196-205	HIG1 hypoxia inducible domain family member 1A	Homo sapiens	24-30
22998676-4	2013	RESULTS: Similar to the TOP2-targeting drug, etoposide (VP-16), the NO-donor, S-nitrosoglutathione (GSNO), induces skin melanomas formation in 7,12-dimethyl- benz[a]anthracene (DMBA)-initiated mice.	Etoposide	45-54	host cell factor C1	Homo sapiens	56-61
23417673-6	2013	Here, we show that HIC1 silencing in human fibroblasts impacts the repair of DNA double-strand breaks whereas ectopic expression of wild-type HIC1, but not of nonsumoylatable mutants, leads to a reduced number of gammaH2AX foci induced by etoposide treatment.	Etoposide	239-248	HIC ZBTB transcriptional repressor 1	Homo sapiens	19-23
23417673-6	2013	Here, we show that HIC1 silencing in human fibroblasts impacts the repair of DNA double-strand breaks whereas ectopic expression of wild-type HIC1, but not of nonsumoylatable mutants, leads to a reduced number of gammaH2AX foci induced by etoposide treatment.	Etoposide	239-248	HIC ZBTB transcriptional repressor 1	Homo sapiens	142-146
23579276-7	2013	In addition, etoposide activated p38 mitogen-activated protein kinase (MAPK), AKT and c-Jun N-terminal kinase.	Etoposide	13-22	mitogen-activated protein kinase 14	Homo sapiens	33-69
23579276-7	2013	In addition, etoposide activated p38 mitogen-activated protein kinase (MAPK), AKT and c-Jun N-terminal kinase.	Etoposide	13-22	AKT serine/threonine kinase 1	Homo sapiens	78-81
23579276-9	2013	Importantly, SB203580-etoposide cotreatment also reduced cell migration and invasion by affecting cyclooxygenase-2, intercellular adhesion molecule-1, C-X-C chemokine receptor-4 and matrix metalloprotease-9.	Etoposide	22-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	98-149
23415866-4	2013	Similarly, endogenous PICOT was cleaved in cell death responses induced by staurosporine and etoposide.	Etoposide	93-102	glutaredoxin 3	Homo sapiens	22-27
23348423-4	2013	We show here that siRNA knockdown of the insulin receptor enhanced the cytotoxic action of native Pseudomonas exotoxin and enhanced SS1P toxicity on several human cell lines, but did not affect the response to other cytotoxic agents such as TRAIL, etoposide, and cycloheximide.	Etoposide	248-257	insulin receptor	Homo sapiens	41-57
23274042-6	2013	Serum AMH levels were significantly lower in the patients who had received a regimen including etoposide than in the patients who had not received treatment with etoposide (0.71 vs. 1.30 ng/mL, P=0.027).	Etoposide	95-104	anti-Mullerian hormone	Homo sapiens	6-9
23274042-6	2013	Serum AMH levels were significantly lower in the patients who had received a regimen including etoposide than in the patients who had not received treatment with etoposide (0.71 vs. 1.30 ng/mL, P=0.027).	Etoposide	162-171	anti-Mullerian hormone	Homo sapiens	6-9
23275004-8	2013	SiRNA inhibition of both Nrf2 and Bcl-xL increased the susceptibility of cancer cells to etoposide-mediated cell death and reduced cell survival.	Etoposide	89-98	nuclear factor, erythroid derived 2, like 2	Mus musculus	25-29
23275004-8	2013	SiRNA inhibition of both Nrf2 and Bcl-xL increased the susceptibility of cancer cells to etoposide-mediated cell death and reduced cell survival.	Etoposide	89-98	BCL2-like 1	Mus musculus	34-40
23247865-3	2013	Using a quantitative gene expression analysis, we found that a reduction in telomeric repeat-binding factor 1 (TRF1), protection of telomeres (POT1), and TRF1-interacting ankyrin-related ADP-ribose polymerase 1 (TNKS1) mRNAs was observed in etoposide- and doxorubicin-treated HeLa and U-2 OS cells, while an increased TRF2-interacting telomeric protein (RAP1) mRNA level was observed in U-2 OS cells.	Etoposide	241-250	tankyrase	Homo sapiens	154-210
23415866-7	2013	Interestingly, overexpression of either PICOT wild type or the D101A/D226A double point mutant accelerated etoposide-induced activation of caspase-3 whereas siRNA-mediated knockdown of PICOT blocked this phenomenon.	Etoposide	107-116	glutaredoxin 3	Homo sapiens	40-45
23415866-7	2013	Interestingly, overexpression of either PICOT wild type or the D101A/D226A double point mutant accelerated etoposide-induced activation of caspase-3 whereas siRNA-mediated knockdown of PICOT blocked this phenomenon.	Etoposide	107-116	caspase 3	Homo sapiens	139-148
23382381-4	2013	Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53.	Etoposide	44-53	supervillin	Homo sapiens	107-118
23382381-4	2013	Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endogenous supervillin coincident with increases in p53.	Etoposide	44-53	tumor protein p53	Homo sapiens	148-151
23497288-9	2013	Inversely, the overexpression of miR-125b in parental EWS cells resulted in enhanced drug resistance, not only to doxorubicin, but also to etoposide and vincristine.	Etoposide	139-148	EWS RNA binding protein 1	Homo sapiens	54-57
23402364-0	2013	Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213).	Etoposide	65-74	host cell factor C1	Homo sapiens	76-81
23402364-2	2013	Here, we examined the hypothesis that ( )NO generation contributes to cancer cell drug resistance toward the widely used anticancer drug Etoposide (VP-16).	Etoposide	137-146	host cell factor C1	Homo sapiens	148-153
23161404-3	2013	In this study, we demonstrated that lithium and SB216763, which are pharmacological inhibitors of GSK3, attenuated p53 accumulation and caspase-3 activation, as shown by PARP cleavage induced by the DNA-damaging agents doxorubicin, etoposide and camptothecin.	Etoposide	232-241	tumor protein p53	Homo sapiens	115-118
23328075-3	2013	The aim of this study was to examine any modulations in the DDC mRNA levels in gastric cancer cells after their treatment with the chemotherapeutic agents 5-fluorouracil, leucovorin, irinotecan, etoposide, cisplatin, and taxol.	Etoposide	195-204	dopa decarboxylase	Homo sapiens	60-63
23768637-9	2013	l-asparaginase-containing regimens such as SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) are effective for ENKL.	Etoposide	105-114	asparaginase and isoaspartyl peptidase 1	Homo sapiens	0-14
23768637-9	2013	l-asparaginase-containing regimens such as SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) are effective for ENKL.	Etoposide	105-114	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	43-48
23161404-7	2013	GSK3 inhibition also reduced the phosphorylation of wild-type p53 at serine 33, which is induced by doxorubicin, etoposide and camptothecin in the mitochondria.	Etoposide	113-122	tumor protein p53	Homo sapiens	62-65
23161404-8	2013	Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization.	Etoposide	37-46	tumor protein p53	Homo sapiens	70-73
23161404-8	2013	Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization.	Etoposide	37-46	BCL2 apoptosis regulator	Homo sapiens	79-83
23161404-8	2013	Moreover, inhibition of GSK3 reduced etoposide-induced association of p53 with Bcl2 and Bax oligomerization.	Etoposide	37-46	BCL2 associated X, apoptosis regulator	Homo sapiens	88-91
23274112-3	2013	We have recently published that coilin is tightly associated with nucleic acid, displays RNase activity in vitro, and is redistributed to the ribosomal RNA (rRNA)-rich nucleoli in cells treated with the DNA-damaging agents cisplatin and etoposide.	Etoposide	237-246	coilin	Homo sapiens	32-38
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	150-164
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	58-67	ras homolog family member A	Homo sapiens	219-223
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	69-72	ATP binding cassette subfamily B member 1	Homo sapiens	150-164
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	69-72	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
23303573-1	2013	Previously, we reported that repeated oral treatment with etoposide (ETP) causes attenuation of oral morphine analgesia through upregulation of ileal P-glycoprotein (P-gp) mediated by Ras homolog gene family, member A (RhoA) activation.	Etoposide	69-72	ras homolog family member A	Homo sapiens	219-223
23303573-5	2013	Here, we examined the involvement of ERM in the changes in expression of P-gp via RhoA and ROCK in ileal membrane induced by ETP.	Etoposide	125-128	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
23303573-5	2013	Here, we examined the involvement of ERM in the changes in expression of P-gp via RhoA and ROCK in ileal membrane induced by ETP.	Etoposide	125-128	ras homolog family member A	Homo sapiens	82-86
22469985-6	2013	Moreover, viral reactivation compromised p53-dependent apoptosis in PEL cells treated with genotoxic anti-cancer agents doxorubicin and etoposide.	Etoposide	136-145	tumor protein p53	Homo sapiens	41-44
23254912-1	2013	Etoposide, used for the treatment of breast cancer, is mainly metabolized             via hepatic cytochrome P450 (CYP) 3A4 in humans and is also a substrate for p-glycoprotein             (P-gp).	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-123
23254912-1	2013	Etoposide, used for the treatment of breast cancer, is mainly metabolized             via hepatic cytochrome P450 (CYP) 3A4 in humans and is also a substrate for p-glycoprotein             (P-gp).	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	162-176
23254912-1	2013	Etoposide, used for the treatment of breast cancer, is mainly metabolized             via hepatic cytochrome P450 (CYP) 3A4 in humans and is also a substrate for p-glycoprotein             (P-gp).	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	190-194
23254912-10	2013	Taken             together, greater AUC and slower CL of etoposide in DMBA-WM rats could possibly             be due to the inhibition of hepatic CYP3A (intravenous) and mainly due to the             inhibition of intestinal CYP3A and P-gp (oral) by morin.	Etoposide	57-66	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	146-151
23254912-10	2013	Taken             together, greater AUC and slower CL of etoposide in DMBA-WM rats could possibly             be due to the inhibition of hepatic CYP3A (intravenous) and mainly due to the             inhibition of intestinal CYP3A and P-gp (oral) by morin.	Etoposide	57-66	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	225-230
23254912-10	2013	Taken             together, greater AUC and slower CL of etoposide in DMBA-WM rats could possibly             be due to the inhibition of hepatic CYP3A (intravenous) and mainly due to the             inhibition of intestinal CYP3A and P-gp (oral) by morin.	Etoposide	57-66	phosphoglycolate phosphatase	Rattus norvegicus	235-239
23856142-14	2013	CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.	Etoposide	261-270	BCL2 apoptosis regulator	Homo sapiens	66-71
23856142-14	2013	CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.	Etoposide	261-270	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
23264746-6	2013	The microRNA cluster miR-17-92a, a post-transcriptional regulator, was significantly reduced during dexamethasone, etoposide and tumor necrosis factor alpha (TNF-alpha)-induced osteoblasts apoptosis.	Etoposide	115-124	microRNA 17	Homo sapiens	21-27
25309961-13	2013	Notably, enforced expression of BCL11B in ALL-SIL T-ALL cells conferred resistance to the topoisomerase IIalpha poison etoposide.	Etoposide	119-128	BAF chromatin remodeling complex subunit BCL11B	Homo sapiens	32-38
25309961-13	2013	Notably, enforced expression of BCL11B in ALL-SIL T-ALL cells conferred resistance to the topoisomerase IIalpha poison etoposide.	Etoposide	119-128	STIL centriolar assembly protein	Homo sapiens	46-49
23333390-6	2013	The steady and etoposide-induced phosphorylated H2AX (gamma-H2AX) were higher in PES1-silenced cells than in control cells.	Etoposide	15-24	H2A.X variant histone	Homo sapiens	48-52
23333390-6	2013	The steady and etoposide-induced phosphorylated H2AX (gamma-H2AX) were higher in PES1-silenced cells than in control cells.	Etoposide	15-24	H2A.X variant histone	Homo sapiens	54-64
23333390-6	2013	The steady and etoposide-induced phosphorylated H2AX (gamma-H2AX) were higher in PES1-silenced cells than in control cells.	Etoposide	15-24	pescadillo ribosomal biogenesis factor 1	Homo sapiens	81-85
23333390-7	2013	Besides, etoposide-induced gamma-H2AX persisted longer in PES1-silenced cells after removing the etoposide.	Etoposide	9-18	H2A.X variant histone	Homo sapiens	27-37
23333390-7	2013	Besides, etoposide-induced gamma-H2AX persisted longer in PES1-silenced cells after removing the etoposide.	Etoposide	9-18	pescadillo ribosomal biogenesis factor 1	Homo sapiens	58-62
23333390-7	2013	Besides, etoposide-induced gamma-H2AX persisted longer in PES1-silenced cells after removing the etoposide.	Etoposide	97-106	H2A.X variant histone	Homo sapiens	27-37
23333390-7	2013	Besides, etoposide-induced gamma-H2AX persisted longer in PES1-silenced cells after removing the etoposide.	Etoposide	97-106	pescadillo ribosomal biogenesis factor 1	Homo sapiens	58-62
23287532-3	2013	To investigate these phenomena and their relationship to pluripotency and senescence, we examined the response of the TP53-competent embryonal carcinoma (EC) cell line PA-1 to etoposide-induced DNA damage.	Etoposide	176-185	tumor protein p53	Homo sapiens	118-122
23163762-5	2013	Ataxia telangiectasia-derived cell lines showed high levels of TOP2A that were associated with hypersensitivity to the TOP2 inhibitor etoposide.	Etoposide	134-143	DNA topoisomerase II alpha	Homo sapiens	63-68
23433111-0	2013	Egr-1 regulates the transcription of the BRCA1 gene by etoposide.	Etoposide	55-64	early growth response 1	Homo sapiens	0-5
23433111-0	2013	Egr-1 regulates the transcription of the BRCA1 gene by etoposide.	Etoposide	55-64	BRCA1 DNA repair associated	Homo sapiens	41-46
23433111-4	2013	In this study, we investigated the transcriptional regulation of BRCA1 in HeLa cells treated with etoposide.	Etoposide	98-107	BRCA1 DNA repair associated	Homo sapiens	65-70
23433111-8	2013	Knockdown of Egr-1 through the expression of a small hairpin RNA (shRNA) attenuated etoposide-induced BRCA1 promoter activity.	Etoposide	84-93	early growth response 1	Homo sapiens	13-18
23433111-8	2013	Knockdown of Egr-1 through the expression of a small hairpin RNA (shRNA) attenuated etoposide-induced BRCA1 promoter activity.	Etoposide	84-93	BRCA1 DNA repair associated	Homo sapiens	102-107
23433111-9	2013	We conclude that Egr-1 targets the BRCA1 gene in HeLa cells exposed to etoposide.	Etoposide	71-80	early growth response 1	Homo sapiens	17-22
23433111-9	2013	We conclude that Egr-1 targets the BRCA1 gene in HeLa cells exposed to etoposide.	Etoposide	71-80	BRCA1 DNA repair associated	Homo sapiens	35-40
23129580-9	2013	Interestingly, etoposide treatment also reduced TCF/LEF activity, beta-catenin and cyclin D1 levels commensurate with induction of DNA damage and apoptosis.	Etoposide	15-24	hepatocyte nuclear factor 4 alpha	Homo sapiens	48-51
23129580-9	2013	Interestingly, etoposide treatment also reduced TCF/LEF activity, beta-catenin and cyclin D1 levels commensurate with induction of DNA damage and apoptosis.	Etoposide	15-24	catenin beta 1	Homo sapiens	66-78
23129580-9	2013	Interestingly, etoposide treatment also reduced TCF/LEF activity, beta-catenin and cyclin D1 levels commensurate with induction of DNA damage and apoptosis.	Etoposide	15-24	cyclin D1	Homo sapiens	83-92
23287532-4	2013	Nuclear POU5F1/OCT4A and P21CIP1 were upregulated in the same cells following etoposide-induced G 2M arrest.	Etoposide	78-87	POU class 5 homeobox 1	Homo sapiens	8-14
23287532-4	2013	Nuclear POU5F1/OCT4A and P21CIP1 were upregulated in the same cells following etoposide-induced G 2M arrest.	Etoposide	78-87	cyclin dependent kinase inhibitor 1A	Homo sapiens	25-32
23372380-0	2013	Effect of heat shock protein 72 expression on etoposide-induced cell death of rat retinal ganglion cells.	Etoposide	46-55	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	10-31
23178572-4	2013	Conversely, knock-down of endogenous HIC1 in BJ-Tert through RNA interference up-regulates p21 in basal conditions and further potentiates this CKI in response to apoptotic etoposide-induced DNA damage.	Etoposide	173-182	HIC ZBTB transcriptional repressor 1	Homo sapiens	37-41
23178572-4	2013	Conversely, knock-down of endogenous HIC1 in BJ-Tert through RNA interference up-regulates p21 in basal conditions and further potentiates this CKI in response to apoptotic etoposide-induced DNA damage.	Etoposide	173-182	telomerase reverse transcriptase	Homo sapiens	48-52
23178572-4	2013	Conversely, knock-down of endogenous HIC1 in BJ-Tert through RNA interference up-regulates p21 in basal conditions and further potentiates this CKI in response to apoptotic etoposide-induced DNA damage.	Etoposide	173-182	choline kinase alpha	Homo sapiens	144-147
23610963-0	2013	Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.	Etoposide	16-25	BCL2 apoptosis regulator	Homo sapiens	62-67
23610963-0	2013	Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.	Etoposide	16-25	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	72-77
23054080-0	2013	Nifedipine prevents etoposide-induced caspase-3 activation, prenyl transferase degradation and loss in cell viability in pancreatic beta-cells.	Etoposide	20-29	caspase 3	Rattus norvegicus	38-47
23054080-3	2013	We report herein that exposure of insulin-secreting INS 832/13 cells or normal rat islets to etoposide leads to significant activation of caspase-3 and subsequent degradation of the common alpha-subunit of farnesyl/geranylgeranyl transferases (FTase/GGTase).	Etoposide	93-102	caspase 3	Rattus norvegicus	138-147
23054080-6	2013	Moreover, nifedipine, a calcium channel blocker, markedly attenuated etoposide-induced caspase-3 activation, FTase/GGTase alpha-subunit degradation in INS 832/13 cells and normal rat islets.	Etoposide	69-78	caspase 3	Rattus norvegicus	87-96
23054080-8	2013	Based on these findings, we conclude that etoposide induces loss in cell viability by inducing mitochondrial dysfunction, caspase-3 activation and degradation of FTase/GGTase alpha-subunit.	Etoposide	42-51	caspase 3	Rattus norvegicus	122-131
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	Etoposide	180-184	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	34-42
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	Etoposide	180-184	mitogen-activated protein kinase 1	Homo sapiens	103-106
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	Etoposide	180-184	mitogen-activated protein kinase 3	Homo sapiens	158-162
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	Etoposide	180-184	mitogen-activated protein kinase 1	Homo sapiens	166-170
23098854-9	2013	Consistent with the activation of DNA-PKcs being required for NHEJ, we demonstrated that inhibition of ERK activation using U0126, MEK1K97M, and knockdown of ERK1 or ERK2 enhanced ETOP-induced activation of DNA-PKcs.	Etoposide	180-184	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	207-215
23098854-10	2013	Conversely, enforcing ERK activation by MEK1Q56P reduced ETOP-initiated DNA-PKcs activation.	Etoposide	57-61	mitogen-activated protein kinase 1	Homo sapiens	22-25
23098854-10	2013	Conversely, enforcing ERK activation by MEK1Q56P reduced ETOP-initiated DNA-PKcs activation.	Etoposide	57-61	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	72-80
24189426-0	2013	Radixin influences the changes in the small intestinal P-glycoprotein by etoposide treatment.	Etoposide	73-82	radixin	Homo sapiens	0-7
24189426-0	2013	Radixin influences the changes in the small intestinal P-glycoprotein by etoposide treatment.	Etoposide	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	61-70	radixin	Homo sapiens	160-167
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	61-70	moesin	Homo sapiens	168-174
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	72-75	radixin	Homo sapiens	160-167
24189426-1	2013	Previously, we reported that repeated oral administration of etoposide (ETP) increases P-glycoprotein (P-gp) expression in association with activation of ezrin/radixin/moesin (ERM) in the small intestine.	Etoposide	72-75	moesin	Homo sapiens	168-174
24189426-4	2013	Here, we examined whether radixin is involved in the increased P-gp expression in the small intestine after ETP treatment.	Etoposide	108-111	radixin	Homo sapiens	26-33
24189426-5	2013	Repeated oral treatment with ETP (10 mg/kg/day) for 7 d significantly increased ERM proteins bound to P-gp in the small intestine as determined by immunoprecipitation analysis.	Etoposide	29-32	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
24189426-7	2013	In conclusion, radixin may contribute, at least in part, to an increase in the expression of the small intestinal P-gp upon induction with repeated oral treatment with ETP.	Etoposide	168-171	radixin	Homo sapiens	15-22
24189426-7	2013	In conclusion, radixin may contribute, at least in part, to an increase in the expression of the small intestinal P-gp upon induction with repeated oral treatment with ETP.	Etoposide	168-171	ATP binding cassette subfamily B member 1	Homo sapiens	114-118
23054612-6	2013	Importantly, when p53 was activated following the administration of either of three different anticancer chemotherapeutic agents (cisplatin, etoposide or doxorubicin), it was able to induce CYP3A genes, which are the main factors in systemic clearance of these agents.	Etoposide	141-150	tumor protein p53	Homo sapiens	18-21
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	prominin 1	Homo sapiens	5-10
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	plasminogen activator, urokinase receptor	Homo sapiens	12-16
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	prominin 1	Homo sapiens	22-27
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	plasminogen activator, urokinase receptor	Homo sapiens	29-33
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	prominin 1	Homo sapiens	22-27
23066953-11	2013	Both CD133+/CD87- and CD133-/CD87+ subpopulations showed a higher resistance to etoposide and paclitaxel and greater re-populating ability than the CD133-/CD87- subpopulation.	Etoposide	80-89	plasminogen activator, urokinase receptor	Homo sapiens	29-33
24455332-9	2013	Combination therapy with cisplatin and etoposide resulted in a substantial reduction in tumor size, near-complete regression of his liver metastasis, and dramatic decrease in ACTH secretion.	Etoposide	39-48	proopiomelanocortin	Homo sapiens	175-179
23000346-0	2013	Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells.	Etoposide	45-54	checkpoint kinase 2	Homo sapiens	29-33
23000346-0	2013	Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells.	Etoposide	45-54	mitogen-activated protein kinase 14	Homo sapiens	38-41
23000346-4	2013	Since both CHK2 and FHIT are being influenced by DNA damage, we have evaluated the interplay of p38, CHK2 and FHIT in response to etoposide-induced cell death.	Etoposide	130-139	mitogen-activated protein kinase 14	Homo sapiens	96-99
23000346-4	2013	Since both CHK2 and FHIT are being influenced by DNA damage, we have evaluated the interplay of p38, CHK2 and FHIT in response to etoposide-induced cell death.	Etoposide	130-139	checkpoint kinase 2	Homo sapiens	101-105
23000346-10	2013	Besides, etoposide induced p38 and CHK2 phosphorylation and reduced FHIT expression in a time-dependent manner.	Etoposide	9-18	mitogen-activated protein kinase 14	Homo sapiens	27-30
23000346-10	2013	Besides, etoposide induced p38 and CHK2 phosphorylation and reduced FHIT expression in a time-dependent manner.	Etoposide	9-18	checkpoint kinase 2	Homo sapiens	35-39
23000346-13	2013	Inhibition of p38 kinase and CHK2 prevented etoposide induced alteration in FHIT expression.	Etoposide	44-53	mitogen-activated protein kinase 14	Homo sapiens	14-17
23000346-13	2013	Inhibition of p38 kinase and CHK2 prevented etoposide induced alteration in FHIT expression.	Etoposide	44-53	checkpoint kinase 2	Homo sapiens	29-33
23000346-14	2013	Furthermore, p38 inhibitors augmented etoposide-induced CHK2 phosphorylation.	Etoposide	38-47	mitogen-activated protein kinase 14	Homo sapiens	13-16
23000346-14	2013	Furthermore, p38 inhibitors augmented etoposide-induced CHK2 phosphorylation.	Etoposide	38-47	checkpoint kinase 2	Homo sapiens	56-60
23000346-15	2013	These results indicate that etoposide lowers FHIT expression and induces cell death via p38 and CHK2 phosphorylation.	Etoposide	28-37	mitogen-activated protein kinase 14	Homo sapiens	88-91
23000346-15	2013	These results indicate that etoposide lowers FHIT expression and induces cell death via p38 and CHK2 phosphorylation.	Etoposide	28-37	checkpoint kinase 2	Homo sapiens	96-100
23000346-16	2013	These results demonstrate a time dependent complex crosstalk of FHIT, p38 and CHK2 pathways in response to etoposide.	Etoposide	107-116	mitogen-activated protein kinase 14	Homo sapiens	70-73
23000346-16	2013	These results demonstrate a time dependent complex crosstalk of FHIT, p38 and CHK2 pathways in response to etoposide.	Etoposide	107-116	checkpoint kinase 2	Homo sapiens	78-82
23615303-10	2013	In addition, VP-16-induced apoptosis is mediated through the mitochondrial pathway in a p53-related manner.	Etoposide	13-18	transformation related protein 53, pseudogene	Mus musculus	88-91
24858458-7	2013	In comparison to treatment with curcumin and etoposide alone, co-treatment with these compounds increased the extent of DNA damage, the percentage of cells arrested in the G2/M phase and the number of annexin-V-positive cells.	Etoposide	45-54	annexin A5	Rattus norvegicus	201-210
23242346-8	2013	Co-incubation with honokiol and etoposide (VP-16) activated a complex death modality, which was composed of necrotic cell death and apoptosis.	Etoposide	32-41	host cell factor C1	Homo sapiens	43-48
23197647-5	2013	In stomach cancer cell lines, the protein expression level of multidrug resistance-associated protein 1 (MRP1) was inversely correlated with etoposide sensitivity.	Etoposide	141-150	ATP binding cassette subfamily C member 1	Homo sapiens	62-103
23197647-5	2013	In stomach cancer cell lines, the protein expression level of multidrug resistance-associated protein 1 (MRP1) was inversely correlated with etoposide sensitivity.	Etoposide	141-150	ATP binding cassette subfamily C member 1	Homo sapiens	105-109
23197647-6	2013	MK571, an MRP inhibitor, increased both the cell-to-medium ratio of etoposide and the etoposide sensitivity of MRP1-expressing stomach cancer cell lines.	Etoposide	86-95	ATP binding cassette subfamily C member 1	Homo sapiens	10-13
23197647-6	2013	MK571, an MRP inhibitor, increased both the cell-to-medium ratio of etoposide and the etoposide sensitivity of MRP1-expressing stomach cancer cell lines.	Etoposide	86-95	ATP binding cassette subfamily C member 1	Homo sapiens	111-115
23197647-9	2013	These results suggest that MRP1 modulates the etoposide sensitivity of stomach cancer cell lines and RFC1 modulates the MTX sensitivity of breast cancer cell lines.	Etoposide	46-55	ATP binding cassette subfamily C member 1	Homo sapiens	27-31
23232555-0	2013	Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: screening of 60 cytotoxic agents.	Etoposide	0-9	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	20-58
23232555-6	2013	Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells.	Etoposide	0-9	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	34-38
23232555-6	2013	Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells.	Etoposide	0-9	fms related receptor tyrosine kinase 1	Homo sapiens	58-61
23232555-6	2013	Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells.	Etoposide	0-9	thymidine kinase 1	Homo sapiens	136-139
23232555-6	2013	Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells.	Etoposide	0-9	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	172-176
23232555-6	2013	Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells.	Etoposide	0-9	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	172-176
23232555-7	2013	The inhibition of ENT1 activity by dipyridamol or S-(p-nitrobenzyl)-6-thioinosine repressed the etoposide-induced cell death in HeLa cells, whereas it induced no changes in the other cell lines.	Etoposide	96-105	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	18-22
23232555-8	2013	In conclusion, etoposide is identified as a potent inducer for ENT1 activity and [(3)H]FLT uptake.	Etoposide	15-24	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	63-67
23232555-8	2013	In conclusion, etoposide is identified as a potent inducer for ENT1 activity and [(3)H]FLT uptake.	Etoposide	15-24	fms related receptor tyrosine kinase 1	Homo sapiens	87-90
23232555-9	2013	The role of ENT1 activity by etoposide was cell-type dependent, which requests caution for the application of ENT1-mediated [(18)F]FLT flare for treatment monitoring.	Etoposide	29-38	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	12-16
23150668-9	2013	Furthermore, we showed that PHF1 regulates cell growth arrest and etoposide-induced apoptosis in a p53-dependent manner.	Etoposide	66-75	PHD finger protein 1	Homo sapiens	28-32
23150668-9	2013	Furthermore, we showed that PHF1 regulates cell growth arrest and etoposide-induced apoptosis in a p53-dependent manner.	Etoposide	66-75	tumor protein p53	Homo sapiens	99-102
23098854-5	2013	In comparison to the vehicle control (DMSO), etoposide (ETOP)-induced DSBs in MCF7 cells were more rapidly repaired in the presence of U0126, a specific MEK inhibitor, based on the reduction of gammaH2AX and tail moments.	Etoposide	45-54	mitogen-activated protein kinase kinase 7	Homo sapiens	153-156
23098854-5	2013	In comparison to the vehicle control (DMSO), etoposide (ETOP)-induced DSBs in MCF7 cells were more rapidly repaired in the presence of U0126, a specific MEK inhibitor, based on the reduction of gammaH2AX and tail moments.	Etoposide	56-60	mitogen-activated protein kinase kinase 7	Homo sapiens	153-156
22960274-0	2013	ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis.	Etoposide	69-78	ATM serine/threonine kinase	Homo sapiens	0-3
22960274-0	2013	ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis.	Etoposide	69-78	serine/threonine kinase 11	Homo sapiens	8-12
22960274-0	2013	ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis.	Etoposide	69-78	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	37-41
22960274-1	2013	The present study aims to determine the effect of AMPK on etoposide-induced apoptosis of cancer cells.	Etoposide	58-67	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	50-54
22960274-2	2013	Our results revealed that etoposide induced AMPK activation in prostate C4-2 cancer cells, an event that was attenuated by ATM siRNA.	Etoposide	26-35	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	44-48
22960274-2	2013	Our results revealed that etoposide induced AMPK activation in prostate C4-2 cancer cells, an event that was attenuated by ATM siRNA.	Etoposide	26-35	ATM serine/threonine kinase	Homo sapiens	123-126
22960274-5	2013	Finally, etoposide displayed a potent pro-apoptotic effect in cancer cells with functional LKB1 and AMPK.	Etoposide	9-18	serine/threonine kinase 11	Homo sapiens	91-95
22960274-5	2013	Finally, etoposide displayed a potent pro-apoptotic effect in cancer cells with functional LKB1 and AMPK.	Etoposide	9-18	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	100-104
22802018-8	2013	Finally, we revealed that BiP protein was degraded when cells were treated with DNA-damaging reagents, such as etoposide and doxorubicin; this finding suggests that the expression level of BiP is tightly regulated at the post-translational level, rather than at the transcriptional level, in the presence of DNA damage.	Etoposide	111-120	heat shock protein family A (Hsp70) member 5	Homo sapiens	26-29
22802018-8	2013	Finally, we revealed that BiP protein was degraded when cells were treated with DNA-damaging reagents, such as etoposide and doxorubicin; this finding suggests that the expression level of BiP is tightly regulated at the post-translational level, rather than at the transcriptional level, in the presence of DNA damage.	Etoposide	111-120	heat shock protein family A (Hsp70) member 5	Homo sapiens	189-192
23784839-8	2013	Finally, exposure of spermatocytes to double strand break DNA-damaging agents such as cisplatin, bleomycin or etoposide also induced ATR relocalization and intense H2AX phosphorylation and led to anomalies in synaptonemal assembly.	Etoposide	110-119	ataxia telangiectasia and Rad3 related	Mus musculus	133-136
23784839-8	2013	Finally, exposure of spermatocytes to double strand break DNA-damaging agents such as cisplatin, bleomycin or etoposide also induced ATR relocalization and intense H2AX phosphorylation and led to anomalies in synaptonemal assembly.	Etoposide	110-119	H2A.X variant histone	Mus musculus	164-168
23372380-3	2013	The effect of Hsp72 expression on etoposide-induced apoptotic cell death was examined by microscopic analysis and confirmed by cell proliferation assay.	Etoposide	34-43	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	14-19
24250670-1	2013	Etoposide, a widely used anticancer drug, exhibits low and variable oral bioavailability mainly because of being substrate for the efflux transporter, P-glycoprotein (P-gp).	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	151-165
24250670-1	2013	Etoposide, a widely used anticancer drug, exhibits low and variable oral bioavailability mainly because of being substrate for the efflux transporter, P-glycoprotein (P-gp).	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	167-171
24250670-2	2013	Therefore, the present study was aimed to investigate the effect of D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and PEG 400 as P-gp inhibitors on the intestinal absorption of etoposide.	Etoposide	192-201	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	144-148
24250670-5	2013	The absorptive transport of etoposide was significantly enhanced (p &lt; 0.001) in the presence of verapamil (100 mug/mL) and TPGS (over the concentration range of 0.002- 0.1 mg/mL), suggesting that the inhibition of P-gp located in the intestine may be involved in the enhancement of etoposide absorption.	Etoposide	28-37	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	217-221
22705319-0	2012	BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage response.	Etoposide	62-71	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
23457546-3	2013	Here, we show that a human myeloid cell line constitutively overexpressing EVI1 after infection with a retroviral vector (U937_EVI1) was partially resistant to etoposide and daunorubicin as compared to empty vector infected control cells (U937_vec).	Etoposide	160-169	MDS1 and EVI1 complex locus	Homo sapiens	75-79
23457546-6	2013	Notably, mRNA levels of 26 of these genes were altered by both stimuli, indicating that EVI1 regulated genes were strongly enriched among etoposide regulated genes and vice versa.	Etoposide	138-147	MDS1 and EVI1 complex locus	Homo sapiens	88-92
23457546-7	2013	One of the genes that were induced by both EVI1 and etoposide was CDKN1A/p21/WAF, which in addition to its function as a cell cycle regulator plays an important role in conferring chemotherapy resistance in various tumor types.	Etoposide	52-61	MDS1 and EVI1 complex locus	Homo sapiens	43-47
23457546-7	2013	One of the genes that were induced by both EVI1 and etoposide was CDKN1A/p21/WAF, which in addition to its function as a cell cycle regulator plays an important role in conferring chemotherapy resistance in various tumor types.	Etoposide	52-61	cyclin dependent kinase inhibitor 1A	Homo sapiens	66-72
23457546-7	2013	One of the genes that were induced by both EVI1 and etoposide was CDKN1A/p21/WAF, which in addition to its function as a cell cycle regulator plays an important role in conferring chemotherapy resistance in various tumor types.	Etoposide	52-61	cyclin dependent kinase inhibitor 1A	Homo sapiens	73-76
23437304-13	2013	Ectopic expression of miR-18a significantly inhibited the repair of DNA damage induced by etoposide (p&lt;0.001), leading to accumulation of DNA damage, increase in cell apoptosis and poor clonogenic survival.	Etoposide	90-99	microRNA 18a	Homo sapiens	22-29
22982667-5	2012	Here, we examined the involvement of RhoA in the changes in ileal P-gp protein expression and activity induced by repeated orally administered ETP.	Etoposide	143-146	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
22982667-12	2012	RhoA activation induced by repeated oral ETP administration may be involved in the up-regulation of ileal P-gp protein expression and activity, leading to a decrease in the analgesic effect of oral morphine.	Etoposide	41-44	ras homolog family member A	Homo sapiens	0-4
22982667-12	2012	RhoA activation induced by repeated oral ETP administration may be involved in the up-regulation of ileal P-gp protein expression and activity, leading to a decrease in the analgesic effect of oral morphine.	Etoposide	41-44	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
23213260-4	2012	Moreover, although Trim39 loss inhibited etoposide-induced apoptosis in p53-negative cells, apoptosis was enhanced by Trim39 knockdown in p53-positive cells.	Etoposide	41-50	tripartite motif-containing 39	Mus musculus	19-25
23213260-4	2012	Moreover, although Trim39 loss inhibited etoposide-induced apoptosis in p53-negative cells, apoptosis was enhanced by Trim39 knockdown in p53-positive cells.	Etoposide	41-50	transformation related protein 53, pseudogene	Mus musculus	72-75
23213260-4	2012	Moreover, although Trim39 loss inhibited etoposide-induced apoptosis in p53-negative cells, apoptosis was enhanced by Trim39 knockdown in p53-positive cells.	Etoposide	41-50	transformation related protein 53, pseudogene	Mus musculus	138-141
23146242-7	2013	Frontal displacement experiments with multiple concentrations of etoposide were run and the binding affinity was determined to be 4.54 muM, which is in close agreement with literature.	Etoposide	65-74	latexin	Homo sapiens	135-138
23824011-5	2013	After the exposure of breast cancer cells to (-)-xanthatin or etoposide, a prolonged and marked up-regulation in the expression of c-fos, a proapoptotic molecule, was detected together with GADD45gamma; and the expression of these molecules was stabilized by ROS and abrogated by the pretreatment with N-acetyl-L-cysteine (NAC), a potent ROS scavenger.	Etoposide	62-71	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	131-136
23824011-5	2013	After the exposure of breast cancer cells to (-)-xanthatin or etoposide, a prolonged and marked up-regulation in the expression of c-fos, a proapoptotic molecule, was detected together with GADD45gamma; and the expression of these molecules was stabilized by ROS and abrogated by the pretreatment with N-acetyl-L-cysteine (NAC), a potent ROS scavenger.	Etoposide	62-71	growth arrest and DNA damage inducible gamma	Homo sapiens	190-201
23824011-5	2013	After the exposure of breast cancer cells to (-)-xanthatin or etoposide, a prolonged and marked up-regulation in the expression of c-fos, a proapoptotic molecule, was detected together with GADD45gamma; and the expression of these molecules was stabilized by ROS and abrogated by the pretreatment with N-acetyl-L-cysteine (NAC), a potent ROS scavenger.	Etoposide	62-71	X-linked Kx blood group	Homo sapiens	323-326
23824011-6	2013	(-)-Xanthatin in particular exhibited stronger anti-proliferative potential than that of etoposide, which underlies the marked induction of c-fos/GADD45gamma and ROS production.	Etoposide	89-98	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	140-145
23824011-6	2013	(-)-Xanthatin in particular exhibited stronger anti-proliferative potential than that of etoposide, which underlies the marked induction of c-fos/GADD45gamma and ROS production.	Etoposide	89-98	growth arrest and DNA damage inducible gamma	Homo sapiens	146-157
23945651-2	2013	Here we show that even sublethal concentrations of DNA-damaging drugs, such as etoposide and cisplatin, induce the expression of autophagy-related protein 5 (ATG5), which is both necessary and sufficient for the subsequent induction of mitotic catastrophe.	Etoposide	79-88	autophagy related 5	Homo sapiens	129-156
23945651-2	2013	Here we show that even sublethal concentrations of DNA-damaging drugs, such as etoposide and cisplatin, induce the expression of autophagy-related protein 5 (ATG5), which is both necessary and sufficient for the subsequent induction of mitotic catastrophe.	Etoposide	79-88	autophagy related 5	Homo sapiens	158-162
23409080-7	2013	After knock-down of PRAME using vector based RNA interference we observed increased sensitivity for cisplatin, etoposide and retinoic acid.	Etoposide	111-120	PRAME nuclear receptor transcriptional regulator	Homo sapiens	20-25
22982667-0	2012	RhoA affects oral morphine analgesia depending on functional variation in intestinal P-glycoprotein induced by repeated etoposide treatment.	Etoposide	120-129	ras homolog family member A	Homo sapiens	0-4
22982667-0	2012	RhoA affects oral morphine analgesia depending on functional variation in intestinal P-glycoprotein induced by repeated etoposide treatment.	Etoposide	120-129	ATP binding cassette subfamily B member 1	Homo sapiens	85-99
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	238-242
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
22982667-2	2012	We previously reported that repeated administration of oral etoposide (ETP), an anticancer drug that is a substrate of P-glycoprotein (P-gp), caused attenuation of the analgesic effect of oral morphine through up-regulation of intestinal P-gp.	Etoposide	71-74	ATP binding cassette subfamily B member 1	Homo sapiens	238-242
22982667-5	2012	Here, we examined the involvement of RhoA in the changes in ileal P-gp protein expression and activity induced by repeated orally administered ETP.	Etoposide	143-146	ras homolog family member A	Homo sapiens	37-41
22705319-7	2012	BCR/ABL was shown to significantly alter the response to etoposide in many cases.	Etoposide	57-66	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
22705319-12	2012	Furthermore we found that multiple protein phosphorylation changes mediated by BCR/ABL were connected to the increased activation of NFkappaB, a key survival transcription factor, after etoposide exposure.	Etoposide	186-195	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	79-86
22705319-12	2012	Furthermore we found that multiple protein phosphorylation changes mediated by BCR/ABL were connected to the increased activation of NFkappaB, a key survival transcription factor, after etoposide exposure.	Etoposide	186-195	nuclear factor kappa B subunit 1	Homo sapiens	133-141
22841979-6	2012	Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIbeta (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.	Etoposide	59-68	DNA topoisomerase II alpha	Homo sapiens	32-37
22841979-6	2012	Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIbeta (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.	Etoposide	59-68	DNA topoisomerase II beta	Homo sapiens	96-116
22841979-6	2012	Additional consideration of our TOP2A model in light of an etoposide-inhibited complex of human topoisomerase IIbeta (TOP2B) suggests possible modification points for developing paralog-specific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.	Etoposide	59-68	DNA topoisomerase II beta	Homo sapiens	118-123
23089312-3	2012	Adenoviral transduction of Huh7 tumor cells with the TIS21 gene accelerated the repair of DSBs induced by etoposide treatment as evaluated by clearance of gammaH2AX foci and the Comet assay.	Etoposide	106-115	MIR7-3 host gene	Homo sapiens	27-31
23089312-3	2012	Adenoviral transduction of Huh7 tumor cells with the TIS21 gene accelerated the repair of DSBs induced by etoposide treatment as evaluated by clearance of gammaH2AX foci and the Comet assay.	Etoposide	106-115	BTG anti-proliferation factor 2	Homo sapiens	53-58
23089312-6	2012	The loss of Chk2 activation after etoposide treatment reduced apoptosis in the cells by downregulating the expression of E2F1 and Bax.	Etoposide	34-43	checkpoint kinase 2	Homo sapiens	12-16
23089312-6	2012	The loss of Chk2 activation after etoposide treatment reduced apoptosis in the cells by downregulating the expression of E2F1 and Bax.	Etoposide	34-43	E2F transcription factor 1	Homo sapiens	121-125
23089312-6	2012	The loss of Chk2 activation after etoposide treatment reduced apoptosis in the cells by downregulating the expression of E2F1 and Bax.	Etoposide	34-43	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
22203382-1	2012	This case report focuses on an elderly gentleman with extensive stage small cell lung cancer (SCLC) who experienced episodes of bowel obstruction shortly after commencing first-line chemotherapy with cisplatin and etoposide.	Etoposide	214-223	SCLC1	Homo sapiens	94-98
22960157-8	2012	Furthermore, the XM462-induced survival response is able to reduce etoposide toxicity in HCG27 and HCT116 cancer cells.	Etoposide	67-76	HLA complex group 27	Homo sapiens	89-94
23085065-3	2012	Here, we show that translation of the mRNA with the Apaf-1 5" UTR is relatively resistant to apoptosis induced by etoposide when eIF4E is sequestered by 4E-BP and eIF4G is partially cleaved.	Etoposide	114-123	apoptotic peptidase activating factor 1	Homo sapiens	52-58
23028047-7	2012	E2F1-driven DOK1 transcription occurred in the presence of cellular stresses, such as accumulation of DNA damage induced by etoposide.	Etoposide	124-133	E2F transcription factor 1	Homo sapiens	0-4
23028047-7	2012	E2F1-driven DOK1 transcription occurred in the presence of cellular stresses, such as accumulation of DNA damage induced by etoposide.	Etoposide	124-133	docking protein 1	Homo sapiens	12-16
23028047-8	2012	DOK1 silencing promoted cell proliferation and protected against etoposide-induced apoptosis, indicating that DOK1 acts as a key mediator of cellular stress-induced cell death.	Etoposide	65-74	docking protein 1	Homo sapiens	0-4
23028047-8	2012	DOK1 silencing promoted cell proliferation and protected against etoposide-induced apoptosis, indicating that DOK1 acts as a key mediator of cellular stress-induced cell death.	Etoposide	65-74	docking protein 1	Homo sapiens	110-114
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	29-58
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	60-63
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	ATR serine/threonine kinase	Homo sapiens	91-94
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	DNA topoisomerase II binding protein 1	Homo sapiens	98-129
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	DNA topoisomerase II binding protein 1	Homo sapiens	131-137
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	0-9	mutY DNA glycosylase	Homo sapiens	163-167
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	11-14	ATM serine/threonine kinase	Homo sapiens	29-58
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	11-14	ATM serine/threonine kinase	Homo sapiens	60-63
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	11-14	ATR serine/threonine kinase	Homo sapiens	91-94
23226797-1	2012	Etoposide (ETP) treatment of ataxia telangiectasia mutated (ATM) and Rad3-related protein (ATR)-, topoisomerase-binding protein-1 (TopBP1) and human MutY homolog (hMYH)-depleted cells results in a significant reduction in apoptotic signaling.	Etoposide	11-14	DNA topoisomerase II binding protein 1	Homo sapiens	98-129
23226797-3	2012	In hMYH knockdown cells, the interaction between ATR and TopBP1 decreased following ETP treatment.	Etoposide	84-87	mutY DNA glycosylase	Homo sapiens	3-7
23226797-3	2012	In hMYH knockdown cells, the interaction between ATR and TopBP1 decreased following ETP treatment.	Etoposide	84-87	ATR serine/threonine kinase	Homo sapiens	49-52
23226797-3	2012	In hMYH knockdown cells, the interaction between ATR and TopBP1 decreased following ETP treatment.	Etoposide	84-87	DNA topoisomerase II binding protein 1	Homo sapiens	57-63
23226797-4	2012	We suggest that hMYH functions as a sensor of ETP-induced apoptosis.	Etoposide	46-49	mutY DNA glycosylase	Homo sapiens	16-20
23085065-3	2012	Here, we show that translation of the mRNA with the Apaf-1 5" UTR is relatively resistant to apoptosis induced by etoposide when eIF4E is sequestered by 4E-BP and eIF4G is partially cleaved.	Etoposide	114-123	eukaryotic translation initiation factor 4E	Homo sapiens	129-134
22948151-6	2012	Induction of p53 can be achieved by several means, such as UV radiation and treatment with anti-cancer agents (including doxorubicin, etoposide, roscovitine, flavopiridol, and nutlin-3).	Etoposide	134-143	tumor protein p53	Homo sapiens	13-16
23058634-0	2012	Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells.	Etoposide	29-38	ATM serine/threonine kinase	Homo sapiens	14-17
23058634-3	2012	Indeed, we showed that etoposide could influence transcription and was able to activate DDR in resting human T cells by inducing phosphorylation of ATM and its substrates, H2AX and p53.	Etoposide	23-32	ATM serine/threonine kinase	Homo sapiens	148-151
23058634-3	2012	Indeed, we showed that etoposide could influence transcription and was able to activate DDR in resting human T cells by inducing phosphorylation of ATM and its substrates, H2AX and p53.	Etoposide	23-32	H2A.X variant histone	Homo sapiens	172-176
23058634-3	2012	Indeed, we showed that etoposide could influence transcription and was able to activate DDR in resting human T cells by inducing phosphorylation of ATM and its substrates, H2AX and p53.	Etoposide	23-32	tumor protein p53	Homo sapiens	181-184
22249269-9	2012	In addition, treatment with si-JNK greatly increased etoposide- and ionizing radiation (IR)-induced cell death in glioma spheres.	Etoposide	53-62	mitogen-activated protein kinase 8	Homo sapiens	31-34
23189085-5	2012	However, there are additional genes that are relevant for the metabolism, activity, and/or transport of other chemotherapy drugs that are widely use in ALL, such as methotrexate, cyclophosphamide, vincristine, L-asparaginase, etoposide, cytarabine, or cytotoxic antibiotics.	Etoposide	226-235	asparaginase and isoaspartyl peptidase 1	Homo sapiens	210-224
23012366-6	2012	Both the lipid-lowering drug lovastatin and the Rac1-specific inhibitor NSC23766 attenuated doxorubicin- and etoposide-stimulated H2AX phosphorylation, induction of DNA strand breaks, and topo II-DNA complex formation.	Etoposide	109-118	Rac family small GTPase 1	Rattus norvegicus	48-52
23012366-12	2012	Pharmacological inhibition of Rac1 signaling counteracts doxorubicin- and etoposide-stimulated DDR by disabling the formation of the topo II-DNA cleavable complex.	Etoposide	74-83	Rac family small GTPase 1	Rattus norvegicus	30-34
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Etoposide	194-197	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-7	2012	However, low dose (10 muM) or IC50 (70 muM) Eto doses showed G2/M or S-phase arrests, respectively (P&lt;0.001).	Etoposide	44-47	latexin	Homo sapiens	39-42
23248400-9	2012	Moreover, Eto (10 muM) led to decreased percent of cells in G2/M phase when combined with LiCl (P&lt;0.05).	Etoposide	10-13	latexin	Homo sapiens	18-21
22919026-3	2012	A novel regimen dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) showed promise in phase 1/2 studies with restrictive recruitment criteria.	Etoposide	77-86	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	88-93
22415601-9	2012	Moreover, HER4 knockdown increased the chemosensitivity of NBL cells to cisplatin, doxorubicin, etoposide, and activated ifosfamide.	Etoposide	96-105	erb-b2 receptor tyrosine kinase 4	Homo sapiens	10-14
23027940-2	2012	Using nuclear factor-kappaB (NF-kappaB) as a glucose-responsive transcription factor, we show that cells use the hexosamine biosynthesis pathway and O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) to potentiate gene expression in response to tumor necrosis factor (TNF) or etoposide.	Etoposide	288-297	O-linked N-acetylglucosamine (GlcNAc) transferase	Homo sapiens	184-192
22904106-8	2012	The 14-3-3zeta gene is favorable for cancer-cell survival, as its ectopic expression in LNCaP cells contributes to cell proliferation and the acquired resistance to etoposide-induced apoptosis.	Etoposide	165-174	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	4-14
22983592-0	2012	Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin.	Etoposide	10-19	transferrin	Homo sapiens	105-116
22974980-0	2012	PKCdelta promotes etoposide-induced cell death by phosphorylating Hsp27 in HeLa cells.	Etoposide	18-27	heat shock protein family B (small) member 1	Homo sapiens	66-71
22974980-0	2012	PKCdelta promotes etoposide-induced cell death by phosphorylating Hsp27 in HeLa cells.	Etoposide	18-27	protein kinase C delta	Homo sapiens	0-8
22974980-1	2012	We investigated the regulation of Hsp27 phosphorylation by protein kinase C delta (PKCdelta) during etoposide-induced apoptosis.	Etoposide	100-109	heat shock protein family B (small) member 1	Homo sapiens	34-39
22974980-1	2012	We investigated the regulation of Hsp27 phosphorylation by protein kinase C delta (PKCdelta) during etoposide-induced apoptosis.	Etoposide	100-109	protein kinase C delta	Homo sapiens	59-81
22639106-8	2012	Recent studies, however, have identified that L-asparaginase-containing regimens, such as SMILE (steroid, methotrexate, ifosfamide, L-asparaginase and etoposide), are effective for ENKL.	Etoposide	151-160	asparaginase and isoaspartyl peptidase 1	Homo sapiens	46-60
22974980-1	2012	We investigated the regulation of Hsp27 phosphorylation by protein kinase C delta (PKCdelta) during etoposide-induced apoptosis.	Etoposide	100-109	protein kinase C delta	Homo sapiens	83-91
22714278-6	2012	In addition, ATM, p53 and Bax proteins, associated with DNA damage responses and apoptosis, were all upregulated in tilapia liver after treatment with the stress inducers etoposide and CdCl(2).	Etoposide	171-180	cellular tumor antigen p53	Oreochromis niloticus	18-21
22673749-3	2012	The DNA repair protein XRCC4, which is a regulator of DNA ligase IV activity, might be a key contributor to not only chemoresistance to anticancer agents, e.g., etoposide, but also radioresistance.	Etoposide	161-170	DNA repair protein XRCC4	Cricetulus griseus	23-28
22895528-0	2012	Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells.	Etoposide	0-9	BCL2 apoptosis regulator	Homo sapiens	98-103
22895528-5	2012	Furthermore, this study was conducted to examine whether etoposide overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells.	Etoposide	57-66	BCL2 apoptosis regulator	Homo sapiens	105-110
22895528-10	2012	Importantly, etoposide can effectively induce cell death in Bcl-2-overexpressing Hep3B cells.	Etoposide	13-22	BCL2 apoptosis regulator	Homo sapiens	60-65
22895528-14	2012	To this end, we observed that etoposide-induced mixed type of programmed cell death is associated with the dissociation of Bcl-2 from Beclin-1.	Etoposide	30-39	BCL2 apoptosis regulator	Homo sapiens	123-128
22895528-14	2012	To this end, we observed that etoposide-induced mixed type of programmed cell death is associated with the dissociation of Bcl-2 from Beclin-1.	Etoposide	30-39	beclin 1	Homo sapiens	134-142
22895528-15	2012	Taken together, etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells.	Etoposide	16-25	BCL2 apoptosis regulator	Homo sapiens	114-119
22871320-4	2012	In this study, we demonstrate that genotoxic agents (doxorubicin, camptothecin, etoposide and cisplatin), alter the balance between CDC25C splice variants in human breast cancer cell lines both at the mRNA and protein levels.	Etoposide	80-89	cell division cycle 25C	Homo sapiens	132-138
22986342-0	2012	Coilin levels modulate cell cycle progression and gammaH2AX levels in etoposide treated U2OS cells.	Etoposide	70-79	coilin	Homo sapiens	0-6
22907752-8	2012	Silencing of hnRNPC reduced cell proliferation and enhanced etoposide-induced apoptosis.	Etoposide	60-69	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	13-19
22895574-3	2012	E2-EPF             knockdown also increases the chemosensitivity to topoisomerase I inhibitor (topotecan)             and II (etoposide and doxorubicin).	Etoposide	126-135	ubiquitin conjugating enzyme E2 S	Homo sapiens	0-6
22782899-5	2012	However, DCA, associated with etoposide or irradiation, induced a Bax-dependent apoptosis in CSCs in vitro and decreased their proliferation in vivo.	Etoposide	30-39	BCL2 associated X, apoptosis regulator	Rattus norvegicus	66-69
22986342-2	2012	In this report, we investigated the role of coilin in the DNA damage response and found that coilin reduction correlated with significantly increased levels of soluble gammaH2AX in etoposide treated U2OS cells.	Etoposide	181-190	coilin	Homo sapiens	44-50
22986342-2	2012	In this report, we investigated the role of coilin in the DNA damage response and found that coilin reduction correlated with significantly increased levels of soluble gammaH2AX in etoposide treated U2OS cells.	Etoposide	181-190	coilin	Homo sapiens	93-99
22986342-3	2012	Additionally, coilin levels influenced the proliferation rate and cell cycle distribution of cells exposed to etoposide.	Etoposide	110-119	coilin	Homo sapiens	14-20
22986342-4	2012	Moreover, coilin overexpression inhibited nucleolar localization of endogenous coilin in etoposide treated U2OS cells.	Etoposide	89-98	coilin	Homo sapiens	10-16
22986342-4	2012	Moreover, coilin overexpression inhibited nucleolar localization of endogenous coilin in etoposide treated U2OS cells.	Etoposide	89-98	coilin	Homo sapiens	79-85
22116711-8	2012	In contrast, the IC(50)  values of three clinical anticancer drugs, etoposide, paclitaxel and vinblastine were significantly elevated in HER2 and/or P-glycoprotein overexpressing cells.	Etoposide	68-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
22116711-8	2012	In contrast, the IC(50)  values of three clinical anticancer drugs, etoposide, paclitaxel and vinblastine were significantly elevated in HER2 and/or P-glycoprotein overexpressing cells.	Etoposide	68-77	ATP binding cassette subfamily B member 1	Homo sapiens	149-163
22963202-3	2012	In one patient, a combination of bleomycin, etoposide, and cisplatin was effective after initial surgery for malignant GCT.	Etoposide	44-53	glutaminyl-peptide cyclotransferase	Homo sapiens	119-122
22728163-5	2012	The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1.	Etoposide	110-119	host cell factor C1	Homo sapiens	121-125
22954140-8	2012	TMEM45A expression was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e. under hypoxia in the presence of taxol or etoposide.	Etoposide	266-275	transmembrane protein 45A	Homo sapiens	0-7
22954140-12	2012	CONCLUSION: Altogether, our results unravel a new mechanism for taxol and etoposide resistance mediated by TMEM45A.	Etoposide	74-83	transmembrane protein 45A	Homo sapiens	107-114
22892391-8	2012	Ectopic miR-204 expression significantly increased sensitivity to cisplatin and etoposide in vitro.	Etoposide	80-89	microRNA 204	Homo sapiens	8-15
23091446-8	2012	RESULTS: Anti-cancer drug-induced cell death was significantly enhanced by knockdown of MKP-1, and this effect was most prominent in cells treated with irinotecan and etoposide.	Etoposide	167-176	dual specificity phosphatase 1	Homo sapiens	88-93
23139668-3	2012	We present a case of tonsillar SCC successfully treated with induction chemotherapy using carboplatin and etoposide followed by concurrent chemoradiation therapy with cisplatin as radiosensitizer.	Etoposide	106-115	serpin family B member 3	Homo sapiens	31-34
22728163-5	2012	The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1.	Etoposide	110-119	telomerase reverse transcriptase	Homo sapiens	240-272
22728163-5	2012	The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1.	Etoposide	110-119	telomerase reverse transcriptase	Homo sapiens	274-279
22728163-5	2012	The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1.	Etoposide	110-119	tripeptidyl peptidase 1	Homo sapiens	315-319
22728163-5	2012	The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1.	Etoposide	110-119	protection of telomeres 1	Homo sapiens	324-328
22766503-7	2012	Moreover, iASPP and iASPPsv could both help the thymocytes of transgenic mice to resist the growth inhibition and apoptosis caused by dexamethasone (Dex) or VP-16.	Etoposide	157-162	protein phosphatase 1, regulatory subunit 13 like	Mus musculus	10-15
22543673-3	2012	PATIENTS AND METHODS: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy.	Etoposide	241-250	ATP binding cassette subfamily B member 1	Homo sapiens	76-81
22759219-0	2012	The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide.	Etoposide	76-85	RB transcriptional corepressor 1	Homo sapiens	17-31
22681126-6	2012	Drug ratio dependent synergistic cytotoxicity of micellar ETO/17-AAG was observed in MCF-7 cancer cells and of micellar BTZ/17-AAG in MCF-7, PC3, MDA-MB-231 and HepG2 cells.	Etoposide	58-61	N-methylpurine DNA glycosylase	Homo sapiens	65-68
22812606-3	2012	Via proteomic, bioinformatic, and biochemical approaches we identified 31 and 33 proteins co-immunoprecipitating with PKCzeta from nuclear membranes (NMs) of, respectively, untreated or VP-16-exposed C4-I cells.	Etoposide	186-191	protein kinase C zeta	Homo sapiens	118-125
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	protein kinase C zeta	Homo sapiens	38-45
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	BCL10 immune signaling adaptor	Homo sapiens	46-51
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	protein kinase C zeta	Homo sapiens	97-104
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	BCL10 immune signaling adaptor	Homo sapiens	120-125
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	protein kinase C zeta	Homo sapiens	97-104
22812606-7	2012	Notably, in VP-16-treated C4-I cells, PKCzeta Bcl10 complexes increasingly accrued at NMs, where PKCzeta phosphorylated Bcl10, as PKCzeta also did in vitro and in cell-free systems, both processes being thwarted by interfering RNA (iRNA) PKCzeta depletion.	Etoposide	12-17	protein kinase C zeta	Homo sapiens	97-104
22435726-0	2012	Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death.	Etoposide	79-88	CD8a molecule	Homo sapiens	124-127
22613767-0	2012	zVAD-fmk upregulates caspase-9 cleavage and activity in etoposide-induced cell death of mouse embryonic fibroblasts.	Etoposide	56-65	caspase 9	Mus musculus	21-30
22613767-7	2012	In both primary and immortalized (by AgT or 3T9 protocol) MEFs, zVAD-fmk increased etoposide-induced loss of DeltaPsim.	Etoposide	83-92	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	37-40
22613767-11	2012	Indeed, zVAD-fmk inhibited effector caspases (caspases-3, -6, -7) as expected but increased caspase-9 cleavage and activity in etoposide-treated MEFs.	Etoposide	127-136	caspase 9	Mus musculus	92-101
22613767-12	2012	Q-VD-OPh, another caspase inhibitor, also increased both loss of DeltaPsim and caspase-9 cleavage in etoposide-treated MEFs.	Etoposide	101-110	caspase 9	Mus musculus	79-88
22613767-15	2012	Altogether, our data suggest that caspase-9 activity is up-regulated by zVAD-fmk and is involved in an amplification loop of etoposide-induced cell death at the mitochondrial level in MEFs.	Etoposide	125-134	caspase 9	Mus musculus	34-43
22763759-6	2012	However, the growth-inhibitory activity of vincristine, doxorubicin, carboplatin, etoposide, and temozolomide was significantly impaired by silencing of TP53.	Etoposide	82-91	tumor protein p53	Homo sapiens	153-157
22684020-4	2012	Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels.	Etoposide	212-221	kelch like ECH associated protein 1	Homo sapiens	34-39
22435726-5	2012	Following treatment with the classic chemotherapeutic agent etoposide, a topoisomerase II inhibitor, apoptosis was increased in CD8(+) CD28(-)  when compared to CD8(+) CD28(+)  T cells and correlated with an impaired DDR in this cell type.	Etoposide	60-69	CD8a molecule	Homo sapiens	128-131
22435726-5	2012	Following treatment with the classic chemotherapeutic agent etoposide, a topoisomerase II inhibitor, apoptosis was increased in CD8(+) CD28(-)  when compared to CD8(+) CD28(+)  T cells and correlated with an impaired DDR in this cell type.	Etoposide	60-69	CD8a molecule	Homo sapiens	161-164
22435726-7	2012	Interleukin (IL)-15 could prevent etoposide-mediated apoptosis of CD8(+) CD28(-)  T cells, suggesting a role for IL-15 in the survival and the age-dependent accumulation of CD8(+) CD28(-)  T cells in humans.	Etoposide	34-43	interleukin 15	Homo sapiens	0-19
22435726-7	2012	Interleukin (IL)-15 could prevent etoposide-mediated apoptosis of CD8(+) CD28(-)  T cells, suggesting a role for IL-15 in the survival and the age-dependent accumulation of CD8(+) CD28(-)  T cells in humans.	Etoposide	34-43	CD8a molecule	Homo sapiens	66-69
22435726-7	2012	Interleukin (IL)-15 could prevent etoposide-mediated apoptosis of CD8(+) CD28(-)  T cells, suggesting a role for IL-15 in the survival and the age-dependent accumulation of CD8(+) CD28(-)  T cells in humans.	Etoposide	34-43	interleukin 15	Homo sapiens	113-118
22435726-7	2012	Interleukin (IL)-15 could prevent etoposide-mediated apoptosis of CD8(+) CD28(-)  T cells, suggesting a role for IL-15 in the survival and the age-dependent accumulation of CD8(+) CD28(-)  T cells in humans.	Etoposide	34-43	CD8a molecule	Homo sapiens	173-176
21573958-5	2012	Considering that Sal sensitizes doxorubicin (DOX)- or etoposide (ETO)-treated cancer cells by causing DNA damage and reducing p21 expression, the results from our study suggest that the mechanism underlying Sal sensitization is conserved in both chemo- and radiation-treated cells.	Etoposide	54-63	H3 histone pseudogene 16	Homo sapiens	126-129
22491967-5	2012	Second, we have highlighted that during etoposide or TNF-alpha treatments, intracellular ROS level, MMP and cell death are all regulated by caspases and Bcl-2, with caspases acting early in the process.	Etoposide	40-49	BCL2 apoptosis regulator	Homo sapiens	153-158
22739265-6	2012	In addition, etoposide induced p53 phosphorylation and H2AX foci formation in proliferating SH-SY5Y cells but failed to do so in differentiated SH-SY5Y cells.	Etoposide	13-22	tumor protein p53	Homo sapiens	31-34
22739265-6	2012	In addition, etoposide induced p53 phosphorylation and H2AX foci formation in proliferating SH-SY5Y cells but failed to do so in differentiated SH-SY5Y cells.	Etoposide	13-22	H2A.X variant histone	Homo sapiens	55-59
22739265-7	2012	Moreover, while inhibition of ATM in undifferentiated SH-SY5Y cells partially protected them from etoposide-induced apoptosis, the same treatment had no effect on cell viability in differentiated SH-SY5Y cells.	Etoposide	98-107	ATM serine/threonine kinase	Homo sapiens	30-33
22376221-1	2012	INTRODUCTION: Etoposide (VP16) is a drug used not only for the treatment of lymphoma but also for the collection of peripheral blood stem cells (PBSCs).	Etoposide	14-23	host cell factor C1	Homo sapiens	25-29
22675173-1	2012	PURPOSE: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein-Barr virus (EBV)-associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) recently showed promising results.	Etoposide	219-228	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	157-162
21573958-5	2012	Considering that Sal sensitizes doxorubicin (DOX)- or etoposide (ETO)-treated cancer cells by causing DNA damage and reducing p21 expression, the results from our study suggest that the mechanism underlying Sal sensitization is conserved in both chemo- and radiation-treated cells.	Etoposide	65-68	H3 histone pseudogene 16	Homo sapiens	126-129
22576130-8	2012	In clonogenic survival assays, KU-0060648 increased the cytotoxicity of etoposide and doxorubicin across the panel of DNA-PKcs-proficient cells, but not in DNA-PKcs-deficient cells, thus confirming that enhanced cytotoxicity was due to DNA-PK inhibition.	Etoposide	72-81	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	118-126
22886978-0	2012	Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells.	Etoposide	25-34	CD274 antigen	Mus musculus	47-52
22886978-1	2012	This study investigated the effect of etoposide, an anticancer chemotherapy drug, on B7-H1 expression in retinoblastoma (Rb) cells and the role of miR-513a-5p in the process.	Etoposide	38-47	CD274 antigen	Mus musculus	85-90
22886978-9	2012	The results showed that etoposide stimulated the mRNA and protein expression of B7-H1 in Rb cells, which reached a maximal level after treatment with 5 mug/mL etoposide (P&lt;0.05).	Etoposide	24-33	CD274 antigen	Mus musculus	80-85
22886978-9	2012	The results showed that etoposide stimulated the mRNA and protein expression of B7-H1 in Rb cells, which reached a maximal level after treatment with 5 mug/mL etoposide (P&lt;0.05).	Etoposide	159-168	CD274 antigen	Mus musculus	80-85
22886978-14	2012	It was concluded that etoposide can promote B7-H1 expression in Rb cells, which may be associated with chemoresistance.	Etoposide	22-31	CD274 antigen	Mus musculus	44-49
22886978-15	2012	The promoting effect of etoposide on B7-H1 expression can be reversed by miR-513a-5p mimics.	Etoposide	24-33	CD274 antigen	Mus musculus	37-42
22576130-8	2012	In clonogenic survival assays, KU-0060648 increased the cytotoxicity of etoposide and doxorubicin across the panel of DNA-PKcs-proficient cells, but not in DNA-PKcs-deficient cells, thus confirming that enhanced cytotoxicity was due to DNA-PK inhibition.	Etoposide	72-81	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	118-124
22830357-6	2012	In accordance with this hypothesis, etoposide or nutlin-3 treatment or a small interfering RNA (siRNA) against BCL6 (B-cell lymphoma 6) inhibited the proliferation of DoHH2 cells by up-regulating p53 without affecting either miR-34a or c-MYC levels.	Etoposide	36-45	tumor protein p53	Homo sapiens	196-199
22627769-8	2012	Constitutive T-plastin expression in SS was associated with resistance to etoposide-induced apoptosis and cell migration toward chemokines (TARC/CCL17, IP-10).	Etoposide	74-83	plastin 3	Homo sapiens	13-22
23134856-1	2012	OBJECTIVE: To explore the effectivity and safety of single high-dose (HD) etoposide (Vp16) with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood stem cells (PBSC) in patients with hematologic malignancies.	Etoposide	74-83	host cell factor C1	Homo sapiens	85-89
23134856-14	2012	CONCLUSION: Single high-dose etoposide with G-CSF for mobilization of APBSC has a higher achievement ratio, a controllable adverse effect, a promising hematopoiesis recovery, which is an effective and safe mobilizing regimen for patients with hematologic malignancies.	Etoposide	29-38	colony stimulating factor 3	Homo sapiens	44-49
22904680-6	2012	By contrast, p53-72P was more effective in promoting p21-dependent accelerated senescence, alone or in the presence of etoposide.	Etoposide	119-128	tumor protein p53	Homo sapiens	13-16
22528119-6	2012	It was recently shown that the antitumor activity of etoposide was due primarily to the inhibition of Top2alpha, whereas inhibition of Top2beta was responsible for the development of secondary malignancies, pointing to the need for more selective Top2alpha inhibitors.	Etoposide	53-62	DNA topoisomerase II alpha	Homo sapiens	102-111
22528119-9	2012	We further confirmed that Top2alpha inhibition was due to a catalytic inhibition of the enzyme because it did not induce DNA double-strand breaks in CEM-treated cells but prevented the formation of Top2alpha- rather than Top2beta-DNA covalent complexes induced by etoposide.	Etoposide	264-273	DNA topoisomerase II alpha	Homo sapiens	26-35
22528119-9	2012	We further confirmed that Top2alpha inhibition was due to a catalytic inhibition of the enzyme because it did not induce DNA double-strand breaks in CEM-treated cells but prevented the formation of Top2alpha- rather than Top2beta-DNA covalent complexes induced by etoposide.	Etoposide	264-273	DNA topoisomerase II alpha	Homo sapiens	198-207
22528119-9	2012	We further confirmed that Top2alpha inhibition was due to a catalytic inhibition of the enzyme because it did not induce DNA double-strand breaks in CEM-treated cells but prevented the formation of Top2alpha- rather than Top2beta-DNA covalent complexes induced by etoposide.	Etoposide	264-273	DNA topoisomerase II beta	Homo sapiens	221-229
22904680-5	2012	In vitro, p53-72P was less effective than p53-72R in inducing apoptosis and inhibiting survival of p53-null LAN-1 cells treated with etoposide, topotecan, or ionizing radiation but not taxol.	Etoposide	133-142	tumor protein p53	Homo sapiens	10-13
22595795-9	2012	However, drugs that also increase pro-oxidant species can complement the antitumor efficacy of the hIFNbeta gene and clearly caused potentiated effects (bleomycin, bortezomib, carboplatin, etoposide and vincristine).	Etoposide	189-198	interferon beta 1	Homo sapiens	99-107
22550167-0	2012	Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.	Etoposide	56-65	thymoma viral proto-oncogene 1	Mus musculus	29-32
22550167-12	2012	CONCLUSION: Akt inhibition by MK-2206 increased the efficacy of etoposide or rapamycin.	Etoposide	64-73	thymoma viral proto-oncogene 1	Mus musculus	12-15
22851953-3	2012	Topoisomerase II inhibitors, including etoposide and teniposide, frequently cause rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome 11q23, which is associated with secondary leukemia.	Etoposide	39-48	lysine methyltransferase 2A	Homo sapiens	135-138
22851953-4	2012	The prognosis is extremely poor for leukemias associated with rearrangements in the MLL gene, including etoposide-related secondary leukemias.	Etoposide	104-113	lysine methyltransferase 2A	Homo sapiens	84-87
23124518-4	2012	Although TRAIL-R2 expression increased in IMR-32 cells in response to etoposide treatment, cell death was not increased by concurrent treatment with TRAIL compared with etoposide alone, because the cells lacked caspase 8 expression.	Etoposide	70-79	TNF receptor superfamily member 10b	Homo sapiens	9-17
23124518-4	2012	Although TRAIL-R2 expression increased in IMR-32 cells in response to etoposide treatment, cell death was not increased by concurrent treatment with TRAIL compared with etoposide alone, because the cells lacked caspase 8 expression.	Etoposide	70-79	TNF superfamily member 10	Homo sapiens	9-14
23124518-0	2012	Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL.	Etoposide	0-9	caspase 8	Homo sapiens	52-61
23124518-0	2012	Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL.	Etoposide	0-9	TNF superfamily member 10	Homo sapiens	65-70
23124518-6	2012	Moreover, pretreatment with etoposide increased TRAIL-induced apoptosis in caspase 8 restored IMR-32 cells through activation of a caspase cascade that included caspases 8, 9 and 3.	Etoposide	28-37	TNF superfamily member 10	Homo sapiens	48-53
23124518-2	2012	We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC.	Etoposide	43-52	TNF superfamily member 10	Homo sapiens	76-81
23124518-2	2012	We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC.	Etoposide	43-52	TNF receptor superfamily member 10b	Homo sapiens	122-125
23124518-2	2012	We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC.	Etoposide	43-52	TNF receptor superfamily member 10b	Homo sapiens	127-143
23124518-2	2012	We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC.	Etoposide	43-52	TNF receptor superfamily member 10b	Homo sapiens	147-155
23124518-2	2012	We provide evidence that pretreatment with etoposide significantly enhanced TRAIL-mediated apoptosis via up-regulation of DR5 (death receptor 5 or TRAIL-R2) expression in the caspase 8 expressing neuroblastoma cell line, SK-N-MC.	Etoposide	43-52	caspase 8	Homo sapiens	175-184
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	39-48	caspase 3	Homo sapiens	69-88
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	39-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	101-106
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	39-48	BH3 interacting domain death agonist	Homo sapiens	120-123
23124518-6	2012	Moreover, pretreatment with etoposide increased TRAIL-induced apoptosis in caspase 8 restored IMR-32 cells through activation of a caspase cascade that included caspases 8, 9 and 3.	Etoposide	28-37	caspase 8	Homo sapiens	75-84
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	39-48	TNF superfamily member 10	Homo sapiens	185-190
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	171-180	TNF superfamily member 10	Homo sapiens	53-58
23124518-6	2012	Moreover, pretreatment with etoposide increased TRAIL-induced apoptosis in caspase 8 restored IMR-32 cells through activation of a caspase cascade that included caspases 8, 9 and 3.	Etoposide	28-37	caspase 8	Homo sapiens	161-180
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	171-180	caspase 3	Homo sapiens	69-88
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	171-180	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	101-106
23124518-7	2012	These results indicate that the etoposide-mediated sensitization of neuroblastoma cells to TRAIL is associated with an increase in TRAIL-R2 expression and requires caspase 8 expression.	Etoposide	32-41	TNF superfamily member 10	Homo sapiens	91-96
23124518-3	2012	In addition, sequential treatment with etoposide and TRAIL increased caspases 8, 9 and 3 activation, Mcl-1 cleavage and Bid truncation, which suggests that the ability of etoposide and TRAIL to induce apoptosis is mediated through activation of an intrinsic signalling pathway.	Etoposide	171-180	BH3 interacting domain death agonist	Homo sapiens	120-123
23124518-7	2012	These results indicate that the etoposide-mediated sensitization of neuroblastoma cells to TRAIL is associated with an increase in TRAIL-R2 expression and requires caspase 8 expression.	Etoposide	32-41	TNF receptor superfamily member 10b	Homo sapiens	131-139
23124518-7	2012	These results indicate that the etoposide-mediated sensitization of neuroblastoma cells to TRAIL is associated with an increase in TRAIL-R2 expression and requires caspase 8 expression.	Etoposide	32-41	caspase 8	Homo sapiens	164-173
22553204-11	2012	Furthermore, we demonstrated that Bfl-1 knockdown sensitizes HTLV-1-infected T-cells to ABT-737 or etoposide treatment.	Etoposide	99-108	BCL2 related protein A1	Homo sapiens	34-39
22922139-9	2012	The NUDT21 (nudix, nucleoside diphosphate linked moiety X-type, motif 21) gene showed the strongest correlation with resistance to etoposide (FDR&lt;0.0001%).	Etoposide	131-140	nudix hydrolase 21	Homo sapiens	4-10
22615413-5	2012	We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIbeta, but that topoisomerase IIalpha and -beta occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML.	Etoposide	18-27	lysine methyltransferase 2A	Homo sapiens	61-64
22511763-8	2012	Etoposide treatment also resulted in activation of the upstream promoter as well as nuclear accumulation of TLP and p53.	Etoposide	0-9	TATA-box binding protein like 1	Homo sapiens	108-111
22511763-8	2012	Etoposide treatment also resulted in activation of the upstream promoter as well as nuclear accumulation of TLP and p53.	Etoposide	0-9	tumor protein p53	Homo sapiens	116-119
22615413-5	2012	We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIbeta, but that topoisomerase IIalpha and -beta occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML.	Etoposide	18-27	DNA topoisomerase II beta	Homo sapiens	161-192
22615413-5	2012	We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIbeta, but that topoisomerase IIalpha and -beta occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML.	Etoposide	18-27	lysine methyltransferase 2A	Homo sapiens	340-343
22615413-5	2012	We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIbeta, but that topoisomerase IIalpha and -beta occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML.	Etoposide	103-112	lysine methyltransferase 2A	Homo sapiens	340-343
22615413-5	2012	We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIbeta, but that topoisomerase IIalpha and -beta occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML.	Etoposide	103-112	lysine methyltransferase 2A	Homo sapiens	340-343
22556124-3	2012	When the level of ER beta was high, DHEA (10 - 7  mol/l) could effectively amplify the proliferation and inhibit the etoposide-induced apoptosis of hMG63 cells (p&lt;0.01 and p&lt;0.05, respectively), which was blocked by U0126.	Etoposide	117-126	estrogen receptor 2	Homo sapiens	18-25
22617334-3	2012	Analysis of the dynamic phosphorylation and location of phospho-Bcl-xL(Ser62) in unperturbed, synchronized cells and during DNA damage-induced G 2 arrest discloses that a pool of phospho-Bcl-xL(Ser62) accumulates into nucleolar structures in etoposide-exposed cells during G 2 arrest.	Etoposide	242-251	BCL2 like 1	Homo sapiens	64-70
22764771-5	2012	Important examples include ketoconazole inhibition of hepatic CYP3A4 in order to increase systemic exposure to docetaxel, irinotecan and etoposide, and cyclosporine inhibition of intestinal ATP-binding cassette transporters in order to decrease the toxicity of irinotecan and increase the bioavailability of oral docetaxel, paclitaxel and topotecan.	Etoposide	137-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
22593196-6	2012	In contrast, loss of RASSF3 promoted cell-cycle progression, abrogated UVB- and VP-16-induced G(1)-S arrest, decreased p53 protein and target gene expression, and prevented DNA repair.	Etoposide	80-85	Ras association domain family member 3	Homo sapiens	21-27
22238053-0	2012	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.	Etoposide	175-184	BCL2 apoptosis regulator	Homo sapiens	64-68
22238053-0	2012	Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.	Etoposide	175-184	BCL2 like 12	Homo sapiens	78-85
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Etoposide	54-63	BCL2 like 12	Homo sapiens	107-114
22238053-12	2012	Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated.	Etoposide	14-23	BCL2 apoptosis regulator	Homo sapiens	63-67
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Etoposide	54-63	BCL2 apoptosis regulator	Homo sapiens	93-97
22238053-12	2012	Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated.	Etoposide	14-23	BCL2 associated X, apoptosis regulator	Homo sapiens	115-118
22238053-11	2012	Treatment of AGS cells with 10 muM cisplatin, 0.5 muM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells.	Etoposide	54-63	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102
22564744-0	2012	p53 Retards cell-growth and suppresses etoposide-induced apoptosis in Pin1-deficient mouse embryonic fibroblasts.	Etoposide	39-48	transformation related protein 53, pseudogene	Mus musculus	0-3
22967374-11	2012	The SKM-1/HHT cell line showed significant drug resistance to HHT, VCR, DNR and etoposide, the resistance indices of HHT, VCR, DNR and etoposide were 17.94, 8.75, 5.99 and 13.76 respectively.	Etoposide	80-89	sodium voltage-gated channel alpha subunit 4	Homo sapiens	4-9
22967374-11	2012	The SKM-1/HHT cell line showed significant drug resistance to HHT, VCR, DNR and etoposide, the resistance indices of HHT, VCR, DNR and etoposide were 17.94, 8.75, 5.99 and 13.76 respectively.	Etoposide	135-144	sodium voltage-gated channel alpha subunit 4	Homo sapiens	4-9
22564744-0	2012	p53 Retards cell-growth and suppresses etoposide-induced apoptosis in Pin1-deficient mouse embryonic fibroblasts.	Etoposide	39-48	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	70-74
22564744-1	2012	We studied the effects of Pin1, a regulatory molecule of the oncosuppressor p53, on both cell cycle arrest and apoptosis by treating primary mouse embryonic fibroblasts (MEFs) with etoposide.	Etoposide	181-190	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	26-30
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	50-54
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	61-65
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	152-155
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	170-174
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	152-155
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	184-188
22564744-2	2012	Etoposide induced G1 arrest in both wild-type and Pin1 null (pin1(-/-)) MEFs, and G2/M arrest and apoptotic cell death in MEFs lacking either p53 only (p53(-/-)) or both Pin1 and p53 (pin1(-/-)p53(-/-)).	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	152-155
22564744-4	2012	In response to etoposide treatment, apoptotic cell death was displayed in pin1(-/-)p53(-/-) MEFs but not in pin1(-/-) MEFs.	Etoposide	15-24	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	74-78
22564744-4	2012	In response to etoposide treatment, apoptotic cell death was displayed in pin1(-/-)p53(-/-) MEFs but not in pin1(-/-) MEFs.	Etoposide	15-24	transformation related protein 53, pseudogene	Mus musculus	83-86
22564744-5	2012	These results suggest that p53 retards growth and suppresses etoposide-induced apoptosis in pin1(-/-) MEFs.	Etoposide	61-70	transformation related protein 53, pseudogene	Mus musculus	27-30
22564744-5	2012	These results suggest that p53 retards growth and suppresses etoposide-induced apoptosis in pin1(-/-) MEFs.	Etoposide	61-70	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	92-96
22528748-6	2012	The FRET-based CE system is composed of a homemade CE system and a laser source for detecting the dynamics of caspase-3 in various cells expressing sensors of caspase-3 that have been treated with anticancer drugs, such as cell cycle-independent drug cisplatin and specific cell cycle drugs camptothecin and etoposide, as well as their combination with tumor necrosis factor (TNF).	Etoposide	308-317	caspase 3	Homo sapiens	110-119
22673516-0	2012	Nemo-like kinase promotes etoposide-induced apoptosis of male germ cell-derived GC-1 cells in vitro.	Etoposide	26-35	nemo like kinase	Mus musculus	0-16
22673516-5	2012	NLK overexpression promoted etoposide-induced apoptosis of male germ cell-derived GC-1 cells, while knockdown of NLK by RNA interference (RNAi) attenuated etoposide-induced apoptosis.	Etoposide	28-37	nemo like kinase	Mus musculus	0-3
22673516-5	2012	NLK overexpression promoted etoposide-induced apoptosis of male germ cell-derived GC-1 cells, while knockdown of NLK by RNA interference (RNAi) attenuated etoposide-induced apoptosis.	Etoposide	155-164	nemo like kinase	Mus musculus	113-116
22673516-6	2012	Our findings suggest that NLK plays an important role in etoposide-induced germ cell apoptosis and may be associated with spermatogenesis.	Etoposide	57-66	nemo like kinase	Mus musculus	26-29
22528748-6	2012	The FRET-based CE system is composed of a homemade CE system and a laser source for detecting the dynamics of caspase-3 in various cells expressing sensors of caspase-3 that have been treated with anticancer drugs, such as cell cycle-independent drug cisplatin and specific cell cycle drugs camptothecin and etoposide, as well as their combination with tumor necrosis factor (TNF).	Etoposide	308-317	caspase 3	Homo sapiens	159-168
22529100-5	2012	Accordingly, small interfering ribonucleic acid-mediated knockdown of Cdh1 stabilized MOAP-1, thereby enhancing etoposide-induced Bax activation and apoptosis.	Etoposide	112-121	cadherin 1	Homo sapiens	70-74
22529100-5	2012	Accordingly, small interfering ribonucleic acid-mediated knockdown of Cdh1 stabilized MOAP-1, thereby enhancing etoposide-induced Bax activation and apoptosis.	Etoposide	112-121	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
22888539-6	2012	Our data suggest the possibility that the increased acetylation of eEF1A could be a new mechanism for the antitumour effect of etoposide.	Etoposide	127-136	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	67-72
22508727-0	2012	Mutant p53 cooperates with ETS2 to promote etoposide resistance.	Etoposide	43-52	tumor protein p53	Homo sapiens	7-10
22389449-7	2012	Hypoxic cells containing VDAC1-DeltaC were less sensitive to staurosporine- and etoposide-induced cell death, and silencing of VDAC1-DeltaC or treatment with the tetracycline antibiotics restored sensitivity.	Etoposide	80-89	voltage dependent anion channel 1	Homo sapiens	25-30
22508727-0	2012	Mutant p53 cooperates with ETS2 to promote etoposide resistance.	Etoposide	43-52	ETS proto-oncogene 2, transcription factor	Homo sapiens	27-31
22508727-4	2012	Importantly, we identified TDP2, a 5"-tyrosyl DNA phosphodiesterase involved in the repair of DNA damage caused by etoposide, as a transcriptional target of mtp53.	Etoposide	115-124	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	27-31
22508727-4	2012	Importantly, we identified TDP2, a 5"-tyrosyl DNA phosphodiesterase involved in the repair of DNA damage caused by etoposide, as a transcriptional target of mtp53.	Etoposide	115-124	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	35-67
22508727-5	2012	We demonstrate that suppression of TDP2 sensitizes mtp53-expressing cells to etoposide and that mtp53 and TDP2 are frequently overexpressed in human lung cancer; thus, our analysis identifies a potentially "druggable" component of mtp53"s gain-of-function activity.	Etoposide	77-86	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	35-39
22275372-8	2012	Moreover, dysfunctional/mutant inhibitor of Nrf2 (INrf2) in human lung cancer cells failed to degrade Nrf2, resulting in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	160-169	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48
22420656-0	2012	Etoposide modulates the effects of oral morphine analgesia by targeting the intestinal P-glycoprotein.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
22420656-1	2012	OBJECTIVES: Opioids and anticancer compounds such as etoposide (ETP) are substrates of P-glycoprotein (P-gp), an ATP-dependent efflux pump.	Etoposide	53-62	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
22420656-1	2012	OBJECTIVES: Opioids and anticancer compounds such as etoposide (ETP) are substrates of P-glycoprotein (P-gp), an ATP-dependent efflux pump.	Etoposide	53-62	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
22420656-1	2012	OBJECTIVES: Opioids and anticancer compounds such as etoposide (ETP) are substrates of P-glycoprotein (P-gp), an ATP-dependent efflux pump.	Etoposide	64-67	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
22420656-1	2012	OBJECTIVES: Opioids and anticancer compounds such as etoposide (ETP) are substrates of P-glycoprotein (P-gp), an ATP-dependent efflux pump.	Etoposide	64-67	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
22420656-7	2012	KEY FINDINGS: ETP and morphine significantly decreased the intestinal Rhodamine 123 efflux activity of P-gp.	Etoposide	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
22420656-9	2012	However, repeated pretreatment (7 days) with oral ETP significantly decreased the oral morphine-induced analgesia, in a cyclosporine A (a P-gp inhibitor) reversible manner.	Etoposide	50-53	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
22375014-4	2012	We found that Tdp1-/- cells were not only hypersensitive to camptothecin and bleomycin but also to etoposide, methyl methanesulfonate (MMS), H(2)O(2), and ionizing radiation.	Etoposide	99-108	tyrosyl-DNA phosphodiesterase 1	Gallus gallus	14-18
22389472-0	2012	Inhibition of OCTN2-mediated transport of carnitine by etoposide.	Etoposide	55-64	solute carrier family 22 member 5	Homo sapiens	14-19
22389472-6	2012	Of these inhibitors, etoposide was itself a transported substrate of hOCTN2 and mOctn2.	Etoposide	21-30	solute carrier family 22 member 5	Homo sapiens	69-75
22389472-6	2012	Of these inhibitors, etoposide was itself a transported substrate of hOCTN2 and mOctn2.	Etoposide	21-30	solute carrier family 22 (organic cation transporter), member 5	Mus musculus	80-86
22389472-7	2012	Etoposide uptake by hOCTN2 was reversed in the presence of excess carnitine.	Etoposide	0-9	solute carrier family 22 member 5	Homo sapiens	20-26
22389472-11	2012	Collectively, these findings indicate that etoposide can inhibit hOCTN2 function, potentially disturb carnitine homeostasis, and that this phenomenon can contribute to treatment-related toxicities.	Etoposide	43-52	solute carrier family 22 member 5	Homo sapiens	65-71
22275372-8	2012	Moreover, dysfunctional/mutant inhibitor of Nrf2 (INrf2) in human lung cancer cells failed to degrade Nrf2, resulting in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	160-169	kelch like ECH associated protein 1	Homo sapiens	50-55
22275372-8	2012	Moreover, dysfunctional/mutant inhibitor of Nrf2 (INrf2) in human lung cancer cells failed to degrade Nrf2, resulting in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	160-169	NFE2 like bZIP transcription factor 2	Homo sapiens	51-55
22275372-10	2012	Furthermore, the specific knockdown of Bcl-2 in Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival and growth/proliferation.	Etoposide	92-101	BCL2 apoptosis regulator	Homo sapiens	39-44
22275372-10	2012	Furthermore, the specific knockdown of Bcl-2 in Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival and growth/proliferation.	Etoposide	92-101	NFE2 like bZIP transcription factor 2	Homo sapiens	48-52
21923755-6	2012	Using HEK cells, etoposide was identified as a substrate of OATP1B1.	Etoposide	17-26	solute carrier organic anion transporter family member 1B1	Homo sapiens	60-67
22167413-3	2012	The mTOR signaling pathway is frequently activated in acute myelogenous leukemia (AML) and we previously showed the safety of combining the mTOR inhibitor, sirolimus, with mitoxantrone, etoposide, and cytarabine (MEC) chemotherapy.	Etoposide	186-195	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22200537-0	2012	Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.	Etoposide	26-35	tumor protein p53	Homo sapiens	54-57
22200537-1	2012	The objective of present investigation was to develop and assess comparative enhancement in cytotoxicity of liposomal Etoposide and Docetaxel in non-small cell lung cancer cell lines after pre-treatment and co-administration of p53 tumor suppressor gene and to assess direct lung targeting of optimized formulations by dry powder inhaler technology.	Etoposide	118-127	tumor protein p53	Homo sapiens	228-231
21923755-7	2012	Intracellular concentrations of etoposide equivalents (i.e. parent compound plus metabolites) were affected only to a minor extent by the absence or presence of OATP1B1/UGT1A1/MRP2.	Etoposide	32-41	solute carrier organic anion transporter family member 1B1	Homo sapiens	161-168
21923755-2	2012	However, limited data are available on transport of drugs (e.g. ezetimibe, etoposide) and their glucuronidated metabolites by human MRP2 in intact cell systems.	Etoposide	75-84	ATP binding cassette subfamily C member 2	Homo sapiens	132-136
21923755-7	2012	Intracellular concentrations of etoposide equivalents (i.e. parent compound plus metabolites) were affected only to a minor extent by the absence or presence of OATP1B1/UGT1A1/MRP2.	Etoposide	32-41	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	169-175
21923755-7	2012	Intracellular concentrations of etoposide equivalents (i.e. parent compound plus metabolites) were affected only to a minor extent by the absence or presence of OATP1B1/UGT1A1/MRP2.	Etoposide	32-41	ATP binding cassette subfamily C member 2	Homo sapiens	176-180
21923755-8	2012	In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line.	Etoposide	36-45	ATP binding cassette subfamily C member 2	Homo sapiens	127-131
21923755-8	2012	In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line.	Etoposide	36-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	138-145
21923755-8	2012	In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line.	Etoposide	36-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	157-164
21923755-8	2012	In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line.	Etoposide	36-45	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	165-171
21923755-8	2012	In contrast, apical accumulation of etoposide equivalents was significantly higher in monolayers of both cell lines expressing MRP2 (MDCK-OATP1B1-MRP2, MDCK-OATP1B1-UGT1A1-MRP2) compared with the single-transfected (OATP1B1) and the control cell line.	Etoposide	36-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	157-164
21923755-10	2012	Moreover, etoposide and possibly also its glucuronide are substrates of MRP2.	Etoposide	10-19	ATP binding cassette subfamily C member 2	Homo sapiens	72-76
22525550-5	2012	After induction chemotherapy with ICE (Ifosfamide, Carboplatin, Etoposide), she developed neutropenia and high fever without apparent infective foci.	Etoposide	64-73	carboxylesterase 2	Homo sapiens	34-37
22445976-1	2012	OBJECTIVE: To observe the influence of Cx26/Cx32 gap junction channel on the antineoplastic effect of etoposide in Hela cervical cancer cells.	Etoposide	102-111	gap junction protein beta 2	Homo sapiens	39-43
22058208-8	2012	Furthermore, re-expression of TWIST2 resulted in increased sensitivity to the chemotherapeutic agents etoposide, daunorubicin and dexamethasone and TWIST2 hypermethylation was almost invariably found in relapsed adult acute lymphoblastic leukemia (91% of samples hypermethylated).	Etoposide	102-111	twist family bHLH transcription factor 2	Homo sapiens	30-36
22349704-3	2012	After knockdown of FOXO3 or expression of a dominant-negative FOXO3 mutant we observed that etoposide- and doxorubicin-induced elevation of cellular ROS depends on FOXO3 activation and induction of its transcriptional target BCL2L11 (Bim).	Etoposide	92-101	forkhead box O3	Homo sapiens	19-24
22349704-3	2012	After knockdown of FOXO3 or expression of a dominant-negative FOXO3 mutant we observed that etoposide- and doxorubicin-induced elevation of cellular ROS depends on FOXO3 activation and induction of its transcriptional target BCL2L11 (Bim).	Etoposide	92-101	forkhead box O3	Homo sapiens	62-67
22349704-3	2012	After knockdown of FOXO3 or expression of a dominant-negative FOXO3 mutant we observed that etoposide- and doxorubicin-induced elevation of cellular ROS depends on FOXO3 activation and induction of its transcriptional target BCL2L11 (Bim).	Etoposide	92-101	forkhead box O3	Homo sapiens	62-67
22349704-3	2012	After knockdown of FOXO3 or expression of a dominant-negative FOXO3 mutant we observed that etoposide- and doxorubicin-induced elevation of cellular ROS depends on FOXO3 activation and induction of its transcriptional target BCL2L11 (Bim).	Etoposide	92-101	BCL2 like 11	Homo sapiens	225-232
22053010-0	2012	Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.	Etoposide	150-159	mitogen-activated protein kinase 14	Homo sapiens	14-17
22053010-1	2012	Etoposide (VP-16), a topoisomerase II inhibitor, is an effective anticancer drug currently used for the treatment of a wide range of cancers.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
22053010-4	2012	In this study, the effects of p38 mitogen-activated protein kinase (MAPK) signal on the ERCC1 expression induced by etoposide in non-small cell lung cancer (NSCLC) cell lines was investigated.	Etoposide	116-125	mitogen-activated protein kinase 14	Homo sapiens	30-66
22053010-4	2012	In this study, the effects of p38 mitogen-activated protein kinase (MAPK) signal on the ERCC1 expression induced by etoposide in non-small cell lung cancer (NSCLC) cell lines was investigated.	Etoposide	116-125	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	88-93
22053010-5	2012	Etoposide increased phosphorylated MAPK kinase 3/6 (MKK3/6)-p38 MAPK and ERCC1 protein and mRNA levels in A549 and H1975 cells.	Etoposide	0-9	mitogen-activated protein kinase kinase 3	Homo sapiens	52-58
22053010-5	2012	Etoposide increased phosphorylated MAPK kinase 3/6 (MKK3/6)-p38 MAPK and ERCC1 protein and mRNA levels in A549 and H1975 cells.	Etoposide	0-9	mitogen-activated protein kinase 14	Homo sapiens	60-63
22053010-5	2012	Etoposide increased phosphorylated MAPK kinase 3/6 (MKK3/6)-p38 MAPK and ERCC1 protein and mRNA levels in A549 and H1975 cells.	Etoposide	0-9	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	73-78
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	138-147	mitogen-activated protein kinase 14	Homo sapiens	22-25
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	138-147	mitogen-activated protein kinase 14	Homo sapiens	53-56
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	138-147	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	156-161
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	204-213	mitogen-activated protein kinase 14	Homo sapiens	22-25
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	204-213	mitogen-activated protein kinase 14	Homo sapiens	53-56
22053010-6	2012	Moreover, SB202190, a p38 inhibitor, or knockdown of p38 expression by specific short interfering RNA (siRNA) significantly decreased the etoposide-induced ERCC1 protein levels and DNA repair capacity in etoposide-exposed NSCLC cells.	Etoposide	204-213	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	156-161
22053010-8	2012	Specific inhibition of ERCC1 by siRNA significantly enhanced the etoposide-induced cytotoxicity and hypoxanthine guanine phosphoribosyltransferase (hprt) gene mutation rate.	Etoposide	65-74	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	23-28
22053010-9	2012	Moreover, the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) could decrease the etoposide-induced p38 MAPK-mediated ERCC1 expression and augment the cytotoxic effect and growth inhibition by etopsoside.	Etoposide	97-106	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
22053010-9	2012	Moreover, the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) could decrease the etoposide-induced p38 MAPK-mediated ERCC1 expression and augment the cytotoxic effect and growth inhibition by etopsoside.	Etoposide	97-106	mitogen-activated protein kinase 14	Homo sapiens	115-118
22053010-9	2012	Moreover, the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) could decrease the etoposide-induced p38 MAPK-mediated ERCC1 expression and augment the cytotoxic effect and growth inhibition by etopsoside.	Etoposide	97-106	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	133-138
22053010-10	2012	17-AAG and etoposide-induced synergistic cytotoxic effect and DNA repair capacity decrease could be abrogated in lung cancer cells with MKK6E or HA-p38 MAPK expression vector transfection.	Etoposide	11-20	mitogen-activated protein kinase kinase 6	Homo sapiens	136-141
22053010-10	2012	17-AAG and etoposide-induced synergistic cytotoxic effect and DNA repair capacity decrease could be abrogated in lung cancer cells with MKK6E or HA-p38 MAPK expression vector transfection.	Etoposide	11-20	mitogen-activated protein kinase 14	Homo sapiens	148-151
22053010-11	2012	Our results suggest that in human NSCLC cells, ERCC1 is induced by etoposide through the p38 MAPK pathway, and this phenomenon is required for NSCLC survival and resistant DNA damage.	Etoposide	67-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52
22053010-11	2012	Our results suggest that in human NSCLC cells, ERCC1 is induced by etoposide through the p38 MAPK pathway, and this phenomenon is required for NSCLC survival and resistant DNA damage.	Etoposide	67-76	mitogen-activated protein kinase 14	Homo sapiens	89-92
22445976-0	2012	[Influence of Cx26/Cx32 gap junction channel on antineoplastic effect of etoposide in Hela cells].	Etoposide	73-82	gap junction protein beta 2	Homo sapiens	14-18
22445976-0	2012	[Influence of Cx26/Cx32 gap junction channel on antineoplastic effect of etoposide in Hela cells].	Etoposide	73-82	gap junction protein beta 1	Homo sapiens	19-23
22445976-1	2012	OBJECTIVE: To observe the influence of Cx26/Cx32 gap junction channel on the antineoplastic effect of etoposide in Hela cervical cancer cells.	Etoposide	102-111	gap junction protein beta 1	Homo sapiens	44-48
22445976-8	2012	CONCLUSION: The antineoplastic effect of etoposide is reduced in Hela cells with a decreased gap junction intercellular communication mediated by Cx26/Cx32 and is enhanced in cells with an increased gap junction intercellular communication.	Etoposide	41-50	gap junction protein beta 2	Homo sapiens	146-150
22445976-8	2012	CONCLUSION: The antineoplastic effect of etoposide is reduced in Hela cells with a decreased gap junction intercellular communication mediated by Cx26/Cx32 and is enhanced in cells with an increased gap junction intercellular communication.	Etoposide	41-50	gap junction protein beta 1	Homo sapiens	151-155
22227404-8	2012	Similarly, etoposide-induced blood MN-RET were not evident 1 day after administration began, but a robust effect was apparent 2 days after treatments were initiated.	Etoposide	11-20	ret proto-oncogene	Canis lupus familiaris	38-41
22108201-4	2012	Ectopically expressed C-terminal fragment, but not N-terminal fragment of phospholipase D1, is exclusively imported into the nucleus via a nuclear localization sequence; however, endogenous C-terminal fragment of phospholipase D1 from etoposide-induced apoptotic cells and Alzheimer"s disease brain tissues with active caspase-3, was localized in the cytosolic fraction as well as the nuclear fraction.	Etoposide	235-244	phospholipase D1	Homo sapiens	213-229
21725365-4	2012	GSK3beta inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients.	Etoposide	44-53	glycogen synthase kinase 3 beta	Homo sapiens	0-8
22222202-0	2012	EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide.	Etoposide	76-85	epidermal growth factor	Homo sapiens	0-3
22222202-1	2012	To enhance the therapeutic potential of etoposide (ETO), we devised a targeted drug delivery system (TDDS) of epidermal growth factor-chitosan-carboxyl single-walled carbon nanotubes-ETO (EGF/CHI/SWNT-COOHs/ETO) using modified SWNTs (m-SWNTs) as the carrier, EGF-functionalized SWNTs (f-SWNTs) as the targeted moiety and ETO as the drug.	Etoposide	40-49	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	51-54
22222202-1	2012	To enhance the therapeutic potential of etoposide (ETO), we devised a targeted drug delivery system (TDDS) of epidermal growth factor-chitosan-carboxyl single-walled carbon nanotubes-ETO (EGF/CHI/SWNT-COOHs/ETO) using modified SWNTs (m-SWNTs) as the carrier, EGF-functionalized SWNTs (f-SWNTs) as the targeted moiety and ETO as the drug.	Etoposide	40-49	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	183-186
22222202-1	2012	To enhance the therapeutic potential of etoposide (ETO), we devised a targeted drug delivery system (TDDS) of epidermal growth factor-chitosan-carboxyl single-walled carbon nanotubes-ETO (EGF/CHI/SWNT-COOHs/ETO) using modified SWNTs (m-SWNTs) as the carrier, EGF-functionalized SWNTs (f-SWNTs) as the targeted moiety and ETO as the drug.	Etoposide	40-49	epidermal growth factor	Homo sapiens	188-210
22222202-1	2012	To enhance the therapeutic potential of etoposide (ETO), we devised a targeted drug delivery system (TDDS) of epidermal growth factor-chitosan-carboxyl single-walled carbon nanotubes-ETO (EGF/CHI/SWNT-COOHs/ETO) using modified SWNTs (m-SWNTs) as the carrier, EGF-functionalized SWNTs (f-SWNTs) as the targeted moiety and ETO as the drug.	Etoposide	40-49	epidermal growth factor	Homo sapiens	188-191
22222202-1	2012	To enhance the therapeutic potential of etoposide (ETO), we devised a targeted drug delivery system (TDDS) of epidermal growth factor-chitosan-carboxyl single-walled carbon nanotubes-ETO (EGF/CHI/SWNT-COOHs/ETO) using modified SWNTs (m-SWNTs) as the carrier, EGF-functionalized SWNTs (f-SWNTs) as the targeted moiety and ETO as the drug.	Etoposide	40-49	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	183-186
22285073-0	2012	Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.	Etoposide	87-96	topoisomerase (DNA) II alpha	Mus musculus	23-28
22285073-0	2012	Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.	Etoposide	87-96	mutL homolog 1	Mus musculus	39-43
22285073-2	2012	Etoposide is a topoisomerase II alpha (TOP2A) inhibitor, which is used in the treatment of breast cancer.	Etoposide	0-9	DNA topoisomerase II alpha	Homo sapiens	39-44
22285073-4	2012	In this study, expression changes in TOP2A gene and two important mismatch repair (MMR) genes MSH2 and MLH1 were examined in order to understand the relationship between differential expression of these genes and drug resistance against etoposide.	Etoposide	237-246	DNA topoisomerase II alpha	Homo sapiens	37-42
22285073-4	2012	In this study, expression changes in TOP2A gene and two important mismatch repair (MMR) genes MSH2 and MLH1 were examined in order to understand the relationship between differential expression of these genes and drug resistance against etoposide.	Etoposide	237-246	mutS homolog 2	Homo sapiens	94-98
22285073-4	2012	In this study, expression changes in TOP2A gene and two important mismatch repair (MMR) genes MSH2 and MLH1 were examined in order to understand the relationship between differential expression of these genes and drug resistance against etoposide.	Etoposide	237-246	mutL homolog 1	Homo sapiens	103-107
22285073-10	2012	TOP2A, MSH2 and MLH1 expressions decreased in etoposide resistant sublines relative to MCF7/S cells.	Etoposide	46-55	DNA topoisomerase II alpha	Homo sapiens	0-5
22285073-10	2012	TOP2A, MSH2 and MLH1 expressions decreased in etoposide resistant sublines relative to MCF7/S cells.	Etoposide	46-55	mutS homolog 2	Homo sapiens	7-11
22285073-10	2012	TOP2A, MSH2 and MLH1 expressions decreased in etoposide resistant sublines relative to MCF7/S cells.	Etoposide	46-55	mutL homolog 1	Homo sapiens	16-20
22285073-14	2012	CONCLUSIONS: Decrease in the expression levels of TOP2A, MSH2 and MLH1 may play significant roles in the development of chemotherapeutic resistance to etoposide in breast cancer.	Etoposide	151-160	DNA topoisomerase II alpha	Homo sapiens	50-55
22285073-14	2012	CONCLUSIONS: Decrease in the expression levels of TOP2A, MSH2 and MLH1 may play significant roles in the development of chemotherapeutic resistance to etoposide in breast cancer.	Etoposide	151-160	mutS homolog 2	Homo sapiens	57-61
22285073-14	2012	CONCLUSIONS: Decrease in the expression levels of TOP2A, MSH2 and MLH1 may play significant roles in the development of chemotherapeutic resistance to etoposide in breast cancer.	Etoposide	151-160	mutL homolog 1	Homo sapiens	66-70
22282239-13	2012	But etoposide, a nucleoside analogue, which could activate DNA-PKcs and ATM, increased Pim expression in ECs.	Etoposide	4-13	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	59-67
21503882-0	2012	Involvement of TACE/ADAM17 and ADAM10 in etoposide-induced apoptosis of germ cells in rat spermatogenesis.	Etoposide	41-50	ADAM metallopeptidase domain 17	Rattus norvegicus	15-19
21503882-0	2012	Involvement of TACE/ADAM17 and ADAM10 in etoposide-induced apoptosis of germ cells in rat spermatogenesis.	Etoposide	41-50	ADAM metallopeptidase domain 17	Rattus norvegicus	20-26
21503882-0	2012	Involvement of TACE/ADAM17 and ADAM10 in etoposide-induced apoptosis of germ cells in rat spermatogenesis.	Etoposide	41-50	ADAM metallopeptidase domain 10	Rattus norvegicus	31-37
21503882-2	2012	We have recently shown that in vitro, etoposide induces upregulation of TACE/ADAM17 and ADAM10, two membrane-bound extracellular metalloproteases.	Etoposide	38-47	ADAM metallopeptidase domain 17	Rattus norvegicus	72-76
21503882-2	2012	We have recently shown that in vitro, etoposide induces upregulation of TACE/ADAM17 and ADAM10, two membrane-bound extracellular metalloproteases.	Etoposide	38-47	ADAM metallopeptidase domain 17	Rattus norvegicus	77-83
21503882-2	2012	We have recently shown that in vitro, etoposide induces upregulation of TACE/ADAM17 and ADAM10, two membrane-bound extracellular metalloproteases.	Etoposide	38-47	ADAM metallopeptidase domain 10	Rattus norvegicus	88-94
21503882-6	2012	Pharmacological in vivo inhibition of TACE/ADAM17 and ADAM10 prevents etoposide-induced germ cell apoptosis.	Etoposide	70-79	ADAM metallopeptidase domain 17	Rattus norvegicus	38-42
21503882-6	2012	Pharmacological in vivo inhibition of TACE/ADAM17 and ADAM10 prevents etoposide-induced germ cell apoptosis.	Etoposide	70-79	ADAM metallopeptidase domain 17	Rattus norvegicus	43-49
21503882-6	2012	Pharmacological in vivo inhibition of TACE/ADAM17 and ADAM10 prevents etoposide-induced germ cell apoptosis.	Etoposide	70-79	ADAM metallopeptidase domain 10	Rattus norvegicus	54-60
21503882-7	2012	Finally, Gleevec (STI571) a pharmacological inhibitor of p73, a master gene controlling apoptosis induced by etoposide, prevented the increase of TACE/ADAM17 levels.	Etoposide	109-118	tumor protein p73	Rattus norvegicus	57-60
21503882-7	2012	Finally, Gleevec (STI571) a pharmacological inhibitor of p73, a master gene controlling apoptosis induced by etoposide, prevented the increase of TACE/ADAM17 levels.	Etoposide	109-118	ADAM metallopeptidase domain 17	Rattus norvegicus	146-150
22282239-13	2012	But etoposide, a nucleoside analogue, which could activate DNA-PKcs and ATM, increased Pim expression in ECs.	Etoposide	4-13	ATM serine/threonine kinase	Homo sapiens	72-75
22282239-13	2012	But etoposide, a nucleoside analogue, which could activate DNA-PKcs and ATM, increased Pim expression in ECs.	Etoposide	4-13	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	87-90
22791162-0	2012	Schedule-dependent cytotoxicity of etoposide (VP-16) and cyclophosphamide in leukemia cell line K-562.	Etoposide	35-44	host cell factor C1	Homo sapiens	46-51
21893328-4	2012	RESULTS: Del1 prevented endothelial cell apoptosis in response to TNFalpha/IFNgamma, etoposide, and anoikis, but had no effect on proliferation.	Etoposide	85-94	EGF like repeats and discoidin domains 3	Homo sapiens	9-13
22142473-6	2012	Moreover, targeting the Nrf2/HO-1 axis sensitized GI-ME-N cells to etoposide more than GSH depletion.	Etoposide	67-76	NFE2 like bZIP transcription factor 2	Homo sapiens	24-28
22142473-6	2012	Moreover, targeting the Nrf2/HO-1 axis sensitized GI-ME-N cells to etoposide more than GSH depletion.	Etoposide	67-76	heme oxygenase 1	Homo sapiens	29-33
22178074-3	2012	We found that Ro52(low) HeLa cells were significantly more resistant to apoptosis than wild-type HeLa cells when stimulated by H(2)O(2)- or diamide-induced oxidative stress, IFN-alpha, IFN-gamma and anti-Fas antibody, etoposide, or gamma-irradiation.	Etoposide	218-227	tripartite motif containing 21	Homo sapiens	14-18
22117068-3	2012	Etoposide-induced death of MLO-Y4 osteocyte-like cells, assessed by trypan blue staining, caspase-3 cleavage, and TUNEL assays, was completely prevented when cells were pre-treated with 17beta-estradiol.	Etoposide	0-9	caspase 3	Mus musculus	90-99
22019627-5	2012	Significant correlations were demonstrated between the peak number of CD34(+) cells and residual growth of colony-forming unit granulocyte-macrophage (CFU-GM) after maphosphamide (R = 0.550; p = 0.0003) and after etoposide (R = 0.793; p = 0.0003).	Etoposide	213-222	CD34 molecule	Homo sapiens	70-74
21999765-2	2012	We showed that ectopic expression of BMI-1 in B-cell lymphoma cell lines, HT and RL, conferred resistance to etoposide and oxaliplatin, known to enhance sensitivity by targeting the survivin gene, but not to irinotecan, which is not relevant to the downregulation of survivin expression.	Etoposide	109-118	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	37-42
21999765-6	2012	Knockdown of either BMI-1 or survivin restored sensitivity to etoposide in the BMI-1-overexpressing lymphoma cells.	Etoposide	62-71	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	20-25
21999765-6	2012	Knockdown of either BMI-1 or survivin restored sensitivity to etoposide in the BMI-1-overexpressing lymphoma cells.	Etoposide	62-71	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	79-84
22953108-3	2012	Concurrent chemoradiotherapy using cisplatin (CDDP) and etoposide (VP-16) was given, which achieved complete response (CR).	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
22182671-6	2012	However, TRPA1 was absent in the etoposide-resistant counterpart.	Etoposide	33-42	transient receptor potential cation channel subfamily A member 1	Homo sapiens	9-14
22420547-7	2012	A decrease in Il-6 level after application of Cisplatin and Methotrexate and a 5-10 fold increase in the level of Il-6 after application of Etoposide, Carboplatin, Cytarabine, and Gemcitabine were registered in the medium with ganglioneuroblastoma.	Etoposide	140-149	interleukin 6	Homo sapiens	114-118
22182671-7	2012	Even though both types of RB cells express TRPV1 as well as TRPM8 and CB1, the capsaicin (50 muM) (CAP)-induced Ca(2+) rise caused by TRPV1 activation was prompt and transient only in etoposide-resistant RB cells (n = 8).	Etoposide	184-193	latexin	Homo sapiens	93-96
22182671-7	2012	Even though both types of RB cells express TRPV1 as well as TRPM8 and CB1, the capsaicin (50 muM) (CAP)-induced Ca(2+) rise caused by TRPV1 activation was prompt and transient only in etoposide-resistant RB cells (n = 8).	Etoposide	184-193	transient receptor potential cation channel subfamily V member 1	Homo sapiens	134-139
22182671-9	2012	Therefore, using genetic approaches to upregulate TRPA1 expression could provide a means to induce etoposide sensitivity and suppress RB cell tumorigenesis.	Etoposide	99-108	transient receptor potential cation channel subfamily A member 1	Homo sapiens	50-55
22419889-3	2012	In this study, we assessed the role of filamin-A in modulating cancer cell sensitivity to Topo II poisons, including etoposide and doxorubicin.	Etoposide	117-126	filamin A	Homo sapiens	39-48
22419889-4	2012	Intriguingly, we found that cells with filamin-A expression are more sensitive to Topo II poisons than those with defective filamin-A, and filamin-A proficient xenograft melanomas have better response to etoposide treatment than the filamin-A deficient tumors.	Etoposide	204-213	filamin A	Homo sapiens	39-48
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	176-185	BH3 interacting domain death agonist	Homo sapiens	268-271
23353839-1	2012	OBJECTIVES: Etoposide (Vepesid, VP-16), an inhibitor of topoisomerase II, is a chemotherapeutic drug commonly used for treatment of different types of malignant diseases.	Etoposide	12-21	host cell factor C1	Homo sapiens	32-37
21935580-0	2012	Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport             and resistance to the drug in HEK-293 cells.	Etoposide	57-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	36-41
21935580-0	2012	Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport             and resistance to the drug in HEK-293 cells.	Etoposide	57-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	42-46
21935580-1	2012	Resistance to etoposide has been associated with the overexpression of P-glycoprotein             and MRP1 in human tumor cells.	Etoposide	14-23	ATP binding cassette subfamily C member 1	Homo sapiens	102-106
21935580-2	2012	However, the role of BCRP in resistance to etoposide             has not been clearly established, especially the significance of arginine 482             mutations in drug transport (cellular uptake and efflux).	Etoposide	43-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	21-25
21935580-3	2012	Different levels of             resistance to etoposide have been recently observed in cells expressing BCRP in             terms of cytotoxicity.	Etoposide	46-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	104-108
21935580-4	2012	The aim of this work was to study the effects of these             mutations on the functional involvement of BCRP in etoposide transport.	Etoposide	118-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	110-114
21935580-10	2012	Drug efflux measurements showed that fumitremorgin C             was able to increase the residual cellular [3H]-etoposide uptake in BCRP-transfected             cells and especially in HEK/R482G ones.	Etoposide	113-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	133-137
21935580-11	2012	Our data show that the R482G mutation             in BCRP is able to increase efflux of etoposide and that mutation analysis at             codon 482 may be of clinical importance in cancers treated with etoposide.	Etoposide	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	53-57
21935580-11	2012	Our data show that the R482G mutation             in BCRP is able to increase efflux of etoposide and that mutation analysis at             codon 482 may be of clinical importance in cancers treated with etoposide.	Etoposide	204-213	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	53-57
22862175-6	2012	CD133+ cells (CD133 is marker of CSC in some tumors) isolated from NBL, osteosarcoma and Ewing sarcoma cell lines are resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones.	Etoposide	155-164	prominin 1	Homo sapiens	0-5
22862175-6	2012	CD133+ cells (CD133 is marker of CSC in some tumors) isolated from NBL, osteosarcoma and Ewing sarcoma cell lines are resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones.	Etoposide	155-164	prominin 1	Homo sapiens	14-19
22862175-6	2012	CD133+ cells (CD133 is marker of CSC in some tumors) isolated from NBL, osteosarcoma and Ewing sarcoma cell lines are resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones.	Etoposide	155-164	prominin 1	Homo sapiens	14-19
23093908-0	2012	Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells.	Etoposide	95-104	BH3 interacting domain death agonist	Homo sapiens	0-3
23093908-0	2012	Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells.	Etoposide	95-104	AKT serine/threonine kinase 1	Homo sapiens	66-69
23093908-2	2012	However, the effects of Bid on hepatocellular carcinoma (HCC) cell proliferation in response to etoposide-induced DNA damage have not been sufficiently investigated.	Etoposide	96-105	BH3 interacting domain death agonist	Homo sapiens	24-27
23093908-3	2012	METHODS: Using a stable Bid-overexpression HCC cell line, Bid/PLC/PRF/5, overexpression of Bid promoted loss of viability in response to etoposide-induced DNA damage.	Etoposide	137-146	BH3 interacting domain death agonist	Homo sapiens	24-27
23093908-3	2012	METHODS: Using a stable Bid-overexpression HCC cell line, Bid/PLC/PRF/5, overexpression of Bid promoted loss of viability in response to etoposide-induced DNA damage.	Etoposide	137-146	BH3 interacting domain death agonist	Homo sapiens	58-61
23093908-3	2012	METHODS: Using a stable Bid-overexpression HCC cell line, Bid/PLC/PRF/5, overexpression of Bid promoted loss of viability in response to etoposide-induced DNA damage.	Etoposide	137-146	heparan sulfate proteoglycan 2	Homo sapiens	62-65
23093908-3	2012	METHODS: Using a stable Bid-overexpression HCC cell line, Bid/PLC/PRF/5, overexpression of Bid promoted loss of viability in response to etoposide-induced DNA damage.	Etoposide	137-146	BH3 interacting domain death agonist	Homo sapiens	58-61
23093908-5	2012	The phosphorylations of Akt and mitogen-activated protein kinases (MAPKs) in response to etoposide-induced DNA damage were analyzed by Western blotting.	Etoposide	89-98	AKT serine/threonine kinase 1	Homo sapiens	24-27
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	307-316	BH3 interacting domain death agonist	Homo sapiens	73-76
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	307-316	mitogen-activated protein kinase 3	Homo sapiens	220-226
23093908-6	2012	RESULTS: The survival rates of 100 muM etoposide on the cells with control vector and Bid/PLC/PRF/5 at 48 hours amounted to 71% +- 0.75% and 59% +- 0.60% with MTT assay, and similar results of 85% +- 0.08% and 63% +- 0.14% with BrdU-labeling assay respectively.	Etoposide	39-48	BH3 interacting domain death agonist	Homo sapiens	86-89
22760199-6	2012	RESULTS: XIAP KD cells were more sensitive to etoposide, Rsv, vincristine and doxorubicin compared to wild-type (WT) cells.	Etoposide	46-55	X-linked inhibitor of apoptosis	Homo sapiens	9-13
21981993-4	2012	Here we demonstrate that knockdown of CRD-BP with a specific sh-RNA enhances the effect of dacarbazine, temozolomide, vinblastine, and etoposide on both primary and metastatic melanoma cell lines.	Etoposide	135-144	insulin like growth factor 2 mRNA binding protein 1	Homo sapiens	38-44
23093908-6	2012	RESULTS: The survival rates of 100 muM etoposide on the cells with control vector and Bid/PLC/PRF/5 at 48 hours amounted to 71% +- 0.75% and 59% +- 0.60% with MTT assay, and similar results of 85% +- 0.08% and 63% +- 0.14% with BrdU-labeling assay respectively.	Etoposide	39-48	heparan sulfate proteoglycan 2	Homo sapiens	90-93
23093908-7	2012	Moreover, overexpression of Bid sensitized the cells to apoptosis at a high dose of etoposide (causing irreparable damage).	Etoposide	84-93	BH3 interacting domain death agonist	Homo sapiens	28-31
23093908-10	2012	Overexpression of Bid suppressed the activation of Akt with respect to etoposide-induced DNA damage.	Etoposide	71-80	BH3 interacting domain death agonist	Homo sapiens	18-21
23093908-10	2012	Overexpression of Bid suppressed the activation of Akt with respect to etoposide-induced DNA damage.	Etoposide	71-80	AKT serine/threonine kinase 1	Homo sapiens	51-54
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	176-185	BH3 interacting domain death agonist	Homo sapiens	73-76
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	176-185	mitogen-activated protein kinase 3	Homo sapiens	158-164
23093908-13	2012	CONCLUSION: Taken together, these results suggest that overexpression of Bid suppressed the activation of Akt, p38, and c-Jun, and promoted the activation of ERK1/2 induced by etoposide, suggesting that the promotion of ERK1/2 activation may have a negative effect on Bid-mediated HCC DNA damage induced by etoposide.	Etoposide	176-185	mitogen-activated protein kinase 3	Homo sapiens	220-226
23272236-4	2012	Etoposide-treated cells exhibited a senescent phenotype characterized by senile morphology, positive staining for senescence-associated beta-galactosidase, growth arrest and induction of p53 and p21(WAF1/CIP1).	Etoposide	0-9	galactosidase beta 1	Homo sapiens	136-154
23272236-4	2012	Etoposide-treated cells exhibited a senescent phenotype characterized by senile morphology, positive staining for senescence-associated beta-galactosidase, growth arrest and induction of p53 and p21(WAF1/CIP1).	Etoposide	0-9	tumor protein p53	Homo sapiens	187-190
23272236-4	2012	Etoposide-treated cells exhibited a senescent phenotype characterized by senile morphology, positive staining for senescence-associated beta-galactosidase, growth arrest and induction of p53 and p21(WAF1/CIP1).	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	195-198
23272236-4	2012	Etoposide-treated cells exhibited a senescent phenotype characterized by senile morphology, positive staining for senescence-associated beta-galactosidase, growth arrest and induction of p53 and p21(WAF1/CIP1).	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	199-208
22900064-8	2012	FILIP1L levels increase markedly through transcriptional mechanisms following treatment with doxorubicin and other TOP2 poisons, including etoposide and mitoxantrone, but not by the TOP2 catalytic inhibitors merbarone or dexrazoxane (ICRF187), or by UV irradiation.	Etoposide	139-148	filamin A interacting protein 1 like	Homo sapiens	0-7
23226323-3	2012	Here we show that annexin A2 accumulates in the nucleus in response to genotoxic agents including gamma-radiation, UV radiation, etoposide and chromium VI and that this event is mediated by the nuclear export sequence of annexin A2.	Etoposide	129-138	annexin A2	Homo sapiens	18-28
23226323-3	2012	Here we show that annexin A2 accumulates in the nucleus in response to genotoxic agents including gamma-radiation, UV radiation, etoposide and chromium VI and that this event is mediated by the nuclear export sequence of annexin A2.	Etoposide	129-138	annexin A2	Homo sapiens	221-231
23139748-9	2012	BIM and NOXA are important mediators of etoposide-induced cell death in HepG2 cells and the hypoxia-induced modification of these proteins abundance or post-translational modifications partly account for chemoresistance.	Etoposide	40-49	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	8-12
23029531-5	2012	Induction of apoptosis by etoposide results in recruitment of p150 to the c-MYC promoter and to repression of c-MYC.	Etoposide	26-35	chromatin assembly factor 1 subunit A	Homo sapiens	62-66
23029531-5	2012	Induction of apoptosis by etoposide results in recruitment of p150 to the c-MYC promoter and to repression of c-MYC.	Etoposide	26-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
23029531-5	2012	Induction of apoptosis by etoposide results in recruitment of p150 to the c-MYC promoter and to repression of c-MYC.	Etoposide	26-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	110-115
22957056-3	2012	Previous studies showed that inhibition of HDAC6 induces DNA damage and sensitizes transformed cells to anti-tumor agents such as etoposide and doxorubicin.	Etoposide	130-139	histone deacetylase 6	Homo sapiens	43-48
23144714-0	2012	UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIalpha levels.	Etoposide	26-35	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	53-57
23144714-6	2012	Conversely, PERK activation did not contribute to changes in Topo IIalpha protein levels, but it did play a significant role in the UPR-induced decreased sensitivity to etoposide.	Etoposide	169-178	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	12-16
23028682-4	2012	Cyclin A-Cdk2 catalyzed the phosphorylation of Rad9 at serine 328 in HeLa cells during apoptosis induced by etoposide, an inhibitor of topoisomeraseII.	Etoposide	108-117	cyclin A2	Homo sapiens	0-8
23028682-4	2012	Cyclin A-Cdk2 catalyzed the phosphorylation of Rad9 at serine 328 in HeLa cells during apoptosis induced by etoposide, an inhibitor of topoisomeraseII.	Etoposide	108-117	cyclin dependent kinase 2	Homo sapiens	9-13
23028682-4	2012	Cyclin A-Cdk2 catalyzed the phosphorylation of Rad9 at serine 328 in HeLa cells during apoptosis induced by etoposide, an inhibitor of topoisomeraseII.	Etoposide	108-117	RAD9 checkpoint clamp component A	Homo sapiens	47-51
22072718-8	2011	Further studies showed that overexpression of INrf2 enhanced degradation of PGAM5-Bcl-xL complex, led to etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	105-114	kelch like ECH associated protein 1	Homo sapiens	46-51
22715377-6	2012	A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65(S547A) identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE).	Etoposide	208-217	RELA proto-oncogene, NF-kB subunit	Homo sapiens	96-99
22715377-6	2012	A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65(S547A) identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE).	Etoposide	208-217	RELA proto-oncogene, NF-kB subunit	Homo sapiens	136-139
22715377-6	2012	A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65(S547A) identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE).	Etoposide	208-217	C-X-C motif chemokine ligand 8	Homo sapiens	234-237
22715377-6	2012	A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65(S547A) identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE).	Etoposide	208-217	immunoglobulin kappa variable 1-27	Homo sapiens	239-242
22715377-6	2012	A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65(S547A) identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE).	Etoposide	208-217	selectin E	Homo sapiens	244-248
22396773-9	2012	Studies have also demonstrated that other chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-beta secretion and elevated MHC I expression.	Etoposide	72-81	interferon beta 1	Homo sapiens	149-157
22363533-4	2012	Upon exposure to etoposide, the cells lacking CCDC6 did not achieve S-phase accumulation.	Etoposide	17-26	coiled-coil domain containing 6	Sus scrofa	46-51
22185299-6	2011	Etoposide-induced apoptosis induces down-regulation of MEIS1 expression or PREP1 up-regulation in chemotherapy-resistant cells.	Etoposide	0-9	Meis homeobox 1	Homo sapiens	55-60
22185299-6	2011	Etoposide-induced apoptosis induces down-regulation of MEIS1 expression or PREP1 up-regulation in chemotherapy-resistant cells.	Etoposide	0-9	PBX/knotted 1 homeobox 1	Homo sapiens	75-80
22479651-9	2012	Etoposide affects Cdt1 stability in HepG2 cells and not in HeLa cells.	Etoposide	0-9	chromatin licensing and DNA replication factor 1	Homo sapiens	18-22
22027829-5	2011	We show that HSS-7 associates with topoisomerase IIalpha (Top2) in vivo and that induction of endogenous TNF mRNA expression is suppressed by etoposide, a Top2 inhibitor.	Etoposide	142-151	tumor necrosis factor	Homo sapiens	105-108
22185299-5	2011	Importantly, silencing of MEIS1 decreases the proliferation of leukemia-derived cells but increases their survival after etoposide treatment.	Etoposide	121-130	Meis homeobox 1	Homo sapiens	26-31
22072718-8	2011	Further studies showed that overexpression of INrf2 enhanced degradation of PGAM5-Bcl-xL complex, led to etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	105-114	BCL2 like 1	Homo sapiens	82-88
22072718-8	2011	Further studies showed that overexpression of INrf2 enhanced degradation of PGAM5-Bcl-xL complex, led to etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	105-114	BCL2 associated X, apoptosis regulator	Homo sapiens	140-143
20614162-6	2011	Furthermore, the Smac-mimetics synergize with Cytarabine, Etoposide and especially with TRAIL in combination treatments.	Etoposide	58-67	diablo IAP-binding mitochondrial protein	Homo sapiens	17-21
21590687-7	2011	RESULTS: In vitro BDNF treatment induced Akt phosphorylation and rescued cells from etoposide-induced cell death in cells with high TrkB expression, but not in cells with low TrkB expression.	Etoposide	84-93	brain derived neurotrophic factor	Mus musculus	18-22
21590687-7	2011	RESULTS: In vitro BDNF treatment induced Akt phosphorylation and rescued cells from etoposide-induced cell death in cells with high TrkB expression, but not in cells with low TrkB expression.	Etoposide	84-93	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	132-136
21590687-8	2011	Pretreatment of high TrkB-expressing TB3 cells with perifosine blocked BDNF/TrkB-induced Akt phosphorylation and inhibited BDNF"s protection of TB3 cells from etoposide treatment.	Etoposide	159-168	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	21-25
21590687-8	2011	Pretreatment of high TrkB-expressing TB3 cells with perifosine blocked BDNF/TrkB-induced Akt phosphorylation and inhibited BDNF"s protection of TB3 cells from etoposide treatment.	Etoposide	159-168	brain derived neurotrophic factor	Mus musculus	71-75
21590687-8	2011	Pretreatment of high TrkB-expressing TB3 cells with perifosine blocked BDNF/TrkB-induced Akt phosphorylation and inhibited BDNF"s protection of TB3 cells from etoposide treatment.	Etoposide	159-168	brain derived neurotrophic factor	Mus musculus	123-127
21590687-9	2011	In vivo, tumors with high TrkB expression were found to have elevated levels of phosphorylated Akt and were less sensitive to etoposide treatment compared with tumors with low TrkB expression.	Etoposide	126-135	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	26-30
22120628-7	2011	Unlike Doxorubicin, Etoposide, Actinomycin D and Wortmannin, a proteasome inhibitor MG132 significantly enhanced TRAIL-induced apoptosis.	Etoposide	20-29	TNF superfamily member 10	Homo sapiens	113-118
22101268-4	2011	BMAL1 deficient fibroblasts had an increased sensitivity to hydrogen peroxide treatment, and reduced sensitivity to DNA damaging anticancer drugs etoposide and daunorubicin.	Etoposide	146-155	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	0-5
22101269-9	2011	Finally, apoptosis induced by etoposide increased in c-Myb-silenced TGFbeta-treated ER(+) cell lines.	Etoposide	30-39	MYB proto-oncogene, transcription factor	Homo sapiens	53-58
22101269-9	2011	Finally, apoptosis induced by etoposide increased in c-Myb-silenced TGFbeta-treated ER(+) cell lines.	Etoposide	30-39	transforming growth factor beta 1	Homo sapiens	68-75
22167279-9	2011	After primary surgical resection, 6 patients received chemotherapy with cisplatin (CDDP) and etoposide (VP-16).	Etoposide	93-102	host cell factor C1	Homo sapiens	104-109
21905773-8	2011	RESULTS: Vincristine, doxorubicin, etoposide, cisplatin, and fludarabine, each at a concentration of 10 muM, decreased the number of chordoma cells when given alone down to 11%, 0%, 30%, 67%, and 3%, respectively.	Etoposide	35-44	latexin	Homo sapiens	104-107
21905773-9	2011	Etoposide and cisplatin, each at a concentration of 10 muM, reduced the percentage of viable chordoma cells in a more effective way when given with 1 muM ATRA simultaneously, reducing the number of viable cells to 14% and 9%, respectively.	Etoposide	0-9	latexin	Homo sapiens	55-58
21905773-9	2011	Etoposide and cisplatin, each at a concentration of 10 muM, reduced the percentage of viable chordoma cells in a more effective way when given with 1 muM ATRA simultaneously, reducing the number of viable cells to 14% and 9%, respectively.	Etoposide	0-9	latexin	Homo sapiens	150-153
21896713-4	2011	We imposed cellular stress by starvation or administration of etoposide (0.5-50 muM), sorafenib (1-40 muM), staurosporine (20-500 nM), or thapsigargin (20-500 nM) (1, 2, or 3 h) and measured the formation of WIPI-1 positive autophagosomal membranes.	Etoposide	62-71	latexin	Homo sapiens	80-83
21880625-4	2011	Treatment of UW228-3 cells stably expressing RASSF1A with an anti-CD95 antibody to induce extrinsic apoptosis and etoposide or cisplatin to activate intrinsic apoptosis augmented tumor cell killing in a caspase-dependent manner.	Etoposide	114-123	Ras association domain family member 1	Homo sapiens	45-52
21880625-4	2011	Treatment of UW228-3 cells stably expressing RASSF1A with an anti-CD95 antibody to induce extrinsic apoptosis and etoposide or cisplatin to activate intrinsic apoptosis augmented tumor cell killing in a caspase-dependent manner.	Etoposide	114-123	Fas cell surface death receptor	Homo sapiens	66-70
21689642-7	2011	Regarding their sensitivity to anticancer treatments, we observed that cells overexpressing catalase were more sensitive to paclitaxel, etoposide and arsenic trioxide.	Etoposide	136-145	catalase	Homo sapiens	92-100
21745461-11	2011	Accordingly, etoposide-induced DNA damage is strongly attenuated in the presence of COX-2 inhibitors.	Etoposide	13-22	prostaglandin-endoperoxide synthase 2	Homo sapiens	84-89
21552291-7	2011	By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide.	Etoposide	133-142	tumor protein p53	Homo sapiens	13-16
21946411-5	2011	Moreover, miR-129-5p accentuated the anti-proliferative effects of other cancer drugs such as etoposide or human alpha-lactalbumin made lethal for tumor cells (HAMLET).	Etoposide	94-103	microRNA 1295a	Homo sapiens	10-19
22013119-4	2011	Treatment of human cells with etoposide led to the induction of IFN-stimulated genes and the IFN-alpha and IFN-lambda genes.	Etoposide	30-39	interferon alpha 1	Homo sapiens	64-67
22013119-4	2011	Treatment of human cells with etoposide led to the induction of IFN-stimulated genes and the IFN-alpha and IFN-lambda genes.	Etoposide	30-39	interferon alpha 1	Homo sapiens	93-102
22013119-4	2011	Treatment of human cells with etoposide led to the induction of IFN-stimulated genes and the IFN-alpha and IFN-lambda genes.	Etoposide	30-39	interferon alpha 1	Homo sapiens	93-96
22059741-15	2011	The apoptotic inducers including actinomycin D, camptothecin and etoposide are also the chemotherapeutic drugs in clinical cancer therapy and PTMA siRNA can accelerate apoptotic progression in cells treated with those apoptosis inducers.	Etoposide	65-74	prothymosin alpha	Homo sapiens	142-146
21617849-0	2011	Aspirin reduces the apoptotic effect of etoposide via Akt activation and up-regulation of p21(cip).	Etoposide	40-49	AKT serine/threonine kinase 1	Homo sapiens	54-57
21646862-9	2011	Caspase-3 activation and pyknosis induced by two other pro-apoptotic stimuli, MK801 and etoposide, were likewise found to be associated with Beclin 1-independent autophagy and reduced by the knockdown of Atg7 but not Beclin 1.	Etoposide	88-97	caspase 3	Homo sapiens	0-9
21646862-9	2011	Caspase-3 activation and pyknosis induced by two other pro-apoptotic stimuli, MK801 and etoposide, were likewise found to be associated with Beclin 1-independent autophagy and reduced by the knockdown of Atg7 but not Beclin 1.	Etoposide	88-97	beclin 1	Homo sapiens	141-149
21646862-9	2011	Caspase-3 activation and pyknosis induced by two other pro-apoptotic stimuli, MK801 and etoposide, were likewise found to be associated with Beclin 1-independent autophagy and reduced by the knockdown of Atg7 but not Beclin 1.	Etoposide	88-97	autophagy related 7	Homo sapiens	204-208
21646862-9	2011	Caspase-3 activation and pyknosis induced by two other pro-apoptotic stimuli, MK801 and etoposide, were likewise found to be associated with Beclin 1-independent autophagy and reduced by the knockdown of Atg7 but not Beclin 1.	Etoposide	88-97	beclin 1	Homo sapiens	217-225
22072486-4	2011	With this device, human non-small cell lung cancer cell line (SPCA-1) was cultured well; the expression and the activity of multidrug resistance-associated protein (MRP1) were detected by immunofluorescence assay for the cells pretreated with or without MK-571, a known inhibitor of MRP1; apoptosis percentages were assayed for the cells after being treated by the anticancer drug etoposide (VP-16).	Etoposide	381-390	ATP binding cassette subfamily C member 1	Homo sapiens	165-169
21904904-13	2011	CONCLUSIONS: In vitro, the levels of TopoIIa protein expression correlate with response to etoposide but also multiple molecular events namely DNA-PK and MDR also play a role in cell sensitivity to etoposide.	Etoposide	198-207	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	143-149
21903579-4	2011	A focused real-time quantitative reverse transcription PCR array of known p53-regulated genes identified p21(WAF1) (CDKN1A) as the highest ranked gene to be differentially expressed between B-cell precursor (BCP)-ALL and T-ALL xenografts following exposure to the DNA-damaging drug etoposide.	Etoposide	282-291	tumor protein p53	Homo sapiens	74-77
21903579-4	2011	A focused real-time quantitative reverse transcription PCR array of known p53-regulated genes identified p21(WAF1) (CDKN1A) as the highest ranked gene to be differentially expressed between B-cell precursor (BCP)-ALL and T-ALL xenografts following exposure to the DNA-damaging drug etoposide.	Etoposide	282-291	cyclin dependent kinase inhibitor 1A	Homo sapiens	105-108
21903579-4	2011	A focused real-time quantitative reverse transcription PCR array of known p53-regulated genes identified p21(WAF1) (CDKN1A) as the highest ranked gene to be differentially expressed between B-cell precursor (BCP)-ALL and T-ALL xenografts following exposure to the DNA-damaging drug etoposide.	Etoposide	282-291	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-113
21903579-4	2011	A focused real-time quantitative reverse transcription PCR array of known p53-regulated genes identified p21(WAF1) (CDKN1A) as the highest ranked gene to be differentially expressed between B-cell precursor (BCP)-ALL and T-ALL xenografts following exposure to the DNA-damaging drug etoposide.	Etoposide	282-291	cyclin dependent kinase inhibitor 1A	Homo sapiens	116-122
21751122-8	2011	Etoposide and doxorubicin induced DR5 but not DR4 in NB cell lines.	Etoposide	0-9	TNF receptor superfamily member 10b	Homo sapiens	34-37
20352292-1	2011	Etoposide (VP-16), a topoisomerase II (Topo II) inhibitor, has been widely used to treat malignancies.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
21617849-0	2011	Aspirin reduces the apoptotic effect of etoposide via Akt activation and up-regulation of p21(cip).	Etoposide	40-49	H3 histone pseudogene 16	Homo sapiens	90-93
21617849-3	2011	In the present study, we observed that aspirin caused G0/G1 phase cell cycle arrest and reduced etoposide induced caspase-3 activation in hepatocellular carcinoma G2 (HepG2) cells.	Etoposide	96-105	caspase 3	Homo sapiens	114-123
21784088-0	2011	Inactivation of PTEN is responsible for the survival of Hep G2 cells in response to etoposide-induced damage.	Etoposide	84-93	phosphatase and tensin homolog	Homo sapiens	16-20
21538355-6	2011	Other nonionizable P-gp substrates (digoxin, dexamethasone, paclitaxel, and etoposide) responded to acidic pH (4.5) in a manner similar to colchicine.	Etoposide	76-85	PGP	Canis lupus familiaris	19-23
21784088-8	2011	Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt.	Etoposide	121-130	AKT serine/threonine kinase 1	Homo sapiens	81-84
21784088-8	2011	Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt.	Etoposide	121-130	AKT serine/threonine kinase 1	Homo sapiens	90-93
21784088-8	2011	Either Hep G2 or Chang Liver cells when transfected with plasmid carrying active Akt (myr-Akt) become resistance towards etoposide compared to the cells transfected with empty vectors or kinase defective Akt.	Etoposide	121-130	AKT serine/threonine kinase 1	Homo sapiens	90-93
21784088-10	2011	These results suggest that inactivation of PTEN, which renders activation of Akt, may contribute largely for the etoposide-resistance character of Hep G2 cells.	Etoposide	113-122	phosphatase and tensin homolog	Homo sapiens	43-47
21784088-10	2011	These results suggest that inactivation of PTEN, which renders activation of Akt, may contribute largely for the etoposide-resistance character of Hep G2 cells.	Etoposide	113-122	AKT serine/threonine kinase 1	Homo sapiens	77-80
21911424-9	2011	Deletion of Bak and Bax rendered megakaryocytes resistant to etoposide and ABT-737.	Etoposide	61-70	BCL2-associated X protein	Mus musculus	20-23
21623701-5	2011	In PCM rats, the CL(NR) (AUC(0- )) of intravenous etoposide was significantly slower (greater) than that in controls, because of the significant decrease in the hepatic CYP3A subfamily and P-gp.	Etoposide	50-59	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-193
22593728-5	2011	The patient was started on chemotherapy with cisplatin (CDDP) and etoposide (VP-16), which had been reported to be effective for small-cell lung cancer.	Etoposide	66-75	host cell factor C1	Homo sapiens	77-82
21600761-12	2011	In addition, UNC5C inhibited tumour cell proliferation, migration and enhanced chemosensitivity to cisplatin and etoposide.	Etoposide	113-122	unc-5 netrin receptor C	Homo sapiens	13-18
21883722-5	2011	Intriguingly, POLQ-null cells exhibited higher sensitivity than did POLQ-inactive cells to etoposide and gamma-irradiation, both of which induce double-strand breaks (DSBs).	Etoposide	91-100	polymerase (DNA directed), theta	Mus musculus	14-18
21883722-0	2011	Comparison of two POLQ mutants reveals that a polymerase-inactive POLQ retains significant function in tolerance to etoposide and gamma-irradiation in mouse B cells.	Etoposide	116-125	polymerase (DNA directed), theta	Mus musculus	18-22
21843105-5	2011	Tdp1 inhibitors should synergize not only with Top1-targeting drugs (camptothecins, indenoisoquinolines), but also with bleomycin, topoisomerase II (Top2) inhibitors (etoposide, doxorubicin) and DNA alkylating agents.	Etoposide	167-176	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
21883722-5	2011	Intriguingly, POLQ-null cells exhibited higher sensitivity than did POLQ-inactive cells to etoposide and gamma-irradiation, both of which induce double-strand breaks (DSBs).	Etoposide	91-100	polymerase (DNA directed), theta	Mus musculus	68-72
21883722-0	2011	Comparison of two POLQ mutants reveals that a polymerase-inactive POLQ retains significant function in tolerance to etoposide and gamma-irradiation in mouse B cells.	Etoposide	116-125	polymerase (DNA directed), theta	Mus musculus	66-70
21883722-8	2011	These results suggest that the polymerase and other functional domains of POLQ both play important roles in tolerance to etoposide and gamma-irradiation but are dispensable for AID-mediated class switch recombination.	Etoposide	121-130	polymerase (DNA directed), theta	Mus musculus	74-78
21523861-4	2011	Our previous studies showed ODC overexpression prevented etoposide-, paclitaxel-, and cisplatin-induced apoptosis.	Etoposide	57-66	ornithine decarboxylase 1	Homo sapiens	28-31
21807966-8	2011	Finally, FIP200 KO MEFs also showed deficient DNA damage repair and increased cell death compared with control MEFs, when treated with etoposide, a topoisomerase II inhibitor and another anticancer agent.	Etoposide	135-144	RB1 inducible coiled-coil 1	Homo sapiens	9-15
21712253-6	2011	Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU).	Etoposide	165-174	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
21441950-8	2011	Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study.	Etoposide	98-107	tumor protein p53	Homo sapiens	43-47
21441950-8	2011	Instead, a natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide, but only less so by the other anthracyclines under study.	Etoposide	98-107	WD repeat containing antisense to TP53	Homo sapiens	49-55
21423217-0	2011	Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53.	Etoposide	44-53	BH3 interacting domain death agonist	Mus musculus	0-3
21423217-4	2011	Bid has also been implicated in the apoptotic response to ionizing radiation (IR) and the topoisomerase inhibitor etoposide, anti-cancer regimens that cause double-strand (ds)DNA breaks.	Etoposide	114-123	BH3 interacting domain death agonist	Mus musculus	0-3
21423217-7	2011	We used Bid-deficient mouse embryonic fibroblast (MEF) lines that were reconstituted with Bid to control the cellular background and demonstrated that the Bid-dependent apoptotic pathway induced by IR and etoposide operates in MEFs that are transformed by SV40, but is not evident in E1A/Ras-transformed MEFs.	Etoposide	205-214	BH3 interacting domain death agonist	Mus musculus	8-11
21423217-7	2011	We used Bid-deficient mouse embryonic fibroblast (MEF) lines that were reconstituted with Bid to control the cellular background and demonstrated that the Bid-dependent apoptotic pathway induced by IR and etoposide operates in MEFs that are transformed by SV40, but is not evident in E1A/Ras-transformed MEFs.	Etoposide	205-214	BH3 interacting domain death agonist	Mus musculus	90-93
21423217-7	2011	We used Bid-deficient mouse embryonic fibroblast (MEF) lines that were reconstituted with Bid to control the cellular background and demonstrated that the Bid-dependent apoptotic pathway induced by IR and etoposide operates in MEFs that are transformed by SV40, but is not evident in E1A/Ras-transformed MEFs.	Etoposide	205-214	BH3 interacting domain death agonist	Mus musculus	90-93
21423217-9	2011	In these cells, Bid acted in a conventional manner in that it required its BH3 domain to mediate apoptosis in response to IR and etoposide, and triggered apoptotic execution by indirect activation of Bak/Bax, mitochondrial permeabilization and caspase-9 activation.	Etoposide	129-138	BH3 interacting domain death agonist	Mus musculus	16-19
21423217-10	2011	However, the mechanism of Bid activation was unconventional, because elimination of all known or suspected cleavage sites for caspases or other proteolytic enzymes and even complete elimination of its unstructured cleavage loop left Bid"s pro-apoptotic role in the response to IR and etoposide unaffected.	Etoposide	284-293	BH3 interacting domain death agonist	Mus musculus	26-29
22687664-0	2011	Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.	Etoposide	109-118	proopiomelanocortin	Homo sapiens	44-48
22687664-3	2011	Etoposide is metabolised by cytochrome P450 3A4.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-47
22687664-5	2011	There is an additional increased risk of toxicity due to a potential interaction between etoposide and ketoconazole, which is a strong inhibitor of cytochrome P450 3A4, and theoretically can lead to greater myelosuppression.	Etoposide	89-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-167
21801448-0	2011	Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.	Etoposide	70-79	caspase 8	Homo sapiens	18-27
20807285-7	2011	Hsp72 proved to be required for the survival effects of TAp73alpha as antisense knockdown of Hsp72 resulted in an abolishment of the anti-apoptotic effect of TAp73alpha in SCLC cells upon Etoposide treatment.	Etoposide	188-197	heat shock protein family A (Hsp70) member 1A	Homo sapiens	0-5
20807285-7	2011	Hsp72 proved to be required for the survival effects of TAp73alpha as antisense knockdown of Hsp72 resulted in an abolishment of the anti-apoptotic effect of TAp73alpha in SCLC cells upon Etoposide treatment.	Etoposide	188-197	heat shock protein family A (Hsp70) member 1A	Homo sapiens	93-98
21680522-9	2011	Consistently, E1B-55K expression in A549, A172, and HepG2 cells, all containing wild-type (wt) p53, also enhanced etoposide-induced cytotoxicity, whereas in p53-null H1299 cells, E1B-55K had no effects.	Etoposide	114-123	small nucleolar RNA, H/ACA box 73A	Homo sapiens	14-17
21680522-13	2011	Furthermore, most of these E1B-55K mutants could sensitize HCT116 cells to etoposide and doxorubicin.	Etoposide	75-84	small nucleolar RNA, H/ACA box 73A	Homo sapiens	27-30
21544552-7	2011	However, combined exposure to vincristine or etoposide with an inhibitor of Mrp1 efficiently decreased cell viability by up to 80%.	Etoposide	45-54	ATP binding cassette subfamily C member 1	Homo sapiens	76-80
21867601-1	2011	This study was aimed to investigate the expression of Na(+)/H(+) exchanger 1 (NHE1) in K562 and HL-60 cells undergoing DNA damage induced by etoposide and to elucidate the regulating mechanism.	Etoposide	141-150	solute carrier family 9 member A1	Homo sapiens	54-76
21867601-1	2011	This study was aimed to investigate the expression of Na(+)/H(+) exchanger 1 (NHE1) in K562 and HL-60 cells undergoing DNA damage induced by etoposide and to elucidate the regulating mechanism.	Etoposide	141-150	solute carrier family 9 member A1	Homo sapiens	78-82
21801448-10	2011	CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	177-186	tumor protein p73	Homo sapiens	142-145
21801448-11	2011	Our data suggest the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	132-141	caspase 8	Homo sapiens	35-44
21867601-2	2011	Real-time quantitative PCR (RQ-PCR) and Western blot methods were used to determine the expression of NHE1 in K562 cells after the treating with etoposide.	Etoposide	145-154	solute carrier family 9 member A1	Homo sapiens	102-106
21801448-0	2011	Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.	Etoposide	70-79	tumor protein p53	Homo sapiens	31-34
21867601-4	2011	The luciferase reporter vector containing NHE1 promoter was constructed to measure relative luciferase activity after treating with different etoposide concentrations.	Etoposide	142-151	solute carrier family 9 member A1	Homo sapiens	42-46
21867601-5	2011	The results showed that the mRNA and protein of NHE1 increased in accordance with apoptosis ratio in HL-60 cells after treated with etoposide (p &lt; 0.05), but no such obvious increase in K562 cells.	Etoposide	132-141	solute carrier family 9 member A1	Homo sapiens	48-52
21867601-6	2011	Treatment with NHE1 specific inhibitor could block etoposide induced alkalization and reduce the apoptosis ratio of HL-60 cells.	Etoposide	51-60	solute carrier family 9 member A1	Homo sapiens	15-19
21801448-11	2011	Our data suggest the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	132-141	tumor protein p53	Homo sapiens	93-96
21801448-11	2011	Our data suggest the importance of caspase-8-mediated positive feedback amplification in the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	132-141	tumor protein p73	Homo sapiens	97-100
21867601-8	2011	Relative luciferase activity of reporter vector containing NHE1 promoter however increased in K562 cells after treated with etoposide.	Etoposide	124-133	solute carrier family 9 member A1	Homo sapiens	59-63
21801448-0	2011	Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.	Etoposide	70-79	tumor protein p73	Homo sapiens	35-38
21867601-9	2011	It is concluded that the expression of NHE1 is up-regulated in the process of apoptosis of HL-60 cells induced by etoposide and depends on the pHi increasing caused by NHE1 up-regulation which is not found in K562 cells although the transcriptional activity increased.	Etoposide	114-123	solute carrier family 9 member A1	Homo sapiens	39-43
21801448-4	2011	RESULTS: We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant.	Etoposide	89-98	tumor protein p53	Homo sapiens	22-25
21801448-4	2011	RESULTS: We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant.	Etoposide	89-98	tumor protein p73	Homo sapiens	26-29
21801448-4	2011	RESULTS: We show that p53/p73-dependent caspase-8 activation is required for sensitizing etoposide-induced apoptosis by utilizing HOC313 cells carrying a temperature-sensitive p53G285K mutant.	Etoposide	89-98	caspase 8	Homo sapiens	40-49
21801448-6	2011	In addition to p53 restoration, caspase-8 reconstitution was needed for sensitization to etoposide-induced apoptosis, mitochondria depolarization, and cleavage of the procaspases-3, and -9.	Etoposide	89-98	caspase 8	Homo sapiens	32-41
21801448-6	2011	In addition to p53 restoration, caspase-8 reconstitution was needed for sensitization to etoposide-induced apoptosis, mitochondria depolarization, and cleavage of the procaspases-3, and -9.	Etoposide	89-98	caspase 3	Homo sapiens	167-188
21801448-7	2011	In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage.	Etoposide	3-12	tumor protein p73	Homo sapiens	95-98
21801448-7	2011	In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage.	Etoposide	117-126	tumor protein p53	Homo sapiens	78-81
21801448-7	2011	In etoposide-sensitive Ca9-22 cells carrying a temperature-insensitive mutant p53, siRNA-based p73 knockdown blocked etoposide-induced apoptosis and procaspase-8 cleavage.	Etoposide	117-126	tumor protein p73	Homo sapiens	95-98
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	caspase 9	Homo sapiens	13-22
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	caspase 9	Homo sapiens	48-57
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	caspase 8	Homo sapiens	90-99
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	BH3 interacting domain death agonist	Homo sapiens	112-115
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	tumor protein p53	Homo sapiens	176-179
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	tumor protein p73	Homo sapiens	180-183
21801448-9	2011	Finally, the caspase-9 inhibitor Ac-LEHD-CHO or caspase-9 siRNA blocked etoposide-induced caspase-8 activation, Bid cleavage, and apoptosis in both cell lines, indicating that p53/p73-dependent caspase-8 activation lies downstream of mitochondria.	Etoposide	72-81	caspase 8	Homo sapiens	194-203
21801448-10	2011	CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	177-186	tumor protein p53	Homo sapiens	30-33
21801448-10	2011	CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	177-186	tumor protein p73	Homo sapiens	38-41
21801448-10	2011	CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	177-186	caspase 8	Homo sapiens	96-105
21801448-10	2011	CONCLUSIONS: we conclude that p53 and p73 can act as upstream regulators of caspase-8, and that caspase-8 is an essential mediator of the p53/p73-dependent apoptosis induced by etoposide in HNSCC cells.	Etoposide	177-186	tumor protein p53	Homo sapiens	138-141
21730367-4	2011	MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking  Akt-1(CA).	Etoposide	115-124	AKT serine/threonine kinase 1	Homo sapiens	55-60
21468663-0	2011	Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment.	Etoposide	63-72	X protein	Hepatitis B virus	26-29
21468663-4	2011	In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis.	Etoposide	30-39	caspase 8	Homo sapiens	60-69
21468663-4	2011	In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis.	Etoposide	30-39	caspase 3	Homo sapiens	74-83
21468663-4	2011	In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis.	Etoposide	30-39	tumor protein p53	Homo sapiens	109-112
21468663-4	2011	In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis.	Etoposide	30-39	BH3 interacting domain death agonist	Homo sapiens	114-117
21468663-4	2011	In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis.	Etoposide	30-39	poly(ADP-ribose) polymerase 1	Homo sapiens	122-126
21468663-5	2011	Furthermore, p53 and Bid were accumulated in cytoplasm following etoposide treatment.	Etoposide	65-74	tumor protein p53	Homo sapiens	13-16
21468663-5	2011	Furthermore, p53 and Bid were accumulated in cytoplasm following etoposide treatment.	Etoposide	65-74	BH3 interacting domain death agonist	Homo sapiens	21-24
21468663-6	2011	However, HBx significantly attenuated etoposide-induced cell death.	Etoposide	38-47	X protein	Hepatitis B virus	9-12
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Etoposide	273-282	transforming growth factor beta 1	Homo sapiens	45-52
21555371-3	2011	We show here that exposure of tumor cells to TGFbeta and TNFalpha induces EMT and, more importantly, generates cells with a stable BCSC phenotype which is shown by increased self-renewing capacity, greatly increased tumorigenicity, and increased resistance to oxaliplatin, etoposide, and paclitaxel.	Etoposide	273-282	tumor necrosis factor	Homo sapiens	57-65
21565980-7	2011	DNA-damaging chemotherapeutics, such as etoposide, activate a functional loop linking SIRT1 and p53 through the induction of miR-34a.	Etoposide	40-49	sirtuin 1	Homo sapiens	86-91
21565980-7	2011	DNA-damaging chemotherapeutics, such as etoposide, activate a functional loop linking SIRT1 and p53 through the induction of miR-34a.	Etoposide	40-49	tumor protein p53	Homo sapiens	96-99
21565980-7	2011	DNA-damaging chemotherapeutics, such as etoposide, activate a functional loop linking SIRT1 and p53 through the induction of miR-34a.	Etoposide	40-49	microRNA 34a	Homo sapiens	125-132
21565980-8	2011	When leukemic cells are simultaneously exposed to nicotinamide and etoposide, we observe a significant increase in miR-34a levels with a concomitant inhibition of SIRT1.	Etoposide	67-76	microRNA 34a	Homo sapiens	115-122
21565980-8	2011	When leukemic cells are simultaneously exposed to nicotinamide and etoposide, we observe a significant increase in miR-34a levels with a concomitant inhibition of SIRT1.	Etoposide	67-76	sirtuin 1	Homo sapiens	163-168
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Etoposide	58-67	AKT serine/threonine kinase 1	Homo sapiens	106-111
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Etoposide	58-67	AKT serine/threonine kinase 1	Homo sapiens	112-114
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Etoposide	58-67	AKT serine/threonine kinase 1	Homo sapiens	106-109
21778401-3	2011	We present the crystal structure of a large fragment of human TOP2beta complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex.	Etoposide	115-124	DNA topoisomerase II beta	Homo sapiens	62-70
21642373-5	2011	Specific inhibition of DNA polymerase beta reduced the numbers of cells surviving treatment with etoposide and increased the amount of DNA damage in cells.	Etoposide	97-106	DNA polymerase beta	Homo sapiens	23-42
21642373-6	2011	Conversely, stable overexpression of NKX2.2 increased cell survival in response to etoposide in SCLC cell lines.	Etoposide	83-92	NK2 homeobox 2	Homo sapiens	37-43
21610153-0	2011	Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.	Etoposide	101-110	mechanistic target of rapamycin kinase	Homo sapiens	15-19
21610153-0	2011	Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.	Etoposide	101-110	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	135-140
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	Etoposide	45-54	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	Etoposide	45-54	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
21729327-5	2011	Moreover, our in vitro studies showed that Abeta1-42 and DNA-damaging drugs, namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas the knockdown of ATBF1 in these neurons protected against neuronal death induced by Abeta1-42, etoposide, and homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances.	Etoposide	85-94	zinc finger homeobox 3	Rattus norvegicus	138-143
21729327-5	2011	Moreover, our in vitro studies showed that Abeta1-42 and DNA-damaging drugs, namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas the knockdown of ATBF1 in these neurons protected against neuronal death induced by Abeta1-42, etoposide, and homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances.	Etoposide	85-94	zinc finger homeobox 3	Rattus norvegicus	208-213
21729327-5	2011	Moreover, our in vitro studies showed that Abeta1-42 and DNA-damaging drugs, namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas the knockdown of ATBF1 in these neurons protected against neuronal death induced by Abeta1-42, etoposide, and homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances.	Etoposide	85-94	zinc finger homeobox 3	Rattus norvegicus	208-213
21729327-5	2011	Moreover, our in vitro studies showed that Abeta1-42 and DNA-damaging drugs, namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas the knockdown of ATBF1 in these neurons protected against neuronal death induced by Abeta1-42, etoposide, and homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances.	Etoposide	286-295	zinc finger homeobox 3	Rattus norvegicus	208-213
21729327-5	2011	Moreover, our in vitro studies showed that Abeta1-42 and DNA-damaging drugs, namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas the knockdown of ATBF1 in these neurons protected against neuronal death induced by Abeta1-42, etoposide, and homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances.	Etoposide	286-295	zinc finger homeobox 3	Rattus norvegicus	208-213
21468663-9	2011	Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm.	Etoposide	113-122	mitogen-activated protein kinase 1	Homo sapiens	185-188
21468663-9	2011	Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm.	Etoposide	113-122	poly(ADP-ribose) polymerase 1	Homo sapiens	232-236
21468663-9	2011	Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm.	Etoposide	113-122	tumor protein p53	Homo sapiens	268-271
21468663-9	2011	Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm.	Etoposide	113-122	BH3 interacting domain death agonist	Homo sapiens	276-279
21468663-11	2011	TSA in combination with etoposide can significantly overcome the increased resistance of HBx-expressing HCC cells to chemotherapy.	Etoposide	24-33	X protein	Hepatitis B virus	89-92
21549093-0	2011	A novel mouse PKCdelta splice variant, PKCdeltaIX, inhibits etoposide-induced apoptosis.	Etoposide	60-69	protein kinase C, delta	Mus musculus	14-22
21549093-2	2011	The catalytic fragment of PKCdelta generated by caspase-dependent cleavage is essential for the initiation of etoposide-induced apoptosis.	Etoposide	110-119	protein kinase C, delta	Mus musculus	26-34
21514380-6	2011	Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype.	Etoposide	107-112	TNF superfamily member 10	Homo sapiens	13-18
21514380-6	2011	Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype.	Etoposide	107-112	ATP binding cassette subfamily B member 1	Homo sapiens	122-126
21514380-6	2011	Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype.	Etoposide	107-112	TNF superfamily member 10	Homo sapiens	214-219
21554433-8	2011	Both Odora cells (an olfactive cell line) and OM cells treated with etoposide, a p53 activity inducer, exhibited mitochondrial-dependent apoptosis that was inhibited by the pan-caspase inhibitor zVAD-fmk.	Etoposide	68-77	tumor protein p53	Homo sapiens	81-84
21554433-10	2011	Insulin addition to the culture medium reduced p53 phosphorylation, caspase-3 and caspase-9 cleavage, and caspase-3 enzymatic activity induced by etoposide.	Etoposide	146-155	insulin	Homo sapiens	0-7
21554433-10	2011	Insulin addition to the culture medium reduced p53 phosphorylation, caspase-3 and caspase-9 cleavage, and caspase-3 enzymatic activity induced by etoposide.	Etoposide	146-155	caspase 3	Homo sapiens	106-115
21730367-4	2011	MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking  Akt-1(CA).	Etoposide	115-124	AKT serine/threonine kinase 1	Homo sapiens	68-77
21730367-4	2011	MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking  Akt-1(CA).	Etoposide	115-124	AKT serine/threonine kinase 1	Homo sapiens	68-73
21730367-4	2011	MCF-7 cells which expressed a constitutively-activated Akt-1 gene [ Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking  Akt-1(CA).	Etoposide	115-124	AKT serine/threonine kinase 1	Homo sapiens	74-76
21558800-6	2011	Compared to AML3 cells, AML2 cells are more sensitive to the treatment of the DNA-damaging compounds (doxorubicin and etoposide) and a specific p53-inducing compound (nutlin-3).	Etoposide	118-127	RUNX family transcription factor 3	Homo sapiens	24-28
21595477-4	2011	Etoposide is metabolized by CYP3A4 to etoposide catechol, which can be further oxidized to etoposide quinone.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
21595477-5	2011	A CYP3A4 variant is associated with a lower risk of etoposide-related leukemias, suggesting that etoposide metabolites may be involved in leukemogenesis.	Etoposide	52-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	2-8
21595477-5	2011	A CYP3A4 variant is associated with a lower risk of etoposide-related leukemias, suggesting that etoposide metabolites may be involved in leukemogenesis.	Etoposide	97-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	2-8
21414716-4	2011	We establish that the loss of FANCD2 increases cell death in response to etoposide.	Etoposide	73-82	FA complementation group D2	Homo sapiens	30-36
21639828-0	2011	CYB5D2 enhances HeLa cells survival of etoposide-induced cytotoxicity.	Etoposide	39-48	cytochrome b5 domain containing 2	Homo sapiens	0-6
21639828-3	2011	Consistent with these observations, we report here that CYB5D2 enhances HeLa cells survival of etoposide (ETOP)-mediated cytotoxicity.	Etoposide	95-104	cytochrome b5 domain containing 2	Homo sapiens	56-62
21639828-3	2011	Consistent with these observations, we report here that CYB5D2 enhances HeLa cells survival of etoposide (ETOP)-mediated cytotoxicity.	Etoposide	106-110	cytochrome b5 domain containing 2	Homo sapiens	56-62
21639828-4	2011	Overexpression of CYB5D2 enhanced the survival of HeLa cells compared with HeLa cells transfected with empty vector (EV) upon ETOP treatment.	Etoposide	126-130	cytochrome b5 domain containing 2	Homo sapiens	18-24
21639828-8	2011	Collectively, CYB5D2 enhances HeLa cell survival of ETOP-induced cytotoxicity with some specificity.	Etoposide	52-56	cytochrome b5 domain containing 2	Homo sapiens	14-20
21639828-10	2011	Both domains are required for CYB5D2-mediated protection of HeLa cells from ETOP-induced cytotoxicity.	Etoposide	76-80	cytochrome b5 domain containing 2	Homo sapiens	30-36
21639828-12	2011	Although ectopic CYB5D2 does not massively alter gene expression, the expression of several transcripts was affected more than 2-fold, suggesting that they may contribute to CYB5D2-mediated HeLa cell survival of ETOP treatment.	Etoposide	212-216	cytochrome b5 domain containing 2	Homo sapiens	17-23
21639828-12	2011	Although ectopic CYB5D2 does not massively alter gene expression, the expression of several transcripts was affected more than 2-fold, suggesting that they may contribute to CYB5D2-mediated HeLa cell survival of ETOP treatment.	Etoposide	212-216	cytochrome b5 domain containing 2	Homo sapiens	174-180
21548574-12	2011	Therefore, to address the potential contributions of the D-ring to the activity of etoposide, we characterized drug derivatives in which the C13 carbonyl was moved to the C11 position (retroetoposide and retroDEPT) or the D-ring was opened (D-ring diol).	Etoposide	83-92	homeobox C13	Homo sapiens	141-144
21414716-5	2011	FANCD2 promotes homologous recombination repair (HRR) and prevents DNA double-strand break formation and chromosomal aberrations in etoposide-treated cells.	Etoposide	132-141	FA complementation group D2	Homo sapiens	0-6
21479364-4	2011	NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC.	Etoposide	148-157	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-4
21517844-6	2011	In that system, activation of the DNA double strand break signaling kinase ataxia telangiectasia-mutated protein kinase, p53 and p53-dependent apoptosis required lower etoposide concentrations than did the p53-independent induction of nucleolar stress.	Etoposide	168-177	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	121-124
21517844-6	2011	In that system, activation of the DNA double strand break signaling kinase ataxia telangiectasia-mutated protein kinase, p53 and p53-dependent apoptosis required lower etoposide concentrations than did the p53-independent induction of nucleolar stress.	Etoposide	168-177	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	129-132
21517844-6	2011	In that system, activation of the DNA double strand break signaling kinase ataxia telangiectasia-mutated protein kinase, p53 and p53-dependent apoptosis required lower etoposide concentrations than did the p53-independent induction of nucleolar stress.	Etoposide	168-177	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	129-132
21356302-3	2011	The purpose of the present study was to evaluate the effect of N-octyl-O-sulfate chitosan (NOSC) on the absorption of etoposide (VP16), a substrate of P-gp with low water solubility.	Etoposide	118-127	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
21707856-10	2011	Importantly, the phosphorylation of XIAP at the site by PKC significantly increased cell survival up to approximately 2.5 times under the condition of apoptosis induced by 25 microg/ml etoposide.	Etoposide	185-194	X-linked inhibitor of apoptosis	Homo sapiens	36-40
21610657-5	2011	ETBP16 displays similarity with the ser-rich domain in E2F-4, a transcription factor in cell cycle-regulated genes, suggesting that etoposide might interact with E2F-4 via this domain.	Etoposide	132-141	E2F transcription factor 4 S homeolog	Xenopus laevis	55-60
21610657-5	2011	ETBP16 displays similarity with the ser-rich domain in E2F-4, a transcription factor in cell cycle-regulated genes, suggesting that etoposide might interact with E2F-4 via this domain.	Etoposide	132-141	E2F transcription factor 4 S homeolog	Xenopus laevis	162-167
21610657-6	2011	SPR analysis confirmed the specific binding of etoposide to recombinant E2F-4 is in the order of 10-5 M. Furthermore, etoposide was shown to inhibit luciferase reporter gene expression mediated by the heterodimeric E2F-4/DP complex.	Etoposide	47-56	E2F transcription factor 4 S homeolog	Xenopus laevis	72-77
21610657-6	2011	SPR analysis confirmed the specific binding of etoposide to recombinant E2F-4 is in the order of 10-5 M. Furthermore, etoposide was shown to inhibit luciferase reporter gene expression mediated by the heterodimeric E2F-4/DP complex.	Etoposide	47-56	E2F transcription factor 4 S homeolog	Xenopus laevis	215-220
21610657-6	2011	SPR analysis confirmed the specific binding of etoposide to recombinant E2F-4 is in the order of 10-5 M. Furthermore, etoposide was shown to inhibit luciferase reporter gene expression mediated by the heterodimeric E2F-4/DP complex.	Etoposide	118-127	E2F transcription factor 4 S homeolog	Xenopus laevis	72-77
21610657-6	2011	SPR analysis confirmed the specific binding of etoposide to recombinant E2F-4 is in the order of 10-5 M. Furthermore, etoposide was shown to inhibit luciferase reporter gene expression mediated by the heterodimeric E2F-4/DP complex.	Etoposide	118-127	E2F transcription factor 4 S homeolog	Xenopus laevis	215-220
21610657-7	2011	Taken together, our results suggest that etoposide directly binds to E2F-4 and inhibits subsequent gene transcription mediated by heterodimeric E2F-4/DP complexes in the nucleus.	Etoposide	41-50	E2F transcription factor 4 S homeolog	Xenopus laevis	69-74
21610657-7	2011	Taken together, our results suggest that etoposide directly binds to E2F-4 and inhibits subsequent gene transcription mediated by heterodimeric E2F-4/DP complexes in the nucleus.	Etoposide	41-50	E2F transcription factor 4 S homeolog	Xenopus laevis	144-149
21356302-3	2011	The purpose of the present study was to evaluate the effect of N-octyl-O-sulfate chitosan (NOSC) on the absorption of etoposide (VP16), a substrate of P-gp with low water solubility.	Etoposide	129-133	ATP binding cassette subfamily B member 1	Homo sapiens	151-155
21506134-9	2011	Therefore, the enhanced oral bioavailability of etoposide in the presence of curcumin might be due mainly to inhibition of the P-gp efflux pump in the small intestine and possibly by reduced first-pass metabolism of etoposide in the small intestine by inhibition of CYP3A activity in rats.	Etoposide	48-57	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	127-131
21217779-5	2011	Ablation of CBP or p300 impaired IR-induced DSB repair and sensitized lung cancer cells to IR and the anti-cancer drug, etoposide, which induces DSBs that are repaired by NHEJ.	Etoposide	120-129	CREB binding protein	Homo sapiens	12-15
21217779-5	2011	Ablation of CBP or p300 impaired IR-induced DSB repair and sensitized lung cancer cells to IR and the anti-cancer drug, etoposide, which induces DSBs that are repaired by NHEJ.	Etoposide	120-129	E1A binding protein p300	Homo sapiens	19-23
21506134-9	2011	Therefore, the enhanced oral bioavailability of etoposide in the presence of curcumin might be due mainly to inhibition of the P-gp efflux pump in the small intestine and possibly by reduced first-pass metabolism of etoposide in the small intestine by inhibition of CYP3A activity in rats.	Etoposide	48-57	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	266-271
21332719-5	2011	In U87MG, U373MG, and T98G human glioma cells, there was a positive correlation between ITGB3 expression and the sensitivity to BCNU and etoposide, suggesting an important role of ITGB3 in glioma cell death.	Etoposide	137-146	integrin subunit beta 3	Homo sapiens	88-93
21332719-5	2011	In U87MG, U373MG, and T98G human glioma cells, there was a positive correlation between ITGB3 expression and the sensitivity to BCNU and etoposide, suggesting an important role of ITGB3 in glioma cell death.	Etoposide	137-146	integrin subunit beta 3	Homo sapiens	180-185
20976614-10	2011	Of these, only etoposide"s effect could be confirmed in a limited Cox multiple regression analysis.	Etoposide	15-24	cytochrome c oxidase subunit 8A	Homo sapiens	66-69
21160137-2	2011	The DNA repair protein Ku70 is a key contributor to chemoresistance to anticancer agents, e.g., etoposide and bleomycin, or radioresistance.	Etoposide	96-105	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	23-27
21333639-0	2011	Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue.	Etoposide	64-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-41
21274505-5	2011	Inhibition of autophagy by either 3-methyladenine (3MA) or beclin-1 small interfering RNA enhanced etoposide-induced cell death.	Etoposide	99-108	beclin 1	Homo sapiens	59-67
21107697-9	2011	However, distinct differences in the repair process following doxorubicin versus etoposide were seen in concentration dependency, time-course and requirement of Ku70 and Rad51 proteins.	Etoposide	81-90	X-ray repair cross complementing 6	Homo sapiens	161-165
21107697-9	2011	However, distinct differences in the repair process following doxorubicin versus etoposide were seen in concentration dependency, time-course and requirement of Ku70 and Rad51 proteins.	Etoposide	81-90	RAD51 recombinase	Homo sapiens	170-175
21333639-10	2011	The results suggested that PA-1-mediated enhancement in the oral bioavailability of etoposide could possibly be due to its ability to modify P-gp/CYP 3A4 mediated drug disposition mechanisms.	Etoposide	84-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-153
21107697-0	2011	Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage.	Etoposide	78-87	X-ray repair cross complementing 6	Homo sapiens	0-4
21107697-0	2011	Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage.	Etoposide	78-87	RAD51 recombinase	Homo sapiens	9-14
21274505-6	2011	Furthermore, activation of p53 and AMPK was detected in etoposide-treated cells and inhibition of AMPK triggered apoptosis through suppression of autophagy.	Etoposide	56-65	tumor protein p53	Homo sapiens	27-30
21274505-6	2011	Furthermore, activation of p53 and AMPK was detected in etoposide-treated cells and inhibition of AMPK triggered apoptosis through suppression of autophagy.	Etoposide	56-65	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	35-39
21274505-9	2011	Moreover, AMPK activation is clearly associated with etoposide-induced autophagy.	Etoposide	53-62	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	10-14
21329675-3	2011	Etoposide treatment could not alter the mRNA level of IK1 but it could shorten the half-life of IK1.	Etoposide	0-9	IKAROS family zinc finger 1	Homo sapiens	96-99
21252239-6	2011	We also established that two PKCdelta-regulated genes, FOSL1 and BCL2A1, mediate the apoptotic effect of phorbol esters or the chemotherapeutic agent etoposide in prostate cancer cells.	Etoposide	150-159	protein kinase C delta	Homo sapiens	29-37
21252239-6	2011	We also established that two PKCdelta-regulated genes, FOSL1 and BCL2A1, mediate the apoptotic effect of phorbol esters or the chemotherapeutic agent etoposide in prostate cancer cells.	Etoposide	150-159	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	55-60
21252239-6	2011	We also established that two PKCdelta-regulated genes, FOSL1 and BCL2A1, mediate the apoptotic effect of phorbol esters or the chemotherapeutic agent etoposide in prostate cancer cells.	Etoposide	150-159	BCL2 related protein A1	Homo sapiens	65-71
21245486-5	2011	A DNA-PK specific inhibitor, NU7026, enhanced inhibitory activity of etoposide on M059K as well as on ATL cells.	Etoposide	69-78	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	2-8
21102524-5	2011	Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation.	Etoposide	58-67	ELAV like RNA binding protein 1	Homo sapiens	89-92
21102524-5	2011	Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation.	Etoposide	58-67	X-linked inhibitor of apoptosis	Homo sapiens	118-122
21102524-5	2011	Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation.	Etoposide	58-67	ELAV like RNA binding protein 1	Homo sapiens	140-143
21102524-5	2011	Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation.	Etoposide	58-67	X-linked inhibitor of apoptosis	Homo sapiens	207-211
21329675-4	2011	Co-treatment with the proteasome inhibitor MG132 or epoxomicin but not calpain inhibitor calpeptin inhibited etoposide-induced Ikaros downregulation.	Etoposide	109-118	IKAROS family zinc finger 1	Homo sapiens	127-133
21329675-5	2011	Overexpression of IK1 could accelerate etoposide-induced apoptosis in NB4 cells, as evidenced by the increase of Annexin V positive cells and the more early activation of caspase 3.	Etoposide	39-48	IKAROS family zinc finger 1	Homo sapiens	18-21
21329675-5	2011	Overexpression of IK1 could accelerate etoposide-induced apoptosis in NB4 cells, as evidenced by the increase of Annexin V positive cells and the more early activation of caspase 3.	Etoposide	39-48	annexin A5	Homo sapiens	113-122
20506295-4	2011	CHI3L1 suppression by shRNA reduced glioma cell invasion, anchorage-independent growth and increased cell death triggered by several anticancer drugs, including cisplatin, etoposide and doxorubicin, whereas CHI3L1 overexpression had the opposite effect in glioma cells.	Etoposide	172-181	chitinase 3 like 1	Homo sapiens	0-6
21498714-6	2011	RESULTS: A549RT-eto cells had an IC(50) for etoposide of 176 muM, 28-fold higher than parental cells, due to increased levels of MDR1 gene and P-glycoprotein (P-gp), resulting in greater drug efflux.	Etoposide	44-53	ATP binding cassette subfamily B member 1	Homo sapiens	129-133
21394211-3	2011	Here, we have analyzed the p53-regulated pathways induced by Actinomycin D and Etoposide treatment resulting in more growth arrested versus apoptotic cells respectively.	Etoposide	79-88	tumor protein p53	Homo sapiens	27-30
21498714-6	2011	RESULTS: A549RT-eto cells had an IC(50) for etoposide of 176 muM, 28-fold higher than parental cells, due to increased levels of MDR1 gene and P-glycoprotein (P-gp), resulting in greater drug efflux.	Etoposide	44-53	ATP binding cassette subfamily B member 1	Homo sapiens	143-157
21247380-0	2011	Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.	Etoposide	96-105	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	27-31
21168391-10	2011	These changes were not observed with other p53 activators, like etoposide and nutlin-3a that increased the p21 protein level.	Etoposide	64-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	107-110
20865015-4	2011	Further studies showed that INrf2 enhanced etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	43-52	kelch like ECH associated protein 1	Homo sapiens	28-33
20865015-4	2011	Further studies showed that INrf2 enhanced etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	43-52	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
20865015-4	2011	Further studies showed that INrf2 enhanced etoposide-mediated accumulation of Bax, increased release of cytochrome c from mitochondria, activated caspase-3/7, and enhanced DNA fragmentation and apoptosis.	Etoposide	43-52	caspase 3	Homo sapiens	146-155
20865015-6	2011	Moreover, dysfunctional/mutant INrf2 in human lung cancer cells failed to degrade Bcl-2, resulting in decreased etoposide and UV/gamma radiation-mediated DNA fragmentation.	Etoposide	112-121	kelch like ECH associated protein 1	Homo sapiens	31-36
21247380-5	2011	This suggests that Pin1 inhibition possibly reduces the induction of initial DNA damage by etoposide, which was supported by a decrease in the levels of chromatin bound topoIIalpha.	Etoposide	91-100	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	19-23
21097707-0	2011	Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.	Etoposide	39-48	myeloperoxidase	Homo sapiens	0-15
22099936-4	2011	The aim of this study is to evaluate the response rate of salvage chemotherapy by the ICE (Ifosfamide, Carboplatin, and Etoposide) regimen when administered to previously treated primary refractory or progressive high risk neuroblastoma patients.	Etoposide	120-129	carboxylesterase 2	Homo sapiens	86-89
21135858-5	2011	In fact, chronic exposure of human embryonic stem cells (hESCs) to etoposide induces MLL rearrangements and makes hESC more prone to acquire subsequent chromosomal abnormalities than postnatal CD34(+) cells, linking embryonic exposure to topoisomerase II inhibitors to genomic instability and MLL rearrangements.	Etoposide	67-76	lysine methyltransferase 2A	Homo sapiens	85-88
21135858-5	2011	In fact, chronic exposure of human embryonic stem cells (hESCs) to etoposide induces MLL rearrangements and makes hESC more prone to acquire subsequent chromosomal abnormalities than postnatal CD34(+) cells, linking embryonic exposure to topoisomerase II inhibitors to genomic instability and MLL rearrangements.	Etoposide	67-76	CD34 molecule	Homo sapiens	193-197
21135858-5	2011	In fact, chronic exposure of human embryonic stem cells (hESCs) to etoposide induces MLL rearrangements and makes hESC more prone to acquire subsequent chromosomal abnormalities than postnatal CD34(+) cells, linking embryonic exposure to topoisomerase II inhibitors to genomic instability and MLL rearrangements.	Etoposide	67-76	lysine methyltransferase 2A	Homo sapiens	293-296
21097707-4	2011	We hypothesized, therefore, that one-electron oxidation of etoposide by MPO to its phenoxyl radical is important for converting this anticancer drug to genotoxic and carcinogenic species in human CD34(+) myeloid progenitor cells.	Etoposide	59-68	myeloperoxidase	Homo sapiens	72-75
21097707-4	2011	We hypothesized, therefore, that one-electron oxidation of etoposide by MPO to its phenoxyl radical is important for converting this anticancer drug to genotoxic and carcinogenic species in human CD34(+) myeloid progenitor cells.	Etoposide	59-68	CD34 molecule	Homo sapiens	196-200
21097707-0	2011	Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.	Etoposide	39-48	CD34 molecule	Homo sapiens	77-81
21097707-5	2011	In the present study, using electron paramagnetic resonance spectroscopy, we provide conclusive evidence for MPO-dependent formation of etoposide phenoxyl radicals in growth factor-mobilized CD34(+) cells isolated from human umbilical cord blood and demonstrate that MPO-induced oxidation of etoposide is amplified in the presence of phenol.	Etoposide	136-145	myeloperoxidase	Homo sapiens	109-112
21097707-3	2011	Previous studies demonstrated that the phenoxyl radical of etoposide can be produced by action of myeloperoxidase (MPO), an enzyme found in developing myeloid progenitor cells, the likely origin for myeloid leukemias.	Etoposide	59-68	myeloperoxidase	Homo sapiens	98-113
21097707-5	2011	In the present study, using electron paramagnetic resonance spectroscopy, we provide conclusive evidence for MPO-dependent formation of etoposide phenoxyl radicals in growth factor-mobilized CD34(+) cells isolated from human umbilical cord blood and demonstrate that MPO-induced oxidation of etoposide is amplified in the presence of phenol.	Etoposide	136-145	CD34 molecule	Homo sapiens	191-195
21097707-5	2011	In the present study, using electron paramagnetic resonance spectroscopy, we provide conclusive evidence for MPO-dependent formation of etoposide phenoxyl radicals in growth factor-mobilized CD34(+) cells isolated from human umbilical cord blood and demonstrate that MPO-induced oxidation of etoposide is amplified in the presence of phenol.	Etoposide	136-145	myeloperoxidase	Homo sapiens	267-270
21097707-6	2011	Formation of etoposide radicals resulted in the oxidation of endogenous thiols, thus providing evidence for etoposide-mediated MPO-catalyzed redox cycling that may play a role in enhanced etoposide genotoxicity.	Etoposide	13-22	myeloperoxidase	Homo sapiens	127-130
21097707-6	2011	Formation of etoposide radicals resulted in the oxidation of endogenous thiols, thus providing evidence for etoposide-mediated MPO-catalyzed redox cycling that may play a role in enhanced etoposide genotoxicity.	Etoposide	108-117	myeloperoxidase	Homo sapiens	127-130
21097707-7	2011	In separate studies, etoposide-induced DNA damage and MLL gene rearrangements were demonstrated to be dependent in part on MPO activity in CD34(+) cells.	Etoposide	21-30	myeloperoxidase	Homo sapiens	123-126
21097707-7	2011	In separate studies, etoposide-induced DNA damage and MLL gene rearrangements were demonstrated to be dependent in part on MPO activity in CD34(+) cells.	Etoposide	21-30	CD34 molecule	Homo sapiens	139-143
21097707-8	2011	Together, our results are consistent with the idea that MPO-dependent oxidation of etoposide in human hematopoietic CD34(+) cells makes these cells especially prone to the induction of etoposide-related acute myeloid leukemia.	Etoposide	83-92	myeloperoxidase	Homo sapiens	56-59
21097707-8	2011	Together, our results are consistent with the idea that MPO-dependent oxidation of etoposide in human hematopoietic CD34(+) cells makes these cells especially prone to the induction of etoposide-related acute myeloid leukemia.	Etoposide	83-92	CD34 molecule	Homo sapiens	116-120
21097707-8	2011	Together, our results are consistent with the idea that MPO-dependent oxidation of etoposide in human hematopoietic CD34(+) cells makes these cells especially prone to the induction of etoposide-related acute myeloid leukemia.	Etoposide	185-194	myeloperoxidase	Homo sapiens	56-59
21097707-8	2011	Together, our results are consistent with the idea that MPO-dependent oxidation of etoposide in human hematopoietic CD34(+) cells makes these cells especially prone to the induction of etoposide-related acute myeloid leukemia.	Etoposide	185-194	CD34 molecule	Homo sapiens	116-120
21097707-3	2011	Previous studies demonstrated that the phenoxyl radical of etoposide can be produced by action of myeloperoxidase (MPO), an enzyme found in developing myeloid progenitor cells, the likely origin for myeloid leukemias.	Etoposide	59-68	myeloperoxidase	Homo sapiens	115-118
21087997-7	2011	CtIP"s function for repairing etoposide-induced DSBs by NHEJ in G0/G1 requires the Thr-847 but not the Ser-327 phosphorylation site, both of which are needed for resection during HR.	Etoposide	30-39	RB binding protein 8, endonuclease	Homo sapiens	0-4
21087997-0	2011	CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1.	Etoposide	51-60	RB binding protein 8, endonuclease	Homo sapiens	0-4
21087997-8	2011	This finding establishes that CtIP promotes NHEJ of etoposide-induced DSBs during G0/G1 phase with an end-processing function that is distinct to its resection function.	Etoposide	52-61	RB binding protein 8, endonuclease	Homo sapiens	30-34
21087997-6	2011	Here, we show that human cells arrested in G0/G1 repair etoposide-induced DSBs by NHEJ and, surprisingly, require the MRN complex (the ortholog of MRX) and CtIP.	Etoposide	56-65	discs large MAGUK scaffold protein 3	Homo sapiens	147-150
20973777-0	2011	Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.	Etoposide	70-79	H3 histone pseudogene 16	Homo sapiens	128-131
21087997-6	2011	Here, we show that human cells arrested in G0/G1 repair etoposide-induced DSBs by NHEJ and, surprisingly, require the MRN complex (the ortholog of MRX) and CtIP.	Etoposide	56-65	RB binding protein 8, endonuclease	Homo sapiens	156-160
21035156-10	2011	CONCLUSION: Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine.	Etoposide	128-137	gastrin releasing peptide	Homo sapiens	25-28
21325296-8	2011	A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment.	Etoposide	202-211	cAMP responsive element binding protein 1	Homo sapiens	38-42
21325296-8	2011	A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment.	Etoposide	202-211	membrane spanning 4-domains A1	Homo sapiens	94-100
21325296-8	2011	A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment.	Etoposide	202-211	mitogen-activated protein kinase 1	Homo sapiens	166-169
21325296-8	2011	A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment.	Etoposide	202-211	AKT serine/threonine kinase 1	Homo sapiens	171-174
21325296-8	2011	A significantly lowered expression of CREB target genes involved in cell cycle control (CyA1, B1, D1), and in the mitogen-activated protein kinase signaling pathway (ERK, AKT, DUSP1/4), was found after Etoposide treatment.	Etoposide	202-211	dual specificity phosphatase 14	Homo sapiens	176-183
21314987-4	2011	Using HeLa cells treated with etoposide as a model, we tried to determine whether FMRP could play a role in cell survival.	Etoposide	30-39	fragile X messenger ribonucleoprotein 1	Homo sapiens	82-86
21314987-8	2011	RESULTS: An increased FMRP expression was measured in etoposide-treated HeLa cells, which was induced by PI3K-Akt activation.	Etoposide	54-63	fragile X messenger ribonucleoprotein 1	Homo sapiens	22-26
21314987-10	2011	In addition, FMRP over-expression lead to the activation of PI3K-Akt signalling pathway as well as increased FMRP and BcL-xL expression, which culminates with the increased cell survival in etoposide-treated HeLa cells.	Etoposide	190-199	fragile X messenger ribonucleoprotein 1	Homo sapiens	13-17
21314987-10	2011	In addition, FMRP over-expression lead to the activation of PI3K-Akt signalling pathway as well as increased FMRP and BcL-xL expression, which culminates with the increased cell survival in etoposide-treated HeLa cells.	Etoposide	190-199	fragile X messenger ribonucleoprotein 1	Homo sapiens	109-113
21326872-0	2011	PKCdelta sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage.	Etoposide	72-81	protein kinase C delta	Homo sapiens	0-8
21326872-9	2011	Moreover, PKCdelta overexpression enhances the sensitivity of NB cells to etoposide, a well-characterised drug, commonly used in neuroblastoma therapy.	Etoposide	74-83	protein kinase C delta	Homo sapiens	10-18
21386980-6	2011	Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation.	Etoposide	35-44	tumor protein p53	Homo sapiens	72-75
21386980-6	2011	Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation.	Etoposide	35-44	DNA damage regulated autophagy modulator 1	Homo sapiens	88-92
21386980-6	2011	Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation.	Etoposide	35-44	VRK serine/threonine kinase 1	Homo sapiens	117-121
21386980-6	2011	Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation.	Etoposide	35-44	tumor protein p53	Homo sapiens	156-159
21056653-9	2011	MnSOD also induces up-regulation of Bcl-2 and prevents docetaxel-, etoposide-, or TNF-induced cell death.	Etoposide	67-76	superoxide dismutase 2	Homo sapiens	0-5
20973777-8	2011	We found that pH2AX, pBRCA1, p53BP1 and pChk1 levels were greatly increased after co-treatment of Sal with DOX or ETO.	Etoposide	114-117	tumor protein p53 binding protein 1	Homo sapiens	29-35
20973777-9	2011	The level of anti-apoptotic p21 protein was increased by DOX or ETO but decreased by Sal, which increased proteasome activity.	Etoposide	64-67	H3 histone pseudogene 16	Homo sapiens	28-31
20973777-11	2011	Overall, we demonstrated that the ability of Sal to sensitize cancer cells to the effects of DOX or ETO is associated with an increase in DNA damage and a decrease in anti-apoptotic protein p21 levels.	Etoposide	100-103	H3 histone pseudogene 16	Homo sapiens	190-193
21274871-7	2011	In addition, increased ACHE expression could remarkably sensitize HCC cells to chemotherapeutic drugs (i.e., adriamycin and etoposide).	Etoposide	124-133	acetylcholinesterase (Cartwright blood group)	Homo sapiens	23-27
21266351-4	2011	The nucleolar localization of hPuf-A would redistribute to the nucleoplasm after the treatment of RNA polymerase inhibitors (actinomycin D and 5,6-dichlorobenzimidazole riboside) and topoisomerase inhibitors [camptothecin (CPT) and etoposide].	Etoposide	232-241	pumilio RNA binding family member 3	Homo sapiens	30-36
20856196-8	2011	Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1"s acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide.	Etoposide	223-232	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	66-70
21159109-1	2011	Etoposide (VP-16) is one of the most widely used antitumor agents in pediatric oncology as well as chemotherapeutic agents used in conditioning regimen prior to allo-HSCT for childhood ALL.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
20856196-8	2011	Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1"s acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide.	Etoposide	223-232	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	66-70
20856196-8	2011	Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1"s acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide.	Etoposide	223-232	ATP binding cassette subfamily B member 1	Homo sapiens	166-170
21030584-5	2011	We also show that TDP2-deleted DT40 cells are highly sensitive to the anticancer Top2 poison, etoposide, but are not hypersensitive to the Top1 poison camptothecin or the DNA-alkyating agent methyl methanesulfonate.	Etoposide	94-103	tyrosyl-DNA phosphodiesterase 2	Gallus gallus	18-22
21255398-11	2011	Knockdown of RAD21 in the MDA-MB-231 breast cancer cell line significantly enhanced sensitivity to cyclophosphamide, 5-fluorouracil and etoposide.	Etoposide	136-145	RAD21 cohesin complex component	Homo sapiens	13-18
22130238-4	2011	The CD31 and CD47 levels on the cell surface of apoptotic Jurkat cells had decreased after treatment with etoposide.	Etoposide	106-115	platelet and endothelial cell adhesion molecule 1	Homo sapiens	4-8
20800622-0	2011	Etoposide induces apoptosis and upregulation of TACE/ADAM17 and ADAM10 in an in vitro male germ cell line model.	Etoposide	0-9	ADAM metallopeptidase domain 17	Homo sapiens	48-52
20800622-0	2011	Etoposide induces apoptosis and upregulation of TACE/ADAM17 and ADAM10 in an in vitro male germ cell line model.	Etoposide	0-9	ADAM metallopeptidase domain 17	Homo sapiens	53-59
20800622-0	2011	Etoposide induces apoptosis and upregulation of TACE/ADAM17 and ADAM10 in an in vitro male germ cell line model.	Etoposide	0-9	ADAM metallopeptidase domain 10	Homo sapiens	64-70
20800622-4	2011	The aim of this work was to evaluate if etoposide induces upregulation of ADAM10 or TACE/ADAM17 in two cell lines (GC-1 and GC-2) derived from male germ cells.	Etoposide	40-49	ADAM metallopeptidase domain 10	Homo sapiens	74-80
20800622-4	2011	The aim of this work was to evaluate if etoposide induces upregulation of ADAM10 or TACE/ADAM17 in two cell lines (GC-1 and GC-2) derived from male germ cells.	Etoposide	40-49	ADAM metallopeptidase domain 17	Homo sapiens	84-88
20800622-4	2011	The aim of this work was to evaluate if etoposide induces upregulation of ADAM10 or TACE/ADAM17 in two cell lines (GC-1 and GC-2) derived from male germ cells.	Etoposide	40-49	ADAM metallopeptidase domain 17	Homo sapiens	89-95
20800622-4	2011	The aim of this work was to evaluate if etoposide induces upregulation of ADAM10 or TACE/ADAM17 in two cell lines (GC-1 and GC-2) derived from male germ cells.	Etoposide	40-49	olfactomedin 4	Homo sapiens	115-119
20800622-4	2011	The aim of this work was to evaluate if etoposide induces upregulation of ADAM10 or TACE/ADAM17 in two cell lines (GC-1 and GC-2) derived from male germ cells.	Etoposide	40-49	solute carrier family 25 member 18	Homo sapiens	124-128
20800622-5	2011	Results showed that etoposide induced apoptosis in a dose-response manner in both GC-1 and GC-2 cells.	Etoposide	20-29	olfactomedin 4	Homo sapiens	82-86
20800622-5	2011	Results showed that etoposide induced apoptosis in a dose-response manner in both GC-1 and GC-2 cells.	Etoposide	20-29	solute carrier family 25 member 18	Homo sapiens	91-95
20800622-6	2011	Apoptosis started to increase 6h after etoposide addition in GC-2 cells, whereas the same was observed 18h after addition to the GC-1 cells.	Etoposide	39-48	solute carrier family 25 member 18	Homo sapiens	61-65
20800622-7	2011	Protein and mRNA levels of ADAM10 and TACE/ADAM17 increased 18h after etoposide was removed from the GC-1 cells.	Etoposide	70-79	ADAM metallopeptidase domain 10	Homo sapiens	27-33
20800622-7	2011	Protein and mRNA levels of ADAM10 and TACE/ADAM17 increased 18h after etoposide was removed from the GC-1 cells.	Etoposide	70-79	ADAM metallopeptidase domain 17	Homo sapiens	38-42
20800622-7	2011	Protein and mRNA levels of ADAM10 and TACE/ADAM17 increased 18h after etoposide was removed from the GC-1 cells.	Etoposide	70-79	ADAM metallopeptidase domain 17	Homo sapiens	43-49
20800622-7	2011	Protein and mRNA levels of ADAM10 and TACE/ADAM17 increased 18h after etoposide was removed from the GC-1 cells.	Etoposide	70-79	olfactomedin 4	Homo sapiens	101-105
20800622-8	2011	In GC-2 cells, the protein levels of both proteins increased 12h after etoposide was removed.	Etoposide	71-80	solute carrier family 25 member 18	Homo sapiens	3-7
20800622-9	2011	ADAM10 mRNA increased after 3h and then steadily decreased up to 12h after removal, whereas TACE/ADAM17 mRNA decreased after etoposide removal.	Etoposide	125-134	ADAM metallopeptidase domain 17	Homo sapiens	92-96
20800622-9	2011	ADAM10 mRNA increased after 3h and then steadily decreased up to 12h after removal, whereas TACE/ADAM17 mRNA decreased after etoposide removal.	Etoposide	125-134	ADAM metallopeptidase domain 17	Homo sapiens	97-103
20800622-10	2011	Finally, apoptosis was prevented in GC-1 and GC-2 cells by the addition of pharmacological inhibitors of ADAM10 and TACE/ADAM17 to the culture medium of etoposide-treated cells.	Etoposide	153-162	olfactomedin 4	Homo sapiens	36-40
20800622-10	2011	Finally, apoptosis was prevented in GC-1 and GC-2 cells by the addition of pharmacological inhibitors of ADAM10 and TACE/ADAM17 to the culture medium of etoposide-treated cells.	Etoposide	153-162	solute carrier family 25 member 18	Homo sapiens	45-49
20800622-10	2011	Finally, apoptosis was prevented in GC-1 and GC-2 cells by the addition of pharmacological inhibitors of ADAM10 and TACE/ADAM17 to the culture medium of etoposide-treated cells.	Etoposide	153-162	ADAM metallopeptidase domain 10	Homo sapiens	105-111
20800622-10	2011	Finally, apoptosis was prevented in GC-1 and GC-2 cells by the addition of pharmacological inhibitors of ADAM10 and TACE/ADAM17 to the culture medium of etoposide-treated cells.	Etoposide	153-162	ADAM metallopeptidase domain 17	Homo sapiens	116-120
20800622-10	2011	Finally, apoptosis was prevented in GC-1 and GC-2 cells by the addition of pharmacological inhibitors of ADAM10 and TACE/ADAM17 to the culture medium of etoposide-treated cells.	Etoposide	153-162	ADAM metallopeptidase domain 17	Homo sapiens	121-127
20800622-11	2011	Our results show for the first time that etoposide upregulates ADAM10 and TACE/ADAM17 mRNA and protein levels.	Etoposide	41-50	ADAM metallopeptidase domain 10	Homo sapiens	63-69
20800622-11	2011	Our results show for the first time that etoposide upregulates ADAM10 and TACE/ADAM17 mRNA and protein levels.	Etoposide	41-50	ADAM metallopeptidase domain 17	Homo sapiens	74-78
20800622-11	2011	Our results show for the first time that etoposide upregulates ADAM10 and TACE/ADAM17 mRNA and protein levels.	Etoposide	41-50	ADAM metallopeptidase domain 17	Homo sapiens	79-85
20800622-12	2011	In addition, we also show that ADAM10 and TACE/ADAM17 have a role in etoposide-induced apoptosis.	Etoposide	69-78	ADAM metallopeptidase domain 10	Homo sapiens	31-37
20800622-12	2011	In addition, we also show that ADAM10 and TACE/ADAM17 have a role in etoposide-induced apoptosis.	Etoposide	69-78	ADAM metallopeptidase domain 17	Homo sapiens	42-46
20800622-12	2011	In addition, we also show that ADAM10 and TACE/ADAM17 have a role in etoposide-induced apoptosis.	Etoposide	69-78	ADAM metallopeptidase domain 17	Homo sapiens	47-53
20888374-8	2011	Different from the cases with FR or sulforaphane, etoposide- or doxorubicin-induced cell death was suppressed with co-treatment of caspase-9 inhibitor, and the drugs failed to induce significant autophagy in MCF-7 cells.	Etoposide	50-59	caspase 9	Homo sapiens	131-140
22130238-0	2011	Decreases in CD31 and CD47 levels on the cell surface during etoposide-induced Jurkat cell apoptosis.	Etoposide	61-70	platelet and endothelial cell adhesion molecule 1	Homo sapiens	13-17
22130238-0	2011	Decreases in CD31 and CD47 levels on the cell surface during etoposide-induced Jurkat cell apoptosis.	Etoposide	61-70	CD47 molecule	Homo sapiens	22-26
22130238-4	2011	The CD31 and CD47 levels on the cell surface of apoptotic Jurkat cells had decreased after treatment with etoposide.	Etoposide	106-115	CD47 molecule	Homo sapiens	13-17
20931131-3	2011	This report describes a series of high-throughput LanthaScreen  time-resolved Forster resonance energy transfer (TR-FRET) immunoassays for detection of intracellular p53 phosphorylation of Ser15 and acetylation of Lys382 upon treatment with DNA damage agents, such as etoposide.	Etoposide	268-277	tumor protein p53	Homo sapiens	166-169
20931131-5	2011	First, BacMam-mediated overexpression of SIRT1 resulted in dose-dependent deacetylation of GFP-p53 following etoposide treatment of U-2 OS cells, confirming that GFP-p53 serves as a SIRT1 substrate in this assay format.	Etoposide	109-118	tumor protein p53	Homo sapiens	166-169
21143116-7	2011	Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone).	Etoposide	169-178	ATP binding cassette subfamily C member 1	Homo sapiens	26-30
21143116-7	2011	Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone).	Etoposide	169-178	ATP binding cassette subfamily C member 1	Homo sapiens	31-36
22187664-3	2011	RNAi-mediated knockdown of alpha-enolase in A549 and H460 lung, MCF7 breast and CaOV3 ovarian cancer cells caused a significant increase in the sensitivity of these cells to antitubulin chemotherapeutics (e.g., vincristine and taxol), but not to doxorubicin, etoposide or cisplatinum.	Etoposide	259-268	enolase 1	Homo sapiens	27-40
21785230-6	2011	The XRCC4-deficient cells were highly sensitive to etoposide and 5-fluoro-2"-deoxyuridine as well as IR, and moderately sensitive to camptothecin, methyl methanesulfonate, cisplatin, mitomycin C, aphidicolin and hydroxyurea, compared to the parental HCT116 cells.	Etoposide	51-60	X-ray repair cross complementing 4	Homo sapiens	4-9
20931131-5	2011	First, BacMam-mediated overexpression of SIRT1 resulted in dose-dependent deacetylation of GFP-p53 following etoposide treatment of U-2 OS cells, confirming that GFP-p53 serves as a SIRT1 substrate in this assay format.	Etoposide	109-118	sirtuin 1	Homo sapiens	41-46
20931131-5	2011	First, BacMam-mediated overexpression of SIRT1 resulted in dose-dependent deacetylation of GFP-p53 following etoposide treatment of U-2 OS cells, confirming that GFP-p53 serves as a SIRT1 substrate in this assay format.	Etoposide	109-118	tumor protein p53	Homo sapiens	95-98
22110660-10	2011	Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones.	Etoposide	72-77	cytidine/uridine monophosphate kinase 1	Homo sapiens	140-143
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	Janus kinase 2	Homo sapiens	76-80
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	erythropoietin receptor	Mus musculus	112-116
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	erythropoietin	Mus musculus	112-115
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	Janus kinase 2	Mus musculus	173-177
22087308-4	2011	Etoposide or doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.	Etoposide	0-9	Janus kinase 2	Homo sapiens	173-177
22216167-3	2011	Here we show that exogenous caspase-3 sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus the anti-apoptotic role of caspase-3s.	Etoposide	126-135	caspase 3	Homo sapiens	28-37
22216167-3	2011	Here we show that exogenous caspase-3 sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus the anti-apoptotic role of caspase-3s.	Etoposide	211-220	caspase 3	Homo sapiens	28-37
22216167-3	2011	Here we show that exogenous caspase-3 sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus the anti-apoptotic role of caspase-3s.	Etoposide	211-220	caspase 3	Homo sapiens	182-191
22216167-4	2011	In caspase-3 transfected cells, lamin-A and alpha-fodrin were cleaved when caspase-3 was activated by etoposide or methotrexate.	Etoposide	102-111	caspase 3	Homo sapiens	3-12
22216167-4	2011	In caspase-3 transfected cells, lamin-A and alpha-fodrin were cleaved when caspase-3 was activated by etoposide or methotrexate.	Etoposide	102-111	spectrin alpha, non-erythrocytic 1	Homo sapiens	44-56
22216167-4	2011	In caspase-3 transfected cells, lamin-A and alpha-fodrin were cleaved when caspase-3 was activated by etoposide or methotrexate.	Etoposide	102-111	caspase 3	Homo sapiens	75-84
22216167-6	2011	Depletion of caspase-3 by RNA interference in HBL100 containing endogenous caspase-3s caused reduction in etoposide and methotrexate-induced apoptosis, whereas the depletion of caspase-3s sensitized cells to chemotherapy.	Etoposide	106-115	caspase 3	Homo sapiens	13-22
22216167-6	2011	Depletion of caspase-3 by RNA interference in HBL100 containing endogenous caspase-3s caused reduction in etoposide and methotrexate-induced apoptosis, whereas the depletion of caspase-3s sensitized cells to chemotherapy.	Etoposide	106-115	caspase 3	Homo sapiens	75-84
22216167-6	2011	Depletion of caspase-3 by RNA interference in HBL100 containing endogenous caspase-3s caused reduction in etoposide and methotrexate-induced apoptosis, whereas the depletion of caspase-3s sensitized cells to chemotherapy.	Etoposide	106-115	caspase 3	Homo sapiens	75-84
22110660-10	2011	Increased basal apoptosis and sensitivities to ara-C, daunorubicin, and VP-16 accompanied by down-regulated Bcl-2 were also detected in the CMK GATA1 shRNA knockdown clones.	Etoposide	72-77	GATA binding protein 1	Homo sapiens	144-149
21980415-7	2011	We also demonstrated that treatment of MCF7/casp3-10b cells with staurosporine and etoposides induced apoptosis and knockdown of CAAP expression.	Etoposide	83-93	caspase activity and apoptosis inhibitor 1	Homo sapiens	129-133
20149834-0	2010	Functional inactivation of triosephosphate isomerase through phosphorylation during etoposide-induced apoptosis in HeLa cells: potential role of Cdk2.	Etoposide	84-93	triosephosphate isomerase 1	Homo sapiens	27-52
21935404-11	2011	Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional chemotherapeutic drugs such as taxol and etoposide may directly target CD44(+) tumor-initiating cells; and 3) DTCs generated via chronic drug selection involve epigenetic mechanisms.	Etoposide	124-133	CD44 molecule (Indian blood group)	Homo sapiens	154-158
21203533-9	2010	Accordingly, knock-down of Praf2 increases clonogenicity of U2OS cells following etoposide treatment by reducing cell death.	Etoposide	81-90	PRA1 domain family member 2	Homo sapiens	27-32
20921231-4	2010	During etoposide-induced apoptosis in Jurkat cells, the cleavage of MST1 directly corresponded with strong H2AX phosphorylation.	Etoposide	7-16	macrophage stimulating 1	Homo sapiens	68-72
20921231-4	2010	During etoposide-induced apoptosis in Jurkat cells, the cleavage of MST1 directly corresponded with strong H2AX phosphorylation.	Etoposide	7-16	H2A.X variant histone	Homo sapiens	107-111
20921231-10	2010	Histone H2AX phosphorylation and DNA fragmentation were suppressed in MST1 knockdown Jurkat cells after etoposide treatment.	Etoposide	104-113	H2A.X variant histone	Homo sapiens	8-12
20921231-10	2010	Histone H2AX phosphorylation and DNA fragmentation were suppressed in MST1 knockdown Jurkat cells after etoposide treatment.	Etoposide	104-113	macrophage stimulating 1	Homo sapiens	70-74
20149834-2	2010	In this study, we applied a phospho-proteomic technique to screen target molecules of Cdk2 during etoposide-induced apoptosis.	Etoposide	98-107	cyclin dependent kinase 2	Homo sapiens	86-90
20149834-5	2010	The cellular levels of these phosphoproteins were markedly reduced in the presence of etoposide in HeLa cells transfected with dominant negative mutant construct of Cdk2.	Etoposide	86-95	cyclin dependent kinase 2	Homo sapiens	165-169
20149834-6	2010	Among the six candidate phosphoproteins, human triosephosphate isomerase (TPI), a glycolytic enzyme, was found to be a direct substrate of Cdk2 during etoposide-induced apoptosis.	Etoposide	151-160	triosephosphate isomerase 1	Homo sapiens	47-72
20149834-6	2010	Among the six candidate phosphoproteins, human triosephosphate isomerase (TPI), a glycolytic enzyme, was found to be a direct substrate of Cdk2 during etoposide-induced apoptosis.	Etoposide	151-160	triosephosphate isomerase 1	Homo sapiens	74-77
20149834-6	2010	Among the six candidate phosphoproteins, human triosephosphate isomerase (TPI), a glycolytic enzyme, was found to be a direct substrate of Cdk2 during etoposide-induced apoptosis.	Etoposide	151-160	cyclin dependent kinase 2	Homo sapiens	139-143
20149834-11	2010	Loss of catalytic activity of TPI as a consequence of phosphorylation of this glycolytic enzyme may disrupt energy production in etoposide-treated HeLa cells, rendering these cells prone to undergo apoptosis.	Etoposide	129-138	triosephosphate isomerase 1	Homo sapiens	30-33
21212465-12	2010	Re-addition of serum caused mTOR-dependent senescence in the presence of etoposide or doxorubicin.	Etoposide	73-82	mechanistic target of rapamycin kinase	Homo sapiens	28-32
20840860-6	2010	Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation after adriamycin and/or etoposide treatments.	Etoposide	123-132	tumor protein p53	Homo sapiens	18-21
20840860-6	2010	Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation after adriamycin and/or etoposide treatments.	Etoposide	123-132	BCL2 associated X, apoptosis regulator	Homo sapiens	35-38
20840860-6	2010	Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation after adriamycin and/or etoposide treatments.	Etoposide	123-132	growth arrest and DNA damage inducible alpha	Homo sapiens	46-58
20840860-6	2010	Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation after adriamycin and/or etoposide treatments.	Etoposide	123-132	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	79-87
20940140-10	2010	Forced Cyp26a1 overexpression significantly reduced the sensitivity of ESCs to etoposide-induced apoptosis, with reductions in p53 (P &lt; 0.01) and Fas (P &lt; 0.05) proteins versus control, while in contrast, FasL (P &lt; 0.01) and proliferating cell nuclear antigen (P &lt; 0.05) proteins increased.	Etoposide	79-88	cytochrome P450, family 26, subfamily a, polypeptide 1	Rattus norvegicus	7-14
20940140-10	2010	Forced Cyp26a1 overexpression significantly reduced the sensitivity of ESCs to etoposide-induced apoptosis, with reductions in p53 (P &lt; 0.01) and Fas (P &lt; 0.05) proteins versus control, while in contrast, FasL (P &lt; 0.01) and proliferating cell nuclear antigen (P &lt; 0.05) proteins increased.	Etoposide	79-88	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	127-130
20940140-10	2010	Forced Cyp26a1 overexpression significantly reduced the sensitivity of ESCs to etoposide-induced apoptosis, with reductions in p53 (P &lt; 0.01) and Fas (P &lt; 0.05) proteins versus control, while in contrast, FasL (P &lt; 0.01) and proliferating cell nuclear antigen (P &lt; 0.05) proteins increased.	Etoposide	79-88	Fas ligand	Rattus norvegicus	211-215
20940140-10	2010	Forced Cyp26a1 overexpression significantly reduced the sensitivity of ESCs to etoposide-induced apoptosis, with reductions in p53 (P &lt; 0.01) and Fas (P &lt; 0.05) proteins versus control, while in contrast, FasL (P &lt; 0.01) and proliferating cell nuclear antigen (P &lt; 0.05) proteins increased.	Etoposide	79-88	proliferating cell nuclear antigen	Rattus norvegicus	234-268
20929928-5	2010	Moreover, the content of mitochondrial EGFR transfer was decreased when the cells were exposed to the apoptotic inducer etoposide.	Etoposide	120-129	epidermal growth factor receptor	Homo sapiens	39-43
21176346-3	2010	The purpose of this study was to investigate the synergistic killing effect of SG611-pdcd5 and low-dose etoposide (VP-16) on K562 cells.	Etoposide	104-113	host cell factor C1	Homo sapiens	115-120
20971076-9	2010	Moreover, siRNA-mediated knockdown of LCK effectively restored the sensitivity of glioma cells to cisplatin and etoposide.	Etoposide	112-121	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	38-41
20980392-7	2010	Furthermore, DNA-damage-inducing agents doxorubicin, etoposide and sodium arsenite induced ferritin H mRNA expression in HIPK2(+/+) MEF cells, whereas it was significantly impaired in HIPK2(-/-) MEF cells.	Etoposide	53-62	homeodomain interacting protein kinase 2	Homo sapiens	121-126
20980392-7	2010	Furthermore, DNA-damage-inducing agents doxorubicin, etoposide and sodium arsenite induced ferritin H mRNA expression in HIPK2(+/+) MEF cells, whereas it was significantly impaired in HIPK2(-/-) MEF cells.	Etoposide	53-62	homeodomain interacting protein kinase 2	Homo sapiens	184-189
21116747-5	2010	The SMILE (steroid, methotrexate, ifosfamide, L: -asparaginase and etoposide) regimen is one of the promising regimens for advanced or relapsed/refractory ENKL, but its myelotoxicity is strong.	Etoposide	67-76	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	4-9
21037108-2	2010	Here we show that chemical inhibition with the HDAC6-selective inhibitor tubacin significantly enhances cell death induced by the topoisomerase II inhibitors etoposide and doxorubicin and the pan-HDAC inhibitor SAHA (vorinostat) in transformed cells (LNCaP, MCF-7), an effect not observed in normal cells (human foreskin fibroblast cells).	Etoposide	158-167	histone deacetylase 6	Homo sapiens	47-52
21037108-4	2010	Further, we show that down-regulation of HDAC6 expression by shRNA in LNCaP cells enhances cell death induced by etoposide, doxorubicin, and SAHA.	Etoposide	113-122	histone deacetylase 6	Homo sapiens	41-46
21037108-5	2010	Tubacin in combination with SAHA or etoposide is more potent than either drug alone in activating the intrinsic apoptotic pathway in transformed cells, as evidenced by an increase in PARP cleavage and partial inhibition of this effect by the pan-caspase inhibitor Z-VAD-fmk.	Etoposide	36-45	collagen type XI alpha 2 chain	Homo sapiens	183-187
21037108-7	2010	Tubacin enhances DNA damage induced by etoposide or SAHA as indicated by increased accumulation of gammaH2AX and activation of the checkpoint kinase Chk2.	Etoposide	39-48	checkpoint kinase 2	Homo sapiens	149-153
20851854-8	2010	HMGB2 knockdown by small interfering RNAs decreased cell proliferation, and overexpression of HMGB2 by expression vectors diminished cisplatin- and etoposide-induced cell death.	Etoposide	148-157	high mobility group box 2	Homo sapiens	94-99
20847343-6	2010	Upregulation of the ATP-dependent transporter ABCC3 by p23 conferred resistance to the chemotherapeutic agents etoposide and doxorubicin in MCF-7+p23 cells.	Etoposide	111-120	ATP binding cassette subfamily C member 3	Homo sapiens	46-51
20847343-6	2010	Upregulation of the ATP-dependent transporter ABCC3 by p23 conferred resistance to the chemotherapeutic agents etoposide and doxorubicin in MCF-7+p23 cells.	Etoposide	111-120	prostaglandin E synthase 3	Homo sapiens	55-58
20876284-4	2010	Although, DNA-damaging agents such as 5-fluorouracil (5-FU), etoposide and adriamycin have been successfully employed due to their ability to trigger cFLIP(L) and cFLIP(s) down-regulation the molecular mechanisms underneath their action have been only partially elucidated.	Etoposide	61-70	CASP8 and FADD like apoptosis regulator	Homo sapiens	150-155
20876284-4	2010	Although, DNA-damaging agents such as 5-fluorouracil (5-FU), etoposide and adriamycin have been successfully employed due to their ability to trigger cFLIP(L) and cFLIP(s) down-regulation the molecular mechanisms underneath their action have been only partially elucidated.	Etoposide	61-70	CASP8 and FADD like apoptosis regulator	Homo sapiens	163-168
20959489-5	2010	Notably, doubly mutant RAP80(-/-)BRCA1(-/-) cells were more sensitive to etoposide than were BRCA1(-/-) cells, revealing that RAP80 performs a BRCA1-independent repair function.	Etoposide	73-82	BRCA1 DNA repair associated	Gallus gallus	33-38
20847343-6	2010	Upregulation of the ATP-dependent transporter ABCC3 by p23 conferred resistance to the chemotherapeutic agents etoposide and doxorubicin in MCF-7+p23 cells.	Etoposide	111-120	prostaglandin E synthase 3	Homo sapiens	146-149
20637859-0	2010	Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation.	Etoposide	50-59	mitogen-activated protein kinase 3	Homo sapiens	5-9
20978201-4	2010	IR, doxorubicin, and etoposide induced the phosphorylation of H2A.X on Ser(139) (gammaH2AX) and DNA damage foci formation.	Etoposide	21-30	H2A.X variant histone	Homo sapiens	62-67
20637859-0	2010	Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation.	Etoposide	50-59	mitogen-activated protein kinase 1	Homo sapiens	14-18
20637859-8	2010	Knockdown of either kinases significantly reduced ATM activation in response to etoposide treatment, and thereby attenuated phosphorylation of the ATM substrates, including the S139 of H2AX (gammaH2AX), p53 S15, and CHK2 T68.	Etoposide	80-89	ATM serine/threonine kinase	Homo sapiens	147-150
20637859-8	2010	Knockdown of either kinases significantly reduced ATM activation in response to etoposide treatment, and thereby attenuated phosphorylation of the ATM substrates, including the S139 of H2AX (gammaH2AX), p53 S15, and CHK2 T68.	Etoposide	80-89	H2A.X variant histone	Homo sapiens	185-189
20637859-0	2010	Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation.	Etoposide	50-59	ATM serine/threonine kinase	Homo sapiens	95-98
20637859-8	2010	Knockdown of either kinases significantly reduced ATM activation in response to etoposide treatment, and thereby attenuated phosphorylation of the ATM substrates, including the S139 of H2AX (gammaH2AX), p53 S15, and CHK2 T68.	Etoposide	80-89	checkpoint kinase 2	Homo sapiens	216-220
20637859-8	2010	Knockdown of either kinases significantly reduced ATM activation in response to etoposide treatment, and thereby attenuated phosphorylation of the ATM substrates, including the S139 of H2AX (gammaH2AX), p53 S15, and CHK2 T68.	Etoposide	80-89	ATM serine/threonine kinase	Homo sapiens	50-53
20637859-9	2010	Consistent with these observations, knockdown of either ERK1 or ERK2 reduced etoposide-induced CDC25C S216 phosphorylation and significantly compromised etoposide-induced G2/M arrest in MCF7 cells.	Etoposide	77-86	mitogen-activated protein kinase 3	Homo sapiens	56-60
20637859-9	2010	Consistent with these observations, knockdown of either ERK1 or ERK2 reduced etoposide-induced CDC25C S216 phosphorylation and significantly compromised etoposide-induced G2/M arrest in MCF7 cells.	Etoposide	77-86	mitogen-activated protein kinase 1	Homo sapiens	64-68
20637859-9	2010	Consistent with these observations, knockdown of either ERK1 or ERK2 reduced etoposide-induced CDC25C S216 phosphorylation and significantly compromised etoposide-induced G2/M arrest in MCF7 cells.	Etoposide	77-86	cell division cycle 25C	Homo sapiens	95-101
20637859-9	2010	Consistent with these observations, knockdown of either ERK1 or ERK2 reduced etoposide-induced CDC25C S216 phosphorylation and significantly compromised etoposide-induced G2/M arrest in MCF7 cells.	Etoposide	153-162	mitogen-activated protein kinase 3	Homo sapiens	56-60
20637859-9	2010	Consistent with these observations, knockdown of either ERK1 or ERK2 reduced etoposide-induced CDC25C S216 phosphorylation and significantly compromised etoposide-induced G2/M arrest in MCF7 cells.	Etoposide	153-162	mitogen-activated protein kinase 1	Homo sapiens	64-68
20637859-10	2010	Taken together, we demonstrated that both ERK1 and ERK2 kinases play a role in etoposide-induced G2/M arrest by facilitating activation of the ATM pathway.	Etoposide	79-88	mitogen-activated protein kinase 3	Homo sapiens	42-46
20637859-10	2010	Taken together, we demonstrated that both ERK1 and ERK2 kinases play a role in etoposide-induced G2/M arrest by facilitating activation of the ATM pathway.	Etoposide	79-88	mitogen-activated protein kinase 1	Homo sapiens	51-55
21163134-2	2010	This study aimed to investigate the mechanism of human small cell lung cancer cell line resistance to etoposide (VP-16), H446/VP.	Etoposide	102-111	host cell factor C1	Homo sapiens	113-118
20733350-1	2010	Expression of zinc-finger protein 143 (ZNF143), a human homolog of the Xenopus transcriptional activator protein Staf, is induced by various DNA-damaging agents including etoposide, doxorubicin, and gamma-irradiation.	Etoposide	171-180	zinc finger protein 143	Homo sapiens	14-37
20538454-2	2010	This study was designed to investigate the potential therapeutic benefit of combination therapy with temozolomide (TMZ) and oral etoposide (VP-16) in children with progressive or relapsed MB.	Etoposide	129-138	host cell factor C1	Homo sapiens	140-145
20127861-0	2010	CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.	Etoposide	155-164	C-C motif chemokine receptor 9	Homo sapiens	0-4
20127861-0	2010	CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.	Etoposide	155-164	C-C motif chemokine receptor 9	Homo sapiens	98-102
20127861-0	2010	CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.	Etoposide	155-164	C-C motif chemokine ligand 25	Homo sapiens	103-108
20127861-7	2010	Furthermore, the cytotoxic effect of etoposide was significantly inhibited in the presence of CCL25, and this inhibitory effect of CCL25 was abrogated when CCR9-CCL25 interaction was blocked using anti-CCR9 monoclonal antibodies.	Etoposide	37-46	C-C motif chemokine ligand 25	Homo sapiens	94-99
20127861-7	2010	Furthermore, the cytotoxic effect of etoposide was significantly inhibited in the presence of CCL25, and this inhibitory effect of CCL25 was abrogated when CCR9-CCL25 interaction was blocked using anti-CCR9 monoclonal antibodies.	Etoposide	37-46	C-C motif chemokine ligand 25	Homo sapiens	131-136
20127861-7	2010	Furthermore, the cytotoxic effect of etoposide was significantly inhibited in the presence of CCL25, and this inhibitory effect of CCL25 was abrogated when CCR9-CCL25 interaction was blocked using anti-CCR9 monoclonal antibodies.	Etoposide	37-46	C-C motif chemokine receptor 9	Homo sapiens	156-160
20127861-7	2010	Furthermore, the cytotoxic effect of etoposide was significantly inhibited in the presence of CCL25, and this inhibitory effect of CCL25 was abrogated when CCR9-CCL25 interaction was blocked using anti-CCR9 monoclonal antibodies.	Etoposide	37-46	C-C motif chemokine ligand 25	Homo sapiens	131-136
20127861-7	2010	Furthermore, the cytotoxic effect of etoposide was significantly inhibited in the presence of CCL25, and this inhibitory effect of CCL25 was abrogated when CCR9-CCL25 interaction was blocked using anti-CCR9 monoclonal antibodies.	Etoposide	37-46	C-C motif chemokine receptor 9	Homo sapiens	202-206
23605487-6	2010	The specific topoisomerase poisons camptothecin and etoposide caused comparable effects, underlining that TDP1 plays an important role in the repair of topoisomerase-mediated DNA damage.	Etoposide	52-61	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	106-110
20637859-10	2010	Taken together, we demonstrated that both ERK1 and ERK2 kinases play a role in etoposide-induced G2/M arrest by facilitating activation of the ATM pathway.	Etoposide	79-88	ATM serine/threonine kinase	Homo sapiens	143-146
20870738-3	2010	Here, we report that DNA-damaging anticancer agents such as Adriamycin and etoposide suppressed the expression of GLUT3, but not GLUT1, in HeLa cells and a tumorigenic HeLa cell hybrid.	Etoposide	75-84	solute carrier family 2 member 3	Homo sapiens	114-119
20870738-3	2010	Here, we report that DNA-damaging anticancer agents such as Adriamycin and etoposide suppressed the expression of GLUT3, but not GLUT1, in HeLa cells and a tumorigenic HeLa cell hybrid.	Etoposide	75-84	solute carrier family 2 member 1	Homo sapiens	129-134
21080495-10	2010	We used this method to study differences in protein localization in HCT116 cells either with or without p53, and studied the differences in cellular response to DNA damage following treatment of HCT116 cells with etoposide in both p53 wild-type and null genetic backgrounds.	Etoposide	213-222	tumor protein p53	Homo sapiens	231-234
20733350-1	2010	Expression of zinc-finger protein 143 (ZNF143), a human homolog of the Xenopus transcriptional activator protein Staf, is induced by various DNA-damaging agents including etoposide, doxorubicin, and gamma-irradiation.	Etoposide	171-180	zinc finger protein 143	Homo sapiens	39-45
20733350-1	2010	Expression of zinc-finger protein 143 (ZNF143), a human homolog of the Xenopus transcriptional activator protein Staf, is induced by various DNA-damaging agents including etoposide, doxorubicin, and gamma-irradiation.	Etoposide	171-180	zinc finger protein 143 S homeolog	Xenopus laevis	113-117
20637734-0	2010	BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway.	Etoposide	35-44	BCL2 interacting protein 3	Homo sapiens	0-5
20877355-10	2010	Only actinomycin D and TRAIL, and etoposide with TRAIL or FasL, enhanced death compared with either agent alone.	Etoposide	34-43	TNF superfamily member 10	Homo sapiens	49-54
20877355-10	2010	Only actinomycin D and TRAIL, and etoposide with TRAIL or FasL, enhanced death compared with either agent alone.	Etoposide	34-43	Fas ligand	Homo sapiens	58-62
21048951-4	2010	Chromosome translocations involving the MLL gene on 11q23 are the most frequent chromosome abnormalities in secondary leukemias associated with chemotherapy employing etoposide, a topoisomerase II poison.	Etoposide	167-176	lysine methyltransferase 2A	Homo sapiens	40-43
21048951-5	2010	Here we show that ATM deficiency results in the excessive binding of the DNA recombination protein RAD51 at the translocation breakpoint hotspot of 11q23 chromosome translocation after etoposide exposure.	Etoposide	185-194	ATM serine/threonine kinase	Homo sapiens	18-21
21048951-5	2010	Here we show that ATM deficiency results in the excessive binding of the DNA recombination protein RAD51 at the translocation breakpoint hotspot of 11q23 chromosome translocation after etoposide exposure.	Etoposide	185-194	RAD51 recombinase	Homo sapiens	99-104
20637734-9	2010	Together, these results suggest that autophagy might be involved in etoposide-induced cell death only under normoxia and that BNIP3 is a major effector of the protective mechanism conferred by hypoxia to protect cancer cells against etoposide-induced apoptotic cell death.	Etoposide	233-242	BCL2 interacting protein 3	Homo sapiens	126-131
21060845-3	2010	In S. cerevisiae, deficiency in MRE11, which encodes a highly conserved factor, greatly enhances sensitivity to treatment with CPT or ETP.	Etoposide	134-137	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	32-37
21060845-5	2010	Here we report that an S. cerevisiae strain expressing the mre11-H59A allele, mutant at a conserved active site histidine, is sensitive to hydroxyurea and also to ionizing radiation, which induces DSBs, but not to CPT or ETP.	Etoposide	221-224	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	59-64
21060845-6	2010	We show that TDP1, which encodes a tyrosyl-DNA phosphodiesterase activity able to release both 5"- and 3"-covalent topoisomerase-DNA complexes in vitro, contributes to ETP-resistance but not CPT-resistance in the mre11-H59A background.	Etoposide	168-171	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	13-17
20955597-13	2010	We further show that down-regulation of caspase 3 via overexpression of RASSF1C reduces breast cancer cells" sensitivity to the apoptosis inducing agent, etoposide.	Etoposide	154-163	caspase 3	Homo sapiens	40-49
20637734-6	2010	Using Atg5 siRNA, we show that etoposide-induced autophagy promotes apoptotic cell death under normoxia but not under hypoxia.	Etoposide	31-40	autophagy related 5	Homo sapiens	6-10
20637734-8	2010	We show that the silencing of BNIP3 does not affect autophagy whatever the pO(2) but participates in the protective effect of hypoxia against etoposide-induced apoptosis.	Etoposide	142-151	BCL2 interacting protein 3	Homo sapiens	30-35
22993597-6	2010	In our in vivo studies, oral etoposide inhibited fibroblast growth factor 2 and VEGF-induced corneal neovascularization, VEGF-induced vascular permeability and increased levels of the endogenous angiogenesis inhibitor endostatin in mice.	Etoposide	29-38	vascular endothelial growth factor A	Mus musculus	121-125
20731388-1	2010	ei24 (etoposide-induced 2.4 kb transcript, also designated PIG8 (p53-induced gene 8)), is a DNA damage response gene involved in growth suppression and apoptosis.	Etoposide	6-15	etoposide induced 2.4 mRNA	Mus musculus	0-4
20731388-1	2010	ei24 (etoposide-induced 2.4 kb transcript, also designated PIG8 (p53-induced gene 8)), is a DNA damage response gene involved in growth suppression and apoptosis.	Etoposide	6-15	etoposide induced 2.4 mRNA	Mus musculus	59-63
20731388-1	2010	ei24 (etoposide-induced 2.4 kb transcript, also designated PIG8 (p53-induced gene 8)), is a DNA damage response gene involved in growth suppression and apoptosis.	Etoposide	6-15	etoposide induced 2.4 mRNA	Mus musculus	65-83
20519366-0	2010	p73 participates in male germ cells apoptosis induced by etoposide.	Etoposide	57-66	tumor protein p73	Rattus norvegicus	0-3
20519366-3	2010	The aim of this study was to evaluate the participation of p73, a member of the p53 family, in apoptosis induced by etoposide in male germ cells.	Etoposide	116-125	tumor protein p73	Rattus norvegicus	59-62
20519366-3	2010	The aim of this study was to evaluate the participation of p73, a member of the p53 family, in apoptosis induced by etoposide in male germ cells.	Etoposide	116-125	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	80-83
20519366-5	2010	We found an important increase in p73 protein levels, along with the c-Abl kinase, its physiological activator, in response to etoposide.	Etoposide	127-136	tumor protein p73	Rattus norvegicus	34-37
20519366-8	2010	Also, the in vitro knockdown of p73 or p53 by shRNA, significantly prevented the decrease in cell viability after etoposide treatment.	Etoposide	114-123	tumor protein p73	Rattus norvegicus	32-35
20519366-8	2010	Also, the in vitro knockdown of p73 or p53 by shRNA, significantly prevented the decrease in cell viability after etoposide treatment.	Etoposide	114-123	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	39-42
20519366-9	2010	In an in vivo model-21-day-old rat testes-we observed an up-regulation of the protein levels of p73 and phosphorylated p73-at c-Abl site Tyr99-in response to the etoposide injection.	Etoposide	162-171	tumor protein p73	Rattus norvegicus	96-99
20519366-9	2010	In an in vivo model-21-day-old rat testes-we observed an up-regulation of the protein levels of p73 and phosphorylated p73-at c-Abl site Tyr99-in response to the etoposide injection.	Etoposide	162-171	tumor protein p73	Rattus norvegicus	119-122
20519366-10	2010	STI571 (a pharmacological inhibitor of c-Abl) or PFT co-injection prevented etoposide-induced up-regulation of phospho-p73 and pro-apoptotic TAp73 isoform levels.	Etoposide	76-85	tumor protein p73	Rattus norvegicus	119-122
20519366-11	2010	Moreover, caspases-3, -8, -9 activation and germ cell death induced by etoposide were significantly decreased by these drugs.	Etoposide	71-80	caspase 3	Rattus norvegicus	10-28
20519366-12	2010	These results support the notion that the c-Abl/p73 pathway is activated in germ cells after etoposide treatment, triggering apoptosis, possibly assisting p53.	Etoposide	93-102	tumor protein p73	Rattus norvegicus	48-51
20519366-12	2010	These results support the notion that the c-Abl/p73 pathway is activated in germ cells after etoposide treatment, triggering apoptosis, possibly assisting p53.	Etoposide	93-102	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	155-158
20940407-4	2010	Additionally, CD9 was highly expressed on SCLC cell lines rendered resistant to cisplatin or etoposide, and was upregulated in parental chemosensitive cells within 48 hours after exposure to either of these compounds.	Etoposide	93-102	CD9 molecule	Homo sapiens	14-17
20655369-4	2010	Our results revealed a significant P53-induction by actinomycin D, methyl methanesulfonate and etoposide.	Etoposide	95-104	tumor protein p53	Homo sapiens	35-38
20886683-0	2010	Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.	Etoposide	103-112	DNA topoisomerase II beta	Homo sapiens	29-50
20886683-8	2010	These results suggest a potential epigenetic mechanism of regulation of the topoisomerase II-beta gene and a possible role for its increased expression in the sensitivity of SK-N-AS neuroblastoma cells to etoposide.	Etoposide	205-214	DNA topoisomerase II beta	Homo sapiens	76-97
20622893-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H(2)O(2), and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	188-197	BRCA1 DNA repair associated	Homo sapiens	0-5
20622893-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H(2)O(2), and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	188-197	tumor protein p53	Homo sapiens	75-78
20622893-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H(2)O(2), and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	188-197	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	79-83
20691667-5	2010	Livin-transfected, MYCN-amplified NBL cells showed increased resistance to doxorubicin and etoposide.	Etoposide	91-100	baculoviral IAP repeat containing 7	Homo sapiens	0-5
20691667-5	2010	Livin-transfected, MYCN-amplified NBL cells showed increased resistance to doxorubicin and etoposide.	Etoposide	91-100	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	19-23
20824055-3	2010	In this report, by using knock down experiments, we demonstrated that Top2alpha was largely responsible for the induction of gammaH2AX and cytotoxicity by the Top2 poisons idarubicin and etoposide in normal human cells.	Etoposide	187-196	DNA topoisomerase II alpha	Homo sapiens	70-79
20062098-0	2010	Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX.	Etoposide	0-9	metaxin 1	Homo sapiens	124-127
22993597-5	2010	Etoposide inhibited endothelial and tumor cell proliferation, decreased vascular endothelial growth factor (VEGF) production by tumor cells and suppressed endothelial tube formation at non-cytotoxic concentrations.	Etoposide	0-9	vascular endothelial growth factor A	Homo sapiens	72-106
22993597-5	2010	Etoposide inhibited endothelial and tumor cell proliferation, decreased vascular endothelial growth factor (VEGF) production by tumor cells and suppressed endothelial tube formation at non-cytotoxic concentrations.	Etoposide	0-9	vascular endothelial growth factor A	Homo sapiens	108-112
22993597-6	2010	In our in vivo studies, oral etoposide inhibited fibroblast growth factor 2 and VEGF-induced corneal neovascularization, VEGF-induced vascular permeability and increased levels of the endogenous angiogenesis inhibitor endostatin in mice.	Etoposide	29-38	fibroblast growth factor 2	Mus musculus	49-75
22993597-6	2010	In our in vivo studies, oral etoposide inhibited fibroblast growth factor 2 and VEGF-induced corneal neovascularization, VEGF-induced vascular permeability and increased levels of the endogenous angiogenesis inhibitor endostatin in mice.	Etoposide	29-38	vascular endothelial growth factor A	Mus musculus	80-84
22993597-6	2010	In our in vivo studies, oral etoposide inhibited fibroblast growth factor 2 and VEGF-induced corneal neovascularization, VEGF-induced vascular permeability and increased levels of the endogenous angiogenesis inhibitor endostatin in mice.	Etoposide	29-38	collagen, type XVIII, alpha 1	Mus musculus	218-228
20576619-4	2010	Suppressing Bmal1 expression in murine colon cancer cells (C26) and fibroblast cells (L929) decreased apoptosis induced by Etoposid, reduced the distribution of cells in the G2/M phases treated by Docetaxel and decreased DNA damage induced by Cisplatin.	Etoposide	123-131	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	12-17
20660297-3	2010	Down-regulation of ERbeta by short hairpin RNA constructs sensitized NSCLC cells to various apoptosis-inducing agents such as cisplatin, taxol, and etoposide.	Etoposide	148-157	estrogen receptor 2	Homo sapiens	19-25
20845286-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of UVC, high dosages of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	159-168	BRCA1 DNA repair associated	Homo sapiens	0-5
20635445-5	2010	RESULTS: While YD-9 cells showed high resistance to chemotherapeutic agents such as etoposide and 5-fluorouraci (5-FU), HSP70 antisense oligonucelotides sensitized chemoresistant YD-9 cells to etoposide and 5-FU.	Etoposide	193-202	heat shock protein family A (Hsp70) member 4	Homo sapiens	120-125
20643100-7	2010	Moreover, blocking nuclear translocation of TPPII in etoposide-treated cells, by using a peptide-derived inhibitor (Z-Gly-Leu-Ala-OH), attenuated expression of gamma-H2AX in gamma-irradiated melanoma cells.	Etoposide	53-62	tripeptidyl peptidase 2	Homo sapiens	44-49
20309692-6	2010	However, MDR1 (2005T) cells were less resistant to paclitaxel (28.2 +/- 2.1 vs. 91.8 +/- 3.5 nM; P &lt; 0.05) and etoposide (119.7 +/- 6.5 vs. 546.8 +/- 9.5 nM; P &lt; 0.05).	Etoposide	114-123	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
20847952-2	2010	The appearance and resolution of gammaH2AX foci in murine embryonic fibroblast cell lines, wild type and null for DNA topoisomerase IIbeta, was measured after exposure to ionising radiation (IR) or etoposide.	Etoposide	198-207	H2A.X variant histone	Mus musculus	33-42
20847952-6	2010	Etoposide triggered the formation of topoisomerase II-DNA adducts and the phosphorylation of histone H2AX, the gammaH2AX foci appeared more slowly with etoposide than with IR.	Etoposide	0-9	H2A.X variant histone	Mus musculus	93-105
20847952-6	2010	Etoposide triggered the formation of topoisomerase II-DNA adducts and the phosphorylation of histone H2AX, the gammaH2AX foci appeared more slowly with etoposide than with IR.	Etoposide	0-9	H2A.X variant histone	Mus musculus	111-120
20847952-6	2010	Etoposide triggered the formation of topoisomerase II-DNA adducts and the phosphorylation of histone H2AX, the gammaH2AX foci appeared more slowly with etoposide than with IR.	Etoposide	152-161	H2A.X variant histone	Mus musculus	93-105
20847952-6	2010	Etoposide triggered the formation of topoisomerase II-DNA adducts and the phosphorylation of histone H2AX, the gammaH2AX foci appeared more slowly with etoposide than with IR.	Etoposide	152-161	H2A.X variant histone	Mus musculus	111-120
20573984-6	2010	HIPK2-/- MEF cells were more susceptible to apoptosis induced by etoposide, a DNA-damaging agent, than HIPK2+/+ cells.	Etoposide	65-74	homeodomain interacting protein kinase 2	Homo sapiens	0-5
20573984-7	2010	Etoposide activated CRE-dependent transcription in HIPK2+/+ MEF cells but not in HIPK2-/- cells.	Etoposide	0-9	homeodomain interacting protein kinase 2	Homo sapiens	51-56
20573984-8	2010	HIPK2 knockdown in SH-SY5Y cells decreased etoposide-induced BDNF mRNA expression.	Etoposide	43-52	homeodomain interacting protein kinase 2	Homo sapiens	0-5
20573984-8	2010	HIPK2 knockdown in SH-SY5Y cells decreased etoposide-induced BDNF mRNA expression.	Etoposide	43-52	brain derived neurotrophic factor	Homo sapiens	61-65
20226587-3	2010	Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1).	Etoposide	16-25	tumor protein p53	Homo sapiens	118-121
20226587-3	2010	Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1).	Etoposide	16-25	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
20226587-3	2010	Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1).	Etoposide	16-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	164-167
20226587-3	2010	Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1).	Etoposide	16-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	168-172
20226587-3	2010	Co-treatment of etoposide and KG-135 markedly elevated the expression and phosphorylation at the serine 15 residue of p53 as well as the cellular levels of Bax and p21(Waf1/Cip1).	Etoposide	16-25	cyclin dependent kinase inhibitor 1A	Homo sapiens	173-177
20226587-5	2010	Moreover, co-treatment of etoposide and KG-135 enhanced mitochondrial localization of Bax.	Etoposide	26-35	BCL2 associated X, apoptosis regulator	Homo sapiens	86-89
20226587-6	2010	Our results indicate that etoposide-induced apoptosis in HeLa cells can be potentiated in the presence of KG-135 through a mechanism that involves the stabilization of p53 and the stimulation of Bax- and p21-mediated apoptotic signaling pathways.	Etoposide	26-35	tumor protein p53	Homo sapiens	168-171
20226587-6	2010	Our results indicate that etoposide-induced apoptosis in HeLa cells can be potentiated in the presence of KG-135 through a mechanism that involves the stabilization of p53 and the stimulation of Bax- and p21-mediated apoptotic signaling pathways.	Etoposide	26-35	BCL2 associated X, apoptosis regulator	Homo sapiens	195-198
20226587-6	2010	Our results indicate that etoposide-induced apoptosis in HeLa cells can be potentiated in the presence of KG-135 through a mechanism that involves the stabilization of p53 and the stimulation of Bax- and p21-mediated apoptotic signaling pathways.	Etoposide	26-35	cyclin dependent kinase inhibitor 1A	Homo sapiens	204-207
20845286-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of UVC, high dosages of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	159-168	tumor protein p53	Homo sapiens	71-74
20845286-7	2010	BRCA1-IRIS abrogation of the homeostatic balance maintained by p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of UVC, high dosages of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses.	Etoposide	159-168	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	75-79
20232424-10	2010	RESULTS: Inhibition of Aurora Kinase A induces cell death in medulloblastoma cells and lowers the IC(50) of other chemotherapeutic agents (etoposide and cisplatin) used in medulloblastoma treatment.	Etoposide	139-148	aurora kinase A	Homo sapiens	23-38
20596674-1	2010	Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor chemotherapeutic agent.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
20642818-1	2010	BACKGROUND: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after chemotherapy induction may be classified into three groups: (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.	Etoposide	111-120	CD34 molecule	Homo sapiens	72-76
20647761-3	2010	As expected, Mcl-1(-/-) MEFs had delayed Chk1 phosphorylation following etoposide treatment, compared to wild type MEFs.	Etoposide	72-81	myeloid cell leukemia sequence 1	Mus musculus	13-18
20395290-5	2010	We found that hypoxia-induced EGFR activation and cell migration could be prevented by targeting EGFR signaling with the tyrosine kinase inhibitor tyrphostin, the phospholipase C inhibitor U73122, or by inhibiting the expression of the alpha subunit of hypoxia-inducible factor 2 via RNA interference or the topoisomerase II inhibitor etoposide.	Etoposide	335-344	epidermal growth factor receptor	Homo sapiens	30-34
20647761-5	2010	In addition, appearance of gamma-H2AX was delayed in the Mcl-1(-/-) MEFs treated with etoposide.	Etoposide	86-95	H2A.X variant histone	Mus musculus	27-37
20647761-5	2010	In addition, appearance of gamma-H2AX was delayed in the Mcl-1(-/-) MEFs treated with etoposide.	Etoposide	86-95	myeloid cell leukemia sequence 1	Mus musculus	57-62
20647761-7	2010	Immunoprecipitation of etoposide-treated extracts with anti-MCL-1 antibody showed association of MCL-1 with gamma-H2AX as well as NBS1.	Etoposide	23-32	myeloid cell leukemia sequence 1	Mus musculus	60-65
20647761-7	2010	Immunoprecipitation of etoposide-treated extracts with anti-MCL-1 antibody showed association of MCL-1 with gamma-H2AX as well as NBS1.	Etoposide	23-32	myeloid cell leukemia sequence 1	Mus musculus	97-102
20647761-7	2010	Immunoprecipitation of etoposide-treated extracts with anti-MCL-1 antibody showed association of MCL-1 with gamma-H2AX as well as NBS1.	Etoposide	23-32	H2A.X variant histone	Mus musculus	108-118
20647761-7	2010	Immunoprecipitation of etoposide-treated extracts with anti-MCL-1 antibody showed association of MCL-1 with gamma-H2AX as well as NBS1.	Etoposide	23-32	nibrin	Mus musculus	130-134
20647761-10	2010	Finally, in a direct demonstration of the importance of MCL-1 in allowing proper repair of DNA damage, we found that treatment for two brief exposures to etoposide , followed by periods of recovery, which mimics the clinical situation of etoposide use, resulted in greater accumulation of chromosomal abnormalities in the MEFs that lacked MCL-1.	Etoposide	154-163	myeloid cell leukemia sequence 1	Mus musculus	56-61
20647761-10	2010	Finally, in a direct demonstration of the importance of MCL-1 in allowing proper repair of DNA damage, we found that treatment for two brief exposures to etoposide , followed by periods of recovery, which mimics the clinical situation of etoposide use, resulted in greater accumulation of chromosomal abnormalities in the MEFs that lacked MCL-1.	Etoposide	154-163	myeloid cell leukemia sequence 1	Mus musculus	339-344
20647761-10	2010	Finally, in a direct demonstration of the importance of MCL-1 in allowing proper repair of DNA damage, we found that treatment for two brief exposures to etoposide , followed by periods of recovery, which mimics the clinical situation of etoposide use, resulted in greater accumulation of chromosomal abnormalities in the MEFs that lacked MCL-1.	Etoposide	238-247	myeloid cell leukemia sequence 1	Mus musculus	56-61
20395290-5	2010	We found that hypoxia-induced EGFR activation and cell migration could be prevented by targeting EGFR signaling with the tyrosine kinase inhibitor tyrphostin, the phospholipase C inhibitor U73122, or by inhibiting the expression of the alpha subunit of hypoxia-inducible factor 2 via RNA interference or the topoisomerase II inhibitor etoposide.	Etoposide	335-344	epidermal growth factor receptor	Homo sapiens	97-101
20237821-9	2010	Additionally, ANXA4 translocates to the nucleus together with p50, and imparts greater resistance to apoptotic stimulation by etoposide.	Etoposide	126-135	annexin A4	Homo sapiens	14-19
20094062-5	2010	Detailed kinetic analysis of cells lacking cathepsin B or L or treated with the cysteine protease inhibitor, E64d, revealed a delay in these cells in etoposide- and IL-3 deprivation-induced caspase-3 activation and apoptosis induction but not clonogenic survival, indicating that cathepsins amplify rather than initiate apoptosis.	Etoposide	150-159	caspase 3	Homo sapiens	190-199
20237821-7	2010	Following treatment with TNF-alpha or PMA, ANXA4 also suppressed NF-kappaB transcriptional activity, which was upregulated significantly early after etoposide treatment.	Etoposide	149-158	tumor necrosis factor	Homo sapiens	25-34
20237821-7	2010	Following treatment with TNF-alpha or PMA, ANXA4 also suppressed NF-kappaB transcriptional activity, which was upregulated significantly early after etoposide treatment.	Etoposide	149-158	annexin A4	Homo sapiens	43-48
20509890-9	2010	Cells over-expressing TGFBI displayed increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine.	Etoposide	63-72	transforming growth factor beta induced	Homo sapiens	22-27
20177738-3	2010	In this study, VP-16-induced RBL-2H3 cells apoptosis was accompanied by the activation of Akt and ERK.	Etoposide	15-20	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
20177738-3	2010	In this study, VP-16-induced RBL-2H3 cells apoptosis was accompanied by the activation of Akt and ERK.	Etoposide	15-20	Eph receptor B1	Rattus norvegicus	98-101
20177738-6	2010	Over expression of Cbl-b significantly enhanced VP-16-induced cell apoptosis with inhibition of Akt activity, while a dominant negative (DN) RING Finger domain mutation completely abolished this enhancement.	Etoposide	48-53	Cbl proto-oncogene B	Rattus norvegicus	19-24
20177738-6	2010	Over expression of Cbl-b significantly enhanced VP-16-induced cell apoptosis with inhibition of Akt activity, while a dominant negative (DN) RING Finger domain mutation completely abolished this enhancement.	Etoposide	48-53	AKT serine/threonine kinase 1	Rattus norvegicus	96-99
20177738-9	2010	These observations indicate that Cbl-b promotes RBL-2H3 apoptosis induced by VP-16 or Ara-c, probably through inhibition of Akt and activation of ERK.	Etoposide	77-82	Cbl proto-oncogene B	Rattus norvegicus	33-38
20427266-5	2010	In vitro, the TAT-crmA fusion protein was efficiently translocated into target cells and inhibited apoptosis mediated through caspase-8, caspase-9, and caspase-3 after stimulation with alpha-Fas, etoposide, doxorubicin, or staurosporine.	Etoposide	196-205	CrmA or CPXV207 protein	Cowpox virus	18-22
20388502-0	2010	Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.	Etoposide	13-22	ATP binding cassette subfamily C member 3	Homo sapiens	45-84
20388502-0	2010	Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.	Etoposide	13-22	prominin 1	Homo sapiens	94-99
20388502-2	2010	This study is to observe the influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in glioblastoma stem-like cells.	Etoposide	42-51	ATP binding cassette subfamily C member 3	Homo sapiens	74-113
20388502-8	2010	After Etoposide intervention, only livinalpha was suppressed markedly (p&lt;0.05), while livin expression was not notably decreased with livinbeta increased on the contrary (p&lt;0.05).	Etoposide	6-15	baculoviral IAP repeat containing 7	Homo sapiens	35-40
20451370-3	2010	The goal of this study was to evaluate the anticancer efficacy of a HDAC inhibitor (valproate: VPA) on SCLC cells in combination with the standard chemotherapeutic first-line regimen (cisplatin+etoposide).	Etoposide	194-203	histone deacetylase 9	Homo sapiens	68-72
19757185-9	2010	The dephosphorylation of FOXO1 inhibited proliferation of Jurkat cells and Namalwa cells, promoted their apoptosis and sensitized Non-Hodgkin lymphoma cells to etoposide.	Etoposide	160-169	forkhead box O1	Homo sapiens	25-30
20561412-0	2010	[Role of Na(+)/H(+) exchanger 1 in apoptosis of HL-60 cells induced by etoposide and its mechanism].	Etoposide	71-80	solute carrier family 9 member A1	Homo sapiens	9-31
20561412-1	2010	This study was aimed to investigate the role of Na(+)/H(+) exchanger 1 (NHE1) in apoptosis of HL-60 cells induced by etoposide.	Etoposide	117-126	solute carrier family 9 member A1	Homo sapiens	48-70
20561412-1	2010	This study was aimed to investigate the role of Na(+)/H(+) exchanger 1 (NHE1) in apoptosis of HL-60 cells induced by etoposide.	Etoposide	117-126	solute carrier family 9 member A1	Homo sapiens	72-76
20561412-2	2010	Real-time quantitative PCR (RQ-PCR) and Western blot methods were used to determine the expression of NHE1 in HL-60 cells after the treatment with etoposide.	Etoposide	147-156	solute carrier family 9 member A1	Homo sapiens	102-106
20561412-6	2010	The expression level of NHE1 mRNA increased by 2.848 +/- 0.886 times after treatment with etoposide for 12 hours (p &lt; 0.01), and the expression of NHE1 protein was also up-regulated (p &lt; 0.01).	Etoposide	90-99	solute carrier family 9 member A1	Homo sapiens	24-28
20561412-6	2010	The expression level of NHE1 mRNA increased by 2.848 +/- 0.886 times after treatment with etoposide for 12 hours (p &lt; 0.01), and the expression of NHE1 protein was also up-regulated (p &lt; 0.01).	Etoposide	90-99	solute carrier family 9 member A1	Homo sapiens	150-154
20561412-9	2010	It is concluded that the expression of NHE1 is up-regulated in process of apoptosis of HL-60 cells induced by etoposide and the apoptosis depends on the pH increase caused by NHE1 higher expression.	Etoposide	110-119	solute carrier family 9 member A1	Homo sapiens	39-43
20576107-5	2010	This potent augmentation required endogenous Noxa protein since RNAi directed against Noxa but not against Bim or Puma reduced apoptosis induction by the combination of ABT-737 and etoposide or vinblastine.	Etoposide	181-190	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	45-49
20576107-5	2010	This potent augmentation required endogenous Noxa protein since RNAi directed against Noxa but not against Bim or Puma reduced apoptosis induction by the combination of ABT-737 and etoposide or vinblastine.	Etoposide	181-190	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	86-90
20576107-6	2010	At the level of mitochondria, etoposide-treatment had a similar sensitizing activity and allowed for ABT-737-induced release of cytochrome c.	Etoposide	30-39	cytochrome c, somatic	Homo sapiens	128-140
20540776-4	2010	SSBP2 localizes to PML- Nuclear Bodies (PML-NBs) in response to inhibition of nuclear export, treatment with etoposide, hydroxyurea or gamma irradiation only in HEK293 cells.	Etoposide	109-118	single stranded DNA binding protein 2	Homo sapiens	0-5
20540776-4	2010	SSBP2 localizes to PML- Nuclear Bodies (PML-NBs) in response to inhibition of nuclear export, treatment with etoposide, hydroxyurea or gamma irradiation only in HEK293 cells.	Etoposide	109-118	PML nuclear body scaffold	Homo sapiens	19-22
20299546-2	2010	In this study, we show that TCDD treatment counteracts the p53 activation (phosphorylation and acetylation) elicited by a genotoxic compound, etoposide, in the human hepatocarcinoma cell line HepG2 and we delineated the mechanisms of this interaction.	Etoposide	142-151	tumor protein p53	Homo sapiens	59-62
20561412-7	2010	The pHi of HL-60 cells increased from 7.11 to 7.46 after treatment with etoposide for 24 hours.	Etoposide	72-81	glucose-6-phosphate isomerase	Homo sapiens	4-7
20218732-10	2010	Apoptosis assays with annexin V and etoposide demonstrated that AIRE-positive cells suffer more spontaneous apoptosis and are less resistant to apoptosis induction.	Etoposide	36-45	autoimmune regulator (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)	Mus musculus	64-68
21364648-0	2010	p53-mediated delayed NF-kappaB activity enhances etoposide-induced cell death in medulloblastoma.	Etoposide	49-58	tumor protein p53	Homo sapiens	0-3
21364648-0	2010	p53-mediated delayed NF-kappaB activity enhances etoposide-induced cell death in medulloblastoma.	Etoposide	49-58	nuclear factor kappa B subunit 1	Homo sapiens	21-30
21364648-2	2010	Using several MB cell lines, we have demonstrated that the chemotherapeutic drug etoposide induces a p53- and caspase-dependent cell death.	Etoposide	81-90	tumor protein p53	Homo sapiens	101-104
21364648-8	2010	Taken together, our results shed light on the mechanism of NF-kappaB activation by etoposide in brain tumours and show that the genetic background of MB and GM cells determines their sensitivity to chemotherapy and has to be taken into account for efficient therapeutic intervention.	Etoposide	83-92	nuclear factor kappa B subunit 1	Homo sapiens	59-68
20233592-6	2010	Etoposide and Fas treatments gradually shifted HspB1 towards large but differently phosphorylated oligomeric structures.	Etoposide	0-9	heat shock protein family B (small) member 1	Homo sapiens	47-52
19787780-2	2010	Here, we investigated the role of replication protein A (RPA) in cisplatin and etoposide resistance.	Etoposide	79-88	replication protein A1	Homo sapiens	34-55
20171199-5	2010	Knocking down of Livin expression in HCT-8/V cells by specific RNAi facilitated the apoptosis of HCT-8/V cells in response to vincristine (VCR), etoposide (VP-16), and 5-flourouracil (5-FU).	Etoposide	145-154	baculoviral IAP repeat containing 7	Homo sapiens	17-22
19787780-2	2010	Here, we investigated the role of replication protein A (RPA) in cisplatin and etoposide resistance.	Etoposide	79-88	replication protein A1	Homo sapiens	57-60
19787780-8	2010	CONCLUSION: Loss of RPA2 hyperphosphorylation occurs in HNSCC cells and may be a marker of cellular sensitivities to cisplatin and etoposide in HNSCC.	Etoposide	131-140	replication protein A2	Homo sapiens	20-24
20189983-9	2010	Bcl-2- and Mcl-1-mediated protection from apoptosis induced by staurosporine or etoposide was enhanced in cells expressing InsP(3)R, demonstrating that their interactions with InsP(3)R enable Bcl-2 and Mcl-1 to be fully efficacious anti-apoptotic mediators.	Etoposide	80-89	BCL2 apoptosis regulator	Homo sapiens	0-5
19921488-3	2010	In this study, we report that stimulation of DAOY with HGF resulted in the protection of these cells against etoposide-induced apoptosis, this anti-apoptotic effect being correlated with an increase in the expression of tissue factor (TF), the initiator of the extrinsic pathway of coagulation.	Etoposide	109-118	coagulation factor III, tissue factor	Homo sapiens	220-233
19921488-5	2010	Accordingly, stimulation of DAOY with FVIIa, the physiological ligand of TF, also resulted in a significant protection from etoposide-mediated cytotoxicity.	Etoposide	124-133	coagulation factor III, tissue factor	Homo sapiens	73-75
19921488-3	2010	In this study, we report that stimulation of DAOY with HGF resulted in the protection of these cells against etoposide-induced apoptosis, this anti-apoptotic effect being correlated with an increase in the expression of tissue factor (TF), the initiator of the extrinsic pathway of coagulation.	Etoposide	109-118	hepatocyte growth factor	Homo sapiens	55-58
20189983-9	2010	Bcl-2- and Mcl-1-mediated protection from apoptosis induced by staurosporine or etoposide was enhanced in cells expressing InsP(3)R, demonstrating that their interactions with InsP(3)R enable Bcl-2 and Mcl-1 to be fully efficacious anti-apoptotic mediators.	Etoposide	80-89	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	11-16
20154083-0	2010	High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.	Etoposide	49-58	HtrA serine peptidase 3	Homo sapiens	0-31
20416058-0	2010	Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.	Etoposide	16-25	caspase 8	Homo sapiens	79-88
20416058-0	2010	Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.	Etoposide	16-25	TNF superfamily member 10	Homo sapiens	92-97
20416058-4	2010	RESULTS: We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to apoptotic effects of TRAIL.	Etoposide	46-55	caspase 8	Homo sapiens	98-107
20416058-4	2010	RESULTS: We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to apoptotic effects of TRAIL.	Etoposide	46-55	TNF superfamily member 10	Homo sapiens	132-137
20416058-8	2010	CONCLUSIONS: Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells expressing caspase-8 to treatment with TRAIL.	Etoposide	80-89	caspase 8	Homo sapiens	132-141
20416058-8	2010	CONCLUSIONS: Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells expressing caspase-8 to treatment with TRAIL.	Etoposide	80-89	TNF superfamily member 10	Homo sapiens	160-165
20154083-0	2010	High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.	Etoposide	49-58	HtrA serine peptidase 3	Homo sapiens	33-38
20154083-2	2010	Here we show for the first time that HtrA3 is a mitochondrial stress-response factor that promotes cytotoxicity to etoposide and cisplatin in lung cancer cell lines.	Etoposide	115-124	HtrA serine peptidase 3	Homo sapiens	37-42
20154083-3	2010	Exogenous expression of wild type HtrA3 domain variants significantly attenuated cell survival with etoposide and cisplatin treatment in lung cancer cell lines H157 and A549 compared with expression of protease inactive mutants (S305A) or vector control.	Etoposide	100-109	HtrA serine peptidase 3	Homo sapiens	34-39
20154083-4	2010	Conversely, HtrA3 suppression promoted cell survival with etoposide and cisplatin treatment in lung cancer cell lines Hop62 and HCC827.	Etoposide	58-67	HtrA serine peptidase 3	Homo sapiens	12-17
20154083-6	2010	HtrA3 also co-fractionated and co-localized with mitochondrial markers with both endogenous and exogenous expression in normal lung and lung cancer cell lines but was translocated from mitochondria following etoposide treatment.	Etoposide	208-217	HtrA serine peptidase 3	Homo sapiens	0-5
20697588-2	2010	A sensitive apoptotic analysis method is integrated into this microfluidic system for studying apoptosis of HeLa cells under the influence of anticancer drug, etoposide, with various concentrations in parallel; it measures the yellow fluorescent proteincyan fluorescent protein fluorescence resonance energy transfer (FRET) signal that responds to the activation of caspase-3, an indicator of cell apoptosis.	Etoposide	159-168	caspase 3	Homo sapiens	366-375
20154083-8	2010	Taken together, these results suggest that HtrA3 may be a previously uncharacterized mitochondrial cell death effector whose serine protease function may be crucial to modulating etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.	Etoposide	179-188	HtrA serine peptidase 3	Homo sapiens	43-48
20154083-8	2010	Taken together, these results suggest that HtrA3 may be a previously uncharacterized mitochondrial cell death effector whose serine protease function may be crucial to modulating etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines.	Etoposide	179-188	coagulation factor II, thrombin	Homo sapiens	125-140
20101227-4	2010	In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide- and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK.	Etoposide	74-83	mitogen-activated protein kinase 8	Mus musculus	29-50
20101227-4	2010	In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide- and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK.	Etoposide	74-83	mitogen-activated protein kinase 8	Mus musculus	52-55
20101227-4	2010	In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide- and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK.	Etoposide	74-83	mitogen-activated protein kinase 8	Mus musculus	221-224
20101227-4	2010	In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide- and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK.	Etoposide	74-83	mitogen-activated protein kinase 8	Mus musculus	221-224
20183801-0	2010	Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.	Etoposide	0-9	ataxia telangiectasia mutated	Mus musculus	93-96
20183801-0	2010	Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	97-100
20183801-2	2010	In our previous studies, it was shown that VP-16 induces S-phase accumulation and G2/M arrest, eventually resulting in apoptosis, through p53-related pathway in the mouse fetal brain.	Etoposide	43-48	transformation related protein 53, pseudogene	Mus musculus	138-141
20183801-6	2010	Phosphorylation of ataxia telangiectasia-mutated kinase (ATM) at Ser1981 and gammaH2AX after VP-16 treatment showed DNA damage.	Etoposide	93-98	ataxia telangiectasia mutated	Mus musculus	19-55
20183801-6	2010	Phosphorylation of ataxia telangiectasia-mutated kinase (ATM) at Ser1981 and gammaH2AX after VP-16 treatment showed DNA damage.	Etoposide	93-98	ataxia telangiectasia mutated	Mus musculus	57-60
20183801-6	2010	Phosphorylation of ataxia telangiectasia-mutated kinase (ATM) at Ser1981 and gammaH2AX after VP-16 treatment showed DNA damage.	Etoposide	93-98	H2A.X variant histone	Mus musculus	77-86
20183801-10	2010	It is also indicated that VP-16-induced G2/M arrest is caused by p21, which inactivates cyclin B-Cdc2 complex and eventually prevents mitotic entry.	Etoposide	26-31	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	65-68
20183801-10	2010	It is also indicated that VP-16-induced G2/M arrest is caused by p21, which inactivates cyclin B-Cdc2 complex and eventually prevents mitotic entry.	Etoposide	26-31	cyclin-dependent kinase 1	Mus musculus	97-101
20183801-12	2010	It is suggested that VP-16 induced p53-independent S-phase accumulation, and p53-dependent G2/M arrest and apoptosis of the neural progenitor cells in fetal mouse brain.	Etoposide	21-26	transformation related protein 53, pseudogene	Mus musculus	35-38
20183801-12	2010	It is suggested that VP-16 induced p53-independent S-phase accumulation, and p53-dependent G2/M arrest and apoptosis of the neural progenitor cells in fetal mouse brain.	Etoposide	21-26	transformation related protein 53, pseudogene	Mus musculus	77-80
20437127-2	2010	We report the results of three cases of limited-stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy.	Etoposide	122-131	host cell factor C1	Homo sapiens	133-138
20212154-6	2010	Here we show that following etoposide-induced DNA damage translation of c-Myc is repressed by miR-34c via a highly conserved target-site within the 3(") UTR.	Etoposide	28-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	72-77
20383188-4	2010	He was treated with four cycles of etoposide and cisplatin chemotherapy, but his hCG level had not returned to normal at the end of the treatment.	Etoposide	35-44	chorionic gonadotropin subunit beta 5	Homo sapiens	81-84
20212154-6	2010	Here we show that following etoposide-induced DNA damage translation of c-Myc is repressed by miR-34c via a highly conserved target-site within the 3(") UTR.	Etoposide	28-37	microRNA 34c	Homo sapiens	94-101
20212154-9	2010	Inhibition of miR-34c activity prevents S-phase arrest in response to DNA damage leading to increased DNA synthesis, DNA damage, and checkpoint activation in addition to that induced by etoposide alone, which are all reversed by subsequent c-Myc depletion.	Etoposide	186-195	microRNA 34c	Homo sapiens	14-21
20176514-0	2010	Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice.	Etoposide	30-39	PAXIP1 associated glutamate rich protein 1A	Mus musculus	102-106
20176514-0	2010	Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice.	Etoposide	144-153	PAXIP1 associated glutamate rich protein 1A	Mus musculus	65-69
20176514-0	2010	Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice.	Etoposide	144-153	PAXIP1 associated glutamate rich protein 1A	Mus musculus	102-106
20176514-1	2010	In the present investigation, a UPLC-qTOF-MS/MS method has been developed for the simultaneous determination of etoposide and a piperine analogue, namely, 4-ethyl 5-(3,4-methylenedioxyphenyl)-2E,4E-pentadienoic acid piperidide (PA-1).	Etoposide	112-121	PAXIP1 associated glutamate rich protein 1A	Mus musculus	228-232
20176514-12	2010	The method was used for a pharmacokinetic study which showed that PA-1 enhanced the oral bioavailability of etoposide in mice by 2.32-fold.	Etoposide	108-117	PAXIP1 associated glutamate rich protein 1A	Mus musculus	66-70
19799994-1	2010	Although DNA damage proteins are infrequently regulated at the transcriptional level, RAD52 mRNA levels appear to be significantly induced in human cells following methyl methanesulphonate (MMS) and Etoposide treatment.	Etoposide	199-208	RAD52 homolog, DNA repair protein	Homo sapiens	86-91
20075077-4	2010	Treatment with the genotoxic agents, doxorubicin or etoposide, induced Foxp3 expression in p53-positive carcinoma cells, but not in cells lacking p53 function.	Etoposide	52-61	forkhead box P3	Homo sapiens	71-76
20075077-4	2010	Treatment with the genotoxic agents, doxorubicin or etoposide, induced Foxp3 expression in p53-positive carcinoma cells, but not in cells lacking p53 function.	Etoposide	52-61	tumor protein p53	Homo sapiens	91-94
20369051-7	2010	RESULTS: Maspin significantly decreased the survival to doxorubicin and etoposide, whereas did not affect the survival to cisplatin in the NCI-H157 cells.	Etoposide	72-81	serpin family B member 5	Homo sapiens	9-15
20369051-11	2010	CONCLUSION: Lung cancer cells lacking maspin could be resistant to chemotherapeutic drugs such as doxorubicin or etoposide, at least in part by maintaining Akt phosphorylation.	Etoposide	113-122	serpin family B member 5	Homo sapiens	38-44
20369051-11	2010	CONCLUSION: Lung cancer cells lacking maspin could be resistant to chemotherapeutic drugs such as doxorubicin or etoposide, at least in part by maintaining Akt phosphorylation.	Etoposide	113-122	AKT serine/threonine kinase 1	Homo sapiens	156-159
19688296-10	2010	In all piglets, the mean fourth ventricular CSF peak etoposide level exceeded the mean peak lumbar etoposide levels by greater than 10-fold.	Etoposide	53-62	colony stimulating factor 2	Homo sapiens	44-47
20338106-9	2010	Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC.	Etoposide	243-252	AKT serine/threonine kinase 1	Homo sapiens	108-111
20015864-7	2010	Additionally, the reduced expression of endogenous ANP32B by specific small interfering RNA enhances caspase-3 activation and apoptosis induction by NSC606985 and etoposide.	Etoposide	163-172	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	51-57
20174550-8	2010	Ats-1 inhibited etoposide-induced cytochrome c release from mitochondria, PARP cleavage, and apoptosis in mammalian cells, as well as Bax-induced yeast apoptosis.	Etoposide	16-25	cytochrome c, somatic	Homo sapiens	34-46
20174550-8	2010	Ats-1 inhibited etoposide-induced cytochrome c release from mitochondria, PARP cleavage, and apoptosis in mammalian cells, as well as Bax-induced yeast apoptosis.	Etoposide	16-25	poly(ADP-ribose) polymerase 1	Homo sapiens	74-78
20174550-10	2010	Bax redistribution was inhibited in both etoposide-induced and Bax-induced apoptosis by Ats-1.	Etoposide	41-50	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
20145135-6	2010	In contrast, enforced expression of either hnRNP H or A-Raf partially counteracted apoptosis induced by etoposide.	Etoposide	104-113	heterogeneous nuclear ribonucleoprotein H1	Homo sapiens	43-50
20145135-6	2010	In contrast, enforced expression of either hnRNP H or A-Raf partially counteracted apoptosis induced by etoposide.	Etoposide	104-113	zinc fingers and homeoboxes 2	Homo sapiens	56-59
19879873-2	2010	In our study, we found that it was more potent than etoposide (VP-16).	Etoposide	52-61	host cell factor C1	Homo sapiens	63-68
19426747-4	2010	Induction of apoptosis in G-292 human osteoblastic cells by exposure to etoposide or the inflammatory cytokine TNF-alpha promoted acute caspase-3/7 activity and this increased activity was inhibited by pretreatment with estradiol.	Etoposide	72-81	caspase 3	Homo sapiens	136-145
20060811-4	2010	Overexpression of MG23 in human embryonic kidney 293T cells specifically enhanced apoptosis triggered by etoposide, a DNA-damaging anti-cancer drug.	Etoposide	105-114	transmembrane protein 109	Homo sapiens	18-22
19701081-2	2010	Treatment with a comprehensive program using second-line chemotherapy with ICE (ifosfamide, carboplatin, etoposide) before HDT/ASCT identified a clinical prognostic model, but prognostic biologic markers in relapsed/refractory HL remain unclear.	Etoposide	105-114	carboxylesterase 2	Homo sapiens	75-78
19901967-9	2010	TCTP also protects cells against the proapoptotic effects of tunicamycin and etoposide, but not against those of arsenite.	Etoposide	77-86	tumor protein, translationally-controlled 1	Homo sapiens	0-4
20094661-2	2010	The new compounds show improved potency and efficacy with respect to the parent molecule etoposide (VP-16), one of the semisynthetic derivatives of podophyllotoxin.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
19943111-5	2010	RNAi mediated silencing of MyoD in either 23A2 or C2C12 myoblasts renders these cells resistant to apoptosis induced by serum withdrawal, or by treatment with etoposide or thapsigargin.	Etoposide	159-168	myogenic differentiation 1	Mus musculus	27-31
19796682-6	2010	DNA damage by UV radiation, etoposide or camptothecin caused a preferential down-regulation of nuclear BARD1 at 6h post-treatment.	Etoposide	28-37	BRCA1 associated RING domain 1	Homo sapiens	103-108
19858003-3	2010	In the present study 1h treatment with 25muM etoposide was highly toxic and initiated a double-stranded DNA damage response as reflected by the recruitment of ATM, MDC1 and DNA-PKcs to gammaH2AX foci.	Etoposide	45-54	ATM serine/threonine kinase	Homo sapiens	159-162
19858003-3	2010	In the present study 1h treatment with 25muM etoposide was highly toxic and initiated a double-stranded DNA damage response as reflected by the recruitment of ATM, MDC1 and DNA-PKcs to gammaH2AX foci.	Etoposide	45-54	mediator of DNA damage checkpoint 1	Homo sapiens	164-168
19858003-3	2010	In the present study 1h treatment with 25muM etoposide was highly toxic and initiated a double-stranded DNA damage response as reflected by the recruitment of ATM, MDC1 and DNA-PKcs to gammaH2AX foci.	Etoposide	45-54	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	173-181
20102612-0	2010	Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.	Etoposide	57-66	nuclear factor kappa B subunit 1	Homo sapiens	88-97
20102612-0	2010	Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.	Etoposide	57-66	baculoviral IAP repeat containing 3	Homo sapiens	112-117
20102612-6	2010	Supporting this crosstalk, the activation of NF-kappaB by retinoids in T47D cells antagonizes the apoptosis triggered by the chemotherapeutic drugs etoposide, camptothecin or doxorubicin.	Etoposide	148-157	nuclear factor kappa B subunit 1	Homo sapiens	45-54
20102612-9	2010	However, ectopic overexpression of a NF-kappaB repressor increases apoptosis by retinoids moderately and abrogates almost completely the retinoid-dependent inhibition of etoposide-induced apoptosis.	Etoposide	170-179	nuclear factor kappa B subunit 1	Homo sapiens	37-46
20102612-10	2010	Our data exclude cIAP2 and suggest that retinoids target other regulator(s) of the NF-kappaB signaling pathway to induce resistance to etoposide on certain breast cancer cells.	Etoposide	135-144	nuclear factor kappa B subunit 1	Homo sapiens	83-92
20068077-4	2010	We also show the effects of HtrA3 downregulation on MTT reduction and clonogenic survival with etoposide and cisplatin treatment and the corresponding effects of HtrA3 re-expression during treatment.	Etoposide	95-104	HtrA serine peptidase 3	Homo sapiens	28-33
20068077-9	2010	Additional studies indicate resistance to etoposide and cisplatin cytotoxicity as a functional consequence of HtrA3 loss.	Etoposide	42-51	HtrA serine peptidase 3	Homo sapiens	110-115
20028753-4	2010	RESULTS: P-gp restricted the oral (re)uptake of unchanged etoposide, and mediated its excretion across the gut wall.	Etoposide	58-67	phosphoglycolate phosphatase	Mus musculus	9-13
19817749-5	2010	Evidence for an etoposide-specific resistance, which develops as a consequence of inhibiting the PHD activity, was further supported in a tetracycline-inducible PHD2 knockdown HeLa cell model.	Etoposide	16-25	egl-9 family hypoxia inducible factor 1	Homo sapiens	161-165
19817749-6	2010	The etoposide-resistance was mediated by HIF-1alpha as shown in mouse embryonic fibroblast HIF-1alpha(+/+) and HIF-1alpha(-/-) cells.	Etoposide	4-13	hypoxia inducible factor 1, alpha subunit	Mus musculus	41-51
19817749-6	2010	The etoposide-resistance was mediated by HIF-1alpha as shown in mouse embryonic fibroblast HIF-1alpha(+/+) and HIF-1alpha(-/-) cells.	Etoposide	4-13	hypoxia inducible factor 1, alpha subunit	Mus musculus	91-101
19817749-6	2010	The etoposide-resistance was mediated by HIF-1alpha as shown in mouse embryonic fibroblast HIF-1alpha(+/+) and HIF-1alpha(-/-) cells.	Etoposide	4-13	hypoxia inducible factor 1, alpha subunit	Mus musculus	91-101
19817749-7	2010	Decreased cellular cytotoxicity after etoposide treatment inversely correlated with a dimethyloxaloylglycine (DMOG)-inducible, HIF-1alpha-dependent enhanced MDR-1 expression and efflux activity as determined by RT-PCR, immunoblots, and with the fluorescent dye DiOC2.	Etoposide	38-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	127-137
19817749-7	2010	Decreased cellular cytotoxicity after etoposide treatment inversely correlated with a dimethyloxaloylglycine (DMOG)-inducible, HIF-1alpha-dependent enhanced MDR-1 expression and efflux activity as determined by RT-PCR, immunoblots, and with the fluorescent dye DiOC2.	Etoposide	38-47	ATP binding cassette subfamily B member 1	Homo sapiens	157-162
19914607-9	2010	Lastly, etoposide treatment of immature thymocytes induced both p53 and ERK1/2 activation, but ERK1/2 activity did not affect the phosphorylation and stabilization of p53.	Etoposide	8-17	transformation related protein 53, pseudogene	Mus musculus	64-67
19914607-9	2010	Lastly, etoposide treatment of immature thymocytes induced both p53 and ERK1/2 activation, but ERK1/2 activity did not affect the phosphorylation and stabilization of p53.	Etoposide	8-17	mitogen-activated protein kinase 3	Mus musculus	72-78
20028753-0	2010	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.	Etoposide	80-89	phosphoglycolate phosphatase	Mus musculus	16-20
20028753-0	2010	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.	Etoposide	80-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26
19864107-0	2010	The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance.	Etoposide	113-122	Wnt family member 3A	Homo sapiens	4-7
19864107-9	2010	Also, Wnt3a enhanced the in vitro sensitivity of Nalm-16 to etoposide (VP-16) while treatment with canonical antagonists protected leukemic cells from chemotherapy-induced cell death.	Etoposide	60-69	Wnt family member 3A	Homo sapiens	6-11
19864107-9	2010	Also, Wnt3a enhanced the in vitro sensitivity of Nalm-16 to etoposide (VP-16) while treatment with canonical antagonists protected leukemic cells from chemotherapy-induced cell death.	Etoposide	71-76	Wnt family member 3A	Homo sapiens	6-11
20028753-0	2010	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.	Etoposide	80-89	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	29-34
20028753-9	2010	CONCLUSIONS: P-gp, ABCC2, and ABCC3 significantly affect the pharmacokinetics of etoposide and/or etoposide glucuronide.	Etoposide	81-90	phosphoglycolate phosphatase	Mus musculus	13-17
20028753-0	2010	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.	Etoposide	80-89	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	40-45
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	phosphoglycolate phosphatase	Mus musculus	48-52
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	98-103
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	105-109
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	115-120
20028753-9	2010	CONCLUSIONS: P-gp, ABCC2, and ABCC3 significantly affect the pharmacokinetics of etoposide and/or etoposide glucuronide.	Etoposide	81-90	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	19-24
20028753-2	2010	We aimed to study the impact of P-glycoprotein (P-gp/ABCB1) and the multidrug resistance proteins ABCC2 (MRP2) and ABCC3 (MRP3) on the pharmacokinetics of etoposide.	Etoposide	155-164	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	122-126
20028753-9	2010	CONCLUSIONS: P-gp, ABCC2, and ABCC3 significantly affect the pharmacokinetics of etoposide and/or etoposide glucuronide.	Etoposide	81-90	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	30-35
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Etoposide	87-96	zinc finger protein 420	Homo sapiens	173-177
22615609-0	2010	Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells.	Etoposide	55-64	WW domain containing oxidoreductase	Homo sapiens	8-12
22615609-0	2010	Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells.	Etoposide	55-64	mitogen-activated protein kinase 8	Homo sapiens	33-36
22615609-3	2010	Upon etoposide induced DNA damage, many stress signaling pathways including JNK are activated.	Etoposide	5-14	mitogen-activated protein kinase 8	Homo sapiens	76-79
22615609-5	2010	In this study the activation of WWOX and JNK and their interaction following etoposide treatment were evaluated.	Etoposide	77-86	WW domain containing oxidoreductase	Homo sapiens	32-36
22615609-5	2010	In this study the activation of WWOX and JNK and their interaction following etoposide treatment were evaluated.	Etoposide	77-86	mitogen-activated protein kinase 8	Homo sapiens	41-44
22615609-10	2010	Moreover, JNK inhibition enhances etoposide induced cytotoxicity in HEK293.	Etoposide	34-43	mitogen-activated protein kinase 8	Homo sapiens	10-13
22615609-11	2010	CONCLUSION: Taken together, our results indicate that etoposide induces cytotoxicity and WWOX phosphorylation and the cytotoxicty is augmented by blocking JNK pathway.	Etoposide	54-63	WW domain containing oxidoreductase	Homo sapiens	89-93
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Etoposide	141-150	colony stimulating factor 3	Homo sapiens	39-76
21123967-0	2010	Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.	Etoposide	141-150	colony stimulating factor 3	Homo sapiens	78-83
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Etoposide	138-143	colony stimulating factor 3	Homo sapiens	52-89
21123967-1	2010	We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia.	Etoposide	138-143	colony stimulating factor 3	Homo sapiens	91-96
21123967-13	2010	G-CSF potentiates Ara-C- and VP-16-induced cytotoxicities through apoptosis induction by mobilizing resting G0-G1-phase cells into S phase.	Etoposide	29-34	colony stimulating factor 3	Homo sapiens	0-5
22615609-11	2010	CONCLUSION: Taken together, our results indicate that etoposide induces cytotoxicity and WWOX phosphorylation and the cytotoxicty is augmented by blocking JNK pathway.	Etoposide	54-63	mitogen-activated protein kinase 8	Homo sapiens	155-158
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Etoposide	87-96	zinc finger protein 420	Homo sapiens	214-218
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Etoposide	87-96	tumor protein p53	Homo sapiens	224-227
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Etoposide	87-96	tumor protein p53	Homo sapiens	257-260
19956877-0	2010	Etoposide induces growth arrest and disrupts androgen receptor signaling in prostate cancer cells.	Etoposide	0-9	androgen receptor	Homo sapiens	45-62
20053727-2	2010	Our results indicate that DNA damage-inducing agents, including doxorubicin (adriamycin), etoposide, and ionizing and UV radiation, strongly downregulate DOC45 expression, whereas endoplasmic reticulum stress-inducing agents do not.	Etoposide	90-99	Obg like ATPase 1	Homo sapiens	154-159
20053762-7	2010	This compound abrogates an etoposide-induced G(2) arrest with an IC(50) of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion.	Etoposide	27-36	tumor protein p53	Homo sapiens	234-237
19956877-2	2010	The present study indicates that the topoisomerase II inhibitor etoposide strikingly inhibits androgen/AR-mediated cell growth and androgen-stimulated DNA synthesis in prostate cancer cells.	Etoposide	64-73	androgen receptor	Homo sapiens	103-105
19956877-3	2010	Etoposide significantly repressed the AR mRNA and protein expression in a dose-dependent manner.	Etoposide	0-9	androgen receptor	Homo sapiens	38-40
19956877-4	2010	Etoposide-mediated down-regulation of AR was associated with blocking androgen-induced AR translocation from cytoplasm into nucleus of cells.	Etoposide	0-9	androgen receptor	Homo sapiens	38-40
19956877-4	2010	Etoposide-mediated down-regulation of AR was associated with blocking androgen-induced AR translocation from cytoplasm into nucleus of cells.	Etoposide	0-9	androgen receptor	Homo sapiens	87-89
19956877-5	2010	Additionally, etoposide disrupted the association of AR and heat shock protein 90 and impeded binding of the synthetic androgen [3H]R1881 to AR in LNCaP cells.	Etoposide	14-23	androgen receptor	Homo sapiens	53-55
19956877-5	2010	Additionally, etoposide disrupted the association of AR and heat shock protein 90 and impeded binding of the synthetic androgen [3H]R1881 to AR in LNCaP cells.	Etoposide	14-23	androgen receptor	Homo sapiens	141-143
19956877-6	2010	Etoposide simultaneously reduced the intracellular and secreted PSA levels, a marker for the progression of prostate cancer.	Etoposide	0-9	aminopeptidase puromycin sensitive	Homo sapiens	64-67
19956877-7	2010	These findings collectively reveal that etoposide not only serves as a traditional genotoxic agent but directly targets AR as an AR disrupting therapeutic strategy in prostate cancer.	Etoposide	40-49	androgen receptor	Homo sapiens	120-122
19956877-7	2010	These findings collectively reveal that etoposide not only serves as a traditional genotoxic agent but directly targets AR as an AR disrupting therapeutic strategy in prostate cancer.	Etoposide	40-49	androgen receptor	Homo sapiens	129-131
20552320-0	2009	Distinct roles for JNK1 and JNK3 during TNF-alpha- or etoposide-induced apoptosis in HeLa cells.	Etoposide	54-63	mitogen-activated protein kinase 8	Homo sapiens	19-23
20187579-0	2010	Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells.	Etoposide	17-26	host cell factor C1	Homo sapiens	28-33
20187579-2	2010	Etoposide (VP-16), a drug commonly used in chemotherapy, leads to enhanced accumulation of cell populations in G2/M phase and increases levels of apoptosis as a topoisomerase II inhibitor.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
20552320-0	2009	Distinct roles for JNK1 and JNK3 during TNF-alpha- or etoposide-induced apoptosis in HeLa cells.	Etoposide	54-63	mitogen-activated protein kinase 10	Homo sapiens	28-32
20552320-1	2009	Here, we show that JNK1 and JNK3 have different roles in TNF-alpha- or etoposide-induced apoptosis in HeLa cells.	Etoposide	71-80	mitogen-activated protein kinase 8	Homo sapiens	19-23
20552320-1	2009	Here, we show that JNK1 and JNK3 have different roles in TNF-alpha- or etoposide-induced apoptosis in HeLa cells.	Etoposide	71-80	mitogen-activated protein kinase 10	Homo sapiens	28-32
20552320-2	2009	Dominant negative JNK1 inhibited TNF-alpha- or etoposide-induced apoptosis, while dominant negative JNK3 promoted TNF-alpha- or etoposide-induced apoptosis.	Etoposide	128-137	mitogen-activated protein kinase 10	Homo sapiens	100-104
19751709-8	2009	This effect correlated with lowered basal levels of p53, as well as with an attenuated p53 response induced by etoposide and leptomycin B.	Etoposide	111-120	tumor protein p53	Homo sapiens	87-90
19858204-0	2009	TATA-binding Protein (TBP)-like Protein Is Engaged in Etoposide-induced Apoptosis through Transcriptional Activation of Human TAp63 Gene.	Etoposide	54-63	TATA-box binding protein	Homo sapiens	0-20
19858204-0	2009	TATA-binding Protein (TBP)-like Protein Is Engaged in Etoposide-induced Apoptosis through Transcriptional Activation of Human TAp63 Gene.	Etoposide	54-63	TATA-box binding protein	Homo sapiens	22-25
19858204-6	2009	Additionally, cells treated with anti-cancer drug etoposide underwent apoptosis in association with the transcriptional enhancement of TAp63 in a p53-independent manner, and the knockdown of the endogenous TLP reduced etoposide-induced apoptosis through repression of TAp63 expression.	Etoposide	50-59	tumor protein p53	Homo sapiens	146-149
19858204-6	2009	Additionally, cells treated with anti-cancer drug etoposide underwent apoptosis in association with the transcriptional enhancement of TAp63 in a p53-independent manner, and the knockdown of the endogenous TLP reduced etoposide-induced apoptosis through repression of TAp63 expression.	Etoposide	50-59	TATA-box binding protein like 1	Homo sapiens	206-209
19858204-6	2009	Additionally, cells treated with anti-cancer drug etoposide underwent apoptosis in association with the transcriptional enhancement of TAp63 in a p53-independent manner, and the knockdown of the endogenous TLP reduced etoposide-induced apoptosis through repression of TAp63 expression.	Etoposide	218-227	TATA-box binding protein like 1	Homo sapiens	206-209
19934311-5	2009	First, loss of SPL caused resistance to the toxic effects of etoposide and doxorubicin.	Etoposide	61-70	sphingosine-1-phosphate lyase 1	Homo sapiens	15-18
19920073-13	2009	The antioxidant activation of Nrf2 reduced etoposide-mediated DNA fragmentation and promoted cell survival in PKC-delta(+/+) but not in PKC-delta(-/-) cells.	Etoposide	43-52	NFE2 like bZIP transcription factor 2	Homo sapiens	30-34
19544527-7	2009	Moreover, knock-down of 1-8D provided partial protection from Etoposide and UV-induced apoptosis.	Etoposide	62-71	interferon induced transmembrane protein 2	Homo sapiens	24-28
19567453-1	2009	BACKGROUND: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL).	Etoposide	89-98	angiotensin I converting enzyme	Homo sapiens	100-103
19629135-6	2009	DNA-damaging agents (which included etoposide) increased BIN1 levels, unless E2F1 was deficient.	Etoposide	36-45	bridging integrator 1	Homo sapiens	57-61
19782705-0	2009	Mixed lineage kinase 3 negatively regulates IKK activity and enhances etoposide-induced cell death.	Etoposide	70-79	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	0-22
19782705-6	2009	Silencing mlk3 expression conferred resistance of cells to etoposide-induced apoptotic cell death and overexpression of wild type MLK3 (MLK3-WT) or kinase-dead MLK3 (MLK3-KD) promoted apoptotic cell death and cleavage of poly (ADP-ribose) polymerase (PARP).	Etoposide	59-68	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	10-14
19782705-7	2009	Overexpression of MLK3-WT or MLK3-KD enhanced etoposide-induced apoptotic cell death and cleavage of PARP.	Etoposide	46-55	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	29-36
19782705-7	2009	Overexpression of MLK3-WT or MLK3-KD enhanced etoposide-induced apoptotic cell death and cleavage of PARP.	Etoposide	46-55	poly(ADP-ribose) polymerase 1	Homo sapiens	101-105
19782705-8	2009	These data suggest that MLK3 functions to limit IKK activity, and depleting MLK3 helps protect cells from etoposide-induced cell death through activation of IKK-dependent signaling.	Etoposide	106-115	mitogen-activated protein kinase kinase kinase 11	Homo sapiens	76-80
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Etoposide	191-200	zinc finger protein 330	Homo sapiens	104-109
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Etoposide	191-200	zinc finger protein 330	Homo sapiens	110-116
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Etoposide	202-205	zinc finger protein 330	Homo sapiens	104-109
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Etoposide	202-205	zinc finger protein 330	Homo sapiens	110-116
19629135-7	2009	Moreover, endogenous E2F1 protein interacted directly with the BIN1 gene promoter in chromatin, particularly after etoposide treatment.	Etoposide	115-124	E2F transcription factor 1	Homo sapiens	21-25
19629135-7	2009	Moreover, endogenous E2F1 protein interacted directly with the BIN1 gene promoter in chromatin, particularly after etoposide treatment.	Etoposide	115-124	bridging integrator 1	Homo sapiens	63-67
19629135-8	2009	Notably, suppression of BIN1 expression using an antisense (AS) technique attenuated the cell death mediated by E2F1 and etoposide.	Etoposide	121-130	bridging integrator 1	Homo sapiens	24-28
19741725-5	2009	The RP2Ds of clofarabine, cyclophosphamide and etoposide were 40, 440 and 100 mg/m(2)/day, respectively.	Etoposide	47-56	RP2 activator of ARL3 GTPase	Homo sapiens	4-7
19747716-7	2009	We found that the sensitivity to other genotoxic agents such as cyclophosphamide, doxorubicine and etoposide was also increased by down-regulation of MUC16.	Etoposide	99-108	mucin 16, cell surface associated	Homo sapiens	150-155
20009466-6	2009	Although postoperative adjuvant chemotherapy consisting of carboplatin (CBDCA) +etoposide (VP-16) was administered, the patient died three months after surgery.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-96
19843632-9	2009	Furthermore, we showed that acquired TRAIL resistance was effectively eliminated by combination with etoposide, doxorubicin, or paclitaxel.	Etoposide	101-110	TNF superfamily member 10	Homo sapiens	37-42
20025574-0	2009	Association of p53 with Bid induces cell death in response to etoposide treatment in hepatocellular carcinoma.	Etoposide	62-71	tumor protein p53	Homo sapiens	15-18
20025574-0	2009	Association of p53 with Bid induces cell death in response to etoposide treatment in hepatocellular carcinoma.	Etoposide	62-71	BH3 interacting domain death agonist	Homo sapiens	24-27
20025574-6	2009	Here, we showed that etoposide-induced DNA damage could significantly induce p53 and Bid nuclear export.	Etoposide	21-30	tumor protein p53	Homo sapiens	77-80
20025574-6	2009	Here, we showed that etoposide-induced DNA damage could significantly induce p53 and Bid nuclear export.	Etoposide	21-30	BH3 interacting domain death agonist	Homo sapiens	85-88
20025574-7	2009	When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria.	Etoposide	30-39	tumor protein p53	Homo sapiens	41-44
20025574-7	2009	When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria.	Etoposide	30-39	BH3 interacting domain death agonist	Homo sapiens	81-84
20025574-7	2009	When cells were stimulated by etoposide, p53 could, through the association with Bid, cause translocation of Bid from the nucleus to the cytoplasm and on to its ultimate location in the mitochondria.	Etoposide	30-39	BH3 interacting domain death agonist	Homo sapiens	109-112
20025574-8	2009	p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide.	Etoposide	106-115	tumor protein p53	Homo sapiens	0-3
20025574-8	2009	p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide.	Etoposide	106-115	tumor protein p53	Homo sapiens	49-52
20025574-8	2009	p53 was physically associated with Bid, and both p53 and Bid cooperatively promoted cell death induced by etoposide.	Etoposide	106-115	BH3 interacting domain death agonist	Homo sapiens	57-60
20025574-9	2009	Knockdown of Bid expression notably attenuated cell death induced by etoposide and also released p53 from the mitochondria.	Etoposide	69-78	BH3 interacting domain death agonist	Homo sapiens	13-16
20025574-10	2009	These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC.	Etoposide	180-189	tumor protein p53	Homo sapiens	49-52
20025574-10	2009	These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC.	Etoposide	180-189	BH3 interacting domain death agonist	Homo sapiens	72-75
20025574-10	2009	These findings reveal a novel mechanism by which p53 is associated with Bid in the nucleus to facilitate exportation of Bid to the mitochondria and induce apoptosis in response to etoposide-induced DNA damage in HCC.	Etoposide	180-189	BH3 interacting domain death agonist	Homo sapiens	120-123
20054496-3	2009	Transfection of siRNAs against RCAN1.4 resulted in enhanced Fas- and etoposide-induced apoptosis, which was associated with increased expression and translocation of Bax to mitochondria.	Etoposide	69-78	regulator of calcineurin 1	Homo sapiens	31-36
19461676-7	2009	Moreover, etoposide increased the e23(scFv)-PE40 transcription up to 8.5 times.	Etoposide	10-19	immunglobulin heavy chain variable region	Homo sapiens	38-42
19920393-3	2009	We started combination chemotherapy with 5-fluorouracil (5-FU), Leucovorin (LV), etoposide (VP-16) and cis-diaminedichloroplatinum (CDDP) (designated as FLEP)in August 1999.	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
19551611-9	2009	Investigation of the toxic potential of the alkaloids on HL-60 and HL-60/MX1 showed a significantly higher effect against HL-60/MX1, a multidrug-resistant cell line, compared with the control etoposide (p &lt; 0.05).	Etoposide	192-201	MX dynamin like GTPase 1	Homo sapiens	73-76
19777212-7	2009	Camptothecin and etoposide caused an increase of protein expression of several cell-cycle regulators and induced the cleavage of Bcl-2 family of proteins.	Etoposide	17-26	BCL2 apoptosis regulator	Homo sapiens	129-134
19551611-9	2009	Investigation of the toxic potential of the alkaloids on HL-60 and HL-60/MX1 showed a significantly higher effect against HL-60/MX1, a multidrug-resistant cell line, compared with the control etoposide (p &lt; 0.05).	Etoposide	192-201	MX dynamin like GTPase 1	Homo sapiens	128-131
19648965-4	2009	Stimulation of the M(3)-muscarinic receptor was shown to inhibit the ability of the DNA-damaging chemotherapeutic agent, etoposide, from mediating apoptosis.	Etoposide	121-130	cholinergic receptor muscarinic 3	Homo sapiens	19-43
19834905-9	2009	In a series of in vitro assays, we confirmed the increased toxicity of etoposide and cisplatin to TRAIL resistant HL-60/P1 cells, and adenosine and vidarabine to HL-60/P2, compared with TRAIL-sensitive HL-60 cells.	Etoposide	71-80	TNF superfamily member 10	Homo sapiens	98-103
19834905-9	2009	In a series of in vitro assays, we confirmed the increased toxicity of etoposide and cisplatin to TRAIL resistant HL-60/P1 cells, and adenosine and vidarabine to HL-60/P2, compared with TRAIL-sensitive HL-60 cells.	Etoposide	71-80	TNF superfamily member 10	Homo sapiens	186-191
19684621-5	2009	However, Pdcd4 knockout cells show an increased sensitivity to agents that cause DNA damage, such as UV light, etoposide or ethyl-methanesulfonate.	Etoposide	111-120	programmed cell death 4	Gallus gallus	9-14
19748889-7	2009	This signaling pathway also explained the pro-survival effects of GIP on INS-1 cells exposed to two other promoters of stress: thapsigargin (endoplasmic reticulum stress) and etoposide (genotoxic stress).	Etoposide	175-184	gastric inhibitory polypeptide	Rattus norvegicus	66-69
19528037-6	2009	We show that the epigenetically silenced NOXA gene locus is opened after HDAC2 depletion and that NOXA upregulation is sufficient to sensitise PDAC cells towards etoposide-induced apoptosis.	Etoposide	162-171	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	98-102
19657746-6	2009	In particular, ATG2A was the only upregulated gene in the etoposide-induced apoptosis of HeLa cells.	Etoposide	58-67	autophagy related 2A	Homo sapiens	15-20
19856060-3	2009	Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed efficacy in targeting the small cell carcinoma.	Etoposide	120-129	gastrin releasing peptide	Homo sapiens	38-67
19528037-3	2009	We show that HDAC2, but not HDAC1, confers resistance towards the topoisomerase II inhibitor etoposide in PDAC cells.	Etoposide	93-102	histone deacetylase 2	Homo sapiens	13-18
19528037-6	2009	We show that the epigenetically silenced NOXA gene locus is opened after HDAC2 depletion and that NOXA upregulation is sufficient to sensitise PDAC cells towards etoposide-induced apoptosis.	Etoposide	162-171	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	41-45
19856060-3	2009	Following an increase in the level of pro-gastrin-releasing peptide (ProGRP), combined chemotherapy with cisplatin plus etoposide was implemented and showed efficacy in targeting the small cell carcinoma.	Etoposide	120-129	gastrin releasing peptide	Homo sapiens	69-75
19502564-3	2009	Other chemotherapeutic inducers of apoptosis such as etoposide and camptothecin also led to a robust induction of Hsp70 surface expression.	Etoposide	53-62	heat shock protein family A (Hsp70) member 4	Homo sapiens	114-119
19794957-0	2009	Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide.	Etoposide	126-135	tumor protein p53	Homo sapiens	28-31
19794957-0	2009	Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide.	Etoposide	126-135	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	62-67
19794957-4	2009	Whereas the profile of c-Myc and NF-kappaB activity did not fit the effect of hypoxia on caspase 3 activity, hypoxia decreased basal p53 abundance and DNA binding activity as well as p53 etoposide-induced activation.	Etoposide	187-196	tumor protein p53	Homo sapiens	183-186
19794957-5	2009	Short interfering RNA (siRNA) silencing evidenced that p53 was required for etoposide-induced apoptosis under normoxia.	Etoposide	76-85	tumor protein p53	Homo sapiens	55-58
19794957-8	2009	We showed that Bak1 was involved in the etoposide-induced apoptosis because Bak1 siRNA decreased it.	Etoposide	40-49	BCL2 antagonist/killer 1	Homo sapiens	15-19
19794957-8	2009	We showed that Bak1 was involved in the etoposide-induced apoptosis because Bak1 siRNA decreased it.	Etoposide	40-49	BCL2 antagonist/killer 1	Homo sapiens	76-80
19794957-9	2009	Conversely, hypoxia increased c-jun DNA binding activity in the presence of etoposide.	Etoposide	76-85	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
19794957-10	2009	siRNA-mediated silencing of c-jun increased the responsiveness of cells to etoposide under hypoxia, as shown by an increase in caspase 3 activity and lactate dehydrogenase release.	Etoposide	75-84	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
19794957-10	2009	siRNA-mediated silencing of c-jun increased the responsiveness of cells to etoposide under hypoxia, as shown by an increase in caspase 3 activity and lactate dehydrogenase release.	Etoposide	75-84	caspase 3	Homo sapiens	127-136
19794957-12	2009	These data evidenced that hypoxia decreased the responsiveness of HepG2 cells to etoposide at least by two independent pathways involving p53 inhibition and c-jun activation.	Etoposide	81-90	tumor protein p53	Homo sapiens	138-141
19794957-12	2009	These data evidenced that hypoxia decreased the responsiveness of HepG2 cells to etoposide at least by two independent pathways involving p53 inhibition and c-jun activation.	Etoposide	81-90	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	157-162
19794965-0	2009	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.	Etoposide	145-154	vascular endothelial growth factor A	Homo sapiens	44-78
19794965-0	2009	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.	Etoposide	145-154	C-X-C motif chemokine ligand 8	Homo sapiens	83-96
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	49-58	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	49-58	vascular endothelial growth factor A	Homo sapiens	100-104
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	49-58	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-115
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	60-65	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	60-65	vascular endothelial growth factor A	Homo sapiens	100-104
19794965-5	2009	We have examined whether the DNA-damaging agents etoposide (VP-16) and doxorubicin can affect IL-8, VEGF, and HIF-1 expressions in human melanoma cancer cells.	Etoposide	60-65	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-115
19794965-7	2009	We have demonstrated that A(2B) receptor blockade can impair IL-8 production, whereas blocking A(3) receptors, it is possible to further decrease VEGF secretion in melanoma cells treated with VP-16 and doxorubicin.	Etoposide	192-197	vascular endothelial growth factor A	Homo sapiens	146-150
19587093-10	2009	These data show that chronic exposure of developmentally early stem cells to etoposide induces MLL rearrangements and make hESCs more prone to acquire other chromosomal abnormalities than postnatal CD34(+) cells, linking embryonic genotoxic exposure to genomic instability.	Etoposide	77-86	lysine methyltransferase 2A	Homo sapiens	95-98
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	141-150	ATP binding cassette subfamily B member 1	Homo sapiens	66-96
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	141-150	ATP binding cassette subfamily C member 1	Homo sapiens	98-102
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	141-150	ATP binding cassette subfamily C member 1	Homo sapiens	103-108
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	152-156	ATP binding cassette subfamily B member 1	Homo sapiens	66-96
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	152-156	ATP binding cassette subfamily C member 1	Homo sapiens	98-102
19725578-1	2009	Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.	Etoposide	152-156	ATP binding cassette subfamily C member 1	Homo sapiens	103-108
19587093-0	2009	Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	18-21
19587093-5	2009	We addressed whether: (i) low doses of etoposide promote MLL rearrangements in hESCs and hESCs-derived hematopoietic cells; (ii) MLL rearrangements are sufficient to confer hESCs with a selective growth advantage and (iii) continuous exposure to low doses of etoposide induces hESCs to acquire other chromosomal abnormalities.	Etoposide	39-48	lysine methyltransferase 2A	Homo sapiens	57-60
19587093-6	2009	In contrast to cord blood-derived CD34(+) and hESC-derived hematopoietic cells, exposure of undifferentiated hESCs to a single low dose of etoposide induced a pronounced cell death.	Etoposide	139-148	CD34 molecule	Homo sapiens	34-38
19657228-8	2009	Overexpression of IFNgammaR2 (wild type and IFNgammaR2(296-337)) rescued cells from etoposide and staurosporine, which are known to induce Bax-mediated cell death.	Etoposide	84-93	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
19628579-3	2009	Overexpression of XAF1 can inhibit cancer cell growth and sensitize tumor necrosis factor-related apoptosis-inducing ligand- or etoposide-induced apoptosis.	Etoposide	128-137	XIAP associated factor 1	Homo sapiens	18-22
19421231-7	2009	p21(WAF1) which is overexpressed in the latter, is involved in this protective effect, as siRNA-mediated inhibition of p21(WAF1) restores sensitivity to etoposide.	Etoposide	153-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	119-127
19726787-4	2009	Overexpression of the antiapoptotic protein Bcl-XL, alone or in combination with the inhibitor Z-VAD-FMK, attenuated caspase activation in HeLa cells exposed to doxorubicin, etoposide, or cell death siRNA.	Etoposide	174-183	BCL2 like 1	Homo sapiens	44-50
19299014-0	2009	siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.	Etoposide	70-79	protein phosphatase 1 regulatory subunit 13 like	Homo sapiens	34-39
19587093-7	2009	Etoposide induced MLL rearrangements in hESCs and their hematopoietic derivatives.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	18-21
19648273-7	2009	Finally, cells deficient in IRF8 exhibited growth suppression and increased sensitivity to apoptosis induced by etoposide or IL-21.	Etoposide	112-121	interferon regulatory factor 8	Mus musculus	28-32
19734705-0	2009	[A case of primary small cell carcinoma of the esophagus responding remarkably to carboplatin (CBDCA) + etoposide (VP-16) combination therapy and radiation therapy].	Etoposide	104-113	host cell factor C1	Homo sapiens	115-120
19549763-2	2009	Etoposide induces the caspase-3-dependent cleavage of PKCdelta to its active p40 fragment, and active PKCdelta triggers the processing of caspase-3 by a positive-feedback mechanism.	Etoposide	0-9	caspase 3	Homo sapiens	138-147
19549763-3	2009	Treatment of cells with the caspase-3-specific inhibitor N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone or caspase-3-specific small interacting RNA (siRNA) prevented the etoposide-induced activation of caspase-8 and inhibited apoptosis.	Etoposide	179-188	caspase 3	Homo sapiens	28-37
19549763-3	2009	Treatment of cells with the caspase-3-specific inhibitor N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone or caspase-3-specific small interacting RNA (siRNA) prevented the etoposide-induced activation of caspase-8 and inhibited apoptosis.	Etoposide	179-188	caspase 3	Homo sapiens	116-125
19549763-3	2009	Treatment of cells with the caspase-3-specific inhibitor N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone or caspase-3-specific small interacting RNA (siRNA) prevented the etoposide-induced activation of caspase-8 and inhibited apoptosis.	Etoposide	179-188	caspase 8	Homo sapiens	211-220
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	17-26	caspase 2	Homo sapiens	49-58
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	17-26	caspase 8	Homo sapiens	86-95
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	17-26	caspase 2	Homo sapiens	212-220
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 8	Homo sapiens	138-147
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 2	Homo sapiens	175-184
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 2	Homo sapiens	212-220
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 8	Homo sapiens	138-147
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 2	Homo sapiens	175-184
19549763-5	2009	Furthermore, the etoposide-induced processing of caspase-2 required the expression of caspase-8, and the etoposide-mediated processing of caspase-8 required the expression of caspase-2, indicating that these two caspases activate each other after etoposide treatment.	Etoposide	105-114	caspase 2	Homo sapiens	212-220
19549763-6	2009	We also observed that etoposide-mediated apoptosis was decreased by treating the cells with the caspase-6-specific inhibitor benzyloxycarbonyl-Val-Glu(OMe)-Ile-Asp-(OMe)-fluoromethyl ketone and that caspase-6 was activated by a caspase-8-dependent mechanism.	Etoposide	22-31	caspase 6	Homo sapiens	96-105
19549763-6	2009	We also observed that etoposide-mediated apoptosis was decreased by treating the cells with the caspase-6-specific inhibitor benzyloxycarbonyl-Val-Glu(OMe)-Ile-Asp-(OMe)-fluoromethyl ketone and that caspase-6 was activated by a caspase-8-dependent mechanism.	Etoposide	22-31	caspase 6	Homo sapiens	199-208
19549763-6	2009	We also observed that etoposide-mediated apoptosis was decreased by treating the cells with the caspase-6-specific inhibitor benzyloxycarbonyl-Val-Glu(OMe)-Ile-Asp-(OMe)-fluoromethyl ketone and that caspase-6 was activated by a caspase-8-dependent mechanism.	Etoposide	22-31	caspase 8	Homo sapiens	228-237
19549763-7	2009	Finally, we show that rottlerin blocks etoposide-induced apoptosis by inhibiting the PKCdelta-mediated activation of caspase-3 and by degrading caspase-2, which prevents caspase-8 activation.	Etoposide	39-48	protein kinase C delta	Homo sapiens	85-93
19549763-7	2009	Finally, we show that rottlerin blocks etoposide-induced apoptosis by inhibiting the PKCdelta-mediated activation of caspase-3 and by degrading caspase-2, which prevents caspase-8 activation.	Etoposide	39-48	caspase 3	Homo sapiens	117-126
19549763-7	2009	Finally, we show that rottlerin blocks etoposide-induced apoptosis by inhibiting the PKCdelta-mediated activation of caspase-3 and by degrading caspase-2, which prevents caspase-8 activation.	Etoposide	39-48	caspase 2	Homo sapiens	144-153
19549763-7	2009	Finally, we show that rottlerin blocks etoposide-induced apoptosis by inhibiting the PKCdelta-mediated activation of caspase-3 and by degrading caspase-2, which prevents caspase-8 activation.	Etoposide	39-48	caspase 8	Homo sapiens	170-179
19421231-7	2009	p21(WAF1) which is overexpressed in the latter, is involved in this protective effect, as siRNA-mediated inhibition of p21(WAF1) restores sensitivity to etoposide.	Etoposide	153-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-8
19549763-0	2009	Etoposide induces protein kinase Cdelta- and caspase-3-dependent apoptosis in neuroblastoma cancer cells.	Etoposide	0-9	caspase 3	Homo sapiens	45-54
19549763-1	2009	In this report, we reveal that etoposide inhibits the proliferation of SK-N-AS neuroblastoma cancer cells and promotes protein kinase Cdelta (PKCdelta)- and caspase-dependent apoptosis.	Etoposide	31-40	protein kinase C delta	Homo sapiens	142-150
19549763-2	2009	Etoposide induces the caspase-3-dependent cleavage of PKCdelta to its active p40 fragment, and active PKCdelta triggers the processing of caspase-3 by a positive-feedback mechanism.	Etoposide	0-9	caspase 3	Homo sapiens	22-31
19549763-2	2009	Etoposide induces the caspase-3-dependent cleavage of PKCdelta to its active p40 fragment, and active PKCdelta triggers the processing of caspase-3 by a positive-feedback mechanism.	Etoposide	0-9	protein kinase C delta	Homo sapiens	54-62
19549763-2	2009	Etoposide induces the caspase-3-dependent cleavage of PKCdelta to its active p40 fragment, and active PKCdelta triggers the processing of caspase-3 by a positive-feedback mechanism.	Etoposide	0-9	interleukin 9	Homo sapiens	77-80
19734705-2	2009	Carboplatin (CBDCA) + etoposide (VP-16) combination chemotherapy and radiation therapy was performed.	Etoposide	22-31	host cell factor C1	Homo sapiens	33-38
19654298-2	2009	Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increased sensitivity to MRP1 substrate drugs (vincristine, etoposide, and doxorubicin) compared with tumors containing both copies of wild-type MRP1, indicating that MRP1 plays a significant role in the drug resistance in this tumor type and defining this multidrug transporter as a target for pharmacologic suppression.	Etoposide	148-157	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	27-31
19662097-8	2009	Additionally, silencing of C/EBPalpha expression by small interfering RNAs enhanced, while inducible expression of C/EBPalpha inhibited NSC606985/etoposide-induced apoptosis in leukemic cells.	Etoposide	146-155	CCAAT enhancer binding protein alpha	Homo sapiens	115-125
19410573-8	2009	Namely, bortezomib abrogated both etoposide-induced NF-kappaB activation and etoposide-induced bcl-2 up-regulation.	Etoposide	77-86	BCL2 apoptosis regulator	Homo sapiens	95-100
19662097-4	2009	METHODOLOGY/PRINCIPAL FINDINGS: Upon onset of apoptosis induced by various kinds of inducers such as NSC606985, etoposide and others, C/EBPalpha expression presented a profound down-regulation in leukemic cell lines and primary cells via induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test, real-time quantitative RT-PCR and luciferase reporter assay.	Etoposide	112-121	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
19459852-0	2009	Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide.	Etoposide	89-98	acyl-CoA synthetase long-chain family member 1	Mus musculus	0-19
19723047-0	2009	Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells.	Etoposide	77-86	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
19488905-2	2009	Etoposide initiated DNA-damage signaling via ATM kinase and activated p53 pathway and caspase-2.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	45-48
19488905-2	2009	Etoposide initiated DNA-damage signaling via ATM kinase and activated p53 pathway and caspase-2.	Etoposide	0-9	tumor protein p53	Homo sapiens	70-73
19459852-8	2009	Correspondingly, ACS inhibition synergistically potentiated the glioma cell death induced by etoposide, a well-known activator of apoptosis.	Etoposide	93-102	acyl-CoA synthetase long-chain family member 1	Mus musculus	17-20
19488905-2	2009	Etoposide initiated DNA-damage signaling via ATM kinase and activated p53 pathway and caspase-2.	Etoposide	0-9	caspase 2	Homo sapiens	86-95
19488905-5	2009	The pharmacological inhibition of relevant induced targets proved the importance of ATM and caspase-2 in etoposide-mediated cytotoxicity and apoptosis.	Etoposide	105-114	ATM serine/threonine kinase	Homo sapiens	84-87
19488905-5	2009	The pharmacological inhibition of relevant induced targets proved the importance of ATM and caspase-2 in etoposide-mediated cytotoxicity and apoptosis.	Etoposide	105-114	caspase 2	Homo sapiens	92-101
19459852-10	2009	These results indicate that ACS is an apoptosis suppressor and that ACS inhibition could be a rational strategy to amplify the antitumor effect of etoposide.	Etoposide	147-156	acyl-CoA synthetase long-chain family member 1	Mus musculus	28-31
19459852-10	2009	These results indicate that ACS is an apoptosis suppressor and that ACS inhibition could be a rational strategy to amplify the antitumor effect of etoposide.	Etoposide	147-156	acyl-CoA synthetase long-chain family member 1	Mus musculus	68-71
19734716-3	2009	This compound inhibited caspase- 3 induction in U937 cells with an IC(50) value of 40 microM after 8 h of etoposide treatment.	Etoposide	106-115	caspase 3	Homo sapiens	24-34
19637078-6	2009	Other genes regulated by the transformation-related protein 53 (Trp53/p53) such as Bcl2-associated X protein (Bax) or etoposide-induced-2.4 (Ei24/PIG8) were not upregulated.	Etoposide	118-127	tumor protein p53	Homo sapiens	29-62
19148680-1	2009	PURPOSE: This study was to investigate whether the topoisomerase (Top) I inhibitor topotecan and the Top II inhibitor etoposide could modulate the hypoxia-induced HIF-1alpha expression in non-small cell lung cancer (NSCLC) cell lines.	Etoposide	118-127	hypoxia inducible factor 1 subunit alpha	Homo sapiens	163-173
19494003-3	2009	We found that the Topo I inhibitor camptothecin and, to a lesser extent, the Topo II inhibitor etoposide are potent inhibitors of the transcription and replication function of the EBV-encoded immediate-early protein Zta (also referred to as ZEBRA, EB1, and BZLF1).	Etoposide	95-104	protein Zta	Human gammaherpesvirus 4	257-262
19237191-3	2009	UPR inhibition using inositol-requiring enzyme 1alpha (IRE1alpha) or activating transcription factor 6 (ATF6) dominant-negative mutants diminished the ability of Bcr-Abl to protect the cells from etoposide- and imatinib-induced apoptosis.	Etoposide	196-205	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	162-169
18703556-2	2009	METHODS: The RB database was used to identify children with heritable, bilateral RB treated with primary chemotherapy (six cycles of vincristine, etoposide and carboplatin).	Etoposide	146-155	RB transcriptional corepressor 1	Homo sapiens	81-83
19438576-0	2009	Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide.	Etoposide	175-184	TNF receptor superfamily member 8	Homo sapiens	18-22
19655264-5	2009	We observed that caspases-3, -8, -9 and pan caspase inhibitors resulted in significant inhibition of etoposide-induced DNA fragmentation.	Etoposide	101-110	caspase 3	Homo sapiens	17-35
19655264-5	2009	We observed that caspases-3, -8, -9 and pan caspase inhibitors resulted in significant inhibition of etoposide-induced DNA fragmentation.	Etoposide	101-110	caspase 1	Homo sapiens	17-24
19322021-5	2009	Furthermore, SHP protected differentiated cells from etoposide-induced cellular apoptosis through the induction and cytoplasmic sequestration of p21WAF1.	Etoposide	53-62	nuclear receptor subfamily 0 group B member 2	Homo sapiens	13-16
19556823-6	2009	RESULTS: Partial remission as evidenced by regression of the tumor mass and return to normal serum cortisol and ACTH levels occurred after the first course of combination chemotherapy using cisplatin and etoposide.	Etoposide	204-213	proopiomelanocortin	Homo sapiens	112-116
19487283-7	2009	Up-regulation of CD and down-regulation of eEF1 seemed to be specific to senescence, as they were observed during cellular senescence induced by hydrogen peroxide or anticancer drugs (camptothecin, etoposide, or 50 ng doxorubicin) but not during apoptosis induced by Taxol or 10 microg doxorubicin or autophagy induced by tamoxifen.	Etoposide	198-207	eukaryotic translation elongation factor 1 beta 2	Homo sapiens	43-47
19408126-0	2009	Glycogen synthase kinase-3beta regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells.	Etoposide	41-50	glycogen synthase kinase 3 beta	Mus musculus	0-30
19408126-0	2009	Glycogen synthase kinase-3beta regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells.	Etoposide	41-50	B cell leukemia/lymphoma 2	Mus musculus	73-78
19408126-0	2009	Glycogen synthase kinase-3beta regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells.	Etoposide	41-50	caspase 3	Mus musculus	88-97
19408126-3	2009	Genotoxic stress induced by etoposide promoted apoptotic signaling by GSK3beta activation in C3H10T1/2 cells, a mouse mesenchymal cell line.	Etoposide	28-37	glycogen synthase kinase 3 beta	Mus musculus	70-78
19408126-4	2009	Etoposide led to the time-dependent activation of GSK3beta and caspase-3, which resulted in PARP cleavage.	Etoposide	0-9	glycogen synthase kinase 3 beta	Mus musculus	50-58
19408126-4	2009	Etoposide led to the time-dependent activation of GSK3beta and caspase-3, which resulted in PARP cleavage.	Etoposide	0-9	caspase 3	Mus musculus	63-72
19408126-4	2009	Etoposide led to the time-dependent activation of GSK3beta and caspase-3, which resulted in PARP cleavage.	Etoposide	0-9	poly (ADP-ribose) polymerase family, member 1	Mus musculus	92-96
19408126-5	2009	LiCl (a specific inhibitor) and siRNA (gene knock-down) of GSK3beta prevented the effects of etoposide on apoptosis.	Etoposide	93-102	glycogen synthase kinase 3 beta	Mus musculus	59-67
19408126-7	2009	Bcl-2 was decreased in the cells by exposure to etoposide.	Etoposide	48-57	B cell leukemia/lymphoma 2	Mus musculus	0-5
19408126-9	2009	In conclusion, etoposide-induced apoptosis in C3H10T1/2 cells is mediated by GSK3beta, which leads to caspase-3 activation via decrease in Bcl-2 expression.	Etoposide	15-24	glycogen synthase kinase 3 beta	Mus musculus	77-85
19408126-9	2009	In conclusion, etoposide-induced apoptosis in C3H10T1/2 cells is mediated by GSK3beta, which leads to caspase-3 activation via decrease in Bcl-2 expression.	Etoposide	15-24	caspase 3	Mus musculus	102-111
19408126-9	2009	In conclusion, etoposide-induced apoptosis in C3H10T1/2 cells is mediated by GSK3beta, which leads to caspase-3 activation via decrease in Bcl-2 expression.	Etoposide	15-24	B cell leukemia/lymphoma 2	Mus musculus	139-144
19516899-6	2009	By comparing the level of DSBs, H2AX phosphorylation and toxicity induced by etoposide and calicheamicin, we found that only 10% of etoposide-induced DSBs resulted in histone H2AX phosphorylation and toxicity.	Etoposide	132-141	H2A.X variant histone	Homo sapiens	32-36
19516899-6	2009	By comparing the level of DSBs, H2AX phosphorylation and toxicity induced by etoposide and calicheamicin, we found that only 10% of etoposide-induced DSBs resulted in histone H2AX phosphorylation and toxicity.	Etoposide	132-141	H2A.X variant histone	Homo sapiens	175-179
19516899-7	2009	There was a close match between toxicity and histone H2AX phosphorylation for calicheamicin and etoposide suggesting that the few etoposide-induced DSBs that activated H2AX phosphorylation were responsible for toxicity.	Etoposide	96-105	H2A.X variant histone	Homo sapiens	53-57
19516899-7	2009	There was a close match between toxicity and histone H2AX phosphorylation for calicheamicin and etoposide suggesting that the few etoposide-induced DSBs that activated H2AX phosphorylation were responsible for toxicity.	Etoposide	96-105	H2A.X variant histone	Homo sapiens	168-172
19516899-7	2009	There was a close match between toxicity and histone H2AX phosphorylation for calicheamicin and etoposide suggesting that the few etoposide-induced DSBs that activated H2AX phosphorylation were responsible for toxicity.	Etoposide	130-139	H2A.X variant histone	Homo sapiens	53-57
19516899-7	2009	There was a close match between toxicity and histone H2AX phosphorylation for calicheamicin and etoposide suggesting that the few etoposide-induced DSBs that activated H2AX phosphorylation were responsible for toxicity.	Etoposide	130-139	H2A.X variant histone	Homo sapiens	168-172
19516899-8	2009	CONCLUSIONS/SIGNIFICANCE: These results show that only 0.3% of all strand breaks produced by etoposide activate H2AX phosphorylation and suggests that over 99% of the etoposide induced DNA damage does not contribute to its toxicity.	Etoposide	93-102	H2A.X variant histone	Homo sapiens	112-116
19516899-8	2009	CONCLUSIONS/SIGNIFICANCE: These results show that only 0.3% of all strand breaks produced by etoposide activate H2AX phosphorylation and suggests that over 99% of the etoposide induced DNA damage does not contribute to its toxicity.	Etoposide	167-176	H2A.X variant histone	Homo sapiens	112-116
19488402-5	2009	We report that treatment of neurons with the DNA damaging agent etoposide or gamma-irradiation promotes cleavage of wild type (WT) and mutant Htt, generating N-terminal fragments of 80-90 kDa.	Etoposide	64-73	huntingtin	Homo sapiens	142-145
19488402-9	2009	When IKKbeta expression is blocked, etoposide treatment does not decrease Bcl-xL and activation of caspases is diminished.	Etoposide	36-45	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	5-12
19488402-10	2009	Similar to silencing of IKKbeta, increasing the level of Bcl-xL in neurons prevents etoposide-induced caspase activation and Htt proteolysis.	Etoposide	84-93	BCL2 like 1	Homo sapiens	57-63
19424800-3	2009	Etoposide treatment or UV irradiation resulted in sustained activation of JNK, correlating with the induction of apoptosis.	Etoposide	0-9	mitogen-activated protein kinase 8	Homo sapiens	74-77
19424800-6	2009	Etoposide-induced JNK phosphorylation was unaffected by PKCdelta knockdown, implying that JNK can regulate apoptosis by PKCdelta-dependent and independent pathways, according to stimulus and cell type.	Etoposide	0-9	mitogen-activated protein kinase 8	Homo sapiens	18-21
19424800-6	2009	Etoposide-induced JNK phosphorylation was unaffected by PKCdelta knockdown, implying that JNK can regulate apoptosis by PKCdelta-dependent and independent pathways, according to stimulus and cell type.	Etoposide	0-9	mitogen-activated protein kinase 8	Homo sapiens	90-93
19424800-6	2009	Etoposide-induced JNK phosphorylation was unaffected by PKCdelta knockdown, implying that JNK can regulate apoptosis by PKCdelta-dependent and independent pathways, according to stimulus and cell type.	Etoposide	0-9	protein kinase C delta	Homo sapiens	120-128
19346530-4	2009	We found that one intratesticular injection of etoposide (1.2 microg/testis) induced a significant increase in spermatocytes undergoing apoptosis, along with activation of caspase-9, -8 and -3 after 24 h of treatment.	Etoposide	47-56	caspase 9	Rattus norvegicus	172-192
19289494-6	2009	Using PRMT1 small interfering RNA in U2OS cells, we further show that PRMT1-deficient cells are hypersensitive to the DNA damaging agent etoposide and exhibit a defect in the recruitment of the homologous recombination RAD51 recombinase to DNA damage foci.	Etoposide	137-146	protein arginine methyltransferase 1	Homo sapiens	70-75
19346530-6	2009	Etoposide induces a significant stabilization/activation of p53, resulting in an increase level of this protein.	Etoposide	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	60-63
19346530-7	2009	The mRNA of Bcl-2 antagonist of cell death (BAD), a pro-apoptotic gene and a transcriptional target of p53, was significantly increased after etoposide treatment.	Etoposide	142-151	BCL2, apoptosis regulator	Rattus norvegicus	12-17
19346530-7	2009	The mRNA of Bcl-2 antagonist of cell death (BAD), a pro-apoptotic gene and a transcriptional target of p53, was significantly increased after etoposide treatment.	Etoposide	142-151	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	103-106
19346530-8	2009	Thus, our results suggest a single injection of etoposide induces apoptosis in healthy pachytene spermatocytes mediated by p53 and caspase activation.	Etoposide	48-57	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	123-126
19346530-8	2009	Thus, our results suggest a single injection of etoposide induces apoptosis in healthy pachytene spermatocytes mediated by p53 and caspase activation.	Etoposide	48-57	caspase 8	Rattus norvegicus	131-138
19491197-9	2009	In addition, endogenous E2F1 induced by etoposide treatment bound to the HIC1 promoter.	Etoposide	40-49	E2F transcription factor 1	Homo sapiens	24-28
19470245-4	2009	When Jab1 was overexpressed in U2OS cells followed by etoposide or hydrogen peroxide (H(2)O(2)), cell death induced by such stresses was protected against.	Etoposide	54-63	COP9 signalosome subunit 5	Homo sapiens	5-9
19491197-9	2009	In addition, endogenous E2F1 induced by etoposide treatment bound to the HIC1 promoter.	Etoposide	40-49	HIC ZBTB transcriptional repressor 1	Homo sapiens	73-77
19491197-10	2009	Moreover, inhibition of E2F1 strongly reduced the expression of etoposide-induced HIC1.	Etoposide	64-73	E2F transcription factor 1	Homo sapiens	24-28
19491197-10	2009	Moreover, inhibition of E2F1 strongly reduced the expression of etoposide-induced HIC1.	Etoposide	64-73	HIC ZBTB transcriptional repressor 1	Homo sapiens	82-86
19509240-8	2009	IGF1R depletion induced apoptosis, blocked cell survival, and sensitized to 5-fluorouracil and etoposide.	Etoposide	95-104	insulin like growth factor 1 receptor	Homo sapiens	0-5
19509259-8	2009	These findings support a model of hypoxia-induced drug resistance in which etoposide-induced DNA damage is prevented by HIF-1-dependent adaptations to hypoxia.	Etoposide	75-84	hypoxia inducible factor 1 subunit alpha	Homo sapiens	120-125
19470245-5	2009	On the contrary, when the level of Jab1 was suppressed in U2OS cells, cytotoxicity imposed by etoposide and H(2)O(2) was dramatically increased, suggesting a cell protective role for Jab1.	Etoposide	94-103	COP9 signalosome subunit 5	Homo sapiens	35-39
19334674-8	2009	The transport of both substrates, MTX and LTC(4), was inhibited by etoposide, confirming a higher affinity of ABCC3 for LTC(4) than for MTX.	Etoposide	67-76	ATP binding cassette subfamily C member 3	Homo sapiens	110-115
19246337-9	2009	Treatment with cisplatin or etoposide, alone or in combination with ABT-737, resulted in substantial down-regulation of Mcl-1L, a known inhibitor of ABT-737 action.	Etoposide	28-37	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	120-126
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Etoposide	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
19281794-5	2009	More intriguingly, the suppression of PU.1 expression by small interfering RNAs (siRNAs) significantly inhibits DNA-damaging agents NSC606985 and etoposide-induced apoptosis in leukemic cells, together with the up-regulated expression of anti-apoptotic bcl-2 gene.	Etoposide	146-155	Spi-1 proto-oncogene	Homo sapiens	38-42
19360472-3	2009	The nuclear translocation of DHFR protein during apoptosis was independent of the cellular context, but it was more sensitive in cell death induction by DNA damaging agents such as doxorubicin, etoposide and ultraviolent radiation than endoplasmic reticulum stressors (brefeldin-A and tunicamycin) and anti-microtubule agents (paclitaxel and nocodozole).	Etoposide	194-203	dihydrofolate reductase	Homo sapiens	29-33
19366611-5	2009	Ant1-deficient mice are resistant to death induced by systemic exposure to the brain excitotoxin, kainic acid (KA), and their hippocampal and cortical neurons are significantly more resistant to neuronal death induced by glutamate, KA, and etoposide.	Etoposide	240-249	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4	Mus musculus	0-4
19212831-1	2009	The upregulation of GRP78 and GRP94 under the induction of A23187 and its function in drug resistance to etoposide (VP-16) was investigated in human lung cancer cell line SK-MES-1.	Etoposide	105-114	heat shock protein family A (Hsp70) member 5	Homo sapiens	20-25
19212831-1	2009	The upregulation of GRP78 and GRP94 under the induction of A23187 and its function in drug resistance to etoposide (VP-16) was investigated in human lung cancer cell line SK-MES-1.	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
19201990-3	2009	Several of these therapeutic drugs, such as methotrexate, vincristine, and etoposide, are substrates of the multidrug resistance-associated protein 2 (MRP2).	Etoposide	75-84	ATP binding cassette subfamily C member 2	Homo sapiens	108-149
19201990-3	2009	Several of these therapeutic drugs, such as methotrexate, vincristine, and etoposide, are substrates of the multidrug resistance-associated protein 2 (MRP2).	Etoposide	75-84	ATP binding cassette subfamily C member 2	Homo sapiens	151-155
19100260-10	2009	In agreement with its effect on enhancing MOAP-1 stability, TRIM39 sensitizes cells to etoposide-induced apoptosis.	Etoposide	87-96	modulator of apoptosis 1	Homo sapiens	42-48
18846424-3	2009	In this report, we demonstrate that Staurosporine (STS) and Etoposide (ETS) induced apoptotic cell death of NSC by a mechanism requiring Caspase 3 activation, poly (ADP-ribose) polymerase and Lamin A/C cleavage.	Etoposide	60-69	lamin A	Mus musculus	192-201
18846424-3	2009	In this report, we demonstrate that Staurosporine (STS) and Etoposide (ETS) induced apoptotic cell death of NSC by a mechanism requiring Caspase 3 activation, poly (ADP-ribose) polymerase and Lamin A/C cleavage.	Etoposide	71-74	lamin A	Mus musculus	192-201
18937067-0	2009	Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide.	Etoposide	118-127	hypoxia inducible factor 1 subunit alpha	Homo sapiens	10-41
18937067-8	2009	HIF-1alpha-siRNA transfected cells were significantly more sensitive to doxorubicin and etoposide compared to non-transfected cells.	Etoposide	88-97	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
19233849-3	2009	Cells stably depleted of Bid were far less sensitive than control-transfected cells to etoposide-induced apoptosis.	Etoposide	87-96	BH3 interacting domain death agonist	Homo sapiens	25-28
19100260-10	2009	In agreement with its effect on enhancing MOAP-1 stability, TRIM39 sensitizes cells to etoposide-induced apoptosis.	Etoposide	87-96	tripartite motif containing 39	Homo sapiens	60-66
19100260-11	2009	Conversely, knockdown of TRIM39 reduces the sensitivity of cells to etoposide-stimulated apoptosis.	Etoposide	68-77	tripartite motif containing 39	Homo sapiens	25-31
19212674-3	2009	Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002.	Etoposide	118-127	AKT serine/threonine kinase 1	Homo sapiens	9-12
19302957-9	2009	One patient treated with maxillectomy, postoperative radiotherapy, and 5 courses of VIP chemotherapy (cisplatinum, etoposide, ifosfomide) died with brain metastases 10 months after diagnosis.	Etoposide	115-124	vasoactive intestinal peptide	Homo sapiens	84-87
19211844-7	2009	Low-dose activation of FKHRL1 sensitized to the DNA-damaging agents doxorubicin and etoposide, whereas the overexpression of Survivin diminished FKHRL1 sensitization to these drugs.	Etoposide	84-93	forkhead box O3	Homo sapiens	23-29
19261878-4	2009	Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a.	Etoposide	153-162	tumor protein p53	Homo sapiens	103-106
19261878-4	2009	Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a.	Etoposide	153-162	tumor protein p53	Homo sapiens	103-106
19305157-0	2009	Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.	Etoposide	117-126	tumor protein p53	Homo sapiens	88-91
19296337-9	2009	Radiation-induced accumulation was considerably less in Sf9 even as an analogous ATM/ATR-dependent nuclear translocation was observed following gamma-irradiation and etoposide.	Etoposide	166-175	ATM serine/threonine kinase	Homo sapiens	81-84
19296337-9	2009	Radiation-induced accumulation was considerably less in Sf9 even as an analogous ATM/ATR-dependent nuclear translocation was observed following gamma-irradiation and etoposide.	Etoposide	166-175	ATR serine/threonine kinase	Homo sapiens	85-88
19414395-2	2009	This study was designed to investigate the effects of quercetin (3,5,7,3",4"-pentahydroxyflavanone), a P-gp and CYP3A inhibitor, on the pharmacokinetics of etoposide in rats.	Etoposide	156-165	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	103-107
19414395-2	2009	This study was designed to investigate the effects of quercetin (3,5,7,3",4"-pentahydroxyflavanone), a P-gp and CYP3A inhibitor, on the pharmacokinetics of etoposide in rats.	Etoposide	156-165	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	112-117
19414395-11	2009	The enhanced oral bioavailability of etoposide by quercetin could mainly be due to inhibition of P-gp-mediated efflux and CYP3A-catalyzed metabolism in the intestine by quercetin.	Etoposide	37-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-101
19414395-11	2009	The enhanced oral bioavailability of etoposide by quercetin could mainly be due to inhibition of P-gp-mediated efflux and CYP3A-catalyzed metabolism in the intestine by quercetin.	Etoposide	37-46	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	122-127
19109225-0	2009	Etoposide induces TRP53-dependent apoptosis and TRP53-independent cell cycle arrest in trophoblasts of the developing mouse placenta.	Etoposide	0-9	transformation related protein 53	Mus musculus	18-23
19109225-0	2009	Etoposide induces TRP53-dependent apoptosis and TRP53-independent cell cycle arrest in trophoblasts of the developing mouse placenta.	Etoposide	0-9	transformation related protein 53	Mus musculus	48-53
19109225-7	2009	The accumulation and phosphorylation of TRP53 protein were detected 8 and 6 h after etoposide injection and irradiation, respectively.	Etoposide	84-93	transformation related protein 53	Mus musculus	40-45
19109225-8	2009	In Trp53-deficient placentas, the induction of etoposide-induced trophoblastic apoptosis is abrogated, while the reduction of proliferation occurred similarly as in wild-type placentas.	Etoposide	47-56	transformation related protein 53	Mus musculus	3-8
19109225-9	2009	CDC2A, a regulator of G2/M progression, was inactivated by phosphorylation after etoposide injection and irradiation, suggesting that the cell cycle was arrested at the G2/M border by treatment.	Etoposide	81-90	cyclin-dependent kinase 1	Mus musculus	0-5
19109225-10	2009	Our study demonstrated that etoposide injection induced TRP53-dependent apoptosis and TRP53-independent cell cycle arrest in labyrinthine trophoblasts, providing insights into the molecular pathway of placental disorders.	Etoposide	28-37	transformation related protein 53	Mus musculus	56-61
19109225-10	2009	Our study demonstrated that etoposide injection induced TRP53-dependent apoptosis and TRP53-independent cell cycle arrest in labyrinthine trophoblasts, providing insights into the molecular pathway of placental disorders.	Etoposide	28-37	transformation related protein 53	Mus musculus	86-91
19335276-7	2009	In stromal cell co-cultures, CXCR4 antagonists also sensitize SCLC cells to cytotoxic drugs, such as etoposide, and thereby antagonize cell adhesion-mediated drug resistance.	Etoposide	101-110	C-X-C motif chemokine receptor 4	Homo sapiens	29-34
19379585-11	2009	Up-regulating expression of Ahi-1 protein with 140 kD in the nucleus was found in Jurkat cells after exposure to meisoindigo, cytarabine, homoharringtonine, methotrexate and etoposide, down-regulating expression of Ahi-1 with 140 kD in the cytoplasm was observed after treatment with meisoindigo.	Etoposide	174-183	Abelson helper integration site 1	Homo sapiens	28-33
19196156-5	2009	We synthesized a novel legumain-cleavable prodrug, carbobenzyloxy-alanine-alanine-asparagine-ethylenediamine-etoposide, which releases the chemotherapeutic agent, etoposide, as the active drug.	Etoposide	109-118	legumain	Homo sapiens	23-31
19065652-3	2009	Doxorubicin, VP16 and the cytotoxic ligand TRAIL trigger NF-kappaB activation, whereas cisplatin and taxol have no impact on NF-kappaB activity.	Etoposide	13-17	nuclear factor kappa B subunit 1	Homo sapiens	57-66
19223549-7	2009	This XIAP-dependent event occurs in response to camptotechin or etoposide/VP16; however, XIAP is dispensable for activation of NF-kappaB by doxorubicin, which engages a MEK-ERK pathway to activate IKK.	Etoposide	64-73	X-linked inhibitor of apoptosis	Homo sapiens	5-9
19223549-7	2009	This XIAP-dependent event occurs in response to camptotechin or etoposide/VP16; however, XIAP is dispensable for activation of NF-kappaB by doxorubicin, which engages a MEK-ERK pathway to activate IKK.	Etoposide	74-78	X-linked inhibitor of apoptosis	Homo sapiens	5-9
19212674-3	2009	Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002.	Etoposide	118-127	AKT serine/threonine kinase 1	Homo sapiens	153-156
19212674-3	2009	Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002.	Etoposide	118-127	AKT serine/threonine kinase 1	Homo sapiens	153-156
19060098-6	2009	Because enzymes associated with the synthesis of PGE(2), including PTGS2, are up-regulated in response to a deciduogenic stimulus and because PGE(2) was more effective than the PGI(2) analogues and PPARD and RXRA agonists in increasing EVP and inducing decidualization, we suggest that PGE(2) is most likely the PG involved in the initiation of decidualization in the rat.	Etoposide	236-239	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	67-72
19214144-7	2009	None of these mutations had any effect on MRP1/ABCC1 expression and trafficking, but that Arg723Gln mutation significantly reduced MRP1/ABCC1-mediated resistance to daunorubicin, doxorubicin, etoposide, vinblastine, and vincristine.	Etoposide	192-201	ATP binding cassette subfamily C member 1	Homo sapiens	131-135
19214144-7	2009	None of these mutations had any effect on MRP1/ABCC1 expression and trafficking, but that Arg723Gln mutation significantly reduced MRP1/ABCC1-mediated resistance to daunorubicin, doxorubicin, etoposide, vinblastine, and vincristine.	Etoposide	192-201	multidrug resistance-associated protein 1	Cricetulus griseus	136-141
19349754-4	2009	This compound showed inhibitory activity on caspase-3 induction, a major protease of the apoptosis cascade, with an IC50 value of 38.96 microM after 8 h of etoposide treatment in U937 cells.	Etoposide	156-165	caspase 3	Homo sapiens	44-53
19349754-5	2009	The expression level of caspase-3 and poly(ADP-ribose) polymerase (PARP) were dose-dependently inhibited by the compound, suggesting that rengyolone inhibits etoposide-induced apoptosis via downregulation of caspases.	Etoposide	158-167	caspase 3	Homo sapiens	24-33
19349754-5	2009	The expression level of caspase-3 and poly(ADP-ribose) polymerase (PARP) were dose-dependently inhibited by the compound, suggesting that rengyolone inhibits etoposide-induced apoptosis via downregulation of caspases.	Etoposide	158-167	poly(ADP-ribose) polymerase 1	Homo sapiens	67-71
19261311-5	2009	The chimeric enzymes of Arabidopsis thaliana UGT71C1 and UGT71C2 showed major changes in acceptor substrate specificity and were able to glycosylate etoposide significantly better than the parental UGT71C1 and UGT71C2 enzymes, with K(cat) and efficiency coefficients 3.0 and 2.6 times higher, respectively.	Etoposide	149-158	UDP-glucosyl transferase 71C1	Arabidopsis thaliana	45-52
19261311-5	2009	The chimeric enzymes of Arabidopsis thaliana UGT71C1 and UGT71C2 showed major changes in acceptor substrate specificity and were able to glycosylate etoposide significantly better than the parental UGT71C1 and UGT71C2 enzymes, with K(cat) and efficiency coefficients 3.0 and 2.6 times higher, respectively.	Etoposide	149-158	UDP-glucosyl transferase 71C2	Arabidopsis thaliana	57-64
19261311-5	2009	The chimeric enzymes of Arabidopsis thaliana UGT71C1 and UGT71C2 showed major changes in acceptor substrate specificity and were able to glycosylate etoposide significantly better than the parental UGT71C1 and UGT71C2 enzymes, with K(cat) and efficiency coefficients 3.0 and 2.6 times higher, respectively.	Etoposide	149-158	UDP-glucosyl transferase 71C1	Arabidopsis thaliana	198-205
19261311-5	2009	The chimeric enzymes of Arabidopsis thaliana UGT71C1 and UGT71C2 showed major changes in acceptor substrate specificity and were able to glycosylate etoposide significantly better than the parental UGT71C1 and UGT71C2 enzymes, with K(cat) and efficiency coefficients 3.0 and 2.6 times higher, respectively.	Etoposide	149-158	UDP-glucosyl transferase 71C2	Arabidopsis thaliana	210-217
19036079-5	2009	This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29).	Etoposide	307-316	colony stimulating factor 3	Homo sapiens	83-120
19046404-6	2009	In the presence of additional apoptotic challenges (staurosporine, etoposide, and hydrogen peroxide), cells bearing mSOD1 inclusions were susceptible to further apoptosis suggesting they were in a pro-apoptotic state, thus confirming that inclusions are linked to toxicity.	Etoposide	67-76	superoxide dismutase 1, soluble	Mus musculus	116-121
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Etoposide	117-126	erythropoietin	Homo sapiens	0-3
18806833-0	2009	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.	Etoposide	117-126	colony stimulating factor 3	Homo sapiens	24-29
19155314-8	2009	Furthermore, sensitivity to agents in other chemotherapeutic classes (e.g., vinblastine and etoposide) also increased with the mutation of Pldn.	Etoposide	92-101	biogenesis of lysosomal organelles complex 1 subunit 6	Homo sapiens	139-143
19003983-10	2009	The potential therapeutic value in targeting TOP2A by Etoposide, as a single agent, and in combination with Doxorubicin was also explored.	Etoposide	54-63	DNA topoisomerase II alpha	Homo sapiens	45-50
19106640-8	2009	We further demonstrated that inhibition of PKR signaling via either siRNA or Ad-Delta6PKR sensitizes cancer cells to etoposide or cisplatin-mediated cell death.	Etoposide	117-126	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	43-46
19225928-9	2009	The patient was treated postoperatively with three cycles of chemotherapy consisting of bleomycin, etoposide, and cisplatin; with this regimen, serum AFP decreased to 16 ng/ml from 12 600 ng/ml just before the initiation of chemotherapy.	Etoposide	99-108	alpha fetoprotein	Homo sapiens	150-153
19020542-3	2009	BCR/ABL-expressing cell lines show an increase in DNA breaks after treatment with etoposide as compared to control cells.	Etoposide	82-91	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
19043076-9	2009	Down-regulation of CKIdelta and CKIepsilon also led to reduced formation of etoposide stabilized topo II-DNA cleavable complex.	Etoposide	76-85	TPTEP2-CSNK1E readthrough	Homo sapiens	32-42
19190824-2	2009	In the present research approach, our objective was to investigate the possible alterations in the mRNA expression levels of KLK5 and KLK11 genes in prostate cancer cells PC3 as a response to treatment with mitoxantrone, etoposide, doxorubicin and carboplatin.	Etoposide	221-230	kallikrein related peptidase 5	Homo sapiens	125-129
18816698-0	2009	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children"s Oncology Group.	Etoposide	54-63	keratin 20	Homo sapiens	123-127
18816698-1	2009	BACKGROUND: To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).	Etoposide	191-200	keratin 20	Homo sapiens	85-89
19190824-2	2009	In the present research approach, our objective was to investigate the possible alterations in the mRNA expression levels of KLK5 and KLK11 genes in prostate cancer cells PC3 as a response to treatment with mitoxantrone, etoposide, doxorubicin and carboplatin.	Etoposide	221-230	kallikrein related peptidase 11	Homo sapiens	134-139
19134217-7	2009	On the other hand, down-regulation of c-MYC reduced apoptosis and decreased the sensitivity of human MB cells to IR, cisplatin, and etoposide.	Etoposide	132-141	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	38-43
18983998-0	2009	YNK1, the yeast homolog of human metastasis suppressor NM23, is required for repair of UV radiation- and etoposide-induced DNA damage.	Etoposide	105-114	nucleoside diphosphate kinase	Saccharomyces cerevisiae S288C	0-4
18983998-0	2009	YNK1, the yeast homolog of human metastasis suppressor NM23, is required for repair of UV radiation- and etoposide-induced DNA damage.	Etoposide	105-114	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	55-59
18983998-4	2009	Ablation of YNK1 delayed repair of UV- and etoposide-induced nuclear DNA damage by 3-6h.	Etoposide	43-52	nucleoside diphosphate kinase	Saccharomyces cerevisiae S288C	12-16
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	56-65	myotubularin related protein 6	Homo sapiens	30-35
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	56-65	myotubularin related protein 9	Homo sapiens	40-45
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	188-197	myotubularin related protein 6	Homo sapiens	30-35
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	188-197	myotubularin related protein 6	Homo sapiens	109-114
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	188-197	myotubularin related protein 9	Homo sapiens	119-124
19038970-9	2009	Furthermore, co-expression of MTMR6 and MTMR9 decreased etoposide-induced apoptosis, whereas decreasing both MTMR6 and MTMR9 by RNA interference led to increased cell death in response to etoposide treatment when compared with that seen with RNA interference of MTMR6 alone.	Etoposide	188-197	myotubularin related protein 6	Homo sapiens	109-114
19118018-6	2009	Culturing IL-6R-positive neuroblastoma cells in the presence of BMSC or recombinant human IL-6 increased proliferation and protected tumor cells from etoposide-induced apoptosis, whereas it had no effect on IL-6R-negative tumor cells.	Etoposide	150-159	interleukin 6 receptor	Homo sapiens	10-15
18504641-4	2009	We then treated the metastatic lesions with CBDCA and etoposide (VP-16), and were able to stop disease progression.	Etoposide	54-63	host cell factor C1	Homo sapiens	65-70
19183886-7	2009	The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol.	Etoposide	37-46	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	101-124
19183886-7	2009	The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol.	Etoposide	37-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	129-143
19183886-7	2009	The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol.	Etoposide	37-46	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	145-149
19118001-7	2009	In this drug-sensitive cellular background, MRP7 conferred high levels of resistance to docetaxel (46-fold), paclitaxel (116-fold), SN-38 (65-fold), daunorubicin (7.5-fold), etoposide (11-fold), and vincristine (56-fold).	Etoposide	174-183	ATP binding cassette subfamily C member 10	Homo sapiens	44-48
19118018-6	2009	Culturing IL-6R-positive neuroblastoma cells in the presence of BMSC or recombinant human IL-6 increased proliferation and protected tumor cells from etoposide-induced apoptosis, whereas it had no effect on IL-6R-negative tumor cells.	Etoposide	150-159	interleukin 6	Homo sapiens	10-14
19118055-10	2009	Interestingly, the subcohort of 6 SCLC patients with resistance to platinum/etoposide chemotherapy all scored positively for peripheral blood SCG3 transcript (P = 0.022).	Etoposide	76-85	secretogranin III	Homo sapiens	142-146
21637660-0	2009	Preferential induction of MLL(Mixed Lineage Leukemia) rearrangements in human lymphocyte cultures treated with etoposide.	Etoposide	111-120	lysine methyltransferase 2A	Homo sapiens	26-29
18828157-7	2009	The integration of array CGH and gene expression data highlights a robust cis-acting DNA targeted genes signature that may be critical for glioblastoma progression, with two tumor suppressor genes PCDH9 and STARD13 that could be involved in tumor invasiveness and resistance to etoposide.	Etoposide	278-287	protocadherin 9	Homo sapiens	197-202
18828157-7	2009	The integration of array CGH and gene expression data highlights a robust cis-acting DNA targeted genes signature that may be critical for glioblastoma progression, with two tumor suppressor genes PCDH9 and STARD13 that could be involved in tumor invasiveness and resistance to etoposide.	Etoposide	278-287	StAR related lipid transfer domain containing 13	Homo sapiens	207-214
21637660-7	2009	This greater susceptibility to etoposide-induced cleavage may explain the more frequent involvement of MLL in treatment-related leukemia.	Etoposide	31-40	lysine methyltransferase 2A	Homo sapiens	103-106
19899124-1	2009	The yield of CD34+ cells collected by apheresis for autologous peripheral blood stem cell (PBSC) transplantation was greatly increased when the appropriate timing was determined to begin using G-CSF after COAEP (Cytoxan, Vinblastine, Arabinosylcytosin, Etoposide and Prednisone) mobilization.	Etoposide	253-262	CD34 molecule	Homo sapiens	13-17
19050044-7	2009	We then investigated whether selective silencing of the different BDNF mRNAs using specific siRNAs could reduce cell survival in response to serum deprivation or the anticancer drugs cisplatin, doxorubicin and etoposide.	Etoposide	210-219	brain derived neurotrophic factor	Homo sapiens	66-70
19148830-6	2009	Induction of apoptosis by treating miR17-92 or E2F1 transduced T-ALL cells with etoposide led to reduced or enhanced cell viability, respectively.	Etoposide	80-89	E2F transcription factor 1 L homeolog	Xenopus laevis	47-51
19333541-2	2009	The aim of this study was to evaluate the effectiveness of combination chemotherapy with carboplatin and etoposide (CE) in SCC of the pancreas.	Etoposide	105-114	serpin family B member 3	Homo sapiens	123-126
19012752-8	2009	Finally, these deleterious effects of MGO on STAT3 signaling led to down-regulation of a STAT3 target gene, Bcl-2, and sensitized cellular toxicity induced by H(2)O(2) and etoposide.	Etoposide	172-181	signal transducer and activator of transcription 3	Homo sapiens	45-50
19492242-0	2009	JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway.	Etoposide	79-88	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	0-3
19492242-0	2009	JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway.	Etoposide	79-88	mitogen-activated protein kinase 8	Homo sapiens	93-96
19492242-4	2009	Data showed that JWA expression was reduced significantly by etoposide (VP16) in JAR MDR cells (JAR/VP16) compared to parent JAR cells.	Etoposide	61-70	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	17-20
19492242-4	2009	Data showed that JWA expression was reduced significantly by etoposide (VP16) in JAR MDR cells (JAR/VP16) compared to parent JAR cells.	Etoposide	72-76	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	17-20
19547715-6	2009	We found a borderline correlation between the bcrp mRNA expression and the response of xenografts to etoposide.	Etoposide	101-110	BCR pseudogene 1	Homo sapiens	46-50
18674816-4	2009	Transient expression of pig7 in leukemic cells exhibited no evident effect on cell proliferation and differentiation, but could intensify inhibitory efficacy of etoposide (VP16) and daunorubicin (DNR).	Etoposide	161-170	lipopolysaccharide induced TNF factor	Homo sapiens	24-28
18674816-4	2009	Transient expression of pig7 in leukemic cells exhibited no evident effect on cell proliferation and differentiation, but could intensify inhibitory efficacy of etoposide (VP16) and daunorubicin (DNR).	Etoposide	172-176	lipopolysaccharide induced TNF factor	Homo sapiens	24-28
19309222-8	2009	There was a high correlation between PGP, MRP1 and LRP expression and IC50 values for imatinib and etoposide.	Etoposide	99-108	phosphoglycolate phosphatase	Homo sapiens	37-40
19309222-8	2009	There was a high correlation between PGP, MRP1 and LRP expression and IC50 values for imatinib and etoposide.	Etoposide	99-108	ATP binding cassette subfamily C member 1	Homo sapiens	42-46
19309222-8	2009	There was a high correlation between PGP, MRP1 and LRP expression and IC50 values for imatinib and etoposide.	Etoposide	99-108	LDL receptor related protein 1	Homo sapiens	51-54
18957415-9	2008	PKR supports stress signaling in REH cells, as suppression of PKR promoted chemoresistance to etoposide.	Etoposide	94-103	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	0-3
19996654-1	2009	OBJECTIVES: To investigate the safety and efficacy in terms of PSA response of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16) in hormone- refractory prostate cancer (HRPC) patients.	Etoposide	143-152	host cell factor C1	Homo sapiens	154-158
18927073-4	2008	Cells stably overexpressing Bcl-2/Bcl-x(L) or stably depleted of Apaf-1 were equally resistant to apoptosis induced by the DNA-damaging anticancer drug etoposide as determined by phosphatidylserine externalization and caspase activation.	Etoposide	152-161	BCL2 apoptosis regulator	Homo sapiens	28-33
18927073-4	2008	Cells stably overexpressing Bcl-2/Bcl-x(L) or stably depleted of Apaf-1 were equally resistant to apoptosis induced by the DNA-damaging anticancer drug etoposide as determined by phosphatidylserine externalization and caspase activation.	Etoposide	152-161	apoptotic peptidase activating factor 1	Homo sapiens	65-71
18927073-6	2008	Furthermore, we found that etoposide-induced apoptosis and mitochondrial events were inhibited in cells stably overexpressing either full-length X-linked inhibitor of apoptosis protein (XIAP) or the BIR1/BIR2 domains of XIAP.	Etoposide	27-36	X-linked inhibitor of apoptosis	Homo sapiens	145-184
18927073-6	2008	Furthermore, we found that etoposide-induced apoptosis and mitochondrial events were inhibited in cells stably overexpressing either full-length X-linked inhibitor of apoptosis protein (XIAP) or the BIR1/BIR2 domains of XIAP.	Etoposide	27-36	X-linked inhibitor of apoptosis	Homo sapiens	186-190
18927073-6	2008	Furthermore, we found that etoposide-induced apoptosis and mitochondrial events were inhibited in cells stably overexpressing either full-length X-linked inhibitor of apoptosis protein (XIAP) or the BIR1/BIR2 domains of XIAP.	Etoposide	27-36	potassium inwardly rectifying channel subfamily J member 6	Homo sapiens	199-203
18927073-6	2008	Furthermore, we found that etoposide-induced apoptosis and mitochondrial events were inhibited in cells stably overexpressing either full-length X-linked inhibitor of apoptosis protein (XIAP) or the BIR1/BIR2 domains of XIAP.	Etoposide	27-36	X-linked inhibitor of apoptosis	Homo sapiens	220-224
18957415-9	2008	PKR supports stress signaling in REH cells, as suppression of PKR promoted chemoresistance to etoposide.	Etoposide	94-103	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	62-65
18957415-13	2008	Cells expressing wild-type B56alpha but not S28A B56alpha were sensitized to etoposide.	Etoposide	77-86	protein phosphatase 2 regulatory subunit B'alpha	Homo sapiens	27-35
18674614-1	2008	KU70(-/-) and DNA-PKcs(-/-/-)chicken DT40 cells are reportedly highly sensitive to the DNA topoisomerase II inhibitor etoposide.	Etoposide	118-127	X-ray repair cross complementing 6	Gallus gallus	0-4
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	274-283	BCL2 like 11	Homo sapiens	212-215
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	274-283	HUS1 checkpoint clamp component	Homo sapiens	250-254
18794804-6	2008	Moreover, we found that Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to etoposide-induced apoptosis.	Etoposide	97-106	BCL2 like 11	Homo sapiens	47-50
18794804-6	2008	Moreover, we found that Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to etoposide-induced apoptosis.	Etoposide	97-106	HUS1 checkpoint clamp component	Homo sapiens	73-77
18794804-8	2008	Taken together, these results suggest that loss of Hus1 sensitizes cells to etoposide-induced apoptosis not only by inducing Bim and Puma expressions but also by releasing Rad9 into the cytosol to augment mitochondrial apoptosis.	Etoposide	76-85	HUS1 checkpoint clamp component	Homo sapiens	51-55
18794804-8	2008	Taken together, these results suggest that loss of Hus1 sensitizes cells to etoposide-induced apoptosis not only by inducing Bim and Puma expressions but also by releasing Rad9 into the cytosol to augment mitochondrial apoptosis.	Etoposide	76-85	BCL2 like 11	Homo sapiens	125-128
18774953-0	2008	Etoposide-initiated MLL rearrangements: the pitfalls of  inverse PCR.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	20-23
18651620-3	2008	Pre-incubation with PTHrP (107-139) for 1-24 h dose-dependently (0.1-100 nM) inhibited dexamethasone- or etoposide-induced cell death in human osteoblastic MG-63 cells and human osteoblast-like cells from trabecular bone.	Etoposide	105-114	parathyroid hormone like hormone	Homo sapiens	20-25
18695355-10	2008	In addition, constitutively active MEK and myristoylated-Akt adenovirus suppressed the cleavage of pro-caspase-9 and -3 and inhibited osteoclast apoptosis induced by etoposide.	Etoposide	166-175	mitogen-activated protein kinase kinase 7	Homo sapiens	35-38
18695355-10	2008	In addition, constitutively active MEK and myristoylated-Akt adenovirus suppressed the cleavage of pro-caspase-9 and -3 and inhibited osteoclast apoptosis induced by etoposide.	Etoposide	166-175	AKT serine/threonine kinase 1	Homo sapiens	57-60
18794804-0	2008	Loss of Hus1 sensitizes cells to etoposide-induced apoptosis by regulating BH3-only proteins.	Etoposide	33-42	HUS1 checkpoint clamp component	Homo sapiens	8-12
18794804-4	2008	Here, we report that etoposide treatment dramatically upregulates the BH3-only proteins, Bim and Puma, in Hus1-deficient cells.	Etoposide	21-30	BCL2 like 11	Homo sapiens	89-92
18794804-4	2008	Here, we report that etoposide treatment dramatically upregulates the BH3-only proteins, Bim and Puma, in Hus1-deficient cells.	Etoposide	21-30	HUS1 checkpoint clamp component	Homo sapiens	106-110
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	101-110	BCL2 like 11	Homo sapiens	21-24
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	101-110	HUS1 checkpoint clamp component	Homo sapiens	47-51
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	101-110	BCL2 like 11	Homo sapiens	212-215
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	101-110	HUS1 checkpoint clamp component	Homo sapiens	250-254
18794804-5	2008	Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment.	Etoposide	274-283	HUS1 checkpoint clamp component	Homo sapiens	47-51
18492488-4	2008	MG132 and ALLN inhibited the release of cytochrome c from mitochondria into the cytosol in the absence of survival factors and suppressed the cleavage of pro-caspase-9 and -3 to its active forms induced by etoposide.	Etoposide	206-215	cytochrome c, somatic	Homo sapiens	40-52
18492488-4	2008	MG132 and ALLN inhibited the release of cytochrome c from mitochondria into the cytosol in the absence of survival factors and suppressed the cleavage of pro-caspase-9 and -3 to its active forms induced by etoposide.	Etoposide	206-215	caspase 3	Homo sapiens	154-174
18842680-8	2008	In etoposide-treated cells, cell cycle control and p53-dependent gene expression were not affected by the absence of HIF-1alpha.	Etoposide	3-12	transformation related protein 53, pseudogene	Mus musculus	51-54
18509329-6	2008	Moreover, in 25 cell lines, etoposide-induced MLL fusions did not differ in sensitive vs. resistant lines at equitoxic concentrations (P = 0.65).	Etoposide	28-37	lysine methyltransferase 2A	Homo sapiens	46-49
18726991-8	2008	Interestingly, proteasome inhibitor celastrol- and chemotherapeutic drug VP-16-stimulated AR breakdown was attenuated by calpain inhibitors calpastatin and N-acetyl-L-leucyl-L-leucyl-L-methioninal.	Etoposide	73-78	androgen receptor	Homo sapiens	90-92
18674614-1	2008	KU70(-/-) and DNA-PKcs(-/-/-)chicken DT40 cells are reportedly highly sensitive to the DNA topoisomerase II inhibitor etoposide.	Etoposide	118-127	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	14-22
18674614-2	2008	Here we report that KU70 and DNA-PKcs unexpectedly function together during the induction of apoptosis after exposure to high levels of etoposide.	Etoposide	136-145	X-ray repair cross complementing 6	Gallus gallus	20-24
18674614-2	2008	Here we report that KU70 and DNA-PKcs unexpectedly function together during the induction of apoptosis after exposure to high levels of etoposide.	Etoposide	136-145	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	29-37
18674614-6	2008	When cells were treated with high doses of etoposide, the chromatin binding of DNA-PKcs was impaired by deletion of KU70 but not of Artemis, suggesting that KU70 acts upstream of DNA-PKcs and Artemis acts downstream of DNA-PKcs in the apoptotic pathway like the NHEJ pathway.	Etoposide	43-52	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	79-87
18674614-6	2008	When cells were treated with high doses of etoposide, the chromatin binding of DNA-PKcs was impaired by deletion of KU70 but not of Artemis, suggesting that KU70 acts upstream of DNA-PKcs and Artemis acts downstream of DNA-PKcs in the apoptotic pathway like the NHEJ pathway.	Etoposide	43-52	X-ray repair cross complementing 6	Gallus gallus	116-120
18674614-6	2008	When cells were treated with high doses of etoposide, the chromatin binding of DNA-PKcs was impaired by deletion of KU70 but not of Artemis, suggesting that KU70 acts upstream of DNA-PKcs and Artemis acts downstream of DNA-PKcs in the apoptotic pathway like the NHEJ pathway.	Etoposide	43-52	X-ray repair cross complementing 6	Gallus gallus	157-161
18674614-6	2008	When cells were treated with high doses of etoposide, the chromatin binding of DNA-PKcs was impaired by deletion of KU70 but not of Artemis, suggesting that KU70 acts upstream of DNA-PKcs and Artemis acts downstream of DNA-PKcs in the apoptotic pathway like the NHEJ pathway.	Etoposide	43-52	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	179-187
18674614-6	2008	When cells were treated with high doses of etoposide, the chromatin binding of DNA-PKcs was impaired by deletion of KU70 but not of Artemis, suggesting that KU70 acts upstream of DNA-PKcs and Artemis acts downstream of DNA-PKcs in the apoptotic pathway like the NHEJ pathway.	Etoposide	43-52	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	179-187
18442869-13	2008	CL(VP16) and AUC(VP16) correlate significantly with overall survival of patients with SCLC patients receiving etoposide regimens.	Etoposide	110-119	host cell factor C1	Homo sapiens	3-7
19230382-0	2008	Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.	Etoposide	40-49	DNA topoisomerase II beta	Homo sapiens	101-126
19230382-0	2008	Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.	Etoposide	40-49	nucleolin	Homo sapiens	132-141
19230382-0	2008	Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.	Etoposide	40-49	BCR pseudogene 2	Homo sapiens	147-152
19230382-0	2008	Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.	Etoposide	40-49	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	160-163
18442869-1	2008	PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC).	Etoposide	69-78	host cell factor C1	Homo sapiens	120-124
18557930-7	2008	On the other hand, p53 activator, etoposide, decreased the MMP-1 expression in both normal and p53-overexpressed cells.	Etoposide	34-43	tumor protein p53	Homo sapiens	19-22
18557930-7	2008	On the other hand, p53 activator, etoposide, decreased the MMP-1 expression in both normal and p53-overexpressed cells.	Etoposide	34-43	matrix metallopeptidase 1	Homo sapiens	59-64
18557930-7	2008	On the other hand, p53 activator, etoposide, decreased the MMP-1 expression in both normal and p53-overexpressed cells.	Etoposide	34-43	tumor protein p53	Homo sapiens	95-98
18622892-9	2008	On the other hand, pitavastatin antagonized dexamethasone- or etoposide-induced apoptosis in a dose-dependent manner, and Smad3 inactivation by dominant negative Smad3 or an inhibition of endogenous TGF-beta action by SB431542 antagonized anti-apoptotic effects of pitavastatin, indicating that pitavastatin suppressed osteoblast apoptosis partly through TGF-beta-Smad3 pathway.	Etoposide	62-71	transforming growth factor, beta 1	Mus musculus	355-363
18723777-6	2008	Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold.	Etoposide	144-153	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
18442869-13	2008	CL(VP16) and AUC(VP16) correlate significantly with overall survival of patients with SCLC patients receiving etoposide regimens.	Etoposide	110-119	host cell factor C1	Homo sapiens	17-21
18626752-2	2008	We investigated small-intestinal absorption of the P-glycoprotein (P-gp) substrates etoposide and digoxin in monkeys to clarify the influence of efflux transport on their intestinal permeability.	Etoposide	84-93	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	51-65
18626752-10	2008	CONCLUSION: Low bioavailability of etoposide in monkeys is due to poor intestinal uptake resulting from low influx from the apical side, rather than secretion via P-gp.	Etoposide	35-44	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	163-167
18722352-3	2008	Inactivation of DJ-1 by RNA-mediated interference (RNAi) in leukemia cell lines K562 and HL60 resulted in inhibition of the proliferation potential and enhancement of the sensitivity of leukemia cells to chemotherapeutic drug etoposide.	Etoposide	226-235	Parkinsonism associated deglycase	Homo sapiens	16-20
19267105-1	2008	Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide.	Etoposide	149-158	interferon beta 1	Homo sapiens	0-15
19138287-0	2008	Anti-Ma2 paraneoplastic encephalitis associated with testicular germ cell tumor treated by carboplatin, etoposide and bleomycin.	Etoposide	104-113	PNMA family member 2	Homo sapiens	5-8
18565644-4	2008	The expression of EndoG correlated positively with sensitivity to cisplatin and etoposide, and the silencing of EndoG by siRNA decreased the sensitivity of the cells to the chemotherapeutic agents in the two EndoG-expressing cell lines.	Etoposide	80-89	endonuclease G	Homo sapiens	18-23
18565644-5	2008	5-aza-2"-deoxycytidine caused hypomethylation of the EndoG promoter in PC3 cells, induced EndoG mRNA and protein expression, and made the cells sensitive to both cisplatin and etoposide.	Etoposide	176-185	endonuclease G	Homo sapiens	53-58
18674571-3	2008	We have previously shown that LEI overexpression protects cells from etoposide-induced apoptosis.	Etoposide	69-78	serpin family B member 1	Homo sapiens	30-33
18674571-6	2008	The protease inhibited is cathepsin D, released from the lysosome during etoposide treatment.	Etoposide	73-82	cathepsin D	Homo sapiens	26-37
18674571-8	2008	This let us presume that high expression of LEI in tumor cells may reduce the efficiency of etoposide as a chemotherapeutic agent.	Etoposide	92-101	serpin family B member 1	Homo sapiens	44-47
19016746-8	2008	Suppression of galectin-3 resulted in G0/G1 progression of human colon cancer cells arrested at S, S/G2 and G2/M phase in the presence of doxorubicin, and etoposide or nocodazole, respectively.	Etoposide	155-164	galectin 3	Homo sapiens	15-25
19016746-9	2008	Compared to cells in which ATP synthase d-subunit was suppressed alone, sub-G1 fraction caused by etoposide or nocodazole was decreased in cells with galectin-3 suppression alone.	Etoposide	98-107	galectin 3	Homo sapiens	150-160
19016746-11	2008	In the presence of cell cycle synchronizing drugs, doxorubicin, etoposide, or nocodazole, suppression of galectin-3 induced cell cycle progression to G0/G1 phase.	Etoposide	64-73	galectin 3	Homo sapiens	105-115
19138287-4	2008	To our knowledge, this is the first case in which orchiectomy followed by carboplatin, etoposide and bleomycin for a testicular tumor with anti-Ma2 encephalitis was performed.	Etoposide	87-96	PNMA family member 2	Homo sapiens	144-147
18510699-1	2008	Rearrangements initiating within the well-characterized break-point cluster region of the mixed lineage leukemia (MLL) gene on 11q23 are a hallmark of therapy-related leukemias following treatment with topoisomerase II poisons including etoposide.	Etoposide	237-246	lysine methyltransferase 2A	Homo sapiens	114-117
18827617-2	2008	Beta-human chorionic gonadotropin and alpha-fetoprotein were elevated at presentation and responded to four cycles of bleomycin, etoposide, and cisplatin although the tumor did not regress.	Etoposide	129-138	alpha fetoprotein	Homo sapiens	38-55
18813358-0	2008	Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.	Etoposide	67-76	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-33
18813358-0	2008	Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.	Etoposide	67-76	thymoma viral proto-oncogene 1	Mus musculus	126-129
18813358-5	2008	Inhibition of either PI3K or Akt by synthetic inhibitors sensitized the wild type but not the PAI-1-deficient cells to etoposide-induced cell death.	Etoposide	119-128	thymoma viral proto-oncogene 1	Mus musculus	29-32
18813358-6	2008	More importantly, reintroduction of PAI-1 expression in PAI-1-deficient cells induced an increase in Akt activity and protection against etoposide-induced apoptosis.	Etoposide	137-146	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	36-41
18813358-6	2008	More importantly, reintroduction of PAI-1 expression in PAI-1-deficient cells induced an increase in Akt activity and protection against etoposide-induced apoptosis.	Etoposide	137-146	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	56-61
18813358-7	2008	Concordantly, silencing of PAI-1 by RNA interference in wild type fibrosarcoma cells decreased the level of active Akt, and this was accompanied by a sensitization of the cells to etoposide-induced cell death.	Etoposide	180-189	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	27-32
18813358-8	2008	Altogether, our data suggest that PAI-1 influences sensitivity to etoposide-induced apoptosis through the PI3K/Akt cell survival pathway by acting upstream of PI3K and Akt.	Etoposide	66-75	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	34-39
18813358-8	2008	Altogether, our data suggest that PAI-1 influences sensitivity to etoposide-induced apoptosis through the PI3K/Akt cell survival pathway by acting upstream of PI3K and Akt.	Etoposide	66-75	thymoma viral proto-oncogene 1	Mus musculus	111-114
18813358-8	2008	Altogether, our data suggest that PAI-1 influences sensitivity to etoposide-induced apoptosis through the PI3K/Akt cell survival pathway by acting upstream of PI3K and Akt.	Etoposide	66-75	thymoma viral proto-oncogene 1	Mus musculus	168-171
18728186-6	2008	Through this signaling system EPAC activation can thereby impact on the Ser-473 phosphorylation status of PKB/Akt and the repair of etoposide-induced DSBs.	Etoposide	132-141	Rap guanine nucleotide exchange factor 3	Homo sapiens	30-34
18687701-4	2008	DNA damage by etoposide causes E2F1-dependent induction of E1AF expression at transcriptional level.	Etoposide	14-23	E2F transcription factor 1 L homeolog	Xenopus laevis	31-35
18687701-5	2008	Furthermore, disruption of E1AF expression by E1AF RNAi decreased E2F1-induced apoptosis in response to etoposide.	Etoposide	104-113	E2F transcription factor 1 L homeolog	Xenopus laevis	66-70
18550533-5	2008	Treatment of chicken DT40 cells with various genotoxic agents, UV light, etoposide, or camptothecin induced Chk1 cleavage, which was inhibited by a pan-caspase inhibitor, benzyloxycarbonyl-VAD-fluoromethyl ketone.	Etoposide	73-82	opsin, green sensitive (rhodopsin-like)	Gallus gallus	108-112
18503785-7	2008	Cross-resistance to adriamycin, vincristine and etoposide (VP-16) was consistent with overexpression of P-glycoprotein (P-gp).	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
18758060-1	2008	Here, we confirmed that stable expression of B-cell lymphoma-xL (Bcl-xL) in N18TG neuroglioma cells could suppress c-Jun N-terminal protein kinase (JNK) activation, nuclear fragmentation, and cell death caused by etoposide treatment.	Etoposide	213-222	BCL2 like 1	Homo sapiens	45-63
18758060-1	2008	Here, we confirmed that stable expression of B-cell lymphoma-xL (Bcl-xL) in N18TG neuroglioma cells could suppress c-Jun N-terminal protein kinase (JNK) activation, nuclear fragmentation, and cell death caused by etoposide treatment.	Etoposide	213-222	BCL2 like 1	Homo sapiens	65-71
18510699-0	2008	Etoposide-initiated MLL rearrangements detected at high frequency in human primitive hematopoietic stem cells with in vitro and in vivo long-term repopulating potential.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	20-23
18510699-3	2008	Although etoposide treatment is sufficient to induce readily detectable MLL rearrangements in primary human CD34+ cells, the majority of cells that gain translocations do not proliferate in culture possibly due to reduced proliferative capacity of most CD34+ cells during normal differentiation [Blood 2005;105:2124].	Etoposide	9-18	lysine methyltransferase 2A	Homo sapiens	72-75
18510699-3	2008	Although etoposide treatment is sufficient to induce readily detectable MLL rearrangements in primary human CD34+ cells, the majority of cells that gain translocations do not proliferate in culture possibly due to reduced proliferative capacity of most CD34+ cells during normal differentiation [Blood 2005;105:2124].	Etoposide	9-18	CD34 molecule	Homo sapiens	108-112
18510699-3	2008	Although etoposide treatment is sufficient to induce readily detectable MLL rearrangements in primary human CD34+ cells, the majority of cells that gain translocations do not proliferate in culture possibly due to reduced proliferative capacity of most CD34+ cells during normal differentiation [Blood 2005;105:2124].	Etoposide	9-18	CD34 molecule	Homo sapiens	253-257
18510699-6	2008	Similar to results in CD34+ cells, a significant proportion of etoposide-treated HSC-derived clones harbored stable MLL rearrangements, including duplications, inversions and translocations.	Etoposide	63-72	CD34 molecule	Homo sapiens	22-26
18695893-0	2008	Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide.	Etoposide	111-120	H2A.X variant histone	Mus musculus	8-20
18695893-2	2008	Etoposide is an inhibitor of DNA topoisomerase II, which causes DNA breaks and induces H2AX phosphorylation.	Etoposide	0-9	H2A.X variant histone	Mus musculus	87-91
18695893-3	2008	To elucidate whether H2AX may affect cellular sensitivity to etoposide, we studied the response to this agent in immortalized embryonic fibroblasts derived from H2AX knockout mice.	Etoposide	61-70	H2A.X variant histone	Mus musculus	21-25
18695893-5	2008	In both cell lines, etoposide induced micronuclei formation and nuclear fragmentation; however, in H2AX deficient cells nuclear fragmentation was observed at a lower drug concentration.	Etoposide	20-29	H2A.X variant histone	Mus musculus	99-103
18695893-6	2008	Flow cytometric analysis showed that etoposide induced a G2/M cell cycle arrest in both cell lines, which occurred at lower drug concentrations in H2AX deficient cells.	Etoposide	37-46	H2A.X variant histone	Mus musculus	147-151
18695893-8	2008	Taken together, our observations suggest that H2AX takes part to the cellular response to etoposide and confirm its role in the maintenance of genome stability.	Etoposide	90-99	H2A.X variant histone	Mus musculus	46-50
18510699-6	2008	Similar to results in CD34+ cells, a significant proportion of etoposide-treated HSC-derived clones harbored stable MLL rearrangements, including duplications, inversions and translocations.	Etoposide	63-72	lysine methyltransferase 2A	Homo sapiens	116-119
18510699-7	2008	These results indicate HSC are highly susceptible to etoposide-induced and potentially oncogenic rearrangements initiating within MLL, and these HSC are particularly proficient for continued long-term proliferation both in vivo and in vitro.	Etoposide	53-62	lysine methyltransferase 2A	Homo sapiens	130-133
18698031-5	2008	RESULTS: Transient Chk1 down-regulation sensitized HCT-116 cells, p53-/- more than the p53 wild-type counterpart, to DNA-damaging agents 5-fluorouracil (5-FU), doxorubicin, and etoposide treatments, with no modification of Taxol and PS341 cytotoxic activities.	Etoposide	177-186	checkpoint kinase 1	Homo sapiens	19-23
18524851-4	2008	In contrast, ligand-dependent AHR activation protects these cells from etoposide-induced cell death.	Etoposide	71-80	aryl hydrocarbon receptor	Homo sapiens	30-33
18754885-5	2008	Anticancer drugs including doxorubicin, etoposide and 5-fluorouracil also induced cyclin G2 expression during induction of growth arrest of the MCF-7 cell at the G1 phase or G2/M phase.	Etoposide	40-49	cyclin G2	Homo sapiens	82-91
18495871-2	2008	Increased expression of nuclear Mcl-1 and/or a previously reported short nuclear form of Mcl-1, snMcl-1, was observed in response to treatment with low concentrations of etoposide or low doses of UV irradiation.	Etoposide	170-179	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	32-37
18495871-2	2008	Increased expression of nuclear Mcl-1 and/or a previously reported short nuclear form of Mcl-1, snMcl-1, was observed in response to treatment with low concentrations of etoposide or low doses of UV irradiation.	Etoposide	170-179	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	89-94
18495871-3	2008	We showed that after etoposide treatment, Mcl-1 could coimmunoprecipitate with the regulatory kinase, Chk1.	Etoposide	21-30	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	42-47
18495871-3	2008	We showed that after etoposide treatment, Mcl-1 could coimmunoprecipitate with the regulatory kinase, Chk1.	Etoposide	21-30	checkpoint kinase 1	Homo sapiens	102-106
18636193-5	2008	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay indicated that overexpression of S100P sensitized OVCAR3 cells for chemotherapeutic drugs (paclitaxel, oxaliplatin, 5-fluorouracil, etoposide and epirubicin) induced cytotoxicity more than vector-only controls.	Etoposide	197-206	S100 calcium binding protein P	Homo sapiens	98-103
18708359-7	2008	Resistance of TuBEC to chemotherapeutic agents such as CPT-11, etoposide, and temozolomide can be overcome by knockdown of GRP78 using small interfering RNA or chemical inhibition of its catalytic site.	Etoposide	63-72	heat shock protein family A (Hsp70) member 5	Homo sapiens	123-128
18665234-6	2008	While Bid-deficient cells were equally sensitive to ER stress-induced apoptosis, they showed moderate, but significantly reduced levels of apoptosis, as well as increased clonogenic survival in response to the genotoxic drugs Etoposide, Oxaliplatin, and Doxorubicin.	Etoposide	226-235	BH3 interacting domain death agonist	Homo sapiens	6-9
18665234-8	2008	Interestingly, Bid-deficient cells were dramatically protected from apoptosis when subtoxic concentrations of ER stressors, Etoposide or Oxaliplatin were combined with subtoxic TRAIL concentrations.	Etoposide	124-133	BH3 interacting domain death agonist	Homo sapiens	15-18
18626023-8	2008	Hemizygous male mutant cells showed a strikingly enhanced DNA damage response via the ATM/p53 pathway after treatment with etoposide with a significant number of DNA damage foci colocalizing with telomeres in cytological preparations.	Etoposide	123-132	transformation related protein 53, pseudogene	Mus musculus	90-93
18583959-7	2008	Apoptosis gene expression and chromatin immunoprecipitation analyses indicated that HU and the DSB inducer etoposide caused complex patterns of NF-kappaB-dependent pro- and antiapoptotic gene expression with the overall outcome for the former being pro-apoptotic, whereas the latter antiapoptotic.	Etoposide	107-116	nuclear factor kappa B subunit 1	Homo sapiens	144-153
18455292-9	2008	Etoposide strongly increased expression of IL-6 and decreased that of OPG.	Etoposide	0-9	interleukin 6	Homo sapiens	43-47
18455292-9	2008	Etoposide strongly increased expression of IL-6 and decreased that of OPG.	Etoposide	0-9	basic transcription factor 3 pseudogene 11	Homo sapiens	70-73
18455292-11	2008	Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression.	Etoposide	26-35	basic transcription factor 3 pseudogene 11	Homo sapiens	39-42
18455292-11	2008	Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression.	Etoposide	26-35	estrogen receptor 2	Homo sapiens	61-67
18455292-12	2008	E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta.	Etoposide	36-45	estrogen receptor 1	Homo sapiens	132-139
18455292-12	2008	E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta.	Etoposide	36-45	estrogen receptor 2	Homo sapiens	144-150
18455292-14	2008	In addition, E2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity.	Etoposide	36-45	small nucleolar RNA, H/ACA box 62	Homo sapiens	13-23
18455292-14	2008	In addition, E2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity.	Etoposide	36-45	interleukin 6	Homo sapiens	66-70
18455292-14	2008	In addition, E2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity.	Etoposide	36-45	basic transcription factor 3 pseudogene 11	Homo sapiens	87-90
18455292-15	2008	These anti-resorptive effects of E2 and Osp upon etoposide challenge differed from each other and they seemed to be differentially mediated in ERalpha and ERbeta expressing osteoblast-derived U2OS cells.	Etoposide	49-58	small nucleolar RNA, H/ACA box 62	Homo sapiens	33-43
18612434-4	2008	Furthermore, LC-CD133(+), unlike LC-CD133(-), highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy.	Etoposide	182-191	prominin 1	Homo sapiens	16-21
18628477-10	2008	Slug down-regulation increased sensitivity to apoptosis induced by imatinib mesylate, etoposide, or doxorubicin.	Etoposide	86-95	snail family transcriptional repressor 2	Homo sapiens	0-4
18590557-2	2008	Here, we investigate the clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel, doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.	Etoposide	220-229	diablo IAP-binding mitochondrial protein	Homo sapiens	51-99
19007041-1	2008	Etoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp).	Etoposide	0-9	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	35-59
19007041-1	2008	Etoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp).	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	83-97
19007041-1	2008	Etoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp).	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	99-103
18573848-5	2008	Chemotherapy consisted of ifosfamide, cisplatin and etoposide (ICE chemotherapy).	Etoposide	52-61	carboxylesterase 2	Homo sapiens	63-66
18594537-0	2008	Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine.	Etoposide	98-107	tumor protein p53	Homo sapiens	11-14
18398293-7	2008	We also noticed that the content of mitochondrial EGFR transfer is decreased when the cells are exposed to the apoptotic inducer etoposide.	Etoposide	129-138	epidermal growth factor receptor	Homo sapiens	50-54
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	BRCA2 DNA repair associated	Homo sapiens	30-35
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	BRCA2 DNA repair associated	Homo sapiens	61-66
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	RAD51 recombinase	Homo sapiens	127-132
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	BRCA2 DNA repair associated	Homo sapiens	61-66
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	BRCA2 DNA repair associated	Homo sapiens	61-66
18593900-5	2008	We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function.	Etoposide	233-242	BRCA2 DNA repair associated	Homo sapiens	61-66
18200038-0	2008	A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.	Etoposide	31-40	ATM serine/threonine kinase	Homo sapiens	90-93
18200038-0	2008	A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.	Etoposide	31-40	tumor protein p53	Homo sapiens	98-102
18590557-2	2008	Here, we investigate the clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel, doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.	Etoposide	220-229	diablo IAP-binding mitochondrial protein	Homo sapiens	101-105
18590557-2	2008	Here, we investigate the clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel, doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.	Etoposide	220-229	diablo IAP-binding mitochondrial protein	Homo sapiens	106-112
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Etoposide	174-183	diablo IAP-binding mitochondrial protein	Homo sapiens	27-31
18590557-6	2008	RESULTS: Overexpression of Smac/DIABLO gene (full-length or Delta55 Smac/DIABLO) or treatment with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide, tamoxifen, and irradiation in breast cancer cells.	Etoposide	174-183	diablo IAP-binding mitochondrial protein	Homo sapiens	32-38
18434324-5	2008	The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA.	Etoposide	28-37	protein kinase C delta	Homo sapiens	120-128
18434324-0	2008	Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide.	Etoposide	172-181	protein kinase C delta	Homo sapiens	19-40
18434324-0	2008	Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide.	Etoposide	172-181	mitogen-activated protein kinase 3	Homo sapiens	103-109
18434324-5	2008	The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA.	Etoposide	28-37	protein kinase C delta	Homo sapiens	120-128
18434324-0	2008	Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide.	Etoposide	172-181	dual specificity phosphatase 1	Homo sapiens	133-138
18434324-6	2008	We recently reported that phosphorylation of PKCdelta on tyrosines 64 and 187 was essential for the apoptotic effect of etoposide.	Etoposide	120-129	protein kinase C delta	Homo sapiens	45-53
18434324-1	2008	The mechanism underlying the important role of protein kinase Cdelta (PKCdelta) in the apoptotic effect of etoposide in glioma cells is incompletely understood.	Etoposide	107-116	protein kinase C delta	Homo sapiens	47-68
18434324-1	2008	The mechanism underlying the important role of protein kinase Cdelta (PKCdelta) in the apoptotic effect of etoposide in glioma cells is incompletely understood.	Etoposide	107-116	protein kinase C delta	Homo sapiens	70-78
18434324-7	2008	Using PKCdeltatyrosine mutants, we found that the phosphorylation of PKCdeltaon these tyrosine residues, but not on tyrosine 155, was also essential for the activation of Erk1/2 by etoposide.	Etoposide	181-190	mitogen-activated protein kinase 3	Homo sapiens	171-177
18434324-2	2008	Here, we examined the role of PKCdelta in the activation of Erk1/2 by etoposide.	Etoposide	70-79	protein kinase C delta	Homo sapiens	30-38
18434324-9	2008	Etoposide induced down-regulation of kinase phosphatase-1 (MKP-1), which correlated with persistent phosphorylation of Erk1/2 and was dependent on the tyrosine phosphorylation of PKCdelta.	Etoposide	0-9	dual specificity phosphatase 1	Homo sapiens	59-64
18434324-2	2008	Here, we examined the role of PKCdelta in the activation of Erk1/2 by etoposide.	Etoposide	70-79	mitogen-activated protein kinase 3	Homo sapiens	60-66
18434324-3	2008	We found that etoposide induced persistent activation of Erk1/2 and nuclear translocation of phospho-Erk1/2.	Etoposide	14-23	mitogen-activated protein kinase 3	Homo sapiens	57-63
18434324-3	2008	We found that etoposide induced persistent activation of Erk1/2 and nuclear translocation of phospho-Erk1/2.	Etoposide	14-23	mitogen-activated protein kinase 3	Homo sapiens	101-107
18434324-9	2008	Etoposide induced down-regulation of kinase phosphatase-1 (MKP-1), which correlated with persistent phosphorylation of Erk1/2 and was dependent on the tyrosine phosphorylation of PKCdelta.	Etoposide	0-9	mitogen-activated protein kinase 3	Homo sapiens	119-125
18434324-9	2008	Etoposide induced down-regulation of kinase phosphatase-1 (MKP-1), which correlated with persistent phosphorylation of Erk1/2 and was dependent on the tyrosine phosphorylation of PKCdelta.	Etoposide	0-9	protein kinase C delta	Homo sapiens	179-187
18434324-4	2008	MEK1 inhibitors decreased the apoptotic effect of etoposide, whereas inhibitors of p38 and JNK did not.	Etoposide	50-59	mitogen-activated protein kinase kinase 1	Homo sapiens	0-4
18434324-5	2008	The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA.	Etoposide	28-37	mitogen-activated protein kinase 3	Homo sapiens	18-24
18434324-10	2008	Moreover, silencing of MKP-1 increased the phosphorylation of Erk1/2 and the apoptotic effect of etoposide.	Etoposide	97-106	dual specificity phosphatase 1	Homo sapiens	23-28
18434324-5	2008	The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA.	Etoposide	28-37	protein kinase C delta	Homo sapiens	56-64
18434324-11	2008	Etoposide induced polyubiquitylation and degradation of MKP-1 that was dependent on PKCdelta and on its tyrosine phosphorylation.	Etoposide	0-9	dual specificity phosphatase 1	Homo sapiens	56-61
18434324-5	2008	The activation of Erk1/2 by etoposide was downstream of PKCdelta since the phosphorylation of Erk1/2 was inhibited by a PKCdelta-KD mutant and PKCdelta small interfering RNA.	Etoposide	28-37	mitogen-activated protein kinase 3	Homo sapiens	94-100
18434324-11	2008	Etoposide induced polyubiquitylation and degradation of MKP-1 that was dependent on PKCdelta and on its tyrosine phosphorylation.	Etoposide	0-9	protein kinase C delta	Homo sapiens	84-92
18375382-5	2008	Under conditions when the expression of endogenous c-Myc, caspase-2, or Apaf-1 is reduced 80-90%, cisplatin (or etoposide)-induced apoptosis is significantly decreased.	Etoposide	112-121	apoptotic peptidase activating factor 1	Homo sapiens	72-78
18559532-4	2008	In this study, we show that Tax sensitizes p53-mutant cells to a broad range of DNA-damaging agents, including mitomycin C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing radiation, a double-strand break agent, or vinblastine, a tubulin poison.	Etoposide	150-159	tumor protein p53	Homo sapiens	43-46
18421578-11	2008	MEK kinase 1 (MEKK1) is a serine threonine kinase that is activated following etoposide treatment and activates NF-kappaB.	Etoposide	78-87	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	14-19
18421578-11	2008	MEK kinase 1 (MEKK1) is a serine threonine kinase that is activated following etoposide treatment and activates NF-kappaB.	Etoposide	78-87	nuclear factor kappa B subunit 1	Homo sapiens	112-121
18421578-12	2008	Expression of the kinase inactive MEKK1 (MEKK1-KM) abrogates the up-regulation of DR4 after etoposide treatment.	Etoposide	92-101	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	34-39
18421578-12	2008	Expression of the kinase inactive MEKK1 (MEKK1-KM) abrogates the up-regulation of DR4 after etoposide treatment.	Etoposide	92-101	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	41-46
18421578-12	2008	Expression of the kinase inactive MEKK1 (MEKK1-KM) abrogates the up-regulation of DR4 after etoposide treatment.	Etoposide	92-101	TNF receptor superfamily member 10a	Homo sapiens	82-85
18421578-13	2008	Taken together, NF-kappaB plays a role in up-regulation of DR4 following etoposide treatment.	Etoposide	73-82	nuclear factor kappa B subunit 1	Homo sapiens	16-25
18421578-13	2008	Taken together, NF-kappaB plays a role in up-regulation of DR4 following etoposide treatment.	Etoposide	73-82	TNF receptor superfamily member 10a	Homo sapiens	59-62
18413364-7	2008	In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide.	Etoposide	195-204	NFE2 like bZIP transcription factor 2	Homo sapiens	47-51
18413364-7	2008	In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide.	Etoposide	195-204	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
18403493-3	2008	Overexpression of GRP78 in glioma cells decreases caspase 7 activation and renders the cells resistant to etoposide- and cisplatin-induced apoptosis, whereas silencing of GRP78 decreases cell growth and sensitizes glioma cells to etoposide, cisplatin, and gamma-radiation.	Etoposide	106-115	heat shock protein family A (Hsp70) member 5	Homo sapiens	18-23
18403493-3	2008	Overexpression of GRP78 in glioma cells decreases caspase 7 activation and renders the cells resistant to etoposide- and cisplatin-induced apoptosis, whereas silencing of GRP78 decreases cell growth and sensitizes glioma cells to etoposide, cisplatin, and gamma-radiation.	Etoposide	230-239	heat shock protein family A (Hsp70) member 5	Homo sapiens	18-23
18375382-5	2008	Under conditions when the expression of endogenous c-Myc, caspase-2, or Apaf-1 is reduced 80-90%, cisplatin (or etoposide)-induced apoptosis is significantly decreased.	Etoposide	112-121	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
18375382-5	2008	Under conditions when the expression of endogenous c-Myc, caspase-2, or Apaf-1 is reduced 80-90%, cisplatin (or etoposide)-induced apoptosis is significantly decreased.	Etoposide	112-121	caspase 2	Homo sapiens	58-67
18560576-7	2008	Moreover, HDAC inhibitor showed selective synergy with nucleoside analog-induced DNA damage to inhibit cell proliferation, but showed no such effect with other DNA damage stresses such as gamma-ray and UV, etoposide or cisplatin.	Etoposide	206-215	histone deacetylase 9	Homo sapiens	10-14
18523641-0	2008	Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity.	Etoposide	69-78	mitogen-activated protein kinase 14	Mus musculus	14-22
18523641-8	2008	Using these cells we assessed the requirement of etoposide, doxorubicin, 5-fluorouracil, and docetaxel for p38 MAPK in inflammatory cytokine production and cytotoxicity.	Etoposide	49-58	mitogen-activated protein kinase 14	Mus musculus	107-115
18523641-9	2008	Study findings demonstrate that clinically relevant doses of etoposide, doxorubicin, and 5-FU activated p38 MAPK in both macrophages and LLC1 cells.	Etoposide	61-70	mitogen-activated protein kinase 14	Mus musculus	104-112
18421578-0	2008	Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.	Etoposide	96-105	TNF receptor superfamily member 10a	Homo sapiens	0-16
18421578-0	2008	Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.	Etoposide	96-105	TNF receptor superfamily member 10a	Homo sapiens	18-21
18421578-0	2008	Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.	Etoposide	96-105	nuclear factor kappa B subunit 1	Homo sapiens	71-80
18421578-2	2008	DNA damaging agents (genotoxins) such as etoposide increase DR4 expression and when combined with TRAIL induce a synergistic apoptotic response.	Etoposide	41-50	TNF receptor superfamily member 10a	Homo sapiens	60-63
18421578-5	2008	Increased expression of DR4 following etoposide treatment is blocked by inhibition of the NF-kappaB pathway.	Etoposide	38-47	TNF receptor superfamily member 10a	Homo sapiens	24-27
18421578-5	2008	Increased expression of DR4 following etoposide treatment is blocked by inhibition of the NF-kappaB pathway.	Etoposide	38-47	nuclear factor kappa B subunit 1	Homo sapiens	90-99
18421578-7	2008	Indeed, knockdown of p65 by RNA interference blocked etoposide up-regulation of DR4.	Etoposide	53-62	RELA proto-oncogene, NF-kB subunit	Homo sapiens	21-24
18421578-7	2008	Indeed, knockdown of p65 by RNA interference blocked etoposide up-regulation of DR4.	Etoposide	53-62	TNF receptor superfamily member 10a	Homo sapiens	80-83
18421578-10	2008	Furthermore, electromobility shift assays and chromatin immunoprecipitaton suggest that NF-kappaB binds to this site upon etoposide treatment.	Etoposide	122-131	nuclear factor kappa B subunit 1	Homo sapiens	88-97
18421578-11	2008	MEK kinase 1 (MEKK1) is a serine threonine kinase that is activated following etoposide treatment and activates NF-kappaB.	Etoposide	78-87	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	0-12
18567557-1	2008	BACKGROUND: ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) plus granulocyte-colony stimulating factor (G-CSF) is an effective regimen of therapy for advanced non-Hodgkin"s lymphoma (NHL) and peripheral blood progenitor cell (PBPC) mobilization.	Etoposide	19-28	colony stimulating factor 3	Homo sapiens	114-119
18282684-0	2008	Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplasic cell line.	Etoposide	76-85	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
18282684-0	2008	Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplasic cell line.	Etoposide	87-91	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
18071312-0	2008	Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.	Etoposide	62-71	apoptosis inducing factor mitochondria associated 1	Homo sapiens	97-100
18183572-4	2008	But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer.	Etoposide	56-65	host cell factor C1	Homo sapiens	49-54
18183572-4	2008	But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer.	Etoposide	56-65	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	156-159
18183572-4	2008	But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer.	Etoposide	56-65	RUNX family transcription factor 1	Homo sapiens	192-196
18183572-4	2008	But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer.	Etoposide	56-65	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	201-204
18494554-4	2008	METHODS AND FINDINGS: Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin.	Etoposide	195-204	vascular endothelial growth factor A	Homo sapiens	35-39
18494554-4	2008	METHODS AND FINDINGS: Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin.	Etoposide	195-204	vascular endothelial growth factor A	Homo sapiens	45-49
18071312-3	2008	Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells.	Etoposide	37-46	histone deacetylase 9	Homo sapiens	62-85
18071312-4	2008	Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.	Etoposide	45-49	BCL2 like 1	Homo sapiens	143-149
18071312-4	2008	Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.	Etoposide	45-49	BCL2 associated X, apoptosis regulator	Homo sapiens	170-173
18071312-4	2008	Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.	Etoposide	45-49	apoptosis inducing factor mitochondria associated 1	Homo sapiens	218-243
18071312-4	2008	Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducing factor (AIF)-dependent death pathway.	Etoposide	45-49	apoptosis inducing factor mitochondria associated 1	Homo sapiens	245-248
18373075-0	2008	Bid exhibits S phase checkpoint activation and plays a pro-apoptotic role in response to etoposide-induced DNA damage in hepatocellular carcinoma cells.	Etoposide	89-98	BH3 interacting domain death agonist	Homo sapiens	0-3
18373075-2	2008	The role of Bid in etoposide-induced-DNA damage in HCC has not been investigated.	Etoposide	19-28	BH3 interacting domain death agonist	Homo sapiens	12-15
18373075-4	2008	Upon the administration of a high dose of etoposide (causing irreparable damage), Bid sensitized cells to apoptosis.	Etoposide	42-51	BH3 interacting domain death agonist	Homo sapiens	82-85
18373075-5	2008	However, at a low dose of etoposide (repairable damage), Bid activated the S phase checkpoint through the up-regulation of p21 and p27, which are both p53-independent.	Etoposide	26-35	BH3 interacting domain death agonist	Homo sapiens	57-60
18373075-5	2008	However, at a low dose of etoposide (repairable damage), Bid activated the S phase checkpoint through the up-regulation of p21 and p27, which are both p53-independent.	Etoposide	26-35	H3 histone pseudogene 16	Homo sapiens	123-126
18373075-5	2008	However, at a low dose of etoposide (repairable damage), Bid activated the S phase checkpoint through the up-regulation of p21 and p27, which are both p53-independent.	Etoposide	26-35	interferon alpha inducible protein 27	Homo sapiens	131-134
18373075-5	2008	However, at a low dose of etoposide (repairable damage), Bid activated the S phase checkpoint through the up-regulation of p21 and p27, which are both p53-independent.	Etoposide	26-35	tumor protein p53	Homo sapiens	151-154
18373075-7	2008	In conclusion, our study demonstrates that Bid both exhibits S phase checkpoint activation and plays a pro-apoptotic role in response to different degrees of etoposide-induced DNA damage in HCC cells.	Etoposide	158-167	BH3 interacting domain death agonist	Homo sapiens	43-46
18270325-5	2008	Similarly, the chemotherapeutic agent etoposide induced Txnip expression en route to apoptosis, which was blocked by inhibitors of ceramide production.	Etoposide	38-47	thioredoxin interacting protein	Homo sapiens	56-61
18431490-11	2008	First, etoposide induced ATM-dependent phosphorylation of AMPK alpha subunit at Thr172, indicative of AMPK activation.	Etoposide	7-16	ATM serine/threonine kinase	Homo sapiens	25-28
18431490-14	2008	CONCLUSIONS/SIGNIFICANCE: These results suggest that activation of ATM by etoposide can lead to mitochondrial biogenesis through AMPK activation.	Etoposide	74-83	ATM serine/threonine kinase	Homo sapiens	67-70
18080832-6	2008	We found that administration of various apoptosis inducing agents and conditions (serum starvation, anisomycin, LY294002, etoposide, and cisplatin) led to the proteolytic cleavage of PKR in PC12 cells.	Etoposide	122-131	eukaryotic translation initiation factor 2-alpha kinase 2	Rattus norvegicus	183-186
18080832-10	2008	The activation of caspase-3 preceded the cleavage of PKR after serum withdrawal, anisomycin and etoposide treatment, while coincided with it in cells treated with LY294002 or cisplatin.	Etoposide	96-105	caspase 3	Rattus norvegicus	18-27
18080832-10	2008	The activation of caspase-3 preceded the cleavage of PKR after serum withdrawal, anisomycin and etoposide treatment, while coincided with it in cells treated with LY294002 or cisplatin.	Etoposide	96-105	eukaryotic translation initiation factor 2-alpha kinase 2	Rattus norvegicus	53-56
18431490-0	2008	Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation.	Etoposide	0-9	ATM serine/threonine kinase	Homo sapiens	18-21
18431490-6	2008	Here we provide evidence for a novel role of ATM in mitochondrial biogenesis through AMPK activation in response to etoposide-induced DNA damage.	Etoposide	116-125	ATM serine/threonine kinase	Homo sapiens	45-48
18431490-8	2008	Cells treated with etoposide exhibited an ATM-dependent increase in mitochondrial mass as measured by 10-N-Nonyl-Acridine Orange and MitoTracker Green FM staining, as well as an increase in mitochondrial DNA content.	Etoposide	19-28	ATM serine/threonine kinase	Homo sapiens	42-45
18431490-9	2008	In addition, the expression of several known mitochondrial biogenesis regulators such as the major mitochondrial transcription factor NRF-1, PGC-1alpha and TFAM was also elevated in response to etoposide treatment as monitored by RT-PCR.	Etoposide	194-203	nuclear respiratory factor 1	Homo sapiens	134-139
18431490-9	2008	In addition, the expression of several known mitochondrial biogenesis regulators such as the major mitochondrial transcription factor NRF-1, PGC-1alpha and TFAM was also elevated in response to etoposide treatment as monitored by RT-PCR.	Etoposide	194-203	PPARG coactivator 1 alpha	Homo sapiens	141-151
18431490-9	2008	In addition, the expression of several known mitochondrial biogenesis regulators such as the major mitochondrial transcription factor NRF-1, PGC-1alpha and TFAM was also elevated in response to etoposide treatment as monitored by RT-PCR.	Etoposide	194-203	transcription factor A, mitochondrial	Homo sapiens	156-160
18431490-10	2008	Three pieces of evidence suggest that etoposide-induced mitochondrial biogenesis is due to ATM-dependent activation of AMPK.	Etoposide	38-47	ATM serine/threonine kinase	Homo sapiens	91-94
18270325-10	2008	Taken together, we show that ceramide exhibits a mechanism of transcriptional regulation involving up-regulation of Txnip expression, also induced by etoposide, which results in ASK1 activation, ER stress, and p38 and JNK phosphorylation, all leading to apoptosis.	Etoposide	150-159	mitogen-activated protein kinase 8	Homo sapiens	218-221
18270325-10	2008	Taken together, we show that ceramide exhibits a mechanism of transcriptional regulation involving up-regulation of Txnip expression, also induced by etoposide, which results in ASK1 activation, ER stress, and p38 and JNK phosphorylation, all leading to apoptosis.	Etoposide	150-159	thioredoxin interacting protein	Homo sapiens	116-121
18270325-10	2008	Taken together, we show that ceramide exhibits a mechanism of transcriptional regulation involving up-regulation of Txnip expression, also induced by etoposide, which results in ASK1 activation, ER stress, and p38 and JNK phosphorylation, all leading to apoptosis.	Etoposide	150-159	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	178-182
18270325-10	2008	Taken together, we show that ceramide exhibits a mechanism of transcriptional regulation involving up-regulation of Txnip expression, also induced by etoposide, which results in ASK1 activation, ER stress, and p38 and JNK phosphorylation, all leading to apoptosis.	Etoposide	150-159	mitogen-activated protein kinase 14	Homo sapiens	210-213
17610126-0	2008	Inducible expression of maize polyamine oxidase in the nucleus of MCF-7 human breast cancer cells confers sensitivity to etoposide.	Etoposide	121-130	polyamine oxidase 1	Zea mays	30-47
18096571-3	2008	Employing the Mdm2 2A10 antibody and phosphatase treatment we found that Mdm2 accumulated in HepG2 cells when exposed to low concentrations of genotoxic compounds such as mitomycin C, etoposide, 5-fluorouracil, and benzo[a]pyrene (BP).	Etoposide	184-193	MDM2 proto-oncogene	Homo sapiens	73-77
18071290-0	2008	Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin"s lymphoma.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
18381449-4	2008	Here, we provide biochemical and cytologic evidence that topoisomerase 2 alpha is conjugated to SUMO-2/3 during interphase and mitosis in response to topoisomerase 2 inhibitors and "poisons" (ICRF-187, etoposide, doxorubicin) that stabilize catalytic intermediates (cleavage complexes, closed clamp forms) of the enzyme onto target DNA.	Etoposide	202-211	small ubiquitin like modifier 2	Homo sapiens	96-102
17941090-0	2008	Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator.	Etoposide	0-9	heat shock protein family A (Hsp70) member 5	Homo sapiens	114-119
17941090-2	2008	The induction of drug resistance can be partly explained by the fact that GRP78 can block activation of caspase-7 induced by treatment with etoposide.	Etoposide	140-149	heat shock protein family A (Hsp70) member 5	Homo sapiens	74-79
17941090-2	2008	The induction of drug resistance can be partly explained by the fact that GRP78 can block activation of caspase-7 induced by treatment with etoposide.	Etoposide	140-149	caspase 7	Homo sapiens	104-113
18285460-3	2008	The depletion of Rvb1 increases the amount and persistence of phosphorylation on chromatin-associated H2AX after the exposure of cells to UV irradiation or to mitomycin C, cisplatin, camptothecin, or etoposide, without increasing the amount of DNA damage.	Etoposide	200-209	RuvB like AAA ATPase 1	Homo sapiens	17-21
18285460-3	2008	The depletion of Rvb1 increases the amount and persistence of phosphorylation on chromatin-associated H2AX after the exposure of cells to UV irradiation or to mitomycin C, cisplatin, camptothecin, or etoposide, without increasing the amount of DNA damage.	Etoposide	200-209	H2A.X variant histone	Homo sapiens	102-106
18330707-5	2008	ISG12a enhanced etoposide induced cytochrome c release, Bax activation and loss of mitochondrial membrane potential.	Etoposide	16-25	interferon alpha inducible protein 27	Homo sapiens	0-6
18330707-5	2008	ISG12a enhanced etoposide induced cytochrome c release, Bax activation and loss of mitochondrial membrane potential.	Etoposide	16-25	cytochrome c, somatic	Homo sapiens	34-46
18330707-5	2008	ISG12a enhanced etoposide induced cytochrome c release, Bax activation and loss of mitochondrial membrane potential.	Etoposide	16-25	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
18330707-6	2008	siRNA-mediated inhibition of ectopic ISG12a protein expression prevented the sensitization to etoposide-induced apoptosis and also decreased the ability of IFN-beta pretreatment to sensitize cells to etoposide, thereby demonstrating a role for ISG12a in this process.	Etoposide	94-103	interferon alpha inducible protein 27	Homo sapiens	37-43
18330707-6	2008	siRNA-mediated inhibition of ectopic ISG12a protein expression prevented the sensitization to etoposide-induced apoptosis and also decreased the ability of IFN-beta pretreatment to sensitize cells to etoposide, thereby demonstrating a role for ISG12a in this process.	Etoposide	200-209	interferon alpha inducible protein 27	Homo sapiens	37-43
18330707-6	2008	siRNA-mediated inhibition of ectopic ISG12a protein expression prevented the sensitization to etoposide-induced apoptosis and also decreased the ability of IFN-beta pretreatment to sensitize cells to etoposide, thereby demonstrating a role for ISG12a in this process.	Etoposide	200-209	interferon beta 1	Homo sapiens	156-164
17579865-1	2008	BACKGROUND: The addition of etoposide to the CHOP protocol (CHOEP) has been shown to improve outcome in patients with aggressive non-Hodgkin"s lymphoma.	Etoposide	28-37	DNA damage inducible transcript 3	Homo sapiens	45-49
18258603-2	2008	Our previous study demonstrated that silencing of the AChE gene blocked the interaction between cytochrome c and apoptotic protease-activating factor-1 (Apaf-1) in etoposide-induced apoptosis of HT-29 cells.	Etoposide	164-173	acetylcholinesterase (Cartwright blood group)	Homo sapiens	54-58
18258603-2	2008	Our previous study demonstrated that silencing of the AChE gene blocked the interaction between cytochrome c and apoptotic protease-activating factor-1 (Apaf-1) in etoposide-induced apoptosis of HT-29 cells.	Etoposide	164-173	cytochrome c, somatic	Homo sapiens	96-108
18258603-2	2008	Our previous study demonstrated that silencing of the AChE gene blocked the interaction between cytochrome c and apoptotic protease-activating factor-1 (Apaf-1) in etoposide-induced apoptosis of HT-29 cells.	Etoposide	164-173	apoptotic peptidase activating factor 1	Homo sapiens	113-151
18258603-2	2008	Our previous study demonstrated that silencing of the AChE gene blocked the interaction between cytochrome c and apoptotic protease-activating factor-1 (Apaf-1) in etoposide-induced apoptosis of HT-29 cells.	Etoposide	164-173	apoptotic peptidase activating factor 1	Homo sapiens	153-159
18059034-7	2008	In addition, hSRBC elevated apoptotic sensitivity of tumor cells to genotoxic agents, such as 5-FU, etoposide and ultraviolet.	Etoposide	100-109	caveolae associated protein 3	Homo sapiens	13-18
18206427-8	2008	Etoposide-induced phosphorylation of p53 relied mainly on RIP, whereas activation of Chk1, Chk2 depended largely on TIP.	Etoposide	0-9	tumor protein p53	Homo sapiens	37-40
18174237-2	2008	Here, we showed that lack of Bcl-2-interacting mediator of cell death (Bim)(EL) protein expression, a BH3-only member of the Bcl-2 family proteins, conferred resistance of a T-ALL cell line, Sup-T1, to etoposide-induced apoptosis.	Etoposide	202-211	BCL2 like 11	Homo sapiens	29-69
18174237-6	2008	Pretreatment of Sup-T1 cells with a specific JNK inhibitor, SP600125, also increased the Bim(EL) level and resensitized the cells to etoposide-induced apoptosis.	Etoposide	133-142	mitogen-activated protein kinase 8	Homo sapiens	45-48
18377724-6	2008	CAS overexpression enhanced p53 accumulation induced by doxorubicin, 5-fluorouracil, cisplatin, tamoxifen, and etoposide.	Etoposide	111-120	chromosome segregation 1 like	Homo sapiens	0-3
18377724-6	2008	CAS overexpression enhanced p53 accumulation induced by doxorubicin, 5-fluorouracil, cisplatin, tamoxifen, and etoposide.	Etoposide	111-120	tumor protein p53	Homo sapiens	28-31
18366759-6	2008	Of note is the inhibition of the etoposide-induced activation of p53 under hypoxia.	Etoposide	33-42	tumor protein p53	Homo sapiens	65-68
18366759-8	2008	Cluster analysis of data unravels several possible pathways involved in the hypoxia-induced protection against etoposide-induced apoptosis: one of them could be the inhibition of p53 activity under hypoxia since caspase 3 activity parallels Bax and Bak expression profile.	Etoposide	111-120	tumor protein p53	Homo sapiens	179-182
18366759-8	2008	Cluster analysis of data unravels several possible pathways involved in the hypoxia-induced protection against etoposide-induced apoptosis: one of them could be the inhibition of p53 activity under hypoxia since caspase 3 activity parallels Bax and Bak expression profile.	Etoposide	111-120	caspase 3	Homo sapiens	212-221
18366759-8	2008	Cluster analysis of data unravels several possible pathways involved in the hypoxia-induced protection against etoposide-induced apoptosis: one of them could be the inhibition of p53 activity under hypoxia since caspase 3 activity parallels Bax and Bak expression profile.	Etoposide	111-120	BCL2 associated X, apoptosis regulator	Homo sapiens	241-244
18366759-8	2008	Cluster analysis of data unravels several possible pathways involved in the hypoxia-induced protection against etoposide-induced apoptosis: one of them could be the inhibition of p53 activity under hypoxia since caspase 3 activity parallels Bax and Bak expression profile.	Etoposide	111-120	BCL2 antagonist/killer 1	Homo sapiens	249-252
18309293-3	2008	Using Xenopus laevis egg extracts, we demonstrate that Plx1, the Xenopus orthologue of Plk1, is required for DNA replication in the presence of stalled replication forks induced by aphidicolin, etoposide or reduced levels of DNA-bound Mcm complexes.	Etoposide	194-203	polo like kinase 1 L homeolog	Xenopus laevis	55-59
18309293-3	2008	Using Xenopus laevis egg extracts, we demonstrate that Plx1, the Xenopus orthologue of Plk1, is required for DNA replication in the presence of stalled replication forks induced by aphidicolin, etoposide or reduced levels of DNA-bound Mcm complexes.	Etoposide	194-203	polo like kinase 1 L homeolog	Xenopus laevis	87-91
18166153-6	2008	In osteoblast apoptosis assay, only sFRP-3 increased etoposide-induced apoptosis in MC3T3-E1 mouse osteoblasts.	Etoposide	53-62	frizzled-related protein	Mus musculus	36-42
21885003-5	2008	Several layers of evidence indicate that ERCC1 mRNA expression could be a predictive marker for cisplatin alone or in combination with certain drugs such as etoposide, gemcitabine, and 5-fluorouracil but not in combination with antimicrotubule drugs.	Etoposide	157-166	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
18206427-8	2008	Etoposide-induced phosphorylation of p53 relied mainly on RIP, whereas activation of Chk1, Chk2 depended largely on TIP.	Etoposide	0-9	TOR signaling pathway regulator	Homo sapiens	116-119
18206427-9	2008	Both RIP and TIP played roles in activating non-homologous end joining pathway, while only RIP modulated etoposide-induced cell killing in a p53-dependent manner.	Etoposide	105-114	tumor protein p53	Homo sapiens	141-144
18292947-3	2008	PSP treatment enhanced the cytotoxicity of doxorubicin (Doxo), etoposide (VP-16) but not cytarabine (Ara-C).	Etoposide	63-72	host cell factor C1	Homo sapiens	74-79
17918772-0	2008	Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.	Etoposide	52-61	colony stimulating factor 3	Homo sapiens	67-104
17918772-2	2008	We previously reported the effectiveness of low dose cytarabine (Ara-C) and etoposide (VP-16) (AV therapy) for those elderly AML patients ineligible for intensive chemotherapy.	Etoposide	76-85	host cell factor C1	Homo sapiens	87-92
18292948-6	2008	Transduction of one each of WT1 isoforms with exon 5 [17AA(+)KTS(+) and 17AA(+)KTS(-)] prevented mitochondrial damage induced by ETP or TRAIL and inhibited apoptosis.	Etoposide	129-132	WT1 transcription factor	Homo sapiens	28-31
18164262-4	2008	Our results show that etoposide treatment caused a rapid increase in eIF-4E phosphorylation.	Etoposide	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
17920123-6	2008	In the present studies, we examined the effects of chemopreventive agents, paclitaxel, etoposide and 5-fluorouracil, on the surface expression of programmed death-1-ligand 1 (PD-L1), a negative regulator of T cell anti-tumor immunity.	Etoposide	87-96	CD274 molecule	Homo sapiens	146-173
17920123-6	2008	In the present studies, we examined the effects of chemopreventive agents, paclitaxel, etoposide and 5-fluorouracil, on the surface expression of programmed death-1-ligand 1 (PD-L1), a negative regulator of T cell anti-tumor immunity.	Etoposide	87-96	CD274 molecule	Homo sapiens	175-180
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	Etoposide	65-74	mitogen-activated protein kinase 8	Homo sapiens	11-14
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	Etoposide	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	83-89
17487491-5	2008	RESULTS AND CONCLUSIONS: The results showed that PAP changes in all cell lines, in response to apoptosis induced by etoposide, in many cases even prior to hallmarks of apoptosis (endonucleosomal cleavage of DNA, DeltaPsi(m) reduction).	Etoposide	116-125	poly(A) polymerase alpha	Homo sapiens	49-52
18305397-0	2008	Etoposide-induced Smad6 expression is required for the G1 to S phase transition of the cell cycle in CMT-93 mouse intestinal epithelial cells.	Etoposide	0-9	SMAD family member 6	Mus musculus	18-23
18305397-3	2008	Here we demonstrate that etoposide, which induces double strand breaks during DNA replication, significantly up-regulates the transcription of the Smad6 gene in CMT-93 mouse intestinal cells by increasing specific DNA binding proteins.	Etoposide	25-34	SMAD family member 6	Mus musculus	147-152
18305397-5	2008	These findings strongly suggest that Smad6 plays a distinct role in the signaling of etoposide-induced DNA damage.	Etoposide	85-94	SMAD family member 6	Mus musculus	37-42
18191951-0	2008	Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway.	Etoposide	25-34	tumor protein p53	Homo sapiens	91-94
18191951-4	2008	IFNalpha enhanced etoposide-induced growth inhibition and apoptosis in p53-wild U2OS cells but not p53-mutant MG63 cells in a dose- and time-dependent manner.	Etoposide	18-27	interferon alpha 1	Homo sapiens	0-8
18191951-4	2008	IFNalpha enhanced etoposide-induced growth inhibition and apoptosis in p53-wild U2OS cells but not p53-mutant MG63 cells in a dose- and time-dependent manner.	Etoposide	18-27	tumor protein p53	Homo sapiens	71-74
18191951-5	2008	Etoposide-induced G2/M phase arrest was also enhanced by IFNalpha.	Etoposide	0-9	interferon alpha 1	Homo sapiens	57-65
18191951-7	2008	IFNalpha also activated caspases-3, -8 and -9 protein kinases and PARP cleavage in response to etoposide in U2OS cells.	Etoposide	95-104	interferon alpha 1	Homo sapiens	0-8
18191951-7	2008	IFNalpha also activated caspases-3, -8 and -9 protein kinases and PARP cleavage in response to etoposide in U2OS cells.	Etoposide	95-104	caspase 3	Homo sapiens	24-45
18191951-7	2008	IFNalpha also activated caspases-3, -8 and -9 protein kinases and PARP cleavage in response to etoposide in U2OS cells.	Etoposide	95-104	collagen type XI alpha 2 chain	Homo sapiens	66-70
18191951-9	2008	Thus we conclude that IFNalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent and caspase-activation pathway.	Etoposide	40-49	interferon alpha 1	Homo sapiens	22-30
18191951-9	2008	Thus we conclude that IFNalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent and caspase-activation pathway.	Etoposide	40-49	tumor protein p53	Homo sapiens	106-109
18319618-3	2008	HAX-1 was cleaved by CASP3 during etoposide-(ETO) induced apoptosis, and this event was inhibited by a CASP3-specific inhibitor.	Etoposide	34-44	HCLS1 associated protein X-1	Homo sapiens	0-5
18319618-3	2008	HAX-1 was cleaved by CASP3 during etoposide-(ETO) induced apoptosis, and this event was inhibited by a CASP3-specific inhibitor.	Etoposide	34-44	caspase 3	Homo sapiens	21-26
18319618-3	2008	HAX-1 was cleaved by CASP3 during etoposide-(ETO) induced apoptosis, and this event was inhibited by a CASP3-specific inhibitor.	Etoposide	34-44	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	45-48
18319618-3	2008	HAX-1 was cleaved by CASP3 during etoposide-(ETO) induced apoptosis, and this event was inhibited by a CASP3-specific inhibitor.	Etoposide	34-44	caspase 3	Homo sapiens	103-108
20727268-5	2008	RESULTS: The resistance index of A549/Gem" to gemcitabine was 163.228, and the cell line also exhibited cross-resistance to vinorelbine, taxotere, fluorouraci, etoposide and cisplatin, but kept sensitivity to paclitaxol and oxaliplatin.	Etoposide	160-169	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	38-41
18060501-7	2008	We demonstrate in vitro and in vivo that CSN6 is cleaved most effectively by caspase 3 at D23 after 2-3 h of apoptosis induced by anti-Fas-Ab or etoposide.	Etoposide	145-154	COP9 signalosome subunit 6	Homo sapiens	41-45
18060501-7	2008	We demonstrate in vitro and in vivo that CSN6 is cleaved most effectively by caspase 3 at D23 after 2-3 h of apoptosis induced by anti-Fas-Ab or etoposide.	Etoposide	145-154	caspase 3	Homo sapiens	77-86
18245554-9	2008	Moreover, CTCL death induction by conventional antineoplastic agents etoposide and vincristine was potentiated by AS602868.	Etoposide	69-78	TSPY like 2	Homo sapiens	10-14
18245478-3	2008	In vitro treatment with etoposide only and in vivo treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression (600-fold) and promotes nuclear translocation of p53, and results in apoptosis of leukemic clam hemocytes.	Etoposide	24-33	tumor protein p53	Homo sapiens	188-191
18245478-3	2008	In vitro treatment with etoposide only and in vivo treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression (600-fold) and promotes nuclear translocation of p53, and results in apoptosis of leukemic clam hemocytes.	Etoposide	73-82	tumor protein p53	Homo sapiens	188-191
18245478-4	2008	Pretreatment with wheat germ agglutinin followed by etoposide treatment induces DNA damage and elevates p53 expression (893-fold) but does not overcome cytoplasmic sequestration of p53 or induce apoptosis.	Etoposide	52-61	tumor protein p53	Homo sapiens	104-107
18162445-7	2008	We also show that over-expression of MBD4(tru) in DLD1 alters the colony survival after exposure to cisplatin or etoposide.	Etoposide	113-122	methyl-CpG binding domain 4, DNA glycosylase	Homo sapiens	37-41
18162445-7	2008	We also show that over-expression of MBD4(tru) in DLD1 alters the colony survival after exposure to cisplatin or etoposide.	Etoposide	113-122	methyl-CpG binding domain 4, DNA glycosylase	Homo sapiens	42-45
17935137-0	2008	Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.	Etoposide	113-122	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	0-25
18041764-2	2008	We found that overexpressing Par-4 by stable transfection sensitizes Caki cells to induction of apoptosis by TRAIL and drugs that induce endoplasmic reticulum (ER) stress [thapsigargin (TG), tunicamycin (TU) and etoposide].	Etoposide	212-221	pro-apoptotic WT1 regulator	Homo sapiens	29-34
17932621-11	2008	Under basal growth conditions and in response to the chemotherapeutic agent, etoposide, WIP1 antagonized p53-mediated apoptosis in medulloblastoma cell lines.	Etoposide	77-86	tumor protein p53	Homo sapiens	105-108
18314485-7	2008	Rat-1 cells genetically altered to overexpress DNMT1 were also shown to be resistant to the cytotoxicity of H(2)O(2), etoposide, and cisplatin.	Etoposide	118-127	DNA methyltransferase 1	Rattus norvegicus	47-52
17935137-0	2008	Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.	Etoposide	113-122	AKT serine/threonine kinase 1	Homo sapiens	26-29
17935137-4	2008	Etoposide and doxorubicin stimulated Akt and PI3K activities in 2 gastric cancer cell lines (BGC-823 and SGC-7901), and the activities were concentration and time-dependent.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	37-40
17935137-5	2008	Up-regulation of PTEN expression in BGC-823 cells by PEAK8-PTEN transient transfection obviously decreased the basal and anticancer drugs induced Akt activities, then sensitized BGC-823 cells to etoposide and doxorubicin.	Etoposide	195-204	phosphatase and tensin homolog	Homo sapiens	17-21
17935137-5	2008	Up-regulation of PTEN expression in BGC-823 cells by PEAK8-PTEN transient transfection obviously decreased the basal and anticancer drugs induced Akt activities, then sensitized BGC-823 cells to etoposide and doxorubicin.	Etoposide	195-204	phosphatase and tensin homolog	Homo sapiens	59-63
19271688-0	2008	Quantitative analysis of expression level of BCL2 and BAX genes in Hep-2 and HL-60 cells after treatment with etoposide.	Etoposide	110-119	BCL2 apoptosis regulator	Homo sapiens	45-49
19271688-0	2008	Quantitative analysis of expression level of BCL2 and BAX genes in Hep-2 and HL-60 cells after treatment with etoposide.	Etoposide	110-119	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
19271688-6	2008	In HL-60 cells the expression level of BCL2 decreased after 6 h of treatment and expression of BAX increased both 6 h and 12 h of treatment with etoposide.	Etoposide	145-154	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
17959229-9	2008	Treatment of endometrial cancer cells with etoposide resulted in a translocation of PKC delta from cytoplasm to nucleus concomitant with induction of apoptosis.	Etoposide	43-52	protein kinase C delta	Homo sapiens	84-93
19075668-14	2008	ATP7A-overexpressing cells are resistant to many anticancer drugs including SN-38, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), vincristine, paclitaxel, etoposide, doxorubicin (Dox), and mitoxantron.	Etoposide	185-194	ATPase copper transporting alpha	Homo sapiens	0-5
18260357-8	2008	The histological diagnosis was PSS, and the patient received VIP (etoposide, ifosfamide, cisplatin) chemotherapy regimen.	Etoposide	66-75	vasoactive intestinal peptide	Homo sapiens	61-64
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Etoposide	170-179	alpha fetoprotein	Homo sapiens	16-33
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Etoposide	170-179	alpha fetoprotein	Homo sapiens	35-38
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Etoposide	229-238	alpha fetoprotein	Homo sapiens	16-33
18260360-5	2008	Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.	Etoposide	229-238	alpha fetoprotein	Homo sapiens	35-38
18260360-8	2008	Then he was given one more cycle of VIP therapy (etoposide, ifosfamide, cisplatin), but the serum AFP level was increased to 56 ng/ml.	Etoposide	49-58	vasoactive intestinal peptide	Homo sapiens	36-39
18260360-8	2008	Then he was given one more cycle of VIP therapy (etoposide, ifosfamide, cisplatin), but the serum AFP level was increased to 56 ng/ml.	Etoposide	49-58	alpha fetoprotein	Homo sapiens	98-101
18497069-5	2008	We demonstrate that wt or mutated catalytically inactive CD strongly enhances chemo-sensitivity and apoptotic response to etoposide.	Etoposide	122-131	cathepsin D	Homo sapiens	57-59
18036819-3	2008	VETOPEC, a combination of vincristine (VCR), etoposide (VP-16) and escalated dose cyclophosphamide (CPA), has been shown to be highly active in clinical trials.	Etoposide	45-54	host cell factor C1	Homo sapiens	56-61
17920329-4	2008	Here, we show that following a short exposure to the DNA-damaging compound etoposide, c-Jun phosphorylation is restricted to S63/S73.	Etoposide	75-84	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-91
18571971-7	2008	GSTO1-1 expression is elevated in some cell lines that are resistant to the cytotoxic cancer drugs adriamycin, etoposide and cisplatinum but its specific contribution to multi drug resistance has not been evaluated.	Etoposide	111-120	glutathione S-transferase omega 1	Homo sapiens	0-7
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	86-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-35
18669163-4	2008	Recently, it was observed that overexpression of Aurora-A renders cells resistant to cisplatin (CDDP)-, etoposide-, and paclitaxel-induced apoptosis.	Etoposide	104-113	aurora kinase A	Homo sapiens	49-57
18683587-3	2008	Our findings provide the first evidence that the pattern of immunostaning for alpha-tubulin, acetylated alpha-tubulin and tyrosinated alpha-tubulin in cells dividing at various periods after etoposide treatment.	Etoposide	191-200	tubulin alpha-1B chain	Cricetulus griseus	78-91
18683587-3	2008	Our findings provide the first evidence that the pattern of immunostaning for alpha-tubulin, acetylated alpha-tubulin and tyrosinated alpha-tubulin in cells dividing at various periods after etoposide treatment.	Etoposide	191-200	tubulin alpha-1B chain	Cricetulus griseus	104-117
18683587-3	2008	Our findings provide the first evidence that the pattern of immunostaning for alpha-tubulin, acetylated alpha-tubulin and tyrosinated alpha-tubulin in cells dividing at various periods after etoposide treatment.	Etoposide	191-200	tubulin alpha-1B chain	Cricetulus griseus	104-117
17574594-5	2008	MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid.	Etoposide	194-202	BCL2 apoptosis regulator	Homo sapiens	23-28
18389626-4	2008	The down-regulation of CIAPIN1 significantly enhanced the sensitivity of SGC7901/VCR cells to vincristine (VCR), adriamycin (ADR) and etoposide (VP-16), but not to 5-fluorouracil (5-FU) and cisplatin (CDDP).	Etoposide	134-143	cytokine induced apoptosis inhibitor 1	Homo sapiens	23-30
18497550-5	2008	METHODS: Extracellular release of CK8 was examined using A549 human non-small cell lung cancer (NSCLC) cells after apoptosis induction by etoposide.	Etoposide	138-147	keratin 8	Homo sapiens	34-37
18939359-0	2008	[Changes in etoposide-induced apoptosis of HeLa tumor cells transfected with antisense oligonucleotide for BCL-2 mRNA].	Etoposide	12-21	BCL2 apoptosis regulator	Homo sapiens	107-112
18939359-13	2008	The use of the anti-BCL-2 oligonucleotide in combination with etoposide results in significant deacrease of proliferation in cell cultures and this phenomenon is a result of synergy between used chemotherapy and gene therapy.	Etoposide	62-71	BCL2 apoptosis regulator	Homo sapiens	20-25
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	86-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	86-95	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	97-100	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-35
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	97-100	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Etoposide	97-100	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	131-134
17694514-8	2007	Inhibition of caspase-9 specifically reduced v-Myc-stimulated apoptosis, whereas inhibition of caspase-8 and -3/7 reduced apoptosis both in v-myc-expressing and parental ETO-treated U-937 cells.	Etoposide	170-173	caspase 8	Homo sapiens	95-111
18084622-8	2007	Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays.	Etoposide	27-36	tumor protein p53	Homo sapiens	57-60
18028422-6	2007	We further demonstrate that nuclear TFAM confers significant cytoprotection against the chemotherapeutic drugs etoposide, camptothecin, and cisplatin.	Etoposide	111-120	transcription factor A, mitochondrial	Homo sapiens	36-40
18087215-4	2007	When the H460 human lung cancer cell line was treated with hypoxia and etoposide, a chemotherapy agent that induces double-stranded DNA breaks, the dominant transcriptional response was regulated by DNA damage in a p53-dependent manner.	Etoposide	71-80	tumor protein p53	Homo sapiens	215-218
18089706-9	2007	Using real-time, dynamic measurements of cell survival, we found that 6 to 8 h after etoposide treatment was the period during which critical events regulating the induction of cell death or BDNF/TrkB-induced protection occurred.	Etoposide	85-94	brain derived neurotrophic factor	Homo sapiens	191-195
18089706-9	2007	Using real-time, dynamic measurements of cell survival, we found that 6 to 8 h after etoposide treatment was the period during which critical events regulating the induction of cell death or BDNF/TrkB-induced protection occurred.	Etoposide	85-94	neurotrophic receptor tyrosine kinase 2	Homo sapiens	196-200
18089706-10	2007	During this period, etoposide treatment was associated with the dephosphorylation and activation of GSK-3beta in the mitochondria that was blocked by BDNF activation of TrkB.	Etoposide	20-29	glycogen synthase kinase 3 beta	Homo sapiens	100-109
18089706-10	2007	During this period, etoposide treatment was associated with the dephosphorylation and activation of GSK-3beta in the mitochondria that was blocked by BDNF activation of TrkB.	Etoposide	20-29	brain derived neurotrophic factor	Homo sapiens	150-154
18089706-10	2007	During this period, etoposide treatment was associated with the dephosphorylation and activation of GSK-3beta in the mitochondria that was blocked by BDNF activation of TrkB.	Etoposide	20-29	neurotrophic receptor tyrosine kinase 2	Homo sapiens	169-173
18089708-2	2007	Here, we report that the antineoplastic agents, daunorubicin hydrochloride, etoposide, and vincristine sulfate inhibited the ability of 1,25(OH)(2)D(3) to cause the accumulation of mRNA for kidney 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24), an enzyme which catabolizes this hormone.	Etoposide	76-85	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	236-241
18084622-8	2007	Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays.	Etoposide	27-36	androgen receptor	Homo sapiens	97-99
18084622-8	2007	Moreover, we noted that in etoposide treated LNCaP cells p53 bound to the promoter region of the AR gene, which contains a potential p53 DNA-binding consensus sequence, in chromatin immunoprecipitation assays.	Etoposide	27-36	tumor protein p53	Homo sapiens	133-136
17620057-10	2007	Overexpression of SIRT1 in either confluent or etoposide-treated cells resulted in a significant reduction in Rb acetylation, which was restored with nicotinamide.	Etoposide	47-56	sirtuin 1	Homo sapiens	18-23
17533374-9	2007	Finally, inhibition of IL-8 signaling potentiated etoposide-induced cell death in hypoxic PC3 cells.	Etoposide	50-59	C-X-C motif chemokine ligand 8	Homo sapiens	23-27
17765869-2	2007	BRI3BP, when overexpressed, augmented the apoptosis of human embryonic kidney 293T cells challenged with drugs including the anti-cancer agent etoposide.	Etoposide	143-152	BRI3 binding protein	Homo sapiens	0-6
17765869-4	2007	BRI3BP overexpression enhanced both mitochondrial cytochrome c release and caspase-3 activity in etoposide-treated cells.	Etoposide	97-106	BRI3 binding protein	Homo sapiens	0-6
17765869-4	2007	BRI3BP overexpression enhanced both mitochondrial cytochrome c release and caspase-3 activity in etoposide-treated cells.	Etoposide	97-106	caspase 3	Homo sapiens	75-84
17546047-3	2007	In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent.	Etoposide	334-343	diablo IAP-binding mitochondrial protein	Homo sapiens	240-244
17546047-3	2007	In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent.	Etoposide	334-343	diablo IAP-binding mitochondrial protein	Homo sapiens	245-251
17981155-0	2007	Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide.	Etoposide	66-75	EI24 autophagy associated transmembrane protein	Homo sapiens	34-38
17981155-0	2007	Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide.	Etoposide	66-75	EI24 autophagy associated transmembrane protein	Homo sapiens	39-43
17981155-3	2007	Here it is demonstrated that suppression of EI24/PIG8 in fibroblasts and breast cancer cells significantly inhibits the apoptotic response to etoposide treatment.	Etoposide	142-151	EI24 autophagy associated transmembrane protein	Homo sapiens	44-48
17981155-3	2007	Here it is demonstrated that suppression of EI24/PIG8 in fibroblasts and breast cancer cells significantly inhibits the apoptotic response to etoposide treatment.	Etoposide	142-151	EI24 autophagy associated transmembrane protein	Homo sapiens	49-53
17785460-6	2007	The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage.	Etoposide	74-83	BCL2 apoptosis regulator	Homo sapiens	17-22
17785460-6	2007	The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage.	Etoposide	122-131	BCL2 apoptosis regulator	Homo sapiens	17-22
17785460-6	2007	The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage.	Etoposide	122-131	protein kinase C epsilon	Homo sapiens	89-99
17785460-6	2007	The induction of Bcl-2 inhibited apoptosis induced by serum starvation or etoposide, and PKCepsilon activation attenuated etoposide-induced caspase-3 cleavage.	Etoposide	122-131	caspase 3	Homo sapiens	140-149
17704753-7	2007	Adenoviral delivery of the ABCC2 antisense construct resulted in a reduced IC(50) for doxorubicin (12-fold), vincristine (50-fold), cisplatin (25-fold) and etoposide (VP-16) (25-fold).	Etoposide	156-165	ATP binding cassette subfamily C member 2	Homo sapiens	27-32
17634410-6	2007	This was further investigated with cell lines stably expressing CYP3A4 that exhibited an increased resistance to doxorubicin and etoposide.	Etoposide	129-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
19383392-0	2007	p53 is required for etoposide-induced apoptosis of human embryonic stem cells.	Etoposide	20-29	tumor protein p53	Homo sapiens	0-3
17659913-5	2007	Myeloid enriched BM cells from gadd45a and gadd45b deficient mice were observed to be more sensitive to ultraviolet radiation (UVC), VP-16, and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Etoposide	133-138	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	43-50
17659913-8	2007	Both gadd45a and gadd45b deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45.	Etoposide	111-116	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	17-24
17659913-8	2007	Both gadd45a and gadd45b deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45.	Etoposide	111-116	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	5-11
17983804-7	2007	The Topo II inhibitors, merbarone and etoposide, suppressed the beta-catenin-mediated TCF/lymphoid enhancer factor transcriptional activity.	Etoposide	38-47	catenin beta 1	Homo sapiens	64-76
17983804-7	2007	The Topo II inhibitors, merbarone and etoposide, suppressed the beta-catenin-mediated TCF/lymphoid enhancer factor transcriptional activity.	Etoposide	38-47	hepatocyte nuclear factor 4 alpha	Homo sapiens	86-89
17534580-10	2007	Finally, a significant increase in caspase-3 activity and apoptosis was observed in the presence of both VPA and etoposide compared to either agent alone.	Etoposide	113-122	caspase 3	Homo sapiens	35-44
17952061-3	2007	Downregulation of AK2 attenuates etoposide- or staurosporine-induced apoptosis in human cells, but not that induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) or Fas ligand (FasL).	Etoposide	33-42	adenylate kinase 2	Homo sapiens	18-21
17659913-18	2007	These observations set the stage to evaluate, in clinically relevant settings, the impact that the status of gadd45a and gadd45b might have on the efficacy of DNR or VP-16 in killing leukemic cells.	Etoposide	166-171	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	121-128
17534580-11	2007	CONCLUSION: Our study demonstrates that VPA sensitizes U87, U251, and LN18 cells to the cytotoxic effects of etoposide in vitro by inducing differentiation and up-regulating the expression of p21/WAF1 and both isoforms of topoisomerase-II.	Etoposide	109-118	cyclin dependent kinase inhibitor 1A	Homo sapiens	192-195
17534580-11	2007	CONCLUSION: Our study demonstrates that VPA sensitizes U87, U251, and LN18 cells to the cytotoxic effects of etoposide in vitro by inducing differentiation and up-regulating the expression of p21/WAF1 and both isoforms of topoisomerase-II.	Etoposide	109-118	cyclin dependent kinase inhibitor 1A	Homo sapiens	196-200
17699571-15	2007	Consistent with these findings, the expression of replication-promoting viral genes was positively influenced by p53 overexpression or treatment with the p53 agonist etoposide.	Etoposide	166-175	transformation related protein 53, pseudogene	Mus musculus	154-157
19383392-2	2007	Here we investigate the role of p53 in etoposide-induced apoptosis.	Etoposide	39-48	tumor protein p53	Homo sapiens	32-35
19383392-4	2007	Etoposide treatment results in a rapid and extensive induction of apoptosis and leads to a further increase in p53 and PUMA expression as well as Bax processing.	Etoposide	0-9	tumor protein p53	Homo sapiens	111-114
19383392-6	2007	hESC stably transduced with p53 shRNA display 80% reduction of endogenous p53 and exhibit an 80% reduction in etoposide-induced apoptosis accompanied by constitutive downregulation of Bax and an attenuated upregulation of PUMA.	Etoposide	110-119	tumor protein p53	Homo sapiens	28-31
19383392-8	2007	Our study demonstrates that p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular mechanism of DNA-damage-induced apoptosis in hESC.	Etoposide	48-57	tumor protein p53	Homo sapiens	28-31
17681274-5	2007	Here, in p53 negative K562 myeloid leukemia cells, etoposide-induced mitotic catastrophe is shown to be time and/or concentration dependent.	Etoposide	51-60	tumor protein p53	Homo sapiens	9-12
17971859-7	2007	Treatment of cells with honokiol or chemotherapeutics agent etoposide enhanced the increase in apoptosis and GRP94 degradation.	Etoposide	60-69	heat shock protein 90 beta family member 1	Homo sapiens	109-114
17912033-4	2007	The highest levels of cell death were observed when Plk2-deficient cells were released from both aphidicolin and etoposide treatment.	Etoposide	113-122	polo like kinase 2	Homo sapiens	52-56
17686459-5	2007	When JNK3 activity is down-regulated in etoposide-induced HeLa cells by transiently overexpressing a dominant negative version of JNK3 (DN-JNK3), the caspase-3 activity as well as PARP cleavages are markedly enhanced.	Etoposide	40-49	mitogen-activated protein kinase 10	Homo sapiens	5-9
17686459-5	2007	When JNK3 activity is down-regulated in etoposide-induced HeLa cells by transiently overexpressing a dominant negative version of JNK3 (DN-JNK3), the caspase-3 activity as well as PARP cleavages are markedly enhanced.	Etoposide	40-49	mitogen-activated protein kinase 10	Homo sapiens	130-134
17686459-5	2007	When JNK3 activity is down-regulated in etoposide-induced HeLa cells by transiently overexpressing a dominant negative version of JNK3 (DN-JNK3), the caspase-3 activity as well as PARP cleavages are markedly enhanced.	Etoposide	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	180-184
17956665-0	2007	[Adenovirus-mediated PDCD5 gene transfer sensitizes apoptosis of K562 cells induced by etoposide].	Etoposide	87-96	programmed cell death 5	Homo sapiens	21-26
17610064-0	2007	Mitochondrial anchoring of PKCalpha by PICK1 confers resistance to etoposide-induced apoptosis.	Etoposide	67-76	protein kinase C alpha	Homo sapiens	27-35
17610064-0	2007	Mitochondrial anchoring of PKCalpha by PICK1 confers resistance to etoposide-induced apoptosis.	Etoposide	67-76	protein interacting with PRKCA 1	Homo sapiens	39-44
17610064-3	2007	In this study, we show that over-expression of PICK1 in leukemia REH confers resistance to etoposide-induced apoptosis, which requires an interaction with PKCalpha as the non-interacting mutant PICK1 loses the pro-survival activity.	Etoposide	91-100	protein interacting with PRKCA 1	Homo sapiens	47-52
17610064-3	2007	In this study, we show that over-expression of PICK1 in leukemia REH confers resistance to etoposide-induced apoptosis, which requires an interaction with PKCalpha as the non-interacting mutant PICK1 loses the pro-survival activity.	Etoposide	91-100	protein kinase C alpha	Homo sapiens	155-163
17610064-3	2007	In this study, we show that over-expression of PICK1 in leukemia REH confers resistance to etoposide-induced apoptosis, which requires an interaction with PKCalpha as the non-interacting mutant PICK1 loses the pro-survival activity.	Etoposide	91-100	protein interacting with PRKCA 1	Homo sapiens	194-199
17610064-5	2007	Disruption of PICK1/PKCalpha interactions by inhibitory peptides significantly increases cellular susceptibility to etoposide.	Etoposide	116-125	protein interacting with PRKCA 1	Homo sapiens	14-19
17610064-5	2007	Disruption of PICK1/PKCalpha interactions by inhibitory peptides significantly increases cellular susceptibility to etoposide.	Etoposide	116-125	protein kinase C alpha	Homo sapiens	20-28
17700070-0	2007	Replication protein A is required for etoposide-induced assembly of MRE11/RAD50/NBS1 complex repair foci.	Etoposide	38-47	replication protein A1	Homo sapiens	0-21
17700070-0	2007	Replication protein A is required for etoposide-induced assembly of MRE11/RAD50/NBS1 complex repair foci.	Etoposide	38-47	MRE11 homolog, double strand break repair nuclease	Homo sapiens	68-73
17700070-0	2007	Replication protein A is required for etoposide-induced assembly of MRE11/RAD50/NBS1 complex repair foci.	Etoposide	38-47	RAD50 double strand break repair protein	Homo sapiens	74-79
17700070-0	2007	Replication protein A is required for etoposide-induced assembly of MRE11/RAD50/NBS1 complex repair foci.	Etoposide	38-47	nibrin	Homo sapiens	80-84
17700070-4	2007	Depletion of RPA-p70 decreased the ability of cells to form phospho-Nbs1 foci and increased levels of DNA double-strand breaks (DSBs) following treatment with etoposide (ETOP).	Etoposide	159-168	replication protein A1	Homo sapiens	13-20
17700070-4	2007	Depletion of RPA-p70 decreased the ability of cells to form phospho-Nbs1 foci and increased levels of DNA double-strand breaks (DSBs) following treatment with etoposide (ETOP).	Etoposide	170-174	replication protein A1	Homo sapiens	13-20
17673902-1	2007	The genetic risk factors for etoposide-induced leukemia with MLL translocations remain largely unknown.	Etoposide	29-38	lysine methyltransferase 2A	Homo sapiens	61-64
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	130-139	cyclin dependent kinase 1	Homo sapiens	45-70
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	130-139	cyclin A2	Homo sapiens	71-79
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	130-139	tumor protein p53	Homo sapiens	91-94
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	167-176	cyclin dependent kinase 1	Homo sapiens	45-70
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	167-176	cyclin A2	Homo sapiens	71-79
17636382-0	2007	New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.	Etoposide	167-176	tumor protein p53	Homo sapiens	91-94
17636382-6	2007	The p53-negative myeloid leukemia cell lines K562 and HL-60 were used to determine Cdk1 phosphorylation status during etoposide treatment.	Etoposide	118-127	cyclin dependent kinase 1	Homo sapiens	83-87
17636382-13	2007	These findings suggest novel Cdk1 phosphorylation sites, which appear to be associated with p53-independent cell death following etoposide treatment.	Etoposide	129-138	cyclin dependent kinase 1	Homo sapiens	29-33
17636382-13	2007	These findings suggest novel Cdk1 phosphorylation sites, which appear to be associated with p53-independent cell death following etoposide treatment.	Etoposide	129-138	tumor protein p53	Homo sapiens	92-95
17917963-6	2007	and total CD34+ cells harvested were higher in patients mobilized with intermediate dose etoposide (p = 0.003 and p = 0.004, respectively).	Etoposide	89-98	CD34 molecule	Homo sapiens	10-14
18229610-7	2007	VP-16 significantly decreased inflammatory cell infiltration and the degree of infiltration reaction, and decreased the level of TNF-a in serum and the expression of ICAM-l in skin.	Etoposide	0-5	tumor necrosis factor	Mus musculus	129-134
17956665-1	2007	This study was purposed to investigate the effect of adenovirus-mediated transfer of PDCD5 gene on apoptosis of K562 cells induced by etoposide.	Etoposide	134-143	programmed cell death 5	Homo sapiens	85-90
17956665-4	2007	The effects of etoposide in combination with Ad-PDCD5 on the proliferation and apoptosis of K562 cells were measured by using MTT assay and flow cytometry with Annexin-V-FITC/PI dual labeling technique, respectively.	Etoposide	15-24	annexin A5	Homo sapiens	160-169
17894897-8	2007	Etoposide increased p53 activity in all cell lines while hypoxia alone decreased it only in HepG2 cells.	Etoposide	0-9	tumor protein p53	Homo sapiens	20-23
17894897-10	2007	Using low density DNA arrays to detect the expression of genes involved in the regulation of apoptosis, etoposide and hypoxia were shown to each influence the expression of numerous genes, many of the ones influenced by etoposide being p53 target genes.	Etoposide	104-113	tumor protein p53	Homo sapiens	236-239
17894897-10	2007	Using low density DNA arrays to detect the expression of genes involved in the regulation of apoptosis, etoposide and hypoxia were shown to each influence the expression of numerous genes, many of the ones influenced by etoposide being p53 target genes.	Etoposide	220-229	tumor protein p53	Homo sapiens	236-239
17894897-12	2007	CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type.	Etoposide	111-120	tumor protein p53	Homo sapiens	129-132
17894897-12	2007	CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type.	Etoposide	207-216	tumor protein p53	Homo sapiens	129-132
17894897-12	2007	CONCLUSION: These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type.	Etoposide	207-216	tumor protein p53	Homo sapiens	158-161
17618321-2	2007	Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation.	Etoposide	0-9	CD34 molecule	Homo sapiens	72-76
17420721-5	2007	Siah-1S is shown to upregulate beta-catenin-dependent Tcf/Lef transcriptional activation and antagonize Siah-1"s potentiation effect on the apoptosis induced by etoposide in MCF-7 cells.	Etoposide	161-170	catenin beta 1	Homo sapiens	31-43
17420721-5	2007	Siah-1S is shown to upregulate beta-catenin-dependent Tcf/Lef transcriptional activation and antagonize Siah-1"s potentiation effect on the apoptosis induced by etoposide in MCF-7 cells.	Etoposide	161-170	siah E3 ubiquitin protein ligase 1	Homo sapiens	0-6
17420723-4	2007	We found that in cells treated with etoposide or ionizing radiation (IR), H4(D10S170) underwent ATM-mediated phosphorylation at Thr 434, stabilizing nuclear H4.	Etoposide	36-45	coiled-coil domain containing 6	Homo sapiens	74-84
17420723-4	2007	We found that in cells treated with etoposide or ionizing radiation (IR), H4(D10S170) underwent ATM-mediated phosphorylation at Thr 434, stabilizing nuclear H4.	Etoposide	36-45	ATM serine/threonine kinase	Homo sapiens	96-99
17970065-4	2007	The UBE2I-v5-transfected cells were more sensitive than the parental cells to anticancer drugs such as vincristine (VCR), mitoxantrone (MIT) and etoposide (VP16).	Etoposide	145-154	ubiquitin-conjugating enzyme E2I	Mus musculus	4-9
17970065-4	2007	The UBE2I-v5-transfected cells were more sensitive than the parental cells to anticancer drugs such as vincristine (VCR), mitoxantrone (MIT) and etoposide (VP16).	Etoposide	156-160	ubiquitin-conjugating enzyme E2I	Mus musculus	4-9
17827720-0	2007	Enhanced expression of membrane-associated sialidase Neu3 decreases GD3 and increases GM3 on the surface of Jurkat cells during etoposide-induced apoptosis.	Etoposide	128-137	neuraminidase 3	Homo sapiens	53-57
17827720-5	2007	We found an increase in GM3 and a decrease in GD3 during the early stage (4 h) of etoposide-induced apoptosis that preceded the increase in cell surface exposure of phosphatidylserine (4 to 6 h).	Etoposide	82-91	GRDX	Homo sapiens	46-49
17827720-7	2007	Furthermore, etoposide caused a gradual up-regulation of Neu3 mRNA expression but not Neu1 mRNA expression.	Etoposide	13-22	neuraminidase 3	Homo sapiens	57-61
17827720-9	2007	These results indicate that Neu3 is up-regulated in Jurkat cells undergoing etoposide-induced apoptosis through intracellular signaling events downstream of caspase 3 activation and that enhanced Neu3 activity is closely related to the changes of cell surface ganglioside composition.	Etoposide	76-85	neuraminidase 3	Homo sapiens	28-32
17827720-9	2007	These results indicate that Neu3 is up-regulated in Jurkat cells undergoing etoposide-induced apoptosis through intracellular signaling events downstream of caspase 3 activation and that enhanced Neu3 activity is closely related to the changes of cell surface ganglioside composition.	Etoposide	76-85	caspase 3	Homo sapiens	157-166
17585339-4	2007	Here, we demonstrate that etoposide and ionizing radiation induce the exit of BID from the nucleus and that leptomycin B, a specific inhibitor of the nuclear export receptor CRM1, prevents the nuclear exit of BID.	Etoposide	26-35	BH3 interacting domain death agonist	Homo sapiens	78-81
17585339-4	2007	Here, we demonstrate that etoposide and ionizing radiation induce the exit of BID from the nucleus and that leptomycin B, a specific inhibitor of the nuclear export receptor CRM1, prevents the nuclear exit of BID.	Etoposide	26-35	exportin 1	Homo sapiens	174-178
17599100-5	2007	Depletion of Penk by RNA interference (RNAi) substantially preserves viable cell number following exposure to UV-C irradiation or hydrogen peroxide and confers transient protection in cells exposed to the genotoxin etoposide.	Etoposide	215-224	proenkephalin	Homo sapiens	13-17
17585339-4	2007	Here, we demonstrate that etoposide and ionizing radiation induce the exit of BID from the nucleus and that leptomycin B, a specific inhibitor of the nuclear export receptor CRM1, prevents the nuclear exit of BID.	Etoposide	26-35	BH3 interacting domain death agonist	Homo sapiens	209-212
17562707-4	2007	Here we show that full-length PKC delta transiently accumulates in the nucleus in response to etoposide and that nuclear translocation precedes caspase cleavage of PKC delta.	Etoposide	94-103	protein kinase C delta	Homo sapiens	30-39
17881904-5	2007	SP-cells from multiple tumorigenic human cell lines, which are most often resistant to chemotherapeutic agents such as etoposide, cisplatin and 5-FU, are more sensitive to TRAIL than non-SP cells.	Etoposide	119-128	TNF superfamily member 10	Homo sapiens	172-177
17881906-6	2007	Moreover, using the MTS viability assay, AC-EGFP cells were more resistant to cell death induced by doxorubicin, cisplatin, etoposide, gemcitabine or C6-ceramide.	Etoposide	124-133	N-acylsphingosine amidohydrolase 1	Homo sapiens	41-43
17881906-8	2007	In addition, mass spectroscopic analysis of sphingolipids indicated that long chain ceramide levels were decreased in AC-EGFP cells treated with either doxorubicin or etoposide.	Etoposide	167-176	N-acylsphingosine amidohydrolase 1	Homo sapiens	118-120
18004241-6	2007	Nevertheless, pretreatment of MT-4 but not Namalwa cells with fucoidan followed by the exposure to DNA topoisomerase II inhibitor etoposide led to about two-fold increase in the relative apoptotic index as compared with etoposide alone.	Etoposide	130-139	metallothionein 4	Homo sapiens	30-34
18004241-6	2007	Nevertheless, pretreatment of MT-4 but not Namalwa cells with fucoidan followed by the exposure to DNA topoisomerase II inhibitor etoposide led to about two-fold increase in the relative apoptotic index as compared with etoposide alone.	Etoposide	220-229	metallothionein 4	Homo sapiens	30-34
18004241-8	2007	CONCLUSION: The present findings demonstrate for the first time that fucoidan enhances etoposide induced caspase-dependent cell death pathway in MT-4 but not Namalwa cell line.	Etoposide	87-96	metallothionein 4	Homo sapiens	145-149
17691049-4	2007	Most of the target compounds (except for all these compounds against SPCA-1) exhibited more pronounced cytotoxicity against several neoplastic cell lines than that of the prototypical inhibitor etoposide.	Etoposide	194-203	ATPase secretory pathway Ca2+ transporting 1	Homo sapiens	69-75
17467952-7	2007	The characteristic electron spin resonance (ESR) signal of etoposide phenoxyl radical, which occurs in the presence of myeloperoxidase, H2O2 and etoposide, was quenched by quercetin in a dose-dependent manner (0.1-0.5 microM).	Etoposide	59-68	myeloperoxidase	Homo sapiens	119-134
17310986-11	2007	This was shown by studying DNA damage-induced apoptosis in fibroblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53.	Etoposide	148-157	tumor protein p53	Homo sapiens	220-223
17627812-2	2007	In this study, IFN-gamma mediated up-regulation of caspase-8 in human MB cells was found to result in chemosensitization to cisplatin, doxorubicin and etoposide, and sensitisation to radiation.	Etoposide	151-160	interferon gamma	Homo sapiens	15-24
17697545-4	2007	The inhibitory effects of cisplatin (DDP), vincristine (VCR), adriamycin (ADM) and etoposide (VP-16) used alone or in combination with tetrandrine on the proliferation of KB-3-1 and KB-MRP1 cells were evaluated by MTT assay.	Etoposide	83-92	host cell factor C1	Homo sapiens	94-99
17544220-6	2007	This protection was accompanied by abrogation of etoposide-induced stimulation of caspase activity via a mechanism dependent on Erk and PI3K.	Etoposide	49-58	mitogen-activated protein kinase 1	Homo sapiens	128-131
17544220-8	2007	Etoposide decreased the expression of Bcl-2, which was reversed by LPA.	Etoposide	0-9	BCL2 apoptosis regulator	Homo sapiens	38-43
17544220-9	2007	Etoposide decreased the phosphorylation level of the proapoptotic protein Bad in an Erk-dependent manner, without changing Bad expression.	Etoposide	0-9	mitogen-activated protein kinase 1	Homo sapiens	84-87
17464323-3	2007	Here, we report that selective p57(Kip2) expression sensitizes cancer cells to apoptotic agents such as cisplatin, etoposide and staurosporine (STS) via a mechanism, which does not require p57(Kip2)-mediated inhibition of CDK.	Etoposide	115-124	cyclin dependent kinase inhibitor 1C	Homo sapiens	31-34
17464323-3	2007	Here, we report that selective p57(Kip2) expression sensitizes cancer cells to apoptotic agents such as cisplatin, etoposide and staurosporine (STS) via a mechanism, which does not require p57(Kip2)-mediated inhibition of CDK.	Etoposide	115-124	cyclin dependent kinase inhibitor 1C	Homo sapiens	35-39
17473910-3	2007	We first characterized p53-dependent PC12 cell death induced by etoposide (a DNA damaging agent).	Etoposide	64-73	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	23-26
17473910-4	2007	We showed that etoposide increased p53 stabilization, phosphorylation (Ser-15), nuclear translocation and transcriptional activity.	Etoposide	15-24	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	35-38
17473910-8	2007	FGF1 inhibited etoposide-induced p53 phosphorylation, stabilization, nuclear translocation and transcriptional activity.	Etoposide	15-24	fibroblast growth factor 1	Rattus norvegicus	0-4
17473910-8	2007	FGF1 inhibited etoposide-induced p53 phosphorylation, stabilization, nuclear translocation and transcriptional activity.	Etoposide	15-24	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	33-36
17671173-0	2007	BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.	Etoposide	50-59	BRCA1 DNA repair associated	Homo sapiens	0-5
17671173-0	2007	BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.	Etoposide	50-59	BRCA2 DNA repair associated	Homo sapiens	11-16
17671173-3	2007	Here, we show that both BRCA1 and BRCA2 determine the sensitivity to the cytotoxic drug, etoposide, using genetic complementation of BRCA-deficient cells.	Etoposide	89-98	BRCA1 DNA repair associated	Homo sapiens	24-29
17671173-3	2007	Here, we show that both BRCA1 and BRCA2 determine the sensitivity to the cytotoxic drug, etoposide, using genetic complementation of BRCA-deficient cells.	Etoposide	89-98	BRCA2 DNA repair associated	Homo sapiens	34-39
17174951-4	2007	Etoposide treatment resulted in an early upregulation of Fas and cytoplasmic release of mitochondrial cytochrome c.	Etoposide	0-9	cytochrome c, somatic	Homo sapiens	102-114
17627812-2	2007	In this study, IFN-gamma mediated up-regulation of caspase-8 in human MB cells was found to result in chemosensitization to cisplatin, doxorubicin and etoposide, and sensitisation to radiation.	Etoposide	151-160	caspase 8	Homo sapiens	51-60
17570360-5	2007	Here we report that the expression of RAI mRNA was increased in non-transformed lymphocytes and fibroblasts induced to undergo apoptosis by various means, such as treatment with etoposide, calcium ions, or interleukin-2 and/or serum deprivation.	Etoposide	178-187	SHC adaptor protein 3	Homo sapiens	38-41
17683387-2	2007	We report an elderly patient with C-ALCL which recurred after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy, but was effectively treated with the third-generation etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) regimen.	Etoposide	190-199	DNA damage inducible transcript 3	Homo sapiens	121-125
17515610-6	2007	Suppression of Rad51 expression, required for homologous recombination repair, blocked the ability of mutant p53 to antagonize arrest induced by etoposide, but not aphidicolin.	Etoposide	145-154	RAD51 recombinase	Homo sapiens	15-20
17515610-6	2007	Suppression of Rad51 expression, required for homologous recombination repair, blocked the ability of mutant p53 to antagonize arrest induced by etoposide, but not aphidicolin.	Etoposide	145-154	tumor protein p53	Homo sapiens	109-112
17515610-8	2007	However, when replication stress is associated with DNA strand breaks (such as with etoposide), up-regulation of homologous recombination repair in response to p53 disruption becomes important.	Etoposide	84-93	tumor protein p53	Homo sapiens	160-163
17699715-0	2007	Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage.	Etoposide	71-80	AKT serine/threonine kinase 1	Homo sapiens	34-37
17699715-3	2007	We identified that etoposide, a topoisomerase II inhibitor, caused selective killing of myristylated Akt (Akt-myr)-transduced Ink4a/Arf(-/-) astrocytes and U87MG cells in a dose- and time-dependent manner.	Etoposide	19-28	AKT serine/threonine kinase 1	Homo sapiens	101-104
17699715-3	2007	We identified that etoposide, a topoisomerase II inhibitor, caused selective killing of myristylated Akt (Akt-myr)-transduced Ink4a/Arf(-/-) astrocytes and U87MG cells in a dose- and time-dependent manner.	Etoposide	19-28	AKT serine/threonine kinase 1	Homo sapiens	106-113
17699715-3	2007	We identified that etoposide, a topoisomerase II inhibitor, caused selective killing of myristylated Akt (Akt-myr)-transduced Ink4a/Arf(-/-) astrocytes and U87MG cells in a dose- and time-dependent manner.	Etoposide	19-28	cyclin dependent kinase inhibitor 2A	Homo sapiens	126-131
17699715-4	2007	Etoposide-selective cytotoxicity in the Akt-myr-transduced cells was shown to be caused by nonapoptotic cell death and occurred in a p53-independent manner.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	40-43
17699715-4	2007	Etoposide-selective cytotoxicity in the Akt-myr-transduced cells was shown to be caused by nonapoptotic cell death and occurred in a p53-independent manner.	Etoposide	0-9	tumor protein p53	Homo sapiens	133-136
17699715-5	2007	Etoposide caused severe reactive oxygen species (ROS) accumulation preferentially in the Akt-myr-transduced cells, and elevated ROS rendered these cells highly sensitive to cell death.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	89-92
17699715-6	2007	The etoposide-selective cell death of Akt-myr-transduced cells was attenuated by pepstatin A, a lysosomal protease inhibitor.	Etoposide	4-13	AKT serine/threonine kinase 1	Homo sapiens	38-41
17699715-7	2007	In the present study, we show that etoposide might possess a novel therapeutic activity for oncogenic Akt-transduced cancer cells to kill preferentially through ROS-mediated damage.	Etoposide	35-44	AKT serine/threonine kinase 1	Homo sapiens	102-105
17297441-6	2007	Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide.	Etoposide	186-195	clock circadian regulator	Homo sapiens	121-126
17297441-6	2007	Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide.	Etoposide	186-195	activating transcription factor 4	Homo sapiens	130-134
17623797-9	2007	siRNA knockdown of HDAC1 gene expression sensitized CHLA-136 neuroblastoma cells to etoposide up to fivefold relative to the parental cell line or scrambled siRNA-transfected cells (P&lt;.001).	Etoposide	84-93	histone deacetylase 1	Homo sapiens	19-24
17570360-6	2007	Treatment with etoposide increased the content of RAI protein, too, and caused it to translocate to the nucleus.	Etoposide	15-24	SHC adaptor protein 3	Homo sapiens	50-53
17630856-0	2007	Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM.	Etoposide	43-52	tumor protein p53	Homo sapiens	11-14
17252195-2	2007	Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.	Etoposide	231-240	cyclin A2	Homo sapiens	31-39
17252195-2	2007	Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.	Etoposide	231-240	cyclin dependent kinase 2	Homo sapiens	40-44
17252195-2	2007	Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.	Etoposide	231-240	collagen type XI alpha 2 chain	Homo sapiens	91-95
17252195-3	2007	Etoposide-induced apoptotic cell death is efficiently prevented in cells that overexpress a dominant negative mutant of Cdk2 (Cdk2-dn) or p21(WAF1/CIP1), a specific Cdk inhibitor.	Etoposide	0-9	cyclin dependent kinase 2	Homo sapiens	120-124
17252195-3	2007	Etoposide-induced apoptotic cell death is efficiently prevented in cells that overexpress a dominant negative mutant of Cdk2 (Cdk2-dn) or p21(WAF1/CIP1), a specific Cdk inhibitor.	Etoposide	0-9	cyclin dependent kinase 2	Homo sapiens	126-130
17252195-3	2007	Etoposide-induced apoptotic cell death is efficiently prevented in cells that overexpress a dominant negative mutant of Cdk2 (Cdk2-dn) or p21(WAF1/CIP1), a specific Cdk inhibitor.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	138-141
17252195-3	2007	Etoposide-induced apoptotic cell death is efficiently prevented in cells that overexpress a dominant negative mutant of Cdk2 (Cdk2-dn) or p21(WAF1/CIP1), a specific Cdk inhibitor.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	142-146
17252195-3	2007	Etoposide-induced apoptotic cell death is efficiently prevented in cells that overexpress a dominant negative mutant of Cdk2 (Cdk2-dn) or p21(WAF1/CIP1), a specific Cdk inhibitor.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	147-151
17252195-5	2007	Disruption of the mitochondrial transmembrane potential in etoposide-induced cells is prevented in cells that overexpress Cdk2-dn or p21(WAF1/CIP1), while this transition is prominently promoted in Cyclin A-expressing cells.	Etoposide	59-68	cyclin dependent kinase 2	Homo sapiens	122-126
17252195-5	2007	Disruption of the mitochondrial transmembrane potential in etoposide-induced cells is prevented in cells that overexpress Cdk2-dn or p21(WAF1/CIP1), while this transition is prominently promoted in Cyclin A-expressing cells.	Etoposide	59-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	133-136
17252195-5	2007	Disruption of the mitochondrial transmembrane potential in etoposide-induced cells is prevented in cells that overexpress Cdk2-dn or p21(WAF1/CIP1), while this transition is prominently promoted in Cyclin A-expressing cells.	Etoposide	59-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	137-141
17252195-5	2007	Disruption of the mitochondrial transmembrane potential in etoposide-induced cells is prevented in cells that overexpress Cdk2-dn or p21(WAF1/CIP1), while this transition is prominently promoted in Cyclin A-expressing cells.	Etoposide	59-68	cyclin dependent kinase inhibitor 1A	Homo sapiens	142-146
17252195-5	2007	Disruption of the mitochondrial transmembrane potential in etoposide-induced cells is prevented in cells that overexpress Cdk2-dn or p21(WAF1/CIP1), while this transition is prominently promoted in Cyclin A-expressing cells.	Etoposide	59-68	cyclin A2	Homo sapiens	198-206
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	50-59	cyclin dependent kinase 2	Homo sapiens	30-34
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	50-59	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	50-59	cyclin dependent kinase 2	Homo sapiens	247-251
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	159-168	cyclin dependent kinase 2	Homo sapiens	30-34
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	159-168	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119
17252195-6	2007	We screened for mitochondrial Cdk2 targets in the etoposide-induced cells and found that the mitochondrial level of Bax is elevated by more than three fold in etoposide-treated cells and this elevation is effectively prevented in cells expressing Cdk2-dn under the same conditions.	Etoposide	159-168	cyclin dependent kinase 2	Homo sapiens	247-251
17630856-4	2007	Intriguingly, despite the apoptotic function of p53, BLM(/)TP53(/) cells were more sensitive than either single mutant to etoposide, an anticancer agent that poisons DNA topoisomerase II.	Etoposide	122-131	BLM RecQ like helicase	Homo sapiens	53-56
17630856-5	2007	Our results suggest a direct, BLM-independent role for p53 in etoposide-induced, topoisomerase II-mediated DNA damage in human cells.	Etoposide	62-71	BLM RecQ like helicase	Homo sapiens	30-33
17630856-5	2007	Our results suggest a direct, BLM-independent role for p53 in etoposide-induced, topoisomerase II-mediated DNA damage in human cells.	Etoposide	62-71	tumor protein p53	Homo sapiens	55-58
17637928-9	2007	In Bcl-2-transfected PT-67 cells, phosphorylated JNK1/2 levels were much lower after apoptogenic stimulus, and apoptosis induced by cadmium or etoposide was reduced compared with control.	Etoposide	143-152	B cell leukemia/lymphoma 2	Mus musculus	3-8
17545612-4	2007	As evidenced by increased Ser(139)-phosphorylated histone H2AX (gammaH2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect.	Etoposide	188-197	H2A.X variant histone	Homo sapiens	50-62
18079577-4	2007	Among the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide) have been the most studied.	Etoposide	39-48	vasoactive intestinal peptide	Homo sapiens	34-37
17575151-6	2007	We show that MDM2 SNP309 rendered a panel of cancer cell lines that are homozygous for SNP309 selectively resistant (approximately 10-fold) to certain TopoII-targeting chemotherapeutic drugs (etoposide, mitoxantrone, amsacrine, and ellipticine).	Etoposide	192-201	transformed mouse 3T3 cell double minute 2	Mus musculus	13-17
17302912-4	2007	Inhibition of phosphoinositide-3-kinase (PI3K)/Akt pathway with wortmannin or Akt small hairpin RNA (shRNA) abolished the ability of peroxynitrite to prevent etoposide-induced apoptotic death.	Etoposide	158-167	AKT serine/threonine kinase 1	Rattus norvegicus	47-50
17302912-4	2007	Inhibition of phosphoinositide-3-kinase (PI3K)/Akt pathway with wortmannin or Akt small hairpin RNA (shRNA) abolished the ability of peroxynitrite to prevent etoposide-induced apoptotic death.	Etoposide	158-167	AKT serine/threonine kinase 1	Rattus norvegicus	78-81
17710163-5	2007	E2-EPF knockdown sensitized HeLa cells to the topoisomerase (topo) II inhibitors etoposide and doxorubicin and also increased topo IIalpha protein levels.	Etoposide	81-90	ubiquitin conjugating enzyme E2 S	Homo sapiens	0-6
18219994-5	2007	The increase in MLD content was registered as early as 60 min after the addition of etoposide coinciding with the time course of caspase-3 activation.	Etoposide	84-93	caspase 3	Homo sapiens	129-138
17578914-1	2007	Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use.	Etoposide	57-66	host cell factor C1	Homo sapiens	68-73
17441964-5	2007	We also confirmed that the phosphorylated form of DNA-PK was increased by treatment with both etoposide and SN-38.	Etoposide	94-103	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	50-56
17545612-4	2007	As evidenced by increased Ser(139)-phosphorylated histone H2AX (gammaH2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect.	Etoposide	188-197	X-ray repair cross complementing 6	Homo sapiens	85-89
17544840-4	2007	Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells.	Etoposide	182-191	galectin 3	Homo sapiens	14-24
17611394-5	2007	Treatment with XIAP siRNA in combination with Paclitaxel, Cisplatin, Fluorouracil and Etoposide enhanced chemosensitivity.	Etoposide	86-95	X-linked inhibitor of apoptosis	Homo sapiens	15-19
17544840-4	2007	Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells.	Etoposide	182-191	BCL2 apoptosis regulator	Homo sapiens	88-93
17510313-12	2007	At concentrations increasing the flow cytometric pre-G(1) phase, doxorubicin or etoposide treatment caused serine phosphorylations in G alpha(12)-/- or G alpha(12/13)-/- cells, but did not induce mdm4.	Etoposide	80-89	G protein subunit alpha 12	Homo sapiens	134-145
17570219-10	2007	XAF1 expression suppressed tumor cell growth and enhanced cellular response to various apoptotic stimuli, such as 5-fluorouracil, etoposide, H(2)O(2), gamma-irradiation, ultraviolet, and tumor necrosis factor-alpha, whereas knockdown of its expression protected cells from the stresses.	Etoposide	130-139	XIAP associated factor 1	Homo sapiens	0-4
17266041-8	2007	Furthermore, melanoma cells with a reduced YB-1 expression showed a decreased resistance to the chemotherapeutic agents cisplatin and etoposide.	Etoposide	134-143	Y-box binding protein 1	Homo sapiens	43-47
17437058-5	2007	Moreover, targeted inhibition of livin by RNAi markedly sensitized RCC cells towards proapoptotic stimuli, such as UV irradiation or the chemotherapeutic drugs etoposide, 5-fluorouracil, and vinblastine.	Etoposide	160-169	baculoviral IAP repeat containing 7	Homo sapiens	33-38
17266398-8	2007	RESULTS: Knockdown of PKI gamma substantially extended the anti-apoptotic effects of PTH, whether apoptosis was induced by etoposide or dexamethasone.	Etoposide	123-132	cAMP-dependent protein kinase inhibitor gamma	Rattus norvegicus	22-31
17416635-7	2007	Stable transfection with the CUDR gene was found to induce resistance to doxorubicin and etoposide as well as drug-induced apoptosis in A431 cells.	Etoposide	89-98	urothelial cancer associated 1	Homo sapiens	29-33
17485829-1	2007	Previously, we found that an intraperitoneally administered chemotactic peptide, N-formyl-Met-Leu-Phe (fMLP), and MMK-1, a selective agonist of formyl peptide receptor-like 1 (FPRL1) receptor, the low affinity subtype of the fMLP receptor, prevented the alopecia in neonatal rats induced by the anticancer agent etoposide.	Etoposide	312-321	formyl peptide receptor 2	Rattus norvegicus	144-174
17485829-1	2007	Previously, we found that an intraperitoneally administered chemotactic peptide, N-formyl-Met-Leu-Phe (fMLP), and MMK-1, a selective agonist of formyl peptide receptor-like 1 (FPRL1) receptor, the low affinity subtype of the fMLP receptor, prevented the alopecia in neonatal rats induced by the anticancer agent etoposide.	Etoposide	312-321	formyl peptide receptor 2	Rattus norvegicus	176-181
17513603-9	2007	Furthermore, c-FLIP gene silencing sensitized MDA435 cells to other chemotherapies, including etoposide, mitoxantrone, and SN-38.	Etoposide	94-103	CASP8 and FADD like apoptosis regulator	Homo sapiens	13-19
17510313-12	2007	At concentrations increasing the flow cytometric pre-G(1) phase, doxorubicin or etoposide treatment caused serine phosphorylations in G alpha(12)-/- or G alpha(12/13)-/- cells, but did not induce mdm4.	Etoposide	80-89	G protein subunit alpha 12	Homo sapiens	152-165
17510313-12	2007	At concentrations increasing the flow cytometric pre-G(1) phase, doxorubicin or etoposide treatment caused serine phosphorylations in G alpha(12)-/- or G alpha(12/13)-/- cells, but did not induce mdm4.	Etoposide	80-89	MDM4 regulator of p53	Homo sapiens	196-200
17276981-6	2007	In support of an apoptosis rather than necrosis process, Aph-1 and Pen-2 also lower staurosporine- and etoposide-induced caspase-3 expression and diminished caspase-3 activity and poly(ADP-ribose) polymerase inactivation.	Etoposide	103-112	aph-1 homolog A, gamma-secretase subunit	Homo sapiens	57-62
17390037-0	2007	Expression of cyclin A in human leukemia cell line HL-60 following treatment with doxorubicin and etoposide: the potential involvement of cyclin A in apoptosis.	Etoposide	98-107	cyclin A2	Homo sapiens	14-22
17390037-1	2007	We investigated expression of cyclin A in HL-60 cells after induction of apoptosis with doxorubicin and etoposide.	Etoposide	104-113	cyclin A2	Homo sapiens	30-38
17390037-5	2007	Cells treated with lower doses of doxorubicin and etoposide as well as the untreated cells were found to have cyclin A scattered mainly throughout the nucleus.	Etoposide	50-59	cyclin A2	Homo sapiens	110-118
17390037-6	2007	However, immunogold labeling of cyclin A in both cell lines treated with 5- and 10-microM doses of doxorubicin, and 20 and 200 microM of etoposide was observed more often in the cytoplasm than in the nucleus.	Etoposide	137-146	cyclin A2	Homo sapiens	32-40
17057733-7	2007	This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant.	Etoposide	37-46	tumor protein p53	Homo sapiens	84-87
17057733-7	2007	This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant.	Etoposide	37-46	tumor protein p53	Homo sapiens	138-141
17057733-8	2007	Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide.	Etoposide	157-166	ribosomal protein S27 like	Homo sapiens	32-38
17057733-8	2007	Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide.	Etoposide	157-166	ribosomal protein S27 like	Homo sapiens	118-124
17564107-6	2007	The patient received 5 cycles of cisplatin-based PEP chemotherapy (cisplatin, etoposide and peplomycin) after which all the tumor markers fell to within the normal range.	Etoposide	78-87	progestagen associated endometrial protein	Homo sapiens	49-52
17371003-6	2007	One of the most potent DNA-PK inhibitors identified, 2-(4-methoxyphenyl)-6-(morpholin-4-yl)pyran-4-one (16; DNA-PK; IC50=220 nM) effectively sensitized HeLa cells to the topoisomerase II inhibitor etoposide in vitro.	Etoposide	197-206	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	23-29
17276981-6	2007	In support of an apoptosis rather than necrosis process, Aph-1 and Pen-2 also lower staurosporine- and etoposide-induced caspase-3 expression and diminished caspase-3 activity and poly(ADP-ribose) polymerase inactivation.	Etoposide	103-112	presenilin enhancer, gamma-secretase subunit	Homo sapiens	67-72
17276981-6	2007	In support of an apoptosis rather than necrosis process, Aph-1 and Pen-2 also lower staurosporine- and etoposide-induced caspase-3 expression and diminished caspase-3 activity and poly(ADP-ribose) polymerase inactivation.	Etoposide	103-112	caspase 3	Homo sapiens	121-130
17315145-2	2007	It was reported that etoposide is a substrate for P-gp and metabolized mainly via CYP3A4 and to a lesser degree via CYP1A2 and 2E1.	Etoposide	21-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-54
17351391-12	2007	Multidrug resistance protein 1 expression correlates positively with the GI50 values of several drugs, e.g. vinblastine and etoposide, and negatively with the GI50 values of 5-fluorouracil.	Etoposide	124-133	ATP binding cassette subfamily B member 1	Homo sapiens	0-30
17086211-3	2007	Stable expression of APIP in C2C12 (C2C12/APIP) cells suppressed cell death induced by hypoxia and etoposide.	Etoposide	99-108	APAF1 interacting protein	Mus musculus	21-25
17086211-3	2007	Stable expression of APIP in C2C12 (C2C12/APIP) cells suppressed cell death induced by hypoxia and etoposide.	Etoposide	99-108	APAF1 interacting protein	Mus musculus	36-46
17315145-2	2007	It was reported that etoposide is a substrate for P-gp and metabolized mainly via CYP3A4 and to a lesser degree via CYP1A2 and 2E1.	Etoposide	21-30	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	116-122
17409444-8	2007	ASNS overexpression also induced resistance to apoptosis triggered by cisplatin [cis-diammine-dichloroplatinum (CDDP)] and carboplatin, but not by 5-fluorouracil, paclitaxel, etoposide, or gemcitabine.	Etoposide	175-184	asparagine synthetase (glutamine-hydrolyzing)	Homo sapiens	0-4
17363570-5	2007	Long-term silencing of XPC gene expression led to an increased sensitivity to etoposide, a topoisomerase II inhibitor that creates DSBs through the progression of DNA replication forks.	Etoposide	78-87	XPC complex subunit, DNA damage recognition and repair factor	Homo sapiens	23-26
17431117-5	2007	The TRAIL- and drug-resistant prostate carcinoma PC-3 cell line was treated with CDDP, VP-16, ADR, and vincristine.	Etoposide	87-92	TNF superfamily member 10	Homo sapiens	4-9
17332941-2	2007	We previously reported that nuclear textural changes observed in the OV1-VCR etoposide-resistant ovarian carcinoma cell line were associated with an increased acetylated histone H4 level.	Etoposide	77-86	protein tyrosine phosphatase 4A2	Homo sapiens	69-72
17431107-0	2007	Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells.	Etoposide	69-78	gastrin releasing peptide	Homo sapiens	57-65
17431107-3	2007	Our research was based on the role of bombesin in modulating the mitochondrial membrane potential (Delta psi(m)) in cell death induced by etoposide on PC-3 cells.	Etoposide	138-147	gastrin releasing peptide	Homo sapiens	38-46
17431107-9	2007	The loss of Delta psi(m) in etoposide-treated PC-3 cells was prevented by bombesin.	Etoposide	28-37	gastrin releasing peptide	Homo sapiens	74-82
17431107-10	2007	The quantitative analysis of JC-1-stained cells revealed a significant decrease in the red (high Delta psi(m)) to green (low Delta psi(m)) ratio in etoposide-treated cells when compared with control cells, which was restored in the presence of bombesin (P &lt; 0.00001).	Etoposide	148-157	gastrin releasing peptide	Homo sapiens	244-252
17279585-8	2007	In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin.	Etoposide	32-41	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
16797120-7	2007	Furthermore, we have found that reactive oxygen species (ROS) is an upstream signal of AMPK, and the combined treatment of EGCG and chemotherapeutic agents, 5-FU or Etoposide, exert a novel therapeutic effect on chemo-resistant colon cancer cells.	Etoposide	165-174	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	87-91
17107344-5	2007	In contrast with direct apoptotic stimuli, such as the anti-cancer drug etoposide, leading to caspase-dependent degradation of S1 and S5a, the effect of IEX-1 is independent of proteolytic cleavage of these proteins.	Etoposide	72-81	immediate early response 3	Homo sapiens	153-158
17372087-0	2007	The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.	Etoposide	78-87	CD44 molecule (Indian blood group)	Homo sapiens	28-32
17229476-0	2007	Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding.	Etoposide	75-84	poly(ADP-ribose) polymerase family member 4	Homo sapiens	23-27
17229476-0	2007	Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding.	Etoposide	75-84	cullin 7	Homo sapiens	28-32
17229476-2	2007	Expression of a dominant interfering variant of mouse p193/CUL7 (designated 1152stop) conferred resistance to MG132- and etoposide-induced apoptosis in U2OS cells.	Etoposide	121-130	cullin 7	Mus musculus	54-58
17229476-2	2007	Expression of a dominant interfering variant of mouse p193/CUL7 (designated 1152stop) conferred resistance to MG132- and etoposide-induced apoptosis in U2OS cells.	Etoposide	121-130	cullin 7	Mus musculus	59-63
17071631-7	2007	Securin overexpression in HCT116 cells inhibited etoposide-induced double-stranded DNA damage repair activity, and repressed Ku heterodimer function.	Etoposide	49-58	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	0-7
17279585-10	2007	Cytotoxicity assays showed that the resistance of the osteosarcoma cell lines to etoposide correlated with PXR protein expression levels and activation of P450 3A4 and could be prevented by ketoconazole.	Etoposide	81-90	nuclear receptor subfamily 1 group I member 2	Homo sapiens	107-110
17071631-8	2007	Additionally, we observed that securin and Ku70 showed a reciprocal cytosol-nuclear translocation in response to etoposide-induced dsDNA damage.	Etoposide	113-122	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	31-38
17071631-8	2007	Additionally, we observed that securin and Ku70 showed a reciprocal cytosol-nuclear translocation in response to etoposide-induced dsDNA damage.	Etoposide	113-122	X-ray repair cross complementing 6	Homo sapiens	43-47
17151191-0	2007	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.	Etoposide	72-81	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-31
17441316-12	2007	Cisplatin and etoposide could enhance the killing effect of TRAIL on SH-SY5Y cells.	Etoposide	14-23	TNF superfamily member 10	Homo sapiens	60-65
17332306-6	2007	RESULTS: We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3(+) MLL-fusion gene leukemia cells.	Etoposide	23-32	N-methylpurine DNA glycosylase	Homo sapiens	65-68
17332306-6	2007	RESULTS: We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3(+) MLL-fusion gene leukemia cells.	Etoposide	23-32	fms related receptor tyrosine kinase 3	Homo sapiens	108-112
17332306-6	2007	RESULTS: We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3(+) MLL-fusion gene leukemia cells.	Etoposide	23-32	lysine methyltransferase 2A	Homo sapiens	116-119
17332306-7	2007	Cells with an internal tandem duplication (ITD) FLT3 (Molm13 and MV4;11) were more sensitive to etoposide/17-AAG than leukemias with wild-type FLT3 (HPB-Null and RS4;11).	Etoposide	96-105	fms related receptor tyrosine kinase 3	Homo sapiens	48-52
17332306-10	2007	CONCLUSIONS: The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 especially leukemias with ITD-FLT3.	Etoposide	60-69	fms related receptor tyrosine kinase 3	Homo sapiens	127-131
17332306-10	2007	CONCLUSIONS: The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 especially leukemias with ITD-FLT3.	Etoposide	60-69	fms related receptor tyrosine kinase 3	Homo sapiens	162-166
17332306-11	2007	These data suggest a rational therapeutic strategy for FLT3(+) leukemias that combines etoposide or other DNA-damaging agents with Hsp90/FLT3 inhibitors such as 17-AAG.	Etoposide	87-96	fms related receptor tyrosine kinase 3	Homo sapiens	55-59
17441316-8	2007	Cisplatin and etoposide could enhance the sensitivity of TRAIL on SH-SY5Y cells.	Etoposide	14-23	TNF superfamily member 10	Homo sapiens	57-62
17151191-0	2007	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.	Etoposide	210-219	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-31
17151191-2	2007	In this study, three isomeric glucuronides of etoposide, including one phenolic (EPG) and two alcoholic glucuronides (EAG1 and EAG2), were biosynthesized in vitro with human liver microsomes (HLMs), and identified by liquid chromatography-electrospray ionization-mass spectrometry and confirmed by beta-glucuronidase cleavage.	Etoposide	46-55	potassium voltage-gated channel subfamily H member 1	Homo sapiens	118-122
17151191-2	2007	In this study, three isomeric glucuronides of etoposide, including one phenolic (EPG) and two alcoholic glucuronides (EAG1 and EAG2), were biosynthesized in vitro with human liver microsomes (HLMs), and identified by liquid chromatography-electrospray ionization-mass spectrometry and confirmed by beta-glucuronidase cleavage.	Etoposide	46-55	potassium voltage-gated channel subfamily H member 5	Homo sapiens	127-131
17151191-3	2007	In vitro UDP-glucuronosyltransferase (UGT) reaction screening with 12 recombinant human UGTs demonstrated that etoposide glucuronidation is mainly catalyzed by UGT1A1.	Etoposide	111-120	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	9-36
17151191-3	2007	In vitro UDP-glucuronosyltransferase (UGT) reaction screening with 12 recombinant human UGTs demonstrated that etoposide glucuronidation is mainly catalyzed by UGT1A1.	Etoposide	111-120	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	38-41
17151191-3	2007	In vitro UDP-glucuronosyltransferase (UGT) reaction screening with 12 recombinant human UGTs demonstrated that etoposide glucuronidation is mainly catalyzed by UGT1A1.	Etoposide	111-120	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	160-166
17151191-4	2007	Although UGT1A8 and 1A3 also catalyzed the glucuronidation of etoposide, their activities were approximately 10 and 1% of UGT1A1.	Etoposide	62-71	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	9-15
17151191-4	2007	Although UGT1A8 and 1A3 also catalyzed the glucuronidation of etoposide, their activities were approximately 10 and 1% of UGT1A1.	Etoposide	62-71	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	122-128
17151191-9	2007	The data indicated that UGT1A1 is principally responsible for the formation of etoposide glucuronides, mainly in the form of phenolic glucuronide, suggesting that etoposide can be used as a highly selective probe substrate for human UGT1A1 in vitro.	Etoposide	79-88	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	24-30
17151191-9	2007	The data indicated that UGT1A1 is principally responsible for the formation of etoposide glucuronides, mainly in the form of phenolic glucuronide, suggesting that etoposide can be used as a highly selective probe substrate for human UGT1A1 in vitro.	Etoposide	79-88	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	233-239
17363491-0	2007	ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment.	Etoposide	26-35	chloride voltage-gated channel 3	Homo sapiens	0-5
17363491-7	2007	ClC-3 overexpression increased the acidity of intracellular vesicles, as assessed by acridine orange staining, and enhanced resistance to the chemotherapeutic drug etoposide by almost doubling the IC(50) in either BON or HEK293 cell lines.	Etoposide	164-173	chloride voltage-gated channel 3	Homo sapiens	0-5
17363491-10	2007	The probable mechanism of enhanced etoposide resistance can be attributed to the increase of vesicular acidification as consequence of ClC-3 overexpression.	Etoposide	35-44	chloride voltage-gated channel 3	Homo sapiens	135-140
17380453-0	2007	[Protein kinase B inhibitor enhance sensitivity of gastric cancer cell to etoposide].	Etoposide	74-83	protein tyrosine kinase 2 beta	Homo sapiens	1-17
17380453-1	2007	OBJECTIVE: To observe the effects of etoposide on protein kinase B (PKB) activity in distinct differentiated gastric cancer cell lines and the change of sensitivity to etoposide after pretreatment by wortmannin, a PKB inhibitor.	Etoposide	37-46	protein tyrosine kinase 2 beta	Homo sapiens	50-66
17380453-2	2007	To explore the relationship between PKB activity in gastric cancer cells and their sensitivity to etoposide chemotherapy.	Etoposide	98-107	protein tyrosine kinase 2 beta	Homo sapiens	36-39
17380453-1	2007	OBJECTIVE: To observe the effects of etoposide on protein kinase B (PKB) activity in distinct differentiated gastric cancer cell lines and the change of sensitivity to etoposide after pretreatment by wortmannin, a PKB inhibitor.	Etoposide	37-46	protein tyrosine kinase 2 beta	Homo sapiens	68-71
17380453-4	2007	The PKB activities of these cell lines were detected by nonradioactive protein-kinase assay at different time points after etoposide treatment for 0,3,6,12,24 h with or without wortmannin pretreatment.	Etoposide	123-132	protein tyrosine kinase 2 beta	Homo sapiens	4-7
17380453-7	2007	Etoposide treatment resulted in increase in PKB activity and apoptosis rate,and decrease in cell survival rate in a time-dependent manner in gastric cancer cell lines.	Etoposide	0-9	protein tyrosine kinase 2 beta	Homo sapiens	44-47
17380453-1	2007	OBJECTIVE: To observe the effects of etoposide on protein kinase B (PKB) activity in distinct differentiated gastric cancer cell lines and the change of sensitivity to etoposide after pretreatment by wortmannin, a PKB inhibitor.	Etoposide	168-177	protein tyrosine kinase 2 beta	Homo sapiens	214-217
17380453-9	2007	CONCLUSIONS: Etoposide can induce the PKB activity in gastric cancer cell lines.	Etoposide	13-22	protein tyrosine kinase 2 beta	Homo sapiens	38-41
17268080-2	2007	Here, we show that Chk1 is cleaved in the treatment of apoptotic dose of etoposide (ETP) or cisplatin (CIS) but not of viable dose in HeLa S3 cells.	Etoposide	73-82	checkpoint kinase 1	Homo sapiens	19-23
17268080-2	2007	Here, we show that Chk1 is cleaved in the treatment of apoptotic dose of etoposide (ETP) or cisplatin (CIS) but not of viable dose in HeLa S3 cells.	Etoposide	84-87	checkpoint kinase 1	Homo sapiens	19-23
17143545-11	2007	Furthermore, exogenous BRCC3 expression was associated with a delay in etoposide-induced cell death and an increase in cell proliferation.	Etoposide	71-80	BRCA1/BRCA2-containing complex subunit 3	Homo sapiens	23-28
16778834-2	2007	Previously, we found BDNF activation of TrkB through PI3K/Akt protects NB from etoposide/cisplatin-induced cell death.	Etoposide	79-88	brain derived neurotrophic factor	Homo sapiens	21-25
16778834-2	2007	Previously, we found BDNF activation of TrkB through PI3K/Akt protects NB from etoposide/cisplatin-induced cell death.	Etoposide	79-88	neurotrophic receptor tyrosine kinase 2	Homo sapiens	40-44
16778834-2	2007	Previously, we found BDNF activation of TrkB through PI3K/Akt protects NB from etoposide/cisplatin-induced cell death.	Etoposide	79-88	AKT serine/threonine kinase 1	Homo sapiens	58-61
17490511-0	2007	hMRE11 plays an important role in U937 cellular response to DNA double-strand breaks following etoposide.	Etoposide	95-104	MRE11 homolog, double strand break repair nuclease	Homo sapiens	0-6
17490511-1	2007	MRE11 plays an important role in the signal transduction of DNA damage response, therefore this study was purposed to explore the relationship between hMRE11 focus formation and DNA double-strand breaks (DSBs) caused by etoposide (VP-16) in human promonocytic cells U937.	Etoposide	220-229	MRE11 homolog, double strand break repair nuclease	Homo sapiens	0-5
17490511-1	2007	MRE11 plays an important role in the signal transduction of DNA damage response, therefore this study was purposed to explore the relationship between hMRE11 focus formation and DNA double-strand breaks (DSBs) caused by etoposide (VP-16) in human promonocytic cells U937.	Etoposide	220-229	MRE11 homolog, double strand break repair nuclease	Homo sapiens	151-157
17490511-1	2007	MRE11 plays an important role in the signal transduction of DNA damage response, therefore this study was purposed to explore the relationship between hMRE11 focus formation and DNA double-strand breaks (DSBs) caused by etoposide (VP-16) in human promonocytic cells U937.	Etoposide	220-229	host cell factor C1	Homo sapiens	231-236
17062569-3	2007	We have developed new immnunological reagents to study the properties of human Cdc7 kinase in cells challenged with the ribonucleotide reductase inhibitor hydroxyurea or with the DNA topoisomerase II inhibitor etoposide.	Etoposide	210-219	cell division cycle 7	Homo sapiens	79-83
17062569-5	2007	Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4.	Etoposide	59-68	cell division cycle 7	Homo sapiens	0-4
17062569-5	2007	Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4.	Etoposide	59-68	minichromosome maintenance complex component 2	Homo sapiens	102-106
17062569-5	2007	Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4.	Etoposide	59-68	cell division cycle 7	Homo sapiens	119-123
17062569-5	2007	Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4.	Etoposide	59-68	minichromosome maintenance complex component 4	Homo sapiens	214-218
17159503-5	2007	Etoposide decreased the viability of COLO 205 cells with a concomitant increase in the 50-kDa clusterin concentration in the cell nucleus.	Etoposide	0-9	clusterin	Homo sapiens	94-103
17092291-0	2007	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.	Etoposide	110-119	epidermal growth factor receptor	Homo sapiens	18-50
17092291-1	2007	OBJECTIVE: To investigate the effect of the epidermal growth factor receptor (EGFR) on the induction of apoptosis by the chemotherapeutic agent etoposide (VP16), and to examine the effect of combining VP16 with gefitinib to see if the cell-survival mechanism can be prevented.	Etoposide	144-153	epidermal growth factor receptor	Homo sapiens	44-76
17092291-1	2007	OBJECTIVE: To investigate the effect of the epidermal growth factor receptor (EGFR) on the induction of apoptosis by the chemotherapeutic agent etoposide (VP16), and to examine the effect of combining VP16 with gefitinib to see if the cell-survival mechanism can be prevented.	Etoposide	144-153	epidermal growth factor receptor	Homo sapiens	78-82
17092291-1	2007	OBJECTIVE: To investigate the effect of the epidermal growth factor receptor (EGFR) on the induction of apoptosis by the chemotherapeutic agent etoposide (VP16), and to examine the effect of combining VP16 with gefitinib to see if the cell-survival mechanism can be prevented.	Etoposide	155-159	epidermal growth factor receptor	Homo sapiens	44-76
17092291-1	2007	OBJECTIVE: To investigate the effect of the epidermal growth factor receptor (EGFR) on the induction of apoptosis by the chemotherapeutic agent etoposide (VP16), and to examine the effect of combining VP16 with gefitinib to see if the cell-survival mechanism can be prevented.	Etoposide	155-159	epidermal growth factor receptor	Homo sapiens	78-82
17261498-3	2007	K562/AS-3 was found to be about 7-fold more resistant to As2O3 than the parent cells (IC50=12.9 microM for K562/AS-3 and 1.8 microM for K562), and also showed cross resistance to VP-16 and vincristine.	Etoposide	179-184	PDS5 cohesin associated factor B	Homo sapiens	5-9
17297310-0	2007	Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.	Etoposide	75-84	ATM serine/threonine kinase	Homo sapiens	13-16
17297310-0	2007	Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.	Etoposide	75-84	H2A.X variant histone	Homo sapiens	37-41
17297310-4	2007	Using multiparameter cytometry we measured the expression of ATM-S1981P and gammaH2AX as well as initiation of apoptosis (caspase-3 activation) in relation to the cell cycle phase in etoposide-treated human lymphoblastoid TK6 cells.	Etoposide	183-192	ATM serine/threonine kinase	Homo sapiens	61-67
17297310-4	2007	Using multiparameter cytometry we measured the expression of ATM-S1981P and gammaH2AX as well as initiation of apoptosis (caspase-3 activation) in relation to the cell cycle phase in etoposide-treated human lymphoblastoid TK6 cells.	Etoposide	183-192	caspase 3	Homo sapiens	122-131
17297310-7	2007	The extent of etoposide-induced H2AX phosphorylation was partially reduced by N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species (ROS).	Etoposide	14-23	H2A.X variant histone	Homo sapiens	32-36
17297310-7	2007	The extent of etoposide-induced H2AX phosphorylation was partially reduced by N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species (ROS).	Etoposide	14-23	X-linked Kx blood group	Homo sapiens	99-102
17297310-9	2007	NAC also protected a fraction of G(1) cells from etoposide-induced apoptosis, but had no such effect on S or G(2)M cells.	Etoposide	49-58	X-linked Kx blood group	Homo sapiens	0-3
16960658-17	2007	THC significantly increased the sensitivity of vinblastine, mitoxantrone and etoposide in drug resistance KB-V-1, MCF7AdrVp3000 and MRP1-HEK 293 cells, respectively.	Etoposide	77-86	ATP binding cassette subfamily C member 1	Homo sapiens	132-136
17121854-7	2007	With a similar timing, the proteolytic processing of APP is rapidly affected by the genotoxic stress: in fact, the cleavage of the APP COOH-terminal fragments by gamma-secretase is induced soon after the exposure of cells to etoposide, in a Fe65-dependent manner.	Etoposide	225-234	amyloid beta (A4) precursor protein-binding, family B, member 1	Mus musculus	241-245
17013895-1	2007	In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-beta) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines.	Etoposide	343-352	epidermal growth factor receptor	Homo sapiens	133-165
17013895-1	2007	In this study, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, with other chemotherapeutic drugs including estrogen receptor-beta (ER-beta) antagonist (tamoxifen) and topoisomerase II inhibitor (etoposide) on some metastatic prostate cancer (PC) cell lines.	Etoposide	343-352	epidermal growth factor receptor	Homo sapiens	167-171
17013895-7	2007	These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-beta signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.	Etoposide	102-111	epidermal growth factor receptor	Homo sapiens	67-71
17013895-7	2007	These findings indicate that the combined use of inhibitors of EGF-EGFR and E2-ER-beta signaling with etoposide, which act by increasing the cellular ceramide levels and caspase activity, represents a promising strategy for a more effective treatment of metastatic PC forms.	Etoposide	102-111	estrogen receptor 2	Homo sapiens	79-86
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Etoposide	354-363	CD93 molecule	Homo sapiens	45-49
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Etoposide	365-368	CD93 molecule	Homo sapiens	45-49
17237293-1	2007	Topoisomerase IIalpha (topo IIalpha) is an important target for several chemotherapeutic agents, including etoposide and doxorubicin.	Etoposide	107-116	ATPase, class II, type 9A	Mus musculus	14-21
17237293-1	2007	Topoisomerase IIalpha (topo IIalpha) is an important target for several chemotherapeutic agents, including etoposide and doxorubicin.	Etoposide	107-116	ATPase, class II, type 9A	Mus musculus	28-35
17158148-5	2007	When compared with wild-type HCT116 cells, RAD18-/- cells, defective in the repair of X-ray-induced chromosomal aberrations, were significantly hypersensitive to X-ray-irradiation and also to the topoisomerase I inhibitor camptothecin (CPT) capable of inducing single-strand breaks but were not so sensitive to the topoisomerase II inhibitor etoposide capable of inducing double-strand breaks.	Etoposide	342-351	RAD18 E3 ubiquitin protein ligase	Homo sapiens	43-48
17187072-5	2007	Administration of recombinant CRT or inhibitors of protein phosphatase 1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo.	Etoposide	134-143	calreticulin	Mus musculus	30-72
17187072-5	2007	Administration of recombinant CRT or inhibitors of protein phosphatase 1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo.	Etoposide	134-143	protein phosphatase 1, regulatory subunit 15A	Mus musculus	73-79
17097066-2	2006	The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide.	Etoposide	150-159	TNF superfamily member 10	Homo sapiens	13-18
17516866-7	2007	Levels of p53 in PF and NA marrow increased in response to ETO treatment, but this did not occur in ND bone marrow.	Etoposide	59-62	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	10-13
21182806-9	2006	Spearman correlation assay showed that there was a correlation between the chemotherapeutics resistance to ADM, VP-16, VCR, TPT and the expression of GRP78 in NSCLC (P &lt; 0.05).	Etoposide	112-117	heat shock protein family A (Hsp70) member 5	Homo sapiens	150-155
17057225-7	2006	Of note, treatment of cancer cells with etoposide induces TEF activation and promotes the expression of bcl-gS.	Etoposide	40-49	TEF transcription factor, PAR bZIP family member	Homo sapiens	58-61
17057225-8	2006	Furthermore, blockade of bcl-gS or TEF expression by a small interfering RNA strategy or transfection with tDBP significantly reduces the etoposide-mediated apoptotic cell death.	Etoposide	138-147	TEF transcription factor, PAR bZIP family member	Homo sapiens	35-38
17046751-7	2006	The EndoG-positive WDNI cells were more sensitive to etoposide- or camptothecin-induced cell death than EndoG-negative PDI cells.	Etoposide	53-62	endonuclease G	Homo sapiens	4-9
16767158-3	2006	We show that caspase-10 is activated in etoposide-treated cells in a dose- and time-dependent manner.	Etoposide	40-49	caspase 10	Homo sapiens	13-23
17046751-8	2006	Silencing of EndoG caused inhibited of SK-BR-3 WDNI cell death induced by etoposide.	Etoposide	74-83	endonuclease G	Homo sapiens	13-18
16767158-6	2006	siRNA-mediated downregulation of Apaf-1 prevents etoposide-mediated activation of caspase-10.	Etoposide	49-58	apoptotic peptidase activating factor 1	Homo sapiens	33-39
16767158-6	2006	siRNA-mediated downregulation of Apaf-1 prevents etoposide-mediated activation of caspase-10.	Etoposide	49-58	caspase 10	Homo sapiens	82-92
16960866-5	2006	Both inhibitors and stable expression of SR-IkB are associated with down-modulation of the antiapoptotic protein Bcl-xL, suggesting that the survival pathway activated by Etoposide involves NF-kB-mediated Bcl-xL expression.	Etoposide	171-180	BCL2 like 1	Homo sapiens	113-119
17140455-10	2006	Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells.	Etoposide	150-159	prominin 1	Homo sapiens	13-18
17140455-10	2006	Furthermore, CD133 positive cells were significantly resistant to chemotherapeutic agents including temozolomide, carboplatin, paclitaxel (Taxol) and etoposide (VP16) compared to autologous CD133 negative cells.	Etoposide	161-165	prominin 1	Homo sapiens	13-18
16960866-5	2006	Both inhibitors and stable expression of SR-IkB are associated with down-modulation of the antiapoptotic protein Bcl-xL, suggesting that the survival pathway activated by Etoposide involves NF-kB-mediated Bcl-xL expression.	Etoposide	171-180	BCL2 like 1	Homo sapiens	205-211
17106245-5	2006	Here we show that, when overexpressed in HEK293 and REN mesothelioma cells, PECAM-1 confers resistance to apoptosis induced by the DNA-damaging chemotherapeutic agent, etoposide.	Etoposide	168-177	platelet and endothelial cell adhesion molecule 1	Homo sapiens	76-83
17384250-0	2006	Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide.	Etoposide	193-202	BCL2 apoptosis regulator	Homo sapiens	58-62
17384250-0	2006	Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide.	Etoposide	193-202	caspase 3	Homo sapiens	74-83
17384250-0	2006	Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide.	Etoposide	193-202	BCL2 like 12	Homo sapiens	106-113
17384250-3	2006	The aim of the present research approach to investigate the expression of the apoptosis-related genes BCL2 (Bcl-2), FAS, Caspase-3, BAX and the new member BCL2L12, cloned by our group, along with treatment of HL-60 leukemia cells with etoposide.	Etoposide	235-244	BCL2 apoptosis regulator	Homo sapiens	102-106
17384250-3	2006	The aim of the present research approach to investigate the expression of the apoptosis-related genes BCL2 (Bcl-2), FAS, Caspase-3, BAX and the new member BCL2L12, cloned by our group, along with treatment of HL-60 leukemia cells with etoposide.	Etoposide	235-244	BCL2 like 12	Homo sapiens	155-162
17106245-6	2006	Surprisingly, PECAM-1-mediated cytoprotection was found to be largely independent of its ability to form a signaling complex with the protein-tyrosine phosphatase SHP-2, as virtually no tyrosine phosphorylation of, or SHP-2 association with, PECAM-1 could be detected after etoposide treatment.	Etoposide	274-283	platelet and endothelial cell adhesion molecule 1	Homo sapiens	14-21
17123296-5	2006	RESULTS: Costaining etoposide-treated leukemoid cells with lactadherin and annexin V indicated progressive PS exposure with dim, intermediate, and bright staining.	Etoposide	20-29	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	59-70
17168690-1	2006	Etoposide (VP-16), a DNA topoisomerase II poison widely used as an antineoplastic agent is also known to cause leukemia.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
17168690-10	2006	Therefore, the presence of etoposide-OH, which can be formed from etoposide metabolism by CYP3A4, is essential for formation of the GSH conjugate.	Etoposide	27-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
17123296-5	2006	RESULTS: Costaining etoposide-treated leukemoid cells with lactadherin and annexin V indicated progressive PS exposure with dim, intermediate, and bright staining.	Etoposide	20-29	annexin A5	Homo sapiens	75-84
16982679-3	2006	We report that etoposide and gamma irradiation induce apoptosis of salivary acinar cells from FVB control mice in vitro and in vivo; however, apoptosis is reduced in transgenic mice expressing a constitutively activated mutant of Akt1 (myr-Akt1).	Etoposide	15-24	thymoma viral proto-oncogene 1	Mus musculus	230-234
17089011-6	2006	SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	Etoposide	109-114	DNA topoisomerase II alpha	Homo sapiens	64-69
17089011-6	2006	SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	Etoposide	109-114	fatty acid synthase	Homo sapiens	156-159
16982679-7	2006	Reduction of MDM2 levels in myr-Akt1 primary salivary acinar cells with small interfering RNA increases the levels of p53 protein and renders these cells susceptible to etoposide-induced apoptosis in spite of the presence of activated Akt1.	Etoposide	169-178	transformed mouse 3T3 cell double minute 2	Mus musculus	13-17
17158769-7	2006	The inhibition of PKCdelta suppressed etoposide-induced apoptosis, while overexpression of PKCdelta enhanced it.	Etoposide	38-47	protein kinase C delta	Homo sapiens	18-26
17158769-8	2006	In contrast, inhibition of PKCalpha elevated basal levels of apoptosis and potentiated etoposide-induced cell death.	Etoposide	87-96	protein kinase C alpha	Homo sapiens	27-35
17158769-9	2006	Etoposide treatment also selectively activated PKCdelta, but resulted in both cytosolic translocation and decreased activity of PKCalpha.	Etoposide	0-9	protein kinase C delta	Homo sapiens	47-55
17158769-9	2006	Etoposide treatment also selectively activated PKCdelta, but resulted in both cytosolic translocation and decreased activity of PKCalpha.	Etoposide	0-9	protein kinase C alpha	Homo sapiens	128-136
17158769-10	2006	A fraction of PKCdelta also underwent caspase-dependent cleavage, in response to etoposide.	Etoposide	81-90	protein kinase C delta	Homo sapiens	14-22
16971506-10	2006	p53 phosphorylation was induced by serum withdrawal and other chemotherapeutic reagents such as actinomycin D, doxorubicin, and etoposide.	Etoposide	128-137	tumor protein p53	Homo sapiens	0-3
16971507-0	2006	Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.	Etoposide	33-42	tumor protein p53	Homo sapiens	107-110
16971507-3	2006	Here we show that human astrocytoma ADF cells (which are resistant to "mitochondriotropic" agents as well as to the antineoplastic drug etoposide and to proteasome inhibitors when used alone) undergo dramatic apoptotic death when exposed to a combination protocol based on the use of etoposide in the presence of proteasome inhibitors.	Etoposide	136-145	destrin, actin depolymerizing factor	Homo sapiens	36-39
16971507-3	2006	Here we show that human astrocytoma ADF cells (which are resistant to "mitochondriotropic" agents as well as to the antineoplastic drug etoposide and to proteasome inhibitors when used alone) undergo dramatic apoptotic death when exposed to a combination protocol based on the use of etoposide in the presence of proteasome inhibitors.	Etoposide	284-293	destrin, actin depolymerizing factor	Homo sapiens	36-39
17189930-7	2006	After surgery, the patient received 5 cycles of adjuvant chemotherapy with VIP (etoposide, ifosfamide, and cisplatin) regimen.	Etoposide	80-89	vasoactive intestinal peptide	Homo sapiens	75-78
17119454-6	2006	We analysed dose-dependent release of cytochrome c, caspase-9 activation, cleavage of PARP and activation of effector caspases in etoposide and cisplatin-resistant cells after exposure to etoposide, teniposide, cisplatin or fotemustine.	Etoposide	130-139	caspase 9	Homo sapiens	118-126
17119454-6	2006	We analysed dose-dependent release of cytochrome c, caspase-9 activation, cleavage of PARP and activation of effector caspases in etoposide and cisplatin-resistant cells after exposure to etoposide, teniposide, cisplatin or fotemustine.	Etoposide	188-197	poly(ADP-ribose) polymerase 1	Homo sapiens	86-90
16982679-3	2006	We report that etoposide and gamma irradiation induce apoptosis of salivary acinar cells from FVB control mice in vitro and in vivo; however, apoptosis is reduced in transgenic mice expressing a constitutively activated mutant of Akt1 (myr-Akt1).	Etoposide	15-24	thymoma viral proto-oncogene 1	Mus musculus	240-244
17119454-6	2006	We analysed dose-dependent release of cytochrome c, caspase-9 activation, cleavage of PARP and activation of effector caspases in etoposide and cisplatin-resistant cells after exposure to etoposide, teniposide, cisplatin or fotemustine.	Etoposide	188-197	caspase 9	Homo sapiens	118-126
16982679-4	2006	Expression of myr-Akt1 in the salivary glands results in a significant reduction in phosphorylation of p53 at serine(18), total p53 protein accumulation, and p21(WAF1) or Bax mRNA following etoposide or gamma irradiation of primary salivary acinar cells.	Etoposide	190-199	thymoma viral proto-oncogene 1	Mus musculus	14-22
16878160-7	2006	ErbB-4 CYT-1 and CYT-2 had different phenotypic effects in cultured MB cells: in response to neuregulin treatment, CYT-2 overexpression inhibited proliferation whereas CYT-1, which includes a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2, enhanced resistance to starvation- and etoposide-induced apoptosis by activating PI3K/Akt signalling.	Etoposide	307-316	erb-b2 receptor tyrosine kinase 4	Homo sapiens	0-12
17172428-7	2006	Interestingly, exposure of cells infected with an anti-stathmin adenovirus to Taxol or etoposide resulted in a complete loss of proliferation and clonogenicity, whereas exposure of the same cells to 5-FU or Adriamycin potentiated the growth-inhibitory effects of the anti-stathmin ribozyme, but the cells continued to proliferate.	Etoposide	87-96	stathmin 1	Homo sapiens	55-63
17172428-7	2006	Interestingly, exposure of cells infected with an anti-stathmin adenovirus to Taxol or etoposide resulted in a complete loss of proliferation and clonogenicity, whereas exposure of the same cells to 5-FU or Adriamycin potentiated the growth-inhibitory effects of the anti-stathmin ribozyme, but the cells continued to proliferate.	Etoposide	87-96	stathmin 1	Homo sapiens	272-280
17172428-9	2006	In contrast, cells infected with the anti-stathmin adenovirus showed a marked increase in apoptosis on exposure to Taxol or etoposide and a modest increase on exposure to 5-FU or Adriamycin.	Etoposide	124-133	stathmin 1	Homo sapiens	42-50
17172428-11	2006	Moreover, triple combination of anti-stathmin ribozyme with low noninhibitory concentrations of Taxol and etoposide resulted in a profound synergistic inhibition of proliferation, clonogenicity, and marked induction of apoptosis.	Etoposide	106-115	stathmin 1	Homo sapiens	37-45
16931776-10	2006	In vitro exposure of hMSCs to cisplatin, vincristine, and etoposide resulted in an increased p53 expression, independent of apoptosis induction.	Etoposide	58-67	tumor protein p53	Homo sapiens	93-96
16973621-6	2006	Using both top2beta knock-out mouse embryonic fibroblasts and Top2beta small interfering RNA knockdown PC12 cells, as well as postmitotic neurons in which TopIIalpha was absent, we showed that VP-16-induced DNA damage signals were attenuated upon proteasome inhibition, suggesting the involvement of proteasome in the repair/processing of both TopIIalpha-DNA and TopIIbeta-DNA adducts.	Etoposide	193-198	topoisomerase (DNA) II beta	Mus musculus	11-19
16973621-6	2006	Using both top2beta knock-out mouse embryonic fibroblasts and Top2beta small interfering RNA knockdown PC12 cells, as well as postmitotic neurons in which TopIIalpha was absent, we showed that VP-16-induced DNA damage signals were attenuated upon proteasome inhibition, suggesting the involvement of proteasome in the repair/processing of both TopIIalpha-DNA and TopIIbeta-DNA adducts.	Etoposide	193-198	topoisomerase (DNA) II beta	Mus musculus	62-70
17217622-7	2006	Furthermore, endogenous levels of pro-caspase-3 were decreased by overexpression of SAG/ROC-SCF(beta-TrCP) E3 Ub ligases, but increased on siRNA silencing of SAG, regulator of cullin-1 (ROC1), or beta-TrCPs, leading to increased apoptosis by etoposide and TNF-related apoptosis-inducing ligand through increased activation of caspase-3.	Etoposide	242-251	caspase 3	Homo sapiens	34-47
17217622-7	2006	Furthermore, endogenous levels of pro-caspase-3 were decreased by overexpression of SAG/ROC-SCF(beta-TrCP) E3 Ub ligases, but increased on siRNA silencing of SAG, regulator of cullin-1 (ROC1), or beta-TrCPs, leading to increased apoptosis by etoposide and TNF-related apoptosis-inducing ligand through increased activation of caspase-3.	Etoposide	242-251	caspase 3	Homo sapiens	38-47
17253948-3	2006	Transduced hADSCs, expressing high levels of CXCR4, displayed an increased capacity for cellular growth and protection against etoposide-induced cell death.	Etoposide	127-136	C-X-C motif chemokine receptor 4	Homo sapiens	45-50
17098234-1	2006	We found that heme-binding protein 2/SOUL sensitised NIH3T3 cells to cell death induced by A23187 and etoposide, but it did not affect reactive oxygen species formation.	Etoposide	102-111	heme binding protein 2	Mus musculus	14-36
17098234-1	2006	We found that heme-binding protein 2/SOUL sensitised NIH3T3 cells to cell death induced by A23187 and etoposide, but it did not affect reactive oxygen species formation.	Etoposide	102-111	heme binding protein 2	Mus musculus	37-41
17098234-4	2006	Flow cytometry analysis showed that SOUL promoted necrotic death in A23187 and etoposide treated cells, which effect was prevented by CsA.	Etoposide	79-88	heme binding protein 2	Mus musculus	36-40
16753237-5	2006	The CYP3A4 enzyme shows a distinctly different reactivity to deoxypodophyllotoxin compared to the semi-synthetic derivatives etoposide and teniposide, which are degraded by 3-O-demethylation.	Etoposide	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
16894566-5	2006	Ectopic expression of Aurora-A renders cells resistant to cisplatin (CDDP), etoposide and paclitaxel-induced apoptosis and stimulates Akt1 and Akt2 activity in wild-type p53 but not p53-null ovarian cancer cells.	Etoposide	76-85	aurora kinase A	Homo sapiens	22-30
16715131-4	2006	In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).	Etoposide	20-29	annexin A5	Homo sapiens	137-146
16715131-4	2006	In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).	Etoposide	20-29	caspase 3	Homo sapiens	173-182
17046572-4	2006	Following exposure to the topoisomerase II inhibitor, etoposide (VP-16), stromal cell MMP-2 protein expression is reduced.	Etoposide	54-63	host cell factor C1	Homo sapiens	65-70
16715131-4	2006	In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).	Etoposide	20-29	poly(ADP-ribose) polymerase 1	Homo sapiens	218-246
16715131-4	2006	In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).	Etoposide	20-29	poly(ADP-ribose) polymerase 1	Homo sapiens	248-252
17013758-3	2006	We have previously shown that caspase-3 reconstitution significantly sensitized MCF-7 cells to doxorubicin and etoposide.	Etoposide	111-120	caspase 3	Homo sapiens	30-39
16914690-8	2006	Second, the subsequent, complete digestion of the DNA by the nuclease could be inhibited by etoposide, suggesting that the nuclease digestion requires TOP2B religation of the cleaved DNA.	Etoposide	92-101	DNA topoisomerase II beta	Homo sapiens	151-156
17046572-4	2006	Following exposure to the topoisomerase II inhibitor, etoposide (VP-16), stromal cell MMP-2 protein expression is reduced.	Etoposide	54-63	matrix metallopeptidase 2	Homo sapiens	86-91
17260735-0	2006	[Studies on the electron transfer between etoposide (VP-16) and DNA].	Etoposide	42-51	host cell factor C1	Homo sapiens	53-58
16873896-0	2006	Down-regulation of beta1,4-galactosyltransferase V is a critical part of etoposide-induced apoptotic process and could be mediated by decreasing Sp1 levels in human glioma cells.	Etoposide	73-82	beta-1,4-galactosyltransferase 5	Homo sapiens	19-50
16873896-4	2006	In this study, interfering with the expression of beta1,4GalT V by its antisense cDNA in SHG44 human glioma cells markedly promoted apoptosis induced by etoposide and the activation of caspases as well as processing of Bid and expression of Bax and Bak.	Etoposide	153-162	beta-1,4-galactosyltransferase 5	Homo sapiens	50-63
16873896-5	2006	Conversely, the ectopic expression of beta1,4GalT V attenuated the apoptotic effect of etoposide on SHG44 cells.	Etoposide	87-96	beta-1,4-galactosyltransferase 5	Homo sapiens	38-51
16873896-6	2006	In addition, both the beta1,4GalT V transcription and the binding of total or membrane glycoprotein with Ricinus communis agglutinin-I (RCA-I) were partially reduced in etoposide-treated SHG44 cells, correlated well with a decreased level of Sp1 that has been identified as an activator of beta1,4GalT V transcription.	Etoposide	169-178	beta-1,4-galactosyltransferase 5	Homo sapiens	22-35
17260735-1	2006	In the present study, the electron transfer between Etoposide (VP-16) and GMP or DNA was investigated using pulse radiolysis and circular dichroism technology.	Etoposide	52-61	host cell factor C1	Homo sapiens	63-68
16873896-6	2006	In addition, both the beta1,4GalT V transcription and the binding of total or membrane glycoprotein with Ricinus communis agglutinin-I (RCA-I) were partially reduced in etoposide-treated SHG44 cells, correlated well with a decreased level of Sp1 that has been identified as an activator of beta1,4GalT V transcription.	Etoposide	169-178	beta-1,4-galactosyltransferase 5	Homo sapiens	290-303
16873896-7	2006	Collectively, our results suggest that the down-regulation of beta1,4GalT V expression plays an important role in etoposide-induced apoptosis and could be mediated by a decreasing level of Sp1 in SHG44 cells, indicating that inhibitors of beta1,4GalT V may enhance the therapeutic efficiency of etoposide for malignant glioma.	Etoposide	114-123	beta-1,4-galactosyltransferase 5	Homo sapiens	62-75
17016621-8	2006	Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors.	Etoposide	41-50	host cell factor C1	Homo sapiens	52-57
16873896-7	2006	Collectively, our results suggest that the down-regulation of beta1,4GalT V expression plays an important role in etoposide-induced apoptosis and could be mediated by a decreasing level of Sp1 in SHG44 cells, indicating that inhibitors of beta1,4GalT V may enhance the therapeutic efficiency of etoposide for malignant glioma.	Etoposide	295-304	beta-1,4-galactosyltransferase 5	Homo sapiens	62-75
16882877-4	2006	The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA).	Etoposide	41-45	tumor protein p53	Homo sapiens	66-69
16882877-4	2006	The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA).	Etoposide	41-45	tumor protein p53	Homo sapiens	127-130
16882877-4	2006	The induction of WI38 cell senescence by Etop was associated with p53 activation and could be attenuated by down-regulation of p53 using alpha-pifithrin (alpha-PFT) or p53 small interference RNA (siRNA).	Etoposide	41-45	tumor protein p53	Homo sapiens	127-130
16427189-7	2006	These results suggest that hypoxia confers resistance to UV- or etoposide-mediated apoptosis in lung cancer cells via the activations of the PI3K/Akt and the ERK pathways.	Etoposide	64-73	mitogen-activated protein kinase 1	Homo sapiens	158-161
16965834-5	2006	We observed that the targeted inhibition of livin strongly sensitized NSCLC cells to different pro-apoptotic stimuli, such as UV-irradiation or the chemotherapeutic drug etoposide.	Etoposide	170-179	baculoviral IAP repeat containing 7	Homo sapiens	44-49
17121917-6	2006	In line with our previous data, statins were found to attenuate the etoposide-induced p53 response.	Etoposide	68-77	tumor protein p53	Homo sapiens	86-89
17132229-2	2006	Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells.	Etoposide	107-116	nuclear factor kappa B subunit 1	Homo sapiens	56-62
17132229-2	2006	Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells.	Etoposide	107-116	nuclear factor kappa B subunit 1	Homo sapiens	64-73
17215959-2	2006	Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells.	Etoposide	107-116	nuclear factor kappa B subunit 1	Homo sapiens	56-62
17215959-2	2006	Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells.	Etoposide	107-116	nuclear factor kappa B subunit 1	Homo sapiens	64-73
16427189-6	2006	Moreover, hypoxia activated the PI3K/Akt and ERK pathways, and blocking the activation of either pathway reversed resistance to UV- and etoposide-induced apoptosis in response to hypoxia.	Etoposide	136-145	AKT serine/threonine kinase 1	Homo sapiens	37-40
16427189-6	2006	Moreover, hypoxia activated the PI3K/Akt and ERK pathways, and blocking the activation of either pathway reversed resistance to UV- and etoposide-induced apoptosis in response to hypoxia.	Etoposide	136-145	mitogen-activated protein kinase 1	Homo sapiens	45-48
16427189-7	2006	These results suggest that hypoxia confers resistance to UV- or etoposide-mediated apoptosis in lung cancer cells via the activations of the PI3K/Akt and the ERK pathways.	Etoposide	64-73	AKT serine/threonine kinase 1	Homo sapiens	146-149
16702944-6	2006	Meanwhile, PLSCR1-overexpressing U937 cells also underwent granulocyte-like differentiation with increased sensitivity to etoposide-induced apoptosis.	Etoposide	122-131	phospholipid scramblase 1	Homo sapiens	11-17
16702948-0	2006	A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.	Etoposide	146-150	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	29-38
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Etoposide	36-45	mitogen-activated protein kinase 1	Homo sapiens	95-103
17047652-1	2006	Etoposide (VP-16) is a topoisomerase II (topo II) inhibitor chemotherapeutic agent.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
16721826-9	2006	The p38 inhibitor, PD169316, partially inhibited etoposide-induced ASMC apoptosis, but induced apoptosis in VSMCs.	Etoposide	49-58	mitogen-activated protein kinase 1	Homo sapiens	4-7
17095187-0	2006	Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner.	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	80-83
17095187-11	2006	The present results suggest that VP-16 might induce cell cycle arrest at G2/M phase and apoptosis in a p53-related manner.	Etoposide	33-38	transformation related protein 53, pseudogene	Mus musculus	103-106
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Etoposide	36-45	cyclin dependent kinase 20	Homo sapiens	95-98
16721826-10	2006	The effects of etoposide and paclitaxel on Akt also differed between ASMCs and VSMCs.	Etoposide	15-24	AKT serine/threonine kinase 1	Homo sapiens	43-46
16721826-7	2006	Treatment with either paclitaxel or etoposide caused a transient phosphorylation/activation of p42 MAPK in ASMCs and DFs, but had no effect on phospho-p42/44 MAPK in VSMCs.	Etoposide	36-45	mitogen-activated protein kinase 1	Homo sapiens	99-103
16721826-8	2006	High-dose etoposide enhanced p38 MAPK activation in ASMCs, but not in VSMCs.	Etoposide	10-19	mitogen-activated protein kinase 1	Homo sapiens	29-32
16721826-8	2006	High-dose etoposide enhanced p38 MAPK activation in ASMCs, but not in VSMCs.	Etoposide	10-19	mitogen-activated protein kinase 1	Homo sapiens	33-37
16909101-6	2006	XAF1 expression enhanced the apoptotic response of tumor cells to chemotherapeutic agents, such as etoposide or 5-FU.	Etoposide	99-108	XIAP associated factor 1	Homo sapiens	0-4
17047058-3	2006	Ad-hTERT-CD conferred sensitivity to 5-fluorocytosine (5-FC) in bladder cancer cells, which could be enhanced by etoposide treatment, but not in normal cells.	Etoposide	113-122	telomerase reverse transcriptase	Homo sapiens	3-8
17047058-5	2006	By contrast, etoposide activated p53 and down-regulated hTERT promoter activity in normal cells.	Etoposide	13-22	tumor protein p53	Homo sapiens	33-36
17047058-5	2006	By contrast, etoposide activated p53 and down-regulated hTERT promoter activity in normal cells.	Etoposide	13-22	telomerase reverse transcriptase	Homo sapiens	56-61
17047058-7	2006	Combination index analysis revealed that combined therapy of Ad-hTERT-CD (10(9) plaque-forming units)/5-FC (200 mg/kg) with etoposide (2 mg/kg) synergistically suppressed tumor growth and prolonged survival in mice bearing syngeneic MBT-2 bladder tumors.	Etoposide	124-133	telomerase reverse transcriptase	Homo sapiens	64-69
17047058-9	2006	Furthermore, increased infiltrating CD4(+) and CD8(+) T cells and necrosis within tumors were found in mice receiving combination therapy of Ad-hTERT-CD and etoposide compared with those treated with either treatment alone.	Etoposide	157-166	CD4 antigen	Mus musculus	36-39
17047058-9	2006	Furthermore, increased infiltrating CD4(+) and CD8(+) T cells and necrosis within tumors were found in mice receiving combination therapy of Ad-hTERT-CD and etoposide compared with those treated with either treatment alone.	Etoposide	157-166	telomerase reverse transcriptase	Homo sapiens	144-149
17003255-5	2006	The aim of this study was to determine whether the cancer chemotherapy drug etoposide (VP-16), which is known to activate p38 MAPK, could induce inflammatory cytokine production by murine macrophages and sickness-like behaviors when injected into mice.	Etoposide	76-85	mitogen-activated protein kinase 14	Mus musculus	122-130
17003255-5	2006	The aim of this study was to determine whether the cancer chemotherapy drug etoposide (VP-16), which is known to activate p38 MAPK, could induce inflammatory cytokine production by murine macrophages and sickness-like behaviors when injected into mice.	Etoposide	87-92	mitogen-activated protein kinase 14	Mus musculus	122-130
17003255-6	2006	VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK- dependent manner.	Etoposide	0-5	mitogen-activated protein kinase 14	Mus musculus	16-24
17003255-6	2006	VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK- dependent manner.	Etoposide	0-5	interleukin 6	Mus musculus	37-41
17003255-6	2006	VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK- dependent manner.	Etoposide	0-5	mitogen-activated protein kinase 14	Mus musculus	80-88
17003255-7	2006	VP-16 administration rapidly increased serum levels of IL-6 in healthy mice and induced sickness-like behaviors as evidenced by a decrease in food intake, body weight, hemoglobin level, and voluntary wheel-running activity.	Etoposide	0-5	interleukin 6	Mus musculus	55-59
16951922-5	2006	Etoposide-induced apoptosis in HL60 cells was significantly increased in ascorbate-loaded cells as measured by caspase-3 activation and DNA degradation, and this appeared to reflect a decrease in the number of necrotic cells rather than increased cytotoxicity.	Etoposide	0-9	caspase 3	Homo sapiens	111-120
16982771-6	2006	Further, we showed that EGCG interfered with the formation of the antiapoptotic GRP78-caspase-7 complex, which resulted in an increased etoposide-induced apoptosis in cancer cells.	Etoposide	136-145	heat shock protein family A (Hsp70) member 5	Homo sapiens	80-85
16982771-0	2006	(-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78.	Etoposide	53-62	heat shock protein family A (Hsp70) member 5	Homo sapiens	119-147
16982737-0	2006	Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia.	Etoposide	54-63	DNA fragmentation factor, beta subunit	Mus musculus	27-50
16982737-1	2006	Etoposide-induced treatment-related acute myelogenous leukemia (t-AML) is characterized by rearrangements of the mixed lineage leukemia (MLL) gene with one of its &gt;50 partner genes, most probably as a consequence of etoposide-induced DNA double-strand breaks (DSBs).	Etoposide	0-9	lysine (K)-specific methyltransferase 2A	Mus musculus	137-140
16982771-6	2006	Further, we showed that EGCG interfered with the formation of the antiapoptotic GRP78-caspase-7 complex, which resulted in an increased etoposide-induced apoptosis in cancer cells.	Etoposide	136-145	caspase 7	Homo sapiens	86-95
16982737-1	2006	Etoposide-induced treatment-related acute myelogenous leukemia (t-AML) is characterized by rearrangements of the mixed lineage leukemia (MLL) gene with one of its &gt;50 partner genes, most probably as a consequence of etoposide-induced DNA double-strand breaks (DSBs).	Etoposide	219-228	lysine (K)-specific methyltransferase 2A	Mus musculus	137-140
16982737-2	2006	Recent studies have shown that etoposide-induced DSBs occur predominantly within the breakpoint cluster region (bcr) of the MLL gene.	Etoposide	31-40	lysine (K)-specific methyltransferase 2A	Mus musculus	124-127
16809075-0	2006	Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	79-82
16982737-4	2006	Here, we test the involvement of caspase-activated DNase (CAD) and other apoptotic components in etoposide-induced gene rearrangements using two methods.	Etoposide	97-106	DNA fragmentation factor, beta subunit	Mus musculus	33-56
16982737-4	2006	Here, we test the involvement of caspase-activated DNase (CAD) and other apoptotic components in etoposide-induced gene rearrangements using two methods.	Etoposide	97-106	DNA fragmentation factor, beta subunit	Mus musculus	58-61
16982737-6	2006	Etoposide strongly stimulated plasmid integration in CAD cDNA-complemented mouse embryonic fibroblasts (MEFs) but not in CAD knockout (KO) MEFs.	Etoposide	0-9	DNA fragmentation factor, beta subunit	Mus musculus	53-56
16982737-7	2006	Consistently, down-regulation of ICAD (inhibitor of CAD, also required for proper folding of CAD) in an HT29-derived cell line, which leads to decreased CAD activity, significantly reduced etoposide-induced plasmid integration.	Etoposide	189-198	DNA fragmentation factor, alpha subunit	Mus musculus	33-37
16982737-7	2006	Consistently, down-regulation of ICAD (inhibitor of CAD, also required for proper folding of CAD) in an HT29-derived cell line, which leads to decreased CAD activity, significantly reduced etoposide-induced plasmid integration.	Etoposide	189-198	DNA fragmentation factor, alpha subunit	Mus musculus	39-55
16982737-7	2006	Consistently, down-regulation of ICAD (inhibitor of CAD, also required for proper folding of CAD) in an HT29-derived cell line, which leads to decreased CAD activity, significantly reduced etoposide-induced plasmid integration.	Etoposide	189-198	DNA fragmentation factor, beta subunit	Mus musculus	34-37
16982737-7	2006	Consistently, down-regulation of ICAD (inhibitor of CAD, also required for proper folding of CAD) in an HT29-derived cell line, which leads to decreased CAD activity, significantly reduced etoposide-induced plasmid integration.	Etoposide	189-198	DNA fragmentation factor, beta subunit	Mus musculus	52-55
16982737-9	2006	Etoposide stimulated MLL fusion product formation in CAD cDNA-complemented MEFs but not in CAD KO MEFs.	Etoposide	0-9	lysine (K)-specific methyltransferase 2A	Mus musculus	21-24
16982737-9	2006	Etoposide stimulated MLL fusion product formation in CAD cDNA-complemented MEFs but not in CAD KO MEFs.	Etoposide	0-9	DNA fragmentation factor, beta subunit	Mus musculus	53-56
16982737-10	2006	Together, these results suggest that CAD and other apoptotic components may play an important role in etoposide-induced t-AML.	Etoposide	102-111	DNA fragmentation factor, beta subunit	Mus musculus	37-40
16781710-4	2006	Clones of the lung carcinoma cells U1810 with down-regulated expression of PrxV, or with its impaired enzymatic function (expression of redox-negative PrxV), demonstrated increased sensitivity to treatment with anticancer drugs etoposide and adriamycin.	Etoposide	228-237	peroxiredoxin 5	Homo sapiens	75-79
16844113-0	2006	Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway.	Etoposide	37-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	71-76
16844113-10	2006	Specific inhibition of AP-1 decreased the protection effect of hypoxia against etoposide-induced apoptosis.	Etoposide	79-88	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	23-27
16809075-10	2006	There is a clear clinical association between previous exposure to etoposide and therapy-related acute myeloid leukemia (t-AML) characterized by chromosomal rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome band 11q23 [C.A.	Etoposide	67-76	lysine methyltransferase 2A	Homo sapiens	210-213
16860483-4	2006	In addition, we showed that the silencing of Mitogenin I resulted in an increase in the number of trypan blue-positive cells and the silencing of mtSSB resulted in an enhancement of the sensitivity of the cells to apoptotic stimulation by etoposide.	Etoposide	239-248	polymerase (DNA-directed), delta interacting protein 2	Mus musculus	45-56
16905201-7	2006	Taken together, our results clearly suggest that the differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.	Etoposide	397-406	thymoma viral proto-oncogene 1	Mus musculus	89-92
16905201-7	2006	Taken together, our results clearly suggest that the differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.	Etoposide	397-406	mitogen-activated protein kinase 3	Mus musculus	94-100
16905201-7	2006	Taken together, our results clearly suggest that the differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.	Etoposide	397-406	mitogen-activated protein kinase 14	Mus musculus	106-109
16905201-6	2006	We also observed that PI3K/Akt and sustained ERK activation were associated intimately with the etoposide-induced apoptosis.	Etoposide	96-105	thymoma viral proto-oncogene 1	Mus musculus	27-30
16905201-6	2006	We also observed that PI3K/Akt and sustained ERK activation were associated intimately with the etoposide-induced apoptosis.	Etoposide	96-105	mitogen-activated protein kinase 1	Mus musculus	45-48
16860483-4	2006	In addition, we showed that the silencing of Mitogenin I resulted in an increase in the number of trypan blue-positive cells and the silencing of mtSSB resulted in an enhancement of the sensitivity of the cells to apoptotic stimulation by etoposide.	Etoposide	239-248	single-stranded DNA binding protein 1	Mus musculus	146-151
16797759-3	2006	By Western blot, the expression of 14-3-3sigma, p53 and p21 was coordinately upregulated in astrocytes following exposure to hydrogen peroxide, 4-hydroxy-2-nonenal (4-HNE) or etoposide, a topoisomerase II inhibitor.	Etoposide	175-184	stratifin	Homo sapiens	35-46
16442262-4	2006	To show conventional chemotherapy drugs can trigger the caspase cascade, including caspase-8, -9, -3 and DNA fragmentation factor, Jurkat T leukemia cells were treated with cisplatin or etoposide in a dose-dependent and a time-dependent manner.	Etoposide	186-195	caspase 8	Homo sapiens	83-129
16550346-9	2006	Except for the younger rats, all the etoposide-treated rats showed diminution of transferrin immunolabeling in the seminiferous epithelium, and consequently, of total labeled testicular tissue volume density.	Etoposide	37-46	transferrin	Rattus norvegicus	81-92
16598770-8	2006	The over-expression of p53 protein in the etoposide treated cells indicated a significant level of DNA fragmentation and apoptosis.	Etoposide	42-51	tumor protein p53	Homo sapiens	23-26
16940541-3	2006	Jurkat cell lines constitutively expressing M-T2 were generated and shown to be resistant to UV irradiation-, etoposide-, and cycloheximide-induced death.	Etoposide	110-119	M-T2	Myxoma virus	44-48
16905201-7	2006	Taken together, our results clearly suggest that the differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.	Etoposide	397-406	mitogen-activated protein kinase 1	Mus musculus	110-114
16905201-7	2006	Taken together, our results clearly suggest that the differential regulation of the PI3K/Akt, ERK1/2, and p38 MAPK signaling pathways are crucial in the context of DNA-damaging drug-induced apoptosis, and this has compelled us to propose that the sustained activation of ERK1/2 pathway may be generally involved in the apoptosis induced by anticancer DNA-damaging drugs, including doxorubicin and etoposide.	Etoposide	397-406	mitogen-activated protein kinase 3	Mus musculus	271-277
16985058-5	2006	Prolonged hypoxia of 1 to 7 days leads to reduction in vincristine- and etoposide-induced apoptosis in SH-SY5Y and SH-EP1 cells, and this was reflected in increased clonogenic survival under these conditions.	Etoposide	72-81	prostaglandin E receptor 1	Homo sapiens	118-121
16892051-6	2006	DNA damage by etoposide causes E2F1-dependent induction of SirT1 expression and knockdown of SirT1 increases sensitivity to etoposide.	Etoposide	14-23	E2F transcription factor 1	Homo sapiens	31-35
16892051-6	2006	DNA damage by etoposide causes E2F1-dependent induction of SirT1 expression and knockdown of SirT1 increases sensitivity to etoposide.	Etoposide	14-23	sirtuin 1	Homo sapiens	59-64
16892051-6	2006	DNA damage by etoposide causes E2F1-dependent induction of SirT1 expression and knockdown of SirT1 increases sensitivity to etoposide.	Etoposide	124-133	E2F transcription factor 1	Homo sapiens	31-35
16892051-6	2006	DNA damage by etoposide causes E2F1-dependent induction of SirT1 expression and knockdown of SirT1 increases sensitivity to etoposide.	Etoposide	124-133	sirtuin 1	Homo sapiens	93-98
16797759-3	2006	By Western blot, the expression of 14-3-3sigma, p53 and p21 was coordinately upregulated in astrocytes following exposure to hydrogen peroxide, 4-hydroxy-2-nonenal (4-HNE) or etoposide, a topoisomerase II inhibitor.	Etoposide	175-184	tumor protein p53	Homo sapiens	48-51
16797759-3	2006	By Western blot, the expression of 14-3-3sigma, p53 and p21 was coordinately upregulated in astrocytes following exposure to hydrogen peroxide, 4-hydroxy-2-nonenal (4-HNE) or etoposide, a topoisomerase II inhibitor.	Etoposide	175-184	H3 histone pseudogene 16	Homo sapiens	56-59
16797759-6	2006	Microarray analysis of etoposide-treated astrocytes verified upregulation of p53-responsive genes and concurrent downregulation of mitotic checkpoint-regulatory genes.	Etoposide	23-32	tumor protein p53	Homo sapiens	77-80
16868026-7	2006	PML-dependent ssDNA focus formation was found to be particularly efficient during S-phase of the cell cycle, and PML-depleted cells became retarded in S-phase upon growth in the presence of etoposide.	Etoposide	190-199	PML nuclear body scaffold	Homo sapiens	0-3
16572399-0	2006	c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling.	Etoposide	16-25	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	0-5
16572399-0	2006	c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling.	Etoposide	16-25	BCL2 associated X, apoptosis regulator	Rattus norvegicus	67-70
16572399-4	2006	We found that c-Myc overexpression potentiated etoposide-, doxorubicin-, and cisplatin-induced cell death in mouse fibroblasts.	Etoposide	47-56	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	14-19
16572399-7	2006	Apoptosis was paralleled by c-Myc-dependent Bax-activation after etoposide and doxorubicin treatment, but not after cisplatin administration.	Etoposide	65-74	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	28-33
16572399-7	2006	Apoptosis was paralleled by c-Myc-dependent Bax-activation after etoposide and doxorubicin treatment, but not after cisplatin administration.	Etoposide	65-74	BCL2 associated X, apoptosis regulator	Rattus norvegicus	44-47
16572399-9	2006	Furthermore, etoposide treatment of c-Myc expressing cells resulted in PKCdelta cleavage, while inhibition of PKCdelta reduced etoposide-induced apoptosis and prevented Bax activation.	Etoposide	13-22	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	36-41
16572399-10	2006	Taken together, these findings suggest that Bax and caspase activation, together with PKCdelta signaling are involved in c-Myc-dependent etoposide-induced apoptosis.	Etoposide	137-146	BCL2 associated X, apoptosis regulator	Rattus norvegicus	44-47
16572399-10	2006	Taken together, these findings suggest that Bax and caspase activation, together with PKCdelta signaling are involved in c-Myc-dependent etoposide-induced apoptosis.	Etoposide	137-146	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	121-126
16598774-8	2006	Furthermore, siRNA suppression of HSP27 expression significantly decreased KNG inhibition of etoposide-induced caspase-3 activation and apoptosis in these cells.	Etoposide	93-102	heat shock protein family B (small) member 1	Homo sapiens	34-39
16598774-8	2006	Furthermore, siRNA suppression of HSP27 expression significantly decreased KNG inhibition of etoposide-induced caspase-3 activation and apoptosis in these cells.	Etoposide	93-102	kininogen 1	Homo sapiens	75-78
16598774-8	2006	Furthermore, siRNA suppression of HSP27 expression significantly decreased KNG inhibition of etoposide-induced caspase-3 activation and apoptosis in these cells.	Etoposide	93-102	caspase 3	Homo sapiens	111-120
16598774-9	2006	In summary, KNG modulate bone marrow derived stromal/preosteoblast cell proliferation and suppress etoposide-induced apoptosis through ERK and HSP27 activation, respectively.	Etoposide	99-108	kininogen 1	Homo sapiens	12-15
16868026-7	2006	PML-dependent ssDNA focus formation was found to be particularly efficient during S-phase of the cell cycle, and PML-depleted cells became retarded in S-phase upon growth in the presence of etoposide.	Etoposide	190-199	PML nuclear body scaffold	Homo sapiens	113-116
16800842-3	2006	METHODS: We analyzed the effect of etoposide on cell viability and uptake of F-18-fluoro-deoxy-D-glucose or the glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose (2-NBDG) in vitro.	Etoposide	35-44	mastermind like domain containing 1	Homo sapiens	77-81
16547497-5	2006	In addition, by monitoring caspase-3 activity and Hoechst staining, we determined that hTDE1 overexpression partially protects cells from serum starvation- and etoposide-induced apoptosis.	Etoposide	160-169	serine incorporator 3	Homo sapiens	87-92
16607284-5	2006	We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide.	Etoposide	78-87	tumor protein p53	Homo sapiens	13-16
16619047-3	2006	Within the same time frame, hTERT depletion facilitated the induction of apoptotic cell death by cisplatin, etoposide, mitomycin C and reactive oxygen species, yet failed to sensitize cells to death induction via the CD95 death receptor.	Etoposide	108-117	telomerase reverse transcriptase	Homo sapiens	28-33
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Etoposide	40-49	BCL2 apoptosis regulator	Homo sapiens	124-128
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Etoposide	40-49	BCL2 like 12	Homo sapiens	130-137
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Etoposide	40-49	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
16895478-0	2006	Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.	Etoposide	40-49	caspase 9	Homo sapiens	144-153
16895478-3	2006	In the case of etoposide, down-regulation of the BCL2L12-A gene variant and of CASPASE-9, as well as upregulation of BAX, was observed, whereas treatment of MCF-7 cells with taxol led to down-regulation of the mRNA levels of all genes examined.	Etoposide	15-24	BCL2 like 12	Homo sapiens	49-56
16895478-3	2006	In the case of etoposide, down-regulation of the BCL2L12-A gene variant and of CASPASE-9, as well as upregulation of BAX, was observed, whereas treatment of MCF-7 cells with taxol led to down-regulation of the mRNA levels of all genes examined.	Etoposide	15-24	caspase 9	Homo sapiens	79-88
16895478-3	2006	In the case of etoposide, down-regulation of the BCL2L12-A gene variant and of CASPASE-9, as well as upregulation of BAX, was observed, whereas treatment of MCF-7 cells with taxol led to down-regulation of the mRNA levels of all genes examined.	Etoposide	15-24	BCL2 associated X, apoptosis regulator	Homo sapiens	117-120
16800842-8	2006	In a small fraction of viable cells, etoposide might downregulate glucose transporters and/or hexokinase activity and by that inhibit glucose uptake.	Etoposide	37-46	hexokinase 1	Homo sapiens	94-104
16423888-4	2006	RESULTS: In this study we report that fully activated human HSC/MFs did not undergo spontaneous apoptosis and survived to prolonged serum deprivation, Fas activation, or exposure to nerve growth factor, tumour necrosis factor alpha (TNF-alpha), oxidative stress mediators, doxorubicin, and etoposide.	Etoposide	290-299	fucosyltransferase 1 (H blood group)	Homo sapiens	60-63
16682503-0	2006	Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis.	Etoposide	31-40	protein phosphatase 2 phosphatase activator	Homo sapiens	57-71
17039395-3	2006	Consistent with an antimutator function, ablation of the yeast NM23 homolog, YNK1, results in increased mutation rates following exposure to UV irradiation and exposure to the DNA damaging agents etoposide, cisplatin, and MMS.	Etoposide	196-205	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	63-67
17039395-3	2006	Consistent with an antimutator function, ablation of the yeast NM23 homolog, YNK1, results in increased mutation rates following exposure to UV irradiation and exposure to the DNA damaging agents etoposide, cisplatin, and MMS.	Etoposide	196-205	nucleoside diphosphate kinase	Saccharomyces cerevisiae S288C	77-81
16863850-9	2006	TRAIL sensitivity was enhanced in resistant cell lines by treating with etoposide that concomitantly increased TRAIL-R expression and diminished survivin expression.	Etoposide	72-81	TNF superfamily member 10	Homo sapiens	0-5
16863850-9	2006	TRAIL sensitivity was enhanced in resistant cell lines by treating with etoposide that concomitantly increased TRAIL-R expression and diminished survivin expression.	Etoposide	72-81	TNF superfamily member 10	Homo sapiens	111-116
16690782-4	2006	Here, we demonstrate that cardiolipin oxidation during apoptosis is realized not via a random cardiolipin peroxidation mechanism but rather proceeds as a result of peroxidase reaction in a tight cytochrome c/cardiolipin complex that restrains interactions of etoposide with radical intermediates generated in the course of the reaction.	Etoposide	259-268	cytochrome c, somatic	Homo sapiens	195-207
16682503-3	2006	Here, we report a novel role of lithium on the blockage of ceramide- and etoposide-induced apoptosis via inhibition of protein phosphatase 2A (PP2A) activity.	Etoposide	73-82	protein phosphatase 2 phosphatase activator	Homo sapiens	127-141
16690782-6	2006	We further show that etoposide can inhibit cytochrome c-catalyzed oxidation of cardiolipin competing with it as a peroxidase substrate.	Etoposide	21-30	cytochrome c, somatic	Homo sapiens	43-55
16682503-3	2006	Here, we report a novel role of lithium on the blockage of ceramide- and etoposide-induced apoptosis via inhibition of protein phosphatase 2A (PP2A) activity.	Etoposide	73-82	protein phosphatase 2 phosphatase activator	Homo sapiens	143-147
16682503-5	2006	Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70.	Etoposide	39-48	BCL2 apoptosis regulator	Homo sapiens	57-62
16682503-6	2006	Furthermore, ceramide- and etoposide-induced PP2A activation involved methylation of PP2A C subunit, which lithium suppressed.	Etoposide	27-36	protein phosphatase 2 phosphatase activator	Homo sapiens	45-49
16682503-6	2006	Furthermore, ceramide- and etoposide-induced PP2A activation involved methylation of PP2A C subunit, which lithium suppressed.	Etoposide	27-36	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	85-91
16700071-6	2006	Both gammaH2AX and RAD51 were rapidly recruited to irradiation- or etoposide-damaged chromatin.	Etoposide	67-76	RAD51 recombinase	Homo sapiens	19-24
16518603-1	2006	Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma.	Etoposide	53-62	DNA damage inducible transcript 3	Homo sapiens	167-171
16923369-8	2006	Expression of DR5 protein was not detected in SKNDZ cells but an increased DR5 protein expression was found after treatment with adriamycin or etoposide.	Etoposide	143-152	TNF receptor superfamily member 10b	Homo sapiens	14-17
16923369-8	2006	Expression of DR5 protein was not detected in SKNDZ cells but an increased DR5 protein expression was found after treatment with adriamycin or etoposide.	Etoposide	143-152	TNF receptor superfamily member 10b	Homo sapiens	75-78
16923369-10	2006	The early apoptosis rates of the adriamycin /etoposide + IFNgamma+TRAIL groups [(17.9 +/- 3.6)%, (14.8 +/- 3.3)%] were higher than that of the IFNgamma+TRAIL group [(3.9 +/- 1.2)% ](F=26.233, P &lt; 0.01).	Etoposide	45-54	interferon gamma	Homo sapiens	143-151
16923369-10	2006	The early apoptosis rates of the adriamycin /etoposide + IFNgamma+TRAIL groups [(17.9 +/- 3.6)%, (14.8 +/- 3.3)%] were higher than that of the IFNgamma+TRAIL group [(3.9 +/- 1.2)% ](F=26.233, P &lt; 0.01).	Etoposide	45-54	TNF superfamily member 10	Homo sapiens	152-157
16518414-7	2006	Constitutive expression of 17AA(+)WT1 isoforms inhibited apoptosis of K562 leukemia cells induced by apoptosis-inducing agents, etoposide and doxorubicin, through the protection of mitochondrial membrane damages, and DNA-binding zinc-finger region of 17AA(+)WT1 isoform was essential for the antiapoptotic functions.	Etoposide	128-137	WT1 transcription factor	Homo sapiens	34-37
16474845-6	2006	The increased IL-1beta secretion was accompanied by an elevated formation of nitric oxide (NO) and a NO-dependent inhibition of the etoposide-induced caspase-3/-7/-8/-9 activity.	Etoposide	132-141	interleukin 1 beta	Homo sapiens	14-22
16474845-8	2006	Conversely, IL-1beta or the NO-donor SNAP decreased caspase activation and apoptosis in etoposide-treated PT45-P1 cells.	Etoposide	88-97	interleukin 1 beta	Homo sapiens	12-20
16709574-4	2006	Phosphorylation of Bax by JNK and p38 kinase activated after treatment with staurosporine, H(2)O(2), etoposide, and UV light was demonstrated by the shift in the pI value of Bax on two-dimensional gels and confirmed by metabolic labeling with inorganic [(32)P]phosphate in HepG2 cells.	Etoposide	101-110	BCL2 associated X, apoptosis regulator	Homo sapiens	19-22
16709574-4	2006	Phosphorylation of Bax by JNK and p38 kinase activated after treatment with staurosporine, H(2)O(2), etoposide, and UV light was demonstrated by the shift in the pI value of Bax on two-dimensional gels and confirmed by metabolic labeling with inorganic [(32)P]phosphate in HepG2 cells.	Etoposide	101-110	mitogen-activated protein kinase 8	Homo sapiens	26-29
16709574-4	2006	Phosphorylation of Bax by JNK and p38 kinase activated after treatment with staurosporine, H(2)O(2), etoposide, and UV light was demonstrated by the shift in the pI value of Bax on two-dimensional gels and confirmed by metabolic labeling with inorganic [(32)P]phosphate in HepG2 cells.	Etoposide	101-110	mitogen-activated protein kinase 14	Homo sapiens	34-37
16709574-4	2006	Phosphorylation of Bax by JNK and p38 kinase activated after treatment with staurosporine, H(2)O(2), etoposide, and UV light was demonstrated by the shift in the pI value of Bax on two-dimensional gels and confirmed by metabolic labeling with inorganic [(32)P]phosphate in HepG2 cells.	Etoposide	101-110	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	MAGE family member A2	Homo sapiens	41-47
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	tumor protein p53	Homo sapiens	110-113
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	tumor protein p53	Homo sapiens	173-176
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	histone deacetylase 3	Homo sapiens	218-239
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	tumor protein p53	Homo sapiens	173-176
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	138-147	tumor protein p53	Homo sapiens	173-176
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	MAGE family member A2	Homo sapiens	41-47
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	tumor protein p53	Homo sapiens	110-113
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	tumor protein p53	Homo sapiens	173-176
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	histone deacetylase 3	Homo sapiens	218-239
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	histone deacetylase 3	Homo sapiens	241-246
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	MAGE family member A2	Homo sapiens	251-257
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	tumor protein p53	Homo sapiens	173-176
16847267-4	2006	Here we present evidence indicating that MageA2 protein, belonging to the MAGE-A subfamily, confers wild-type-p53-sensitive resistance to etoposide (ET) by inducing a novel p53 inhibitory loop involving recruitment of histone deacetylase 3 (HDAC3) to MageA2/p53 complex, thus strongly down-regulating p53 transactivation function.	Etoposide	149-151	tumor protein p53	Homo sapiens	173-176
16847267-7	2006	In addition, combined trichostatin A/ET treatment in melanoma cells expressing high MAGE-A levels reestablishes p53 response and reverts the chemoresistance.	Etoposide	37-39	tumor protein p53	Homo sapiens	112-115
16801388-1	2006	We show that caspase-3 cleaves Cdc6 at D(290)/S and D(442)/G sites, producing p32-tCdc6 (truncated Cdc6) and p49-tCdc6, respectively, during etoposide- or tumor necrosis factor (TNF)-alpha-induced apoptosis.	Etoposide	141-150	caspase 3	Homo sapiens	13-22
16801388-1	2006	We show that caspase-3 cleaves Cdc6 at D(290)/S and D(442)/G sites, producing p32-tCdc6 (truncated Cdc6) and p49-tCdc6, respectively, during etoposide- or tumor necrosis factor (TNF)-alpha-induced apoptosis.	Etoposide	141-150	cell division cycle 6	Homo sapiens	31-35
16801388-2	2006	The expression of these tCdc6 proteins, p32- and p49-tCdc6, promotes etoposide-induced apoptosis.	Etoposide	69-78	inhibitor of growth family member 2	Homo sapiens	40-43
16841962-0	2006	Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells.	Etoposide	40-49	myeloperoxidase	Homo sapiens	0-15
16841962-3	2006	Previous studies showed that the phenoxyl radical of etoposide can be generated by myeloperoxidase (MPO), an enzyme prevalent in myeloid progenitor cells that can derive myelogenous leukemias.	Etoposide	53-62	myeloperoxidase	Homo sapiens	83-98
16841962-3	2006	Previous studies showed that the phenoxyl radical of etoposide can be generated by myeloperoxidase (MPO), an enzyme prevalent in myeloid progenitor cells that can derive myelogenous leukemias.	Etoposide	53-62	myeloperoxidase	Homo sapiens	100-103
16841962-8	2006	MPO-expressing human myeloid leukemia HL60 cells were treated with etoposide for 0.5 h in the presence and absence of the cosubstrate of MPO, hydrogen peroxide.	Etoposide	67-76	myeloperoxidase	Homo sapiens	0-3
16841962-13	2006	These results are consistent with the idea that MPO is responsible for the conversion of etoposide to its ortho-quinone in these cells.	Etoposide	89-98	myeloperoxidase	Homo sapiens	48-51
16571667-0	2006	Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells.	Etoposide	45-54	granulocyte macrophage antigen 3	Mus musculus	34-37
16571667-3	2006	The GM3-reconstituted cells were resistant to apoptosis induced by etoposide and doxorubicin.	Etoposide	67-76	granulocyte macrophage antigen 3	Mus musculus	4-7
16571667-5	2006	To understand the mechanism of the etoposide-resistant phenotype acquired in the GM3-reconstituted cells, we investigated their apoptotic signaling.	Etoposide	35-44	granulocyte macrophage antigen 3	Mus musculus	81-84
16571667-6	2006	Although no difference was observed in the phosphorylation of p53 at serine-15-residue site by etoposide between the GM3-reconstituted cells and mock-transfected cells, the activation of both caspase-3 and caspase-9 was specifically inhibited in the former.	Etoposide	95-104	transformation related protein 53, pseudogene	Mus musculus	62-65
16547931-0	2006	The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax.	Etoposide	14-23	tumor protein p53	Homo sapiens	66-69
16547931-0	2006	The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax.	Etoposide	14-23	BCL2 associated X, apoptosis regulator	Homo sapiens	74-77
16839361-8	2006	CONCLUSION: Etoposide-induced apoptosis in THP-1 cells evokes a procoagulant response by increasing TF activity associated with an increased PtdSer exposure.	Etoposide	12-21	GLI family zinc finger 2	Homo sapiens	43-48
16839361-8	2006	CONCLUSION: Etoposide-induced apoptosis in THP-1 cells evokes a procoagulant response by increasing TF activity associated with an increased PtdSer exposure.	Etoposide	12-21	coagulation factor III, tissue factor	Homo sapiens	100-102
16632474-3	2006	Capn4(-/-) MEFs displayed resistance to puromycin, camptothecin, etoposide, hydrogen peroxide, ultraviolet light, and serum starvation, which was consistent with pro-apoptotic roles for calpain.	Etoposide	65-74	calpain, small subunit 1	Mus musculus	0-5
16819303-3	2006	Over-expression of GSTP1 in HEK293 cells inhibited both DMEKK1- and etoposide-induced apoptosis, and inhibited pro-caspase-3 activation and PARP cleavage.	Etoposide	68-77	glutathione S-transferase pi 1	Homo sapiens	19-24
16819303-6	2006	GSTP1 inhibition of etoposide-induced cell apoptosis was mainly due to its ability to suppress MEKK1 kinase activity.	Etoposide	20-29	glutathione S-transferase pi 1	Homo sapiens	0-5
16819303-6	2006	GSTP1 inhibition of etoposide-induced cell apoptosis was mainly due to its ability to suppress MEKK1 kinase activity.	Etoposide	20-29	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	95-100
16778171-3	2006	When TAL1 expression is reduced in CEM T leukemia cells, basal NFKB1 expression is increased, and the levels of p65:cRel complex and transcription of its target gene, such as intercellular adhesion molecule-1 (ICAM-1), are reduced in response to etoposide treatment.	Etoposide	246-255	TAL bHLH transcription factor 1, erythroid differentiation factor	Homo sapiens	5-9
16518603-13	2006	The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma.	Etoposide	16-25	DNA damage inducible transcript 3	Homo sapiens	43-47
16518603-13	2006	The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma.	Etoposide	16-25	DNA damage inducible transcript 3	Homo sapiens	82-86
16740724-7	2006	Finally, we showed that T/t-common could specifically sensitize HER2/neu-overexpressing human cancer cell lines, but not HER2/neu low-expressing human cancer cell lines, to chemotherapeutic agent etoposide.	Etoposide	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-68
16740724-7	2006	Finally, we showed that T/t-common could specifically sensitize HER2/neu-overexpressing human cancer cell lines, but not HER2/neu low-expressing human cancer cell lines, to chemotherapeutic agent etoposide.	Etoposide	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-72
16799873-11	2006	Cyclin A1 but not cyclin A2 was upregulated in etoposide-treated tumor cells undergoing p53-dependent apoptosis and mitotic catastrophe.	Etoposide	47-56	cyclin A1	Homo sapiens	0-9
16799873-11	2006	Cyclin A1 but not cyclin A2 was upregulated in etoposide-treated tumor cells undergoing p53-dependent apoptosis and mitotic catastrophe.	Etoposide	47-56	tumor protein p53	Homo sapiens	88-91
16740724-7	2006	Finally, we showed that T/t-common could specifically sensitize HER2/neu-overexpressing human cancer cell lines, but not HER2/neu low-expressing human cancer cell lines, to chemotherapeutic agent etoposide.	Etoposide	196-205	erb-b2 receptor tyrosine kinase 2	Homo sapiens	64-72
16702184-1	2006	The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL).	Etoposide	115-124	carboxylesterase 2	Homo sapiens	85-88
16964701-3	2006	Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans.	Etoposide	203-211	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
16964701-3	2006	Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans.	Etoposide	203-211	phosphoglycolate phosphatase	Homo sapiens	86-90
16794509-7	2006	After a second IPA course and 2 courses of carboplatin and etoposide, the boy"s clinical condition was excellent with normal alpha-fetoprotein but minimal regression and increased calcification in the tumor mass.	Etoposide	59-68	alpha fetoprotein	Homo sapiens	125-142
16819137-0	2006	Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment.	Etoposide	160-169	cAMP responsive element binding protein 1	Homo sapiens	0-50
16819137-0	2006	Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment.	Etoposide	160-169	cAMP responsive element binding protein 1	Homo sapiens	52-56
16818498-10	2006	To confirm that the increase in sensitivity was not solely due to the elevated expression of TOP2 or due to specific effects of the drug-hypersensitive TOP2 alleles, we also found that deletion of genes required for NHEJ increased the sensitivity of rad52 deletions to both etoposide and mAMSA.	Etoposide	274-283	recombinase RAD52	Saccharomyces cerevisiae S288C	250-255
16768139-6	2006	After three cycles of combination chemotherapy consisting of ifosfamide, cisplatin, and etoposide, followed by whole brain irradiation with a total dose of 24 Gy, the CSF hCG level fell below the detection limit, but MR imaging demonstrated no significant change.	Etoposide	88-97	hypertrichosis 2 (generalised, congenital)	Homo sapiens	171-174
16434973-4	2006	We have discovered that endogenous AR activity in LNCaP cells is inhibited in response to the chemotherapeutic agents etoposide and cisplatin.	Etoposide	118-127	androgen receptor	Homo sapiens	35-37
16556605-6	2006	When COS-1 cells transiently transfected with gelsolin cDNA were treated with etoposide or staurosporine, apoptosis-inducing agents, N-myristoylated tGelsolin was generated, as demonstrated by in vivo metabolic labeling.	Etoposide	78-87	gelsolin	Homo sapiens	46-54
16707463-6	2006	However, such resistance was readily reversed when Apo2L/TRAIL was used in combination with clinically relevant chemotherapeutic drugs, including taxol, etoposide, doxorubicin, cisplatin, or the histone deacetylase inhibitor suberoylanilide hydroxamic acid.	Etoposide	153-162	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	51-56
16574265-0	2006	Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition.	Etoposide	0-9	phosphoglycolate phosphatase	Mus musculus	99-113
16613901-4	2006	Etoposide, but not methylmethanesulfate, also promotes mtDNA lesions in cells expressing active hTERT, indicating genotoxic specificity in this response.	Etoposide	0-9	telomerase reverse transcriptase	Homo sapiens	96-101
16385570-7	2006	The Hsp90 inhibitors geldanamycin, 17-AAG (17-allylamino-17-demethoxygeldanamycin) and radicicol significantly enhanced the activity of the topoisomerase II poisons etoposide and mitoxantrone in vitro and in vivo.	Etoposide	165-174	heat shock protein 90 alpha family class A member 1	Homo sapiens	4-9
16819137-4	2006	K562 erythroleukemia cell survival to 1.5 Gy ionising radiation with or without etoposide treatment seemed to involve Erk phosphorylation which, regulating p90 RSK, should activate CREB.	Etoposide	80-89	mitogen-activated protein kinase 1	Homo sapiens	118-121
16819137-4	2006	K562 erythroleukemia cell survival to 1.5 Gy ionising radiation with or without etoposide treatment seemed to involve Erk phosphorylation which, regulating p90 RSK, should activate CREB.	Etoposide	80-89	ribosomal protein S6 kinase A1	Homo sapiens	156-163
16819137-4	2006	K562 erythroleukemia cell survival to 1.5 Gy ionising radiation with or without etoposide treatment seemed to involve Erk phosphorylation which, regulating p90 RSK, should activate CREB.	Etoposide	80-89	cAMP responsive element binding protein 1	Homo sapiens	181-185
16819137-6	2006	Thus, endogenous CREB activation, triggering a potent survival signal in K562 cells exposed to 1.5 Gy with or without etoposide, led us to suggest that using specific inhibitors against CREB, such as modified phosphorothionate oligodeoxynucleotides (ODN) corresponding to CREB-1 sequence, anticancer therapy efficacy could be improved.	Etoposide	118-127	cAMP responsive element binding protein 1	Homo sapiens	17-21
16818517-5	2006	We envisioned that dp-VP16 would be converted to the active chemotherapeutic agent VP-16 by the same rabbit carboxylesterase (rCE) that we have previously shown to efficiently activate the prodrug irinotecan (CPT-11).	Etoposide	83-88	host cell factor C1	Homo sapiens	22-26
16543234-8	2006	Interaction of NO with the cyt c.CL complex inhibited its peroxidase activity with three different substrates: CL, etoposide, and 3,3"-diaminobenzidine.	Etoposide	115-124	cytochrome c, somatic	Homo sapiens	27-32
16827139-7	2006	ZBP-89 potentiated p53-mediated cell death with 10 nM staurosporine and 100 nM etoposide, but did not in the presence of the R273H p53 mutation.	Etoposide	79-88	zinc finger protein 148	Homo sapiens	0-6
16583432-1	2006	BACKGROUND: The purpose of the current study was to determine the toxicity and response of a fixed dose intracerebrospinal fluid (CSF) etoposide in the treatment of patients with newly diagnosed neoplastic meningitis (NM).	Etoposide	135-144	colony stimulating factor 2	Homo sapiens	130-133
16827139-7	2006	ZBP-89 potentiated p53-mediated cell death with 10 nM staurosporine and 100 nM etoposide, but did not in the presence of the R273H p53 mutation.	Etoposide	79-88	tumor protein p53	Homo sapiens	19-22
16364925-4	2006	Interestingly, while the susceptibilities of Tbeta4 overexpressers to 5-FU and irinotecan remained unchanged, they were more resistant to doxorubicin and etoposide which triggered apoptosis via a mitochondrial pathway.	Etoposide	154-163	thymosin beta 4 X-linked	Homo sapiens	45-51
16575541-0	2006	Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines.	Etoposide	46-55	diablo IAP-binding mitochondrial protein	Homo sapiens	10-14
16527552-0	2006	Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.	Etoposide	57-66	AKT serine/threonine kinase 1	Homo sapiens	14-17
16527552-0	2006	Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.	Etoposide	57-66	mitogen-activated protein kinase 3	Homo sapiens	22-25
16527552-9	2006	Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein.	Etoposide	83-92	mitogen-activated protein kinase 3	Homo sapiens	8-14
16527552-9	2006	Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein.	Etoposide	83-92	AKT serine/threonine kinase 1	Homo sapiens	16-19
16527552-9	2006	Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein.	Etoposide	83-92	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	47-52
16527552-9	2006	Phospho-ERK1/2, Akt activity and expression of c-Myc were significantly induced by etoposide in a time-dependent manner; moreover, there was a weak effect on the expression of p53 protein.	Etoposide	83-92	tumor protein p53	Homo sapiens	176-179
16527552-10	2006	Both Wortmannin and PD98059 elevated the level of p53 expression strikingly, however, only PD98059 suppressed the up-regulation trend of c-Myc expression induced by etoposide.	Etoposide	165-174	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	137-142
16574402-2	2006	We have extended these studies and found that ML-7 stimulates the ability of etoposide to induce apoptosis in Mm5MT mouse mammary adenocarcinoma cells and Mat-Ly-Lu rat prostate cancer cells in vitro.	Etoposide	77-86	solute carrier family 25 (mitochondrial carrier, Graves disease autoantigen), member 16	Mus musculus	46-50
16574402-5	2006	Moreover, ML-7 significantly stimulates the ability of etoposide to prevent the growth of established mammary tumours in mice and prostate tumours in rats.	Etoposide	55-64	solute carrier family 25 (mitochondrial carrier, Graves disease autoantigen), member 16	Mus musculus	10-14
16697734-8	2006	Recombinant wild-type TFF1 significantly inhibited cell growth; A10D and E13K lost this tumor-suppressive property along with the ability to block etoposide-induced apoptosis.	Etoposide	147-156	trefoil factor 1	Homo sapiens	22-26
16651419-4	2006	Furthermore, PAF inhibited etoposide-induced increases in caspase-3, caspase-8, and caspase-9 activities, as well as cell death.	Etoposide	27-36	patchy fur	Mus musculus	13-16
16651419-4	2006	Furthermore, PAF inhibited etoposide-induced increases in caspase-3, caspase-8, and caspase-9 activities, as well as cell death.	Etoposide	27-36	caspase 3	Mus musculus	58-67
16651419-4	2006	Furthermore, PAF inhibited etoposide-induced increases in caspase-3, caspase-8, and caspase-9 activities, as well as cell death.	Etoposide	27-36	caspase 8	Mus musculus	69-78
16651419-4	2006	Furthermore, PAF inhibited etoposide-induced increases in caspase-3, caspase-8, and caspase-9 activities, as well as cell death.	Etoposide	27-36	caspase 9	Mus musculus	84-93
16651419-5	2006	p50/p65 heterodimer increased the mRNA expression of Bcl-2 and Bcl-xL and decreased etoposide-induced caspase activities and cell death.	Etoposide	84-93	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-3
16651419-5	2006	p50/p65 heterodimer increased the mRNA expression of Bcl-2 and Bcl-xL and decreased etoposide-induced caspase activities and cell death.	Etoposide	84-93	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	4-7
16651419-5	2006	p50/p65 heterodimer increased the mRNA expression of Bcl-2 and Bcl-xL and decreased etoposide-induced caspase activities and cell death.	Etoposide	84-93	B cell leukemia/lymphoma 2	Mus musculus	53-58
16651419-6	2006	In an in vivo model in which Matrigel was injected s.c., PAF augmented the growth of B16F10 cells and attenuated etoposide-induced inhibition of B16F10 cells growth.	Etoposide	113-122	patchy fur	Mus musculus	57-60
16644697-4	2006	2) Overexpression of a constitutively active form of the antiapoptotic protein kinase Akt1 in 832/13 cells provides significant protection against cell killing induced by camptothecin and etoposide but no protection against cytokine-mediated damage.	Etoposide	188-197	AKT serine/threonine kinase 1	Rattus norvegicus	86-90
16644697-7	2006	In contrast, camptothecin- and etoposide-induced killing is associated with robust increases in caspase 3 activation and annexin V staining.	Etoposide	31-40	caspase 3	Rattus norvegicus	96-105
16484320-8	2006	PTH as well as LiCl(2), which mimics the effects of the Wnt-beta-catenin pathway, rescued the dexamethasone- and etoposide-induced apoptosis of osteoblastic cells.	Etoposide	113-122	parathyroid hormone	Mus musculus	0-3
16484320-8	2006	PTH as well as LiCl(2), which mimics the effects of the Wnt-beta-catenin pathway, rescued the dexamethasone- and etoposide-induced apoptosis of osteoblastic cells.	Etoposide	113-122	catenin (cadherin associated protein), beta 1	Mus musculus	60-72
16575541-5	2006	Caspase activity assay showed that our peptide successfully increased the activity of caspase-3 and caspase-9 in etoposide-induced apoptosis.	Etoposide	113-122	caspase 3	Homo sapiens	86-95
16575541-5	2006	Caspase activity assay showed that our peptide successfully increased the activity of caspase-3 and caspase-9 in etoposide-induced apoptosis.	Etoposide	113-122	caspase 9	Homo sapiens	100-109
16575541-8	2006	Finally, we demonstrated that Smac peptide could enhance the growth inhibition effect of etoposide compared with control peptides.	Etoposide	89-98	diablo IAP-binding mitochondrial protein	Homo sapiens	30-34
16499868-5	2006	Expression of PAL31 resulted in the marked rescue of Rat1 cells from etoposide and UV radiation-induced apoptosis and the cytoprotection was correlated with the levels of PAL31 protein.	Etoposide	69-78	acidic nuclear phosphoprotein 32 family member B	Rattus norvegicus	14-19
16365881-7	2006	Similar to CD95-induced cell death, apoptosis triggered by the DNA topoisomerase inhibitors, camptothecin or etoposide was shifted to necrosis when capsase activation was inhibited.	Etoposide	109-118	Fas cell surface death receptor	Homo sapiens	11-15
16731765-7	2006	Our data suggest that the antiapoptotic effect of aspirin operates in vivo through the activation of AKT-glycogen synthase kinase pathway causing a decrease in the outcome of VP-16-based therapy.	Etoposide	175-180	thymoma viral proto-oncogene 1	Mus musculus	101-104
16532434-2	2006	The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT.	Etoposide	83-92	caveolin 2	Homo sapiens	152-155
16452485-6	2006	Etoposide and gamma-irradiation-induced activation of p53 is similar in primary parotid cells and parotid glands from PKCdelta(+/+) and PKCdelta(-/-) mice, indicating that PKCdelta functions downstream of the DNA damage response.	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	54-57
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Etoposide	146-155	serpin family B member 3	Homo sapiens	44-47
16613690-2	2006	This study was to observe the efficacy and side effect of intrapericardial infusion of etoposide (VP-16) and cisplatin (DDP) on malignant pericardial effusion of non-small cell lung cancer (NSCLC).	Etoposide	87-96	host cell factor C1	Homo sapiens	98-103
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Etoposide	146-155	serpin family B member 3	Homo sapiens	87-90
16377807-0	2006	MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells.	Etoposide	47-56	lysine methyltransferase 2A	Homo sapiens	0-3
16377807-8	2006	Immunophenotyping of MLL translocations revealed a significant increase in positive flow cytometry events at low etoposide concentrations and were consistent with MLL recombination.	Etoposide	113-122	lysine methyltransferase 2A	Homo sapiens	21-24
16536759-11	2006	CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.	Etoposide	146-155	serpin family B member 3	Homo sapiens	87-90
16377807-11	2006	Our data indicate that low acute doses of etoposide can cause DNA strand breaks and chromosomal rearrangements involving MLL in human fetal HSC.	Etoposide	42-51	lysine methyltransferase 2A	Homo sapiens	121-124
16503501-7	2006	The CD34 cell dose collected was greater in bolus etoposide patients (44 million per kilogram) than in continuous etoposide patients (10.9 million per kilogram; P&lt;.0001).	Etoposide	50-59	CD34 molecule	Homo sapiens	4-8
16734880-4	2006	Four courses of chemotherapy, including cisplatin, etoposide, and bleomycin, normalized the level of DU-PAN-2, and the metastatic lesions disappeared.	Etoposide	51-60	poly(A) specific ribonuclease subunit PAN2	Homo sapiens	104-109
16213583-5	2006	Overexpression of sorcin protein by gene transfection in K562 cells resulted in increased drug resistance, from 4.1- to 22.5-fold, to a variety of chemotherapeutic agents, including doxorubicin, etoposide, homoharringtonine and vincristine.	Etoposide	195-204	sorcin	Homo sapiens	18-24
16183167-0	2006	Orally administered FPRL1 receptor agonist peptide MMK-1 inhibits etoposide-induced alopecia by a mechanism different from intraperitoneally administered MMK-1.	Etoposide	66-75	formyl peptide receptor 2	Rattus norvegicus	20-25
16183167-1	2006	Oral administration for 6 days of 100 mg/kg MMK-1, an agonist peptide selective for the FPRL1 receptor, suppressed alopecia induced by the anticancer drug etoposide in neonatal rats.	Etoposide	155-164	formyl peptide receptor 2	Rattus norvegicus	88-93
16183167-5	2006	These results suggest that MMK-1 bound to FPRL1 receptor might suppress etoposide-induced apoptosis of hair follicle cells and alopecia by way of PGE2 release and NF-kappaB activation.	Etoposide	72-81	formyl peptide receptor 2	Rattus norvegicus	42-47
16875555-6	2006	FCM Annexin V-FITC/PI dual labeling technique was performed to investigate the etoposide (Vp16) induced NB4/VEGF-C cells apoptosis and bcl-2 gene expression level in these cells was analysed by RQ-PCR.	Etoposide	79-88	annexin A5	Homo sapiens	4-13
16875555-6	2006	FCM Annexin V-FITC/PI dual labeling technique was performed to investigate the etoposide (Vp16) induced NB4/VEGF-C cells apoptosis and bcl-2 gene expression level in these cells was analysed by RQ-PCR.	Etoposide	79-88	host cell factor C1	Homo sapiens	90-94
16875555-6	2006	FCM Annexin V-FITC/PI dual labeling technique was performed to investigate the etoposide (Vp16) induced NB4/VEGF-C cells apoptosis and bcl-2 gene expression level in these cells was analysed by RQ-PCR.	Etoposide	79-88	vascular endothelial growth factor A	Homo sapiens	108-112
16540661-6	2006	Similarly, Gal-3-negative cells showed 43.8% apoptosis after treatment with 300 micromol/L etoposide for 48 hours, whereas only 15.38% and 14.51% of Gal-3-expressing LNCaP cells were apoptotic.	Etoposide	91-100	galectin 3	Homo sapiens	11-16
16412978-4	2006	In response to etoposide-induced DNA damage, ubiquitinated XRCC4 became more pronounced and was additionally phosphorylated.	Etoposide	15-24	X-ray repair cross complementing 4	Homo sapiens	59-64
16211087-0	2006	Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.	Etoposide	47-56	diablo IAP-binding mitochondrial protein	Homo sapiens	16-20
16211087-3	2006	Constitutive expression of Smac resulted in enhanced Bax accumulation on mitochondria upon etoposide stimulation and inhibited Bcl-2-induced antiapoptosis activity.	Etoposide	91-100	diablo IAP-binding mitochondrial protein	Homo sapiens	27-31
16211087-3	2006	Constitutive expression of Smac resulted in enhanced Bax accumulation on mitochondria upon etoposide stimulation and inhibited Bcl-2-induced antiapoptosis activity.	Etoposide	91-100	BCL2 associated X, apoptosis regulator	Homo sapiens	53-56
16699130-2	2006	In this study, the authors describe a multiplexed assay for caspase 3 activation, nuclear condensation, and cell viability in a neuronal precursor cell line Ntera-2, injured with staurosporine and etoposide.	Etoposide	197-206	caspase 3	Homo sapiens	60-69
16525683-6	2006	Flow cytometric analyses revealed that the etoposide-resistant subclones showed significantly increased cell surface expression of CD40 compared to the parent cells, which expressed undetectable levels of CD40.	Etoposide	43-52	CD40 molecule	Homo sapiens	131-135
16525683-6	2006	Flow cytometric analyses revealed that the etoposide-resistant subclones showed significantly increased cell surface expression of CD40 compared to the parent cells, which expressed undetectable levels of CD40.	Etoposide	43-52	CD40 molecule	Homo sapiens	205-209
16525683-7	2006	However, the expression of some integrin receptor subunits, such as CD29, CD49a and CD49f, was apparently reduced in the etoposide-resistant subclones.	Etoposide	121-130	integrin subunit beta 1	Homo sapiens	68-72
16525683-7	2006	However, the expression of some integrin receptor subunits, such as CD29, CD49a and CD49f, was apparently reduced in the etoposide-resistant subclones.	Etoposide	121-130	integrin subunit alpha 1	Homo sapiens	74-79
16525683-7	2006	However, the expression of some integrin receptor subunits, such as CD29, CD49a and CD49f, was apparently reduced in the etoposide-resistant subclones.	Etoposide	121-130	integrin subunit alpha 6	Homo sapiens	84-89
16525683-10	2006	Differential expression of integrin receptors and CD40 may be involved in the acquisition of etoposide resistance by cervical squamous cancer cells.	Etoposide	93-102	CD40 molecule	Homo sapiens	50-54
16638224-7	2006	It is concluded that high-dose etoposide with G-CSF is an effective and safe mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with hematologic malignancies.	Etoposide	31-40	colony stimulating factor 3	Homo sapiens	46-51
16319070-8	2006	When given with tumor necrosis factor-related apoptosis-inducing ligand or caspase-dependent chemotherapeutic agents, such as etoposide and paclitaxel, troglitazone exhibited a synergistic effect by facilitating caspase-8/9 activities.	Etoposide	126-135	caspase 8	Homo sapiens	212-221
16503501-7	2006	The CD34 cell dose collected was greater in bolus etoposide patients (44 million per kilogram) than in continuous etoposide patients (10.9 million per kilogram; P&lt;.0001).	Etoposide	114-123	CD34 molecule	Homo sapiens	4-8
16465381-0	2006	Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.	Etoposide	52-61	phosphoglycolate phosphatase	Mus musculus	17-31
16569192-8	2006	The inhibition of PARP cleavage by PCGEM1 overexpression was also observed in LNCaP-PCGEM1 cells incubated with etoposide and sodium selenite.	Etoposide	112-121	poly(ADP-ribose) polymerase 1	Homo sapiens	18-22
16569192-8	2006	The inhibition of PARP cleavage by PCGEM1 overexpression was also observed in LNCaP-PCGEM1 cells incubated with etoposide and sodium selenite.	Etoposide	112-121	PCGEM1 prostate-specific transcript	Homo sapiens	35-41
16569192-8	2006	The inhibition of PARP cleavage by PCGEM1 overexpression was also observed in LNCaP-PCGEM1 cells incubated with etoposide and sodium selenite.	Etoposide	112-121	PCGEM1 prostate-specific transcript	Homo sapiens	84-90
16465381-0	2006	Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.	Etoposide	52-61	phosphoglycolate phosphatase	Mus musculus	102-106
16465381-5	2006	Resistance to vincristine was unchanged, but resistance to etoposide (VP-16) was 3.7-fold higher in A40P than A20 (itself 97-fold higher than wild-type).	Etoposide	59-68	tumor necrosis factor, alpha-induced protein 3	Mus musculus	110-113
16465381-5	2006	Resistance to vincristine was unchanged, but resistance to etoposide (VP-16) was 3.7-fold higher in A40P than A20 (itself 97-fold higher than wild-type).	Etoposide	70-75	tumor necrosis factor, alpha-induced protein 3	Mus musculus	110-113
16478794-7	2006	CONCLUSIONS: Our findings suggest that the MDR1 2677G&gt;T and 3435C&gt;T polymorphisms can be used for predicting treatment response to etoposide-cisplatin chemotherapy in SCLC patients.	Etoposide	137-146	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
16437214-6	2006	In addition, silencing of Livin beta, but not of Livin alpha, sensitized HeLa cells to different proapoptotic stimuli such as UV irradiation, tumor necrosis factor alpha, or etoposide.	Etoposide	174-183	baculoviral IAP repeat containing 7	Homo sapiens	26-31
16541742-6	2006	The standard chemotherapy for extensive SCLC is the combination of cisplatin and irinotecan or etoposide.	Etoposide	95-104	SCLC1	Homo sapiens	40-44
16722146-8	2006	Further, in Ca922 and HSC6 but not in HOC313, caspase 8 inhibitor restored loss of viability induced either with LY294002 and TRAIL or even with etoposide alone.	Etoposide	145-154	caspase 8	Homo sapiens	46-55
16478794-0	2006	MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer.	Etoposide	43-52	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
16787360-2	2006	Their capability to restore/potentiate the antiproliferative activity of clinically useful drugs, such as doxorubicin (Doxo), vincristine (VCR) and etoposide (VP16), in drug-resistant human nasopharyngeal carcinoma KB cells (KB(WT), KB(MDR), KB(7D)and KB(V20C)) was evaluated.	Etoposide	148-157	host cell factor C1	Homo sapiens	159-163
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Etoposide	96-105	major vault protein	Homo sapiens	0-3
16465425-4	2006	MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration.	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
16274701-2	2006	Introduction of wild-type (WT)-CKIepsilon into interleukin-3 (IL-3)-dependent 32D cells increased the sensitivity to genotoxic stresses, such as gamma-irradiation, etoposide, and IL-3 deprivation, whereas kinase-negative (KN)-CKIepsilon suppressed it.	Etoposide	164-173	TPTEP2-CSNK1E readthrough	Homo sapiens	31-41
16200630-2	2006	APE (cytosine arabinoside, cisplatin, etoposide) is a non-cross-resistant regimen with limited toxicities.	Etoposide	38-47	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-3
16274701-2	2006	Introduction of wild-type (WT)-CKIepsilon into interleukin-3 (IL-3)-dependent 32D cells increased the sensitivity to genotoxic stresses, such as gamma-irradiation, etoposide, and IL-3 deprivation, whereas kinase-negative (KN)-CKIepsilon suppressed it.	Etoposide	164-173	interleukin 3	Mus musculus	47-60
16274701-2	2006	Introduction of wild-type (WT)-CKIepsilon into interleukin-3 (IL-3)-dependent 32D cells increased the sensitivity to genotoxic stresses, such as gamma-irradiation, etoposide, and IL-3 deprivation, whereas kinase-negative (KN)-CKIepsilon suppressed it.	Etoposide	164-173	interleukin 3	Mus musculus	62-66
16325212-6	2006	Together, our data indicate that p33ING1b prominently enhances etoposide-induced apoptosis through p53-dependent pathways in human osteosarcoma cells.	Etoposide	63-72	tumor protein p53	Homo sapiens	99-102
16021489-5	2006	Upon treating the cells with etoposide in the presence of 10 microM curcuminoids, the sensitivity of etoposide was increased by several folds only in MRP1 expressing and not in pcDNA3.1-HEK 293 cells.	Etoposide	29-38	ATP binding cassette subfamily C member 1	Homo sapiens	150-154
16325212-0	2006	The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells.	Etoposide	85-94	inhibitor of growth family member 1	Homo sapiens	4-12
16325212-0	2006	The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells.	Etoposide	85-94	tumor protein p53	Homo sapiens	46-49
16325212-4	2006	p33ING1b increased etoposide-induced growth inhibition and apoptosis to a much greater degree in p53+/+ U2OS cells than in p53-mutant MG63 cells.	Etoposide	19-28	inhibitor of growth family member 1	Homo sapiens	0-8
16325212-4	2006	p33ING1b increased etoposide-induced growth inhibition and apoptosis to a much greater degree in p53+/+ U2OS cells than in p53-mutant MG63 cells.	Etoposide	19-28	tumor protein p53	Homo sapiens	97-100
16325212-5	2006	Moreover, ectopic expression of p33ING1b markedly upregulated p53, p21WAF1 and bax protein levels and activated caspase-3 protein kinase in etoposide-treated U2OS cells.	Etoposide	140-149	inhibitor of growth family member 1	Homo sapiens	32-40
16325212-5	2006	Moreover, ectopic expression of p33ING1b markedly upregulated p53, p21WAF1 and bax protein levels and activated caspase-3 protein kinase in etoposide-treated U2OS cells.	Etoposide	140-149	BCL2 associated X, apoptosis regulator	Homo sapiens	79-82
16325212-6	2006	Together, our data indicate that p33ING1b prominently enhances etoposide-induced apoptosis through p53-dependent pathways in human osteosarcoma cells.	Etoposide	63-72	inhibitor of growth family member 1	Homo sapiens	33-41
16331277-4	2006	Conversely, restoration of procaspase-3 sensitizes MCF-7 cells to chemotherapeutics including epirubicine, etoposide and taxol.	Etoposide	107-116	caspase 3	Homo sapiens	27-39
16452227-0	2006	The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway.	Etoposide	44-53	nibrin	Homo sapiens	92-96
16021489-5	2006	Upon treating the cells with etoposide in the presence of 10 microM curcuminoids, the sensitivity of etoposide was increased by several folds only in MRP1 expressing and not in pcDNA3.1-HEK 293 cells.	Etoposide	101-110	ATP binding cassette subfamily C member 1	Homo sapiens	150-154
16452227-0	2006	The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway.	Etoposide	44-53	ATR serine/threonine kinase	Homo sapiens	106-140
16452227-0	2006	The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway.	Etoposide	44-53	checkpoint kinase 1	Homo sapiens	141-145
16467399-0	2006	IFNgamma pretreatment sensitizes human choriocarcinoma cells to etoposide-induced apoptosis.	Etoposide	64-73	interferon gamma	Homo sapiens	0-8
16452227-8	2006	Etoposide also triggers the dispersal of replicative proteins, proliferating cell nuclear antigen and DNA ligase I, from replication factories.	Etoposide	0-9	proliferating cell nuclear antigen	Homo sapiens	63-97
16452227-11	2006	Finally, our analysis evidences a critical role of Nbs1 in the etoposide-induced inhibition of DNA replication in early S phase.	Etoposide	63-72	nibrin	Homo sapiens	51-55
16467098-6	2006	Using antisense oligonucleotides against Mcl-1, MDA-MB-231 cells were rendered sensitive to etoposide-induced apoptosis similar to herceptin, but combined treatment of antisense against Mcl-1 and herceptin failed to give a significant increase in apoptosis.	Etoposide	92-101	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	41-46
16467098-6	2006	Using antisense oligonucleotides against Mcl-1, MDA-MB-231 cells were rendered sensitive to etoposide-induced apoptosis similar to herceptin, but combined treatment of antisense against Mcl-1 and herceptin failed to give a significant increase in apoptosis.	Etoposide	92-101	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	186-191
16467098-8	2006	DISCUSSION: Using murine fibroblasts that express human ErbB2, but no other ErbB family member (NE2), these cells showed resistance to both taxol- and etoposide-induced apoptosis compared with parental cells.	Etoposide	151-160	erb-b2 receptor tyrosine kinase 2	Homo sapiens	56-61
16467098-8	2006	DISCUSSION: Using murine fibroblasts that express human ErbB2, but no other ErbB family member (NE2), these cells showed resistance to both taxol- and etoposide-induced apoptosis compared with parental cells.	Etoposide	151-160	epidermal growth factor receptor	Homo sapiens	56-60
16508731-9	2006	An additional three courses of BEP and five courses of VIP (cisplatin, ifosfamide, etoposide) normalized the beta-hCG level.	Etoposide	83-92	vasoactive intestinal peptide	Homo sapiens	55-58
16572900-2	2006	This was carried out by studying the effects of downregulation of XIAP expression on cellular viability, cellular apoptosis and on the response to two chemotherapeutical drugs, etoposide and doxorubicin.	Etoposide	177-186	X-linked inhibitor of apoptosis	Homo sapiens	66-70
16513841-6	2006	Subsequent stimulation of these cells with an anticancer agent, etoposide, results in augmented NF-kappaB-dependent p21(waf1/cip1) induction and increased chemoresistance of the leukemia cells.	Etoposide	64-73	cyclin dependent kinase inhibitor 1A	Homo sapiens	116-129
16467399-5	2006	In JAR cells, etoposide increased expression of the proteins including IFNgammaR, p53 and pro-caspase 3 as well as IRF-1 mRNA and IFNgamma-pretreatment apparently promoted up-regulation of these molecules expression.	Etoposide	14-23	tumor protein p53	Homo sapiens	82-85
16467399-5	2006	In JAR cells, etoposide increased expression of the proteins including IFNgammaR, p53 and pro-caspase 3 as well as IRF-1 mRNA and IFNgamma-pretreatment apparently promoted up-regulation of these molecules expression.	Etoposide	14-23	caspase 3	Homo sapiens	90-103
16467399-5	2006	In JAR cells, etoposide increased expression of the proteins including IFNgammaR, p53 and pro-caspase 3 as well as IRF-1 mRNA and IFNgamma-pretreatment apparently promoted up-regulation of these molecules expression.	Etoposide	14-23	interferon regulatory factor 1	Homo sapiens	115-120
16467399-5	2006	In JAR cells, etoposide increased expression of the proteins including IFNgammaR, p53 and pro-caspase 3 as well as IRF-1 mRNA and IFNgamma-pretreatment apparently promoted up-regulation of these molecules expression.	Etoposide	14-23	interferon gamma	Homo sapiens	71-79
16467399-7	2006	IRF-1 knock down assays demonstrated that IRF-1 directly mediated IFNgamma pretreatment enhanced sensitivity of JAR cells to etoposide-induced apoptosis and that pro-caspase 3 was one of the target genes of IRF-1.	Etoposide	125-134	interferon regulatory factor 1	Homo sapiens	42-47
16467399-7	2006	IRF-1 knock down assays demonstrated that IRF-1 directly mediated IFNgamma pretreatment enhanced sensitivity of JAR cells to etoposide-induced apoptosis and that pro-caspase 3 was one of the target genes of IRF-1.	Etoposide	125-134	interferon gamma	Homo sapiens	66-74
16467399-7	2006	IRF-1 knock down assays demonstrated that IRF-1 directly mediated IFNgamma pretreatment enhanced sensitivity of JAR cells to etoposide-induced apoptosis and that pro-caspase 3 was one of the target genes of IRF-1.	Etoposide	125-134	interferon regulatory factor 1	Homo sapiens	42-47
16424010-5	2006	Deletion of a specific Egr-1-binding site present in the PTEN promoter blocked etoposide-induced PTEN activity and elevated expression of PLD decreased the sensitivity to apoptosis induced by ectopic expression of Egr-1.	Etoposide	79-88	early growth response 1	Homo sapiens	214-219
16505093-2	2006	We previously showed that the EGFR inhibitor gefitinib modulated repair of DNA damage following exposure to cisplatin and etoposide involving the DNA-dependent protein kinase (DNA-PK) pathway.	Etoposide	122-131	epidermal growth factor receptor	Homo sapiens	30-34
16505093-2	2006	We previously showed that the EGFR inhibitor gefitinib modulated repair of DNA damage following exposure to cisplatin and etoposide involving the DNA-dependent protein kinase (DNA-PK) pathway.	Etoposide	122-131	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	146-174
16505093-2	2006	We previously showed that the EGFR inhibitor gefitinib modulated repair of DNA damage following exposure to cisplatin and etoposide involving the DNA-dependent protein kinase (DNA-PK) pathway.	Etoposide	122-131	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	176-182
16325773-5	2006	Klotho protein also reduced H(2)O(2)- and etoposide-induced apoptosis in HUVEC.	Etoposide	42-51	klotho	Homo sapiens	0-6
16424010-0	2006	Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10.	Etoposide	25-34	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-15
16424010-0	2006	Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10.	Etoposide	25-34	early growth response 1	Homo sapiens	85-124
16424010-2	2006	We show for the first time that elevated expression of PLD isozymes attenuates expression of the tumor suppressors early growth response-1 (Egr-1) and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) tumor suppressor and apoptosis during etoposide treatment.	Etoposide	258-267	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	55-58
16424010-2	2006	We show for the first time that elevated expression of PLD isozymes attenuates expression of the tumor suppressors early growth response-1 (Egr-1) and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) tumor suppressor and apoptosis during etoposide treatment.	Etoposide	258-267	early growth response 1	Homo sapiens	140-145
16611405-3	2006	GrB/scFvMEL showed synergistic cytotoxicity when coadministered with doxorubicin, vincristine or cisplatin, and additive effects, in combination with etoposide or cytarabine.	Etoposide	150-159	granzyme B	Homo sapiens	0-3
16170349-4	2006	Forced downregulation of MSP expression in H1299 cells, derived from a large-cell lung carcinoma, confers increased resistance against etoposide-induced cell death.	Etoposide	135-144	macrophage stimulating 1	Homo sapiens	25-28
16424027-6	2006	In contrast to these results, another chemotherapeutic drug etoposide activates NF-kappaB and induces expression of these target genes.	Etoposide	60-69	nuclear factor kappa B subunit 1	Homo sapiens	80-89
16424010-2	2006	We show for the first time that elevated expression of PLD isozymes attenuates expression of the tumor suppressors early growth response-1 (Egr-1) and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) tumor suppressor and apoptosis during etoposide treatment.	Etoposide	258-267	phosphatase and tensin homolog	Homo sapiens	214-218
16424010-3	2006	When formation of phosphatidic acid was inhibited by overexpression of catalytically inactive PLD during etoposide treatment, expression of Egr-1 and PTEN and the apoptotic effect of etoposide were not inhibited.	Etoposide	105-114	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	94-97
16424010-3	2006	When formation of phosphatidic acid was inhibited by overexpression of catalytically inactive PLD during etoposide treatment, expression of Egr-1 and PTEN and the apoptotic effect of etoposide were not inhibited.	Etoposide	183-192	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	94-97
16424010-5	2006	Deletion of a specific Egr-1-binding site present in the PTEN promoter blocked etoposide-induced PTEN activity and elevated expression of PLD decreased the sensitivity to apoptosis induced by ectopic expression of Egr-1.	Etoposide	79-88	early growth response 1	Homo sapiens	23-28
16424010-5	2006	Deletion of a specific Egr-1-binding site present in the PTEN promoter blocked etoposide-induced PTEN activity and elevated expression of PLD decreased the sensitivity to apoptosis induced by ectopic expression of Egr-1.	Etoposide	79-88	phosphatase and tensin homolog	Homo sapiens	57-61
16424010-5	2006	Deletion of a specific Egr-1-binding site present in the PTEN promoter blocked etoposide-induced PTEN activity and elevated expression of PLD decreased the sensitivity to apoptosis induced by ectopic expression of Egr-1.	Etoposide	79-88	phosphatase and tensin homolog	Homo sapiens	97-101
16424010-6	2006	Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	32-35
16424010-6	2006	Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels.	Etoposide	0-9	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	73-76
16434323-0	2006	Genotoxicity of etoposide: greater susceptibility of MLL than other target genes.	Etoposide	16-25	lysine methyltransferase 2A	Homo sapiens	53-56
16434323-3	2006	The effects of etoposide on the MLL, RUNX1, and MLLT3 genes were simultaneously studied in the same hemopoietic cell population.	Etoposide	15-24	lysine methyltransferase 2A	Homo sapiens	32-35
16424010-6	2006	Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels.	Etoposide	0-9	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	81-84
16434323-3	2006	The effects of etoposide on the MLL, RUNX1, and MLLT3 genes were simultaneously studied in the same hemopoietic cell population.	Etoposide	15-24	MLLT3 super elongation complex subunit	Homo sapiens	48-53
16434323-4	2006	We found MLL to be more susceptible to etoposide-induced cleavage than RUNX1 and MLLT3, with maximum cleavage at a lower drug concentration.	Etoposide	39-48	lysine methyltransferase 2A	Homo sapiens	9-12
16424010-6	2006	Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels.	Etoposide	0-9	early growth response 1	Homo sapiens	111-116
16424010-6	2006	Etoposide-induced activation of Akt was potentiated by overexpression of PLD and PLD-stimulated suppression of Egr-1 was blocked by inhibition of phosphatidylinositol 3-kinase/Akt survival pathway at the both transcriptional and posttranscriptional levels.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	176-179
16316634-5	2006	This report demonstrates that pretreatment of cells with a polypeptide, which inhibits c-Myc transcriptional function causes cells to be more susceptible to the topoisomerase II inhibitors doxorubicin and etoposide.	Etoposide	205-214	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	87-92
16297990-3	2006	We have evaluated in the present study the role of AM in prostate cancer cell apoptosis, induced either by serum deprivation or treatment with the chemotherapeutic agent etoposide (which acts as an inhibitor of topoisomerase II).	Etoposide	170-179	adrenomedullin	Homo sapiens	51-53
16297990-7	2006	When treated with etoposide, AM prevented apoptosis in PC-3 and LNCaP cells, but not in DU 145 cells.	Etoposide	18-27	adrenomedullin	Homo sapiens	29-31
16297990-8	2006	Cell cycle analysis demonstrated a significant decrease in the percentage of AM-overexpressing PC-3 cells in the subG0/G1 phase after treatment with etoposide, as compared to the percentage of mock-transfected PC-3 treated cells.	Etoposide	149-158	adrenomedullin	Homo sapiens	77-79
16297990-9	2006	Western blot showed that protein levels of phosphorylated ERK1/2 increased in parental PC-3 cells after treatment with etoposide.	Etoposide	119-128	mitogen-activated protein kinase 3	Homo sapiens	58-64
16297990-10	2006	In PC-3 cells overexpressing AM, phosphorylated ERK1/2 basal levels were lower than basal levels of parental PC-3 cells, and treatment with etoposide did not result in such an increase.	Etoposide	140-149	adrenomedullin	Homo sapiens	29-31
16297990-11	2006	Etoposide produced a significant increase in cleaved PARP in parental PC-3 cells.	Etoposide	0-9	collagen type XI alpha 2 chain	Homo sapiens	53-57
16297990-12	2006	However, PC-3 clones overexpressing AM that were treated with etoposide only showed a mild increase in fragmented PARP.	Etoposide	62-71	adrenomedullin	Homo sapiens	36-38
16297990-12	2006	However, PC-3 clones overexpressing AM that were treated with etoposide only showed a mild increase in fragmented PARP.	Etoposide	62-71	collagen type XI alpha 2 chain	Homo sapiens	114-118
16297990-13	2006	The ratio Bcl-2/Bax was reduced in parental or mock-transfected PC-3 cells after treatment with etoposide.	Etoposide	96-105	BCL2 apoptosis regulator	Homo sapiens	10-15
16297990-13	2006	The ratio Bcl-2/Bax was reduced in parental or mock-transfected PC-3 cells after treatment with etoposide.	Etoposide	96-105	BCL2 associated X, apoptosis regulator	Homo sapiens	16-19
16316634-7	2006	Furthermore, the c-Myc inhibitor affects the cell cycle distribution of MCF-7 breast cancer cells by enhancing the G(0)/G(1) accumulation induced by doxorubicin and etoposide.	Etoposide	165-174	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
16533421-2	2006	Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan.	Etoposide	54-63	fragile histidine triad diadenosine triphosphatase	Homo sapiens	14-18
16271715-6	2006	However, K-ras(tmDelta4A/tmDelta4A) ES cells were more resistant to etoposide-induced apoptosis than K-ras(-/-) cells.	Etoposide	68-77	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	9-14
16897187-3	2006	Here, we report a novel role of the DFNA5 gene in p53-mediated etoposide-induced cell death.	Etoposide	63-72	gasdermin E	Mus musculus	36-41
16897187-3	2006	Here, we report a novel role of the DFNA5 gene in p53-mediated etoposide-induced cell death.	Etoposide	63-72	transformation related protein 53, pseudogene	Mus musculus	50-53
16897187-8	2006	The ectopic expression of DFNA5 enhanced etoposide-induced cell death in the presence of p53; however, it was inhibited in the absence of p53.	Etoposide	41-50	gasdermin E	Mus musculus	26-31
16897187-8	2006	The ectopic expression of DFNA5 enhanced etoposide-induced cell death in the presence of p53; however, it was inhibited in the absence of p53.	Etoposide	41-50	transformation related protein 53, pseudogene	Mus musculus	89-92
16114066-5	2006	Additionally, E2F1-expressing cells are more sensitive to etoposide-induced apoptosis.	Etoposide	58-67	E2F transcription factor 1	Homo sapiens	14-18
16568831-12	2006	Both cell lines exhibited high sensitivity to etoposide, classical inductor of unrepairable DSBs and p53.	Etoposide	46-55	tumor protein p53	Homo sapiens	101-104
16322251-7	2005	It was revealed that the survivin protein level was up-regulated by the coexpression of HER2 and EGFR, leading to the increased resistance against etoposide-induced apoptosis in breast cancer cells.	Etoposide	147-156	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92
16219768-4	2005	Here, we determined that UV light, anisomycin, etoposide, and hypoxic stress rapidly induced phosphorylation of p53 at Ser46 and WOX1 at Tyr33 (phospho-WOX1) and their binding interactions in several tested cancer cells.	Etoposide	47-56	tumor protein p53	Homo sapiens	112-115
16219768-4	2005	Here, we determined that UV light, anisomycin, etoposide, and hypoxic stress rapidly induced phosphorylation of p53 at Ser46 and WOX1 at Tyr33 (phospho-WOX1) and their binding interactions in several tested cancer cells.	Etoposide	47-56	WW domain containing oxidoreductase	Homo sapiens	129-133
16219768-4	2005	Here, we determined that UV light, anisomycin, etoposide, and hypoxic stress rapidly induced phosphorylation of p53 at Ser46 and WOX1 at Tyr33 (phospho-WOX1) and their binding interactions in several tested cancer cells.	Etoposide	47-56	WW domain containing oxidoreductase	Homo sapiens	152-156
16150937-0	2005	mTOR regulates cell survival after etoposide treatment in primary AML cells.	Etoposide	35-44	mechanistic target of rapamycin kinase	Homo sapiens	0-4
16150937-6	2005	Furthermore, etoposide consistently decreased the engraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and this effect was enhanced by coincubation with rapamycin, demonstrating that mTOR regulates survival of AML stem cells after etoposide treatment.	Etoposide	13-22	mechanistic target of rapamycin kinase	Homo sapiens	228-232
16150937-6	2005	Furthermore, etoposide consistently decreased the engraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and this effect was enhanced by coincubation with rapamycin, demonstrating that mTOR regulates survival of AML stem cells after etoposide treatment.	Etoposide	276-285	mechanistic target of rapamycin kinase	Homo sapiens	228-232
16091739-6	2005	Cells lacking pRb are more sensitive to etoposide-induced cytotoxicity.	Etoposide	40-49	RB transcriptional corepressor 1	Homo sapiens	14-17
16091739-10	2005	The functional status of pRb, therefore, may influence sensitivity to etoposide by facilitating the repair of trapped TOP2-DNA complexes as well as by enforcing cell cycle checkpoints.	Etoposide	70-79	RB transcriptional corepressor 1	Homo sapiens	25-28
16322251-7	2005	It was revealed that the survivin protein level was up-regulated by the coexpression of HER2 and EGFR, leading to the increased resistance against etoposide-induced apoptosis in breast cancer cells.	Etoposide	147-156	epidermal growth factor receptor	Homo sapiens	97-101
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Etoposide	130-135	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	14-21
16288046-6	2005	Pretreatment with 17-AAG, which induced hsp70, inhibited 1-beta-D-arabinofuranosylcytosine or etoposide-induced apoptosis in HL-60 cells.	Etoposide	94-103	N-methylpurine DNA glycosylase	Homo sapiens	21-24
16288046-6	2005	Pretreatment with 17-AAG, which induced hsp70, inhibited 1-beta-D-arabinofuranosylcytosine or etoposide-induced apoptosis in HL-60 cells.	Etoposide	94-103	heat shock protein family A (Hsp70) member 4	Homo sapiens	40-45
16288014-6	2005	Therefore, we identified a novel transcriptional mechanism that is likely to contribute to BRCA1-mediated resistance to etoposide.	Etoposide	120-129	BRCA1 DNA repair associated	Homo sapiens	91-96
16007125-4	2005	Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate.	Etoposide	228-237	BCL2 interacting killer	Homo sapiens	26-29
16007125-4	2005	Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate.	Etoposide	228-237	BCL2 interacting killer	Homo sapiens	30-33
16044155-0	2005	A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.	Etoposide	81-90	diablo IAP-binding mitochondrial protein	Homo sapiens	17-21
16044155-10	2005	In combinational treatments with TRAIL or etoposide, Smac-mimic significantly sensitized cells to growth suppression in MDA-MB-231 cells, but to a lesser extent in T47D and MDA-MB-453 cells.	Etoposide	42-51	diablo IAP-binding mitochondrial protein	Homo sapiens	53-57
16044155-12	2005	Thus, in these cell lines, Smac-mimic acts in an apparent IAPs dependent manner to induce apoptosis alone as well as sensitizes breast cancer cells to TRAIL or etoposide induced apoptosis via caspase-3 activation.	Etoposide	160-169	diablo IAP-binding mitochondrial protein	Homo sapiens	27-31
16044155-12	2005	Thus, in these cell lines, Smac-mimic acts in an apparent IAPs dependent manner to induce apoptosis alone as well as sensitizes breast cancer cells to TRAIL or etoposide induced apoptosis via caspase-3 activation.	Etoposide	160-169	caspase 3	Homo sapiens	192-201
16110520-6	2005	Of pharmacological importance is the fact that most of these found-in-wine water-soluble ellagitannin derivatives are much more potent than etoposide (VP-16) at inhibiting top2-mediated DNA decatenation in vitro (top2=topoisomerase II)).	Etoposide	140-149	host cell factor C1	Homo sapiens	151-156
16170381-4	2005	BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wild-type (wt) cells.	Etoposide	130-135	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	27-34
16170381-7	2005	Both gadd45a- and gadd45b-deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45.	Etoposide	112-117	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	5-12
16170381-7	2005	Both gadd45a- and gadd45b-deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45.	Etoposide	112-117	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	18-25
16281866-2	2005	After 4 courses of chemotherapy with cisplatin (CDDP), etoposide (VP-16) and bleomycin hydrochloride (BLM), the mediastinal mass reduced in size significantly and the serum AFP level reached within normal range.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
15936818-4	2005	Valproate induced a clear G1 phase arrest and up-regulated cyclin D1 expression in the presence of Ara-C and etoposide.	Etoposide	109-118	cyclin D1	Homo sapiens	59-68
15887249-2	2005	Expression of a myristoylated constitutively active form of Akt (myr-Akt) in PC12 cells could override cell-growth arrest at G2/M phase and apoptosis that were induced by etoposide treatment.	Etoposide	171-180	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
15887249-2	2005	Expression of a myristoylated constitutively active form of Akt (myr-Akt) in PC12 cells could override cell-growth arrest at G2/M phase and apoptosis that were induced by etoposide treatment.	Etoposide	171-180	AKT serine/threonine kinase 1	Rattus norvegicus	69-72
16260623-3	2005	Compared to vector-transfected cells, H1299 cells expressing mutant p53 showed a survival advantage when treated with etoposide, a common chemotherapeutic agent; however, cells expressing the transactivation-deficient triple mutant p53-D281G (L22Q/W23S) had significantly lower resistance to etoposide.	Etoposide	118-127	tumor protein p53	Homo sapiens	68-71
16260623-3	2005	Compared to vector-transfected cells, H1299 cells expressing mutant p53 showed a survival advantage when treated with etoposide, a common chemotherapeutic agent; however, cells expressing the transactivation-deficient triple mutant p53-D281G (L22Q/W23S) had significantly lower resistance to etoposide.	Etoposide	292-301	tumor protein p53	Homo sapiens	68-71
16281866-2	2005	After 4 courses of chemotherapy with cisplatin (CDDP), etoposide (VP-16) and bleomycin hydrochloride (BLM), the mediastinal mass reduced in size significantly and the serum AFP level reached within normal range.	Etoposide	55-64	alpha fetoprotein	Homo sapiens	173-176
16331887-4	2005	Overexpression of EZH2 resulted in decreased cell survival and clonogenic capacity following DNA damage induced independently by etoposide and ionizing radiation.	Etoposide	129-138	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	18-22
16260623-6	2005	Treatment of H1299 cells expressing p53-R175H with small interfering RNA specific for NF-kappaB2 made these cells more sensitive to etoposide.	Etoposide	132-141	tumor protein p53	Homo sapiens	36-39
16264263-8	2005	The PTEN-overexpressing SUN-5 and -216 cells were more sensitive to death induced by etoposide and adriamycin that induce DNA damage than the pcDNA3-transfected cells.	Etoposide	85-94	phosphatase and tensin homolog	Homo sapiens	4-8
16264263-8	2005	The PTEN-overexpressing SUN-5 and -216 cells were more sensitive to death induced by etoposide and adriamycin that induce DNA damage than the pcDNA3-transfected cells.	Etoposide	85-94	Sad1 and UNC84 domain containing 5	Homo sapiens	24-29
16267399-6	2005	Etoposide activated NF-kB through PI3-kinase/Akt, and the transcription activation domain (TAD) of p65 was further activated by wild-type PDK-1.	Etoposide	0-9	AKT serine/threonine kinase 1	Homo sapiens	45-48
16267399-6	2005	Etoposide activated NF-kB through PI3-kinase/Akt, and the transcription activation domain (TAD) of p65 was further activated by wild-type PDK-1.	Etoposide	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	99-102
16267399-6	2005	Etoposide activated NF-kB through PI3-kinase/Akt, and the transcription activation domain (TAD) of p65 was further activated by wild-type PDK-1.	Etoposide	0-9	pyruvate dehydrogenase kinase 1	Homo sapiens	138-143
16267399-7	2005	Overexpression of a dominant negative PDK-1 mutant decreased etoposide-induced NF-kB transcription and further down-regulated the ectopic HDAC1-mediated decrease in NF-kB transcriptional activity.	Etoposide	61-70	pyruvate dehydrogenase kinase 1	Homo sapiens	38-43
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	93-102	chemokine (C-X-C motif) receptor 4	Mus musculus	135-140
16123041-5	2005	Subsequently, etoposide caused activation of caspase-7, cleavage of Claspin, and dephosphorylation of Chk1.	Etoposide	14-23	checkpoint kinase 1	Homo sapiens	102-106
16002426-1	2005	We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL).	Etoposide	99-108	host cell factor C1	Homo sapiens	110-115
16204039-6	2005	Its overexpression inhibited pro-caspase-9 activation, leading to the suppression of the cell death induced by a protein kinase inhibitor, staurosporine, or a chemotherapeutic reagent, etoposide (VP-16).	Etoposide	185-194	caspase 9	Homo sapiens	33-42
16204039-6	2005	Its overexpression inhibited pro-caspase-9 activation, leading to the suppression of the cell death induced by a protein kinase inhibitor, staurosporine, or a chemotherapeutic reagent, etoposide (VP-16).	Etoposide	196-201	caspase 9	Homo sapiens	33-42
16204039-7	2005	In contrast, specific small interfering RNA-mediated suppression of TUCAN-54 expression in tumor cells increased the VP-16-induced cell death rate, indicating that expression of TUCAN-54 might be associated with chemoresistance of tumor cells.	Etoposide	117-122	caspase recruitment domain family member 8	Homo sapiens	68-73
16204039-7	2005	In contrast, specific small interfering RNA-mediated suppression of TUCAN-54 expression in tumor cells increased the VP-16-induced cell death rate, indicating that expression of TUCAN-54 might be associated with chemoresistance of tumor cells.	Etoposide	117-122	caspase recruitment domain family member 8	Homo sapiens	178-183
16123041-4	2005	In cells, induction of DNA damage by etoposide at first produced rapid phosphorylation of Chk1 at a site targeted by ATR.	Etoposide	37-46	checkpoint kinase 1	Homo sapiens	90-94
16123041-4	2005	In cells, induction of DNA damage by etoposide at first produced rapid phosphorylation of Chk1 at a site targeted by ATR.	Etoposide	37-46	ATR serine/threonine kinase	Homo sapiens	117-120
16123041-5	2005	Subsequently, etoposide caused activation of caspase-7, cleavage of Claspin, and dephosphorylation of Chk1.	Etoposide	14-23	caspase 7	Homo sapiens	45-54
16123041-5	2005	Subsequently, etoposide caused activation of caspase-7, cleavage of Claspin, and dephosphorylation of Chk1.	Etoposide	14-23	claspin	Homo sapiens	68-75
16151644-0	2005	p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide.	Etoposide	123-132	mitogen-activated protein kinase 14	Homo sapiens	0-3
16151644-2	2005	Here we examine the role of p38 in regulation of apoptosis and cell cycle checkpoint in Daudi B-cell lymphoma cells treated with the topoisomerase II inhibitor etoposide.	Etoposide	160-169	mitogen-activated protein kinase 14	Homo sapiens	28-31
16151644-3	2005	Etoposide activated p38, inhibited the G2/M transition with the persistent inhibitory phosphorylation of Cdc2 on Tyr15, and caused apoptosis of Daudi cells.	Etoposide	0-9	mitogen-activated protein kinase 14	Homo sapiens	20-23
16151644-3	2005	Etoposide activated p38, inhibited the G2/M transition with the persistent inhibitory phosphorylation of Cdc2 on Tyr15, and caused apoptosis of Daudi cells.	Etoposide	0-9	cyclin dependent kinase 1	Homo sapiens	105-109
16151644-4	2005	Inducible expression of a dominant negative p38alpha mutant in Daudi cells reduced the inhibition of Cdc2 as well as G2/M arrest and augmented apoptosis induced by etoposide.	Etoposide	164-173	mitogen-activated protein kinase 14	Homo sapiens	44-52
16151644-5	2005	SB203580, a specific inhibitor of p38alpha and p38beta, similarly reduced the inhibitory phosphorylation of Cdc2 as well as G2/M arrest and augmented apoptosis of Daudi cells treated with etoposide.	Etoposide	188-197	mitogen-activated protein kinase 14	Homo sapiens	34-42
16151644-5	2005	SB203580, a specific inhibitor of p38alpha and p38beta, similarly reduced the inhibitory phosphorylation of Cdc2 as well as G2/M arrest and augmented apoptosis of Daudi cells treated with etoposide.	Etoposide	188-197	mitogen-activated protein kinase 11	Homo sapiens	47-54
16151644-5	2005	SB203580, a specific inhibitor of p38alpha and p38beta, similarly reduced the inhibitory phosphorylation of Cdc2 as well as G2/M arrest and augmented apoptosis of Daudi cells treated with etoposide.	Etoposide	188-197	cyclin dependent kinase 1	Homo sapiens	108-112
16151644-6	2005	These results suggest that p38 plays a role in G2/M checkpoint activation through induction of the persistent inhibitory phosphorylation of Cdc2 and, thereby, inhibits apoptosis of Daudi cells treated with etoposide.	Etoposide	206-215	mitogen-activated protein kinase 14	Homo sapiens	27-30
16151644-6	2005	These results suggest that p38 plays a role in G2/M checkpoint activation through induction of the persistent inhibitory phosphorylation of Cdc2 and, thereby, inhibits apoptosis of Daudi cells treated with etoposide.	Etoposide	206-215	cyclin dependent kinase 1	Homo sapiens	140-144
16123594-4	2005	NFkappaB activation induces death receptor 5 (DR5) expression following DNA damaging agent etoposide treatment but not following growth factor EGF treatment.	Etoposide	91-100	nuclear factor kappa B subunit 1	Homo sapiens	0-8
16123594-4	2005	NFkappaB activation induces death receptor 5 (DR5) expression following DNA damaging agent etoposide treatment but not following growth factor EGF treatment.	Etoposide	91-100	TNF receptor superfamily member 10b	Homo sapiens	28-44
16123594-4	2005	NFkappaB activation induces death receptor 5 (DR5) expression following DNA damaging agent etoposide treatment but not following growth factor EGF treatment.	Etoposide	91-100	TNF receptor superfamily member 10b	Homo sapiens	46-49
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	93-102	chemokine (C-X-C motif) ligand 12	Mus musculus	175-204
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	93-102	chemokine (C-X-C motif) ligand 12	Mus musculus	206-212
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	104-109	chemokine (C-X-C motif) receptor 4	Mus musculus	135-140
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	104-109	chemokine (C-X-C motif) ligand 12	Mus musculus	175-204
16219541-1	2005	OBJECTIVE: We have previously demonstrated that bone marrow stromal cells (BMSCs) exposed to etoposide (VP-16) have reduced support of CXCR4(+) cell chemotaxis and diminished stromal cell derived factor-1 (CXCL12) in the supernatants.	Etoposide	104-109	chemokine (C-X-C motif) ligand 12	Mus musculus	206-212
16219541-3	2005	METHODS: BMSCs exposed to VP-16 were evaluated for MMP-2 expression by gelatin zymography, ELISA, and western blot.	Etoposide	26-31	matrix metallopeptidase 2	Mus musculus	51-56
16219541-5	2005	RESULTS: BMSC exposure to VP-16 resulted in an immediate, transient, increase in MMP-2, followed by reduced MMP-2 protein expression.	Etoposide	26-31	matrix metallopeptidase 2	Mus musculus	81-86
16219541-5	2005	RESULTS: BMSC exposure to VP-16 resulted in an immediate, transient, increase in MMP-2, followed by reduced MMP-2 protein expression.	Etoposide	26-31	matrix metallopeptidase 2	Mus musculus	108-113
16219541-9	2005	VP-16-induced reduction of BMSC support of hematopoietic cell migration was restored by supplementing cultures with recombinant MMP-2 protein.	Etoposide	0-5	matrix metallopeptidase 2	Mus musculus	128-133
16227394-0	2005	A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin.	Etoposide	72-81	protein kinase C zeta	Homo sapiens	11-18
16247664-0	2005	Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.	Etoposide	126-135	neurofibromin 1	Homo sapiens	71-95
16142308-6	2005	Using siRNA designed to target T-fimbrin, we demonstrated that silencing endogenous T-fimbrin causes a marked increase in the cellular sensitivity to VP-16 and UV irradiation.	Etoposide	150-155	plastin 3	Homo sapiens	31-40
16142308-6	2005	Using siRNA designed to target T-fimbrin, we demonstrated that silencing endogenous T-fimbrin causes a marked increase in the cellular sensitivity to VP-16 and UV irradiation.	Etoposide	150-155	plastin 3	Homo sapiens	84-93
16177192-3	2005	Biotinylation of K12 in histone H4 decreased by 50% as early as 10-20 min after initiation of treatment with etoposide.	Etoposide	109-118	keratin 12	Homo sapiens	17-20
16130169-3	2005	In comparison with controls cells, the differential proteomic analysis of HUVECs treated by the pro-apoptotic topoisomerase inhibitor etoposide further revealed the variation of eight proteins, namely, GRP78, GRP94, valosin-containing protein, proteinase inhibitor 9, cofilin, 37-kDa laminin receptor protein, bovine apolipoprotein, and tropomyosin.	Etoposide	134-143	heat shock protein family A (Hsp70) member 5	Bos taurus	202-207
16130169-3	2005	In comparison with controls cells, the differential proteomic analysis of HUVECs treated by the pro-apoptotic topoisomerase inhibitor etoposide further revealed the variation of eight proteins, namely, GRP78, GRP94, valosin-containing protein, proteinase inhibitor 9, cofilin, 37-kDa laminin receptor protein, bovine apolipoprotein, and tropomyosin.	Etoposide	134-143	heat shock protein 90 beta family member 1	Bos taurus	209-214
16130169-3	2005	In comparison with controls cells, the differential proteomic analysis of HUVECs treated by the pro-apoptotic topoisomerase inhibitor etoposide further revealed the variation of eight proteins, namely, GRP78, GRP94, valosin-containing protein, proteinase inhibitor 9, cofilin, 37-kDa laminin receptor protein, bovine apolipoprotein, and tropomyosin.	Etoposide	134-143	valosin containing protein	Bos taurus	216-266
16130169-3	2005	In comparison with controls cells, the differential proteomic analysis of HUVECs treated by the pro-apoptotic topoisomerase inhibitor etoposide further revealed the variation of eight proteins, namely, GRP78, GRP94, valosin-containing protein, proteinase inhibitor 9, cofilin, 37-kDa laminin receptor protein, bovine apolipoprotein, and tropomyosin.	Etoposide	134-143	ribosomal protein SA	Bos taurus	277-300
16105724-5	2005	Hydroxyzine inhibited the efflux of P-gp substrates like etoposide and chlorpheniramine across the olfactory mucosa.	Etoposide	57-66	phosphoglycolate phosphatase	Bos taurus	36-40
16202244-0	2005	Release of cytochrome c from isolated mitochondria by etoposide.	Etoposide	54-63	cytochrome c, somatic	Homo sapiens	11-23
16202244-3	2005	Here we showed that etoposide can induce the similar degree of cell death in p53-deficient HCT 116 cells, whereas 5"-FU-mediated cell death is strongly dependent on the existence of functional p53 in HCT 116 cells.	Etoposide	20-29	tumor protein p53	Homo sapiens	77-80
16202244-4	2005	Further, we provide the evidence that etoposide can induce the cytochrome c release from isolated mitochondria, and etoposide-induced cytochrome c release is not accompanied with the large amplitude swelling of mitochondria.	Etoposide	38-47	cytochrome c, somatic	Homo sapiens	63-75
16202244-4	2005	Further, we provide the evidence that etoposide can induce the cytochrome c release from isolated mitochondria, and etoposide-induced cytochrome c release is not accompanied with the large amplitude swelling of mitochondria.	Etoposide	116-125	cytochrome c, somatic	Homo sapiens	134-146
16202244-5	2005	These data suggest that etoposide can directly induce the mitochondrial dysfunction irrespective of p53 status, and it may, at least in part, account for the p53-independent pathway in cell death induced by chemotherapeutic agents.	Etoposide	24-33	tumor protein p53	Homo sapiens	158-161
16023314-12	2005	Digoxin efflux permeability remained unchanged when incubated with P-gp substrates (e.g., etoposide, rhodamine123, taxol).	Etoposide	90-99	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
15849751-5	2005	Transport of 2 previously identified MRP2 substrates, etoposide and vinblastine, was likewise stimulated by probenecid.	Etoposide	54-63	ATP binding cassette subfamily C member 2	Homo sapiens	37-41
16115632-4	2005	Etoposide and ionizing radiation inhibited nuclear export of wild-type p53 and the phosphor-mutant to comparable extents, indicating nuclear export inhibition does not require N-terminal phosphorylation.	Etoposide	0-9	transformation related protein 53, pseudogene	Mus musculus	71-74
15927428-2	2005	Our treatment consisted of carboplatin (CBDCA) and etoposide (VP-16) in the same way as small cell carcinoma of the lung is treated.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	96-105	mitogen-activated protein kinase 1	Homo sapiens	46-49
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	96-105	mitogen-activated protein kinase 1	Homo sapiens	223-226
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	205-214	mitogen-activated protein kinase 1	Homo sapiens	46-49
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	205-214	mitogen-activated protein kinase 1	Homo sapiens	223-226
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	205-214	poly(ADP-ribose) polymerase 1	Homo sapiens	274-301
16014620-4	2005	We were also able to determine that sustained ERK activation was intimately associated with the etoposide-induced apoptosis of HaCaT cells, and treatment with 3,4"-DHF induced a significant suppression of etoposide-induced ERK activation, concomitant with the repression of poly(ADP-ribose) polymerase or the cleavage of pro-caspase 3.	Etoposide	205-214	caspase 3	Homo sapiens	321-334
16014620-8	2005	Taken together, our data clearly indicate that a host of phytochemicals, including etoposide and a variety of flavonoids, differentially regulate the apoptosis of human HaCaT keratinocytes via the differential modulation of intracellular ROS production, coupled with the concomitant activation of the ERK signaling pathway.	Etoposide	83-92	mitogen-activated protein kinase 1	Homo sapiens	301-304
15901238-4	2005	Etoposide, an effective antitumour drug, traps eukaryotic DNA topoisomerase II in a covalent complex with DNA.	Etoposide	0-9	DNA topoisomerase ii	Leishmania donovani	58-78
16212410-6	2005	Nucleolin is more abundant in lines resistant to etoposide and mitoxantrone, while the mitotic checkpoint protein BUB 3 is more abundant in the line resistant to adriamycin/verapamil.	Etoposide	49-58	nucleolin	Homo sapiens	0-9
16077943-7	2005	Furthermore, like AMR and AMROH, adriamycin (ADM) and etoposide (VP-16) are DNA topoisomerase II inhibitors, and the effects of these 4 agents on 44 degrees C hyperthermia were compared.	Etoposide	54-63	host cell factor C1	Homo sapiens	65-70
16131458-5	2005	Pretreatment with calyculin A, an inhibitor of protein phosphatase-1 (PP-1) as well as fumonisin B1, an inhibitor of ceramide synthase, prevented etoposide-induced alternative splicing of Fas mRNA.	Etoposide	146-155	inorganic pyrophosphatase 1	Homo sapiens	47-68
16131458-5	2005	Pretreatment with calyculin A, an inhibitor of protein phosphatase-1 (PP-1) as well as fumonisin B1, an inhibitor of ceramide synthase, prevented etoposide-induced alternative splicing of Fas mRNA.	Etoposide	146-155	inorganic pyrophosphatase 1	Homo sapiens	70-74
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	tumor protein p53	Homo sapiens	88-91
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	MDM2 proto-oncogene	Homo sapiens	92-96
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-41
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	MDM2 proto-oncogene	Homo sapiens	46-50
16002781-3	2005	In the present study, we tested the hypothesis that dose-escalated chemotherapy, with etoposide as a model chemotherapeutic agent, activates the transforming growth factor beta-1 (TGF-beta1) signaling pathway in bone marrow stromal cells.	Etoposide	86-95	transforming growth factor beta 1	Homo sapiens	145-178
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	tumor protein p53	Homo sapiens	88-91
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	MDM2 proto-oncogene	Homo sapiens	92-96
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-41
16093994-0	2005	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	MDM2 proto-oncogene	Homo sapiens	46-50
16077961-5	2005	Similarly, although etoposide induced-apoptosis was inhibited in Bax(-/-)/Bak(-/-)mouse embryonic fibroblasts, autophagy was not inhibited, which was regulated by Bcl-xL.	Etoposide	20-29	BCL2-associated X protein	Mus musculus	65-68
16077961-5	2005	Similarly, although etoposide induced-apoptosis was inhibited in Bax(-/-)/Bak(-/-)mouse embryonic fibroblasts, autophagy was not inhibited, which was regulated by Bcl-xL.	Etoposide	20-29	BCL2-antagonist/killer 1	Mus musculus	74-77
16002781-3	2005	In the present study, we tested the hypothesis that dose-escalated chemotherapy, with etoposide as a model chemotherapeutic agent, activates the transforming growth factor beta-1 (TGF-beta1) signaling pathway in bone marrow stromal cells.	Etoposide	86-95	transforming growth factor beta 1	Homo sapiens	180-189
16002781-4	2005	After high-dose etoposide exposure in vitro, Smad3 protein was phosphorylated in a time-and dose-dependent manner in marrow-derived stromal cells, coincident with the release of active and latent TGF-beta1 from the extracellular matrix.	Etoposide	16-25	SMAD family member 3	Homo sapiens	45-50
16002781-4	2005	After high-dose etoposide exposure in vitro, Smad3 protein was phosphorylated in a time-and dose-dependent manner in marrow-derived stromal cells, coincident with the release of active and latent TGF-beta1 from the extracellular matrix.	Etoposide	16-25	transforming growth factor beta 1	Homo sapiens	196-205
16002781-6	2005	Etoposide induced activation of TGF-beta1 followed the generation of reactive oxygen species and required matrix metalloproteinase-2 (MMP-2) protein availability.	Etoposide	0-9	transforming growth factor beta 1	Homo sapiens	32-41
16002781-6	2005	Etoposide induced activation of TGF-beta1 followed the generation of reactive oxygen species and required matrix metalloproteinase-2 (MMP-2) protein availability.	Etoposide	0-9	matrix metallopeptidase 2	Homo sapiens	106-132
16002781-6	2005	Etoposide induced activation of TGF-beta1 followed the generation of reactive oxygen species and required matrix metalloproteinase-2 (MMP-2) protein availability.	Etoposide	0-9	matrix metallopeptidase 2	Homo sapiens	134-139
16122426-5	2005	In contrast, introducing a nonphosphorylatable BID mutant did not restore accumulation in the S phase and resulted in an increase in cellular sensitivity to etoposide-induced apoptosis.	Etoposide	157-166	BH3 interacting domain death agonist	Mus musculus	47-50
15914462-8	2005	Treatment of colon and ovarian carcinoma cells with the anticancer genotoxic agent etoposide up-regulated both p53 and proline oxidase, activated calcineurin, and induced apoptosis.	Etoposide	83-92	tumor protein p53	Homo sapiens	111-114
16120219-7	2005	Both etoposide and CLP induced an accumulation of p53 protein and upregulation of p53 transcriptional target genes.	Etoposide	5-14	tumor protein p53	Homo sapiens	50-53
16120219-7	2005	Both etoposide and CLP induced an accumulation of p53 protein and upregulation of p53 transcriptional target genes.	Etoposide	5-14	tumor protein p53	Homo sapiens	82-85
15856005-2	2005	Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells.	Etoposide	228-237	fibroblast growth factor 2	Homo sapiens	26-31
16103078-4	2005	We found that 24-hour hypoxia (&lt;0.1% O2) alone (no serum deprivation) showed sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) associated with bcl-2 up-regulation and resistance to etoposide-induced (5 mumol/L) apoptosis.	Etoposide	209-218	mitogen-activated protein kinase 1	Homo sapiens	104-145
16103078-4	2005	We found that 24-hour hypoxia (&lt;0.1% O2) alone (no serum deprivation) showed sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) associated with bcl-2 up-regulation and resistance to etoposide-induced (5 mumol/L) apoptosis.	Etoposide	209-218	mitogen-activated protein kinase 3	Homo sapiens	147-153
16103078-5	2005	Treatment with anti-VEGF and anti-Flt1 antibodies inhibited ERK1/2 activation, down-regulated bcl-2, and reversed the hypoxia-mediated drug resistance to etoposide.	Etoposide	154-163	vascular endothelial growth factor A	Homo sapiens	20-24
16103078-5	2005	Treatment with anti-VEGF and anti-Flt1 antibodies inhibited ERK1/2 activation, down-regulated bcl-2, and reversed the hypoxia-mediated drug resistance to etoposide.	Etoposide	154-163	fms related receptor tyrosine kinase 1	Homo sapiens	34-38
16103078-13	2005	We also found that three other Flt1-expressing neuroblastoma cell lines show hypoxia-mediated drug resistance to etoposide, melphalan, doxorubicin, and cyclophosphamide.	Etoposide	113-122	fms related receptor tyrosine kinase 1	Homo sapiens	31-35
16010441-13	2005	We also found that etoposide bypassed Fas-FADD interaction in MML-1R by activating caspase-8 and caspase-3.	Etoposide	19-28	Fas associated via death domain	Homo sapiens	42-46
16086873-1	2005	BACKGROUND &amp; OBJECTIVE: Etoposide (VP-16) is one of the most common chemotherapy drugs, but its usage is limited by drug resistance.	Etoposide	28-37	host cell factor C1	Homo sapiens	39-44
16061639-3	2005	In a 3-day cytotoxicity assay, human SPF45 overexpression conferred 3- to 21-fold resistance to carboplatin, vinorelbine, doxorubicin, etoposide, mitoxantrone, and vincristine.	Etoposide	135-144	RNA binding motif protein 17	Homo sapiens	37-42
16061639-5	2005	Knockdown of SPF45 in parental A2780 cells using a hammerhead ribozyme sensitized A2780 cells to etoposide by approximately 5-fold relative to a catalytically inactive ribozyme control and untransfected cells, suggesting a role for SPF45 in intrinsic resistance to some drugs.	Etoposide	97-106	RNA binding motif protein 17	Homo sapiens	13-18
16010441-13	2005	We also found that etoposide bypassed Fas-FADD interaction in MML-1R by activating caspase-8 and caspase-3.	Etoposide	19-28	caspase 8	Homo sapiens	83-92
16010441-13	2005	We also found that etoposide bypassed Fas-FADD interaction in MML-1R by activating caspase-8 and caspase-3.	Etoposide	19-28	caspase 3	Homo sapiens	97-106
15908423-4	2005	Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15.	Etoposide	92-101	tumor protein p53	Homo sapiens	24-27
15861398-2	2005	On the other hand, the PARP-1 deficient cells exhibited resistance to conventional inhibitors of topoisomerase II such as etoposide or doxorubicin (DOX).	Etoposide	122-131	poly (ADP-ribose) polymerase family, member 1	Mus musculus	23-29
16022921-2	2005	Etoposide is another drug that is effective for SCLC.	Etoposide	0-9	SCLC1	Homo sapiens	48-52
16022921-11	2005	This irinotecan and etoposide regimen is active against ED-SCLC with relatively mild toxicity.	Etoposide	20-29	SCLC1	Homo sapiens	59-63
15978941-6	2005	Decreased expression of BCR/ABL gene was also found after cell stimulation by selectively pro-apoptotic agent etoposide and by ABL-RNAi leading to apoptosis.	Etoposide	110-119	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	24-31
15978941-6	2005	Decreased expression of BCR/ABL gene was also found after cell stimulation by selectively pro-apoptotic agent etoposide and by ABL-RNAi leading to apoptosis.	Etoposide	110-119	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	28-31
15908423-4	2005	Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15.	Etoposide	92-101	MDM2 proto-oncogene	Homo sapiens	39-43
16024605-3	2005	We found that overexpression of RhoGDI increased resistance of cancer cells (MDA-MB-231 human breast cancer cells and JLP-119 lymphoma cells) to the induction of apoptosis by two chemotherapeutic agents: etoposide and doxorubicin.	Etoposide	204-213	Rho GDP dissociation inhibitor alpha	Homo sapiens	32-38
15999103-5	2005	Lowering the GSTP1 level significantly increased (about 3.3-fold) the sensitivity of A375-ASPi1 cells to etoposide.	Etoposide	105-114	glutathione S-transferase pi 1	Homo sapiens	13-18
15999103-8	2005	In conclusion, GSTP1 can act in a combined fashion with MRP1 to protect melanoma cells from toxic effects of etoposide.	Etoposide	109-118	glutathione S-transferase pi 1	Homo sapiens	15-20
15999103-8	2005	In conclusion, GSTP1 can act in a combined fashion with MRP1 to protect melanoma cells from toxic effects of etoposide.	Etoposide	109-118	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
16602625-6	2005	MRP2 induction by staurosporine and H-7 was shown to have phenotypic consequences in whole cells, rendering them more resistant to etoposide and increasing their ability to export calcein through the plasma membrane.	Etoposide	131-140	ATP binding cassette subfamily C member 2	Homo sapiens	0-4
15994954-6	2005	Suppression of GRP78 through the use of lentiviral vector expressing small interfering RNA sensitizes human breast cancer cells to etoposide-mediated cell death.	Etoposide	131-140	heat shock protein family A (Hsp70) member 5	Homo sapiens	15-20
15942663-7	2005	The transient transfection of a constitutively active and non-phosphorylable S9AGSK-3beta mutant sensitized cells to etoposide cytotoxic effects while cell treatment with the small GSK-3beta inhibitor SB-415286 repressed the sensitizing effect of LY294002 on chemotherapy-induced apoptosis and caspase-8 activation.	Etoposide	117-126	glycogen synthase kinase 3 beta	Homo sapiens	80-89
15726362-3	2005	Using multivariate Cox regression analysis BEAM conditioning (carmustine, cytarabine, etoposide and melphalan) was predictive for favourable outcome, better disease-/progression-free survival and a significantly lower risk for relapse.	Etoposide	86-95	cytochrome c oxidase subunit 8A	Homo sapiens	19-22
15968678-4	2005	Fluorescence microscopy and flow cytometric measurements with a lipophilic dye revealed an accumulation of cytoplasmic lipid droplets in isolated EL-4 cells undergoing etoposide-induced apoptosis.	Etoposide	168-177	epilepsy 4	Mus musculus	146-150
15906374-6	2005	Furthermore, the addition of etoposide to proliferating H19-7 cells caused the diminished binding of Hip-1 to Dyrk1 and the levels of phosphorylated Hip-1 remarkably decreased.	Etoposide	29-38	huntingtin interacting protein 1	Rattus norvegicus	101-106
15906374-6	2005	Furthermore, the addition of etoposide to proliferating H19-7 cells caused the diminished binding of Hip-1 to Dyrk1 and the levels of phosphorylated Hip-1 remarkably decreased.	Etoposide	29-38	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	110-115
15906374-6	2005	Furthermore, the addition of etoposide to proliferating H19-7 cells caused the diminished binding of Hip-1 to Dyrk1 and the levels of phosphorylated Hip-1 remarkably decreased.	Etoposide	29-38	huntingtin interacting protein 1	Rattus norvegicus	149-154
15906374-7	2005	Simultaneously, the dissociated Hip-1 from Dyrk1 bound to caspase-3 in response to etoposide, which led to its activation and consequently cell death in H19-7 cells.	Etoposide	83-92	huntingtin interacting protein 1	Rattus norvegicus	32-37
15906374-7	2005	Simultaneously, the dissociated Hip-1 from Dyrk1 bound to caspase-3 in response to etoposide, which led to its activation and consequently cell death in H19-7 cells.	Etoposide	83-92	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	43-48
15906374-7	2005	Simultaneously, the dissociated Hip-1 from Dyrk1 bound to caspase-3 in response to etoposide, which led to its activation and consequently cell death in H19-7 cells.	Etoposide	83-92	caspase 3	Rattus norvegicus	58-67
15906374-9	2005	The interaction between Dyrk1 and Hip-1 appeared to be differentially modulated by different kinds of stimuli, such as bFGF and etoposide in H19-7 cells.	Etoposide	128-137	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	24-29
15906374-9	2005	The interaction between Dyrk1 and Hip-1 appeared to be differentially modulated by different kinds of stimuli, such as bFGF and etoposide in H19-7 cells.	Etoposide	128-137	huntingtin interacting protein 1	Rattus norvegicus	34-39
15924153-6	2005	Since etoposide-induced apoptosis involved caspase 3 activation in Hank-1 and NK-YS cells, the caspase 3-dependent apoptotic machinery appears to be intact.	Etoposide	6-15	caspase 3	Homo sapiens	43-52
16277093-0	2005	Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.	Etoposide	123-132	tumor protein p53	Homo sapiens	14-17
16028013-4	2005	Flux of etoposide, a substrate reported to be primarily effluxed by P-gp, across bovine olfactory and nasal respiratory mucosae was measured using Sweetana-Grass (Navicyte) vertical diffusion cells.	Etoposide	8-17	phosphoglycolate phosphatase	Bos taurus	68-72
16028013-13	2005	CONCLUSIONS: P-gp was localized in the epithelial cells, nasal glands, and the vascular endothelium of both the bovine olfactory and nasal respiratory mucosae, and the expressed P-gp was capable of effluxing a substrate such as etoposide.	Etoposide	228-237	phosphoglycolate phosphatase	Bos taurus	13-17
16028013-13	2005	CONCLUSIONS: P-gp was localized in the epithelial cells, nasal glands, and the vascular endothelium of both the bovine olfactory and nasal respiratory mucosae, and the expressed P-gp was capable of effluxing a substrate such as etoposide.	Etoposide	228-237	phosphoglycolate phosphatase	Bos taurus	178-182
15964798-4	2005	Herein, we determined that etoposide-induced DR5 expression requires the first intronic region of the DR5 gene.	Etoposide	27-36	TNF receptor superfamily member 10b	Homo sapiens	45-48
15964798-4	2005	Herein, we determined that etoposide-induced DR5 expression requires the first intronic region of the DR5 gene.	Etoposide	27-36	TNF receptor superfamily member 10b	Homo sapiens	102-105
15814571-1	2005	Multidrug resistance protein 3 (MRP3) is an ATP-binding cassette transporter that is able to confer resistance to anticancer agents such as etoposide and to transport lipophilic anions such as bile acids and glucuronides.	Etoposide	140-149	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	0-30
15814571-1	2005	Multidrug resistance protein 3 (MRP3) is an ATP-binding cassette transporter that is able to confer resistance to anticancer agents such as etoposide and to transport lipophilic anions such as bile acids and glucuronides.	Etoposide	140-149	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	32-36
15817479-12	2005	Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2.	Etoposide	29-38	BCL2 apoptosis regulator	Homo sapiens	157-162
15922021-7	2005	In particular, U L 46 and U L 47 are known to modulate the effects of VP16 on immediate early promoters.	Etoposide	70-74	tegument protein VP11/12	Human alphaherpesvirus 1	15-21
15922021-7	2005	In particular, U L 46 and U L 47 are known to modulate the effects of VP16 on immediate early promoters.	Etoposide	70-74	tegument protein VP13/14	Human alphaherpesvirus 1	26-32
15817479-0	2005	Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation.	Etoposide	28-37	BCL2 apoptosis regulator	Homo sapiens	0-5
15882989-7	2005	Mouse embryonic fibroblast cells lacking MEKK1 expression are also resistant to etoposide-induced mitochondrial Smac/Diablo release.	Etoposide	80-89	mitogen-activated protein kinase kinase kinase 1	Mus musculus	41-46
15817479-0	2005	Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation.	Etoposide	28-37	caspase 2	Homo sapiens	90-99
15817479-4	2005	Stress stimuli, including ceramide and etoposide, caused caspase-2 activation, mitochondrial damage followed by downstream caspase-9 and -3 activation, and cell apoptosis in human lung epithelial cell line A549.	Etoposide	39-48	caspase 2	Homo sapiens	57-66
15817479-4	2005	Stress stimuli, including ceramide and etoposide, caused caspase-2 activation, mitochondrial damage followed by downstream caspase-9 and -3 activation, and cell apoptosis in human lung epithelial cell line A549.	Etoposide	39-48	caspase 9	Homo sapiens	123-139
15817479-6	2005	Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis.	Etoposide	48-57	BCL2 apoptosis regulator	Homo sapiens	18-23
15817479-6	2005	Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis.	Etoposide	48-57	caspase 2	Homo sapiens	66-75
15817479-10	2005	Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment.	Etoposide	87-96	BCL2 apoptosis regulator	Homo sapiens	28-33
15817479-12	2005	Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2.	Etoposide	29-38	caspase 2	Homo sapiens	93-102
15688372-4	2005	Overexpression of FAF1 enhanced DEF assembly and cell death induced by chemotherapeutics such as staurosporine (STS), cisplatin (CDDP) and etoposide (VP16).	Etoposide	139-148	Fas associated factor 1	Homo sapiens	18-22
15688372-4	2005	Overexpression of FAF1 enhanced DEF assembly and cell death induced by chemotherapeutics such as staurosporine (STS), cisplatin (CDDP) and etoposide (VP16).	Etoposide	150-154	Fas associated factor 1	Homo sapiens	18-22
15882989-7	2005	Mouse embryonic fibroblast cells lacking MEKK1 expression are also resistant to etoposide-induced mitochondrial Smac/Diablo release.	Etoposide	80-89	diablo, IAP-binding mitochondrial protein	Mus musculus	112-116
15882989-7	2005	Mouse embryonic fibroblast cells lacking MEKK1 expression are also resistant to etoposide-induced mitochondrial Smac/Diablo release.	Etoposide	80-89	diablo, IAP-binding mitochondrial protein	Mus musculus	117-123
15896459-0	2005	Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
15896459-0	2005	Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.	Etoposide	0-9	tumor protein p53	Homo sapiens	76-79
15896459-1	2005	In this work, we described the proliferation of human non-small-cell-lung-cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo.	Etoposide	195-204	tumor protein p53	Homo sapiens	111-114
15896459-1	2005	In this work, we described the proliferation of human non-small-cell-lung-cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo.	Etoposide	195-204	host cell factor C1	Homo sapiens	206-211
15941391-5	2005	However, in this paper we show that chicken cells lacking Rad52 do exhibit increased sensitivity to the Top2 inhibitor VP-16.	Etoposide	119-124	RAD52 homolog, DNA repair protein	Gallus gallus	58-63
15815728-4	2005	Here we show that CML CD34(+) progenitors are sensitive to several apoptosis-inducing stimuli including the chemotherapeutic agents Ara-C and VP-16, radiation, arsenic trioxide, ceramide, growth factor withdrawal, and the death receptor activators TNFalpha and TRAIL.	Etoposide	142-147	CD34 molecule	Homo sapiens	22-26
16050481-11	2005	We performed pelvic radiotherapy, and chemotherapy using carboplatin (CBDCA) and etoposide (VP-16).	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
15832344-0	2005	JNK/p53 mediated cell death response in K562 exposed to etoposide-ionizing radiation combined treatment.	Etoposide	56-65	mitogen-activated protein kinase 8	Homo sapiens	0-3
15832344-0	2005	JNK/p53 mediated cell death response in K562 exposed to etoposide-ionizing radiation combined treatment.	Etoposide	56-65	tumor protein p53	Homo sapiens	4-7
15832344-3	2005	In this study, we examined the role played by JNK/SAPK, p53, and mitochondrial pathways in cell death response of K562 cells to etoposide and IR treatment.	Etoposide	128-137	mitogen-activated protein kinase 8	Homo sapiens	46-49
15832344-4	2005	Our results let us suppose that the induction of cell death, already evident in 15 Gy exposed cells, mainly in 15 Gy plus etoposide, may be mediated by JNK/SAPK pathway.	Etoposide	122-131	mitogen-activated protein kinase 8	Homo sapiens	152-155
15832344-5	2005	Moreover, p53 is a potential substrate for JNK and may act as a JNK target for etoposide and ionizing radiation.	Etoposide	79-88	tumor protein p53	Homo sapiens	10-13
15832344-5	2005	Moreover, p53 is a potential substrate for JNK and may act as a JNK target for etoposide and ionizing radiation.	Etoposide	79-88	mitogen-activated protein kinase 8	Homo sapiens	43-46
15832344-5	2005	Moreover, p53 is a potential substrate for JNK and may act as a JNK target for etoposide and ionizing radiation.	Etoposide	79-88	mitogen-activated protein kinase 8	Homo sapiens	64-67
15972853-3	2005	Cells that activated NF-kappaB in response to ionizing radiation or etoposide arrested in the G2-M phase for a prolonged time, which was followed by increased cell cycle reentry and survival.	Etoposide	68-77	nuclear factor kappa B subunit 1	Homo sapiens	21-30
15790566-5	2005	Importantly, our results demonstrated that C53 deficiency conferred partial resistance to genotoxic agents such as etoposide and x-ray irradiation, whereas ectopic expression of C53 rendered cells susceptible to multiple genotoxins that usually trigger G(2)/M arrest.	Etoposide	115-124	CDK5 regulatory subunit associated protein 3	Homo sapiens	43-46
15790566-6	2005	Furthermore, we found that Cdk1 activity was required for etoposide-induced apoptosis of HeLa cells.	Etoposide	58-67	cyclin dependent kinase 1	Homo sapiens	27-31
15857611-6	2005	Although transcription of the SNK gene was also regulated by tunicamycin, etoposide, or staurosporine, FK506 did not show any effects on these regulations.	Etoposide	74-83	polo like kinase 2	Homo sapiens	30-33
15692060-4	2005	Enforced expression of Apaf-1 increased its concentration in the cytosolic compartment, restored cytochrome c-dependent caspase activation, and rendered the prototypic Raji BL cell line sensitive to etoposide- and staurosporine-induced apoptosis.	Etoposide	199-208	apoptotic peptidase activating factor 1	Homo sapiens	23-29
15798770-3	2005	K562/MX2 cells were more resistant to MX2 than the parent cells, and also showed cross-resistance to etoposide and doxorubicin.	Etoposide	101-110	MX dynamin like GTPase 2	Homo sapiens	5-8
15909125-0	2005	Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
15909125-0	2005	Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis.	Etoposide	0-9	tumor protein p53	Homo sapiens	29-32
15909125-0	2005	Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis.	Etoposide	0-9	caspase 7	Homo sapiens	85-94
15862760-5	2005	PAI-1 gene-deficient and wild-type mice displayed similar sensitivity to treatment with etoposide, suggesting a differential effect of PAI-1 expression between cancer cells and normal cells.	Etoposide	88-97	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-5
15827163-5	2005	Unexpectedly, however, both nef+ and nef-defective HIV-1 infection blocked apoptosis in cells treated with UV light or etoposide but not cell death induced by CD95 antibody, TRAIL, Ly294002, or serum starvation.	Etoposide	119-128	Nef	Human immunodeficiency virus 1	28-31
15827163-5	2005	Unexpectedly, however, both nef+ and nef-defective HIV-1 infection blocked apoptosis in cells treated with UV light or etoposide but not cell death induced by CD95 antibody, TRAIL, Ly294002, or serum starvation.	Etoposide	119-128	Nef	Human immunodeficiency virus 1	37-40
15897237-4	2005	In this report, we show that treatment of U937 leukemia cells with the chemotherapy drug etoposide (VP-16) results in cathepsin D release into the cytosol within 4 hours after initiation of drug treatment.	Etoposide	89-98	cathepsin D	Homo sapiens	118-129
15897237-4	2005	In this report, we show that treatment of U937 leukemia cells with the chemotherapy drug etoposide (VP-16) results in cathepsin D release into the cytosol within 4 hours after initiation of drug treatment.	Etoposide	100-105	cathepsin D	Homo sapiens	118-129
15884115-10	2005	A strong correlation was only found between the level of MRP3 expression and the IC(50) values of etoposide, doxorubicin and pirarubicin (r = 0.86-0.98, P&lt;0.05).	Etoposide	98-107	ATP binding cassette subfamily C member 3	Homo sapiens	57-61
15884115-13	2005	MRP3 was correlated with resistance of CCA cell lines to etoposide, doxorubicin and pirarubicin, whereas other chemotherapeutic drugs showed no association.	Etoposide	57-66	ATP binding cassette subfamily C member 3	Homo sapiens	0-4
15846088-5	2005	The cell line that showed greatest reduction (85-90%) of p53 expression showed decreased p21 promoter activation after DNA damage with camptothecin, etoposide and MMS.	Etoposide	149-158	tumor protein p53	Homo sapiens	57-60
15846088-5	2005	The cell line that showed greatest reduction (85-90%) of p53 expression showed decreased p21 promoter activation after DNA damage with camptothecin, etoposide and MMS.	Etoposide	149-158	H3 histone pseudogene 16	Homo sapiens	89-92
15798770-10	2005	We concluded that the mechanism of drug resistance to MX2 and etoposide in K562/MX2 cells might be the combination of decreased expression of Topo IIalpha gene and increased methylation, and that 5AZ could prove to be a novel treatment for etoposide-resistant cell lines, such as K562/MX2.	Etoposide	62-71	MX dynamin like GTPase 2	Homo sapiens	80-83
15798770-10	2005	We concluded that the mechanism of drug resistance to MX2 and etoposide in K562/MX2 cells might be the combination of decreased expression of Topo IIalpha gene and increased methylation, and that 5AZ could prove to be a novel treatment for etoposide-resistant cell lines, such as K562/MX2.	Etoposide	62-71	MX dynamin like GTPase 2	Homo sapiens	80-83
15798770-10	2005	We concluded that the mechanism of drug resistance to MX2 and etoposide in K562/MX2 cells might be the combination of decreased expression of Topo IIalpha gene and increased methylation, and that 5AZ could prove to be a novel treatment for etoposide-resistant cell lines, such as K562/MX2.	Etoposide	240-249	MX dynamin like GTPase 2	Homo sapiens	54-57
15782144-6	2005	In addition, these PTPL1-reduced cells were more sensitive to etoposide-induced apoptosis than the controls.	Etoposide	62-71	protein tyrosine phosphatase non-receptor type 13	Homo sapiens	19-24
15843040-4	2005	While ERK1/2 activation was a general phenomenon, irrespective of the used cell type or antitumour drug, the MEK/ERK inhibitors only reduced cisplatin toxicity in human myeloid cells (THP-1, HL-60 and NB-4), but not in RAW 264.7 mouse macrophages and NRK-52E rat renal tubular cells; and failed to reduce the toxicity etoposide, camptothecin, melphalan and arsenic trioxide, in U-937 cells.	Etoposide	318-327	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
15876872-3	2005	Furthermore, functional analysis of apoptosis sensitivity showed that lymphomas with a caspase 9 inhibition profile were indeed relatively resistant to Etoposide induced apoptosis.	Etoposide	152-161	caspase 9	Homo sapiens	87-96
15814645-0	2005	A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children"s Oncology Group experience.	Etoposide	165-174	thrombopoietin	Homo sapiens	57-71
15814645-0	2005	A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children"s Oncology Group experience.	Etoposide	165-174	colony stimulating factor 3	Homo sapiens	76-113
15900709-4	2005	Etoposide exposure induces dissolution of stress fibres and an increase in actin and cofilin in membrane patches and apoptotic blebs.	Etoposide	0-9	cofilin 1	Homo sapiens	85-92
15900709-2	2005	Here we examine changes in the localisation of actin, cofilin and the Arp2/3 complex during the apoptotic process in response to etoposide.	Etoposide	129-138	cofilin 1	Homo sapiens	54-61
15694838-5	2005	By contrast, Sp1 and NFkappaB binding capacities were lost in all myeloid cell lines undergoing etoposide-induced fast apoptosis.	Etoposide	96-105	nuclear factor kappa B subunit 1	Homo sapiens	21-29
15900709-2	2005	Here we examine changes in the localisation of actin, cofilin and the Arp2/3 complex during the apoptotic process in response to etoposide.	Etoposide	129-138	actin related protein 2	Homo sapiens	70-74
15694838-7	2005	However, sustained NFkappaB binding to the FasL promoter was noticed in apoptosis undergoing HEL cells treated by etoposide.	Etoposide	114-123	nuclear factor kappa B subunit 1	Homo sapiens	19-27
15694838-7	2005	However, sustained NFkappaB binding to the FasL promoter was noticed in apoptosis undergoing HEL cells treated by etoposide.	Etoposide	114-123	Fas ligand	Homo sapiens	43-47
15843754-9	2005	Restoration of XAF1 expression resulted in enhanced apoptotic response to etoposide and 5-flurouracil, whereas knockdown of XAF1 expression by siRNA transfection significantly inhibited chemotherapeutic drug-induced apoptosis.	Etoposide	74-83	XIAP associated factor 1	Homo sapiens	15-19
15615731-2	2005	Although many tumor cells are resistant to TRAIL-induced apoptosis alone, they can often be sensitized by co-treatment with DNA-damaging agents such as etoposide.	Etoposide	152-161	TNF superfamily member 10	Homo sapiens	43-48
15615731-6	2005	Finally, we show that the extensive caspase 8 cleavage seen during TRAIL-etoposide synergy is a consequence and not a cause of the apoptotic cascade activated downstream of Bid.	Etoposide	73-82	caspase 8	Homo sapiens	36-45
15615731-6	2005	Finally, we show that the extensive caspase 8 cleavage seen during TRAIL-etoposide synergy is a consequence and not a cause of the apoptotic cascade activated downstream of Bid.	Etoposide	73-82	TNF superfamily member 10	Homo sapiens	67-72
17343329-0	2005	Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study.	Etoposide	19-28	host cell factor C1	Homo sapiens	12-17
17343329-1	2005	PURPOSE: This phase II study was conducted to evaluate the efficacy and tolerability of vinorelbine (navelbine) and oral VP-16 (etoposide) in pretreated metastatic breast cancer (MBC) patients.	Etoposide	128-137	host cell factor C1	Homo sapiens	121-126
15653682-2	2005	The induction of replication stress by hydroxyurea (HU) or DNA damage by camptothecin (CAMPT), etoposide (ETOP), or mitomycin C (MMC) led to the formation of nuclear foci containing phosphorylated Nbs1.	Etoposide	95-104	nibrin	Homo sapiens	197-201
15653682-2	2005	The induction of replication stress by hydroxyurea (HU) or DNA damage by camptothecin (CAMPT), etoposide (ETOP), or mitomycin C (MMC) led to the formation of nuclear foci containing phosphorylated Nbs1.	Etoposide	106-110	nibrin	Homo sapiens	197-201
15653682-4	2005	After ETOP treatment, phospho-Nbs1 and RPA foci were detected but not within the same cell.	Etoposide	6-10	nibrin	Homo sapiens	30-34
15653682-4	2005	After ETOP treatment, phospho-Nbs1 and RPA foci were detected but not within the same cell.	Etoposide	6-10	replication protein A1	Homo sapiens	39-42
15653682-6	2005	Consistent with the presence or absence of RPA foci, RPA hyperphosphorylation was present following HU, CAMPT, and ETOP treatment but absent following MMC treatment.	Etoposide	115-119	replication protein A1	Homo sapiens	53-56
15653682-7	2005	The lack of co-localization of phospho-Nbs1 and RPA foci may be due to relatively shorter stretches of single-stranded DNA generated following ETOP and MMC treatment.	Etoposide	143-147	replication protein A1	Homo sapiens	48-51
15703783-8	2005	An inducible activated form of Akt protects normal myeloid cells from Ara-C and etoposide-mediated apoptosis.	Etoposide	80-89	AKT serine/threonine kinase 1	Homo sapiens	31-34
15781622-2	2005	PIG8 was also identified as a gene induced by etoposide and named etoposide-induced gene 24 (EI24).	Etoposide	46-55	EI24 autophagy associated transmembrane protein	Sus scrofa	93-97
15674326-0	2005	Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis.	Etoposide	77-86	checkpoint kinase 1	Homo sapiens	32-36
15674326-0	2005	Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis.	Etoposide	77-86	AKT serine/threonine kinase 1	Homo sapiens	99-102
15674326-3	2005	Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells.	Etoposide	129-138	erythropoietin	Mus musculus	20-34
15674326-3	2005	Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells.	Etoposide	129-138	interleukin 3	Mus musculus	38-42
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	erythropoietin	Homo sapiens	0-14
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	interleukin 3	Homo sapiens	18-22
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	checkpoint kinase 1	Homo sapiens	103-107
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	cyclin dependent kinase 1	Homo sapiens	143-147
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	cell division cycle 25C	Homo sapiens	162-167
15674326-4	2005	Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15.	Etoposide	46-55	cyclin dependent kinase 1	Homo sapiens	162-166
15674326-5	2005	The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively.	Etoposide	54-63	cyclin dependent kinase 1	Homo sapiens	15-19
15674326-5	2005	The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively.	Etoposide	54-63	checkpoint kinase 1	Homo sapiens	112-116
15674326-5	2005	The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively.	Etoposide	54-63	checkpoint kinase 1	Homo sapiens	136-140
15674326-6	2005	The G2/M arrest induced by etoposide was also enhanced or inhibited by expression of a constitutively activated or dominant-negative Akt mutant, respectively.	Etoposide	27-36	AKT serine/threonine kinase 1	Homo sapiens	133-136
15674326-7	2005	Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide.	Etoposide	143-152	AKT serine/threonine kinase 1	Homo sapiens	85-88
15674326-7	2005	Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide.	Etoposide	143-152	checkpoint kinase 1	Homo sapiens	103-107
15674326-8	2005	These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Etoposide	60-69	AKT serine/threonine kinase 1	Homo sapiens	149-152
15674326-8	2005	These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Etoposide	60-69	checkpoint kinase 1	Homo sapiens	214-218
15674326-8	2005	These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Etoposide	60-69	cyclin dependent kinase 1	Homo sapiens	242-246
15674333-3	2005	Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD).	Etoposide	134-143	BCL2 apoptosis regulator	Homo sapiens	227-232
15674333-3	2005	Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD).	Etoposide	134-143	BCL2 like 1	Homo sapiens	233-241
15674333-3	2005	Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD).	Etoposide	134-143	superoxide dismutase 1	Homo sapiens	246-266
15674333-3	2005	Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD).	Etoposide	134-143	superoxide dismutase 1	Homo sapiens	268-271
15674333-3	2005	Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X(L) and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD).	Etoposide	134-143	superoxide dismutase 2	Homo sapiens	288-293
15827325-8	2005	We have tested the effect of chemically synthesized siRNAs for target sequence 5 (CS #5) on the response of HeLa cells 72 hours after transfection to gamma radiation and etoposide, as this showed the maximum inhibition of Ku70 expression.	Etoposide	170-179	X-ray repair cross complementing 6	Homo sapiens	222-226
15827325-11	2005	Studies with HCT116 cells using the same Ku70 siRNA (CS #5) showed a direct correlation between expression of Ku70 and sensitization to radiation and etoposide treatments.	Etoposide	150-159	X-ray repair cross complementing 6	Homo sapiens	41-45
15827325-11	2005	Studies with HCT116 cells using the same Ku70 siRNA (CS #5) showed a direct correlation between expression of Ku70 and sensitization to radiation and etoposide treatments.	Etoposide	150-159	X-ray repair cross complementing 6	Homo sapiens	110-114
15788689-7	2005	The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with SN38 or etoposide and completely blocked these events induced by MSeA/paclitaxel.	Etoposide	133-142	mitogen-activated protein kinase 8	Homo sapiens	4-7
15788689-7	2005	The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with SN38 or etoposide and completely blocked these events induced by MSeA/paclitaxel.	Etoposide	133-142	caspase 8	Homo sapiens	69-77
15788689-10	2005	A JNK-independent suppression of survivin by SN38 and etoposide, but not by paclitaxel, was also observed.	Etoposide	54-63	mitogen-activated protein kinase 8	Homo sapiens	2-5
15674334-6	2005	The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs).	Etoposide	20-29	tumor protein p53	Homo sapiens	40-43
15843892-1	2005	Procaspase-2S has been reported to selectively prevent membrane blebbing and apoptotic body formation in human monocytic-like leukemic U937 cells after etoposide (VP-16) treatment (Droin et al., Oncogene 20.	Etoposide	152-161	host cell factor C1	Homo sapiens	163-168
15796210-0	2005	Quantitation of apoptosis induction by etoposide or hydroxyurea in mouse interleukin 3-dependent lymphoma cells.	Etoposide	39-48	interleukin 3	Mus musculus	73-86
15868939-0	2005	Involvement of Bax, Bcl-2 and caspase 3 in hydroxyurea- or etoposide-induced apoptosis of mouse interleukin-3-dependent lymphoma cells.	Etoposide	59-68	BCL2-associated X protein	Mus musculus	15-18
15868939-0	2005	Involvement of Bax, Bcl-2 and caspase 3 in hydroxyurea- or etoposide-induced apoptosis of mouse interleukin-3-dependent lymphoma cells.	Etoposide	59-68	B cell leukemia/lymphoma 2	Mus musculus	20-25
15868939-0	2005	Involvement of Bax, Bcl-2 and caspase 3 in hydroxyurea- or etoposide-induced apoptosis of mouse interleukin-3-dependent lymphoma cells.	Etoposide	59-68	caspase 3	Mus musculus	30-39
15868939-0	2005	Involvement of Bax, Bcl-2 and caspase 3 in hydroxyurea- or etoposide-induced apoptosis of mouse interleukin-3-dependent lymphoma cells.	Etoposide	59-68	interleukin 3	Mus musculus	96-109
15868939-1	2005	BACKGROUND: The apoptosis action induced by hydroxyurea or etoposide in interleukin 3-dependent lymphoma cells (DA-1) was studied.	Etoposide	59-68	interleukin 3	Mus musculus	72-85
15528316-8	2005	Thus, etoposide promotes specific rearrangements of MLL consistent with the full spectrum of oncogenic events identified in leukemic samples.	Etoposide	6-15	lysine methyltransferase 2A	Homo sapiens	52-55
15528316-0	2005	Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion.	Etoposide	78-87	lysine methyltransferase 2A	Homo sapiens	44-47
15528316-0	2005	Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion.	Etoposide	78-87	CD34 molecule	Homo sapiens	105-109
15528316-1	2005	Rearrangements involving the MLL gene on chromosome band 11q23 are a hallmark of therapy-related acute myeloid leukemias following treatment with topoisomerase II poisons including etoposide.	Etoposide	181-190	lysine methyltransferase 2A	Homo sapiens	29-32
15528316-3	2005	Repair of etoposide-stabilized DNA topoisomerase II covalent complexes may initiate MLL rearrangements observed in patients.	Etoposide	10-19	lysine methyltransferase 2A	Homo sapiens	84-87
15528316-4	2005	We used a culture system of primary human hematopoietic CD34+ cells and inverse polymerase chain reaction to characterize the spectrum of stable genomic rearrangements promoted by etoposide exposure originating within an MLL translocation hotspot in therapy-related leukemia.	Etoposide	180-189	CD34 molecule	Homo sapiens	56-60
15528316-4	2005	We used a culture system of primary human hematopoietic CD34+ cells and inverse polymerase chain reaction to characterize the spectrum of stable genomic rearrangements promoted by etoposide exposure originating within an MLL translocation hotspot in therapy-related leukemia.	Etoposide	180-189	lysine methyltransferase 2A	Homo sapiens	221-224
15771622-9	2005	Etoposide, ceramide, serum depletion and confluence all led to elevated YKL-40.	Etoposide	0-9	chitinase 3 like 1	Homo sapiens	72-78
15796210-1	2005	BACKGROUND: The apoptosis induction by etoposide or hydroxyurea in mouse interleukin 3-dependent lymphoma cells (DA-1) was studied.	Etoposide	39-48	interleukin 3	Mus musculus	73-86
15611097-6	2005	Using an in vivo affinity labeling approach, we demonstrate that caspase-8 is activated in etoposide-treated cells in vivo in the absence of the receptor-induced death-inducing signaling complex formation.	Etoposide	91-100	caspase 8	Homo sapiens	65-74
15767545-0	2005	Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.	Etoposide	88-97	RAD21 cohesin complex component	Homo sapiens	15-20
15767545-7	2005	Moreover, MCF-7 cell sensitivity to two DNA-damaging chemotherapeutic agents, etoposide and bleomycin, was increased after inhibition of RAD21 expression with a dose reduction factor 50 (DRF50) of 1.42 and 3.71, respectively.	Etoposide	78-87	RAD21 cohesin complex component	Homo sapiens	137-142
15767545-8	2005	At the highest concentrations of etoposide and bleomycin administered, cells transfected with a single siRNA duplex targeted against RAD21 showed 57% and 60% survival as compared with control cells, respectively.	Etoposide	33-42	RAD21 cohesin complex component	Homo sapiens	133-138
15735017-3	2005	If transfected with betaTRCP1, PT45-P1 cells exhibit an elevated NF-kappaB activity and become less sensitive towards anticancer drug treatment (i.e., etoposide).	Etoposide	151-160	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	20-29
15388581-1	2005	Bcr-Abl-expressing primary or cultured leukemia cells display high levels of the antiapoptotic heat shock protein (hsp) 70 and are resistant to cytarabine (Ara-C), etoposide, or Apo-2L/TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis.	Etoposide	164-173	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
15708362-8	2005	SCD activity appeared linked to the events of programmed cell death, since incubations with 40 microM etoposide induced apoptosis in SV40 cells, and led to a decrease in fatty acid synthesis, SCD activity and in MUFA cellular levels.	Etoposide	102-111	stearoyl-CoA desaturase	Homo sapiens	0-3
15708362-8	2005	SCD activity appeared linked to the events of programmed cell death, since incubations with 40 microM etoposide induced apoptosis in SV40 cells, and led to a decrease in fatty acid synthesis, SCD activity and in MUFA cellular levels.	Etoposide	102-111	stearoyl-CoA desaturase	Homo sapiens	192-195
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	caspase 9	Homo sapiens	284-293
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	caspase 3	Homo sapiens	298-307
15388581-7	2005	Expression of the dominant negative (DN) STAT5 resensitized HL-60/hsp70 cells to cytarabine, etoposide, and Apo-2L/TRAIL-induced apoptosis.	Etoposide	93-102	signal transducer and activator of transcription 5A	Homo sapiens	41-46
15746061-3	2005	The purpose of this study was to determine whether the novel IGF-I receptor (IGF-IR) kinase inhibitor, NVP-ADW742, sensitizes SCLC cell lines to etoposide and carboplatin, which are commonly used in the treatment of SCLC.	Etoposide	145-154	insulin like growth factor 1 receptor	Homo sapiens	61-75
15746061-3	2005	The purpose of this study was to determine whether the novel IGF-I receptor (IGF-IR) kinase inhibitor, NVP-ADW742, sensitizes SCLC cell lines to etoposide and carboplatin, which are commonly used in the treatment of SCLC.	Etoposide	145-154	insulin like growth factor 1 receptor	Homo sapiens	77-83
15746061-12	2005	CONCLUSIONS: Inhibition of IGF-IR signaling synergistically enhances the sensitivity of SCLC to etoposide and carboplatin.	Etoposide	96-105	insulin like growth factor 1 receptor	Homo sapiens	27-33
15691372-6	2005	In this study we show that the heterologous expression of the previously uncharacterised Herpesvirus pan BHRF1 in the human Burkitt"s lymphoma cell line Ramos-BL provides similar anti-apoptotic functions to that of EBV BHRF1 in response to apoptosis triggered by serum withdrawal, etoposide treatment and ultraviolet (UV) radiation.	Etoposide	281-290	apoptosis regulator BHRF1	Human gammaherpesvirus 4	105-110
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	heat shock protein family A (Hsp70) member 4	Homo sapiens	22-27
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	heat shock protein family A (Hsp70) member 4	Homo sapiens	50-55
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	BCL2 associated X, apoptosis regulator	Homo sapiens	95-98
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	cytochrome c, somatic	Homo sapiens	189-201
15388581-7	2005	Expression of the dominant negative (DN) STAT5 resensitized HL-60/hsp70 cells to cytarabine, etoposide, and Apo-2L/TRAIL-induced apoptosis.	Etoposide	93-102	heat shock protein family A (Hsp70) member 4	Homo sapiens	66-71
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	diablo IAP-binding mitochondrial protein	Homo sapiens	203-207
15388581-4	2005	Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3.	Etoposide	77-86	HtrA serine peptidase 2	Homo sapiens	217-222
15846068-5	2005	Upregulation of RPL6 was associated with enhanced resistance to multiple anticancer drugs (adriamycin, vincristine, etoposide, 5-fluorouracil and cisplatin) and to adriamycin-induced apoptosis.	Etoposide	116-125	ribosomal protein L6	Homo sapiens	16-20
15705874-9	2005	Finally, both Cdk and Chk1 inhibitors enhanced the cytotoxity of etoposide, a DNA-damaging agent.	Etoposide	65-74	checkpoint kinase 1	Homo sapiens	22-26
15735914-3	2005	The authors used combination of lower doses of both cisplatin and carboplatin combined with etoposide (VP-16) to minimize side effects of these agents.	Etoposide	92-101	host cell factor C1	Homo sapiens	103-108
15676214-1	2005	OBJECTIVE: Chemotherapy agents (CA) such as cytosine arabinoside (ara-C), idarubicin (IDA), and etoposide (VP-16) are widely used in the treatment of acute myeloid leukemia (AML) However, their effects on signaling pathways leading to cytotoxicity have only been described recently.	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
15746654-11	2005	Pretreatment with calyculin A, an inhibitor of protein phosphatase-1, blocked etoposide-induced alternative splicing of caspase-2 mRNA.	Etoposide	78-87	caspase 2	Homo sapiens	120-129
15751272-6	2005	Etoposide (VP-16) accumulation and efflux studies were carried out in the parental cell lines and their drug resistant cell lines.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
15668641-0	2005	Vindesine and etoposide: A practical and well-tolerated therapy for elderly patients or patients in reduced clinical condition with extensive-stage small-cell lung cancer (SCLC).	Etoposide	14-23	SCLC1	Homo sapiens	172-176
15668641-7	2005	CONCLUSIONS: Therapy of advanced SCLC with vindesine and etoposide can be applied in an ambulant setting and offers an improved quality of life with equivalent therapeutic effectivity.	Etoposide	57-66	SCLC1	Homo sapiens	33-37
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Etoposide	62-71	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	128-133
15643515-3	2005	Specifically, both RhoA and caRhoA induce statistically significant resistance to statin, etoposide, 5-FU and taxol while increasing sensitivity to vincristine (all p&lt;0.001).	Etoposide	90-99	ras homolog family member A	Homo sapiens	19-23
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Etoposide	62-71	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	198-201
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Etoposide	62-71	BCL2-associated X protein	Mus musculus	203-206
15668400-8	2005	We investigated whether cells expressing the DNA-PKcs variants had any other DNA repair deficits and found that these cells are considerably more sensitive to both etoposide and mitomycin C than cells that express no DNA-PKcs at all.	Etoposide	164-173	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	45-53
15455353-4	2005	LMP1 also potentiates etoposide-induced processing and activation of caspase-2 in this model and enhances the dissipation of mitochondrial transmembrane potential and the release of cytochrome c in response to etoposide.	Etoposide	210-219	cytochrome c, somatic	Homo sapiens	182-194
15682461-5	2005	The etoposide resistant clone showed overexpression of the following proteins: peroxiredoxin 1, beta-galactoside soluble lectin binding protein, vimentin (three protein spots), heat shock 27 kDa protein (two protein spots) and heterogeneous nuclear ribonucleoprotein K. In addition, we also found down-regulation of dUTP pyrophosphatase.	Etoposide	4-13	peroxiredoxin 1	Homo sapiens	79-94
15682461-5	2005	The etoposide resistant clone showed overexpression of the following proteins: peroxiredoxin 1, beta-galactoside soluble lectin binding protein, vimentin (three protein spots), heat shock 27 kDa protein (two protein spots) and heterogeneous nuclear ribonucleoprotein K. In addition, we also found down-regulation of dUTP pyrophosphatase.	Etoposide	4-13	vimentin	Homo sapiens	145-153
15682461-5	2005	The etoposide resistant clone showed overexpression of the following proteins: peroxiredoxin 1, beta-galactoside soluble lectin binding protein, vimentin (three protein spots), heat shock 27 kDa protein (two protein spots) and heterogeneous nuclear ribonucleoprotein K. In addition, we also found down-regulation of dUTP pyrophosphatase.	Etoposide	4-13	heat shock protein family B (small) member 1	Homo sapiens	177-202
15658872-1	2005	Etoposide (VP-16) is a potent human DNA topoisomerase II poison, derived from 4"-demethylepipodophyllotoxin, widely used in cancer chemotherapy.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
15455353-1	2005	Previous studies have shown that Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) enhances etoposide-induced apoptosis in epithelial cells.	Etoposide	108-117	PDZ and LIM domain 7	Homo sapiens	66-91
15617835-0	2005	Potentiation by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells.	Etoposide	50-59	ATP binding cassette subfamily B member 1	Homo sapiens	72-102
15617835-5	2005	Functional blockade by TOS of MRP1 was confirmed by the enhanced accumulation of etoposide (VP-16), an MRP1-substrate drug.	Etoposide	81-90	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
15617835-5	2005	Functional blockade by TOS of MRP1 was confirmed by the enhanced accumulation of etoposide (VP-16), an MRP1-substrate drug.	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
15617835-5	2005	Functional blockade by TOS of MRP1 was confirmed by the enhanced accumulation of etoposide (VP-16), an MRP1-substrate drug.	Etoposide	81-90	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
15455353-1	2005	Previous studies have shown that Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) enhances etoposide-induced apoptosis in epithelial cells.	Etoposide	108-117	PDZ and LIM domain 7	Homo sapiens	93-97
15561098-3	2005	Whereas exposure of human cells to topoisomerase inhibitors camptothecin, etoposide, or adriamycin resulted in rapid (within 1 h) activation of the pathway including degradation of the Cdc25A phosphatase and inhibition of cyclin E/CDK2 kinase activity, taxol failed to activate this checkpoint even after a prolonged treatment.	Etoposide	74-83	cell division cycle 25A	Homo sapiens	185-191
15455353-3	2005	Using an inducible system of LMP1 expression in HeLa cells, we show herein that etoposide-triggered apoptosis, as evidenced by nuclear condensation and caspase-3 activation, is enhanced by LMP1.	Etoposide	80-89	PDZ and LIM domain 7	Homo sapiens	29-33
15455353-3	2005	Using an inducible system of LMP1 expression in HeLa cells, we show herein that etoposide-triggered apoptosis, as evidenced by nuclear condensation and caspase-3 activation, is enhanced by LMP1.	Etoposide	80-89	caspase 3	Homo sapiens	152-161
15455353-3	2005	Using an inducible system of LMP1 expression in HeLa cells, we show herein that etoposide-triggered apoptosis, as evidenced by nuclear condensation and caspase-3 activation, is enhanced by LMP1.	Etoposide	80-89	PDZ and LIM domain 7	Homo sapiens	189-193
15455353-4	2005	LMP1 also potentiates etoposide-induced processing and activation of caspase-2 in this model and enhances the dissipation of mitochondrial transmembrane potential and the release of cytochrome c in response to etoposide.	Etoposide	22-31	PDZ and LIM domain 7	Homo sapiens	0-4
15455353-4	2005	LMP1 also potentiates etoposide-induced processing and activation of caspase-2 in this model and enhances the dissipation of mitochondrial transmembrane potential and the release of cytochrome c in response to etoposide.	Etoposide	22-31	caspase 2	Homo sapiens	69-78
15455353-4	2005	LMP1 also potentiates etoposide-induced processing and activation of caspase-2 in this model and enhances the dissipation of mitochondrial transmembrane potential and the release of cytochrome c in response to etoposide.	Etoposide	210-219	PDZ and LIM domain 7	Homo sapiens	0-4
15561098-3	2005	Whereas exposure of human cells to topoisomerase inhibitors camptothecin, etoposide, or adriamycin resulted in rapid (within 1 h) activation of the pathway including degradation of the Cdc25A phosphatase and inhibition of cyclin E/CDK2 kinase activity, taxol failed to activate this checkpoint even after a prolonged treatment.	Etoposide	74-83	cyclin dependent kinase 2	Homo sapiens	231-235
15543231-8	2005	At the opposite, upon treatment with topoisomerase II inhibitors (doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells.	Etoposide	81-90	tumor protein p53	Homo sapiens	168-172
15607317-4	2005	The method was applied to study the alteration of BRCA1 gene expression after exposure to taxol, doxorubicin, 5-fluorouracil, etoposide or gamma irradiation in human MCF-7 breast cancer cells.	Etoposide	126-135	BRCA1 DNA repair associated	Homo sapiens	50-55
16076696-6	2005	On the other hand, the etoposide-resistant human leukemia cell line K562/MX2 and the parental cell line K562/P did not show enhanced sensitivity against etoposide or an increase in human Topoisomerase IIa mRNA.	Etoposide	23-32	MX dynamin like GTPase 2	Homo sapiens	73-76
15499378-7	2005	In both DU145 and PC3, IGF1R knockdown led to enhancement of sensitivity to mitoxantrone, etoposide, nitrogen mustard and ionizing radiation.	Etoposide	90-99	insulin like growth factor 1 receptor	Homo sapiens	23-28
15606549-0	2005	Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.	Etoposide	107-116	interleukin 11	Homo sapiens	54-68
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Etoposide	292-301	CD40 molecule	Homo sapiens	102-106
16305477-5	2005	For example, IGF-I prevents apoptosis induced by overexpression of c-myc in fibroblasts, by interleukin-3 withdrawal in interleukin-3-dependent hemopoietic cells, etoposide, a topoisomerase I inhibitor, anti-cancer drugs, UV-B irradiations, and serum deprivation.	Etoposide	163-172	insulin like growth factor 1	Homo sapiens	13-18
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Etoposide	292-301	eukaryotic translation initiation factor 4E	Homo sapiens	160-191
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Etoposide	292-301	eukaryotic translation initiation factor 4E	Homo sapiens	235-266
16110137-7	2005	CONCLUSIONS: Because of the increase in dose and dose-density afforded by the administration of GM-CSF, the relative dose intensity was increased by twofold for cyclophosphamide (400 vs 200 mg/m2/wk) and etoposide (120 vs 60 mg/m2/wk), and by 1.3-fold for doxorubicin (16.7 vs 12.5 mg/m2/wk).	Etoposide	204-213	colony stimulating factor 2	Homo sapiens	96-102
15273254-5	2004	Treatment with PKI166, an EGFR inhibitor, suppressed etoposide-induced activation of DNA-PK in A375SM metastatic melanoma cells.	Etoposide	53-62	epidermal growth factor receptor	Homo sapiens	26-30
15829155-0	2005	Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity.	Etoposide	39-48	insulin like growth factor 1	Homo sapiens	0-28
15829155-0	2005	Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity.	Etoposide	39-48	BCL2 apoptosis regulator	Homo sapiens	97-102
15829155-0	2005	Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity.	Etoposide	39-48	caspase 3	Homo sapiens	129-134
15829155-10	2005	Etoposide increased the expression of wild-type p53, activated CPP32 (but not ICE) activity, and induced apoptosis in these cells.	Etoposide	0-9	tumor protein p53	Homo sapiens	48-51
15471885-6	2004	Comparison of the activity of unphosphorylated and phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide in HCT116 and RKO cells revealed no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes and to induce p53-dependent apoptosis.	Etoposide	117-126	tumor protein p53	Homo sapiens	66-69
15611646-3	2004	We find that E2F4 levels are diminished following treatment with cyclin dependent kinase inhibitors (flavopiridol, roscovitine and BMS-387032) or with DNA damaging drugs (cisplatin and VP16).	Etoposide	185-189	E2F transcription factor 4	Homo sapiens	13-17
15657350-9	2005	Additionally, (-)-gossypol was more efficient than etoposide at inducing caspase-3 activation and phosphatidylserine externalization in the setting of Bcl-2 or Bcl-X(L) overexpression.	Etoposide	51-60	caspase 3	Homo sapiens	73-82
15657350-9	2005	Additionally, (-)-gossypol was more efficient than etoposide at inducing caspase-3 activation and phosphatidylserine externalization in the setting of Bcl-2 or Bcl-X(L) overexpression.	Etoposide	51-60	BCL2 like 1	Homo sapiens	160-168
15829155-10	2005	Etoposide increased the expression of wild-type p53, activated CPP32 (but not ICE) activity, and induced apoptosis in these cells.	Etoposide	0-9	caspase 3	Homo sapiens	63-68
15829155-11	2005	IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	16-25	insulin like growth factor 1	Homo sapiens	0-5
15829155-11	2005	IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	16-25	BCL2 apoptosis regulator	Homo sapiens	76-81
15829155-11	2005	IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	16-25	caspase 3	Homo sapiens	113-118
15829155-12	2005	IGF-IR antisense enhanced the apoptotic effect of etoposide.	Etoposide	50-59	insulin like growth factor 1 receptor	Homo sapiens	0-6
15829155-13	2005	CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	29-38	insulin like growth factor 1	Homo sapiens	13-18
15829155-13	2005	CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	29-38	BCL2 apoptosis regulator	Homo sapiens	105-110
15829155-13	2005	CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32.	Etoposide	29-38	caspase 3	Homo sapiens	142-147
15829155-14	2005	The antisense of IGF-IR increased etoposide-induced apoptosis.	Etoposide	34-43	insulin like growth factor 1 receptor	Homo sapiens	17-23
15539949-4	2004	In line with this, Hsp70 localizes to the membranes of lysosomes in human colon carcinoma cells and immortalized murine embryonic fibroblasts (MEFs) and prevents lysosomal membrane permeabilization and cell death induced by tumor necrosis factor (TNF), etoposide and H2O2.	Etoposide	253-262	heat shock protein family A (Hsp70) member 4	Homo sapiens	19-24
15590186-0	2004	Multidrug-resistant hela cells overexpressing MRP1 exhibit sensitivity to cell killing by hyperthermia: interactions with etoposide.	Etoposide	122-131	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
15590186-4	2004	METHODS AND MATERIALS: Cytotoxicity of hyperthermia and/or etoposide was evaluated using sulforhodamine-B in HeLa cells overexpressing MRP1 and their drug-sensitive counterparts.	Etoposide	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
15273254-5	2004	Treatment with PKI166, an EGFR inhibitor, suppressed etoposide-induced activation of DNA-PK in A375SM metastatic melanoma cells.	Etoposide	53-62	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	85-91
15634660-0	2004	Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.	Etoposide	18-27	TNF receptor superfamily member 10a	Homo sapiens	93-116
15572670-6	2004	N-Methyl-N"-nitro-N-nitrosoguanidine, etoposide, and bleomycin also induced C/EBPalpha.	Etoposide	38-47	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
15634660-0	2004	Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.	Etoposide	18-27	TNF superfamily member 10	Homo sapiens	145-200
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Etoposide	25-34	host cell factor C1	Homo sapiens	36-41
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Etoposide	25-34	TNF receptor superfamily member 25	Homo sapiens	106-122
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Etoposide	25-34	TNF receptor superfamily member 10a	Homo sapiens	135-151
15638086-4	2004	There was a statistically significant (p &lt; 0.05) increase in serum BSP levels with CYP3A and P-gp substrates and/or inhibitors, cyclosporine-A, nitrendipine, quinidine, indinavir, daxorubicin, etoposide and erythromycin by 27%, 35%, 32%, 12%, 5%, 22%, and 106%, respectively.	Etoposide	196-205	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	86-91
15631665-1	2004	The aim was to study the protective effects of amifostine (AMF) on normal hematopoietic stem/progenitor cells against the chemotherapeutic damage from etoposide (VP-16).	Etoposide	151-160	host cell factor C1	Homo sapiens	162-167
15507659-4	2004	Treatment with tumor necrosis factor alpha did not induce apoptosis of EBNA2- or EBNA2DeltaCR4-expressing cells, but EBNA2DeltaCR4 cells were susceptible to etoposide and 5-fluorouracil, Nur77-mediated inducers of apoptosis.	Etoposide	157-166	tumor necrosis factor	Homo sapiens	15-42
15494717-5	2004	Expression of exogenous clusterin in both cell types resulted in its relocation from the cytoplasm and a nuclear accumulation of the protein, as was also seen in the same cells when apoptosis was induced by etoposide treatment.	Etoposide	207-216	clusterin	Homo sapiens	24-33
15516715-1	2004	We established several focal adhesion kinase (FAK) cDNA-transfected cells and found that FAK-transfected HL-60 (HL-60/FAK) cells are resistant to apoptosis induced with hydrogen peroxide, etoposide and radiation compared with the parental HL-60 or the vector-transfected (HL-60/Vect) cells.	Etoposide	188-197	protein tyrosine kinase 2	Homo sapiens	89-92
15516715-1	2004	We established several focal adhesion kinase (FAK) cDNA-transfected cells and found that FAK-transfected HL-60 (HL-60/FAK) cells are resistant to apoptosis induced with hydrogen peroxide, etoposide and radiation compared with the parental HL-60 or the vector-transfected (HL-60/Vect) cells.	Etoposide	188-197	protein tyrosine kinase 2	Homo sapiens	112-121
15548330-8	2004	In addition, prosaptide TX14A, saposin C, or prosaposin decreased the growth-inhibitory effect, caspase-3/7 activity, and apoptotic cell death induced by etoposide.	Etoposide	154-163	prosaposin	Mus musculus	45-55
15548330-8	2004	In addition, prosaptide TX14A, saposin C, or prosaposin decreased the growth-inhibitory effect, caspase-3/7 activity, and apoptotic cell death induced by etoposide.	Etoposide	154-163	caspase 3	Mus musculus	96-105
15345715-8	2004	Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner.	Etoposide	30-39	tumor protein p53	Homo sapiens	70-73
15345715-8	2004	Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner.	Etoposide	30-39	transforming growth factor beta 1	Homo sapiens	85-93
15345715-8	2004	Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner.	Etoposide	30-39	collagen type I alpha 2 chain	Homo sapiens	109-115
15345715-8	2004	Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner.	Etoposide	30-39	tumor protein p53	Homo sapiens	162-165
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Etoposide	104-113	glycogen synthase kinase 3 beta	Homo sapiens	47-56
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Etoposide	104-113	tumor protein p53	Homo sapiens	176-179
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Etoposide	104-113	Fas cell surface death receptor	Homo sapiens	209-213
15322115-3	2004	Treatment of HeLa cells with etoposide results in phosphorylation of STAT1 on Ser(727) and the association of STAT1 with PKCdelta.	Etoposide	29-38	signal transducer and activator of transcription 1	Homo sapiens	69-74
15322115-3	2004	Treatment of HeLa cells with etoposide results in phosphorylation of STAT1 on Ser(727) and the association of STAT1 with PKCdelta.	Etoposide	29-38	signal transducer and activator of transcription 1	Homo sapiens	110-115
15322115-3	2004	Treatment of HeLa cells with etoposide results in phosphorylation of STAT1 on Ser(727) and the association of STAT1 with PKCdelta.	Etoposide	29-38	protein kinase C delta	Homo sapiens	121-129
15322115-4	2004	Etoposide increases transcription from STAT1-dependent reporter constructs.	Etoposide	0-9	signal transducer and activator of transcription 1	Homo sapiens	39-44
15322115-8	2004	Nuclear accumulation of STAT1, phospho-Ser(727) STAT1, and PKCdelta are detectable 30-60 min after treatment with etoposide.	Etoposide	114-123	signal transducer and activator of transcription 1	Homo sapiens	24-29
15322115-8	2004	Nuclear accumulation of STAT1, phospho-Ser(727) STAT1, and PKCdelta are detectable 30-60 min after treatment with etoposide.	Etoposide	114-123	signal transducer and activator of transcription 1	Homo sapiens	48-53
15322115-8	2004	Nuclear accumulation of STAT1, phospho-Ser(727) STAT1, and PKCdelta are detectable 30-60 min after treatment with etoposide.	Etoposide	114-123	protein kinase C delta	Homo sapiens	59-67
15475575-5	2004	Multiple copies of a short oligopeptide derived from a minimal transactivation domain of human beta-catenin was stronger than VP-16.	Etoposide	126-131	catenin beta 1	Homo sapiens	95-107
15217836-4	2004	The ETV6/RUNX1(+) samples were significantly more sensitive than ETV6/RUNX1(-) samples to doxorubicin, etoposide, amsacrine, and dexamethasone, whereas the opposite was true for cytarabine.	Etoposide	103-112	ETS variant transcription factor 6	Homo sapiens	4-8
15369772-1	2004	We have demonstrated that focal adhesion kinase (FAK)-overexpressed (HL-60/FAK) cells have marked resistance against various apoptotic stimuli such as hydrogen peroxide, etoposide, and ionizing radiation compared with the vector-transfected (HL-60/Vect) cells.	Etoposide	170-179	protein tyrosine kinase 2	Homo sapiens	26-47
15369772-1	2004	We have demonstrated that focal adhesion kinase (FAK)-overexpressed (HL-60/FAK) cells have marked resistance against various apoptotic stimuli such as hydrogen peroxide, etoposide, and ionizing radiation compared with the vector-transfected (HL-60/Vect) cells.	Etoposide	170-179	protein tyrosine kinase 2	Homo sapiens	49-52
15369772-1	2004	We have demonstrated that focal adhesion kinase (FAK)-overexpressed (HL-60/FAK) cells have marked resistance against various apoptotic stimuli such as hydrogen peroxide, etoposide, and ionizing radiation compared with the vector-transfected (HL-60/Vect) cells.	Etoposide	170-179	protein tyrosine kinase 2	Homo sapiens	75-78
15217836-4	2004	The ETV6/RUNX1(+) samples were significantly more sensitive than ETV6/RUNX1(-) samples to doxorubicin, etoposide, amsacrine, and dexamethasone, whereas the opposite was true for cytarabine.	Etoposide	103-112	RUNX family transcription factor 1	Homo sapiens	9-14
15217836-4	2004	The ETV6/RUNX1(+) samples were significantly more sensitive than ETV6/RUNX1(-) samples to doxorubicin, etoposide, amsacrine, and dexamethasone, whereas the opposite was true for cytarabine.	Etoposide	103-112	ETS variant transcription factor 6	Homo sapiens	65-69
15217836-4	2004	The ETV6/RUNX1(+) samples were significantly more sensitive than ETV6/RUNX1(-) samples to doxorubicin, etoposide, amsacrine, and dexamethasone, whereas the opposite was true for cytarabine.	Etoposide	103-112	RUNX family transcription factor 1	Homo sapiens	70-75
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Etoposide	40-49	caspase 2	Homo sapiens	143-166
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Etoposide	40-49	caspase 9	Homo sapiens	179-188
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Etoposide	40-49	apoptotic peptidase activating factor 1	Homo sapiens	197-203
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Etoposide	40-49	apoptotic peptidase activating factor 1	Homo sapiens	211-217
15351743-5	2004	Furthermore, expression of Gab1 PI3K-m, but not Gab1 SHP2-m, in TT human medullary thyroid carcinoma cells expressing RET with a multiple endocrine neoplasia 2A mutation enhanced cytochrome c release, and apoptosis induced by etoposide, suggesting that PI3K is involved in survival of TT cells via a mitochondrial pathway.	Etoposide	226-235	GRB2 associated binding protein 1	Homo sapiens	27-31
15300802-7	2004	ZNF143 is an inducible gene by other DNA damaging agents such as gamma-irradiation, etoposide and adriamycin.	Etoposide	84-93	zinc finger protein 143	Homo sapiens	0-6
15381332-7	2004	Mrp1 is involved in the excretion of etoposide at the basolateral membrane of the CPE, but its contribution to the excretion of organic anions, especially amphipathic conjugated metabolites, remains controversial.	Etoposide	37-46	mutS homolog 3	Homo sapiens	0-4
15351743-5	2004	Furthermore, expression of Gab1 PI3K-m, but not Gab1 SHP2-m, in TT human medullary thyroid carcinoma cells expressing RET with a multiple endocrine neoplasia 2A mutation enhanced cytochrome c release, and apoptosis induced by etoposide, suggesting that PI3K is involved in survival of TT cells via a mitochondrial pathway.	Etoposide	226-235	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	32-38
15596925-0	2004	VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.	Etoposide	5-14	vasoactive intestinal peptide	Homo sapiens	0-3
15368357-1	2004	Jurkat T leukemic cells respond to Etoposide, antineoplastic agent which targets the DNA unwinding enzyme, Topoisomerase II, and TNF-Related-Apoptosis-Inducing-Ligand (TRAIL), 34 kDa transmembrane protein, which displays minimal or no toxicity on normal cells and tissues, not only disclosing the occurrence of apoptosis but also a kind of resistance.	Etoposide	35-44	TNF superfamily member 10	Homo sapiens	129-166
15378410-1	2004	In a previous research, we have shown that adequate levels of polyamines are required in transformed mouse fibroblasts for the correlated activations of MAPK subtypes (ERK and JNK) and caspases induced by etoposide and leading to apoptosis.	Etoposide	205-214	mitogen-activated protein kinase 8	Mus musculus	176-179
15326378-0	2004	Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells.	Etoposide	22-31	caveolin 1	Homo sapiens	8-18
15368357-1	2004	Jurkat T leukemic cells respond to Etoposide, antineoplastic agent which targets the DNA unwinding enzyme, Topoisomerase II, and TNF-Related-Apoptosis-Inducing-Ligand (TRAIL), 34 kDa transmembrane protein, which displays minimal or no toxicity on normal cells and tissues, not only disclosing the occurrence of apoptosis but also a kind of resistance.	Etoposide	35-44	TNF superfamily member 10	Homo sapiens	168-173
15368357-0	2004	PI-3-kinase/NF-kappaB mediated response of Jurkat T leukemic cells to two different chemotherapeutic drugs, etoposide and TRAIL.	Etoposide	108-117	nuclear factor kappa B subunit 1	Homo sapiens	12-21
15368357-4	2004	On the other hand, in Etoposide Jurkat exposed cells Ser 32-36 phosphorylation of IkappaB alpha is not sufficient to overbalance the apoptotic fate of the cells, since Bax increase, IAP decrease, and caspase-3 activation determine the persistence of the apoptotic state along with the occurrence of cell death by necrosis.	Etoposide	22-31	NFKB inhibitor alpha	Homo sapiens	82-95
15262979-0	2004	Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis.	Etoposide	90-99	caspase 2	Homo sapiens	11-20
15367606-8	2004	Although Tax1 and Tax2 expression mediated elevated resistance to apoptosis in Jurkat cells after serum deprivation, Tax1 was unique in protection from apoptosis after exposure to camptothecin and etoposide, inhibitors of topoisomerase I and II, respectively.	Etoposide	197-206	contactin 2	Homo sapiens	117-121
15326479-4	2004	Here, we show that overexpression of the catalytic subunit of telomerase (hTERT) protects a maturation-resistant acute promyelocytic leukemia (APL) cell line from apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL) and not from apoptosis induced by chemotherapeutic drugs such as etoposide or cisplatin.	Etoposide	330-339	telomerase reverse transcriptase	Homo sapiens	74-79
15262979-0	2004	Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis.	Etoposide	90-99	caspase 8	Homo sapiens	25-34
15262979-9	2004	Similarly, sequential caspase-2 and caspase-8 activation upstream of mitochondria was also observed in etoposide-induced apoptosis.	Etoposide	103-112	caspase 2	Homo sapiens	22-31
15262979-9	2004	Similarly, sequential caspase-2 and caspase-8 activation upstream of mitochondria was also observed in etoposide-induced apoptosis.	Etoposide	103-112	caspase 8	Homo sapiens	36-45
15262979-10	2004	These data suggest sequential initiator caspase-2 and caspase-8 activation in the mitochondrial apoptotic pathway induced by ceramide or etoposide.	Etoposide	137-146	caspase 2	Homo sapiens	40-49
15262979-10	2004	These data suggest sequential initiator caspase-2 and caspase-8 activation in the mitochondrial apoptotic pathway induced by ceramide or etoposide.	Etoposide	137-146	caspase 8	Homo sapiens	54-63
15319341-0	2004	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism.	Etoposide	52-61	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	38-42
15273737-3	2004	TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide.	Etoposide	95-104	tumor necrosis factor	Homo sapiens	0-8
15273737-3	2004	TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide.	Etoposide	95-104	caspase 3	Homo sapiens	68-77
15319341-6	2004	9 +/- 3.1 microM; V(max) = 19.4 +/- 0.4 pmol of catechol/min/nmol of P450) may be involved in etoposide metabolism at therapeutic concentrations of free drug.	Etoposide	94-103	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-73
15319341-9	2004	Etoposide (40, 5, 1, and 0.25 microM) caused a slight increase in CYP3A4 mRNA in three of five batches of hepatocytes but did not result in proportionately increased CYP3A4 protein levels.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
15319341-10	2004	At high concentrations, etoposide induced only a modest increase in CYP3A5 mRNA and protein levels in four of five batches of hepatocytes.	Etoposide	24-33	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	68-74
15319341-2	2004	The cytochrome P450 (P450)-derived catechol and quinone metabolites of etoposide may be important in the damage to the MLL (mixed lineage leukemia) gene and other genes resulting in leukemia-associated chromosomal translocations.	Etoposide	71-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-19
15319341-2	2004	The cytochrome P450 (P450)-derived catechol and quinone metabolites of etoposide may be important in the damage to the MLL (mixed lineage leukemia) gene and other genes resulting in leukemia-associated chromosomal translocations.	Etoposide	71-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-25
15319341-2	2004	The cytochrome P450 (P450)-derived catechol and quinone metabolites of etoposide may be important in the damage to the MLL (mixed lineage leukemia) gene and other genes resulting in leukemia-associated chromosomal translocations.	Etoposide	71-80	lysine methyltransferase 2A	Homo sapiens	119-122
15287915-0	2004	ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.	Etoposide	30-39	carboxylesterase 2	Homo sapiens	0-3
15319341-4	2004	CYP3A4 was found to play a major role in etoposide metabolism (K(m) = 77.7 +/- 27.8 microM; V(max) = 314 +/- 84 pmol of catechol/min/nmol of P450).	Etoposide	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15287915-1	2004	OBJECTIVE: To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate.	Etoposide	53-62	carboxylesterase 2	Homo sapiens	23-26
15319341-4	2004	CYP3A4 was found to play a major role in etoposide metabolism (K(m) = 77.7 +/- 27.8 microM; V(max) = 314 +/- 84 pmol of catechol/min/nmol of P450).	Etoposide	41-50	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	141-145
15454884-5	2004	Treatment of HUVECs with LLL-CHO, etoposide, or C2-ceramide induced DeltaPsim, activation of caspase-3, caspase-8, and caspase-9 and the appearance of hypodiploid DNA-positive cells.	Etoposide	34-43	caspase 3	Homo sapiens	93-102
15454884-5	2004	Treatment of HUVECs with LLL-CHO, etoposide, or C2-ceramide induced DeltaPsim, activation of caspase-3, caspase-8, and caspase-9 and the appearance of hypodiploid DNA-positive cells.	Etoposide	34-43	caspase 8	Homo sapiens	104-113
15454884-5	2004	Treatment of HUVECs with LLL-CHO, etoposide, or C2-ceramide induced DeltaPsim, activation of caspase-3, caspase-8, and caspase-9 and the appearance of hypodiploid DNA-positive cells.	Etoposide	34-43	caspase 9	Homo sapiens	119-128
15322234-0	2004	Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4"-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4"-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.	Etoposide	232-241	DNA topoisomerase II beta	Homo sapiens	24-48
15143129-5	2004	This is in contrast to chemotherapeutic agents such as etoposide, actinomycin D, and ultraviolet irradiation, whereby overexpression of Bcl-2 confers resistance against apoptosis.	Etoposide	55-64	BCL2 apoptosis regulator	Homo sapiens	136-141
15304327-0	2004	Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks.	Etoposide	58-67	peroxiredoxin 5	Homo sapiens	18-33
15253890-5	2004	In contrast, IGF-1 partially inhibited etoposide-induced apoptosis, confirming the presence of a functional IGF-1 receptor signalling system.	Etoposide	39-48	insulin like growth factor 1	Homo sapiens	13-18
15253890-5	2004	In contrast, IGF-1 partially inhibited etoposide-induced apoptosis, confirming the presence of a functional IGF-1 receptor signalling system.	Etoposide	39-48	insulin like growth factor 1	Homo sapiens	108-113
15175350-7	2004	Conversely, interference with Bcl-2 function by co-administration of the small molecule Bcl-2 inhibitor HA14-1 or down-regulation of Bcl-2 expression by small interfering RNA or antisense strategies significantly increased mitochondrial dysfunction and apoptosis induced by imatinib mesylate and the topoisomerase inhibitor VP-16 in LAMA-R cells.	Etoposide	324-329	BCL2 apoptosis regulator	Homo sapiens	30-35
15510828-3	2004	In April 2002, while in non-complete remission, she subsequently underwent total body irradiation (TBI) and treatment with cyclophosphamide (CY) and etoposide (VP-16) before receiving an allogeneic peripheral blood stem cell transplant from her HLA-identical brother.	Etoposide	149-158	host cell factor C1	Homo sapiens	160-165
15304327-3	2004	We also studied etoposide-induced phosphorylation of histone H2AX (gamma-H2AX) in human cells in which PrxV activity was downregulated (knockdown, KD-clones) or compromised by overexpression of redox-negative (RD) protein.	Etoposide	16-25	H2A.X variant histone	Homo sapiens	53-65
15304327-3	2004	We also studied etoposide-induced phosphorylation of histone H2AX (gamma-H2AX) in human cells in which PrxV activity was downregulated (knockdown, KD-clones) or compromised by overexpression of redox-negative (RD) protein.	Etoposide	16-25	peroxiredoxin 5	Homo sapiens	103-107
15304327-4	2004	In KD clones, but not in RD-clones, formation of etoposide-induced gamma-H2AX was increased, indicating that PrxV inhibits conversion of topoisomerase II cleavage complexes into double-strand DNA breaks but this inhibition is not caused by its antioxidant activity.	Etoposide	49-58	peroxiredoxin 5	Homo sapiens	109-113
15298724-1	2004	We investigated the expression of mouse 8-oxoguanine DNA glycosylase 1 (mOGG1) in mouse non-parenchymal hepatocytes (NCTC) during etoposide- or mitomycin C (MMC)-induced apoptosis.	Etoposide	130-139	8-oxoguanine DNA-glycosylase 1	Mus musculus	72-77
14742315-3	2004	We show that a 399 bp fragment from the MLL bcr is sufficient to cause a 3-4-fold stimulation of spontaneously occurring DNA exchange and to respond to etoposide by up to 10-fold further elevated frequencies, i.e. to mimic the fragility of the 8.3 kb bcr during chemotherapy.	Etoposide	152-161	lysine methyltransferase 2A	Homo sapiens	40-43
14742315-5	2004	Consistent with the proposed role of p53 as a suppressor of error-prone recombination, both p53 proteins down-regulated recombination with most of the sequences tested, even with the MLL bcr after etoposide treatment.	Etoposide	197-206	tumor protein p53	Homo sapiens	92-95
14742315-5	2004	Consistent with the proposed role of p53 as a suppressor of error-prone recombination, both p53 proteins down-regulated recombination with most of the sequences tested, even with the MLL bcr after etoposide treatment.	Etoposide	197-206	lysine methyltransferase 2A	Homo sapiens	183-186
15287952-7	2004	When employed at 5 micromol/l, the Akt inhibitors markedly reduced the resistance of the leukaemic cell lines to etoposide or cytarabine.	Etoposide	113-122	AKT serine/threonine kinase 1	Homo sapiens	35-38
15289343-7	2004	Frozen sections of tumors confirmed the greater intensity of gammaH2AX staining in cells close to blood vessels of tumors soon after treatment with etoposide and the opposite pattern for tumors exposed to tirapazamine.	Etoposide	148-157	H2A.X variant histone	Mus musculus	61-70
15298724-4	2004	The mOGG1 fragment existed in both the cytoplasm and nucleus of the etoposide-treated NCTC, indicating that the mOGG1 fragment could be transferred into the nucleus.	Etoposide	68-77	8-oxoguanine DNA-glycosylase 1	Mus musculus	4-9
15298724-4	2004	The mOGG1 fragment existed in both the cytoplasm and nucleus of the etoposide-treated NCTC, indicating that the mOGG1 fragment could be transferred into the nucleus.	Etoposide	68-77	8-oxoguanine DNA-glycosylase 1	Mus musculus	112-117
15298724-5	2004	In addition, 8-hydroxyguanine (8-OH-Gua, 7,8-dihydro-8-oxoguanine) accumulated in the DNA of NCTC treated with etoposide, suggesting that the mOGG1 fragment might not function as a normal repair enzyme in etoposide-treated NCTC.	Etoposide	111-120	8-oxoguanine DNA-glycosylase 1	Mus musculus	142-147
15254227-0	2004	Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death.	Etoposide	194-203	caspase 8	Homo sapiens	22-31
15215046-5	2004	Mock-transfected and CD44-transfected cells were exposed to etoposide to induce apoptosis.	Etoposide	60-69	CD44 molecule (Indian blood group)	Homo sapiens	21-25
15215046-7	2004	It was observed that resistance to apoptosis induced by etoposide is promoted by CD44 expression in SW620, and this resistance is better sustained by the full variant isoform, v3-10.	Etoposide	56-65	CD44 molecule (Indian blood group)	Homo sapiens	81-85
15460906-2	2004	We have attempted to reverse the multidrug resistance (MDR) phenotype by treating etoposide resistant glioma cell lines (T98G-VP and Gli36-VP) with RP1 antisense oligonucleotides.	Etoposide	82-91	RP1 axonemal microtubule associated	Homo sapiens	148-151
15460906-3	2004	20-mer phosphorothioate oligodeoxynucleotide (0.3 microM), complementary to the coding region in the MRP cDNA sequence, could significantly inhibit the growth of multidrug resistant cell lines, T98G-VP and Gli36-VP, cultured in etoposide containing medium.	Etoposide	228-237	ATP binding cassette subfamily C member 1	Homo sapiens	101-104
15242764-8	2004	Upon engagement of the mitochondrial pathway of apoptosis, etoposide provoked cytosolic accumulation of Smac along with cytochrome c and loss of the mitochondrial membrane potential.	Etoposide	59-68	cytochrome c, somatic	Homo sapiens	120-132
15242764-11	2004	Co-treatment of SCLC with the IAP-binding peptide Smac-N7 enhanced etoposide-induced apoptosis in a concentration-dependent manner, whereas Smac downregulation by small interfering RNA (siRNA) did not influence caspase-3/-7 activities, nuclear morphological changes, DNA fragmentation, and plasma membrane integrity.	Etoposide	67-76	alkaline phosphatase, intestinal	Homo sapiens	30-33
15254227-4	2004	In MDA-MB231 breast cancer cells treated with etoposide (VP16), active caspase 8 is detected only in the membrane fraction, which contains both mitochondria and endoplasmic reticulum (ER), as revealed by fractionation studies.	Etoposide	46-55	host cell factor C1	Homo sapiens	57-61
15254227-4	2004	In MDA-MB231 breast cancer cells treated with etoposide (VP16), active caspase 8 is detected only in the membrane fraction, which contains both mitochondria and endoplasmic reticulum (ER), as revealed by fractionation studies.	Etoposide	46-55	caspase 8	Homo sapiens	71-80
15223313-6	2004	Further, both stable and adenovirus-mediated expression of a dominant negative PKC delta(KR) abrogated etoposide-induced PKC delta expression.	Etoposide	103-112	protein kinase C, delta	Mus musculus	79-88
15246365-9	2004	Cancer cells treated with the chemotherapeutic agent, etoposide, showed an 88% increase in the binding of F-18 labeled annexin V compared to untreated cells.	Etoposide	54-63	mastermind like domain containing 1	Homo sapiens	106-110
15246365-9	2004	Cancer cells treated with the chemotherapeutic agent, etoposide, showed an 88% increase in the binding of F-18 labeled annexin V compared to untreated cells.	Etoposide	54-63	annexin A5	Homo sapiens	119-128
15254697-1	2004	The EAP combination of etoposide (ETP), doxorubicin (ADM) and cisplatin (CDDP) has been reported to be highly active for advanced gastric cancer.	Etoposide	23-32	glutamyl aminopeptidase	Homo sapiens	4-7
15254697-1	2004	The EAP combination of etoposide (ETP), doxorubicin (ADM) and cisplatin (CDDP) has been reported to be highly active for advanced gastric cancer.	Etoposide	34-37	glutamyl aminopeptidase	Homo sapiens	4-7
15223313-6	2004	Further, both stable and adenovirus-mediated expression of a dominant negative PKC delta(KR) abrogated etoposide-induced PKC delta expression.	Etoposide	103-112	protein kinase C, delta	Mus musculus	121-130
15251430-6	2004	Moreover, HepG2 cells with exogenous ING4 could significantly increase cell death, as exposed to some DNA-damage agents, such as etoposide and doxorubicin, implying that ING4 could enhance chemosensitivity to certain DNA-damage agents in HepG2 cells.	Etoposide	129-138	inhibitor of growth family member 4	Homo sapiens	37-41
15223313-7	2004	Etoposide-stimulated PKC delta transcription but not PKC delta mRNA stability was blocked completely by pretreatment with rottlerin.	Etoposide	0-9	protein kinase C, delta	Mus musculus	21-30
15251430-6	2004	Moreover, HepG2 cells with exogenous ING4 could significantly increase cell death, as exposed to some DNA-damage agents, such as etoposide and doxorubicin, implying that ING4 could enhance chemosensitivity to certain DNA-damage agents in HepG2 cells.	Etoposide	129-138	inhibitor of growth family member 4	Homo sapiens	170-174
15223313-0	2004	Transcriptional and post-transcriptional regulation of the PKC delta gene by etoposide in L1210 murine leukemia cells: implication of PKC delta autoregulation.	Etoposide	77-86	protein kinase C, delta	Mus musculus	59-68
15223313-3	2004	In this study, we found that the amount of steady-state PKC delta mRNA and protein was increased by etoposide in mouse L1210 leukemia cells.	Etoposide	100-109	protein kinase C, delta	Mus musculus	56-65
15168357-4	2004	The neuropeptides bombesin and calcitonin, which inhibit etoposide-induced apoptosis, also inhibit the etoposide-induced elemental changes in prostate carcinoma cells.	Etoposide	57-66	gastrin releasing peptide	Homo sapiens	18-26
15223313-4	2004	The transcriptional rate of the PKC delta gene and the stability of PKC delta mRNA were increased by treatment with etoposide, resulting in the accumulation of PKC delta protein.	Etoposide	116-125	protein kinase C, delta	Mus musculus	32-41
15223313-4	2004	The transcriptional rate of the PKC delta gene and the stability of PKC delta mRNA were increased by treatment with etoposide, resulting in the accumulation of PKC delta protein.	Etoposide	116-125	protein kinase C, delta	Mus musculus	68-77
15223313-4	2004	The transcriptional rate of the PKC delta gene and the stability of PKC delta mRNA were increased by treatment with etoposide, resulting in the accumulation of PKC delta protein.	Etoposide	116-125	protein kinase C, delta	Mus musculus	68-77
15223313-5	2004	Rottlerin inhibited etoposide-induced PKC delta gene expression significantly, while Go6976, LY294002 and PD98059 had no effect.	Etoposide	20-29	protein kinase C, delta	Mus musculus	38-47
15205610-4	2004	In contrast, the average IC50 values of adriamycin (ADM), 4"-epidoxorubicin (EDR), mitomycin C (MMC), cisplatin and vepesid (VP-16) were 0.96, 0.74, 2.81, 7.27 and 26.66 microM, respectively.	Etoposide	116-123	host cell factor C1	Homo sapiens	125-130
15117953-3	2004	We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells.	Etoposide	131-140	BH3 interacting domain death agonist	Homo sapiens	53-56
15117953-3	2004	We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells.	Etoposide	131-140	tumor protein p53	Homo sapiens	164-167
15117953-6	2004	Caspase-2, which has been implicated as inducer caspase in DNA damage pathways, appeared to be processed in response to etoposide and gamma-radiation but downstream of caspase-9.	Etoposide	120-129	caspase 2	Homo sapiens	0-9
15117953-6	2004	Caspase-2, which has been implicated as inducer caspase in DNA damage pathways, appeared to be processed in response to etoposide and gamma-radiation but downstream of caspase-9.	Etoposide	120-129	caspase 2	Homo sapiens	48-55
15068397-6	2004	Furthermore, apoptosis in CHO cells induced by the DNA-damaging agent, etoposide, is associated with a fall in the levels of the anti-apoptotic Bcl-2 protein.	Etoposide	71-80	apoptosis regulator Bcl-2	Cricetulus griseus	144-149
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Etoposide	124-133	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	78-83
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Etoposide	124-133	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	156-161
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Etoposide	124-133	mitogen-activated protein kinase kinase 7	Homo sapiens	162-166
15001534-5	2004	It is noteworthy that pretreatment with paclitaxel significantly up-regulated MEKK1 expression, resulting in enhancement of etoposide- or cisplatin-induced MEKK1/MKK7-dependent JNK activation and apoptosis in LNCaP and DU145 cells.	Etoposide	124-133	mitogen-activated protein kinase 8	Homo sapiens	177-180
15168357-4	2004	The neuropeptides bombesin and calcitonin, which inhibit etoposide-induced apoptosis, also inhibit the etoposide-induced elemental changes in prostate carcinoma cells.	Etoposide	103-112	gastrin releasing peptide	Homo sapiens	18-26
15304155-7	2004	There were positive correlations between HSP27 overexpression and growth arrest and G2 / M accumulation when the cell lines were treated with etoposide, colcemid, or vincristine, but not with paclitaxel.	Etoposide	142-151	heat shock protein family B (small) member 1	Homo sapiens	41-46
15191568-0	2004	FPRL1 receptor agonist peptides prevent etoposide-induced alopecia in neonatal rats.	Etoposide	40-49	formyl peptide receptor 2	Rattus norvegicus	0-5
15503822-0	2004	PAP modulations in Daudi cells and Molt-3 cells treated with etoposide are mutually associated with morphological evidence of apoptosis.	Etoposide	61-70	poly(A) polymerase alpha	Homo sapiens	0-3
15503822-4	2004	In this study we identified PAP activity levels and isoform modulations in two different cell lines (Daudi and Molt-3) and related them to DNA fragmentation (a hallmark of apoptosis) and cell cycle phase specificity in terms of the temporal sequence of events and the time that elapsed between administration of the apoptosis inducer (the widely used anticancer drug etoposide) and the observed effects.	Etoposide	367-376	poly(A) polymerase alpha	Homo sapiens	28-31
15201971-1	2004	We have previously shown that treatment of human glioma U87-MG cells expressing wild-type p53 with a DNA topoisomerase II inhibitor, etoposide resulted in ceramide-dependent apoptotic cell death.	Etoposide	133-142	tumor protein p53	Homo sapiens	90-93
15191662-0	2004	[p33(ING1b) enhances chemosensitivity of osteosarcoma cell U2OS to etoposide].	Etoposide	67-76	inhibitor of growth family member 1	Homo sapiens	1-4
15087450-7	2004	In addition, we demonstrate that a caspase-3 cleavage-resistant D418E MLH1 mutant inhibits etoposide-induced apoptosis but has little effect on TRAIL-induced apoptosis.	Etoposide	91-100	caspase 3	Homo sapiens	35-44
15087450-7	2004	In addition, we demonstrate that a caspase-3 cleavage-resistant D418E MLH1 mutant inhibits etoposide-induced apoptosis but has little effect on TRAIL-induced apoptosis.	Etoposide	91-100	mutL homolog 1	Homo sapiens	70-74
14988151-6	2004	Furthermore, p53 gene silencing resulted in decreased p21 mRNA levels and reduced the sensitivity of CD34+ cells toward the cytotoxic drug etoposide.	Etoposide	139-148	tumor protein p53	Homo sapiens	13-16
14988151-6	2004	Furthermore, p53 gene silencing resulted in decreased p21 mRNA levels and reduced the sensitivity of CD34+ cells toward the cytotoxic drug etoposide.	Etoposide	139-148	CD34 molecule	Homo sapiens	101-105
15147950-5	2004	Intriguingly, however, DNA-PKcs-null cells display considerably less severe phenotype than other NHEJ mutants in terms of hypersensitivity to VP-16, a Top2 poison that stabilizes cleavable complexes.	Etoposide	142-147	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	23-31
15147950-6	2004	The results indicate that two distinct NHEJ pathways, involving or not involving DNA-PKcs, are important for the repair of VP-16-induced DNA damage, providing additional evidence for the biological relevance of DNA-PKcs-independent NHEJ.	Etoposide	123-128	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	81-89
15147950-6	2004	The results indicate that two distinct NHEJ pathways, involving or not involving DNA-PKcs, are important for the repair of VP-16-induced DNA damage, providing additional evidence for the biological relevance of DNA-PKcs-independent NHEJ.	Etoposide	123-128	protein kinase, DNA-activated, catalytic polypeptide	Gallus gallus	211-219
15087450-5	2004	Furthermore, MLH1 is rapidly proteolyzed by caspase-3 in cancer cells induced to undergo apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA.	Etoposide	215-224	mutL homolog 1	Homo sapiens	13-17
15087450-5	2004	Furthermore, MLH1 is rapidly proteolyzed by caspase-3 in cancer cells induced to undergo apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA.	Etoposide	215-224	caspase 3	Homo sapiens	44-53
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	inhibitor of growth family member 1	Homo sapiens	44-47
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	tumor protein p53	Homo sapiens	100-103
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	cyclin dependent kinase inhibitor 1A	Homo sapiens	133-136
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	cyclin dependent kinase inhibitor 1A	Homo sapiens	137-141
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
15191662-11	2004	CONCLUSION: These observations suggest that p33(ING1b) up-regulates p53 protein, and cooperate with p53 in stimulating expression of p21(WAF1) and Bax gene, thus to enhance etoposide-induced apoptosis via p53-dependent pathways.	Etoposide	173-182	tumor protein p53	Homo sapiens	100-103
15161627-5	2004	The appearance of diminished FRET was inhibited by a pan-caspase inhibitor z-VAD or D-&gt;A mutations in the LEVD sequence and was markedly increased by apoptosis-inducing agents, etoposide and camptothecin, or overexpression of a caspase 8-red fluorescent protein fusion protein.	Etoposide	180-189	caspase 8	Homo sapiens	231-240
15161627-5	2004	The appearance of diminished FRET was inhibited by a pan-caspase inhibitor z-VAD or D-&gt;A mutations in the LEVD sequence and was markedly increased by apoptosis-inducing agents, etoposide and camptothecin, or overexpression of a caspase 8-red fluorescent protein fusion protein.	Etoposide	180-189	caspase 4	Homo sapiens	57-64
14742324-0	2004	RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide.	Etoposide	121-130	RAS p21 protein activator 1	Homo sapiens	0-28
14615911-1	2004	We report on a 21-year-old man with a mediastinal germ cell tumor (MGCT) who developed a myelodysplastic syndrome (MDS) (refractory anemia with ringed sideroblasts, RARS) 10 months after the start of successful treatment with cisplatin, etoposide, ifosfamide, and paclitaxel.	Etoposide	237-246	MGCT	Homo sapiens	67-71
14742324-7	2004	In response to etoposide (ET), RasGAP fragment N was further cleaved in direct dependence on caspase-3 activity, which was more pronounced in NSCLC cells.	Etoposide	15-24	RAS p21 protein activator 1	Homo sapiens	31-37
14742324-7	2004	In response to etoposide (ET), RasGAP fragment N was further cleaved in direct dependence on caspase-3 activity, which was more pronounced in NSCLC cells.	Etoposide	15-24	caspase 3	Homo sapiens	93-102
14742324-7	2004	In response to etoposide (ET), RasGAP fragment N was further cleaved in direct dependence on caspase-3 activity, which was more pronounced in NSCLC cells.	Etoposide	26-28	RAS p21 protein activator 1	Homo sapiens	31-37
14742324-7	2004	In response to etoposide (ET), RasGAP fragment N was further cleaved in direct dependence on caspase-3 activity, which was more pronounced in NSCLC cells.	Etoposide	26-28	caspase 3	Homo sapiens	93-102
15128823-6	2004	Moreover, ablation of the native PAF-R in the epithelial cell line HaCaT using an inducible antisense PAF-R strategy inhibited etoposide-induced cytokine production.	Etoposide	127-136	platelet activating factor receptor	Homo sapiens	33-38
15189346-5	2004	U-373 cell viability showed a three-fold decrease (from 20 to 60% cell death) following treatment with staurosporine, C2-ceramide or etoposide, when either alpha2,6ST and GnT-V genes were stably overexpressed.	Etoposide	133-142	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	171-176
15189356-1	2004	Activation of metabotropic glutamate receptor 5 (mGluR5) has been shown to reduce caspase-dependent apoptosis in primary neuronal cultures induced by staurosporine and etoposide.	Etoposide	168-177	glutamate metabotropic receptor 5	Rattus norvegicus	14-47
14990976-6	2004	Our results demonstrate a dosage-dependent effect of MLL-AF4 fusion oncoprotein on cell cycle progression, with increasing expression levels resulting in the accumulation in G1, prolonged doubling time, both findings that might be responsible for the increased resistance to etoposide-mediated cytotoxicity.	Etoposide	275-284	lysine methyltransferase 2A	Homo sapiens	53-56
14990976-6	2004	Our results demonstrate a dosage-dependent effect of MLL-AF4 fusion oncoprotein on cell cycle progression, with increasing expression levels resulting in the accumulation in G1, prolonged doubling time, both findings that might be responsible for the increased resistance to etoposide-mediated cytotoxicity.	Etoposide	275-284	AF4/FMR2 family member 1	Homo sapiens	57-60
15150097-6	2004	It is especially noteworthy that stably transfected API2-MALT1 significantly suppressed both UV- and etoposide-induced apoptosis in HeLa cells, thus demonstrating for the first time that API2-MALT1 indeed possesses antiapoptotic function.	Etoposide	101-110	baculoviral IAP repeat containing 3	Homo sapiens	52-56
15150097-6	2004	It is especially noteworthy that stably transfected API2-MALT1 significantly suppressed both UV- and etoposide-induced apoptosis in HeLa cells, thus demonstrating for the first time that API2-MALT1 indeed possesses antiapoptotic function.	Etoposide	101-110	MALT1 paracaspase	Homo sapiens	57-62
15189356-1	2004	Activation of metabotropic glutamate receptor 5 (mGluR5) has been shown to reduce caspase-dependent apoptosis in primary neuronal cultures induced by staurosporine and etoposide.	Etoposide	168-177	glutamate receptor, ionotropic, kainate 1	Mus musculus	49-55
15312348-1	2004	OBJECTIVE: To observe the combined effect of etoposide (Vp-16) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) on mobilization of autologous peripheral blood stem cells (APBSC) in malignant tumor patients and find out the suitable dose of Vp-16.	Etoposide	45-54	host cell factor C1	Homo sapiens	56-61
15150097-6	2004	It is especially noteworthy that stably transfected API2-MALT1 significantly suppressed both UV- and etoposide-induced apoptosis in HeLa cells, thus demonstrating for the first time that API2-MALT1 indeed possesses antiapoptotic function.	Etoposide	101-110	baculoviral IAP repeat containing 3	Homo sapiens	187-191
15150097-6	2004	It is especially noteworthy that stably transfected API2-MALT1 significantly suppressed both UV- and etoposide-induced apoptosis in HeLa cells, thus demonstrating for the first time that API2-MALT1 indeed possesses antiapoptotic function.	Etoposide	101-110	MALT1 paracaspase	Homo sapiens	192-197
14990581-5	2004	In particular, we show that c-Myc is required for the induction of apoptosis by doxorubicin and etoposide, whereas it is not required for camptothecin-induced cell death.	Etoposide	96-105	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
15128823-6	2004	Moreover, ablation of the native PAF-R in the epithelial cell line HaCaT using an inducible antisense PAF-R strategy inhibited etoposide-induced cytokine production.	Etoposide	127-136	platelet activating factor receptor	Homo sapiens	102-107
15171819-0	2004	Caspase-3 is dually regulated by apoptogenic factors mitochondrial release and by SAPK/JNK metabolic pathway in leukemic cells exposed to etoposide-ionizing radiation combined treatment.	Etoposide	138-147	caspase 3	Homo sapiens	0-9
14988393-6	2004	Similar decreases in SK1 protein were observed with other DNA damaging agents such as doxorubicin, etoposide, and gamma-irradiation.	Etoposide	99-108	sphingosine kinase 1	Homo sapiens	21-24
15031723-2	2004	The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin.	Etoposide	134-143	BCL2 apoptosis regulator	Homo sapiens	62-67
15031723-2	2004	The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin.	Etoposide	134-143	X-linked inhibitor of apoptosis	Homo sapiens	71-75
15031723-6	2004	Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin.	Etoposide	75-84	BCL2 apoptosis regulator	Homo sapiens	29-34
15031723-6	2004	Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin.	Etoposide	75-84	X-linked inhibitor of apoptosis	Homo sapiens	38-42
15370291-2	2004	To test the hypothesis that estradiol (E2) and cyclosporin A (CsA) can interfere within programmed cell death in human umbilical vein endothelial cells (HUVECs), apoptosis was induced by etoposide with and without E2 or CsA.	Etoposide	187-196	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
15370291-4	2004	For CsA a dual effect was observed: used at 1 or 10 microg/mL in coincubation with etoposide, CsA significantly reduced etoposide-induced apoptosis but complete inhibition was not reached, whereas used at 50 microg/mL CsA did not protect HUVECs anymore and even had deleterious effects.	Etoposide	83-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
15370291-4	2004	For CsA a dual effect was observed: used at 1 or 10 microg/mL in coincubation with etoposide, CsA significantly reduced etoposide-induced apoptosis but complete inhibition was not reached, whereas used at 50 microg/mL CsA did not protect HUVECs anymore and even had deleterious effects.	Etoposide	83-92	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
15370291-4	2004	For CsA a dual effect was observed: used at 1 or 10 microg/mL in coincubation with etoposide, CsA significantly reduced etoposide-induced apoptosis but complete inhibition was not reached, whereas used at 50 microg/mL CsA did not protect HUVECs anymore and even had deleterious effects.	Etoposide	120-129	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
15370291-4	2004	For CsA a dual effect was observed: used at 1 or 10 microg/mL in coincubation with etoposide, CsA significantly reduced etoposide-induced apoptosis but complete inhibition was not reached, whereas used at 50 microg/mL CsA did not protect HUVECs anymore and even had deleterious effects.	Etoposide	120-129	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	94-97
15370291-5	2004	Furthermore, a 24-h pretreatment of HUVECs by CsA at 10 microg/mL significantly protected the cells by preventing both bcl-2 level decrease and caspase-3 activation related to etoposide-induced apoptosis.	Etoposide	176-185	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	46-49
15370291-5	2004	Furthermore, a 24-h pretreatment of HUVECs by CsA at 10 microg/mL significantly protected the cells by preventing both bcl-2 level decrease and caspase-3 activation related to etoposide-induced apoptosis.	Etoposide	176-185	caspase 3	Homo sapiens	144-153
15171819-0	2004	Caspase-3 is dually regulated by apoptogenic factors mitochondrial release and by SAPK/JNK metabolic pathway in leukemic cells exposed to etoposide-ionizing radiation combined treatment.	Etoposide	138-147	mitogen-activated protein kinase 9	Homo sapiens	82-86
15171819-0	2004	Caspase-3 is dually regulated by apoptogenic factors mitochondrial release and by SAPK/JNK metabolic pathway in leukemic cells exposed to etoposide-ionizing radiation combined treatment.	Etoposide	138-147	mitogen-activated protein kinase 9	Homo sapiens	87-90
15029247-2	2004	Recently, we found that ARTS is also important for cell killing by other pro-apoptotic factors, such as arabinoside, etoposide, staurosporine and Fas.	Etoposide	117-126	septin 4	Homo sapiens	24-28
15040005-6	2004	Consistent with the observation that SHP-2 participates in pro-survival signaling fibroblasts expressing a deletion within exon 3 of SHP-2, which results in a truncation of the amino-terminus SH2 domain (SHP-2(Ex3-/-)), were hypersensitive to etoposide-induced cell death.	Etoposide	243-252	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	37-42
15040005-6	2004	Consistent with the observation that SHP-2 participates in pro-survival signaling fibroblasts expressing a deletion within exon 3 of SHP-2, which results in a truncation of the amino-terminus SH2 domain (SHP-2(Ex3-/-)), were hypersensitive to etoposide-induced cell death.	Etoposide	243-252	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	133-138
15040005-6	2004	Consistent with the observation that SHP-2 participates in pro-survival signaling fibroblasts expressing a deletion within exon 3 of SHP-2, which results in a truncation of the amino-terminus SH2 domain (SHP-2(Ex3-/-)), were hypersensitive to etoposide-induced cell death.	Etoposide	243-252	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	133-138
15040005-7	2004	SHP-2(Ex3-/-) fibroblasts exhibited enhanced levels of etoposide-induced caspase 3 activity as compared to wild-type fibroblasts and the enhanced level of caspase 3 activity was suppressed by a caspase 3-specific inhibitor.	Etoposide	55-64	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	0-5
15040005-7	2004	SHP-2(Ex3-/-) fibroblasts exhibited enhanced levels of etoposide-induced caspase 3 activity as compared to wild-type fibroblasts and the enhanced level of caspase 3 activity was suppressed by a caspase 3-specific inhibitor.	Etoposide	55-64	caspase 3	Homo sapiens	73-82
15040005-8	2004	Re-introduction of wild-type SHP-2 into the SHP-2(Ex3-/-) fibroblasts rescued the hypersensitivity to etoposide-induced caspase 3 activation.	Etoposide	102-111	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	29-34
15040005-8	2004	Re-introduction of wild-type SHP-2 into the SHP-2(Ex3-/-) fibroblasts rescued the hypersensitivity to etoposide-induced caspase 3 activation.	Etoposide	102-111	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	44-49
15040005-8	2004	Re-introduction of wild-type SHP-2 into the SHP-2(Ex3-/-) fibroblasts rescued the hypersensitivity to etoposide-induced caspase 3 activation.	Etoposide	102-111	caspase 3	Homo sapiens	120-129
15069724-8	2004	RESULTS: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro.	Etoposide	62-71	collagen, type XVIII, alpha 1	Mus musculus	100-110
15069724-10	2004	In animal experiments, the combined therapy of topoisomerase inhibitor, etoposide with the rAAV-endostatin vector had the best tumor-suppressive effect and tumor foci were barely observed in livers of the treated mice.	Etoposide	72-81	collagen, type XVIII, alpha 1	Mus musculus	96-106
15069724-11	2004	Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice.	Etoposide	21-30	collagen, type XVIII, alpha 1	Mus musculus	54-64
15069724-11	2004	Pretreatment with an etoposide increased the level of endostatin in the liver and serum of rAAV-endostatin treated mice.	Etoposide	21-30	collagen, type XVIII, alpha 1	Mus musculus	96-106
21215012-1	2004	BACKGROUND: To evaluate the effect of combination chemotherapy with etoposide plus ifosfamide and cisplatin (VIP) for small cell lung cancer (SCLC).	Etoposide	68-77	SCLC1	Homo sapiens	142-146
15049699-12	2004	The high transition state energies of wild-type P-glycoprotein, when transporting etoposide or colchicine, increase the probability of nonproductive degradation of the transition state without transport.	Etoposide	82-91	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
15049699-13	2004	G185V P-glycoprotein transports etoposide or colchicine in an energetically more efficient way with decreased enthalpic and entropic components of the activation energy.	Etoposide	32-41	ATP binding cassette subfamily B member 1	Homo sapiens	6-20
14726695-6	2004	It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells.	Etoposide	148-157	RNA polymerase I subunit H	Homo sapiens	36-41
14726695-6	2004	It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells.	Etoposide	148-157	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
15050749-10	2004	Induction of NFkappaB, cIAP1, and cIAP2 correlated with partial protection from apoptotic cell death caused by etoposide.	Etoposide	111-120	nuclear factor kappa B subunit 1	Homo sapiens	13-21
15003732-6	2004	RESULTS: MCF-7 cells treated with taxol and etoposide were found positive for all hTERT splicing variants, while the expression of hTERT beta plus transcript did not differ significantly before and after exposure.	Etoposide	44-53	telomerase reverse transcriptase	Homo sapiens	82-87
15003732-6	2004	RESULTS: MCF-7 cells treated with taxol and etoposide were found positive for all hTERT splicing variants, while the expression of hTERT beta plus transcript did not differ significantly before and after exposure.	Etoposide	44-53	telomerase reverse transcriptase	Homo sapiens	131-136
15050749-10	2004	Induction of NFkappaB, cIAP1, and cIAP2 correlated with partial protection from apoptotic cell death caused by etoposide.	Etoposide	111-120	baculoviral IAP repeat containing 2	Homo sapiens	23-28
15050749-10	2004	Induction of NFkappaB, cIAP1, and cIAP2 correlated with partial protection from apoptotic cell death caused by etoposide.	Etoposide	111-120	baculoviral IAP repeat containing 3	Homo sapiens	34-39
14966827-1	2004	BACKGROUND: Etoposide (VP-16) is a topoisomerase II inhibitor that is effective in a broad spectrum of pediatric and adult malignancies.	Etoposide	12-21	host cell factor C1	Homo sapiens	23-28
15020609-8	2004	Population pharmacokinetic analysis demonstrated that the clearances of mitoxantrone and etoposide were decreased by 59% and 50%, respectively, supporting the empiric dose reductions in the PSC-MEC arm designed in anticipation of drug interactions between valspodar and the chemotherapeutic agents.	Etoposide	89-98	C-C motif chemokine ligand 28	Homo sapiens	194-197
15019164-4	2004	Neutralization of IGF-II significantly increased response to the chemotherapeutic agents cisplatin and etoposide especially at lower, cytostatic doses.	Etoposide	103-112	insulin like growth factor 2	Homo sapiens	18-24
14750184-7	2004	The effects of cisplatin (CDDP) and etoposide (VP-16) on the HL-60 cultured in vivo were in good agreement with those obtained by a conventional colorimetric assay.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
15050919-4	2004	Furthermore, BCR/ABL increases DNA double-strand damage after etoposide treatment and leads to a defect in an intra-S phase checkpoint, causing a radioresistant DNA synthesis (RDS) phenotype.	Etoposide	62-71	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	13-20
14730338-6	2004	Pre-transplant cumulative doses of etoposide &gt;750 mg/m(2) were associated with low CD34(+) cell collections on multivariate analysis.	Etoposide	35-44	CD34 molecule	Homo sapiens	86-90
14871251-3	2004	Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF.	Etoposide	37-46	integrin subunit alpha X	Homo sapiens	215-220
14871251-3	2004	Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF.	Etoposide	37-46	colony stimulating factor 3	Homo sapiens	370-375
15035084-2	2004	After 3 courses of chemotherapy with cisplatin (CDDP) and etoposide (VP-16), the serum level decreased to normal range.	Etoposide	58-67	host cell factor C1	Homo sapiens	69-74
15072444-0	2004	Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.	Etoposide	24-33	insulin like growth factor 2	Homo sapiens	100-129
15072444-8	2004	While P-gp, IGF-IR and IGF-I were not affected, enhanced inhibition of PKC, and IGF-II were observed in brain tumor cells treated with tamoxifen and etoposide combination as compared to cells treated with either drug alone.	Etoposide	149-158	insulin like growth factor 1 receptor	Homo sapiens	12-18
15072444-8	2004	While P-gp, IGF-IR and IGF-I were not affected, enhanced inhibition of PKC, and IGF-II were observed in brain tumor cells treated with tamoxifen and etoposide combination as compared to cells treated with either drug alone.	Etoposide	149-158	insulin like growth factor 1	Homo sapiens	12-17
15072444-8	2004	While P-gp, IGF-IR and IGF-I were not affected, enhanced inhibition of PKC, and IGF-II were observed in brain tumor cells treated with tamoxifen and etoposide combination as compared to cells treated with either drug alone.	Etoposide	149-158	insulin like growth factor 2	Homo sapiens	80-86
15133299-6	2004	Furthermore, etoposide- and radiosensitive phenotype of xrs-6 cells were corrected by an introduction of the tagged Ku80.	Etoposide	13-22	X-ray repair cross complementing 5	Homo sapiens	116-120
14991905-8	2004	Treatment of U937 cells with etoposide rapidly induced cell death and allowed the detection of active caspase-3 with approximately 2500 cells (0.8 pg of protein).	Etoposide	29-38	caspase 3	Homo sapiens	102-111
14737078-6	2004	In addition, HA14-1 abrogated PKC alpha"s ability to protect REH cells from etoposide.	Etoposide	76-85	protein kinase C alpha	Homo sapiens	30-39
14660614-7	2004	These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Etoposide	31-40	transcription factor 3	Homo sapiens	118-121
14660614-7	2004	These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Etoposide	31-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	145-148
14660614-7	2004	These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Etoposide	31-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	149-153
14660614-7	2004	These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Etoposide	31-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	154-158
14984497-0	2004	Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.	Etoposide	87-96	colony stimulating factor 2	Homo sapiens	0-48
14970849-1	2004	Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin.	Etoposide	212-216	ALL1	Homo sapiens	22-27
14970849-1	2004	Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin.	Etoposide	212-216	lysine methyltransferase 2A	Homo sapiens	28-32
14872059-8	2004	However, two inhibitors of the ATM- and Rad3-related (ATR) protein kinase activity prevented ETOP-induced Thr21 phosphorylation.	Etoposide	93-97	ATM serine/threonine kinase	Homo sapiens	31-34
14745596-11	2004	Bcl-XL was expressed endogenously in both cell lines and had reduced expression in EBV-negative cells after etoposide treatment.	Etoposide	108-117	BCL2 like 1	Homo sapiens	0-6
14745596-14	2004	Etoposide induced cleavage of caspase-9 in both cell lines, with the EBV-positive cells having proportionally less cleavage product, in agreement with their lower levels of apoptosis.	Etoposide	0-9	caspase 9	Homo sapiens	30-39
14745596-15	2004	Caspase-3 cleavage occurred in the EBV-negative etoposide-treated cells but not in the EBV-positive cells.	Etoposide	48-57	caspase 3	Homo sapiens	0-9
14751676-5	2004	Following 24 h of culture both compounds caused a statistically significant increase in the mRNA levels of the cell cycle inhibitory protein, gadd153, whereas p21 was statistically altered by etoposide only.	Etoposide	192-201	KRAS proto-oncogene, GTPase	Rattus norvegicus	159-162
14716293-4	2004	Interestingly, overexpression of DENN-SV enhanced cell replication and resistance to treatments with TNFalpha, vinblastine, etoposide and gamma-radiation.	Etoposide	124-133	MAP kinase activating death domain	Homo sapiens	33-37
14661052-4	2004	The anti-GPC3 ribozyme-containing clones reduced the mitoxantrone resistance level up to 21% of the original resistance and the crossresistance against etoposide to 33% of the original value.	Etoposide	152-161	glypican 3	Homo sapiens	9-13
14744945-3	2004	Etoposide, a substrate of both P-glycoprotein and CYP3A, was used as a model drug.	Etoposide	0-9	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	50-55
14700555-3	2004	By stably transfecting PC12 cells with an antisense PTEN construct, endogenous PTEN protein levels were reduced by approximately 50% and etoposide-induced apoptosis was markedly decreased.	Etoposide	137-146	phosphatase and tensin homolog	Rattus norvegicus	52-56
14749764-5	2004	Here, we examine the effects of commonly utilized chemotherapeutics, including doxorubicin, etoposide, and cisplatin, on cell cycle arrest in MEFs, and we define the p53 dependence of these effects.	Etoposide	92-101	transformation related protein 53, pseudogene	Mus musculus	166-169
15015589-7	2004	In conclusion, actinomycin D and etoposide stimulated caspase-3 activation in a Ewing tumor cell line and in freshly isolated tumor cells, causing drug-induced cell death.	Etoposide	33-42	caspase 3	Homo sapiens	54-63
14985455-4	2004	In so doing, we found that disruption of E-cadherin-mediated adhesion sensitizes multicellular spheroids of HT29 in vitro to treatment with 5-fluorouracil, paclitaxel, vinblastine, and etoposide but not cisplatin.	Etoposide	185-194	cadherin 1	Homo sapiens	41-51
14672900-7	2004	LLL-CHO, etoposide, and C2-ceramide also caused DeltaPsim, the increment of both hypodiploid DNA(+) cells and TUNEL(+) cells, and the activation of both Leu-Glu-His-Asp ase (LEHDase; caspase-9 like activity) and Asp-Glu-Val-Asp ase (DEVDase; caspase-3 like activity) in synovial cells.	Etoposide	9-18	caspase 9	Homo sapiens	183-192
14672900-7	2004	LLL-CHO, etoposide, and C2-ceramide also caused DeltaPsim, the increment of both hypodiploid DNA(+) cells and TUNEL(+) cells, and the activation of both Leu-Glu-His-Asp ase (LEHDase; caspase-9 like activity) and Asp-Glu-Val-Asp ase (DEVDase; caspase-3 like activity) in synovial cells.	Etoposide	9-18	caspase 3	Homo sapiens	242-251
14583630-3	2004	Viability assays showed that caspase-7-/- clones are more resistant to the common apoptosis-inducing drugs etoposide and staurosporine.	Etoposide	107-116	caspase 7	Gallus gallus	29-38
14630694-0	2004	Etoposide induces chimeric Mll gene fusions.	Etoposide	0-9	lysine (K)-specific methyltransferase 2A	Mus musculus	27-30
12969965-1	2004	Etoposide is a substrate for P-glycoprotein, CYP3A4, CYP3A5, and UGT1A1.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
12969965-1	2004	Etoposide is a substrate for P-glycoprotein, CYP3A4, CYP3A5, and UGT1A1.	Etoposide	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	53-59
12969965-1	2004	Etoposide is a substrate for P-glycoprotein, CYP3A4, CYP3A5, and UGT1A1.	Etoposide	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	65-71
15193283-6	2004	Etoposide treatment consistently induces a decrease in K and an increase in Na, which are inhibited by bombesin or calcitonin.	Etoposide	0-9	gastrin releasing peptide	Homo sapiens	103-111
15193283-7	2004	The Na/K ratio increased markedly after exposure to etoposide, and both bombesin and calcitonin blocked this increase.	Etoposide	52-61	gastrin releasing peptide	Homo sapiens	72-80
15649014-4	2004	Down-regulation of ZNRD1 significantly enhanced the sensitivity of SGC7901/VCR cells to vincristine, adriamycin and etoposide, but not to 5-fluorouracil and cisplatin.	Etoposide	116-125	RNA polymerase I subunit H	Homo sapiens	19-24
14695654-0	2004	Toxic action of etoposide on mouse peritoneal macrophages and its modulation by interleukin 3.	Etoposide	16-25	interleukin 3	Mus musculus	80-93
14695654-5	2004	We have also investigated a possible influence of interleukin 3 on DNA degradation induced by etoposide.	Etoposide	94-103	interleukin 3	Mus musculus	50-63
14695654-6	2004	The changes of Bax levels induced by etoposide that we have observed seemed to be modulated by this cytokine.	Etoposide	37-46	BCL2-associated X protein	Mus musculus	15-18
14695654-7	2004	From these results, a possible role of interleukin 3 can be suggested in the attenuation of some toxic effects produced by etoposide in mouse peritoneal macrophages.	Etoposide	123-132	interleukin 3	Mus musculus	39-52
14630694-1	2004	MLL gene fusions are the hallmark of more than 70% of therapy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause leukemia in murine transgenic models.	Etoposide	138-147	lysine (K)-specific methyltransferase 2A	Mus musculus	0-3
14630694-3	2004	We detected Mll fusions at a higher frequency following 100 microM etoposide for 8 h (16x10(-6) cell(-1)) than in no-drug controls (1.0x10(-6) cell(-1), P=0.0002) or after treatment with a comparably cytotoxic exposure to the antimicrotubule drug vincristine (1.0x10(-6) cell(-1), P=0.0047).	Etoposide	67-76	lysine (K)-specific methyltransferase 2A	Mus musculus	12-15
14630694-4	2004	The fusion points in Mll chimeric products induced by etoposide were localized to a 1.5 kb region between exons 9 and 11, analogous to the MLL breakpoint cluster region in human leukemia.	Etoposide	54-63	lysine methyltransferase 2A	Homo sapiens	21-24
14630694-4	2004	The fusion points in Mll chimeric products induced by etoposide were localized to a 1.5 kb region between exons 9 and 11, analogous to the MLL breakpoint cluster region in human leukemia.	Etoposide	54-63	lysine methyltransferase 2A	Homo sapiens	139-142
14630694-7	2004	These findings indicate that etoposide triggers the formation of Mll gene fusions, a critical step for the development of treatment-induced leukemic transformation.	Etoposide	29-38	lysine (K)-specific methyltransferase 2A	Mus musculus	65-68
14525959-10	2004	Apoptosis induced by etoposide was evaluated by DNA fragmentation, the presence of cytoplasmic histone-associated DNA fragments, and annexin V labeling.	Etoposide	21-30	annexin A5	Rattus norvegicus	133-142
14734478-9	2004	Treatment with rNEP before subtoxic concentrations of etoposide (0.1 micro M) significantly promoted mitochondrial apoptosis compared with only etoposide in PC-3 cells (P &lt; 0.01) but not in PrEC cells.	Etoposide	54-63	membrane metallo-endopeptidase	Rattus norvegicus	15-19
14734478-9	2004	Treatment with rNEP before subtoxic concentrations of etoposide (0.1 micro M) significantly promoted mitochondrial apoptosis compared with only etoposide in PC-3 cells (P &lt; 0.01) but not in PrEC cells.	Etoposide	144-153	membrane metallo-endopeptidase	Rattus norvegicus	15-19
14525959-12	2004	In contrast, in RBL/PR3 and in RBL/PR3S203A, the membrane expression of PR3 and PR3S203A increased with etoposide concentrations and appeared closely related to annexin V labeling.	Etoposide	104-113	proteinase 3	Homo sapiens	20-23
14525959-12	2004	In contrast, in RBL/PR3 and in RBL/PR3S203A, the membrane expression of PR3 and PR3S203A increased with etoposide concentrations and appeared closely related to annexin V labeling.	Etoposide	104-113	proteinase 3	Homo sapiens	35-38
14525959-12	2004	In contrast, in RBL/PR3 and in RBL/PR3S203A, the membrane expression of PR3 and PR3S203A increased with etoposide concentrations and appeared closely related to annexin V labeling.	Etoposide	104-113	annexin A5	Rattus norvegicus	161-170
15520873-6	2004	In contrast to this, dCK activity was found to be elevated several fold upon short-term treatments of normal human lymphocytes with therapeutic nucleoside analogs, and other genotoxic agents as well as by DNA damaging agents including the DNA polymerase inhibitor aphidicolin, the topoisomerase II inhibitor etoposide and gamma-irradiation, which might be a potentially important phenomenon with respect to the clinical practice, too.	Etoposide	308-317	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	21-24
15015771-0	2004	Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1.	Etoposide	112-121	ATP binding cassette subfamily C member 1	Homo sapiens	40-44
14630082-0	2004	Dual role of NF-kappaB in apoptosis of THP-1 cells during treatment with etoposide and lipopolysaccharide.	Etoposide	73-82	nuclear factor kappa B subunit 1	Homo sapiens	13-22
14630082-2	2004	In this study, we demonstrated that a potent NF-kappaB inhibitor, Nalpha-tosyl-L-lysinyl chloromethyl ketone (TLCK), inhibits apoptosis of THP-1 cells triggered by etoposide (VP16), and actinomycin D (ACT D) or cycloheximide inhibits apoptosis.	Etoposide	164-173	nuclear factor kappa B subunit 1	Homo sapiens	45-54
14757846-1	2004	We have recently shown that the topoisomerase II inhibitor, etoposide (VP16), could trigger caspase-2 pre-mRNA splicing in human leukemic cell lines.	Etoposide	60-69	caspase 2	Homo sapiens	92-101
14757846-1	2004	We have recently shown that the topoisomerase II inhibitor, etoposide (VP16), could trigger caspase-2 pre-mRNA splicing in human leukemic cell lines.	Etoposide	71-75	caspase 2	Homo sapiens	92-101
15341131-5	2004	The elevation of Hsp70 quantity, irrespective of the way it was performed, leads to the inhibition of apoptosis in cells treated with two substances, etoposide or adriamycin.	Etoposide	150-159	heat shock protein family A (Hsp70) member 4	Homo sapiens	17-22
14722239-12	2004	In particular, salvinal exhibited similar inhibitory activity against parental KB, P-glycoprotein-overexpressing KB vin10 and KB taxol-50 cells, and multidrug resistance-associated protein (MRP)-expressing etoposide-resistant KB 7D cells.	Etoposide	206-215	ATP binding cassette subfamily C member 3	Homo sapiens	190-193
15616148-2	2004	The most common first-line therapy regimen is cisplatin (Platinol; Bristol-Myers Squibb; Princeton, NJ) plus etoposide (Etopophos; Bristol-Myers Squibb)--PE, which is associated with overall response rates &gt;80% in patients with limited SCLC.	Etoposide	109-118	SCLC1	Homo sapiens	239-243
15138368-0	2004	Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.	Etoposide	125-134	cadherin 1	Homo sapiens	31-41
15138368-2	2004	The aim of the present study was to investigate the impact of wild-type (wt) E-cadherin and tumor-derived mutant E-cadherin variants on the proliferation rate of MDA-MB-435S mammary carcinoma cells and the sensitivity of the cells to the chemotherapeutic drugs cisplatin, etoposide and 5-fluorouracil (5-FU) and whether p53 is involved in the chemotherapeutic response.	Etoposide	272-281	cadherin 1	Homo sapiens	113-123
15138368-10	2004	In contrast, chemosensitivity of parental, wt or mutant E-cadherin-expressing MDA-MB-435S cells measured after etoposide or 5-FU exposure was found to be similar in all tested cell lines.	Etoposide	111-120	cadherin 1	Homo sapiens	56-66
14517210-8	2003	Pretreatment with PTH or overexpression of Smad3 decreased the number of apoptotic cells induced by dexamethasone and etoposide.	Etoposide	118-127	parathyroid hormone	Mus musculus	18-21
14517210-8	2003	Pretreatment with PTH or overexpression of Smad3 decreased the number of apoptotic cells induced by dexamethasone and etoposide.	Etoposide	118-127	SMAD family member 3	Mus musculus	43-48
14693066-2	2003	This study was designed to evaluate the response and tolerance of oxaliplatin,leucovorin (LV), 5-fluorouracil (5-FU),and etoposide (VP-16) as first-line regimen in advanced gastric cancer, and compare with traditional chemotherapy regimen.	Etoposide	121-130	host cell factor C1	Homo sapiens	132-137
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	Etoposide	201-210	TNF superfamily member 10	Homo sapiens	151-156
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	Etoposide	201-210	TNF superfamily member 10	Homo sapiens	157-162
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	Etoposide	212-216	TNF superfamily member 10	Homo sapiens	151-156
14601052-3	2003	Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells.	Etoposide	212-216	TNF superfamily member 10	Homo sapiens	157-162
12816733-8	2003	Human lung carcinoma tumor cells ectopically expressing GPC3 demonstrated increased apoptosis response when exposed to etoposide and growth inhibition when implanted in nude mice.	Etoposide	119-128	glypican 3	Homo sapiens	56-60
14668599-2	2003	He was treated with platinum/etoposide/bleomycin chemotherapy with a decrease in serum alpha-fetoprotein and in the size of the primary tumor.	Etoposide	29-38	alpha fetoprotein	Homo sapiens	87-104
14714958-5	2003	Combination chemotherapy with cisplatin and etoposide (VP16) was administered to control tumor progression, and achieved marked therapeutic effects.	Etoposide	44-53	host cell factor C1	Homo sapiens	55-59
14645667-5	2003	Increased expression of GADD153 raised the background level of apoptosis and increased apoptosis induced by fenretinide or the chemotherapeutic drugs cisplatin and etoposide.	Etoposide	164-173	DNA damage inducible transcript 3	Homo sapiens	24-31
14660748-9	2003	Furthermore, we showed that c-myc-overexpressing cells retain a functional p53 pathway and thus respond to etoposide.	Etoposide	107-116	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
14660748-9	2003	Furthermore, we showed that c-myc-overexpressing cells retain a functional p53 pathway and thus respond to etoposide.	Etoposide	107-116	tumor protein p53	Homo sapiens	75-78
14627986-3	2003	Etoposide-, etoposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	129-132
14761607-0	2003	[Topoisomerase II inhibitors etoposide and doxorubicin induced rearrangement and fusion of AML1 gene].	Etoposide	29-38	RUNX family transcription factor 1	Homo sapiens	91-95
14761607-2	2003	METHODS: The rearrangements of AML1 and ETO genes were detected by Southern Blot and the AML1-ETO fusion gene by nested RT-PCR combined with sequencing in K562 cells treated with etoposide (Vp16) and doxorubicin (DOX).	Etoposide	179-188	RUNX family transcription factor 1	Homo sapiens	31-35
14761607-2	2003	METHODS: The rearrangements of AML1 and ETO genes were detected by Southern Blot and the AML1-ETO fusion gene by nested RT-PCR combined with sequencing in K562 cells treated with etoposide (Vp16) and doxorubicin (DOX).	Etoposide	179-188	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	40-43
14761607-2	2003	METHODS: The rearrangements of AML1 and ETO genes were detected by Southern Blot and the AML1-ETO fusion gene by nested RT-PCR combined with sequencing in K562 cells treated with etoposide (Vp16) and doxorubicin (DOX).	Etoposide	179-188	RUNX family transcription factor 1	Homo sapiens	89-93
14761607-2	2003	METHODS: The rearrangements of AML1 and ETO genes were detected by Southern Blot and the AML1-ETO fusion gene by nested RT-PCR combined with sequencing in K562 cells treated with etoposide (Vp16) and doxorubicin (DOX).	Etoposide	179-188	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	94-97
14627986-3	2003	Etoposide-, etoposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay.	Etoposide	0-9	MLLT3 super elongation complex subunit	Homo sapiens	137-141
14981920-7	2003	NaF reduced the glucose consumption at early stage, possibly by inhibition of glycolysis, whereas cisplatin and etoposide reduced the glucose consumption at later stage, suggesting that early decline of glucose consumption is rather specific to NaF.	Etoposide	112-121	C-X-C motif chemokine ligand 8	Homo sapiens	245-248
12960154-5	2003	We found that cleavage at Asp720 occurred concurrently with caspase 3 activation and the increased production of total secreted Abeta and Abeta1-42 in association with staurosporine- and etoposide-induced apoptosis.	Etoposide	187-196	caspase-3	Cricetulus griseus	60-69
12829606-7	2003	Clones overexpressing BACH2 were more sensitive to etoposide, doxorubicin, and cytarabine than control RAJI cells, whereas there were no significant differences in the sensitivity of either cells to methotrexate or vincristine.	Etoposide	51-60	BTB domain and CNC homolog 2	Homo sapiens	22-27
14688482-6	2003	Following treatment with etoposide or adriamycin, induction of caspase 10 occurred at both the mRNA and protein levels.	Etoposide	25-34	caspase 10	Homo sapiens	63-73
14646211-6	2003	Beta-Cx inhibited the etoposide-induced activation of caspase-3 activity in a dose-dependent manner.	Etoposide	22-31	caspase 3	Mus musculus	54-63
14560006-4	2003	Here we show that the mechanism by which fibroblast growth factor 2 (FGF-2) protects small cell lung cancer (SCLC) cells from etoposide-induced cell death involves inhibition of Smac release but not of cytochrome c release.	Etoposide	126-135	fibroblast growth factor 2	Homo sapiens	41-67
14568942-4	2003	Even the cell populations containing very early apoptotic cells, such as IL-2-dependent CTLL-2 cells cultured in the absence of IL-2 for 4 h and a murine leukemic cell line, P388 cells, treated with etoposide for 5 h, were phagocytosed by macrophages.	Etoposide	199-208	interleukin 2	Mus musculus	73-77
14560006-4	2003	Here we show that the mechanism by which fibroblast growth factor 2 (FGF-2) protects small cell lung cancer (SCLC) cells from etoposide-induced cell death involves inhibition of Smac release but not of cytochrome c release.	Etoposide	126-135	fibroblast growth factor 2	Homo sapiens	69-74
14560006-4	2003	Here we show that the mechanism by which fibroblast growth factor 2 (FGF-2) protects small cell lung cancer (SCLC) cells from etoposide-induced cell death involves inhibition of Smac release but not of cytochrome c release.	Etoposide	126-135	diablo IAP-binding mitochondrial protein	Homo sapiens	178-182
14560006-6	2003	Exogenous expression of XIAP is sufficient to inhibit caspase 9 activation, Smac release, and cell death induced by etoposide.	Etoposide	116-125	X-linked inhibitor of apoptosis	Homo sapiens	24-28
14555241-5	2003	Etoposide- and doxorubicin-treated cells showed similar changes in the distribution of F-actin, vimentin and tubulin.	Etoposide	0-9	vimentin	Homo sapiens	96-104
14572633-3	2003	Combination with proapoptotic agents such as etoposide, pamidronate, and ceramide resulted in additive proapoptotic effects, whereas Bcl-X(L) protected from apoptosis caused via CD95/Fas stimulation.	Etoposide	45-54	Fas cell surface death receptor	Homo sapiens	178-182
14502243-5	2003	It is highly unlikely that caspase-2, which is a relatively zVAD-fmk-resistant caspase, is mediating etoposide-induced PARP cleavage, as a preferred inhibitor of this caspase could not prevent cleavage.	Etoposide	101-110	poly(ADP-ribose) polymerase 1	Homo sapiens	119-123
14520473-2	2003	We now report that CD26/DPPIV enhances sensitivity to apoptosis induced by the antineoplastic agents doxorubicin and etoposide.	Etoposide	117-126	dipeptidyl peptidase 4	Homo sapiens	19-23
14520473-2	2003	We now report that CD26/DPPIV enhances sensitivity to apoptosis induced by the antineoplastic agents doxorubicin and etoposide.	Etoposide	117-126	dipeptidyl peptidase 4	Homo sapiens	24-29
14655759-4	2003	TRAIL also triggered apoptosis in resistant glioma cell lines through the same pathways, but only if the cells were pretreated with chemotherapeutic agents, cisplatin, camptothecin and etoposide.	Etoposide	185-194	TNF superfamily member 10	Homo sapiens	0-5
14583449-5	2003	Interestingly, ionizing radiation or etoposide, both of which stabilize and activate p53, diminished p53 binding in chromatin immunoprecipitation assays, concomitant with a 5-fold increase in Dnmt1 levels.	Etoposide	37-46	tumor protein p53	Homo sapiens	85-88
14583449-5	2003	Interestingly, ionizing radiation or etoposide, both of which stabilize and activate p53, diminished p53 binding in chromatin immunoprecipitation assays, concomitant with a 5-fold increase in Dnmt1 levels.	Etoposide	37-46	tumor protein p53	Homo sapiens	101-104
14583449-5	2003	Interestingly, ionizing radiation or etoposide, both of which stabilize and activate p53, diminished p53 binding in chromatin immunoprecipitation assays, concomitant with a 5-fold increase in Dnmt1 levels.	Etoposide	37-46	DNA methyltransferase 1	Homo sapiens	192-197
14550815-1	2003	OBJECTIVE: The rationale for this retrospective study was to identify the long-term overall and event-free survival, relapse, and treatment-related mortality rates of high-risk pediatric and adult first (CR1) and second remission (CR2) patients with acute lymphoblastic leukemia (ALL) who were treated with a single preparatory regimen consisting of fractionated total-body irradiation (FTBI) and high-dose etoposide (VP-16) prior to allogeneic hematopoietic cell transplantation.	Etoposide	407-416	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	204-207
14559807-5	2003	Most notably we demonstrate that BRCA1 induces a 10-1000-fold increase in resistance to a range of DNA-damaging agents, in particular those that give rise to double-strand breaks such as etoposide or bleomycin.	Etoposide	187-196	BRCA1 DNA repair associated	Homo sapiens	33-38
14499628-0	2003	Bcl-2 prevents abnormal mitochondrial proliferation during etoposide-induced apoptosis.	Etoposide	59-68	BCL2 apoptosis regulator	Homo sapiens	0-5
14550815-1	2003	OBJECTIVE: The rationale for this retrospective study was to identify the long-term overall and event-free survival, relapse, and treatment-related mortality rates of high-risk pediatric and adult first (CR1) and second remission (CR2) patients with acute lymphoblastic leukemia (ALL) who were treated with a single preparatory regimen consisting of fractionated total-body irradiation (FTBI) and high-dose etoposide (VP-16) prior to allogeneic hematopoietic cell transplantation.	Etoposide	418-423	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	204-207
14513051-5	2003	Furthermore, the mRNA expression of the telomere binding protein TRF2 was upregulated early and reversibly after etoposide treatment.	Etoposide	113-122	telomeric repeat binding factor 2	Homo sapiens	65-69
14577595-3	2003	The IAP is capable of converting a relatively non-cytotoxic prodrug, etoposide phosphate (EP), into etoposide with a significant antitumor activity.	Etoposide	69-78	alkaline phosphatase, intestinal	Homo sapiens	4-7
14517333-1	2003	We show that Cdc6, an essential initiation factor for DNA replication, undergoes caspase-3-mediated cleavage in the early stages of apoptosis in HeLa cells and SK-HEP-1 cells induced by etoposide, paclitaxel, ginsenoside Rh2, or tumor necrosis factor-related apoptosis-inducing ligand.	Etoposide	186-195	cell division cycle 6	Homo sapiens	13-17
14517333-1	2003	We show that Cdc6, an essential initiation factor for DNA replication, undergoes caspase-3-mediated cleavage in the early stages of apoptosis in HeLa cells and SK-HEP-1 cells induced by etoposide, paclitaxel, ginsenoside Rh2, or tumor necrosis factor-related apoptosis-inducing ligand.	Etoposide	186-195	caspase 3	Homo sapiens	81-90
14577595-8	2003	Especially, the cell population of G2/M phase was increased in EP-treated SNU638/ IAP cells because P4 DNA unknotting activity of topoisomerase II was decreased by EP treatment such as the action mechanism of etoposide.	Etoposide	209-218	alkaline phosphatase, intestinal	Homo sapiens	82-85
14517333-6	2003	Supporting this is that the ectopic expression of p49-tCdc6 not only promotes apoptosis of etoposide-induced HeLa cells but also induces apoptosis in untreated cells.	Etoposide	91-100	serum response factor binding protein 1	Homo sapiens	50-53
14519653-5	2003	The remaining cell lines and primary cultures were resistant to TRAIL, but cisplatin, chemptothecin, and etoposide sensitized the resistant cell lines and primary cultures to TRAIL-induced apoptosis, which also occurred through the caspase-8-initiated caspase cascade.	Etoposide	105-114	TNF superfamily member 10	Homo sapiens	175-180
14505568-4	2003	Reducing H1.2 expression enhanced cellular resistance to apoptosis induced by X-ray irradiation or etoposide, but not that induced by other stimuli including TNF-alpha and UV irradiation.	Etoposide	99-108	histocompatibility 12	Mus musculus	9-13
14575542-7	2003	In conclusion, the combination of Z-LLL-CHO and VP16 enhanced their individual cytotoxic effect by inducing apoptosis, in which increase of S + G2/M fraction in cell cycle as well as the enhanced cleavage of Bcl-2 are the possible mechanism of the additive effect on leukemic cells by Z-LLL-CHO and VP16.	Etoposide	48-52	BCL2 apoptosis regulator	Homo sapiens	208-213
14519653-5	2003	The remaining cell lines and primary cultures were resistant to TRAIL, but cisplatin, chemptothecin, and etoposide sensitized the resistant cell lines and primary cultures to TRAIL-induced apoptosis, which also occurred through the caspase-8-initiated caspase cascade.	Etoposide	105-114	caspase 8	Homo sapiens	232-241
14517345-0	2003	Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro.	Etoposide	116-125	N-acetyltransferase 1	Homo sapiens	0-31
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF receptor superfamily member 10a	Homo sapiens	137-153
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF receptor superfamily member 10a	Homo sapiens	154-157
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF superfamily member 10	Homo sapiens	137-142
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF receptor superfamily member 10b	Homo sapiens	179-182
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF superfamily member 10	Homo sapiens	162-167
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Etoposide	66-75	TNF superfamily member 10	Homo sapiens	162-167
12970779-9	2003	Our findings demonstrate that, at a concentration which does not affect PI3K activity, the Akt inhibitor markedly reduced resistance of HL60AR cells to etoposide, cytarabine, TRAIL, ATRA, and ionizing radiation.	Etoposide	152-161	AKT serine/threonine kinase 1	Homo sapiens	91-94
14666661-0	2003	c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.	Etoposide	87-96	baculoviral IAP repeat containing 2	Homo sapiens	0-6
14517345-4	2003	Analysis of the effect of active NAT-1 overexpression in a normal luminal epithelial-derived cell line demonstrated enhanced growth properties and etoposide resistance relative to control cells.	Etoposide	147-156	N-acetyltransferase 1	Homo sapiens	33-38
12835328-2	2003	Suppression of Omi/HtrA2 by RNA interference in human cell lines reduces cell death in response to TRAIL and etoposide.	Etoposide	109-118	HtrA serine peptidase 2	Homo sapiens	19-24
12924948-2	2003	Like MRP1, MRP3 confers resistance to etoposide (VP-16) and actively transports 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G), cysteinyl leukotriene 4 (LTC(4)), and methotrexate, although with generally lower affinity.	Etoposide	38-47	ATP binding cassette subfamily C member 1	Homo sapiens	5-9
12924948-2	2003	Like MRP1, MRP3 confers resistance to etoposide (VP-16) and actively transports 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G), cysteinyl leukotriene 4 (LTC(4)), and methotrexate, although with generally lower affinity.	Etoposide	38-47	ATP binding cassette subfamily C member 3	Homo sapiens	11-15
12924948-2	2003	Like MRP1, MRP3 confers resistance to etoposide (VP-16) and actively transports 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G), cysteinyl leukotriene 4 (LTC(4)), and methotrexate, although with generally lower affinity.	Etoposide	38-47	host cell factor C1	Homo sapiens	49-54
14513771-0	2003	[Investigation of the cause of polyurethane catheter cracking during constant infusion of etoposide (VP-16) injection (2)--Analysis of ethanol eluting materials from catheter].	Etoposide	90-99	host cell factor C1	Homo sapiens	101-106
14513771-1	2003	We studied the cause of cracking of clinically used polyurethane (PU) catheters during the constant infusion of etoposide (VP-16) injection (Lastet inj.)	Etoposide	112-121	host cell factor C1	Homo sapiens	123-128
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	mitogen-activated protein kinase 8	Homo sapiens	191-196
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	insulin like growth factor binding protein 3	Homo sapiens	183-189
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	tumor necrosis factor	Homo sapiens	173-181
12851679-3	2003	In this study, we show that radioresistant T98G glioblastoma cells can develop sensitivity to DNA damage induced by irradiation and etoposide as a result of the introduction of a DNA repair-associated histone, H2AX.	Etoposide	132-141	H2A.X variant histone	Homo sapiens	210-214
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	198-202
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	DNA damage inducible transcript 3	Homo sapiens	207-214
12815281-8	2003	Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10.	Etoposide	78-87	DNA damage inducible transcript 3	Homo sapiens	215-221
12907245-0	2003	The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.	Etoposide	126-135	mitogen-activated protein kinase 8	Homo sapiens	4-7
12907245-0	2003	The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.	Etoposide	126-135	mitogen-activated protein kinase 1	Homo sapiens	9-12
12907245-0	2003	The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.	Etoposide	126-135	tumor protein p53	Homo sapiens	17-20
12907245-4	2003	Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release.	Etoposide	29-38	host cell factor C1	Homo sapiens	40-45
12907245-4	2003	Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release.	Etoposide	29-38	poly(ADP-ribose) polymerase 1	Homo sapiens	134-138
12907245-4	2003	Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release.	Etoposide	29-38	caspase 3	Homo sapiens	149-158
12907245-4	2003	Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release.	Etoposide	29-38	cytochrome c, somatic	Homo sapiens	189-201
12897808-1	2003	We sought to determine the efficiency of the intracellular functional P-gp- and MRP1-mediated pumping of THP into acidic organelles in SiHa cells and etoposide-resistant SiHa/VP16 cells.	Etoposide	150-159	ATP binding cassette subfamily C member 1	Homo sapiens	80-84
12902488-2	2003	In this study, we demonstrated that various pathogen-associated molecular patterns up-regulated Fas expression in macrophages and sensitized them specifically to Fas ligand (FasL), but not to other apoptosis-inducing agents such as TNF-alpha, etoposide (VP-16), and staurosporine.	Etoposide	243-252	Fas ligand (TNF superfamily, member 6)	Mus musculus	162-172
12902488-2	2003	In this study, we demonstrated that various pathogen-associated molecular patterns up-regulated Fas expression in macrophages and sensitized them specifically to Fas ligand (FasL), but not to other apoptosis-inducing agents such as TNF-alpha, etoposide (VP-16), and staurosporine.	Etoposide	243-252	Fas ligand (TNF superfamily, member 6)	Mus musculus	174-178
12902488-2	2003	In this study, we demonstrated that various pathogen-associated molecular patterns up-regulated Fas expression in macrophages and sensitized them specifically to Fas ligand (FasL), but not to other apoptosis-inducing agents such as TNF-alpha, etoposide (VP-16), and staurosporine.	Etoposide	254-259	Fas ligand (TNF superfamily, member 6)	Mus musculus	162-172
12902488-2	2003	In this study, we demonstrated that various pathogen-associated molecular patterns up-regulated Fas expression in macrophages and sensitized them specifically to Fas ligand (FasL), but not to other apoptosis-inducing agents such as TNF-alpha, etoposide (VP-16), and staurosporine.	Etoposide	254-259	Fas ligand (TNF superfamily, member 6)	Mus musculus	174-178
12935974-7	2003	Treatment with etoposide, fludarabine or Ga(mu)-Ab enhanced both apoptosis and CD10 expression.	Etoposide	15-24	membrane metalloendopeptidase	Homo sapiens	79-83
13677932-5	2003	The ratios for Fas antigen expression induced in non-treated U937 by 24 h incubations with ara-C, VP-16 or VCR were 1.90, 1.36 and 1.00, respectively.	Etoposide	98-103	Fas cell surface death receptor	Homo sapiens	15-26
12897149-2	2003	Here we show that HSP27 overexpression in various cell types enhances the degradation of ubiquitinated proteins by the 26S proteasome in response to stressful stimuli, such as etoposide or tumor necrosis factor alpha (TNF-alpha).	Etoposide	176-185	heat shock protein family B (small) member 1	Homo sapiens	18-23
12897149-5	2003	HSP27 overexpression increases NF-kappaB nuclear relocalization, DNA binding, and transcriptional activity induced by etoposide, TNF-alpha, and interleukin 1beta.	Etoposide	118-127	heat shock protein family B (small) member 1	Homo sapiens	0-5
12948018-11	2003	For structurally diverse P-gp substrates (acebutolol, colchicine, digoxin, etoposide, methylprednisolone, prednisolone, quinidine, and talinolol) apparent Km was approximately 3 to 8-fold greater in absorptive vs. secretory transport direction, whereas apparent J(max) was somewhat similar in both transport directions.	Etoposide	75-84	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
12885813-2	2003	To evaluate response to 2-chlorodeoxyadenosine (2-CDA) and etoposide (VP-16) in patients who did not respond to mitoxantrone and cytarabine.	Etoposide	59-68	host cell factor C1	Homo sapiens	70-75
12869645-8	2003	The ability of aspirin to activate AKT protein was observed also in presence of etoposide cotreatment.	Etoposide	80-89	AKT serine/threonine kinase 1	Homo sapiens	35-38
12880985-9	2003	These findings demonstrate that etoposide can be designed as a prodrug substrate for tyrosine hydroxylase and thereby establish proof of concept for neuroblastoma directed enzyme prodrug therapy.	Etoposide	32-41	tyrosine hydroxylase	Mus musculus	85-105
12736248-8	2003	In addition, the levels of dig2 mRNA were up-regulated after treatment with the apoptosis-inducing chemotherapeutic drug etoposide.	Etoposide	121-130	DNA-damage-inducible transcript 4	Mus musculus	27-31
12880985-0	2003	Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.	Etoposide	63-72	tyrosine hydroxylase	Mus musculus	92-112
12881702-4	2003	BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6.	Etoposide	127-136	BCL6 transcription repressor	Homo sapiens	0-4
12880985-2	2003	In order to accomplish this goal in neuroblastoma, we rationally designed a prodrug of etoposide as substrate for tyrosine hydroxylase, a well established neuroblastoma associated enzyme.	Etoposide	87-96	tyrosine hydroxylase	Mus musculus	114-134
12881702-4	2003	BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6.	Etoposide	127-136	BCL6 transcription repressor	Homo sapiens	190-194
12881702-5	2003	BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis.	Etoposide	39-48	BCL6 transcription repressor	Homo sapiens	0-4
12881702-6	2003	In these lymphoma cell lines, etoposide increased the generation of reactive oxygen species (ROS) and reduced mitochondria membrane potential, both of which were inhibited by the antioxidant N-acetyl-L-cysteine (NAC).	Etoposide	30-39	X-linked Kx blood group	Homo sapiens	212-215
12881702-8	2003	Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents.	Etoposide	110-119	BCL6 transcription repressor	Homo sapiens	13-17
12881712-3	2003	FOXO3a was cleaved in vivo by caspases in leukemic Jurkat cells following engagement of Fas (CD95) receptor, staurosporine, and etoposide treatment, but not following engagement of CD99, a caspase-independent cell death inducer.	Etoposide	128-137	forkhead box O3	Homo sapiens	0-6
12881712-3	2003	FOXO3a was cleaved in vivo by caspases in leukemic Jurkat cells following engagement of Fas (CD95) receptor, staurosporine, and etoposide treatment, but not following engagement of CD99, a caspase-independent cell death inducer.	Etoposide	128-137	caspase 8	Homo sapiens	30-38
12838325-7	2003	Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5.	Etoposide	102-111	TNF superfamily member 10	Homo sapiens	139-144
12874009-2	2003	Here, we investigate the role of p53 in the G(2) arrest that occurs in response to the topoisomerase inhibitors etoposide and merbarone.	Etoposide	112-121	tumor protein p53	Homo sapiens	33-36
12874009-3	2003	In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR).	Etoposide	75-84	tumor protein p53	Homo sapiens	55-58
12874009-3	2003	In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR).	Etoposide	75-84	ATM serine/threonine kinase	Homo sapiens	228-257
12874009-3	2003	In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR).	Etoposide	75-84	ATM serine/threonine kinase	Homo sapiens	259-262
12874009-3	2003	In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR).	Etoposide	75-84	ATM serine/threonine kinase	Homo sapiens	63-66
12874009-3	2003	In HT1080 cells expressing a dominant-negative form of p53, treatment with etoposide still caused G(2) arrest, but the arrest could be overcome by additional treatment with caffeine, which inhibits the damage-responsive kinases ataxia telangiectasia mutated (ATM) and atm and rad3-related (ATR).	Etoposide	75-84	ATR serine/threonine kinase	Homo sapiens	290-293
12874009-5	2003	We conclude that etoposide activates two pathways, one of which depends on p53 and the other of which is sensitive to caffeine, and that either pathway is sufficient to activate G(2) arrest.	Etoposide	17-26	tumor protein p53	Homo sapiens	75-78
12707267-5	2003	We showed that JNK was activated by TRAIL and by etoposide and that the activation was enhanced by the combination of the two treatments.	Etoposide	49-58	mitogen-activated protein kinase 8	Homo sapiens	15-18
12707267-8	2003	In cells treated with TRAIL plus etoposide, JNK inhibition increased cell survival and decreased apoptosis significantly.	Etoposide	33-42	mitogen-activated protein kinase 8	Homo sapiens	44-47
12838325-7	2003	Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5.	Etoposide	102-111	TNF superfamily member 10	Homo sapiens	145-150
12838325-7	2003	Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5.	Etoposide	102-111	TNF receptor superfamily member 10a	Homo sapiens	241-244
12838325-7	2003	Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5.	Etoposide	102-111	TNF receptor superfamily member 10b	Homo sapiens	249-252
12926090-8	2003	CONCLUSION: Etoposide had a supra-additive effect in combination with irradiation for radioresistant NMT-1R cells due to the induction of apoptosis.	Etoposide	12-21	N-myristoyltransferase 1	Rattus norvegicus	101-106
12799643-5	2003	Cyclin E-overexpressing cells were less sensitive to doxorubicin-induced inhibition of cell growth but not to other antineoplastic drugs, such as paclitaxel, vincristine, etoposide and methotrexate.	Etoposide	171-180	cyclin E1	Rattus norvegicus	0-8
12623853-0	2003	Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.	Etoposide	25-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	52-57
12623853-0	2003	Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.	Etoposide	25-34	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	93-98
12623853-8	2003	In summary, the hydrolytically activated etoposide prodrugs proved effective against multidrug-resistant T-cell leukemia in vitro and in vivo and provide proof of concept for a highly promising new strategy for the treatment of MDR-1 drug-resistant malignancies.	Etoposide	41-50	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	228-233
12712436-0	2003	The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.	Etoposide	21-30	RAD51 recombinase	Homo sapiens	12-17
12712436-0	2003	The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.	Etoposide	32-36	RAD51 recombinase	Homo sapiens	12-17
12858347-8	2003	In addition, IL-2Ralpha-expressing cells were significantly more resistant to apoptosis induction by a tripeptidyl proteasome inhibitor (ALLN) and two chemotherapeutic drugs (VP-16 and taxol) than the control or IL-2Rgamma+ cells.	Etoposide	175-180	interleukin 2 receptor subunit alpha	Homo sapiens	13-23
12823542-0	2003	Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703.	Etoposide	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	22-25
12823542-3	2003	In dissecting the mechanism underlying this synergistic effect, we found that treatment with etoposide alone resulted in the upregulation of Bax, while the level of truncated Bid (tBid) was unchanged.	Etoposide	93-102	BCL2 associated X, apoptosis regulator	Homo sapiens	141-144
12823542-7	2003	The RT-PCR and Western blotting results demonstrated that the levels of both mRNA and protein for death receptor-4, death receptor-5 and decoy receptor-2 remained unchanged in response to etoposide, indicating that the synergistic effect of TRAIL and etoposide is not a result of increasing the expression for TRAIL receptors, but rather is associated with amplification of the mitochondrial signal pathway.	Etoposide	188-197	TNF receptor superfamily member 10a	Homo sapiens	98-153
12767922-5	2003	Wortmannin, an ATM- and DNA-dependent protein kinase inhibitor, partially inhibited p21(WAF1/Cip1) expression induced by genistein and etoposide, whereas UCN-01, a Chk1 inhibitor, partially blocked etoposide, but not genistein-induced p21(WAF1/Cip1) expression.	Etoposide	135-144	cyclin dependent kinase inhibitor 1A	Homo sapiens	84-87
12767922-0	2003	P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells.	Etoposide	52-61	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-3
12767944-6	2003	While coexpression of active CaMKIV with wild-type p65 led to a recovery from etoposide-induced apoptosis and an increase of Bcl-2 protein in cells, cells expressing S535A mutant did not.	Etoposide	78-87	calcium/calmodulin dependent protein kinase IV	Homo sapiens	29-35
12767944-6	2003	While coexpression of active CaMKIV with wild-type p65 led to a recovery from etoposide-induced apoptosis and an increase of Bcl-2 protein in cells, cells expressing S535A mutant did not.	Etoposide	78-87	RELA proto-oncogene, NF-kB subunit	Homo sapiens	51-54
12767922-2	2003	Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549.	Etoposide	61-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	79-82
12767922-5	2003	Wortmannin, an ATM- and DNA-dependent protein kinase inhibitor, partially inhibited p21(WAF1/Cip1) expression induced by genistein and etoposide, whereas UCN-01, a Chk1 inhibitor, partially blocked etoposide, but not genistein-induced p21(WAF1/Cip1) expression.	Etoposide	135-144	cyclin dependent kinase inhibitor 1A	Homo sapiens	88-92
12767922-2	2003	Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549.	Etoposide	61-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	83-87
12767922-2	2003	Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549.	Etoposide	61-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	88-92
12767922-5	2003	Wortmannin, an ATM- and DNA-dependent protein kinase inhibitor, partially inhibited p21(WAF1/Cip1) expression induced by genistein and etoposide, whereas UCN-01, a Chk1 inhibitor, partially blocked etoposide, but not genistein-induced p21(WAF1/Cip1) expression.	Etoposide	135-144	cyclin dependent kinase inhibitor 1A	Homo sapiens	93-97
12767922-2	2003	Here we show that topoisomerase II inhibitors, genistein and etoposide, induce p21(WAF1/Cip1) expression mainly in a p53-dependent manner in human lung cancer cell line A549.	Etoposide	61-70	tumor protein p53	Homo sapiens	117-120
12767922-6	2003	These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner.	Etoposide	43-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	60-63
12767922-4	2003	Caffeine, an ataxia telangiectasia-mutated (ATM), and ATM- and Rad3-related kinase (ATR) inhibitor, abrogated genistein-induced p21(WAF1/Cip1) and largely blocked etoposide-induced p21(WAF1/Cip1) expression.	Etoposide	163-172	ATR serine/threonine kinase	Homo sapiens	54-82
12767922-4	2003	Caffeine, an ataxia telangiectasia-mutated (ATM), and ATM- and Rad3-related kinase (ATR) inhibitor, abrogated genistein-induced p21(WAF1/Cip1) and largely blocked etoposide-induced p21(WAF1/Cip1) expression.	Etoposide	163-172	ATR serine/threonine kinase	Homo sapiens	84-87
12767922-6	2003	These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner.	Etoposide	43-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-68
12767922-6	2003	These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner.	Etoposide	43-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	69-73
12767922-6	2003	These data suggest that both genistein and etoposide induce p21(WAF1/Cip1) expression in a p53-dependent manner.	Etoposide	43-52	tumor protein p53	Homo sapiens	91-94
12767922-7	2003	Genistein appears to stimulate p21(WAF1/Cip1) expression through p53 via ATM, whereas etoposide may activate both ATM and ATR pathways.	Etoposide	86-95	ATM serine/threonine kinase	Homo sapiens	114-117
12767922-7	2003	Genistein appears to stimulate p21(WAF1/Cip1) expression through p53 via ATM, whereas etoposide may activate both ATM and ATR pathways.	Etoposide	86-95	ATR serine/threonine kinase	Homo sapiens	122-125
12767922-8	2003	Our results suggest different mechanisms participate in genistein and etoposide induced p21(WAF1/Cip1) expression.	Etoposide	70-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	88-91
12767922-8	2003	Our results suggest different mechanisms participate in genistein and etoposide induced p21(WAF1/Cip1) expression.	Etoposide	70-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	92-96
12767922-8	2003	Our results suggest different mechanisms participate in genistein and etoposide induced p21(WAF1/Cip1) expression.	Etoposide	70-79	cyclin dependent kinase inhibitor 1A	Homo sapiens	97-101
12665508-3	2003	We report here that without the use of endoplasmic reticulum (ER) stress inducers, specific overexpression of GRP78 results in reduced apoptosis and higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin, and topoisomerase I inhibitor, camptothecin.	Etoposide	222-231	heat shock protein family A (Hsp70) member 5	Homo sapiens	110-115
12663670-3	2003	We have observed that four DNA-damaging agents (cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.	Etoposide	83-92	mitogen-activated protein kinase 8	Homo sapiens	191-194
12663670-3	2003	We have observed that four DNA-damaging agents (cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.	Etoposide	83-92	mitogen-activated protein kinase 1	Homo sapiens	196-199
12663670-3	2003	We have observed that four DNA-damaging agents (cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.	Etoposide	83-92	mitogen-activated protein kinase 1	Homo sapiens	205-242
12663670-3	2003	We have observed that four DNA-damaging agents (cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.	Etoposide	83-92	mitogen-activated protein kinase 1	Homo sapiens	244-247
12665508-5	2003	Caspase-7, an executor caspase that is associated with the ER, is activated by etoposide.	Etoposide	79-88	caspase 7	Homo sapiens	0-9
12663670-3	2003	We have observed that four DNA-damaging agents (cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.	Etoposide	83-92	activating transcription factor 2	Homo sapiens	292-296
12665508-6	2003	We show here that specific expression of GRP78 blocks caspase-7 activation by etoposide both in vivo and in vitro, and this effect can be reversed by addition of dATP in a cell-free system.	Etoposide	78-87	heat shock protein family A (Hsp70) member 5	Homo sapiens	41-46
12702731-5	2003	While staurosporine, H7, etoposide, and chelerythrine released cytochrome c from mitochondria in intact cells, only chelerythrine released cytochrome c from isolated mitochondria.	Etoposide	25-34	cytochrome c, somatic	Homo sapiens	63-75
12665508-6	2003	We show here that specific expression of GRP78 blocks caspase-7 activation by etoposide both in vivo and in vitro, and this effect can be reversed by addition of dATP in a cell-free system.	Etoposide	78-87	caspase 7	Homo sapiens	54-63
12665508-11	2003	Lastly, a GRP78 mutant deleted of its ATP binding domain fails to bind procaspase-7 and loses its protective effect against etoposide-induced apoptosis.	Etoposide	124-133	heat shock protein family A (Hsp70) member 5	Homo sapiens	10-15
12764618-4	2003	Using cleavage site-directed antibodies, specific intracellular detection for cleaved fragments of caspase-8 and -9 was accomplished during apoptosis induced by staurosporine and etoposide.	Etoposide	179-188	caspase 8	Homo sapiens	99-115
12738983-7	2003	After genotoxic stress such as etoposide treatment, AS2 expressing cells readily progressed into apoptosis through p53 and caspase-3 activations.	Etoposide	31-40	tumor protein p53	Homo sapiens	115-118
12736715-4	2003	Our results indicate that cells with endogenous or transfected exogenous c-myc overexpression (SW613-12A1 and -2G1mycP2Tu1 cell lines, respectively), activate the apoptotic machinery in response to the treatment with etoposide, doxorubicin and vitamin D3, which induce apoptosis through the death receptor Fas.	Etoposide	217-226	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78
14653077-5	2003	The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P &lt; 0.05).	Etoposide	242-251	DNA damage inducible transcript 3	Homo sapiens	142-146
14653077-5	2003	The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P &lt; 0.05).	Etoposide	259-263	DNA damage inducible transcript 3	Homo sapiens	142-146
12738983-7	2003	After genotoxic stress such as etoposide treatment, AS2 expressing cells readily progressed into apoptosis through p53 and caspase-3 activations.	Etoposide	31-40	caspase 3	Homo sapiens	123-132
12817896-3	2003	Etoposide transport was also determined in P-glycoprotein-deficient mdr1a(-/-) mice perfused with both etoposide and mrpl inhibitors like probenecid or MK571.	Etoposide	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	68-73
12775738-10	2003	CONCLUSION: tAPL is not exceptional, and develops usually less than 3 years after a primary neoplasm (especially breast carcinoma) treated in particular with topoisomerase II-targeted drugs (anthracyclines or mitoxantrone and less often etoposide).	Etoposide	237-246	ATP binding cassette subfamily B member 9	Homo sapiens	12-16
12773551-4	2003	p53 response to treatment with gamma irradiation or etoposide is lost due to a mutation at codon 242 of p53 (C--&gt;W).	Etoposide	52-61	tumor protein p53	Homo sapiens	104-107
12817896-8	2003	There was also a significant P-gp-mediated efflux of etoposide in studies with P-glycoprotein-deficient mdr1a(-/-) mice.	Etoposide	53-62	phosphoglycolate phosphatase	Mus musculus	29-33
12817896-8	2003	There was also a significant P-gp-mediated efflux of etoposide in studies with P-glycoprotein-deficient mdr1a(-/-) mice.	Etoposide	53-62	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	104-109
12712406-8	2003	In addition, stable transfection with dominant-negative MKK7, by which JNK activation was inhibited, canceled both the up-regulation of Fas and the formation of DISC by etoposide.	Etoposide	169-178	mitogen-activated protein kinase kinase 7	Homo sapiens	56-60
12817896-9	2003	Perfusion of mdr1a(-/-) mice etoposide plus probenecid or MK571 did not affect the brain transport of etoposide.	Etoposide	29-38	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	13-18
12712406-8	2003	In addition, stable transfection with dominant-negative MKK7, by which JNK activation was inhibited, canceled both the up-regulation of Fas and the formation of DISC by etoposide.	Etoposide	169-178	mitogen-activated protein kinase 8	Homo sapiens	71-74
12712406-0	2003	c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells.	Etoposide	66-75	mitogen-activated protein kinase 8	Homo sapiens	0-25
12712406-0	2003	c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells.	Etoposide	66-75	tumor protein p53	Homo sapiens	97-100
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Etoposide	276-285	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
12751957-7	2003	Etoposide, an inhibitor of topoisomerase II generating double-strand breaks, triggered the concentration of KIN17 into punctuate intranuclear foci.	Etoposide	0-9	Kin17 DNA and RNA binding protein	Homo sapiens	108-113
12700406-6	2003	Our results revealed a strong linear negative correlation between basal MT levels and etoposide-induced apoptosis in the human tumor cell lines PLC/PRF/5, H460, and HepG2 (r = -0.991).	Etoposide	86-95	heparan sulfate proteoglycan 2	Homo sapiens	144-147
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Etoposide	276-285	AKT serine/threonine kinase 1	Homo sapiens	132-135
12761491-5	2003	We found that transformed mouse embryonic fibroblasts deficient for HIF-1alpha are more susceptible to the treatment with carboplatin, etoposide and ionizing radiation than wild-type cells.	Etoposide	135-144	hypoxia inducible factor 1, alpha subunit	Mus musculus	68-78
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Etoposide	276-285	erb-b2 receptor tyrosine kinase 3	Homo sapiens	62-66
12706714-7	2003	We observe fewer etoposide-induced DSBs in RAD51-overexpressing cells and that HR repair of etoposide-induced DSBs is faster.	Etoposide	17-26	RAD51 recombinase	Homo sapiens	43-48
12637521-5	2003	This results in the termination of virus-induced NF-kappaB activity and the inhibition of tumor necrosis factor alpha and etoposide-induced NF-kappaB activation in infected cells.	Etoposide	122-131	nuclear factor kappa B subunit 1	Homo sapiens	140-149
12601006-5	2003	The presence of the PAF-R in these models resulted in an augmentation of apoptosis induced by chemotherapeutic agents etoposide and mitomycin C but not by tumor necrosis factor-related apoptosis-inducing ligand or by C(2) ceramide.	Etoposide	118-127	platelet activating factor receptor	Homo sapiens	20-25
12706714-3	2003	Here, we have investigated the role of RAD51 in the repair of different types of damage induced during DNA replication with etoposide, hydroxyurea or thymidine.	Etoposide	124-133	RAD51 recombinase	Homo sapiens	39-44
12706714-7	2003	We observe fewer etoposide-induced DSBs in RAD51-overexpressing cells and that HR repair of etoposide-induced DSBs is faster.	Etoposide	92-101	RAD51 recombinase	Homo sapiens	43-48
12605597-4	2003	Indeed, using Jurkat cells as a model system, we demonstrate that NO donors block Fas- and etoposide-induced caspase activation and apoptosis (downstream of mitochondrial membrane depolarization) and cytochrome c release.	Etoposide	91-100	caspase 8	Homo sapiens	109-116
12605597-4	2003	Indeed, using Jurkat cells as a model system, we demonstrate that NO donors block Fas- and etoposide-induced caspase activation and apoptosis (downstream of mitochondrial membrane depolarization) and cytochrome c release.	Etoposide	91-100	cytochrome c, somatic	Homo sapiens	200-212
12695347-0	2003	Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1.	Etoposide	19-28	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	84-115
12771025-6	2003	Furthermore, northern analysis showed that induction of this gene is independent of p53, as increased expression of the gene was observed in p53 null H1299/Neo control cells when the temperature was shifted to 32 degrees C. Moreover, a DNA damaging agent, etoposide, also induced beta1 subunit expression in multiple human tumor cells, regardless of p53 status.	Etoposide	256-265	tumor protein p53	Homo sapiens	141-144
12771025-6	2003	Furthermore, northern analysis showed that induction of this gene is independent of p53, as increased expression of the gene was observed in p53 null H1299/Neo control cells when the temperature was shifted to 32 degrees C. Moreover, a DNA damaging agent, etoposide, also induced beta1 subunit expression in multiple human tumor cells, regardless of p53 status.	Etoposide	256-265	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	280-285
12771025-6	2003	Furthermore, northern analysis showed that induction of this gene is independent of p53, as increased expression of the gene was observed in p53 null H1299/Neo control cells when the temperature was shifted to 32 degrees C. Moreover, a DNA damaging agent, etoposide, also induced beta1 subunit expression in multiple human tumor cells, regardless of p53 status.	Etoposide	256-265	tumor protein p53	Homo sapiens	141-144
12771025-7	2003	Thus, the beta1 subunit of AMPK is not a p53 downstream target gene, but can be induced by cold shock or the chemotherapeutic drug, etoposide in a p53-independent manner.	Etoposide	132-141	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	10-15
12771025-7	2003	Thus, the beta1 subunit of AMPK is not a p53 downstream target gene, but can be induced by cold shock or the chemotherapeutic drug, etoposide in a p53-independent manner.	Etoposide	132-141	tumor protein p53	Homo sapiens	147-150
12695347-6	2003	The kinetic parameters of etoposide glucuronidation were K(m) = 439.6 +/- 70.7 microM and V(max) = 255.6 +/- 19.2 pmol/min/mg of protein in human liver microsomes and K(m) = 503.2 +/- 110.2 microM and V(max) = was 266.5 +/- 28.6 pmol/min/mg of protein in recombinant UGT1A1.	Etoposide	26-35	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	267-273
12695347-11	2003	These results demonstrate that etoposide glucuronidation in human liver microsomes is specifically catalyzed by UGT1A1.	Etoposide	31-40	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	112-118
12697681-0	2003	CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4.	Etoposide	90-99	CD40 antigen	Mus musculus	0-4
12684687-4	2003	We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel.	Etoposide	210-219	tumor protein p53	Homo sapiens	35-38
12697681-6	2003	In three different assays for apoptosis, including trypan blue exclusion, changes in nuclear morphology, and fluorescence-activated cell sorting staining for annexin V/propidium iodide, CD40L significantly inhibited apoptosis of MLO-Y4 cells induced by dexamethasone, TNF alpha, or etoposide.	Etoposide	282-291	CD40 ligand	Mus musculus	186-191
12839679-3	2003	RESULTS: The activation of NF-kappa B induced by Ara-C and Vp-16 was obviously correlated to apoptosis in P388 cells.	Etoposide	59-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-37
14641820-7	2003	Overexpression of rat Abcc1 elicited high resistance to etoposide.	Etoposide	56-65	ATP binding cassette subfamily C member 1	Rattus norvegicus	22-27
12717439-2	2003	We report that checkpoint kinase 2 (Chk2) regulates E2F-1 activity in response to the DNA-damaging agent etoposide.	Etoposide	105-114	checkpoint kinase 2	Homo sapiens	15-34
12717439-2	2003	We report that checkpoint kinase 2 (Chk2) regulates E2F-1 activity in response to the DNA-damaging agent etoposide.	Etoposide	105-114	checkpoint kinase 2	Homo sapiens	36-40
12717439-2	2003	We report that checkpoint kinase 2 (Chk2) regulates E2F-1 activity in response to the DNA-damaging agent etoposide.	Etoposide	105-114	E2F transcription factor 1	Homo sapiens	52-57
12717439-5	2003	Moreover, E2F-1 is resistant to induction by etoposide in tumour cells expressing mutant chk2.	Etoposide	45-54	E2F transcription factor 1	Homo sapiens	10-15
12717439-5	2003	Moreover, E2F-1 is resistant to induction by etoposide in tumour cells expressing mutant chk2.	Etoposide	45-54	checkpoint kinase 2	Homo sapiens	89-93
12703990-3	2003	This study was designed to investigate the experimental therapeutic effect of the combination of topoisomerase I inhibitor hydroxycamptothecin (HCPT) with topoisomerase II inhibitor etoposide (VP-16) on nasopharyngeal carcinoma (NPC), the effect of the combination of HCPT with VP-16 against NPC was studied in vitro and in vivo.	Etoposide	182-191	host cell factor C1	Homo sapiens	193-198
12576482-4	2003	Our data show that toxic stimuli, such as etoposide, significantly increased cyr61 mRNA levels in immortalized hippocampal progenitor (H19-7) cells.	Etoposide	42-51	cellular communication network factor 1	Rattus norvegicus	77-82
12576482-6	2003	To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested.	Etoposide	178-187	cellular communication network factor 1	Rattus norvegicus	56-61
12576482-6	2003	To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested.	Etoposide	178-187	mitogen-activated protein kinase 8	Rattus norvegicus	108-111
12576482-6	2003	To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested.	Etoposide	178-187	mitogen activated protein kinase 14	Rattus norvegicus	115-118
12576482-6	2003	To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested.	Etoposide	178-187	cellular communication network factor 1	Rattus norvegicus	147-152
12576482-7	2003	Transfection of the cells with a kinase-deficient mutant MEKK, an upstream activator of JNK, significantly decreased the cyr61 expression induced by etoposide.	Etoposide	149-158	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
12576482-7	2003	Transfection of the cells with a kinase-deficient mutant MEKK, an upstream activator of JNK, significantly decreased the cyr61 expression induced by etoposide.	Etoposide	149-158	cellular communication network factor 1	Rattus norvegicus	121-126
12576482-11	2003	Furthermore, the blockade of cyr61 gene expression using an antisense encoding cyr61 sequence significantly inhibited the cell death induced by etoposide.	Etoposide	144-153	cellular communication network factor 1	Rattus norvegicus	29-34
12576482-11	2003	Furthermore, the blockade of cyr61 gene expression using an antisense encoding cyr61 sequence significantly inhibited the cell death induced by etoposide.	Etoposide	144-153	cellular communication network factor 1	Rattus norvegicus	79-84
12673712-3	2003	This study updated the intergroup trial that compared the standard therapy of bleomycin, etoposide, and cisplatin (BEP) with etoposide, ifosfamide, and cisplatin (VIP) in advanced germ cell tumors and reanalyzed the results using the IGCCCG staging system.	Etoposide	125-134	vasoactive intestinal peptide	Homo sapiens	163-166
12673724-4	2003	METHODS: The authors conducted a Phase I study of temozolomide in combination with escalating doses of oral etoposide (VP-16) to determine the maximum tolerated doses of these two agents when given together.	Etoposide	108-117	host cell factor C1	Homo sapiens	119-124
12704006-4	2003	The BCRP-overexpressing tumor cells are resistant to mitoxantrone, adriamycin, daunorubicin, etoposide, topotecan and irinotecan, but lack resistance to paclitaxel and vincristine.	Etoposide	93-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	4-8
12684054-7	2003	Consistent with the drug-binding results, non-toxic concentrations of CHAPS and Brij35 reversed vincristine and etoposide (VP16) toxicity in MRP1 expressing cells.	Etoposide	112-121	ATP binding cassette subfamily C member 1	Homo sapiens	141-145
12684054-7	2003	Consistent with the drug-binding results, non-toxic concentrations of CHAPS and Brij35 reversed vincristine and etoposide (VP16) toxicity in MRP1 expressing cells.	Etoposide	123-127	ATP binding cassette subfamily C member 1	Homo sapiens	141-145
12703990-3	2003	This study was designed to investigate the experimental therapeutic effect of the combination of topoisomerase I inhibitor hydroxycamptothecin (HCPT) with topoisomerase II inhibitor etoposide (VP-16) on nasopharyngeal carcinoma (NPC), the effect of the combination of HCPT with VP-16 against NPC was studied in vitro and in vivo.	Etoposide	182-191	host cell factor C1	Homo sapiens	278-283
12679732-3	2003	Here, we show, in drug-sensitive lung cancer cells (A549, Calu-6 or NCI-H69), that exposure to cytotoxic drugs (taxol, doxorubicin or etoposide) is sufficient to strongly up-regulate caveolin 1 and 2 protein levels.	Etoposide	134-143	caveolin 1	Homo sapiens	183-193
12691917-0	2003	DR1-like element in human topoisomerase IIalpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand.	Etoposide	80-89	peroxisome proliferator activated receptor gamma	Homo sapiens	111-120
12656744-0	2003	Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.	Etoposide	23-32	host cell factor C1	Homo sapiens	34-39
12691917-1	2003	OBJECTIVE: The nuclear peroxisome proliferator-activated receptor gamma (PPARgamma) ligands may enhance the etoposide-induced apoptosis by modulating the topoisomerase (Topo) IIalpha expression through binding to direct repeat 1 (DR1)-like element.	Etoposide	108-117	peroxisome proliferator activated receptor gamma	Homo sapiens	23-71
12691917-1	2003	OBJECTIVE: The nuclear peroxisome proliferator-activated receptor gamma (PPARgamma) ligands may enhance the etoposide-induced apoptosis by modulating the topoisomerase (Topo) IIalpha expression through binding to direct repeat 1 (DR1)-like element.	Etoposide	108-117	peroxisome proliferator activated receptor gamma	Homo sapiens	73-82
12691917-2	2003	METHODS: To investigate the effect of etoposide-induced apoptosis by PPARgamma ligands, leukemia cell lines were treated with troglitazone and 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) in the presence of etoposide and studied about various biological responses.	Etoposide	38-47	peroxisome proliferator activated receptor gamma	Homo sapiens	69-78
12691917-3	2003	RESULTS: We found the enhancement of etoposide-induced apoptosis by PPARgamma ligands in several leukemia cell lines, which was dependent on the expression of PPARgamma and specific for TopoIIalpha inhibitor.	Etoposide	37-46	peroxisome proliferator activated receptor gamma	Homo sapiens	68-77
12691917-3	2003	RESULTS: We found the enhancement of etoposide-induced apoptosis by PPARgamma ligands in several leukemia cell lines, which was dependent on the expression of PPARgamma and specific for TopoIIalpha inhibitor.	Etoposide	37-46	peroxisome proliferator activated receptor gamma	Homo sapiens	159-168
12691917-7	2003	CONCLUSIONS: We conclude that the induction of TopoIIalpha expression by PPARgamma ligands via DR1-like site is an important mechanism for the enhancement of etoposide-induced apoptosis and a DR1-like site in TopoIIalpha promoter is involved in transcriptional regulation dependent on PPARgamma ligands and PPARgamma/RXRalpha heterodimer.	Etoposide	158-167	peroxisome proliferator activated receptor gamma	Homo sapiens	73-82
12594176-4	2003	Here, we show that overexpression of wild-type human TERT in HeLa cells, and in a cells lacking TERT but containing the telomerase RNA template, increases their resistance to apoptosis induced by the DNA damaging agent etoposide or the bacterial alkaloid staurosporine.	Etoposide	219-228	telomerase reverse transcriptase	Homo sapiens	53-57
12691917-7	2003	CONCLUSIONS: We conclude that the induction of TopoIIalpha expression by PPARgamma ligands via DR1-like site is an important mechanism for the enhancement of etoposide-induced apoptosis and a DR1-like site in TopoIIalpha promoter is involved in transcriptional regulation dependent on PPARgamma ligands and PPARgamma/RXRalpha heterodimer.	Etoposide	158-167	peroxisome proliferator activated receptor gamma	Homo sapiens	285-294
12691917-7	2003	CONCLUSIONS: We conclude that the induction of TopoIIalpha expression by PPARgamma ligands via DR1-like site is an important mechanism for the enhancement of etoposide-induced apoptosis and a DR1-like site in TopoIIalpha promoter is involved in transcriptional regulation dependent on PPARgamma ligands and PPARgamma/RXRalpha heterodimer.	Etoposide	158-167	peroxisome proliferator activated receptor gamma	Homo sapiens	285-294
12691917-7	2003	CONCLUSIONS: We conclude that the induction of TopoIIalpha expression by PPARgamma ligands via DR1-like site is an important mechanism for the enhancement of etoposide-induced apoptosis and a DR1-like site in TopoIIalpha promoter is involved in transcriptional regulation dependent on PPARgamma ligands and PPARgamma/RXRalpha heterodimer.	Etoposide	158-167	retinoid X receptor alpha	Homo sapiens	317-325
12755380-8	2003	RESULTS: Spleen cells from etoposide-treated mice secreted lower amounts of IL-6 and TNF as compared to the control animals.	Etoposide	27-36	interleukin 6	Mus musculus	76-80
12755380-8	2003	RESULTS: Spleen cells from etoposide-treated mice secreted lower amounts of IL-6 and TNF as compared to the control animals.	Etoposide	27-36	tumor necrosis factor	Mus musculus	85-88
12755380-9	2003	In addition, in vitro etoposide-exposed macrophages showed reduced capacity to produce TNF, IL-6 and MIP-1alpha.	Etoposide	22-31	tumor necrosis factor	Mus musculus	87-90
12755380-9	2003	In addition, in vitro etoposide-exposed macrophages showed reduced capacity to produce TNF, IL-6 and MIP-1alpha.	Etoposide	22-31	interleukin 6	Mus musculus	92-96
12755380-9	2003	In addition, in vitro etoposide-exposed macrophages showed reduced capacity to produce TNF, IL-6 and MIP-1alpha.	Etoposide	22-31	chemokine (C-C motif) ligand 3	Mus musculus	101-111
12649196-0	2003	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.	Etoposide	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
12731672-10	2003	The patient did not respond to combination chemotherapy consisting of vincristine, prednisolone, cyclophosphamide, L-asparaginase, and doxorubicin, but administration of etoposide resulted in complete remission.	Etoposide	170-179	asparaginase and isoaspartyl peptidase 1	Homo sapiens	115-129
12649196-8	2003	In contrast, use of GF120918 to inhibit P-gp in wild-type mice increased the plasma levels of etoposide after oral administration 4-5-fold.	Etoposide	94-103	phosphoglycolate phosphatase	Mus musculus	40-44
12618199-0	2003	Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential.	Etoposide	0-9	TNF superfamily member 10	Homo sapiens	69-124
12618199-0	2003	Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential.	Etoposide	0-9	TNF superfamily member 10	Homo sapiens	126-131
12618199-3	2003	In the present study, we examined whether etoposide sensitizes tumor cells with multiple-drug-resistance to TRAIL-induced apoptosis.	Etoposide	42-51	TNF superfamily member 10	Homo sapiens	108-113
12618199-7	2003	The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs.	Etoposide	120-129	TNF superfamily member 10	Homo sapiens	19-24
12618199-7	2003	The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs.	Etoposide	120-129	TNF superfamily member 10	Homo sapiens	36-41
12618199-7	2003	The density of the TRAIL-receptors (TRAIL-Rs) was not appreciably modulated by the etoposide treatment, suggesting that etoposide targets molecule(s) downstream of the TRAIL-Rs.	Etoposide	120-129	TNF superfamily member 10	Homo sapiens	36-41
12618199-8	2003	Regardless of the molecular mechanisms underlying the cell death, sequential treatment with etoposide and TRAIL could be useful in the design of treatment modalities for patients with SCC, especially those with elevated levels of Bcl-x(L).	Etoposide	92-101	BCL2 like 1	Homo sapiens	230-238
12646163-2	2003	In this report, we investigated the disappearance of tensin from cell adhesion sites of chicken embryonic fibroblast cells (CEFs) exposed to etoposide and demonstrated that loss of tensin from cell adhesions during etoposide-induced apoptosis may be due to degradation of tensin by caspase-3.	Etoposide	141-150	tensin 1	Gallus gallus	53-59
12646163-2	2003	In this report, we investigated the disappearance of tensin from cell adhesion sites of chicken embryonic fibroblast cells (CEFs) exposed to etoposide and demonstrated that loss of tensin from cell adhesions during etoposide-induced apoptosis may be due to degradation of tensin by caspase-3.	Etoposide	215-224	tensin 1	Gallus gallus	181-187
12646163-2	2003	In this report, we investigated the disappearance of tensin from cell adhesion sites of chicken embryonic fibroblast cells (CEFs) exposed to etoposide and demonstrated that loss of tensin from cell adhesions during etoposide-induced apoptosis may be due to degradation of tensin by caspase-3.	Etoposide	215-224	tensin 1	Gallus gallus	181-187
12646163-2	2003	In this report, we investigated the disappearance of tensin from cell adhesion sites of chicken embryonic fibroblast cells (CEFs) exposed to etoposide and demonstrated that loss of tensin from cell adhesions during etoposide-induced apoptosis may be due to degradation of tensin by caspase-3.	Etoposide	215-224	caspase 3	Gallus gallus	282-291
12569581-9	2003	FR901228 also effectively inhibited growth of etoposide-resistant UMCC-1/VP-16, irinotecan-resistant PC-6/SN2-5H and cisplatin-resistant H526/CDDP cells having decreased expression of hTERT mRNA and telomerase activity, as well as their parental cells.	Etoposide	46-55	host cell factor C1	Homo sapiens	66-78
12605983-14	2003	The HIF-1alpha antisense treatment exerted an oxygen-independent, and additive but not synergistic effect to the cytotoxicity of cisplatin, etoposide, and vincristine.	Etoposide	140-149	hypoxia inducible factor 1 subunit alpha	Homo sapiens	4-14
12649196-9	2003	It may thus be worthwhile to test inhibition of P-gp in humans to improve the oral availability of etoposide.	Etoposide	99-108	phosphoglycolate phosphatase	Homo sapiens	48-52
12649196-0	2003	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.	Etoposide	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-51
12649196-0	2003	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.	Etoposide	102-111	phosphoglycolate phosphatase	Mus musculus	154-168
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
12649196-4	2003	Transduced wild-type Bcrp1 cDNA mediated resistance to etoposide and teniposide in fibroblast lines and trans-epithelial etoposide transport in polarized Madin-Darby canine kidney II cells.	Etoposide	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
12649196-4	2003	Transduced wild-type Bcrp1 cDNA mediated resistance to etoposide and teniposide in fibroblast lines and trans-epithelial etoposide transport in polarized Madin-Darby canine kidney II cells.	Etoposide	121-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
14505429-7	2003	Analysis of the kinetics of apoptosis showed that caspase-3 activation was maximal at 8 h of etoposide or BFA treatment in the parotid cells and at 8-18 h in the submandibular cells.	Etoposide	93-102	caspase 3	Bos taurus	50-59
12700630-3	2003	Our results indicate that, while certain typical features of apoptosis induced by etoposide--namely classical morphological changes and the ability to degrade DNA into oligonucleosomal fragments - are caspase-3-dependent, loss of cell adhesion to plastic and the capacity to interact with, and to be phagocytosed by, human monocyte-derived macrophages - both by CD14-dependent and CD14-independent mechanisms--do not require caspase-3.	Etoposide	82-91	caspase 3	Homo sapiens	201-210
12700630-3	2003	Our results indicate that, while certain typical features of apoptosis induced by etoposide--namely classical morphological changes and the ability to degrade DNA into oligonucleosomal fragments - are caspase-3-dependent, loss of cell adhesion to plastic and the capacity to interact with, and to be phagocytosed by, human monocyte-derived macrophages - both by CD14-dependent and CD14-independent mechanisms--do not require caspase-3.	Etoposide	82-91	CD14 molecule	Homo sapiens	362-366
12700630-3	2003	Our results indicate that, while certain typical features of apoptosis induced by etoposide--namely classical morphological changes and the ability to degrade DNA into oligonucleosomal fragments - are caspase-3-dependent, loss of cell adhesion to plastic and the capacity to interact with, and to be phagocytosed by, human monocyte-derived macrophages - both by CD14-dependent and CD14-independent mechanisms--do not require caspase-3.	Etoposide	82-91	CD14 molecule	Homo sapiens	381-385
12700630-3	2003	Our results indicate that, while certain typical features of apoptosis induced by etoposide--namely classical morphological changes and the ability to degrade DNA into oligonucleosomal fragments - are caspase-3-dependent, loss of cell adhesion to plastic and the capacity to interact with, and to be phagocytosed by, human monocyte-derived macrophages - both by CD14-dependent and CD14-independent mechanisms--do not require caspase-3.	Etoposide	82-91	caspase 3	Homo sapiens	425-434
12700630-4	2003	Furthermore, both etoposide-induced caspase-3-positive and -negative MCF-7 cells suppressed proinflammatory cytokine release by macrophages.	Etoposide	18-27	caspase 3	Homo sapiens	36-45
12700634-2	2003	IGF1 significantly suppressed etoposide-induced apoptosis, measured by caspase 3 activation and quantitation of cellular subG(1) DNA content, in rat parotid salivary acinar cells (C5).	Etoposide	30-39	insulin-like growth factor 1	Rattus norvegicus	0-4
12700634-2	2003	IGF1 significantly suppressed etoposide-induced apoptosis, measured by caspase 3 activation and quantitation of cellular subG(1) DNA content, in rat parotid salivary acinar cells (C5).	Etoposide	30-39	caspase 3	Rattus norvegicus	71-80
12700634-3	2003	Transduction of C5 cells with an adenovirus expressing a constitutively activated mutant of Akt-suppressed etoposide-induced apoptosis, whereas a kinase-inactive mutant of Akt suppressed the protective effect of IGF1.	Etoposide	107-116	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
12700634-5	2003	EGF was unable to suppress apoptosis induced by etoposide, but was able to synergize with IGF1 to further suppress caspase 3 activation and DNA cleavage after etoposide treatment.	Etoposide	159-168	epidermal growth factor	Rattus norvegicus	0-3
12700634-5	2003	EGF was unable to suppress apoptosis induced by etoposide, but was able to synergize with IGF1 to further suppress caspase 3 activation and DNA cleavage after etoposide treatment.	Etoposide	159-168	insulin-like growth factor 1	Rattus norvegicus	90-94
12644023-0	2003	Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide.	Etoposide	122-131	CD34 molecule	Homo sapiens	97-101
12644023-2	2003	Here we sought to systematically evaluate the basic molecular components and main pathways that govern and mediate cellular response initiated within human CD34(+) cells to etoposide-induced apoptosis.	Etoposide	173-182	CD34 molecule	Homo sapiens	156-160
12644023-5	2003	RESULTS: We identified a set of apoptosis-related genes expressed in highly purified normal human CB CD34(+) cells and determined how the expression of these genes changed in response to etoposide treatment.	Etoposide	187-196	CD34 molecule	Homo sapiens	101-105
12644023-8	2003	CONCLUSION: p53, c-Myc, and BAFF pathways are main pathways utilized by CD34(+) cells to arrest cell-cycle progression at multiple checkpoints, to halt proliferation, and to induce apoptosis as part of their cellular response to etoposide.	Etoposide	229-238	tumor protein p53	Homo sapiens	12-15
12644023-8	2003	CONCLUSION: p53, c-Myc, and BAFF pathways are main pathways utilized by CD34(+) cells to arrest cell-cycle progression at multiple checkpoints, to halt proliferation, and to induce apoptosis as part of their cellular response to etoposide.	Etoposide	229-238	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
12644023-8	2003	CONCLUSION: p53, c-Myc, and BAFF pathways are main pathways utilized by CD34(+) cells to arrest cell-cycle progression at multiple checkpoints, to halt proliferation, and to induce apoptosis as part of their cellular response to etoposide.	Etoposide	229-238	TNF superfamily member 13b	Homo sapiens	28-32
12644023-8	2003	CONCLUSION: p53, c-Myc, and BAFF pathways are main pathways utilized by CD34(+) cells to arrest cell-cycle progression at multiple checkpoints, to halt proliferation, and to induce apoptosis as part of their cellular response to etoposide.	Etoposide	229-238	CD34 molecule	Homo sapiens	72-76
12644023-9	2003	Multiple known pro-survival and pro-apoptotic pathways are simultaneously activated in etoposide-treated CD34(+) cells.	Etoposide	87-96	CD34 molecule	Homo sapiens	105-109
12657726-1	2003	The multidrug resistance-associated protein 1 (ABCC1) gene from human (hMRP1), dog (canMRP1), and mouse (muMRP1) all encode proteins that efficiently transport the endogenous MRP1 substrate glutathione-S-leukotriene C(4) and confer resistance to anticancer agents, including vincristine and etoposide.	Etoposide	291-300	ATP binding cassette subfamily C member 1	Homo sapiens	4-45
12657726-1	2003	The multidrug resistance-associated protein 1 (ABCC1) gene from human (hMRP1), dog (canMRP1), and mouse (muMRP1) all encode proteins that efficiently transport the endogenous MRP1 substrate glutathione-S-leukotriene C(4) and confer resistance to anticancer agents, including vincristine and etoposide.	Etoposide	291-300	ATP binding cassette subfamily C member 1	Homo sapiens	47-52
12657726-1	2003	The multidrug resistance-associated protein 1 (ABCC1) gene from human (hMRP1), dog (canMRP1), and mouse (muMRP1) all encode proteins that efficiently transport the endogenous MRP1 substrate glutathione-S-leukotriene C(4) and confer resistance to anticancer agents, including vincristine and etoposide.	Etoposide	291-300	ATP binding cassette subfamily C member 1	Homo sapiens	71-76
12657726-1	2003	The multidrug resistance-associated protein 1 (ABCC1) gene from human (hMRP1), dog (canMRP1), and mouse (muMRP1) all encode proteins that efficiently transport the endogenous MRP1 substrate glutathione-S-leukotriene C(4) and confer resistance to anticancer agents, including vincristine and etoposide.	Etoposide	291-300	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	72-76
12511567-8	2003	However, cells with excess Smac protein were greatly sensitized to apoptotic triggers such as etoposide exposure.	Etoposide	94-103	diablo IAP-binding mitochondrial protein	Homo sapiens	27-31
12606765-2	2003	The administration of the H(2)O(2)-specific scavenger catalase attenuated the generation of apoptosis by the antitumor drugs etoposide, camptothecin, doxorubicin, and cisplatin in U-937 human promonocytic cells.	Etoposide	125-134	catalase	Homo sapiens	54-62
12581860-6	2003	The DNA damaging agents camptothecin and etoposide enhanced IFN-gamma-induced NO production and showed I-kappaB degradation, indicating that the increase in NO production was due to direct DNA damage.	Etoposide	41-50	interferon gamma	Mus musculus	60-69
12475977-7	2003	NFBD1 foci are also detected in response to camptothecin, etoposide, and methylmethanesulfonate treatments.	Etoposide	58-67	mediator of DNA damage checkpoint 1	Homo sapiens	0-5
12566077-7	2003	In comparison, Bcl-2 overexpression drastically reduced apoptotic DNA fragmentation by etoposide, acting via topoisomerase II-mediated DNA damage, but had no effect on apoptotic DNA fragmentation by helenalin A, which reacts with proteins but not DNA.	Etoposide	87-96	BCL2 apoptosis regulator	Homo sapiens	15-20
12468545-5	2003	After treatment with Vp16 or mitomycin C, control cells underwent apoptosis in a p53-dependent manner; however, overexpression of catalase inhibited this apoptosis.	Etoposide	21-25	tumor protein p53	Homo sapiens	81-84
12468545-5	2003	After treatment with Vp16 or mitomycin C, control cells underwent apoptosis in a p53-dependent manner; however, overexpression of catalase inhibited this apoptosis.	Etoposide	21-25	catalase	Homo sapiens	130-138
12458215-6	2003	Furthermore, activation of pro-death IRES during the etoposide-induced apoptosis is caspase-dependent and correlates with the expression of apoptotic fragments of two members of the eIF4G translation initiation factor family, p97/DAP5/NAT1 and eIF4GI.	Etoposide	53-62	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	226-229
12458215-6	2003	Furthermore, activation of pro-death IRES during the etoposide-induced apoptosis is caspase-dependent and correlates with the expression of apoptotic fragments of two members of the eIF4G translation initiation factor family, p97/DAP5/NAT1 and eIF4GI.	Etoposide	53-62	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	230-234
12458215-6	2003	Furthermore, activation of pro-death IRES during the etoposide-induced apoptosis is caspase-dependent and correlates with the expression of apoptotic fragments of two members of the eIF4G translation initiation factor family, p97/DAP5/NAT1 and eIF4GI.	Etoposide	53-62	N-acetyltransferase 1	Homo sapiens	235-239
12458215-6	2003	Furthermore, activation of pro-death IRES during the etoposide-induced apoptosis is caspase-dependent and correlates with the expression of apoptotic fragments of two members of the eIF4G translation initiation factor family, p97/DAP5/NAT1 and eIF4GI.	Etoposide	53-62	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	244-250
12536201-8	2003	Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.	Etoposide	118-127	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	18-23
12569391-3	2003	We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G(2)-M arrest mediated by the antineoplastic agent etoposide.	Etoposide	146-155	dipeptidyl peptidase 4	Homo sapiens	31-35
12569391-3	2003	We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G(2)-M arrest mediated by the antineoplastic agent etoposide.	Etoposide	146-155	dipeptidyl peptidase 4	Homo sapiens	36-41
12569391-3	2003	We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G(2)-M arrest mediated by the antineoplastic agent etoposide.	Etoposide	146-155	dipeptidyl peptidase 4	Homo sapiens	66-70
12569391-4	2003	The increased sensitivity to etoposide-induced G(2)-M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34(cdc2) kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression.	Etoposide	29-38	alpha and gamma adaptin binding protein	Homo sapiens	156-159
12569391-4	2003	The increased sensitivity to etoposide-induced G(2)-M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34(cdc2) kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression.	Etoposide	29-38	cyclin dependent kinase 1	Homo sapiens	160-164
12569391-4	2003	The increased sensitivity to etoposide-induced G(2)-M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34(cdc2) kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression.	Etoposide	29-38	cell division cycle 25C	Homo sapiens	184-190
12569391-4	2003	The increased sensitivity to etoposide-induced G(2)-M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34(cdc2) kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression.	Etoposide	29-38	cyclin B1	Homo sapiens	241-250
12569391-5	2003	CD26/DPPIV-associated enhancement of doxorubicin and etoposide-induced G(2)-M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors.	Etoposide	53-62	dipeptidyl peptidase 4	Homo sapiens	0-4
12569391-5	2003	CD26/DPPIV-associated enhancement of doxorubicin and etoposide-induced G(2)-M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors.	Etoposide	53-62	dipeptidyl peptidase 4	Homo sapiens	5-10
12569391-5	2003	CD26/DPPIV-associated enhancement of doxorubicin and etoposide-induced G(2)-M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors.	Etoposide	53-62	dipeptidyl peptidase 4	Homo sapiens	148-152
12536201-8	2003	Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.	Etoposide	118-127	BCL2 apoptosis regulator	Homo sapiens	28-33
12504087-2	2003	We have previously shown that the cells become resistant to topoisomerase II alpha (topo II alpha) targeted cancer chemotherapeutic drug such as etoposide (VP-16) when GRP78 is up-regulated by various means.	Etoposide	145-154	endoplasmic reticulum chaperone BiP	Cricetulus griseus	168-173
12581564-10	2003	In conclusion, aside classical variables such as age and performance status, high serum CYFRA 21-1 and high serum CgA level in SCLC are both prognostic determinants of prognosis, in particular in patients receiving conventional chemotherapy consisting of cisplatin and etoposide-based combinations.	Etoposide	269-278	chromogranin A	Homo sapiens	114-117
12527362-0	2003	Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death.	Etoposide	95-104	BCL2 like 13	Homo sapiens	0-9
12504087-2	2003	We have previously shown that the cells become resistant to topoisomerase II alpha (topo II alpha) targeted cancer chemotherapeutic drug such as etoposide (VP-16) when GRP78 is up-regulated by various means.	Etoposide	156-161	endoplasmic reticulum chaperone BiP	Cricetulus griseus	168-173
12504087-5	2003	However, mechanisms of association of GRP78 up-regulation and resistance to VP-16 remained obscured under the conditions outlined above.	Etoposide	76-81	endoplasmic reticulum chaperone BiP	Cricetulus griseus	38-43
12736226-0	2003	Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin"s lymphoma.	Etoposide	62-71	carboxylesterase 2	Homo sapiens	75-78
12509267-10	2003	p53 deficient cells were cross-resistant to another topoisomerase II inhibitor etoposide, which also provoked increased DNA strand breakage in p53 wt cells.	Etoposide	79-88	tumor protein p53	Homo sapiens	0-3
12509267-10	2003	p53 deficient cells were cross-resistant to another topoisomerase II inhibitor etoposide, which also provoked increased DNA strand breakage in p53 wt cells.	Etoposide	79-88	tumor protein p53	Homo sapiens	143-146
12579475-0	2003	Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-96
14695446-9	2003	The Cdk2 inhibitor, roscovitine, decreased the resistance to apoptosis on etoposide-treated UMG1-2.	Etoposide	74-83	cyclin dependent kinase 2	Homo sapiens	4-8
12542493-7	2003	Also, there was an upregulation in tissue factor (TF) mRNA expression in etoposide-, methotrexate- and vincristine-treated monolayers compared with controls, as well as an upregulation in TF protein production in vincristine-treated cells.	Etoposide	73-82	coagulation factor III, tissue factor	Homo sapiens	35-48
12542493-7	2003	Also, there was an upregulation in tissue factor (TF) mRNA expression in etoposide-, methotrexate- and vincristine-treated monolayers compared with controls, as well as an upregulation in TF protein production in vincristine-treated cells.	Etoposide	73-82	coagulation factor III, tissue factor	Homo sapiens	50-52
12538359-6	2003	Microsatellite analysis of Aprt mutant clones indicated a dominant role for mitotic recombination (MR) in generating spontaneous, DMBA- and etoposide-induced LOH at APRT: However, over 80% of the MMC-induced Aprt LOH mutants had lost heterozygosity for all markers tested, suggesting that either the crossover points were located close to the centromere or that these mutants arose by chromosome loss and duplication of the remaining chromosome 8.	Etoposide	140-149	adenine phosphoribosyl transferase	Mus musculus	165-169
12551835-0	2003	Contribution of the induction of heme oxygenase-1 to etoposide-induced apoptosis in acute myeloblastic leukemia.	Etoposide	53-62	heme oxygenase 1	Homo sapiens	33-49
14695446-0	2003	Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation.	Etoposide	76-85	cyclin dependent kinase 2	Homo sapiens	109-113
14695446-8	2003	Cellular expression of Cdk2 was increased in UMG1- 2 after etoposide treatment while the expression of E2F-1 in UMG1-2 was decreased as compared with that in U373MG.	Etoposide	59-68	cyclin dependent kinase 2	Homo sapiens	23-27
15314975-0	2003	Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.	Etoposide	121-130	cyclin dependent kinase inhibitor 1A	Homo sapiens	14-17
15314976-0	2003	Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.	Etoposide	112-119	tumor protein p53	Homo sapiens	14-17
12621489-0	2003	Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
12546364-8	2003	The LY294002 significantly augmented the cytotoxicity induced by etoposide in PTEN-deficient cells, but not in PTEN-wt cells.	Etoposide	65-74	phosphatase and tensin homolog	Homo sapiens	78-82
12529653-6	2003	K562 cells transfected with the mutated SHIP-V684E cDNA showed a growth advantage even at lower serum concentrations and resistance to apoptosis induced by serum deprivation and exposure to etoposide.	Etoposide	190-199	inositol polyphosphate-5-phosphatase D	Homo sapiens	40-44
12835511-2	2003	Here we present evidence obtained in studies of adult mice and neuronal cell cultures showing that p53 protein is present in synapses where its level and amount of phosphorylation are increased following exposure of the cells to the DNA-damaging agent etoposide.	Etoposide	252-261	transformation related protein 53, pseudogene	Mus musculus	99-102
12835511-4	2003	Increased levels of p53 also precede loss of synapsin I immunoreactive terminals in cultured hippocampal neurons exposed to etoposide.	Etoposide	124-133	transformation related protein 53, pseudogene	Mus musculus	20-23
12835511-4	2003	Increased levels of p53 also precede loss of synapsin I immunoreactive terminals in cultured hippocampal neurons exposed to etoposide.	Etoposide	124-133	synapsin I	Mus musculus	45-55
12835511-6	2003	Finally, we show that a synthetic inhibitor of p53 (PFT-alpha) protects synaptosomes from wild-type mice against oxidative and excitotoxic injuries, and preserves presynaptic terminals in cultured hippocampal neurons exposed to etoposide.	Etoposide	228-237	transformation related protein 53, pseudogene	Mus musculus	47-50
12688678-11	2003	Surprisingly, our studies have shown that HL-60/MX2 cell line and also THP-1 cell line, resistant to etoposide, were susceptible to methyl- and methoxy-substituted indolo[2,3-b]quinoline derivatives.	Etoposide	101-110	MX dynamin like GTPase 2	Homo sapiens	48-51
12688678-11	2003	Surprisingly, our studies have shown that HL-60/MX2 cell line and also THP-1 cell line, resistant to etoposide, were susceptible to methyl- and methoxy-substituted indolo[2,3-b]quinoline derivatives.	Etoposide	101-110	GLI family zinc finger 2	Homo sapiens	71-76
14586153-3	2003	The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy.	Etoposide	15-24	host cell factor C1	Homo sapiens	26-31
12169392-0	2002	Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells.	Etoposide	26-35	caspase 2	Homo sapiens	43-52
12683237-0	2003	[Effect of etoposide and amsacrine on mitotic progression of GM-130 and Hep-2 cell lines.	Etoposide	11-20	golgin A2	Homo sapiens	61-67
12683237-2	2003	It has been shown that inhibitors of topoisomerase II (topo II) etoposide and amsacrine results in accumulation of GM-130 and Hep-2 cells with 4c DNA amount.	Etoposide	64-73	golgin A2	Homo sapiens	115-121
12683237-5	2003	GM-130 and Hep-2 cells that were first blocked and then washed from nocodazole, and after that treated with 50 microM etoposide or 20 microM amsacrine, were shown to enter pseudo-G1 with 4c DNA amount per cell.	Etoposide	118-127	golgin A2	Homo sapiens	0-6
12504573-3	2002	Using the epithelial cell line HeLa in which the expression of LMP1 is inducibly regulated by tetracycline, we demonstrate that apoptosis triggered by ligation of the death receptor, Fas, or by the chemotherapeutic agent, etoposide, is potentiated by LMP1.	Etoposide	222-231	PDZ and LIM domain 7	Homo sapiens	63-67
12520735-1	2002	BACKGROUND &amp; OBJECTIVE: The previous study has identified two novel antisense oligonucleotides (AS-ODN) of new target point in the translation initiation and the coding region of bcl-2 mRNA that could increase the sensitivity of HL-60 and K562 cells lines to etoposide, daunorubicin, and araninosyl cytosine (Ara-C).	Etoposide	263-272	BCL2 apoptosis regulator	Homo sapiens	183-188
12520751-1	2002	BACKGROUND &amp; OBJECTIVE: EP regimen[etoposide (VP-16) + cisplatin (DDP)] is a standard regimen for treatment of small cell lung cancer (SCLC), but the cure rate is still low.	Etoposide	39-48	host cell factor C1	Homo sapiens	50-55
12426377-2	2002	Here we show that PKCdelta is imported into the nucleus of etoposide-treated cells, that nuclear import is required for apoptosis and that it is mediated by a nuclear localization signal (NLS) in the C-terminus of PKCdelta.	Etoposide	59-68	protein kinase C delta	Homo sapiens	18-26
12426377-2	2002	Here we show that PKCdelta is imported into the nucleus of etoposide-treated cells, that nuclear import is required for apoptosis and that it is mediated by a nuclear localization signal (NLS) in the C-terminus of PKCdelta.	Etoposide	59-68	protein kinase C delta	Homo sapiens	214-222
12420214-3	2002	Induction of IRF-1 protein by either ionizing radiation (IR) or etoposide occurs through a concerted mechanism involving increased IRF-1 expression/synthesis and an increase in the half-life of the IRF-1 protein.	Etoposide	64-73	interferon regulatory factor 1	Homo sapiens	13-18
12420214-3	2002	Induction of IRF-1 protein by either ionizing radiation (IR) or etoposide occurs through a concerted mechanism involving increased IRF-1 expression/synthesis and an increase in the half-life of the IRF-1 protein.	Etoposide	64-73	interferon regulatory factor 1	Homo sapiens	131-136
12420214-3	2002	Induction of IRF-1 protein by either ionizing radiation (IR) or etoposide occurs through a concerted mechanism involving increased IRF-1 expression/synthesis and an increase in the half-life of the IRF-1 protein.	Etoposide	64-73	interferon regulatory factor 1	Homo sapiens	131-136
12359364-4	2002	Overexpression of PPT1 protected against apoptosis induced by etoposide and the ketoamide and the inhibitory effect of the two was additive.	Etoposide	62-71	palmitoyl-protein thioesterase 1	Homo sapiens	18-22
12460902-7	2002	Furthermore, we found that PARP-DBD sensitized LNCaP cells to DNA-damaging agents, such as ionizing radiation and etoposide.	Etoposide	114-123	poly(ADP-ribose) polymerase 1	Homo sapiens	27-35
12460902-8	2002	Androgen (R1881) -dependent stimulation of PARP-DBD expression resulted in a 2-fold growth inhibition in LNCaP cells as compared with controls, and an augmented apoptotic cell death in response to ionizing radiation or etoposide.	Etoposide	219-228	poly(ADP-ribose) polymerase 1	Homo sapiens	43-51
12424735-6	2002	We found that etoposide increases the activation of p42 and p44 mitogen-activated protein (MAP) kinases, and that activation of the MAP kinases by etoposide requires AMPA receptor activation.	Etoposide	14-23	erythrocyte membrane protein band 4.2	Homo sapiens	52-55
12424735-6	2002	We found that etoposide increases the activation of p42 and p44 mitogen-activated protein (MAP) kinases, and that activation of the MAP kinases by etoposide requires AMPA receptor activation.	Etoposide	14-23	interferon induced protein 44	Homo sapiens	60-63
12424735-7	2002	Pharmacological blockade of AMPA receptors and p42/p44 MAP kinases, but not of NMDA receptors, exacerbated etoposide-induced cell death.	Etoposide	107-116	erythrocyte membrane protein band 4.2	Homo sapiens	47-50
12424735-7	2002	Pharmacological blockade of AMPA receptors and p42/p44 MAP kinases, but not of NMDA receptors, exacerbated etoposide-induced cell death.	Etoposide	107-116	interferon induced protein 44	Homo sapiens	51-54
12424735-8	2002	These findings suggest that, although etoposide is neurotoxic, it also activates a cell survival pathway involving AMPA receptor-mediated activation of p42/p44 MAP kinases.	Etoposide	38-47	erythrocyte membrane protein band 4.2	Homo sapiens	152-155
12424735-8	2002	These findings suggest that, although etoposide is neurotoxic, it also activates a cell survival pathway involving AMPA receptor-mediated activation of p42/p44 MAP kinases.	Etoposide	38-47	interferon induced protein 44	Homo sapiens	156-159
12516967-12	2002	Thus, canMRP1 is similar to MRP1 in conferring resistance to vincristine and etoposide, transporting calcein-a.m., and being inhibited by LY402913.	Etoposide	77-86	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
12218061-3	2002	Here we demonstrate that the first 4-8 N-terminal amino acids of Smac/DIABLO fused to the Drosophila antennapaedia penetratin sequence, a carrier peptide, enhance the induction of apoptosis and long term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in MCF-7 breast cancer cells.	Etoposide	285-294	diablo	Drosophila melanogaster	65-69
12218061-3	2002	Here we demonstrate that the first 4-8 N-terminal amino acids of Smac/DIABLO fused to the Drosophila antennapaedia penetratin sequence, a carrier peptide, enhance the induction of apoptosis and long term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in MCF-7 breast cancer cells.	Etoposide	285-294	diablo	Drosophila melanogaster	70-76
12169392-1	2002	Etoposide (VP-16) is an anticancer agent that induces apoptosis in human leukemic cell lines such as U937 and HL60.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
12553012-2	2002	Over-expression of Bcl-xl inhibits apoptotic changes induced by Etoposide including cytochrome-c release, caspase-3 activation and DNA fragmentation.	Etoposide	64-73	BCL2 like 1	Homo sapiens	19-25
12553012-3	2002	However, Etoposide treatment resulted in cell death in U937 cells over-expressing Bcl-xl, which had a necrotic-like phenotype with no evidence of caspase-3 activation.	Etoposide	9-18	BCL2 like 1	Homo sapiens	82-88
12553001-0	2002	DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.	Etoposide	32-41	cyclin dependent kinase inhibitor 1A	Homo sapiens	51-63
12553001-0	2002	DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.	Etoposide	32-41	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-96
12642689-2	2002	We have observed that exogenous expression of MRITalpha1/cFLIP(L) isoform also protects against cell death induced by a diverse group of chemotherapeutic drugs with different mechanisms of action, including doxorubicin, etoposide, cytosine arabinoside, daunorubicin, chlorambucil and cisplatin.	Etoposide	220-229	CASP8 and FADD like apoptosis regulator	Homo sapiens	57-62
12553001-2	2002	To investigate the mechanism by which etoposide acts as an anticancer agent, the relationship between p21WAF1/CIP1 (p21) and c-Myc was studied.	Etoposide	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-114
12553001-2	2002	To investigate the mechanism by which etoposide acts as an anticancer agent, the relationship between p21WAF1/CIP1 (p21) and c-Myc was studied.	Etoposide	38-47	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-105
12553001-2	2002	To investigate the mechanism by which etoposide acts as an anticancer agent, the relationship between p21WAF1/CIP1 (p21) and c-Myc was studied.	Etoposide	38-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	125-130
12553001-7	2002	RESULTS: Ectopic c-Myc-expressing K562 (K562/c-Myc) cells showed more extensive apoptosis than K562 cells after continuous exposure to 200 microM etoposide for 24 hours.	Etoposide	146-155	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
12553001-7	2002	RESULTS: Ectopic c-Myc-expressing K562 (K562/c-Myc) cells showed more extensive apoptosis than K562 cells after continuous exposure to 200 microM etoposide for 24 hours.	Etoposide	146-155	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	45-50
12553001-9	2002	Etoposide activated the p21 promoter in a concentration-dependent manner, and etoposide-induced luciferase activity was suppressed by co-transfection of c-Myc.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	24-27
12553001-9	2002	Etoposide activated the p21 promoter in a concentration-dependent manner, and etoposide-induced luciferase activity was suppressed by co-transfection of c-Myc.	Etoposide	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	153-158
12414644-5	2002	Analysis of the drug sensitivity of MRP6-transfected cells revealed low levels of resistance to several natural product agents, including etoposide, teniposide, doxorubicin, and daunorubicin.	Etoposide	138-147	ATP binding cassette subfamily C member 6	Homo sapiens	36-40
12370750-4	2002	The HCT-8DDP/anti-MRP Rz cells were more sensitive to doxorubicin (DOX) and etoposide (VP-16) by 2.5- and 4.1-fold, respectively, compared with HCT-8DDP cells.	Etoposide	76-85	ATP binding cassette subfamily C member 3	Homo sapiens	18-21
12370750-4	2002	The HCT-8DDP/anti-MRP Rz cells were more sensitive to doxorubicin (DOX) and etoposide (VP-16) by 2.5- and 4.1-fold, respectively, compared with HCT-8DDP cells.	Etoposide	76-85	host cell factor C1	Homo sapiens	87-92
12370759-9	2002	We also observed enhanced induction of apoptosis by chemotherapeutic reagents, including cisplatin, docetaxel and etoposide, in DN-hTERT-expressing A549 cells, as compared with WT-hTERT-expressing cells.	Etoposide	114-123	telomerase reverse transcriptase	Homo sapiens	131-136
12370759-9	2002	We also observed enhanced induction of apoptosis by chemotherapeutic reagents, including cisplatin, docetaxel and etoposide, in DN-hTERT-expressing A549 cells, as compared with WT-hTERT-expressing cells.	Etoposide	114-123	telomerase reverse transcriptase	Homo sapiens	180-185
12410562-6	2002	BRCA2 mRNA levels were upregulated in thymocytes treated with the DNA-damaging agent etoposide.	Etoposide	85-94	BRCA2 DNA repair associated	Homo sapiens	0-5
12533044-4	2002	JM-1, SUP-B 15 and RS4 leukemic cell lines cleaved Bcl-2 to its 23 kDa form when exposed to the chemotherapeutic agents 1-beta-D-arabinofuranosyl-cytosine (Ara-C) or etoposide (VP-16).	Etoposide	166-175	BCL2 apoptosis regulator	Homo sapiens	51-56
12410562-9	2002	Thymocytes from these Brca2(Delta27/Delta27) mice displayed decreased apoptosis in response to etoposide-induced DNA damage compared with wild-type thymocytes.	Etoposide	95-104	breast cancer 2, early onset	Mus musculus	22-27
12677090-10	2002	Etoposide, cisplatin (CIS), and 5-fluorouracil (5-FU) showed the least cooperation (&lt;or=11.5% over the additive single therapy values) with E2F-1.	Etoposide	0-9	E2F transcription factor 1	Homo sapiens	143-148
12489056-7	2002	A prospective trial of 2 cycles of etoposide plus cisplatin adjuvant chemotherapy for patients with pN2 tumors showed that this regimen was highly effective in achieving relapse-free survival.	Etoposide	35-44	amyloid beta precursor protein	Homo sapiens	100-103
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Etoposide	249-258	E2F transcription factor 1	Homo sapiens	3-8
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Etoposide	249-258	cyclin A2	Homo sapiens	57-65
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Etoposide	249-258	cyclin A2	Homo sapiens	169-177
12384553-0	2002	An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents.	Etoposide	144-153	X-ray repair cross complementing 5	Homo sapiens	47-51
12434296-5	2002	We report that lack of the Pms2 gene is associated with an increased sensitivity, ranging from 2-6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin, etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the antimetabolite gemcitabine.	Etoposide	192-201	PMS1 homolog 2, mismatch repair system component	Homo sapiens	27-31
12384553-5	2002	Moreover, transfection of M059K cells with Ku86 antisense ASOs markedly increased cell death after treatment with ionizing radiation, bleomycin, and etoposide.	Etoposide	149-158	X-ray repair cross complementing 5	Homo sapiens	43-47
12384553-7	2002	As expected, transfection of M059J cells with Ku86 antisense ASOs did not result in any sensitization to ionizing radiation, bleomycin, or DNA cross-linking agents, but there was a 2-fold increase in sensitivity to etoposide.	Etoposide	215-224	X-ray repair cross complementing 5	Homo sapiens	46-50
12207174-12	2002	Finally blockage of NFkappaB activation eliminates the synergistic apoptotic response of TRAIL and etoposide.	Etoposide	99-108	nuclear factor kappa B subunit 1	Homo sapiens	20-28
12207175-2	2002	Here we report that overexpression of Je2 in CEM-C7 T-cell line is able to suppress CD95-mediated apoptosis, and apoptosis induced by TNFalpha and the glucocorticoid analogue dexamethasone, but was not able to suppress death induced by the topoisomerase II inhibitor etoposide.	Etoposide	267-276	Fas cell surface death receptor	Homo sapiens	84-88
12207175-2	2002	Here we report that overexpression of Je2 in CEM-C7 T-cell line is able to suppress CD95-mediated apoptosis, and apoptosis induced by TNFalpha and the glucocorticoid analogue dexamethasone, but was not able to suppress death induced by the topoisomerase II inhibitor etoposide.	Etoposide	267-276	tumor necrosis factor	Homo sapiens	134-142
12391694-4	2002	They underwent 2 courses of systemic chemotherapy [cisplatin (CDDP) + etoposide (VP-16)] with concurrent radiotherapy (40 Gy).	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
12239596-0	2002	The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.	Etoposide	104-113	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-21
12417047-3	2002	We found that the overexpression of FADD sensitizes etoposide-induced apoptosis through a rapid activation of c-Jun NH(2)-terminal kinase (JNK) and, subsequently, of caspase 3.	Etoposide	52-61	mitogen-activated protein kinase 8	Homo sapiens	110-137
12417047-3	2002	We found that the overexpression of FADD sensitizes etoposide-induced apoptosis through a rapid activation of c-Jun NH(2)-terminal kinase (JNK) and, subsequently, of caspase 3.	Etoposide	52-61	mitogen-activated protein kinase 8	Homo sapiens	139-142
12417047-3	2002	We found that the overexpression of FADD sensitizes etoposide-induced apoptosis through a rapid activation of c-Jun NH(2)-terminal kinase (JNK) and, subsequently, of caspase 3.	Etoposide	52-61	caspase 3	Homo sapiens	166-175
12220664-0	2002	Caspase activation in etoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion.	Etoposide	22-31	mitogen-activated protein kinase 1	Mus musculus	69-72
12417047-7	2002	Interestingly, FADD was phosphorylated, and etoposide-induced JNK/caspase activation and apoptosis were enhanced in the cells arrested at G2/M transition, but not in those overexpressing mutant FADD, in which 194 serine was replaced by alanine.	Etoposide	44-53	mitogen-activated protein kinase 8	Homo sapiens	62-65
12417047-8	2002	Our results demonstrate that phosphorylated FADD-dependent activation of the JNK/caspase pathway plays a pivotal role in sensitization to etoposide-induced apoptosis in prostate cancer cells.	Etoposide	138-147	mitogen-activated protein kinase 8	Homo sapiens	77-80
12389116-14	2002	Etoposide and vinblastine were found to effectively inactivate the androgen-independent cell lines, in which p53 is dysfunctional.	Etoposide	0-9	tumor protein p53	Homo sapiens	109-112
12242663-4	2002	Overexpression of kinase inactive MEKK1 inhibits MEKK1-mediated apoptosis and effectively blocks death receptor upregulation following etoposide treatment.	Etoposide	135-144	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	34-39
12121973-6	2002	Importantly, forced expression of PKC-epsilon in NCI-H82 human SCLC cells confers a significant resistance to the chemotherapeutic drugs, etoposide and doxorubicin.	Etoposide	138-147	protein kinase C epsilon	Homo sapiens	34-45
12121973-8	2002	Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	32-41	cytochrome c, somatic	Homo sapiens	110-122
12121973-8	2002	Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	32-41	caspase 9	Homo sapiens	175-184
12121973-8	2002	Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	32-41	caspase 3	Homo sapiens	189-198
12121973-8	2002	Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	32-41	poly(ADP-ribose) polymerase 1	Homo sapiens	216-243
12121973-8	2002	Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	32-41	poly(ADP-ribose) polymerase 1	Homo sapiens	245-249
12121973-10	2002	Furthermore, caspase-specific inhibitors, z-VAD-fmk and z-DEVD-fmk, significantly attenuate the accumulation of sub-G(1) population and block the PARP cleavage in response to etoposide.	Etoposide	175-184	poly(ADP-ribose) polymerase 1	Homo sapiens	146-150
12121973-12	2002	Finally, down-regulation of PKC-epsilon expression by the antisense cDNA in NSCLC cells results in increased sensitivity to etoposide.	Etoposide	124-133	protein kinase C epsilon	Homo sapiens	28-39
12080052-5	2002	Here, we show that HEK-Trx2 cells are more resistant toward etoposide.	Etoposide	60-69	thioredoxin 2	Homo sapiens	19-27
12297287-4	2002	Cells expressing CD44 were significantly resistant to etoposide-induced apoptosis.	Etoposide	54-63	CD44 molecule (Indian blood group)	Homo sapiens	17-21
12220664-2	2002	Treatment of mouse fibroblasts with 20 microM etoposide elicited a sustained phosphorylation of ERK 1/2, that increased until 24 h from the treatment in parallel with caspase activity.	Etoposide	46-55	mitogen-activated protein kinase 3	Mus musculus	96-103
12220664-5	2002	In etoposide-treated cells, DFMO also abolished phosphorylation of c-Jun NH(2)-terminal kinases triggered by the drug.	Etoposide	3-12	jun proto-oncogene	Mus musculus	67-72
12220664-6	2002	Polyamine replenishment with exogenous putrescine restored the ability of the cells to undergo caspase activation and ERK 1/2 phosphorylation in response to etoposide.	Etoposide	157-166	mitogen-activated protein kinase 3	Mus musculus	118-125
12220664-7	2002	Ornithine decarboxylase activity decreased after etoposide, indicating that DFMO exerts its effect by depleting cellular polyamines before induction of apoptosis.	Etoposide	49-58	ornithine decarboxylase, structural 1	Mus musculus	0-23
12218384-8	2002	RESULTS: Ritonavir inhibited the functional activity of MRP-1 similarly to probenecid, as demonstrated by re-sensitization of MRP-1 over-expressing cells to cytotoxic effects of etoposide.	Etoposide	178-187	ATP binding cassette subfamily C member 1	Homo sapiens	56-61
12218384-8	2002	RESULTS: Ritonavir inhibited the functional activity of MRP-1 similarly to probenecid, as demonstrated by re-sensitization of MRP-1 over-expressing cells to cytotoxic effects of etoposide.	Etoposide	178-187	ATP binding cassette subfamily C member 1	Homo sapiens	126-131
12218384-10	2002	Other anti-HIV drugs didn"t affect the MRP-1 mediated efflux of etoposide.	Etoposide	64-73	ATP binding cassette subfamily C member 1	Homo sapiens	39-44
12127563-4	2002	The results presented here demonstrate that the treatment of Jurkat cells with the apoptosis inducers anti-Fas, TRAIL, staurosporine, and etoposide induces proteolytic fragments of beta-catenin, as did TRAIL and staurosporine in U937 cells.	Etoposide	138-147	catenin beta 1	Homo sapiens	181-193
12208754-4	2002	It is important that the expression of NLS-defective XAPC7 also diminished the induction of resistance to etoposide and doxorubicin, typical topoisomerase II-directed drugs.	Etoposide	106-115	proteasome 20S subunit alpha 7	Homo sapiens	53-58
12210605-6	2002	METHODS: Murine T-cell lymphoma YAC-1 cells were treated with etoposide to induce apoptosis.	Etoposide	62-71	ADP-ribosyltransferase 1	Mus musculus	32-37
12210605-7	2002	Etoposide-treated YAC-1 target cells were stained subsequently with 7-AAD and then coincubated with resident peritoneal macrophages to allow phagocytosis.	Etoposide	0-9	ADP-ribosyltransferase 1	Mus musculus	18-23
12209353-0	2002	The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.	Etoposide	118-127	host cell factor C1	Homo sapiens	129-134
12189165-5	2002	We demonstrate that, compared to normal controls, CLN3-deficient immortalization of lymphoblasts homozygous for this deletion grow at a slower rate, and show increased sensitivity to etoposide-induced apoptosis, supporting the notion that CLN3 may negatively regulate apoptosis.	Etoposide	183-192	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	50-54
12189165-7	2002	Protection from etoposide-induced apoptosis occurs and the cell growth rate is restored following transfection of JNCL lymphoblasts with mutant CLN3 cDNA that includes exons 11 or 13.	Etoposide	16-25	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	114-118
12189165-7	2002	Protection from etoposide-induced apoptosis occurs and the cell growth rate is restored following transfection of JNCL lymphoblasts with mutant CLN3 cDNA that includes exons 11 or 13.	Etoposide	16-25	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	144-148
12127563-4	2002	The results presented here demonstrate that the treatment of Jurkat cells with the apoptosis inducers anti-Fas, TRAIL, staurosporine, and etoposide induces proteolytic fragments of beta-catenin, as did TRAIL and staurosporine in U937 cells.	Etoposide	138-147	TNF superfamily member 10	Homo sapiens	202-207
12105221-2	2002	In U937-zeta J and U937-zeta B cells, enforced PKC zeta expression, conferred by stable transfection of PKC zeta cDNA, resulted in total inhibition of VP-16- and mitoxantrone-induced apoptosis and decreased drug-induced cytotoxicity, compared with U937-neo control cells.	Etoposide	151-156	protein kinase C zeta	Homo sapiens	47-55
12481412-13	2002	Expression of CA Akt by itself also induced resistance to etoposide-mediated apoptosis.	Etoposide	58-67	AKT serine/threonine kinase 1	Homo sapiens	17-20
12105221-2	2002	In U937-zeta J and U937-zeta B cells, enforced PKC zeta expression, conferred by stable transfection of PKC zeta cDNA, resulted in total inhibition of VP-16- and mitoxantrone-induced apoptosis and decreased drug-induced cytotoxicity, compared with U937-neo control cells.	Etoposide	151-156	protein kinase C zeta	Homo sapiens	104-112
12105221-3	2002	In PKC zeta-overexpressing cells, drug resistance correlated with decreased VP-16-induced DNA strand breaks and DNA protein cross-links measured by alkaline elution.	Etoposide	76-81	protein kinase C zeta	Homo sapiens	3-11
12065594-0	2002	Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis.	Etoposide	79-88	caspase 2	Homo sapiens	0-9
12065594-0	2002	Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis.	Etoposide	79-88	cytochrome c, somatic	Homo sapiens	51-63
12065594-3	2002	We demonstrate here a role for caspase-2 in etoposide-induced cytochrome c release.	Etoposide	44-53	caspase 2	Homo sapiens	31-40
12065594-3	2002	We demonstrate here a role for caspase-2 in etoposide-induced cytochrome c release.	Etoposide	44-53	cytochrome c, somatic	Homo sapiens	62-74
12065594-5	2002	Experiments performed using a reconstituted cell-free system indicate that etoposide-induced cytochrome c release by way of caspase-2 occurs independently of cytosolic factors, suggesting that the nuclear pool of pro-caspase-2 is critical to this process.	Etoposide	75-84	cytochrome c, somatic	Homo sapiens	93-105
12065594-5	2002	Experiments performed using a reconstituted cell-free system indicate that etoposide-induced cytochrome c release by way of caspase-2 occurs independently of cytosolic factors, suggesting that the nuclear pool of pro-caspase-2 is critical to this process.	Etoposide	75-84	caspase 2	Homo sapiens	124-133
12065594-5	2002	Experiments performed using a reconstituted cell-free system indicate that etoposide-induced cytochrome c release by way of caspase-2 occurs independently of cytosolic factors, suggesting that the nuclear pool of pro-caspase-2 is critical to this process.	Etoposide	75-84	caspase 2	Homo sapiens	217-226
12065594-7	2002	Taken together, our data indicate that caspase-2 provides an important link between etoposide-induced DNA damage and the engagement of the mitochondrial apoptotic pathway.	Etoposide	84-93	caspase 2	Homo sapiens	39-48
12174631-5	2002	After 2 courses of chemotherapy [cisplatin (CDDP) and etoposide (VP-16)], serum AFP level decreased to 25 ng/ml, and the tumor was resected with pericardium (the tumor size was 14 x 10 x 20 cm).	Etoposide	54-63	alpha fetoprotein	Homo sapiens	80-83
12154052-0	2002	The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.	Etoposide	81-90	poly(ADP-ribose) polymerase 1	Homo sapiens	4-33
12154052-0	2002	The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.	Etoposide	81-90	deoxyribonuclease 1 like 3	Homo sapiens	57-64
12154052-0	2002	The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.	Etoposide	148-157	poly(ADP-ribose) polymerase 1	Homo sapiens	4-33
12154052-0	2002	The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.	Etoposide	148-157	deoxyribonuclease 1 like 3	Homo sapiens	57-64
12154052-1	2002	The cytotoxic effect of the chemotherapeutic drug etoposide (VP-16) is thought to result from its ability to induce DNA damage and thereby to trigger apoptosis.	Etoposide	50-59	host cell factor C1	Homo sapiens	61-66
12151055-4	2002	To explore its molecular mechanism, we successfully transferred the anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation and observed the apoptosis process of HeLa cells induced by etoposide with flow cytometry.	Etoposide	203-212	programmed cell death 5	Homo sapiens	73-79
12215019-5	2002	Another risk factor of infection was the HD-ICE regimen (ifosfamide, carboplatin, etoposide) given to patients with solid tumors (OR, 8.00; 95% confidence interval, 1.61-39.7).	Etoposide	82-91	carboxylesterase 2	Homo sapiens	44-47
12174631-5	2002	After 2 courses of chemotherapy [cisplatin (CDDP) and etoposide (VP-16)], serum AFP level decreased to 25 ng/ml, and the tumor was resected with pericardium (the tumor size was 14 x 10 x 20 cm).	Etoposide	65-70	alpha fetoprotein	Homo sapiens	80-83
11901153-1	2002	The role of protein kinase C-beta(II) (PKC-beta(II)) in etoposide (VP-16)-induced apoptosis was studied using polyomavirus-transformed pyF111 rat fibroblasts in which PKC-beta(II) specific activity in the nuclear membrane (NM) doubled and the enzyme was cleaved into catalytic fragments.	Etoposide	56-65	phospholipase C, beta 2	Rattus norvegicus	39-50
12138192-8	2002	Interestingly, the zinc finger domain is also required for NF-kappa B activation by two other slow and weak inducers, camptothecin and etoposide.	Etoposide	135-144	nuclear factor kappa B subunit 1	Homo sapiens	59-69
12437111-9	2002	Lysosomal integrity was preserved and cathepsin D remained still confined in vesicular structures in apoptotic cells treated with either TNFalpha or etoposide.	Etoposide	149-158	cathepsin D	Mus musculus	38-49
12136643-7	2002	We demonstrated that dCK activity was increased within 1 h after exposure to etoposide.	Etoposide	77-86	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	21-24
12215217-3	2002	That is, HL-60/FAK cells were highly resistant to hydrogen peroxide or etoposide-induced apoptosis compared with the vector-transfected cells.	Etoposide	71-80	protein tyrosine kinase 2	Homo sapiens	15-18
12090052-2	2002	A 39-year-old woman with non-resectable mesenteric malignant lymphoma obtained a better QOL and outcome from prolonged oral administration of low-dose etoposide as a maintenance therapy after CHOP therapy.	Etoposide	151-160	DNA damage inducible transcript 3	Homo sapiens	192-196
12079522-9	2002	All cell lines were resistant to mitomycin-C (MMC) and etoposide (VP-16).	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
12513785-9	2002	Bcr-abl fusion gene prevented apoptosis induced by etoposide or camptothecin, but did not prevent apoptosis induced by CIK cells.	Etoposide	51-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
12111698-10	2002	CTPE cells also exhibited lower caspase-3 activity vs. RWPE-1 after etoposide treatment.	Etoposide	68-77	caspase 3	Homo sapiens	32-41
12223143-1	2002	OBJECTIVE: To study the changes of telomerase activity and protein expression of phosphorylated (activated) extracellular regulated protein kinases (ERK1 and ERK2) in the course of inhibiting hepatocarcinomatous cell proliferation and inducing cell apoptosis by three kinds of chemotherapy drugs: Harringtonine (HRT), Vincristine (VCR), and Etoposide (Vp16).	Etoposide	341-350	mitogen-activated protein kinase 3	Homo sapiens	149-153
12223143-1	2002	OBJECTIVE: To study the changes of telomerase activity and protein expression of phosphorylated (activated) extracellular regulated protein kinases (ERK1 and ERK2) in the course of inhibiting hepatocarcinomatous cell proliferation and inducing cell apoptosis by three kinds of chemotherapy drugs: Harringtonine (HRT), Vincristine (VCR), and Etoposide (Vp16).	Etoposide	352-356	mitogen-activated protein kinase 3	Homo sapiens	149-153
12216117-3	2002	Sox-4 induction by several apoptotic inducer such as A23187 (Ca(2+) ionophore) and etoposide (topoisomerase II inhibitor) and Sox-4 transfection into the cells were able to induce apoptosis as observed by the cellular DNA fragmentation.	Etoposide	83-92	SRY-box transcription factor 4	Homo sapiens	0-5
12036601-8	2002	Concerning etoposide-induced apoptosis, PRL had a double-faceted effect depending on the applied dose: high, pharmacological doses (corresponding to hyperprolactinemia), inhibited apoptosis, whereas near physiological doses exerted a pro-apoptotic effect.	Etoposide	11-20	prolactin	Homo sapiens	40-43
12063570-9	2002	Further studies in this area are warranted as the roles of p21WAF1, Bax/Bcl-2 and NF-kappaB may be important molecular events in mediating the antiproliferative and apoptosis inducing effect of etoposide in combination with ciprofloxacin in HRPC cells.	Etoposide	194-203	BCL2 associated X, apoptosis regulator	Homo sapiens	68-71
12063570-9	2002	Further studies in this area are warranted as the roles of p21WAF1, Bax/Bcl-2 and NF-kappaB may be important molecular events in mediating the antiproliferative and apoptosis inducing effect of etoposide in combination with ciprofloxacin in HRPC cells.	Etoposide	194-203	BCL2 apoptosis regulator	Homo sapiens	72-77
11964397-9	2002	Interestingly, the proliferation of MCF-7 cells was enhanced by overexpression of RACK1, whereas IGF-1-mediated protection from etoposide killing was greatly reduced.	Etoposide	128-137	insulin like growth factor 1	Homo sapiens	97-102
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	173-182	TNF superfamily member 10	Homo sapiens	13-18
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	173-182	TNF superfamily member 10	Homo sapiens	19-24
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	173-182	TNF superfamily member 10	Homo sapiens	67-72
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	184-187	TNF superfamily member 10	Homo sapiens	13-18
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	184-187	TNF superfamily member 10	Homo sapiens	19-24
11992538-6	2002	In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM).	Etoposide	184-187	TNF superfamily member 10	Homo sapiens	67-72
12060385-4	2002	Etoposide and cisplatin induced apoptosis in drug-sensitive MeWo cells as indicated by dose-dependent (i) cytochrome c release, (ii) caspase activation, (iii) DNA fragmentation, and (iv) cleavage of poly(ADP-ribose)polymerase.	Etoposide	0-9	cytochrome c, somatic	Homo sapiens	106-118
12060385-4	2002	Etoposide and cisplatin induced apoptosis in drug-sensitive MeWo cells as indicated by dose-dependent (i) cytochrome c release, (ii) caspase activation, (iii) DNA fragmentation, and (iv) cleavage of poly(ADP-ribose)polymerase.	Etoposide	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	199-225
12042670-8	2002	In contrast to the reduced LTC4 and oestrone sulphate transport, stably transfected HeLa cells expressing Arg433Ser mutant MRP1 were 2.1-fold more resistant to doxorubicin than cells expressing wild-type MRP1, while resistance to VP-16 and vincristine was unchanged.	Etoposide	230-235	ATP binding cassette subfamily C member 1	Homo sapiens	123-127
11901153-1	2002	The role of protein kinase C-beta(II) (PKC-beta(II)) in etoposide (VP-16)-induced apoptosis was studied using polyomavirus-transformed pyF111 rat fibroblasts in which PKC-beta(II) specific activity in the nuclear membrane (NM) doubled and the enzyme was cleaved into catalytic fragments.	Etoposide	67-72	phospholipase C, beta 2	Rattus norvegicus	39-50
11901153-3	2002	By 30 min after normal nuclei were mixed with cytoplasms from VP-16-treated, but not untreated, cells, PKC-beta(II) holoprotein had moved from the apoptotic cytoplasm to the normal NM, and lamin B1 was phosphorylated before cleavage by caspase-6.	Etoposide	62-67	phospholipase C, beta 2	Rattus norvegicus	103-115
11901153-3	2002	By 30 min after normal nuclei were mixed with cytoplasms from VP-16-treated, but not untreated, cells, PKC-beta(II) holoprotein had moved from the apoptotic cytoplasm to the normal NM, and lamin B1 was phosphorylated before cleavage by caspase-6.	Etoposide	62-67	lamin B1	Rattus norvegicus	189-197
11901153-3	2002	By 30 min after normal nuclei were mixed with cytoplasms from VP-16-treated, but not untreated, cells, PKC-beta(II) holoprotein had moved from the apoptotic cytoplasm to the normal NM, and lamin B1 was phosphorylated before cleavage by caspase-6.	Etoposide	62-67	caspase 6	Rattus norvegicus	236-245
11901153-5	2002	Thus, a PKC-beta(II) response to VP-16 seems necessary for lamin B1 cleavage by caspase-6 and nuclear lamina dissolution in apoptosing pyF111 fibroblasts.	Etoposide	33-38	phospholipase C, beta 2	Rattus norvegicus	8-20
11901153-5	2002	Thus, a PKC-beta(II) response to VP-16 seems necessary for lamin B1 cleavage by caspase-6 and nuclear lamina dissolution in apoptosing pyF111 fibroblasts.	Etoposide	33-38	lamin B1	Rattus norvegicus	59-67
11901153-5	2002	Thus, a PKC-beta(II) response to VP-16 seems necessary for lamin B1 cleavage by caspase-6 and nuclear lamina dissolution in apoptosing pyF111 fibroblasts.	Etoposide	33-38	caspase 6	Rattus norvegicus	80-89
11916527-1	2002	The relationship between p53 gene status and the expression of DR5 and Fas was evaluated as a function of sensitivity of 11 acute lymphoblastic leukemia cell lines to adriamycin, etoposide, vincristine, methotrexate and dexamethasone.	Etoposide	179-188	TNF receptor superfamily member 10b	Homo sapiens	63-66
12076523-1	2002	Etoposide (VP-16) is known to promote cell apoptosis either in cancer or in normal cells as a side effect.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
11864976-0	2002	The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c.	Etoposide	14-23	tumor protein p53	Homo sapiens	65-68
11864976-0	2002	The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c.	Etoposide	14-23	cytochrome c, somatic	Homo sapiens	108-120
11864976-1	2002	Treatment of L929 fibroblasts by the topoisomerase II inhibitor etoposide killed 50% of the cells within 72 h. The cell killing was preceded by the release of cytochrome c from the mitochondria.	Etoposide	64-73	cytochrome c, somatic	Homo sapiens	159-171
11864976-3	2002	Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK).	Etoposide	0-9	tumor protein p53	Homo sapiens	40-43
11864976-3	2002	Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK).	Etoposide	0-9	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	107-135
11864976-3	2002	Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK).	Etoposide	0-9	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	137-143
11864976-4	2002	The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.	Etoposide	25-34	tumor protein p53	Homo sapiens	18-21
11864976-4	2002	The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.	Etoposide	25-34	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
11864976-6	2002	Stably transfected L929 fibroblasts that overexpress Akt were resistant to etoposide and did not translocate Bax to the mitochondria or release cytochrome c.	Etoposide	75-84	AKT serine/threonine kinase 1	Homo sapiens	53-56
12076523-8	2002	The inhibition of the VP-16-induced MPT by antioxidants agrees with the prevention of etoposide-induced apoptosis by GSH and NAC and suggests the generation of oxidant species as a potential mechanism underlying the MPT that may trigger the release of mitochondrial apoptogenic factors responsible for apoptotic cascade activation.	Etoposide	86-95	host cell factor C1	Homo sapiens	22-27
11877397-6	2002	We show by chromatin immunoprecipitation assay that treatment with the TOPII inhibitor etoposide induces association of acetylated histone 3 with the promoter of IRF-7 gene, indicating that TOPII-mediated changes in chromatin structure could be responsible for the induction.	Etoposide	87-96	interferon regulatory factor 7	Homo sapiens	162-167
12042984-29	2002	Therapy with a similar regimen, combining ifosfamide, carboplatin, and etoposide in standard doses (ICE) has also been described.	Etoposide	71-80	carboxylesterase 2	Homo sapiens	100-103
12007020-7	2002	An increase in myosin expression was most marked in the etoposide- and doxorubicin-resistant RD cell lines.	Etoposide	56-65	myosin heavy chain 14	Homo sapiens	15-21
12009851-1	2002	Early stages of rat thymocyte apoptosis measured as annexin-V positive events and induced by methylprednisolone (MPS), etoposide, and thapsigargin, showed a sequential increase in nitric oxide (NO) production by mitochondrial and endoplasmic reticulum membranes.	Etoposide	119-128	annexin A5	Rattus norvegicus	52-61
11821411-7	2002	Furthermore, the Myc level dropped sharply following VP-16 exposure, which varied inversely with the induction of Cluster C genes, suggesting Myc normally represses their transcription.	Etoposide	53-58	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	17-20
12009851-9	2002	Caspase 3 activity was markedly increased by the three apoptosis inducers; caspase 6 was only activated by MPS and etoposide, while caspase 8 was not activated by any of these inducers.	Etoposide	115-124	caspase 3	Rattus norvegicus	0-9
12009851-9	2002	Caspase 3 activity was markedly increased by the three apoptosis inducers; caspase 6 was only activated by MPS and etoposide, while caspase 8 was not activated by any of these inducers.	Etoposide	115-124	caspase 6	Rattus norvegicus	75-84
12054581-1	2002	We have established that focal adhesion kinase (FAK)-transfected HL-60 (HL-60/FAK) cells were highly resistant to hydrogen peroxide and etoposide-induced apoptosis compared to vector-transfected cells.	Etoposide	136-145	protein tyrosine kinase 2	Homo sapiens	25-46
12054581-1	2002	We have established that focal adhesion kinase (FAK)-transfected HL-60 (HL-60/FAK) cells were highly resistant to hydrogen peroxide and etoposide-induced apoptosis compared to vector-transfected cells.	Etoposide	136-145	protein tyrosine kinase 2	Homo sapiens	48-51
12054581-1	2002	We have established that focal adhesion kinase (FAK)-transfected HL-60 (HL-60/FAK) cells were highly resistant to hydrogen peroxide and etoposide-induced apoptosis compared to vector-transfected cells.	Etoposide	136-145	protein tyrosine kinase 2	Homo sapiens	72-81
11867204-7	2002	Importantly, we found that hTERT-transfected K562 cells are protected against apoptosis induced by serum deprivation and double-stranded DNA break inducing agents (ionizing irradiation, and etoposide (VP-16)), but not against DNA synthesis inhibitors (1-beta-D-arabinofuranosylcytosine and hydroxyurea).	Etoposide	190-199	telomerase reverse transcriptase	Homo sapiens	27-32
11867204-7	2002	Importantly, we found that hTERT-transfected K562 cells are protected against apoptosis induced by serum deprivation and double-stranded DNA break inducing agents (ionizing irradiation, and etoposide (VP-16)), but not against DNA synthesis inhibitors (1-beta-D-arabinofuranosylcytosine and hydroxyurea).	Etoposide	201-206	telomerase reverse transcriptase	Homo sapiens	27-32
11956083-8	2002	Surprisingly, the ability of etoposide to cause increased association of eIF4E with 4E-BP1 does require PKR activity.	Etoposide	29-38	eukaryotic translation initiation factor 4E	Homo sapiens	73-78
11956083-8	2002	Surprisingly, the ability of etoposide to cause increased association of eIF4E with 4E-BP1 does require PKR activity.	Etoposide	29-38	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	84-90
11956083-8	2002	Surprisingly, the ability of etoposide to cause increased association of eIF4E with 4E-BP1 does require PKR activity.	Etoposide	29-38	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	104-107
11821411-7	2002	Furthermore, the Myc level dropped sharply following VP-16 exposure, which varied inversely with the induction of Cluster C genes, suggesting Myc normally represses their transcription.	Etoposide	53-58	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	142-145
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	50-59	mitogen-activated protein kinase 1	Mus musculus	155-161
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	50-59	mitogen-activated protein kinase 1	Mus musculus	155-158
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	50-59	E74-like factor 4 (ets domain transcription factor)	Mus musculus	213-216
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	61-65	mitogen-activated protein kinase 1	Mus musculus	155-161
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	61-65	mitogen-activated protein kinase 1	Mus musculus	155-158
11821415-2	2002	We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells.	Etoposide	61-65	E74-like factor 4 (ets domain transcription factor)	Mus musculus	213-216
11821415-3	2002	ERK activation in response to ETOP was abolished in ATM-/- fibroblasts (GM05823) and was independent of p53.	Etoposide	30-34	mitogen-activated protein kinase 1	Homo sapiens	0-3
11821415-3	2002	ERK activation in response to ETOP was abolished in ATM-/- fibroblasts (GM05823) and was independent of p53.	Etoposide	30-34	ATM serine/threonine kinase	Homo sapiens	52-55
11821415-7	2002	Inhibition of ERK activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP.	Etoposide	153-157	mitogen-activated protein kinase 1	Homo sapiens	14-17
11821415-7	2002	Inhibition of ERK activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP.	Etoposide	153-157	H3 histone pseudogene 16	Homo sapiens	60-63
11821415-7	2002	Inhibition of ERK activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP.	Etoposide	153-157	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-68
11914104-7	2002	Furthermore, adhesion of SCLC cells to fibronectin, laminin and collagen IV through beta1 integrins enhances tumorigenicity and confers resistance to apoptosis induced by standard chemotherapeutic agents, including etoposide, cis-platinum and adriamycin.	Etoposide	215-224	fibronectin 1	Homo sapiens	39-50
11815602-0	2002	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis.	Etoposide	140-149	BCL2 apoptosis regulator	Homo sapiens	74-79
11815602-0	2002	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis.	Etoposide	140-149	mitogen-activated protein kinase kinase 7	Homo sapiens	86-89
11815602-2	2002	Here we report that FGF-2 prevented etoposide-induced apoptosis in H-510 SCLC cells.	Etoposide	36-45	fibroblast growth factor 2	Homo sapiens	20-25
11815602-5	2002	Moreover, in H-69 SCLC cells, the failure of FGF-2 to prevent etoposide-induced apoptosis correlated with uncoupling from MEK activation.	Etoposide	62-71	fibroblast growth factor 2	Homo sapiens	45-50
11815602-6	2002	However, the introduction of an activated MEK rendered these cells resistant to etoposide killing.	Etoposide	80-89	mitogen-activated protein kinase kinase 7	Homo sapiens	42-45
11815602-10	2002	The induction of the pro-apoptotic protein Bad by etoposide was also blocked by FGF-2 in a MEK-dependent fashion.	Etoposide	50-59	fibroblast growth factor 2	Homo sapiens	80-85
11815602-10	2002	The induction of the pro-apoptotic protein Bad by etoposide was also blocked by FGF-2 in a MEK-dependent fashion.	Etoposide	50-59	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
11959808-13	2002	Residual ETOP efflux in mdr1a (-/-) tissues was abolished by the MRP inhibitor MK571, indicating involvement of both PGP and <protein-id="27416">MRP.	Etoposide	9-13	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	24-29
11959808-13	2002	Residual ETOP efflux in mdr1a (-/-) tissues was abolished by the MRP inhibitor MK571, indicating involvement of both PGP and <protein-id="27416">MRP.	Etoposide	9-13	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	65-68
11959808-13	2002	Residual ETOP efflux in mdr1a (-/-) tissues was abolished by the MRP inhibitor MK571, indicating involvement of both PGP and <protein-id="27416">MRP.	Etoposide	9-13	phosphoglycolate phosphatase	Mus musculus	117-120
12207053-6	2002	However, we found also that the p138 protein level increased during an arrest at G2/M caused by etoposide.	Etoposide	96-105	golgi integral membrane protein 4	Homo sapiens	32-36
12207053-10	2002	Rather, the expression of p138 protein seems to be coupled with a change in cell size since both thymidine block and etoposide inhibition resulted in an apparent increase in cell size.	Etoposide	117-126	golgi integral membrane protein 4	Homo sapiens	26-30
11815602-0	2002	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis.	Etoposide	140-149	fibroblast growth factor 2	Homo sapiens	0-26
11815602-0	2002	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis.	Etoposide	140-149	BCL2 like 1	Homo sapiens	63-69
12007787-5	2002	Permanent expression of the WTH3 transgene in MDR cell lines increased to varying degrees their sensitivity to several anticancer drugs, which included doxorubicin, taxol, vinblastine, vincristine, and etoposide, as compared to the control sublines transfected with the empty vector.	Etoposide	202-211	RAB6C, member RAS oncogene family	Homo sapiens	28-32
11921051-10	2002	We show that flupirtine aborts etoposide-induced apoptosis in CLN1-, CLN2-, CLN3-, and CLN6-deficient as well as normal lymphoblasts.	Etoposide	31-40	palmitoyl-protein thioesterase 1	Homo sapiens	62-66
11921051-10	2002	We show that flupirtine aborts etoposide-induced apoptosis in CLN1-, CLN2-, CLN3-, and CLN6-deficient as well as normal lymphoblasts.	Etoposide	31-40	tripeptidyl peptidase 1	Homo sapiens	69-73
11921051-10	2002	We show that flupirtine aborts etoposide-induced apoptosis in CLN1-, CLN2-, CLN3-, and CLN6-deficient as well as normal lymphoblasts.	Etoposide	31-40	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	76-80
11929841-8	2002	The down-regulation of bcl-xL in both DU145 (and to a much lesser extent in LNCaP) cells led to their resistance to cytotoxic agents, including docetaxel, mitoxantrone, etoposide, vinblastine, and carboplatin.	Etoposide	169-178	BCL2 like 1	Homo sapiens	23-29
11914104-7	2002	Furthermore, adhesion of SCLC cells to fibronectin, laminin and collagen IV through beta1 integrins enhances tumorigenicity and confers resistance to apoptosis induced by standard chemotherapeutic agents, including etoposide, cis-platinum and adriamycin.	Etoposide	215-224	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	84-89
11914104-8	2002	Adhesion to ECM proteins stimulated protein tyrosine kinase (PTK) activity in both untreated and etoposide-treated cells.	Etoposide	97-106	protein tyrosine kinase 2 beta	Homo sapiens	61-64
11937320-1	2002	Improving etoposide efficacy in BCR-ABL-positive CML cells.	Etoposide	10-19	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	32-39
11901101-0	2002	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).	Etoposide	72-81	ATP binding cassette subfamily C member 1	Canis lupus familiaris	164-209
11901101-0	2002	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).	Etoposide	72-81	ATP binding cassette subfamily C member 2	Homo sapiens	269-274
11901101-3	2002	Etoposide transport kinetics were characterized in Caco-2 cells and in well established Madin-Darby canine kidney (MDCKII) cell lines that were stably-transfected with a human cDNA encoding P-glycoprotein (Pgp), human multidrug resistance protein (MRP1), or the canalicular multispecific organic anion (cMOAT) transporters to determine the roles of these transporters in etoposide efflux.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	190-204
11901101-4	2002	Etoposide transport kinetics were concentration-dependent in the MDCKII-MDR1 and MDCKII-cMOAT cells.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Canis lupus familiaris	65-76
11901101-4	2002	Etoposide transport kinetics were concentration-dependent in the MDCKII-MDR1 and MDCKII-cMOAT cells.	Etoposide	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	88-93
11901101-7	2002	Moderate inhibition of etoposide efflux by leukotriene C4 (LTC4) was observed in MDCKII-cMOAT cells.	Etoposide	23-32	ATP binding cassette subfamily C member 2	Homo sapiens	88-93
11901101-9	2002	The flux of etoposide in MDCKII-MRP1 cells was similar to that in MDCKII/wt control cells.	Etoposide	12-21	ATP binding cassette subfamily C member 1	Canis lupus familiaris	32-36
11901101-10	2002	The current results demonstrate that the secretory transport mechanism of etoposide involves multiple transporters, including Pgp and cMOAT but not MRP1.	Etoposide	74-83	PGP	Canis lupus familiaris	126-129
11901101-10	2002	The current results demonstrate that the secretory transport mechanism of etoposide involves multiple transporters, including Pgp and cMOAT but not MRP1.	Etoposide	74-83	ATP binding cassette subfamily C member 2	Homo sapiens	134-139
11901101-11	2002	These results demonstrate that Pgp and cMOAT are involved in the intestinal secretory transport of etoposide.	Etoposide	99-108	PGP	Canis lupus familiaris	31-34
11901101-11	2002	These results demonstrate that Pgp and cMOAT are involved in the intestinal secretory transport of etoposide.	Etoposide	99-108	ATP binding cassette subfamily C member 2	Homo sapiens	39-44
11799106-8	2002	The cytosolic p53 x IkappaBalpha complex rapidly dissociated in response to apoptotic stress, etoposide- and UV-mediated DNA damage, hypoxia, and TGF-beta1-mediated growth suppression.	Etoposide	94-103	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	14-17
12018110-1	2002	A 48-year-old woman with small-cell lung cancer received combined chemotherapy consisting of cisplatin (CDDP) and etoposide (Vp-16).	Etoposide	114-123	host cell factor C1	Homo sapiens	125-130
11884589-5	2002	PTP-1B-deficient cells exhibited enhanced IGF-I-mediated protection from apoptosis in response to serum withdrawal or etoposide killing, as well as enhanced plating efficiency and IGF-I-mediated motility.	Etoposide	118-127	insulin-like growth factor 1	Mus musculus	42-47
11799106-8	2002	The cytosolic p53 x IkappaBalpha complex rapidly dissociated in response to apoptotic stress, etoposide- and UV-mediated DNA damage, hypoxia, and TGF-beta1-mediated growth suppression.	Etoposide	94-103	NFKB inhibitor alpha	Rattus norvegicus	20-32
11799106-9	2002	Also, a rapid increase in the formation of the nuclear p53 x IkappaBalpha complex was observed during exposure to etoposide and UV.	Etoposide	114-123	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	55-58
11799106-9	2002	Also, a rapid increase in the formation of the nuclear p53 x IkappaBalpha complex was observed during exposure to etoposide and UV.	Etoposide	114-123	NFKB inhibitor alpha	Rattus norvegicus	61-73
11912135-6	2002	In contrast, SNAP did prevent activation of caspase 9 in etoposide-treated cells.	Etoposide	57-66	caspase 9	Homo sapiens	44-53
12014636-4	2002	RESULTS: Treatment with suboptimal concentrations of etoposide or doxorubicin rendered T-47D cells sensitive to anti-Fas antibody or TRAIL, consistent with Fas and TRAIL-R1 mRNA expression by T-47D cells following drug treatment.	Etoposide	53-62	TNF superfamily member 10	Homo sapiens	133-138
11912160-5	2002	Using a histone H1 phosphorylation assay, we showed that both tumor necrosis factor alpha and etoposide activate PKCzeta in U937 human leukemic cells.	Etoposide	94-103	protein kinase C zeta	Homo sapiens	113-120
11912160-8	2002	PKCzeta inhibition accelerates the occurrence of apoptosis in leukemic cells exposed to etoposide and tumor necrosis factor alpha.	Etoposide	88-97	protein kinase C zeta	Homo sapiens	0-7
11912160-10	2002	In addition, PKCzeta inhibition sensitized tumor cells grown in nude mice to etoposide.	Etoposide	77-86	protein kinase C zeta	Homo sapiens	13-20
12014636-4	2002	RESULTS: Treatment with suboptimal concentrations of etoposide or doxorubicin rendered T-47D cells sensitive to anti-Fas antibody or TRAIL, consistent with Fas and TRAIL-R1 mRNA expression by T-47D cells following drug treatment.	Etoposide	53-62	TNF receptor superfamily member 10a	Homo sapiens	164-172
11935300-6	2002	RESULTS: Ex vivo chemosensitivity testing showed that tumors with p53 mutations were significantly more resistant to the cyclophosphamide/etoposide/epirubicin regimen than with normal p53 gene ( P = 0.012).	Etoposide	138-147	tumor protein p53	Homo sapiens	66-69
11915738-1	2002	The high incidence of side effects for EAP (etoposide, adriamycin, cisplatin) combination chemotherapy led to the recent decline in its use.	Etoposide	44-53	glutamyl aminopeptidase	Homo sapiens	39-42
11901191-2	2002	Etoposide and paclitaxel induced Cer formation and apoptosis in PKCdelta-positive LNCaP and DU145 cells but not in PKCdelta-negative LN-TPA or PC-3 cells.	Etoposide	0-9	protein kinase C delta	Homo sapiens	64-72
11901191-9	2002	Furthermore, the specific caspase-9 inhibitor LEHD-fmk significantly inhibited etoposide-induced nSMase activation, Cer accumulation, and PKCdelta mitochondrial translocation.	Etoposide	79-88	caspase 9	Homo sapiens	26-35
11901191-9	2002	Furthermore, the specific caspase-9 inhibitor LEHD-fmk significantly inhibited etoposide-induced nSMase activation, Cer accumulation, and PKCdelta mitochondrial translocation.	Etoposide	79-88	sphingomyelin phosphodiesterase 2	Homo sapiens	97-103
11942326-4	2002	Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6.	Etoposide	46-55	host cell factor C1	Homo sapiens	57-62
11901191-9	2002	Furthermore, the specific caspase-9 inhibitor LEHD-fmk significantly inhibited etoposide-induced nSMase activation, Cer accumulation, and PKCdelta mitochondrial translocation.	Etoposide	79-88	protein kinase C delta	Homo sapiens	138-146
12065845-14	2002	However, a Bax cleavage product was noted which was substantially increased by cotreatment with ROS or etoposide.	Etoposide	103-112	BCL2 associated X, apoptosis regulator	Homo sapiens	11-14
11861801-4	2002	Pretreatment with a broad caspase inhibitor [benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone] markedly decreased the incidence of apoptotic cells induced by FTY720, etoposide, and anti-Fas antibody, through the abrogation of cleavage of Bid, poly(ADP-ribose) polymerase, and caspases 3, 8, and 9.	Etoposide	173-182	caspase 8	Homo sapiens	26-33
11861801-4	2002	Pretreatment with a broad caspase inhibitor [benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone] markedly decreased the incidence of apoptotic cells induced by FTY720, etoposide, and anti-Fas antibody, through the abrogation of cleavage of Bid, poly(ADP-ribose) polymerase, and caspases 3, 8, and 9.	Etoposide	173-182	BH3 interacting domain death agonist	Homo sapiens	245-248
11861801-4	2002	Pretreatment with a broad caspase inhibitor [benzyloxycarbonyl-Val-Ala-Asp-(Ome) fluoromethyl ketone] markedly decreased the incidence of apoptotic cells induced by FTY720, etoposide, and anti-Fas antibody, through the abrogation of cleavage of Bid, poly(ADP-ribose) polymerase, and caspases 3, 8, and 9.	Etoposide	173-182	poly(ADP-ribose) polymerase 1	Homo sapiens	250-303
11861801-5	2002	The overexpression of Bcl-2 gene prevented FTY720- and etoposide-mediated apoptosis, but not Fas-mediated apoptosis.	Etoposide	55-64	BCL2 apoptosis regulator	Homo sapiens	22-27
11942326-4	2002	Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6.	Etoposide	46-55	nuclear factor kappa B subunit 1	Homo sapiens	96-105
11942326-4	2002	Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6.	Etoposide	46-55	interleukin 6	Homo sapiens	162-166
11827710-0	2002	Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro.	Etoposide	82-91	tumor protein p53	Homo sapiens	33-36
11827710-0	2002	Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro.	Etoposide	93-97	tumor protein p53	Homo sapiens	33-36
11850823-8	2002	Investigation of TC21"s effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt.	Etoposide	114-123	related RAS viral (r-ras) oncogene 2	Mus musculus	17-21
11729185-5	2002	U87MG/PTEN glioblastoma cells are more sensitive than U87MG/PTEN null cells to death induced by etoposide, a chemotherapeutic agent that induces DNA damage.	Etoposide	96-105	phosphatase and tensin homolog	Homo sapiens	6-10
11850823-8	2002	Investigation of TC21"s effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt.	Etoposide	114-123	related RAS viral (r-ras) oncogene 2	Mus musculus	69-73
11850823-8	2002	Investigation of TC21"s effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt.	Etoposide	114-123	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	229-238
11850823-8	2002	Investigation of TC21"s effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt.	Etoposide	114-123	thymoma viral proto-oncogene 1	Mus musculus	263-266
11841447-4	2002	The p53-transfected cells showed a decreased ability to arrest in G2 and an increase in apoptosis in response to etoposide treatment, relative to the control mock-transfected cells.	Etoposide	113-122	tumor protein p53	Homo sapiens	4-7
11841447-5	2002	p53-transfected and control cells were treated with etoposide and trapped at mitosis with nocodazole.	Etoposide	52-61	tumor protein p53	Homo sapiens	0-3
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	90-99	cyclin dependent kinase 1	Homo sapiens	230-234
11841447-6	2002	The mitotic index of p53-transfected cells was higher than that of the control cells, which suggests that p53 abrogates the G2 checkpoint response to etoposide treatment in K562 cells.	Etoposide	150-159	tumor protein p53	Homo sapiens	21-24
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	193-202	checkpoint kinase 1	Homo sapiens	66-70
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	193-202	tumor protein p53	Homo sapiens	108-111
11841447-6	2002	The mitotic index of p53-transfected cells was higher than that of the control cells, which suggests that p53 abrogates the G2 checkpoint response to etoposide treatment in K562 cells.	Etoposide	150-159	tumor protein p53	Homo sapiens	106-109
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	193-202	cyclin dependent kinase 1	Homo sapiens	230-234
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	90-99	checkpoint kinase 1	Homo sapiens	66-70
11841447-8	2002	We conclude, therefore, that p53 overrides the strong G2 checkpoint response to etoposide in K562 cells, by directly or indirectly downregulating Chk1 expression, which, in turn, contributes to the proapoptotic effect of p53.	Etoposide	80-89	tumor protein p53	Homo sapiens	29-32
11841447-8	2002	We conclude, therefore, that p53 overrides the strong G2 checkpoint response to etoposide in K562 cells, by directly or indirectly downregulating Chk1 expression, which, in turn, contributes to the proapoptotic effect of p53.	Etoposide	80-89	checkpoint kinase 1	Homo sapiens	146-150
11841447-7	2002	We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15).	Etoposide	90-99	tumor protein p53	Homo sapiens	108-111
11841447-8	2002	We conclude, therefore, that p53 overrides the strong G2 checkpoint response to etoposide in K562 cells, by directly or indirectly downregulating Chk1 expression, which, in turn, contributes to the proapoptotic effect of p53.	Etoposide	80-89	tumor protein p53	Homo sapiens	221-224
11896462-8	2002	Finally, in Jurkat T cells stably expressing iAkt, CID-induced Akt activation rescued cells from apoptosis triggered by multiple apoptotic stimuli, including staurosporine, anti-Fas antibodies, PI3K inhibitors and the DNA damaging agent, etoposide.	Etoposide	238-247	AKT serine/threonine kinase 1	Homo sapiens	46-49
11830551-4	2002	Culture supernatants from both cell lines induced NF-kappaB activity in chemosensitive PT45-P1 pancreatic carcinoma cells and significantly attenuated etoposide-induced apoptosis in a NF-kappaB-dependent fashion, similar to that seen in PT45-P1 cells treated with recombinant IL-1beta.	Etoposide	151-160	nuclear factor kappa B subunit 1	Homo sapiens	184-193
11830551-4	2002	Culture supernatants from both cell lines induced NF-kappaB activity in chemosensitive PT45-P1 pancreatic carcinoma cells and significantly attenuated etoposide-induced apoptosis in a NF-kappaB-dependent fashion, similar to that seen in PT45-P1 cells treated with recombinant IL-1beta.	Etoposide	151-160	interleukin 1 beta	Homo sapiens	276-284
12113067-3	2002	On the other hand, newly developed EMP-based combination regimens with etoposide, pacitaxel, carboplatin or docetaxel demonstrated promising PSA response rate (43-77%) with moderate to severe toxicity in the rate of thromboembolic event (5-18%) and of neutropenia (9-41%).	Etoposide	71-80	aminopeptidase puromycin sensitive	Homo sapiens	141-144
11857030-5	2002	ALP-mediated dephosphorylation of etoposide phosphate generates the potent topoisomerase II inhibitor etoposide.	Etoposide	34-43	alkaline phosphatase, placental	Homo sapiens	0-3
11968736-6	2002	The cancer was clinically diagnosed as stage C. Pelvic radiotherapy combined with chemotherapy using cisplatin (CDDP) and etoposide (VP-16) was started according to the treatment for limited small cell cancer of the lung.	Etoposide	122-131	host cell factor C1	Homo sapiens	133-138
11784858-15	2002	Moreover, in etoposide-treated cells, Hsp27 still delayed the release of cytochrome c from mitochondria and Bid intracellular redistribution in conditions where F-actin was not altered.	Etoposide	13-22	heat shock protein family B (small) member 1	Homo sapiens	38-43
11856485-6	2002	Bromocriptine restored the anticancer effect of DXR, VCR, vinblastine, vinorelbine and etoposide on MDR-tumor cells overexpressing P-gp.	Etoposide	87-96	phosphoglycolate phosphatase	Homo sapiens	131-135
11784858-15	2002	Moreover, in etoposide-treated cells, Hsp27 still delayed the release of cytochrome c from mitochondria and Bid intracellular redistribution in conditions where F-actin was not altered.	Etoposide	13-22	cytochrome c, somatic	Homo sapiens	73-85
11784858-15	2002	Moreover, in etoposide-treated cells, Hsp27 still delayed the release of cytochrome c from mitochondria and Bid intracellular redistribution in conditions where F-actin was not altered.	Etoposide	13-22	BH3 interacting domain death agonist	Homo sapiens	108-111
11774266-4	2002	Northern blot analysis revealed that T-fimbrin gene expression was induced not only by X-radiation but also by a topoisomerase II inhibitor, etoposide.	Etoposide	141-150	plastin 3	Homo sapiens	37-46
12513833-1	2002	The objective of this study was to explore the effect of p21(WAF1) on the sensitivity to chemotherapeutic agent VP-16, etoposide, in leukemia cell line K562.	Etoposide	119-128	cyclin dependent kinase inhibitor 1A	Homo sapiens	57-60
12513833-1	2002	The objective of this study was to explore the effect of p21(WAF1) on the sensitivity to chemotherapeutic agent VP-16, etoposide, in leukemia cell line K562.	Etoposide	119-128	cyclin dependent kinase inhibitor 1A	Homo sapiens	61-65
12513833-1	2002	The objective of this study was to explore the effect of p21(WAF1) on the sensitivity to chemotherapeutic agent VP-16, etoposide, in leukemia cell line K562.	Etoposide	119-128	host cell factor C1	Homo sapiens	112-117
11900223-2	2002	The authors previously reported that calcitonin and bombesin inhibited etoposide-induced apoptosis in these cells.	Etoposide	71-80	gastrin releasing peptide	Homo sapiens	52-60
11900223-7	2002	Both bombesin and calcitonin inhibited the etoposide-induced changes in the cellular Na/K ratio, and calcitonin, but not bombesin, inhibited the changes in the P/S ratio.	Etoposide	43-52	gastrin releasing peptide	Homo sapiens	5-13
11900223-9	2002	CONCLUSIONS: The neuropeptides bombesin and calcitonin, which inhibited etoposide-induced apoptosis, also inhibited the etoposide-induced elemental changes in prostate carcinoma cells.	Etoposide	72-81	gastrin releasing peptide	Homo sapiens	31-39
11900223-9	2002	CONCLUSIONS: The neuropeptides bombesin and calcitonin, which inhibited etoposide-induced apoptosis, also inhibited the etoposide-induced elemental changes in prostate carcinoma cells.	Etoposide	120-129	gastrin releasing peptide	Homo sapiens	31-39
16120290-1	2002	During etoposide-induced apoptosis in HL-60 cells, cytochrome c release was associated with mitochondrial swelling caused by increased mitochondrial potassium uptake.	Etoposide	7-16	cytochrome c, somatic	Homo sapiens	51-63
12513834-4	2002	DEX and VP-16 could promote apoptosis of RMA cells while upregulating the expression of Fas and FasL without affecting the expression of Bcl-2.	Etoposide	8-13	Fas ligand (TNF superfamily, member 6)	Mus musculus	96-100
12513834-12	2002	Fas-FasL system participated in the apoptosis induced by DEX and VP-16; different drugs induce apoptosis by different pathway of signal transduction.	Etoposide	65-70	Fas ligand (TNF superfamily, member 6)	Mus musculus	4-8
11694507-0	2002	Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposide-induced apoptosis.	Etoposide	77-86	deoxyribonuclease 1 like 3	Homo sapiens	14-21
11803469-2	2002	We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs.	Etoposide	56-65	nuclear factor kappa B subunit 1	Homo sapiens	93-102
11803469-2	2002	We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs.	Etoposide	56-65	TNF superfamily member 10	Homo sapiens	175-180
11803469-2	2002	We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs.	Etoposide	56-65	TNF receptor superfamily member 10b	Homo sapiens	205-208
11803475-6	2002	PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide.	Etoposide	151-160	phosphatase and tensin homolog	Homo sapiens	0-4
11694507-6	2002	The induction by etoposide of apoptosis in human osteosarcoma cells (which were shown not to express endogenous DNAS1L3) was accompanied by internucleosomal DNA fragmentation only after transfection of the cells with a plasmid encoding DNAS1L3.	Etoposide	17-26	deoxyribonuclease 1 like 3	Homo sapiens	236-243
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	caspase 3	Homo sapiens	16-25
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	poly(ADP-ribose) polymerase 1	Homo sapiens	36-42
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	deoxyribonuclease 1 like 3	Homo sapiens	55-62
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	deoxyribonuclease 1 like 3	Homo sapiens	199-206
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	caspase 3	Homo sapiens	255-264
11694507-9	2002	Coexpression of caspase-3-resistant PARP-1 mutant with DNAS1L3 in osteosarcoma cells blocked etoposide-induced internucleosomal DNA fragmentation and resulted in persistent poly(ADP-ribosyl)ation of DNAS1L3; it did not, however, prevent the activation of caspase-3 and the consequent cleavage of endogenous PARP-1.	Etoposide	93-102	poly(ADP-ribose) polymerase 1	Homo sapiens	307-313
12429914-5	2002	BL also inhibited the p53-dependent increase of p21 protein expression in cells exposed to the DNA damag-ing agent etoposide, and favored a greater G2/M arrest as compared to the non-BL exposed cells.	Etoposide	115-124	tumor protein p53	Homo sapiens	22-25
12587780-2	2002	Here we show that 10 microg/ml etoposide elicited only minor changes in Bowes human melanoma cells (temporary decrease in cell viability and proliferation, transient phospatidylserine externalization and caspase-3 activation), which weren"t clearly capable to start apoptotic pathway in the entire treated population.	Etoposide	31-40	caspase 3	Homo sapiens	204-213
12416471-9	2002	Several regimens have been proposed for stem cells mobilization including: High-dose cyclophosphamide and G or GM-CSF, G-CSF alone, and cyclophosphamide and etoposide with G-CSF... ect.. Further attempts to improve the results of autotransplantation have included intensification with tandem transplantations (double transplants) and reduction of tumor cells in stem cell infusion.	Etoposide	157-166	colony stimulating factor 3	Homo sapiens	172-177
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	PAXIP1 associated glutamate rich protein 1	Homo sapiens	3-6
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	tumor protein p53	Homo sapiens	32-35
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	poly(ADP-ribose) polymerase 1	Homo sapiens	113-117
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	tumor protein p53	Homo sapiens	237-240
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	tumor protein p53	Homo sapiens	237-240
11791171-5	2002	In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation.	Etoposide	156-165	caspase 9	Homo sapiens	55-62
12429914-5	2002	BL also inhibited the p53-dependent increase of p21 protein expression in cells exposed to the DNA damag-ing agent etoposide, and favored a greater G2/M arrest as compared to the non-BL exposed cells.	Etoposide	115-124	cyclin dependent kinase inhibitor 1A	Homo sapiens	48-51
11885806-0	2002	The effect of heat shock, cisplatin, etoposide and quercetin on Hsp27 expression in human normal and tumour cells.	Etoposide	37-46	heat shock protein family B (small) member 1	Homo sapiens	64-69
11918083-7	2002	We found that stromal ECM protected LiM6 cells from the toxicity of etoposide and LS174T, but not LiM6 cells, from the toxicity of camptothecin.	Etoposide	68-77	multimerin 1	Homo sapiens	22-25
11918083-10	2002	Stromal-derived ECM may protect colon cancer cells from etoposide and camptothecin-induced apotosis, through a mechanism that is not bcl-2 or bcl-x(L) dependant.	Etoposide	56-65	multimerin 1	Homo sapiens	16-19
12112386-0	2002	Mutagenicity of gamma-radiation, mitomycin C, and etoposide in the Hprt and Tk genes of Tk(+/-) mice.	Etoposide	50-59	hypoxanthine guanine phosphoribosyl transferase	Mus musculus	67-71
11885806-2	2002	Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin have an effect on the expression of heat shock protein 27 in tumour cells such as: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and also in normal human skin fibroblasts (HSF) cultured in two-dimensional (2D) and three-dimensional (3D) conditions.	Etoposide	81-90	heat shock protein family B (small) member 1	Homo sapiens	141-162
11885806-2	2002	Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin have an effect on the expression of heat shock protein 27 in tumour cells such as: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and also in normal human skin fibroblasts (HSF) cultured in two-dimensional (2D) and three-dimensional (3D) conditions.	Etoposide	81-90	interleukin 6	Homo sapiens	297-300
11747551-8	2002	Although no overall increase could be observed in whole testis samples of the etoposide-treated rat, stage-specific analysis revealed an induction of p21 expression in stages XIII-I.	Etoposide	78-87	KRAS proto-oncogene, GTPase	Rattus norvegicus	150-153
12803126-1	2002	BACKGROUND: Big ICE chemotherapy (consisting of Idarubicin, high dose Cytosine arabinoside and Etoposide), has proven its efficacy in the treatment of patients with relapse/refractory acute myeloblastic leukemia.	Etoposide	95-104	carboxylesterase 2	Homo sapiens	16-19
12138235-8	2002	CONCLUSIONS: Intra-arterial chemotherapy using cisplatin and etoposide seems to have some anti-tumor effect against advanced HCC, although a high rate of life- threatening complications precludes the indication of this regimen at least for patients with non-compensated cirrhosis.	Etoposide	61-70	HCC	Homo sapiens	125-128
11801733-5	2002	In contrast, Rad51 antisense inhibition reduces p21 protein levels and sensitizes cells to etoposide treatment.	Etoposide	91-100	RAD51 recombinase	Homo sapiens	13-18
12112003-0	2002	Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y.	Etoposide	44-53	glutathione S-transferase pi 1	Homo sapiens	8-16
12112003-4	2002	Etoposide treatment was able to induce GST P1-1 polymerization and activation of apoptosis.	Etoposide	0-9	glutathione S-transferase pi 1	Homo sapiens	39-47
12112003-5	2002	The data obtained from our etoposide-resistant clone and the possibility to reverse the sensitive phenotype to a resistant one by means of hexyl-glutathione preincubation, seem to suggest that cellular levels of glutathione have a key role in protecting GST P1-1 by oxidation and consequently the cell"s decision between life and death.	Etoposide	27-36	glutathione S-transferase pi 1	Homo sapiens	254-262
12415617-0	2002	Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells.	Etoposide	56-65	interleukin 1 alpha	Homo sapiens	0-19
12415617-4	2002	The present investigation demonstrated that IL-1 alpha dramatically increased the sensitivity of MG-63, SAOS-2, and TE-85 osteosarcoma cells to etoposide when the two agents were used simultaneously.	Etoposide	144-153	interleukin 1 alpha	Homo sapiens	44-54
12415617-5	2002	The cytostatic activity of 1 microM etoposide was increased from 35 to 70%, 30 to 65%, and 4 to 90%, respectively, by 5.0 U/ml IL-1 alpha.	Etoposide	36-45	interleukin 1 alpha	Homo sapiens	127-137
11840269-4	2002	MDR-1 (but not tNGFR) expression was associated with verapamil-sensitive rhodamine efflux and resistance to killing by etoposide.	Etoposide	119-128	malic enzyme complex, mitochondrial	Mus musculus	0-5
11739733-0	2002	Tyrosine phosphorylation of protein kinase Cdelta is essential for its apoptotic effect in response to etoposide.	Etoposide	103-112	protein kinase C delta	Homo sapiens	28-49
11739733-2	2002	In this study, we characterized the role of PKCdelta in the apoptosis of C6 glioma cells in response to etoposide.	Etoposide	104-113	protein kinase C delta	Homo sapiens	44-52
11739733-4	2002	Overexpression of PKCdelta increased the apoptotic effect induced by etoposide, whereas the PKCdelta selective inhibitor rottlerin and the PKCdelta dominant-negative mutant K376R reduced this effect compared to control cells.	Etoposide	69-78	protein kinase C delta	Homo sapiens	18-26
11739733-5	2002	Etoposide-induced tyrosine phosphorylation of PKCdelta and its translocation to the nucleus within 3 h was followed by caspase-dependent cleavage of the enzyme.	Etoposide	0-9	protein kinase C delta	Homo sapiens	46-54
11739733-7	2002	The role of tyrosine phosphorylation of PKCdelta in the effects of etoposide was examined using cells overexpressing a PKCdelta mutant in which five tyrosine residues were mutated to phenylalanine (PKCdelta5).	Etoposide	67-76	protein kinase C delta	Homo sapiens	40-48
11739733-10	2002	Using mutants of PKCdelta altered at individual tyrosine residues, we identified tyrosine 64 and tyrosine 187 as important phosphorylation sites in the apoptotic effect induced by etoposide.	Etoposide	180-189	protein kinase C delta	Homo sapiens	17-25
11739733-11	2002	Our results suggest a role of PKCdelta in the apoptosis induced by etoposide and implicate tyrosine phosphorylation of PKCdelta as an important regulator of this effect.	Etoposide	67-76	protein kinase C delta	Homo sapiens	30-38
11739733-11	2002	Our results suggest a role of PKCdelta in the apoptosis induced by etoposide and implicate tyrosine phosphorylation of PKCdelta as an important regulator of this effect.	Etoposide	67-76	protein kinase C delta	Homo sapiens	119-127
12476615-0	2002	The effect of cisplatin, etoposide and quercetin on Hsp72 expression.	Etoposide	25-34	heat shock protein family A (Hsp70) member 1A	Homo sapiens	52-57
12476615-2	2002	Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin influence the expression of heat shock protein 72 in tumour cells: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and normal human skin fibroblasts (HSF).	Etoposide	81-90	heat shock protein family A (Hsp70) member 1A	Homo sapiens	133-154
12476615-2	2002	Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin influence the expression of heat shock protein 72 in tumour cells: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and normal human skin fibroblasts (HSF).	Etoposide	81-90	interleukin 6	Homo sapiens	273-276
11581266-3	2001	Stable clones overproducing MRP3 were resistant to the epipodophyllotoxins etoposide and teniposide but not to vincristine, doxorubicin, and cisplatin, drugs suggested to be MRP3 substrates by others.	Etoposide	75-84	ATP binding cassette subfamily C member 3	Homo sapiens	28-32
11741320-0	2001	Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR.	Etoposide	0-9	checkpoint kinase 2	Homo sapiens	78-82
11741320-1	2001	We have investigated the effects of three unrelated topoisomerase 2 inhibitors, genistein, adriamycin, and etoposide, on phosphorylation/activation of the checkpoint kinase Chk2 in normal or ATM-deficient (ATM-) human fibroblasts and in cells overexpressing a catalytically inactive ATR kinase.	Etoposide	107-116	checkpoint kinase 2	Homo sapiens	173-177
11741320-2	2001	We demonstrate that genistein activates Chk2 in a strictly ATM-dependent manner, whereas etoposide and adriamycin can trigger Chk2 activation in long-term cultures of ATM- cells.	Etoposide	89-98	checkpoint kinase 2	Homo sapiens	126-130
11741320-2	2001	We demonstrate that genistein activates Chk2 in a strictly ATM-dependent manner, whereas etoposide and adriamycin can trigger Chk2 activation in long-term cultures of ATM- cells.	Etoposide	89-98	ATM serine/threonine kinase	Homo sapiens	167-170
11746439-11	2001	Taken together, our data suggest that Bcl-X(L) prevents etoposide-induced neuronal death by exerting its anticaspase and anticalpain effect on cellular events after the formation of topoisomerase II-DNA cleavable complex that may not be a major contributor to cell death.	Etoposide	56-65	BCL2-like 1	Mus musculus	38-46
11755216-7	2001	In addition, etoposide-treated P388 cells induced neutrophil infiltration as well as MIP-2 production upon injection into the peritoneal cavity of either normal mice or mice with sterile peritonitis.	Etoposide	13-22	chemokine (C-X-C motif) ligand 2	Mus musculus	85-90
11598139-10	2001	Functionally, the transient overexpression of fortilin in HeLa cells prevented them, in a dose-dependent fashion, from undergoing etoposide-induced apoptosis.	Etoposide	130-139	tumor protein, translationally-controlled 1	Homo sapiens	46-54
11598139-11	2001	Consistently, U2OS cells stably expressing fortilin protected the cells from cell death induced by etoposide over various concentrations and durations of exposure.	Etoposide	99-108	tumor protein, translationally-controlled 1	Homo sapiens	43-51
11581266-6	2001	The transport of estradiol 17-beta-D-glucuronide by MRP3 was inhibited in a concentration-dependent manner by both etoposide and methotrexate.	Etoposide	115-124	ATP binding cassette subfamily C member 3	Homo sapiens	52-56
11581266-7	2001	Even though etoposide glucuronide is an excellent substrate for MRP3, this compound is not involved in the etoposide resistance of our MRP3 cells, as these cells extrude unmodified etoposide rather than etoposide glucuronide.	Etoposide	12-21	ATP binding cassette subfamily C member 3	Homo sapiens	64-68
11581266-5	2001	Membrane vesicles from infected insect cells expressing MRP3 mediated ATP-dependent transport of estradiol 17-beta-D-glucuronide, leukotriene C(4), dinitrophenyl S-glutathione but not glutathione itself, and etoposide glucuronide, a major metabolite of etoposide in vivo.	Etoposide	208-217	ATP binding cassette subfamily C member 3	Homo sapiens	56-60
11718848-4	2001	Overexpression of TERT in PC12 cells increases their resistance to the topoisomerase inhibitors camptothecin and etoposide.	Etoposide	113-122	telomerase reverse transcriptase	Rattus norvegicus	18-22
11684284-0	2001	p53 and redox state in etoposide-induced acute myeloblastic leukemia cell death.	Etoposide	23-32	tumor protein p53	Homo sapiens	0-3
11684284-1	2001	We investigated whether p53, being a redox-sensitive protein, has a role in the responsiveness of AML cells to etoposide.	Etoposide	111-120	tumor protein p53	Homo sapiens	24-27
11684284-6	2001	After etoposide exposure for up to 24 hours, some nuclear accumulation of p53 was observed in the ER subclone, as analysed by Western blotting.	Etoposide	6-15	tumor protein p53	Homo sapiens	74-77
11742497-5	2001	In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin.	Etoposide	119-128	MDM2 proto-oncogene	Homo sapiens	36-40
11794709-0	2001	Acute myeloid leukemia with t(11;19)(q23;p13) developing in an adult T-cell leukemia patient treated with combined chemotherapy including etoposide.	Etoposide	138-147	H3 histone pseudogene 6	Homo sapiens	41-44
11698292-9	2001	In contrast, in vitro treatment with cytarabine and etoposide induced p53 protein, CD95 receptor expression, CD95 sensitivity, and CD95 receptor-ligand interaction in stimulated cycling lymphocytes, but no such induction was seen in resting cells.	Etoposide	52-61	tumor protein p53	Homo sapiens	70-73
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Etoposide	190-199	phosphoglycolate phosphatase	Mus musculus	14-18
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Etoposide	190-199	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Etoposide	190-199	phosphoglycolate phosphatase	Mus musculus	86-90
11707575-5	2001	Consistently, P-gp modulators dramatically altered the pattern of cross-resistance of P-gp-expressing cells to different P-gp substrates: an increase in resistance to Adr, daunorubicin, and etoposide was accompanied by cell sensitization to Vinca alkaloids, gramicidin D, and Taxol with no effect on cell sensitivity to colchicine, actinomycin D, puromycin, and colcemid, as well as to several non-P-gp substrates.	Etoposide	190-199	phosphoglycolate phosphatase	Mus musculus	86-90
11698292-9	2001	In contrast, in vitro treatment with cytarabine and etoposide induced p53 protein, CD95 receptor expression, CD95 sensitivity, and CD95 receptor-ligand interaction in stimulated cycling lymphocytes, but no such induction was seen in resting cells.	Etoposide	52-61	Fas cell surface death receptor	Homo sapiens	83-87
11698292-9	2001	In contrast, in vitro treatment with cytarabine and etoposide induced p53 protein, CD95 receptor expression, CD95 sensitivity, and CD95 receptor-ligand interaction in stimulated cycling lymphocytes, but no such induction was seen in resting cells.	Etoposide	52-61	Fas cell surface death receptor	Homo sapiens	109-113
11698292-9	2001	In contrast, in vitro treatment with cytarabine and etoposide induced p53 protein, CD95 receptor expression, CD95 sensitivity, and CD95 receptor-ligand interaction in stimulated cycling lymphocytes, but no such induction was seen in resting cells.	Etoposide	52-61	Fas cell surface death receptor	Homo sapiens	109-113
11691792-2	2001	Myeloperoxidase (MPO)-catalyzed one-electron oxidation of the etoposide phenolic ring and/or interaction of this phenolic moiety with reactive radicals yields its phenoxyl radical, whose reactivity may determine the pro- or antioxidant effects of this molecule in cells.	Etoposide	62-71	myeloperoxidase	Homo sapiens	0-15
11822756-16	2001	The MTD was reached at the doses of 100 mg/m2 topotecan and 75 mg/m2 etoposide.	Etoposide	69-78	metallothionein 1E	Homo sapiens	4-7
11911275-6	2001	MG-132 was found to be more effective in combination with drugs such as doxorubicin and etoposide that act in the S/G2-phase of the cell cycle via a mechanism that involves stabilization of cyclin B1 and increased expression of Bax.	Etoposide	88-97	cyclin B1	Homo sapiens	190-199
11911275-6	2001	MG-132 was found to be more effective in combination with drugs such as doxorubicin and etoposide that act in the S/G2-phase of the cell cycle via a mechanism that involves stabilization of cyclin B1 and increased expression of Bax.	Etoposide	88-97	BCL2 associated X, apoptosis regulator	Homo sapiens	228-231
11691792-2	2001	Myeloperoxidase (MPO)-catalyzed one-electron oxidation of the etoposide phenolic ring and/or interaction of this phenolic moiety with reactive radicals yields its phenoxyl radical, whose reactivity may determine the pro- or antioxidant effects of this molecule in cells.	Etoposide	62-71	myeloperoxidase	Homo sapiens	17-20
11691792-9	2001	Whereas one-electron oxidation of etoposide by free radical scavenging and/or by MPO results in a phenoxyl radical with low reactivity toward lipids, its high reactivity toward thiols is a determinant of its pro-oxidant effects in HL-60 cells.	Etoposide	34-43	myeloperoxidase	Homo sapiens	81-84
11691792-3	2001	Using MPO-rich HL-60 cells, we directly demonstrated that both anti- and pro-oxidant activities of etoposide are realized in cells.	Etoposide	99-108	myeloperoxidase	Homo sapiens	6-9
11691792-4	2001	Etoposide acted as an effective radical scavenger and antioxidant protector of phosphatidylethanolamine, phosphatidylcholine, and other intracellular phospholipids against H2O2-induced oxidation in HL-60 cells with constitutively high MPO activity and in HL-60 cells depleted of MPO by an inhibitor of heme synthesis, succinyl acetone.	Etoposide	0-9	myeloperoxidase	Homo sapiens	235-238
11691792-4	2001	Etoposide acted as an effective radical scavenger and antioxidant protector of phosphatidylethanolamine, phosphatidylcholine, and other intracellular phospholipids against H2O2-induced oxidation in HL-60 cells with constitutively high MPO activity and in HL-60 cells depleted of MPO by an inhibitor of heme synthesis, succinyl acetone.	Etoposide	0-9	myeloperoxidase	Homo sapiens	279-282
12109062-10	2001	MRP1 transduced fibroblasts were more resistant to doxorubicin, vincristine, and etoposide and their chemoprotection was increased after selection with chemotherapeutic agents in the presence of glutathione, a co-factor for MRP1 function.	Etoposide	81-90	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	0-4
11785305-4	2001	At the same time the strain with overexpression of a protease dcp-1 gene and the strain with the defect of antiapoptosis diap-1/th gene decreased the life span after irradiation and etoposide treatment.	Etoposide	182-191	Death caspase-1	Drosophila melanogaster	62-67
11745417-6	2001	Basal MVP expression correlated with resistance against diverse antineoplastic drugs including anthracyclins, cisplatin and etoposide.	Etoposide	124-133	major vault protein	Homo sapiens	6-9
11785305-4	2001	At the same time the strain with overexpression of a protease dcp-1 gene and the strain with the defect of antiapoptosis diap-1/th gene decreased the life span after irradiation and etoposide treatment.	Etoposide	182-191	Death-associated inhibitor of apoptosis 1	Drosophila melanogaster	121-127
11574073-4	2001	We found that an actin binding protein, filamin, was cleaved from 280 kDa to 170, 150, and 120 kDa major N-terminal fragments, and 135, 120, and 110 kDa major C-terminal fragments when apoptosis was induced by etoposide in both the human monoblastic leukemia cell line U937, and the human T lymphoblastic cell line Jurkat.	Etoposide	210-219	filamin C	Homo sapiens	40-47
11593023-3	2001	The LIG4(-/-) cells showed a marked sensitivity to X-rays, bleomycin, and VP-16 and were more x-ray-sensitive in G(1) than late S or G(2)/M, suggesting a critical role of Lig4 in DSB repair by NHEJ.	Etoposide	74-79	ligase IV, DNA, ATP-dependent	Mus musculus	4-8
11641785-4	2001	Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine.	Etoposide	90-99	BRCA1 DNA repair associated	Homo sapiens	24-29
11595714-10	2001	Characterization of the resistant cell lines indicated the presence of increased mdr-1 and P-gp expression, which resulted in resistance to the agents doxorubicin, etoposide, and vincristine but not cisplatin.	Etoposide	164-173	ATP binding cassette subfamily B member 1	Homo sapiens	81-86
11595714-10	2001	Characterization of the resistant cell lines indicated the presence of increased mdr-1 and P-gp expression, which resulted in resistance to the agents doxorubicin, etoposide, and vincristine but not cisplatin.	Etoposide	164-173	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
11576999-13	2001	Since over 50% of human tumors contain a functionally defective p53 that reduces sensitivity to commonly used chemotherapeutic agents, such as etoposide and cisplatin, the ability of tachpyridine to induce apoptosis independently of p53 may offer an advantage in anti-tumor therapy.	Etoposide	143-152	tumor protein p53	Homo sapiens	64-67
11585429-0	2001	Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival.	Etoposide	57-66	host cell factor C1	Homo sapiens	68-73
11585429-5	2001	Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months.	Etoposide	23-32	host cell factor C1	Homo sapiens	34-39
11604558-5	2001	Etoposide rapidly induced apoptosis, dependent on caspase-3 and -8, but inhibition of these caspases did not prevent major cell death, but promoted a switch in late morphology.	Etoposide	0-9	caspase 3	Homo sapiens	50-66
11535527-5	2001	Cellular adhesion by means of beta1 integrins resulted in a 40% to 60% reduction in mitoxantrone- and etoposide-induced DNA double-strand breaks.	Etoposide	102-111	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	30-35
11594568-4	2001	Mobilization of CD34+ stem cells was achieved with etoposide and G-CSF.	Etoposide	51-60	CD34 molecule	Homo sapiens	16-20
11593412-4	2001	Also both NF-kappaB and Ku activities were activated or inhibited by treatment with etoposide (VP-16) or MG-132 (a proteasome inhibitor), respectively.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	10-19
11593412-4	2001	Also both NF-kappaB and Ku activities were activated or inhibited by treatment with etoposide (VP-16) or MG-132 (a proteasome inhibitor), respectively.	Etoposide	95-100	nuclear factor kappa B subunit 1	Homo sapiens	10-19
11697847-3	2001	Between 1994 and 1997, three patients with SCC of the esophagus were treated at Besancon University Hospital and this represented 1.85% of all esophageal malignancies diagnosed during this period: one patient had a limited tumor and underwent initial surgical resection, then chemotherapy with cisplatine and etoposide, and radiotherapy for recurrences.	Etoposide	309-318	serpin family B member 3	Homo sapiens	43-46
11604558-7	2001	Hence, this study provides support for caspase-8-mediated apoptosis in U-937 GTB when exposed to etoposide.	Etoposide	97-106	caspase 8	Homo sapiens	39-48
11848465-6	2001	HA-bax clones were significantly more sensitive to cell death induction by cis-diamminedichloroplatinum, etoposide, doxorubicin and gamma-radiation than vector control cells.	Etoposide	105-114	BCL2 associated X, apoptosis regulator	Homo sapiens	3-6
11502888-7	2001	In this study, we show that I kappa B alpha M expression inhibits stress-induced NF-kappa B activation and prevents BFA-, hypoxia-, and OA-induced resistance to etoposide.	Etoposide	161-170	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	28-43
11601682-5	2001	In fact, several antineoplastic drugs used in the neuroblastoma high-risk chemotherapeutic protocol are potential substrates of GSTP1-1 (etoposide, adriamycin and carboplatin).	Etoposide	137-146	glutathione S-transferase pi 1	Homo sapiens	128-135
11473362-5	2001	We found that the activating transcription factor 3 (ATF3) protein, a repressor of cyclic-AMP responsive element (CRE)-dependent transcription, was strongly induced among CRE-BP/ATF members and subsequently accumulated in nuclei following camptothecin or etoposide treatment.	Etoposide	255-264	activating transcription factor 3	Homo sapiens	18-51
11473362-5	2001	We found that the activating transcription factor 3 (ATF3) protein, a repressor of cyclic-AMP responsive element (CRE)-dependent transcription, was strongly induced among CRE-BP/ATF members and subsequently accumulated in nuclei following camptothecin or etoposide treatment.	Etoposide	255-264	activating transcription factor 3	Homo sapiens	53-57
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	89-92
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	89-92
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily C member 1	Homo sapiens	167-171
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	89-92
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily C member 1	Homo sapiens	167-171
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	52-55
11504821-8	2001	The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1).	Etoposide	14-23	ATP binding cassette subfamily C member 1	Homo sapiens	60-64
11571709-3	2001	METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab).	Etoposide	278-287	BCL2 apoptosis regulator	Homo sapiens	84-89
11571709-3	2001	METHODS AND RESULTS: We report an accurate method for quantitative detection of the bcl-2/IgH translocation marker of follicular lymphoma in a series of patients in various stages of remission and relapse who had been treated with a combination of ifosfamide, mitoxantrone, and etoposide (MINE) chemotherapy and monoclonal anti-CD20 antibody (Rituximab).	Etoposide	278-287	immunoglobulin heavy locus	Homo sapiens	90-93
11502888-8	2001	These results indicate that NF-kappa B activation mediates both chemical and physiological drug resistance to etoposide.	Etoposide	110-119	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	28-38
11511102-3	2001	In Rat-1 cells, cleavage of paxillin by caspase-3 was suppressed by zVAD-fmk or zDEVD-cmk, making caspase-3 a likely executioner during etoposide-induced apoptosis.	Etoposide	136-145	caspase 3	Rattus norvegicus	40-49
11406628-1	2001	VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement.	Etoposide	0-5	lysine methyltransferase 2A	Homo sapiens	133-136
11406628-1	2001	VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement.	Etoposide	0-5	lysine methyltransferase 2A	Homo sapiens	200-203
11406628-1	2001	VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement.	Etoposide	7-16	lysine methyltransferase 2A	Homo sapiens	133-136
11406628-1	2001	VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (bcr), suggesting a role of TOP2 in MLL gene rearrangement.	Etoposide	7-16	lysine methyltransferase 2A	Homo sapiens	200-203
11511102-3	2001	In Rat-1 cells, cleavage of paxillin by caspase-3 was suppressed by zVAD-fmk or zDEVD-cmk, making caspase-3 a likely executioner during etoposide-induced apoptosis.	Etoposide	136-145	caspase 3	Rattus norvegicus	98-107
11534713-3	2001	It was possible to separate the substances 5-fluorouracil (5-FU), methotrexate (MTX), 7-hydroxymethotrexate (7-OH-MTX), and etoposide (VP-16) in one chromatographic run.	Etoposide	124-133	host cell factor C1	Homo sapiens	135-140
11507071-9	2001	Loss of p53 function was selectively achieved by transduction of human papillomavirus 16 E6 (which degrades p53) into two drug-sensitive neuroblastoma cell lines with intact p53, causing high-level drug resistance to L-PAM, carboplatin, and etoposide.	Etoposide	241-250	tumor protein p53	Homo sapiens	8-11
11399756-4	2001	Accordingly, we explored whether the well described mitochondrial apoptotic stimuli staurosporine (STS) and etoposide activate Akt and whether such activation impacts apoptosis.	Etoposide	108-117	thymoma viral proto-oncogene 1	Mus musculus	127-130
11399756-5	2001	Both STS and etoposide activated Akt in NIH 3T3 cells, maximally at 8 and 2 h, respectively, preceding the onset of apoptosis and poly(ADP-ribose) polymerase cleavage.	Etoposide	13-22	thymoma viral proto-oncogene 1	Mus musculus	33-36
11481424-4	2001	Unlike p33ING1b, p33ING2 is induced by the DNA-damaging agents etoposide and neocarzinostatin.	Etoposide	63-72	inhibitor of growth family member 2	Homo sapiens	17-24
11521193-0	2001	Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis.	Etoposide	71-80	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
11513857-6	2001	However, subsequent exposure of CCCP-treated cells to etoposide or staurosporine for 48 h results in rapid cell death and cytochrome c release that is accompanied by Bax association with mitochondria, demonstrating competency of these mitochondria to release cytochrome c with additional triggers.	Etoposide	54-63	cytochrome c, somatic	Homo sapiens	122-134
11513857-6	2001	However, subsequent exposure of CCCP-treated cells to etoposide or staurosporine for 48 h results in rapid cell death and cytochrome c release that is accompanied by Bax association with mitochondria, demonstrating competency of these mitochondria to release cytochrome c with additional triggers.	Etoposide	54-63	BCL2 associated X, apoptosis regulator	Homo sapiens	166-169
11513857-6	2001	However, subsequent exposure of CCCP-treated cells to etoposide or staurosporine for 48 h results in rapid cell death and cytochrome c release that is accompanied by Bax association with mitochondria, demonstrating competency of these mitochondria to release cytochrome c with additional triggers.	Etoposide	54-63	cytochrome c, somatic	Homo sapiens	259-271
11521193-5	2001	Bax up-regulation occurred at the whole cell level after DNA damage induced by etoposide.	Etoposide	79-88	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
11521193-6	2001	However, after incubation with etoposide, Bax failed to translocate to mitochondria and as a result, the apoptotic process was blocked.	Etoposide	31-40	BCL2 associated X, apoptosis regulator	Homo sapiens	42-45
11521193-10	2001	The increased levels of mitochondrial Bax sensitized cells to etoposide-induced activation of caspases-2, -3 and -9 and apoptosis.	Etoposide	62-71	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
11521193-10	2001	The increased levels of mitochondrial Bax sensitized cells to etoposide-induced activation of caspases-2, -3 and -9 and apoptosis.	Etoposide	62-71	caspase 2	Homo sapiens	94-115
11521193-11	2001	However, after transient transfection with the Apaf-1 gene, K/Bax cells were sensitized to etoposide-induced caspase activation and apoptosis to a larger extent compared with Bax or Apaf-1 transfection alone.	Etoposide	91-100	apoptotic peptidase activating factor 1	Homo sapiens	47-53
11521193-11	2001	However, after transient transfection with the Apaf-1 gene, K/Bax cells were sensitized to etoposide-induced caspase activation and apoptosis to a larger extent compared with Bax or Apaf-1 transfection alone.	Etoposide	91-100	BCL2 associated X, apoptosis regulator	Homo sapiens	62-65
11521193-12	2001	We therefore conclude that two mechanisms contribute to the resistance of K562 cells to etoposide-induced apoptosis; firstly failure of Bax targeting to mitochondria and, secondly, deficiency of Apaf-1.	Etoposide	88-97	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139
11521193-12	2001	We therefore conclude that two mechanisms contribute to the resistance of K562 cells to etoposide-induced apoptosis; firstly failure of Bax targeting to mitochondria and, secondly, deficiency of Apaf-1.	Etoposide	88-97	apoptotic peptidase activating factor 1	Homo sapiens	195-201
11521193-13	2001	Uncoupling of Bax translocation from Bax induction can occur in response to etoposide-induced DNA damage.	Etoposide	76-85	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
11521193-13	2001	Uncoupling of Bax translocation from Bax induction can occur in response to etoposide-induced DNA damage.	Etoposide	76-85	BCL2 associated X, apoptosis regulator	Homo sapiens	37-40
11469800-0	2001	Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.	Etoposide	221-230	peroxiredoxin 2	Homo sapiens	0-24
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	Etoposide	154-163	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	Etoposide	165-168	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11487718-12	2001	It was shown that BAX Nf increased in cells treated with CPT, STP, ETO, 2CdA and NIM, whereas BAX Cf rose after STP and NIM.	Etoposide	67-70	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
11469800-0	2001	Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.	Etoposide	221-230	peroxiredoxin 1	Homo sapiens	26-41
11469800-4	2001	Transfection of mouse WEHI7.2 lymphoma cells with human TrxP-1 or TrxP-2, but not TrxP-4, protects the cells against H(2)O(2) induced apoptosis but does not protect against apoptosis induced by dexamethasone, etoposide, or doxorubicin.	Etoposide	209-218	peroxiredoxin 2	Homo sapiens	56-62
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Etoposide	374-383	colony stimulating factor 3	Homo sapiens	128-133
11489834-2	2001	We previously reported that GLO1 was a resistant factor to antitumor agent-induced apoptosis, and that S-p-bromobenzylglutathione cyclopentyl diester (BBGC), an effective inhibitor of GLO1, selectively sensitized to etoposide the drug-resistant human leukemia cells that overexpressed GLO1.	Etoposide	216-225	glyoxalase I	Homo sapiens	28-32
11489834-2	2001	We previously reported that GLO1 was a resistant factor to antitumor agent-induced apoptosis, and that S-p-bromobenzylglutathione cyclopentyl diester (BBGC), an effective inhibitor of GLO1, selectively sensitized to etoposide the drug-resistant human leukemia cells that overexpressed GLO1.	Etoposide	216-225	glyoxalase I	Homo sapiens	184-188
11489834-2	2001	We previously reported that GLO1 was a resistant factor to antitumor agent-induced apoptosis, and that S-p-bromobenzylglutathione cyclopentyl diester (BBGC), an effective inhibitor of GLO1, selectively sensitized to etoposide the drug-resistant human leukemia cells that overexpressed GLO1.	Etoposide	216-225	glyoxalase I	Homo sapiens	184-188
11459812-7	2001	Among the compounds tested, two inhibitors of topo II, amsacrine and etoposide, attenuated the formation of osteoclast-like cells via reciprocal regulation of the expression of mRNAs for RANKL and OPG in ST2 cells, acting similarly to genistein.	Etoposide	69-78	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	187-192
11459812-7	2001	Among the compounds tested, two inhibitors of topo II, amsacrine and etoposide, attenuated the formation of osteoclast-like cells via reciprocal regulation of the expression of mRNAs for RANKL and OPG in ST2 cells, acting similarly to genistein.	Etoposide	69-78	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	197-200
11463563-3	2001	METHODS: Between November 1981 and June 1996, 75 patients in stage I--III A, many of them with a bulky cN2 tumor at presentation, were exposed to VP-16 based cytoreductive chemotherapy.	Etoposide	146-151	carnosine dipeptidase 2	Homo sapiens	103-106
11466671-1	2001	BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.	Etoposide	301-310	colony stimulating factor 3	Homo sapiens	128-133
11506966-4	2001	The protection was dose- and time-dependent -- maximal protection requiring pre-incubation with 100 ng/ml HGF for 48 h. Western blotting analysis and flow cytometric studies revealed that HGF inhibited doxorubicin- and etoposide-induced decreases in the levels of the anti-apoptotic proteins Bcl-X(L), and to a lesser extent Bcl-2, without inducing changes in the pro-apoptotic Bax protein.	Etoposide	219-228	hepatocyte growth factor	Homo sapiens	106-109
11506966-4	2001	The protection was dose- and time-dependent -- maximal protection requiring pre-incubation with 100 ng/ml HGF for 48 h. Western blotting analysis and flow cytometric studies revealed that HGF inhibited doxorubicin- and etoposide-induced decreases in the levels of the anti-apoptotic proteins Bcl-X(L), and to a lesser extent Bcl-2, without inducing changes in the pro-apoptotic Bax protein.	Etoposide	219-228	hepatocyte growth factor	Homo sapiens	188-191
11573250-6	2001	Survivin antisense oligonucleotide markedly sensitized HeLa cells to cell death induced by agents acting at the level of cell surface receptor (Fas pathway) or at the level of mitochondria (etoposide).	Etoposide	190-199	Deterin	Drosophila melanogaster	0-8
11589488-0	2001	Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC).	Etoposide	62-71	carboxylesterase 2	Homo sapiens	73-76
11551417-5	2001	Also, H460/CIS cells exhibited cross-resistance to DNA damaging agents such as doxorubicin (DXR) and etoposide.	Etoposide	101-110	cytokine inducible SH2 containing protein	Homo sapiens	6-14
11454692-1	2001	We examined the role of multidrug resistance protein (MRP) 1 (ABCC1) in the emergence of mitoxantrone (MX) cross-resistance in a MCF7 breast cancer cell line selected for resistance to etoposide.	Etoposide	185-194	ATP binding cassette subfamily C member 1	Homo sapiens	62-67
11724338-1	2001	It was previously reported that thymic lymphomas of anti HY-TCR transgenic mice were resistant to ionomycin but were sensitive to 50 microM of etoposide.	Etoposide	143-152	T cell receptor alpha variable 6-3	Mus musculus	60-63
11323435-7	2001	Finally, using an antisense strategy, we demonstrated that a reduction of 40% in Twist expression decreased significantly the ability of IGF-1 to rescue NWTb3 cells from etoposide-induced apoptosis.	Etoposide	170-179	insulin like growth factor 1	Homo sapiens	137-142
11331275-9	2001	In contrast to vitamin D(3), cisplatin and etoposide down-regulated Akt levels only modestly, did not promote significant loss of MEK expression, and did not up-regulate MEKK-1.	Etoposide	43-52	thymoma viral proto-oncogene 1	Mus musculus	68-71
11431014-0	2001	Resistance of CD4-positive T lymphocytes to etoposide-induced apoptosis mediated by upregulation of Bcl-xL expression in patients with HTLV-I-associated myelopathy.	Etoposide	44-53	CD4 molecule	Homo sapiens	14-17
11431014-0	2001	Resistance of CD4-positive T lymphocytes to etoposide-induced apoptosis mediated by upregulation of Bcl-xL expression in patients with HTLV-I-associated myelopathy.	Etoposide	44-53	BCL2 like 1	Homo sapiens	100-106
11431014-5	2001	Apoptosis was induced by etoposide, which induces mitochondria-dependent apoptosis through the release of cytochrome c from the mitochondria.	Etoposide	25-34	cytochrome c, somatic	Homo sapiens	106-118
11431014-6	2001	The percentage of apoptotic cells that expressed hypodiploid DNA among etoposide-treated CD4(+) T lymphocytes was significantly lower in HAM patients than in the control.	Etoposide	71-80	CD4 molecule	Homo sapiens	89-92
11472983-6	2001	TRAIL plus chemotherapy (doxorubicin, cis-platinum, etoposide, or gemcitabine) acted cooperatively to induce apoptosis in mesothelioma cells (M28, REN, VAMT, and MS-1).	Etoposide	52-61	TNF superfamily member 10	Homo sapiens	0-5
11416148-3	2001	We show here that in Rat1 cells expressing an exogenous c-myc allele, distinct apoptotic pathways can be inhibited by Bcl-2 or Bcl-acta yet be distinguished by their sensitivity to Bcl-cb5 as either susceptible (serum withdrawal, taxol, and ceramide) or refractory (etoposide and doxorubicin).	Etoposide	266-275	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	56-61
11469679-3	2001	In order to gain insight into the molecular basis for these observations, we investigated the effect of hyperthermia and/or carboplatin on the stress protein GRP78, which is known to affect VP-16 cytotoxicity.	Etoposide	190-195	heat shock protein 5	Mus musculus	158-163
11473730-5	2001	SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression.	Etoposide	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
11486401-1	2001	Continuous exposure to naturally-derived chemotherapy agents such as etoposide may theoretically override drug resistance due to overexpression of the multidrug resistance gene product, p-glycoprotein.	Etoposide	69-78	ATP binding cassette subfamily B member 1	Homo sapiens	186-200
11449356-6	2001	Etoposide-induced expression of the cleaved, proteolytically active form of caspase 3, and DEVD-ase activity, detected prior to nuclear damage, were blocked in the presence of calpain inhibitors.	Etoposide	0-9	caspase 3	Mus musculus	76-85
11473400-1	2001	The anticancer drug etoposide is associated with leukemias with MLL gene translocations and other translocations as a treatment complication.	Etoposide	20-29	lysine methyltransferase 2A	Homo sapiens	64-67
11473400-2	2001	The genotype of cytochrome P450 3A4 (CYP3A4), which converts etoposide to its catechol metabolite, influences the risk.	Etoposide	61-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-35
11473400-2	2001	The genotype of cytochrome P450 3A4 (CYP3A4), which converts etoposide to its catechol metabolite, influences the risk.	Etoposide	61-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
11473732-0	2001	Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
11516723-8	2001	Moreover, the detection of mutants at the Aprt locus gives an indication of the potential of etoposide to cause chromosomal mutations that may lead to secondary malignancy.	Etoposide	93-102	adenine phosphoribosyltransferase	Homo sapiens	42-46
11391579-2	2001	The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma.	Etoposide	131-140	vasoactive intestinal peptide	Homo sapiens	169-172
11423989-6	2001	Adriamycin, etoposide, cisplatinum, colcemid and resveratrol induce distinct cellular responses; however, absence of p21 favors apoptosis-induction by adriamycin, etoposide and colcemid.	Etoposide	163-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	117-120
11395572-2	2001	The line, named WEHI-3B/CPX, expresses a specific resistance to ciprofloxacin (CPX; resistance index=17.3+/-2.2), and does not show cross-resistance with other fluoroquinolones, camptothecin and topoisomerase II inhibitors such as doxorubicin, etoposide and teniposide.	Etoposide	244-253	coproporphyrinogen oxidase	Mus musculus	16-27
11453544-6	2001	The expression of the suppressor PML protein and heat shock protein HSC70 were significantly upregulated after etoposide treatment, while NuMA, a nuclear mitotic apparatus protein, was down regulated.	Etoposide	111-120	PML nuclear body scaffold	Homo sapiens	33-36
11391686-7	2001	RESULTS: Anti-IL-6 Ab (with saline or etoposide) induced tumor apoptosis and regression ( approximately 60% compared to initial tumor size).	Etoposide	38-47	interleukin 6	Mus musculus	14-18
11389098-9	2001	In contrast, overexpression of PKCdelta rendered the U87 cells more sensitive to the apoptotic effect of etoposide, and PKCdelta was cleaved in these cells by a caspase-dependent process.	Etoposide	105-114	protein kinase C delta	Homo sapiens	31-39
11389098-10	2001	Furthermore, the glioma cell line U373, which expresses endogenous PKCdelta, underwent apoptosis in response to etoposide, and the apoptotic response was blocked by the PKCdelta inhibitor rottlerin.	Etoposide	112-121	protein kinase C delta	Homo sapiens	67-75
11389098-10	2001	Furthermore, the glioma cell line U373, which expresses endogenous PKCdelta, underwent apoptosis in response to etoposide, and the apoptotic response was blocked by the PKCdelta inhibitor rottlerin.	Etoposide	112-121	protein kinase C delta	Homo sapiens	169-177
11453544-6	2001	The expression of the suppressor PML protein and heat shock protein HSC70 were significantly upregulated after etoposide treatment, while NuMA, a nuclear mitotic apparatus protein, was down regulated.	Etoposide	111-120	heat shock protein family A (Hsp70) member 8	Homo sapiens	68-73
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Etoposide	38-47	BCL2 apoptosis regulator	Homo sapiens	242-247
11410522-2	2001	Cancer Res., 5: 673-680, 1999), we found, in a panel of 23 lung cancer cell lines that had not been selected for in vitro drug resistance, that the mRNA levels of MRP3 and MRP1, two members of the ATP-binding cassette superfamily of transport proteins, correlated with resistance to doxorubicin, vincristine, VP-16, and cis-diamminedicholoroplatinum(II).	Etoposide	309-314	ATP binding cassette subfamily C member 3	Homo sapiens	163-167
11410522-2	2001	Cancer Res., 5: 673-680, 1999), we found, in a panel of 23 lung cancer cell lines that had not been selected for in vitro drug resistance, that the mRNA levels of MRP3 and MRP1, two members of the ATP-binding cassette superfamily of transport proteins, correlated with resistance to doxorubicin, vincristine, VP-16, and cis-diamminedicholoroplatinum(II).	Etoposide	309-314	ATP binding cassette subfamily C member 1	Homo sapiens	172-176
11410522-8	2001	Finally, we found that both MRP3 and MRP1, but not MRP2, protein levels correlated with decreased sensitivity of these lung cancer cell lines to doxorubicin, VCR, VP-16, and cis-diamminedicholoroplatinum(II).	Etoposide	163-168	ATP binding cassette subfamily C member 3	Homo sapiens	28-32
11410522-8	2001	Finally, we found that both MRP3 and MRP1, but not MRP2, protein levels correlated with decreased sensitivity of these lung cancer cell lines to doxorubicin, VCR, VP-16, and cis-diamminedicholoroplatinum(II).	Etoposide	163-168	ATP binding cassette subfamily C member 1	Homo sapiens	37-41
11498763-12	2001	In addition, we determined the effects of DNA damage produced by the DNA topoisomerase II inhibitor etoposide on wild-type p53 transfected lymphoma cells.	Etoposide	100-109	tumor protein p53	Homo sapiens	123-126
11387205-2	2001	Here we provide evidence that overexpression of Gas2 efficiently increases cell susceptibility to apoptosis following UV irradiation, etoposide and methyl methanesulfonate treatments, and that these effects are dependent on increased p53 stability and transcription activity.	Etoposide	134-143	growth arrest specific 2	Homo sapiens	48-52
11387205-2	2001	Here we provide evidence that overexpression of Gas2 efficiently increases cell susceptibility to apoptosis following UV irradiation, etoposide and methyl methanesulfonate treatments, and that these effects are dependent on increased p53 stability and transcription activity.	Etoposide	134-143	tumor protein p53	Homo sapiens	234-237
11484935-2	2001	We found that four anticancer agents: etoposide, doxorubicin, bleomycin and paclitaxel induced apoptosis in human umbilical vein endothelial cells (HUVECs) (as judged by DNA fragmentation) with a time- and concentration-dependent decrease in bcl-2 protein but without the involvement of p53.	Etoposide	38-47	tumor protein p53	Homo sapiens	287-290
11484935-3	2001	As revealed by immunoblotting, bax protein was expressed in HUVECs treated with 1 mg/ml etoposide whereas bcl-2 protein disappeared.	Etoposide	88-97	BCL2 associated X, apoptosis regulator	Homo sapiens	31-34
11400655-5	2001	All the patients were treated with etoposide (VP-16), 200 mg/m2 for 3 consecutive days, with 15 cycles at intervals of 3 weeks between each cycle, followed by maintenance therapy with IFN-alpha.	Etoposide	35-44	host cell factor C1	Homo sapiens	46-51
11391533-10	2001	The antilethal effect of etoposide was also confirmed in GalN/TNF-alpha-induced fulminant hepatic failure.	Etoposide	25-34	tumor necrosis factor	Mus musculus	62-71
11391533-11	2001	Etoposide treatment reduced CPP32/caspase-3 activity in the liver, although it did not alter the serum TNF-alpha levels or hepatic TNFR1 mRNA expressions.	Etoposide	0-9	caspase 3	Mus musculus	28-33
11391533-11	2001	Etoposide treatment reduced CPP32/caspase-3 activity in the liver, although it did not alter the serum TNF-alpha levels or hepatic TNFR1 mRNA expressions.	Etoposide	0-9	caspase 3	Mus musculus	34-43
11391533-12	2001	In addition, etoposide treatment enhanced the mRNA and protein expression of Bcl-xL, an antiapoptotic molecule in the liver.	Etoposide	13-22	BCL2-like 1	Mus musculus	77-83
11391533-13	2001	The present findings suggest that etoposide prevents endotoxin-induced lethal liver injury by up-regulation of Bcl-xL, and that etoposide could be useful for the treatment of TNF-alpha-mediated liver diseases.	Etoposide	34-43	BCL2-like 1	Mus musculus	111-117
11391533-13	2001	The present findings suggest that etoposide prevents endotoxin-induced lethal liver injury by up-regulation of Bcl-xL, and that etoposide could be useful for the treatment of TNF-alpha-mediated liver diseases.	Etoposide	128-137	tumor necrosis factor	Mus musculus	175-184
11513147-7	2001	A synergistic effect in the induction of apoptosis has also been documented between antibodies specific for CD33 and the chemotherapic agent etoposide.	Etoposide	141-150	CD33 molecule	Homo sapiens	108-112
11377013-0	2001	A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma.	Etoposide	91-100	host cell factor C1	Homo sapiens	102-107
11468031-0	2001	Diazepam enhances etoposide-induced cytotoxicity in U-87 MG human glioma cell line.	Etoposide	18-27	small nucleolar RNA, C/D box 87	Homo sapiens	52-56
11468031-4	2001	In this work, we sought to enhance cytotoxic effect of etoposide (VP-16) by a PBR ligand, diazepam (DZ) in U-87 MG human glioma cells.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
11468031-4	2001	In this work, we sought to enhance cytotoxic effect of etoposide (VP-16) by a PBR ligand, diazepam (DZ) in U-87 MG human glioma cells.	Etoposide	55-64	translocator protein	Homo sapiens	78-81
11468031-4	2001	In this work, we sought to enhance cytotoxic effect of etoposide (VP-16) by a PBR ligand, diazepam (DZ) in U-87 MG human glioma cells.	Etoposide	55-64	small nucleolar RNA, C/D box 87	Homo sapiens	107-111
11463801-1	2001	BACKGROUND: The aim of this study was to examine the effectiveness of radio-chemotherapy using nimustine hydrochloride (ACNU) and etoposide (VP-16) for malignant gliomas.	Etoposide	130-139	host cell factor C1	Homo sapiens	141-146
11556390-2	2001	We studied the cytotoxic effects of exposure to topoisomerase I inhibitor SN-38 and topoisomerase II inhibitor etoposide (VP-16) in lung cancer cell line Ma-1 using WST-1 assay and isobologram analysis.	Etoposide	111-120	host cell factor C1	Homo sapiens	122-127
11380620-5	2001	RESULTS: Using immunocytochemistry, we found that WRNp forms distinct nuclear foci in response to DNA damaging agents, including camptothecin (CPT), etoposide, 4-nitroquinolin-N-oxide and bleomycin.	Etoposide	149-158	WRN RecQ like helicase	Homo sapiens	50-54
11295289-0	2001	Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.	Etoposide	95-100	ATPase, class II, type 9A	Mus musculus	24-31
11482451-8	2001	In the TP53 mutant cell lines, DU145 and BM1604, dose enhancement factors (EFs) were found to be in the region of 4.20 for cisplatin, 3.70 for vinblastine, and 3.20 for etoposide.	Etoposide	169-178	tumor protein p53	Homo sapiens	7-11
11482451-9	2001	In the TP53 wild-type cell line, LNCaP, the enhancement factors were low and in the region of 1.20 for cisplatin, vinblastine and etoposide.	Etoposide	130-139	tumor protein p53	Homo sapiens	7-11
11355877-1	2001	We have previously shown that Bax translocation was crucial in TNFalpha or etoposide-induced apoptosis.	Etoposide	75-84	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
11355877-2	2001	Overexpression of Bax sensitized chronic myeloid leukemic K562 cells to etoposide-induced apoptosis.	Etoposide	72-81	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
11322928-0	2001	Alteration of nuclear factor-kappaB (NF-kappaB) expression in bone marrow stromal cells treated with etoposide.	Etoposide	101-110	nuclear factor kappa B subunit 1	Homo sapiens	14-35
11322928-0	2001	Alteration of nuclear factor-kappaB (NF-kappaB) expression in bone marrow stromal cells treated with etoposide.	Etoposide	101-110	nuclear factor kappa B subunit 1	Homo sapiens	37-46
11322928-4	2001	In this study, we show that down-regulation of VCAM-1 by the chemotherapeutic agent etoposide (VP-16) is associated with altered cellular localization of NF-kappaB.	Etoposide	84-93	vascular cell adhesion molecule 1	Homo sapiens	47-53
11322928-4	2001	In this study, we show that down-regulation of VCAM-1 by the chemotherapeutic agent etoposide (VP-16) is associated with altered cellular localization of NF-kappaB.	Etoposide	84-93	host cell factor C1	Homo sapiens	95-100
11322928-4	2001	In this study, we show that down-regulation of VCAM-1 by the chemotherapeutic agent etoposide (VP-16) is associated with altered cellular localization of NF-kappaB.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	154-163
11350857-2	2001	In addition, over-expression of the N-terminal and the first domain of the protein (144 amino acids, clone ANX1-S), which does not contain the Ca2+ binding sites, gives susceptibility to cell apoptosis following activation by either 5 ng ml(-1) tumour necrosis factor (TNF)-alpha or 1 - 40 microg ml-1 etoposide.	Etoposide	302-311	annexin A1	Homo sapiens	107-111
11471856-2	2001	This study examines the effect of the anti-cancer therapies CDDP, doxorubicin (ADM) and etoposide (VP-16) on the cell cycle and their cytotoxicity against two gastric carcinoma cell lines: MKN-28 (well differentiated) and MKN-45 (poorly differentiated).	Etoposide	88-97	host cell factor C1	Homo sapiens	99-104
11297734-0	2001	DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells.	Etoposide	40-49	gasdermin E	Homo sapiens	0-5
11284689-2	2001	The G185V mutation near transmembrane domain 3 of human Pgp increases its relative ability to transport several drugs, including etoposide, but decreases the transport of other substrates.	Etoposide	129-138	phosphoglycolate phosphatase	Homo sapiens	56-59
11284689-3	2001	MDR1 cDNA with the G185V substitution was used in a function-based selection to identify mutations that would further increase Pgp-mediated resistance to etoposide.	Etoposide	154-163	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
11284689-3	2001	MDR1 cDNA with the G185V substitution was used in a function-based selection to identify mutations that would further increase Pgp-mediated resistance to etoposide.	Etoposide	154-163	phosphoglycolate phosphatase	Homo sapiens	127-130
11145960-2	2001	A change in the degree of phosphorylation of HMGA1a has been observed during apoptosis induced in four leukemic cell lines (HL60, K562, NB4, and U937) by drugs (etoposide, camptothecin) or herpes simplex virus type-1.	Etoposide	161-170	high mobility group AT-hook 1	Homo sapiens	45-51
11320150-8	2001	Moreover, with etoposide, a clastogen that also induces apoptosis, we observed that the percentages of aberrant cells and numbers of micronuclei were significantly increased in CTLL-2 cells compared with CTLL-2 Bcl2 cells.	Etoposide	15-24	B cell leukemia/lymphoma 2	Mus musculus	211-215
11331310-6	2001	53BP1 foci formation is not restricted to gamma-radiation but is also detected in response to UV radiation as well as hydroxyurea, camptothecin, etoposide, and methylmethanesulfonate treatment.	Etoposide	145-154	tumor protein p53 binding protein 1	Homo sapiens	0-5
11402324-7	2001	We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression.	Etoposide	124-133	BCL2 apoptosis regulator	Homo sapiens	38-43
11402324-8	2001	Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum.	Etoposide	106-115	BCL2 apoptosis regulator	Homo sapiens	19-24
11360198-6	2001	Mutant K-ras potentiated the effect of etoposide-derived DNA damage by increasing apoptosis, whereas absence of K-ras had the opposite effect.	Etoposide	39-48	KRAS proto-oncogene, GTPase	Homo sapiens	7-12
11360178-3	2001	In Rat-1 cells, a Bcl-2 mutant targeted exclusively to the endoplasmic reticulum (Bcl-cb5) was effective at inhibiting apoptosis induced by serum starvation/myc, or ceramide but not apoptosis induced by etoposide.	Etoposide	203-212	BCL2, apoptosis regulator	Rattus norvegicus	18-23
11360178-5	2001	By contrast, when cells are exposed to etoposide, a situation in which cytochrome c release and membrane localization of the pro-apoptotic protein Bax precede loss of Deltapsi(m), wild type Bcl-2 but not Bcl-cb5 prevents apoptosis.	Etoposide	39-48	BCL2 associated X, apoptosis regulator	Rattus norvegicus	147-150
11360178-5	2001	By contrast, when cells are exposed to etoposide, a situation in which cytochrome c release and membrane localization of the pro-apoptotic protein Bax precede loss of Deltapsi(m), wild type Bcl-2 but not Bcl-cb5 prevents apoptosis.	Etoposide	39-48	BCL2, apoptosis regulator	Rattus norvegicus	190-195
11297734-0	2001	DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells.	Etoposide	40-49	gasdermin E	Homo sapiens	7-14
11297734-3	2001	By that approach it could be demonstrated that the expression level of a mRNA encoded by a gene found to be mutated in non-syndromic hearing impairment, DFNA5 (ICERE-1), was distinctly decreased in the 33-fold etoposide-resistant melanoma cell line MeWo ETO 1.	Etoposide	210-219	gasdermin E	Homo sapiens	153-158
11297734-3	2001	By that approach it could be demonstrated that the expression level of a mRNA encoded by a gene found to be mutated in non-syndromic hearing impairment, DFNA5 (ICERE-1), was distinctly decreased in the 33-fold etoposide-resistant melanoma cell line MeWo ETO 1.	Etoposide	210-219	gasdermin E	Homo sapiens	160-167
11297734-4	2001	To evaluate the hypothesis that a decrease in DFNA5 mRNA expression level contributes to the acquired etoposide resistance phenotype exhibited by MeWo ETO 1 cells, this drug-resistant line was stably transfected with the DFNA5-encoding cDNA.	Etoposide	102-111	gasdermin E	Homo sapiens	46-51
11400161-9	2001	Induction of endogenous p53 expression by etoposide also inhibited promoter activity and minigene inducibility.	Etoposide	42-51	tumor protein p53	Homo sapiens	24-27
11297734-6	2001	Furthermore, etoposide exposure of stable DFNA5 transfectants resulted in an increase of caspase-3-mediated apoptotic events in DFNA5-transfected clones in comparison to MeWo ETO 1 cells and controls.	Etoposide	13-22	gasdermin E	Homo sapiens	42-47
11297734-6	2001	Furthermore, etoposide exposure of stable DFNA5 transfectants resulted in an increase of caspase-3-mediated apoptotic events in DFNA5-transfected clones in comparison to MeWo ETO 1 cells and controls.	Etoposide	13-22	caspase 3	Homo sapiens	89-98
11297734-6	2001	Furthermore, etoposide exposure of stable DFNA5 transfectants resulted in an increase of caspase-3-mediated apoptotic events in DFNA5-transfected clones in comparison to MeWo ETO 1 cells and controls.	Etoposide	13-22	gasdermin E	Homo sapiens	128-133
11400169-3	2001	We have recently shown that nitrosation of the activator protein-1 (AP-1) transcriptional factor is crucial for NO-mediated inhibition of cell death triggered by etoposide or ceramide.	Etoposide	162-171	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	47-66
11400169-3	2001	We have recently shown that nitrosation of the activator protein-1 (AP-1) transcriptional factor is crucial for NO-mediated inhibition of cell death triggered by etoposide or ceramide.	Etoposide	162-171	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	68-72
11256964-11	2001	In Gy cells depleted of polyamines by DFMO, polyamine replenishment with either spermidine or spermine was sufficient to restore caspase activity induced by etoposide, indicating that, in this model, polyamines have an interchangeable role in supporting caspase activation.	Etoposide	157-166	caspase 9	Mus musculus	129-136
11256964-6	2001	The lack of spermine did not affect the expression of Bcl-2, and caspases 3 and 9 were activated by etoposide in both N and Gy cells, indicating that spermine is dispensable for caspase activation.	Etoposide	100-109	caspase 3	Mus musculus	65-81
11398878-6	2001	Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF.	Etoposide	8-17	colony stimulating factor 2	Homo sapiens	81-87
11398878-6	2001	Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF.	Etoposide	8-17	colony stimulating factor 2	Homo sapiens	239-245
11398878-6	2001	Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF.	Etoposide	187-196	colony stimulating factor 2	Homo sapiens	81-87
11256964-13	2001	Some inducers of apoptosis, for example etoposide, absolutely require polyamines for caspase activation, yet the lack of polyamines, particularly spermine, strongly increases caspase activation when induced by UV irradiation.	Etoposide	40-49	caspase 9	Mus musculus	85-92
11256964-6	2001	The lack of spermine did not affect the expression of Bcl-2, and caspases 3 and 9 were activated by etoposide in both N and Gy cells, indicating that spermine is dispensable for caspase activation.	Etoposide	100-109	caspase 9	Mus musculus	65-72
11279616-3	2001	Expression of cx43 in human glioblastoma cells significantly increased sensitivity to several common chemotherapeutic agents, including etoposide, paclitaxel (Taxol) and doxorubicin, compared with control-transfected cells.	Etoposide	136-145	gap junction protein alpha 1	Homo sapiens	14-18
11393276-1	2001	Recently, it has been demonstrated that Etoposide, a topoisomerase II inhibitor, can induce apoptosis in MDM2-overexpressing tumor cells by inhibition of MDM2 synthesis.	Etoposide	40-49	MDM2 proto-oncogene	Homo sapiens	105-109
11393276-1	2001	Recently, it has been demonstrated that Etoposide, a topoisomerase II inhibitor, can induce apoptosis in MDM2-overexpressing tumor cells by inhibition of MDM2 synthesis.	Etoposide	40-49	MDM2 proto-oncogene	Homo sapiens	154-158
11393276-9	2001	When combined with Adriamycin or Etoposide, E2F-1 adenovirus therapy resulted in approximately 95% and 85% decrease in tumor size, respectively, compared to controls (P&lt;.05).	Etoposide	33-42	E2F transcription factor 1	Homo sapiens	44-49
11306462-2	2001	However, we found that etoposide induced apoptosis in P39 cells, a myelodysplastic syndrome-derived cell line, without the release of cytochrome c.	Etoposide	23-32	ATPase H+ transporting V0 subunit d1	Homo sapiens	54-57
11306462-3	2001	Furthermore, in etoposide-treated P39 cells, no changes in mitochondrial membrane potential (delta psi m) were detected by flow cytometry.	Etoposide	16-25	ATPase H+ transporting V0 subunit d1	Homo sapiens	34-37
11306462-4	2001	Flow cytometry using a pH-sensitive probe demonstrated that lysosomal pH increased during early apoptosis in P39 cells treated with etoposide.	Etoposide	132-141	ATPase H+ transporting V0 subunit d1	Homo sapiens	109-112
11306462-7	2001	Although etoposide-induced activation of caspase-3 was followed by DNA ladder formation in P39 cells, E-64d, an inhibitor of lysosomal thiol proteases, specifically suppressed etoposide-induced activation of caspase-3.	Etoposide	9-18	caspase 3	Homo sapiens	41-50
11306462-7	2001	Although etoposide-induced activation of caspase-3 was followed by DNA ladder formation in P39 cells, E-64d, an inhibitor of lysosomal thiol proteases, specifically suppressed etoposide-induced activation of caspase-3.	Etoposide	9-18	ATPase H+ transporting V0 subunit d1	Homo sapiens	91-94
11306462-7	2001	Although etoposide-induced activation of caspase-3 was followed by DNA ladder formation in P39 cells, E-64d, an inhibitor of lysosomal thiol proteases, specifically suppressed etoposide-induced activation of caspase-3.	Etoposide	9-18	caspase 3	Homo sapiens	208-217
11306462-7	2001	Although etoposide-induced activation of caspase-3 was followed by DNA ladder formation in P39 cells, E-64d, an inhibitor of lysosomal thiol proteases, specifically suppressed etoposide-induced activation of caspase-3.	Etoposide	176-185	ATPase H+ transporting V0 subunit d1	Homo sapiens	91-94
11306462-7	2001	Although etoposide-induced activation of caspase-3 was followed by DNA ladder formation in P39 cells, E-64d, an inhibitor of lysosomal thiol proteases, specifically suppressed etoposide-induced activation of caspase-3.	Etoposide	176-185	caspase 3	Homo sapiens	208-217
11306462-9	2001	These findings indicate that lysosomal dysfunction induced by a reduction in ATP results in leakage of lysosomal enzymes into the cytosolic compartment and that lysosomal enzyme(s) may be involved in activation of caspase-3 during apoptosis in P39 cells treated with etoposide.	Etoposide	267-276	caspase 3	Homo sapiens	214-223
11279616-6	2001	Over-expression of bcl-2 in cx43-transfected cells partially confers the resistance to apoptosis induced by etoposide, suggesting that the cx43-mediated apoptosis to chemotherapeutic agents is regulated in part through the down-regulation of bcl-2 expression.	Etoposide	108-117	BCL2 apoptosis regulator	Homo sapiens	19-24
11279616-6	2001	Over-expression of bcl-2 in cx43-transfected cells partially confers the resistance to apoptosis induced by etoposide, suggesting that the cx43-mediated apoptosis to chemotherapeutic agents is regulated in part through the down-regulation of bcl-2 expression.	Etoposide	108-117	gap junction protein alpha 1	Homo sapiens	28-32
11279616-6	2001	Over-expression of bcl-2 in cx43-transfected cells partially confers the resistance to apoptosis induced by etoposide, suggesting that the cx43-mediated apoptosis to chemotherapeutic agents is regulated in part through the down-regulation of bcl-2 expression.	Etoposide	108-117	gap junction protein alpha 1	Homo sapiens	139-143
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	tumor protein p53	Homo sapiens	18-21
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	MDM2 proto-oncogene	Homo sapiens	57-61
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	caspase 3	Homo sapiens	94-103
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	RB transcriptional corepressor 1	Homo sapiens	155-158
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	poly(ADP-ribose) polymerase 1	Homo sapiens	164-193
11306736-4	2001	When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages.	Etoposide	46-55	poly(ADP-ribose) polymerase 1	Homo sapiens	195-199
11306736-6	2001	However, the level of MDM2 was partially restored by proteasome inhibitors such as LLnL and lactacystin, even in the presence of etoposide.	Etoposide	129-138	MDM2 proto-oncogene	Homo sapiens	22-26
11289130-8	2001	ALLN-resistant, MRP1-overexpressing cells were found to be cross-resistant to 4A6 and the classical multidrug resistance drugs doxorubicin, vincristine, and etoposide.	Etoposide	157-166	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	16-20
11346470-0	2001	Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells.	Etoposide	49-58	apoptotic peptidase activating factor 1	Homo sapiens	19-25
11346470-0	2001	Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells.	Etoposide	49-58	caspase 9	Homo sapiens	30-39
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	apoptotic peptidase activating factor 1	Homo sapiens	81-87
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	apoptotic peptidase activating factor 1	Homo sapiens	89-98
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	caspase 9	Homo sapiens	205-214
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	caspase 9	Homo sapiens	216-225
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	apoptotic peptidase activating factor 1	Homo sapiens	93-98
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	apoptotic peptidase activating factor 1	Homo sapiens	277-286
11346470-4	2001	The degree of apoptosis in etoposide-treated U-373MG cells infected with Adv for Apaf-1 (Adv-APAF1) was higher (27%) than that in cells infected with control Adv (14%), that in cells infected with Adv for caspase-9 (Adv-Casp9) was higher (34%) than that in cells infected with Adv-APAF1, and that in cells infected with both Adv-APAF1 and Adv-Casp9 was the highest (41%).	Etoposide	27-36	caspase 9	Homo sapiens	339-348
11346470-5	2001	Treatment with etoposide increased expression of p53 and decreased expression of Bcl-X(L) in U-373MG cells which harbored mutant p53.	Etoposide	15-24	tumor protein p53	Homo sapiens	49-52
11346470-5	2001	Treatment with etoposide increased expression of p53 and decreased expression of Bcl-X(L) in U-373MG cells which harbored mutant p53.	Etoposide	15-24	BCL2 like 1	Homo sapiens	81-89
11346470-5	2001	Treatment with etoposide increased expression of p53 and decreased expression of Bcl-X(L) in U-373MG cells which harbored mutant p53.	Etoposide	15-24	tumor protein p53	Homo sapiens	129-132
11401473-6	2001	Accumulation of P53 and its target gene bax then sensitized HeLa cells to cell-cycle arrest, cell death/apoptosis induced by cisplatin, and etoposide.	Etoposide	140-149	tumor protein p53	Homo sapiens	16-19
11401473-6	2001	Accumulation of P53 and its target gene bax then sensitized HeLa cells to cell-cycle arrest, cell death/apoptosis induced by cisplatin, and etoposide.	Etoposide	140-149	BCL2 associated X, apoptosis regulator	Homo sapiens	40-43
11115510-2	2001	Treatment of human nonsmall cell lung carcinoma (NSCLC-3 or NSCLC-5) cells with the topo I poison SN-38 or the topo II poison etoposide (VP-16) leads to activation of NF-kappaB before induction of apoptosis.	Etoposide	126-135	host cell factor C1	Homo sapiens	137-142
11313880-4	2001	Superoxide dismutase (SOD), a selective antioxidant for O2-*, had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide.	Etoposide	164-173	superoxide dismutase 1	Homo sapiens	0-20
11313880-2	2001	Treatment of human glioma cells with etoposide caused apoptosis only in cells expressing functional p53.	Etoposide	37-46	tumor protein p53	Homo sapiens	100-103
11313880-4	2001	Superoxide dismutase (SOD), a selective antioxidant for O2-*, had no effects on p53 expression but inhibited ceramide generation and apoptotic cell death caused by etoposide.	Etoposide	164-173	superoxide dismutase 1	Homo sapiens	22-25
11313880-7	2001	In contrast, human glioma cells lacking functional p53, either due to mutation or the expression of E6 protein of human papillomavirus, were highly resistant to etoposide and exhibited no significant change in the ceramide level.	Etoposide	161-170	tumor protein p53	Homo sapiens	51-54
11260076-2	2001	We have tested the hypothesis that the susceptibility of Bcl-XL-expressing leukaemic cells to apoptosis induced by VP16 (etoposide) can be enhanced by pharmacological downregulation of Bcl-XL in vivo.	Etoposide	115-119	BCL2 like 1	Homo sapiens	57-63
11313858-5	2001	In addition to characteristics of BLM(-/-) cells reported previously by the other group, they are hypersensitive to genotoxic agents such as etoposide, bleomycin and 4-nitroquinoline-1-oxide and irradiation with the short wave length of UV (UVC) light, whereas they exhibit normal sensitivity to X-ray irradiation and hydroxyurea.	Etoposide	141-150	BLM RecQ like helicase	Homo sapiens	34-37
11396179-7	2001	The MTT assay showed increased IC50 values or resistance to doxorubicin (DOX), etoposide (VP-16) and cisplatin (CDDP) in KB8-5/alpha MRP-Rz cells.	Etoposide	79-88	host cell factor C1	Homo sapiens	90-95
11396179-7	2001	The MTT assay showed increased IC50 values or resistance to doxorubicin (DOX), etoposide (VP-16) and cisplatin (CDDP) in KB8-5/alpha MRP-Rz cells.	Etoposide	79-88	ATP binding cassette subfamily C member 3	Homo sapiens	133-136
11290874-1	2001	Etoposide, an anti-neoplastic agent and a substrate of P-glycoprotein (P-gp), exhibits variable oral bioavailability.	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-69
11290874-1	2001	Etoposide, an anti-neoplastic agent and a substrate of P-glycoprotein (P-gp), exhibits variable oral bioavailability.	Etoposide	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	71-75
11313693-4	2001	These observations suggest that clonal rearrangement of the MLL gene is caused by etoposide.	Etoposide	82-91	lysine methyltransferase 2A	Homo sapiens	60-63
11260076-2	2001	We have tested the hypothesis that the susceptibility of Bcl-XL-expressing leukaemic cells to apoptosis induced by VP16 (etoposide) can be enhanced by pharmacological downregulation of Bcl-XL in vivo.	Etoposide	115-119	BCL2 like 1	Homo sapiens	185-191
11260076-2	2001	We have tested the hypothesis that the susceptibility of Bcl-XL-expressing leukaemic cells to apoptosis induced by VP16 (etoposide) can be enhanced by pharmacological downregulation of Bcl-XL in vivo.	Etoposide	121-130	BCL2 like 1	Homo sapiens	57-63
11260076-2	2001	We have tested the hypothesis that the susceptibility of Bcl-XL-expressing leukaemic cells to apoptosis induced by VP16 (etoposide) can be enhanced by pharmacological downregulation of Bcl-XL in vivo.	Etoposide	121-130	BCL2 like 1	Homo sapiens	185-191
11279841-9	2001	After that, a rapid increase of PSA was controlled for 7 months by oral chemotherapy with estramustine phosphate sodium and VP-16.	Etoposide	124-129	kallikrein related peptidase 3	Homo sapiens	32-35
11345781-3	2001	CHOP + etoposide (CHOP-E) was used as an initial chemotherapy and as a chemotherapy agent for the purpose of cell harvesting.	Etoposide	7-16	DNA damage inducible transcript 3	Homo sapiens	18-22
11237055-3	2001	We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea, mafosfamide or etoposide would display synergistic activity in BCR-ABL-positive chronic myelogenous leukemia (CML) cell lines derived from patients in blast crisis.	Etoposide	125-134	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	177-180
11237055-8	2001	At growth inhibition levels of over 50%, STI571 + cytarabine as well as STI571 + etoposide were significantly synergistic (CI &lt; 1, P &lt; 0.05) in the BCR-ABL-positive cell lines evaluated.	Etoposide	81-90	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	158-161
11471558-13	2001	Primary neuronal cultures from DFF45 knockouts failed to show DNA laddering in response to staurosporine, but did show prominent, albeit delayed, DNA fragmentation following treatment with etoposide.	Etoposide	189-198	DNA fragmentation factor, alpha subunit	Mus musculus	31-36
11096068-7	2001	In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells.	Etoposide	44-53	tumor protein p53	Homo sapiens	81-84
11136718-4	2001	We provide evidence for the in vivo significance of the topo II-HDAC1 association, showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.	Etoposide	195-204	histone deacetylase 1	Homo sapiens	64-69
11096068-7	2001	In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells.	Etoposide	44-53	checkpoint kinase 2	Homo sapiens	89-93
11096068-7	2001	In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells.	Etoposide	44-53	ATM serine/threonine kinase	Homo sapiens	97-100
11096068-7	2001	In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells.	Etoposide	44-53	ATM serine/threonine kinase	Homo sapiens	114-117
11161717-5	2001	SP-A protected primary cultures of rat type II alveolar cells against the apoptotic effects of etoposide and UV light and also protected the H441 human Clara lung tumor cell line against staurosporine-induced apoptosis.	Etoposide	95-104	surfactant protein A1	Rattus norvegicus	0-4
11245453-4	2001	Mice deficient in the three genes, mdr1a/1b and mrp1, exhibited a 128-fold increase in toxicity to vincristine and a 3-5-fold increase in toxicity to etoposide; increased toxicity to embryonic fibroblast cells from triple knockout mice also occurred with vincristine and etoposide.	Etoposide	150-159	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	35-40
11245453-4	2001	Mice deficient in the three genes, mdr1a/1b and mrp1, exhibited a 128-fold increase in toxicity to vincristine and a 3-5-fold increase in toxicity to etoposide; increased toxicity to embryonic fibroblast cells from triple knockout mice also occurred with vincristine and etoposide.	Etoposide	150-159	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	48-52
11245453-4	2001	Mice deficient in the three genes, mdr1a/1b and mrp1, exhibited a 128-fold increase in toxicity to vincristine and a 3-5-fold increase in toxicity to etoposide; increased toxicity to embryonic fibroblast cells from triple knockout mice also occurred with vincristine and etoposide.	Etoposide	271-280	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	35-40
11245453-4	2001	Mice deficient in the three genes, mdr1a/1b and mrp1, exhibited a 128-fold increase in toxicity to vincristine and a 3-5-fold increase in toxicity to etoposide; increased toxicity to embryonic fibroblast cells from triple knockout mice also occurred with vincristine and etoposide.	Etoposide	271-280	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	48-52
11170441-0	2001	Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.	Etoposide	0-9	lysine methyltransferase 2A	Homo sapiens	85-88
11170441-10	2001	Not only etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation breakpoints in in vitro assays.	Etoposide	9-18	lysine methyltransferase 2A	Homo sapiens	89-92
11314019-0	2001	Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin.	Etoposide	92-101	nuclear factor kappa B subunit 1	Homo sapiens	14-23
11314019-0	2001	Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin.	Etoposide	103-107	nuclear factor kappa B subunit 1	Homo sapiens	14-23
11314019-4	2001	Treatment with various NF-kappaB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the IkappaBalpha super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells.	Etoposide	180-184	nuclear factor kappa B subunit 1	Homo sapiens	23-32
11156966-7	2001	IRF-3/DRAF1 target gene expression is also induced in response to a distinct apoptotic stimulus, the DNA damaging agent etoposide.	Etoposide	120-129	interferon regulatory factor 3	Homo sapiens	0-5
11162625-3	2001	We observed that in cells treated with etoposide, cyclosporin A, 4-hydroxynonenal (HNE), or okadaic acid, there was an early reduction in the protein levels of p35, and later also in cdk5 with all treatments except etoposide.	Etoposide	39-48	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	160-163
11162625-3	2001	We observed that in cells treated with etoposide, cyclosporin A, 4-hydroxynonenal (HNE), or okadaic acid, there was an early reduction in the protein levels of p35, and later also in cdk5 with all treatments except etoposide.	Etoposide	39-48	cyclin-dependent kinase 5	Rattus norvegicus	183-187
11162625-3	2001	We observed that in cells treated with etoposide, cyclosporin A, 4-hydroxynonenal (HNE), or okadaic acid, there was an early reduction in the protein levels of p35, and later also in cdk5 with all treatments except etoposide.	Etoposide	215-224	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	160-163
11162625-5	2001	The changes in the p35 and p25 protein levels coincided with decreases in cdk5 activity and tau phosphorylation after treatment with HNE and etoposide.	Etoposide	141-150	cyclin-dependent kinase 5 regulatory subunit 1	Rattus norvegicus	19-22
11162625-5	2001	The changes in the p35 and p25 protein levels coincided with decreases in cdk5 activity and tau phosphorylation after treatment with HNE and etoposide.	Etoposide	141-150	lipocalin 2	Rattus norvegicus	27-30
11162625-5	2001	The changes in the p35 and p25 protein levels coincided with decreases in cdk5 activity and tau phosphorylation after treatment with HNE and etoposide.	Etoposide	141-150	cyclin-dependent kinase 5	Rattus norvegicus	74-78
11157492-4	2001	Short-term culture of immature B cell lines in the presence of apoptogenic stimuli such as serum starvation, etoposide, or salicylic acid induced double-strand breaks (DSBs) in intron 5 of the TEL gene and intron 1 of the AML1 gene.	Etoposide	109-118	ETS variant transcription factor 6	Homo sapiens	193-196
11157492-4	2001	Short-term culture of immature B cell lines in the presence of apoptogenic stimuli such as serum starvation, etoposide, or salicylic acid induced double-strand breaks (DSBs) in intron 5 of the TEL gene and intron 1 of the AML1 gene.	Etoposide	109-118	RUNX family transcription factor 1	Homo sapiens	222-226
11223551-5	2001	The two MRP3 antisense transfectants showed 2- to 5-fold increases in drug sensitivity to etoposide and cisplatin compared with NHG2 cells, but their sensitivity to vincristine or nitrosourea was not changed.	Etoposide	90-99	ATP binding cassette subfamily C member 3	Homo sapiens	8-12
11372740-5	2001	The mean number of CD34+ cells harvested per apheresis was larger in the group receiving high-dose cytosine arabinoside or high-dose etoposide plus granulocyte colony-stimulating factor (G-CSF) than in the group receiving conventional chemotherapy plus G-CSF.	Etoposide	133-142	CD34 molecule	Homo sapiens	19-23
11223551-6	2001	Two MRP3 cDNA sense transfectants of pig kidney cell lines showed 4- to 6-fold drug resistance to etoposide, but only 1.4- to 1.5-fold to cisplatin.	Etoposide	98-107	ATP binding cassette subfamily C member 3	Homo sapiens	4-8
11275460-1	2001	Chronic oral VP-16 (etoposide) is a chemotherapy regimen with a wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi"s sarcoma, and primary brain tumors.	Etoposide	20-29	host cell factor C1	Homo sapiens	13-18
11313965-3	2001	FTase/GGTase-alpha (49 kDa) was cleaved to 35 kDa (p35) in the Rat-2/H-ras, W4 and Rat-1 cells treated with FTase inhibitor (LB42708), anti-Fas antibody and etoposide, respectively.	Etoposide	157-166	annexin A1	Rattus norvegicus	51-54
11053413-2	2001	In this work, we report that PARG is cleaved during etoposide-, staurosporine-, and Fas-induced apoptosis in human cells.	Etoposide	52-61	poly(ADP-ribose) glycohydrolase	Homo sapiens	29-33
11162602-4	2001	The reduction in cyclin B1 expression and G2 arrest were also seen after treatment with etoposide and irinotecan.	Etoposide	88-97	cyclin B1	Homo sapiens	17-26
11163333-2	2001	Recently, stimulation of dCK activity was shown by these analogues and by other genotoxic agents such as etoposide and NaF, all of which cause severe inhibition of DNA synthesis in cell cultures.	Etoposide	105-114	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	25-28
11139337-1	2001	ASC (apoptosis-associated speck-like protein containing a CARD) was first identified as a cytosolic soluble protein that forms insoluble aggregates and enhances etoposide-induced apoptosis.	Etoposide	161-170	PYD and CARD domain containing	Mus musculus	0-3
11162503-3	2001	We demonstrate here that the expression levels of p62 mRNA and protein were increased in Neuro-2a cells and cultured rat hippocampal neurons by different types of proapoptotic treatments, including serum deprivation, okadaic acid, etoposide, and trichostatin A.	Etoposide	231-240	nucleoporin 62	Mus musculus	50-53
11244505-3	2001	Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNFalpha-induced p22PRG1/IEX-1 expression and increased the sensitivity to apoptosis induced by TNFalpha, an activating Fas-antibody or the anti-cancer drug etoposide.	Etoposide	232-241	tumor necrosis factor	Homo sapiens	75-83
11244505-3	2001	Blockade of NF-kappaB activation by various NF-kappaB inhibitors abolished TNFalpha-induced p22PRG1/IEX-1 expression and increased the sensitivity to apoptosis induced by TNFalpha, an activating Fas-antibody or the anti-cancer drug etoposide.	Etoposide	232-241	tumor necrosis factor	Homo sapiens	171-179
11244505-4	2001	Surprisingly, ectopic expression of p22PRG1/IEX-1 in HeLa cells transfected with an inducible p22PRG1/IEX-1-expression vector augments the susceptibility to apoptosis initiated by death-receptor ligands or by etoposide.	Etoposide	209-218	immediate early response 3	Homo sapiens	44-49
11244505-4	2001	Surprisingly, ectopic expression of p22PRG1/IEX-1 in HeLa cells transfected with an inducible p22PRG1/IEX-1-expression vector augments the susceptibility to apoptosis initiated by death-receptor ligands or by etoposide.	Etoposide	209-218	immediate early response 3	Homo sapiens	102-107
11137708-1	2001	The cell cycle phase-dependent induction of DNA damage and apoptosis by etoposide (VP-16) and its modulation by 1-[N,O-bis(1, 5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-piperazine (KN-62), an inhibitor of calcium-calmodulin-dependent enzymes, were examined in sensitive (HL-60/S) and VP-16-resistant (HL-60/DOX0.05) HL-60 cells.	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
11764930-8	2001	Transfection of mouse WEHI7.2 thymoma cells with human thioredoxin peroxidase-2 was found to protect the cells from apoptosis induced by H2O2 but not from apoptosis induced by dexamethasone, doxorubicin or etoposide.	Etoposide	206-215	peroxiredoxin 1	Homo sapiens	55-79
11137708-1	2001	The cell cycle phase-dependent induction of DNA damage and apoptosis by etoposide (VP-16) and its modulation by 1-[N,O-bis(1, 5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-piperazine (KN-62), an inhibitor of calcium-calmodulin-dependent enzymes, were examined in sensitive (HL-60/S) and VP-16-resistant (HL-60/DOX0.05) HL-60 cells.	Etoposide	72-81	host cell factor C1	Homo sapiens	287-292
11123359-1	2001	Expression of the transforming oncogene bcr-abl in chronic myelogenous leukemia (CML) cells is reported to confer resistance against apoptosis induced by many chemotherapeutic agents such as etoposide, ara-C, and staurosporine.	Etoposide	191-200	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	40-47
11269739-0	2001	Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction.	Etoposide	28-37	host cell factor C1	Homo sapiens	39-44
11269739-1	2001	PURPOSE: The highly schedule-dependent cytotoxic agent etoposide (VP-16) is initially effective in the treatment of small-cell lung cancer (SCLC), particularly in multidrug combination chemotherapy.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
11589008-4	2001	Similarly, inhibition of PPT1 with a synthetic inhibitor (AcG-palmitoyl diaminoproprionate-VKIKK) (DAP1) (100 microM) increased the susceptibility of the cells to apoptosis induced by either C2-ceramide or etoposide and Adriamycin (doxorubicin), common chemotherapeutic agents used in the treatment of solid tumours.	Etoposide	206-215	palmitoyl-protein thioesterase 1	Homo sapiens	25-29
11589008-4	2001	Similarly, inhibition of PPT1 with a synthetic inhibitor (AcG-palmitoyl diaminoproprionate-VKIKK) (DAP1) (100 microM) increased the susceptibility of the cells to apoptosis induced by either C2-ceramide or etoposide and Adriamycin (doxorubicin), common chemotherapeutic agents used in the treatment of solid tumours.	Etoposide	206-215	death associated protein	Homo sapiens	99-103
11154867-2	2001	It has been demonstrated that the protease caspase-3, a downstream molecule of the CD95 pathway, is activated in UV-exposed HaCaT cells, and that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is cleaved by interleukin-1beta converting enzyme (ICE)-like protease during apoptosis induced by X-rays, staurosporine and etoposide.	Etoposide	332-341	caspase 3	Homo sapiens	43-52
11154867-2	2001	It has been demonstrated that the protease caspase-3, a downstream molecule of the CD95 pathway, is activated in UV-exposed HaCaT cells, and that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is cleaved by interleukin-1beta converting enzyme (ICE)-like protease during apoptosis induced by X-rays, staurosporine and etoposide.	Etoposide	332-341	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	150-196
11154867-2	2001	It has been demonstrated that the protease caspase-3, a downstream molecule of the CD95 pathway, is activated in UV-exposed HaCaT cells, and that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is cleaved by interleukin-1beta converting enzyme (ICE)-like protease during apoptosis induced by X-rays, staurosporine and etoposide.	Etoposide	332-341	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	198-206
11154867-2	2001	It has been demonstrated that the protease caspase-3, a downstream molecule of the CD95 pathway, is activated in UV-exposed HaCaT cells, and that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is cleaved by interleukin-1beta converting enzyme (ICE)-like protease during apoptosis induced by X-rays, staurosporine and etoposide.	Etoposide	332-341	caspase 1	Homo sapiens	222-257
11791127-10	2001	LRP was initially cloned from a non-small cell lung carcinoma cell line, SW1573/2R120 which is resistant to DXR, vincristine, etoposide and gramicidin D and does not express P-gp.	Etoposide	126-135	major vault protein	Homo sapiens	0-3
11196185-0	2001	Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.	Etoposide	85-94	caspase 3	Homo sapiens	18-27
11205919-0	2001	A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.	Etoposide	153-162	colony stimulating factor 3	Homo sapiens	80-117
11846007-0	2001	Two-color fluorescence detection of Poly (ADP-Ribose) Polymerase-1 (PARP-1) cleavage and DNA strand breaks in etoposide-induced apoptotic cells.	Etoposide	110-119	poly(ADP-ribose) polymerase 1	Homo sapiens	36-66
11846007-0	2001	Two-color fluorescence detection of Poly (ADP-Ribose) Polymerase-1 (PARP-1) cleavage and DNA strand breaks in etoposide-induced apoptotic cells.	Etoposide	110-119	poly(ADP-ribose) polymerase 1	Homo sapiens	68-74
11846007-6	2001	The presence of p89 was observed both in cells with advanced signs of apoptosis (where the PARP-1 fragment is extruded from the nucleus into the cytoplasm) and in TUNEL-negative cells, with only incipient signs of chromatin condensation; this evidence indicates that PARP-1 degradation in etoposide-treated apoptotic cells may precede DNA cleavage.	Etoposide	289-298	inner membrane mitochondrial protein	Homo sapiens	16-19
27405526-8	2001	Our results suggest different mechanisms of acquired resistance to LAK cells are operative in etoposide- or LAK-selected sublines, involving deterioration of LFA-1 molecule expression and altered conjugation properties, respectively.	Etoposide	94-103	integrin subunit alpha L	Homo sapiens	158-163
11149426-5	2001	In previous studies, we have shown that short-term treatment of EBV-positive lymphoblastoid cell lines (LCLs) with LMP-1 antisense oligodeoxynucleotides can dramatically reduce levels of LMP-1 protein in association with inhibition of proliferation, stimulation of apoptosis, down-regulation of Bcl-2 and Mcl-1 and enhanced sensitivity to the chemotherapeutic agent, etoposide.	Etoposide	367-376	PDZ and LIM domain 7	Homo sapiens	115-120
11149426-5	2001	In previous studies, we have shown that short-term treatment of EBV-positive lymphoblastoid cell lines (LCLs) with LMP-1 antisense oligodeoxynucleotides can dramatically reduce levels of LMP-1 protein in association with inhibition of proliferation, stimulation of apoptosis, down-regulation of Bcl-2 and Mcl-1 and enhanced sensitivity to the chemotherapeutic agent, etoposide.	Etoposide	367-376	PDZ and LIM domain 7	Homo sapiens	187-192
11149426-8	2001	In addition, LMP-1 antisense sensitizes LCLs to chemotherapeutic drugs from diverse classes, including etoposide, vincristine and dexamethasone, by enhancing apoptotic cell death.	Etoposide	103-112	PDZ and LIM domain 7	Homo sapiens	13-18
11123279-3	2001	We report that in CD4(+) human lymphoblastoid cell lines transfected with the nef cDNA obtained from three different HIV-1 strains, expression of the Nef protein enhances and accelerates the response to four unrelated apoptotic agents (staurosporine, anisomycin, camptothecin, and etoposide) but not to an anti-Fas agonist Ab.	Etoposide	281-290	S100 calcium binding protein B	Homo sapiens	78-81
11123279-3	2001	We report that in CD4(+) human lymphoblastoid cell lines transfected with the nef cDNA obtained from three different HIV-1 strains, expression of the Nef protein enhances and accelerates the response to four unrelated apoptotic agents (staurosporine, anisomycin, camptothecin, and etoposide) but not to an anti-Fas agonist Ab.	Etoposide	281-290	Nef	Human immunodeficiency virus 1	150-153
11712680-0	2001	Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy.	Etoposide	55-64	vimentin	Homo sapiens	25-33
11125034-0	2001	MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.	Etoposide	50-59	MDM2 proto-oncogene	Homo sapiens	0-4
11125034-0	2001	MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.	Etoposide	50-59	tumor protein p53	Homo sapiens	35-38
11125034-3	2001	Data presented here indicate that hyperactive nuclear export of p53 suppresses etoposide-induced apoptosis but does not prevent growth arrest.	Etoposide	79-88	tumor protein p53	Homo sapiens	64-67
11125034-5	2001	Our data show etoposide induces complete trans-location of p53 to the nucleus and activation of apoptosis in the neuroblastic NB cell line SH-SY5Y (N-type), which expresses low levels of MDM2.	Etoposide	14-23	tumor protein p53	Homo sapiens	59-62
11125034-5	2001	Our data show etoposide induces complete trans-location of p53 to the nucleus and activation of apoptosis in the neuroblastic NB cell line SH-SY5Y (N-type), which expresses low levels of MDM2.	Etoposide	14-23	MDM2 proto-oncogene	Homo sapiens	187-191
11125034-11	2001	These results demonstrate for the first time that hyperactive nuclear export of p53 attenuates chemotherapy-induced apoptosis in NB cells, and our findings suggest that inhibitors of MDM2 may enhance the therapeutic efficacy of etoposide by promoting apoptosis rather than trans-differentiation.	Etoposide	228-237	tumor protein p53	Homo sapiens	80-83
11125034-11	2001	These results demonstrate for the first time that hyperactive nuclear export of p53 attenuates chemotherapy-induced apoptosis in NB cells, and our findings suggest that inhibitors of MDM2 may enhance the therapeutic efficacy of etoposide by promoting apoptosis rather than trans-differentiation.	Etoposide	228-237	MDM2 proto-oncogene	Homo sapiens	183-187
11712680-1	2001	This study was undertaken to examine the influence of etoposide and doxorubicin on the distribution of vimentin in cells of human leukemia cell line K-562 by using immunofluorescence microscopy.	Etoposide	54-63	vimentin	Homo sapiens	103-111
11915179-0	2001	The expression of vimentin in HL-60 cells induced with etoposide using immunofluorescence and immunogold methods.	Etoposide	55-64	vimentin	Homo sapiens	18-26
11915179-2	2001	Changes in the distribution of vimentin were found to be dependent on the concentration of etoposide.	Etoposide	91-100	vimentin	Homo sapiens	31-39
11915179-5	2001	In control cells and those treated with 0.02, 0.2 and 2 microM/L etoposide, vimentin was seen rather as a ring often with the increased concentration near one pole of the cells.	Etoposide	65-74	vimentin	Homo sapiens	76-84
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	TNF receptor superfamily member 10b	Homo sapiens	82-85
11112520-7	2000	Cell growth assays showed 5-fold and 14-fold increase in the IC(50) of HeLa-MRP1 to Rh123 and the Etoposide VP16 relative to HeLa cells, respectively.	Etoposide	98-107	ATP binding cassette subfamily C member 1	Homo sapiens	76-80
11112520-7	2000	Cell growth assays showed 5-fold and 14-fold increase in the IC(50) of HeLa-MRP1 to Rh123 and the Etoposide VP16 relative to HeLa cells, respectively.	Etoposide	98-107	host cell factor C1	Homo sapiens	108-112
11090076-8	2000	These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis.	Etoposide	44-53	TNF receptor superfamily member 10b	Homo sapiens	90-93
11162435-5	2000	In addition, we show that overexpression of KIAP enhances apoptosis induced by etoposide, and, that KIAP fails to block apoptosis induced by overexpression of Fas.	Etoposide	79-88	baculoviral IAP repeat containing 7	Homo sapiens	44-48
10978339-8	2000	In contrast, MCL1(Delta)(4A) retained its anti-apoptotic function in HeLa cells when challenged by Etoposide.	Etoposide	99-108	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-17
11156370-8	2000	Furthermore, a cell-permeable inhibitor of caspase-9, Ac-LEHD.CHO, which did not inhibit T-cell apoptosis induced by anti-Fas Ab, markedly inhibited apoptosis induced by etoposide or by coculture of Jurkat with SCCHN cells.	Etoposide	170-179	caspase-9	Cricetulus griseus	43-52
11213398-10	2000	Although randomized studies are not available, adjuvant therapy using other agents instead of mitotane (o,p-DDD), such as the combination of cisplatin and etoposide (VP-16), seems reasonable in the locally advanced stages.	Etoposide	155-164	host cell factor C1	Homo sapiens	166-171
11090076-8	2000	These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis.	Etoposide	44-53	tumor protein p53	Homo sapiens	106-109
11090076-8	2000	These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis.	Etoposide	44-53	TNF superfamily member 10	Homo sapiens	174-180
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	TNF receptor superfamily member 10a	Homo sapiens	94-97
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	TNF receptor superfamily member 10c	Homo sapiens	104-108
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	TNF receptor superfamily member 10d	Homo sapiens	110-114
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	Fas ligand	Homo sapiens	116-126
11090076-6	2000	Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels.	Etoposide	39-48	TNF superfamily member 10	Homo sapiens	131-137
11125949-4	2000	Therapy with etoposide and carboplatin induced a temporary partial remission, with fairly good quality of life and decrease of the NSE levels (down to 15.0 ng/mL).	Etoposide	13-22	enolase 2	Homo sapiens	131-134
11103783-7	2000	In this report, we have presented the novel observation that the transcription factor Oct-1 is induced after cells are exposed to multiple DNA-damaging agents and therapeutic agents, including UV radiation, methylmethane sulfonate, ionizing radiation, etoposide, cisplatin, and camptothecin.	Etoposide	252-261	POU class 2 homeobox 1	Homo sapiens	86-91
11210163-3	2000	We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity.	Etoposide	33-42	host cell factor C1	Homo sapiens	44-49
11210163-3	2000	We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity.	Etoposide	33-42	vasoactive intestinal peptide	Homo sapiens	73-76
11095975-4	2000	We also found that etoposide caused a much more discrete phosphorylation of both p38alpha and p38gamma than either cisplatin or UV treatment.	Etoposide	19-28	mitogen-activated protein kinase 14	Homo sapiens	81-89
11095975-4	2000	We also found that etoposide caused a much more discrete phosphorylation of both p38alpha and p38gamma than either cisplatin or UV treatment.	Etoposide	19-28	mitogen-activated protein kinase 12	Homo sapiens	94-102
11127271-7	2000	In vitro experiments with the human leukaemia T cell line Jurkat, subjected to apoptosis by etoposide, showed that apoH was bound to the membrane of apoptotic cells.	Etoposide	92-101	apolipoprotein H	Homo sapiens	115-119
11040047-7	2000	When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level.	Etoposide	38-47	BCL2 apoptosis regulator	Homo sapiens	155-160
11040047-7	2000	When treated with an anticancer drug (etoposide or cisplatin) or the kinase inhibitor staurosporin, the cells containing a high G(1) population and a high Bcl-2 protein level were much more resistant to the induced apoptosis than the cells containing a high S phase population and a low Bcl-2 protein level.	Etoposide	38-47	BCL2 apoptosis regulator	Homo sapiens	287-292
10961984-0	2000	Distinct pathways for stimulation of cytochrome c release by etoposide.	Etoposide	61-70	cytochrome c, somatic	Homo sapiens	37-49
10961984-1	2000	Induction of apoptosis by DNA-damaging agents, such as etoposide, is known to involve the release of mitochondrial cytochrome c, although the mechanism responsible for this event is unclear.	Etoposide	55-64	cytochrome c, somatic	Homo sapiens	115-127
10961984-2	2000	In the present study, using Jurkat T-lymphocytes, a reconstituted cell-free system, or isolated liver mitochondria, we demonstrate the ability of etoposide to induce cytochrome c release via two distinct pathways.	Etoposide	146-155	cytochrome c, somatic	Homo sapiens	166-178
10961984-7	2000	We propose that lower doses of etoposide predominantly target the nucleus and stimulate the release of caspase-sensitive protein factor(s) that interact with mitochondria to trigger cytochrome c release, whereas higher doses of the drug impart a more direct effect on mitochondria and thus are not mitigated by caspase inhibition.	Etoposide	31-40	cytochrome c, somatic	Homo sapiens	182-194
11033421-5	2000	(1) The inhibition by H(2)O(2) of VP-16-induced apoptosis and cellular caspase-3 activity can be overcome by adding inhibitors of poly(ADP-ribose) polymerase (PARP) at sub-stoichiometric concentrations.	Etoposide	34-39	poly(ADP-ribose) polymerase 1	Homo sapiens	130-157
11020216-6	2000	Similarly, inhibition of PPT1 with a synthetic inhibitor (AcG-palmitoyl diaminoproprionate-VKIKK) (DAP1) (100 microM) increased the susceptibility of the cells to apoptosis induced by either C(2)-ceramide or etoposide, a common chemotherapeutic agent used in the treatment of neuroblastoma.	Etoposide	208-217	palmitoyl-protein thioesterase 1	Homo sapiens	25-29
11020216-6	2000	Similarly, inhibition of PPT1 with a synthetic inhibitor (AcG-palmitoyl diaminoproprionate-VKIKK) (DAP1) (100 microM) increased the susceptibility of the cells to apoptosis induced by either C(2)-ceramide or etoposide, a common chemotherapeutic agent used in the treatment of neuroblastoma.	Etoposide	208-217	death associated protein	Homo sapiens	99-103
11045764-12	2000	Clonogenic assays showed that Ad5CMV-p21 reduced the sensitivity of MDA-MB-231 to VP-16 and paclitaxel.	Etoposide	82-87	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-40
10993652-4	2000	The p53(+)/RB(-)cells were susceptible to apoptosis under various experimental conditions: 1) incubation in serum-free culture for 72 h, 2) short-term (6 h) or long-term (48 h) exposure to etoposide, and 3) culturing in soft agar.	Etoposide	189-198	tumor protein p53	Homo sapiens	4-7
11033421-5	2000	(1) The inhibition by H(2)O(2) of VP-16-induced apoptosis and cellular caspase-3 activity can be overcome by adding inhibitors of poly(ADP-ribose) polymerase (PARP) at sub-stoichiometric concentrations.	Etoposide	34-39	poly(ADP-ribose) polymerase 1	Homo sapiens	159-163
11033421-6	2000	(2) Delayed addition of H(2)O(2) to VP-16-treated cells prevents additional caspase induction but does not inhibit the caspase activity that has already been generated.	Etoposide	36-41	caspase 9	Homo sapiens	76-83
10996201-5	2000	These data indicate that abrogation of bax-mediated apoptosis can be implicated in development of etoposide resisance.	Etoposide	98-107	BCL2 associated X, apoptosis regulator	Homo sapiens	39-42
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	tumor protein p53	Homo sapiens	100-103
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	tumor protein p53	Homo sapiens	144-147
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	cyclin dependent kinase inhibitor 1A	Homo sapiens	169-174
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	cyclin dependent kinase inhibitor 1A	Homo sapiens	175-178
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	proliferating cell nuclear antigen	Homo sapiens	180-184
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	S100 calcium binding protein A2	Homo sapiens	191-197
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	growth differentiation factor 15	Homo sapiens	202-211
11005251-5	2000	In etoposide model with chip hybridization, we defined signaling pathways that mediate apoptosis in p53 dependent manner (through activation of p53 target genes such as Waf-1/p21, PCNA, GPX, S100A2 and PTGF-beta) as well as in p53-independent manner (through activation of ODC and TGF-beta receptor, among others).	Etoposide	3-12	tumor protein p53	Homo sapiens	144-147
11021755-0	2000	The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow.	Etoposide	109-118	malic enzyme complex, mitochondrial	Mus musculus	66-71
11021755-4	2000	Retrovirally-mediated expression of MDR1 in murine bone marrow resulted in partial protection against the clastogenic activity of etoposide relative to mock transduced control mice.	Etoposide	130-139	malic enzyme complex, mitochondrial	Mus musculus	36-40
10996201-8	2000	Our findings suggest that down regulation of topo IIalpha in association with p53 deficiency can confer chromosomal instability in etoposide-resistant K562 cells.	Etoposide	131-140	tumor protein p53	Homo sapiens	78-81
11008007-1	2000	PURPOSE: Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC).	Etoposide	30-39	host cell factor C1	Homo sapiens	41-45
10930537-5	2000	Pretreatment of U937 cells with MG132 or LLnL inhibited etoposide-induced morphological apoptosis and caspase-3 activation.	Etoposide	56-65	caspase 3	Homo sapiens	102-111
11029754-3	2000	Here we report that before the initiation of apoptotic execution by etoposide or staurosporin, an active calpain activity cleaves Bax at its N-terminus, generating a potent proapoptotic 18-kDa fragment (Bax/p18).	Etoposide	68-77	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
11029754-7	2000	Pretreatment with a specific calpain inhibitor calpeptin inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and caspase-3 activation.	Etoposide	67-76	cytochrome c, somatic	Homo sapiens	119-131
11029754-7	2000	Pretreatment with a specific calpain inhibitor calpeptin inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and caspase-3 activation.	Etoposide	67-76	caspase 3	Homo sapiens	145-154
11029754-10	2000	Finally, Bcl-2 overexpression inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and apoptosis.	Etoposide	40-49	BCL2 apoptosis regulator	Homo sapiens	9-14
11029754-10	2000	Finally, Bcl-2 overexpression inhibited etoposide-induced calpain activation, Bax cleavage, cytochrome c release, and apoptosis.	Etoposide	40-49	cytochrome c, somatic	Homo sapiens	92-104
10930537-7	2000	Other inhibitors of NF-kappaB activation, including pyrrrolidine dithiocarbamate (an antioxidant) and the peptide SN50 (an inhibitor of translocation of activated NF-kappaB into the nucleus), also attenuated etoposide-induced apoptosis.	Etoposide	208-217	nuclear factor kappa B subunit 1	Homo sapiens	20-29
10930537-8	2000	In leukemia blasts, although proteasome inhibitors suppressed NF-kappaB activation induced by etoposide, they were unable to prevent morphological apoptosis.	Etoposide	94-103	nuclear factor kappa B subunit 1	Homo sapiens	62-71
10930537-10	2000	These results suggest that the role that NF-kappaB plays in apoptosis induced by etoposide in a human leukemia cell line may be different from the role it plays in freshly isolated leukemia blasts.	Etoposide	81-90	nuclear factor kappa B subunit 1	Homo sapiens	41-50
11071269-11	2000	In K562 cells, treatment with etoposide in the absence of p21WAF1 induction resulted in post-transcriptional down-modulation of c-IAP1 levels.	Etoposide	30-39	baculoviral IAP repeat containing 2	Homo sapiens	128-134
10961894-6	2000	Moreover, ionizing radiation, aracytine, and etoposide not only increase GrB and PFN expression but also conferred potent cellular cytotoxicity to these cells toward various cellular targets.	Etoposide	45-54	granzyme B	Homo sapiens	73-76
10961896-3	2000	Modulation of cytarabine (Ara-C) and etoposide (VP-16) efficacy by bone marrow stromal cells in vitro was investigated.	Etoposide	37-46	host cell factor C1	Homo sapiens	48-53
11042671-9	2000	Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation.	Etoposide	82-91	BCL2 associated X, apoptosis regulator	Homo sapiens	160-163
11042671-9	2000	Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation.	Etoposide	82-91	BCL2 apoptosis regulator	Homo sapiens	164-169
11042671-9	2000	Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation.	Etoposide	82-91	cytochrome c, somatic	Homo sapiens	199-211
11042671-9	2000	Taken together, these results suggest that ceramide may function as a mediator of etoposide-induced apoptosis of C6 glioma cells, which induces increase in the Bax/Bcl-2 ratio followed by release of cytochrome c leading to caspases-9 and -3 activation.	Etoposide	82-91	caspase 9	Homo sapiens	223-240
11062729-7	2000	Among the cell cycle controlling genes, c-Myc and P21Cip1/WAF1 showed impressive responses to the two etoposide concentrations.	Etoposide	102-111	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
11062729-7	2000	Among the cell cycle controlling genes, c-Myc and P21Cip1/WAF1 showed impressive responses to the two etoposide concentrations.	Etoposide	102-111	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-57
11062729-7	2000	Among the cell cycle controlling genes, c-Myc and P21Cip1/WAF1 showed impressive responses to the two etoposide concentrations.	Etoposide	102-111	cyclin dependent kinase inhibitor 1A	Homo sapiens	58-62
11062729-11	2000	Differing responses of c-Myc and p21Cip1/WAF1 at two concentrations may govern the antiproliferative effects of etoposide.	Etoposide	112-121	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	23-28
11062729-11	2000	Differing responses of c-Myc and p21Cip1/WAF1 at two concentrations may govern the antiproliferative effects of etoposide.	Etoposide	112-121	cyclin dependent kinase inhibitor 1A	Homo sapiens	33-40
11062729-11	2000	Differing responses of c-Myc and p21Cip1/WAF1 at two concentrations may govern the antiproliferative effects of etoposide.	Etoposide	112-121	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-45
11042671-0	2000	Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells.	Etoposide	84-93	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
11042671-0	2000	Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells.	Etoposide	84-93	BCL2 apoptosis regulator	Homo sapiens	60-65
11042671-1	2000	Etoposide (VP-16) a topoisomerase II inhibitor induces apoptosis of tumor cells.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
11042671-3	2000	Etoposide induced increased formation of ceramide from sphingomyelin and release of mitochondrial cytochrome c followed by activation of caspase-9 and caspase-3, but not caspase-1.	Etoposide	0-9	cytochrome c, somatic	Homo sapiens	98-110
11042671-3	2000	Etoposide induced increased formation of ceramide from sphingomyelin and release of mitochondrial cytochrome c followed by activation of caspase-9 and caspase-3, but not caspase-1.	Etoposide	0-9	caspase 9	Homo sapiens	137-146
11042671-3	2000	Etoposide induced increased formation of ceramide from sphingomyelin and release of mitochondrial cytochrome c followed by activation of caspase-9 and caspase-3, but not caspase-1.	Etoposide	0-9	caspase 3	Homo sapiens	151-160
11042671-4	2000	In addition, exposure of cells to etoposide resulted in decreased expression of Bcl-2 with reciprocal increase in Bax protein.	Etoposide	34-43	BCL2 apoptosis regulator	Homo sapiens	80-85
11042671-4	2000	In addition, exposure of cells to etoposide resulted in decreased expression of Bcl-2 with reciprocal increase in Bax protein.	Etoposide	34-43	BCL2 associated X, apoptosis regulator	Homo sapiens	114-117
11042671-6	2000	Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio.	Etoposide	144-153	caspase 3	Homo sapiens	192-201
11042671-6	2000	Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio.	Etoposide	144-153	BCL2 associated X, apoptosis regulator	Homo sapiens	231-234
11042671-6	2000	Reduced glutathione or N-acetylcysteine, which could reduce ceramide formation by inhibiting sphingomyelinase activity, prevented C6 cells from etoposide-induced apoptosis through blockage of caspase-3 activation and change of the Bax/Bcl-2 ratio.	Etoposide	144-153	BCL2 apoptosis regulator	Homo sapiens	235-240
11070791-4	2000	Restoration of p53 protein function in LN382 cells at 34 degrees C reduced the cytotoxicity of etoposide and paclitaxel, whereas that of cisplatin and ACNU was not affected.	Etoposide	95-104	tumor protein p53	Homo sapiens	15-18
11070791-6	2000	Transduction of wild-type p53 in LN382 cells also reduced the sensitivity of the cells to etoposide.	Etoposide	90-99	tumor protein p53	Homo sapiens	26-29
11070791-8	2000	These results indicate that cell cycle arrest induced by wild-type p53 function may abrogate the cytotoxic effects of etoposide and paclitaxel, which are dependent on G2M-associated apoptosis.	Etoposide	118-127	tumor protein p53	Homo sapiens	67-70
11071269-14	2000	CONCLUSIONS: Etoposide-mediated apoptosis involves down-modulation of the anti-apoptotic protein c-IAP1.	Etoposide	13-22	baculoviral IAP repeat containing 2	Homo sapiens	97-103
10816597-5	2000	The stress inducers arsenite, butyrate, and etoposide also increased pMDR1(-1202) promoter activity, but the increase was not inhibited (in the case of butyrate) or was only partially inhibited (in the case of arsenite and etoposide) by HSF1(-).	Etoposide	44-53	heat shock transcription factor 1	Homo sapiens	237-241
10910943-3	2000	Using 2 myeloid cell lines, HL60 and NB4, evidence is presented that prior incubation with the CD44-specific monoclonal antibody (mAb) A3D8, reported to induce differentiation of AML blasts, significantly decreases apoptosis induced by 3 drugs used in AML chemotherapy: daunorubicin (DNR), mitoxantrone, and etoposide.	Etoposide	308-317	CD44 molecule (Indian blood group)	Homo sapiens	95-99
10818098-6	2000	Interestingly, wt alpha-synuclein drastically reduces the caspase activation of TSM1 neurons upon three distinct apoptotic stimuli including staurosporine, etoposide, and ceramide C(2) when compared with mock-transfected cells.	Etoposide	156-165	synuclein, alpha	Mus musculus	18-33
10818098-8	2000	Comparison of wild-type and mutated alpha-synuclein-expressing cells also indicates that the former exhibits much less vulnerability in response to staurosporine and etoposide as measured by the sodium 3"-[1-(phenylaminocarbonyl)-3, 4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid assay.	Etoposide	166-175	synuclein, alpha	Mus musculus	36-51
10913345-0	2000	Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.	Etoposide	61-70	CD82 molecule	Homo sapiens	52-56
10913345-0	2000	Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.	Etoposide	61-70	tumor protein p53	Homo sapiens	86-89
10913345-0	2000	Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.	Etoposide	61-70	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	94-99
10913345-2	2000	We found that etoposide, a topoisomerase II inhibitor, is able to activate the expression of the KAI1 gene in a dose-dependent manner in human prostate cancer cell lines, ALVA, DU145, and PC-3 as well as in human lung carcinoma cell A549.	Etoposide	14-23	CD82 molecule	Homo sapiens	97-101
10913345-2	2000	We found that etoposide, a topoisomerase II inhibitor, is able to activate the expression of the KAI1 gene in a dose-dependent manner in human prostate cancer cell lines, ALVA, DU145, and PC-3 as well as in human lung carcinoma cell A549.	Etoposide	14-23	proprotein convertase subtilisin/kexin type 1	Homo sapiens	188-192
10900222-8	2000	Coexpression of GSTpi with MRP1 conferred significant resistance above that seen for MRP1 alone to chlorambucil, etoposide, ethacrynic acid, and vincristine.	Etoposide	113-122	ATP binding cassette subfamily C member 1	Homo sapiens	27-31
10930016-0	2000	Wild-type p53-dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells.	Etoposide	24-33	caspase 3	Homo sapiens	64-73
10930016-7	2000	A CPP32 inhibition assay was used to determine whether a specific CPP32 inhibitor, DEVD-CHO, affects the apoptosis induced by etoposide in malignant glioma cells.	Etoposide	126-135	caspase 3	Homo sapiens	66-71
10930016-8	2000	Etoposide significantly inhibited the growth of U-87MG and T-98G/p53 cells in a dose-dependent manner compared with the growth of the T-98G cells.	Etoposide	0-9	tumor protein p53	Homo sapiens	65-68
10930016-9	2000	Treatment with low concentrations of etoposide resulted in the increased expression of wild-type p53; it also initiated CPP32 activity and induced apoptosis in the U-87MG cells.	Etoposide	37-46	tumor protein p53	Homo sapiens	97-100
10930016-9	2000	Treatment with low concentrations of etoposide resulted in the increased expression of wild-type p53; it also initiated CPP32 activity and induced apoptosis in the U-87MG cells.	Etoposide	37-46	caspase 3	Homo sapiens	120-125
10930016-11	2000	Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity.	Etoposide	35-44	tumor protein p53	Homo sapiens	81-84
10930016-11	2000	Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity.	Etoposide	35-44	tumor protein p53	Homo sapiens	144-147
10930016-11	2000	Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity.	Etoposide	35-44	BCL2 apoptosis regulator	Homo sapiens	178-183
10930016-11	2000	Furthermore, low concentrations of etoposide also induced apoptosis in the T-98G/p53 cells by enhancing the expression of transfected wild-type p53, decreasing the expression of bcl-2, and activating CPP32 activity.	Etoposide	35-44	caspase 3	Homo sapiens	200-205
10982237-0	2000	Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF.	Etoposide	18-27	colony stimulating factor 3	Homo sapiens	223-228
10930016-0	2000	Wild-type p53-dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells.	Etoposide	24-33	tumor protein p53	Homo sapiens	10-13
10930016-13	2000	Etoposide-induced apoptosis can be suppressed by the CPP32 inhibitor DEVD-CHO.	Etoposide	0-9	caspase 3	Homo sapiens	53-58
10918609-3	2000	Etoposide, cisplatin and tumor necrosis factor-alpha induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3.	Etoposide	0-9	cytochrome c, somatic	Homo sapiens	223-235
10930016-14	2000	CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide.	Etoposide	107-116	tumor protein p53	Homo sapiens	52-55
10930016-14	2000	CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide.	Etoposide	107-116	caspase 3	Homo sapiens	57-62
10930016-14	2000	CONCLUSIONS: These findings indicate that wild-type p53, CPP32, and bcl-2 may mediate apoptosis induced by etoposide.	Etoposide	107-116	BCL2 apoptosis regulator	Homo sapiens	68-73
10930016-15	2000	Forced expression of wild-type p53 increases etoposide cytotoxicity in human glioma cells by inducing apoptosis and may have important therapeutic implications.	Etoposide	45-54	tumor protein p53	Homo sapiens	31-34
10908664-4	2000	Derangement of its transcriptional activity manifested as inhibition of p53-mediated apoptosis by etoposide, a representative antineoplastic agent.	Etoposide	98-107	tumor protein p53	Homo sapiens	72-75
10918614-4	2000	The topoisomerase II inhibitor etoposide induced p53-dependent death, which suggests that DNA damage may not be its primary mechanism of cytotoxicity in this cell type.	Etoposide	31-40	transformation related protein 53, pseudogene	Mus musculus	49-52
10918609-3	2000	Etoposide, cisplatin and tumor necrosis factor-alpha induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3.	Etoposide	0-9	caspase 9	Rattus norvegicus	271-288
10918609-5	2000	Bax overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation.	Etoposide	28-37	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
10918609-5	2000	Bax overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation.	Etoposide	28-37	cytochrome c, somatic	Homo sapiens	80-92
10918609-5	2000	Bax overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation.	Etoposide	28-37	caspase 9	Rattus norvegicus	105-113
10918609-9	2000	In addition, transient overexpression of Bcl-xL also exerted inhibitory effects on ceramide formation and apoptotic cell death induced by etoposide.	Etoposide	138-147	BCL2 like 1	Homo sapiens	41-47
10897015-6	2000	In view of these findings, the authors treated STS patients with an etoposide, cisplatin, and ifosfamide (VIP) combination.	Etoposide	68-77	vasoactive intestinal peptide	Homo sapiens	106-109
10918425-3	2000	A total of 600 mg/m2 BCNU, 900 mg/m2 thiotepa and 1500 or 750 mg/m2 etoposide (VP-16) was administered followed by autologous bone marrow reinfusion (ABMR).	Etoposide	68-77	host cell factor C1	Homo sapiens	79-84
11038146-1	2000	PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16.	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
11038146-1	2000	PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16.	Etoposide	72-81	host cell factor C1	Homo sapiens	143-148
10963117-0	2000	Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines.	Etoposide	59-68	gastrin releasing peptide	Homo sapiens	14-22
10963117-0	2000	Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines.	Etoposide	59-68	calcitonin related polypeptide alpha	Homo sapiens	27-37
10963117-7	2000	METHODS: LNCaP, PC-3 and DU 145 prostatic cancer cell lines were induced to undergo apoptosis after treatment with etoposide alone or plus androgen ablation.	Etoposide	115-124	chromobox 8	Homo sapiens	16-20
10963117-8	2000	We tested the role of neuropeptides bombesin and calcitonin at modulating etoposide induced apoptosis.	Etoposide	74-83	calcitonin related polypeptide alpha	Homo sapiens	49-59
10963117-12	2000	Calcitonin addition prevents apoptosis in PC-3, LNCaP and in an etoposide dose-dependent way in DU 145.	Etoposide	64-73	calcitonin related polypeptide alpha	Homo sapiens	0-10
10963117-13	2000	CONCLUSION: Neuropeptides bombesin and calcitonin can modulate the apoptotic response of prostate cancer cells by inducing resistance to etoposide-induced apoptosis, suggesting that neuropeptides can be used as a target of therapeutical approach in prostatic carcinoma.	Etoposide	137-146	gastrin releasing peptide	Homo sapiens	26-34
10963117-13	2000	CONCLUSION: Neuropeptides bombesin and calcitonin can modulate the apoptotic response of prostate cancer cells by inducing resistance to etoposide-induced apoptosis, suggesting that neuropeptides can be used as a target of therapeutical approach in prostatic carcinoma.	Etoposide	137-146	calcitonin related polypeptide alpha	Homo sapiens	39-49
10867130-2	2000	Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent with a 5-day mitoxantrone/etoposide regimen in patients over age 55 with newly diagnosed AML.	Etoposide	165-174	phosphoglycolate phosphatase	Homo sapiens	6-9
10901311-14	2000	The MOS/ADR1 cells were found to exhibit cross-resistance only to substrates for P-glycoprotein (such as doxorubicin, vincristine, and etoposide), whereas the MOS/IR1 cells were resistant to all of the drugs studied (including cisplatin and methotrexate).	Etoposide	135-144	Moloney sarcoma oncogene	Mus musculus	4-7
10797287-0	2000	Expression of E-cadherin reduces bcl-2 expression and increases sensitivity to etoposide-induced apoptosis.	Etoposide	79-88	cadherin 1	Rattus norvegicus	14-24
10871854-2	2000	Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E.	Etoposide	43-52	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	108-163
10871854-2	2000	Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E.	Etoposide	43-52	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	165-171
10871854-2	2000	Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E.	Etoposide	43-52	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	239-245
10871854-2	2000	Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E.	Etoposide	43-52	eukaryotic translation initiation factor 4E	Rattus norvegicus	257-262
10912951-3	2000	In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed.	Etoposide	46-55	ATP binding cassette subfamily B member 1	Homo sapiens	91-105
10912951-3	2000	In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed.	Etoposide	46-55	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
10912951-4	2000	The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.	Etoposide	4-13	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
10822279-4	2000	Here, we show that BID is cleaved in response to multiple death-inducing stimuli (staurosporine, UV radiation, cycloheximide, etoposide).	Etoposide	126-135	BH3 interacting domain death agonist	Homo sapiens	19-22
10834929-4	2000	PLC-gamma1 was fragmented when Molt-4 cells were treated with several apoptotic stimuli such as etoposide, ceramides, and tumor necrosis factor alpha.	Etoposide	96-105	phospholipase C gamma 1	Homo sapiens	0-10
10871865-2	2000	It has recently been shown that the abundance of p27KIP1 is also regulated during apoptosis; p27KIP1 is cleaved by a Z-VAD-fmk-sensitive caspase during apoptosis induced by growth factor deprivation in endothelial cells, and also following exposure of myeloid leukaemia cells to etoposide.	Etoposide	279-288	cyclin dependent kinase inhibitor 1B	Homo sapiens	49-56
10871865-2	2000	It has recently been shown that the abundance of p27KIP1 is also regulated during apoptosis; p27KIP1 is cleaved by a Z-VAD-fmk-sensitive caspase during apoptosis induced by growth factor deprivation in endothelial cells, and also following exposure of myeloid leukaemia cells to etoposide.	Etoposide	279-288	cyclin dependent kinase inhibitor 1B	Homo sapiens	93-100
10871865-4	2000	We observe that p27KIP1 is down-regulated following exposure to a variety of apoptotic stimuli including an agonistic anti-Fas antibody, cycloheximide and etoposide.	Etoposide	155-164	cyclin dependent kinase inhibitor 1B	Homo sapiens	16-23
10871865-7	2000	In contrast, the loss of p27KIP1 in cells exposed to cycloheximide and etoposide occurs in the absence of caspase-8 or any Z-VAD-fmk- or Boc-D-fmk-sensitive caspase activities.	Etoposide	71-80	cyclin dependent kinase inhibitor 1B	Homo sapiens	25-32
10747957-4	2000	Vanadate-induced nucleotide trapping in MRP1 was found to be stimulated by reduced glutathione, glutathione disulfide, and etoposide and to be synergistically stimulated by the presence of etoposide and either glutathione.	Etoposide	123-132	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
10747957-4	2000	Vanadate-induced nucleotide trapping in MRP1 was found to be stimulated by reduced glutathione, glutathione disulfide, and etoposide and to be synergistically stimulated by the presence of etoposide and either glutathione.	Etoposide	189-198	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
10747957-5	2000	These results suggest that glutathione and etoposide interact with MRP1 at different sites and that those bindings cooperatively stimulate the nucleotide trapping.	Etoposide	43-52	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
11225846-4	2000	When HL-60 cells were induced to undergo apoptosis by treating with 50 microM etoposide (VP-16) for 4 hours, 77 kDa and 40 kDa polypeptides accumulated in nuclear fractions.	Etoposide	78-87	host cell factor C1	Homo sapiens	89-94
10850456-9	2000	Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide.	Etoposide	110-119	BCL2 apoptosis regulator	Homo sapiens	27-32
10850456-9	2000	Tumor cells overexpressing Bcl-2 or Bcl-xL become resistant to apoptosis induced by the chemotherapeutic drug etoposide.	Etoposide	110-119	BCL2 like 1	Homo sapiens	36-42
10797287-3	2000	Using rat breast carcinoma cells selected for loss of hormone responsiveness, we found that parental E-cadherin-expressing cells (E cells) were more sensitive to etoposide-induced apoptosis than hormone-non-responsive cells (F cells), which failed to express E-cadherin.	Etoposide	162-171	cadherin 1	Rattus norvegicus	101-111
10797287-6	2000	Stable clonal isolates expressing E-cadherin (F. Cad) showed increased sensitivity to etoposide treatment compared with control clones (F.Neo).	Etoposide	86-95	cadherin 1	Rattus norvegicus	34-44
10797287-11	2000	Unlike F cells, F.Cad transfectants were not able to express Bcl-2, but transient transfection of bcl-2 resulted in re-expression and resistance to etoposide treatment.	Etoposide	148-157	BCL2, apoptosis regulator	Rattus norvegicus	98-103
10821872-4	2000	FAK-transfected HL-60 (HL-60/FAK) cells were highly resistant to apoptosis induced with hydrogen peroxide (1 mm) and etoposide (50 microg/ml) compared with the parental HL-60 cells or the vector-transfected cells, when determined using viability assay, DNA fragmentation, and flow cytometry analysis.	Etoposide	117-126	protein tyrosine kinase 2	Homo sapiens	0-3
10821872-4	2000	FAK-transfected HL-60 (HL-60/FAK) cells were highly resistant to apoptosis induced with hydrogen peroxide (1 mm) and etoposide (50 microg/ml) compared with the parental HL-60 cells or the vector-transfected cells, when determined using viability assay, DNA fragmentation, and flow cytometry analysis.	Etoposide	117-126	protein tyrosine kinase 2	Homo sapiens	23-32
10807791-5	2000	When overexpressed in human Jurkat cells, GLO1 inhibited etoposide- and adriamycin-induced caspase activation and apoptosis, indicating the involvement of GLO1 in apoptosis suppression caused by these drugs.	Etoposide	57-66	glyoxalase I	Homo sapiens	42-46
10825136-2	2000	The objective of the study was to elucidate whether other modes of DNA damage induced by doxorubicin, topotecan, and etoposide (VP-16) could elicit a similar cytotoxic response in TS- cells by signaling via the Fas death receptor.	Etoposide	117-126	host cell factor C1	Homo sapiens	128-133
10807791-6	2000	Moreover, cotreatment with S-p-bromobenzylglutathione cyclopentyl diester (BBGC), a cell-permeable inhibitor of GLO1, enhanced etoposide-induced apoptosis in resistant UK711 cells but not in parental U937 cells.	Etoposide	127-136	glyoxalase I	Homo sapiens	112-116
10788521-9	2000	Using both a modified alkaline comet assay and a DNA cleavage assay, we demonstrate that 14-3-3epsilon negatively affects the ability of the chemotherapeutic, etoposide, to trap topo II in cleavable complexes with DNA, thereby preventing DNA strand breaks.	Etoposide	159-168	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	Homo sapiens	89-102
10797013-2	2000	The c-IAP1 and XIAP inhibitors of apoptosis were selectively lost in glucocorticoid- or etoposide-treated thymocytes in a proteasome-dependent manner before death.	Etoposide	88-97	baculoviral IAP repeat containing 2	Homo sapiens	4-10
10797013-2	2000	The c-IAP1 and XIAP inhibitors of apoptosis were selectively lost in glucocorticoid- or etoposide-treated thymocytes in a proteasome-dependent manner before death.	Etoposide	88-97	X-linked inhibitor of apoptosis	Homo sapiens	15-19
10811113-2	2000	The induction of the CD95/CD95L pathway can be activated by the activator protein-1 (AP-1)-mediated up-regulation of the CD95L promoter, which is responsible for the induction of apoptosis elicited by stimuli such as etoposide.	Etoposide	217-226	Fas cell surface death receptor	Homo sapiens	21-25
10779415-8	2000	In addition, the levels of Hrk were up-regulated after treatment with the chemotherapeutic drug etoposide.	Etoposide	96-105	harakiri, BCL2 interacting protein (contains only BH3 domain)	Mus musculus	27-30
10800080-6	2000	In contrast, activation of group I mGluR, including selective activation of mGluR5, significantly attenuated apoptotic cell death induced by both staurosporine and etoposide.	Etoposide	164-173	glutamate receptor, ionotropic, kainate 1	Mus musculus	76-82
10811113-2	2000	The induction of the CD95/CD95L pathway can be activated by the activator protein-1 (AP-1)-mediated up-regulation of the CD95L promoter, which is responsible for the induction of apoptosis elicited by stimuli such as etoposide.	Etoposide	217-226	Fas ligand	Homo sapiens	26-31
10811113-2	2000	The induction of the CD95/CD95L pathway can be activated by the activator protein-1 (AP-1)-mediated up-regulation of the CD95L promoter, which is responsible for the induction of apoptosis elicited by stimuli such as etoposide.	Etoposide	217-226	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-83
10811113-2	2000	The induction of the CD95/CD95L pathway can be activated by the activator protein-1 (AP-1)-mediated up-regulation of the CD95L promoter, which is responsible for the induction of apoptosis elicited by stimuli such as etoposide.	Etoposide	217-226	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	85-89
10811113-2	2000	The induction of the CD95/CD95L pathway can be activated by the activator protein-1 (AP-1)-mediated up-regulation of the CD95L promoter, which is responsible for the induction of apoptosis elicited by stimuli such as etoposide.	Etoposide	217-226	Fas ligand	Homo sapiens	121-126
11261838-5	2000	The expression of hST3Gal III and hST3Gal IV mRNAs were down-regulated and sialidase activity on the cell surface increased threefold within 2 h of etoposide treatment.	Etoposide	148-157	tumor-suppressor, HELA cell type	Homo sapiens	18-22
11261838-5	2000	The expression of hST3Gal III and hST3Gal IV mRNAs were down-regulated and sialidase activity on the cell surface increased threefold within 2 h of etoposide treatment.	Etoposide	148-157	tumor-suppressor, HELA cell type	Homo sapiens	34-38
10758153-3	2000	The MLL BCR DNA cleavage was shown in primary progenitor hematopoietic cells from healthy newborns and adults as well as in cell lines; it colocalized with the MLL BCR cleavage site induced by chemotherapeutic agents, such as etoposide (VP16) and doxorubicin (Dox).	Etoposide	226-235	lysine methyltransferase 2A	Homo sapiens	4-7
10939640-0	2000	Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells.	Etoposide	0-9	nuclear receptor subfamily 4 group A member 1	Homo sapiens	92-108
10830185-0	2000	Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome.	Etoposide	150-159	RANBP2 like and GRIP domain containing 2	Homo sapiens	14-25
10830185-0	2000	Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome.	Etoposide	150-159	nucleoporin 98 and 96 precursor	Homo sapiens	32-37
10830185-0	2000	Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome.	Etoposide	150-159	DEAD-box helicase 10	Homo sapiens	75-80
10758153-3	2000	The MLL BCR DNA cleavage was shown in primary progenitor hematopoietic cells from healthy newborns and adults as well as in cell lines; it colocalized with the MLL BCR cleavage site induced by chemotherapeutic agents, such as etoposide (VP16) and doxorubicin (Dox).	Etoposide	226-235	lysine methyltransferase 2A	Homo sapiens	160-163
10758153-3	2000	The MLL BCR DNA cleavage was shown in primary progenitor hematopoietic cells from healthy newborns and adults as well as in cell lines; it colocalized with the MLL BCR cleavage site induced by chemotherapeutic agents, such as etoposide (VP16) and doxorubicin (Dox).	Etoposide	237-241	lysine methyltransferase 2A	Homo sapiens	4-7
10758153-3	2000	The MLL BCR DNA cleavage was shown in primary progenitor hematopoietic cells from healthy newborns and adults as well as in cell lines; it colocalized with the MLL BCR cleavage site induced by chemotherapeutic agents, such as etoposide (VP16) and doxorubicin (Dox).	Etoposide	237-241	lysine methyltransferase 2A	Homo sapiens	160-163
10758153-6	2000	Reversibility experiments demonstrated a religation of the bioflavonoid as well as the VP16-induced MLL cleavage site.	Etoposide	87-91	lysine methyltransferase 2A	Homo sapiens	100-103
10901300-1	2000	We have previously reported that novobiocin potentiates the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26) in a number of experimental tumor cell lines by inhibition of the efflux of the epipodophyllotoxins by an ATP-requiring transporter.	Etoposide	82-91	host cell factor C1	Homo sapiens	93-98
11232603-4	2000	We employed the anticancer drug, etoposide (VP-16), as a model phenolic compound to study the sensitivity of ryanodine-sensitive Ca2+ channel (RyR) to VP-16 phenoxyl radicals.	Etoposide	33-42	host cell factor C1	Homo sapiens	44-49
11232603-0	2000	Reversible thiol-dependent activation of ryanodine-sensitive Ca2+ release channel by etoposide (VP-16) phenoxyl radical.	Etoposide	85-94	host cell factor C1	Homo sapiens	96-101
10898537-0	2000	Plasma pharmacokinetics of etoposide (VP-16) after i.v.	Etoposide	27-36	host cell factor C1	Homo sapiens	38-43
10898537-2	2000	The pharmacokinetics of etoposide (VP-16), a semi-synthetic derivative of podophyllotoxin, were studied in 16 pediatric patients (median age 8.3 years; range 4 months to 22 years) including two girls with Down"s syndrome (DS).	Etoposide	24-33	host cell factor C1	Homo sapiens	35-40
11232603-4	2000	We employed the anticancer drug, etoposide (VP-16), as a model phenolic compound to study the sensitivity of ryanodine-sensitive Ca2+ channel (RyR) to VP-16 phenoxyl radicals.	Etoposide	33-42	host cell factor C1	Homo sapiens	151-156
10759716-0	2000	Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide.	Etoposide	139-148	superoxide dismutase 2	Homo sapiens	27-57
10811471-4	2000	Ad-p53 and DNA-damaging agents (cis-diamminedichloroplatinum(II), etoposide, and 7-ethyl-10-hydrocycamptothecin) showed synergistic effects in six of seven cell lines but additive effects against a p53-mutated cell line.	Etoposide	66-75	tumor protein p53	Homo sapiens	3-6
10778981-1	2000	The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and has been associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, respectively.	Etoposide	183-192	E2F transcription factor 1	Homo sapiens	33-38
10778981-1	2000	The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and has been associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, respectively.	Etoposide	183-192	transcription factor Dp-1	Homo sapiens	39-43
10738279-3	2000	METHODS: Experimentally determined CFDs for VP-16 (etoposide)-induced apoptosis were measured by phosphotidylserine surface expression and mitochondrial membrane potential dissipation (DeltaPsi(m)) in BV173 leukemia cells.	Etoposide	51-60	host cell factor C1	Homo sapiens	44-49
10822824-0	2000	[Effect of chronic low-dose irradiation and etoposide on the life spain of Drosophila melanogaster strain mei-41].	Etoposide	44-53	meiotic 41	Drosophila melanogaster	106-112
10744629-3	2000	On induction of apoptosis by staurosporin, c-Myc, etoposide, or ceramide, AIF (but not hsp60) translocates to the nucleus.	Etoposide	50-59	apoptosis inducing factor mitochondria associated 1	Homo sapiens	74-77
10708807-3	2000	Treatment of U-937 and HL-60 cells with K-1 inhibited etoposide (ETO)-induced apoptosis in both cell lines in a dose-dependent manner, IC(50)=200 microg/ml.	Etoposide	54-63	keratin 1	Homo sapiens	40-43
10708807-3	2000	Treatment of U-937 and HL-60 cells with K-1 inhibited etoposide (ETO)-induced apoptosis in both cell lines in a dose-dependent manner, IC(50)=200 microg/ml.	Etoposide	65-68	keratin 1	Homo sapiens	40-43
10708807-7	2000	These findings suggest that K-1 may serve as a potent inhibitor of apoptosis initiated by ETO or nitric oxide.	Etoposide	90-93	keratin 1	Homo sapiens	28-31
10713325-4	2000	Etoposide caused an increase in the mean fluorescence intensity of FasR in both subclones, and an induction of FasL in the ES subclone.	Etoposide	0-9	Fas ligand	Homo sapiens	111-115
10786805-2	2000	It serves as a target for several useful antichemotherapeutic agents, such as etoposide (VP-16) and teniposide (VM26).	Etoposide	78-87	host cell factor C1	Homo sapiens	89-94
10749135-0	2000	The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.	Etoposide	51-60	BH3 interacting domain death agonist	Homo sapiens	35-38
10749135-1	2000	Ectopic overexpression of Apaf-1 (2.5-fold) in human acute myelogenous leukemia HL-60 cells (HL-60/Apaf-1 cells) induced apoptosis and sensitized HL-60/Apaf-1 cells to etoposide- and paclitaxel-induced apoptosis (C. Perkins et al., Cancer Res., 58: 4561-4566, 1998).	Etoposide	168-177	apoptotic peptidase activating factor 1	Homo sapiens	26-32
10749135-7	2000	In contrast, a transient transfection of dominant negative caspase-8 or CrmA or exposure to caspase-8 inhibitor zIETD-fmk inhibited the processing of procaspase-8 and Bid but did not inhibit the cytosolic accumulation of cyt c in either the untreated HL-60/Apaf-1 cells or the etoposide-treated HL-60/Apaf-1 and HL-60/neo cells.	Etoposide	277-286	caspase 8	Homo sapiens	59-68
10749135-7	2000	In contrast, a transient transfection of dominant negative caspase-8 or CrmA or exposure to caspase-8 inhibitor zIETD-fmk inhibited the processing of procaspase-8 and Bid but did not inhibit the cytosolic accumulation of cyt c in either the untreated HL-60/Apaf-1 cells or the etoposide-treated HL-60/Apaf-1 and HL-60/neo cells.	Etoposide	277-286	caspase 8	Homo sapiens	92-101
10692394-6	2000	Significantly, in human tumor monocytic cells undergoing apoptosis after treatment with either etoposide or N-tosyl-l-phenylalanyl chloromethyl ketone (TPCK), the approximately 700-kDa Apaf-1 containing apoptosome complex was predominately formed.	Etoposide	95-104	apoptotic peptidase activating factor 1	Homo sapiens	185-191
10759716-2	2000	Cell death after 24 h exposure to 10 micromol/l etoposide was about 60% and 70% in the ES subclone and about 20% and 25% in the ER subclone, when analysed by trypan blue and annexin V respectively.	Etoposide	48-57	annexin A5	Homo sapiens	174-183
10686577-4	2000	p130cas was also degraded in cells treated with staurosporine or etoposide, suggesting that degradation of focal adhesion proteins is a characteristic feature of apoptosis.	Etoposide	65-74	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	0-7
10759716-6	2000	Etoposide caused a potent induction of MnSOD, more than 400% at 12 h, in the ER but not in the ES subclone.	Etoposide	0-9	superoxide dismutase 2	Homo sapiens	39-44
10759716-8	2000	In conclusion, we suggest that MnSOD might have a special role in the protection of AML cells against etoposide-induced cell death.	Etoposide	102-111	superoxide dismutase 2	Homo sapiens	31-36
10712510-0	2000	Caspase-mediated cleavage of p130cas in etoposide-induced apoptotic Rat-1 cells.	Etoposide	40-49	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	29-36
10779024-1	2000	PURPOSE: The activity of etoposide (VP-16) has been demonstrated to be schedule-dependent.	Etoposide	25-34	host cell factor C1	Homo sapiens	36-41
10712510-2	2000	We investigated the changes in focal adhesion proteins during etoposide-induced apoptosis in Rat-1 cells and found that during apoptosis, p130cas (Crk-associated substrate [Cas]) is cleaved by caspase-3.	Etoposide	62-71	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	138-145
10712510-2	2000	We investigated the changes in focal adhesion proteins during etoposide-induced apoptosis in Rat-1 cells and found that during apoptosis, p130cas (Crk-associated substrate [Cas]) is cleaved by caspase-3.	Etoposide	62-71	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	147-171
10712510-2	2000	We investigated the changes in focal adhesion proteins during etoposide-induced apoptosis in Rat-1 cells and found that during apoptosis, p130cas (Crk-associated substrate [Cas]) is cleaved by caspase-3.	Etoposide	62-71	caspase 3	Rattus norvegicus	193-202
10669740-8	2000	Finally, Akt-transformed cells were shown to require NF-kappaB to suppress the ability of etoposide to induce apoptosis.	Etoposide	90-99	AKT serine/threonine kinase 1	Homo sapiens	9-12
10839193-0	2000	Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells.	Etoposide	48-57	BCL2 apoptosis regulator	Homo sapiens	26-31
10839193-4	2000	Processing of caspase-3 was slightly detected from 12 h and became obvious at 24 h with 100 microM etoposide.	Etoposide	99-108	caspase 3	Homo sapiens	14-23
10839193-7	2000	Changes of the mRNA levels of most apoptosis-regulating genes were not prominent at both concentrations, except for the rapid induction of c-IAP-2/HIAP-1 and the down-regulation of Bcl-X(L) by 100 microM etoposide.	Etoposide	204-213	BCL2 like 1	Homo sapiens	181-188
10839193-8	2000	The downregulation of Bcl-X(L) protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-X(L) and Bax, which precedes the activation of caspase-3.	Etoposide	208-217	BCL2 like 1	Homo sapiens	22-30
10774745-4	2000	They were also slightly more resistant than the parental cell (AML-2/WT) to etoposide, camptothecin and daunorubicin.	Etoposide	76-85	RUNX family transcription factor 3	Homo sapiens	63-68
10839193-8	2000	The downregulation of Bcl-X(L) protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-X(L) and Bax, which precedes the activation of caspase-3.	Etoposide	208-217	BCL2 associated X, apoptosis regulator	Homo sapiens	64-67
10839193-8	2000	The downregulation of Bcl-X(L) protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-X(L) and Bax, which precedes the activation of caspase-3.	Etoposide	208-217	BCL2 like 1	Homo sapiens	262-270
10839193-8	2000	The downregulation of Bcl-X(L) protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-X(L) and Bax, which precedes the activation of caspase-3.	Etoposide	208-217	BCL2 associated X, apoptosis regulator	Homo sapiens	275-278
10839193-8	2000	The downregulation of Bcl-X(L) protein occurred from 6 h, while Bax protein conversely showed a slight increase from 6 h. Taken together, the present findings show that the dose-dependent apoptotic effect of etoposide is based on a change in the balance between Bcl-X(L) and Bax, which precedes the activation of caspase-3.	Etoposide	208-217	caspase 3	Homo sapiens	313-322
10679758-9	2000	In a chemosensitivity test, PSK-1 cells were found to be sensitive in vitro to cisplatin, etoposide, and doxorubicin, but resistant to dacarbazine and 5-fluorouracil.	Etoposide	90-99	TAO kinase 2	Homo sapiens	28-33
10774251-5	2000	The patient was treated with continuous-drip infusion of low-dose cytarabine and etoposide with G-CSF (AVG therapy).	Etoposide	81-90	colony stimulating factor 3	Homo sapiens	96-101
10732775-5	2000	Also, inhibition of the SCC Ag-1 expression in tumour cells by transfection of antisense SCC Ag-1 cDNA was accompanied by significantly increased sensitivity of these cells to apoptosis induced by etoposide or TNF-alpha.	Etoposide	197-206	serpin family B member 3	Homo sapiens	24-27
20937210-6	2000	RESULTS: The MDR cell line expressing P-gp was established , which exhibited a typical drug resistance to vincristine (VCR) , vindesin (VDS) , etoposide (VP-16) , mitomycin (MMC) , taxol and navelbine (NOR) .	Etoposide	143-152	phosphoglycolate phosphatase	Mus musculus	38-42
20937210-6	2000	RESULTS: The MDR cell line expressing P-gp was established , which exhibited a typical drug resistance to vincristine (VCR) , vindesin (VDS) , etoposide (VP-16) , mitomycin (MMC) , taxol and navelbine (NOR) .	Etoposide	154-159	phosphoglycolate phosphatase	Mus musculus	38-42
10706092-3	2000	Here we show that the DNA-damaging chemotherapeutic drugs, cis-diamminedichloroplatinum(II) (CDDP) and etoposide, elicited increased expression of DR5 in human glioma cells.	Etoposide	103-112	TNF receptor superfamily member 10b	Homo sapiens	147-150
10706092-4	2000	Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA.	Etoposide	83-92	TNF superfamily member 10	Homo sapiens	49-54
10706092-4	2000	Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA.	Etoposide	83-92	TNF superfamily member 10	Homo sapiens	161-166
10706092-4	2000	Exposure of such cells in vitro to soluble human TRAIL in combination with CDDP or etoposide resulted in synergistic cell death that could be blocked by soluble TRAIL-neutralizing DR5-Fc or the caspase inhibitors, Z-Asp-CH2-DCB and CrmA.	Etoposide	83-92	TNF receptor superfamily member 10b	Homo sapiens	180-183
11227493-1	2000	Apoptosis induced by etoposide (VP-16) in HL-60 cells was confirmed to be caspase-dependent.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
10732775-5	2000	Also, inhibition of the SCC Ag-1 expression in tumour cells by transfection of antisense SCC Ag-1 cDNA was accompanied by significantly increased sensitivity of these cells to apoptosis induced by etoposide or TNF-alpha.	Etoposide	197-206	serpin family B member 3	Homo sapiens	89-92
10648907-6	2000	Since etoposide blocks religation of the cut made by type II topoisomerases, repair of DNA damage may result in rejoining of the original DNA strands, undoing the reciprocal exchange that had already occurred and resulting in reduced crossing-over despite a normal frequency of MLH1 foci.	Etoposide	6-15	mutL homolog 1	Mus musculus	278-282
10675353-7	2000	We show here that the lack of Mrp1 protein causes etoposide levels to increase about 10-fold in the CSF after intravenous administration of the drug.	Etoposide	50-59	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	30-34
10784401-6	2000	The combination of 2-CdA with doxorubicin or mitoxantrone had a synergistic effect on the induction of apoptosis (p&lt;0.001) in both normal and neoplastic lymphocytes, whereas 2-CdA plus etoposide or cytosine arabinoside were only additive.	Etoposide	188-197	cytidine deaminase	Homo sapiens	21-24
10723177-0	2000	[Treatment results of VIP (etoposide, ifosfamide and cisplatin) chemotherapy as a first-line therapy in metastatic germ cell tumors].	Etoposide	27-36	vasoactive intestinal peptide	Homo sapiens	22-25
10723177-2	2000	PATIENTS AND METHODS: From March 1994 to October 1997, we treated 16 patients with VIP therapy consisting of etoposide (100 mg/m2), ifosfamide, (1.2 g/m2) and cisplatin (20 mg/m2), all of which were generally given daily for 5 consecutive days every 3 weeks.	Etoposide	109-118	vasoactive intestinal peptide	Homo sapiens	83-86
10713734-0	2000	The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.	Etoposide	46-55	Fas cell surface death receptor	Homo sapiens	65-69
10713734-5	2000	Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists.	Etoposide	9-18	Fas ligand	Homo sapiens	44-55
10713734-5	2000	Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists.	Etoposide	9-18	Fas cell surface death receptor	Homo sapiens	44-48
10713737-2	2000	By investigating the ordering of molecular events during genotoxic stress-induced apoptosis, we found that ionizing radiation (IR) and etoposide induced the release of cyto c from mitochondria in two distinct stages.	Etoposide	135-144	cytochrome c, somatic	Homo sapiens	168-174
10640289-5	2000	After interleukin-3 withdrawal or etoposide treatment, exogenous IGF-1 prevented apoptosis and elevated levels of Cdc2, a biochemical indicator of a functional IGF-1 receptor pathway.	Etoposide	34-43	insulin-like growth factor 1	Mus musculus	65-70
10713660-0	2000	Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385).	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
10639160-9	2000	p53-dependent cell death in the AGS human gastric cancer cell line after etoposide was similarly inhibited by transient expression of ITF but not a C-terminal truncation mutant of ITF, and it required functional phosphatidylinositol 3-kinase and EGF receptor.	Etoposide	73-82	tumor protein p53	Homo sapiens	0-3
10639160-9	2000	p53-dependent cell death in the AGS human gastric cancer cell line after etoposide was similarly inhibited by transient expression of ITF but not a C-terminal truncation mutant of ITF, and it required functional phosphatidylinositol 3-kinase and EGF receptor.	Etoposide	73-82	trefoil factor 3	Homo sapiens	134-137
10620629-0	2000	Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.	Etoposide	41-50	BCL2 like 1	Homo sapiens	65-73
10667597-11	2000	Importantly, ZK7-overexpressing cells had lower sensitivity to ionizing radiation and the chemotherapeutic agent etoposide than U937 parent cells or HZF16-overexpressing cells.	Etoposide	113-122	zinc finger protein 124	Homo sapiens	13-16
10683851-3	2000	The cellular A beta 42 increase was caused by 3-day treatments with H2O2, etoposide or melphalan, all of which induce genotoxic apoptosis, but not by treatment with sodium azide, which causes necrosis.	Etoposide	74-83	amyloid beta precursor protein	Homo sapiens	13-19
10620629-10	2000	Activation of surface protein CD40 increased Bcl-x(L) protein levels via an (E)-capsaicin-inhibitable activation of NF-kappaB; i.e. , (E)-capsaicin restored etoposide sensitivity.	Etoposide	157-166	CD40 molecule	Homo sapiens	30-34
10620629-0	2000	Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.	Etoposide	41-50	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
10620629-10	2000	Activation of surface protein CD40 increased Bcl-x(L) protein levels via an (E)-capsaicin-inhibitable activation of NF-kappaB; i.e. , (E)-capsaicin restored etoposide sensitivity.	Etoposide	157-166	BCL2 like 1	Homo sapiens	45-53
10620629-12	2000	VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.	Etoposide	110-119	vascular cell adhesion molecule 1	Homo sapiens	0-6
10618379-5	2000	The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant.	Etoposide	78-87	tumor protein p53	Homo sapiens	4-7
10620629-12	2000	VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.	Etoposide	110-119	interleukin 4	Homo sapiens	12-25
10620629-12	2000	VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.	Etoposide	110-119	BCL2 associated X, apoptosis regulator	Homo sapiens	80-83
10620629-12	2000	VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.	Etoposide	110-119	BCL2 associated X, apoptosis regulator	Homo sapiens	155-158
10620629-12	2000	VCAM-1- and interleukin 4-mediated signals diminished conformational changes in Bax protein and prevented the etoposide-induced disruption of constitutive Bax-Bcl-x(L) binding.	Etoposide	110-119	BCL2 like 1	Homo sapiens	159-164
10620629-13	2000	CONCLUSIONS: Microenvironmental factors reduce the sensitivity of a B-cell lymphoma to etoposide in vitro by modulating the expression and functions of Bax and Bcl-x(L).	Etoposide	87-96	BCL2 associated X, apoptosis regulator	Homo sapiens	152-155
10620629-13	2000	CONCLUSIONS: Microenvironmental factors reduce the sensitivity of a B-cell lymphoma to etoposide in vitro by modulating the expression and functions of Bax and Bcl-x(L).	Etoposide	87-96	BCL2 like 1	Homo sapiens	160-165
10620618-9	2000	We show that lymphocytes that cannot be killed by FasL, such as those from Fas-deficient lpr mice or transgenic mice expressing a dominant negative mutant of Fas-associated death domain protein (FADD/MORT1), are as sensitive as normal lymphocytes to killing by gamma radiation or the cytotoxic drugs cis-platin, doxorubicin, and etoposide.	Etoposide	329-338	Fas (TNFRSF6)-associated via death domain	Mus musculus	195-199
10618379-5	2000	The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant.	Etoposide	78-87	growth differentiation factor 15	Homo sapiens	43-52
10618379-5	2000	The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant.	Etoposide	78-87	tumor protein p53	Homo sapiens	91-94
10618379-5	2000	The p53 binding and transactivation of the PTGF-beta promoter was enhanced by etoposide, a p53 activator, and was largely blocked by a dominant negative p53 mutant.	Etoposide	78-87	tumor protein p53	Homo sapiens	91-94
10618379-6	2000	Furthermore, expression of endogenous PTGF-beta was remarkably induced by etoposide in p53-positive, but not in p53-negative, cell lines.	Etoposide	74-83	growth differentiation factor 15	Homo sapiens	38-47
10618379-6	2000	Furthermore, expression of endogenous PTGF-beta was remarkably induced by etoposide in p53-positive, but not in p53-negative, cell lines.	Etoposide	74-83	tumor protein p53	Homo sapiens	87-90
10769693-3	2000	Apoptosis in the bax-transfected gastric cancer cells was enhanced following the treatment of various chemotherapeutic agents including adriamycin (ADM), cisplatin (CDDP), etoposide (VP-16) and taxotere (TXT) as compared to those of neo gene-transfected cells.	Etoposide	172-181	BCL2 associated X, apoptosis regulator	Homo sapiens	17-20
11154989-1	2000	It is known that the topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of lymphoma.	Etoposide	81-90	host cell factor C1	Homo sapiens	74-79
10713725-3	2000	In this report we demonstrate by subcellular fractionation a significant shift in Bax localization from cytosol to cellular membranes in two human tumor cell lines exposed to staurosporine or etoposide.	Etoposide	192-201	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
10769650-4	2000	Induction of p53-dependent apoptosis was observed in the etoposide treatment group, the X-ray irradiation group, and the combined (etoposide + X-ray irradiation) group.	Etoposide	57-66	tumor protein p53	Homo sapiens	13-16
10769650-4	2000	Induction of p53-dependent apoptosis was observed in the etoposide treatment group, the X-ray irradiation group, and the combined (etoposide + X-ray irradiation) group.	Etoposide	131-140	tumor protein p53	Homo sapiens	13-16
10722231-2	2000	Here we report that cells of thymic lymphoma overexpressing Ras/Raf proteins, initially resistant to TCR-dependent apoptosis but sensitive to dexamethasone- and etoposide-induced cell death, became insensitive to dexamethasone after long-time culture.	Etoposide	161-170	zinc fingers and homeoboxes 2	Homo sapiens	64-67
10722231-4	2000	Interestingly, lymphoma cells were still sensitive to p53-mediated apoptosis induced by etoposide.	Etoposide	88-97	tumor protein p53	Homo sapiens	54-57
10755319-0	2000	Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.	Etoposide	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	85-99
10755319-0	2000	Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.	Etoposide	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	101-105
10755319-13	2000	CONCLUSION: These findings suggest that a small degree of the enhanced myelosuppression observed with CsA combined with etoposide might be attributable to inhibition of P-glycoprotein in bone marrow precursor cells.	Etoposide	120-129	ATP binding cassette subfamily B member 1	Homo sapiens	169-183
10713725-7	2000	High level overexpression of the anti-apoptotic protein Bcl-2 prevented Bax redistribution to the mitochondria, caspase activation and apoptosis following exposure to staurosporine or etoposide.	Etoposide	184-193	BCL2 apoptosis regulator	Homo sapiens	56-61
11325040-3	2000	Enforced expression of E2F-1 in interleukin-3-dependent myeloid cells led to preferential sensitivity to the topoisomerase II inhibitor, etoposide, which was independent of p53 accumulation.	Etoposide	137-146	E2F transcription factor 1 L homeolog	Xenopus laevis	23-28
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	angiotensin I converting enzyme	Homo sapiens	105-108
11325040-4	2000	Pretreatment of the E2F-1-expressing cells with ICRF-193, a second topoisomerase II inhibitor that does not cause DNA damage, protected these cells against etoposide-induced apoptosis.	Etoposide	156-165	E2F transcription factor 1 L homeolog	Xenopus laevis	20-25
10949401-0	2000	Effect of adjuvant chemotherapy using pirarubicin, cisplatin, and etoposide (PEP) for stage IVB endometrial carcinoma: a case report.	Etoposide	66-75	progestagen associated endometrial protein	Homo sapiens	77-80
10949401-5	2000	She showed a remarkable response to a PEP (pirarubicin, etoposide, cisplatin) regimen and has survived without disease over 8 years.	Etoposide	56-65	progestagen associated endometrial protein	Homo sapiens	38-41
10644891-7	2000	The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells.	Etoposide	200-209	tumor protein p53	Homo sapiens	72-75
16232914-3	2000	The ratio of MI, which is defined by the dose of colcemid to that of the supplement with etoposide as an anti-tumor agent and is designated MIR, was 10% at an exposure of 2 h, suggesting that etoposide blocks the cell cycle before 2 h of the mitotic phase.	Etoposide	192-201	membrane associated ring-CH-type finger 8	Homo sapiens	140-143
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	colony stimulating factor 3	Homo sapiens	169-206
10637255-4	2000	Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support.	Etoposide	94-103	colony stimulating factor 3	Homo sapiens	208-213
11043829-1	2000	Intermediate high dose VIP (etoposide, ifosfamide, cisplatin) achieved comparable efficacy and improved tolerance in comparison with high-dose chemotherapy plus PBSC in poor risk germ cell tumors.	Etoposide	28-37	vasoactive intestinal peptide	Homo sapiens	23-26
10594023-4	2000	The mechanism of the synergistic effect results from the etoposide-mediated increase in the expression of the death receptors 4 (DR4) and 5 (DR5).	Etoposide	57-66	TNF receptor superfamily member 10a	Homo sapiens	110-127
10594023-4	2000	The mechanism of the synergistic effect results from the etoposide-mediated increase in the expression of the death receptors 4 (DR4) and 5 (DR5).	Etoposide	57-66	TNF receptor superfamily member 10a	Homo sapiens	129-132
10594023-4	2000	The mechanism of the synergistic effect results from the etoposide-mediated increase in the expression of the death receptors 4 (DR4) and 5 (DR5).	Etoposide	57-66	TNF receptor superfamily member 10b	Homo sapiens	141-144
10594023-5	2000	Inhibition of NF-kappaB activation by expression of kinase-inactive MEK kinase 1(MEKK1) or dominant-negative IkappaB (DeltaIkappaB) blocked the increase in DR4 and DR5 expression following etoposide treatment.	Etoposide	189-198	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	68-80
10594023-5	2000	Inhibition of NF-kappaB activation by expression of kinase-inactive MEK kinase 1(MEKK1) or dominant-negative IkappaB (DeltaIkappaB) blocked the increase in DR4 and DR5 expression following etoposide treatment.	Etoposide	189-198	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	81-86
10594023-5	2000	Inhibition of NF-kappaB activation by expression of kinase-inactive MEK kinase 1(MEKK1) or dominant-negative IkappaB (DeltaIkappaB) blocked the increase in DR4 and DR5 expression following etoposide treatment.	Etoposide	189-198	TNF receptor superfamily member 10a	Homo sapiens	156-159
10594023-5	2000	Inhibition of NF-kappaB activation by expression of kinase-inactive MEK kinase 1(MEKK1) or dominant-negative IkappaB (DeltaIkappaB) blocked the increase in DR4 and DR5 expression following etoposide treatment.	Etoposide	189-198	TNF receptor superfamily member 10b	Homo sapiens	164-167
10594023-6	2000	Addition of a soluble decoy DR4 fusion protein (DR4:Fc) to cell cultures reduced the amount of etoposide-induced apoptosis in a dose-dependent manner.	Etoposide	95-104	TNF receptor superfamily member 10a	Homo sapiens	28-31
10594023-6	2000	Addition of a soluble decoy DR4 fusion protein (DR4:Fc) to cell cultures reduced the amount of etoposide-induced apoptosis in a dose-dependent manner.	Etoposide	95-104	TNF receptor superfamily member 10a	Homo sapiens	48-51
10594023-7	2000	The addition of a soluble TNF decoy receptor (TNFR:Fc) was without effect, demonstrating the specificity of DR4 binding ligands in the etoposide-induced apoptosis response.	Etoposide	135-144	TNF receptor superfamily member 10a	Homo sapiens	108-111
10594023-0	2000	Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL.	Etoposide	109-118	TNF receptor superfamily member 10a	Homo sapiens	24-47
10683315-3	2000	However, we show CpG oligonucleotides (ODN) blocking caspase-dependent fas(CD95) ligand-mediated apoptosis as well as caspase-independent etoposide-mediated apoptosis and etoposide-zVAD-mediated necrosis.	Etoposide	138-147	Putative inactive caspase subunit p14	Caenorhabditis elegans	118-125
10642996-5	2000	After the operation, we treated him with additional radiation and chemotherapy using ifosfamide, cisplatin, and etoposide (namely ICE therapy).	Etoposide	112-121	carboxylesterase 2	Homo sapiens	130-133
11216669-0	2000	Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
11216669-1	2000	We have previously reported that the antibiotic novobiocin enhanced the toxicity of the anticancer agent etoposide (VP-16) to several drug-sensitive and -resistant tumor cell lines.	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
20929637-1	1999	BACKGROUND: To evaluate the effect and toxicity of combination chemotherapy with carboplatin and cisplatin plus etoposide (CPE regimen) and carboplatin plus etoposide (CE regimen) in the treatment of small cell lung cancer (SCLC) .	Etoposide	112-121	carboxypeptidase E	Homo sapiens	123-126
10674004-8	1999	Enhancement of dCK activity could also be achieved with the topoisomerase II inhibitor, etoposide.	Etoposide	88-97	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	15-18
10606242-7	1999	The MRP3-transfected cells displayed approximately 4-fold resistance to etoposide and approximately 2-fold resistance to vincristine, compared with control transfected cells.	Etoposide	72-81	ATP binding cassette subfamily C member 3	Homo sapiens	4-8
10606242-10	1999	The MRP-transfected cells exhibited reduced accumulation of radiolabeled etoposide, consistent with the operation of a plasma membrane efflux pump.	Etoposide	73-82	ATP binding cassette subfamily C member 1	Homo sapiens	4-7
10577849-1	1999	PURPOSE: To evaluate a chemotherapy regimen that consisted of ifosfamide administered as an infusion with bolus carboplatin, and etoposide (ICE) supported by granulocyte colony-stimulating factor (G-CSF) for cytoreduction and stem-cell mobilization in transplant-eligible patients with primary refractory or relapsed non-Hodgkin"s lymphoma (NHL).	Etoposide	129-138	carboxylesterase 2	Homo sapiens	140-143
10674004-0	1999	Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity.	Etoposide	70-79	deoxycytidine kinase	Homo sapiens	89-109
10565860-5	1999	Cytotoxicity assays revealed that TER199 significantly reversed the resistance of MRP1-transfected NIH3T3 cells for vincristine, doxorubicin, etoposide, and mitoxantrone.	Etoposide	142-151	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	82-86
10570059-5	1999	These results show that both topo IIalpha and beta are in vivo targets for etoposide, mitoxantrone, and amsacrine (mAMSA) in topo IIbeta +/+ cells.	Etoposide	75-84	ATPase, class II, type 9A	Mus musculus	34-41
10570059-5	1999	These results show that both topo IIalpha and beta are in vivo targets for etoposide, mitoxantrone, and amsacrine (mAMSA) in topo IIbeta +/+ cells.	Etoposide	75-84	ATPase, class II, type 9B	Mus musculus	130-136
10570059-8	1999	Increased survival of topo IIbeta -/- cells compared with topo IIbeta +/+ cells was observed after treatment with amsacrine (mAMSA), methyl N-(4"-[9-acridinylamino]-2-methoxyphenyl) carbamate hydrochloride (AMCA), methyl N-(4"-[9-acridinylamino]-2-methoxyphenyl)carbamate hydrochloride (mAMCA), mitoxantrone, and etoposide.	Etoposide	313-322	ATPase, class II, type 9B	Mus musculus	27-33
10556359-8	1999	Viabilities of control and mcl-1 transfected cells after treatment with the cytotoxin etoposide (20 microgram/ml), were 37.9 +/- 3.9% and 78.2 +/- 2.0%, respectively.	Etoposide	86-95	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	27-32
10637446-3	1999	Overexpression of human caspase-3 alone could not induce apoptosis of tumor cell lines, but apoptosis was markedly enhanced by the addition of etoposide.	Etoposide	143-152	caspase 3	Homo sapiens	24-33
10637446-4	1999	In an AH130 liver tumor model, transduction of human caspase- 3, but not the empty vector, induced extensive apoptosis and reduced tumor volume when combined with etoposide administration.	Etoposide	163-172	caspase 3	Homo sapiens	53-63
10567338-7	1999	The antisense oligonucleotides of ASC were found to reduce the expression of ASC, and consequently, etoposide-mediated apoptosis of HL-60 cells was suppressed.	Etoposide	100-109	PYD and CARD domain containing	Homo sapiens	34-37
10567338-7	1999	The antisense oligonucleotides of ASC were found to reduce the expression of ASC, and consequently, etoposide-mediated apoptosis of HL-60 cells was suppressed.	Etoposide	100-109	PYD and CARD domain containing	Homo sapiens	77-80
10581415-8	1999	On the contrary, okadaic acid and etoposide only slightly affected the expression of PTEN although they induce a prominent apoptosis in Neuro-2a cells.	Etoposide	34-43	phosphatase and tensin homolog	Mus musculus	85-89
10576649-1	1999	The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold.	Etoposide	230-239	ATP binding cassette subfamily B member 1	Homo sapiens	26-40
10544021-3	1999	In the present study, we showed that the topoisomerase II inhibitor of widely used anticancer drugs etoposide and doxorubicin activated wt p53 in BL2, a Burkitt"s lymphoma cell line which overexpressed MDM2.	Etoposide	100-109	tumor protein p53	Homo sapiens	139-142
10544021-3	1999	In the present study, we showed that the topoisomerase II inhibitor of widely used anticancer drugs etoposide and doxorubicin activated wt p53 in BL2, a Burkitt"s lymphoma cell line which overexpressed MDM2.	Etoposide	100-109	cell adhesion molecule 1	Homo sapiens	146-149
10544021-3	1999	In the present study, we showed that the topoisomerase II inhibitor of widely used anticancer drugs etoposide and doxorubicin activated wt p53 in BL2, a Burkitt"s lymphoma cell line which overexpressed MDM2.	Etoposide	100-109	MDM2 proto-oncogene	Homo sapiens	202-206
10544021-8	1999	This p53 was co-immunoprecipitated with MDM2, but p53 activated by etoposide or doxorubicin barely complexed with MDM2.	Etoposide	67-76	tumor protein p53	Homo sapiens	5-8
10544021-8	1999	This p53 was co-immunoprecipitated with MDM2, but p53 activated by etoposide or doxorubicin barely complexed with MDM2.	Etoposide	67-76	tumor protein p53	Homo sapiens	50-53
10544021-8	1999	This p53 was co-immunoprecipitated with MDM2, but p53 activated by etoposide or doxorubicin barely complexed with MDM2.	Etoposide	67-76	MDM2 proto-oncogene	Homo sapiens	114-118
10631466-0	1999	Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress.	Etoposide	149-158	glutamate-cysteine ligase catalytic subunit	Homo sapiens	101-134
10631466-13	1999	In neither of the subclones was induction of gamma-GCS observed during 24-hour exposure to etoposide.	Etoposide	91-100	glutamate-cysteine ligase catalytic subunit	Homo sapiens	45-54
10631466-15	1999	When glutathione was depleted by treatment with buthionine sulfoximine, a direct inhibitor of gamma-GCS, the sensitivity to etoposide was increased, particularly in the ER subclone.	Etoposide	124-133	glutamate-cysteine ligase catalytic subunit	Homo sapiens	94-103
10631466-17	1999	The molecular mechanisms mediating glutathione depletion during etoposide exposure might include the cleavage of the catalytic subunit of gamma-GCS.	Etoposide	64-73	glutamate-cysteine ligase catalytic subunit	Homo sapiens	138-147
10556184-16	1999	These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients.	Etoposide	59-68	PML nuclear body scaffold	Homo sapiens	105-108
10556184-16	1999	These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients.	Etoposide	59-68	retinoic acid receptor alpha	Homo sapiens	109-117
10556191-2	1999	Cells from continuous T-cell lines did not normally express CD10, but became CD10(+) when induced into apoptosis by human immunodeficiency virus (HIV) infection and exposure to CD95 monoclonal antibody, etoposide, or staurosporin.	Etoposide	203-212	membrane metalloendopeptidase	Homo sapiens	77-81
10576649-1	1999	The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold.	Etoposide	230-239	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
10544189-2	1999	The present study demonstrates that HSP27 overexpression decreases U937 human leukemic cell sensitivity to etoposide-induced cytotoxicity by preventing apoptosis.	Etoposide	107-116	heat shock protein family B (small) member 1	Homo sapiens	36-41
10554032-4	1999	We found that both endogenous and exogenous added recombinant Bax translocated to the mitochondria more efficiently in the presence of cytosol from cells with VP16-induced apoptosis than with cytoplasm from normal cells.	Etoposide	159-163	BCL2 associated X, apoptosis regulator	Homo sapiens	62-65
10544189-9	1999	We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.	Etoposide	32-41	heat shock protein family B (small) member 1	Homo sapiens	17-22
10544189-9	1999	We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.	Etoposide	32-41	cytochrome c, somatic	Homo sapiens	74-86
10544189-9	1999	We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.	Etoposide	32-41	caspase 9	Homo sapiens	118-127
10544189-9	1999	We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.	Etoposide	32-41	cytochrome c, somatic	Homo sapiens	143-155
10557062-3	1999	Treatment with anticancer drugs such as doxorubicin, methotrexate, cytarabine, etoposide and cisplatin at therapeutic concentrations leads to induction of CD95-ligand (CD95-L).	Etoposide	79-88	Fas ligand	Homo sapiens	155-166
10637744-4	1999	BEP regimen (bleomycin, etoposide and cisplatin) salvaged with VIP (etoposide, ifosfamide and cisplatin) would be the standard therapy for advanced germ cell tumors since high-dose chemotherapy had no advantage on survival over the standard-dose regimen.	Etoposide	68-77	vasoactive intestinal peptide	Homo sapiens	63-66
10502297-2	1999	The stable expression of wild-type p53 resulted in a significant increase in sensitivity to the topoisomerase II poisons etoposide and doxorubicin, but not to the topoisomerase II inhibitors razoxane and ADR-529.	Etoposide	121-130	tumor protein p53	Homo sapiens	35-38
10557062-3	1999	Treatment with anticancer drugs such as doxorubicin, methotrexate, cytarabine, etoposide and cisplatin at therapeutic concentrations leads to induction of CD95-ligand (CD95-L).	Etoposide	79-88	Fas ligand	Homo sapiens	168-174
10502412-6	1999	Apoptosis induced by diverse chemical agents (hygromycin, beauvericin, etoposide, H(2)O(2)) was blocked by E1B 19 kDa expression.	Etoposide	71-80	small nucleolar RNA, H/ACA box 73a	Mus musculus	107-110
10531310-9	1999	In cells, overexpressing IGF-I receptors alone, IGF-I addition enhanced cellular proliferation, even in the presence of etoposide and MMS.	Etoposide	120-129	insulin-like growth factor 1	Mus musculus	25-30
10531310-9	1999	In cells, overexpressing IGF-I receptors alone, IGF-I addition enhanced cellular proliferation, even in the presence of etoposide and MMS.	Etoposide	120-129	insulin-like growth factor 1	Mus musculus	48-53
10511592-11	1999	CONCLUSIONS: LRP is involved in resistance to doxorubicin, vincristine, etoposide, paclitaxel, and gramicidin D and has an important role in the transport of doxorubicin from the nucleus to the cytoplasm.	Etoposide	72-81	major vault protein	Homo sapiens	13-16
10507772-3	1999	The expression of nm23-H1 protein was examined immunohistochemically in 32 eligible patients with OSCC who underwent adjuvant chemotherapy with cisplatin, etoposide, and 5-fluorouracil after tumour resection.	Etoposide	155-164	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	18-25
10587291-1	1999	The effect of tamoxifen (TAM) on the pharmacokinetics of oral administration of etoposide (VP-16) in patients with nonoperable hepatocellular carcinoma was investigated.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-96
10507772-10	1999	MTT (3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H tetrazolium bromide) assay showed that reduced expression of the nm23-H1 protein in AS clones was consistent with the degree of increased resistance to cisplatin but not etoposide or 5-fluorouracil.	Etoposide	218-227	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	113-120
10525268-6	1999	Using an electron paramagnetic resonance spectrometric (EPR) method, we established that the level of thiol-dependent quenching of phenoxyl radicals of etoposide was decreased &gt;40% in pulmonary tissue of mice that received TDI intrabronchially.	Etoposide	152-161	TLX1 neighbor	Homo sapiens	226-229
10540334-2	1999	Exposure of U937 cells to etoposide (VP-16) or the nitric oxide (NO) donor DETA-NO, both inducers of apoptosis in these cells, was associated with increased expression of the chemokines IL-8 and macrophage inflammatory protein-1 alpha.	Etoposide	26-35	host cell factor C1	Homo sapiens	37-42
10540334-2	1999	Exposure of U937 cells to etoposide (VP-16) or the nitric oxide (NO) donor DETA-NO, both inducers of apoptosis in these cells, was associated with increased expression of the chemokines IL-8 and macrophage inflammatory protein-1 alpha.	Etoposide	26-35	C-X-C motif chemokine ligand 8	Homo sapiens	186-190
10540334-2	1999	Exposure of U937 cells to etoposide (VP-16) or the nitric oxide (NO) donor DETA-NO, both inducers of apoptosis in these cells, was associated with increased expression of the chemokines IL-8 and macrophage inflammatory protein-1 alpha.	Etoposide	26-35	C-C motif chemokine ligand 3	Homo sapiens	195-234
10561359-1	1999	PURPOSE: The Cancer and Leukemia Group B conducted parallel phase I trials of cytarabine, daunorubicin, and etoposide (ADE) with or without PSC-833 (P), a modulator of p-glycoprotein-mediated multidrug resistance.	Etoposide	108-117	ATP binding cassette subfamily B member 1	Homo sapiens	168-182
10706456-0	1999	Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin"s lymphoma.	Etoposide	30-39	colony stimulating factor 3	Homo sapiens	45-50
10440872-12	1999	In contrast, CDDP, VP-16, and the protein synthesis inhibitors, Act-D and CHX sensitized DU145 cells to TNF-alpha killing.	Etoposide	19-24	tumor necrosis factor	Homo sapiens	104-113
10471758-7	1999	The renal function partially recovered after a course of therapy combining VP-16 (etoposide) and dexamethasone and remained stable over 4-year follow-up.	Etoposide	82-91	host cell factor C1	Homo sapiens	75-80
10505853-7	1999	Analysis of cell cycle and apoptosis in etoposide-treated cells corroborated the inability of NP-29 to die by apoptosis, suggesting that this wt p53 cell line lacks p53 downstream functions in the apoptosis pathway.	Etoposide	40-49	tumor protein p53	Homo sapiens	145-148
10464158-5	1999	Interestingly,DT40/Lyn(-), but not DT40/Syk(-) and DT40/Btk(-) cells, become resistant to apoptosis induced by adriamycin and etoposide, topoisomerase II (Topo II) inhibitory agents, compared to wild-type DT40 cells, as assessed by DNA fragmentation and TUNEL analyses.	Etoposide	126-135	LYN proto-oncogene, Src family tyrosine kinase	Gallus gallus	19-22
10497210-0	1999	The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis.	Etoposide	152-161	heat shock protein 90 beta family member 1	Homo sapiens	49-54
10497210-2	1999	We report here that during apoptosis induced by the topoisomerase II inhibitor etoposide, a fraction of GRP94 associated with the endoplasmic reticulum membrane undergoes specific proteolytic cleavage, coinciding with the activation of the caspase CPP32 and initiation of DNA fragmentation.	Etoposide	79-88	heat shock protein 90 beta family member 1	Homo sapiens	104-109
10497210-2	1999	We report here that during apoptosis induced by the topoisomerase II inhibitor etoposide, a fraction of GRP94 associated with the endoplasmic reticulum membrane undergoes specific proteolytic cleavage, coinciding with the activation of the caspase CPP32 and initiation of DNA fragmentation.	Etoposide	79-88	caspase 3	Homo sapiens	248-253
10497210-3	1999	In vivo, inhibitors of caspases able to block etoposide-induced apoptosis can only partially protect GRP94 from proteolytic cleavage, whereas complete inhibition is observed with calpain inhibitor I but not with the proteasome inhibitor.	Etoposide	46-55	heat shock protein 90 beta family member 1	Homo sapiens	101-106
10497210-7	1999	Further, immunohistochemical staining reveals specific co-localization of GRP94 with calpain in the perinuclear region following etoposide treatment.	Etoposide	129-138	heat shock protein 90 beta family member 1	Homo sapiens	74-79
10497210-8	1999	We further showed that reduction of GRP94 by antisense decreased cell viability in etoposide-treated Jurkat cells.	Etoposide	83-92	heat shock protein 90 beta family member 1	Homo sapiens	36-41
10791901-5	1999	Transduction of the human leukemic cell line K562 showed that viral MRP1-PG13 supernatants routinely transfer the MRP1 gene to approximately 35% of target K562 cells, of which at least one third are capable of proliferating in the presence of otherwise toxic concentrations of etoposide.	Etoposide	277-286	ATP binding cassette subfamily C member 1	Homo sapiens	68-72
10791901-5	1999	Transduction of the human leukemic cell line K562 showed that viral MRP1-PG13 supernatants routinely transfer the MRP1 gene to approximately 35% of target K562 cells, of which at least one third are capable of proliferating in the presence of otherwise toxic concentrations of etoposide.	Etoposide	277-286	ATP binding cassette subfamily C member 1	Homo sapiens	114-118
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	interferon induced protein with tetratricopeptide repeats 2	Homo sapiens	218-221
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	162-167
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	mitogen-activated protein kinase 8	Homo sapiens	191-195
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	mitogen-activated protein kinase 9	Homo sapiens	222-226
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	mitogen-activated protein kinase 9	Homo sapiens	197-201
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	293-298
10454518-3	1999	Induction of apoptotic cell death and DNA damage by treatment of U937 cells with etoposide (100 microM) was associated with phosphorylation and activation of the c-Jun NH(2)-terminal kinase (JNK1) SAPK enzymes p46 and p54-JNK2 and transient increases in expression of the transcription factor c-Jun, a primary JNK substrate.	Etoposide	81-90	mitogen-activated protein kinase 8	Homo sapiens	191-194
10454518-11	1999	These findings additionally suggest that activation of the SAPK represents a consequence, rather than an underlying cause, of etoposide-induced apoptosis in myeloid leukemia cells.	Etoposide	126-135	mitogen-activated protein kinase 9	Homo sapiens	59-63
10462537-18	1999	4) A vitamin E homolog, 2,2,5,7, 8-pentamethyl-6-hydroxychromane, a hindered phenolic compound whose phenoxyl radicals do not oxidize endogenous thiols, effectively competes with etoposide as a substrate for myeloperoxidase, thus preventing etoposide-O(.	Etoposide	179-188	myeloperoxidase	Homo sapiens	208-223
10454539-6	1999	In addition, A1 potently inhibited etoposide-induced apoptosis by inhibiting the release of cytochrome c and by blocking caspase 3 activation.	Etoposide	35-44	cytochrome c, somatic	Homo sapiens	92-104
10454539-6	1999	In addition, A1 potently inhibited etoposide-induced apoptosis by inhibiting the release of cytochrome c and by blocking caspase 3 activation.	Etoposide	35-44	caspase 3	Homo sapiens	121-130
10462537-1	1999	Etoposide (VP-16) is extensively used to treat cancer, yet its efficacy is calamitously associated with an increased risk of secondary acute myelogenous leukemia.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
10442630-3	1999	When human Jurkat cells were exposed to etoposide, or UV or gamma radiation, a caspase-3-like protease was activated, and nuclear DNA was fragmented.	Etoposide	40-49	caspase 3	Mus musculus	79-88
10462537-5	1999	formed from etoposide by myeloperoxidase are responsible for its genotoxic effects in bone marrow progenitor cells, which contain constitutively high myeloperoxidase activity.	Etoposide	12-21	myeloperoxidase	Homo sapiens	25-40
10462537-5	1999	formed from etoposide by myeloperoxidase are responsible for its genotoxic effects in bone marrow progenitor cells, which contain constitutively high myeloperoxidase activity.	Etoposide	12-21	myeloperoxidase	Homo sapiens	150-165
10462537-17	1999	Ascorbate also diminishes etoposide-induced topo II-DNA complex formation in myeloperoxidase-rich HL60 cells (but not in HL60 cells with myeloperoxidase activity depleted by pretreatment with succinyl acetone).	Etoposide	26-35	myeloperoxidase	Homo sapiens	77-92
10521679-6	1999	Four testis cancer patients, who 6 years earlier had been treated with etoposide and other cytostatic drugs, showed TCRbeta/gamma VF similar to that in healthy controls.	Etoposide	71-80	T cell receptor beta locus	Homo sapiens	116-123
10430629-5	1999	We also show that overexpression of ICSBP in the human U937 monocytic cell line enhances the rate of spontaneous apoptosis and the sensitivity to apoptosis induced by etoposide, lipopolysaccharide plus ATP, or rapamycin.	Etoposide	167-176	interferon regulatory factor 8	Homo sapiens	36-41
10430629-6	1999	Programmed cell death induced by etoposide was specifically blocked by peptides inhibitory for the caspase-1 or caspase-3 subfamilies of caspases.	Etoposide	33-42	caspase 1	Homo sapiens	99-108
10430629-6	1999	Programmed cell death induced by etoposide was specifically blocked by peptides inhibitory for the caspase-1 or caspase-3 subfamilies of caspases.	Etoposide	33-42	caspase 3	Homo sapiens	112-121
10430629-6	1999	Programmed cell death induced by etoposide was specifically blocked by peptides inhibitory for the caspase-1 or caspase-3 subfamilies of caspases.	Etoposide	33-42	caspase 1	Homo sapiens	137-145
10413292-3	1999	The importance of mrp in protection of normal tissues from the toxicity of the anticancer agent etoposide has been established.	Etoposide	96-105	ATP binding cassette subfamily C member 1	Homo sapiens	18-21
10450749-0	1999	Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).	Etoposide	121-130	colony stimulating factor 2	Homo sapiens	0-48
10428509-0	1999	Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.	Etoposide	67-76	cyclin dependent kinase 5 regulatory subunit 2	Homo sapiens	102-105
10428509-11	1999	Etoposide induced a caspase-dependent cleavage of Bcl-2, while actin remained intact.	Etoposide	0-9	BCL2 apoptosis regulator	Homo sapiens	50-55
10402229-2	1999	Expression of either p16INK4a or p21WAF1 protected cells from the cytotoxic effects of the topoisomerase II inhibitor, etoposide.	Etoposide	119-128	cyclin dependent kinase inhibitor 2A	Homo sapiens	21-29
10402229-3	1999	A lower level of p53 was induced in CDK inhibitor-expressing etoposide-exposed cells suggesting that protection may be due to lower levels of DNA damage in the growth arrested cells.	Etoposide	61-70	tumor protein p53	Homo sapiens	17-20
10402229-4	1999	Exposure of human osteosarcoma cells to either p16INK4a or p21WAF1 prior to and during etoposide therapy protected cells against etoposide-induced cell death.	Etoposide	87-96	cyclin dependent kinase inhibitor 2A	Homo sapiens	47-55
10402229-4	1999	Exposure of human osteosarcoma cells to either p16INK4a or p21WAF1 prior to and during etoposide therapy protected cells against etoposide-induced cell death.	Etoposide	129-138	cyclin dependent kinase inhibitor 2A	Homo sapiens	47-55
10402229-5	1999	Infection of the cells by Ad-p16INK4a or Ad-p21WAF1 following exposure to etoposide resulted in loss of the protective effect with evidence of enhanced growth inhibition.	Etoposide	74-83	cyclin dependent kinase inhibitor 2A	Homo sapiens	29-37
10450749-0	1999	Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).	Etoposide	121-130	colony stimulating factor 2	Homo sapiens	50-56
10383415-1	1999	We have previously shown that parotid C5 salivary acinar cells undergo apoptosis in response to etoposide treatment as indicated by alterations in cell morphology, caspase-3 activation, DNA fragmentation, sustained activation of c-Jun N-terminal kinase, and inactivation of extracellular regulated kinases 1 and 2.	Etoposide	96-105	caspase 3	Rattus norvegicus	164-173
10393722-10	1999	RESULTS/CONCLUSIONS: In addition to increasing ROS, 4-HPR (2.5-10 microM) statistically significantly increased the level of intracellular ceramide (up to approximately 10-fold; P&lt;.001) in a dose-dependent manner in two neuroblastoma cell lines, one of which is highly resistant to alkylating agents and to etoposide.	Etoposide	310-319	haptoglobin-related protein	Homo sapiens	54-57
10383415-7	1999	PKCalpha and PKCbeta1 activities also increase during etoposide-induced apoptosis.	Etoposide	54-63	protein kinase C, alpha	Rattus norvegicus	0-8
10573108-9	1999	MCF-7 cells overexpressing FGF-2 had a greater rate of programmed cell death at baseline and in response to etoposide and 5-fluorouracil in a TUNEL assay by immunofluorescent microphotography and by flow cytometric quantitation.	Etoposide	108-117	fibroblast growth factor 2	Homo sapiens	27-32
10486539-8	1999	DNA-PK is an important actor of DSBs repair (induced by ionising radiations or by drugs like etoposide), but obviously it is not the only mechanism existing in the cell for this function.	Etoposide	93-102	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	0-6
10359813-6	1999	In ovarian carcinoma cells (2008), expression of MRP3 results in low-level resistance to the epipodophyllotoxins etoposide and teniposide.	Etoposide	113-122	ATP binding cassette subfamily C member 3	Homo sapiens	49-53
10405175-0	1999	Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe.	Etoposide	62-71	caspase 3	Homo sapiens	11-20
10405175-4	1999	Using one of these probes, we succeeded in microscopic visualization of caspase-3-like activity within HeLa cells treated with etoposide.	Etoposide	127-136	caspase 3	Homo sapiens	72-81
10573108-8	1999	The clonogenic potential of MCF-7 cells in tissue culture was decreased by the expression of FGF-2 and was additively suppressed by the chemotherapeutic agents etoposide and 5-fluorouracil in a dose and time dependent manner.	Etoposide	160-169	fibroblast growth factor 2	Homo sapiens	93-98
10533459-0	1999	ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.	Etoposide	97-106	ATM serine/threonine kinase	Homo sapiens	0-3
10472567-5	1999	Fourteen children with recurrent or advanced HB were additionally treated with carboplatin and etoposide (CARBO/VP 16), the reason being observations of drug resistance in children with HB after four or more courses of IPA-therapy in the HB 89 study.	Etoposide	95-104	host cell factor C1	Homo sapiens	106-117
10559901-2	1999	Here we demonstrate a cytoprotective role for HO1: cell death produced by serum deprivation, staurosporine or etoposide is markedly accentuated in cells from mice with a targeted deletion of the HO1 gene, and greatly reduced in cells that overexpress HO1.	Etoposide	110-119	heme oxygenase 1	Mus musculus	46-49
10559901-2	1999	Here we demonstrate a cytoprotective role for HO1: cell death produced by serum deprivation, staurosporine or etoposide is markedly accentuated in cells from mice with a targeted deletion of the HO1 gene, and greatly reduced in cells that overexpress HO1.	Etoposide	110-119	heme oxygenase 1	Mus musculus	195-198
10559901-2	1999	Here we demonstrate a cytoprotective role for HO1: cell death produced by serum deprivation, staurosporine or etoposide is markedly accentuated in cells from mice with a targeted deletion of the HO1 gene, and greatly reduced in cells that overexpress HO1.	Etoposide	110-119	heme oxygenase 1	Mus musculus	195-198
10366432-0	1999	Dissociation of CDK2 from cyclin A in response to the topoisomerase II inhibitor etoposide in v-src-transformed but not normal NIH 3T3 cells.	Etoposide	81-90	cyclin-dependent kinase 2	Mus musculus	16-20
10366432-0	1999	Dissociation of CDK2 from cyclin A in response to the topoisomerase II inhibitor etoposide in v-src-transformed but not normal NIH 3T3 cells.	Etoposide	81-90	cyclin A2	Mus musculus	26-34
10366432-1	1999	Our previous work has demonstrated that treatment of NIH 3T3 cells with etoposide (VP16), an inhibitor of DNA topoisomerase II and widely used anticancer agent, results in G2/M-phase arrest, whereas treatment of cells transformed by v-src, v-ras, or v-raf results in an S-phase blockage.	Etoposide	72-81	v-raf-leukemia viral oncogene 1	Mus musculus	250-255
10366432-1	1999	Our previous work has demonstrated that treatment of NIH 3T3 cells with etoposide (VP16), an inhibitor of DNA topoisomerase II and widely used anticancer agent, results in G2/M-phase arrest, whereas treatment of cells transformed by v-src, v-ras, or v-raf results in an S-phase blockage.	Etoposide	83-87	v-raf-leukemia viral oncogene 1	Mus musculus	250-255
10376530-4	1999	In this manuscript, we show that Bcl-2 targeted to the endoplasmic reticulum can inhibit Myc-, but not etoposide-induced apoptosis in the Rat-1 fibroblast cell line.	Etoposide	103-112	BCL2, apoptosis regulator	Rattus norvegicus	33-38
10376530-6	1999	We further show both Myc and etoposide trigger disruption of mitochondrial membrane potential (MMP) and induce poly-ADP ribose polymerase (PARP) cleavage, but release of calcium was not evident.	Etoposide	29-38	poly (ADP-ribose) polymerase 1	Rattus norvegicus	111-137
10376530-6	1999	We further show both Myc and etoposide trigger disruption of mitochondrial membrane potential (MMP) and induce poly-ADP ribose polymerase (PARP) cleavage, but release of calcium was not evident.	Etoposide	29-38	poly (ADP-ribose) polymerase 1	Rattus norvegicus	139-143
10376530-8	1999	These results further elucidate the biochemical events associated with Myc- and etoposide-induced apoptosis and significantly advance our understanding of Bcl-2 function.	Etoposide	80-89	BCL2, apoptosis regulator	Rattus norvegicus	155-160
10339661-4	1999	However, the sensitivity to radiation was significantly improved by the transduction and T.Tn/p53 cells became markedly susceptible to cisplatin and etoposide compared with parental cells.	Etoposide	149-158	tumor protein p53	Homo sapiens	94-97
10533488-3	1999	In growth inhibition assays MRP-over-expressing COR L23/R cells were 20 times more resistant to VP16 and doxorubicin compared with the parental COR L23/R human lung carcinoma cells.	Etoposide	96-100	ATP binding cassette subfamily C member 3	Homo sapiens	28-31
10414907-0	1999	Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
10414907-4	1999	Here we report the results of using etoposide as a mobilizing agent in 16 patients with primary resistant or relapsed malignant lymphoma who had failed prior mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide (4 g/m2) followed by G-CSF.	Etoposide	36-45	colony stimulating factor 3	Homo sapiens	252-257
10414907-5	1999	The use of etoposide 500 mg/m2 (days 1-4) + G-CSF resulted in the successful collection of adequate numbers of PBSC with a median harvest of 3.6 x 10(6)/kg (range 2.2-12.6) CD34+ cells in all 16 patients.	Etoposide	11-20	CD34 molecule	Homo sapiens	173-177
10414907-8	1999	In addition, median peak values of circulating CD34+ cells were significantly higher after etoposide as compared to cyclophosphamide (49.2/microl vs 4.7/microl; P = 0.0004).	Etoposide	91-100	CD34 molecule	Homo sapiens	47-51
10424444-4	1999	Analysis of cell survival in etoposide-treated cultures indicated that IL-15 was also more potent than IL-2 as a survival factor for CD56+ cells by virtue of its greater ability to up-regulate bcl-2 expression.	Etoposide	29-38	interleukin 15	Homo sapiens	71-76
10424444-4	1999	Analysis of cell survival in etoposide-treated cultures indicated that IL-15 was also more potent than IL-2 as a survival factor for CD56+ cells by virtue of its greater ability to up-regulate bcl-2 expression.	Etoposide	29-38	neural cell adhesion molecule 1	Homo sapiens	133-137
10424444-4	1999	Analysis of cell survival in etoposide-treated cultures indicated that IL-15 was also more potent than IL-2 as a survival factor for CD56+ cells by virtue of its greater ability to up-regulate bcl-2 expression.	Etoposide	29-38	BCL2 apoptosis regulator	Homo sapiens	193-198
10422441-6	1999	Following the right high orchiectomy, 4 cycles of VIP chemotherapy consisting of ifosfamide, etoposide and cisplatin were given, which resulted in partial response of the retroperitoneal mass and complete regression of the supraculavicular node with normalization of all tumor markers.	Etoposide	93-102	vasoactive intestinal peptide	Homo sapiens	50-53
10321832-7	1999	However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide.	Etoposide	73-82	H3 histone pseudogene 16	Homo sapiens	23-26
10321832-7	1999	However, ECM prevented p21 and Bcl-2 down-regulation induced by taxol or etoposide.	Etoposide	73-82	BCL2 apoptosis regulator	Homo sapiens	31-36
10321832-9	1999	IkappaBalpha levels were not affected by taxol but were reduced by etoposide treatment, while IkappaBbeta levels did not change with drug treatment.	Etoposide	67-76	NFKB inhibitor alpha	Homo sapiens	0-12
10321832-11	1999	Interestingly, levels of IkappaBalpha and IkappaBbeta declined in etoposide-treated ECV cells on ECM concomitant with the elevation of NFkappaB, suggesting that in these cells degradation of IkappaB may be responsible for NFkappaB activation.	Etoposide	66-75	NFKB inhibitor alpha	Homo sapiens	25-37
10321832-11	1999	Interestingly, levels of IkappaBalpha and IkappaBbeta declined in etoposide-treated ECV cells on ECM concomitant with the elevation of NFkappaB, suggesting that in these cells degradation of IkappaB may be responsible for NFkappaB activation.	Etoposide	66-75	NFKB inhibitor beta	Homo sapiens	42-53
10321832-11	1999	Interestingly, levels of IkappaBalpha and IkappaBbeta declined in etoposide-treated ECV cells on ECM concomitant with the elevation of NFkappaB, suggesting that in these cells degradation of IkappaB may be responsible for NFkappaB activation.	Etoposide	66-75	nuclear factor kappa B subunit 1	Homo sapiens	135-143
10321832-11	1999	Interestingly, levels of IkappaBalpha and IkappaBbeta declined in etoposide-treated ECV cells on ECM concomitant with the elevation of NFkappaB, suggesting that in these cells degradation of IkappaB may be responsible for NFkappaB activation.	Etoposide	66-75	nuclear factor kappa B subunit 1	Homo sapiens	222-230
10433362-1	1999	The purpose of these studies was to determine whether interferon-alpha (IFN-alpha) could enhance the sensitivity of human osteosarcoma cells to the cytotoxic actions of etoposide (VP-16).	Etoposide	169-178	interferon alpha 1	Homo sapiens	72-81
10433362-1	1999	The purpose of these studies was to determine whether interferon-alpha (IFN-alpha) could enhance the sensitivity of human osteosarcoma cells to the cytotoxic actions of etoposide (VP-16).	Etoposide	169-178	host cell factor C1	Homo sapiens	180-185
10233413-0	1999	Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.	Etoposide	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	51-65
10318846-0	1999	Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation.	Etoposide	86-95	Fas cell surface death receptor	Homo sapiens	52-56
10318846-0	1999	Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation.	Etoposide	86-95	caspase 8	Homo sapiens	132-141
10318846-2	1999	Variant clones selected for resistance to CD95-induced apoptosis proved cross-resistant to etoposide- and radiation-induced apoptosis, suggesting that the apoptosis pathways induced by these distinct stimuli have critical component(s) in common.	Etoposide	91-100	Fas cell surface death receptor	Homo sapiens	42-46
10318846-5	1999	Both effector caspase processing and cytochrome c release were inhibited in the resistant variant cells as well as in Bcl-2 transfectants, suggesting that, in Jurkat cells, the apoptosis signaling pathways activated by CD95, etoposide, and gamma-radiation are under common mitochondrial control.	Etoposide	225-234	BCL2 apoptosis regulator	Homo sapiens	118-123
10216102-3	1999	Because apoptosis induced by anticancer drugs has been proposed to involve CD95/CD95 ligand interaction, we investigated the mechanism of caspase activation by daunorubicin, doxorubicin, etoposide, and mitomycin C.	Etoposide	187-196	caspase 8	Homo sapiens	138-145
10374873-1	1999	A diagnosis of pro-B acute lymphoblastic leukemia (ALL) with CD15+ was made in a 42-year-old woman, 12 months after the treatment of uterine adenocarcinoma by carboplatinum, anthracyclines, etoposide and radiotherapy.	Etoposide	190-199	fucosyltransferase 4	Homo sapiens	61-65
10381634-0	1999	Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug-induced apoptosis in salivary gland acinar cells.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	32-55
10381634-0	1999	Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug-induced apoptosis in salivary gland acinar cells.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	37-60
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	178-181
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	0-9	mitogen activated protein kinase 3	Rattus norvegicus	207-211
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	0-9	mitogen activated protein kinase 1	Rattus norvegicus	216-220
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	234-243	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
10381634-3	1999	Etoposide also induced activation of c-jun N-terminal kinase (JNK) in parotid C5 cells by 4 h after treatment, with maximal activation at 8 - 10 h. Coincident with activation of JNK, the amount of activated ERK1 and ERK2 decreased in etoposide-treated parotid C5 cells.	Etoposide	234-243	mitogen-activated protein kinase 8	Rattus norvegicus	178-181
10381634-7	1999	Treatment of the parotid C5 cells with Z-VAD-FMK, a caspase inhibitor, inhibited etoposide-induced activation of JNK and DNA fragmentation.	Etoposide	81-90	mitogen-activated protein kinase 8	Rattus norvegicus	113-116
10381634-8	1999	These data suggest that etoposide may induce apoptosis in parotid C5 cells by activating JNKs and suppressing the activation of ERKs, thus creating an imbalance in these two signaling pathways.	Etoposide	24-33	mitogen activated protein kinase 3	Rattus norvegicus	128-132
10481938-2	1999	The combination of dose intensive etoposide (VP-16) followed by cyclophosphamide has clinical efficacy in the treatment of advanced breast cancer.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
10374876-4	1999	Etoposide treatment of these cells triggered a time-dependent activation of type II and type III caspases and cleavage of Bcl-2 yielding a 23 kDa cleavage fragment.	Etoposide	0-9	BCL2 apoptosis regulator	Homo sapiens	122-127
10374876-7	1999	While evidence for cleavage of Bcl-2 in several subcellular compartments of etoposide-treated cells was obtained, this cleavage was detected predominantly in the mitochondrial fraction, thus providing further support for the central role of mitochondria in apoptosis.	Etoposide	76-85	BCL2 apoptosis regulator	Homo sapiens	31-36
10374876-8	1999	Caspase-mediated cleavage following etoposide treatment of these myeloid leukemic cells may represent a means for the attenuation of Bcl-2 function upon apoptosis induction.	Etoposide	36-45	BCL2 apoptosis regulator	Homo sapiens	133-138
10206959-18	1999	The down-regulation of hMMP-1 gene expression by endogenous wt-p53 was shown by treatment of U2-OS cells, a wt-p53-containing osteogenic sarcoma line, and Saos-2 cells, a p53-negative osteogenic sarcoma line, with etoposide, a potent inducer of p53 expression.	Etoposide	214-223	matrix metallopeptidase 1	Homo sapiens	23-29
10220572-10	1999	Expression of human and rat MRP2 enhanced the resistance of MDCK cells to etoposide 5.0-fold and 3.8-fold and to vincristine 2.3- and 6.0-fold, respectively.	Etoposide	74-83	ATP binding cassette subfamily C member 2	Rattus norvegicus	28-32
10220572-12	1999	Human MRP2 overexpressed in HEK-293 cells enhanced the resistance to etoposide (4-fold), cisplatin (10-fold), doxorubicin (7.8-fold), and epirubicin (5-fold).	Etoposide	69-78	ATP binding cassette subfamily C member 2	Homo sapiens	6-10
10206959-18	1999	The down-regulation of hMMP-1 gene expression by endogenous wt-p53 was shown by treatment of U2-OS cells, a wt-p53-containing osteogenic sarcoma line, and Saos-2 cells, a p53-negative osteogenic sarcoma line, with etoposide, a potent inducer of p53 expression.	Etoposide	214-223	tumor protein p53	Homo sapiens	63-66
10207030-8	1999	Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter.	Etoposide	0-9	tumor protein p53	Homo sapiens	118-121
10206959-19	1999	p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells.	Etoposide	18-27	tumor protein p53	Homo sapiens	0-3
10207030-8	1999	Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter.	Etoposide	142-151	tumor protein p53	Homo sapiens	69-72
10207030-4	1999	This site bound to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	79-88	tumor protein p53	Homo sapiens	28-31
10206959-19	1999	p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells.	Etoposide	18-27	matrix metallopeptidase 1	Homo sapiens	46-52
10207030-4	1999	This site bound to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	79-88	tumor protein p53	Homo sapiens	43-46
10207030-7	1999	The p53 binding and transactivation of the GPX promoter were enhanced by etoposide in p53-positive U2-OS cells.	Etoposide	73-82	tumor protein p53	Homo sapiens	4-7
10207030-7	1999	The p53 binding and transactivation of the GPX promoter were enhanced by etoposide in p53-positive U2-OS cells.	Etoposide	73-82	tumor protein p53	Homo sapiens	86-89
10207030-8	1999	Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter.	Etoposide	0-9	tumor protein p53	Homo sapiens	69-72
10207030-8	1999	Etoposide-induced transactivation was blocked by a dominant negative p53 mutant, indicating that endogenous wild type p53, upon activation by etoposide, transactivated the GPX promoter.	Etoposide	142-151	tumor protein p53	Homo sapiens	118-121
10206959-19	1999	p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells.	Etoposide	82-91	tumor protein p53	Homo sapiens	0-3
10206959-19	1999	p53, activated by etoposide, appears to block hMMP-1 promoter activity induced by etoposide in U2-OS cells.	Etoposide	82-91	matrix metallopeptidase 1	Homo sapiens	46-52
10328568-1	1999	The present paper investigates the pharmacokinetics of etoposide (VP-16) and carboplatin (CBDCA) in plasma and the cerebrospinal fluid (CSF), in the space left by tumor removal, of patients with glioma.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
10196170-2	1999	In cells exposed to genotoxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp874 by caspases.	Etoposide	47-56	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	83-88
10189371-6	1999	EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide.	Etoposide	119-128	BCL2 apoptosis regulator	Homo sapiens	36-41
10378670-1	1999	This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination.	Etoposide	82-91	host cell factor C1	Homo sapiens	93-98
10194469-6	1999	These results indicate that the caspases required for the Cer response to etoposide and IR reside at or downstream from the mitochondria.	Etoposide	74-83	caspase 8	Homo sapiens	32-40
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	caspase 3	Homo sapiens	120-144
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	cytochrome c, somatic	Homo sapiens	183-195
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	210-215
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	BCL2 apoptosis regulator	Homo sapiens	245-250
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	BCL2 like 1	Homo sapiens	252-258
10381626-2	1999	Exposure of undifferentiated U937 cells to 50 microM etoposide for 6 h, that triggers apoptosis in 80% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Mcl-1 expression without modifying Bcl-2, Bcl-xL and Bax protein levels.	Etoposide	53-62	BCL2 associated X, apoptosis regulator	Homo sapiens	263-266
10234300-3	1999	These findings suggest that DNA fragmentation was inhibited through maintenance of delta psi m. Z-Asp-CH2-DCB, interleukin-1 beta-converting enzyme (ICE) specific inhibitor, inhibited ETP-induced DNA fragmentation and delta psi m reduction in U937 cells.	Etoposide	184-187	caspase 1	Homo sapiens	111-147
10234300-3	1999	These findings suggest that DNA fragmentation was inhibited through maintenance of delta psi m. Z-Asp-CH2-DCB, interleukin-1 beta-converting enzyme (ICE) specific inhibitor, inhibited ETP-induced DNA fragmentation and delta psi m reduction in U937 cells.	Etoposide	184-187	caspase 1	Homo sapiens	149-152
10194469-7	1999	Bcl-2 overexpression abrogated the Cer response to etoposide and IR and reduced CD95-induced Cer accumulation.	Etoposide	51-60	BCL2 apoptosis regulator	Homo sapiens	0-5
10098834-7	1999	Inhibition of SAPK activation by overexpression of the novel isoform JIP-2a resulted in suppression of etoposide-induced cell death in a neuroglioma cell line, N18TG.	Etoposide	103-112	mitogen-activated protein kinase 9	Homo sapiens	14-18
10214864-2	1999	However, alternative proteins such as the more recently recognized multidrug-associated protein (MRP1), may also contribute to the resistance to anthracyclines and etoposide in AML.	Etoposide	164-173	ATP binding cassette subfamily C member 1	Homo sapiens	97-101
10191118-5	1999	CLN3 overexpression in NT2 cells enhances growth, reverses growth inhibition induced by serum starvation and protects from apoptosis induced by vincristine, staurosporine, and etoposide but not from death caused by ceramide.	Etoposide	176-185	CLN3 lysosomal/endosomal transmembrane protein, battenin	Homo sapiens	0-4
10327070-3	1999	Synergistic interactions at clinically relevant drug concentrations were observed for rhuMAb HER2 in combination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=0.0003).	Etoposide	182-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
10327070-7	1999	Combinations of rhuMAb HER2 plus cyclophosphamide, doxorubicin, paclitaxel, methotrexate, etoposide, and vinblastine in vivo resulted in a significant reduction in xenograft volume compared to chemotherapy alone (P&lt;0.05).	Etoposide	90-99	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27
10376765-3	1999	We further show that the DBA/2 mutation is associated with approximately fourfold lower p53 levels in thymocytes treated with the DNA-damaging agent etoposide in-vitro, and with relative resistance of these thymocytes to apoptosis induced by the DNA-damaging agent etoposide compared with C57BL/6 mice.	Etoposide	149-158	DBA2	Homo sapiens	25-30
10376765-3	1999	We further show that the DBA/2 mutation is associated with approximately fourfold lower p53 levels in thymocytes treated with the DNA-damaging agent etoposide in-vitro, and with relative resistance of these thymocytes to apoptosis induced by the DNA-damaging agent etoposide compared with C57BL/6 mice.	Etoposide	149-158	transformation related protein 53	Mus musculus	88-91
10376765-3	1999	We further show that the DBA/2 mutation is associated with approximately fourfold lower p53 levels in thymocytes treated with the DNA-damaging agent etoposide in-vitro, and with relative resistance of these thymocytes to apoptosis induced by the DNA-damaging agent etoposide compared with C57BL/6 mice.	Etoposide	265-274	DBA2	Homo sapiens	25-30
10376765-3	1999	We further show that the DBA/2 mutation is associated with approximately fourfold lower p53 levels in thymocytes treated with the DNA-damaging agent etoposide in-vitro, and with relative resistance of these thymocytes to apoptosis induced by the DNA-damaging agent etoposide compared with C57BL/6 mice.	Etoposide	265-274	transformation related protein 53	Mus musculus	88-91
10098834-7	1999	Inhibition of SAPK activation by overexpression of the novel isoform JIP-2a resulted in suppression of etoposide-induced cell death in a neuroglioma cell line, N18TG.	Etoposide	103-112	SMAD family member 4	Homo sapiens	69-72
10066381-2	1999	Incubation of U937 cells with 1-beta-d-arabinofuranosylcytosine or the etoposide VP-16 was accompanied by growth arrest in G0/G1 of the cell cycle and an accumulation of a population in the sub-G1 phase which exhibited characteristics typical for the apoptotic pathway.	Etoposide	71-80	host cell factor C1	Homo sapiens	81-86
10368671-7	1999	The present data show that the C/MET metastatic model and the MXT parental line are weakly (if reference is made to the P388 leukemia model) sensitive to adriamycin, clyclophosphamide and etoposide.	Etoposide	188-197	met proto-oncogene	Mus musculus	31-36
10066792-1	1999	A Ser740 --&gt; Trp mutation in yeast topoisomerase II (top2) and of the equivalent Ser83 in gyrase results in resistance to quinolones and confers hypersensitivity to etoposide (VP-16).	Etoposide	168-177	host cell factor C1	Homo sapiens	179-184
10368682-0	1999	Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity.	Etoposide	17-26	cyclin dependent kinase 1	Homo sapiens	7-11
10368682-0	1999	Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity.	Etoposide	17-26	cell division cycle 25C	Homo sapiens	63-68
10368682-2	1999	In response to Etoposide (VP-16) induced DNA damage, cells undergo a G2-phase arrest resulting in the accumulation of inactive CDK1 (CDC2) kinase complexes.	Etoposide	15-24	host cell factor C1	Homo sapiens	26-31
10368682-2	1999	In response to Etoposide (VP-16) induced DNA damage, cells undergo a G2-phase arrest resulting in the accumulation of inactive CDK1 (CDC2) kinase complexes.	Etoposide	15-24	cyclin dependent kinase 1	Homo sapiens	127-131
10368682-2	1999	In response to Etoposide (VP-16) induced DNA damage, cells undergo a G2-phase arrest resulting in the accumulation of inactive CDK1 (CDC2) kinase complexes.	Etoposide	15-24	cyclin dependent kinase 1	Homo sapiens	133-137
10368682-3	1999	Here we report that upon Etoposide treatment CDC2 is phosphorylated on tyrosine 15 and is dephosphorylated and activated in vitro by recombinant CDC25 phosphatase.	Etoposide	25-34	cyclin dependent kinase 1	Homo sapiens	45-49
10368682-3	1999	Here we report that upon Etoposide treatment CDC2 is phosphorylated on tyrosine 15 and is dephosphorylated and activated in vitro by recombinant CDC25 phosphatase.	Etoposide	25-34	cell division cycle 25C	Homo sapiens	145-150
10205305-0	1999	Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).	Etoposide	108-117	host cell factor C1	Homo sapiens	119-124
10368682-4	1999	We also show that inactive CDC2 kinase from Etoposide-treated cells can be used as a substrate in a sensitive two-step assay of CDC25 phosphatase.	Etoposide	44-53	cyclin dependent kinase 1	Homo sapiens	27-31
10205305-1	1999	Etoposide (VP-16)-induced DNA strand breaks and repair and apoptosis of unstimulated human lymphocytes have been studied using DNA comet assay, electrophoresis of low-molecular-weight DNA extracts, and fluorescence microscopy.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
10368682-4	1999	We also show that inactive CDC2 kinase from Etoposide-treated cells can be used as a substrate in a sensitive two-step assay of CDC25 phosphatase.	Etoposide	44-53	cell division cycle 25C	Homo sapiens	128-133
10217181-13	1999	The choice of either etoposide (VIP) or vinblastine (VeIP) can be predicated upon which of these two drugs was associated with best results during premobilization chemotherapy.	Etoposide	21-30	vasoactive intestinal peptide	Homo sapiens	32-35
10082308-3	1999	METHODS: We report here a parallel flow cytometric method for semiquantitative detection of p53 protein and apoptosis (percent of apoptotic cells) in a pre-B leukemic cell line (NALM-6) exposed to various antitumor agents (2.35 microg/ml etoposide; 0.175 microg/ml FCE296; 0.4 microg/ml FCE624; and 1.5 microg/ml L-PAM).	Etoposide	238-247	tumor protein p53	Homo sapiens	92-95
10200574-7	1999	Furthermore, we have provided evidence that while caspase 3 is activated by both inducers, caspase 1 is essential only for the etoposide-induced apoptosis.	Etoposide	127-136	caspase 1	Homo sapiens	91-100
10048977-4	1999	We show that in melanoma cells exhibiting resistance to cisplatin, etoposide and vindesine, the nuclear content of each of the DNA mismatch repair (MMR) proteins hMLH1, hMSH2 and hMSH6 was reduced by 30-70%.	Etoposide	67-76	mutL homolog 1	Homo sapiens	162-167
10732782-7	1999	Etoposide diminished the binding between Bax and Bcl-XL but this was restored by IL-4 and VCAM-1 triggered signals.	Etoposide	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	41-44
10732782-7	1999	Etoposide diminished the binding between Bax and Bcl-XL but this was restored by IL-4 and VCAM-1 triggered signals.	Etoposide	0-9	BCL2 like 1	Homo sapiens	49-55
10732782-7	1999	Etoposide diminished the binding between Bax and Bcl-XL but this was restored by IL-4 and VCAM-1 triggered signals.	Etoposide	0-9	interleukin 4	Homo sapiens	81-85
10732782-7	1999	Etoposide diminished the binding between Bax and Bcl-XL but this was restored by IL-4 and VCAM-1 triggered signals.	Etoposide	0-9	vascular cell adhesion molecule 1	Homo sapiens	90-96
10048975-3	1999	Compared with parental or mock-transfected HAG-1 cells, v-src-transfected HAG/src3-1 cells showed a 3.5-fold resistance to cis-diamminedichloroplatinum (II) (CDDP) but not to doxorubicin, etoposide or 5-fluorouracil.	Etoposide	188-197	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	58-61
10064605-2	1999	In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated.	Etoposide	73-82	host cell factor C1	Homo sapiens	84-89
10064605-2	1999	In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated.	Etoposide	73-82	replication protein A2	Homo sapiens	105-109
10064605-2	1999	In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated.	Etoposide	73-82	replication protein A1	Homo sapiens	105-108
11240760-0	1999	Pregnancy outcome after treatment with etoposide (VP-16) for low-risk gestational trophoblastic tumor.	Etoposide	39-48	host cell factor C1	Homo sapiens	50-55
10048977-4	1999	We show that in melanoma cells exhibiting resistance to cisplatin, etoposide and vindesine, the nuclear content of each of the DNA mismatch repair (MMR) proteins hMLH1, hMSH2 and hMSH6 was reduced by 30-70%.	Etoposide	67-76	mutS homolog 6	Homo sapiens	179-184
10048977-5	1999	A decreased expression level of up to 80% of mRNAs encoding hMLH1 and hMSH2 was observed in drug-resistant melanoma cells selected for cisplatin, etoposide and fotemustine, while vindesine-selected cells showed only moderate reduction.	Etoposide	146-155	mutL homolog 1	Homo sapiens	60-65
10048977-5	1999	A decreased expression level of up to 80% of mRNAs encoding hMLH1 and hMSH2 was observed in drug-resistant melanoma cells selected for cisplatin, etoposide and fotemustine, while vindesine-selected cells showed only moderate reduction.	Etoposide	146-155	mutS homolog 2	Homo sapiens	70-75
10094469-5	1999	Furthermore, endogenous S100A2 mRNA expression is induced by etoposide in p53 positive, but not in p53 negative cells.	Etoposide	61-70	S100 calcium binding protein A2	Homo sapiens	24-30
10022987-10	1999	DNA repair gene XRCC1 mRNA expression in peripheral blood mononuclear cells was analyzed, using the reverse transcriptase-polymerase chain reaction, in 8 patients and was suppressed during etoposide infusion in 2.	Etoposide	189-198	X-ray repair cross complementing 1	Homo sapiens	16-21
10094469-5	1999	Furthermore, endogenous S100A2 mRNA expression is induced by etoposide in p53 positive, but not in p53 negative cells.	Etoposide	61-70	tumor protein p53	Homo sapiens	74-77
10094469-1	1999	S100A2, a calcium binding protein of the EF-hand family, was recently identified to be inducible by etoposide, a p53 activator.	Etoposide	100-109	S100 calcium binding protein A2	Homo sapiens	0-6
10094470-1	1999	DNA chip technology was used in an attempt to identify target genes responsible for apoptosis induced by etoposide, a p53 activating topoisomerase II inhibitor used clinically as an antitumor agent.	Etoposide	105-114	tumor protein p53	Homo sapiens	118-121
10094469-1	1999	S100A2, a calcium binding protein of the EF-hand family, was recently identified to be inducible by etoposide, a p53 activator.	Etoposide	100-109	tumor protein p53	Homo sapiens	113-116
10025887-7	1999	We conclude that L-asparaginase (Leunase) given at 10,000 IU/m2 for nine doses was poorly tolerated and resulted in excessive toxicity, both through its effects as a single agent and possibly through potentiation of etoposide.	Etoposide	216-225	asparaginase and isoaspartyl peptidase 1	Homo sapiens	17-31
10094469-2	1999	A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	155-164	tumor protein p53	Homo sapiens	12-15
10094469-2	1999	A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	155-164	S100 calcium binding protein A2	Homo sapiens	67-73
10094469-2	1999	A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	155-164	tumor protein p53	Homo sapiens	104-107
10094469-2	1999	A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide.	Etoposide	155-164	tumor protein p53	Homo sapiens	104-107
10094469-4	1999	The p53-induced transactivation of the S100A2 promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant.	Etoposide	71-80	tumor protein p53	Homo sapiens	4-7
10094469-4	1999	The p53-induced transactivation of the S100A2 promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant.	Etoposide	71-80	S100 calcium binding protein A2	Homo sapiens	39-45
10359142-2	1999	Camptothecin (CPT) and etoposide (VP-16) produced combination indices (CI) &lt;1.0 in all glioma cell lines tested, including those that were relatively resistant to the two topoisomerase inhibitors individually.	Etoposide	23-32	host cell factor C1	Homo sapiens	34-39
10050878-5	1999	Exposure of mock-transfected U937 cells to 50 microm etoposide activates procaspase-3 and the long isoform of procaspase-2 and induces mitochondrial potential decrease and cytochrome c release from mitochondria to the cytosol.	Etoposide	53-62	caspase 3	Homo sapiens	73-85
10050878-5	1999	Exposure of mock-transfected U937 cells to 50 microm etoposide activates procaspase-3 and the long isoform of procaspase-2 and induces mitochondrial potential decrease and cytochrome c release from mitochondria to the cytosol.	Etoposide	53-62	cytochrome c, somatic	Homo sapiens	172-184
10050878-7	1999	p27Kip1 does not modulate Bcl-2, Bcl-X(L), Mcl-1 and Bax protein level in leukemic cells but suppresses Mcl-1 expression decrease observed in mock-transfected U937 cells undergoing etoposide-induced cell death.	Etoposide	181-190	cyclin dependent kinase inhibitor 1B	Homo sapiens	0-7
10050882-7	1999	Downregulation of Bcl-X(L) to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold.	Etoposide	88-97	BCL2 like 1	Homo sapiens	18-26
10084254-1	1999	We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells.	Etoposide	101-110	host cell factor C1	Homo sapiens	112-117
9927611-6	1999	For instance, complex-stabilizing Topo II inhibitors such as etoposide, teniposide, and doxorubicin, which cause DNA damage, strongly induce FasL expression; by contrast, non-DNA-damaging catalytic Topo II inhibitors such as ICRF-187 and merbarone do not do this.	Etoposide	61-70	Fas ligand	Homo sapiens	141-145
9927204-6	1999	Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect.	Etoposide	75-84	tumor protein p53	Homo sapiens	31-34
9927611-10	1999	Together, our results suggest that DNA damage in response to agents such as etoposide and teniposide might serve as an early signal to induce FasL expression.	Etoposide	76-85	Fas ligand	Homo sapiens	142-146
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-41
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	MDM2 proto-oncogene	Homo sapiens	46-50
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	tumor protein p53	Homo sapiens	88-91
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	54-63	MDM2 proto-oncogene	Homo sapiens	92-96
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	cyclin dependent kinase inhibitor 1A	Homo sapiens	27-41
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	MDM2 proto-oncogene	Homo sapiens	46-50
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	tumor protein p53	Homo sapiens	88-91
10023685-0	1999	Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.	Etoposide	65-74	MDM2 proto-oncogene	Homo sapiens	92-96
10023685-3	1999	We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis.	Etoposide	43-52	MDM2 proto-oncogene	Homo sapiens	94-98
10023685-4	1999	Cytotoxic concentrations of etoposide (IC90 for &gt; 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level.	Etoposide	28-37	MDM2 proto-oncogene	Homo sapiens	82-86
10023685-7	1999	Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription.	Etoposide	67-76	MDM2 proto-oncogene	Homo sapiens	14-18
10023685-9	1999	When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated.	Etoposide	46-55	MDM2 proto-oncogene	Homo sapiens	93-97
10023685-9	1999	When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated.	Etoposide	46-55	tumor protein p53	Homo sapiens	169-172
9927204-5	1999	Clonogenic survival assays revealed that cells overexpressing the p53His175 mutant, but not the p53His273 mutant, recover preferentially from etoposide treatment.	Etoposide	142-151	tumor protein p53	Homo sapiens	66-69
9927204-6	1999	Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect.	Etoposide	75-84	tumor protein p53	Homo sapiens	10-13
10077229-3	1999	In this study, we found that GSH affects the transport of glucuronosyl etoposide as a major metabolite of etoposide in MRP-overexpressing KB/VP-4 cells.	Etoposide	71-80	ATP binding cassette subfamily C member 3	Homo sapiens	119-122
10216478-1	1999	BACKGROUND: We investigated the feasibility and efficacy of high-dose chemotherapy consisting of ifosfamide, carboplatin and etoposide (HD-ICE) facilitated by autologous peripheral blood progenitor cell transplantation (ABPCT) for the treatment of small-cell lung cancer (SCLC).	Etoposide	125-134	carboxylesterase 2	Homo sapiens	139-142
10470375-7	1999	Resistance of cells transfected with human and rat MRP2 to etoposide was enhanced 5-fold and 3.8-fold, and resistance to vincristine was enhanced 2.3-fold and 6.0-fold, respectively.	Etoposide	59-68	ATP binding cassette subfamily C member 2	Rattus norvegicus	51-55
9923540-10	1999	Our observations support the concept that cells carrying the wild-type p53 gene tend to be sensitive to etoposide and DXR and, in particular, deletion of the p53 function results in a greater resistance to anticancer agents.	Etoposide	104-113	tumor protein p53	Homo sapiens	71-74
10226546-4	1999	NCI-H596 cells, which strongly express EGFR, were more resistant to the growth inhibitory effects of cisplatin, doxorubicin and etoposide than were NCI-H358 cells, which only weakly express EGFR.	Etoposide	128-137	epidermal growth factor receptor	Homo sapiens	39-43
10226557-6	1999	Both methods showed strong antagonism (subadditive or protective effect) between docetaxel and etoposide when tested on ABC-1 and EBC-1 cells.	Etoposide	95-104	ATP binding cassette subfamily A member 1	Homo sapiens	120-125
9921985-0	1999	Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.	Etoposide	146-155	interleukin 6 cytokine family signal transducer	Homo sapiens	31-36
9921985-0	1999	Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.	Etoposide	146-155	interleukin 6	Homo sapiens	55-68
9921985-0	1999	Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.	Etoposide	146-155	oncostatin M	Homo sapiens	73-85
9921985-3	1999	METHODS: The effects of oncostatin M (OM), antiinterleukin-6 (IL-6) treatment, or interference with the gp130-mediated signaling on etoposide- or cisplatin-mediated cytotoxicity were investigated.	Etoposide	132-141	interleukin 6 cytokine family signal transducer	Homo sapiens	104-109
9921985-4	1999	RESULTS: Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin.	Etoposide	138-147	interleukin 6	Homo sapiens	39-43
9923540-10	1999	Our observations support the concept that cells carrying the wild-type p53 gene tend to be sensitive to etoposide and DXR and, in particular, deletion of the p53 function results in a greater resistance to anticancer agents.	Etoposide	104-113	tumor protein p53	Homo sapiens	158-161
9925076-1	1999	OBJECTIVE: To determine the applicability and safety of an ifosfamide, cisplatin, and etoposide (VIP) regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion in locally advanced non-small cell lung cancer (NSCLC).	Etoposide	86-95	vasoactive intestinal peptide	Homo sapiens	97-100
10550566-12	1999	CONCLUSION: Oral etoposide and oral cyclophosphamide given days 1-14 every 28 days is well tolerated and results in an acceptable response rate and median survival in poor-prognosis (poor performance status or low serum albumin) extensive disease small-cell lung cancer.	Etoposide	17-26	albumin	Homo sapiens	220-227
10367743-3	1999	PURPOSE: The purpose of this study was to identify the point at which Bcl-2 interrupts the apoptotic cascade initiated following exposure of human tumor cells to etoposide.	Etoposide	162-171	BCL2 apoptosis regulator	Homo sapiens	70-75
10367743-6	1999	RESULTS: Caspase activation, poly(ADP-ribose) polymerase degradation and Bax membrane insertion were initiated rapidly following etoposide removal, concomitantly with cell cycle arrest.	Etoposide	129-138	poly(ADP-ribose) polymerase 1	Homo sapiens	29-56
10367743-6	1999	RESULTS: Caspase activation, poly(ADP-ribose) polymerase degradation and Bax membrane insertion were initiated rapidly following etoposide removal, concomitantly with cell cycle arrest.	Etoposide	129-138	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
10367743-10	1999	However, inhibition of etoposide-induced apoptosis by Bcl-2 resulted in the accumulation of giant, multinucleated cells that eventually lost the ability to exclude trypan blue without apoptotic morphology or DNA degradation.	Etoposide	23-32	BCL2 apoptosis regulator	Homo sapiens	54-59
10218124-5	1999	RESULTS: While a combination of steel factor (SF) and PIXY321 inhibited etoposide-induced apoptosis in 8/11 primary AML samples studied, Bcl-2 and bax protein levels were unaffected by exposure to HGF and/or etoposide.	Etoposide	72-81	KIT ligand	Homo sapiens	32-44
9987657-5	1999	We tested whether etoposide, a topoisomerase II inhibitor, could induce apoptosis in androgen-dependent (LNCaP) as well as independent (PC-3 and DU 145) human prostate cancer cell lines.	Etoposide	18-27	chromobox 8	Homo sapiens	136-151
10218124-6	1999	In contrast, HGF enhanced basal and etoposide-induced p21WAF1/CIP1 protein levels in 9/11 and 7/11 of the cases, respectively.	Etoposide	36-45	cyclin dependent kinase inhibitor 1A	Homo sapiens	62-66
10218133-2	1999	P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption.	Etoposide	98-107	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
9863003-0	1999	p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin.	Etoposide	79-88	tumor protein p53 L homeolog	Xenopus laevis	0-3
10218133-2	1999	P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption.	Etoposide	98-107	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-19
10218133-2	1999	P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption.	Etoposide	126-135	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
10218133-2	1999	P-glycoprotein (Pgp) located in the intestinal brush-border membrane may pump out orally absorbed etoposide and thus decrease etoposide"s absorption.	Etoposide	126-135	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-19
10218133-8	1999	These in vitro data supported the hypothesis that certain dietary components, possibly flavonoid-related compounds, may influence Pgp"s function in intestine and thus increase etoposide"s absorption.	Etoposide	176-185	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	130-133
9863003-0	1999	p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin.	Etoposide	79-88	E2F transcription factor 1 L homeolog	Xenopus laevis	28-33
9863003-2	1999	We show here that E2F-1 protein levels increase in human medulloblastoma, glioma, lung, colon, and bladder cancer cell lines (n=7) following treatment with the DNA damaging agents adriamycin or etoposide.	Etoposide	194-203	E2F transcription factor 1	Homo sapiens	18-23
10555127-2	1999	The present study was designed to assess whether topotecan with cytosine arabinoside (ara-C) or with etoposide (VP-16) should be studied in phase II trials in patients with refractory or relapsed AML.	Etoposide	101-110	host cell factor C1	Homo sapiens	112-117
9863003-5	1999	Rather, induction of E2F-1 in the tumor cells correlates with their sensitivity to adriamycin or to etoposide.	Etoposide	100-109	E2F transcription factor 1 L homeolog	Xenopus laevis	21-26
10742982-6	1999	Numerous investigations with drugs such as digoxin, etoposide, cyclosporine, vinblastine, Taxol, loperamide, dom-peridone, and ondansteron demonstrate that P-gp has an important role in determining the pharmacokinetics of substrate drugs.	Etoposide	52-61	phosphoglycolate phosphatase	Homo sapiens	156-160
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	244-253	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	244-253	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	244-253	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	306-315	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	306-315	ATP binding cassette subfamily B member 1	Homo sapiens	71-75
9864431-1	1999	GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P).	Etoposide	306-315	ATP binding cassette subfamily B member 1	Homo sapiens	162-166
9916997-2	1998	Inappropriate expression of c-Myc under conditions which inhibit growth and down-regulate endogenous c-Myc expression, including serum deprivation and exposure to cytotoxic agents including the anticancer agents vinblastine, etoposide, Ara-C, and nocodazole, usually results in programmed cell death in many different cell types.	Etoposide	225-234	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
9856651-0	1998	Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.	Etoposide	94-103	CASP8 and FADD like apoptosis regulator	Homo sapiens	105-110
10022243-1	1998	Apoptosis, induced in human monocytic THP.1 cells by etoposide and N-tosyl-L-phenylalanyl chloromethyl ketone, was accompanied by the processing/activation of caspases, externalisation of phosphatidylserine (PS) and reduction in mitochondrial membrane potential (delta psi(m)).	Etoposide	53-62	caspase 8	Homo sapiens	159-167
9856651-1	1998	The objective of this phase I-II study was to determine the efficacy and toxicity of combination chemotherapy with 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and oral etoposide (FLAME) in patients with measurable unresectable or metastatic gastric cancer.	Etoposide	179-188	CASP8 and FADD like apoptosis regulator	Homo sapiens	190-195
9879998-9	1998	In both BJAB and Jurkat cells induction of apoptosis with anti-Fas antibody or etoposide also results in the selective loss of eIF4G, which is inhibitable by Z-VAD.FMK.	Etoposide	79-88	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	127-132
14646472-8	1998	Apoptosis was induced by treatment with either the chemotherapeutic agent etoposide (VP-16 at 10 microM) over an 8 h period or with the anti-rheumatic agent hydroxychloroquine (HCQ at 0.28 mM) over a 24 h period.	Etoposide	74-83	host cell factor C1	Homo sapiens	85-90
10070322-2	1998	EAP (etoposide, doxorubicin, cisplatin), a chemotherapeutic combination given over 8 days, proposed by German investigators in cancer of the stomach, has been considered to be too toxic by others.	Etoposide	5-14	glutamyl aminopeptidase	Homo sapiens	0-3
9834241-3	1998	Expression of CBFbeta-SMMHC in Ba/F3 cells reduced p53 induction in response to ionizing radiation or etoposide 3- to 4-fold.	Etoposide	102-111	core binding factor beta	Mus musculus	14-21
9834241-3	1998	Expression of CBFbeta-SMMHC in Ba/F3 cells reduced p53 induction in response to ionizing radiation or etoposide 3- to 4-fold.	Etoposide	102-111	myosin, heavy polypeptide 11, smooth muscle	Mus musculus	22-27
9834241-3	1998	Expression of CBFbeta-SMMHC in Ba/F3 cells reduced p53 induction in response to ionizing radiation or etoposide 3- to 4-fold.	Etoposide	102-111	transformation related protein 53, pseudogene	Mus musculus	51-54
9834241-7	1998	CBFbeta-SMMHC did not slow apoptosis resulting from IL-3 withdrawal, where p53 induction is minimal, but slowed apoptosis in Ba/F3 cells exposed to 10 Gy of ionizing radiation or 3 to 8 microgram/mL etoposide, providing 2-fold protection at 6 or 18 hours.	Etoposide	199-208	core binding factor beta	Mus musculus	0-7
9850095-2	1998	In this study, we show that VEGF also inhibits apoptotic cell death that is induced by exposure to the chemotherapeutic drugs etoposide and doxorubicin.	Etoposide	126-135	vascular endothelial growth factor A	Homo sapiens	28-32
9850095-6	1998	MCL1 decreased the caspase 3 activity induced by exposure to etoposide and increased the viability of the transfected cells after etoposide exposure.	Etoposide	61-70	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-4
9850095-6	1998	MCL1 decreased the caspase 3 activity induced by exposure to etoposide and increased the viability of the transfected cells after etoposide exposure.	Etoposide	61-70	caspase 3	Homo sapiens	19-28
9850095-6	1998	MCL1 decreased the caspase 3 activity induced by exposure to etoposide and increased the viability of the transfected cells after etoposide exposure.	Etoposide	130-139	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-4
9989882-3	1998	As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses.	Etoposide	46-55	colony stimulating factor 3	Homo sapiens	150-155
9876059-0	1998	Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).	Etoposide	45-54	carboxylesterase 2	Homo sapiens	56-59
9885442-0	1998	Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin"s lymphoma.	Etoposide	53-62	carboxylesterase 2	Homo sapiens	73-76
9885442-1	1998	The combination of ifosfamide, carboplatin and etoposide (modified ICE), was evaluated for its toxicity and activity in relapsed or refractory aggressive non-Hodgkin"s lymphoma.	Etoposide	47-56	carboxylesterase 2	Homo sapiens	67-70
10092213-0	1998	Expression of HSP27 results in increased sensitivity to tumor necrosis factor, etoposide, and H2O2 in an oxidative stress-resistant cell line.	Etoposide	79-88	heat shock protein family B (small) member 1	Homo sapiens	14-19
10092213-6	1998	On the other hand, whereas the transfection of the hsp27 gene increased the cell resistance to heat in both cell lines, only in SaOS-2 cells was this associated with protection to the cytotoxic action of tumor necrosis factor-alpha (TNF-alpha) and etoposide.	Etoposide	248-257	heat shock protein family B (small) member 1	Homo sapiens	51-56
9876059-1	1998	We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC).	Etoposide	65-74	carboxylesterase 2	Homo sapiens	76-79
10092213-6	1998	On the other hand, whereas the transfection of the hsp27 gene increased the cell resistance to heat in both cell lines, only in SaOS-2 cells was this associated with protection to the cytotoxic action of tumor necrosis factor-alpha (TNF-alpha) and etoposide.	Etoposide	248-257	tumor necrosis factor	Homo sapiens	233-242
10089064-1	1998	It has been reported that aclarubicin inhibits etoposide (VP-16) induced cytotoxicity in human lung cancer cell lines (1, 2).	Etoposide	47-56	host cell factor C1	Homo sapiens	58-63
9795126-2	1998	We showed that serum deprivation and etoposide induced a distinct pattern of regulation of c-Fos, c-Jun and p53 protein levels, as well as the differential changes in DNA-binding activity of AP-1 and NF-kappaB transcription factors.	Etoposide	37-46	FBJ osteosarcoma oncogene	Mus musculus	91-96
9822738-7	1998	Expression of PS-1 protected against induction of apoptosis in the cortical neurons by etoposide or staurosporine.	Etoposide	87-96	presenilin 1	Homo sapiens	14-18
9864272-0	1998	Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution.	Etoposide	40-49	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	11-25
9864272-1	1998	In this study, P-glycoprotein modulator effects on pharmacokinetics and central nervous system distribution of the chemotherapeutic agent etoposide were evaluated.	Etoposide	138-147	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	15-29
9819442-4	1998	Treatment of HeLa cells with the apoptosis inducers cisplatin and etoposide resulted in cleavage of eIF4G, and the extent of its cleavage correlated with the onset and extent of observed inhibition of cellular translation.	Etoposide	66-75	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	100-105
9921266-0	1998	[The cause of polyurethane catheter cracking during constant infusion of etoposide (VP-16) injection].	Etoposide	73-82	host cell factor C1	Homo sapiens	84-89
9921266-1	1998	We studied the cause of cracking of a clinically used polyurethane (PU) catheter during the constant infusion of etoposide (VP-16) injection (Lastet), administered without dilution to patients as a part of combination high-dose chemotherapy.	Etoposide	113-122	host cell factor C1	Homo sapiens	124-129
9795126-2	1998	We showed that serum deprivation and etoposide induced a distinct pattern of regulation of c-Fos, c-Jun and p53 protein levels, as well as the differential changes in DNA-binding activity of AP-1 and NF-kappaB transcription factors.	Etoposide	37-46	jun proto-oncogene	Mus musculus	98-103
9795126-2	1998	We showed that serum deprivation and etoposide induced a distinct pattern of regulation of c-Fos, c-Jun and p53 protein levels, as well as the differential changes in DNA-binding activity of AP-1 and NF-kappaB transcription factors.	Etoposide	37-46	transformation related protein 53, pseudogene	Mus musculus	108-111
9831202-8	1998	Twenty-six patients with MRP-positive tumors who underwent postoperative chemotherapy with MRP-related anticancer drugs (vindesine and etoposide) had significantly poorer prognoses than did those with MRP-negative tumors (P=.017).	Etoposide	135-144	ATP binding cassette subfamily C member 3	Homo sapiens	25-28
9813182-3	1998	We observed that neuronal apoptosis, induced by serum withdrawal or by treatment with etoposide, okadaic acid or trichostatin A, induced a prominent increase in mSin3A protein expression but did not affect the level of mSin3B protein.	Etoposide	86-95	transcriptional regulator, SIN3A (yeast)	Mus musculus	161-167
9772293-4	1998	With the exception of the etoposide-effected G2/M arrest at high concentrations, which seems to depend on functional p53, since it did not occur in cells with inactive p53.	Etoposide	26-35	tumor protein p53	Homo sapiens	117-120
9772293-7	1998	The accumulated p53 was biochemically active, as measured in a transient transfection assay upon treatment with gemcitabine, cisplatin, etoposide, and Taxol.	Etoposide	136-145	tumor protein p53	Homo sapiens	16-19
9831202-8	1998	Twenty-six patients with MRP-positive tumors who underwent postoperative chemotherapy with MRP-related anticancer drugs (vindesine and etoposide) had significantly poorer prognoses than did those with MRP-negative tumors (P=.017).	Etoposide	135-144	ATP binding cassette subfamily C member 3	Homo sapiens	91-94
9831202-8	1998	Twenty-six patients with MRP-positive tumors who underwent postoperative chemotherapy with MRP-related anticancer drugs (vindesine and etoposide) had significantly poorer prognoses than did those with MRP-negative tumors (P=.017).	Etoposide	135-144	ATP binding cassette subfamily C member 3	Homo sapiens	91-94
9788435-3	1998	The effect of induced p53 and p21waf1 expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed.	Etoposide	98-107	tumor protein p53	Homo sapiens	22-25
10437132-5	1998	DNA and protein syntheses were obviously suppressed by GP4, GP7, and etoposide 10 mmol.L-1 for 48 h. After Molt 4B cells were treated with GP4, GP7, and etoposide 10 mmol.L-1 for 6 and 12 h, the mitotic index was increased by GP4 and reduced by GP7 and etoposide.	Etoposide	153-162	CD36 molecule	Homo sapiens	55-58
10437132-5	1998	DNA and protein syntheses were obviously suppressed by GP4, GP7, and etoposide 10 mmol.L-1 for 48 h. After Molt 4B cells were treated with GP4, GP7, and etoposide 10 mmol.L-1 for 6 and 12 h, the mitotic index was increased by GP4 and reduced by GP7 and etoposide.	Etoposide	153-162	CD36 molecule	Homo sapiens	55-58
9821708-5	1998	However, this regimen was only partially effective to the patient with the pure hepatoid histological subtype, and an etoposide with ifosfamide and cisplatin (VIP) regimen as a salvage chemotherapy combined with complete tumor resection was useful to achieve complete remission (CR).	Etoposide	118-127	vasoactive intestinal peptide	Homo sapiens	159-162
9788601-0	1998	Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.	Etoposide	76-85	apoptotic peptidase activating factor 1	Homo sapiens	18-24
9788601-5	1998	Stably overexpressing Apaf-1 levels significantly sensitized HL-60/Apaf-1 cells to apoptosis induced by clinically achievable concentrations of paclitaxel or etoposide (P &lt; 0.01).	Etoposide	158-167	apoptotic peptidase activating factor 1	Homo sapiens	22-28
9788601-6	1998	This increase in paclitaxel- or etoposide-induced apoptosis of HL-60/Apaf-1 cells was not associated with any significant alterations in Bcl-2, Bcl-xL, Bax, Fas, or Fas ligand expression.	Etoposide	32-41	apoptotic peptidase activating factor 1	Homo sapiens	69-75
9788601-6	1998	This increase in paclitaxel- or etoposide-induced apoptosis of HL-60/Apaf-1 cells was not associated with any significant alterations in Bcl-2, Bcl-xL, Bax, Fas, or Fas ligand expression.	Etoposide	32-41	Fas ligand	Homo sapiens	165-175
9788601-9	1998	These data indicate that the intracellular levels of Apaf-1 is an important molecular determinant of the threshold for apoptosis induced by paclitaxel and etoposide.	Etoposide	155-164	apoptotic peptidase activating factor 1	Homo sapiens	53-59
9781697-5	1998	PARP was activated temporarily and extensive auto-modification occurred on PARP, possibly by the fragmented DNA during apoptosis induced by etoposide in Jurkat cells.	Etoposide	140-149	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
9781697-5	1998	PARP was activated temporarily and extensive auto-modification occurred on PARP, possibly by the fragmented DNA during apoptosis induced by etoposide in Jurkat cells.	Etoposide	140-149	poly(ADP-ribose) polymerase 1	Homo sapiens	75-79
9781697-6	1998	However, the phosphorylation level was not changed for up to 6 h, after PARP cleavage began in apoptosis by the treatment with etoposide.	Etoposide	127-136	poly(ADP-ribose) polymerase 1	Homo sapiens	72-76
9764585-1	1998	High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity.	Etoposide	10-19	colony stimulating factor 3	Homo sapiens	43-80
9840719-0	1998	Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide.	Etoposide	139-148	BCL2 apoptosis regulator	Homo sapiens	0-5
9840719-1	1998	The influence of bcl-2 oncogene expression on etoposide-induced apoptosis and clonogenic survival was investigated in five small cell lung cancer (SCLC) cell lines, three of which were bcl-2-expressing and two of which were non-bcl-2-expressing.	Etoposide	46-55	BCL2 apoptosis regulator	Homo sapiens	17-22
9840719-3	1998	When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines.	Etoposide	85-94	BCL2 apoptosis regulator	Homo sapiens	5-10
9840719-3	1998	When bcl-2-expressing cells were incubated in cystine/ methionine-free (CMF) medium, etoposide-induced apoptosis was restored to levels comparable to those seen in non-bcl-2-expressing lines.	Etoposide	85-94	BCL2 apoptosis regulator	Homo sapiens	168-173
9840719-5	1998	In addition, treatment of the two bcl-2-expressing cell lines with etoposide in CMF medium did not modify their clonogenic survival curves compared to treatment in regular medium.	Etoposide	67-76	BCL2 apoptosis regulator	Homo sapiens	34-39
9840719-6	1998	These results are consistent with the idea that bcl-2 expression modulates etoposide-induced apoptosis but not clonogenic survival.	Etoposide	75-84	BCL2 apoptosis regulator	Homo sapiens	48-53
9764585-1	1998	High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity.	Etoposide	10-19	colony stimulating factor 3	Homo sapiens	82-87
9764585-11	1998	These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF.	Etoposide	34-43	colony stimulating factor 3	Homo sapiens	49-54
9792147-2	1998	In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations.	Etoposide	125-134	BCL2 apoptosis regulator	Homo sapiens	51-56
9764585-11	1998	These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF.	Etoposide	34-43	colony stimulating factor 3	Homo sapiens	218-223
9780138-6	1998	P-glycoprotein effluxes a variety of anticancer drugs, such as doxorubicin, vinca alkaloids, etoposide and taxol, and thereby allows cancer cells to show resistance to these drugs.	Etoposide	93-102	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
9766655-5	1998	These E2F-1 transfectants, although resistant to fluoropyrimidines and serum deprivation, were more sensitive to etoposide, doxorubicin, and SN38 (the active metabolite of irinotecan) but not to Taxol.	Etoposide	113-122	E2F transcription factor 1	Homo sapiens	6-11
9818704-4	1998	She received chemotherapy with the CHOP-etoposide regimen, resulting in partial remission.	Etoposide	40-49	DNA damage inducible transcript 3	Homo sapiens	35-39
9751706-1	1998	PKN, a fatty acid- and Rho-activated serine/threonine kinase having a catalytic domain highly homologous to protein kinase C (PKC), was cleaved at specific sites in apoptotic Jurkat and U937 cells on Fas ligation and treatment with staurosporin or etoposide, respectively.	Etoposide	248-257	protein kinase N1	Homo sapiens	0-3
9733516-4	1998	In cells in which NF-kappaB was inactive, all of these proteins were required to fully suppress TNF-induced apoptosis, whereas c-IAP1 and c-IAP2 were sufficient to suppress etoposide-induced apoptosis.	Etoposide	173-182	baculoviral IAP repeat containing 2	Homo sapiens	127-133
9739169-2	1998	Etoposide treatment increased expression of the p21 gene, a cyclin kinase inhibitor, at both the mRNA and protein levels.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	48-51
9739169-4	1998	A substrate for cyclin kinase, pRB, was unphosphorylated by etoposide treatment, but remained unaffected by deferoxamine, indicating that p21 was functional after etoposide, but not after deferoxamine treatment.	Etoposide	60-69	RB transcriptional corepressor 1	Homo sapiens	31-34
9739169-4	1998	A substrate for cyclin kinase, pRB, was unphosphorylated by etoposide treatment, but remained unaffected by deferoxamine, indicating that p21 was functional after etoposide, but not after deferoxamine treatment.	Etoposide	163-172	RB transcriptional corepressor 1	Homo sapiens	31-34
9739169-4	1998	A substrate for cyclin kinase, pRB, was unphosphorylated by etoposide treatment, but remained unaffected by deferoxamine, indicating that p21 was functional after etoposide, but not after deferoxamine treatment.	Etoposide	163-172	cyclin dependent kinase inhibitor 1A	Homo sapiens	138-141
9739169-7	1998	After etoposide treatment, the level of ubiquitinated p21 was diminished and a high level of unubiquitinated p21 expression was observed.	Etoposide	6-15	cyclin dependent kinase inhibitor 1A	Homo sapiens	54-57
9739169-7	1998	After etoposide treatment, the level of ubiquitinated p21 was diminished and a high level of unubiquitinated p21 expression was observed.	Etoposide	6-15	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-112
9733516-4	1998	In cells in which NF-kappaB was inactive, all of these proteins were required to fully suppress TNF-induced apoptosis, whereas c-IAP1 and c-IAP2 were sufficient to suppress etoposide-induced apoptosis.	Etoposide	173-182	baculoviral IAP repeat containing 3	Homo sapiens	138-144
9730882-4	1998	We show here that the lack of mrp1 protein results in increased etoposide-induced damage to the mucosa of the oropharyngeal cavity and to the seminiferous tubules of the testis.	Etoposide	64-73	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	30-34
9716508-3	1998	The current study was aimed at examining the role of PLA2 in regulating apoptosis in response to several inducers (such as vincristine and etoposide) in lymphoid cell lines.	Etoposide	139-148	phospholipase A2 group IB	Homo sapiens	53-57
10200532-6	1998	We demostrated by Western blotting assay that DXR and etoposide (VP-16) were able to induce CD95L expression after 4 h of treatment.	Etoposide	54-63	host cell factor C1	Homo sapiens	65-70
9716601-4	1998	Furthermore, suppression of LMP-1 was associated with molecular and phenotypic effects that included downregulation of the LMP-1-inducible antiapoptotic genes, Bcl-2 and Mcl-1, inhibition of proliferation, stimulation of apoptosis, and enhancement of sensitivity to the chemotherapeutic agent, etoposide.	Etoposide	294-303	PDZ and LIM domain 7	Homo sapiens	28-33
10200532-6	1998	We demostrated by Western blotting assay that DXR and etoposide (VP-16) were able to induce CD95L expression after 4 h of treatment.	Etoposide	54-63	Fas ligand	Homo sapiens	92-97
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-119
9821108-3	1998	Combined treatment with IL-1 beta and IFN-gamma caused greater inhibition of TGF-beta secretion compared to treatment with IFN-gamma, and almost the same levels of inhibition as treatment with vincristine and etoposide.	Etoposide	209-218	interleukin 1 beta	Homo sapiens	24-33
9821108-3	1998	Combined treatment with IL-1 beta and IFN-gamma caused greater inhibition of TGF-beta secretion compared to treatment with IFN-gamma, and almost the same levels of inhibition as treatment with vincristine and etoposide.	Etoposide	209-218	interferon gamma	Homo sapiens	38-47
9821108-6	1998	This IL-10 secretion was inhibited by treatment with IL-1 beta, IFN-gamma, vincristine, and/or etoposide.	Etoposide	95-104	interleukin 10	Homo sapiens	5-10
9821108-1	1998	The effect of treatment with interleukin-1 beta (IL-1 beta), interferon-gamma (IFN-gamma), vincristine, and etoposide was evaluated on the secretion of transforming growth factor-beta (TGF-beta) and IL-10 and the expression of major histocompatibility complex (MHC) class I, intercellular adhesion molecule-1 (ICAM-1), and CD80 molecules by malignant glioma cells.	Etoposide	108-117	transforming growth factor beta 1	Homo sapiens	152-183
9821108-1	1998	The effect of treatment with interleukin-1 beta (IL-1 beta), interferon-gamma (IFN-gamma), vincristine, and etoposide was evaluated on the secretion of transforming growth factor-beta (TGF-beta) and IL-10 and the expression of major histocompatibility complex (MHC) class I, intercellular adhesion molecule-1 (ICAM-1), and CD80 molecules by malignant glioma cells.	Etoposide	108-117	transforming growth factor beta 1	Homo sapiens	185-193
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	228-237	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
9732391-3	1998	The relationships were assessed with six different human liver microsomes between the 3"-demethylation of etoposide and metabolic activities for substrate probes of the respective CYP isoforms, showing a significant correlation (r = 0.	Etoposide	106-115	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
9821108-10	1998	These results suggest that TGF-beta and IL-10 secretion by malignant glioma cells can be suppressed by treatment with a combination of IL-1 beta, IFN-gamma, vincristine, and etoposide, and the treatment up-regulates MHC class I and ICAM-1 expression on tumor cells.	Etoposide	174-183	transforming growth factor beta 1	Homo sapiens	27-35
9821108-10	1998	These results suggest that TGF-beta and IL-10 secretion by malignant glioma cells can be suppressed by treatment with a combination of IL-1 beta, IFN-gamma, vincristine, and etoposide, and the treatment up-regulates MHC class I and ICAM-1 expression on tumor cells.	Etoposide	174-183	interleukin 10	Homo sapiens	40-45
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	121-124
9821108-10	1998	These results suggest that TGF-beta and IL-10 secretion by malignant glioma cells can be suppressed by treatment with a combination of IL-1 beta, IFN-gamma, vincristine, and etoposide, and the treatment up-regulates MHC class I and ICAM-1 expression on tumor cells.	Etoposide	174-183	intercellular adhesion molecule 1	Homo sapiens	232-238
9732391-9	1998	Furthermore, some supporting agents (vincristine and prednisolone) and the substrates of CYP3A4, which may be coadministered with etoposide during the cancer chemotherapies, inhibit the etoposide 3"-demethylation activity in vitro.	Etoposide	130-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
9732391-1	1998	The metabolism of etoposide was investigated by using human liver microsomes and nine recombinant human cytochrome P450 (CYP) isoforms to identify the CYP isoform(s) involved in the major metabolic pathway (3"-demethylation) of etoposide as well as to evaluate the possible metabolic interactions with several antitumor or supporting agents.	Etoposide	18-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Etoposide	54-63	BCL2 apoptosis regulator	Homo sapiens	133-138
9685354-3	1998	Expression of MRP1 alone confers resistance to several drugs representing the multidrug resistance phenotype, drugs including doxorubicin, vincristine, etoposide, and mitoxantrone.	Etoposide	152-161	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
9688310-6	1998	In addition, extracts from etoposide-treated WW2 cells degraded the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), an important indicator of apoptosis, but this protein was resistant to degradation by BL29 extracts.	Etoposide	27-36	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	119-127
9688315-8	1998	Non-confluent HT29 cells over-expressing p27Kip1 are also more resistant to doxorubicin, etoposide and 5-fluorouracil.	Etoposide	89-98	cyclin dependent kinase inhibitor 1B	Homo sapiens	41-48
9744572-2	1998	Inhibitors of calcium-calmodulin-dependent enzymes sensitize resistant tumor cells to the topo II poison etoposide (VP-16) by enhancing DNA damage and an apoptotic response.	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
9744573-6	1998	These were: bisdioxopiperazine (ICRF-187), a catalytic inhibitor of topoisomerase II, and etoposide (VP-16), an inducer of a cleavable complex of the enzyme with DNA.	Etoposide	90-99	host cell factor C1	Homo sapiens	101-106
9699675-0	1998	Altered expression of ubiquitous kinesin heavy chain results in resistance to etoposide and hypersensitivity to colchicine: mapping of the domain associated with drug response.	Etoposide	78-87	kinesin family member 5B	Homo sapiens	22-52
9699675-4	1998	Surprisingly, overexpression of full-length uKHC and its variants that were deficient in the NH2-terminal motor domain produced a phenotype similar to that of antisense RNA, characterized by resistance to etoposide and collateral sensitivity to colchicine.	Etoposide	205-214	kinesin family member 5B	Homo sapiens	44-48
9699675-7	1998	A sense-oriented genetic suppressor element conferring resistance to etoposide was isolated from a retroviral library of randomly fragmented uKHC cDNA.	Etoposide	69-78	kinesin family member 5B	Homo sapiens	141-145
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Etoposide	54-63	BCL2 like 1	Homo sapiens	142-148
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Etoposide	54-63	BCL2 apoptosis regulator	Homo sapiens	182-187
9699642-1	1998	Taxol, 1-beta-D-arabinofuranosylcytosine (ara-C), and etoposide induce apoptosis in HL-60 cells that is blocked by overexpression of Bcl-2 or Bcl-xL.A 60-amino acid "loop" domain of Bcl-2 and Bcl-xL that contains phosphorylation sites is known to negatively regulate their antiapoptotic function.	Etoposide	54-63	BCL2 like 1	Homo sapiens	192-198
9699642-8	1998	Exposure to etoposide (50 microM) or ara-C (100 microM) for 4 h induced apoptosis in HL-60/neo cells, but not in HL-60/Bcl-2, HL-60/Bcl-xL, HL-60/Bcl-2delta, or HL-60/Bcl-xLdelta cells.	Etoposide	12-21	BCL2 like 1	Homo sapiens	132-138
9726444-0	1998	A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.	Etoposide	42-51	colony stimulating factor 2	Homo sapiens	26-29
9726012-1	1998	Large deletions of exons 2 and 3 of the hprt gene are the most common type of hprt mutation in lymphocytes of newborn infants, and their frequency increases in cultured human T-lymphoid cells as a result of exposure to etoposide.	Etoposide	219-228	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	40-44
9687575-8	1998	Importantly, we could show that MT1 cells are not deficient in the p53-dependent apoptosis pathway; treatment with etoposide, a topoisomerase II inhibitor, resulted in p53 and p21/waf-1 protein expression and apoptosis in both cell lines.	Etoposide	115-124	metallothionein 1I, pseudogene	Homo sapiens	32-35
9687575-8	1998	Importantly, we could show that MT1 cells are not deficient in the p53-dependent apoptosis pathway; treatment with etoposide, a topoisomerase II inhibitor, resulted in p53 and p21/waf-1 protein expression and apoptosis in both cell lines.	Etoposide	115-124	tumor protein p53	Homo sapiens	168-171
9687575-8	1998	Importantly, we could show that MT1 cells are not deficient in the p53-dependent apoptosis pathway; treatment with etoposide, a topoisomerase II inhibitor, resulted in p53 and p21/waf-1 protein expression and apoptosis in both cell lines.	Etoposide	115-124	cyclin dependent kinase inhibitor 1A	Homo sapiens	176-185
9683290-4	1998	The MRP1-transfected line SKOV3-S2 was shown to be cross-resistant to doxorubicin, vincristine and etoposide but not to paclitaxel, vinblastine and platinum agents, such as cisplatin, JM216 [bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV)] and AMD473 [cis-ammine dichloro (2-methyl-pyridine) platinum (II)].	Etoposide	99-108	ATP binding cassette subfamily C member 1	Homo sapiens	4-8
9698071-4	1998	The activity of P-gp in these cells was quantified by measuring cellular accumulation of radiolabeled taxol and etoposide in the presence and absence of the P-gp modulator SDZ PSC-833 (valspodar; a semisynthetic undecapeptide derived from cyclosporin D).	Etoposide	112-121	glycerol-3-phosphate phosphatase	Cricetulus griseus	16-20
9698071-5	1998	The mdr-1b-transfected CHO cells accumulated 2- to 3-fold less taxol and etoposide than the controls, an accumulation defect reversed by the potent MDR modulator PSC-833.	Etoposide	73-82	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	4-10
9698071-8	1998	Treatment with 50 microM of reduced polymer of spermine and glutaraldehyde, a selective blocker of the polyamine transport system, reduced MDR activity in mdr-1-transfected CHO cells and restored cellular accumulation of etoposide and taxol to control levels, effects not observed in mdr-1-transfected CHOMGBG cells.	Etoposide	221-230	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	155-160
9698071-9	1998	Notably, mdr-1-transfected CHO cells were 4- to 16-fold more resistant to the cytotoxic effects of the P-gp substrates doxorubicin, taxol, and etoposide than were the mdr-1-transfected CHOMGBG cells.	Etoposide	143-152	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	9-14
9713486-10	1998	Increased apoptotic responses were generally observed in cell lines that were sensitive to etoposide and this correlated with low ratios of Bcl-2/Bax protein.	Etoposide	91-100	BCL2 apoptosis regulator	Homo sapiens	140-145
9713486-10	1998	Increased apoptotic responses were generally observed in cell lines that were sensitive to etoposide and this correlated with low ratios of Bcl-2/Bax protein.	Etoposide	91-100	BCL2 associated X, apoptosis regulator	Homo sapiens	146-149
9660477-9	1998	Camptothecin and etoposide increased the p53 level after 4 hours of treatment, before the onset of apoptosis.	Etoposide	17-26	tumor protein p53	Homo sapiens	41-44
9730236-0	1998	Binding affinity of Cu(II)-VP-16 (etoposide) complex and its analogues to DNA and hydroxyl radical generation during DNA strand breaks.	Etoposide	34-44	host cell factor C1	Homo sapiens	27-32
9730236-1	1998	Conformational effects and affinities of VP-16 (etoposide) and its derivatives to DNA in the presence of Cu(II) ion were examined by circular dichroic (CD) spectra.	Etoposide	48-57	host cell factor C1	Homo sapiens	41-46
9667732-0	1998	Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase.	Etoposide	13-22	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	68-76
9658339-6	1998	Using a model motor neuronal cell line, NSC19, which we have shown undergoes apoptosis after treatment with classic apoptosis inducers such as the topoisomerase inhibitors camptothecin and etoposide, we unambiguously found that nanomolar thrombin induced characteristic signs of apoptosis.	Etoposide	189-198	coagulation factor II, thrombin	Homo sapiens	238-246
9620867-5	1998	Etoposide caused a rapid accumulation of p53 protein that was not inhibited by LLnV-al, which was also a strong inducer of p53.	Etoposide	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	41-44
9620867-5	1998	Etoposide caused a rapid accumulation of p53 protein that was not inhibited by LLnV-al, which was also a strong inducer of p53.	Etoposide	0-9	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	123-126
9671409-6	1998	Nuclear run-on experiments demonstrate that etoposide increases CASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression.	Etoposide	44-53	BCL2 apoptosis regulator	Homo sapiens	134-139
9789222-6	1998	Total costs per patient per first treatment cycle of chemotherapy for the alternatives cisplatin/etoposide, ifosfamide/etoposide and gemcitabine were Skr 15,131, Skr 25,226, and Skr 13,266, respectively.	Etoposide	119-128	tachykinin receptor 2	Homo sapiens	150-153
9635591-3	1998	In this study, we have demonstrated the existence of an additional pathway, independent of the p34cdc2 kinase activation pathway, that leads to a G2 arrest in etoposide-treated cells.	Etoposide	159-168	cyclin dependent kinase 1	Homo sapiens	95-102
9635591-4	1998	Both the X-ray-induced and the etoposide-induced G2 arrest were associated with inhibition of the p34cdc2 H1 kinase activation pathway as judged by p34cdc2 H1 kinase activity and phosphorylation of cdc25C.	Etoposide	31-40	cyclin dependent kinase 1	Homo sapiens	98-105
9635591-4	1998	Both the X-ray-induced and the etoposide-induced G2 arrest were associated with inhibition of the p34cdc2 H1 kinase activation pathway as judged by p34cdc2 H1 kinase activity and phosphorylation of cdc25C.	Etoposide	31-40	cyclin dependent kinase 1	Homo sapiens	148-155
9635591-4	1998	Both the X-ray-induced and the etoposide-induced G2 arrest were associated with inhibition of the p34cdc2 H1 kinase activation pathway as judged by p34cdc2 H1 kinase activity and phosphorylation of cdc25C.	Etoposide	31-40	cell division cycle 25C	Homo sapiens	198-204
9671409-0	1998	Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis.	Etoposide	59-68	cartilage associated protein	Homo sapiens	16-20
9671409-4	1998	Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase II inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis.	Etoposide	109-118	caspase 2	Homo sapiens	131-137
9671409-4	1998	Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase II inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis.	Etoposide	109-118	caspase 3	Homo sapiens	142-148
9671409-5	1998	This effect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis.	Etoposide	15-24	BCL2 apoptosis regulator	Homo sapiens	59-64
9671409-6	1998	Nuclear run-on experiments demonstrate that etoposide increases CASP gene transcription in U937 cells, an effect that is prevented by Bcl-2 overexpression.	Etoposide	44-53	cartilage associated protein	Homo sapiens	64-68
9667732-4	1998	Ku70- and Ku80-deficient cells can be complemented to an etoposide resistant phenotype by introducing wildtype Ku70 or Ku80 cDNAs.	Etoposide	57-66	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	0-4
9667732-4	1998	Ku70- and Ku80-deficient cells can be complemented to an etoposide resistant phenotype by introducing wildtype Ku70 or Ku80 cDNAs.	Etoposide	57-66	X-ray repair complementing defective repair in Chinese hamster cells 5	Mus musculus	10-14
9667732-4	1998	Ku70- and Ku80-deficient cells can be complemented to an etoposide resistant phenotype by introducing wildtype Ku70 or Ku80 cDNAs.	Etoposide	57-66	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	111-115
9667732-4	1998	Ku70- and Ku80-deficient cells can be complemented to an etoposide resistant phenotype by introducing wildtype Ku70 or Ku80 cDNAs.	Etoposide	57-66	X-ray repair complementing defective repair in Chinese hamster cells 5	Mus musculus	119-123
9667732-5	1998	Mutational analysis of introduced Ku70 cDNAs into murine embryonic stem cells deleted for Ku70 (-/-) showed that mutants where heterodimerization and DNA binding functions of Ku were disrupted, also blocked the restoration of etoposide resistance.	Etoposide	226-235	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	90-94
9667732-6	1998	In contrast with the differential etoposide sensitivity of DNA-PK mutants, both Ku- and DNA-PKcs-deficient cell lines showed G2 ionizing radiation-induced delays, a cell cycle phase where topoisomerase II function is critical.	Etoposide	34-43	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	59-65
9667732-3	1998	Interestingly, either Ku70- or Ku80-deficient cell lines, but not mutant cell lines of the DNA-PK catalytic sub-unit (DNA-PKcs), were found to be hypersensitive to the effects of etoposide VP16.	Etoposide	179-188	X-ray repair complementing defective repair in Chinese hamster cells 6	Mus musculus	22-26
9667732-3	1998	Interestingly, either Ku70- or Ku80-deficient cell lines, but not mutant cell lines of the DNA-PK catalytic sub-unit (DNA-PKcs), were found to be hypersensitive to the effects of etoposide VP16.	Etoposide	179-188	X-ray repair complementing defective repair in Chinese hamster cells 5	Mus musculus	31-35
9652763-5	1998	After treatment of patients with SCLC with either etoposide or teniposide, which are topo-IIalpha-directed drugs, there was an increase in MRP (P &lt; 0.1) and P-gp (P &lt; 0.05) positivity, while topo-IIalpha decreased (P &lt; 0.05).	Etoposide	50-59	ATP binding cassette subfamily C member 1	Homo sapiens	139-142
9593687-4	1998	Here we show that Nedd4, a ubiquitin-protein ligase containing multiple WW domains and a calcium/lipid-binding domain, is also cleaved during apoptosis induced by a variety of stimuli including Fas-ligation, gamma-radiation, tumor necrosis factor-alpha, C-8 ceramide, and etoposide treatment.	Etoposide	272-281	neural precursor cell expressed, developmentally down-regulated 4	Mus musculus	18-23
9632268-0	1998	VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin"s disease.	Etoposide	5-14	vasoactive intestinal peptide	Homo sapiens	0-3
9649010-10	1998	Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression.	Etoposide	55-64	ATP binding cassette subfamily B member 1	Homo sapiens	172-177
9691246-6	1998	The agents did not cause DNA protein linked breaks themselves; nevertheless, VP-16 [etoposide] induced DNA protein linked breaks were increased two fold in the presence of the agents suggesting synergistic effects.	Etoposide	84-93	host cell factor C1	Homo sapiens	77-82
9652763-5	1998	After treatment of patients with SCLC with either etoposide or teniposide, which are topo-IIalpha-directed drugs, there was an increase in MRP (P &lt; 0.1) and P-gp (P &lt; 0.05) positivity, while topo-IIalpha decreased (P &lt; 0.05).	Etoposide	50-59	ATP binding cassette subfamily B member 1	Homo sapiens	160-164
9570926-5	1998	Modulation of cell death by Bcl-xL was also observed in cells treated with etoposide, vinblastine, paclitaxel, and cisplatinum (II) diammine dichloride.	Etoposide	75-84	BCL2 like 1	Homo sapiens	28-34
9588194-4	1998	Etoposide-induced activation of intracellular DEVD-pNa cleaving activity and apoptosis was suppressed by low micromolar concentrations of cell-permeable inhibitors of caspase-3.	Etoposide	0-9	caspase 3	Homo sapiens	167-176
9719484-3	1998	Etoposide accumulation was 50% reduced in both the CEM/E1000 MRP-overexpressing subline and the CEM/VLB100 P-glycoprotein-expressing subline compared to the parental CEM cells, correlating with similar resistance to etoposide (200-fold) of the two sublines.	Etoposide	0-9	ATP binding cassette subfamily C member 3	Homo sapiens	61-64
9719484-9	1998	These results show that modulation of etoposide cytotoxicity in MRP-overexpressing cells may be through changes in glutathione metabolism rather than changes in accumulation and confirm that changes in drug accumulation are not related to drug resistance in MRP-overexpressing cells.	Etoposide	38-47	ATP binding cassette subfamily C member 3	Homo sapiens	64-67
9564841-0	1998	Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment.	Etoposide	79-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	10-29
9564841-4	1998	Northern blot analysis shows that human TR3 orphan receptor expression can be induced rapidly after treatment of LNCaP and PC-3 prostate cancer cells with calcium ionophore or etoposide.	Etoposide	176-185	nuclear receptor subfamily 4 group A member 1	Homo sapiens	40-59
9564841-5	1998	Our data further demonstrate that a much higher concentration of etoposide was needed to kill the same number of cells in LNCaP and PC-3 cells transfected stably with antisense TR3 orphan receptor compared with that in control vector transfectants.	Etoposide	65-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	177-196
9619826-5	1998	CD protein expression was increased by exposure of ML1 cells to etoposide, adriamycin or gamma-radiation.	Etoposide	64-73	interleukin 17F	Homo sapiens	51-54
9719474-1	1998	KB/7D cells represent a multidrug-resistant subclone of human nasopharyngeal carcinoma KB cells generated by continuous exposure to the topoisomerase II inhibitor VP-16 (etoposide).	Etoposide	170-179	host cell factor C1	Homo sapiens	163-168
9516161-3	1998	After high-dose myeloablative chemotherapy (busulfan, cyclophosphamide, etoposide) CD34+) HPC were infused and lymphoid reconstitution was monitored using flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of VDJ T-cell receptor (TcR) sequences.	Etoposide	72-81	CD34 molecule	Homo sapiens	83-87
9557789-4	1998	So-called "starburst cells," which have been purported to be specific for high-dose etoposide (VP-16) therapy, were seen in two cases, but only one of these patients received etoposide.	Etoposide	84-93	host cell factor C1	Homo sapiens	95-100
9516141-2	1998	Apoptotic DNA fragmentation is delayed in the bcr-abl+ K562 and KCL-22 compared with the bcr-abl- U937 and HL-60 cell lines when treated with etoposide concentrations that induce similar DNA damage in the four cell lines.	Etoposide	142-151	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	46-53
9516141-2	1998	Apoptotic DNA fragmentation is delayed in the bcr-abl+ K562 and KCL-22 compared with the bcr-abl- U937 and HL-60 cell lines when treated with etoposide concentrations that induce similar DNA damage in the four cell lines.	Etoposide	142-151	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	89-96
9495807-0	1998	The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex.	Etoposide	52-61	host cell factor C1	Homo sapiens	63-68
9516141-3	1998	By the use of a cell-free system, we show that nuclei from untreated cells that express p210(bcr-abl) remain sensitive to apoptotic DNA fragmentation induced by triton-soluble extracts from p210(bcr-abl-) cells treated with etoposide.	Etoposide	224-233	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	93-100
9516141-3	1998	By the use of a cell-free system, we show that nuclei from untreated cells that express p210(bcr-abl) remain sensitive to apoptotic DNA fragmentation induced by triton-soluble extracts from p210(bcr-abl-) cells treated with etoposide.	Etoposide	224-233	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	195-202
9516141-6	1998	The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone.	Etoposide	80-89	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	17-24
9516141-6	1998	The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone.	Etoposide	80-89	colony stimulating factor 2	Homo sapiens	97-145
9516141-6	1998	The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone.	Etoposide	80-89	colony stimulating factor 2	Homo sapiens	147-153
9516141-7	1998	We conclude that the cytosolic pathway that leads to apoptotic DNA fragmentation in etoposide-treated leukemic cells is delayed upstream of procaspase-3-mediated events in bcr-abl+ cell lines.	Etoposide	84-93	caspase 3	Homo sapiens	140-152
9516141-7	1998	We conclude that the cytosolic pathway that leads to apoptotic DNA fragmentation in etoposide-treated leukemic cells is delayed upstream of procaspase-3-mediated events in bcr-abl+ cell lines.	Etoposide	84-93	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	172-179
9592981-5	1998	RESULTS: G-CSF support significantly reduced the frequency of day-1 drug dose reductions (p &lt; 0.001) and of chemotherapy delays (p &lt; 0.001), and improved the actual delivered doses of adriamycin, cyclophosphamide and etoposide (p &lt; 0.02).	Etoposide	223-232	colony stimulating factor 3	Homo sapiens	9-14
9568726-0	1998	Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.	Etoposide	47-56	interferon alpha 2	Homo sapiens	30-40
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	18-27	mitogen-activated protein kinase 8	Homo sapiens	50-75
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	18-27	mitogen-activated protein kinase 8	Homo sapiens	109-113
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	18-27	mitogen-activated protein kinase 9	Homo sapiens	114-118
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	18-27	caspase 3	Homo sapiens	153-158
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	202-211	mitogen-activated protein kinase 8	Homo sapiens	50-75
9533766-5	1998	2DG inhibited the etoposide-induced activation of c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and the subsequent activation of CPP32, both of which are positive regulators for etoposide-induced apoptosis of U937 cells.	Etoposide	202-211	caspase 3	Homo sapiens	153-158
9506540-3	1998	When p53 was expressed at sublethal levels, it sensitized cells to the DNA-damaging drugs Adriamycin, mitomycin C, actinomycin D, etoposide (VP16), cisplatin and CPT11.	Etoposide	130-139	tumor protein p53	Homo sapiens	5-8
9506540-3	1998	When p53 was expressed at sublethal levels, it sensitized cells to the DNA-damaging drugs Adriamycin, mitomycin C, actinomycin D, etoposide (VP16), cisplatin and CPT11.	Etoposide	141-145	tumor protein p53	Homo sapiens	5-8
9473236-5	1998	Exposure of the control AML HL-60 cells to high-dose Ara-C (HIDAC), etoposide, or sphingoid bases (including C2 ceramide, sphingosine, or sphinganine) caused the accumulation of cyt c in the cytosol, loss of mitochondrial membrane potential (MMP), and increase in the reactive oxygen species (ROS).	Etoposide	68-77	cytochrome c, somatic	Homo sapiens	178-183
9660938-2	1998	We report that activation of the two transcription factors NF-kappa B and AP-1 is crucially involved in FasL expression induced by etoposide, teniposide, and UV irradiation.	Etoposide	131-140	nuclear factor kappa B subunit 1	Homo sapiens	59-69
9660938-2	1998	We report that activation of the two transcription factors NF-kappa B and AP-1 is crucially involved in FasL expression induced by etoposide, teniposide, and UV irradiation.	Etoposide	131-140	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-78
9660938-2	1998	We report that activation of the two transcription factors NF-kappa B and AP-1 is crucially involved in FasL expression induced by etoposide, teniposide, and UV irradiation.	Etoposide	131-140	Fas ligand	Homo sapiens	104-108
9569054-1	1998	The new regimens developed over the last few years have led to an improvement in the treatment of advanced gastric cancer, and our previous experience confirmed the fact that the combination of etoposide, doxorubicin and cisplatin (EAP regimen) is an active treatment that leads to interesting complete remission rates.	Etoposide	194-203	glutamyl aminopeptidase	Homo sapiens	232-235
9563896-0	1998	Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.	Etoposide	44-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	114-120
9570993-2	1998	cisplatin (CDDP) and etoposide (VP-16) as consolidation therapy following pathologically negative second-look surgical reassessment for Stage IIC-IV epithelial ovarian cancer (EOC).	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
9552027-1	1998	PURPOSE: To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide, and cisplatin (VIP) as primary treatment of men with advanced, disseminated germ cell tumors.	Etoposide	113-122	vasoactive intestinal peptide	Homo sapiens	151-154
9569020-2	1998	Treatment of Ph-positive K562, TOM 1 and KCL-22 cells with etoposide for 2d induced cytosolic vacuolation, but not nuclear condensation or DNA fragmentation.	Etoposide	59-68	target of myb1 membrane trafficking protein	Homo sapiens	31-36
9569020-3	1998	The bcr/abl kinase-selective inhibitor herbimycin A increased the induction of nuclear apoptosis by etoposide or gamma-radiation.	Etoposide	100-109	BCR activator of RhoGEF and GTPase	Homo sapiens	4-7
9504636-3	1998	Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P&lt;0.05) with high MDR1 expression being associated with high drug resistance towards these drugs.	Etoposide	37-41	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
9504636-3	1998	Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P&lt;0.05) with high MDR1 expression being associated with high drug resistance towards these drugs.	Etoposide	37-41	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
9472114-0	1998	Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.	Etoposide	63-72	ATP binding cassette subfamily C member 3	Homo sapiens	113-152
9454737-5	1998	Etoposide caused a great increase in NF-(kappa)B binding activity, which was not prevented by forskolin plus theophylline, while AP-1 binding was little affected by the topoisomerase inhibitor.	Etoposide	0-9	nuclear factor kappa B subunit 1	Homo sapiens	37-48
9454737-7	1998	By contrast, the expression of c-myc, which was very high in untreated U-937 cells and only partially inhibited by etoposide, was rapidly and almost totally abolished by the cAMP increasing agents.	Etoposide	115-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
9454737-8	1998	Finally, it was observed that etoposide caused a transient dephosphorylation of retinoblastoma (Rb), which was associated with cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	30-39	RB transcriptional corepressor 1	Homo sapiens	96-98
9454737-8	1998	Finally, it was observed that etoposide caused a transient dephosphorylation of retinoblastoma (Rb), which was associated with cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	30-39	poly(ADP-ribose) polymerase 1	Homo sapiens	139-166
9454737-8	1998	Finally, it was observed that etoposide caused a transient dephosphorylation of retinoblastoma (Rb), which was associated with cleavage of poly(ADP-ribose) polymerase (PARP).	Etoposide	30-39	poly(ADP-ribose) polymerase 1	Homo sapiens	168-172
9495810-8	1998	Consistent with the lysate protease activity, an intracellular marker of caspase activation, poly-ADP ribose polymerase (PARP), was cleaved in a concentration- and time-dependent manner after etoposide-treatment.	Etoposide	192-201	poly(ADP-ribose) polymerase 1	Homo sapiens	93-119
9495810-8	1998	Consistent with the lysate protease activity, an intracellular marker of caspase activation, poly-ADP ribose polymerase (PARP), was cleaved in a concentration- and time-dependent manner after etoposide-treatment.	Etoposide	192-201	poly(ADP-ribose) polymerase 1	Homo sapiens	121-125
9495807-1	1998	Epipodophyllotoxin derivatives, such as etoposide (VP-16), constitute an important class of anticancer agents, the major cytotoxic effects of which are associated with trapping of the topoisomerase II/DNA cleavable complex and formation of protein-DNA cross-links and nicked DNA.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
9660918-5	1998	When overexpressed in mammalian cells, BI-1 suppressed apoptosis included by Bax, etoposide, staurosporine, and growth factor deprivation, but not by Fas (CD95).	Etoposide	82-91	transmembrane BAX inhibitor motif containing 6	Homo sapiens	39-43
9485377-5	1998	These epitope-tagged MRP variants were expressed in HeLa cells to evaluate their ability to confer resistance to the drug etoposide (VP-16).	Etoposide	122-131	ATP binding cassette subfamily C member 1	Homo sapiens	21-24
9485377-5	1998	These epitope-tagged MRP variants were expressed in HeLa cells to evaluate their ability to confer resistance to the drug etoposide (VP-16).	Etoposide	133-138	ATP binding cassette subfamily C member 1	Homo sapiens	21-24
9485038-5	1998	In particular, IGF-II-deficient betaTCs are more sensitive to apoptotic stimuli, such as serum deprivation and staurosporine, and to chemotherapeutic agents, such as daunomycin, etoposide, or vincristine.	Etoposide	178-187	insulin-like growth factor 2	Mus musculus	15-21
9506459-4	1998	Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs.	Etoposide	86-95	interferon beta 1	Homo sapiens	39-47
9507384-1	1998	We previously have exposed U-937 human leukemia cells to stepwise increased concentrations of the anticancer drug etoposide, and this treatment has resulted in stable sublines (termed U-937/RE) exhibiting various extents of resistance to the drug and constitutively expressing c-fms mRNA, a specific marker of monocytic differentiation.	Etoposide	114-123	colony stimulating factor 1 receptor	Homo sapiens	277-282
9485370-2	1998	Although MRP has been identified as an organic anion transporter and Pgp as a transporter of certain positively charged compounds, there is considerable overlap in resistance spectrum, suggesting that both proteins transport important anticancer agents such as doxorubicin, etoposide, and vincristine.	Etoposide	274-283	ATP binding cassette subfamily C member 1	Homo sapiens	9-12
9485370-2	1998	Although MRP has been identified as an organic anion transporter and Pgp as a transporter of certain positively charged compounds, there is considerable overlap in resistance spectrum, suggesting that both proteins transport important anticancer agents such as doxorubicin, etoposide, and vincristine.	Etoposide	274-283	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
9602861-7	1998	In line with a genotoxic mechanism and absence of additional cytotoxic effects, the DNA fragments generated by gamma-irradiation as well as by etoposide and melphalan displayed a distribution between 1 and 4 Mbp with a peak around 2 Mbp.	Etoposide	143-152	myelin basic protein	Homo sapiens	208-211
9602861-7	1998	In line with a genotoxic mechanism and absence of additional cytotoxic effects, the DNA fragments generated by gamma-irradiation as well as by etoposide and melphalan displayed a distribution between 1 and 4 Mbp with a peak around 2 Mbp.	Etoposide	143-152	myelin basic protein	Homo sapiens	233-236
9485009-3	1998	The carbamoylating decomposite, 2-chloroethyl-isocyanate (6-25 microM), also decreased ETO-induced apoptosis in HT58 cells in vitro and their caspase 3-like activity ex vivo, whereas N-(2-chloroethyl)-N-nitrosocarbamoyl-valinamide, an alkylating and mainly intramolecularly carbamoylating nitrosourea derivative (400 microM), did not influence these phenomena.	Etoposide	87-90	caspase 3	Homo sapiens	142-151
9457818-7	1998	etoposide 100 mg/m2/day x 3 days alternating with intravenous cyclophosphamide 1000 mg/m2/day, intravenous doxorubicin 15 mg/m2, and intravenous vincristine 2 mg (CAV) to a total of six cycles every 3 weeks.	Etoposide	0-9	caveolin 2	Homo sapiens	163-166
9535210-5	1998	In addition, preliminary results of a Hoosier Oncology Group phase II study of cisplatin/ifosfamide/etoposide (VIP) in combination with thoracic radiotherapy in patients with limited disease indicate that VIP has an acceptable toxicity profile and should be studied further.	Etoposide	100-109	vasoactive intestinal peptide	Homo sapiens	111-114
9535210-5	1998	In addition, preliminary results of a Hoosier Oncology Group phase II study of cisplatin/ifosfamide/etoposide (VIP) in combination with thoracic radiotherapy in patients with limited disease indicate that VIP has an acceptable toxicity profile and should be studied further.	Etoposide	100-109	vasoactive intestinal peptide	Homo sapiens	205-208
9448741-5	1998	In addition, herbimycin A prevented etoposide-induced NF-kappa B activation.	Etoposide	36-45	nuclear factor kappa B subunit 1	Homo sapiens	54-64
9508359-0	1998	Sister chromatid exchanges and DNA topoisomerase II inhibitors: effect of low concentrations of etoposide (VP-16) in ataxia telangiectasia lymphoblastoid cell lines.	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
9457070-5	1998	Incubation of NIH 3T3 cells with bFGF prior to etoposide or 5-fluorouracil treatment caused a proportionally smaller decrease in colony forming efficiency as a result of drug treatment, while preincubation of MCF-7 cells with bFGF caused a similar but opposite additive increase in drug-induced diminution of colony forming efficiency.	Etoposide	47-56	fibroblast growth factor 2	Mus musculus	33-37
9457070-9	1998	Basic FGF promoted apoptosis and increased the rate of drug-induced cell death with both etoposide and 5-fluorouracil.	Etoposide	89-98	fibroblast growth factor 2	Homo sapiens	6-9
9508359-1	1998	The correlation between etoposide (VP-16) cytotoxicity and the induction of sister chromatid exchanges (SCEs) suggested that the promotion of DNA recombination events may be crucial for the activity of antitopoisomerase drugs.	Etoposide	24-33	host cell factor C1	Homo sapiens	35-40
9434158-5	1998	Detection of topoisomerase II cleavages was strongly dependent upon one specific topoisomerase II poison, etoposide (VP-16).	Etoposide	106-115	host cell factor C1	Homo sapiens	117-122
14646514-0	1998	The anti-cancer drug etoposide can induce caspase-8 processing and apoptosis in the absence of CD95 receptor-ligand interaction.	Etoposide	21-30	caspase 8	Homo sapiens	42-51
14517454-3	1998	NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	0-9
14517454-3	1998	NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	257-266
14517454-3	1998	NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	257-266
14517454-3	1998	NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	257-266
14517454-5	1998	Co-administration of NF-kappaB antisense oligonucleotides inhibited the angiogenesis by doxorubicin and etoposide.	Etoposide	104-113	nuclear factor kappa B subunit 1	Homo sapiens	21-30
14646514-2	1998	We find that, in Jurkat T cells, the DNA damaging anti-cancer drug etoposide induces apoptosis and, surprisingly, processing of caspase-8.	Etoposide	67-76	caspase 8	Homo sapiens	128-137
14646514-3	1998	Therefore, we have investigated whether etoposide involves CD95 receptor activation.	Etoposide	40-49	Fas cell surface death receptor	Homo sapiens	59-63
14646514-6	1998	Apparently, in Jurkat cells, etoposide can induce caspase-8 processing and apoptosis in a CD95-independent fashion.	Etoposide	29-38	caspase 8	Homo sapiens	50-59
14646514-6	1998	Apparently, in Jurkat cells, etoposide can induce caspase-8 processing and apoptosis in a CD95-independent fashion.	Etoposide	29-38	Fas cell surface death receptor	Homo sapiens	90-94
14646514-7	1998	Likewise, we find that thymocytes from the CD95-deficient lpr/lpr mouse strain readily undergo apoptosis in response to etoposide.	Etoposide	120-129	Fas (TNF receptor superfamily member 6)	Mus musculus	43-47
14646514-7	1998	Likewise, we find that thymocytes from the CD95-deficient lpr/lpr mouse strain readily undergo apoptosis in response to etoposide.	Etoposide	120-129	Fas (TNF receptor superfamily member 6)	Mus musculus	58-61
14646514-7	1998	Likewise, we find that thymocytes from the CD95-deficient lpr/lpr mouse strain readily undergo apoptosis in response to etoposide.	Etoposide	120-129	Fas (TNF receptor superfamily member 6)	Mus musculus	62-65
9744779-3	1998	PURPOSE AND METHODS: To develop empiric treatment regimens of combinations and sequences of agents directed against topoisomerase I (irinotecan/CPT-11) and II (etoposide and doxorubicin), in vivo studies were performed in mice bearing the EMT-6 mammary tumor to assess efficacy, host tolerance and the resultant biochemical changes in topoisomerase mRNA and protein.	Etoposide	160-169	carnitine palmitoyltransferase 2	Mus musculus	144-158
9554589-3	1998	Stable expression of Bcl-2 in the human epithelial tumor (HeLa) cell line results in inhibition of apoptosis following exposure to the topoisomerase II poison, etoposide.	Etoposide	160-169	BCL2 apoptosis regulator	Homo sapiens	21-26
9554589-5	1998	PURPOSE: The purpose of this study was to further investigate the role of Bcl-2 in human epithelial tumor cell drug resistance using 5-fluoro-2"-deoxyuridine, staurosporine, and doxorubicin, in addition to etoposide.	Etoposide	206-215	BCL2 apoptosis regulator	Homo sapiens	74-79
9554589-8	1998	RESULTS: Despite profound inhibition to loss of plasma membrane integrity for all agents tested, Bcl-2 was only able to significantly increase clonogenic survival following exposure to 5-fluoro-2"-deoxyuridine and staurosporine, but not following exposure to etoposide or doxorubicin.	Etoposide	259-268	BCL2 apoptosis regulator	Homo sapiens	97-102
9852210-0	1998	Bcl-2- and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis.	Etoposide	92-101	BCL2 apoptosis regulator	Homo sapiens	0-5
9852210-5	1998	Here, we report that expression of the Bcl-2 oncoprotein, an inhibitor of caspases (interleukin 1 -converting enzyme-like proteases), blocked RB dephosphorylation, RB cleavage and apoptosis in etoposide-treated human Jurkat T cells.	Etoposide	193-202	BCL2 apoptosis regulator	Homo sapiens	39-44
9700723-3	1998	Their reversal effect against acquired resistance to VCR, DXR, and etoposide (VP16) was partial but clearly observed in the cell line expressing MRP (KB/VP4).	Etoposide	67-76	ATP binding cassette subfamily C member 3	Homo sapiens	145-148
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Etoposide	173-182	ATP binding cassette subfamily C member 1	Homo sapiens	4-32
9443942-1	1998	The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide.	Etoposide	173-182	ATP binding cassette subfamily C member 1	Homo sapiens	34-37
9700723-3	1998	Their reversal effect against acquired resistance to VCR, DXR, and etoposide (VP16) was partial but clearly observed in the cell line expressing MRP (KB/VP4).	Etoposide	78-82	ATP binding cassette subfamily C member 3	Homo sapiens	145-148
12073232-17	1998	The addition of etoposide as a third drug has yielded prostate-specific antigen (PSA)-response rates of &gt; 50%, but data on quality of life and survival time have not been reported for these combinations.	Etoposide	16-25	kallikrein related peptidase 3	Homo sapiens	54-86
9432038-0	1997	A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.	Etoposide	132-141	C-C motif chemokine ligand 3	Homo sapiens	60-98
9388194-4	1997	Here we demonstrate that when the human TPx II, a member of this family, is stably overexpressed in Molt-4 leukemia cells, it protects from apoptosis induced by serum deprivation, ceramide, or etoposide.	Etoposide	193-202	thyroid peroxidase	Homo sapiens	40-43
9395460-0	1997	Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.	Etoposide	149-158	protein kinase C alpha	Homo sapiens	14-22
9395460-6	1997	Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKCalpha activity during apoptosis in HL60 cells.	Etoposide	23-32	host cell factor C1	Homo sapiens	34-39
9395460-6	1997	Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKCalpha activity during apoptosis in HL60 cells.	Etoposide	23-32	protein kinase C alpha	Homo sapiens	64-72
9373239-9	1997	Collectively, these results suggest that a delay in the signaling cascade upstream of cytochrome c release and caspase activation leads to a long latent period before the active phase of apoptosis is initiated in etoposide-treated K562 cells.	Etoposide	213-222	cytochrome c, somatic	Homo sapiens	86-98
9422071-0	1997	[Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].	Etoposide	65-74	DNA topoisomerase II beta	Homo sapiens	15-55
9393740-5	1997	In the two MRP double knockout clones, the intracellular steady-state concentration of etoposide was twofold greater than that in wild-type cells.	Etoposide	87-96	ATP binding cassette subfamily C member 1	Homo sapiens	11-14
9393741-0	1997	Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.	Etoposide	99-108	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	25-28
9393741-0	1997	Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.	Etoposide	99-108	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	30-58
9393741-0	1997	Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.	Etoposide	110-115	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	25-28
9393741-0	1997	Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.	Etoposide	110-115	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	30-58
9371507-2	1997	For etoposide (VP-16), increased expression of MDR-1 or MRP and alterations in topoisomerase IIalpha have been shown to confer tolerance.	Etoposide	4-13	host cell factor C1	Homo sapiens	15-20
9505216-8	1997	Three out of six clinical failures were also negative for Pgp immunostaining one of which exhibited sinergistic effect between ETO and CSA.	Etoposide	127-130	phosphoglycolate phosphatase	Homo sapiens	58-61
9371511-1	1997	We have shown previously that NAD/poly(ADP-ribose) polymerase-deficient cells that overexpress Mr 78,000 glucose-regulated stress protein (GRP78) are resistant to topoisomerase II inhibitors, such as etoposide, m-amsacrine, and doxorubicin.	Etoposide	200-209	poly [ADP-ribose] polymerase 1	Cricetulus griseus	34-61
9371511-1	1997	We have shown previously that NAD/poly(ADP-ribose) polymerase-deficient cells that overexpress Mr 78,000 glucose-regulated stress protein (GRP78) are resistant to topoisomerase II inhibitors, such as etoposide, m-amsacrine, and doxorubicin.	Etoposide	200-209	endoplasmic reticulum chaperone BiP	Cricetulus griseus	139-144
9494534-8	1997	Levels of p53 mRNA decreased with increasing resistance to vindesine, etoposide and fotemustine.	Etoposide	70-79	tumor protein p53	Homo sapiens	10-13
9359490-0	1997	Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells.	Etoposide	59-68	Fas (TNF receptor superfamily member 6)	Mus musculus	100-104
9494534-9	1997	Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin.	Etoposide	78-87	BCL2 apoptosis regulator	Homo sapiens	14-19
9494534-9	1997	Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin.	Etoposide	78-87	BCL2 associated X, apoptosis regulator	Homo sapiens	36-39
9494534-9	1997	Expression of bcl-2 family members (bax, bcl-x) was modulated by fotemustine, etoposide and cisplatin.	Etoposide	78-87	BCL2 like 1	Homo sapiens	41-46
9362454-5	1997	Bak wt or Bak deltaBH3 were also able to abrogate the protective effect of Bcl-2 in cells expressing Bcl-2 and Bak wt or Bak deltaBH3 when challenged by etoposide or fluorouracil.	Etoposide	153-162	B cell leukemia/lymphoma 2	Mus musculus	75-80
9470808-1	1997	Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
9363869-4	1997	All patients received three cycles of doxorubicin, cyclophosphamide, and etoposide (ACE).	Etoposide	73-82	angiotensin I converting enzyme	Homo sapiens	84-87
9343394-6	1997	Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner.	Etoposide	105-114	tumor protein p53	Homo sapiens	38-41
9343394-6	1997	Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner.	Etoposide	105-114	tumor protein p53	Homo sapiens	92-95
9343394-6	1997	Treatment of U2-OS cells, a wild-type p53-containing osteogenic sarcoma line, with a common p53 inducer, etoposide, induced p53 DNA binding and transactivation activities in a time-dependent manner.	Etoposide	105-114	tumor protein p53	Homo sapiens	92-95
9377550-1	1997	The human small cell lung cancer NCI-H69 cell line selected for resistance to etoposide (H69/VP) has been reported previously to sequentially overexpress both the MRP and MDR1 multidrug resistance-conferring genes.	Etoposide	78-87	ATP binding cassette subfamily C member 1	Homo sapiens	163-166
9377550-1	1997	The human small cell lung cancer NCI-H69 cell line selected for resistance to etoposide (H69/VP) has been reported previously to sequentially overexpress both the MRP and MDR1 multidrug resistance-conferring genes.	Etoposide	78-87	ATP binding cassette subfamily B member 1	Homo sapiens	171-175
9351548-10	1997	Group C was comprised of 2 patients with bone and visceral disease who were treated with etoposide (VP-16) + HDMP; at last follow-up, 1 patient was in CCR at 42+ months and the other patient, who had isolated vulvar recurrence 16 months later, was in CR with treatment with local IFN.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
9359705-7	1997	Moreover, the mrp-/- mice are hypersensitive to the anticancer drug etoposide.	Etoposide	68-77	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	14-17
9378983-5	1997	IGF-I and IGF-II (but not basic fibroblast growth factor) were also able to protect cells from apoptosis induced by etoposide or cycloheximide.	Etoposide	116-125	insulin like growth factor 1	Homo sapiens	0-5
9378983-5	1997	IGF-I and IGF-II (but not basic fibroblast growth factor) were also able to protect cells from apoptosis induced by etoposide or cycloheximide.	Etoposide	116-125	insulin like growth factor 2	Homo sapiens	10-16
9362454-4	1997	In FL5.12 cells expressing Bcl-XL and Bak wt or Bak deltaBH3, both Bak wt or Bak deltaBH3 were able to antagonize the protective effect of Bcl-XL when treated with etoposide or fluorouracil.	Etoposide	164-173	BCL2-like 1	Mus musculus	27-33
9362454-4	1997	In FL5.12 cells expressing Bcl-XL and Bak wt or Bak deltaBH3, both Bak wt or Bak deltaBH3 were able to antagonize the protective effect of Bcl-XL when treated with etoposide or fluorouracil.	Etoposide	164-173	BCL2-like 1	Mus musculus	139-145
9815561-5	1997	Loss of either hMSH2 or hMLH1 function was associated with low level resistance to cisplatin, carboplatin, and etoposide, but there was no resistance to melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel.	Etoposide	111-120	mutS homolog 2	Homo sapiens	15-20
9345336-2	1997	They are commonly used in combination with etoposide (VP-16) in chemotherapeutic regimens.	Etoposide	43-52	host cell factor C1	Homo sapiens	54-59
9331091-7	1997	This work demonstrates that topoisomerase II beta is a pharmacological target for 9-OH-ellipticine, etoposide, or 4"-(9-acridinylamino)methanesulfon-m-anisidide and plays a role in the cytotoxicity of these agents.	Etoposide	100-109	DNA topoisomerase II beta	Homo sapiens	28-49
9331103-3	1997	We have investigated the induction of mutation following etoposide treatment in vivo using the hypoxanthine phosphoribosyltransferase (hprt) T-cell cloning assay in small cell lung cancer patients receiving single-drug etoposide chemotherapy.	Etoposide	57-66	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	95-133
9331103-3	1997	We have investigated the induction of mutation following etoposide treatment in vivo using the hypoxanthine phosphoribosyltransferase (hprt) T-cell cloning assay in small cell lung cancer patients receiving single-drug etoposide chemotherapy.	Etoposide	57-66	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	135-139
9349497-3	1997	Treatment with VP16 induced significantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells.	Etoposide	15-19	Rous sarcoma oncogene	Mus musculus	103-106
9349497-3	1997	Treatment with VP16 induced significantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells.	Etoposide	15-19	zinc fingers and homeoboxes 2	Mus musculus	115-118
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Etoposide	180-189	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9353133-1	1997	The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM).	Etoposide	180-189	ATP binding cassette subfamily B member 1	Homo sapiens	92-96
14555975-6	1997	Z-Asp, an inhibitor of interleukin-1beta converting enzyme (ICE) family proteases, inhibited the appearance of the 50 kDa protein and the emergence of the cell-free apoptosis activity in the etoposide-treated U937 cytosol.	Etoposide	191-200	caspase 1	Homo sapiens	23-58
14555975-6	1997	Z-Asp, an inhibitor of interleukin-1beta converting enzyme (ICE) family proteases, inhibited the appearance of the 50 kDa protein and the emergence of the cell-free apoptosis activity in the etoposide-treated U937 cytosol.	Etoposide	191-200	caspase 1	Homo sapiens	60-63
9815561-5	1997	Loss of either hMSH2 or hMLH1 function was associated with low level resistance to cisplatin, carboplatin, and etoposide, but there was no resistance to melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel.	Etoposide	111-120	mutL homolog 1	Homo sapiens	24-29
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Etoposide	123-132	ATP binding cassette subfamily C member 3	Homo sapiens	44-47
9369914-1	1997	A combination of etoposide and cisplatin (EP) is the current standard chemotherapy for small-cell lung cancer (SCLC).	Etoposide	17-26	SCLC1	Homo sapiens	111-115
9390699-1	1997	Chronic oral VP-16 (Etoposide) is a chemotherapy regimen with wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi sarcoma, and glial brain tumors.	Etoposide	20-29	host cell factor C1	Homo sapiens	13-18
9350240-0	1997	[Expression of ATP binding cassette superfamily (multidrug resistance-1, multidrug resistance-associated protein, human canalicular multispecific organ anion transporter) mRNA in etoposide and m-AMSA resistant cell lines].	Etoposide	179-188	ATP binding cassette subfamily B member 1	Homo sapiens	49-112
9350240-5	1997	Increased MRP mRNA was observed in 48.5% of resistant cell lines (64.7% of etoposide resistant cells and 31.3% of m-AMSA resistant cell lines).	Etoposide	75-84	ATP binding cassette subfamily C member 1	Homo sapiens	10-13
9350240-6	1997	Increased C-MOAT mRNA was also observed in 39.4% of resistant cell lines (41.2% in etoposide resistant cell lines and 37.5% in m-AMSA resistant cell lines).	Etoposide	83-92	ATP binding cassette subfamily C member 2	Homo sapiens	10-16
9401275-3	1997	A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy.	Etoposide	144-153	colony stimulating factor 3	Homo sapiens	94-99
9334814-9	1997	Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected.	Etoposide	123-132	host cell factor C1	Homo sapiens	134-139
9334825-0	1997	Increased MRP expression is associated with resistance to radiation, anthracyclines and etoposide in cells treated with fractionated gamma-radiation.	Etoposide	88-97	ATP binding cassette subfamily C member 3	Homo sapiens	10-13
9413163-4	1997	These agents had little effect on in vitro L1210 DNA topoisomerase II activity at 100 microM but were able to cause synergistic increases in protein-linked DNA breaks when combined with etoposide (VP16).	Etoposide	186-195	host cell factor C1	Homo sapiens	197-201
9427795-0	1997	A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study.	Etoposide	19-28	colony stimulating factor 3	Homo sapiens	64-101
21528231-4	1997	This was also observed with lung cancer, the sensitivity of which to MMC, CDDP, vindesine (VDS) and etoposide (VP-16) was similar to the clinical efficacy.	Etoposide	100-109	host cell factor C1	Homo sapiens	111-116
9331985-0	1997	Breaks in double-strand DNA by Cu(II) complexes of etoposide (VP-16) and its derivatives, as evaluated by S1 nuclease treatment.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
9413193-4	1997	Clear correlations between the MRP gene level and the sensitivity to etoposide (VP-16) and doxorubicin (Dox) were observed except for one cell line which highly expressed DNA topoisomerase II.	Etoposide	69-78	ATP binding cassette subfamily C member 3	Homo sapiens	31-34
9413193-4	1997	Clear correlations between the MRP gene level and the sensitivity to etoposide (VP-16) and doxorubicin (Dox) were observed except for one cell line which highly expressed DNA topoisomerase II.	Etoposide	69-78	host cell factor C1	Homo sapiens	80-85
9446257-4	1997	GM-CSF at the conventional dose of 5 micrograms/kg was utilized to increase the etoposide dose to 900 mg/m2 in a chemotherapy program including also carboplatin and ifosfamide in patients with small cell lung cancer.	Etoposide	80-89	colony stimulating factor 2	Homo sapiens	0-6
9815838-13	1997	Sequential IL-3/G-CSF given prior to and following high-dose etoposide and cyclophosphamide is safe and is a feasible strategy to compare in prospective randomized trials to patients treated with only postchemotherapy IL-3 and G-CSF and to patients treated with peripheral blood stem cell support.	Etoposide	61-70	interleukin 3	Homo sapiens	11-15
9815838-13	1997	Sequential IL-3/G-CSF given prior to and following high-dose etoposide and cyclophosphamide is safe and is a feasible strategy to compare in prospective randomized trials to patients treated with only postchemotherapy IL-3 and G-CSF and to patients treated with peripheral blood stem cell support.	Etoposide	61-70	colony stimulating factor 3	Homo sapiens	16-21
9308634-10	1997	CONCLUSION: A regimen of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor led to the successful collection of adequate numbers of CD34+ cells in most patients without excessive toxicity.	Etoposide	43-52	CD34 molecule	Homo sapiens	152-156
9316641-15	1997	Altogether, these findings show that drug-resistant, Fas(+)-expressing PC-3 and DU145 prostate tumor cells can be sensitized by CDDP and VP-16 to killing by Fas-L-bearing CTL, TIL, and LAK cells.	Etoposide	137-142	Fas ligand	Homo sapiens	157-162
9281370-4	1997	The increase in Mcl-1 protein levels correlates with a reduced extent of apoptotic cell death induced by etoposide or the calcium ionophore A23187.	Etoposide	105-114	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	16-21
9281370-5	1997	The Mcl-1 protein is primarily localized in the mitochondria, and etoposide- or A23187-induced cytochrome c release is reduced in cells in which the mitochondria contain the Mcl-1 protein demonstrable by immunoblots.	Etoposide	66-75	cytochrome c, somatic	Homo sapiens	95-107
9281370-5	1997	The Mcl-1 protein is primarily localized in the mitochondria, and etoposide- or A23187-induced cytochrome c release is reduced in cells in which the mitochondria contain the Mcl-1 protein demonstrable by immunoblots.	Etoposide	66-75	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	174-179
9266822-0	1997	Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).	Etoposide	111-120	host cell factor C1	Homo sapiens	122-127
9364868-0	1997	[Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor].	Etoposide	115-124	colony stimulating factor 3	Homo sapiens	130-167
9266822-1	1997	Etoposide (VP-16) is a widely used anticancer drug whose toxicity involves poisoning of topoisomerase II.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
9242521-4	1997	Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1.	Etoposide	116-125	caspase 3	Homo sapiens	229-238
9264404-8	1997	However, treating the parental U937 cells with antisense oligonucleotides designed to reduce c-Myc expression rendered the cells resistant to etoposide-induced as well as to TNF-alpha-induced apoptosis.	Etoposide	142-151	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	93-98
9264404-9	1997	These results indicate that the reduced expression of c-Myc in UC is strongly associated with the resistance to etoposide-induced apoptosis.	Etoposide	112-121	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	54-59
9242554-3	1997	Using four M-phase specific chemotherapeutic agents, Bcl-XL and Bcl-2 provided similar protection against vincristine and vinblastine whereas Bcl-XL afforded as much as 50% greater cell viability than Bcl-2 against etoposide and teniposide-induced cell death.	Etoposide	215-224	BCL2-like 1	Mus musculus	53-59
9242521-4	1997	Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1.	Etoposide	116-125	caspase 7	Homo sapiens	243-252
9242521-4	1997	Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1.	Etoposide	116-125	poly(ADP-ribose) polymerase 1	Homo sapiens	295-322
9242521-4	1997	Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1.	Etoposide	116-125	poly(ADP-ribose) polymerase 1	Homo sapiens	324-328
9242521-4	1997	Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate-directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1.	Etoposide	116-125	lamin B1	Homo sapiens	334-342
9228015-4	1997	Pretreatment of intact Molt4 leukemia cells with micromolar concentrations of Zn2+ caused an inhibition of PARP proteolysis induced by the chemotherapeutic agent etoposide.	Etoposide	162-171	poly(ADP-ribose) polymerase 1	Homo sapiens	107-111
9639738-5	1997	RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression.	Etoposide	146-155	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
9639738-5	1997	RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression.	Etoposide	146-155	host cell factor C1	Homo sapiens	157-162
16465270-2	1997	Exposure of L929 fibroblasts to tumor necrosis factor (TNF) or etoposide (VP-16) induced apoptotic death with similar kinetics.	Etoposide	63-72	host cell factor C1	Homo sapiens	74-79
9264562-0	1997	Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.	Etoposide	24-33	mucin 16, cell surface associated	Homo sapiens	43-49
9264562-1	1997	The effect of oral etoposide on CA-125 serum levels was evaluated in 17 patients with epithelial ovarian cancer and progressive disease during, or relapsing after, prior chemotherapy.	Etoposide	19-28	mucin 16, cell surface associated	Homo sapiens	32-38
9264562-14	1997	At the given dose schedule, oral etoposide shows activity in advanced ovarian cancer if the rate of change of CA-125 is used as a measure of activity.	Etoposide	33-42	mucin 16, cell surface associated	Homo sapiens	110-116
9311276-8	1997	In January 1996, following the conditioning regimen of nimustine hydrochloride, etoposide (VP-16), Ara-C, thiotepa, he received PBSCT.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-96
9199342-3	1997	We recently identified a unique site within the MLL bcr that is highly susceptible to DNA double-strand cleavage by classic topo II inhibitors (e.g., etoposide and doxorubicin).	Etoposide	150-159	lysine methyltransferase 2A	Homo sapiens	48-51
9230211-2	1997	Abnormal activation of cyclin B-associated CDC 2 kinase has been implicated in apoptosis induced by cancer chemotherapeutic agents such as paclitaxel (Taxol) and etoposide (VP-16).	Etoposide	162-171	cyclin dependent kinase 1	Homo sapiens	43-48
9230211-2	1997	Abnormal activation of cyclin B-associated CDC 2 kinase has been implicated in apoptosis induced by cancer chemotherapeutic agents such as paclitaxel (Taxol) and etoposide (VP-16).	Etoposide	162-171	host cell factor C1	Homo sapiens	173-178
9329558-3	1997	These trials were extended to 2 sequential phase II investigations of WBH plus ifosfamide, carboplatin and etoposide (ICE) for refractory sarcoma patients.	Etoposide	107-116	carboxylesterase 2	Homo sapiens	118-121
9220975-5	1997	The drug-resistance profile of cells stably expressing each mutated P-glycoprotein was investigated by comparing their relative resistance to vinblastine, colchicine, VP16, and adriamycin.	Etoposide	167-171	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
9201973-3	1997	In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation.	Etoposide	125-134	BCL2 apoptosis regulator	Homo sapiens	22-27
9201973-5	1997	Bcl-2 also prevented the etoposide-induced stimulation of MEKK1.	Etoposide	25-34	BCL2 apoptosis regulator	Homo sapiens	0-5
9201973-5	1997	Bcl-2 also prevented the etoposide-induced stimulation of MEKK1.	Etoposide	25-34	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	58-63
21528190-3	1997	We studied the relationship between immunohisto-chemical staining of GST-pi type and cisplatin + etoposide chemotherapy in patients with untreated primary non-small cell lung cancer (NSCLC).	Etoposide	97-106	glutathione S-transferase kappa 1	Homo sapiens	69-72
21528190-12	1997	The results suggest that GST-pi: expression in cancer tissues is related to response to cisplatin + etoposide chemotherapy in untreated primary NSCLC patients, and may be useful as a predictor of chemotherapy response.	Etoposide	100-109	glutathione S-transferase kappa 1	Homo sapiens	25-28
9241501-5	1997	From 1982 to 1986, patients received the BEP chemotherapy protocol which included cis-platinum, bleomycin and etoposide (VP 16).	Etoposide	110-119	host cell factor C1	Homo sapiens	121-126
9167751-0	1997	Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).	Etoposide	151-160	colony stimulating factor 3	Homo sapiens	32-69
9208127-14	1997	By extending the studies, we revealed a TPA-mediated p53 down-regulation in response to etoposide (50 microM), mitomycin C (5 micrograms ml-1) and actinomycin D (2 micrograms ml-1).	Etoposide	88-97	transformation related protein 53, pseudogene	Mus musculus	53-56
9153428-2	1997	It is also the target of several clinically important antineoplastic agents such as the epipodophyllotoxin, VP-16 (etoposide).	Etoposide	115-124	host cell factor C1	Homo sapiens	108-113
9491667-0	1997	Secondary ANLL with t(11;19)(q23;p13) following etoposide and cisplatin for ovarian germ cell tumor.	Etoposide	48-57	H3 histone pseudogene 6	Homo sapiens	33-36
9166762-1	1997	Topoisomerase II-targeted drugs, such as etoposide, "poison" this enzyme and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes.	Etoposide	41-50	Topoisomerase 2	Drosophila melanogaster	0-16
9166762-1	1997	Topoisomerase II-targeted drugs, such as etoposide, "poison" this enzyme and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes.	Etoposide	41-50	Topoisomerase 2	Drosophila melanogaster	121-137
9106647-1	1997	BACKGROUND: Oral etoposide is an active single agent in small-cell lung cancer (SCLC) and is widely prescribed as first-line treatment as an alternative to intravenous combination chemotherapy in patients with extensive disease.	Etoposide	17-26	SCLC1	Homo sapiens	80-84
9175720-4	1997	We report that preincubation of cells with TGF-beta3 for 24 hr resulted in enhanced clonogenicity following exposure to vinblastine, vincristine, etoposide, taxol, ara-C, methotrexate, or 5-FU.	Etoposide	146-155	transforming growth factor beta 3	Homo sapiens	43-52
9377855-1	1997	BACKGROUND: Carboplatin (CBDCA), cyclophosphamide (CTX) and etoposide (VP-16) combination chemotherapy is active in many tumors.	Etoposide	60-69	host cell factor C1	Homo sapiens	71-76
9170523-3	1997	During the past 6-year period, we have performed combination chemotherapy with cisplatin as the primary drug, peplomycin, and etoposide (CPE chemotherapy) as one of the chemotherapeutic regimens for oral cancer.	Etoposide	126-135	carboxypeptidase E	Homo sapiens	137-140
9155147-4	1997	We recently found that amino acid substitutions in the first predicted transmembrane domain of P-glycoprotein increase the ability to confer resistance to important anti-cancer drugs adriamycin and VP-16.	Etoposide	198-203	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
9144536-3	1997	In the present study, we searched a protein data base for potential death substrates possessing the CPP32 cleavage site, DEVD, and identified several candidates including RFC140, the large subunit of replication factor C, which we subsequently demonstrated to be specifically cleaved in a variety of cell types undergoing apoptosis in response to different cytotoxic agents, whereas no degradation is observed in a cell line resistant to etoposide-induced apoptosis.	Etoposide	438-447	caspase 3	Homo sapiens	100-105
9106647-18	1997	CONCLUSIONS: These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease.	Etoposide	67-76	SCLC1	Homo sapiens	146-150
9124184-1	1997	The aim of this study was to define the efficacy of a combination of cisplatin, 5-fluorouracil (5-FU), leucovorin, and etoposide (VP-16) in locally advanced or metastatic non-small-cell lung cancer (NSCLC).	Etoposide	119-128	host cell factor C1	Homo sapiens	130-135
9144536-3	1997	In the present study, we searched a protein data base for potential death substrates possessing the CPP32 cleavage site, DEVD, and identified several candidates including RFC140, the large subunit of replication factor C, which we subsequently demonstrated to be specifically cleaved in a variety of cell types undergoing apoptosis in response to different cytotoxic agents, whereas no degradation is observed in a cell line resistant to etoposide-induced apoptosis.	Etoposide	438-447	replication factor C subunit 1	Homo sapiens	171-177
9124193-2	1997	Carboplatin (CBDCA), etoposide (VP-16), and cyclophosphamide (CTX) combination therapy has proved activity against a wide variety of tumors.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
9193356-1	1997	PURPOSE: To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) are used.	Etoposide	153-162	host cell factor C1	Homo sapiens	164-169
9158184-4	1997	Substituting taxol for etoposide in etoposide, ifosfamide and cisplatin (VIP), followed by high dose, is one possibility.	Etoposide	23-32	vasoactive intestinal peptide	Homo sapiens	73-76
9158184-4	1997	Substituting taxol for etoposide in etoposide, ifosfamide and cisplatin (VIP), followed by high dose, is one possibility.	Etoposide	36-45	vasoactive intestinal peptide	Homo sapiens	73-76
9168451-4	1997	In this report a rare case of S-ALL with MLL-AF4 transcript is described in a 36 year old woman treated for breast carcinoma with chemotherapy which included the topoisomerase II inhibitor, VP-16.	Etoposide	190-195	AF4/FMR2 family member 1	Homo sapiens	45-48
9194475-2	1997	Cisplatin (CDDP), etoposide (VP-16), and mitomycin C (MMC) are well-known anticancer agents that are also active against many of these types of cancer.	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
9209367-5	1997	In 4 secondary APL patients after chemotherapy including etoposide against Langerhans cell histiocytosis, the b/p of the PML gene were located in intron 6, and those of the RARA gene were in a restricted region within intron 2, 1 kb EcoRI-BamHI fragment, while in an APL patient after chemotherapy without etoposide against breast cancer, the b/p of the PML and RARA genes were located in intron 6 and another region within intron 2, respectively.	Etoposide	57-66	PML nuclear body scaffold	Homo sapiens	121-124
9209367-5	1997	In 4 secondary APL patients after chemotherapy including etoposide against Langerhans cell histiocytosis, the b/p of the PML gene were located in intron 6, and those of the RARA gene were in a restricted region within intron 2, 1 kb EcoRI-BamHI fragment, while in an APL patient after chemotherapy without etoposide against breast cancer, the b/p of the PML and RARA genes were located in intron 6 and another region within intron 2, respectively.	Etoposide	306-315	PML nuclear body scaffold	Homo sapiens	121-124
9070648-3	1997	We previously showed that actin is cleaved in vitro by an ICE family protease, distinct from ICE itself, which is activated during VP-16-induced apoptosis.	Etoposide	131-136	caspase 1	Homo sapiens	58-61
9058728-3	1997	To study the mechanism of PS externalization during development of apoptosis, we examined the correlation between the activation of interleukin-1 beta-converting enzyme (ICE) family protease and PS externalization in human monocytic leukemia U937 cells and in their apoptosis-resistant variants, UK711 and UK110, after treatment with etoposide and anti-Fas antibody.	Etoposide	334-343	caspase 1	Homo sapiens	170-173
9058728-5	1997	Furthermore, inhibitors of ICE family proteases, Z-Asp and Z-VAD, prevented apoptosis and PS externalization in etoposide-treated U937 cells.	Etoposide	112-121	caspase 1	Homo sapiens	27-30
9054443-0	1997	Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis.	Etoposide	114-123	caspase 1	Homo sapiens	23-58
9054443-2	1997	In the present study, three complementary techniques were utilized to follow caspase activation during the course of etoposide-induced apoptosis in HL-60 human leukemia cells.	Etoposide	117-126	caspase 1	Homo sapiens	77-84
9054443-3	1997	Immunoblotting revealed that levels of procaspase-2 did not change during etoposide-induced apoptosis, whereas levels of procaspase-3 diminished markedly 2-3 h after etoposide addition.	Etoposide	166-175	caspase 3	Homo sapiens	121-133
9054443-9	1997	These results not only indicate that etoposide-induced apoptosis in HL-60 cells is accompanied by the selective activation of multiple caspases in cytosol and nuclei, but also suggest that other caspase precursors such as procaspase-2 are present but not activated during apoptosis.	Etoposide	37-46	caspase 1	Homo sapiens	135-143
9054443-9	1997	These results not only indicate that etoposide-induced apoptosis in HL-60 cells is accompanied by the selective activation of multiple caspases in cytosol and nuclei, but also suggest that other caspase precursors such as procaspase-2 are present but not activated during apoptosis.	Etoposide	37-46	caspase 1	Homo sapiens	135-142
9052763-1	1997	The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is &gt;9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated.	Etoposide	42-51	host cell factor C1	Homo sapiens	53-58
9096658-0	1997	Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans" cell histiocytosis in Italian and Austrian-German populations.	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
9096658-1	1997	To estimate the risk of secondary leukemias after treatment with etoposide (VP-16), we evaluated subjects treated for Langerhans" cell histiocytosis (LCH) according to cooperative protocols in Italy or in Austria, Germany, Holland and Switzerland (AGDS).	Etoposide	65-74	host cell factor C1	Homo sapiens	76-81
9096663-0	1997	Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.	Etoposide	183-192	ATP binding cassette subfamily C member 3	Homo sapiens	90-93
9115995-5	1997	NADPH quenched directly the EPR signal of phenoxyl radical of a phenolic antitumor drug, etoposide, in the absence of the OR.	Etoposide	89-98	2,4-dienoyl-CoA reductase 1	Homo sapiens	0-5
9115995-14	1997	Phenoxyl radicals with higher redox potential, e.g., phenoxyl radicals of etoposide, oxidize NADPH directly.	Etoposide	74-83	2,4-dienoyl-CoA reductase 1	Homo sapiens	93-98
9062121-4	1997	268, 14394-14398] indicated that the site of action for etoposide on topoisomerase II overlaps those of other DNA cleavage-enhancing drugs.	Etoposide	56-65	Topoisomerase 2	Drosophila melanogaster	69-85
9074631-3	1997	Preincubation of HL-60 cells with the hydrogen peroxide-scavenging enzyme catalase (500 U/ml) inhibited apoptosis due to UV irradiation or low concentrations of camptothecin, etoposide or melphalan, but did not protect against higher concentrations.	Etoposide	175-184	catalase	Homo sapiens	74-82
9070648-3	1997	We previously showed that actin is cleaved in vitro by an ICE family protease, distinct from ICE itself, which is activated during VP-16-induced apoptosis.	Etoposide	131-136	caspase 1	Homo sapiens	93-96
9070648-7	1997	Moreover, Benzyloxycarbonyl-Glu-Val-Asp-CH2OC(O)-2,6,-dichlorobenzene (Z-EVD-CH2-DCB), a selective inhibitor of CPP-32(-like) protease, efficiently inhibited the cleavage of actin and the apoptosis of VP-16-treated U937 cells.	Etoposide	201-206	caspase 3	Homo sapiens	112-118
9137422-1	1997	We studied the combination effect of cisplatin(CDDP) plus etoposide(VP-16) in an established gastric cancer cell line, KATO-III, and also highly purified fresh human tumor cells obtained from 55 gastric cancer patients, using MTT assay.	Etoposide	58-67	host cell factor C1	Homo sapiens	68-73
9095327-3	1997	In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol).	Etoposide	99-108	host cell factor C1	Homo sapiens	110-115
9032231-5	1997	E2F-1 overexpression in the myeloid cells preferentially sensitized cells to apoptosis when they were treated with the topoisomerase II inhibitor etoposide.	Etoposide	146-155	E2F transcription factor 1 L homeolog	Xenopus laevis	0-5
9181898-1	1997	For blood progenitor cell (BPC) mobilization, standard-dose VIP chemotherapy consisting of etoposide, ifosfamide and cisplatin has previously shown effective tumor reduction in solid tumor patients and sufficient progenitor cell mobilization for autologous blood cell transplantation.	Etoposide	91-100	vasoactive intestinal peptide	Homo sapiens	60-63
9041178-0	1997	Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: implications for gene therapy.	Etoposide	38-47	transformation related protein 53, pseudogene	Mus musculus	24-27
9041178-1	1997	We have evaluated the role of p53 in the induction of cell death by the DNA topoisomerase II inhibitor etoposide in M1 myeloid leukemia cells.	Etoposide	103-112	transformation related protein 53, pseudogene	Mus musculus	30-33
9041178-4	1997	Interestingly, the simultaneous induction of apoptosis by both pathways (wild-type p53 and etoposide) leads to suppression of the etoposide-induced G2 block.	Etoposide	130-139	transformation related protein 53, pseudogene	Mus musculus	83-86
9041178-9	1997	Taken together, our results indicate that wild-type p53 can override the etoposide-induced G2 block in at least some cell types.	Etoposide	73-82	transformation related protein 53, pseudogene	Mus musculus	52-55
9032231-6	1997	Although E2F-1 alone induces moderate levels of p53 and treatment with drugs markedly increased p53, the deleterious effects of etoposide in E2F-1-overexpressing cells were independent of p53 accumulation.	Etoposide	128-137	E2F transcription factor 1	Mus musculus	141-146
9032231-7	1997	Coexpression of Bcl-2 and E2F-1 in 32D.3 cells protected them from etoposide-mediated apoptosis.	Etoposide	67-76	B-cell CLL/lymphoma 2 S homeolog	Xenopus laevis	16-21
9032231-7	1997	Coexpression of Bcl-2 and E2F-1 in 32D.3 cells protected them from etoposide-mediated apoptosis.	Etoposide	67-76	E2F transcription factor 1 L homeolog	Xenopus laevis	26-31
9032231-9	1997	Pretreating E2F-1-expressing cells with ICRF-193, a second topoisomerase II inhibitor that does not damage DNA, protected the cells from etoposide-induced apoptosis.	Etoposide	137-146	E2F transcription factor 1	Mus musculus	12-17
9044846-0	1997	Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.	Etoposide	104-113	DNA damage inducible transcript 3	Homo sapiens	10-17
9044846-4	1997	We have investigated the relationships between gadd153 gene expression and apoptosis induction in four human leukemic cell lines with different sensitivities to apoptosis induced by etoposide (VP-16), a topoisomerase II inhibitor.	Etoposide	182-191	DNA damage inducible transcript 3	Homo sapiens	47-54
9044846-4	1997	We have investigated the relationships between gadd153 gene expression and apoptosis induction in four human leukemic cell lines with different sensitivities to apoptosis induced by etoposide (VP-16), a topoisomerase II inhibitor.	Etoposide	182-191	host cell factor C1	Homo sapiens	193-198
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-91
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	mitogen-activated protein kinase 8	Homo sapiens	145-149
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	mitogen-activated protein kinase 9	Homo sapiens	150-154
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	caspase 1	Homo sapiens	189-192
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	caspase 1	Homo sapiens	194-229
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Etoposide	36-45	intraflagellar transport 43	Homo sapiens	231-236
9020283-3	1997	The purpose of this phase I trial was to determine if granulocyte macrophage colony-stimulating factor (GM-CSF) support allows the dosage of the combination of etoposide and carboplatin to be increased above the previously determined MTD.	Etoposide	160-169	colony stimulating factor 2	Homo sapiens	54-102
9020283-3	1997	The purpose of this phase I trial was to determine if granulocyte macrophage colony-stimulating factor (GM-CSF) support allows the dosage of the combination of etoposide and carboplatin to be increased above the previously determined MTD.	Etoposide	160-169	colony stimulating factor 2	Homo sapiens	104-110
9020283-7	1997	With 5 microg/kg/d GM-CSF, the first etoposide and carboplatin cycle of 300 and 150 mg/m2/day x 3, respectively, could be administered with acceptable toxicity.	Etoposide	37-46	colony stimulating factor 2	Homo sapiens	19-25
9020283-9	1997	These results demonstrate that GM-CSF alone has limited capability to support the repeated administration of high doses of etoposide and carboplatin.	Etoposide	123-132	colony stimulating factor 2	Homo sapiens	31-37
9050135-4	1997	Combination of EMP with either vinblastine, paclitaxel or etoposide has produced antitumor responses in 30% to 60% of patients with metastatic hormone-refractory prostate carcinoma as determined by reduction in bidimensionally measurable soft tissue disease, pain, and serum prostate-specific antigen.	Etoposide	58-67	kallikrein related peptidase 3	Homo sapiens	275-300
9073310-4	1997	VX-710 at 0.5-5 microM restored senstivity of MRP-expressing HL60/ADR promyelocytic leukemia cells to the cytotoxic action of doxorubicin, etoposide and vincristine.	Etoposide	139-148	ATP binding cassette subfamily C member 1	Homo sapiens	46-49
9073312-0	1997	Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress.	Etoposide	15-24	host cell factor C1	Homo sapiens	26-31
9040934-7	1997	Levels of p53 protein and the kappa chain sterile transcript increased after exposure of pre-B cells to the DNA damaging agents etoposide and Adriamycin.	Etoposide	128-137	transformation related protein 53, pseudogene	Mus musculus	10-13
21533381-6	1997	Second, we studied the level of serum VEGF in 9 tumor patients during 4 courses of ICE-chemotherapy (ifosfamide, carboplatin, etoposide).	Etoposide	126-135	vascular endothelial growth factor A	Homo sapiens	38-42
14646555-4	1997	p53 and p21/waf1 protein levels were elevated in etoposide-treated cells, but not in cells subjected to serum with-drawal.	Etoposide	49-58	tumor protein p53	Homo sapiens	0-3
9030742-6	1997	Buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, decreased the vincristine and etoposide resistance displayed by the MRP-expressing murine cell lines, but did not affect the accumulation of BCECF.	Etoposide	99-108	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	137-140
9003796-3	1997	Here we demonstrate that vanadate-induced trapping of 8-azido-ATP in MRP was stimulated in the presence of glutathione, oxidized glutathione and the anti-cancer drugs VP-16 and vincristine.	Etoposide	167-172	ATP binding cassette subfamily C member 3	Homo sapiens	69-72
9002967-6	1997	The introduced Mcl-1 gene was found to cause a prolongation of viability under various conditions that cause apoptotic cell death, including exposure to cytotoxic agents (the chemotherapeutic drug etoposide, calcium ionophore, or UV irradiation) and the withdrawal of required growth factors.	Etoposide	197-206	myeloid cell leukemia sequence 1	Mus musculus	15-20
14646555-4	1997	p53 and p21/waf1 protein levels were elevated in etoposide-treated cells, but not in cells subjected to serum with-drawal.	Etoposide	49-58	cyclin dependent kinase inhibitor 1A	Homo sapiens	8-11
14646555-4	1997	p53 and p21/waf1 protein levels were elevated in etoposide-treated cells, but not in cells subjected to serum with-drawal.	Etoposide	49-58	cyclin dependent kinase inhibitor 1A	Homo sapiens	12-16
14646555-7	1997	Serum withdrawal-induced apoptosis was correlated with activation of JNK and suppression of ERK activities, while both JNK and ERK activities were slightly elevated during etoposid- induced apoptosis.	Etoposide	172-180	mitogen-activated protein kinase 8	Homo sapiens	119-122
14646555-7	1997	Serum withdrawal-induced apoptosis was correlated with activation of JNK and suppression of ERK activities, while both JNK and ERK activities were slightly elevated during etoposid- induced apoptosis.	Etoposide	172-180	mitogen-activated protein kinase 1	Homo sapiens	127-130
9493967-6	1997	We have found that in etoposide-treated cells, PARP protein is processed, but the nature of the cleavage is not known.	Etoposide	22-31	Poly-(ADP-ribose) polymerase	Drosophila melanogaster	47-51
9493968-3	1997	PARP is cleaved into two fragments of 29 and 85 kDa (apparent molecular mass) in human promyelomonocytic leukemia cells, HL-60, treated with etoposide to induce apoptosis.	Etoposide	141-150	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
9400948-1	1997	We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer.	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
9400949-16	1997	The recommended dose for use in phase II clinical trials is topotecan 1.0 mg m-2 on days 1-5 and etoposide 40 mg bid on days 6-12 every 4 weeks.	Etoposide	97-106	BH3 interacting domain death agonist	Homo sapiens	113-116
16465207-4	1997	Using PARP proteolysis as an indicator of the activation of the PARP protease, we find that the chemotherapeutic agent, etoposide, induces apoptosis and PARP proteolysis in Molt4 cells as early as 4 h with cell death lagging behind this event.	Etoposide	120-129	collagen type XI alpha 2 chain	Homo sapiens	6-10
9010037-4	1997	Low-level expression of mdr1 and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells.	Etoposide	164-169	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	24-28
9054953-8	1997	Etoposide-induced apoptosis, and its potentiation by staurosporine, were associated with reduced c-myc expression, and a moderate increase in p21WAF1/CIP1 mRNA and protein levels.	Etoposide	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	97-102
9054953-8	1997	Etoposide-induced apoptosis, and its potentiation by staurosporine, were associated with reduced c-myc expression, and a moderate increase in p21WAF1/CIP1 mRNA and protein levels.	Etoposide	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	150-154
9054953-10	1997	The potentiation of etoposide-induced apoptosis by staurosprine was associated with a significant increase in cyclin A-dependent kinase activity.	Etoposide	20-29	cyclin A2	Homo sapiens	110-118
9272128-7	1997	Our studies of combinations of high-dose cyclosporin (CsA) or PSC 833 with etoposide, doxorubicin, or paclitaxel have produced data regarding the role of Pgp in the clinical pharmacology of these agents.	Etoposide	75-84	ATP binding cassette subfamily B member 1	Homo sapiens	154-157
9272134-11	1997	Our previous study indicated that expression of P-glycoprotein in ATL cells might be involved in resistance to chemotherapeutic agents, particularly doxorubicin, vincristine, and etoposide.	Etoposide	179-188	ATP binding cassette subfamily B member 1	Homo sapiens	48-62
16465207-4	1997	Using PARP proteolysis as an indicator of the activation of the PARP protease, we find that the chemotherapeutic agent, etoposide, induces apoptosis and PARP proteolysis in Molt4 cells as early as 4 h with cell death lagging behind this event.	Etoposide	120-129	collagen type XI alpha 2 chain	Homo sapiens	64-68
16465207-4	1997	Using PARP proteolysis as an indicator of the activation of the PARP protease, we find that the chemotherapeutic agent, etoposide, induces apoptosis and PARP proteolysis in Molt4 cells as early as 4 h with cell death lagging behind this event.	Etoposide	120-129	collagen type XI alpha 2 chain	Homo sapiens	64-68
16465207-7	1997	Using this system with extracts from etoposide-treated cells and purified bovine PARP, we demonstrate that extracts from bcl-2 over-expressing cells cause little or no PARP proteolysis.	Etoposide	37-46	BCL2 apoptosis regulator	Bos taurus	121-126
9359032-3	1997	Etoposide-treated thymocytes were reacted in tissue culture medium with biotin-conjugated Annexin V, fixed with glutaraldehyde, and processed for resin embedding; thin sections were incubated with antibiotin antibodies coupled with colloidal gold.	Etoposide	0-9	annexin A5	Homo sapiens	90-99
9154130-1	1997	We investigated the effects of treatment of mitotic human fibroblasts with the topoisomerase II inhibitor etoposide (VP-16) on chromosome segregation at anaphase and the genetic consequence to daughter cells of topoisomerase inhibition during mitosis.	Etoposide	106-115	host cell factor C1	Homo sapiens	117-122
9547675-10	1997	CONCLUSIONS: In pretreated patients, the maximum tolerated dose of etoposide phosphate with G-CSF is 1938 mg/m2 (equivalent to etoposide 1700 mg/m2).	Etoposide	67-76	colony stimulating factor 3	Homo sapiens	92-97
9306430-3	1997	The results demonstrate that deletions in the C-motif of NBD1 or the A-motif of NBD2 have a pronounced effect in reducing resistance levels to adriamycin, vincristine, or etoposide (VP-16).	Etoposide	171-180	host cell factor C1	Homo sapiens	182-187
9046036-7	1997	The Ca2+ activated DNA fragmentation was significantly prevented by the presence of etoposide, genistein and amsacrine with the concentrations of 10(-5) and 10(-4) M in the reaction mixture, although ATA (10(-5) and 10(-4) M) had no effect.	Etoposide	84-93	carbonic anhydrase 2	Rattus norvegicus	4-7
9049828-5	1997	This could reduce the effectiveness of both cisplatin and etoposide (VP-16).	Etoposide	58-67	host cell factor C1	Homo sapiens	69-74
8972182-6	1997	Intriguingly, p38 activation by sorbitol and etoposide was resistant to YVAD-CMK and Z-VAD-FMK, suggesting the existence of an additional mechanism(s) of p38 regulation.	Etoposide	45-54	mitogen-activated protein kinase 14	Homo sapiens	14-17
8972182-6	1997	Intriguingly, p38 activation by sorbitol and etoposide was resistant to YVAD-CMK and Z-VAD-FMK, suggesting the existence of an additional mechanism(s) of p38 regulation.	Etoposide	45-54	cytidine/uridine monophosphate kinase 1	Homo sapiens	77-80
8972182-6	1997	Intriguingly, p38 activation by sorbitol and etoposide was resistant to YVAD-CMK and Z-VAD-FMK, suggesting the existence of an additional mechanism(s) of p38 regulation.	Etoposide	45-54	mitogen-activated protein kinase 14	Homo sapiens	154-157
9018084-0	1996	Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide.	Etoposide	119-128	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	0-28
9306577-0	1997	Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide.	Etoposide	76-85	BCL2 associated X, apoptosis regulator	Homo sapiens	18-21
9306577-3	1997	Sensitivity to cisplatin (CDDP) and etoposide (VP-16) was examined and each stable transfectant was more sensitive to these agents than the parental MCF-7 cells.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
11173634-2	1997	Previously, we have shown, that PMA pretreatment reduced etoposide-(ETO) but enhanced staurosporine- (STA) -induced apoptosis in HT58 cells.	Etoposide	57-67	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	68-71
8980142-5	1996	Furthermore, the etoposide-induced RB cleavage was inhibited by a specific tetrapeptide ICE-like inhibitor.	Etoposide	17-26	RB transcriptional corepressor 1	Homo sapiens	35-37
8961974-4	1996	METHODS: We used the frequency of V(D)J (variable-diversity-joining) recombinase-mediated deletions of exons 2 and 3 of the hypoxanthine phosphoribosyltransferase (HPRT) gene as a biomarker of etoposide-induced, nonhomologous, site-specific DNA rearrangement.	Etoposide	193-202	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	124-162
8961974-4	1996	METHODS: We used the frequency of V(D)J (variable-diversity-joining) recombinase-mediated deletions of exons 2 and 3 of the hypoxanthine phosphoribosyltransferase (HPRT) gene as a biomarker of etoposide-induced, nonhomologous, site-specific DNA rearrangement.	Etoposide	193-202	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	164-168
8943258-1	1996	Bax, a member of the Bcl-2 family of proteins, has been shown to accelerate apoptosis induced by growth factor withdrawal, gamma-irradiation, and the chemotherapeutic agent, etoposide.	Etoposide	174-183	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
8943258-1	1996	Bax, a member of the Bcl-2 family of proteins, has been shown to accelerate apoptosis induced by growth factor withdrawal, gamma-irradiation, and the chemotherapeutic agent, etoposide.	Etoposide	174-183	BCL2 apoptosis regulator	Homo sapiens	21-26
8980142-5	1996	Furthermore, the etoposide-induced RB cleavage was inhibited by a specific tetrapeptide ICE-like inhibitor.	Etoposide	17-26	caspase 1	Homo sapiens	88-91
8954078-2	1996	In this study we show that in the U937 monoblastic leukemia cell line, pretreatment with IFN-gamma enhanced sensitivity to apoptosis triggered by gamma-irradiation or antitumor agents (etoposide or adriamycin), as well as by anti-Fas antibody.	Etoposide	185-194	interferon gamma	Homo sapiens	89-98
8946866-12	1996	CONCLUSION: In 30 women with primary advanced ovarian cancer, G-CSF allowed a 50% dose escalation of etoposide and ifosfamide from 0.8 to 1.2 dose intensity.	Etoposide	101-110	colony stimulating factor 3	Homo sapiens	62-67
9037362-1	1996	PURPOSE: To identify the highest possible dose of cyclophosphamide (C) and etoposide (E) to be given with high-dose doxorubicin (D) and filgrastim (G-CSF) but without stem cell support in high-risk non-Hodgkin"s lymphoma.	Etoposide	75-84	colony stimulating factor 3	Homo sapiens	148-153
8980397-8	1996	Transfection of the TAP genes into TAP-deficient lymphoblastoid T2 cells conferred mild resistance to etoposide, vincristine and doxorubicin (2- to 2.5-fold).	Etoposide	102-111	USO1 vesicle transport factor	Homo sapiens	20-23
8980397-8	1996	Transfection of the TAP genes into TAP-deficient lymphoblastoid T2 cells conferred mild resistance to etoposide, vincristine and doxorubicin (2- to 2.5-fold).	Etoposide	102-111	USO1 vesicle transport factor	Homo sapiens	35-38
8980397-9	1996	Furthermore, etoposide and vincristine inhibited TAP-dependent peptide translocation to the endoplasmic reticulum.	Etoposide	13-22	USO1 vesicle transport factor	Homo sapiens	49-52
8978799-0	1996	[Etoposide (VP-16) in gynecologic malignancy].	Etoposide	1-10	host cell factor C1	Homo sapiens	12-17
8978799-1	1996	Clinical application of etoposide (VP-16) for gynecologic malignancy has been investigated in trophoblastic disease, ovarian, endometrial and cervical cancer.	Etoposide	24-33	host cell factor C1	Homo sapiens	35-40
8944692-6	1996	Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin.	Etoposide	27-36	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	89-103
9045962-9	1996	However, verapamil significantly increased the sensitivity to etoposide, doxorubicin and vincristine in cells highly expressing MRP gene.	Etoposide	62-71	ATP binding cassette subfamily C member 3	Homo sapiens	128-131
9152970-12	1996	GM-CSF toxicity was the following, first dose reaction-one patient, local erythema-two patients, arthralgia-one patient, hypotension, chills, fever requiring GM-CSF discontinuation one patient RDI of cisplatin/etoposide was 0.77/0.62 in GM-CSF group, and 0.90/ 0.80 in patients who didn"t receive Leucomax.	Etoposide	210-219	colony stimulating factor 2	Homo sapiens	0-6
8996576-8	1996	The provider"s average cost per patient for treating an SCLC patient for six cycles in US dollars is $26,764.48 for etoposide versus $26,026.70 for etoposide phosphate.	Etoposide	116-125	SCLC1	Homo sapiens	56-60
8996576-12	1996	Based on these results, etoposide phosphate is a superior pharmacoeconomic alternative compared with standard etoposide chemotherapy in managing SCLC.	Etoposide	24-33	SCLC1	Homo sapiens	145-149
8940082-4	1996	Treatment with vinblastine or etoposide (VP-16) also activated JNK, with maximum increases of 6.5- and 4.3-fold, respectively.	Etoposide	30-39	host cell factor C1	Homo sapiens	41-46
8940082-4	1996	Treatment with vinblastine or etoposide (VP-16) also activated JNK, with maximum increases of 6.5- and 4.3-fold, respectively.	Etoposide	30-39	mitogen-activated protein kinase 8	Homo sapiens	63-66
8950990-1	1996	Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide.	Etoposide	298-303	envoplakin	Mus musculus	44-48
8950990-1	1996	Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide.	Etoposide	304-313	envoplakin	Mus musculus	44-48
8903480-5	1996	Sensitivity of the test samples to the anti-cancer drugs cisplatin (CDDP), doxorubicin (DXR) and etoposide (VP-16) was examined using the MTT?3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl [2H]-tetrazolium bromide?	Etoposide	97-106	host cell factor C1	Homo sapiens	108-113
9042212-0	1996	Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.	Etoposide	74-83	ATP binding cassette subfamily B member 1	Homo sapiens	29-32
8932337-1	1996	Etoposide (VP-16) is an anti-cancer drug commonly used against several types of tumours and leukaemia, either alone or in combination chemotherapy.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
9042238-4	1996	Our results indicate that protracted VP-16 treatment of 1. cells induces, within 24 hours, the arrest of DNA synthesis, repression of growth-related genes and transient induction of the tTG gene.	Etoposide	37-42	transglutaminase 2, C polypeptide	Mus musculus	186-189
8930400-7	1996	A modest decrease in PKC activity was also observed in etoposide-resistant H69 (H69/VP-16) cells but not in Taxol-resistant H69 cells or bleomycin-resistant human head and neck carcinoma A-253 cells.	Etoposide	55-64	proline rich transmembrane protein 2	Homo sapiens	21-24
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Etoposide	96-105	nuclear factor kappa B subunit 1	Homo sapiens	121-130
8912565-0	1996	A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha.	Etoposide	71-80	interleukin 1 alpha	Homo sapiens	130-149
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Etoposide	96-105	nuclear factor kappa B subunit 1	Homo sapiens	132-137
8960144-6	1996	Mitoxantrone, cytarabine and etoposide given with GM-CSF gave a complete response rate and median survival similar to other combination treatments but there was no definite evidence that the duration of neutropenia was reduced by the addition of GM-CSF from the start of treatment.	Etoposide	29-38	colony stimulating factor 2	Homo sapiens	50-56
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Etoposide	96-105	RELA proto-oncogene, NF-kB subunit	Homo sapiens	138-142
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Etoposide	96-105	acyl-CoA thioesterase 1	Homo sapiens	153-158
8940736-8	1996	He then received chemotherapy consisting of ifosfamide (2 g/m2) and etoposide (VP-16) (100 mg/m2) given daily for 3 days every 3 weeks.	Etoposide	68-77	host cell factor C1	Homo sapiens	79-84
8940736-11	1996	Ifosfamide and etoposide (VP-16), known for their usefulness in treatment of adult soft tissue sarcomas, can be used as salvage chemotherapy for patients with MFH who fail the front-line conventional chemotherapy.	Etoposide	15-24	host cell factor C1	Homo sapiens	26-31
8932379-7	1996	In ACH-2 cells latently infected by HIV-1, camptothecin, daunomycin and etoposide are able to enhance virus production.	Etoposide	72-81	acyl-CoA thioesterase 1	Homo sapiens	3-8
8840993-12	1996	High Bcl-2 and Bcl-xL levels in these cells also inhibited Yama protease activity, PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone.	Etoposide	160-169	BCL2 apoptosis regulator	Homo sapiens	5-10
8895510-2	1996	Exposure of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed expression of cyclin B1 mRNA during the G2 arrest.	Etoposide	40-49	cyclin B1	Homo sapiens	123-132
8895510-5	1996	However, with camptothecin or etoposide treatment, while the accumulation of cyclin B1 protein was delayed, its levels eventually surpassed peak levels seen in control cells, in spite of the fact that cells were still blocked in G2.	Etoposide	30-39	cyclin B1	Homo sapiens	77-86
8960661-3	1996	He developed AML (M4) in February 1993 after long-term treatment with oral etoposide (total dose 14,650 mg) t(9; 11) (p21; q23) with rearrangement of MLL genes was recognized.	Etoposide	75-84	H3 histone pseudogene 16	Homo sapiens	118-121
8960661-3	1996	He developed AML (M4) in February 1993 after long-term treatment with oral etoposide (total dose 14,650 mg) t(9; 11) (p21; q23) with rearrangement of MLL genes was recognized.	Etoposide	75-84	lysine methyltransferase 2A	Homo sapiens	150-153
8840993-13	1996	These results suggest that the activation of the Yama protease and PARP degradation are involved in Ara-C-, etoposide-, or mitoxantrone-induced apoptosis.	Etoposide	108-117	caspase 3	Homo sapiens	49-53
8840993-13	1996	These results suggest that the activation of the Yama protease and PARP degradation are involved in Ara-C-, etoposide-, or mitoxantrone-induced apoptosis.	Etoposide	108-117	poly(ADP-ribose) polymerase 1	Homo sapiens	67-71
8840993-12	1996	High Bcl-2 and Bcl-xL levels in these cells also inhibited Yama protease activity, PARP degradation, and apoptosis due to clinically relevant concentrations of etoposide and mitoxantrone.	Etoposide	160-169	BCL2 like 1	Homo sapiens	15-21
8913519-0	1996	Increased deoxycytidine kinase activity by etoposide in L1210 murine leukemic cells.	Etoposide	43-52	deoxycytidine kinase	Mus musculus	10-30
8875976-7	1996	Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C. These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus.	Etoposide	45-54	tumor protein p53	Homo sapiens	265-268
8913519-3	1996	We examined the effect of etoposide on dCK in L1210 cells and found that incubation with 10 microM etoposide for 1 h increased dCK activity to 170% of the control.	Etoposide	99-108	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	39-42
8896444-1	1996	We investigated the role of proteases in the pathway that leads from specific DNA damage induced by etoposide (VP-16), a topoisomerase II inhibitor, to apoptotic DNA fragmentation in the U937 human leukemic cell line.	Etoposide	100-109	host cell factor C1	Homo sapiens	111-116
8870683-5	1996	Following a 2 h dexamethasone treatment, H-topo II mRNA expression, protein production, etoposide-induced DNA-protein complex formation and sensitivity to etoposide were increased in HBT20-hTOP2MAM cells compared with control HBT20-MAM cells and with HBT20-hTOP2MAM cells not treated with dexamethasone.	Etoposide	88-97	sarcoglycan gamma	Homo sapiens	194-197
8870683-5	1996	Following a 2 h dexamethasone treatment, H-topo II mRNA expression, protein production, etoposide-induced DNA-protein complex formation and sensitivity to etoposide were increased in HBT20-hTOP2MAM cells compared with control HBT20-MAM cells and with HBT20-hTOP2MAM cells not treated with dexamethasone.	Etoposide	155-164	sarcoglycan gamma	Homo sapiens	194-197
8913519-3	1996	We examined the effect of etoposide on dCK in L1210 cells and found that incubation with 10 microM etoposide for 1 h increased dCK activity to 170% of the control.	Etoposide	99-108	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	127-130
8913519-4	1996	This effect of etoposide on dCK activity was concentration-dependent up to at least 100 microM of the substance.	Etoposide	15-24	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	28-31
8913519-3	1996	We examined the effect of etoposide on dCK in L1210 cells and found that incubation with 10 microM etoposide for 1 h increased dCK activity to 170% of the control.	Etoposide	26-35	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	39-42
8913519-3	1996	We examined the effect of etoposide on dCK in L1210 cells and found that incubation with 10 microM etoposide for 1 h increased dCK activity to 170% of the control.	Etoposide	26-35	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	127-130
8858979-4	1996	TNF endogenously secreted by human ovarian cancer cell lines is very efficient in potentiating the activity of DNA topoisomerase II inhibitors (doxorubicin, mitoxantrone, VP16).	Etoposide	171-175	tumor necrosis factor	Homo sapiens	0-3
8883415-4	1996	The mdm2 gene, in addition, conferred the resistance of U87-MG cells to the apoptotic cell death induced by etoposide (VP-16) or doxorubicin.	Etoposide	108-117	MDM2 proto-oncogene	Homo sapiens	4-8
8883415-4	1996	The mdm2 gene, in addition, conferred the resistance of U87-MG cells to the apoptotic cell death induced by etoposide (VP-16) or doxorubicin.	Etoposide	119-124	MDM2 proto-oncogene	Homo sapiens	4-8
8813151-8	1996	IGF-IR abundance correlated in a graded fashion with resistance to PCD in response to three different death-inducing paradigms: mitogen withdrawal, hyperosmolar metabolic stress, and treatment with etoposide.	Etoposide	198-207	insulin like growth factor 1 receptor	Homo sapiens	0-6
8898177-0	1996	A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.	Etoposide	35-44	host cell factor C1	Homo sapiens	46-51
8814162-8	1996	When PCV had been given any time previously, only four (19%) of 21 patients responded to salvage chemotherapy; however, four (40%) of 10 patients who received etoposide (VP-16)/cisplatin (CDDP) responded.	Etoposide	159-168	host cell factor C1	Homo sapiens	170-175
8950479-5	1996	In vitro studies with a bladder carcinoma cell line containing a wild type p53 showed that it underwent a G1 checkpoint after etoposide, potentially allowing DNA damage repair, as well as apoptosis.	Etoposide	126-135	tumor protein p53	Homo sapiens	75-78
8913281-0	1996	Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.	Etoposide	79-88	colony stimulating factor 2	Homo sapiens	0-48
8913281-0	1996	Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.	Etoposide	79-88	colony stimulating factor 2	Homo sapiens	50-56
8822941-3	1996	Because etoposide-associated AML is characterized by site-specific illegitimate DNA recombination, we studied whether etoposide could directly cause site-specific deletions of exons 2 and 3 in the hprt gene.	Etoposide	118-127	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	197-201
8797583-3	1996	Etoposide-induced DNA breakage was inhibited by culturing TDECs on gelatin, type IV collagen, laminin, fibronectin, and the integrin ligand hexapeptide, GRGDSP, but not the inactive peptide, GRADSP.	Etoposide	0-9	fibronectin 1	Mus musculus	103-114
8913076-6	1996	After three courses of chemotherapy, consisting of cisplatin, etoposide and bleomycin, the tumor became smaller and the serum AFP level became normal.	Etoposide	62-71	alpha fetoprotein	Homo sapiens	126-129
8798452-0	1996	Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL.	Etoposide	33-42	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
8798452-0	1996	Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL.	Etoposide	33-42	BCL2 like 1	Homo sapiens	19-25
8921272-3	1996	When cerebellar neurons from 15- to 16-day postnatal wild-type mice were treated with ionizing radiation or DNA-damaging agents, massive neuron death occurred after 24-72 h. In contrast, neurons from p53-/- mice evidently resisted gamma-irradiation and some DNA-damaging agents, such as etoposide and bleomycin.	Etoposide	287-296	transformation related protein 53, pseudogene	Mus musculus	200-203
8899175-0	1996	The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease.	Etoposide	42-51	carboxylesterase 2	Homo sapiens	4-7
8781438-0	1996	Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.	Etoposide	94-103	BCL2 apoptosis regulator	Homo sapiens	26-31
8781438-3	1996	Doxorubicin, etoposide, and hydrogen peroxide consistently induced a concentration- and time-dependent upregulation of BCL-2 expression in all myeloma target cell types assayed by flow cytometry and Western blot analysis.	Etoposide	13-22	BCL2 apoptosis regulator	Homo sapiens	119-124
8781438-9	1996	In addition, BCL-2-transfected IM-9 cells, with enhanced expression of BCL-2 which was comparable to that achieved by initial exposure to doxorubicin, were resistant to doxorubicin and etoposide cytotoxicity.	Etoposide	185-194	BCL2 apoptosis regulator	Homo sapiens	13-18
8752171-0	1996	Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival.	Etoposide	31-40	BCL2 apoptosis regulator	Homo sapiens	79-84
8752171-1	1996	The Bcl-2 oncoprotein, which is expressed in a variety of human malignancies, blocks apoptosis induced by chemotherapeutic drugs, including the topoisomerase II inhibitor, etoposide.	Etoposide	172-181	BCL2 apoptosis regulator	Homo sapiens	4-9
8752171-3	1996	In agreement with previous studies, Bcl-2 inhibited loss of cell viability (by trypan blue exclusion), the appearance of morphologically apoptotic cells, and the amount of low molecular weight DNA extracted after etoposide exposure (25 microns, 4 h).	Etoposide	213-222	BCL2 apoptosis regulator	Homo sapiens	36-41
8752171-6	1996	Although Bcl-2 inhibited etoposide-induced apoptosis, it had no effect on the formation of giant, multinucleated cells characteristic of mitotic catastrophe.	Etoposide	25-34	BCL2 apoptosis regulator	Homo sapiens	9-14
8882989-1	1996	A Phase I/II study of combination chemotherapy with cisplatin (CDDP), carboplatin (CBDCA) and etoposide (VP-16) (CPVP) was conducted in patients with small cell lung cancer.	Etoposide	94-103	host cell factor C1	Homo sapiens	105-110
8759037-0	1996	Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.	Etoposide	75-84	regenerating family member 1 alpha	Homo sapiens	62-66
8794901-7	1996	CD34+ cells treated with etoposide (40 microM) or hydroquinone (50 microM) for 18 hr were stained and subjected to fluorescent microscopy as above.	Etoposide	25-34	CD34 molecule	Homo sapiens	0-4
8759037-1	1996	Etoposide (VP-16)-resistant K562 cells (K/VP.5) were 26-fold resistant to VP-16, due in part to a reduction in DNA topoisomerase II (topoisomerase II) protein levels.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8759037-1	1996	Etoposide (VP-16)-resistant K562 cells (K/VP.5) were 26-fold resistant to VP-16, due in part to a reduction in DNA topoisomerase II (topoisomerase II) protein levels.	Etoposide	0-9	host cell factor C1	Homo sapiens	74-79
8759037-0	1996	Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.	Etoposide	75-84	host cell factor C1	Homo sapiens	86-91
8663484-2	1996	Apoptosis in human ML-1 cells induced by etoposide is characterized by intracellular acidification, enhanced Hoechst 33342 fluorescence, DNA digestion, chromatin condensation, and proteolysis of poly(ADP-ribose) polymerase.	Etoposide	41-50	poly(ADP-ribose) polymerase 1	Homo sapiens	195-222
8827879-3	1996	The plasma pharmacokinetics of adriamycin (ADR) and etoposide (VP-16) were investigated in these patients.	Etoposide	52-61	host cell factor C1	Homo sapiens	63-68
8663611-4	1996	In U937 cells, both PI 3-kinase inhibitors (wortmannin and LY294002) and etoposide activated the CPP32 apoptotic protease by cleavage to active p17 subunits.	Etoposide	73-82	caspase 3	Homo sapiens	97-102
8663611-4	1996	In U937 cells, both PI 3-kinase inhibitors (wortmannin and LY294002) and etoposide activated the CPP32 apoptotic protease by cleavage to active p17 subunits.	Etoposide	73-82	family with sequence similarity 72 member B	Homo sapiens	144-147
8700130-2	1996	HL-60 cells selected in 0.05 micrograms/ml doxorubicin (DOX) are 10-fold and &gt; 20-fold resistant to DOX and etoposide (VP-16), respectively.	Etoposide	111-120	host cell factor C1	Homo sapiens	122-127
8663611-6	1996	Furthermore, overexpression of Bcl-xL blocked DNA fragmentation, CPP32 activation and cleavage of poly(ADP-ribose) polymerase in U937 cells treated with both PI 3-kinase inhibitors and etoposide, but not in cells treated with TNFalpha.	Etoposide	185-194	BCL2 like 1	Homo sapiens	31-37
8839908-3	1996	The purpose of this study was to investigate the possibility of increased responses and survival with use of the combination of cisplatin, ifosfamide, etoposide (VIP-16) in comparison to the combination of cisplatin, ifosfamide, vinblastine (VIP) in non-operable NSCLC.	Etoposide	151-160	vasoactive intestinal peptide	Homo sapiens	162-165
8673994-3	1996	Conversely, several studies on gastric carcinoma have demonstrated that the combination of etoposide (VP-16), leucovorin (LV), and 5-FU (ELF) is efficacious and moderately toxic.	Etoposide	91-100	host cell factor C1	Homo sapiens	102-107
8839908-3	1996	The purpose of this study was to investigate the possibility of increased responses and survival with use of the combination of cisplatin, ifosfamide, etoposide (VIP-16) in comparison to the combination of cisplatin, ifosfamide, vinblastine (VIP) in non-operable NSCLC.	Etoposide	151-160	vasoactive intestinal peptide	Homo sapiens	242-245
8877478-1	1996	We investigated the modification of etoposide (i.e. VP-16)-induced cell killing by hyperthermia in a radioresistant human melanoma (Sk-Mel-3) and a human normal (AG1522) cell line.	Etoposide	36-45	host cell factor C1	Homo sapiens	52-57
8706243-3	1996	Sublines that were resistant to melphalan, pyrazafurin, mitoxantrone, etoposide and PALA all retained expression of wild-type p53.	Etoposide	70-79	tumor protein p53	Homo sapiens	126-129
8692539-2	1996	PENT at 0.5 and 1 mM enhanced the cytotoxicity of CDDP and ET on PC-14 and PC-9, respectively.	Etoposide	59-61	proprotein convertase subtilisin/kexin type 9	Homo sapiens	75-79
8673929-4	1996	In vitro investigations have shown intact p53 to play a critical role executing cell death in response to treatment with cytotoxic drugs like 5-fluorouracil, etoposide and doxorubicin.	Etoposide	158-167	tumor protein p53	Homo sapiens	42-45
8741673-3	1996	A serine protease inhibitor TPCK and an ICE-like protease inhibitor VAD-FMK prevented etoposide, camptothecin and ara-C-induced internucleosomal DNA cleavage in human myeloid leukemia HL-60 and U937 cells.	Etoposide	86-95	coagulation factor II, thrombin	Homo sapiens	2-17
8779771-2	1996	A serine protease inhibitor TPCK and an ICE-like protease inhibitor VAD-FMK prevented etoposide, camptothecin and ara-C-induced internucleosomal DNA cleavage.	Etoposide	86-95	coagulation factor II, thrombin	Homo sapiens	2-17
9000172-3	1996	We found that three topo II inhibitors, etoposide (VP-16), ICRF-193 and amsacrine (m-AMSA), greatly enhanced the frequency of G418r colonies.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
8779771-9	1996	These data indicate that serine and ICE-like proteases may be involved in etoposide-induced apoptosis at the different stages, and especially a serine protease may be closely associated with the final step for induction of DNA fragmentation during apoptosis in HL-60 cells.	Etoposide	74-83	coagulation factor II, thrombin	Homo sapiens	144-159
8647646-10	1996	In general, in cell lines, MRP gene expression was correlated with lower chemosensitivity to doxorubicin and etoposide, but not to cisplatin.	Etoposide	109-118	ATP binding cassette subfamily C member 3	Homo sapiens	27-30
8665518-2	1996	TOP-53 exhibited twice the inhibitory activity of etoposide (VP-16) against topoisomerase II and induced DNA strand breaks but showed no inhibitory activity against tubulin polymerization.	Etoposide	50-59	host cell factor C1	Homo sapiens	61-66
8826608-10	1996	GM-CSF coadministration (arm B) or premedication (arm C) with daily chronic oral etoposide was feasible and did not lead to excessive hematological toxicity.	Etoposide	81-90	colony stimulating factor 2	Homo sapiens	0-6
8678544-0	1996	[Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5"-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases].	Etoposide	44-53	host cell factor C1	Homo sapiens	55-60
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	92-101	colony stimulating factor 2	Homo sapiens	107-155
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	92-101	colony stimulating factor 2	Homo sapiens	157-163
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	92-101	colony stimulating factor 2	Homo sapiens	332-338
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	92-101	colony stimulating factor 2	Homo sapiens	332-338
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	290-299	colony stimulating factor 2	Homo sapiens	157-163
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	290-299	colony stimulating factor 2	Homo sapiens	157-163
8826608-1	1996	The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication.	Etoposide	290-299	colony stimulating factor 2	Homo sapiens	157-163
8643303-7	1996	Furthermore, epidermal growth factor-induced, topoisomerase II-mediated DNA strand breaks were additive to those induced by etoposide.	Etoposide	124-133	epidermal growth factor	Homo sapiens	13-36
8645582-0	1996	Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.	Etoposide	124-133	Topoisomerase 2	Drosophila melanogaster	39-55
8645582-2	1996	These studies were conducted to determine whether transfecting a Drosophila (D) topoisomerase II (topo II) gene into HBT20 cells could increase their sensitivity to etoposide.	Etoposide	165-174	Topoisomerase 2	Drosophila melanogaster	80-96
8645582-2	1996	These studies were conducted to determine whether transfecting a Drosophila (D) topoisomerase II (topo II) gene into HBT20 cells could increase their sensitivity to etoposide.	Etoposide	165-174	Topoisomerase 2	Drosophila melanogaster	98-105
8645582-8	1996	By contrast, D-topo II transfected cells were sensitised 3-fold when etoposide treatment was preceded by 24 h Dex stimulation.	Etoposide	69-78	Topoisomerase 2	Drosophila melanogaster	15-22
8645582-11	1996	Measurement of endogenous human topo-II mRNA and protein revealed a decrease after Dex exposure of greater than 24 h. At these distal times, the total cellular topo II levels (endogenous + exogenous) may be decreased, which may explain why increased sensitivity to etoposide could no longer be demonstrated.	Etoposide	265-274	Topoisomerase 2	Drosophila melanogaster	160-167
8645582-12	1996	This model suggests that D-topo II gene transfection can sensitise de novo resistant HBT20 cells to etoposide but that the time frame of that sensitisation is limited.	Etoposide	100-109	Topoisomerase 2	Drosophila melanogaster	27-34
8677446-6	1996	Maximum tolerated doses of the ICE regimen in these trials are 16 to 20.1 g/m2 ifosfamide, 1.8 g/m2 carboplatin, and 1.2 to 3.0 g/m2 etoposide.	Etoposide	133-142	carboxylesterase 2	Homo sapiens	31-34
8677443-2	1996	Etoposide/ifosfamide/cisplatin (VIP) has produced overall response rates of 74% to 100% with complete response rates of 27% to 64% in SCLC patients.	Etoposide	0-9	vasoactive intestinal peptide	Homo sapiens	32-35
8677454-2	1996	The ICE combination (ifosfamide/carboplatin [or cisplatin]/etoposide) has been studied in breast cancer, small cell and non-small cell lung cancer, testicular cancer, lymphoma, and other malignancies with promising results.	Etoposide	59-68	carboxylesterase 2	Homo sapiens	4-7
8711501-7	1996	Presently, this group is evaluating the role of chronic oral etoposide as maintenance chemotherapy for patients with extensive SCLC that responds to initial VIP treatment.	Etoposide	61-70	vasoactive intestinal peptide	Homo sapiens	157-160
9118302-6	1996	Actuarial five-year event-free survival (EFS) was similar in patients receiving fractionated total-body irradiation (FTBI) plus etoposide (VP-16) and cyclophosphamide (Cy) compared with chemotherapy alone consisting of carmustine (BCNU) plus identical doses of VP-16 and Cy (52% vs. 46%, p = 0.08).	Etoposide	128-137	host cell factor C1	Homo sapiens	139-144
8611717-4	1996	In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors.	Etoposide	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	253-258
9387262-1	1996	From August 1984 to August 1994 ninety-one caese of malignant lymphoma (NHL 84 casese, HD 7 cases) were treated with Etoposide (VP-16) combinationn chemotherapy.	Etoposide	117-126	host cell factor C1	Homo sapiens	128-133
8656677-0	1996	Role of serine and ICE-like proteases in induction of apoptosis by etoposide in human leukemia HL-60 cells.	Etoposide	67-76	caspase 1	Homo sapiens	19-22
8656677-8	1996	Our data indicate that serine and ICE-like proteases may be involved in etoposide-induced apoptosis at the different stages, and especially a serine protease may be closely associated with the final step for induction of internucleosomal DNA fragmentation during apoptosis in HL-60 cells.	Etoposide	72-81	caspase 1	Homo sapiens	34-37
8656677-8	1996	Our data indicate that serine and ICE-like proteases may be involved in etoposide-induced apoptosis at the different stages, and especially a serine protease may be closely associated with the final step for induction of internucleosomal DNA fragmentation during apoptosis in HL-60 cells.	Etoposide	72-81	coagulation factor II, thrombin	Homo sapiens	142-157
8611717-7	1996	The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwa/mdr-1 tumor-burdened mice by 129% compared with untreated controls.	Etoposide	59-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	119-124
8695747-9	1996	The expression of p330d/CENP-F and PCNA was also assessed in the growth inhibition of HT-29 cells induced by various concentrations of camptothecin (CPT), etoposide (VP-16), and aphidicolin (APH).	Etoposide	155-164	proliferating cell nuclear antigen	Homo sapiens	35-39
8620501-0	1996	Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio.	Etoposide	47-56	tumor protein p53	Homo sapiens	105-108
8620501-0	1996	Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio.	Etoposide	47-56	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
8620501-0	1996	Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio.	Etoposide	47-56	BCL2 apoptosis regulator	Homo sapiens	124-129
8620501-8	1996	First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment.	Etoposide	97-106	tumor protein p53	Homo sapiens	28-31
8620501-8	1996	First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment.	Etoposide	97-106	tumor protein p53	Homo sapiens	52-55
8620501-8	1996	First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment.	Etoposide	97-106	cyclin dependent kinase inhibitor 1A	Homo sapiens	71-76
8602625-2	1996	To increase the efficacy of bone marrow transplantation (BMT), we have tried to add etoposide (VP-16) to busulfan/cyclophosphamide (BU/CY).	Etoposide	84-93	host cell factor C1	Homo sapiens	95-100
8602629-0	1996	Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.	Etoposide	133-142	colony stimulating factor 2	Homo sapiens	39-87
8602629-1	1996	This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).	Etoposide	195-204	colony stimulating factor 2	Homo sapiens	98-146
8649819-0	1996	Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells.	Etoposide	61-70	etoposide induced 2.4 mRNA	Mus musculus	30-34
8626112-2	1996	Preliminary reports suggested the combination of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) was sufficiently effective to warrant larger trials.	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
8626125-0	1996	Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
8626125-1	1996	OBJECTIVE: The purpose of this study was to evaluate the efficacy of this three-drug regimen--hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16)--in patients with advanced or recurrent mixed mesodermal tumors (MMT) of the uterus who had not undergone previous chemotherapy.	Etoposide	131-140	host cell factor C1	Homo sapiens	142-147
8609902-1	1996	Previous structure-activity studies of the antitumor compound etoposide (VP-16) have suggested that replacement of the glycoside moiety could afford therapeutically active analogues with different biochemical determinants for cellular accumulation and drug resistance.	Etoposide	62-71	host cell factor C1	Homo sapiens	73-78
8649819-0	1996	Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells.	Etoposide	61-70	transformation related protein 53, pseudogene	Mus musculus	54-57
8649819-1	1996	To search for candidate genes involved in p53-mediated apoptosis, the differential display technique was used to identify RNA species whose expression was altered in murine NIH3T3 cells treated with the cytotoxic drug etoposide.	Etoposide	218-227	transformation related protein 53, pseudogene	Mus musculus	42-45
9816212-8	1996	Targeted loss of p53 protein in H460 lung cancer cells using HPV-16 E6 inhibited the etoposide-induced G1 checkpoint but did not decrease chemosensitivity.	Etoposide	85-94	tumor protein p53	Homo sapiens	17-20
8695266-0	1996	Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.	Etoposide	17-26	glutamyl aminopeptidase	Homo sapiens	55-58
8701487-0	1996	Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16).	Etoposide	105-114	host cell factor C1	Homo sapiens	116-121
8649819-2	1996	We report here the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment.	Etoposide	111-120	etoposide induced 2.4 mRNA	Mus musculus	53-57
8640766-8	1996	Those with mdr1 activation demonstrated a broad cross-resistance to vinblastine, doxorubicin, and etoposide, whereas the other 6 mutants were cross-resistant only to the Vinca alkaloids.	Etoposide	98-107	ATP binding cassette subfamily B member 1	Homo sapiens	11-15
8649819-3	1996	Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA.	Etoposide	26-35	etoposide induced 2.4 mRNA	Mus musculus	13-17
8649819-3	1996	Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA.	Etoposide	26-35	transformation related protein 53, pseudogene	Mus musculus	69-72
8649819-3	1996	Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA.	Etoposide	26-35	transformation related protein 53, pseudogene	Mus musculus	203-206
8649819-3	1996	Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA.	Etoposide	26-35	etoposide induced 2.4 mRNA	Mus musculus	265-269
8635136-3	1996	Oral etoposide (VP-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tumors, and lymphomas, A synergistic effect between etoposide and alkylating agents such as estramustine was recently reported.	Etoposide	5-14	host cell factor C1	Homo sapiens	16-21
8635136-3	1996	Oral etoposide (VP-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tumors, and lymphomas, A synergistic effect between etoposide and alkylating agents such as estramustine was recently reported.	Etoposide	167-176	host cell factor C1	Homo sapiens	16-21
8640763-4	1996	Compared to the low-p185(neu) expressing cell lines, we found that the high-p185(neu) expressing cell lines were more resistant to doxorubicin, etoposide, and cis-diamminedichloroplatinum(II) but more sensitive to AG825.	Etoposide	144-153	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	76-80
8640763-4	1996	Compared to the low-p185(neu) expressing cell lines, we found that the high-p185(neu) expressing cell lines were more resistant to doxorubicin, etoposide, and cis-diamminedichloroplatinum(II) but more sensitive to AG825.	Etoposide	144-153	erb-b2 receptor tyrosine kinase 2	Homo sapiens	81-84
8741246-1	1996	We report here a case of vasospastic angina following the administration of Carboplatin (CBDCA) and Etoposide (VP-16) in a patient with small cell lung carcinoma.	Etoposide	100-109	host cell factor C1	Homo sapiens	111-116
8613443-10	1996	Dose survival studies with use of a tetrazolium colorimetric assay showed that the MOS/ADR1 cells were cross-resistant to vincristine, vinblastine, etoposide, bleomycin, mitomycin C, and actinomycin D but not to dacarbazine, cisplatin, carboplatin, cytosine arabinoside, carmustine, cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil.	Etoposide	148-157	Moloney sarcoma oncogene	Mus musculus	83-86
9816174-10	1996	In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P &lt; 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P &lt; 0.05).	Etoposide	15-20	vasopressin	Sus scrofa	22-33
8550190-4	1996	We compared weights and tissue factor activities (TFA) of endocardial vegetations of normal rabbits infected with Streptococcus sanguis with those of rabbits which were treated with the cytostatic drug etoposide (Vepesid; Bristol-Myers Squibb B.V.) to induce a selective monocytopenia.	Etoposide	202-211	tissue factor	Oryctolagus cuniculus	24-37
20650183-0	1996	Reduction of phenoxyl radicals of the antitumour agent etoposide (VP-16) by glutathione and protein sulfhydryls in human leukaemia cells: Implications for cytotoxicity.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
8636749-0	1996	Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.	Etoposide	0-9	colony stimulating factor 2	Homo sapiens	59-62
8636749-2	1996	We prospectively studied 20 children during initial remission of ALL and 16 children at relapse to assess CSF penetration of etoposide.	Etoposide	125-134	colony stimulating factor 2	Homo sapiens	106-109
8636749-7	1996	The CSF etoposide concentration was &gt; or = 10 nmol/L in 20 of 20, five of 10, and two of 11 courses following 300 mg/m2 i.v., 50 mg/m2 orally, and 25 mg/m2 orally, respectively, and was positively related to both the concurrent etoposide plasma concentration (R2 = .64) and to dose (R2 = .73).	Etoposide	8-17	colony stimulating factor 2	Homo sapiens	4-7
8551665-0	1996	An early phase II study of etoposide (VP-16) in advanced gastric cancer.	Etoposide	27-36	host cell factor C1	Homo sapiens	38-43
8632756-2	1996	We found that etoposide (VP-16) induced apoptosis in human DU-145 prostatic carcinoma cells in a time- and concentration-dependent manner.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
8637714-6	1996	Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells.	Etoposide	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
8637714-6	1996	Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells.	Etoposide	70-79	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-143
8637714-6	1996	Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells.	Etoposide	81-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-139
8637714-6	1996	Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells.	Etoposide	81-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	140-143
8699237-0	1996	Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.	Etoposide	46-55	host cell factor C1	Homo sapiens	57-61
20650183-1	1996	Phenoxyl radicals are inevitable intermediates in the oxidative enzymatic metabolism of a phenolic antitumour drug, etoposide (VP-16), by peroxidases, cytochrome P-450, prostaglandin synthetase and tyrosinase, as well as in its interactions with oxygen and peroxyl radicals.	Etoposide	116-125	host cell factor C1	Homo sapiens	127-132
20650183-1	1996	Phenoxyl radicals are inevitable intermediates in the oxidative enzymatic metabolism of a phenolic antitumour drug, etoposide (VP-16), by peroxidases, cytochrome P-450, prostaglandin synthetase and tyrosinase, as well as in its interactions with oxygen and peroxyl radicals.	Etoposide	116-125	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-167
8567633-7	1996	However, the Gly185 to Val mutation significantly increased the stimulation of the MDR1-ATPase by colchicine and etoposide, while slightly decreasing its stimulation by vincristine.	Etoposide	113-122	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
8758442-3	1996	RESULTS: Temporary expression of antisense bcl-2 gene could effectively reduce levels of intrinsic bcl-2 protein of CEM cells and render it more sensitive to etoposide-induced cytotoxicity.	Etoposide	158-167	BCL2 apoptosis regulator	Homo sapiens	43-48
8758442-4	1996	Moreover, a great deal of apoptotic bodies and ladder DNA was always produced during etoposide-mediated killing of CEM and when CEM expressing bcl-2 antisense RNA served as target cells in particular, the amount of ladder DNA increased to around 40%.	Etoposide	85-94	BCL2 apoptosis regulator	Homo sapiens	143-148
8758442-5	1996	CONCLUSION: Programmed cell death is one of the mechanisms by which etoposide kills leukemic cells and is modulated by cellular intrinsic bcl-2 protein.	Etoposide	68-77	BCL2 apoptosis regulator	Homo sapiens	138-143
8567633-7	1996	However, the Gly185 to Val mutation significantly increased the stimulation of the MDR1-ATPase by colchicine and etoposide, while slightly decreasing its stimulation by vincristine.	Etoposide	113-122	dynein axonemal heavy chain 8	Homo sapiens	88-94
8546900-5	1996	The in vivo response of MDA435/LCC6 ascites to several cytotoxic drugs, including doxorubicin, etoposide (VP-16), BCNU and mitomycin C, closely reflects the activity of these single agents in previously untreated breast cancer patients.	Etoposide	95-104	host cell factor C1	Homo sapiens	106-111
9012539-1	1996	Recombinant human interleukin 1 alpha (rh IL-1 alpha) and etoposide (VP-16) synergize for direct growth inhibition of several human tumor cell lines in vitro.	Etoposide	58-67	host cell factor C1	Homo sapiens	69-74
8573144-5	1996	Addition of etoposide enhanced the apoptotic response and c-fos mRNA levels in both spleen and thymic cells.	Etoposide	12-21	FBJ osteosarcoma oncogene	Mus musculus	58-63
8612315-5	1996	The cells express high levels of the mdr1 gene product, P-glycoprotein, and are 25-to 60-fold resistant to doxorubicin (DOX), etoposide (VP-16), vinblastine (VBL), and taxol (TAX).	Etoposide	126-135	ATP binding cassette subfamily B member 1	Homo sapiens	37-41
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Etoposide	81-90	colony stimulating factor 3	Homo sapiens	0-5
8765425-0	1996	Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients.	Etoposide	91-100	interleukin 3	Homo sapiens	36-49
8674162-6	1996	For etoposide, plasma disposition demonstrated biphasic clearance, with mean T1/2 alpha of 2.09 +/- 0.61 h, and T1/2 beta of 5.83 +/- 1.71 h. An AUC as high as 1768.50 micrograms.h/ml was observed at a dose of 1200 mg/m2.	Etoposide	4-13	CD6 molecule	Homo sapiens	77-95
8599980-9	1996	G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only.	Etoposide	81-90	interleukin 3	Homo sapiens	129-133
7492789-4	1995	When anti-B4-bR was combined simultaneously with doxorubicin or etoposide, additive to supra-additive killing of Namalwa and Namalwa/mdr-1 cells was observed.	Etoposide	64-73	ATP binding cassette subfamily B member 1	Homo sapiens	133-138
8884812-0	1996	Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.	Etoposide	123-132	topoisomerase (DNA) II alpha	Mus musculus	10-36
8895198-0	1996	Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.	Etoposide	65-74	host cell factor C1	Homo sapiens	76-81
8519659-5	1995	We found that sensitivity to amsacrine showed a correlation with the level of expression of topoisomerase II alpha protein, and that sensitivity to etoposide showed a similar correlation with the level of expression of topoisomerase II beta protein.	Etoposide	148-157	DNA topoisomerase II beta	Homo sapiens	219-240
8823806-6	1996	Following cell exposure to dexamethasone, DNA-protein cleavable complex formation and cytotoxicity induced by etoposide, doxorubicin, and amsacrine were increased in the MDA-VP-hTOP2MAM cells compared with MDA-VP-MAM cells.	Etoposide	110-119	sarcoglycan gamma	Homo sapiens	182-185
7493640-4	1995	Both MPS- and etoposide-treated thymocytes exhibited enhanced ICE-like protease activity which was maximal 1 h after treatment.	Etoposide	14-23	caspase 1	Rattus norvegicus	62-65
8652276-1	1995	A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).	Etoposide	118-127	host cell factor C1	Homo sapiens	129-134
8721085-4	1995	Gastric cancer expressing multidrug-resistance associated protein (MRP) showed lower sensitivity to several anticancer drugs, including adriamycin and etoposide.	Etoposide	151-160	ATP binding cassette subfamily C member 3	Homo sapiens	26-65
8721085-4	1995	Gastric cancer expressing multidrug-resistance associated protein (MRP) showed lower sensitivity to several anticancer drugs, including adriamycin and etoposide.	Etoposide	151-160	ATP binding cassette subfamily C member 3	Homo sapiens	67-70
8719068-0	1995	Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
7493640-6	1995	Our findings suggest that ICE-like protease activity is critically involved in the early phase of both methylprednisolone- and etoposide-induced apoptosis in thymocytes, whereas the Ca(2+)-regulated serine protease is an obligatory component of the proteolytic cascade in methylprednisolone-induced apoptosis.	Etoposide	127-136	caspase 1	Rattus norvegicus	26-29
8562479-5	1995	HL60 cells transfected with wild-type p53 were more sensitive to stress, such as growth in serum-depleted medium and exposure to a chemotherapeutic agent, etoposide.	Etoposide	155-164	tumor protein p53	Homo sapiens	38-41
7495837-1	1995	In the present work, we studied the effects of phenoxyl radicals, generated by tyrosinase-catalyzed oxidation of a phenolic antitumor drug, Etoposide (VP-16), on a purified dog kidney Na+/K(+)-ATPase by characterizing interactions of VP-16 phenoxyl radicals with the enzyme"s SH-groups by ESR and correlating the loss of the enzymatic activity with the oxidation of its SH-groups, and oxidation of VP-16.	Etoposide	140-149	tyrosinase	Canis lupus familiaris	79-89
7495837-1	1995	In the present work, we studied the effects of phenoxyl radicals, generated by tyrosinase-catalyzed oxidation of a phenolic antitumor drug, Etoposide (VP-16), on a purified dog kidney Na+/K(+)-ATPase by characterizing interactions of VP-16 phenoxyl radicals with the enzyme"s SH-groups by ESR and correlating the loss of the enzymatic activity with the oxidation of its SH-groups, and oxidation of VP-16.	Etoposide	151-156	tyrosinase	Canis lupus familiaris	79-89
7585598-4	1995	MRP transfectants displayed increased resistance to several lipophilic drugs, including doxorubicin, daunorubicin, etoposide, actinomycin D, vincristine, and vinblastine.	Etoposide	115-124	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	0-3
9815936-0	1995	Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.	Etoposide	144-153	tumor protein p53	Homo sapiens	43-46
9815936-1	1995	We characterized three human brain tumor cell lines (D54, HBT-20, and HBT-28) with respect to resistance to etoposide (VP-16), a topoisomerase II-reactive drug.	Etoposide	108-117	host cell factor C1	Homo sapiens	119-124
8590845-0	1995	MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.	Etoposide	19-28	C-C motif chemokine ligand 28	Homo sapiens	0-3
7553641-0	1995	Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.	Etoposide	85-94	interleukin 6	Homo sapiens	11-24
7565798-6	1995	Both Zta and VP16 stimulated rapid assembly of a stable TFIID-TFIIA complex on promoter DNA.	Etoposide	13-17	general transcription factor IIA subunit 1	Homo sapiens	62-67
7476909-0	1995	Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target.	Etoposide	43-52	host cell factor C1	Homo sapiens	54-59
7476909-0	1995	Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target.	Etoposide	43-52	host cell factor C1	Homo sapiens	208-213
7476909-0	1995	Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target.	Etoposide	197-206	host cell factor C1	Homo sapiens	54-59
7476909-0	1995	Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target.	Etoposide	197-206	host cell factor C1	Homo sapiens	208-213
8629231-9	1995	Postoperatively, the patient was treated initially with intravenous administration of ACNU and etoposide (VP16), resulting in a minor response of tumor regression.	Etoposide	95-104	host cell factor C1	Homo sapiens	106-110
7589338-0	1995	Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin"s lymphoma.	Etoposide	29-38	vimentin	Homo sapiens	40-43
7671247-0	1995	Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.	Etoposide	51-60	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	167-170
7671247-0	1995	Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.	Etoposide	62-67	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	167-170
8845473-1	1995	Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which is useful in the treatment of a wide variety of hematological malignancies and solid tumors.	Etoposide	58-67	host cell factor C1	Homo sapiens	69-74
7547247-6	1995	Control cells containing a non-temperature-sensitive mutant p53 (phe132) were sensitive to both etoposide and bleomycin after 24 h at 32 degrees C and 37 degrees C, indicating that the results are not simply due to temperature effects on pharmacokinetics or DNA damage.	Etoposide	96-105	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	60-63
7671238-0	1995	Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide.	Etoposide	108-117	thioredoxin	Homo sapiens	19-30
7671238-5	1995	These thioredoxin antisense transfectants showed increased sensitivity to cisplatin and also to other superoxide-generating agents, i.e., doxorubicin, mitomycin C, etoposide, and hydrogen peroxide, as well as to UV irradiation, but not to the tubulin-targeting agents, vincristine, and colchicine.	Etoposide	164-173	thioredoxin	Homo sapiens	6-17
7474409-1	1995	A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer.	Etoposide	93-102	furin, paired basic amino acid cleaving enzyme	Homo sapiens	104-108
7474409-1	1995	A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer.	Etoposide	93-102	colony stimulating factor 3	Homo sapiens	115-152
7664276-0	1995	Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression.	Etoposide	14-23	apoptosis regulator Bcl-2	Cricetulus griseus	82-87
7500656-0	1995	Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing"s sarcoma.	Etoposide	50-59	membrane metalloendopeptidase	Homo sapiens	0-5
7664276-0	1995	Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression.	Etoposide	25-30	apoptosis regulator Bcl-2	Cricetulus griseus	82-87
7664276-1	1995	Bcl-2 has been shown to inhibit apoptosis induced by several anticancer agents and to cause a dissociation between etoposide (VP-16)-induced protein-cross-linked DNA strand breaks and VP-16-induced cell death.	Etoposide	115-124	apoptosis regulator Bcl-2	Cricetulus griseus	0-5
7664276-1	1995	Bcl-2 has been shown to inhibit apoptosis induced by several anticancer agents and to cause a dissociation between etoposide (VP-16)-induced protein-cross-linked DNA strand breaks and VP-16-induced cell death.	Etoposide	126-131	apoptosis regulator Bcl-2	Cricetulus griseus	0-5
7664276-2	1995	We suggested previously that VP-16-induced cytotoxicity is mediated by a series of events leading from cleavable complex formation to aberrant DNA recombination, as measured by sister chromatid exchange (SCE) and Southern blot analysis of the hypoxanthine phosphoribosyl transferase (hprt) gene mutations.	Etoposide	29-34	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	243-282
7664276-2	1995	We suggested previously that VP-16-induced cytotoxicity is mediated by a series of events leading from cleavable complex formation to aberrant DNA recombination, as measured by sister chromatid exchange (SCE) and Southern blot analysis of the hypoxanthine phosphoribosyl transferase (hprt) gene mutations.	Etoposide	29-34	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	284-288
7664276-5	1995	We subsequently quantitated the relationship between VP-16-induced cytotoxicity, DNA strand breaks, SCE, and mutant frequency at the hprt locus in these Bcl-2-overexpressing cells.	Etoposide	53-58	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	133-137
7664276-5	1995	We subsequently quantitated the relationship between VP-16-induced cytotoxicity, DNA strand breaks, SCE, and mutant frequency at the hprt locus in these Bcl-2-overexpressing cells.	Etoposide	53-58	apoptosis regulator Bcl-2	Cricetulus griseus	153-158
7664276-8	1995	In contrast, VP-16 induced significantly less SCE in Bcl-2-overexpressing cell lines compared with parental V79 and control NeoR cells.	Etoposide	13-18	apoptosis regulator Bcl-2	Cricetulus griseus	53-58
7664276-9	1995	The SCE/chromosome induced by 15 microM VP-16 were 0.65, 0.42, 0.09, and 0.10, respectively, in V79, NeoR, BCL2/2, and BCL2/4.	Etoposide	40-45	apoptosis regulator Bcl-2	Cricetulus griseus	107-113
7664276-9	1995	The SCE/chromosome induced by 15 microM VP-16 were 0.65, 0.42, 0.09, and 0.10, respectively, in V79, NeoR, BCL2/2, and BCL2/4.	Etoposide	40-45	apoptosis regulator Bcl-2	Cricetulus griseus	107-111
7664276-11	1995	Furthermore, VP-16-induced mutant frequencies at the hprt locus were 5-10 times less in BCL-2/2 and BCL-2/4 cells than those observed in the V79 or NeoR control cells.	Etoposide	13-18	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	53-57
7664276-11	1995	Furthermore, VP-16-induced mutant frequencies at the hprt locus were 5-10 times less in BCL-2/2 and BCL-2/4 cells than those observed in the V79 or NeoR control cells.	Etoposide	13-18	apoptosis regulator Bcl-2	Cricetulus griseus	88-95
7664276-11	1995	Furthermore, VP-16-induced mutant frequencies at the hprt locus were 5-10 times less in BCL-2/2 and BCL-2/4 cells than those observed in the V79 or NeoR control cells.	Etoposide	13-18	apoptosis regulator Bcl-2	Cricetulus griseus	88-93
7664276-12	1995	These results indicate that overexpression of Bcl-2 is associated with reduction in VP-16-induced genetic recombination, mutation, and cytotoxicity.	Etoposide	84-89	apoptosis regulator Bcl-2	Cricetulus griseus	46-51
7664276-13	1995	Moreover, they suggest that Bcl-2 modulates cytotoxicity of VP-16 between cleavable complex formation and subsequent induction of DNA recombination events.	Etoposide	60-65	apoptosis regulator Bcl-2	Cricetulus griseus	28-33
7655019-4	1995	Bcl-XL expression dramatically reduces the cytotoxicity of bleomycin, cisplatin, etoposide, vincristine, hygromycin B, and mycophenolic acid for up to 4 days in culture.	Etoposide	81-90	BCL2 like 1	Homo sapiens	0-6
7669558-0	1995	An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.	Etoposide	3-12	ATP binding cassette subfamily C member 3	Homo sapiens	61-100
7669558-11	1995	Our studies indicate that MRP gene expression may be induced by etoposide and may lead to reduced accumulation of the drug.	Etoposide	64-73	ATP binding cassette subfamily C member 3	Homo sapiens	26-29
7488415-10	1995	These findings support the role of etoposide in first line chemotherapy for SCCL.	Etoposide	35-44	SCLC1	Homo sapiens	76-80
7641205-8	1995	These results indicated that the expression of DNA topoisomerase II alpha gene decreased at the transcriptional level through the enhanced expression of Sp3 in our two etoposide/teniposide-resistant cell lines.	Etoposide	168-177	Sp3 transcription factor	Homo sapiens	153-156
7637090-0	1995	Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line.	Etoposide	96-105	phosphoglycolate phosphatase	Homo sapiens	44-62
7545220-1	1995	PURPOSE: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B).	Etoposide	115-124	host cell factor C1	Homo sapiens	126-131
7636550-2	1995	Here we report the use of etoposide (VP-16) administered on a chronic oral schedule as a novel chemotherapeutic approach.	Etoposide	26-35	host cell factor C1	Homo sapiens	37-42
7639514-0	1995	Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical.	Etoposide	94-103	host cell factor C1	Homo sapiens	105-110
7639514-3	1995	In the present work, we studied effects of phenoxyl radicals generated from a phenolic antitumor drug, Etoposide (VP-16), on oxidation of thiols and activity of Ca(2+)-ATPase in sarcoplasmic reticulum (SR) membranes from skeletal muscles.	Etoposide	103-112	host cell factor C1	Homo sapiens	114-119
7622113-2	1995	The tumor was refractory to conventional multiagent chemotherapy that included intravenously administered etoposide (VP-16).	Etoposide	106-115	host cell factor C1	Homo sapiens	117-122
7625373-2	1995	A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting.	Etoposide	77-86	glutamyl aminopeptidase	Homo sapiens	112-115
7640225-7	1995	Accordingly, the topoisomerase II-directed drug etoposide (VP-16) induced an increased number of DNA single-strand breaks in NYH/TPT cells.	Etoposide	48-57	host cell factor C1	Homo sapiens	59-64
7545098-9	1995	A similar shift from one to two cell populations in green fluorescence vs. side scatter-plots, similar to that observed for HL-60 cells, was observed in the THP-1 and U-937 cell lines secondary to etoposide treatment.	Etoposide	197-206	GLI family zinc finger 2	Homo sapiens	157-162
7563607-9	1995	After therapy with plasmapheresis and the CHOP regimen, he was given etoposide.	Etoposide	69-78	DNA damage inducible transcript 3	Homo sapiens	42-46
7624122-7	1995	In contrast, exposure to a DNA-damaging agent, etoposide, resulted in enhanced apoptotic death only in c-myc-transfected Rat-1 cells.	Etoposide	47-56	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	103-108
7611182-2	1995	Several of these agents, such as doxorubicin and etoposide (VP-16), are used to treat non-Hodgkin"s lymphomas (NHL).	Etoposide	49-58	host cell factor C1	Homo sapiens	60-65
7670142-3	1995	The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide.	Etoposide	284-293	ATP binding cassette subfamily B member 1	Homo sapiens	4-18
7654031-5	1995	This effect was due to an increase in the VP 16-induced cleavable-complexes by TNF.	Etoposide	42-47	tumor necrosis factor	Homo sapiens	79-82
7654031-6	1995	These findings suggest that TNF specifically sensitizes human glioma T98G cells to the effects of VP 16 of VM26.	Etoposide	98-103	tumor necrosis factor	Homo sapiens	28-31
7587710-10	1995	Furthermore, the TdT assay identifies DNA fragments formed during apoptosis induced by etoposide and N-methylformamide in HL60 and MOLT-4 cells, including those high molecular weight DNA fragments formed in MOLT-4 cells which were not further cleaved to 180-200bp integer fragments.	Etoposide	87-96	DNA nucleotidylexotransferase	Homo sapiens	17-20
7789893-0	1995	Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.	Etoposide	50-59	host cell factor C1	Homo sapiens	61-66
7789893-1	1995	Hexamethylmelamine (HMM) and oral etoposide (VP-16) have shown to be active against platinum-resistant epithelial ovarian cancer.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
7602350-1	1995	PURPOSE: A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell lung cancer (SCLC) was conducted to assess toxicities, response, and median survival.	Etoposide	91-100	carboxylesterase 2	Homo sapiens	102-105
7651971-2	1995	Etoposide and cytarabine were assayed by high-performance liquid chromatography with a C18 type column and UV detection.	Etoposide	0-9	Bardet-Biedl syndrome 9	Homo sapiens	87-90
7780971-9	1995	Cells were treated either with cisplatinum (CP), 4-hydroperoxy-cyclophosphamide (4-HC), or etoposide (VP-16) to induce apoptosis, and cell viability and DNA degradation were determined.	Etoposide	91-100	host cell factor C1	Homo sapiens	102-107
7582186-5	1995	Etoposide proved effective only against the TSG15 strain.	Etoposide	0-9	ribonuclease P/MRP subunit p30	Homo sapiens	44-49
7582186-6	1995	Moreover, the combined treatment with etoposide and cisplatin produced the most pronounced antitumour effect against the TSG15 strain.	Etoposide	38-47	ribonuclease P/MRP subunit p30	Homo sapiens	121-126
7610394-3	1995	This regimen (VIP), however, has shown promise when used with high-dose carboplatin/etoposide as salvage therapy in patients with germ cell tumors not responding to first-line BEP.	Etoposide	84-93	vasoactive intestinal peptide	Homo sapiens	14-17
7610396-1	1995	The combination of ifosfamide (with mesna uroprotection), carboplatin, and etoposide (ICE) has demonstrated activity in a variety of cancers.	Etoposide	75-84	carboxylesterase 2	Homo sapiens	86-89
7610397-3	1995	Combining ifosfamide, carboplatin, and etoposide, among the most active single agents against SCLC, into the ICE regimen was a logical move that has resulted in improved response and survival rates.	Etoposide	39-48	carboxylesterase 2	Homo sapiens	109-112
7610398-1	1995	We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer.	Etoposide	86-95	carboxylesterase 2	Homo sapiens	125-128
7733847-2	1995	Etoposide (VP-16), administered on a long-term oral schedule, represents a novel chemotherapeutic approach.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
7645949-1	1995	Mechanisms of etoposide (VP-16) resistance have been evaluated in a human promyelocytic leukemia HL60 cell line.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
7750085-1	1995	Anticancer drugs etoposide and mitomycin C increased nuclear p53 protein and decreased proliferating cell nuclear antigen (PCNA) of PLC/PRF/5 human hepatoma cells.	Etoposide	17-26	tumor protein p53	Homo sapiens	61-64
7750085-1	1995	Anticancer drugs etoposide and mitomycin C increased nuclear p53 protein and decreased proliferating cell nuclear antigen (PCNA) of PLC/PRF/5 human hepatoma cells.	Etoposide	17-26	proliferating cell nuclear antigen	Homo sapiens	87-121
7750085-1	1995	Anticancer drugs etoposide and mitomycin C increased nuclear p53 protein and decreased proliferating cell nuclear antigen (PCNA) of PLC/PRF/5 human hepatoma cells.	Etoposide	17-26	proliferating cell nuclear antigen	Homo sapiens	123-127
7750085-1	1995	Anticancer drugs etoposide and mitomycin C increased nuclear p53 protein and decreased proliferating cell nuclear antigen (PCNA) of PLC/PRF/5 human hepatoma cells.	Etoposide	17-26	heparan sulfate proteoglycan 2	Homo sapiens	132-135
7734316-7	1995	Analysis of the cellular content of the c-myc protein showed this to be undetectable by 2, 6 and 12 h after treatment with etoposide, NMF and DEX respectively.	Etoposide	123-132	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
7734314-4	1995	Both T24/ADM-1 and T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a decreased intracellular accumulation of etoposide.	Etoposide	104-113	adrenomedullin 2	Homo sapiens	23-28
7738621-1	1995	PURPOSE: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy.	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
7734314-4	1995	Both T24/ADM-1 and T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a decreased intracellular accumulation of etoposide.	Etoposide	104-113	ATP binding cassette subfamily C member 3	Homo sapiens	54-57
7734314-4	1995	Both T24/ADM-1 and T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a decreased intracellular accumulation of etoposide.	Etoposide	160-169	adrenomedullin 2	Homo sapiens	23-28
7734314-4	1995	Both T24/ADM-1 and T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a decreased intracellular accumulation of etoposide.	Etoposide	160-169	ATP binding cassette subfamily C member 3	Homo sapiens	54-57
9816016-1	1995	Previous reports have demonstrated that a variety of anticancer drugs, e.g., 1-beta-D-arabinofuranosylcytosine (ara-C), mitoxantrone, etoposide, camptothecin, and cisplatin, induce the expression of c-jun oncogene in leukemic cells prior to producing internucleosomal DNA fragmentation and the morphological features of apoptosis.	Etoposide	134-143	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	199-204
7738623-1	1995	PURPOSE: The study was undertaken to determine the activity and toxicity of oral etoposide (VP-16), ifosfamide, and cisplatin combination chemotherapy for previously treated, recurrent small-cell lung cancer (SCLC).	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
7710938-0	1995	Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation.	Etoposide	50-59	ATP binding cassette subfamily C member 3	Homo sapiens	120-159
8826913-0	1995	Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.	Etoposide	41-50	colony stimulating factor 3	Homo sapiens	56-93
7697950-5	1995	Lower serum albumin concentrations, higher bilirubin concentrations, or both are associated with greater effects at a given etoposide exposure.	Etoposide	124-133	albumin	Homo sapiens	6-19
7716769-0	1995	Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
7762995-0	1995	IFN-beta inhibition of etoposide resistance acquisition in vitro: studies using a human glioblastoma cell line.	Etoposide	23-32	interferon beta 1	Homo sapiens	0-8
7762995-1	1995	The inhibition by IFN-beta of acquired resistance to the epipodophillotoxin etoposide was studied using a human glioblastoma cell line, T98G.	Etoposide	76-85	interferon beta 1	Homo sapiens	18-26
7762995-8	1995	The present results show that resistant cells have less topoisomerase II than sensitive cells, suggesting that IFN-beta inhibits the acquisition of resistance to etoposide by suppressing the alteration in topoisomerase II.	Etoposide	162-171	interferon beta 1	Homo sapiens	111-119
7762995-9	1995	The inhibition of acquired resistance to etoposide by IFN-beta suggests that continuous and repeated chemotherapy for glioblastoma and other malignant tumors may be clinically advantageous.	Etoposide	41-50	interferon beta 1	Homo sapiens	54-62
7707117-1	1995	PURPOSE: A phase II study of etoposide (VP-16) and carboplatin was performed in patients with extraocular retinoblastoma to evaluate the response rate with this drug combination.	Etoposide	29-38	host cell factor C1	Homo sapiens	40-45
7850782-7	1995	The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity.	Etoposide	37-46	BCL2 apoptosis regulator	Homo sapiens	72-77
7538635-9	1995	The results indicate that multidisciplinary treatment including combination chemotherapy with cisplatin and etoposide with or without surgery and/or RT is highly effective in the treatment of patients with alpha-fetoprotein-producing intracranial nongerminomatous malignant germ cell tumor.	Etoposide	108-117	alpha fetoprotein	Homo sapiens	206-223
7850782-7	1995	The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity.	Etoposide	37-46	BCL2 apoptosis regulator	Homo sapiens	93-98
7850801-0	1995	Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide.	Etoposide	122-131	poly(ADP-ribose) polymerase 1	Homo sapiens	24-51
7850782-7	1995	The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity.	Etoposide	172-181	BCL2 apoptosis regulator	Homo sapiens	72-77
7850801-0	1995	Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide.	Etoposide	122-131	heat shock protein family A (Hsp70) member 5	Homo sapiens	72-77
7850782-7	1995	The interaction between androgen and etoposide was mediated through the BCL-2 protein, since bcl-2 antisense oligonucleotides blocked the protective effect of androgens on etoposide cytotoxicity.	Etoposide	172-181	BCL2 apoptosis regulator	Homo sapiens	93-98
7850801-2	1995	Furthermore, this overexpression of GRP78 is associated with the acquisition of resistance to topoisomerase II-directed drugs such as etoposide (VP-16); (S. Chatterjee et al., Cancer Res., 54: 4405-4411, 1994).	Etoposide	134-143	heat shock protein family A (Hsp70) member 5	Homo sapiens	36-41
7850801-2	1995	Furthermore, this overexpression of GRP78 is associated with the acquisition of resistance to topoisomerase II-directed drugs such as etoposide (VP-16); (S. Chatterjee et al., Cancer Res., 54: 4405-4411, 1994).	Etoposide	145-150	heat shock protein family A (Hsp70) member 5	Homo sapiens	36-41
7847254-0	1995	A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma.	Etoposide	62-71	colony stimulating factor 2	Homo sapiens	77-125
7850926-1	1995	P-glycoprotein (Pgp) actively pumps a number of antineoplastic drugs, such as etoposide, out of cancer cells and causes multidrug resistance.	Etoposide	78-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-14
7834606-0	1995	Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.	Etoposide	100-109	ATP binding cassette subfamily C member 1	Homo sapiens	58-61
7834606-0	1995	Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.	Etoposide	100-109	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
7834606-0	1995	Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.	Etoposide	100-109	host cell factor C1	Homo sapiens	93-98
7812949-6	1995	The same transient activation and subsequent inactivation of cyclin B1/Cdc2 kinase were observed after DNA damage by etoposide or bis-(2-chloroethyl)methylamine hydrochloride.	Etoposide	117-126	cyclin dependent kinase 1	Homo sapiens	71-75
7812962-0	1995	Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis.	Etoposide	68-77	insulin-like growth factor 1	Mus musculus	0-28
7812962-0	1995	Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis.	Etoposide	68-77	insulin-like growth factor 1	Mus musculus	30-35
7812962-0	1995	Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis.	Etoposide	68-77	insulin-like growth factor I receptor	Mus musculus	45-59
7812962-2	1995	We examined the role of the IGF-I receptor as a possible direct inhibitor of apoptosis induced by the topoisomerase I inhibitor etoposide.	Etoposide	128-137	insulin-like growth factor I receptor	Mus musculus	28-42
7812962-4	1995	The addition of IGF-I markedly inhibited etoposide-induced apoptosis in a concentration-dependent manner.	Etoposide	41-50	insulin-like growth factor 1	Mus musculus	16-21
7805045-9	1995	These findings suggest that in ALL cells, cytocidal activity of Adriamycin and etoposide may be mediated, at least in part, by topoisomerase II beta.	Etoposide	79-88	DNA topoisomerase II beta	Homo sapiens	127-148
7812949-6	1995	The same transient activation and subsequent inactivation of cyclin B1/Cdc2 kinase were observed after DNA damage by etoposide or bis-(2-chloroethyl)methylamine hydrochloride.	Etoposide	117-126	cyclin B1	Homo sapiens	61-70
7850926-1	1995	P-glycoprotein (Pgp) actively pumps a number of antineoplastic drugs, such as etoposide, out of cancer cells and causes multidrug resistance.	Etoposide	78-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	16-19
7850926-3	1995	We hypothesized that inhibition of intestinal Pgp might decrease the efflux of etoposide from the blood into the intestinal lumen, thereby, increasing the bioavailability of etoposide.	Etoposide	79-88	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	46-49
7850926-3	1995	We hypothesized that inhibition of intestinal Pgp might decrease the efflux of etoposide from the blood into the intestinal lumen, thereby, increasing the bioavailability of etoposide.	Etoposide	174-183	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	46-49
7850926-12	1995	The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide.	Etoposide	68-77	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-44
7850926-12	1995	The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide.	Etoposide	174-183	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	41-44
7850926-12	1995	The present data confirm that intestinal Pgp mediates the efflux of etoposide and that the use of Pgp-inhibiting agents such as quinidine may increase the bioavailability of etoposide.	Etoposide	174-183	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	98-101
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Etoposide	178-187	colony stimulating factor 3	Homo sapiens	56-93
8527493-1	1995	We have studied the effect of the chemotherapeutic drug VP-16 (etoposide) on the metabolism of HeLa cells by analysing different cellular parameters considered as markers of apoptosis.	Etoposide	63-72	host cell factor C1	Homo sapiens	56-61
7695978-0	1995	A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy.	Etoposide	92-101	colony stimulating factor 2	Homo sapiens	20-26
16892733-0	1995	Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8580054-0	1995	Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC).	Etoposide	75-84	angiotensin I converting enzyme	Homo sapiens	86-89
8580054-0	1995	Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC).	Etoposide	75-84	colony stimulating factor 3	Homo sapiens	168-173
7758997-4	1995	Experience gathered in recent years shows that idarubicin, cytosine arabinoside, and etoposide together might contribute to the modeling of an improved remission induction regimen: ICE.	Etoposide	85-94	carboxylesterase 2	Homo sapiens	181-184
7536433-0	1995	The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.	Etoposide	178-187	colony stimulating factor 3	Homo sapiens	95-100
7536433-2	1995	This study was conducted to test the feasibility of reducing the interval between cycles of doxorubicin, cyclophosphamide, etoposide (ACE) chemotherapy to 2 weeks, thereby increasing dose intensity, by adding granulocyte colony-stimulating factor (G-CSF) to reduce the duration of neutropenia following a cycle.	Etoposide	123-132	angiotensin I converting enzyme	Homo sapiens	134-137
7597304-10	1995	There is convincing evidence that the synergy between tumor necrosis factor (TNF) and topoisomerase-targeted intercalative (Adriamycin, doxorubicin hydrochloride; m-AMSA, amsacrine; mitoxantrone) and nonintercalative (VM-16, etoposide; VM-26, teniposide) drugs is related to a rapid increase in specific activity of topoisomerase I and II, resulting in enhanced DNA strand breaks and cleavage complex.	Etoposide	225-234	tumor necrosis factor	Homo sapiens	54-75
7799046-1	1995	PURPOSE: Ifosfamide-containing therapy with cisplatin plus either etoposide (VIP) or vinblastine (VeIP) can cure of patients with relapsed germ cell tumors (GCTs), but results in substantial myelotoxicity.	Etoposide	66-75	vasoactive intestinal peptide	Homo sapiens	77-80
7754538-2	1995	METHODS: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy.	Etoposide	90-99	host cell factor C1	Homo sapiens	101-106
7993115-1	1994	Phase I/II study of combination regimen composed of cisplatin (CDDP), carboplatin (CBDCA) and etoposide (VP-16) [CPVP] was conducted for small cell lung cancer.	Etoposide	94-103	host cell factor C1	Homo sapiens	105-110
7705462-3	1994	The binding of [3H]vinblastine to P-glycoprotein was not ATP-dependent, and was inhibited by cytotoxic drugs with the following potency order; vincristine &gt; doxorubicin &gt; etoposide.	Etoposide	177-186	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
7705462-6	1994	These data suggest that P-glycoprotein possesses at least two allosterically coupled drug acceptor sites; receptor site 1 which binds vinblastine, doxorubucin, etoposide and cyclosporin A, and receptor site 2 which binds dexniguldipine-HCl and other 1,4-dihydropyridines.	Etoposide	160-169	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
7993123-1	1994	Intraperitoneal administration of cisplatin (CDDP) etoposide (VP-16) and EAP therapy (combination chemotherapy with CDDP, adriamycin (ADM) and etoposide provided the curative resection for advanced gastric cancer with peritonitis carcinomatosa in a 48-year-old woman.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
7993123-1	1994	Intraperitoneal administration of cisplatin (CDDP) etoposide (VP-16) and EAP therapy (combination chemotherapy with CDDP, adriamycin (ADM) and etoposide provided the curative resection for advanced gastric cancer with peritonitis carcinomatosa in a 48-year-old woman.	Etoposide	143-152	glutamyl aminopeptidase	Homo sapiens	73-76
7986199-2	1994	Treatment of a human promyelocytic leukemia cell line, HL-60, with 10 micrograms/mL etoposide or 2 microM 1-beta-D-arabinofuranosylcytosine induced NF-kappa B activation within 1 hr and subsequently caused apoptosis within 3-4 hr.	Etoposide	84-93	nuclear factor kappa B subunit 1	Homo sapiens	148-158
7989942-1	1994	PURPOSE: This randomized, multicenter, dose-finding study was undertaken to determine the dose of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) that can safely reduce neutropenia after cyclophosphamide, doxorubicin, and etoposide (CAVP-16) chemotherapy in patients with small-cell lung cancer (SCLC).	Etoposide	252-261	colony stimulating factor 2	Homo sapiens	116-164
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	tumor protein p53	Homo sapiens	41-44
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	tumor protein p53	Homo sapiens	92-95
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-115
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	cyclin dependent kinase inhibitor 1A	Homo sapiens	116-120
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	tumor protein p53	Homo sapiens	92-95
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	tumor protein p53	Homo sapiens	92-95
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	cyclin dependent kinase inhibitor 1A	Homo sapiens	280-284
7970699-4	1994	The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression.	Etoposide	23-32	cyclin dependent kinase inhibitor 1A	Homo sapiens	285-289
7947097-1	1994	As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the dynamic changes occurring in small-cell lung cancer (SCLC) cell populations during protracted VP-16 exposure.	Etoposide	120-129	host cell factor C1	Homo sapiens	131-136
7954409-1	1994	The present study assessed the role of the p53 tumor suppressor gene in cell cycle arrest and apoptosis following treatment of Burkitt"s lymphoma and lymphoblastoid cell lines with gamma-rays, etoposide, nitrogen mustard, and cisplatin.	Etoposide	193-202	tumor protein p53	Homo sapiens	43-46
7954409-3	1994	We found that gamma-rays and etoposide induced a strong G1 arrest in the wild-type p53 lines while nitrogen mustard and cisplatin induced relatively little G1 arrest.	Etoposide	29-38	tumor protein p53	Homo sapiens	83-86
7954409-5	1994	The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein.	Etoposide	137-146	tumor protein p53	Homo sapiens	79-82
7954409-5	1994	The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein.	Etoposide	137-146	tumor protein p53	Homo sapiens	182-185
7954409-5	1994	The degree of G1 arrest observed with these agents correlated with the rate of p53 and p21Waf1/Cip1 protein accumulation: gamma-rays and etoposide induced rapid accumulation of both p53 and p21Waf1/Cip1; nitrogen mustard and cisplatin induced slow accumulation of p53 and no major accumulation of the p21Waf1/Cip1 protein.	Etoposide	137-146	tumor protein p53	Homo sapiens	182-185
7954409-8	1994	We also observed an inverse sensitivity relationship between nitrogen mustard/cisplatin and etoposide in the mutant p53 lines and this was found to correlate with topoisomerase II mRNA levels in the cells.	Etoposide	92-101	tumor protein p53	Homo sapiens	116-119
7923989-2	1994	The combination of interferon-beta and interleukin-2 after treatment with etoposide or cisplatin exerted profound therapeutic effects in an experimental model (lung colonization) using colon carcinoma 26, which was resistant to interferon-beta or to interleukin-2 alone.	Etoposide	74-83	interferon beta 1, fibroblast	Mus musculus	19-34
7923989-2	1994	The combination of interferon-beta and interleukin-2 after treatment with etoposide or cisplatin exerted profound therapeutic effects in an experimental model (lung colonization) using colon carcinoma 26, which was resistant to interferon-beta or to interleukin-2 alone.	Etoposide	74-83	interleukin 2	Mus musculus	39-52
7957669-3	1994	When U937 cells were treated with etoposide (VP-16), an inhibitor of DNA topoisomerase II, apoptosis occurred in a large number of cells, and flow-cytometric analysis revealed that the majority of cells in S phase underwent apoptosis within 2 h of the end of treatment.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
7530630-4	1994	Two comparative studies have demonstrated that prophylactic administration of filgrastim 230 micrograms/m2/day significantly reduces the incidence, duration and severity of neutropenia in patients with previously untreated small-cell lung cancer receiving standard-dose chemotherapy with CDE (cyclophosphamide, doxorubicin plus etoposide).	Etoposide	328-337	colony stimulating factor 3	Homo sapiens	78-88
7923116-4	1994	Induction of p53 is also abnormal in AT cells following treatment with methylmethanesulfonate and bleomycin but appears relatively normal following treatment with UV-C irradiation or the topoisomerase inhibitors, etoposide and camptothecin.	Etoposide	213-222	tumor protein p53	Homo sapiens	13-16
7964955-7	1994	RESULTS: The median values for clearance (Cl) and terminal half-life (T1/2 beta) of etoposide were 14.3 mL/min/m2 (range, 6.8 to 29.6) and 5.9 hours (range, 3.7 to 39).	Etoposide	84-93	interleukin 1 receptor like 1	Homo sapiens	70-79
7870198-1	1994	A slight induction of cellular differentiation (myelocytes and granulocytes) of HL-60 cells occurred after treatment with anti-tumor agents etoposide (VP-16), mitoxantrone (MXT), mitomycin C (MMC), actinomycin D (Act-D) or novobiocin (NOVO).	Etoposide	140-149	host cell factor C1	Homo sapiens	151-156
8092107-2	1994	Etoposide (VP 16) is an antineoplastic agent that has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
7858534-1	1994	The purpose of this study was to define the dose-limiting non-hematologic toxicity of carmustine, Ara C, cyclophosphamide and etoposide (BACE).	Etoposide	126-135	beta-secretase 1	Homo sapiens	137-141
7958409-16	1994	Third, we postulate that the slow escape from metaphase arrest in oocytes treated with both etoposide and cycloheximide reflects a gradual decrease of MPF activity due to normal protein turnover without new synthesis.	Etoposide	92-101	mesothelin	Mus musculus	151-154
7969039-1	1994	Etoposide (VP-16) is one of several DNA-damaging agents that induce subcellular structural changes associated with apoptosis.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
7530135-0	1994	Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.	Etoposide	42-51	CD34 molecule	Homo sapiens	115-119
7934159-0	1994	Translocation t(11;11)(q13;q23) and HRX gene rearrangement associated with therapy-related leukemia in a child previously treated with VP16.	Etoposide	135-139	HRX	Homo sapiens	36-39
7934159-1	1994	A child with acute myelomonocytic leukemia, bone marrow eosinophilia and inv(16) received first-line therapy including etoposide (VP-16).	Etoposide	119-128	host cell factor C1	Homo sapiens	130-135
7523606-1	1994	PURPOSE: Estramustine and etoposide (VP-16) have been demonstrated to inhibit the growth of prostate cancer cells in experimental models.	Etoposide	26-35	host cell factor C1	Homo sapiens	37-42
8069859-4	1994	Brief caffeine exposures (5 or 10 mM for 1-2 h) caused specific tyrosine dephosphorylation and activation of p34cdc2 kinase, and mitotic progression to a limited extent, in cells which were arrested in G2 following etoposide treatment.	Etoposide	215-224	cyclin dependent kinase 1	Homo sapiens	109-116
7927879-0	1994	Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells.	Etoposide	133-142	ATP binding cassette subfamily C member 3	Homo sapiens	24-63
7927879-0	1994	Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells.	Etoposide	133-142	ATP binding cassette subfamily C member 3	Homo sapiens	65-68
7927879-4	1994	Out of glioma cell lines, 2, namely IN500 and T98G, which had elevated MRP mRNA levels, showed the highest resistance to multiple anti-cancer agents such as etoposide, vincristine and adriamycin, and decreased intracellular accumulation of etoposide.	Etoposide	157-166	ATP binding cassette subfamily C member 3	Homo sapiens	71-74
7819132-0	1994	Etoposide-induced differentiation of U937 promonocytic cells: AP-1-dependent gene expression and protein kinase C activation.	Etoposide	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	62-66
7927879-4	1994	Out of glioma cell lines, 2, namely IN500 and T98G, which had elevated MRP mRNA levels, showed the highest resistance to multiple anti-cancer agents such as etoposide, vincristine and adriamycin, and decreased intracellular accumulation of etoposide.	Etoposide	240-249	ATP binding cassette subfamily C member 3	Homo sapiens	71-74
7927879-5	1994	In the remaining 5 cell lines, various degrees of sensitivity to adriamycin and etoposide appeared to correlate with their respective MRP mRNA levels.	Etoposide	80-89	ATP binding cassette subfamily C member 3	Homo sapiens	134-137
7847819-3	1994	Treatment of OVCAR-3 cells with cisplatin, etoposide or epirubicin for two hours resulted in a marked augmentation of EGF-R expression and growth inhibition, on the other hand, incubation with substances blocking RNA or protein synthesis, actinomycin-D and cycloheximide, resulted in a reduction of both EGF-R expression and growth rate.	Etoposide	43-52	epidermal growth factor receptor	Homo sapiens	118-123
7847819-3	1994	Treatment of OVCAR-3 cells with cisplatin, etoposide or epirubicin for two hours resulted in a marked augmentation of EGF-R expression and growth inhibition, on the other hand, incubation with substances blocking RNA or protein synthesis, actinomycin-D and cycloheximide, resulted in a reduction of both EGF-R expression and growth rate.	Etoposide	43-52	epidermal growth factor receptor	Homo sapiens	304-309
8075006-3	1994	The non-DNA intercalating topoisomerase II poison, etoposide (VP-16), is the "drug of first choice" in the treatment of LCH by cytotoxic chemotherapy.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
7819132-1	1994	The administration of 150 nM etoposide, an inhibitor of DNA topoisomerase II activity, decreased the proliferation and induced the differentiation of U937 human promonocytic cells, as determined by nitroblue tetrazolium reduction, surface accumulation of CD11b/CD18 and CD11c/CD18 integrins, and c-fms protooncogene expression.	Etoposide	29-38	integrin subunit alpha M	Homo sapiens	255-260
7819132-1	1994	The administration of 150 nM etoposide, an inhibitor of DNA topoisomerase II activity, decreased the proliferation and induced the differentiation of U937 human promonocytic cells, as determined by nitroblue tetrazolium reduction, surface accumulation of CD11b/CD18 and CD11c/CD18 integrins, and c-fms protooncogene expression.	Etoposide	29-38	integrin subunit beta 2	Homo sapiens	261-265
7819132-1	1994	The administration of 150 nM etoposide, an inhibitor of DNA topoisomerase II activity, decreased the proliferation and induced the differentiation of U937 human promonocytic cells, as determined by nitroblue tetrazolium reduction, surface accumulation of CD11b/CD18 and CD11c/CD18 integrins, and c-fms protooncogene expression.	Etoposide	29-38	integrin subunit alpha X	Homo sapiens	270-275
7819132-1	1994	The administration of 150 nM etoposide, an inhibitor of DNA topoisomerase II activity, decreased the proliferation and induced the differentiation of U937 human promonocytic cells, as determined by nitroblue tetrazolium reduction, surface accumulation of CD11b/CD18 and CD11c/CD18 integrins, and c-fms protooncogene expression.	Etoposide	29-38	integrin subunit beta 2	Homo sapiens	276-280
7819132-1	1994	The administration of 150 nM etoposide, an inhibitor of DNA topoisomerase II activity, decreased the proliferation and induced the differentiation of U937 human promonocytic cells, as determined by nitroblue tetrazolium reduction, surface accumulation of CD11b/CD18 and CD11c/CD18 integrins, and c-fms protooncogene expression.	Etoposide	29-38	colony stimulating factor 1 receptor	Homo sapiens	296-301
7819132-3	1994	Etoposide caused little cell damage, as determined by trypan blue exclusion and by apoptotic-like DNA degradation, which was slightly initiated at 48 h. The treatment induced a transient increase in c-fos, c-jun, and jun B mRNA levels, with maximum values at 12 h, a transient increase in collagenase mRNA level, with maximum value at 48 h, and a progressive increase in vimentin and lamin A and C mRNAs.	Etoposide	0-9	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	217-222
7819132-3	1994	Etoposide caused little cell damage, as determined by trypan blue exclusion and by apoptotic-like DNA degradation, which was slightly initiated at 48 h. The treatment induced a transient increase in c-fos, c-jun, and jun B mRNA levels, with maximum values at 12 h, a transient increase in collagenase mRNA level, with maximum value at 48 h, and a progressive increase in vimentin and lamin A and C mRNAs.	Etoposide	0-9	vimentin	Homo sapiens	371-379
7819132-5	1994	Etoposide also caused a transient increase of total AP-1 binding activity, with maximum value at 12 h of treatment, as determined by gel retardation assays.	Etoposide	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-56
7944452-2	1994	For these patients, preoperative intra-arterial injection therapy using EAP-II (etoposide 100 mg, epirubicin 20 mg, carboplatin 100 mg) was given to 24 patients.	Etoposide	80-89	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	72-78
7895594-1	1994	The clinical effect of Carboplatin and Etoposide (CE regimen) on 58 cases of small cell lung cancer (SCLC) and 65 cases of non small cell lung cancer (NSCLC) was observed, and its influence on immunity was investigated simultaneously.	Etoposide	39-48	SCLC1	Homo sapiens	101-105
8083718-1	1994	PURPOSE: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia.	Etoposide	159-168	host cell factor C1	Homo sapiens	170-175
7521905-0	1994	Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.	Etoposide	50-59	colony stimulating factor 3	Homo sapiens	83-120
7934139-0	1994	Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16).	Etoposide	96-105	host cell factor C1	Homo sapiens	107-112
8044789-9	1994	These studies demonstrate a clear association between deficiency of the NAD-poly(ADP-ribose) synthesis system, induction of GRP78 synthesis, and resistance to VP-16.	Etoposide	159-164	endoplasmic reticulum chaperone BiP	Cricetulus griseus	124-129
8028036-1	1994	BACKGROUND: The major known mechanisms of resistance to etoposide include altered expression of its target enzyme, topoisomerase II (Topo II), and the multidrug-resistant phenotypes encoded by the mdr1 and MRP (multidrug resistance-associated protein) genes.	Etoposide	56-65	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
8068642-4	1994	We found by liquid chromatography-ionspray mass spectrometry and electron spin resonance (ESR) that tyrosinase caused oxidation of VP-16 to its o-quinone and aromatized derivative via intermediate formation of the phenoxyl radical.	Etoposide	131-136	tyrosinase	Homo sapiens	100-110
8055445-1	1994	BACKGROUND: The purpose of this study was to assess the ability of administering to patients induction chemotherapy with carboplatin and etoposide (VP-16), followed by full-course radiation therapy and weekly carboplatin with tolerable toxicity as preoperative therapy to down-stage disease thus allowing the resection of clinically staged IIIA non-small cell lung cancer.	Etoposide	137-146	host cell factor C1	Homo sapiens	148-153
8028036-1	1994	BACKGROUND: The major known mechanisms of resistance to etoposide include altered expression of its target enzyme, topoisomerase II (Topo II), and the multidrug-resistant phenotypes encoded by the mdr1 and MRP (multidrug resistance-associated protein) genes.	Etoposide	56-65	ATP binding cassette subfamily C member 3	Homo sapiens	206-209
8028036-1	1994	BACKGROUND: The major known mechanisms of resistance to etoposide include altered expression of its target enzyme, topoisomerase II (Topo II), and the multidrug-resistant phenotypes encoded by the mdr1 and MRP (multidrug resistance-associated protein) genes.	Etoposide	56-65	ATP binding cassette subfamily C member 3	Homo sapiens	211-250
8068039-0	1994	Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells.	Etoposide	31-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	10-15
8037350-3	1994	etoposide (VP-16) at a dose of 150 mg/kg/day for 3 days.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8068039-0	1994	Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells.	Etoposide	31-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-20
8037350-8	1994	CONCLUSIONS: Etoposide (VP-16), an epipodophyllotoxin known for its usefulness in the treatment of malignancies of the monocyte/macrophage lineage, appears to be an effective treatment for the severe multisystem (disseminated) LCH of childhood and should be strongly considered as front-line therapy for this subgroup of patients with poor prognostic factors.	Etoposide	13-22	host cell factor C1	Homo sapiens	24-29
8021737-1	1994	PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity, and plasma concentrations of orally administered etoposide (VP-16) in pediatric oncology patients.	Etoposide	129-138	host cell factor C1	Homo sapiens	140-145
7949251-1	1994	Etoposide (VP-16) and cisplatin are widely used in the treatment of malignancy.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8033146-1	1994	The chemotherapeutic drug etoposide (VP-16) causes the equilibrium reaction between noncleavable and cleavable topoisomerase II-DNA complexes to shift in favor of the cleavabel complex [H. Zang, P. D"Arpa, and L.F. Liu, Cancer Cells (Cold Spring Harbor), 2:23-27, 1990].	Etoposide	26-35	host cell factor C1	Homo sapiens	37-42
7520221-0	1994	[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with EAP (etoposide, adriamycin, cisplatin) therapy].	Etoposide	91-100	alpha fetoprotein	Homo sapiens	11-14
7520221-0	1994	[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with EAP (etoposide, adriamycin, cisplatin) therapy].	Etoposide	91-100	alpha fetoprotein	Homo sapiens	16-33
7520221-0	1994	[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with EAP (etoposide, adriamycin, cisplatin) therapy].	Etoposide	91-100	glutamyl aminopeptidase	Homo sapiens	86-89
7520221-5	1994	Preoperative combination chemotherapy with etoposide, adriamycin and cisplatin resulted in a remarkable decrease in serum AFP level.	Etoposide	43-52	alpha fetoprotein	Homo sapiens	122-125
7948964-0	1994	Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?	Etoposide	64-73	lysine methyltransferase 2A	Homo sapiens	79-82
7948964-0	1994	Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?	Etoposide	110-119	lysine methyltransferase 2A	Homo sapiens	79-82
7948964-1	1994	A patient with secondary acute myelomonocytic leukemia after treatment with chronic oral etoposide (VP-16) for lung cancer is reported.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
8027612-1	1994	We investigated the ability of camptothecin (CPT), an inhibitor of topoisomerase (topo) I, and etoposide (VP-16), an inhibitor of topo II, to potentiate X-radiation response and to inhibit the repair of potentially lethal damage (PLDR) and sublethal damage (SLDR) in confluent cultures of a radioresistant (Sk-Mel-3) and a radiosensitive (HT-144) human melanoma cell line.	Etoposide	95-104	host cell factor C1	Homo sapiens	106-111
21559571-0	1994	Prognostic value of k-ras 12 genotypes in patients with advanced nonsmall cell lung-cancer receiving Carboplatin with either intravenous or chronic oral dose Etoposide.	Etoposide	158-167	KRAS proto-oncogene, GTPase	Homo sapiens	20-25
7830938-0	1994	Nerve growth factor and epidermal growth factor rescue PC12 cells from programmed cell death induced by etoposide: distinct modes of protection against cell death by growth factors and a protein-synthesis inhibitor.	Etoposide	104-113	nerve growth factor	Rattus norvegicus	0-19
7830938-0	1994	Nerve growth factor and epidermal growth factor rescue PC12 cells from programmed cell death induced by etoposide: distinct modes of protection against cell death by growth factors and a protein-synthesis inhibitor.	Etoposide	104-113	epidermal growth factor like 1	Rattus norvegicus	24-47
7830938-4	1994	Furthermore, a difference among protective modes against etoposide-induced death by growth factors and a protein-synthesis inhibitor was observed: the protective effect of either NGF or EGF remained rather constant as a function of incubation time with etoposide whereas that of cycloheximide declined.	Etoposide	57-66	epidermal growth factor like 1	Rattus norvegicus	186-189
7830938-4	1994	Furthermore, a difference among protective modes against etoposide-induced death by growth factors and a protein-synthesis inhibitor was observed: the protective effect of either NGF or EGF remained rather constant as a function of incubation time with etoposide whereas that of cycloheximide declined.	Etoposide	253-262	epidermal growth factor like 1	Rattus norvegicus	186-189
8033046-0	1994	A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies.	Etoposide	51-60	colony stimulating factor 2	Homo sapiens	66-114
8021738-1	1994	PURPOSE: We used two different methods to administer high-dose etoposide (VP-16) during a myeloablative conditioning chemotherapy regimen before bone marrow transplantation (BMT).	Etoposide	63-72	host cell factor C1	Homo sapiens	74-79
7514494-2	1994	In this study, we show that administration of recombinant human (rh) G-CSF decreased the in vitro and in vivo cytotoxic effects of Adriamycin or etoposide on L1210 murine leukemic cells with receptors for rhG-CSF.	Etoposide	145-154	colony stimulating factor 3	Homo sapiens	69-74
8058057-1	1994	In this report we examine biochemical and genetic alterations in DNA topoisomerase II (topoisomerase II) in K562 cells selected for resistance in the presence of etoposide (VP-16).	Etoposide	162-171	host cell factor C1	Homo sapiens	173-178
8205548-7	1994	Clones expressing high levels of Bcl-2 were resistant to cisplatin- and etoposide-induced cytotoxicity in a dose-dependent manner.	Etoposide	72-81	BCL2 apoptosis regulator	Homo sapiens	33-38
8201379-1	1994	PURPOSE: This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing and refractory adult lymphoma patients.	Etoposide	78-87	host cell factor C1	Homo sapiens	89-94
8184552-4	1994	We have established Chinese hamster ovary cell lines which constitutively express the BHRF1 protein and show that this viral protein can protect against apoptosis induced by the DNA-damaging agents cisplatin, etoposide, and mitomycin C.	Etoposide	209-218	apoptosis regulator BHRF1	Human gammaherpesvirus 4	86-91
8078212-2	1994	An operation for lung cancer was performed in February 1991, and she was treated with etoposide (VP-16), a topoisomerase II inhibitor.	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
8201386-1	1994	PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF).	Etoposide	93-102	colony stimulating factor 2	Homo sapiens	171-219
8201386-1	1994	PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF).	Etoposide	93-102	colony stimulating factor 2	Homo sapiens	221-227
8201386-1	1994	PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF).	Etoposide	150-159	colony stimulating factor 2	Homo sapiens	171-219
8201386-17	1994	CONCLUSION: The addition of GM-CSF to a dose-intensive ICE regimen permitted dose escalation of etoposide to 900 mg/m2, with cumulative thrombocytopenia as the dose-limiting toxicity.	Etoposide	96-105	colony stimulating factor 2	Homo sapiens	28-34
8209278-3	1994	We have conducted a phase I study to determine the maximum tolerated dose of etoposide in the ifosfamide/carboplatin/etoposide (ICE) regimen when used with granulocyte-macrophage colony-stimulating factor (GM-CSF) support.	Etoposide	77-86	colony stimulating factor 2	Homo sapiens	156-204
8209278-3	1994	We have conducted a phase I study to determine the maximum tolerated dose of etoposide in the ifosfamide/carboplatin/etoposide (ICE) regimen when used with granulocyte-macrophage colony-stimulating factor (GM-CSF) support.	Etoposide	77-86	colony stimulating factor 2	Homo sapiens	206-212
7514153-6	1994	Both cell lines showed cross-resistance to a number of structurally unrelated cytotoxic drugs including anthracyclines and etoposide (VP-16), although only the CEM/A7 line was cross resistant to Vinca alkaloids.	Etoposide	123-132	host cell factor C1	Homo sapiens	134-139
8128200-1	1994	Neutropenic typhlitis (NPT) was observed in 4 of 5 adult patients with acute leukemia treated with etoposide (VP16; 100 mg/m2/d for 6 days) and high-dose cytosine-arabinoside (HD ARAC, 2 g/m2 twice daily for 6 days) in a period of 11 months.	Etoposide	99-108	host cell factor C1	Homo sapiens	110-114
8142256-1	1994	K562 leukaemia cells were selected for resistance using 0.5 microM etoposide (VP-16).	Etoposide	67-76	host cell factor C1	Homo sapiens	78-83
8186529-3	1994	Postoperatively, she received 5-fluorouracil, cisplatin, and etoposide (VP-16) in conjunction with radiation therapy.	Etoposide	61-70	host cell factor C1	Homo sapiens	72-77
7908989-5	1994	The in vitro chemosensitivity of these cell lines to fluorouracil, doxorubicin, mitomycin C, cisplatin, and etoposide (VP-16) was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric assay.	Etoposide	108-117	host cell factor C1	Homo sapiens	119-124
8170981-7	1994	Expression of the human kinesin heavy-chain gene was decreased in four of four etoposide-resistant HeLa cell lines, derived by conventional drug selection, indicating that downregulation of kinesin represents a natural mechanism of drug resistance in mammalian cells.	Etoposide	79-88	kinesin family member 5B	Homo sapiens	24-43
7510234-0	1994	Interleukin-3 and Bcl-2 cooperatively inhibit etoposide-induced apoptosis in a murine pre-B cell line.	Etoposide	46-55	interleukin 3	Mus musculus	0-13
7510234-0	1994	Interleukin-3 and Bcl-2 cooperatively inhibit etoposide-induced apoptosis in a murine pre-B cell line.	Etoposide	46-55	B cell leukemia/lymphoma 2	Mus musculus	18-23
7510234-2	1994	The topoisomerase II inhibitor etoposide causes a more rapid onset of apoptosis in the IL-3-dependent cell line BAF3, deprived of IL-3.	Etoposide	31-40	interleukin 3	Mus musculus	87-91
7510234-2	1994	The topoisomerase II inhibitor etoposide causes a more rapid onset of apoptosis in the IL-3-dependent cell line BAF3, deprived of IL-3.	Etoposide	31-40	interleukin 3	Mus musculus	130-134
7510234-4	1994	The presence of IL-3 or overexpression of the oncogene bcl-2 caused a marked delay in the induction of apoptosis by etoposide, acting in a cooperative manner.	Etoposide	116-125	interleukin 3	Mus musculus	16-20
7510234-4	1994	The presence of IL-3 or overexpression of the oncogene bcl-2 caused a marked delay in the induction of apoptosis by etoposide, acting in a cooperative manner.	Etoposide	116-125	B cell leukemia/lymphoma 2	Mus musculus	55-60
7911742-1	1994	Etoposide (VP-16) is one of the most important anticancer agents available and is used in many chemotherapeutic regimens.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8114683-3	1994	Using a panel of prototypical substrates and inhibitors for specific cytochromes P450, we identified substrates for CYP3A4 (midazolam, erythromycin, cyclosporin, and dexamethasone) as inhibitors of catechol formation from both etoposide and teniposide.	Etoposide	227-236	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
8114683-10	1994	We conclude that catechol formation from teniposide and etoposide is primarily mediated by human CYP3A4, making these reactions susceptible to inhibition by prototypical 3A substrates and inhibitors.	Etoposide	56-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
7914749-10	1994	Furthermore, 11 AML patients at primary diagnosis, including five AML patients with P-gp overexpression, who were treated with idarubicin, vepesid, and cytarabine V (ara-C) showed a complete remission.	Etoposide	139-146	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
7987995-1	1994	Vincristine (VCR) and etoposide (VP-16) have been shown to be synergistic in a murine model, and this combination was studied in a phase II trial.	Etoposide	22-31	host cell factor C1	Homo sapiens	33-38
7728133-0	1994	Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.	Etoposide	8-17	host cell factor C1	Homo sapiens	19-24
8033300-1	1994	To test the feasibility of a regimen of high-dose cisplatin, ifosfamide, and etoposide (VP-16; VIPP regimen), we registered 15 patients with advanced non-small-cell lung cancer in a phase I trial of the Northern California Oncology Group.	Etoposide	77-86	host cell factor C1	Homo sapiens	88-93
8070019-9	1994	In the second trial, the recommended dose of CPT-11/VP-16 given with recombinant granulocyte colony-stimulating factor (on days 4-17) was found to be 60/60 mg/m2.	Etoposide	52-57	choline phosphotransferase 1	Homo sapiens	45-48
8070020-7	1994	Recent clinical investigations have focused on the use of etoposide in combination with (a) cytokines to ameliorate myelosuppression, the dose-limiting toxicity of etoposide; (b) agents such as cyclosporin A and verapamil to alter the p-glycoprotein (mdr1) function; and (c) topoisomerase I inhibitors to modulate the substrate upon which it acts.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	235-249
8070020-7	1994	Recent clinical investigations have focused on the use of etoposide in combination with (a) cytokines to ameliorate myelosuppression, the dose-limiting toxicity of etoposide; (b) agents such as cyclosporin A and verapamil to alter the p-glycoprotein (mdr1) function; and (c) topoisomerase I inhibitors to modulate the substrate upon which it acts.	Etoposide	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	251-255
7775129-1	1994	In previous studies, we found that VP-16 (etoposide) induced cytotoxicity and protein-concealed strand break formation was prevented in a small cell lung cancer (SCLC) cell line, when the cells were incubated with aclarubicin prior to treatment with VP-16.	Etoposide	42-51	host cell factor C1	Homo sapiens	35-40
8306412-3	1994	In etoposide (VP-16)-treated N231 but not PC-9 cells, DNA fragmentation continued to increase up to 42 h, and the increase was dependent on the concentration of VP-16.	Etoposide	3-12	host cell factor C1	Homo sapiens	14-19
8306412-3	1994	In etoposide (VP-16)-treated N231 but not PC-9 cells, DNA fragmentation continued to increase up to 42 h, and the increase was dependent on the concentration of VP-16.	Etoposide	3-12	host cell factor C1	Homo sapiens	161-166
7505211-4	1994	Comparative studies of CD34 cells showed that the percentage of CD34+ mononuclear cells was greatest in blood samples from patients following mobilization treatment with cyclophosphamide/etoposide/G-CSF averaging 2%.	Etoposide	187-196	CD34 molecule	Homo sapiens	64-68
8174205-9	1994	In conclusion, without substantially increasing the toxicity, IFN can be added to the etoposide/leucovorin/5-fluorouracil combination, at a dose of 3 MU/m2.	Etoposide	86-95	interferon alpha 1	Homo sapiens	62-65
7903202-0	1994	Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.	Etoposide	165-174	ATP binding cassette subfamily C member 3	Homo sapiens	0-39
7903202-1	1994	A human breast cancer cell line (MCF7/WT) was selected for resistance to etoposide (VP-16) by stepwise exposure to 2-fold increasing concentrations of this agent.	Etoposide	73-82	host cell factor C1	Homo sapiens	84-89
7775129-1	1994	In previous studies, we found that VP-16 (etoposide) induced cytotoxicity and protein-concealed strand break formation was prevented in a small cell lung cancer (SCLC) cell line, when the cells were incubated with aclarubicin prior to treatment with VP-16.	Etoposide	42-51	host cell factor C1	Homo sapiens	250-255
7521931-6	1994	In case of incomplete tumor response, patients received a salvage chemotherapy consisting of three treatments with VP 16 (etoposide), ifosfamide, and cisplatinum.	Etoposide	122-131	host cell factor C1	Homo sapiens	115-120
7535146-2	1994	The combination of a standard-dose chemotherapy [VIP: VP16 (etoposide), ifosfamide, cisplatin] in combination with hematopoietic growth factors was shown to provide effective anti-cancer activity as well as to enable sufficient stem cell mobilization for clinical use.	Etoposide	54-58	vasoactive intestinal peptide	Homo sapiens	49-52
7535146-2	1994	The combination of a standard-dose chemotherapy [VIP: VP16 (etoposide), ifosfamide, cisplatin] in combination with hematopoietic growth factors was shown to provide effective anti-cancer activity as well as to enable sufficient stem cell mobilization for clinical use.	Etoposide	60-69	vasoactive intestinal peptide	Homo sapiens	49-52
8267650-7	1993	Basal levels of c-myc were comparable for all three cell lines, but levels of c-jun and c-fos were elevated 2- to 4-fold in VP-16-resistant cell lines.	Etoposide	124-129	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-83
7910418-1	1994	Etoposide (VP-16) is used as an antineoplastic drug in humans.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
8267650-7	1993	Basal levels of c-myc were comparable for all three cell lines, but levels of c-jun and c-fos were elevated 2- to 4-fold in VP-16-resistant cell lines.	Etoposide	124-129	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	88-93
8267650-9	1993	Exposure of both sensitive and resistant cells to 200 microM VP-16 for 5 hr resulted in no further changes in topoisomerase II mRNA levels but caused an additional 2- to 3-fold elevation in the level of c-jun mRNA, indicating that altered basal levels of this gene were not due to deregulation of this gene.	Etoposide	61-66	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	203-208
8269627-1	1993	We have studied the effect of the chemotherapeutic drug VP-16 (etoposide) on the metabolism of HeLa cells by analysing different cellular parameters; in particular we have focused on changes in cellular morphology that are considered as markers of apoptosis.	Etoposide	63-72	host cell factor C1	Homo sapiens	56-61
8269627-7	1993	By means of the activity gel technique, which allows the direct evaluation of automodified poly(ADP-ribose)polymerase, we have observed that in extracts from cells where etoposide-induced DNA fragmentation occurred, the autoribosylated form of the enzyme is greatly increased.	Etoposide	170-179	poly(ADP-ribose) polymerase 1	Homo sapiens	91-117
8106148-0	1993	Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.	Etoposide	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
7694118-0	1993	Hypersensitivity of lymphoblastoid lines derived from ataxia telangiectasia patients to the induction of chromosomal aberrations by etoposide (VP-16).	Etoposide	132-141	host cell factor C1	Homo sapiens	143-148
7694118-1	1993	Mammalian DNA topoisomerase II represents the cellular target of many antitumor drugs, such as epipodophyllotoxin VP-16 (etoposide).	Etoposide	121-130	host cell factor C1	Homo sapiens	114-119
8285174-1	1993	A bisbenzylisoquinoline alkaloid, cepharanthine, significantly enhanced vinblastine, adriamycin and etoposide sensitivities in P-glycoprotein positive renal cancer cells.	Etoposide	100-109	ATP binding cassette subfamily B member 1	Homo sapiens	127-141
7508531-9	1993	He received two courses of EAP chemotherapy (Cis-platin+etoposide+doxorubicin) as an adjuvant chemotherapy following the surgery and he is alive with no evidence of recurrence for 21 months.	Etoposide	56-65	glutamyl aminopeptidase	Homo sapiens	27-30
8278572-4	1993	We found that internucleosomal DNA fragmentation, characteristics of apoptosis, can result from treatment of EL4 and F9 cells with agents that have diverse modes of action: tert-butyl hydroperoxide, diazenedicarboxylic acid bis(N,N-piperidide), and etoposide.	Etoposide	249-258	epilepsy 4	Mus musculus	109-112
8395979-0	1993	bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair.	Etoposide	23-32	BCL2 apoptosis regulator	Homo sapiens	0-5
8398708-1	1993	BACKGROUND: We attempted to determine the maximum tolerated dose and toxicity of etoposide (VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route.	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
8215470-3	1993	PLC/PRF/5 cells were most effectively killed by cisplatin and etoposide, HuH-7 cells by cisplatin and carboplatin, HuH-6 cells by etoposide, and Hep G2 cells by cisplatin.	Etoposide	62-71	heparan sulfate proteoglycan 2	Homo sapiens	0-3
8215470-3	1993	PLC/PRF/5 cells were most effectively killed by cisplatin and etoposide, HuH-7 cells by cisplatin and carboplatin, HuH-6 cells by etoposide, and Hep G2 cells by cisplatin.	Etoposide	130-139	heparan sulfate proteoglycan 2	Homo sapiens	0-3
8215470-6	1993	Combined treatment with cisplatin (0.01-1.0 microgram/ml) and etoposide (0.1 microgram/ml) showed synergistic cytotoxic effects on the colony formation of PLC/PRF/5 cells, while combination of carboplatin (0.01-0.1 microgram/ml) and etoposide (0.1 microgram/ml) caused subadditive cytotoxic effects.	Etoposide	62-71	heparan sulfate proteoglycan 2	Homo sapiens	155-158
8215470-6	1993	Combined treatment with cisplatin (0.01-1.0 microgram/ml) and etoposide (0.1 microgram/ml) showed synergistic cytotoxic effects on the colony formation of PLC/PRF/5 cells, while combination of carboplatin (0.01-0.1 microgram/ml) and etoposide (0.1 microgram/ml) caused subadditive cytotoxic effects.	Etoposide	233-242	heparan sulfate proteoglycan 2	Homo sapiens	155-158
8217877-10	1993	Loss of HSP27 occurred in MCF7 cells made drug resistant to Novatrone, vincristine and etoposide as well as doxorubicin; no detectable change was seen in cells made resistant by 5 fluorouracil or X-irradiation.	Etoposide	87-96	heat shock protein family B (small) member 1	Homo sapiens	8-13
8364925-2	1993	The significance of such variation has been assessed by monitoring molecular and cellular processes induced by etoposide (VP-16) in the human lymphoblastoid T-cell lines CCRF-CEM (CEM) and MOLT-4 contrasted, where appropriate, with those induced by necrotizing injury.	Etoposide	111-120	host cell factor C1	Homo sapiens	122-127
8243480-2	1993	The covalent binding of topoisomerase II to the LTR was strongly stimulated by different inhibitors of the enzyme 4"-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopy ranoside (VP-16), 4"-(9-acridinylamino)methanesulfon-m-anisidine) (m-AMSA) and an ellipticine derivative.	Etoposide	191-196	Topoisomerase 2	Drosophila melanogaster	24-40
8395979-4	1993	In this study, we examined whether bcl-2 overexpression could have effects on etoposide-induced DNA damage and its repair.	Etoposide	78-87	BCL2 apoptosis regulator	Homo sapiens	35-40
8395979-6	1993	Overexpression of bcl-2 protein inhibited etoposide-induced apoptosis and cytotoxicity.	Etoposide	42-51	BCL2 apoptosis regulator	Homo sapiens	18-23
8395979-8	1993	These findings indicate that (a) apoptosis or cytotoxicity induced by etoposide can be separated into early events (formation of double-strand breaks, DNA single-strand breaks, and double-strand breaks) and later events (secondary DNA fragmentation or cell death) and (b) bcl-2 inhibits apoptosis and cytotoxicity induced by etoposide at some steps between these events.	Etoposide	70-79	BCL2 apoptosis regulator	Homo sapiens	272-277
8394080-2	1993	Using alkaline elution assays, ICRF-187 in a dose-dependent manner inhibited the formation of DNA single strand breaks (SSBs) as well as DNA-protein cross-links induced by drugs such as VP-16 (etoposide), m-AMSA [4"-(9-acridinylamino)-methanesulfon-m-anisidide], daunorubicin and doxorubicin (Adriamycin) which are known to stimulate DNA-topoisomerase II cleavable complex formation.	Etoposide	193-202	host cell factor C1	Homo sapiens	186-191
7521751-5	1993	In HUVE, the topoisomerase II selective inhibitors novobiocin, nalidixic acid, and etoposide prevented cytokine-induced VCAM-1 surface expression, but not E-selectin or ICAM-1 surface expression.	Etoposide	83-92	vascular cell adhesion molecule 1	Homo sapiens	120-126
8379671-0	1993	[Etoposide, doxorubicin, cisplatin and 5-FU (EAP-F) therapy of advanced gastric cancer--its antitumor effect and evaluation of quality of life].	Etoposide	1-10	pleckstrin homology and FYVE domain containing 2	Homo sapiens	45-50
8411740-2	1993	Combination chemotherapy, including etoposide (VP-16) and tegafur (FT) allowed the patient to survive for approximately a year after the onset of the initial symptoms.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
8100862-10	1993	P-glycoprotein expression was roughly proportional to the degree of resistance to both doxorubicin and etoposide, but did not always correlate with the effect of verapamil on decreasing doxorubicin resistance.	Etoposide	103-112	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8319201-3	1993	Using an 859-base pair BamHI fragment of human ALL-1 complementary DNA that recognizes the genomic breakpoint region for de novo ALL and AML, we investigated two cases of secondary AML that followed etoposide-treated primary B-lineage ALL.	Etoposide	199-208	ALL1	Homo sapiens	47-52
8390979-3	1993	In two transfectants carrying an intact, full-length Drosophila topoisomerase II cDNA, exposure to the inducing agent, dexamethasone (10 microM), resulted in complementation of the endogenous mutant topoisomerase II and phenotypic reversion to etoposide sensitivity.	Etoposide	244-253	Topoisomerase 2	Drosophila melanogaster	64-80
8390979-4	1993	In the presence of glucocorticoid, etoposide-induced cytotoxicity increased 20-fold, despite the fact that Drosophila topoisomerase II mRNA expression was only 0.1% of that of the endogenous mammalian topoisomerase II.	Etoposide	35-44	Topoisomerase 2	Drosophila melanogaster	118-134
8390979-4	1993	In the presence of glucocorticoid, etoposide-induced cytotoxicity increased 20-fold, despite the fact that Drosophila topoisomerase II mRNA expression was only 0.1% of that of the endogenous mammalian topoisomerase II.	Etoposide	35-44	Topoisomerase 2	Drosophila melanogaster	201-217
7692928-0	1993	Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.	Etoposide	168-172	colony stimulating factor 3	Homo sapiens	65-102
21573322-5	1993	A brief exposure to etoposide causes both cell lines to arrest in G2, with a concomittant increase in cyclin-B levels and accumulation of hyperphosphorylated p34cdc2.	Etoposide	20-29	cyclin dependent kinase 1	Homo sapiens	158-165
8344765-2	1993	The patient was treated with cisplatin, bleomycin, and etoposide (VP-16) combination chemotherapy.	Etoposide	55-64	host cell factor C1	Homo sapiens	66-71
8362688-8	1993	Treatment with diethylstilbestrol diphosphate, etoposide, peplomycin and ifosfamide was effective, resulting in regressed intrapelvic masses and decreased serum prostatic acid phosphatase and prostatic specific antigen levels close to the normal limits.	Etoposide	47-56	acid phosphatase 3	Homo sapiens	161-187
8362689-5	1993	Three courses of salvage chemotherapy of VP-16 (etoposide) were performed.	Etoposide	48-57	host cell factor C1	Homo sapiens	41-46
21573322-6	1993	Failure to activate the p34cdc2 kinase following etoposide treatment to levels comparable with synchronous G2/M-phase cells is not due to inhibition of p34cdc2/cyclin-B complex formation, but relies more on an inability to tyrosine dephosphorylate p34cdc2.	Etoposide	49-58	cyclin dependent kinase 1	Homo sapiens	24-31
8391064-14	1993	The survival of limited-stage patients treated with CAV (with or without TRT) was improved with two cycles of cisplatin and etoposide consolidation therapy.	Etoposide	124-133	caveolin 2	Homo sapiens	52-55
7687859-4	1993	G-CSF (5 micrograms/kg) was administered during the recovery phase in 6/14 courses with Ara-C/Etop and in 4/13 courses with Ara-C/Mit.	Etoposide	94-98	colony stimulating factor 3	Homo sapiens	0-5
7690864-3	1993	In the 1989 study, vinblastine was replaced by etoposide, resulting in a chemotherapeutic regimen of 3 to 4 courses BEP and 3 to 4 courses VIP in patients with stage I to IV.	Etoposide	47-56	vasoactive intestinal peptide	Homo sapiens	139-142
8501820-3	1993	It was postulated that estramustine phosphate (EMP), an estradiol-nitrogen mustard conjugate that binds to the nuclear matrix, might enhance the cytotoxicity of etoposide (VP-16), a topoisomerase II inhibitor that acts at the level of the nuclear matrix.	Etoposide	161-170	host cell factor C1	Homo sapiens	172-177
8485705-2	1993	Activation of p53-DNA binding was seen for treatment with radiation, hydrogen peroxide, actinomycin D, Adriamycin, etoposide, camptothecin, 5-fluorouracil, mitomycin C, and cisplatin.	Etoposide	115-124	tumor protein p53	Homo sapiens	14-17
8467452-4	1993	The combination of CDDP and etoposide (VP-16) has shown synergistic activity in other settings.	Etoposide	28-37	host cell factor C1	Homo sapiens	39-44
8514100-0	1993	[The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
8514100-8	1993	Twenty-three months after discontinuation of etoposide therapy, the patient showed acute myelogenous leukaemia (AML) of M5b-subtype according to the FAB classification.	Etoposide	45-54	FA complementation group B	Homo sapiens	149-152
8483318-4	1993	The DNA topoisomerase inhibitors mitoxantrone, VP-16 (etoposide), and m-AMSA (amsacrine) were more effective in inducing DNA breaks than was hydroxyurea or cytosine arabinoside (AraC).	Etoposide	54-63	host cell factor C1	Homo sapiens	47-52
8395259-9	1993	This IFN combination potentiates the response of the cells to etoposide far more than to cisplatin.	Etoposide	62-71	interferon alpha 1	Homo sapiens	5-8
8281497-6	1993	The patient was successfully treated with VIP regimen (etoposide, ifosfamide and cisplatin) followed by local irradiation.	Etoposide	55-64	vasoactive intestinal peptide	Homo sapiens	42-45
8097746-1	1993	The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens.	Etoposide	39-48	host cell factor C1	Homo sapiens	32-37
8395599-2	1993	Thirty-six compounds that completely inhibited enzyme activity at a concentration of 500 nM or less, as assessed by ATP-dependent unknotting of P4 phage DNA, were at least 100-fold more potent than the clinically useful antitumor agent etoposide (VP-16).	Etoposide	236-245	host cell factor C1	Homo sapiens	247-252
8479523-6	1993	In contrast, homozygous null p53 thymocytes are resistant to induction of apoptosis by radiation or etoposide, but retain normal sensitivity to glucocorticoid and calcium.	Etoposide	100-109	transformation related protein 53, pseudogene	Mus musculus	29-32
8479523-8	1993	Cells heterozygous for p53 deletion are partially resistant to radiation and etoposide.	Etoposide	77-86	transformation related protein 53, pseudogene	Mus musculus	23-26
8382551-1	1993	The Adriamycin-resistant small cell lung carcinoma cell line, GLC4/ADR, showed large differences in cross-resistance to drugs such as Adriamycin, etoposide (VP-16), teniposide (VM-26), 4"-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA), and mitoxantrone, which stimulate the formation of topoisomerase (Topo) II-DNA complexes.	Etoposide	146-155	aldo-keto reductase family 1 member B	Homo sapiens	67-70
8503273-1	1993	A case of a girl with Langerhans cell histiocytosis who had hypofibrinogenemia during etoposide (VP-16) and prednisolone therapy is described.	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
8503273-6	1993	Careful monitoring of fibrinogen is mandatory in patients receiving etoposide and prednisolone.	Etoposide	68-77	fibrinogen beta chain	Homo sapiens	22-32
8471659-7	1993	These drugs, together with etoposide (VP-16) had been found to be very effective in relapsed cases [7].	Etoposide	27-36	host cell factor C1	Homo sapiens	38-43
8382554-1	1993	Type II DNA topoisomerase breaks both DNA strands, and many anticancer agents including etoposide (VP-16) and teniposide (VM-26) have been developed by targeting topoisomerase II molecules.	Etoposide	88-97	host cell factor C1	Homo sapiens	99-104
8457473-0	1993	Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.	Etoposide	21-30	colony stimulating factor 2	Homo sapiens	44-50
7685138-0	1993	[Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].	Etoposide	154-163	colony stimulating factor 3	Homo sapiens	29-66
7685138-1	1993	We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy.	Etoposide	209-218	colony stimulating factor 3	Homo sapiens	74-111
8445942-0	1993	Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.	Etoposide	116-125	colony stimulating factor 2	Homo sapiens	0-48
8447565-0	1993	High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin"s lymphoma.	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
8426196-1	1993	PURPOSE: To describe the occurrence of secondary acute myeloid leukemia (AML) in children with acute lymphoblastic leukemia (ALL) treated with etoposide (VP-16).	Etoposide	143-152	host cell factor C1	Homo sapiens	154-159
8168727-0	1993	Tyrosinase-induced phenoxyl radicals of etoposide (VP-16): interaction with reductants in model systems, K562 leukemic cell and nuclear homogenates.	Etoposide	40-49	tyrosinase	Homo sapiens	0-10
8179244-6	1993	INF-alpha is also used in histiocytosis X alone or in combination with retinoids or with etoposide and has been found effective in several observations.	Etoposide	89-98	interferon alpha 17	Homo sapiens	0-9
8386655-5	1993	The standard drug treatment worldwide for testicular cancer is PEB (cisplatin, etoposide, bleomycin) x3 for good risk and x4 for high risk patients, but there is cumulating evidence that VIP (cisplatin, ifosfamide, etoposide) is more effective for poor risk patients.	Etoposide	79-88	vasoactive intestinal peptide	Homo sapiens	187-190
8386655-5	1993	The standard drug treatment worldwide for testicular cancer is PEB (cisplatin, etoposide, bleomycin) x3 for good risk and x4 for high risk patients, but there is cumulating evidence that VIP (cisplatin, ifosfamide, etoposide) is more effective for poor risk patients.	Etoposide	215-224	vasoactive intestinal peptide	Homo sapiens	187-190
8509818-1	1993	12 patients: (7 males and 5 females) with recurrent brainstem gliomas were treated with the oral topoisomerase inhibitor VP-16 (Etoposide).	Etoposide	128-137	host cell factor C1	Homo sapiens	121-126
7681619-0	1993	Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16).	Etoposide	94-103	host cell factor C1	Homo sapiens	105-119
7681619-1	1993	A co-operative study for patients with intracranial germ cell tumours was performed to analyze their prognosis and the effectiveness of Cisplatin/Etoposide (CDDP/VP-16) chemotherapy.	Etoposide	146-155	host cell factor C1	Homo sapiens	157-167
8436210-3	1993	It has been shown in vitro that etoposide can impair the formation of ara-CTP in leukemia cells.	Etoposide	32-41	solute carrier family 25 member 1	Homo sapiens	74-77
8436210-6	1993	When the cells were incubated in RPMI-1640 with ara-C (10 mumol/l) and etoposide during 2 h, the formation of ara-CTP was decreased to 71 +/- 18 (mean +/- S.D.)	Etoposide	71-80	solute carrier family 25 member 1	Homo sapiens	114-117
8436210-16	1993	It is concluded that the inhibition of ara-CTP formation by etoposide seen in vitro is offset by the high protein binding of etoposide in plasma (96%) and that etoposide does not impair the formation of ara-CTP in leukemia cells in vivo during treatment with standard-dose etoposide.	Etoposide	60-69	solute carrier family 25 member 1	Homo sapiens	43-46
8168727-0	1993	Tyrosinase-induced phenoxyl radicals of etoposide (VP-16): interaction with reductants in model systems, K562 leukemic cell and nuclear homogenates.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
8168727-1	1993	Etoposide (VP-16) is an antitumor drug currently in use for the treatment of a number of human cancers.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
1280674-0	1992	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.	Etoposide	115-124	colony stimulating factor 2	Homo sapiens	0-48
1280674-0	1992	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.	Etoposide	115-124	colony stimulating factor 3	Homo sapiens	52-89
1336489-1	1992	Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4"-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line.	Etoposide	193-202	tumor necrosis factor	Homo sapiens	18-39
1492228-0	1992	High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.	Etoposide	10-19	host cell factor C1	Homo sapiens	21-26
1334113-4	1992	Twenty specimens were identified as MDR1 based upon test results showing resistance to adriamycin, vinca alkaloid, and etoposide.	Etoposide	119-128	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
1336899-4	1992	Single-agent intravenous (IV) etoposide has proven to be among the most active drugs for the treatment of SCLC.	Etoposide	30-39	SCLC1	Homo sapiens	106-110
1336899-7	1992	Given in such a schedule, oral etoposide has been shown to be effective in unfit or elderly (&gt; 70 years of age) patients with SCLC, who represent 25% to 30% of the total SCLC population.	Etoposide	31-40	SCLC1	Homo sapiens	129-133
1336899-7	1992	Given in such a schedule, oral etoposide has been shown to be effective in unfit or elderly (&gt; 70 years of age) patients with SCLC, who represent 25% to 30% of the total SCLC population.	Etoposide	31-40	SCLC1	Homo sapiens	173-177
1403039-1	1992	PURPOSE: A phase II study of etoposide (VP 16) and carboplatin (CBDCA) was performed in patients with metastatic neuroblastoma (NB).	Etoposide	29-38	host cell factor C1	Homo sapiens	40-45
1403040-1	1992	PURPOSE: To determine the maximum-tolerated dose (MTD) of cyclosporine (CsA) infusion administered with etoposide for 3 days in patients with cancer.	Etoposide	104-113	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	72-75
1403041-13	1992	Etoposide doses should be reduced by 50% when used with high-dose CsA in patients with normal renal and liver function.	Etoposide	0-9	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	66-69
1403040-5	1992	RESULTS: Fifty-seven patients were treated with 113 cycles of CsA with etoposide.	Etoposide	71-80	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	62-65
1403040-13	1992	CONCLUSIONS: Serum CsA levels of up to 4 mumol/L (4,800 ng/mL) are achievable during a short-term administration with acceptable toxicities when administered in combination with etoposide.	Etoposide	178-187	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	19-22
1403040-17	1992	When used with high-dose CsA, etoposide doses should be reduced by approximately 50% to compensate for the pharmacokinetic effects of CsA on etoposide (Lum et al, J Clin Oncol, 10:1635-1642, 1992).	Etoposide	30-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
1403040-17	1992	When used with high-dose CsA, etoposide doses should be reduced by approximately 50% to compensate for the pharmacokinetic effects of CsA on etoposide (Lum et al, J Clin Oncol, 10:1635-1642, 1992).	Etoposide	141-150	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
1403040-17	1992	When used with high-dose CsA, etoposide doses should be reduced by approximately 50% to compensate for the pharmacokinetic effects of CsA on etoposide (Lum et al, J Clin Oncol, 10:1635-1642, 1992).	Etoposide	141-150	lumican	Homo sapiens	152-155
1403041-1	1992	PURPOSE: To determine the effects of high-dose cyclosporine (CsA) infusion on the pharmacokinetics of etoposide in patients with cancer.	Etoposide	102-111	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	61-64
1402650-3	1992	In contrast, when cultured in the presence of IL-3, or other growth promoting factors, BAF3 cells are highly resistant to X-irradiation and the cytotoxic drugs etoposide and cisplatin.	Etoposide	160-169	interleukin 3	Mus musculus	46-50
1403041-6	1992	RESULTS: CsA concentrations more than 2,000 ng/mL produced an increase in etoposide AUC of 80% (P less than .001), a 38% decrease in total CL (P &lt; .01), a &gt; twofold increase in T1/2 (P &lt; .01), and a 46% larger Vss (P = .01) compared with etoposide alone.	Etoposide	74-83	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	9-12
1403041-8	1992	Higher CsA levels (&lt; 2,000 ng/mL v &gt; 2,000 ng/mL) resulted in greater changes in etoposide kinetics: Vss (1.4% v 46%) and T1/2 (40% v 108%).	Etoposide	87-96	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	7-10
1403041-9	1992	CsA produced a 38% decrease in renal and a 52% decrease in nonrenal CL of etoposide.	Etoposide	74-83	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-3
1403041-10	1992	Etoposide with CsA levels &gt; 2,000 ng/mL produced a lower WBC count nadir (900/mm3 v 1,600/mm3) compared with baseline etoposide cycles.	Etoposide	0-9	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18
1403041-11	1992	CONCLUSIONS: High-dose CsA produces significant increases in etoposide systemic exposure and leukopenia.	Etoposide	61-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	23-26
1330082-4	1992	The human mdr1 gene was overexpressed in the resistant line, but steady-state concentrations of etoposide were reduced only 1.5-fold.	Etoposide	96-105	ATP binding cassette subfamily B member 1	Homo sapiens	10-14
1358264-8	1992	In the manner evaluated, taxol plus either adriamycin, cisplatin, cyclophosphamide or etoposide (VP-16) were not meaningfully more efficacious than the more effective drug in each of those combination settings.	Etoposide	86-95	host cell factor C1	Homo sapiens	97-102
1421436-2	1992	Surviving populations generated sublines designated DXR-10 which expressed significant resistance to etoposide (VP-16) and vincristine (VCR), but not to adriamycin (ADR) or acute X-irradiation, as judged by clonogenic assays.	Etoposide	101-110	host cell factor C1	Homo sapiens	112-117
1432038-0	1992	Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
1515645-4	1992	This objective VP-16 sensitivity classification, as determined by PE1, remained unaltered when assessed by secondary (PE2) colony inhibition assay (evaluating the self-renewal fraction of AML progenitors), or by cytofluorometric viability assay (evaluating the ultimately differentiated blast cell population).	Etoposide	15-20	chymotrypsin like elastase 2A	Homo sapiens	66-69
1514527-2	1992	Thirty-five patients were entered in a Phase I trial of an admixture infusion of etoposide (VP-16) and carboplatin (CBDCA) administered continuously for 5 or 7 days.	Etoposide	81-90	host cell factor C1	Homo sapiens	92-97
1353119-3	1992	The KK47/ADM exhibited cross-resistance to doxorubicin derivatives (pirarubicin, epirubicin), vinca alkaloids (vinblastine, vincristine) and etoposide, but not to cisplatin, carboplatin, mitomycin C, peplomycin and methotrexate.	Etoposide	141-150	adrenomedullin	Homo sapiens	9-12
1377186-0	1992	Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
1515884-1	1992	Thirty-seven patients with advanced hematologic malignancy were entered into a phase I study designed to define a maximum tolerable dose (MTD) of etoposide (VP-16) and cyclophosphamide (CY) combined with 12 Gy fractionated total body irradiation (TBI) as preparation for marrow transplantation from an HLA-identical sibling (n = 13) or with cryopreserved autologous marrow (n = 24).	Etoposide	146-155	host cell factor C1	Homo sapiens	157-162
1353251-4	1992	When drug-sensitive cells are exposed for 30 min to an ED50 concentration of vinblastine, Adriamycin, colchicine, or VP-16, but not to methotrexate or cisplatin, there is a 3-6-fold induction in the level of c-fos message.	Etoposide	117-122	FBJ osteosarcoma oncogene	Mus musculus	208-213
1517797-6	1992	CSF concentration of VP-16-213 is 3-4 logs higher compared to concurrent plasma levels.	Etoposide	21-26	colony stimulating factor 2	Canis lupus familiaris	0-3
1318951-1	1992	PURPOSE: A phase II study that used combination chemotherapy with carboplatin (CBDCA) and etoposide (VP 16) (CE) was performed on patients with recurrent malignant glioma to investigate tumor control and toxicity.	Etoposide	90-99	host cell factor C1	Homo sapiens	101-106
1534319-0	1992	Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
1354408-7	1992	These results indicate that a decreased activity of topoisomerase II is the major factor for the development of etoposide resistance, and that an overexpression of the MDR1 gene is responsible, in part, for the development of resistance to the drug and some structurally unrelated compounds such as adriamycin and vinca alkaloids.	Etoposide	112-121	ATP binding cassette subfamily B member 1	Homo sapiens	168-172
1525405-0	1992	Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures.	Etoposide	12-21	host cell factor C1	Homo sapiens	23-28
21584513-3	1992	Exposure to inhibitors of DNA topoisomerase I (camptothecin: CPT-11) and II (etoposide: VP-16 and teniposide: VM-26) could efficiently induce CAT activities in both time- and dose-dependent manners.	Etoposide	77-86	host cell factor C1	Homo sapiens	88-93
21584513-3	1992	Exposure to inhibitors of DNA topoisomerase I (camptothecin: CPT-11) and II (etoposide: VP-16 and teniposide: VM-26) could efficiently induce CAT activities in both time- and dose-dependent manners.	Etoposide	77-86	catalase	Homo sapiens	142-145
1534319-1	1992	Cyclosporin A reverses multidrug resistance (MDR) and increases the in vivo cytostatic activity and toxicity of the anticancer agent etoposide (VP 16-213).	Etoposide	133-142	host cell factor C1	Homo sapiens	144-149
1581902-2	1992	The epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) are usually included among the drugs recognized by this MDR phenotype, and the MDR EHR2/DNR cell line is greater than 50-fold cross-resistant to VP-16.	Etoposide	35-44	host cell factor C1	Homo sapiens	46-51
1578365-0	1992	Human cytochrome P450 metabolism of teniposide and etoposide.	Etoposide	51-60	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
1611612-2	1992	Combination chemotherapy with cisplatin (CDDP) and etoposide (VP-16) was given to five children with early recurrent medulloblastoma.	Etoposide	51-60	host cell factor C1	Homo sapiens	62-67
1537631-0	1992	Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity.	Etoposide	80-89	asparaginase and isoaspartyl peptidase 1	Homo sapiens	57-71
1411635-11	1992	The superior efficacy without increased toxicity of more prolonged schedules of etoposide administration has been demonstrated recently in patients with small cell lung cancer (SCLC).	Etoposide	80-89	SCLC1	Homo sapiens	177-181
1411635-12	1992	Although the optimal schedule in any specific tumor is not known, current pharmacodynamic evidence suggests that the efficacy of etoposide, at least in SCLC, is related to the maintenance of prolonged low blood concentrations of drug.	Etoposide	129-138	SCLC1	Homo sapiens	152-156
1346631-7	1992	The resistant lines were cross-resistant to VP-16 (etoposide), despite lack of previous exposure to this drug.	Etoposide	51-60	host cell factor C1	Homo sapiens	44-49
1551112-0	1992	Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide.	Etoposide	143-152	cyclin dependent kinase 1	Homo sapiens	14-21
1551112-0	1992	Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide.	Etoposide	143-152	cyclin dependent kinase 1	Homo sapiens	41-48
1551112-1	1992	p34cdc2 kinase, an enzyme essential for mitosis in mammalian cells, may play a role in etoposide-induced G2 phase arrest of Chinese hamster ovary cells.	Etoposide	87-96	cyclin dependent kinase 1	Homo sapiens	0-7
1551112-2	1992	In this study, etoposide is shown to cause inhibition of a specific p34cdc2 kinase activation pathway, that of tyrosine dephosphorylation.	Etoposide	15-24	cyclin dependent kinase 1	Homo sapiens	68-75
1551112-3	1992	Exposure of asynchronously dividing cells to etoposide caused a simultaneous rapid decline of both mitotic index and p34cdc2 kinase activity, suggesting that the kinase was not activated and that the arrest point was in late G2 phase.	Etoposide	45-54	cyclin dependent kinase 1	Homo sapiens	117-124
1551112-6	1992	A 1-h exposure to etoposide during early G2 phase inhibited p34cdc2 kinase activation, its shift in electrophoretic mobility, and its tyrosine dephosphorylation, all of which correlated with a delay in mitotic progression.	Etoposide	18-27	cyclin dependent kinase 1	Homo sapiens	60-67
1550597-6	1992	By contrast, the DNA topoisomerase II inhibitor, etoposide, equally activated the MDR1, TK and SV 40 promoters.	Etoposide	49-58	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
1537631-1	1992	The effect of L-asparaginase (L-asp) pre-treatment on etoposide-induced DNA strand breakage and cytotoxicity was investigated.	Etoposide	54-63	asparaginase and isoaspartyl peptidase 1	Homo sapiens	14-28
1537631-1	1992	The effect of L-asparaginase (L-asp) pre-treatment on etoposide-induced DNA strand breakage and cytotoxicity was investigated.	Etoposide	54-63	asparaginase and isoaspartyl peptidase 1	Homo sapiens	14-19
1537631-2	1992	In a T-lymphoblastoid cell line, Molt 4, etoposide-induced DNA strand breaks, DNA-protein cross-links and cytotoxicity were reduced by pre-treatment with L-asp for 15 hr, but it did not cause these changes in a promyelocytic-leukemia cell line, HL-60, which is less sensitive than Molt 4 to L-asp.	Etoposide	41-50	asparaginase and isoaspartyl peptidase 1	Homo sapiens	154-159
1537631-2	1992	In a T-lymphoblastoid cell line, Molt 4, etoposide-induced DNA strand breaks, DNA-protein cross-links and cytotoxicity were reduced by pre-treatment with L-asp for 15 hr, but it did not cause these changes in a promyelocytic-leukemia cell line, HL-60, which is less sensitive than Molt 4 to L-asp.	Etoposide	41-50	asparaginase and isoaspartyl peptidase 1	Homo sapiens	291-296
1537631-6	1992	Our data imply that a decrease in S- and G2/M-phase cells following L-asp treatment may explain the reduction of etoposide-induced DNA lesions and cytotoxicity in Molt 4 cells, since topoisomerase-II (Topo-II) content or activity is a function of cellular proliferation status.	Etoposide	113-122	asparaginase and isoaspartyl peptidase 1	Homo sapiens	68-73
1382255-2	1992	Arm 1 patients received 3 courses of chemotherapy with cisplatin (100 mg/m2, day 1) and etoposide (125 mg/m2 i.v., day 1; 250 mg/m2 p.o., day 2-3), followed by radiotherapy (4,000 cGy/20 fractions/4 weeks).	Etoposide	88-97	ADRM1 26S proteasome ubiquitin receptor	Homo sapiens	0-5
1384135-1	1992	We assessed the efficacy and tolerability of VIM (etoposide/ifosfamide/methotrexate) combination therapy in 24 patients who were failing the treatment protocol of the Lymphomes Non Hodgkiniens (LNH) 84 study.	Etoposide	50-59	vimentin	Homo sapiens	45-48
1370437-5	1992	P-glycoprotein-negative sub-lines displayed variable NK susceptibility; within this group, the variants selected for primary etoposide resistance were more susceptible to NK cytolysis than parental cells.	Etoposide	125-134	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
1370437-8	1992	Two MDR lines selected for primary etoposide resistance displayed enhanced LAK susceptibility.	Etoposide	35-44	alpha kinase 1	Homo sapiens	75-78
1729957-3	1992	And after an additional two courses of etoposide for 8 and 4 days, respectively, the tumor disappeared and the serum CA 125 level came to within normal limits.	Etoposide	39-48	mucin 16, cell surface associated	Homo sapiens	117-123
1315778-3	1992	Among nine cell lines of lung cancer tested, small-cell lung cancer lines, which showed higher sensitivity to cisplatin and etoposide, were unexpectedly found to contain significantly higher poly(ADP-ribose) polymerase activity than five non-small-cell lung cancer cell lines.	Etoposide	124-133	poly(ADP-ribose) polymerase 1	Homo sapiens	191-218
1306884-2	1992	The profound myelotoxicity induced by cisplatin (40 mg/m2 daily x 5) and etoposide (150 mg/m2 daily x 3) provides a model to test the clinical value of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric cancer patients; myelosuppression occurred (absolute neutrophil count [ANC] &lt; 500/microL) during 99 of 118 (84%) courses given to 44 children with refractory solid tumors.	Etoposide	73-82	colony stimulating factor 2	Homo sapiens	170-218
1310581-2	1992	In this study, we further show that in addition to m-AMSA and VM26 which we had previously reported, a widely used and clinically available drug, etoposide (VP-16 or VePesid) can irreversibly inhibit CMV replication at the drug concentration (2.5 micrograms/ml) greatly below toxic levels to stationary phase cells.	Etoposide	146-155	host cell factor C1	Homo sapiens	157-173
1310581-5	1992	Because of their irreversible inhibitory effects and approval usage in clinical oncology, it is suggested that this group of compounds, particularly etoposide (VP-16), can be used to control life-threatening CMV infections, such as CMV pneumonitis and CMV retinitis, in cancer and immunocompromised patients or patients with AIDS.	Etoposide	149-158	host cell factor C1	Homo sapiens	160-165
1323814-2	1992	Reasons why EP (etoposide/cisplatin) has been used to treat non-small cell lung cancer (NSCLC), despite the fact that etoposide has demonstrated only a modest degree of activity against this disease, are preclinical suggestions of cisplatin/etoposide synergism and successful results for the combination in treating small cell lung cancer (SCLC).	Etoposide	16-25	SCLC1	Homo sapiens	89-93
1663216-0	1991	[Complete remission of a highly malignant, progressive under therapy Wilm"s tumor using the combination carboplatin and etoposide (VP 16)].	Etoposide	120-129	host cell factor C1	Homo sapiens	131-136
1684908-5	1991	The degree of resistance to H-8 was directly proportional to their extent of resistance to vincristine, adriamycin, and 4"-demethylepipodophyllotoxin-9-(4,6-O-ethylidene)-beta-D-gluco pyr anoside (VP-16) and to that of the expression of P-glycoprotein.	Etoposide	120-195	histocompatibility 8	Mus musculus	28-31
1684908-5	1991	The degree of resistance to H-8 was directly proportional to their extent of resistance to vincristine, adriamycin, and 4"-demethylepipodophyllotoxin-9-(4,6-O-ethylidene)-beta-D-gluco pyr anoside (VP-16) and to that of the expression of P-glycoprotein.	Etoposide	197-202	histocompatibility 8	Mus musculus	28-31
1758445-1	1991	Podophyllotoxin (PD) and its derivative etoposide (VP-16), a clinically useful anticancer drug, exhibit different mechanisms of action.	Etoposide	40-49	host cell factor C1	Homo sapiens	51-56
1755298-2	1991	The initial response to induction chemotherapy, especially to VP16/cisplatin was evaluated by determining t 1/2 for urinary vanillylmandelic acid (VMA), homovanillic acid and serum neuron specific enolase (NSE).	Etoposide	62-66	enolase 2	Homo sapiens	181-204
1683482-5	1991	Treatment of F9 cells with a DNA topoisomerase II inhibitor etoposide (VP-16) during differentiation blocks the accumulation of Hox-2.1 mRNA.	Etoposide	60-69	homeobox B5	Mus musculus	128-135
1683482-5	1991	Treatment of F9 cells with a DNA topoisomerase II inhibitor etoposide (VP-16) during differentiation blocks the accumulation of Hox-2.1 mRNA.	Etoposide	71-76	homeobox B5	Mus musculus	128-135
1683482-6	1991	Nuclear run-on analyses reveal that etoposide inhibits transcription of the Hox-2.1 gene during F9 cell differentiation.	Etoposide	36-45	homeobox B5	Mus musculus	76-83
1722410-1	1991	The possibility of increasing the activity of etoposide (VP-16) by combining this anti-cancer agent with indomethacin (Indo) was investigated by treating murine and human cultured tumor cells with a combination of Indo and VP-16 and quantitating VP-16 cytotoxicity by the [3H]thymidine incorporation assay.	Etoposide	46-55	host cell factor C1	Homo sapiens	57-62
1933864-8	1991	In contrast to senescent and low serum-arrested cells, cdc2 mRNA was expressed at normal levels in cells partially growth arrested by isoleucine deficiency in G1, by aphidicolin at G1-S, by etoposide in G2, or by Colcemid in the M phase of the cell cycle, indicating that cdc2 down-regulation does not always occur upon growth arrest.	Etoposide	190-199	cyclin dependent kinase 1	Homo sapiens	55-59
1779456-2	1991	In this report we investigated pharmacokinetics of enositabine (BHAC), arabinosylcytosine (Ara-C) and etoposide (VP-16) in a patient on maintenance hemodialysis who suffered from acute myelomonocytic leukemia and treated by BHAC-EV regimen.	Etoposide	102-111	host cell factor C1	Homo sapiens	113-118
1960753-9	1991	Patients with lower pretreatment albumin levels are at higher risk of severe myelosuppression during etoposide therapy.	Etoposide	101-110	albumin	Homo sapiens	33-40
1764166-0	1991	Synthesis and biological activity of galactopyranoside derivatives of 4"-demethylepipodophyllotoxin showing VP-16 (etoposide)-like activity.	Etoposide	115-124	host cell factor C1	Homo sapiens	108-113
1768975-5	1991	Univariate analysis identified the following risk factors for neurotoxicity: use of unrelated or HLA-mismatched related donors, administration of etoposide (VP-16) or total body irradiation as part of conditioning, use of corticosteroids for prophylaxis or treatment of acute GVHD, or development of either acute GVHD or clinically significant microangiopathic hemolytic anemia (MAHA) post-BMT.	Etoposide	146-155	host cell factor C1	Homo sapiens	157-162
1743556-0	1991	Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
1741774-5	1991	Exposure of MCF-7 cells to etoposide (VP-16), mitoxantrone and camptothecin resulted in the detection of significant amounts of protein-linked DNA breaks, whereas none were found in MD-treated cells.	Etoposide	27-36	host cell factor C1	Homo sapiens	38-43
1755298-2	1991	The initial response to induction chemotherapy, especially to VP16/cisplatin was evaluated by determining t 1/2 for urinary vanillylmandelic acid (VMA), homovanillic acid and serum neuron specific enolase (NSE).	Etoposide	62-66	enolase 2	Homo sapiens	206-209
1655218-1	1991	Encouraging response rates have been reported in Stage III non-small cell lung cancer when 5-fluorouracil (5-FU), etoposide (VP-16), and cisplatin (FED) have been combined with radiation therapy (RT) or RT and surgery.	Etoposide	114-123	host cell factor C1	Homo sapiens	125-130
1779333-2	1991	Recombinant human tumor necrosis factor (rhTNF) has been shown to enhance the antitumor efficacy of etoposide (VP-16) in the treatment of C1300 murine neuroblastoma.	Etoposide	100-109	tumor necrosis factor	Homo sapiens	18-39
1779333-2	1991	Recombinant human tumor necrosis factor (rhTNF) has been shown to enhance the antitumor efficacy of etoposide (VP-16) in the treatment of C1300 murine neuroblastoma.	Etoposide	111-116	tumor necrosis factor	Homo sapiens	18-39
1654205-2	1991	In order to see whether ICRF-154 and ICRF-193 affect cellular topoisomerase II in situ or not, we examined the effect of these drugs on etoposide (VP-16)-induced, topoisomerase II-mediated DNA breaks in RPMI 8402 cells by alkaline sedimentation analysis.	Etoposide	136-145	host cell factor C1	Homo sapiens	147-152
1681541-5	1991	To evaluate whether VP-16 treatment caused sufficient levels of DNA sequence alterations to interfere with gene product formation, we isolated hypoxanthine (guanine) phosphoribosyltransferase (HPRT)-deficient mutants from Chinese hamster V79 cells grown in the presence or absence of VP-16.	Etoposide	20-25	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	193-197
1681541-7	1991	Most of the VP-16-induced mutants showed partial deletions and/or rearrangements of the HPRT gene.	Etoposide	12-17	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	88-92
1651994-1	1991	A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC).	Etoposide	52-61	host cell factor C1	Homo sapiens	63-68
1955738-2	1991	In this study, we describe the effects of methylprednisolone (MP) and etoposide (VP16) alone or in combination on 5 tumor cell lines (HL-60, a promyelocytic cell line; Molt-4, a T cell leukemia; Daudi, a Burkitt"s lymphoma and R10/8226 and R40/8226, doxorubicin-resistant myeloma cell lines).	Etoposide	70-79	host cell factor C1	Homo sapiens	81-85
1651995-1	1991	The regimen of cisplatin, vincristine, doxorubicin, and etoposide (CODE) was designed to double the dose intensity of these drugs in comparison with a standard regimen (alternating cyclophosphamide, doxorubicin, and vincristine [CAV] and etoposide-cisplatin [EP]) for extensive-stage small-cell lung cancer (SCLC).	Etoposide	56-65	caveolin 2	Homo sapiens	229-232
1657846-1	1991	An etoposide-resistant K562 cell line (K/eto) was obtained by stepwise exposure, in culture, to increasing concentrations of etoposide, without the use of mutagens.	Etoposide	125-134	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	3-6
1720760-1	1991	We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol.	Etoposide	31-40	vimentin	Homo sapiens	91-94
1650363-5	1991	In contrast to etoposide, which stabilizes enzyme-DNA cleavage complexes primarily by inhibiting topoisomerase II-mediated DNA religation, neither quinolone impaired the enzyme"s ability to religate cleaved DNA.	Etoposide	15-24	Topoisomerase 2	Drosophila melanogaster	97-113
1650363-10	1991	Although quinolone cross-resistance was less pronounced than observed for etoposide (approximately 12-fold), it indicates that topoisomerase II is a physiological target for CP-67,804 and CP-115,953 in mammalian cells.	Etoposide	74-83	Topoisomerase 2	Drosophila melanogaster	127-143
1877814-1	1991	Preoperative intra-arterial injection therapy using etoposide, epirubicin and carboplatin (EAP II) was done for patients with resectable advanced gastric cancer.	Etoposide	52-61	tyrosyl-DNA phosphodiesterase 2	Homo sapiens	91-97
1657205-5	1991	Treatment based on combinations of fluorouracil, methotrexate, doxorubicin, etoposide, and cisplatin have shown high response rates (FAMTX [fluorouracil, doxorubicin, and methotrexate], EAP [etoposide, doxorubicin, and cisplatin], ELF [etoposide, leucovorin, and fluorouracil]) and a survival benefit (FAMTX).	Etoposide	76-85	glutamyl aminopeptidase	Homo sapiens	186-189
1849785-4	1991	Responding patients received consolidation therapy with cisplatin and etoposide (VP-16).	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
1910950-8	1991	The mean concentration of etoposide with AT II-induced hypertension in the tumor tissue was 2.2-fold higher than that without AT II-induced hypertension.	Etoposide	26-35	angiotensinogen	Rattus norvegicus	41-46
1920837-1	1991	We investigated the efficacy of oral etoposide (VP-16) for the patients with acute non-lymphocytic leukemia (ANLL) in relapse or refractory to the standard chemotherapy.	Etoposide	37-46	host cell factor C1	Homo sapiens	48-53
1827357-2	1991	Successful control of clinical symptoms and eosinophil counts was obtained with etoposide (VP16-213) for 18 months.	Etoposide	80-89	host cell factor C1	Homo sapiens	91-95
1904980-9	1991	These findings suggest that transcriptional induction of c-jun expression represents a signaling pathway activated in the cellular response to etoposide-induced DNA damage.	Etoposide	143-152	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-62
1645864-3	1991	Protein associated dsb were introduced by treating cells with the DNA topoisomerase II poison; etoposide (VP-16).	Etoposide	95-104	host cell factor C1	Homo sapiens	106-111
1920837-0	1991	[Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia].	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
1648924-2	1991	Although the stabilization of topoisomerase II cleavable complexes by etoposide (VP-16) has been recognized to be important for cell killing, the lethal events following the formation of cleavable complexes remain to be elucidated.	Etoposide	70-79	host cell factor C1	Homo sapiens	81-86
2026183-1	1991	Ten patients with non-Hodgkin"s lymphoma (NHL) and nine with Hodgkin"s Disease (HD) received high-dose busulfan and etoposide (VP-16) prior to autologous bone marrow transplantation (ABMT).	Etoposide	116-125	host cell factor C1	Homo sapiens	127-132
1904980-0	1991	Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide.	Etoposide	83-92	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
1904980-3	1991	The present results demonstrate that etoposide induces expression of the c-jun protooncogene in HL-60 myeloid leukemia cells.	Etoposide	37-46	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	73-78
1904980-6	1991	Nuclear run-on assays demonstrated that the induction of c-jun expression by etoposide is regulated at the transcriptional level.	Etoposide	77-86	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-62
1904980-7	1991	The results further demonstrate that etoposide-induced c-jun expression occurs in association with the appearance of c-fos transcripts.	Etoposide	37-46	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
1904980-7	1991	The results further demonstrate that etoposide-induced c-jun expression occurs in association with the appearance of c-fos transcripts.	Etoposide	37-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-122
1904980-8	1991	Moreover, the c-jun gene is induced by etoposide during periods of oligonucleosomal DNA cleavage, which is characteristic of programmed cell death.	Etoposide	39-48	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-19
1988893-2	1991	CA 125 was measured in 21 women receiving cisplatin, etoposide, and Adriamycin for a total of 275 courses of chemotherapy (median eight).	Etoposide	53-62	mucin 16, cell surface associated	Homo sapiens	0-6
1717863-0	1991	Complete remission of metastatic teratoma from malignant testicular tumor using salvage chemotherapy with VP-16 (etoposide), CDDP, and ACNU--case report.	Etoposide	113-122	host cell factor C1	Homo sapiens	106-111
2012406-0	1991	[Evaluation of EAP (etoposide, adriamycin, cisplatin) for highly advanced gastric cancer in a neoadjuvant setting].	Etoposide	20-29	glutamyl aminopeptidase	Homo sapiens	15-18
2015041-2	1991	We further determined whether NK-250 and NK-252 among the six compounds could potentiate cytocidal activities of etoposide (VP16) as well as VCR against both multidrug-resistant (MDR) cell line (VJ-300) and atypical MDR cell line (KB/VM-4).	Etoposide	113-122	host cell factor C1	Homo sapiens	124-128
1824825-1	1991	To investigate the possibility that anticancer drugs combined with cytokines may show increased activity, human tumor cells were treated with combinations of human recombinant interleukin 1 alpha (rIL-1 alpha) and etoposide (VP-16).	Etoposide	214-223	host cell factor C1	Homo sapiens	225-230
1991703-0	1991	Activity of etoposide (VP-16) in human tumor cells under different growth conditions.	Etoposide	12-21	host cell factor C1	Homo sapiens	23-28
1991703-1	1991	The effect of etoposide (VP-16) on a human epidermoid carcinoma cell line (HEp3) has been evaluated under different growth conditions.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
1848545-1	1991	DNA topoisomerase inhibitors, camptothecin and 4"-demethylepipodophyllotoxin ethylidene-beta-D-glucoside (VP16) had strong differentiation-inducing activity for all five kinds of leukemia cells examined (human HL60, U937, ML1, and K562 cells and mouse M1 cells) as judged from measurements of various differentiation markers.	Etoposide	47-104	interleukin 17F	Homo sapiens	222-225
1848545-1	1991	DNA topoisomerase inhibitors, camptothecin and 4"-demethylepipodophyllotoxin ethylidene-beta-D-glucoside (VP16) had strong differentiation-inducing activity for all five kinds of leukemia cells examined (human HL60, U937, ML1, and K562 cells and mouse M1 cells) as judged from measurements of various differentiation markers.	Etoposide	106-110	interleukin 17F	Homo sapiens	222-225
1673356-8	1991	The addition of the cytotoxic agent etoposide (VP-16) following antibody purging results in a 4.6 log reduction of malignant cells.	Etoposide	36-45	host cell factor C1	Homo sapiens	47-52
1849124-1	1991	Etoposide (VP-16) resistance is expressed following in vitro exposure of HN-1 and MCF-7 human tumor cells to the drug itself or to fractionated X irradiation.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
1849124-1	1991	Etoposide (VP-16) resistance is expressed following in vitro exposure of HN-1 and MCF-7 human tumor cells to the drug itself or to fractionated X irradiation.	Etoposide	0-9	Jupiter microtubule associated homolog 1	Homo sapiens	73-77
2066761-1	1991	We conducted a phase II study of intraperitoneal (IP) cisplatin (CDDP) and etoposide (VP-16) as salvage therapy in patients with ovarian cancer who had persistent disease or who had relapsed after primary systemic chemotherapy and had residual disease of less than 2 cm.	Etoposide	75-84	host cell factor C1	Homo sapiens	86-91
2003744-0	1991	[Therapeutic efficacy of etoposide injected via carotid artery with angiotensin II-induced hypertension in experimental rat gliomas].	Etoposide	25-34	angiotensinogen	Rattus norvegicus	68-82
1991681-1	1991	The RIF-1 tumor line contains cells that are resistant to various anti-neoplastic drugs, including 5-fluorouracil (5FU), methotrexate (MTX), adriamycin (ADR), and etoposide (VP16).	Etoposide	163-172	replication timing regulatory factor 1	Homo sapiens	4-9
1991681-1	1991	The RIF-1 tumor line contains cells that are resistant to various anti-neoplastic drugs, including 5-fluorouracil (5FU), methotrexate (MTX), adriamycin (ADR), and etoposide (VP16).	Etoposide	174-178	replication timing regulatory factor 1	Homo sapiens	4-9
1988106-0	1991	The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture.	Etoposide	68-77	calcineurin binding protein 1	Homo sapiens	85-89
1781917-0	1991	Chemical compatibility of mitoxantrone and etoposide (VP-16).	Etoposide	43-52	host cell factor C1	Homo sapiens	54-59
1646050-2	1991	The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotection and autologous bone marrow support.	Etoposide	87-96	host cell factor C1	Homo sapiens	98-103
1984829-1	1991	Etoposide (VP16-213, NSC 141540) induces a complete response (CR) in 15% to 25% of previously treated patients with acute nonlymphocytic leukemia (ANLL) when used as a single agent.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-15
1984831-1	1991	The epipodophyllotoxin derivative etoposide (VP-16) has been in widespread use both alone and in combination chemotherapy for the past decade.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
2249891-0	1990	Potentiation of TNF-mediated cell killing by VP-16: relationship to DNA single-strand break formation.	Etoposide	45-50	tumor necrosis factor	Mus musculus	16-19
1804597-6	1991	JM8 was administered alone (400 mg/m2) or in combination (300 mg/m2) with vinblastine (6 mg/m2), etoposide (100 mg/m2) or 5-fluorouracil (1,000 mg/m2).	Etoposide	97-106	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	0-3
1835860-0	1991	Increased levels of mitochondrial DNA in an etoposide-resistant human monocytic leukaemia cell line (THP-1/E).	Etoposide	44-53	GLI family zinc finger 2	Homo sapiens	101-108
1835860-1	1991	Electron microscopic observations of THP-1/E (an etoposide-resistant human monocytic leukaemia cell line) showed a remarkable change of mitochondrial structure.	Etoposide	49-58	GLI family zinc finger 2	Homo sapiens	37-44
1702148-1	1991	This is a Southwest Oncology Group (SWOG) prospective randomized trial of cisplatin, vinblastine, and bleomycin (PVB) versus vinblastine, cisplatin, and etoposide (VP-16) (VPV) in the treatment of advanced germ cell tumors of the testis.	Etoposide	153-162	host cell factor C1	Homo sapiens	164-169
2016905-1	1991	Sodium-dependent amino acid transport of methylaminoisobutyric acid (MeAIB) in a human myelogenous leukemic cell line K562 was inhibited by 30 nM etoposide (VP-16).	Etoposide	146-155	host cell factor C1	Homo sapiens	157-162
2174300-1	1990	A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy.	Etoposide	38-47	vasoactive intestinal peptide	Homo sapiens	79-82
2174464-1	1990	In an effort to test clinically the hypothesis that the duration of cellular exposure to etoposide (VP-16) and cisplatin (CDDP) is an important determinant of cytotoxicity, we performed a phase III randomized trial comparing an outpatient bolus regimen of combined VP-16 and CDDP with a sequential infusion over 72 hours of these same two drugs.	Etoposide	89-98	host cell factor C1	Homo sapiens	100-105
2007774-0	1991	Etoposide (VP 16-213) induced hepatitis.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2007774-2	1991	Acute hepatitis is a potential, although rare, complication following administration of high doses of Etoposide (VP 16-213).	Etoposide	102-111	host cell factor C1	Homo sapiens	113-118
2249891-5	1990	In addition, the potentiating effect of VP-16 on TNF-mediated WEHI164.13 cell killing was not associated with an increase in its intrinsic activity with respect to DNA single-strand break formation.	Etoposide	40-45	tumor necrosis factor	Mus musculus	49-52
2249891-7	1990	The inhibitory effect of quinacrine on VP-16/TNF-mediated cell lysis was accompanied by a marked decrease in VP-16-mediated DNA single-strand break generation.	Etoposide	39-44	tumor necrosis factor	Mus musculus	45-48
2249891-7	1990	The inhibitory effect of quinacrine on VP-16/TNF-mediated cell lysis was accompanied by a marked decrease in VP-16-mediated DNA single-strand break generation.	Etoposide	109-114	tumor necrosis factor	Mus musculus	45-48
2249891-8	1990	Taken together, our findings suggest that TNF and TNF/VP-16 treatments may involve different events during cell killing and support the hypothesis that 2 signals are required for optimal induction of cell lysis by the combination of VP-16/TNF: one signal provided by VP-16 resulting in topoisomerase II inhibition and subsequent DNA single-strand break generation, and a second signal involving TNF.	Etoposide	233-238	tumor necrosis factor	Mus musculus	42-45
2249891-8	1990	Taken together, our findings suggest that TNF and TNF/VP-16 treatments may involve different events during cell killing and support the hypothesis that 2 signals are required for optimal induction of cell lysis by the combination of VP-16/TNF: one signal provided by VP-16 resulting in topoisomerase II inhibition and subsequent DNA single-strand break generation, and a second signal involving TNF.	Etoposide	233-238	tumor necrosis factor	Mus musculus	50-53
2249891-8	1990	Taken together, our findings suggest that TNF and TNF/VP-16 treatments may involve different events during cell killing and support the hypothesis that 2 signals are required for optimal induction of cell lysis by the combination of VP-16/TNF: one signal provided by VP-16 resulting in topoisomerase II inhibition and subsequent DNA single-strand break generation, and a second signal involving TNF.	Etoposide	233-238	tumor necrosis factor	Mus musculus	50-53
2249891-8	1990	Taken together, our findings suggest that TNF and TNF/VP-16 treatments may involve different events during cell killing and support the hypothesis that 2 signals are required for optimal induction of cell lysis by the combination of VP-16/TNF: one signal provided by VP-16 resulting in topoisomerase II inhibition and subsequent DNA single-strand break generation, and a second signal involving TNF.	Etoposide	233-238	tumor necrosis factor	Mus musculus	50-53
2226679-0	1990	Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
1979245-3	1990	The drug-resistant variants were resistant to vinblastine (VBL), colchicine (COL), and etoposide (VP-16) in the order VBL greater than COL greater than VP-16 on the basis of 50% inhibitory concentration values obtained by clonogenic assay with continuous drug exposure.	Etoposide	87-96	host cell factor C1	Homo sapiens	98-103
1979245-3	1990	The drug-resistant variants were resistant to vinblastine (VBL), colchicine (COL), and etoposide (VP-16) in the order VBL greater than COL greater than VP-16 on the basis of 50% inhibitory concentration values obtained by clonogenic assay with continuous drug exposure.	Etoposide	87-96	host cell factor C1	Homo sapiens	152-157
2226679-1	1990	We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal human bone marrow; two human leukemia cell lines, K562 and CEM; their MDR variants, K562/DOX and CEM/VLB; and mixtures of normal marrow and leukemic cells.	Etoposide	123-132	host cell factor C1	Homo sapiens	134-139
1699657-5	1990	According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide).	Etoposide	135-144	colony stimulating factor 3	Homo sapiens	58-63
1982999-2	1990	The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.	Etoposide	149-158	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
2228309-0	1990	Chromosome aberrations induced by etoposide (VP-16) are not random.	Etoposide	34-43	host cell factor C1	Homo sapiens	45-50
1982999-2	1990	The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.	Etoposide	364-373	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
1982999-2	1990	The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.	Etoposide	364-373	ATP binding cassette subfamily B member 1	Homo sapiens	189-203
1982999-2	1990	The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.	Etoposide	364-373	ATP binding cassette subfamily B member 1	Homo sapiens	189-203
2263514-3	1990	The major advances in single-agent antineoplastic drug therapy include the introduction of cisplatin almost 20 years ago and of etoposide (VP-16) in the mid-1980s.	Etoposide	128-137	host cell factor C1	Homo sapiens	139-144
1700077-10	1990	In 1978, we initiated salvage therapy with cisplatin plus etoposide (VP-16) in patients not cured with PVB, and 25% of these patients were subsequently cured with this regimen.	Etoposide	58-67	host cell factor C1	Homo sapiens	69-74
2262732-1	1990	The survival of cultured HeLa S3 cells and their progression through the cell cycle after exposure to Etoposide (VP-16) were studied.	Etoposide	102-111	host cell factor C1	Homo sapiens	113-118
2287079-0	1990	[Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].	Etoposide	43-52	host cell factor C1	Homo sapiens	54-59
2135392-5	1990	The dose-response curve of GP-7 on SGC-7901 cell was similar to that of etoposide (VP-16).	Etoposide	72-81	host cell factor C1	Homo sapiens	83-88
2393312-0	1990	[A case of complete remission in brain metastasis from lung adenocarcinoma with EAP (etoposide, adriamycin, cisplatin)].	Etoposide	85-94	glutamyl aminopeptidase	Homo sapiens	80-83
1976136-7	1990	By contrast, the difference between the HT1080 and DR4 lines in etoposide-induced DNA cleavage was much greater in cells than in nuclei.	Etoposide	64-73	major histocompatibility complex, class II, DR beta 4	Homo sapiens	51-54
1976136-9	1990	The specific activities of several antioxidant enzymes, components of the cell"s defense against free-radical damage that may be produced by doxorubicin or etoposide, were significantly different in HT1080 and DR4 cytosolic extracts.	Etoposide	156-165	major histocompatibility complex, class II, DR beta 4	Homo sapiens	210-213
1976136-11	1990	Regardless, the magnitude of the resistance of DR4 to doxorubicin and etoposide cannot be explained solely on the basis of a topoisomerase II-related mechanism.	Etoposide	70-79	major histocompatibility complex, class II, DR beta 4	Homo sapiens	47-50
2255067-0	1990	[Successful therapy of Ph1 positive chronic myelocytic leukemia with oral form of etoposide].	Etoposide	82-91	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	23-26
1976136-1	1990	HT1080/DR4 (DR4) is a doxorubicin-resistant human fibrosarcoma line that exhibits 150-fold cross-resistance to etoposide but does not overexpress P-glycoprotein (one mechanism of multiple drug resistance).	Etoposide	111-120	major histocompatibility complex, class II, DR beta 4	Homo sapiens	7-10
1976136-1	1990	HT1080/DR4 (DR4) is a doxorubicin-resistant human fibrosarcoma line that exhibits 150-fold cross-resistance to etoposide but does not overexpress P-glycoprotein (one mechanism of multiple drug resistance).	Etoposide	111-120	major histocompatibility complex, class II, DR beta 4	Homo sapiens	12-15
1976136-5	1990	Following treatment with AMSA, etoposide, and 5-iminodaunorubicin, topoisomerase II-mediated DNA cleavage in DR4 cells and nuclei was reduced compared with cleavage in HT1080 parent cells and nuclei.	Etoposide	31-40	major histocompatibility complex, class II, DR beta 4	Homo sapiens	109-112
1974823-8	1990	However, in the non-P-glycoprotein-mediated MDR cell lines, resistance levels are lower and a preferential resistance for etoposide is seen.	Etoposide	122-131	ATP binding cassette subfamily B member 1	Homo sapiens	20-34
2387345-1	1990	We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal bone marrow cells.	Etoposide	123-132	host cell factor C1	Homo sapiens	134-139
2171561-7	1990	Tumor necrosis factor alone inhibited the growth and cloning of the NSCLC line H125 but exerted a marked protective effect against higher concentrations of etoposide.	Etoposide	156-165	tumor necrosis factor	Homo sapiens	0-21
2171561-4	1990	The effects of etoposide on the classic SCLC line H209 were potentiated by TNF with a decrease in the IC50 from 3.3 microM to 1.0 microM as determined by FDA/PI.	Etoposide	15-24	tumor necrosis factor	Homo sapiens	75-78
2171561-8	1990	It appears that the interaction of TNF with etoposide varies between cell lines and between subclasses of human lung cancer.	Etoposide	44-53	tumor necrosis factor	Homo sapiens	35-38
2166714-6	1990	With 5 cell lines we also tested whether TNF affected the cytotoxicity of doxorubicin and etoposide, 2 topoisomerase II-targeted drugs which are widely used in the therapy of lung cancer.	Etoposide	90-99	tumor necrosis factor	Homo sapiens	41-44
2364367-11	1990	Cisplatin and etoposide (VP-16) appeared to be the most active chemotherapeutic agents.	Etoposide	14-23	host cell factor C1	Homo sapiens	25-30
2386890-1	1990	The authors administered high-dose chemotherapy with cyclophosphamide, BCNU (carmustine) and VP-16 (etoposide) plus autologous bone marrow transplantation (ABMT) to 22 adult patients with relapsed acute leukemia in second or subsequent remission.	Etoposide	100-109	host cell factor C1	Homo sapiens	93-98
1703510-0	1990	CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin"s disease.	Etoposide	35-44	caveolin 2	Homo sapiens	0-3
2389968-1	1990	In order to deliver a high concentration of anti-cancer drugs in tumor tissue, preoperative intra-arterial injection therapy using Etoposide (VP-16), Pirarubicin (THP-ADM) and Cisplatin (CDDP), was used for 22 patients with resectable advanced gastric cancer.	Etoposide	131-140	host cell factor C1	Homo sapiens	142-147
2164676-4	1990	The reaction is dependent on ATP and is inhibited by VP-16, a specific inhibitor of eukaryotic DNA topoisomerase II.	Etoposide	53-58	DNA topoisomerase 2	Bombyx mori	95-115
1972771-1	1990	The interaction of etoposide (VP-16), Vinca alkaloids, and verapamil with the P-glycoprotein (P-gp) was studied in human breast (MCF-7) and Chinese hamster lung (DC3F) cell lines and the corresponding multidrug-resistant MCF-7/ADR and DC3F/ADX tumor cell lines, selected for resistance to Adriamycin and actinomycin D, respectively, and overexpressing P-gp.	Etoposide	19-28	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
2187601-0	1990	Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells.	Etoposide	41-50	cyclin dependent kinase 1	Homo sapiens	14-21
2187601-7	1990	Treatment of either asynchronous CHO cells or an enriched G2 population with the antitumor agent, etoposide, results in rapid inhibition of immunoprecipitated p34cdc2 kinase activity, which is not due to a direct effect of drug upon the enzyme.	Etoposide	98-107	cyclin dependent kinase 1	Homo sapiens	159-166
2187601-8	1990	p34cdc2 kinase activity recovers as cells arrest in G2 and a second etoposide treatment further inhibits p34cdc2 kinase activity and prolongs G2 arrest.	Etoposide	68-77	cyclin dependent kinase 1	Homo sapiens	0-7
2187601-8	1990	p34cdc2 kinase activity recovers as cells arrest in G2 and a second etoposide treatment further inhibits p34cdc2 kinase activity and prolongs G2 arrest.	Etoposide	68-77	cyclin dependent kinase 1	Homo sapiens	105-112
1972771-1	1990	The interaction of etoposide (VP-16), Vinca alkaloids, and verapamil with the P-glycoprotein (P-gp) was studied in human breast (MCF-7) and Chinese hamster lung (DC3F) cell lines and the corresponding multidrug-resistant MCF-7/ADR and DC3F/ADX tumor cell lines, selected for resistance to Adriamycin and actinomycin D, respectively, and overexpressing P-gp.	Etoposide	19-28	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
2334169-0	1990	[Etoposide delivery to malignant brain tumors by induced hypertension with angiotensin II].	Etoposide	1-10	angiotensinogen	Rattus norvegicus	75-89
2158396-7	1990	Preincubation of the cells with TNF for 30 min or 3 h before the addition of camptothecin or etoposide resulted in no more strand breaks than that observed in cells incubated with the drugs alone.	Etoposide	93-102	tumor necrosis factor	Mus musculus	32-35
2334169-2	1990	Etoposide 2 mg/body was given intravenously (IV) or intracarotidly with (IHIC) or without (IC) intravenously administrated angiotensin II.	Etoposide	0-9	angiotensinogen	Rattus norvegicus	123-137
2334169-6	1990	The etoposide concentration was increased in the tumor and very low in the normal brain tissues in Fischer 344 rats with 9L gliosarcoma by induced hypertension with angiotensin II.	Etoposide	4-13	angiotensinogen	Rattus norvegicus	165-179
2313334-1	1990	Cyclophosphamide, carmustine (BCNU), and etoposide (VP-16) (CBV) is a widely used conditioning regimen in autologous bone marrow transplantation (ABMT) of patients with refractory and relapsed lymphoma.	Etoposide	41-50	host cell factor C1	Homo sapiens	52-57
2316488-1	1990	Sixteen patients with hepatic metastases of histologically documented breast cancer were treated with etoposide (VP 16-213) and cyclophosphamide.	Etoposide	102-111	host cell factor C1	Homo sapiens	113-118
1967551-6	1990	LU-49888 labeling of Pgp was also inhibited by actinomycin D (45%), podophyllotoxin (47%), and amsacrine (82%), marginally by doxorubicin (25%), colchicine (22%), daunorubicin (18%), and etoposide (14%), but not by teniposide.	Etoposide	187-196	ATP binding cassette subfamily B member 1	Homo sapiens	21-24
2314118-1	1990	Diaziquone (AZQ) and etoposide (VP-16) were administered as simultaneous 5-day continuous infusions to 27 patients with acute leukemia (22 with acute myeloid leukemia (AML), three with chronic myeloid leukemia in blast crisis (CML-B), and two with acute lymphocytic leukemia) at four different doses in a phase I trial.	Etoposide	21-30	host cell factor C1	Homo sapiens	32-37
1968359-2	1990	The drug resistance pattern of mdr1-transfected clones includes relatively high resistance to gramicidin D (about 300-fold), vincristine (about 100-fold), and actinomycin D (about 100-fold) and a lower degree of resistance to doxorubicin (about 10-fold), VP16-213 (about 10-fold), and colchicine (about 6-fold).	Etoposide	255-263	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
2156515-1	1990	Etoposide (VP-16) and several other unrelated anti-tumour agents appear to act by inhibiting the enzyme DNA topoisomerase II.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
2297654-1	1990	A Phase II study of the combination of etoposide (VP-16) and cyclophosphamide (CPM) was conducted in an attempt to identify active and potentially less toxic agents for treating patients with osteogenic sarcoma (OS).	Etoposide	39-48	host cell factor C1	Homo sapiens	50-55
2157554-3	1990	In our phase II pilot studies with cisplatin (CDDP) and etoposide (VP-16), we observed a 26% response rate; with CDDP, VP-16, and mitomycin-C, a 38% response rate was obtained in advanced NSCLC patients.	Etoposide	56-65	host cell factor C1	Homo sapiens	67-72
1976450-1	1990	We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16.	Etoposide	18-27	host cell factor C1	Homo sapiens	29-34
1976450-1	1990	We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16.	Etoposide	18-27	host cell factor C1	Homo sapiens	118-123
2297632-2	1990	A prospective clinical trial was done to evaluate the efficacy and toxicity of cisplatin plus etoposide (VP-16) in patients with breast cancer who failed one previous chemotherapy regimen for advanced disease or relapsed within 12 months of adjuvant chemotherapy.	Etoposide	94-103	host cell factor C1	Homo sapiens	105-110
2302390-8	1990	Etoposide (VP-16) at concentrations up to 10 mol% did not compete with [3H]VM-26 for association with dioleoyl-PC.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
1967222-3	1990	GLC4/ADR expressed cross-resistance to teniposide, etoposide, 4"-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), and mitoxantrone.	Etoposide	51-60	aldo-keto reductase family 1 member B	Homo sapiens	5-8
1967222-7	1990	Etoposide and m-AMSA-induced DNA cleavage was 5-fold reduced in cellular extracts from GLC4/ADR.	Etoposide	0-9	aldo-keto reductase family 1 member B	Homo sapiens	92-95
1967222-8	1990	Inhibition of the decatenation activity of Topo II in the presence of VP-16 and m-AMSA was increased twofold in the cellular extracts from GLC4/ADR.	Etoposide	70-75	aldo-keto reductase family 1 member B	Homo sapiens	144-147
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Etoposide	254-263	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Etoposide	265-270	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34
2297586-1	1990	The inhibitory effects of mafosfamide lysine, ASTA-Z 7654 (ASTA-Z) and etoposide, (VP16-213) on human leukemic progenitor cells (AML-CFU) were studied using a clonogenic assay.	Etoposide	71-80	host cell factor C1	Homo sapiens	83-87
2189591-1	1990	The pharmacology, toxicity, and therapeutic effectiveness of etoposide (VP-16) given by the intrapleural route were examined in a phase I trial.	Etoposide	61-70	host cell factor C1	Homo sapiens	72-77
1691246-1	1990	This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease).	Etoposide	152-161	colony stimulating factor 3	Homo sapiens	65-102
2300386-1	1990	The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion.	Etoposide	24-33	host cell factor C1	Homo sapiens	35-40
2295904-1	1990	We conducted a phase II trial of intraperitoneal (IP) cisplatin (DDP) and etoposide (VP-16) in stage III and IV newly diagnosed ovarian carcinoma patients with residual disease of any size.	Etoposide	74-83	host cell factor C1	Homo sapiens	85-90
2294193-2	1990	A vincristine (VCR)-resistant glioma cell line showed a cross resistance to Adriamycin (doxorubicin, ADR) and etoposide (VP-16) to varying extents, suggesting the presence of MDR; the resistance to VCR was considerably decreased by calcium entry blockers.	Etoposide	110-119	host cell factor C1	Homo sapiens	121-126
3813490-1	1986	Ten patients with neuroblastoma were treated with a standard pulsed administration schedule of cis-platinum and etoposide (VP16-213).	Etoposide	112-121	host cell factor C1	Homo sapiens	123-127
2219586-0	1990	Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma.	Etoposide	78-87	tumor necrosis factor	Homo sapiens	51-72
33811160-3	2021	BPTF functions in promoting resistance to doxorubicin and etoposide, but not paclitaxel, and may be selective to cancer cells, as a similar effect was not observed in embryonic stem cells.	Etoposide	58-67	bromodomain PHD finger transcription factor	Mus musculus	0-4
33823233-10	2021	Western blotting was used to detect the level of gamma-H2A.X in transfected cells stimulated with etoposide (ETO, a DSBs inducer), and after 5 muM ETO stimulation of transfected MEPMs, the expression of gamma-H2A.X was increased in Rad54B-knockdown cells.	Etoposide	98-107	H2A.X variant histone	Mus musculus	49-60
6325855-0	1984	Etoposide (VP 16-213; VePesid).	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
33941661-4	2021	In this study, we show that inhibition of VCP/p97 leads to the prolonged accumulation of etoposide-induced TOP2A- and TOP2B- DNA complexes in a manner that is epistatic with the proteasomal pathway.	Etoposide	89-98	valosin containing protein	Homo sapiens	42-49
33941661-4	2021	In this study, we show that inhibition of VCP/p97 leads to the prolonged accumulation of etoposide-induced TOP2A- and TOP2B- DNA complexes in a manner that is epistatic with the proteasomal pathway.	Etoposide	89-98	DNA topoisomerase II alpha	Homo sapiens	107-112
33941661-4	2021	In this study, we show that inhibition of VCP/p97 leads to the prolonged accumulation of etoposide-induced TOP2A- and TOP2B- DNA complexes in a manner that is epistatic with the proteasomal pathway.	Etoposide	89-98	DNA topoisomerase II beta	Homo sapiens	118-123
33941661-5	2021	VCP/p97 inhibition also reduces the etoposide-induced phosphorylation of histone H2AX, indicative of fewer DSBs .	Etoposide	36-45	valosin containing protein	Homo sapiens	0-7
33941661-5	2021	VCP/p97 inhibition also reduces the etoposide-induced phosphorylation of histone H2AX, indicative of fewer DSBs .	Etoposide	36-45	H2A.X variant histone	Homo sapiens	73-85
33811160-4	2021	Sensitization to doxorubicin and etoposide with BPTF knockdown (KD) was associated with increased DNA damage, topoisomerase II (Top2) crosslinking and autophagy; however, there was only a modest increase in apoptosis and no increase in senescence.	Etoposide	33-42	bromodomain PHD finger transcription factor	Mus musculus	48-52
33811160-4	2021	Sensitization to doxorubicin and etoposide with BPTF knockdown (KD) was associated with increased DNA damage, topoisomerase II (Top2) crosslinking and autophagy; however, there was only a modest increase in apoptosis and no increase in senescence.	Etoposide	33-42	topoisomerase (DNA) II alpha	Mus musculus	128-132
33539984-7	2021	High metHb generation, revealing intense OS, was also mostly expressed in paclitaxel "TXL" and etoposide "VP16".	Etoposide	95-104	hemoglobin subunit gamma 2	Homo sapiens	5-10
34710250-9	2022	Low doses of etoposide combined with the PARP5B inhibitor XAV939 induced senescence and apoptosis in human SCC lines.	Etoposide	13-22	tankyrase 2	Homo sapiens	41-47
33590721-1	2021	BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP).	Etoposide	261-270	colony stimulating factor 3	Homo sapiens	142-179
27813122-7	2017	Evidence for the downstream TopoII-independent mutagenic potential of Que was obtained by documenting further increased frequencies of MLL rearrangements in human HSPCs concomitantly treated with Etoposide and Que versus single treatments.	Etoposide	196-205	lysine methyltransferase 2A	Homo sapiens	135-138
26540186-3	2015	We have previously shown that  NO plays a significant role in the detoxification of etoposide (VP-16), a topoisomerase II poison in vitro and in human melanoma cells.	Etoposide	84-93	host cell factor C1	Homo sapiens	95-100
8656261-2	1996	Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16.	Etoposide	154-163	host cell factor C1	Homo sapiens	165-170
8656261-2	1996	Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16.	Etoposide	154-163	host cell factor C1	Homo sapiens	253-258
33803505-6	2021	Next, in an in vivo model, ASB17 deficiency prevented the apoptosis of spermatogonia induced by etoposide in male mice.	Etoposide	96-105	ankyrin repeat and SOCS box-containing 17	Mus musculus	27-32
33761503-11	2021	He received 3 cycles of chemotherapy with ICE regimen (ifosfamide, carboplatin, and etoposide).	Etoposide	84-93	carboxylesterase 2	Homo sapiens	42-45
26628978-0	2015	Role of WNT1-inducible-signaling pathway protein 1 in etoposide resistance in lung adenocarcinoma A549 cells.	Etoposide	54-63	cellular communication network factor 4	Mus musculus	8-50
26628978-1	2015	OBJECT: The aim of this study was to explore the role of WNT1-inducible-signaling Pathway Protein 1 (WISP-1) in etoposide resistance in lung adenocarcinoma A549 cells.	Etoposide	112-121	cellular communication network factor 4	Mus musculus	57-99
26628978-1	2015	OBJECT: The aim of this study was to explore the role of WNT1-inducible-signaling Pathway Protein 1 (WISP-1) in etoposide resistance in lung adenocarcinoma A549 cells.	Etoposide	112-121	cellular communication network factor 4	Mus musculus	101-107
26628978-6	2015	RESULTS: WISP-1 overexpression significantly increased cell viability and decreased cell apoptosis after treatment with UV and etoposide.	Etoposide	127-136	cellular communication network factor 4	Mus musculus	9-15
26628978-7	2015	Decreased expression of Bad and Bax and increased expression of Bcl-2 was found after etoposide treatment in WISP-1 overexpressed cells.	Etoposide	86-95	BCL2-associated X protein	Mus musculus	32-35
26628978-7	2015	Decreased expression of Bad and Bax and increased expression of Bcl-2 was found after etoposide treatment in WISP-1 overexpressed cells.	Etoposide	86-95	B cell leukemia/lymphoma 2	Mus musculus	64-69
26628978-7	2015	Decreased expression of Bad and Bax and increased expression of Bcl-2 was found after etoposide treatment in WISP-1 overexpressed cells.	Etoposide	86-95	cellular communication network factor 4	Mus musculus	109-115
26628978-9	2015	CONCLUSION: Our results demonstrated that WISP-1 may have a facilitating role in etoposide resistance through increasing cell viability and decreasing cell apoptosis.	Etoposide	81-90	cellular communication network factor 4	Mus musculus	42-48
24894814-3	2014	The results showed that WT1(+17AA/-KTS), but not WT1(+17AA/+KTS), enhanced migration and colony forming abilities of U937 cells, and suppressed etoposide-induced U937 cell apoptosis.	Etoposide	144-153	WT1 transcription factor	Homo sapiens	24-27
34528388-8	2022	The A3C interactomes obtained from control cells and cells exposed to the genotoxin etoposide indicated that A3C is a nucleolar protein.	Etoposide	84-93	apolipoprotein B mRNA editing enzyme catalytic subunit 3C	Homo sapiens	4-7
34528388-8	2022	The A3C interactomes obtained from control cells and cells exposed to the genotoxin etoposide indicated that A3C is a nucleolar protein.	Etoposide	84-93	apolipoprotein B mRNA editing enzyme catalytic subunit 3C	Homo sapiens	109-112
34710250-9	2022	Low doses of etoposide combined with the PARP5B inhibitor XAV939 induced senescence and apoptosis in human SCC lines.	Etoposide	13-22	serpin family B member 3	Homo sapiens	107-110
34710250-10	2022	NBS1 overexpression in these cells inhibited the effects of low-dose etoposide/XAV939 treatment.	Etoposide	69-78	nibrin	Homo sapiens	0-4
34663950-3	2021	RESULTS: High SLFN11 associated with improved prognosis to the first-line treatment with DDAs platinum-plus-etoposide in SCLC patients, but was not strongly linked to paclitaxel-platinum response in ovarian cancer patients.	Etoposide	108-117	schlafen family member 11	Homo sapiens	14-20
34550633-7	2022	Enriched etoposide-induced TOP2A cleavage in the relevant MAML2 genomic region supports a TOP2A DNA damage mechanism.	Etoposide	9-18	DNA topoisomerase II alpha	Homo sapiens	27-32
34550633-7	2022	Enriched etoposide-induced TOP2A cleavage in the relevant MAML2 genomic region supports a TOP2A DNA damage mechanism.	Etoposide	9-18	mastermind like transcriptional coactivator 2	Homo sapiens	58-63
34550633-7	2022	Enriched etoposide-induced TOP2A cleavage in the relevant MAML2 genomic region supports a TOP2A DNA damage mechanism.	Etoposide	9-18	DNA topoisomerase II alpha	Homo sapiens	90-95
34887387-6	2021	Furthermore, we provide the first preclinical evidence demonstrating that combined therapy with a DOT1L inhibitor significantly improves the therapeutic efficacy of etoposide in murine orthotopic xenografts of RB by rendering the response to etoposide more potent and stable.	Etoposide	165-174	DOT1-like, histone H3 methyltransferase (S. cerevisiae)	Mus musculus	98-103
34887387-6	2021	Furthermore, we provide the first preclinical evidence demonstrating that combined therapy with a DOT1L inhibitor significantly improves the therapeutic efficacy of etoposide in murine orthotopic xenografts of RB by rendering the response to etoposide more potent and stable.	Etoposide	242-251	DOT1-like, histone H3 methyltransferase (S. cerevisiae)	Mus musculus	98-103
34817176-7	2021	We further demonstrate that myrocins disrupt the interaction of XRCC5 with DNA leading to sensitization of cancer cells to the chemotherapeutic agent etoposide as well as UV-light-induced DNA damage.	Etoposide	150-159	X-ray repair cross complementing 5	Homo sapiens	64-69
34876060-2	2021	In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens.	Etoposide	78-87	epiregulin	Homo sapiens	89-91
34678222-9	2021	DFF40 deficient cells show chemoresistance to antimetabolites (e.g. methotrexate, 6-mercaptopurine and cytarabine) and surprisingly, they are more sensitive to TOP2 inhibitors (e.g. etoposide and teniposide).	Etoposide	182-191	DNA fragmentation factor subunit beta	Homo sapiens	0-5
34678222-11	2021	Etoposide exposure in DFF40 deficient cells induces higher mortality levels and downregulation of Bcl-xL cells compared to DFF40 expressing T cells.	Etoposide	0-9	DNA fragmentation factor subunit beta	Homo sapiens	22-27
34678222-11	2021	Etoposide exposure in DFF40 deficient cells induces higher mortality levels and downregulation of Bcl-xL cells compared to DFF40 expressing T cells.	Etoposide	0-9	BCL2 like 1	Homo sapiens	98-104
34678222-12	2021	The abolition of DFF40 expression in Jurkat cells significantly impairs histone H2AX phosphorylation following etoposide and cytarabine treatments.	Etoposide	111-120	DNA fragmentation factor subunit beta	Homo sapiens	17-22
34960710-5	2021	We determined that treatment of HBc-expressing hepatocytes with genotoxic agents, e.g., etoposide or hydrogen peroxide, activated the host ATM-Chk2 pathway, as determined by increased phosphorylation of ATM at Ser1981 and Chk2 at Thr68.	Etoposide	88-97	ATM serine/threonine kinase	Homo sapiens	139-142
34960710-5	2021	We determined that treatment of HBc-expressing hepatocytes with genotoxic agents, e.g., etoposide or hydrogen peroxide, activated the host ATM-Chk2 pathway, as determined by increased phosphorylation of ATM at Ser1981 and Chk2 at Thr68.	Etoposide	88-97	checkpoint kinase 2	Homo sapiens	143-147
34960710-5	2021	We determined that treatment of HBc-expressing hepatocytes with genotoxic agents, e.g., etoposide or hydrogen peroxide, activated the host ATM-Chk2 pathway, as determined by increased phosphorylation of ATM at Ser1981 and Chk2 at Thr68.	Etoposide	88-97	ATM serine/threonine kinase	Homo sapiens	203-206
34960710-5	2021	We determined that treatment of HBc-expressing hepatocytes with genotoxic agents, e.g., etoposide or hydrogen peroxide, activated the host ATM-Chk2 pathway, as determined by increased phosphorylation of ATM at Ser1981 and Chk2 at Thr68.	Etoposide	88-97	checkpoint kinase 2	Homo sapiens	222-226
34960710-7	2021	Conversely, down-regulation of ATM using ATM-specific siRNAs or inhibitor effectively reduced etoposide-induced HBc phosphorylation.	Etoposide	94-103	ATM serine/threonine kinase	Homo sapiens	31-34
34960710-7	2021	Conversely, down-regulation of ATM using ATM-specific siRNAs or inhibitor effectively reduced etoposide-induced HBc phosphorylation.	Etoposide	94-103	ATM serine/threonine kinase	Homo sapiens	41-44
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	thymoma viral proto-oncogene 1	Mus musculus	160-163
34509085-2	2021	This study aimed at understanding the binding mechanism and structural basis for the interaction of structurally and functionally unrelated chemotherapeutic agent, namely doxorubicin, etoposide, omacetaxine mepesuccinate and paclitaxel with Sorcin by utilizing docking and molecular dynamic simulation approaches.	Etoposide	184-193	sorcin	Homo sapiens	241-247
34509085-3	2021	The docking evaluation of etoposide, omacetaxine mepesuccinate and paclitaxel have shown a high affinity binding with Sorcin at the Ca2+-binding C-terminal domain (SCBD) in a comparable mode and affinity of binding to doxorubicin.	Etoposide	26-35	sorcin	Homo sapiens	118-124
34715493-0	2021	Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway.	Etoposide	26-35	topoisomerase (DNA) II alpha	Mus musculus	0-15
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	187-190
34715493-0	2021	Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway.	Etoposide	26-35	interleukin 10	Mus musculus	45-59
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	interleukin 10	Mus musculus	195-200
34715493-0	2021	Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway.	Etoposide	26-35	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	136-139
34715493-0	2021	Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway.	Etoposide	26-35	thymoma viral proto-oncogene 1	Mus musculus	160-163
34715493-6	2021	Further, in LPS-induced mice sepsis model, the enhanced generation of IL-10 was observed in ETO-treated mice, whereas pro-inflammatory cytokines were decreased, which significantly reduced the mortality of mice from LPS-induced lethal cytokine storm.	Etoposide	92-95	interleukin 10	Mus musculus	70-75
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	36-45	topoisomerase (DNA) II alpha	Mus musculus	55-70
34715493-7	2021	Taken together, these results indicated that ETO may exhibit an anti-inflammatory role by upregulating the alteration of transcription factor Maf and promoting subsequential IL-10 secretion via PI3K/Akt pathway in LPS-induced macrophages.	Etoposide	45-48	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	142-145
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	36-45	topoisomerase (DNA) II alpha	Mus musculus	72-76
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	36-45	interleukin 10	Mus musculus	119-133
34715493-7	2021	Taken together, these results indicated that ETO may exhibit an anti-inflammatory role by upregulating the alteration of transcription factor Maf and promoting subsequential IL-10 secretion via PI3K/Akt pathway in LPS-induced macrophages.	Etoposide	45-48	interleukin 10	Mus musculus	174-179
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	36-45	interleukin 10	Mus musculus	135-140
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	47-50	topoisomerase (DNA) II alpha	Mus musculus	55-70
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	47-50	topoisomerase (DNA) II alpha	Mus musculus	72-76
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	47-50	interleukin 10	Mus musculus	119-133
34715493-7	2021	Taken together, these results indicated that ETO may exhibit an anti-inflammatory role by upregulating the alteration of transcription factor Maf and promoting subsequential IL-10 secretion via PI3K/Akt pathway in LPS-induced macrophages.	Etoposide	45-48	thymoma viral proto-oncogene 1	Mus musculus	199-202
34956497-19	2021	CONCLUSION: With equivalent efficacy, EP regimen is safer than EL regimen in the treatment of SCLC, which suggests that etoposide plus platinum has better clinical application value for SCLC.	Etoposide	120-129	epiregulin	Homo sapiens	38-40
34715493-2	2021	In our present study, we found that etoposide (ETO), a topoisomerase 2 (TOP2) inhibitor, upregulated the production of Interleukin 10 (IL-10) in lipopolysaccharide (LPS)-stimulated macrophages.	Etoposide	47-50	interleukin 10	Mus musculus	135-140
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	interleukin 10	Mus musculus	25-30
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	91-94
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	thymoma viral proto-oncogene 1	Mus musculus	104-107
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	thymoma viral proto-oncogene 1	Mus musculus	160-163
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	187-190
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	9-12	interleukin 10	Mus musculus	195-200
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	interleukin 10	Mus musculus	25-30
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	avian musculoaponeurotic fibrosarcoma oncogene homolog	Mus musculus	91-94
34715493-5	2021	Of note, ETO facilitated IL-10 secretion, which might be regulated by transcription factor Maf via PI3K/AKT pathway, as pharmaceutic blockage of kinase PI3K or AKT attenuated ETO-induced Maf and IL-10 expression.	Etoposide	175-178	thymoma viral proto-oncogene 1	Mus musculus	104-107
33430646-6	2021	Intriguingly, a concomitant cell treatment with a selected SMURF2-targeting compound and the DNA-damaging drug etoposide markedly increased the cytotoxicity produced by this drug in growing cells.	Etoposide	111-120	SMAD specific E3 ubiquitin protein ligase 2	Homo sapiens	59-65
34961037-4	2021	We found that topbp1 mutant seedlings of Arabidopsis thaliana were hypersensitive to cisplatin treatment and the inhibition of TOPII with etoposide produced similar hypersensitivity levels.	Etoposide	138-147	topoisomerase II	Arabidopsis thaliana	127-132
34961037-6	2021	Somatic and meiotic anaphase bridges appeared in the topbp1 mutant at similar frequencies to those when TOPII was inhibited with merbarone, etoposide, or ICFR-187.	Etoposide	140-149	topoisomerase II	Arabidopsis thaliana	104-109
34431578-1	2021	BACKGROUND: The latest published CASPIAN trial demonstrated that adding durvalumab to etoposide and platinum (EP) improved survival dramatically for patients with extensive-stage small cell lung cancer (ES-SCLC).	Etoposide	86-95	epiregulin	Homo sapiens	110-112
34813380-1	2021	It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity.	Etoposide	160-169	host cell factor C1	Homo sapiens	34-39
34813380-1	2021	It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity.	Etoposide	160-169	host cell factor C1	Homo sapiens	66-71
34813380-3	2021	Among these four formulations, 10 wt% of TPGS loaded with VP-16 NMF dramatically enhanced etoposide apparent solubility by 26-folds compared with the native drug.	Etoposide	90-99	host cell factor C1	Homo sapiens	58-63
34813380-8	2021	LC-MS/MS data showed a threefold increase in cellular uptake of VP-16 NMF in MCF-7 cell line compared with the native etoposide.	Etoposide	118-127	host cell factor C1	Homo sapiens	64-69
34784412-0	2021	Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro.	Etoposide	17-26	RB transcriptional corepressor 1	Homo sapiens	103-117
34757813-1	2021	It is hypothesized that L-arginine (ARG) can improve etoposide (VP-16) water solubility while preserving its anticancer activity.	Etoposide	53-62	host cell factor C1	Homo sapiens	64-69
34813380-1	2021	It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity.	Etoposide	24-33	host cell factor C1	Homo sapiens	34-39
34813380-1	2021	It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity.	Etoposide	24-33	host cell factor C1	Homo sapiens	66-71
34679197-7	2021	In parallel, Bcl-xL inhibition by BH3I-1 and p53 induction by etoposide reverted the antiapoptotic effect of Prep1.	Etoposide	62-71	transformation related protein 53, pseudogene	Mus musculus	45-48
34679197-7	2021	In parallel, Bcl-xL inhibition by BH3I-1 and p53 induction by etoposide reverted the antiapoptotic effect of Prep1.	Etoposide	62-71	Pbx/knotted 1 homeobox	Mus musculus	109-114
34674796-5	2022	PEMFs elevated the etoposide-induced PARP cleavage and caspase-7/9 activation and enhanced the etoposide-induced down-regulation of survivin and up-regulation of Bax.	Etoposide	19-28	poly(ADP-ribose) polymerase 1	Homo sapiens	37-41
34488443-10	2021	In consequence, shRNA-mediated p62 KD impairs the ability of LMP1 to regulate its target gene expression, promotes etoposide-induced apoptosis, and reduces the proliferation of lymphoblastic cell lines (LCLs).	Etoposide	115-124	PDZ and LIM domain 7	Homo sapiens	61-65
34488443-15	2021	In consequence, p62 deficiency negatively regulates LMP1-mediated gene expression, promotes etoposide-induced apoptosis, and reduces the proliferation of LCLs.	Etoposide	92-101	nucleoporin 62	Homo sapiens	16-19
34674796-5	2022	PEMFs elevated the etoposide-induced PARP cleavage and caspase-7/9 activation and enhanced the etoposide-induced down-regulation of survivin and up-regulation of Bax.	Etoposide	19-28	caspase 7	Homo sapiens	55-66
34411980-11	2021	Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression).	Etoposide	111-114	tumor protein p53	Homo sapiens	147-150
34674796-5	2022	PEMFs elevated the etoposide-induced PARP cleavage and caspase-7/9 activation and enhanced the etoposide-induced down-regulation of survivin and up-regulation of Bax.	Etoposide	95-104	BCL2 associated X, apoptosis regulator	Homo sapiens	162-165
34674796-9	2022	These results combined indicate that PEMFs enhance etoposide-induced cell death by increasing ROS induction-DNA damage-caspase-dependent apoptosis.	Etoposide	51-60	caspase 9	Homo sapiens	119-126
34411980-11	2021	Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression).	Etoposide	111-114	BCL2 associated X, apoptosis regulator	Homo sapiens	183-186
34411980-11	2021	Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression).	Etoposide	111-114	H3 histone pseudogene 16	Homo sapiens	191-194
34253710-6	2021	CtBP1/2 knockdown induced cancer cell apoptosis, increased genetic instability, and enhanced the sensitivity to DNA damage agents, such as gamma-irradiation and chemotherapy drug (Carboplatin and etoposide).	Etoposide	196-205	C-terminal binding protein 1	Homo sapiens	0-7
34252534-0	2021	The inhibition of GHR enhanced cytotoxic effects of etoposide on neuroblastoma.	Etoposide	52-61	growth hormone receptor	Mus musculus	18-21
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	47-56	growth hormone receptor	Mus musculus	69-92
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	47-56	growth hormone receptor	Mus musculus	94-97
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	47-56	growth hormone receptor	Mus musculus	177-180
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	120-129	growth hormone receptor	Mus musculus	69-92
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	120-129	growth hormone receptor	Mus musculus	94-97
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	120-129	growth hormone receptor	Mus musculus	177-180
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	241-250	growth hormone receptor	Mus musculus	69-92
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	241-250	growth hormone receptor	Mus musculus	94-97
34252534-4	2021	The results of the present study revealed that etoposide upregulated growth hormone receptor (GHR) expression levels in etoposide-resistant neuroblastoma cells, suggesting that GHR upregulation may be involved in the underlying mechanism of etoposide resistance.	Etoposide	241-250	growth hormone receptor	Mus musculus	177-180
34252534-6	2021	The results of cell viability and colony formation assays demonstrated that GHR knockdown enhanced the inhibitory effects of etoposide on cell viability and sensitized cells to etoposide.	Etoposide	125-134	growth hormone receptor	Mus musculus	76-79
34252534-6	2021	The results of cell viability and colony formation assays demonstrated that GHR knockdown enhanced the inhibitory effects of etoposide on cell viability and sensitized cells to etoposide.	Etoposide	177-186	growth hormone receptor	Mus musculus	76-79
34252534-7	2021	The enhanced cell viability was discovered to be, at least in part, due to the increase in etoposide-induced apoptosis following GHR knockdown.	Etoposide	91-100	growth hormone receptor	Mus musculus	129-132
34252534-8	2021	Moreover, the knockdown of GHR enhanced the inhibitory effect of etoposide on cell migration.	Etoposide	65-74	growth hormone receptor	Mus musculus	27-30
34252534-10	2021	Furthermore, the effects of GHR knockdown in etoposide resistance were hypothesized to occur via the inactivation of the MEK/ERK signaling pathway.	Etoposide	45-54	growth hormone receptor	Mus musculus	28-31
34252534-10	2021	Furthermore, the effects of GHR knockdown in etoposide resistance were hypothesized to occur via the inactivation of the MEK/ERK signaling pathway.	Etoposide	45-54	midkine	Mus musculus	121-124
34252534-10	2021	Furthermore, the effects of GHR knockdown in etoposide resistance were hypothesized to occur via the inactivation of the MEK/ERK signaling pathway.	Etoposide	45-54	mitogen-activated protein kinase 1	Mus musculus	125-128
34243013-1	2021	Etoposide is a semi-synthetic glycoside derivative of podophyllotoxin, also known as VP-16.	Etoposide	0-9	host cell factor C1	Homo sapiens	85-90
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	0-9	CREB binding protein	Homo sapiens	200-220
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	0-9	CREB binding protein	Homo sapiens	222-228
34571550-3	2021	Additionally, CD133, ABCB5, sphingosine kinase 1, and sphingosine kinase 2 gene expression was analyzed in WERI-RB1 (WERI RB1) and etoposide-resistant WERI RB1 subclones (WERI ETOR).	Etoposide	131-140	RB transcriptional corepressor 1	Homo sapiens	156-159
34339814-2	2021	In this light, vitamin D3 (vit.D3)-coated micelles were fabricated to encapsulate the cytotoxic drug; etoposide (ETP).	Etoposide	102-111	vitrin	Homo sapiens	27-30
34339814-2	2021	In this light, vitamin D3 (vit.D3)-coated micelles were fabricated to encapsulate the cytotoxic drug; etoposide (ETP).	Etoposide	113-116	vitrin	Homo sapiens	27-30
34339814-4	2021	In vitro cytotoxicity studies showed that fabricated micelles exhibited improved anticancer effect on MDA MB-231 and MCF-7 human breast cancer cell lines in comparison to free vit.D3+ETP without any significant toxicity on normal human lung fibroblast (Wi-38) cells.	Etoposide	183-186	vitrin	Homo sapiens	176-179
34339814-7	2021	Therefore, vit.D3/ETP micelles could serve as a favorable actively targeted anticancer delivery system having a superior effect over the free combination.	Etoposide	18-21	vitrin	Homo sapiens	11-14
34572735-2	2021	Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished the survival of cancer cells treated with doxorubicin, etoposide, and camptothecin.	Etoposide	134-143	MDM2 proto-oncogene	Homo sapiens	14-18
34572735-2	2021	Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished the survival of cancer cells treated with doxorubicin, etoposide, and camptothecin.	Etoposide	134-143	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
34437575-0	2021	Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy.	Etoposide	94-103	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
34437575-11	2021	The results from our study proved that the combination of etoposide with anti-HER2 antibodies was not cytotoxic against breast cancer cells, whereas the combination of etoposide with anti-HER2 antibodies decreased viability and DNA biosynthesis in gastric cancer cells.	Etoposide	58-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
34437575-11	2021	The results from our study proved that the combination of etoposide with anti-HER2 antibodies was not cytotoxic against breast cancer cells, whereas the combination of etoposide with anti-HER2 antibodies decreased viability and DNA biosynthesis in gastric cancer cells.	Etoposide	168-177	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-192
34437575-12	2021	The interaction of etoposide with pertuzumab or trastuzumab induced programmed cell death via extrinsic and intrinsic apoptotic pathways in AGS gastric cancer cells, but did not affect autophagy, where a decrease of Beclin-1, LC3A and LC3B was observed in comparison with the untreated control.	Etoposide	19-28	beclin 1	Homo sapiens	216-224
34437575-12	2021	The interaction of etoposide with pertuzumab or trastuzumab induced programmed cell death via extrinsic and intrinsic apoptotic pathways in AGS gastric cancer cells, but did not affect autophagy, where a decrease of Beclin-1, LC3A and LC3B was observed in comparison with the untreated control.	Etoposide	19-28	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	226-230
34437575-12	2021	The interaction of etoposide with pertuzumab or trastuzumab induced programmed cell death via extrinsic and intrinsic apoptotic pathways in AGS gastric cancer cells, but did not affect autophagy, where a decrease of Beclin-1, LC3A and LC3B was observed in comparison with the untreated control.	Etoposide	19-28	microtubule associated protein 1 light chain 3 beta	Homo sapiens	235-239
34329577-2	2021	The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma.	Etoposide	139-148	carboxylesterase 2	Homo sapiens	153-156
34421356-0	2021	Inhibition of protein PMP22 enhances etoposide-induced cell apoptosis by p53 signaling pathway in Gastric Cancer.	Etoposide	37-46	peripheral myelin protein 22	Mus musculus	22-27
34421356-0	2021	Inhibition of protein PMP22 enhances etoposide-induced cell apoptosis by p53 signaling pathway in Gastric Cancer.	Etoposide	37-46	transformation related protein 53, pseudogene	Mus musculus	73-76
34421356-6	2021	Over-expressed PMP22 inhibits the etoposide-induced apoptosis, meanwhile knockdown of PMP22 promotes the etoposide-induced proliferation suppression, and increases cell apoptosis in GC cells.	Etoposide	34-43	peripheral myelin protein 22	Mus musculus	15-20
34421356-6	2021	Over-expressed PMP22 inhibits the etoposide-induced apoptosis, meanwhile knockdown of PMP22 promotes the etoposide-induced proliferation suppression, and increases cell apoptosis in GC cells.	Etoposide	105-114	peripheral myelin protein 22	Mus musculus	86-91
34421356-7	2021	Furthermore, PMP22 enhanced the inhibition of the p53 transcriptional activities and down-regulated the p53 targeting genes, including p21, BAX and PUMA with or without treatment of etoposide.	Etoposide	182-191	peripheral myelin protein 22	Mus musculus	13-18
34421356-7	2021	Furthermore, PMP22 enhanced the inhibition of the p53 transcriptional activities and down-regulated the p53 targeting genes, including p21, BAX and PUMA with or without treatment of etoposide.	Etoposide	182-191	transformation related protein 53, pseudogene	Mus musculus	50-53
34421356-7	2021	Furthermore, PMP22 enhanced the inhibition of the p53 transcriptional activities and down-regulated the p53 targeting genes, including p21, BAX and PUMA with or without treatment of etoposide.	Etoposide	182-191	transformation related protein 53, pseudogene	Mus musculus	104-107
34421356-8	2021	Finally, our results showed that PMP22 reduced the etoposide-induced tumor growth suppression in nude mice.	Etoposide	51-60	peripheral myelin protein 22	Mus musculus	33-38
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	0-9	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	235-270
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	0-9	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	272-277
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	89-98	CREB binding protein	Homo sapiens	200-220
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	89-98	CREB binding protein	Homo sapiens	222-228
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	89-98	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	235-270
34243013-6	2021	Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP).	Etoposide	89-98	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	272-277
34243013-7	2021	CYP3A4 and CYP3A5 metabolize etoposide to etoposide catechol, which readily oxidizes to etoposide quinone.	Etoposide	29-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
34243013-7	2021	CYP3A4 and CYP3A5 metabolize etoposide to etoposide catechol, which readily oxidizes to etoposide quinone.	Etoposide	29-38	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-17
34243013-7	2021	CYP3A4 and CYP3A5 metabolize etoposide to etoposide catechol, which readily oxidizes to etoposide quinone.	Etoposide	42-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
34243013-7	2021	CYP3A4 and CYP3A5 metabolize etoposide to etoposide catechol, which readily oxidizes to etoposide quinone.	Etoposide	42-51	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-17
34243013-11	2021	Recently, studies have revealed that etoposide metabolites, especially etoposide quinone, can covalently bind to cysteines residues of CREBBP and TCPTP enzymes, .	Etoposide	37-46	CREB binding protein	Homo sapiens	135-141
34243013-11	2021	Recently, studies have revealed that etoposide metabolites, especially etoposide quinone, can covalently bind to cysteines residues of CREBBP and TCPTP enzymes, .	Etoposide	37-46	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	146-151
34243013-13	2021	In brief, current studies suggest that etoposide and its metabolites contribute to etoposide therapy-related leukemia through TOP2 mediated DSB and impairs specific enzyme activity, such as CREBBP and TCPTP.	Etoposide	39-48	CREB binding protein	Homo sapiens	190-196
34243013-13	2021	In brief, current studies suggest that etoposide and its metabolites contribute to etoposide therapy-related leukemia through TOP2 mediated DSB and impairs specific enzyme activity, such as CREBBP and TCPTP.	Etoposide	39-48	protein tyrosine phosphatase non-receptor type 2	Homo sapiens	201-206
34638679-0	2021	Compensatory Protection of Thioredoxin-Deficient Cells from Etoposide-Induced Cell Death by Selenoprotein W via Interaction with 14-3-3.	Etoposide	60-69	selenoprotein W	Homo sapiens	92-107
34638679-9	2021	Compared to control cells, Trx1-deficient cells and SELENOW-deficient cells showed increased levels of both the subG1 population and poly (ADP-ribose) polymerase (PARP) cleavage by etoposide treatment.	Etoposide	181-190	thioredoxin	Homo sapiens	27-31
34638679-9	2021	Compared to control cells, Trx1-deficient cells and SELENOW-deficient cells showed increased levels of both the subG1 population and poly (ADP-ribose) polymerase (PARP) cleavage by etoposide treatment.	Etoposide	181-190	selenoprotein W	Homo sapiens	52-59
34638679-9	2021	Compared to control cells, Trx1-deficient cells and SELENOW-deficient cells showed increased levels of both the subG1 population and poly (ADP-ribose) polymerase (PARP) cleavage by etoposide treatment.	Etoposide	181-190	poly(ADP-ribose) polymerase 1	Homo sapiens	133-161
34638679-9	2021	Compared to control cells, Trx1-deficient cells and SELENOW-deficient cells showed increased levels of both the subG1 population and poly (ADP-ribose) polymerase (PARP) cleavage by etoposide treatment.	Etoposide	181-190	poly(ADP-ribose) polymerase 1	Homo sapiens	163-167
34638679-11	2021	These results indicate that SELENOW can protect Trx1-deficient cells from etoposide-induced cell death through its interaction with 14-3-3beta.	Etoposide	74-83	selenoprotein W	Homo sapiens	28-35
34638679-11	2021	These results indicate that SELENOW can protect Trx1-deficient cells from etoposide-induced cell death through its interaction with 14-3-3beta.	Etoposide	74-83	thioredoxin	Homo sapiens	48-52
34536950-7	2021	ASXL1 gain was associated with resistance to etoposide, doxorubicin and cisplatin (EDP).	Etoposide	45-54	ASXL transcriptional regulator 1	Homo sapiens	0-5
34471223-8	2021	Ultimately, overexpression of wild-type PLD2 but not that of LXXLL-mutant PLD2 protected cells against etoposide-induced apoptosis.	Etoposide	103-112	phospholipase D2	Homo sapiens	40-44
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Etoposide	47-56	autophagy related 5	Homo sapiens	173-177
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Etoposide	47-56	autophagy related 12	Homo sapiens	178-183
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Etoposide	47-56	caspase 8	Homo sapiens	194-203
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Etoposide	47-56	caspase 8	Homo sapiens	240-248
34363313-4	2021	We show that diverse stress stimuli, including etoposide, brefeldin A and paclitaxel, as well as heat stress and gamma-irradiation, caused formation of a complex containing ATG5-ATG12, FADD and caspase-8 leading to activation of downstream caspases in caspase-9-deficient cells.	Etoposide	47-56	caspase 9	Homo sapiens	252-261
34445431-6	2021	Moreover, only insulin-bound IR-A, but not IR-B, protected cells from etoposide-induced cytotoxicity.	Etoposide	70-79	insulin	Homo sapiens	15-22
34333949-5	2021	According to whether or not etoposide (VP-16) was included in the initial therapy, patients were divided into group 1 (VP-16 was not administrated in the initial treatment, n=31) and group 2 (the initial treatment included etoposide, n=12).	Etoposide	28-37	host cell factor C1	Homo sapiens	39-44
34322387-0	2021	Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells.	Etoposide	149-158	ataxin 3	Homo sapiens	18-23
34322387-3	2021	The aim of our study was to explore the role of ATXN3 in the cell death induced by AKT inhibitor (perifosine or MK-2206) or chemotherapy drugs (etoposide or cisplatin) in NB cells.	Etoposide	144-153	ataxin 3	Homo sapiens	48-53
34322387-10	2021	Downregulation of ATXN3 did not increase, but decrease the sensitivity of NB cells to etoposide/cisplatin, and knockdown of Bcl-xl attenuated this decrease in sensitivity.	Etoposide	86-95	ataxin 3	Homo sapiens	18-23
34322387-11	2021	Conclusion: Downregulation of ATXN3 enhanced AKT inhibitors (perifosine or MK-2206) induced cell death by BIM, but decreased the cell death induced by chemotherapeutic drugs (etoposide or cisplatin) via Bcl-xl.	Etoposide	175-184	ataxin 3	Homo sapiens	30-35
34322387-11	2021	Conclusion: Downregulation of ATXN3 enhanced AKT inhibitors (perifosine or MK-2206) induced cell death by BIM, but decreased the cell death induced by chemotherapeutic drugs (etoposide or cisplatin) via Bcl-xl.	Etoposide	175-184	BCL2 like 1	Homo sapiens	203-209
34228897-8	2022	Moreover, L1CAM depletion decreased viability and tumor growth of etoposide-resistant RB cell lines upon etoposide treatment in vitro and in vivo.	Etoposide	66-75	L1 cell adhesion molecule	Gallus gallus	10-15
34228897-8	2022	Moreover, L1CAM depletion decreased viability and tumor growth of etoposide-resistant RB cell lines upon etoposide treatment in vitro and in vivo.	Etoposide	66-75	RB transcriptional corepressor 1	Gallus gallus	86-88
34228897-8	2022	Moreover, L1CAM depletion decreased viability and tumor growth of etoposide-resistant RB cell lines upon etoposide treatment in vitro and in vivo.	Etoposide	105-114	L1 cell adhesion molecule	Gallus gallus	10-15
34228897-8	2022	Moreover, L1CAM depletion decreased viability and tumor growth of etoposide-resistant RB cell lines upon etoposide treatment in vitro and in vivo.	Etoposide	105-114	RB transcriptional corepressor 1	Gallus gallus	86-88
34305242-0	2021	Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide.	Etoposide	104-113	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	13-36
34213982-2	2021	She had been treated with etoposide and prednisolone for non-Hodgkin"s lymphoma.	Etoposide	26-35	Src homology 2 domain containing E	Homo sapiens	0-3
34155349-7	2021	Consistently, FOXM1 depletion in NCI-H1688 SCLC cells reduced migration and enhanced apoptosis and sensitivity to cisplatin and etoposide.	Etoposide	128-137	forkhead box M1	Homo sapiens	14-19
34070855-4	2021	LEDGF-deficient cells exhibited a decreased proliferation and migration as well as an increased sensitivity toward etoposide.	Etoposide	115-124	PC4 and SFRS1 interacting protein 1	Homo sapiens	0-5
34193614-7	2021	We then demonstrated that when the nuclear DNA of GSCs either in vitro or in GBM xenografts in mice was damaged by irradiation or treatment with etoposide, the DNA-PK complex dissociated from SOX2, which then interacted with WWP2, leading to SOX2 degradation and GSC differentiation.	Etoposide	145-154	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	160-166
34193614-7	2021	We then demonstrated that when the nuclear DNA of GSCs either in vitro or in GBM xenografts in mice was damaged by irradiation or treatment with etoposide, the DNA-PK complex dissociated from SOX2, which then interacted with WWP2, leading to SOX2 degradation and GSC differentiation.	Etoposide	145-154	SRY (sex determining region Y)-box 2	Mus musculus	192-196
34193614-7	2021	We then demonstrated that when the nuclear DNA of GSCs either in vitro or in GBM xenografts in mice was damaged by irradiation or treatment with etoposide, the DNA-PK complex dissociated from SOX2, which then interacted with WWP2, leading to SOX2 degradation and GSC differentiation.	Etoposide	145-154	WW domain containing E3 ubiquitin protein ligase 2	Mus musculus	225-229
34193614-7	2021	We then demonstrated that when the nuclear DNA of GSCs either in vitro or in GBM xenografts in mice was damaged by irradiation or treatment with etoposide, the DNA-PK complex dissociated from SOX2, which then interacted with WWP2, leading to SOX2 degradation and GSC differentiation.	Etoposide	145-154	SRY (sex determining region Y)-box 2	Mus musculus	242-246
34203267-15	2021	Overexpression of IGF2BP1 promoted the colony-forming capacity and 5-fluorouracil and etoposide resistance in CRC cells.	Etoposide	86-95	insulin like growth factor 2 mRNA binding protein 1	Homo sapiens	18-25
34208028-6	2021	The inhibition of multiple centrosomes accomplished by treating cells with either roscovitine or centrinone or through the overexpression of NR5A1/SF-1 alleviated ETO-induced senescence, suggesting that ETO triggered senescence via multiple centrosomes.	Etoposide	163-166	nuclear receptor subfamily 5 group A member 1	Homo sapiens	141-146
34208028-6	2021	The inhibition of multiple centrosomes accomplished by treating cells with either roscovitine or centrinone or through the overexpression of NR5A1/SF-1 alleviated ETO-induced senescence, suggesting that ETO triggered senescence via multiple centrosomes.	Etoposide	163-166	splicing factor 1	Homo sapiens	147-151
34208028-6	2021	The inhibition of multiple centrosomes accomplished by treating cells with either roscovitine or centrinone or through the overexpression of NR5A1/SF-1 alleviated ETO-induced senescence, suggesting that ETO triggered senescence via multiple centrosomes.	Etoposide	203-206	nuclear receptor subfamily 5 group A member 1	Homo sapiens	141-146
34208028-6	2021	The inhibition of multiple centrosomes accomplished by treating cells with either roscovitine or centrinone or through the overexpression of NR5A1/SF-1 alleviated ETO-induced senescence, suggesting that ETO triggered senescence via multiple centrosomes.	Etoposide	203-206	splicing factor 1	Homo sapiens	147-151
34208028-8	2021	In the mechanism, DNA-PK-Chk2 signaling was activated by ETO treatment; inhibition of this signaling cascade alleviated multiple ETO-induced centrosomes and primary cilia followed by reducing cellular senescence.	Etoposide	57-60	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	18-24
34208028-8	2021	In the mechanism, DNA-PK-Chk2 signaling was activated by ETO treatment; inhibition of this signaling cascade alleviated multiple ETO-induced centrosomes and primary cilia followed by reducing cellular senescence.	Etoposide	57-60	checkpoint kinase 2	Homo sapiens	25-29
34208028-8	2021	In the mechanism, DNA-PK-Chk2 signaling was activated by ETO treatment; inhibition of this signaling cascade alleviated multiple ETO-induced centrosomes and primary cilia followed by reducing cellular senescence.	Etoposide	129-132	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	18-24
34208028-8	2021	In the mechanism, DNA-PK-Chk2 signaling was activated by ETO treatment; inhibition of this signaling cascade alleviated multiple ETO-induced centrosomes and primary cilia followed by reducing cellular senescence.	Etoposide	129-132	checkpoint kinase 2	Homo sapiens	25-29
34208028-10	2021	Importantly, the inactivation of DNA-PK-Chk2 signaling reduced ETO-triggered autophagy; however, the inhibition of autophagy did not affect DNA-PK-Chk2 activation.	Etoposide	63-66	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	33-39
34208028-10	2021	Importantly, the inactivation of DNA-PK-Chk2 signaling reduced ETO-triggered autophagy; however, the inhibition of autophagy did not affect DNA-PK-Chk2 activation.	Etoposide	63-66	checkpoint kinase 2	Homo sapiens	40-44
34208028-11	2021	Thus, ETO activated the DNA-PK-Chk2 cascade to facilitate autophagy.	Etoposide	6-9	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	24-30
34208028-11	2021	Thus, ETO activated the DNA-PK-Chk2 cascade to facilitate autophagy.	Etoposide	6-9	checkpoint kinase 2	Homo sapiens	31-35
34070855-5	2021	Moreover, LEDGF-depleted cells showed a significant reduction in the recruitment of downstream DDR-related proteins such as replication protein A 32 kDa subunit (RPA32) after exposure to etoposide.	Etoposide	187-196	PC4 and SFRS1 interacting protein 1	Homo sapiens	10-15
34070855-5	2021	Moreover, LEDGF-depleted cells showed a significant reduction in the recruitment of downstream DDR-related proteins such as replication protein A 32 kDa subunit (RPA32) after exposure to etoposide.	Etoposide	187-196	replication protein A2	Homo sapiens	124-160
34070855-5	2021	Moreover, LEDGF-depleted cells showed a significant reduction in the recruitment of downstream DDR-related proteins such as replication protein A 32 kDa subunit (RPA32) after exposure to etoposide.	Etoposide	187-196	replication protein A2	Homo sapiens	162-167
34122547-4	2021	Decades later, we still rely on the same traditional regimen with etoposide and platinum (EP) as the mainstay of treatment with poor prognosis.	Etoposide	66-75	epiregulin	Homo sapiens	90-92
34221568-5	2021	Six cycles of induction chemotherapy with ifosfamide, carboplatin, and etoposide reduced tumor size and decreased AFP levels in both serum and cerebrospinal fluid.	Etoposide	71-80	alpha fetoprotein	Homo sapiens	114-117
34162557-0	2021	Downregulation of GSK3B by miR-132-3p Enhances Etoposide-Induced Breast Cancer Cell Apoptosis.	Etoposide	47-56	glycogen synthase kinase 3 beta	Homo sapiens	18-23
34162557-0	2021	Downregulation of GSK3B by miR-132-3p Enhances Etoposide-Induced Breast Cancer Cell Apoptosis.	Etoposide	47-56	microRNA 1323	Homo sapiens	27-37
34162557-2	2021	However, the correlation between miR-132-3p expression and etoposide (VP16) induced apoptosis in human breast cancer cells remains poorly understood.	Etoposide	59-68	microRNA 1323	Homo sapiens	33-43
34162557-2	2021	However, the correlation between miR-132-3p expression and etoposide (VP16) induced apoptosis in human breast cancer cells remains poorly understood.	Etoposide	70-74	microRNA 1323	Homo sapiens	33-43
35167193-7	2022	Further, we also show that inhibition of HDAC6 activity causes an apoptotic vulnerability to etoposide treatments in ARID1A-deficient cells.	Etoposide	93-102	histone deacetylase 6	Mus musculus	41-46
34076973-1	2021	PURPOSE: To explore the efficacy and safety of etoposide + cisplatin (EP) and irinotecan + cisplatin (IP) sequential chemotherapy combined with radiotherapy in the treatment of extensive-stage small-cell lung cancer (SCLC).	Etoposide	47-56	epiregulin	Homo sapiens	70-72
34515066-1	2021	BACKGROUND: Whether topotecan plus platinum-based chemotherapy (TP) can achieve better results than etoposide plus platinum-based chemotherapy (EP) for small-cell lung cancer (SCLC) treatment is still controversial in clinical applications.	Etoposide	100-109	epiregulin	Homo sapiens	144-146
35584569-13	2022	BAP1 downregulation by siRNA inhibited apoptosis induced by the combined treatment of ODN and oxaliplatin/etoposide.	Etoposide	106-115	BRCA1 associated protein 1	Homo sapiens	0-4
35421634-3	2022	Doxorubicin and etoposide were used to induce cell senescence as determined by the cessation of cell proliferation, augmented senescence-associated beta-galactosidase (SA-beta-Gal) staining, and increased p53 expression levels.	Etoposide	16-25	tumor protein p53	Homo sapiens	205-208
35446347-3	2022	Here, we delineate a secretory autophagy pathway upregulated in response to endolysosomal inhibition, which mediates EVP-associated release of autophagic cargo receptors, including p62/SQSTM1.	Etoposide	117-120	sequestosome 1	Homo sapiens	181-184
35446347-3	2022	Here, we delineate a secretory autophagy pathway upregulated in response to endolysosomal inhibition, which mediates EVP-associated release of autophagic cargo receptors, including p62/SQSTM1.	Etoposide	117-120	sequestosome 1	Homo sapiens	185-191
34844181-0	2021	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.	Etoposide	129-138	colony stimulating factor 3	Homo sapiens	13-50
35167193-7	2022	Further, we also show that inhibition of HDAC6 activity causes an apoptotic vulnerability to etoposide treatments in ARID1A-deficient cells.	Etoposide	93-102	AT rich interactive domain 1A (SWI-like)	Mus musculus	117-123
35596703-6	2022	In addition, patients with adverse clinical outcomes were more sensitive to three small molecule inhibitors (bortezomib, doxorubicin, and etoposide), and their targets (PSMB5 and TOP2A) also have elevated expression levels among these patients.	Etoposide	138-147	proteasome 20S subunit beta 5	Homo sapiens	169-174
35617303-2	2022	For rapidly multiplying malignancies, this has made TOP2alpha/170 an important target for etoposide and other clinically active anticancer drugs.	Etoposide	90-99	DNA topoisomerase II alpha	Homo sapiens	52-65
35617303-4	2022	Our laboratory recently demonstrated reduced levels of TOP2alpha/170 and overexpression of a C-terminal truncated 90-kDa isoform, TOP2alpha/90, due to intronic polyadenylation (IPA; within intron 19) in an acquired etoposide-resistant K562 clonal cell line, K/VP.5.	Etoposide	215-224	DNA topoisomerase II alpha	Homo sapiens	130-142
35617303-5	2022	We previously reported that this isoform heterodimerized with TOP2alpha/170 and was a determinant of acquired resistance to etoposide.	Etoposide	124-133	DNA topoisomerase II alpha	Homo sapiens	62-75
35617303-9	2022	TOP2alpha/170 mRNA/protein expression levels were attenuated in the TOP2alpha gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (gammaH2AX, Comet assays) and growth inhibition.	Etoposide	129-138	DNA topoisomerase II alpha	Homo sapiens	0-13
35617303-9	2022	TOP2alpha/170 mRNA/protein expression levels were attenuated in the TOP2alpha gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (gammaH2AX, Comet assays) and growth inhibition.	Etoposide	129-138	DNA topoisomerase II alpha	Homo sapiens	68-77
35617303-9	2022	TOP2alpha/170 mRNA/protein expression levels were attenuated in the TOP2alpha gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (gammaH2AX, Comet assays) and growth inhibition.	Etoposide	162-171	DNA topoisomerase II alpha	Homo sapiens	0-13
35617303-9	2022	TOP2alpha/170 mRNA/protein expression levels were attenuated in the TOP2alpha gene-edited clones which resulted in resistance to etoposide as assessed by reduced etoposide-induced DNA damage (gammaH2AX, Comet assays) and growth inhibition.	Etoposide	162-171	DNA topoisomerase II alpha	Homo sapiens	68-77
35617303-11	2022	Forced expression of TOP2alpha/90 in the gene-edited K562 cells further decreased etoposide-induced DNA damage in support of a dominant negative role for this truncated isoform.	Etoposide	82-91	DNA topoisomerase II alpha	Homo sapiens	21-33
35614109-4	2022	Apigenin when combined with etoposide or cyclophosphamide-induced apoptosis via the mitochondrial pathway, increasing the expression of pro-apoptotic cytochrome c, SMAC/DIABLO, and HTRA2/OMI, which promoted caspase-9 and -3 activation.	Etoposide	28-37	cytochrome c, somatic	Homo sapiens	150-162
35614109-4	2022	Apigenin when combined with etoposide or cyclophosphamide-induced apoptosis via the mitochondrial pathway, increasing the expression of pro-apoptotic cytochrome c, SMAC/DIABLO, and HTRA2/OMI, which promoted caspase-9 and -3 activation.	Etoposide	28-37	diablo IAP-binding mitochondrial protein	Homo sapiens	164-168
35614109-4	2022	Apigenin when combined with etoposide or cyclophosphamide-induced apoptosis via the mitochondrial pathway, increasing the expression of pro-apoptotic cytochrome c, SMAC/DIABLO, and HTRA2/OMI, which promoted caspase-9 and -3 activation.	Etoposide	28-37	diablo IAP-binding mitochondrial protein	Homo sapiens	169-175
35614109-4	2022	Apigenin when combined with etoposide or cyclophosphamide-induced apoptosis via the mitochondrial pathway, increasing the expression of pro-apoptotic cytochrome c, SMAC/DIABLO, and HTRA2/OMI, which promoted caspase-9 and -3 activation.	Etoposide	28-37	HtrA serine peptidase 2	Homo sapiens	181-190
35604590-4	2022	Here, we explored the DNA repair mechanisms and the genetic consequences of targeting the non-oncogenic addiction to DNA-PKcs of ATM-defective tumor cells after exposure to ETO.	Etoposide	173-176	ATM serine/threonine kinase	Homo sapiens	129-132
35604590-5	2022	We demonstrated that chemical inhibition of DNA-PKcs followed by treatment with ETO resulted in the accumulation of chromatid breaks and decreased mitotic index in both A-T cells and ATM-knocked-down (ATMkd) tumor cells.	Etoposide	80-83	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	44-52
35604590-5	2022	We demonstrated that chemical inhibition of DNA-PKcs followed by treatment with ETO resulted in the accumulation of chromatid breaks and decreased mitotic index in both A-T cells and ATM-knocked-down (ATMkd) tumor cells.	Etoposide	80-83	ATM serine/threonine kinase	Homo sapiens	183-186
35596703-6	2022	In addition, patients with adverse clinical outcomes were more sensitive to three small molecule inhibitors (bortezomib, doxorubicin, and etoposide), and their targets (PSMB5 and TOP2A) also have elevated expression levels among these patients.	Etoposide	138-147	DNA topoisomerase II alpha	Homo sapiens	179-184
35570488-8	2022	Similarly, DNA double strand break (DSB)-specific etoposide damage leads to increased Abeta40 and Abeta42 secretion 2 h and 4 h after treatment in ReN GA2 NPCs.	Etoposide	50-59	renin	Homo sapiens	147-150
35568845-10	2022	Upregulation of RNF38 promoted apoptosis of NPC cells to etoposide but not cisplatin.	Etoposide	57-66	ring finger protein 38	Homo sapiens	16-21
35565244-2	2022	Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by TOP2A), has demonstrated clinical activity in metastatic breast cancer (MBC).	Etoposide	5-14	DNA topoisomerase II alpha	Homo sapiens	68-73
35255342-6	2022	Additionally, 7 at 0.1 and 1.0 microM synergistically enhanced the cytotoxicity of etoposide against SBC-3 cells; compound 7 induced the release of DAMPs; the release of HMGB1, the secretion of ATP, and the exposure of CALR in the SBC-3 cells.	Etoposide	83-92	high mobility group box 1	Homo sapiens	170-175
35255342-6	2022	Additionally, 7 at 0.1 and 1.0 microM synergistically enhanced the cytotoxicity of etoposide against SBC-3 cells; compound 7 induced the release of DAMPs; the release of HMGB1, the secretion of ATP, and the exposure of CALR in the SBC-3 cells.	Etoposide	83-92	calreticulin	Homo sapiens	219-223
35234343-1	2022	BACKGROUND: To assess feasibility and safety of outpatient administration of ifosfamide and etoposide (IE) for pediatric Ewing sarcoma (EWS) patients in a resource-limited setting amid the COVID-19 pandemic.	Etoposide	92-101	EWS RNA binding protein 1	Homo sapiens	136-139
35525474-2	2022	The enzyme l-asparaginase and the small molecule drug etoposide have a known synergistic effect against selected cancer types.	Etoposide	54-63	asparaginase and isoaspartyl peptidase 1	Homo sapiens	11-25
35525474-4	2022	In this study, we present the co-encapsulation of a large hydrophilic enzyme l-asparaginase and the small hydrophobic drug etoposide into a biodegradable, biocompatible, and acid-responsive dextran-based nanoparticle system.	Etoposide	123-132	asparaginase and isoaspartyl peptidase 1	Homo sapiens	77-91
35503721-5	2022	Mechanistically, we discovered that treatment with the genotoxic agent etoposide led to the transcriptional reprogramming of multiple pro-inflammatory cytokines, among which the interferon-alpha and interferon-gamma responses were substantially enriched in resistant cells.	Etoposide	71-80	interferon gamma	Homo sapiens	199-215
35503721-8	2022	Accordingly, targeted inhibition of BCL6 remarkably enhanced etoposide-triggered DNA damage and apoptosis both in vitro and in vivo.	Etoposide	61-70	BCL6 transcription repressor	Homo sapiens	36-40
35565244-2	2022	Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by TOP2A), has demonstrated clinical activity in metastatic breast cancer (MBC).	Etoposide	16-20	DNA topoisomerase II alpha	Homo sapiens	68-73
35409416-4	2022	The objective of this study was to characterize cell line models of an etoposide-sensitive WERI-RB1 and its etoposide-resistant subclone, WERI-ETOR, by proteomic analysis.	Etoposide	71-80	RB transcriptional corepressor 1	Homo sapiens	96-99
35418705-4	2022	In vitro studies using primary mouse cortical neurons show that non-p-tau accumulates perinuclearly together with the tubulin after DSB induction with etoposide, followed by the accumulation of phosphorylated tau.	Etoposide	151-160	microtubule associated protein tau	Homo sapiens	70-73
35418705-4	2022	In vitro studies using primary mouse cortical neurons show that non-p-tau accumulates perinuclearly together with the tubulin after DSB induction with etoposide, followed by the accumulation of phosphorylated tau.	Etoposide	151-160	microtubule associated protein tau	Homo sapiens	209-212
35410995-4	2022	MUC21 transfection into HEK293 cells decreased the number of apoptotic cells in culture media containing etoposide or after ultraviolet light irradiation.	Etoposide	105-114	mucin 21, cell surface associated	Homo sapiens	0-5
35410995-6	2022	When MUC21 was expressed in CHO-K1 cells, it was glycosylated with sialyl T-antigen and the cells showed resistance to etoposide-induced apoptosis.	Etoposide	119-128	mucin-21	Cricetulus griseus	5-10
35410995-7	2022	MUC21 transfection into Lec2 cells, a variant of CHO cells lacking sialylation of glycans, revealed that the presence of nonsialylated T-antigen also renders cells resistant to etoposide-induced apoptosis.	Etoposide	177-186	mucin-21	Cricetulus griseus	0-5
35394839-2	2022	To systematically identify factors driving each response, we analyzed human IMR-90 fibroblasts exposed to increasing doses of the genotoxin etoposide and identified SRC as a key kinase contributing early to this dichotomous decision.	Etoposide	140-149	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	165-168
35438548-7	2022	Etoposide and irradiation increased expression of senescent-related genes in MSCs at early time points, pro-inflammatory cytokine secretion, DNA damage, and production of senescence associated beta-galactosidase.	Etoposide	0-9	galactosidase beta 1	Homo sapiens	193-211
35319066-5	2022	As assessed by their inhibitions of rDNA transcription, pre-rRNA processing and formation of etoposide-induced 53BP1 foci, menadione and plumbagin inhibit also Sirtuin 7 catalytic activity in vivo.	Etoposide	93-102	sirtuin 7	Homo sapiens	160-169
35591977-9	2022	After 3 cycles of etoposide, 5 patients (ITT 20%/PP 23%) had a complete response (CR), partial response (PR), or objective response (OR).	Etoposide	18-27	transmembrane protein 37	Homo sapiens	105-107
35410287-4	2022	RESULTS: By combining single-cell imaging and mathematical modeling of dose-dependent p53 dynamics induced by three chemotherapeutics of distinct mechanism-of-actions, including Etoposide, Nutlin-3a and 5-fluorouracil, and in five cancer cell types, we uncovered novel and highly variable p53 dynamic responses, in particular p53 transitional dynamics induced at intermediate drug concentrations, and identified the functional roles of distinct positive and negative feedback motifs of the p53 pathway in modulating the central p53-Mdm2 negative feedback to generate stimulus- and cell type-specific signaling responses.	Etoposide	178-187	tumor protein p53	Homo sapiens	86-89
35396773-7	2022	Treatment of the patient derived cancer cells with Chb16 exhibited senescence and growth arrest, and increased sensitivity of the TFE3-RCC cells to the genotoxic reagent etoposide.	Etoposide	170-179	transcription factor binding to IGHM enhancer 3	Homo sapiens	130-134
35261636-0	2022	Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide.	Etoposide	109-118	hepatocyte growth factor	Homo sapiens	18-42
35217496-9	2022	CONCLUSIONS: Taken together, we show that DLG2 over expression increases p53 mediated apoptosis in response to etoposide and UVC mediated genotoxicity and reduced DNA replication machinery.	Etoposide	111-120	discs large MAGUK scaffold protein 2	Homo sapiens	42-46
35217496-9	2022	CONCLUSIONS: Taken together, we show that DLG2 over expression increases p53 mediated apoptosis in response to etoposide and UVC mediated genotoxicity and reduced DNA replication machinery.	Etoposide	111-120	tumor protein p53	Homo sapiens	73-76
35231830-5	2022	Moreover, we firstly proved that ATM inhibitors could sensitize Irinotecan and Etoposide in a time-dependent manner on MCF-7 and SW480 cells, antagonism in a short period treatment while synergy at a long-term treatment and ATM agonist worked in an opposite way of ATM inhibitors.	Etoposide	79-88	ATM serine/threonine kinase	Homo sapiens	33-36
35231830-5	2022	Moreover, we firstly proved that ATM inhibitors could sensitize Irinotecan and Etoposide in a time-dependent manner on MCF-7 and SW480 cells, antagonism in a short period treatment while synergy at a long-term treatment and ATM agonist worked in an opposite way of ATM inhibitors.	Etoposide	79-88	ATM serine/threonine kinase	Homo sapiens	224-227
35231830-5	2022	Moreover, we firstly proved that ATM inhibitors could sensitize Irinotecan and Etoposide in a time-dependent manner on MCF-7 and SW480 cells, antagonism in a short period treatment while synergy at a long-term treatment and ATM agonist worked in an opposite way of ATM inhibitors.	Etoposide	79-88	ATM serine/threonine kinase	Homo sapiens	265-268
35261636-3	2022	However, whether HGF has any effect on apoptosis induced by VP-16 (etoposide) in CML cells and its underlying mechanisms are unclear.	Etoposide	67-76	host cell factor C1	Homo sapiens	60-65
35184644-5	2022	When assessing which treatments have the greatest impact on AMH levels, we found that the BEACOPP regimen, and the agents vincristine, etoposide, procarbazine, prednisone and the haematopoietic stem cell transplantation were mainly responsible.	Etoposide	135-144	anti-Mullerian hormone	Homo sapiens	60-63
35369571-10	2022	We further revealed that RNF6 expression in both Y-79 and SO-Rb50 cells could render cells resistant to multiple anti-cancer drugs including carboplatin, vincristine and etoposide, an implication of RNF6 as a biomarker for RB drug resistance.	Etoposide	170-179	ring finger protein 6	Homo sapiens	25-29
35369571-10	2022	We further revealed that RNF6 expression in both Y-79 and SO-Rb50 cells could render cells resistant to multiple anti-cancer drugs including carboplatin, vincristine and etoposide, an implication of RNF6 as a biomarker for RB drug resistance.	Etoposide	170-179	ring finger protein 6	Homo sapiens	199-203
35486884-9	2022	Use of regimens other than R-CHOP was associated with a higher risk of death/progression for patients with DLBCL (rituximab, ifosfamide, carboplatin, and etoposide/ifosfamide, carboplatin, and etoposide) and FL (CHOP).	Etoposide	154-163	DNA damage inducible transcript 3	Homo sapiens	212-216
35178190-0	2022	Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.	Etoposide	0-9	tumor protein p53	Homo sapiens	45-48
35178190-4	2022	We assessed the impact of the loss of p53 function on the formation of DNA damage induced by the Top2 poison etoposide.	Etoposide	109-118	tumor protein p53	Homo sapiens	38-41
35178190-5	2022	Using human HCT116 cells, we found resistance to etoposide in cell growth assays upon the functional loss of p53.	Etoposide	49-58	tumor protein p53	Homo sapiens	109-112
35178190-6	2022	Nonetheless, cells lacking fully functional p53 were etoposide hypersensitive in clonogenic survival assays.	Etoposide	53-62	tumor protein p53	Homo sapiens	44-47
35178190-9	2022	Employing genome-wide siRNA screens, we identified a set of genes for which reduced expression resulted in enhanced synthetic lethality upon etoposide treatment of p53 defective cells.	Etoposide	141-150	tumor protein p53	Homo sapiens	164-167
35178190-10	2022	We focused on one hit from this screen, ATR, and showed that decreased expression sensitized the p53-defective cells to etoposide in all assays and generated elevated levels of Top2cc in both p53 proficient and deficient cells.	Etoposide	120-129	ATR serine/threonine kinase	Homo sapiens	40-43
35178190-10	2022	We focused on one hit from this screen, ATR, and showed that decreased expression sensitized the p53-defective cells to etoposide in all assays and generated elevated levels of Top2cc in both p53 proficient and deficient cells.	Etoposide	120-129	tumor protein p53	Homo sapiens	97-100
35155259-4	2022	Methods: This research retrospectively studied mobilization efficacy and safety using etoposide combined with Cytarabine (etoposide 50-100 mg/m2, qd d1-3; AraC 0.5 g/m2, q12h d1~3) plus G-CSF (5 microg/kg/day, from d5 until the day of apheresis) in 128 patients with MM.	Etoposide	86-95	colony stimulating factor 3	Homo sapiens	186-191
35118589-3	2022	This work was designed to investigate changes in the biochemical parameters as well as alterations in Sertoli cell vimentin expression, ultrastructure and ectoplasmic specializations (ESs) following Eto treatment and to assess the ameliorative effect of omega-3 versus Se on these alterations.	Etoposide	199-202	vimentin	Rattus norvegicus	115-123
35118589-7	2022	Eto administration in group II induced increase in malondialdehyde (MDA), decrease in superoxide dismutase (SOD), collapse of Sertoli cell vimentin filaments and ultrastructural degenerative changes in both Sertoli cells and ESs.	Etoposide	0-3	vimentin	Rattus norvegicus	139-147
35142384-8	2022	In 80 advanced ENKTL patients, 18 received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment.	Etoposide	104-113	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	115-120
35123514-13	2022	The gene-drug interaction network stated that CENPF inhibitors, such as Cisplatin, Sunitinib, and Etoposide, might serve as potential drugs for the therapy of ACC.	Etoposide	98-107	centromere protein F	Homo sapiens	46-51
35110396-3	2022	In this issue of Cancer Research, Porazzi and colleagues report that pretreatment with EZH2 inhibitors opened up the H3K27me3-marked chromatin of acute myeloid leukemia (AML) cells, which enhanced DNA damage and apoptosis induced by chemotherapeutic agents, in particular the topoisomerase II inhibitors, doxorubicin and etoposide.	Etoposide	321-330	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	87-91
35141227-2	2021	This study aims to investigate the mechanism underlying IGF2 mRNA-binding protein 2 (IGF2BP2) and long noncoding RNA DANCR in etoposide resistance of glioblastoma (GBM) cells.	Etoposide	126-135	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	56-83
35141227-2	2021	This study aims to investigate the mechanism underlying IGF2 mRNA-binding protein 2 (IGF2BP2) and long noncoding RNA DANCR in etoposide resistance of glioblastoma (GBM) cells.	Etoposide	126-135	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	85-92
35141227-2	2021	This study aims to investigate the mechanism underlying IGF2 mRNA-binding protein 2 (IGF2BP2) and long noncoding RNA DANCR in etoposide resistance of glioblastoma (GBM) cells.	Etoposide	126-135	differentiation antagonizing non-protein coding RNA	Homo sapiens	117-122
35141227-5	2021	Through functional experiments, we evaluated the interrelationship among IGF2BP2, DANCR, phosphotyrosine interaction domain containing 1 (PID1), and forkhead box protein O1 (FOXO1) and further assessed their impact on the sensitivity of GBM cells to etoposide.	Etoposide	250-259	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	73-80
35141227-5	2021	Through functional experiments, we evaluated the interrelationship among IGF2BP2, DANCR, phosphotyrosine interaction domain containing 1 (PID1), and forkhead box protein O1 (FOXO1) and further assessed their impact on the sensitivity of GBM cells to etoposide.	Etoposide	250-259	forkhead box O1	Homo sapiens	149-172
35141227-5	2021	Through functional experiments, we evaluated the interrelationship among IGF2BP2, DANCR, phosphotyrosine interaction domain containing 1 (PID1), and forkhead box protein O1 (FOXO1) and further assessed their impact on the sensitivity of GBM cells to etoposide.	Etoposide	250-259	forkhead box O1	Homo sapiens	174-179
35141227-7	2021	Mechanistically, overexpression of IGF2BP2 promoted DANCR stability and reduced DANCR methylation, whereas silencing of IGF2BP2 reduced survival of GBM cells and etoposide-resistant cells.	Etoposide	162-171	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	120-127
35056649-8	2022	All tested polyphenols increased the SOD activity in cells co-incubated with etoposide.	Etoposide	77-86	superoxide dismutase 1	Homo sapiens	37-40
35097256-0	2022	Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide.	Etoposide	150-159	poly(ADP-ribose) polymerase 1	Homo sapiens	32-61
35097256-0	2022	Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide.	Etoposide	150-159	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	70-94
35097256-1	2022	Etoposide (VP-16) is used for the treatment of various cancers, including nasopharyngeal carcinoma (NPC); however, cancers develop resistance to this agent by promoting DNA repair.	Etoposide	0-9	host cell factor C1	Homo sapiens	11-16
35387938-4	2022	After four cycles of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy, a second complete response was achieved.	Etoposide	82-91	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	93-98